[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fqB5L8KG2v-6ENud07q9f1TxDalwo296YQpx1RfsUERU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":85,"rows":92},"Merck Sharp & Dohme LLC",[4],2122,false,220,733,2980646,260,66,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Type 2 Diabetes Mellitus",108,{"name":18,"count":19},"Healthy",105,{"name":21,"count":22},"Hepatitis C, Chronic",77,{"name":24,"count":25},"Hepatitis C",62,{"name":27,"count":28},"HIV Infections",57,{"name":30,"count":31},"Hypertension",29,{"name":33,"count":31},"Diabetes Mellitus, Type 2",{"name":35,"count":36},"Melanoma",27,[38,43,48,52,57,62,66,70,75,80],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02362594","Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054\u002F1325-MG\u002FKEYNOTE-054)","2018-01-08","pembrolizumab",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT03553836","Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716\u002FKEYNOTE-716)","2021-06-21","Pembrolizumab",{"nctId":49,"briefTitle":50,"date":51,"intervention":47},"NCT03834493","Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641\u002FKEYNOTE-641)","2022-12-12",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT04489771","A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)","2023-02-10","Belzutifan",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT04956692","Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)","2023-04-04","Pembrolizumab SC",{"nctId":63,"briefTitle":64,"date":65,"intervention":47},"NCT03425643","Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant\u002FAdjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671\u002FKEYNOTE-671)","2023-07-10",{"nctId":67,"briefTitle":68,"date":69,"intervention":56},"NCT04195750","A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)","2024-04-15",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT05224141","Pembrolizumab\u002FVibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008\u002FKEYVIBE-008)","2024-06-04","Pembrolizumab\u002FVibostolimab Co-Formulation",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT05722015","A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)","2024-07-12","Pembrolizumab Formulated with Berahyaluronidase Alfa",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT03765918","Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)","2024-07-25","Pembrolizumab 200 mg",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,238,264,2800,3150,3505,3660,3902,4058,4241,4440,4650,4740,4904,4967,5111,5356,5451,5562,5674,5731,5788,5920,6051,6149,6298,6374,6450,6516,6574,6630,6672,6730,6788,6835,6889,6939,6989,7057,7156,7233,7279,7417,7487,7616,7722,7772,7835,7877,7907,7937,7967,7997,8126,8215,8286,8333,8363,8393,8430,8456,8482,8508,8534,8560,8627,8685,8723,8757,8792,8822,8852,8878,8904,8926,8948,8970,8992,9014,9036,9073,9095,9117,9254,9284,9383,9477,9513,9560,9595,9628,9650,9672,9694,9716,9738,9760,9782,9804,9826,9848,9880,9898,9916,9934,9952,9970,9988,10006,10024,10042,10060,10078,10096,10114,10132,10150,10168,10186,10204,10222,10240,10258,10276,10294,10312,10330,10348,10366,10384,10402,10420,10438,10456,10474,10492,10516,10534,10552,10577,10595,10613,10631,10649,10667,10685,10703,10721,10739,10757,10775,10793,10811,10829,10891,10930,10960,10989,11015,11041,11084,11141,11203,11246,11268,11290,11312,11334,11356,11453,11501,11558,11593,11659,11697,11737,11771,11810,11836,11858,11888,11910,11932,11954,11976,11994,12012,12030,12048,12066,12091,12109,12132,12150,12168,12186,12204,12222,12240,12258,12276,12294,12312,12330,12348,12366,12384,12402,12420,12438,12456,12474,12492,12510,12534,12552,12570,12588,12606,12624,12642,12660,12678,12696,12772,12818,12875,12917,12966,13004,13087,13151,13173,13208,13258,13286,13314,13340,13362,13396,13426,13450,13473,13491,13509,13531,13549,13567,13585,13603,13626,13644,13662,13680,13703,13727,13745,13768,13786,13804,14303,15611,15783,15991,16084,16197,16297,16370,16440,16519,16578,16639,16710,16770,16814,16844,16882,16918,16957,16996,17038,17080,17119,17163,17207,17233,17277,17318,17340,17362,17393,17422,17444,17477,17503,17525,17560,17598,17625,17647,17677,17699,17734,17766,17788,17810,17835,17858,17876,17901,17919,17937,17955,17973,17991,18009,18027,18045,18063,18081,18104,18127,18145,18163,18181,18203,18230,18248,18271,18289,18307,18331,18349,18373,18391,18409,18432,18457,18475,18493,18511,18529,18547,18565,18589,18607,18631,18653,18671,18689,18712,18730,18748,18766,18789,18814,18832,18850,18868,18890,18908,19102,19285,19433,19527,19668,19762,19878,19980,20089,20161,20240,20328,20400,20477,20554,20621,20713,20799,20876,20940,20982,21051,21093,21152,21225,21276,21345,21391,21445,21506,21552,21590,21642,21682,21716,21765,21799,21838,21883,21949,21987,22027,22071,22110,22140,22193,22244,22274,22304,22349,22395,22443,22492,22522,22567,22622,22666,22692,22721,22747,22773,22799,22825,22856,22897,22934,22960,22998,23042,23068,23100,23134,23160,23195,23221,23258,23287,23313,23348,23374,23400,23443,23482,23512,23544,23573,23617,23648,23686,23708,23737,23764,23790,23815,23846,23868,23890,23922,23944,23966,23988,24010,24042,24064,24086,24123,24157,24191,24223,24250,24279,24313,24335,24367,24400,24428,24457,24491,24530,24565,24587,24616,24641,24663,24685,24707,24729,24751,24776,24798,24820,24848,24883,24905,24927,24949,24973,25007,25029,25051,25075,25097,25121,25155,25177,25199,25221,25246,25272,25300,25327,25357,25396,25418,25440,25476,25498,25520,25552,25574,25601,25633,25669,25691,25713,25735,25757,25786,25808,25830,25852,25874,25896,25914,25932,25950,25974,25992,26010,26031,26049,26067,26092,26110,26128,26146,26171,26189,26207,26230,26254,26276,26300,26321,26339,26357,26383,26401,26419,26437,26455,26473,26491,26509,26527,26550,26568,26586,26604,26622,26640,26658,26676,26694,26712,26737,26760,26778,26801,26819,26843,26861,26879,26901,26923,26941,26959,26977,26995,27017,27035,27057,27075,27093,27111,27129,27154,27172,27197,27215,27233,27257,27275,27299,27326,27344,27362,27380,27398,27416,27440,27458,27476,27494,27517,27535,27553,27574,27592,27618,27636,27657,27675,27693,27711,27735,27753,27771,27794,27812,27841,27859,27877,27895,27913,27935,27957,27981,27999,28026,28044,28062,28080,28098,28116,28134,28152,28170,28188,28210,28228,28252,28270,28288,28306,28324,28342,28364,28382,28406,28424,28446,28464,28482,28500,28522,28540,28558,28579,28601,28619,28637,28655,28676,28694,28712,28730,28748,28766,28787,28805,28829,28847,28870,28895,28913,28931,28949,28967,28985,29009,29027,29045,29063,29084,29107,29125,29143,29166,29184,29212,29230,29248,29266,29284,29302,29320,29338,29359,29377,29395,29413,29439,29457,29475,29493,29511,29529,29547,29565,29593,29611,29629,29647,29665,29690,29708,29731,29749,29767,29785,29803,29821,29843,29861,29882,29904,29926,29944,29962,29980,30006,30024,30042,30065,30083,30101,30122,30140,30163,30181,30199,30217,30238,30256,30274,30292,30310,30328,30346,30364,30382,30400,30422,30443,30461,30479,30497,30521,30539,30557,30578,30603,30621,30639,30662,30687,30705,30723,30741,30765,30783,30801,30819,30837,30855,30878,30896,30914,30936,30954,30978,30996,31014,31032,31050,31068,31086,31104,31122,31140,31158,31176,31199,31217,31235,31253,31271,31289,31307,31330,31348,31366,31388,31406,31424,31442,31460,31478,31496,31514,31539,31557,31575,31593,31611,31629,31647,31665,31683,31701,31719,31737,31755,31773,31797,31815,31833,31851,31872,31890,31908,31926,31944,31962,31980,31998,32016,32034,32052,32070,32088,32106,32129,32147,32172,32190,32213,32237,32255,32273,32291,32309,32327,32345,32367,32393,32411,32429,32447,32465,32483,32501,32519,32542,32560,32578,32596,32614,32632,32650,32668,32696,32714,32738,32756,32838,32921,32976,33047,33085,33148,33190,33236,33278,33316,33360,33410,33440,33492,33536,33579,33612,33655,33697,33735,33773,33799,33825,33851,33877,33903,33937,33963,33996,34037,34076,34102,34137,34165,34200,34230,34275,34309,34339,34361,34383,34413,34438,34460,34485,34507,34534,34556,34592,34614,34650,34683,34705,34734,34762,34788,34819,34841,34863,34885,34907,34938,34967,34989,35021,35048,35082,35104,35126,35148,35170,35192,35220,35246,35275,35300,35335,35357,35385,35412,35434,35456,35478,35504,35535,35563,35585,35610,35635,35653,35671,35694,35712,35730,35757,35775,35793,35811,35829,35854,35878,35896,35914,35932,35950,35968,35986,36004,36022,36040,36058,36076,36094,36112,36130,36155,36173,36191,36212,36230,36254,36272,36293,36311,36329,36350,36376,36394,36417,36435,36453,36476,36500,36518,36536,36554,36572,36590,36608,36626,36648,36666,36684,36702,36727,36745,36763,36786,36804,36827,36845,36863,36881,36903,36921,36945,36963,36981,36999,37017,37035,37053,37071,37089,37107,37125,37143,37161,37179,37197,37215,37233,37254,37272,37296,37314,37332,37355,37373,37391,37409,37427,37445,37468,37486,37509,37527,37548,37566,37588,37611,37629,37647,37665,37683,37701,37724,37742,37760,37778,37796,37814,37832,37854,37872,37890,37908,37931,37949,37967,37985,38007,38025,38043,38061,38079,38102,38120,38138,38156,38174,38192,38213,38231,38249,38267,38285,38303,38321,38348,38366,38384,38407,38425,38448,38466,38489,38507,38525,38546,38570,38595,38613,38638,38656,38674,38692,38710,38733,38751,38769,38790,38808,38826,38844,38866,38884,38908,38934,38952,38970,38988,39006,39028,39046,39068,39086,39104,39122,39140,39158,39180,39198,39216,39234,39252,39277,39295,39313,39331,39349,39367,39390,39412,39430,39448,39469,39492,39510,39531,39549,39567,39585,39603,39621,39639,39657,39675,39693,39718,39736,39754,39772,39796,39814,39832,39850,39868,39886,39904,39922,39940,39958,39976,39994,40012,40035,40060,40078,40096,40114,40139,40157,40181,40199,40221,40239,40266,40284,40308,40329,40353,40371,40389,40407,40425,40443,40467,40485,40503,40521,40543,40561,40586,40604,40622,40640,40658,40679,40697,40715,40733,40751,40772,40797,40815,40833,40859,40877,40895,40913,40931,40949,40967,40985,41003,41026,41048,41071,41094,41112,41133,41151,41176,41194,41212,41230,41248,41266,41284,41302,41350,41403,41445,41492,41520,41554,41586,41621,41647,41681,41707,41745,41771,41805,41834,41862,41884,41912,41941,41963,41985,42007,42036,42062,42093,42115,42137,42159,42191,42224,42246,42273,42303,42335,42363,42385,42407,42439,42474,42505,42527,42556,42578,42609,42635,42662,42687,42712,42740,42762,42780,42798,42816,42834,42856,42879,42897,42915,42933,42951,42974,42992,43010,43031,43056,43074,43092,43110,43128,43152,43175,43196,43214,43232,43250,43268,43286,43304,43322,43340,43358,43376,43398,43416,43440,43458,43476,43500,43518,43550,43568,43586,43604,43622,43640,43658,43676,43694,43712,43730,43748,43766,43784,43802,43825,43843,43864,43886,43911,43929,43952,43970,43995,44013,44031,44049,44067,44085,44103,44121,44139,44163,44181,44199,44223,44241,44259,44284,44302,44320,44338,44356,44374,44392,44410,44428,44446,44464,44487,44505,44523,44541,44562,44588,44606,44624,44642,44660,44678,44696,44722,44740,44758,44776,44798,44822,44840,44858,44880,44898,44919,44937,44960,44978,44996,45018,45036,45054,45077,45098,45120,45138,45163,45181,45204,45222,45246,45269,45291,45313,45331,45349,45367,45385,45403,45424,45447,45471,45489,45507,45530,45548,45566,45584,45609,45635,45653,45671,45692,45716,45734,45752,45770,45788,45806,45828,45852,45870,45894,45912,45933,45951,45974,45992,46010,46028,46046,46064,46082,46100,46123,46141,46164,46182,46200,46218,46236,46262,46280,46298,46316,46334,46356,46374,46392,46414,46432,46455,46473,46497,46515,46533,46551,46569,46587,46605,46626,46644,46668,46689,46713,46731,46749,46767,46785,46806,46824,46842,46860,46878,46896,46920,46942,46967,46985,47003,47021,47039,47064,47082,47100,47118,47136,47161,47179,47197,47215,47233,47255,47273,47291,47309,47327,47345,47363,47381,47404,47426,47448,47466,47484,47506,47524,47546,47575,47593,47611,47629,47647,47665,47683,47701,47719,47737,47755,47773,47791,47815,47833,47851,47872,47890,47908,47931,47949,47974,47992,48010,48028,48046,48068,48086,48104,48125,48146,48170,48188,48211,48233,48251,48269,48287,48309,48327,48345,48363,48386,48404,48422,48445,48463,48487,48505,48523,48541,48563,48581,48603,48621,48639,48657,48675,48693,48711,48734,48757,48775,48801,48819,48837,48855,48873,48891,48909,48932,48962,48980,48998,49016,49034,49052,49070,49088,49106,49124,49142,49160,49178,49196,49214,49232,49250,49268,49286,49309,49337,49355,49373,49391,49409,49427,49449,49467,49485,49503,49521,49542,49568,49586,49608,49626,49647,49665,49693,49711,49729,49747,49765,49783,49805,49823,49841,49859,49877,49895,49917,49935,49956,49983,50001,50019,50037,50055,50073,50091,50113,50131,50149,50177,50195,50213,50231,50249,50267,50285,50303,50321,50343,50361,50384,50407,50425,50443,50461,50483,50501,50524,50542,50560,50582,50605,50623,50644,50668,50686,50704,50730,50748,50766,50784,50807,50828,50851,50869,50887,50909,50927,50951,50969,50987,51005,51023,51041,51059,51077,51095,51113,51131,51149,51173,51191,51209,51227,51250,51268,51286,51304,51322,51344,51362,51380,51398,51416,51434,51452,51470,51488,51506,51524,51542,51560,51578,51604,51622,51640,51658,51676,51694,51717,51741,51766,51784,51805,51841,51859,51877,51895,51913,51931,51949,51967,51985,52003,52021,52039,52061,52079,52097,52122,52140,52158,52180,52198,52216,52239,52257,52299,52317,52335,52353,52371,52389,52407,52425,52443,52461,52479,52497,52515,52533,52551,52569,52587,52605,52628,52646,52668,52689,52707,52725,52753,52771,52789,52807,52825,52843,52861,52879,52897,52915,52933,52951,52974,52992,53010,53031,53049,53067,53085,53103,53121,53139,53162,53184,53202,53220,53241,53259,53283,53301,53319,53692,53882,54122,54325,54485,54654,54772,54908,55000,55100,55199,55272,55334,55388,55438,55498,55544,55592,55634,55676,55714,55755,55795,55831,55873,55914,55961,55991,56023,56053,56082,56108,56137,56159,56187,56214,56236,56262,56284,56306,56328,56349,56371,56392,56413,56431,56449,56471,56493,56511,56529,56547,56568,56590,56608,56631,56649,56673,56691,56709,56731,56749,56767,56785,56803,56821,56839,56857],{"intervention":94,"totalTrials":95,"cells":96},"Sotatercept",12,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":123,"PHASE3":203,"PHASE4":225,"NA":236},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[102,114],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":112},"NCT06930664","A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)","COMPLETED",[87],"2025-11-11","2025-11-25","2025-05-16",146,[18],[94,113],"Sotatercept Autoinjector",{"nctId":115,"briefTitle":116,"status":105,"phases":117,"primaryCompletion":118,"completion":118,"start":119,"enrollment":120,"conditions":121,"interventions":122},"NCT06843460","A Clinical Study of MK-7962 in Healthy Chinese Participants (MK-7962-021)",[87],"2024-05-21","2023-11-22",24,[18],[94],{"trials":124,"activeCount":202,"soonestReadout":141},[125,136,147,158,167,178,187],{"nctId":126,"briefTitle":127,"status":128,"phases":129,"primaryCompletion":130,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":135},"NCT06814145","Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)","RECRUITING",[88],"2035-08-10","2025-04-16",130,[134],"Hypertension, Pulmonary",[94],{"nctId":137,"briefTitle":138,"status":139,"phases":140,"primaryCompletion":141,"completion":141,"start":142,"enrollment":132,"conditions":143,"interventions":145},"NCT06925750","A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031\u002FLIGHTRAY EXTENSION)","ACTIVE_NOT_RECRUITING",[88],"2028-06-16","2025-05-12",[144],"Pulmonary Arterial Hypertension",[94,146],"Background PAH Therapy",{"nctId":148,"briefTitle":149,"status":150,"phases":151,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":157},"NCT00931606","Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)","TERMINATED",[88],"2010-11-18","2009-06-01",30,[156],"Chemotherapy Induced Anemia",[94],{"nctId":159,"briefTitle":160,"status":105,"phases":161,"primaryCompletion":162,"completion":162,"start":163,"enrollment":164,"conditions":165,"interventions":166},"NCT06664801","A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)",[88],"2025-11-20","2024-11-14",164,[144],[94,146],{"nctId":168,"briefTitle":169,"status":150,"phases":170,"primaryCompletion":171,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":177},"NCT01190644","Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors",[88],"2012-09-18","2012-10-29","2010-06-01",5,[176],"Solid Tumors",[94],{"nctId":179,"briefTitle":180,"status":128,"phases":181,"primaryCompletion":182,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":186},"NCT05587712","Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)",[88],"2028-09-21","2023-01-19",42,[144],[94],{"nctId":188,"briefTitle":189,"status":105,"phases":190,"primaryCompletion":191,"completion":191,"start":192,"enrollment":193,"conditions":194,"interventions":201},"NCT01736683","Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)",[88],"2018-04-30","2012-11-28",74,[195,196,197,198,199,200],"Anemia","Myelodysplastic Syndromes","Chronic Myelomonocytic Leukemia","Low to Intermediate-1 MDS","Myelodysplastic Syndromes (MDS)","Chronic Myelomonocytic Leukemia (CMML)",[94],3,{"trials":204,"activeCount":224,"soonestReadout":219},[205,215],{"nctId":206,"briefTitle":207,"status":105,"phases":208,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":214},"NCT05818137","A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)",[89],"2024-03-12","2025-11-06","2023-05-10",46,[144],[94],{"nctId":216,"briefTitle":217,"status":128,"phases":218,"primaryCompletion":219,"completion":219,"start":220,"enrollment":221,"conditions":222,"interventions":223},"NCT07218029","A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)",[89],"2028-12-07","2021-05-12",815,[144],[94],1,{"trials":226,"activeCount":224,"soonestReadout":232},[227],{"nctId":228,"briefTitle":229,"status":230,"phases":231,"primaryCompletion":232,"completion":232,"start":233,"enrollment":154,"conditions":234,"interventions":235},"NCT07600723","A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)","NOT_YET_RECRUITING",[90],"2028-04-03","2026-06-24",[144],[94,146],{"trials":237,"activeCount":99},[],{"intervention":146,"totalTrials":202,"cells":239},{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":254,"PHASE4":256,"NA":262},{"trials":241,"activeCount":99},[],{"trials":243,"activeCount":99},[],{"trials":245,"activeCount":224,"soonestReadout":141},[246,250],{"nctId":137,"briefTitle":138,"status":139,"phases":247,"primaryCompletion":141,"completion":141,"start":142,"enrollment":132,"conditions":248,"interventions":249},[88],[144],[94,146],{"nctId":159,"briefTitle":160,"status":105,"phases":251,"primaryCompletion":162,"completion":162,"start":163,"enrollment":164,"conditions":252,"interventions":253},[88],[144],[94,146],{"trials":255,"activeCount":99},[],{"trials":257,"activeCount":224,"soonestReadout":232},[258],{"nctId":228,"briefTitle":229,"status":230,"phases":259,"primaryCompletion":232,"completion":232,"start":233,"enrollment":154,"conditions":260,"interventions":261},[90],[144],[94,146],{"trials":263,"activeCount":99},[],{"intervention":47,"totalTrials":265,"cells":266},239,{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":735,"PHASE3":1625,"PHASE4":2773,"NA":2791},{"trials":268,"activeCount":99},[],{"trials":270,"activeCount":734,"soonestReadout":378},[271,281,294,305,316,328,340,351,361,374,391,401,411,422,438,449,462,473,488,501,510,519,531,543,551,563,573,584,593,607,620,630,641,655,666,682,694,704,715,725],{"nctId":272,"briefTitle":273,"status":105,"phases":274,"primaryCompletion":275,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":280},"NCT02054806","Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028\u002FKEYNOTE-28)",[87],"2021-04-30","2014-02-17",477,[279],"Solid Tumor",[47],{"nctId":282,"briefTitle":283,"status":105,"phases":284,"primaryCompletion":285,"completion":285,"start":286,"enrollment":287,"conditions":288,"interventions":291},"NCT05514444","Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced\u002FMetastatic Solid Tumors (MK-4464-001)",[87],"2025-09-18","2022-09-25",64,[289,290],"Advanced\u002FMetastatic Solid Tumors","Neoplasms",[292,47,293],"MK-4464","89Zr-MK-4464",{"nctId":295,"briefTitle":296,"status":105,"phases":297,"primaryCompletion":298,"completion":298,"start":299,"enrollment":300,"conditions":301,"interventions":303},"NCT03010176","Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced\u002FMetastatic Solid Tumors or Lymphomas (MK-1454-001)",[87],"2022-04-21","2017-02-03",156,[176,302],"Lymphoma",[304,47],"Ulevostinag",{"nctId":306,"briefTitle":307,"status":105,"phases":308,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":315},"NCT02007070","Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025\u002FKEYNOTE-025)",[87],"2015-07-09","2017-03-31","2014-02-28",38,[314],"Non-small Cell Lung Cancer",[47],{"nctId":317,"briefTitle":318,"status":139,"phases":319,"primaryCompletion":320,"completion":320,"start":321,"enrollment":322,"conditions":323,"interventions":325},"NCT06460961","A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced\u002FMetastatic Solid Tumors (MK-6837-001)",[87],"2027-07-13","2024-07-14",168,[324],"Neoplasm Metastasis",[326,47,327],"MK-6837","Rescue Medications",{"nctId":329,"briefTitle":330,"status":150,"phases":331,"primaryCompletion":332,"completion":333,"start":334,"enrollment":335,"conditions":336,"interventions":338},"NCT03099161","Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)",[87],"2017-11-24","2018-02-21","2017-06-27",10,[337],"Neoplasm",[339,42],"preladenant",{"nctId":341,"briefTitle":342,"status":105,"phases":343,"primaryCompletion":344,"completion":345,"start":346,"enrollment":347,"conditions":348,"interventions":350},"NCT02835690","Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032\u002FKEYNOTE-032)",[87],"2017-09-19","2021-12-31","2016-08-04",44,[349],"Non-Small-Cell Lung Cancer",[47],{"nctId":352,"briefTitle":353,"status":105,"phases":354,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":360},"NCT04317066","A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33\u002FKEYNOTE-A33)",[87],"2024-04-11","2020-06-26",7,[359],"Lymphoma, B-Cell",[47],{"nctId":362,"briefTitle":363,"status":150,"phases":364,"primaryCompletion":365,"completion":365,"start":366,"enrollment":367,"conditions":368,"interventions":372},"NCT03948763","A Study of mRNA-5671\u002FV941 as Monotherapy and in Combination With Pembrolizumab (V941-001)",[87],"2022-08-25","2019-06-26",70,[290,369,370,371],"Carcinoma, Non-Small-Cell Lung","Pancreatic Neoplasms","Colorectal Neoplasms",[373,47],"V941",{"nctId":375,"briefTitle":376,"status":139,"phases":377,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":383},"NCT05017012","A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)",[87],"2026-05-19","2021-09-21",72,[382],"Advanced or Metastatic Solid Tumors",[384,47,385,386,387,388,389,390],"Pembrolizumab (+) Berahyaluronidase alfa","Pemetrexed","Carboplatin","Paclitaxel","Nab-paclitaxel","Axitinib","Cisplatin",{"nctId":392,"briefTitle":393,"status":105,"phases":394,"primaryCompletion":395,"completion":395,"start":396,"enrollment":397,"conditions":398,"interventions":399},"NCT05594043","A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)",[87],"2025-05-21","2022-12-21",90,[382],[400,47],"MK-6598",{"nctId":402,"briefTitle":403,"status":150,"phases":404,"primaryCompletion":405,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":409},"NCT03249792","Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced\u002FMetastatic Solid Tumors or Lymphomas (MK-2118-001)",[87],"2023-02-22","2017-09-20",140,[279,302],[410,410,47],"MK-2118",{"nctId":412,"briefTitle":413,"status":150,"phases":414,"primaryCompletion":415,"completion":415,"start":416,"enrollment":417,"conditions":418,"interventions":420},"NCT02972034","Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)",[87],"2022-12-02","2017-01-13",111,[290,419],"Colorectal Cancer",[421,47],"MK-8353",{"nctId":423,"briefTitle":424,"status":105,"phases":425,"primaryCompletion":426,"completion":427,"start":428,"enrollment":429,"conditions":430,"interventions":432},"NCT03374254","Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651\u002FKEYNOTE-651)",[87],"2021-09-08","2023-07-18","2018-02-16",116,[431],"Metastatic Colorectal Cancer",[47,433,434,435,436,437],"Binimetinib","Oxaliplatin","Leucovorin","5-Fluorouracil [5-FU]","Irinotecan",{"nctId":439,"briefTitle":440,"status":105,"phases":441,"primaryCompletion":442,"completion":442,"start":443,"enrollment":444,"conditions":445,"interventions":447},"NCT03364049","Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)",[87],"2020-10-19","2017-12-06",33,[446],"Solid Neoplasms",[448,47],"MK-7162",{"nctId":450,"briefTitle":451,"status":105,"phases":452,"primaryCompletion":453,"completion":453,"start":454,"enrollment":455,"conditions":456,"interventions":457},"NCT02720068","Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab\u002FPembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)",[87],"2024-03-15","2016-05-02",481,[290],[458,47,434,437,435,459,460,461],"Favezelimab","Fluorouracil [5-FU]","Favezelimab\u002FPembrolizumab","Lenvatinib",{"nctId":463,"briefTitle":464,"status":105,"phases":465,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":470},"NCT03564691","Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)",[87],"2025-09-26","2018-07-11",470,[290],[471,47,386,385,461,387,390,472],"MK-4830","MK-4830A",{"nctId":474,"briefTitle":475,"status":105,"phases":476,"primaryCompletion":477,"completion":477,"start":478,"enrollment":479,"conditions":480,"interventions":481},"NCT02964013","Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)",[87],"2024-07-24","2016-12-13",474,[290],[482,42,483,484,485,486,487],"vibostolimab","pemetrexed","carboplatin","pembrolizumab\u002Fvibostolimab coformulation","cisplatin","etoposide",{"nctId":489,"briefTitle":490,"status":128,"phases":491,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":498},"NCT05853367","Study of MK-0472 in Participants With Advanced\u002FMetastatic Solid Tumors (MK-0472-001)",[87],"2028-02-12","2023-07-06",178,[496,497],"Metastatic Solid Tumors","Advanced Solid Tumors",[499,47,500],"MK-0472","MK-1084",{"nctId":502,"briefTitle":503,"status":139,"phases":504,"primaryCompletion":505,"completion":505,"start":506,"enrollment":367,"conditions":507,"interventions":508},"NCT05382325","A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)",[87],"2026-07-31","2022-06-16",[382],[509,47],"MK-1484",{"nctId":511,"briefTitle":512,"status":105,"phases":513,"primaryCompletion":514,"completion":514,"start":515,"enrollment":429,"conditions":516,"interventions":517},"NCT02132754","Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)",[87],"2019-07-31","2014-06-27",[279],[518,47],"MK-4166",{"nctId":520,"briefTitle":521,"status":150,"phases":522,"primaryCompletion":523,"completion":523,"start":524,"enrollment":22,"conditions":525,"interventions":527},"NCT02036502","A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023\u002FKEYNOTE-023)",[87],"2020-03-19","2014-02-14",[526],"Multiple Myeloma",[47,528,529,530],"Lenalidomide","Dexamethasone","Carfilzomib",{"nctId":532,"briefTitle":533,"status":105,"phases":534,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":538,"interventions":541},"NCT03396445","Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)",[87],"2024-09-27","2018-02-18",182,[539,279,369,540],"Pharmacokinetics","Triple Negative Breast Neoplasms",[542,47,385,386,388],"Boserolimab",{"nctId":544,"briefTitle":545,"status":105,"phases":546,"primaryCompletion":547,"completion":547,"start":548,"enrollment":184,"conditions":549,"interventions":550},"NCT02180061","Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041\u002FKEYNOTE-041)",[87],"2017-08-31","2014-07-15",[35],[47],{"nctId":552,"briefTitle":553,"status":105,"phases":554,"primaryCompletion":555,"completion":556,"start":557,"enrollment":558,"conditions":559,"interventions":560},"NCT02622074","Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173\u002FKEYNOTE-173)",[87],"2018-05-31","2019-11-18","2016-01-27",60,[540],[47,388,561,562,386,387],"Anthracycline","Cyclophosphamide",{"nctId":564,"briefTitle":565,"status":105,"phases":566,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":570,"interventions":572},"NCT04153565","A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)",[87],"2022-09-21","2019-12-09",19,[571],"Mesothelioma",[47,385,390],{"nctId":574,"briefTitle":575,"status":105,"phases":576,"primaryCompletion":577,"completion":578,"start":579,"enrollment":580,"conditions":581,"interventions":583},"NCT01295827","Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990\u002FMK-3475-001\u002FKEYNOTE-001)",[87],"2018-11-05","2018-12-11","2011-03-04",1260,[582],"Cancer, Solid Tumor",[47],{"nctId":585,"briefTitle":586,"status":150,"phases":587,"primaryCompletion":588,"completion":588,"start":589,"enrollment":154,"conditions":590,"interventions":591},"NCT03739138","Intratumoral\u002FIntralesional Administration of MK-4621\u002FJetPEI™ With or Without Pembrolizumab in Participants With Advanced\u002FMetastatic or Recurrent Solid Tumors (MK-4621-002)",[87],"2021-03-02","2018-12-18",[497],[592,47],"MK-4621",{"nctId":594,"briefTitle":595,"status":128,"phases":596,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":600,"interventions":601},"NCT05067283","A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)",[87],"2030-02-25","2021-12-17",830,[497],[602,47,484,483,603,604,605,606],"Calderasib","cetuximab","oxaliplatin","leucovorin","5-fluorouracil",{"nctId":608,"briefTitle":609,"status":150,"phases":610,"primaryCompletion":611,"completion":611,"start":612,"enrollment":613,"conditions":614,"interventions":618},"NCT02684617","Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155\u002FKEYNOTE-155)",[87],"2020-04-06","2016-03-29",75,[615,616,617],"rrCLL","rrMM","rrDLBCL",[42,619],"dinaciclib",{"nctId":621,"briefTitle":622,"status":150,"phases":623,"primaryCompletion":624,"completion":624,"start":625,"enrollment":626,"conditions":627,"interventions":628},"NCT03833427","Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced\u002FMetastatic Solid Tumors (MK-5618-001)",[87],"2022-06-28","2019-03-18",32,[289],[629,47],"Selumetinib",{"nctId":631,"briefTitle":632,"status":105,"phases":633,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":638,"interventions":640},"NCT01848834","Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012\u002FKEYNOTE-012)",[87],"2016-04-26","2020-06-30","2013-05-07",297,[639,279],"Cancer",[47],{"nctId":642,"briefTitle":643,"status":139,"phases":644,"primaryCompletion":645,"completion":646,"start":647,"enrollment":154,"conditions":648,"interventions":652},"NCT06049212","Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)",[87],"2026-06-30","2027-01-29","2023-10-26",[314,176,649,650,651],"Programmed Cell Death-1 (PD1, PD-1)","Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)","Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)",[653,47,654],"Sacituzumab tirumotecan","Supportive care measures",{"nctId":656,"briefTitle":657,"status":150,"phases":658,"primaryCompletion":659,"completion":659,"start":660,"enrollment":661,"conditions":662,"interventions":664},"NCT02553499","Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)",[87],"2018-10-17","2015-11-12",37,[663],"Advanced Solid Tumor",[665,42],"MK-1248",{"nctId":667,"briefTitle":668,"status":105,"phases":669,"primaryCompletion":356,"completion":356,"start":670,"enrollment":671,"conditions":672,"interventions":679},"NCT01953692","A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013\u002FKEYNOTE-013)",[87],"2013-11-22",197,[673,526,674,675,676,677,678],"Myelodysplastic Syndrome","Hodgkin Lymphoma","Non-Hodgkin Lymphoma","Diffuse Large B-Cell Lymphoma","Follicular Lymphoma","Primary Mediastinal B-Cell Lymphoma",[47,680,681],"Lenalidomide 20 mg","Lenalidomide 25 mg",{"nctId":683,"briefTitle":684,"status":128,"phases":685,"primaryCompletion":686,"completion":686,"start":687,"enrollment":688,"conditions":689,"interventions":691},"NCT07247110","A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)",[87],"2030-12-01","2025-12-16",250,[690],"Malignant Neoplasm",[692,47,693],"MK-4716","Cetuximab",{"nctId":695,"briefTitle":696,"status":139,"phases":697,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":701,"interventions":703},"NCT05030506","A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080\u002FMK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)",[87],"2027-06-30","2021-10-13",45,[702],"Renal Cell Carcinoma",[56,47,461],{"nctId":705,"briefTitle":706,"status":105,"phases":707,"primaryCompletion":708,"completion":708,"start":709,"enrollment":710,"conditions":711,"interventions":712},"NCT03918278","A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)",[87],"2025-06-09","2019-06-19",222,[290],[713,42,387,388,714,386,385],"MK-0482","Gemcitabine",{"nctId":716,"briefTitle":717,"status":105,"phases":718,"primaryCompletion":719,"completion":720,"start":721,"enrollment":722,"conditions":723,"interventions":724},"NCT02821000","Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151\u002FKEYNOTE-151)",[87],"2017-12-27","2022-11-30","2016-07-08",103,[35],[47],{"nctId":726,"briefTitle":727,"status":105,"phases":728,"primaryCompletion":729,"completion":729,"start":730,"enrollment":174,"conditions":731,"interventions":732},"NCT06894771","A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)",[87],"2025-12-08","2025-04-23",[690],[733,47],"MK-4700",8,{"trials":736,"activeCount":1624,"soonestReadout":909},[737,748,758,770,781,799,809,819,830,844,875,886,895,905,915,925,935,946,956,968,981,996,1006,1016,1028,1037,1048,1060,1077,1090,1101,1115,1125,1137,1145,1154,1163,1175,1184,1193,1203,1214,1223,1233,1242,1255,1266,1276,1291,1303,1314,1326,1334,1343,1353,1362,1370,1380,1391,1402,1413,1423,1433,1446,1462,1472,1484,1493,1505,1516,1525,1535,1544,1554,1565,1573,1585,1595,1606,1615],{"nctId":738,"briefTitle":739,"status":105,"phases":740,"primaryCompletion":741,"completion":741,"start":742,"enrollment":743,"conditions":744,"interventions":745},"NCT02130466","A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022\u002FKEYNOTE-022)",[87,88],"2021-07-14","2014-05-29",184,[35,176],[47,746,747],"Dabrafenib","Trametinib",{"nctId":749,"briefTitle":750,"status":105,"phases":751,"primaryCompletion":752,"completion":752,"start":659,"enrollment":753,"conditions":754,"interventions":757},"NCT03598608","Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)",[87,88],"2026-01-28",137,[755,756,359],"Hodgkin Disease","Lymphoma, Non-Hodgkin",[42,458],{"nctId":759,"briefTitle":760,"status":128,"phases":761,"primaryCompletion":762,"completion":763,"start":764,"enrollment":765,"conditions":766,"interventions":768},"NCT07221474","A Study of Intismeran Autogene (V940)\u002FPlacebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)",[88],"2029-07-02","2031-05-06","2025-12-12",180,[767],"Squamous Non-small Cell Lung Cancer",[769,47,386,387,388],"Intismeran Autogene",{"nctId":771,"briefTitle":772,"status":105,"phases":773,"primaryCompletion":774,"completion":774,"start":775,"enrollment":776,"conditions":777,"interventions":779},"NCT03516981","A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495\u002FKEYNOTE-495)",[88],"2025-06-13","2018-10-01",245,[778],"Advanced Non-Small Cell Lung Cancer",[47,458,461,780],"Quavonlimab",{"nctId":782,"briefTitle":783,"status":128,"phases":784,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":788,"interventions":793},"NCT06469944","Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable\u002FMetastatic Gastroesophageal Adenocarcinoma (MK-3475-06C\u002FKEYMAKER-U06)",[87,88],"2029-09-12","2024-09-20",160,[789,790,791,792],"Gastroesophageal Junction","Gastroesophageal Adenocarcinoma","Esophageal Neoplasms","Esophageal Cancer",[47,794,795,435,796,797,434,798],"Sacituzumab Tirumotecan","Capecitabine","Levoleucovorin","5-Fluorouracil","Patritumab Deruxtecan",{"nctId":800,"briefTitle":801,"status":128,"phases":802,"primaryCompletion":803,"completion":804,"start":645,"enrollment":805,"conditions":806,"interventions":808},"NCT07302347","A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21\u002FKEYNOTE-G21)",[87,88],"2029-03-30","2029-12-31",20,[690,807,302],"Carcinoma, Merkel Cell",[47],{"nctId":810,"briefTitle":811,"status":105,"phases":812,"primaryCompletion":813,"completion":813,"start":814,"enrollment":815,"conditions":816,"interventions":817},"NCT03179436","Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)",[87,88],"2024-04-08","2017-07-02",415,[497],[780,47,818],"Pembrolizumab\u002FQuavonlimab",{"nctId":820,"briefTitle":821,"status":105,"phases":822,"primaryCompletion":823,"completion":824,"start":825,"enrollment":826,"conditions":827,"interventions":829},"NCT02460198","Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164\u002FKEYNOTE-164)",[88],"2019-09-09","2021-02-19","2015-08-25",124,[828],"Colorectal Carcinoma",[47],{"nctId":831,"briefTitle":832,"status":128,"phases":833,"primaryCompletion":834,"completion":834,"start":835,"enrollment":836,"conditions":837,"interventions":839},"NCT06843447","A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)",[87,88],"2029-03-27","2025-04-15",460,[838],"Ovarian Cancer Recurrent",[840,386,387,841,842,47,714,843],"Raludotatug Deruxtecan","Bevacizumab","Rescue Medication","Pegylated liposomal doxorubicin",{"nctId":845,"briefTitle":846,"status":139,"phases":847,"primaryCompletion":848,"completion":848,"start":849,"enrollment":850,"conditions":851,"interventions":874},"NCT02628067","Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158\u002FKEYNOTE-158)",[88],"2027-05-04","2015-12-18",1609,[852,853,854,855,856,857,858,859,860,861,862,863,864,865,866,867,571,868,869,870,871,872,873,497,828],"Advanced Cancer","Anal Carcinoma","Anal Cancer","Biliary Cancer","Cholangiocarcinoma","Bile Duct Cancer","Neuroendocrine Tumor","Carcinoid Tumor","Endometrial Carcinoma","Endometrial Cancer","Cervical Carcinoma","Cervical Cancer","Vulvar Carcinoma","Vulvar Cancer","Small Cell Lung Carcinoma","Small Cell Lung Cancer (SCLC)","Thyroid Carcinoma","Thyroid Cancer","Salivary Gland Carcinoma","Salivary Gland Cancer","Salivary Cancer","Parotid Gland Cancer",[42,42],{"nctId":876,"briefTitle":877,"status":128,"phases":878,"primaryCompletion":879,"completion":880,"start":881,"enrollment":787,"conditions":882,"interventions":884},"NCT06961006","A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012\u002FINTerpath-012)",[88],"2028-07-22","2031-09-05","2025-05-29",[883],"Malignant Melanoma",[885,47],"Intismeran autogene",{"nctId":887,"briefTitle":888,"status":105,"phases":889,"primaryCompletion":890,"completion":890,"start":891,"enrollment":892,"conditions":893,"interventions":894},"NCT04165083","KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B\u002FKEYMAKER-U01B)",[88],"2025-10-31","2019-12-19",102,[369],[47,471,713],{"nctId":896,"briefTitle":897,"status":105,"phases":898,"primaryCompletion":899,"completion":899,"start":900,"enrollment":901,"conditions":902,"interventions":904},"NCT03664024","Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)",[88],"2021-11-05","2018-10-30",118,[903],"Non-Small Cell Lung Cancer",[47,385,386,390],{"nctId":906,"briefTitle":907,"status":139,"phases":908,"primaryCompletion":909,"completion":910,"start":911,"enrollment":912,"conditions":913,"interventions":914},"NCT06099782","A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)",[88],"2025-04-09","2027-02-15","2023-12-26",147,[903,702,35],[384,47],{"nctId":916,"briefTitle":917,"status":105,"phases":918,"primaryCompletion":919,"completion":919,"start":356,"enrollment":920,"conditions":921,"interventions":922},"NCT04305041","Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A\u002FKEYMAKER-U02)",[87,88],"2025-08-25",100,[35],[47,780,923,461,924],"Vibostolimab","ATRA",{"nctId":926,"briefTitle":927,"status":105,"phases":928,"primaryCompletion":929,"completion":929,"start":930,"enrollment":931,"conditions":932,"interventions":934},"NCT04220866","Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)",[88],"2022-09-30","2020-03-04",18,[933],"Head and Neck Squamous Cell Carcinoma (HNSCC)",[304,47],{"nctId":936,"briefTitle":937,"status":128,"phases":938,"primaryCompletion":939,"completion":939,"start":940,"enrollment":941,"conditions":942,"interventions":945},"NCT02332668","A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051\u002FKEYNOTE-051)",[87,88],"2028-02-02","2015-03-19",370,[35,302,279,943,944],"Classical Hodgkin Lymphoma","Microsatellite-instability-high Solid Tumor",[47],{"nctId":947,"briefTitle":948,"status":128,"phases":949,"primaryCompletion":950,"completion":950,"start":891,"enrollment":951,"conditions":952,"interventions":953},"NCT04165070","KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A\u002FKEYMAKER-U01A)",[87,88],"2032-02-13",450,[369],[47,386,387,385,923,542,471,713,954,955],"Ifinatamab Deruxtecan","HER3-DXd",{"nctId":957,"briefTitle":958,"status":105,"phases":959,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":964,"interventions":966},"NCT04428151","Lenvatinib (E7080\u002FMK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009\u002FE7080-G000-228\u002FLEAP-009)",[88],"2024-05-31","2025-10-30","2020-08-06",408,[965],"Squamous Cell Carcinoma of Head and Neck",[461,47,967,795,387,693,461],"Docetaxel",{"nctId":969,"briefTitle":970,"status":128,"phases":971,"primaryCompletion":972,"completion":972,"start":973,"enrollment":558,"conditions":974,"interventions":976},"NCT06788912","Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E\u002FKEYMAKER-U01)",[88],"2032-02-06","2025-03-20",[975],"Lung Neoplasm Malignant",[47,390,714,385,653,977,978,979,529,386,47,387,980],"H1 receptor antagonist","H2 receptor antagonist","Acetaminophen","Steroid mouthwash",{"nctId":982,"briefTitle":983,"status":105,"phases":984,"primaryCompletion":985,"completion":985,"start":986,"enrollment":987,"conditions":988,"interventions":995},"NCT03797326","Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080\u002FMK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005\u002FE7080-G000-224\u002FLEAP-005)",[88],"2024-10-28","2019-02-12",611,[497,989,990,991,419,992,993,994],"Triple Negative Breast Cancer","Ovarian Cancer","Gastric Cancer","Glioblastoma","Biliary Tract Cancers","Pancreatic Cancer",[47,461],{"nctId":997,"briefTitle":998,"status":139,"phases":999,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1003,"interventions":1005},"NCT04976634","Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)",[88],"2027-03-22","2021-08-18",730,[1004],"Neoplasm Malignant",[47,56,461],{"nctId":1007,"briefTitle":1008,"status":105,"phases":1009,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":300,"conditions":1013,"interventions":1015},"NCT02702414","Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224\u002FKEYNOTE-224)",[88],"2021-01-19","2023-09-29","2016-05-31",[1014],"Hepatocellular Carcinoma",[47],{"nctId":1017,"briefTitle":1018,"status":105,"phases":1019,"primaryCompletion":1020,"completion":1021,"start":1022,"enrollment":1023,"conditions":1024,"interventions":1025},"NCT04165096","KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C\u002FKEYMAKER-U01C)",[88],"2025-04-30","2025-05-28","2020-01-21",128,[369],[47,542,471,1026,1027,713],"diphenhydramine","acetaminophen",{"nctId":1029,"briefTitle":1030,"status":139,"phases":1031,"primaryCompletion":1032,"completion":1032,"start":1033,"enrollment":941,"conditions":1034,"interventions":1036},"NCT04626518","Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B\u002FKEYMAKER-U03)",[87,88],"2026-07-17","2020-12-17",[1035],"Carcinoma, Renal Cell",[47,471,56,461,818,460],{"nctId":1038,"briefTitle":1039,"status":1040,"phases":1041,"primaryCompletion":1042,"completion":1043,"start":1044,"enrollment":99,"conditions":1045,"interventions":1046},"NCT03221634","Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668\u002FKEYNOTE-668)","WITHDRAWN",[88],"2019-03-20","2021-06-10","2017-08-01",[526],[47,1047],"Daratumumab",{"nctId":1049,"briefTitle":1050,"status":128,"phases":1051,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":1054,"conditions":1055,"interventions":1057},"NCT05562830","A Substudy of Investigational Agents in Programmed Cell Death-1\u002FLigand 1 (PD-1\u002FL1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)",[87,88],"2029-02-26","2022-11-16",48,[1056],"Urothelial Carcinoma",[1058,47,1059],"Zilovertamab vedotin","MK-3120",{"nctId":1061,"briefTitle":1062,"status":105,"phases":1063,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":110,"conditions":1067,"interventions":1068},"NCT05008224","Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11\u002FKEYNOTE-C11)",[88],"2023-10-11","2024-05-26","2021-10-07",[943],[47,1069,1070,1071,1072,1073,562,1074,1075,1076],"Doxorubicin","Vinblastine","Dacarbazine","Bleomycin","Etoposide","Vincristine","Procarbazine","Prednisone",{"nctId":1078,"briefTitle":1079,"status":128,"phases":1080,"primaryCompletion":1081,"completion":1081,"start":1082,"enrollment":8,"conditions":1083,"interventions":1086},"NCT06428409","A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)",[87,88],"2029-10-16","2024-06-20",[419,1084,1085],"Pancreatic Ductal Adenocarcinoma","Biliary Tract Cancer",[653,1087,1088,1089,654,390,47],"Fluorouracil","Leucovorin (LV) or levoleucovorin","Rescue medication",{"nctId":1091,"briefTitle":1092,"status":105,"phases":1093,"primaryCompletion":1094,"completion":1094,"start":1095,"enrollment":1096,"conditions":1097,"interventions":1098},"NCT02089685","Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029\u002FKEYNOTE-29)",[87,88],"2021-04-01","2014-03-17",295,[702,35],[47,1099,1100],"PegIFN-2b","Ipilimumab",{"nctId":1102,"briefTitle":1103,"status":128,"phases":1104,"primaryCompletion":804,"completion":1105,"start":973,"enrollment":1106,"conditions":1107,"interventions":1110},"NCT06797635","Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive\u002FHER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)",[88],"2034-12-31",372,[1108,1109],"Breast Neoplasms","Breast Cancer",[1111,47,387,386,1112,1113,562,795,1114],"Patritumab deruxtecan","Doxorubicin hydrochloride","Epirubicin hydrochloride","Olaparib",{"nctId":1116,"briefTitle":1117,"status":105,"phases":1118,"primaryCompletion":1119,"completion":1120,"start":1121,"enrollment":1122,"conditions":1123,"interventions":1124},"NCT02447003","Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086\u002FKEYNOTE-086)",[88],"2019-02-18","2020-01-31","2015-06-11",254,[1109],[47],{"nctId":1126,"briefTitle":1127,"status":139,"phases":1128,"primaryCompletion":1129,"completion":1130,"start":1131,"enrollment":1132,"conditions":1133,"interventions":1135},"NCT06305767","A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005\u002FINTerpath-005)",[87,88],"2027-04-23","2031-10-20","2024-03-28",230,[1134],"Bladder Cancer",[47,885,1136],"Enfortumab Vedotin",{"nctId":1138,"briefTitle":1139,"status":128,"phases":1140,"primaryCompletion":1141,"completion":1141,"start":1142,"enrollment":132,"conditions":1143,"interventions":1144},"NCT07252739","KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J\u002FKEYMAKER-U01J)",[88],"2033-01-14","2025-12-19",[690],[500,47,693,386,385],{"nctId":1146,"briefTitle":1147,"status":139,"phases":1148,"primaryCompletion":1032,"completion":1032,"start":1149,"enrollment":1150,"conditions":1151,"interventions":1152},"NCT04626479","Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)",[87,88],"2020-12-16",400,[1035],[47,460,56,461,818,1153],"Vibostolimab\u002FPembrolizumab",{"nctId":1155,"briefTitle":1156,"status":150,"phases":1157,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":224,"conditions":1160,"interventions":1162},"NCT03407170","Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161\u002FKEYNOTE-161)",[88],"2019-08-14","2018-06-28",[1161],"Advanced Melanoma",[42],{"nctId":1164,"briefTitle":1165,"status":105,"phases":1166,"primaryCompletion":1167,"completion":1167,"start":1168,"enrollment":1169,"conditions":1170,"interventions":1173},"NCT03473925","Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced\u002FMetastatic Solid Tumors (MK-7123-034)",[88],"2021-05-19","2018-04-10",107,[176,314,1171,1172],"Castration Resistant Prostate Cancer","Microsatellite Stable Colorectal Cancer",[1174,47],"Navarixin",{"nctId":1176,"briefTitle":1177,"status":105,"phases":1178,"primaryCompletion":1179,"completion":1179,"start":356,"enrollment":110,"conditions":1180,"interventions":1181},"NCT04303169","Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C\u002FKEYMAKER-U02)",[87,88],"2025-09-24",[35],[47,923,1182,471,1183,924],"Gebasaxturev","Favezelimab + Pembrolizumab",{"nctId":1185,"briefTitle":1186,"status":150,"phases":1187,"primaryCompletion":1188,"completion":1188,"start":1189,"enrollment":1190,"conditions":1191,"interventions":1192},"NCT04521621","A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced\u002FMetastatic Solid Tumors (V937-013)",[87,88],"2023-07-25","2020-10-28",76,[324],[1182,47],{"nctId":1194,"briefTitle":1195,"status":105,"phases":1196,"primaryCompletion":1197,"completion":1197,"start":1198,"enrollment":1199,"conditions":1200,"interventions":1202},"NCT02787005","Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199\u002FKEYNOTE-199)",[88],"2022-02-28","2016-07-01",388,[1201],"Metastatic Castration-resistant Prostate Cancer",[47],{"nctId":1204,"briefTitle":1205,"status":105,"phases":1206,"primaryCompletion":1207,"completion":1208,"start":1209,"enrollment":12,"conditions":1210,"interventions":1213},"NCT04875195","A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)",[88],"2023-12-14","2025-10-13","2021-06-07",[1211,1212],"Hodgkin's Lymphoma","Primary Mediastinal Large B-cell Lymphoma (PMBCL)",[47],{"nctId":1215,"briefTitle":1216,"status":105,"phases":1217,"primaryCompletion":1218,"completion":1218,"start":1219,"enrollment":429,"conditions":1220,"interventions":1222},"NCT04740307","Safety and Efficacy of Coformulated Pembrolizumab\u002FQuavonlimab (MK-1308A) in Combination With Lenvatinib (E7080\u002FMK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)",[88],"2025-07-29","2021-03-16",[1221],"Advanced Hepatocellular Carcinoma",[818,461,47],{"nctId":1224,"briefTitle":1225,"status":105,"phases":1226,"primaryCompletion":1227,"completion":1227,"start":1228,"enrollment":397,"conditions":1229,"interventions":1231},"NCT05342636","A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and\u002For Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)",[87,88],"2025-12-05","2022-07-27",[1230],"Esophageal Squamous Cell Carcinoma (ESCC)",[47,1232,471,461,437,387],"Coformulation favezelimab\u002Fpembrolizumab",{"nctId":1234,"briefTitle":1235,"status":1040,"phases":1236,"primaryCompletion":1237,"completion":1237,"start":1238,"enrollment":99,"conditions":1239,"interventions":1240},"NCT06395090","A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B\u002FLIGHTBEAM-U01)",[87,88],"2029-06-30","2025-01-15",[324],[47,458,460,923,1241],"Pembrolizumab\u002FVibostolimab",{"nctId":1243,"briefTitle":1244,"status":105,"phases":1245,"primaryCompletion":1246,"completion":1247,"start":1248,"enrollment":1249,"conditions":1250,"interventions":1252},"NCT02039674","A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021\u002FKEYNOTE-021)",[87,88],"2016-11-07","2021-10-18","2014-02-21",267,[1251],"Non-small Cell Lung Carcinoma",[47,387,386,841,385,1100,1253,1254],"Erlotinib","Gefitinib",{"nctId":1256,"briefTitle":1257,"status":128,"phases":1258,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":1261,"conditions":1262,"interventions":1264},"NCT06780111","Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E\u002FKEYMAKER-U06)",[87,88],"2032-01-04","2025-07-30",298,[1263],"Esophageal Squamous Cell Carcinoma",[47,1265,435,796,797,434,653,842],"I-DXd",{"nctId":1267,"briefTitle":1268,"status":139,"phases":1269,"primaryCompletion":395,"completion":1270,"start":1271,"enrollment":1272,"conditions":1273,"interventions":1274},"NCT04895722","Evaluation of Co-formulated Pembrolizumab\u002FQuavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008\u002FKEYSTEP-008)",[88],"2026-08-13","2021-06-25",302,[419],[47,818,1275,1241,471],"Pembrolizumab\u002FFavezelimab",{"nctId":1277,"briefTitle":1278,"status":105,"phases":1279,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":1282,"conditions":1283,"interventions":1290},"NCT05007106","MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)",[88],"2025-08-05","2021-09-16",613,[1284,1285,965,1286,856,791,540,1014,1287,1288,1289],"Uterine Cervical Neoplasms","Endometrial Neoplasms","Gallbladder Neoplasms","Urinary Bladder Neoplasms","Ovarian Neoplasms","Stomach Neoplasms",[74,47,461,797,390,387,714,386,967,841,795,434],{"nctId":1292,"briefTitle":1293,"status":150,"phases":1294,"primaryCompletion":1295,"completion":1295,"start":1296,"enrollment":1297,"conditions":1298,"interventions":1300},"NCT04152863","Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced\u002FMetastatic Melanoma (V937-011)",[88],"2023-07-12","2020-06-05",85,[1299],"Advanced\u002FMetastatic Melanoma",[1301,1302,47],"Gebasaxturev IV","Gebasaxturev ITu",{"nctId":1304,"briefTitle":1305,"status":105,"phases":1306,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1309,"conditions":1310,"interventions":1311},"NCT02625961","Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057\u002FKEYNOTE-057)",[88],"2025-11-05","2016-02-10",296,[1134],[47,1312,1313],"Pembrolizumab\u002Fvibostolimab coformulation","Favezelimab\u002Fpembrolizumab coformulation",{"nctId":1315,"briefTitle":1316,"status":128,"phases":1317,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1132,"conditions":1321,"interventions":1322},"NCT05319730","A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)\u002F Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)",[87,88],"2027-06-11","2029-04-10","2023-05-16",[1263],[387,437,47,471,461,653,1323,1324,979,529,1325,654],"Antihistamine","H2 Receptor Antagonist","Steroid Mouthwash",{"nctId":1327,"briefTitle":1328,"status":128,"phases":1329,"primaryCompletion":1330,"completion":1330,"start":1331,"enrollment":397,"conditions":1332,"interventions":1333},"NCT06731907","A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G\u002FKEYMAKER U01)",[88],"2032-03-12","2025-03-30",[314],[47,386,387,388,385,955],{"nctId":1335,"briefTitle":1336,"status":105,"phases":1337,"primaryCompletion":1338,"completion":1338,"start":1339,"enrollment":1340,"conditions":1341,"interventions":1342},"NCT02453594","Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087\u002FKEYNOTE-087)",[88],"2023-09-18","2015-06-10",211,[674],[42],{"nctId":1344,"briefTitle":1345,"status":128,"phases":1346,"primaryCompletion":1347,"completion":1347,"start":1348,"enrollment":1349,"conditions":1350,"interventions":1351},"NCT07232602","KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D\u002FKEYMAKER-U04)",[87,88],"2031-07-08","2026-02-09",55,[1134],[1059,1352,47,842],"EV",{"nctId":1354,"briefTitle":1355,"status":150,"phases":1356,"primaryCompletion":1357,"completion":1357,"start":1358,"enrollment":36,"conditions":1359,"interventions":1360},"NCT05394350","A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)",[87,88],"2023-09-07","2022-07-07",[497],[1361,47],"MK-1088",{"nctId":1363,"briefTitle":1364,"status":105,"phases":1365,"primaryCompletion":1064,"completion":1064,"start":1366,"enrollment":722,"conditions":1367,"interventions":1368},"NCT03776136","Efficacy and Safety of Lenvatinib (E7080\u002FMK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1\u002FProgrammed Death-Ligand 1 (PD-1\u002FL1)-Exposed Participants (MK-7902-004\u002FE7080-G000-225\u002FLEAP-004)",[88],"2019-01-30",[1161],[1369,42],"lenvatinib",{"nctId":1371,"briefTitle":1372,"status":139,"phases":1373,"primaryCompletion":1374,"completion":1374,"start":1375,"enrollment":312,"conditions":1376,"interventions":1379},"NCT06483334","A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C\u002FKEYMAKER-U04)",[87,88],"2028-03-31","2024-07-17",[1377,1378],"Metastatic Urothelial Carcinoma","Locally Advanced Urothelial Carcinoma",[653,1136,47,654],{"nctId":1381,"briefTitle":1382,"status":105,"phases":1383,"primaryCompletion":1384,"completion":1385,"start":1386,"enrollment":1387,"conditions":1388,"interventions":1389},"NCT01704287","Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002\u002FP08719\u002FKEYNOTE-002)",[88],"2015-11-16","2019-01-31","2012-11-20",540,[883],[47,386,387,1071,1390],"Temozolomide",{"nctId":1392,"briefTitle":1393,"status":1040,"phases":1394,"primaryCompletion":1395,"completion":1396,"start":1397,"enrollment":99,"conditions":1398,"interventions":1400},"NCT06829199","A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)",[88],"2029-01-18","2031-03-18","2025-03-26",[1399],"Early Triple Negative Breast Cancer",[47,387,386,1069,542,1401,562,795,1114],"Epirubicin Hydrochloride",{"nctId":1403,"briefTitle":1404,"status":105,"phases":1405,"primaryCompletion":1406,"completion":1407,"start":1408,"enrollment":1409,"conditions":1410,"interventions":1412},"NCT03284424","Study of Pembrolizumab (MK-3475) in Adults With Recurrent\u002FMetastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629\u002FKEYNOTE-629)",[88],"2020-07-29","2023-09-13","2017-10-26",159,[1411],"Squamous Cell Carcinoma",[47],{"nctId":1414,"briefTitle":1415,"status":105,"phases":1416,"primaryCompletion":1417,"completion":1417,"start":1418,"enrollment":1419,"conditions":1420,"interventions":1421},"NCT03631407","Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced\u002FMetastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)",[88],"2021-06-08","2018-09-24",41,[371],[1422,47],"Vicriviroc",{"nctId":1424,"briefTitle":1425,"status":139,"phases":1426,"primaryCompletion":1427,"completion":1428,"start":1429,"enrollment":1430,"conditions":1431,"interventions":1432},"NCT06307431","A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).",[88],"2028-01-08","2032-06-08","2024-04-10",272,[702],[885,47],{"nctId":1434,"briefTitle":1435,"status":105,"phases":1436,"primaryCompletion":1437,"completion":1437,"start":1438,"enrollment":1439,"conditions":1440,"interventions":1443},"NCT02335411","A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059\u002FKEYNOTE-059)",[88],"2021-07-23","2015-02-03",318,[1441,1442],"Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[42,486,1444,1445],"5-FU","capecitabine",{"nctId":1447,"briefTitle":1448,"status":139,"phases":1449,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":1453,"interventions":1454},"NCT03407144","Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667\u002FKEYNOTE-667)",[88],"2026-11-06","2018-04-09",340,[674],[42,1455,1456,1457,1458,1459,1460,1461,487],"doxorubicin","vinblastine","dacarbazine","cyclophosphamide","vincristine","prednisone\u002Fprednisolone","bleomycin",{"nctId":1463,"briefTitle":1464,"status":105,"phases":1465,"primaryCompletion":1466,"completion":1467,"start":1468,"enrollment":1469,"conditions":1470,"interventions":1471},"NCT02853344","Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced\u002FMetastatic Renal Cell Carcinoma (MK-3475-427\u002FKEYNOTE-427)",[88],"2021-02-05","2022-04-01","2016-09-30",275,[702],[47],{"nctId":1473,"briefTitle":1474,"status":105,"phases":1475,"primaryCompletion":1476,"completion":1477,"start":1478,"enrollment":1479,"conditions":1480,"interventions":1483},"NCT02576990","Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170\u002FKEYNOTE-170)",[88],"2019-05-28","2020-10-23","2015-12-02",80,[1481,1482],"Mediastinal Large B-cell Lymphoma","Richter Syndrome",[47],{"nctId":1485,"briefTitle":1486,"status":105,"phases":1487,"primaryCompletion":1488,"completion":1488,"start":1489,"enrollment":920,"conditions":1490,"interventions":1491},"NCT03382600","Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659\u002FKEYNOTE-659)",[88],"2021-05-30","2018-03-26",[991],[47,434,1492,390],"TS-1",{"nctId":1494,"briefTitle":1495,"status":105,"phases":1496,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":787,"conditions":1500,"interventions":1503},"NCT05446870","Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)",[88],"2023-12-20","2024-10-16","2022-07-25",[1501,1502],"High-grade Serous Ovarian Carcinoma","Ovarian Carcinoma",[47,387,386,1504,471,967],"Avastin",{"nctId":1506,"briefTitle":1507,"status":105,"phases":1508,"primaryCompletion":1509,"completion":1510,"start":1511,"enrollment":1512,"conditions":1513,"interventions":1515},"NCT02255097","Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055\u002FKEYNOTE-055)",[88],"2016-04-22","2021-06-18","2014-10-24",172,[1514],"Head and Neck Squamous Cell Carcinoma",[42],{"nctId":1517,"briefTitle":1518,"status":105,"phases":1519,"primaryCompletion":1520,"completion":1520,"start":1521,"enrollment":1522,"conditions":1523,"interventions":1524},"NCT04305054","Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B\u002FKEYMAKER-U02)",[87,88],"2026-05-18","2020-07-01",335,[35],[47,923,818,461,460,924],{"nctId":1526,"briefTitle":1527,"status":105,"phases":1528,"primaryCompletion":1529,"completion":1530,"start":1531,"enrollment":1532,"conditions":1533,"interventions":1534},"NCT02674061","Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100\u002FKEYNOTE-100)",[88],"2019-09-18","2021-03-18","2016-02-25",376,[1288],[47],{"nctId":1536,"briefTitle":1537,"status":105,"phases":1538,"primaryCompletion":1539,"completion":1540,"start":891,"enrollment":1541,"conditions":1542,"interventions":1543},"NCT04191135","Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009\u002FKEYLYNK-009)",[88],"2022-12-15","2025-11-26",462,[540],[47,1114,386,714],{"nctId":1545,"briefTitle":1546,"status":105,"phases":1547,"primaryCompletion":1548,"completion":1548,"start":1549,"enrollment":1550,"conditions":1551,"interventions":1553},"NCT04924101","Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99\u002F KEYNOTE-B99)",[88],"2025-06-23","2021-07-15",126,[1552],"Small Cell Lung Cancer",[47,471,542,461,1073,390,386],{"nctId":1555,"briefTitle":1556,"status":105,"phases":1557,"primaryCompletion":1558,"completion":1559,"start":1560,"enrollment":1561,"conditions":1562,"interventions":1564},"NCT02335424","Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052\u002FKEYNOTE-052)",[88],"2018-06-19","2022-02-18","2015-02-24",374,[1563],"Urothelial Cancer",[42],{"nctId":1566,"briefTitle":1567,"status":139,"phases":1568,"primaryCompletion":1569,"completion":1569,"start":556,"enrollment":1570,"conditions":1571,"interventions":1572},"NCT04123366","Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and\u002For Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007\u002FKEYLYNK-007)",[88],"2026-06-29",300,[176],[1114,47],{"nctId":1574,"briefTitle":1575,"status":139,"phases":1576,"primaryCompletion":1577,"completion":1577,"start":1578,"enrollment":1579,"conditions":1580,"interventions":1582},"NCT05845814","A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +\u002F- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B\u002FKEYMAKER-U04)",[87,88],"2027-05-31","2023-06-23",390,[1377,1581],"Urothelial Neoplasms",[1583,1584,1352,47],"Coformulated favezelimab\u002Fpembrolizumab","Coformulated vibostolimab\u002Fpembrolizumab",{"nctId":1586,"briefTitle":1587,"status":105,"phases":1588,"primaryCompletion":1589,"completion":1589,"start":1011,"enrollment":1590,"conditions":1591,"interventions":1593},"NCT06036836","Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)",[88],"2026-03-12",163,[279,1592,861],"Cutaneous Squamous Cell Carcinoma",[1594,42,1369],"favezelimab\u002Fpembrolizumab",{"nctId":1596,"briefTitle":1597,"status":105,"phases":1598,"primaryCompletion":1599,"completion":1600,"start":1478,"enrollment":1601,"conditions":1602,"interventions":1605},"NCT02559687","Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180\u002FKEYNOTE-180)",[88],"2018-07-30","2021-10-29",121,[1603,1604],"Esophageal Carcinoma","Esophagogastric Junction Carcinoma",[42],{"nctId":1607,"briefTitle":1608,"status":105,"phases":1609,"primaryCompletion":1610,"completion":1611,"start":1612,"enrollment":787,"conditions":1613,"interventions":1614},"NCT04704219","Pembrolizumab Plus Lenvatinib for First-line Advanced\u002FMetastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)",[88],"2025-01-27","2025-10-21","2021-02-23",[702],[47,461],{"nctId":1616,"briefTitle":1617,"status":105,"phases":1618,"primaryCompletion":1619,"completion":1619,"start":1620,"enrollment":1621,"conditions":1622,"interventions":1623},"NCT04700072","Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D\u002FKEYMAKER-U02)",[87,88],"2025-10-17","2021-05-03",56,[35],[47,818,461],28,{"trials":1626,"activeCount":661,"soonestReadout":41},[1627,1636,1646,1655,1666,1678,1689,1696,1707,1718,1731,1741,1752,1763,1772,1782,1790,1801,1811,1821,1831,1844,1852,1863,1873,1887,1893,1903,1912,1922,1933,1941,1952,1962,1971,1980,1991,2001,2011,2018,2027,2037,2047,2058,2068,2078,2089,2101,2111,2122,2132,2142,2153,2163,2175,2187,2197,2208,2217,2226,2234,2242,2252,2261,2271,2281,2291,2299,2309,2317,2328,2338,2346,2354,2363,2371,2384,2394,2402,2414,2425,2434,2445,2455,2464,2473,2484,2491,2500,2508,2517,2528,2539,2548,2558,2567,2578,2588,2597,2610,2618,2629,2641,2651,2659,2667,2678,2688,2698,2707,2717,2728,2739,2748,2757,2764],{"nctId":1628,"briefTitle":1629,"status":128,"phases":1630,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":1634,"interventions":1635},"NCT06841354","A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011\u002FTroFuse-011)",[89],"2030-05-18","2025-03-16",1000,[540],[653,47,842,387,388,714,386],{"nctId":1637,"briefTitle":1638,"status":105,"phases":1639,"primaryCompletion":1640,"completion":1641,"start":1642,"enrollment":1643,"conditions":1644,"interventions":1645},"NCT03142334","Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564\u002FKEYNOTE-564)",[89],"2020-12-14","2026-02-04","2017-06-09",994,[702],[47],{"nctId":1647,"briefTitle":1648,"status":105,"phases":1649,"primaryCompletion":1408,"completion":1043,"start":1650,"enrollment":1651,"conditions":1652,"interventions":1653},"NCT02370498","A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric\u002FGastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061\u002FKEYNOTE-061)",[89],"2015-05-11",592,[1441,1442],[42,1654],"paclitaxel",{"nctId":1656,"briefTitle":1657,"status":105,"phases":1658,"primaryCompletion":1659,"completion":1659,"start":1660,"enrollment":1661,"conditions":1662,"interventions":1663},"NCT03036488","Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522\u002FKEYNOTE-522)",[89],"2025-10-14","2017-03-07",1174,[540],[47,386,387,1069,1664,562,1665],"Epirubicin","Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim",{"nctId":1667,"briefTitle":1668,"status":105,"phases":1669,"primaryCompletion":1670,"completion":1671,"start":1672,"enrollment":1673,"conditions":1674,"interventions":1675},"NCT02256436","A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045\u002FKEYNOTE-045)",[89],"2016-09-07","2020-10-01","2014-10-22",542,[1563],[42,1654,1676,1677],"vinflunine","docetaxel",{"nctId":1679,"briefTitle":1680,"status":128,"phases":1681,"primaryCompletion":1682,"completion":1683,"start":1684,"enrollment":1685,"conditions":1686,"interventions":1688},"NCT06170788","Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)",[89],"2028-01-25","2030-05-27","2023-12-15",614,[1687],"Non-small Cell Lung Cancer (NSCLC)",[653,47,654],{"nctId":39,"briefTitle":40,"status":139,"phases":1690,"primaryCompletion":41,"completion":1691,"start":1692,"enrollment":1693,"conditions":1694,"interventions":1695},[89],"2026-11-01","2015-07-16",1019,[35],[42],{"nctId":1697,"briefTitle":1698,"status":105,"phases":1699,"primaryCompletion":1700,"completion":1701,"start":1702,"enrollment":1703,"conditions":1704,"interventions":1706},"NCT03976323","Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)",[89],"2024-02-07","2026-01-29","2019-06-28",1003,[1705],"Carcinoma, Nonsquamous Non-small-cell Lung",[47,385,386,390,1114],{"nctId":1708,"briefTitle":1709,"status":105,"phases":1710,"primaryCompletion":1711,"completion":1712,"start":1713,"enrollment":1714,"conditions":1715,"interventions":1717},"NCT02853305","Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361\u002FKEYNOTE-361)",[89],"2020-04-29","2022-09-15","2016-09-15",1010,[1716],"Urothelial Carcinoma Associated 1 RNA, Human",[47,390,386,714],{"nctId":1719,"briefTitle":1720,"status":105,"phases":1721,"primaryCompletion":1722,"completion":1723,"start":1724,"enrollment":1725,"conditions":1726,"interventions":1728},"NCT04246177","Safety and Efficacy of Lenvatinib (E7080\u002FMK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable\u002FNon-metastatic Hepatocellular Carcinoma (MK-7902-012\u002FE7080-G000-318\u002FLEAP-012)",[89],"2025-08-19","2026-03-26","2020-05-22",479,[1727],"Carcinoma, Hepatocellular",[461,47,1729,1730],"Oral Placebo","IV Placebo",{"nctId":1732,"briefTitle":1733,"status":105,"phases":1734,"primaryCompletion":1735,"completion":1736,"start":1737,"enrollment":1738,"conditions":1739,"interventions":1740},"NCT04221945","Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18\u002FKEYNOTE-A18\u002FENGOT-cx11\u002FGOG-3047)",[89],"2025-01-07","2026-01-26","2020-05-12",1060,[1284],[47,390],{"nctId":1742,"briefTitle":1743,"status":105,"phases":1744,"primaryCompletion":824,"completion":1745,"start":1746,"enrollment":1747,"conditions":1748,"interventions":1749},"NCT02563002","Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177\u002FKEYNOTE-177)",[89],"2023-07-17","2015-11-30",307,[828],[1750,1751,47,841,693],"mFOLFOX6","FOLFIRI",{"nctId":1753,"briefTitle":1754,"status":128,"phases":1755,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":1759,"conditions":1760,"interventions":1762},"NCT06393374","Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)",[89],"2030-12-16","2037-12-14","2024-06-24",1530,[1761],"Triple-Negative Breast Cancer",[47,653,795],{"nctId":1764,"briefTitle":1765,"status":1040,"phases":1766,"primaryCompletion":1767,"completion":1768,"start":1769,"enrollment":99,"conditions":1770,"interventions":1771},"NCT03881111","First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590\u002FKEYNOTE-590)-China Extension Study",[89],"2021-05-11","2022-05-11","2019-01-21",[791],[47,390,1444],{"nctId":1773,"briefTitle":1774,"status":150,"phases":1775,"primaryCompletion":1776,"completion":1777,"start":1778,"enrollment":1779,"conditions":1780,"interventions":1781},"NCT03924869","Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867\u002FKEYNOTE-867)",[89],"2024-06-11","2025-01-20","2019-06-25",448,[903],[47],{"nctId":1783,"briefTitle":1784,"status":105,"phases":1785,"primaryCompletion":973,"completion":1786,"start":1476,"enrollment":1787,"conditions":1788,"interventions":1789},"NCT03867084","Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 \u002F KEYNOTE-937)",[89],"2025-09-30",959,[1014],[47],{"nctId":1791,"briefTitle":1792,"status":105,"phases":1793,"primaryCompletion":1794,"completion":1795,"start":1796,"enrollment":1797,"conditions":1798,"interventions":1800},"NCT05226598","Study of Pembrolizumab\u002FVibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007\u002FKEYVIBE-007)",[89],"2024-09-24","2026-01-09","2022-03-24",739,[1799],"Metastatic Non-Small Cell Lung Cancer",[1241,386,390,387,388,385,47],{"nctId":1802,"briefTitle":1803,"status":139,"phases":1804,"primaryCompletion":1805,"completion":1806,"start":1807,"enrollment":1808,"conditions":1809,"interventions":1810},"NCT05933577","A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)",[89],"2029-10-26","2030-09-26","2023-07-19",1089,[35],[885,47],{"nctId":1812,"briefTitle":1813,"status":128,"phases":1814,"primaryCompletion":1815,"completion":1816,"start":1817,"enrollment":1818,"conditions":1819,"interventions":1820},"NCT06345729","A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004\u002FKANDLELIT-004)",[89],"2029-02-19","2031-02-18","2024-05-24",600,[314],[602,47],{"nctId":1822,"briefTitle":1823,"status":105,"phases":1824,"primaryCompletion":1539,"completion":1825,"start":1826,"enrollment":1827,"conditions":1828,"interventions":1830},"NCT04924062","Pembrolizumab (MK-3475) Plus Gemcitabine\u002FCisplatin Versus Placebo Plus Gemcitabine\u002FCisplatin for First-Line Advanced and\u002For Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966\u002FKEYNOTE-966)-China Extension Study",[89],"2025-03-25","2020-07-10",158,[1829],"Biliary Tract Carcinoma",[47,714,390],{"nctId":1832,"briefTitle":1833,"status":105,"phases":1834,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":1839,"interventions":1841},"NCT03615326","Pembrolizumab\u002FPlacebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811\u002FKEYNOTE-811)",[89],"2024-03-20","2025-11-12","2018-10-05",738,[1840,1442],"Gastric Neoplasms",[47,390,1444,434,795,1842,1843],"S-1","Trastuzumab",{"nctId":1845,"briefTitle":1846,"status":105,"phases":1847,"primaryCompletion":823,"completion":1848,"start":1670,"enrollment":1849,"conditions":1850,"interventions":1851},"NCT02864394","Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033\u002FKEYNOTE-033)",[89],"2022-10-14",425,[369],[47,967],{"nctId":1853,"briefTitle":1854,"status":139,"phases":1855,"primaryCompletion":1856,"completion":1856,"start":1510,"enrollment":1452,"conditions":1857,"interventions":1858},"NCT04895358","Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+\u002FHER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49\u002FKEYNOTE-B49)",[89],"2027-12-18",[1108],[42,1654,1859,1860,1445,1861,1862],"nab-paclitaxel","liposomal doxorubicin","normal saline","dextrose",{"nctId":1864,"briefTitle":1865,"status":105,"phases":1866,"primaryCompletion":1867,"completion":1868,"start":1869,"enrollment":1870,"conditions":1871,"interventions":1872},"NCT03820986","Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902\u002FE7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003\u002FE7080-G000-312\u002FLEAP-003)",[89],"2023-01-18","2024-11-01","2019-03-12",674,[883],[47,461],{"nctId":1874,"briefTitle":1875,"status":105,"phases":1876,"primaryCompletion":1877,"completion":1878,"start":1879,"enrollment":1880,"conditions":1881,"interventions":1883},"NCT02555657","Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119\u002FKEYNOTE-119)",[89],"2019-04-11","2020-11-10","2015-10-13",622,[1882],"Metastatic Triple Negative Breast Cancer",[42,1445,1884,1885,1886],"eribulin","gemcitabine","vinorelbine",{"nctId":63,"briefTitle":64,"status":139,"phases":1888,"primaryCompletion":65,"completion":1569,"start":1889,"enrollment":1890,"conditions":1891,"interventions":1892},[89],"2018-04-24",797,[314],[47,390,714,385],{"nctId":1894,"briefTitle":1895,"status":105,"phases":1896,"primaryCompletion":1897,"completion":1898,"start":1899,"enrollment":951,"conditions":1900,"interventions":1902},"NCT03833167","Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630\u002FKEYNOTE-630)",[89],"2024-06-28","2026-01-20","2019-04-01",[1901],"Carcinoma, Squamous Cell",[47],{"nctId":1904,"briefTitle":1905,"status":105,"phases":1906,"primaryCompletion":1907,"completion":65,"start":1908,"enrollment":1909,"conditions":1910,"interventions":1911},"NCT03189719","First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590\u002FKEYNOTE-590)",[89],"2020-07-02","2017-07-25",749,[791],[47,390,1444],{"nctId":1913,"briefTitle":1914,"status":105,"phases":1915,"primaryCompletion":1916,"completion":1917,"start":1918,"enrollment":1919,"conditions":1920,"interventions":1921},"NCT02494583","Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062\u002FKEYNOTE-062)",[89],"2019-03-26","2022-06-06","2015-07-31",763,[1441],[47,390,1444,795],{"nctId":1923,"briefTitle":1924,"status":105,"phases":1925,"primaryCompletion":1926,"completion":1927,"start":589,"enrollment":1928,"conditions":1929,"interventions":1932},"NCT03740165","Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001\u002FKEYLYNK-001\u002FENGOT-ov43\u002FGOG-3036)",[89],"2024-08-26","2026-04-15",1367,[990,1930,1931],"Fallopian Tube Cancer","Peritoneal Neoplasms",[47,386,387,1114,841,967],{"nctId":1934,"briefTitle":1935,"status":105,"phases":1936,"primaryCompletion":1167,"completion":1937,"start":1938,"enrollment":1169,"conditions":1939,"interventions":1940},"NCT04676412","Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902\u002FE7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007\u002FE7080-G000-314\u002FLEAP-007] - China Extension Study",[89],"2024-03-29","2019-10-23",[314],[47,461],{"nctId":1942,"briefTitle":1943,"status":105,"phases":1944,"primaryCompletion":1945,"completion":1946,"start":1947,"enrollment":1948,"conditions":1949,"interventions":1950},"NCT02775435","A Study of Carboplatin-Paclitaxel\u002FNab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407\u002FKEYNOTE-407)",[89],"2018-04-03","2023-09-14","2016-06-09",559,[314],[47,387,388,386,1951],"Saline placebo for pembrolizumab",{"nctId":1953,"briefTitle":1954,"status":128,"phases":1955,"primaryCompletion":1956,"completion":1957,"start":1958,"enrollment":1959,"conditions":1960,"interventions":1961},"NCT06077760","A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)",[89],"2030-06-25","2035-12-21","2023-12-06",868,[314],[885,47],{"nctId":1963,"briefTitle":1964,"status":105,"phases":1965,"primaryCompletion":1966,"completion":1946,"start":1967,"enrollment":1968,"conditions":1969,"interventions":1970},"NCT03875092","A Study of Carboplatin-Paclitaxel\u002FNab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407\u002FKEYNOTE-407)-China Extension Study",[89],"2020-09-30","2017-04-21",125,[314],[47,387,386,1951],{"nctId":1972,"briefTitle":1973,"status":150,"phases":1974,"primaryCompletion":1975,"completion":1975,"start":1976,"enrollment":1977,"conditions":1978,"interventions":1979},"NCT03019588","Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063\u002FKEYNOTE-063)",[89],"2021-06-29","2017-02-16",94,[1840,1442],[47,387],{"nctId":1981,"briefTitle":1982,"status":105,"phases":1983,"primaryCompletion":1984,"completion":1985,"start":1986,"enrollment":1987,"conditions":1988,"interventions":1989},"NCT02853331","Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426\u002FKEYNOTE-426)",[89],"2018-10-18","2025-12-26","2016-09-16",861,[702],[47,389,1990],"Sunitinib",{"nctId":1992,"briefTitle":1993,"status":105,"phases":1994,"primaryCompletion":1995,"completion":1995,"start":1996,"enrollment":1997,"conditions":1998,"interventions":1999},"NCT02684292","Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204\u002FKEYNOTE-204)",[89],"2026-01-14","2016-05-23",304,[674],[42,2000],"brentuximab vedotin",{"nctId":2002,"briefTitle":2003,"status":105,"phases":2004,"primaryCompletion":2005,"completion":2006,"start":2007,"enrollment":2008,"conditions":2009,"interventions":2010},"NCT03675737","Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859\u002FKEYNOTE-859)",[89],"2022-10-03","2025-03-03","2018-11-08",1579,[1289],[47,390,606,604,1445],{"nctId":2012,"briefTitle":2013,"status":1040,"phases":2014,"primaryCompletion":2015,"completion":2015,"start":2007,"enrollment":99,"conditions":2016,"interventions":2017},"NCT04859582","Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859\u002FKEYNOTE-859)-China Extension",[89],"2024-11-29",[1289],[47,390,606,434,795],{"nctId":2019,"briefTitle":2020,"status":105,"phases":2021,"primaryCompletion":2022,"completion":730,"start":1406,"enrollment":2023,"conditions":2024,"interventions":2026},"NCT04882241","Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585\u002FKEYNOTE-585)-China Extension",[89],"2024-02-16",120,[991,2025],"Gastroesophageal Junction Cancer",[47,390,795,606,967,434,435],{"nctId":2028,"briefTitle":2029,"status":150,"phases":2030,"primaryCompletion":2031,"completion":2032,"start":2033,"enrollment":2034,"conditions":2035,"interventions":2036},"NCT02579863","Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185\u002FKEYNOTE-185)",[89],"2018-07-09","2020-07-13","2015-10-19",310,[526],[47,528,529],{"nctId":2038,"briefTitle":2039,"status":105,"phases":2040,"primaryCompletion":2041,"completion":2042,"start":2043,"enrollment":1349,"conditions":2044,"interventions":2046},"NCT03783078","Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)",[89],"2022-02-15","2024-02-15","2019-02-25",[2045],"Merkel Cell Carcinoma",[47],{"nctId":2048,"briefTitle":2049,"status":105,"phases":2050,"primaryCompletion":2051,"completion":2052,"start":2053,"enrollment":2054,"conditions":2055,"interventions":2057},"NCT04662710","Efficacy and Safety of Lenvatinib (E7080\u002FMK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced\u002FMetastatic Gastroesophageal Adenocarcinoma (MK-7902-015\u002FE7080-G000-321\u002FLEAP-015)",[89],"2024-10-29","2026-03-30","2020-12-30",895,[2056],"Advanced\u002FMetastatic Gastroesophageal Adenocarcinoma",[47,461,434,795,435,1444],{"nctId":2059,"briefTitle":2060,"status":105,"phases":2061,"primaryCompletion":535,"completion":535,"start":2062,"enrollment":2063,"conditions":2064,"interventions":2065},"NCT04776148","Study of Lenvatinib (MK-7902\u002FE7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017\u002FE7080-G000-325\u002FLEAP-017)",[89],"2021-03-29",563,[371],[42,1369,2066,2067],"regorafenib","TAS-102",{"nctId":76,"briefTitle":77,"status":139,"phases":2069,"primaryCompletion":78,"completion":2070,"start":2071,"enrollment":2072,"conditions":2073,"interventions":2075},[89],"2028-05-22","2023-02-14",377,[2074],"Metastatic Non-small Cell Lung Cancer",[79,385,390,386,387,388,47,2076,2077],"Filgrastim","Pegylated filgrastim",{"nctId":2079,"briefTitle":2080,"status":105,"phases":2081,"primaryCompletion":2082,"completion":2083,"start":2084,"enrollment":2085,"conditions":2086,"interventions":2087},"NCT03933449","Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal\u002FEsophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181\u002FKEYNOTE-181)-China Extension Study",[89],"2019-02-13","2022-03-14","2016-12-29",123,[1603,1604],[42,1654,1677,2088],"irinotecan",{"nctId":2090,"briefTitle":2091,"status":105,"phases":2092,"primaryCompletion":2093,"completion":2094,"start":2095,"enrollment":2096,"conditions":2097,"interventions":2099},"NCT02252042","Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040\u002FKEYNOTE-040)",[89],"2017-05-15","2022-08-15","2014-11-17",495,[2098],"Head and Neck Squamous Cell Cancer",[47,2100,967,693],"Methotrexate",{"nctId":2102,"briefTitle":2103,"status":128,"phases":2104,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":2108,"conditions":2109,"interventions":2110},"NCT06623422","A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009\u002FINTerpath-009)",[89],"2033-05-16","2038-01-26","2024-10-21",680,[369],[47,390,386,385,714,387,885],{"nctId":2112,"briefTitle":2113,"status":105,"phases":2114,"primaryCompletion":2115,"completion":2116,"start":2117,"enrollment":2118,"conditions":2119,"interventions":2120},"NCT03515837","Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789\u002FKEYNOTE-789)",[89],"2023-01-17","2023-10-02","2018-06-29",492,[314],[42,483,484,486,2121],"saline solution",{"nctId":2123,"briefTitle":2124,"status":105,"phases":2125,"primaryCompletion":2126,"completion":2126,"start":2127,"enrollment":2128,"conditions":2129,"interventions":2130},"NCT04700124","Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15\u002F KEYNOTE-B15 \u002F EV-304)",[89],"2025-10-27","2021-04-21",808,[1134],[47,2131,714,390],"Enfortumab vedotin",{"nctId":2133,"briefTitle":2134,"status":139,"phases":2135,"primaryCompletion":2136,"completion":2136,"start":2137,"enrollment":2138,"conditions":2139,"interventions":2140},"NCT03725059","Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+\u002FHER2-) Breast Cancer (MK-3475-756\u002FKEYNOTE-756)",[89],"2031-01-24","2018-12-27",1240,[1109],[47,387,1069,1664,562,2141],"Endocrine therapy",{"nctId":2143,"briefTitle":2144,"status":105,"phases":2145,"primaryCompletion":2146,"completion":2147,"start":2148,"enrollment":2149,"conditions":2150,"interventions":2152},"NCT04716933","Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902\u002FE7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006\u002FE7080-G000-315\u002FLEAP-006)-China Extension Study",[89],"2023-08-11","2024-08-30","2019-11-05",201,[2151],"Nonsquamous Non-small Cell Lung Cancer",[47,386,390,385,461],{"nctId":2154,"briefTitle":2155,"status":105,"phases":2156,"primaryCompletion":2157,"completion":1966,"start":2158,"enrollment":2159,"conditions":2160,"interventions":2162},"NCT01905657","Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010\u002FKEYNOTE-010)",[88,89],"2015-09-30","2013-08-09",1034,[2161],"Non Small Cell Lung Cancer (NSCLC)",[47,967],{"nctId":2164,"briefTitle":2165,"status":139,"phases":2166,"primaryCompletion":2167,"completion":2168,"start":2169,"enrollment":2170,"conditions":2171,"interventions":2174},"NCT05116189","Pembrolizumab\u002FPlacebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96\u002FKEYNOTE-B96\u002FENGOT-ov65).",[89],"2025-03-05","2027-07-16","2021-12-13",643,[990,2172,2173],"Carcinoma, Ovarian Epithelial","Fallopian Tube Neoplasms",[47,387,841,967],{"nctId":2176,"briefTitle":2177,"status":139,"phases":2178,"primaryCompletion":2179,"completion":2180,"start":2181,"enrollment":2182,"conditions":2183,"interventions":2185},"NCT04380636","Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012\u002FKEYLYNK-012)",[89],"2027-05-05","2029-07-06","2020-07-06",870,[2184,369],"Lung Neoplasms",[47,1114,1073,386,390,387,385,2186],"Durvalumab",{"nctId":2188,"briefTitle":2189,"status":105,"phases":2190,"primaryCompletion":2191,"completion":2192,"start":2193,"enrollment":2194,"conditions":2195,"interventions":2196},"NCT02504372","Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091\u002FKEYNOTE-091)",[89],"2023-01-24","2026-01-21","2015-11-06",1177,[314],[47],{"nctId":2198,"briefTitle":2199,"status":128,"phases":2200,"primaryCompletion":2201,"completion":2202,"start":2203,"enrollment":2204,"conditions":2205,"interventions":2206},"NCT06312176","A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+\u002FHER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)",[89],"2027-07-11","2031-04-12","2024-04-14",1200,[1108],[653,47,387,388,795,2207],"Liposomal doxorubicin",{"nctId":2209,"briefTitle":2210,"status":105,"phases":2211,"primaryCompletion":2212,"completion":2083,"start":2213,"enrollment":2214,"conditions":2215,"interventions":2216},"NCT02564263","Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal\u002F Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181\u002FKEYNOTE-181)",[89],"2018-10-15","2015-12-01",628,[1603,1604],[42,1654,1677,2088],{"nctId":2218,"briefTitle":2219,"status":105,"phases":2220,"primaryCompletion":1539,"completion":2221,"start":2222,"enrollment":2223,"conditions":2224,"interventions":2225},"NCT04003636","Pembrolizumab (MK-3475) Plus Gemcitabine\u002FCisplatin Versus Placebo Plus Gemcitabine\u002FCisplatin for First-Line Advanced and\u002For Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966\u002FKEYNOTE-966)",[89],"2025-04-01","2019-09-24",1069,[1829],[47,714,390],{"nctId":2227,"briefTitle":2228,"status":105,"phases":2229,"primaryCompletion":1867,"completion":1868,"start":2230,"enrollment":2231,"conditions":2232,"interventions":2233},"NCT04889118","Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902\u002FE7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003\u002FE7080-G000-312\u002FLEAP-003)-China Extension Study",[89],"2020-07-14",131,[883],[47,461],{"nctId":2235,"briefTitle":2236,"status":105,"phases":2237,"primaryCompletion":2146,"completion":2238,"start":366,"enrollment":2239,"conditions":2240,"interventions":2241},"NCT03976375","Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080\u002FMK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008\u002FE7080-G000-316\u002FLEAP-008)",[89],"2024-08-22",422,[1799],[47,461,967],{"nctId":2243,"briefTitle":2244,"status":139,"phases":2245,"primaryCompletion":2246,"completion":2247,"start":2248,"enrollment":2249,"conditions":2250,"interventions":2251},"NCT05239728","A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)",[89],"2026-10-28","2029-09-28","2022-03-15",1800,[1035],[56,47],{"nctId":2253,"briefTitle":2254,"status":150,"phases":2255,"primaryCompletion":2256,"completion":2256,"start":2257,"enrollment":212,"conditions":2258,"interventions":2260},"NCT06295809","A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)",[88,89],"2026-03-05","2024-04-18",[1901,2259],"Skin Neoplasms",[47,885],{"nctId":2262,"briefTitle":2263,"status":105,"phases":2264,"primaryCompletion":2265,"completion":2266,"start":2267,"enrollment":2268,"conditions":2269,"interventions":2270},"NCT03898180","Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902\u002FE7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011\u002FE7080-G000-317\u002F LEAP-011)",[89],"2021-07-26","2024-05-20","2019-05-06",505,[1056],[47,461],{"nctId":2272,"briefTitle":2273,"status":105,"phases":2274,"primaryCompletion":2275,"completion":2276,"start":2277,"enrollment":2278,"conditions":2279,"interventions":2280},"NCT01866319","Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006\u002FKEYNOTE-006)",[89],"2015-03-03","2019-06-03","2013-08-28",834,[35],[47,1100],{"nctId":2282,"briefTitle":2283,"status":105,"phases":2284,"primaryCompletion":2285,"completion":2286,"start":2287,"enrollment":2288,"conditions":2289,"interventions":2290},"NCT05523323","A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080\u002FMK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R\u002FM HNSCC) (MK-7902-010\u002FLEAP-010)-China Extension",[89],"2023-08-25","2025-03-28","2020-10-30",112,[1514],[461,47],{"nctId":2292,"briefTitle":2293,"status":105,"phases":2294,"primaryCompletion":2116,"completion":2295,"start":2296,"enrollment":132,"conditions":2297,"interventions":2298},"NCT04865289","Pembrolizumab (MK-3475) Plus Lenvatinib (E7080\u002FMK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 \u002F MK-7902-001) - China Extension Study",[89],"2025-01-14","2019-10-22",[1285],[461,47,387,386],{"nctId":2300,"briefTitle":2301,"status":139,"phases":2302,"primaryCompletion":2303,"completion":2304,"start":2305,"enrollment":1685,"conditions":2306,"interventions":2307},"NCT05609968","Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)",[89],"2027-01-12","2028-08-23","2023-02-06",[369],[2308,47],"Sacituzumab Govitecan",{"nctId":2310,"briefTitle":2311,"status":105,"phases":2312,"primaryCompletion":2313,"completion":466,"start":183,"enrollment":2314,"conditions":2315,"interventions":2316},"NCT05665595","A Study of Adjuvant Pembrolizumab\u002FVibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010\u002FKEYVIBE-010)",[89],"2024-03-06",1594,[35],[1241,47],{"nctId":2318,"briefTitle":2319,"status":139,"phases":2320,"primaryCompletion":2321,"completion":2322,"start":2323,"enrollment":2324,"conditions":2325,"interventions":2327},"NCT04949256","Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080\u002FMK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014\u002FE7080-G000-320\u002FLEAP-014)",[89],"2025-05-08","2026-06-12","2021-07-28",864,[2326],"Metastatic Esophageal Squamous Cell Carcinoma",[47,461,390,1444,434,435,796,387],{"nctId":2329,"briefTitle":2330,"status":105,"phases":2331,"primaryCompletion":2332,"completion":2333,"start":2334,"enrollment":2335,"conditions":2336,"interventions":2337},"NCT03062358","Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394\u002FKEYNOTE-394)",[89],"2021-06-30","2024-10-15","2017-04-27",453,[1727],[42],{"nctId":2339,"briefTitle":2340,"status":105,"phases":2341,"primaryCompletion":2022,"completion":730,"start":2342,"enrollment":2343,"conditions":2344,"interventions":2345},"NCT03221426","Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585\u002FKEYNOTE-585)",[89],"2017-10-09",1007,[991,2025],[47,390,795,606,967,434,435],{"nctId":2347,"briefTitle":2348,"status":105,"phases":2349,"primaryCompletion":1736,"completion":1520,"start":2350,"enrollment":2351,"conditions":2352,"interventions":2353},"NCT03924856","Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866\u002FKEYNOTE-866)",[89],"2019-06-13",907,[1134],[47,714,390],{"nctId":2355,"briefTitle":2356,"status":105,"phases":2357,"primaryCompletion":2358,"completion":379,"start":2359,"enrollment":2335,"conditions":2360,"interventions":2361},"NCT03066778","A Study of Pembrolizumab (MK-3475) in Combination With Etoposide\u002FPlatinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604\u002FKEYNOTE-604)",[89],"2019-12-02","2017-05-02",[867],[47,2362,386,390,1073],"Normal saline solution",{"nctId":2364,"briefTitle":2365,"status":105,"phases":2366,"primaryCompletion":2005,"completion":73,"start":2367,"enrollment":2368,"conditions":2369,"interventions":2370},"NCT03635567","Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826\u002FKEYNOTE-826)",[89],"2018-10-25",617,[863],[47,387,390,386,841],{"nctId":2372,"briefTitle":2373,"status":105,"phases":2374,"primaryCompletion":2375,"completion":2376,"start":2377,"enrollment":2378,"conditions":2379,"interventions":2381},"NCT04191096","Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991\u002FKEYNOTE-991)",[89],"2022-10-31","2026-04-08","2020-02-12",1251,[2380],"Metastatic Hormone-Sensitive Prostate Cancer",[47,2382,2383],"Enzalutamide","Androgen Deprivation Therapy",{"nctId":2385,"briefTitle":2386,"status":105,"phases":2387,"primaryCompletion":2388,"completion":2389,"start":1702,"enrollment":2390,"conditions":2391,"interventions":2393},"NCT03976362","A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008\u002FKEYLYNK-008)",[89],"2023-09-21","2026-01-30",851,[2392],"Carcinoma, Squamous Cell, Non-small-cell Lung",[47,386,387,388,1114],{"nctId":2395,"briefTitle":2396,"status":139,"phases":2397,"primaryCompletion":2398,"completion":2398,"start":1228,"enrollment":2399,"conditions":2400,"interventions":2401},"NCT05899049","A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab\u002FQuavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study",[89],"2027-06-07",249,[1035],[47,56,818,461],{"nctId":2403,"briefTitle":2404,"status":105,"phases":2405,"primaryCompletion":2083,"completion":2406,"start":2407,"enrollment":2408,"conditions":2409,"interventions":2411},"NCT03834519","Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010\u002FKEYLYNK-010)",[89],"2024-01-27","2019-05-02",793,[2410],"Prostatic Neoplasms",[47,1114,2412,1076,2382,2413],"Abiraterone acetate","Prednisolone",{"nctId":2415,"briefTitle":2416,"status":139,"phases":2417,"primaryCompletion":505,"completion":2418,"start":2419,"enrollment":2420,"conditions":2421,"interventions":2423},"NCT03711032","Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676\u002FKEYNOTE-676)",[89],"2034-11-20","2018-12-24",1397,[2422],"High-risk Non-muscle Invasive Bladder Cancer",[47,2424],"BCG",{"nctId":2426,"briefTitle":2427,"status":128,"phases":2428,"primaryCompletion":2429,"completion":2429,"start":2430,"enrollment":2431,"conditions":2432,"interventions":2433},"NCT06952504","A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033\u002FTroFuse-033\u002FGOG-3119\u002FENGOT-en29)",[89],"2032-05-24","2025-05-22",1123,[861],[47,386,387,967,794],{"nctId":2435,"briefTitle":2436,"status":128,"phases":2437,"primaryCompletion":2438,"completion":2439,"start":2440,"enrollment":2441,"conditions":2442,"interventions":2444},"NCT06966700","A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)",[89],"2033-03-23","2034-12-29","2025-06-30",2400,[1108,540,2443],"HR Low-Positive\u002FHER2-Negative Breast Neoplasms",[653,47,842,386,387,1069,1664,562,795,1114],{"nctId":2446,"briefTitle":2447,"status":105,"phases":2448,"primaryCompletion":2449,"completion":929,"start":2450,"enrollment":2451,"conditions":2452,"interventions":2454},"NCT02611960","Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent\u002FMetastatic Nasopharyngeal Cancer (MK-3475-122\u002FKEYNOTE-122)",[89],"2020-11-30","2016-04-18",233,[2453],"Nasopharyngeal Neoplasms",[47,795,714,967],{"nctId":2456,"briefTitle":2457,"status":139,"phases":2458,"primaryCompletion":2459,"completion":2459,"start":2460,"enrollment":2461,"conditions":2462,"interventions":2463},"NCT05173987","Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93\u002FKEYNOTE-C93\u002FGOG-3064\u002FENGOT-en15)",[89],"2027-05-27","2022-02-03",280,[1285],[42,484,1654,1677,486],{"nctId":2465,"briefTitle":2466,"status":139,"phases":2467,"primaryCompletion":2468,"completion":2468,"start":2469,"enrollment":2470,"conditions":2471,"interventions":2472},"NCT04736706","A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab\u002FQuavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)",[89],"2026-10-29","2021-04-14",1653,[1035],[47,56,818,461],{"nctId":2474,"briefTitle":2475,"status":105,"phases":2476,"primaryCompletion":2477,"completion":2478,"start":2479,"enrollment":2480,"conditions":2481,"interventions":2483},"NCT03040999","Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412\u002FKEYNOTE-412)",[89],"2022-05-31","2024-08-21","2017-04-05",804,[2482],"Head and Neck Neoplasms",[47,390],{"nctId":44,"briefTitle":45,"status":139,"phases":2485,"primaryCompletion":46,"completion":2486,"start":2487,"enrollment":2488,"conditions":2489,"interventions":2490},[89],"2033-10-12","2018-09-12",976,[35],[47],{"nctId":2492,"briefTitle":2493,"status":139,"phases":2494,"primaryCompletion":2495,"completion":2495,"start":2496,"enrollment":2497,"conditions":2498,"interventions":2499},"NCT04634877","Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 \u002F KEYNOTE-B21 \u002F ENGOT-en11 \u002F GOG-3053)",[89],"2026-09-15","2021-01-10",990,[1285],[47,386,387,967,390,390],{"nctId":2501,"briefTitle":2502,"status":105,"phases":2503,"primaryCompletion":2116,"completion":2504,"start":1877,"enrollment":2505,"conditions":2506,"interventions":2507},"NCT03884101","Pembrolizumab (MK-3475) Plus Lenvatinib (E7080\u002FMK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 \u002F MK-7902-001)",[89],"2025-02-05",842,[1285],[461,47,387,386],{"nctId":2509,"briefTitle":2510,"status":105,"phases":2511,"primaryCompletion":2043,"completion":1807,"start":940,"enrollment":2512,"conditions":2513,"interventions":2516},"NCT02358031","A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048\u002FKEYNOTE-048)",[89],882,[2514,2515],"Recurrent Head and Neck Cancer","Metastatic Head and Neck Cancer",[47,390,386,1444,693],{"nctId":2518,"briefTitle":2519,"status":128,"phases":2520,"primaryCompletion":2521,"completion":2522,"start":2523,"enrollment":2390,"conditions":2524,"interventions":2526},"NCT06422143","Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]",[89],"2029-01-12","2031-02-12","2024-06-10",[314,2525],"NSCLC",[47,2527,386,387,388],"sac-TMT",{"nctId":2529,"briefTitle":2530,"status":105,"phases":2531,"primaryCompletion":2532,"completion":2533,"start":2534,"enrollment":2535,"conditions":2536,"interventions":2538},"NCT04738487","Coformulation of Pembrolizumab\u002FVibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)",[89],"2024-09-05","2026-01-27","2021-04-07",1264,[2184,2537],"Non-Small-Cell Lung Carcinoma",[1241,47],{"nctId":2540,"briefTitle":2541,"status":105,"phases":2542,"primaryCompletion":2375,"completion":2543,"start":2544,"enrollment":2545,"conditions":2546,"interventions":2547},"NCT04934722","Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991\u002FKEYNOTE-991)-China Extension",[89],"2025-09-10","2021-05-25",186,[2380],[47,2382,2383],{"nctId":2549,"briefTitle":2550,"status":105,"phases":2551,"primaryCompletion":2552,"completion":2553,"start":2554,"enrollment":2555,"conditions":2556,"interventions":2557},"NCT03850444","Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042\u002FKEYNOTE-042)-China Extension Study",[89],"2018-09-04","2022-09-08","2016-08-01",262,[314],[42,484,1654,483],{"nctId":2559,"briefTitle":2560,"status":105,"phases":2561,"primaryCompletion":2552,"completion":2562,"start":2563,"enrollment":2564,"conditions":2565,"interventions":2566},"NCT02220894","Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042\u002FKEYNOTE-042)",[89],"2022-09-12","2014-10-30",1274,[314],[42,484,1654,483],{"nctId":2568,"briefTitle":2569,"status":105,"phases":2570,"primaryCompletion":2571,"completion":2572,"start":2573,"enrollment":2574,"conditions":2575,"interventions":2577},"NCT02142738","Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024\u002FKEYNOTE-024)",[89],"2016-05-09","2021-05-27","2014-08-25",305,[2576],"Non-Small Cell Lung Carcinoma",[47,387,386,385,390,714],{"nctId":2579,"briefTitle":2580,"status":105,"phases":2581,"primaryCompletion":2582,"completion":2583,"start":2584,"enrollment":2585,"conditions":2586,"interventions":2587},"NCT04199104","A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080\u002FMK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R\u002FM HNSCC) (MK-7902-010) (KEYNOTE-010)",[89],"2023-05-30","2025-03-31","2020-02-05",511,[1514],[461,47],{"nctId":2589,"briefTitle":2590,"status":150,"phases":2591,"primaryCompletion":2031,"completion":2592,"start":2033,"enrollment":2593,"conditions":2594,"interventions":2595},"NCT02576977","Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183\u002FKEYNOTE-183)",[89],"2020-07-16",251,[526],[47,2596,529],"Pomalidomide",{"nctId":2598,"briefTitle":2599,"status":128,"phases":2600,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":2603,"conditions":2604,"interventions":2606},"NCT03486873","Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587\u002FKEYNOTE-587)",[89],"2043-08-04","2018-08-21",3500,[176,2605],"Hematologic Malignancies",[47,2607,461,1114,2608,2609,384],"Standard of Care","MK-4280","MK-4280A",{"nctId":2611,"briefTitle":2612,"status":139,"phases":2613,"primaryCompletion":2614,"completion":2614,"start":2615,"enrollment":920,"conditions":2616,"interventions":2617},"NCT05239741","Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)",[89],"2028-09-19","2022-04-02",[371],[47,434,435,606,437,841,693],{"nctId":2619,"briefTitle":2620,"status":139,"phases":2621,"primaryCompletion":2622,"completion":2623,"start":2624,"enrollment":2625,"conditions":2626,"interventions":2627},"NCT04241185","Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992\u002FKEYNOTE-992)",[89],"2027-01-31","2031-11-01","2020-05-19",520,[1287],[47,390,1087,2628,714],"Mitomycin C",{"nctId":2630,"briefTitle":2631,"status":139,"phases":2632,"primaryCompletion":2192,"completion":2633,"start":2634,"enrollment":2635,"conditions":2636,"interventions":2639},"NCT04210115","Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975\u002FKEYNOTE-975)",[89],"2026-06-26","2020-02-28",703,[1230,2637,2638],"Gastroesophageal Junction Carcinoma (GEJC)","Esophageal Adenocarcinoma (EAC)",[42,486,1444,605,2640,604],"levoleucovorin",{"nctId":2642,"briefTitle":2643,"status":139,"phases":2644,"primaryCompletion":1589,"completion":2645,"start":2646,"enrollment":2647,"conditions":2648,"interventions":2650},"NCT06698042","A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)",[89],"2030-02-11","2024-11-21",67,[2649,903],"Lung Cancer",[384,47],{"nctId":2652,"briefTitle":2653,"status":105,"phases":2654,"primaryCompletion":2655,"completion":427,"start":2407,"enrollment":2656,"conditions":2657,"interventions":2658},"NCT03834506","Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921\u002FKEYNOTE-921)",[89],"2022-06-20",1030,[2410],[47,967,1076,529],{"nctId":2660,"briefTitle":2661,"status":105,"phases":2662,"primaryCompletion":2146,"completion":2147,"start":2663,"enrollment":2664,"conditions":2665,"interventions":2666},"NCT03829319","Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902\u002FE7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006\u002FE7080-G000-315\u002FLEAP-006)",[89],"2019-03-25",761,[2151],[47,386,390,385,461],{"nctId":2668,"briefTitle":2669,"status":139,"phases":2670,"primaryCompletion":2671,"completion":2672,"start":2673,"enrollment":2674,"conditions":2675,"interventions":2677},"NCT03924895","Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905\u002FKEYNOTE-905\u002FEV-303)",[89],"2025-06-06","2027-12-15","2019-07-24",595,[2676],"Urinary Bladder Cancer, Muscle-invasive",[47,1136],{"nctId":2679,"briefTitle":2680,"status":105,"phases":2681,"primaryCompletion":2682,"completion":2683,"start":2684,"enrollment":2685,"conditions":2686,"interventions":2687},"NCT03302234","Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598\u002FKEYNOTE-598)",[89],"2020-09-01","2022-09-07","2017-12-14",568,[369],[47,1100],{"nctId":2689,"briefTitle":2690,"status":105,"phases":2691,"primaryCompletion":2692,"completion":2693,"start":2694,"enrollment":2695,"conditions":2696,"interventions":2697},"NCT02702401","Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240\u002FKEYNOTE-240)",[89],"2019-01-02","2021-09-22","2016-05-26",413,[1014],[47],{"nctId":2699,"briefTitle":2700,"status":105,"phases":2701,"primaryCompletion":1167,"completion":2702,"start":2703,"enrollment":2704,"conditions":2705,"interventions":2706},"NCT03829332","Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902\u002FE7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007\u002FE7080-G000-314\u002FLEAP-007)",[89],"2024-04-24","2019-03-13",623,[314],[47,461],{"nctId":2708,"briefTitle":2709,"status":105,"phases":2710,"primaryCompletion":2711,"completion":1794,"start":2712,"enrollment":2713,"conditions":2714,"interventions":2715},"NCT03713593","Safety and Efficacy of Lenvatinib (E7080\u002FMK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002\u002FE7080-G000-311\u002FLEAP-002)",[89],"2022-06-21","2018-12-31",794,[1727],[1369,42,2716],"saline placebo",{"nctId":2718,"briefTitle":2719,"status":105,"phases":2720,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":2512,"conditions":2724,"interventions":2726},"NCT02819518","Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355\u002FKEYNOTE-355)",[89],"2021-06-15","2023-10-30","2016-07-27",[2725],"Triple Negative Breast Cancer (TNBC)",[47,388,387,714,386,2727],"Normale Saline Solution",{"nctId":2729,"briefTitle":2730,"status":128,"phases":2731,"primaryCompletion":2732,"completion":2733,"start":2734,"enrollment":2735,"conditions":2736,"interventions":2738},"NCT06312137","A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)",[89],"2034-02-21","2034-10-23","2024-04-03",780,[2737],"Non Small Cell Lung Cancer",[653,47,390,385,714,386,387,1089],{"nctId":2740,"briefTitle":2741,"status":128,"phases":2742,"primaryCompletion":2743,"completion":2743,"start":2744,"enrollment":2745,"conditions":2746,"interventions":2747},"NCT07216703","A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036\u002FTroFuse-036\u002FGOG-3123\u002FENGOT-cx22)",[89],"2031-10-29","2026-01-19",1023,[863],[47,794,841,387,390,386,327],{"nctId":2749,"briefTitle":2750,"status":139,"phases":2751,"primaryCompletion":2752,"completion":2070,"start":2753,"enrollment":2754,"conditions":2755,"interventions":2756},"NCT06212752","A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension",[89],"2024-11-06","2023-06-13",39,[2074],[384,385,390,386,387,388,47,2076,2077],{"nctId":49,"briefTitle":50,"status":139,"phases":2758,"primaryCompletion":51,"completion":2759,"start":2760,"enrollment":2761,"conditions":2762,"interventions":2763},[89],"2026-05-29","2019-07-28",1244,[2410],[47,2382],{"nctId":2765,"briefTitle":2766,"status":150,"phases":2767,"primaryCompletion":2768,"completion":427,"start":2769,"enrollment":2770,"conditions":2771,"interventions":2772},"NCT04907227","Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921\u002FKEYNOTE-921)-China Extension",[89],"2022-08-03","2020-09-23",81,[2410],[47,967,1076,529],{"trials":2774,"activeCount":99},[2775,2782],{"nctId":2776,"briefTitle":2777,"status":105,"phases":2778,"primaryCompletion":2478,"completion":2478,"start":1385,"enrollment":2779,"conditions":2780,"interventions":2781},"NCT03715205","Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593\u002FKEYNOTE-593)",[90],150,[369,35],[47],{"nctId":2783,"briefTitle":2784,"status":105,"phases":2785,"primaryCompletion":2786,"completion":1897,"start":2787,"enrollment":2788,"conditions":2789,"interventions":2790},"NCT04489888","A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10\u002FKEYNOTE B10)",[90],"2023-02-20","2020-10-27",101,[965],[47,386,387],{"trials":2792,"activeCount":99},[2793],{"nctId":2794,"briefTitle":2795,"status":2796,"phases":2797,"conditions":2798,"interventions":2799},"NCT02083484","Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)","NO_LONGER_AVAILABLE",[],[35],[47],{"intervention":387,"totalTrials":2801,"cells":2802},65,{"EARLY_PHASE1":2803,"PHASE1":2805,"PHASE2":2836,"PHASE3":2927,"PHASE4":3142,"NA":3148},{"trials":2804,"activeCount":99},[],{"trials":2806,"activeCount":224,"soonestReadout":378},[2807,2820,2824,2828,2832],{"nctId":2808,"briefTitle":2809,"status":105,"phases":2810,"primaryCompletion":2811,"completion":2812,"start":2813,"enrollment":22,"conditions":2814,"interventions":2816},"NCT00848718","A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)",[87],"2011-05-19","2012-05-17","2009-03-17",[2815],"Locally Advanced, Metastatic Solid Tumors",[2817,1677,2818,484,1654,2819],"MK-2206","erlotinib","corticosteroid",{"nctId":375,"briefTitle":376,"status":139,"phases":2821,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":2822,"interventions":2823},[87],[382],[384,47,385,386,387,388,389,390],{"nctId":463,"briefTitle":464,"status":105,"phases":2825,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":2826,"interventions":2827},[87],[290],[471,47,386,385,461,387,390,472],{"nctId":552,"briefTitle":553,"status":105,"phases":2829,"primaryCompletion":555,"completion":556,"start":557,"enrollment":558,"conditions":2830,"interventions":2831},[87],[540],[47,388,561,562,386,387],{"nctId":705,"briefTitle":706,"status":105,"phases":2833,"primaryCompletion":708,"completion":708,"start":709,"enrollment":710,"conditions":2834,"interventions":2835},[87],[290],[713,42,387,388,714,386,385],{"trials":2837,"activeCount":734,"soonestReadout":1318},[2838,2842,2846,2850,2854,2858,2862,2866,2877,2881,2885,2895,2907,2911,2915,2919,2923],{"nctId":759,"briefTitle":760,"status":128,"phases":2839,"primaryCompletion":762,"completion":763,"start":764,"enrollment":765,"conditions":2840,"interventions":2841},[88],[767],[769,47,386,387,388],{"nctId":831,"briefTitle":832,"status":128,"phases":2843,"primaryCompletion":834,"completion":834,"start":835,"enrollment":836,"conditions":2844,"interventions":2845},[87,88],[838],[840,386,387,841,842,47,714,843],{"nctId":947,"briefTitle":948,"status":128,"phases":2847,"primaryCompletion":950,"completion":950,"start":891,"enrollment":951,"conditions":2848,"interventions":2849},[87,88],[369],[47,386,387,385,923,542,471,713,954,955],{"nctId":957,"briefTitle":958,"status":105,"phases":2851,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":2852,"interventions":2853},[88],[965],[461,47,967,795,387,693,461],{"nctId":969,"briefTitle":970,"status":128,"phases":2855,"primaryCompletion":972,"completion":972,"start":973,"enrollment":558,"conditions":2856,"interventions":2857},[88],[975],[47,390,714,385,653,977,978,979,529,386,47,387,980],{"nctId":1102,"briefTitle":1103,"status":128,"phases":2859,"primaryCompletion":804,"completion":1105,"start":973,"enrollment":1106,"conditions":2860,"interventions":2861},[88],[1108,1109],[1111,47,387,386,1112,1113,562,795,1114],{"nctId":1224,"briefTitle":1225,"status":105,"phases":2863,"primaryCompletion":1227,"completion":1227,"start":1228,"enrollment":397,"conditions":2864,"interventions":2865},[87,88],[1230],[47,1232,471,461,437,387],{"nctId":2867,"briefTitle":2868,"status":128,"phases":2869,"primaryCompletion":2870,"completion":2871,"start":2872,"enrollment":2873,"conditions":2874,"interventions":2875},"NCT06445972","Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D\u002FKeymaker-U06)",[87,88],"2028-05-09","2030-08-08","2024-08-07",210,[789,790,791,792],[2876,387,794,327,955],"Ramucirumab",{"nctId":1243,"briefTitle":1244,"status":105,"phases":2878,"primaryCompletion":1246,"completion":1247,"start":1248,"enrollment":1249,"conditions":2879,"interventions":2880},[87,88],[1251],[47,387,386,841,385,1100,1253,1254],{"nctId":1277,"briefTitle":1278,"status":105,"phases":2882,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":1282,"conditions":2883,"interventions":2884},[88],[1284,1285,965,1286,856,791,540,1014,1287,1288,1289],[74,47,461,797,390,387,714,386,967,841,795,434],{"nctId":2886,"briefTitle":2887,"status":105,"phases":2888,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":2891,"conditions":2892,"interventions":2893},"NCT01357161","A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)",[88],"2016-08-08","2011-07-26",136,[990],[2894,1654,484],"adavosertib",{"nctId":2896,"briefTitle":2897,"status":150,"phases":2898,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":2901,"conditions":2902,"interventions":2903},"NCT00954512","Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)",[87,88],"2011-06-07","2009-09-25",15,[290],[386,1664,1843,2904,714,2905,693,387,390,1444,1253,437,2906],"Everolimus","Robatumumab","Folinic Acid",{"nctId":1315,"briefTitle":1316,"status":128,"phases":2908,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1132,"conditions":2909,"interventions":2910},[87,88],[1263],[387,437,47,471,461,653,1323,1324,979,529,1325,654],{"nctId":1327,"briefTitle":1328,"status":128,"phases":2912,"primaryCompletion":1330,"completion":1330,"start":1331,"enrollment":397,"conditions":2913,"interventions":2914},[88],[314],[47,386,387,388,385,955],{"nctId":1381,"briefTitle":1382,"status":105,"phases":2916,"primaryCompletion":1384,"completion":1385,"start":1386,"enrollment":1387,"conditions":2917,"interventions":2918},[88],[883],[47,386,387,1071,1390],{"nctId":1392,"briefTitle":1393,"status":1040,"phases":2920,"primaryCompletion":1395,"completion":1396,"start":1397,"enrollment":99,"conditions":2921,"interventions":2922},[88],[1399],[47,387,386,1069,542,1401,562,795,1114],{"nctId":1494,"briefTitle":1495,"status":105,"phases":2924,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":787,"conditions":2925,"interventions":2926},[88],[1501,1502],[47,387,386,1504,471,967],{"trials":2928,"activeCount":3141,"soonestReadout":60},[2929,2933,2942,2946,2950,2954,2958,2962,2966,2970,2980,2984,2988,2992,2996,3000,3004,3017,3021,3025,3029,3038,3042,3053,3057,3061,3065,3069,3080,3084,3088,3097,3101,3105,3109,3113,3117,3121,3125,3129,3133,3137],{"nctId":1628,"briefTitle":1629,"status":128,"phases":2930,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":2931,"interventions":2932},[89],[540],[653,47,842,387,388,714,386],{"nctId":2934,"briefTitle":2935,"status":128,"phases":2936,"primaryCompletion":2937,"completion":2937,"start":2938,"enrollment":1633,"conditions":2939,"interventions":2940},"NCT07060807","A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)",[89],"2033-07-14","2025-07-21",[1108],[1111,387,388,795,2207,2941],"Trastuzumab deruxtecan",{"nctId":1647,"briefTitle":1648,"status":105,"phases":2943,"primaryCompletion":1408,"completion":1043,"start":1650,"enrollment":1651,"conditions":2944,"interventions":2945},[89],[1441,1442],[42,1654],{"nctId":1656,"briefTitle":1657,"status":105,"phases":2947,"primaryCompletion":1659,"completion":1659,"start":1660,"enrollment":1661,"conditions":2948,"interventions":2949},[89],[540],[47,386,387,1069,1664,562,1665],{"nctId":1667,"briefTitle":1668,"status":105,"phases":2951,"primaryCompletion":1670,"completion":1671,"start":1672,"enrollment":1673,"conditions":2952,"interventions":2953},[89],[1563],[42,1654,1676,1677],{"nctId":1791,"briefTitle":1792,"status":105,"phases":2955,"primaryCompletion":1794,"completion":1795,"start":1796,"enrollment":1797,"conditions":2956,"interventions":2957},[89],[1799],[1241,386,390,387,388,385,47],{"nctId":1853,"briefTitle":1854,"status":139,"phases":2959,"primaryCompletion":1856,"completion":1856,"start":1510,"enrollment":1452,"conditions":2960,"interventions":2961},[89],[1108],[42,1654,1859,1860,1445,1861,1862],{"nctId":1923,"briefTitle":1924,"status":105,"phases":2963,"primaryCompletion":1926,"completion":1927,"start":589,"enrollment":1928,"conditions":2964,"interventions":2965},[89],[990,1930,1931],[47,386,387,1114,841,967],{"nctId":1942,"briefTitle":1943,"status":105,"phases":2967,"primaryCompletion":1945,"completion":1946,"start":1947,"enrollment":1948,"conditions":2968,"interventions":2969},[89],[314],[47,387,388,386,1951],{"nctId":2971,"briefTitle":2972,"status":139,"phases":2973,"primaryCompletion":2974,"completion":2974,"start":2975,"enrollment":987,"conditions":2976,"interventions":2977},"NCT05298423","Study of Pembrolizumab\u002FVibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab\u002FVibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)",[89],"2026-08-19","2022-05-03",[369],[2978,2979,486,483,487,484,1654],"pembrolizumab\u002Fvibostolimab","durvalumab",{"nctId":1963,"briefTitle":1964,"status":105,"phases":2981,"primaryCompletion":1966,"completion":1946,"start":1967,"enrollment":1968,"conditions":2982,"interventions":2983},[89],[314],[47,387,386,1951],{"nctId":1972,"briefTitle":1973,"status":150,"phases":2985,"primaryCompletion":1975,"completion":1975,"start":1976,"enrollment":1977,"conditions":2986,"interventions":2987},[89],[1840,1442],[47,387],{"nctId":76,"briefTitle":77,"status":139,"phases":2989,"primaryCompletion":78,"completion":2070,"start":2071,"enrollment":2072,"conditions":2990,"interventions":2991},[89],[2074],[79,385,390,386,387,388,47,2076,2077],{"nctId":2079,"briefTitle":2080,"status":105,"phases":2993,"primaryCompletion":2082,"completion":2083,"start":2084,"enrollment":2085,"conditions":2994,"interventions":2995},[89],[1603,1604],[42,1654,1677,2088],{"nctId":2102,"briefTitle":2103,"status":128,"phases":2997,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":2108,"conditions":2998,"interventions":2999},[89],[369],[47,390,386,385,714,387,885],{"nctId":2133,"briefTitle":2134,"status":139,"phases":3001,"primaryCompletion":2136,"completion":2136,"start":2137,"enrollment":2138,"conditions":3002,"interventions":3003},[89],[1109],[47,387,1069,1664,562,2141],{"nctId":3005,"briefTitle":3006,"status":128,"phases":3007,"primaryCompletion":3008,"completion":3009,"start":3010,"enrollment":3011,"conditions":3012,"interventions":3013},"NCT07419295","A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)",[89],"2029-07-27","2030-04-23","2026-04-23",590,[1134],[653,3014,967,387,3015,3016],"Vinflunine","Rescue medications for sacituzumab tirumotecan","Rescue medications for chemotherapy",{"nctId":2164,"briefTitle":2165,"status":139,"phases":3018,"primaryCompletion":2167,"completion":2168,"start":2169,"enrollment":2170,"conditions":3019,"interventions":3020},[89],[990,2172,2173],[47,387,841,967],{"nctId":2176,"briefTitle":2177,"status":139,"phases":3022,"primaryCompletion":2179,"completion":2180,"start":2181,"enrollment":2182,"conditions":3023,"interventions":3024},[89],[2184,369],[47,1114,1073,386,390,387,385,2186],{"nctId":2198,"briefTitle":2199,"status":128,"phases":3026,"primaryCompletion":2201,"completion":2202,"start":2203,"enrollment":2204,"conditions":3027,"interventions":3028},[89],[1108],[653,47,387,388,795,2207],{"nctId":3030,"briefTitle":3031,"status":139,"phases":3032,"primaryCompletion":3033,"completion":3033,"start":1958,"enrollment":3034,"conditions":3035,"interventions":3036},"NCT06132958","Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)",[89],"2028-01-10",710,[861],[653,1069,387,388,3037],"Rescue medications",{"nctId":2209,"briefTitle":2210,"status":105,"phases":3039,"primaryCompletion":2212,"completion":2083,"start":2213,"enrollment":2214,"conditions":3040,"interventions":3041},[89],[1603,1604],[42,1654,1677,2088],{"nctId":3043,"briefTitle":3044,"status":150,"phases":3045,"primaryCompletion":3046,"completion":3046,"start":3047,"enrollment":3048,"conditions":3049,"interventions":3051},"NCT00003880","Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer",[88,89],"2001-08","1999-02",132,[990,3050],"Primary Peritoneal Cavity Cancer",[3052,484,1654],"recombinant adenovirus-p53 SCH-58500",{"nctId":2292,"briefTitle":2293,"status":105,"phases":3054,"primaryCompletion":2116,"completion":2295,"start":2296,"enrollment":132,"conditions":3055,"interventions":3056},[89],[1285],[461,47,387,386],{"nctId":2318,"briefTitle":2319,"status":139,"phases":3058,"primaryCompletion":2321,"completion":2322,"start":2323,"enrollment":2324,"conditions":3059,"interventions":3060},[89],[2326],[47,461,390,1444,434,435,796,387],{"nctId":2364,"briefTitle":2365,"status":105,"phases":3062,"primaryCompletion":2005,"completion":73,"start":2367,"enrollment":2368,"conditions":3063,"interventions":3064},[89],[863],[47,387,390,386,841],{"nctId":2385,"briefTitle":2386,"status":105,"phases":3066,"primaryCompletion":2388,"completion":2389,"start":1702,"enrollment":2390,"conditions":3067,"interventions":3068},[89],[2392],[47,386,387,388,1114],{"nctId":3070,"briefTitle":3071,"status":139,"phases":3072,"primaryCompletion":3073,"completion":3074,"start":3075,"enrollment":951,"conditions":3076,"interventions":3078},"NCT06356311","A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced\u002FMetastatic Gastroesophageal Adenocarcinoma (MK-2870-015)",[89],"2027-01-04","2027-05-06","2024-05-03",[3077],"Gastroesophageal Cancer",[653,3079,437,387,967,3037,654],"Trifluridine-Tipiracil",{"nctId":2426,"briefTitle":2427,"status":128,"phases":3081,"primaryCompletion":2429,"completion":2429,"start":2430,"enrollment":2431,"conditions":3082,"interventions":3083},[89],[861],[47,386,387,967,794],{"nctId":2435,"briefTitle":2436,"status":128,"phases":3085,"primaryCompletion":2438,"completion":2439,"start":2440,"enrollment":2441,"conditions":3086,"interventions":3087},[89],[1108,540,2443],[653,47,842,386,387,1069,1664,562,795,1114],{"nctId":58,"briefTitle":59,"status":139,"phases":3089,"primaryCompletion":60,"completion":3090,"start":3091,"enrollment":3092,"conditions":3093,"interventions":3094},[89],"2026-10-14","2021-08-05",531,[903],[61,3095,387,3096,386,390,385],"Pembrolizumab IV","Nab-Paclitaxel",{"nctId":2456,"briefTitle":2457,"status":139,"phases":3098,"primaryCompletion":2459,"completion":2459,"start":2460,"enrollment":2461,"conditions":3099,"interventions":3100},[89],[1285],[42,484,1654,1677,486],{"nctId":2492,"briefTitle":2493,"status":139,"phases":3102,"primaryCompletion":2495,"completion":2495,"start":2496,"enrollment":2497,"conditions":3103,"interventions":3104},[89],[1285],[47,386,387,967,390,390],{"nctId":2501,"briefTitle":2502,"status":105,"phases":3106,"primaryCompletion":2116,"completion":2504,"start":1877,"enrollment":2505,"conditions":3107,"interventions":3108},[89],[1285],[461,47,387,386],{"nctId":2518,"briefTitle":2519,"status":128,"phases":3110,"primaryCompletion":2521,"completion":2522,"start":2523,"enrollment":2390,"conditions":3111,"interventions":3112},[89],[314,2525],[47,2527,386,387,388],{"nctId":2549,"briefTitle":2550,"status":105,"phases":3114,"primaryCompletion":2552,"completion":2553,"start":2554,"enrollment":2555,"conditions":3115,"interventions":3116},[89],[314],[42,484,1654,483],{"nctId":2559,"briefTitle":2560,"status":105,"phases":3118,"primaryCompletion":2552,"completion":2562,"start":2563,"enrollment":2564,"conditions":3119,"interventions":3120},[89],[314],[42,484,1654,483],{"nctId":2568,"briefTitle":2569,"status":105,"phases":3122,"primaryCompletion":2571,"completion":2572,"start":2573,"enrollment":2574,"conditions":3123,"interventions":3124},[89],[2576],[47,387,386,385,390,714],{"nctId":2718,"briefTitle":2719,"status":105,"phases":3126,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":2512,"conditions":3127,"interventions":3128},[89],[2725],[47,388,387,714,386,2727],{"nctId":2729,"briefTitle":2730,"status":128,"phases":3130,"primaryCompletion":2732,"completion":2733,"start":2734,"enrollment":2735,"conditions":3131,"interventions":3132},[89],[2737],[653,47,390,385,714,386,387,1089],{"nctId":2740,"briefTitle":2741,"status":128,"phases":3134,"primaryCompletion":2743,"completion":2743,"start":2744,"enrollment":2745,"conditions":3135,"interventions":3136},[89],[863],[47,794,841,387,390,386,327],{"nctId":2749,"briefTitle":2750,"status":139,"phases":3138,"primaryCompletion":2752,"completion":2070,"start":2753,"enrollment":2754,"conditions":3139,"interventions":3140},[89],[2074],[384,385,390,386,387,388,47,2076,2077],23,{"trials":3143,"activeCount":99},[3144],{"nctId":2783,"briefTitle":2784,"status":105,"phases":3145,"primaryCompletion":2786,"completion":1897,"start":2787,"enrollment":2788,"conditions":3146,"interventions":3147},[90],[965],[47,386,387],{"trials":3149,"activeCount":99},[],{"intervention":386,"totalTrials":367,"cells":3151},{"EARLY_PHASE1":3152,"PHASE1":3154,"PHASE2":3198,"PHASE3":3309,"PHASE4":3497,"NA":3503},{"trials":3153,"activeCount":99},[],{"trials":3155,"activeCount":3197,"soonestReadout":378},[3156,3165,3169,3173,3177,3181,3185,3189,3193],{"nctId":3157,"briefTitle":3158,"status":105,"phases":3159,"primaryCompletion":3160,"completion":3160,"start":3161,"enrollment":3162,"conditions":3163,"interventions":3164},"NCT00648648","A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)",[87],"2014-01-06","2008-02-25",206,[176],[2894,1885,486,484],{"nctId":2808,"briefTitle":2809,"status":105,"phases":3166,"primaryCompletion":2811,"completion":2812,"start":2813,"enrollment":22,"conditions":3167,"interventions":3168},[87],[2815],[2817,1677,2818,484,1654,2819],{"nctId":375,"briefTitle":376,"status":139,"phases":3170,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":3171,"interventions":3172},[87],[382],[384,47,385,386,387,388,389,390],{"nctId":463,"briefTitle":464,"status":105,"phases":3174,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":3175,"interventions":3176},[87],[290],[471,47,386,385,461,387,390,472],{"nctId":474,"briefTitle":475,"status":105,"phases":3178,"primaryCompletion":477,"completion":477,"start":478,"enrollment":479,"conditions":3179,"interventions":3180},[87],[290],[482,42,483,484,485,486,487],{"nctId":532,"briefTitle":533,"status":105,"phases":3182,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":3183,"interventions":3184},[87],[539,279,369,540],[542,47,385,386,388],{"nctId":552,"briefTitle":553,"status":105,"phases":3186,"primaryCompletion":555,"completion":556,"start":557,"enrollment":558,"conditions":3187,"interventions":3188},[87],[540],[47,388,561,562,386,387],{"nctId":594,"briefTitle":595,"status":128,"phases":3190,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":3191,"interventions":3192},[87],[497],[602,47,484,483,603,604,605,606],{"nctId":705,"briefTitle":706,"status":105,"phases":3194,"primaryCompletion":708,"completion":708,"start":709,"enrollment":710,"conditions":3195,"interventions":3196},[87],[290],[713,42,387,388,714,386,385],2,{"trials":3199,"activeCount":3308,"soonestReadout":3242},[3200,3204,3208,3212,3216,3220,3230,3234,3238,3256,3268,3272,3276,3280,3284,3288,3292,3296,3300,3304],{"nctId":759,"briefTitle":760,"status":128,"phases":3201,"primaryCompletion":762,"completion":763,"start":764,"enrollment":765,"conditions":3202,"interventions":3203},[88],[767],[769,47,386,387,388],{"nctId":831,"briefTitle":832,"status":128,"phases":3205,"primaryCompletion":834,"completion":834,"start":835,"enrollment":836,"conditions":3206,"interventions":3207},[87,88],[838],[840,386,387,841,842,47,714,843],{"nctId":896,"briefTitle":897,"status":105,"phases":3209,"primaryCompletion":899,"completion":899,"start":900,"enrollment":901,"conditions":3210,"interventions":3211},[88],[903],[47,385,386,390],{"nctId":947,"briefTitle":948,"status":128,"phases":3213,"primaryCompletion":950,"completion":950,"start":891,"enrollment":951,"conditions":3214,"interventions":3215},[87,88],[369],[47,386,387,385,923,542,471,713,954,955],{"nctId":969,"briefTitle":970,"status":128,"phases":3217,"primaryCompletion":972,"completion":972,"start":973,"enrollment":558,"conditions":3218,"interventions":3219},[88],[975],[47,390,714,385,653,977,978,979,529,386,47,387,980],{"nctId":3221,"briefTitle":3222,"status":105,"phases":3223,"primaryCompletion":3224,"completion":3224,"start":3225,"enrollment":3226,"conditions":3227,"interventions":3228},"NCT00780039","A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)",[88],"2007-09-06","2003-10-01",58,[1288],[3229,386],"Pegylated Liposomal Doxorubicin",{"nctId":1102,"briefTitle":1103,"status":128,"phases":3231,"primaryCompletion":804,"completion":1105,"start":973,"enrollment":1106,"conditions":3232,"interventions":3233},[88],[1108,1109],[1111,47,387,386,1112,1113,562,795,1114],{"nctId":1138,"briefTitle":1139,"status":128,"phases":3235,"primaryCompletion":1141,"completion":1141,"start":1142,"enrollment":132,"conditions":3236,"interventions":3237},[88],[690],[500,47,693,386,385],{"nctId":3239,"briefTitle":3240,"status":128,"phases":3241,"primaryCompletion":3242,"completion":3243,"start":3244,"enrollment":2204,"conditions":3245,"interventions":3247},"NCT02861573","Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365\u002FKEYNOTE-365)",[87,88],"2027-10-22","2028-07-24","2016-11-17",[3246],"Metastatic Castration-Resistant Prostate Cancer",[84,3248,3249,3250,3251,3252,3253,461,3254,386,1073,3255],"Olaparib 400 mg","Docetaxel 75 mg\u002Fm^2","Prednisone 5 mg","Enzalutamide 160 mg","Olaparib 300 mg","Abiraterone acetate 1000 mg","Pembrolizumab\u002FVibostolimab coformulation","Belzutifan 120mg",{"nctId":3257,"briefTitle":3258,"status":128,"phases":3259,"primaryCompletion":3260,"completion":3261,"start":1701,"enrollment":3262,"conditions":3263,"interventions":3265},"NCT07227597","A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)",[87,88],"2030-11-29","2030-12-30",170,[3264],"Small Cell Lung Cancer Extensive Stage",[3266,1265,3267,386,1073,327],"Gocatamig","Atezolizumab",{"nctId":1243,"briefTitle":1244,"status":105,"phases":3269,"primaryCompletion":1246,"completion":1247,"start":1248,"enrollment":1249,"conditions":3270,"interventions":3271},[87,88],[1251],[47,387,386,841,385,1100,1253,1254],{"nctId":1277,"briefTitle":1278,"status":105,"phases":3273,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":1282,"conditions":3274,"interventions":3275},[88],[1284,1285,965,1286,856,791,540,1014,1287,1288,1289],[74,47,461,797,390,387,714,386,967,841,795,434],{"nctId":2886,"briefTitle":2887,"status":105,"phases":3277,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":2891,"conditions":3278,"interventions":3279},[88],[990],[2894,1654,484],{"nctId":2896,"briefTitle":2897,"status":150,"phases":3281,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":2901,"conditions":3282,"interventions":3283},[87,88],[290],[386,1664,1843,2904,714,2905,693,387,390,1444,1253,437,2906],{"nctId":1327,"briefTitle":1328,"status":128,"phases":3285,"primaryCompletion":1330,"completion":1330,"start":1331,"enrollment":397,"conditions":3286,"interventions":3287},[88],[314],[47,386,387,388,385,955],{"nctId":1381,"briefTitle":1382,"status":105,"phases":3289,"primaryCompletion":1384,"completion":1385,"start":1386,"enrollment":1387,"conditions":3290,"interventions":3291},[88],[883],[47,386,387,1071,1390],{"nctId":1392,"briefTitle":1393,"status":1040,"phases":3293,"primaryCompletion":1395,"completion":1396,"start":1397,"enrollment":99,"conditions":3294,"interventions":3295},[88],[1399],[47,387,386,1069,542,1401,562,795,1114],{"nctId":1494,"briefTitle":1495,"status":105,"phases":3297,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":787,"conditions":3298,"interventions":3299},[88],[1501,1502],[47,387,386,1504,471,967],{"nctId":1536,"briefTitle":1537,"status":105,"phases":3301,"primaryCompletion":1539,"completion":1540,"start":891,"enrollment":1541,"conditions":3302,"interventions":3303},[88],[540],[47,1114,386,714],{"nctId":1545,"briefTitle":1546,"status":105,"phases":3305,"primaryCompletion":1548,"completion":1548,"start":1549,"enrollment":1550,"conditions":3306,"interventions":3307},[88],[1552],[47,471,542,461,1073,390,386],9,{"trials":3310,"activeCount":3496,"soonestReadout":60},[3311,3315,3319,3323,3327,3331,3343,3347,3351,3355,3359,3363,3367,3371,3376,3380,3384,3393,3397,3401,3405,3409,3413,3417,3421,3425,3429,3439,3443,3447,3451,3455,3459,3463,3467,3476,3480,3484,3488,3492],{"nctId":1628,"briefTitle":1629,"status":128,"phases":3312,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":3313,"interventions":3314},[89],[540],[653,47,842,387,388,714,386],{"nctId":1656,"briefTitle":1657,"status":105,"phases":3316,"primaryCompletion":1659,"completion":1659,"start":1660,"enrollment":1661,"conditions":3317,"interventions":3318},[89],[540],[47,386,387,1069,1664,562,1665],{"nctId":1697,"briefTitle":1698,"status":105,"phases":3320,"primaryCompletion":1700,"completion":1701,"start":1702,"enrollment":1703,"conditions":3321,"interventions":3322},[89],[1705],[47,385,386,390,1114],{"nctId":1708,"briefTitle":1709,"status":105,"phases":3324,"primaryCompletion":1711,"completion":1712,"start":1713,"enrollment":1714,"conditions":3325,"interventions":3326},[89],[1716],[47,390,386,714],{"nctId":1791,"briefTitle":1792,"status":105,"phases":3328,"primaryCompletion":1794,"completion":1795,"start":1796,"enrollment":1797,"conditions":3329,"interventions":3330},[89],[1799],[1241,386,390,387,388,385,47],{"nctId":3332,"briefTitle":3333,"status":105,"phases":3334,"primaryCompletion":3335,"completion":3336,"start":3337,"enrollment":3338,"conditions":3339,"interventions":3340},"NCT02578680","Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189\u002FKEYNOTE-189)",[89],"2017-11-08","2023-06-22","2016-01-15",616,[2537],[84,390,386,385,3341,3342],"Dexamethasone 4 mg","Saline solution",{"nctId":1923,"briefTitle":1924,"status":105,"phases":3344,"primaryCompletion":1926,"completion":1927,"start":589,"enrollment":1928,"conditions":3345,"interventions":3346},[89],[990,1930,1931],[47,386,387,1114,841,967],{"nctId":1942,"briefTitle":1943,"status":105,"phases":3348,"primaryCompletion":1945,"completion":1946,"start":1947,"enrollment":1948,"conditions":3349,"interventions":3350},[89],[314],[47,387,388,386,1951],{"nctId":2971,"briefTitle":2972,"status":139,"phases":3352,"primaryCompletion":2974,"completion":2974,"start":2975,"enrollment":987,"conditions":3353,"interventions":3354},[89],[369],[2978,2979,486,483,487,484,1654],{"nctId":1963,"briefTitle":1964,"status":105,"phases":3356,"primaryCompletion":1966,"completion":1946,"start":1967,"enrollment":1968,"conditions":3357,"interventions":3358},[89],[314],[47,387,386,1951],{"nctId":76,"briefTitle":77,"status":139,"phases":3360,"primaryCompletion":78,"completion":2070,"start":2071,"enrollment":2072,"conditions":3361,"interventions":3362},[89],[2074],[79,385,390,386,387,388,47,2076,2077],{"nctId":2102,"briefTitle":2103,"status":128,"phases":3364,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":2108,"conditions":3365,"interventions":3366},[89],[369],[47,390,386,385,714,387,885],{"nctId":2112,"briefTitle":2113,"status":105,"phases":3368,"primaryCompletion":2115,"completion":2116,"start":2117,"enrollment":2118,"conditions":3369,"interventions":3370},[89],[314],[42,483,484,486,2121],{"nctId":71,"briefTitle":72,"status":139,"phases":3372,"primaryCompletion":73,"completion":2398,"start":1796,"enrollment":836,"conditions":3373,"interventions":3374},[89],[866],[74,3375,1073,390,3267,386],"Saline placebo",{"nctId":2143,"briefTitle":2144,"status":105,"phases":3377,"primaryCompletion":2146,"completion":2147,"start":2148,"enrollment":2149,"conditions":3378,"interventions":3379},[89],[2151],[47,386,390,385,461],{"nctId":2176,"briefTitle":2177,"status":139,"phases":3381,"primaryCompletion":2179,"completion":2180,"start":2181,"enrollment":2182,"conditions":3382,"interventions":3383},[89],[2184,369],[47,1114,1073,386,390,387,385,2186],{"nctId":3385,"briefTitle":3386,"status":105,"phases":3387,"primaryCompletion":3388,"completion":3336,"start":3389,"enrollment":3390,"conditions":3391,"interventions":3392},"NCT03950674","Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189\u002FKEYNOTE-189)-Japan Extension Study",[89],"2019-05-20","2016-02-22",40,[2537],[84,390,386,385,3341,3342],{"nctId":3043,"briefTitle":3044,"status":150,"phases":3394,"primaryCompletion":3046,"completion":3046,"start":3047,"enrollment":3048,"conditions":3395,"interventions":3396},[88,89],[990,3050],[3052,484,1654],{"nctId":2292,"briefTitle":2293,"status":105,"phases":3398,"primaryCompletion":2116,"completion":2295,"start":2296,"enrollment":132,"conditions":3399,"interventions":3400},[89],[1285],[461,47,387,386],{"nctId":2355,"briefTitle":2356,"status":105,"phases":3402,"primaryCompletion":2358,"completion":379,"start":2359,"enrollment":2335,"conditions":3403,"interventions":3404},[89],[867],[47,2362,386,390,1073],{"nctId":2364,"briefTitle":2365,"status":105,"phases":3406,"primaryCompletion":2005,"completion":73,"start":2367,"enrollment":2368,"conditions":3407,"interventions":3408},[89],[863],[47,387,390,386,841],{"nctId":2385,"briefTitle":2386,"status":105,"phases":3410,"primaryCompletion":2388,"completion":2389,"start":1702,"enrollment":2390,"conditions":3411,"interventions":3412},[89],[2392],[47,386,387,388,1114],{"nctId":2426,"briefTitle":2427,"status":128,"phases":3414,"primaryCompletion":2429,"completion":2429,"start":2430,"enrollment":2431,"conditions":3415,"interventions":3416},[89],[861],[47,386,387,967,794],{"nctId":2435,"briefTitle":2436,"status":128,"phases":3418,"primaryCompletion":2438,"completion":2439,"start":2440,"enrollment":2441,"conditions":3419,"interventions":3420},[89],[1108,540,2443],[653,47,842,386,387,1069,1664,562,795,1114],{"nctId":58,"briefTitle":59,"status":139,"phases":3422,"primaryCompletion":60,"completion":3090,"start":3091,"enrollment":3092,"conditions":3423,"interventions":3424},[89],[903],[61,3095,387,3096,386,390,385],{"nctId":2456,"briefTitle":2457,"status":139,"phases":3426,"primaryCompletion":2459,"completion":2459,"start":2460,"enrollment":2461,"conditions":3427,"interventions":3428},[89],[1285],[42,484,1654,1677,486],{"nctId":3430,"briefTitle":3431,"status":128,"phases":3432,"primaryCompletion":3433,"completion":3434,"start":3435,"enrollment":3436,"conditions":3437,"interventions":3438},"NCT07190248","A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007\u002FKANDLELIT-007)",[89],"2029-12-07","2032-08-06","2025-10-08",675,[314],[602,384,385,390,386],{"nctId":2492,"briefTitle":2493,"status":139,"phases":3440,"primaryCompletion":2495,"completion":2495,"start":2496,"enrollment":2497,"conditions":3441,"interventions":3442},[89],[1285],[47,386,387,967,390,390],{"nctId":2501,"briefTitle":2502,"status":105,"phases":3444,"primaryCompletion":2116,"completion":2504,"start":1877,"enrollment":2505,"conditions":3445,"interventions":3446},[89],[1285],[461,47,387,386],{"nctId":2509,"briefTitle":2510,"status":105,"phases":3448,"primaryCompletion":2043,"completion":1807,"start":940,"enrollment":2512,"conditions":3449,"interventions":3450},[89],[2514,2515],[47,390,386,1444,693],{"nctId":2518,"briefTitle":2519,"status":128,"phases":3452,"primaryCompletion":2521,"completion":2522,"start":2523,"enrollment":2390,"conditions":3453,"interventions":3454},[89],[314,2525],[47,2527,386,387,388],{"nctId":2549,"briefTitle":2550,"status":105,"phases":3456,"primaryCompletion":2552,"completion":2553,"start":2554,"enrollment":2555,"conditions":3457,"interventions":3458},[89],[314],[42,484,1654,483],{"nctId":2559,"briefTitle":2560,"status":105,"phases":3460,"primaryCompletion":2552,"completion":2562,"start":2563,"enrollment":2564,"conditions":3461,"interventions":3462},[89],[314],[42,484,1654,483],{"nctId":2568,"briefTitle":2569,"status":105,"phases":3464,"primaryCompletion":2571,"completion":2572,"start":2573,"enrollment":2574,"conditions":3465,"interventions":3466},[89],[2576],[47,387,386,385,390,714],{"nctId":3468,"briefTitle":3469,"status":139,"phases":3470,"primaryCompletion":3471,"completion":3472,"start":1776,"enrollment":2625,"conditions":3473,"interventions":3474},"NCT06305754","Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)",[89],"2028-08-17","2030-06-14",[1687],[653,385,386,3475,1324,979,529,1325],"H1 Receptor Antagonist",{"nctId":2660,"briefTitle":2661,"status":105,"phases":3477,"primaryCompletion":2146,"completion":2147,"start":2663,"enrollment":2664,"conditions":3478,"interventions":3479},[89],[2151],[47,386,390,385,461],{"nctId":2718,"briefTitle":2719,"status":105,"phases":3481,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":2512,"conditions":3482,"interventions":3483},[89],[2725],[47,388,387,714,386,2727],{"nctId":2729,"briefTitle":2730,"status":128,"phases":3485,"primaryCompletion":2732,"completion":2733,"start":2734,"enrollment":2735,"conditions":3486,"interventions":3487},[89],[2737],[653,47,390,385,714,386,387,1089],{"nctId":2740,"briefTitle":2741,"status":128,"phases":3489,"primaryCompletion":2743,"completion":2743,"start":2744,"enrollment":2745,"conditions":3490,"interventions":3491},[89],[863],[47,794,841,387,390,386,327],{"nctId":2749,"briefTitle":2750,"status":139,"phases":3493,"primaryCompletion":2752,"completion":2070,"start":2753,"enrollment":2754,"conditions":3494,"interventions":3495},[89],[2074],[384,385,390,386,387,388,47,2076,2077],17,{"trials":3498,"activeCount":99},[3499],{"nctId":2783,"briefTitle":2784,"status":105,"phases":3500,"primaryCompletion":2786,"completion":1897,"start":2787,"enrollment":2788,"conditions":3501,"interventions":3502},[90],[965],[47,386,387],{"trials":3504,"activeCount":99},[],{"intervention":653,"totalTrials":3506,"cells":3507},26,{"EARLY_PHASE1":3508,"PHASE1":3510,"PHASE2":3516,"PHASE3":3565,"PHASE4":3656,"NA":3658},{"trials":3509,"activeCount":99},[],{"trials":3511,"activeCount":224,"soonestReadout":645},[3512],{"nctId":642,"briefTitle":643,"status":139,"phases":3513,"primaryCompletion":645,"completion":646,"start":647,"enrollment":154,"conditions":3514,"interventions":3515},[87],[314,176,649,650,651],[653,47,654],{"trials":3517,"activeCount":3308,"soonestReadout":645},[3518,3522,3526,3530,3534,3544,3548,3552,3556],{"nctId":782,"briefTitle":783,"status":128,"phases":3519,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":3520,"interventions":3521},[87,88],[789,790,791,792],[47,794,795,435,796,797,434,798],{"nctId":969,"briefTitle":970,"status":128,"phases":3523,"primaryCompletion":972,"completion":972,"start":973,"enrollment":558,"conditions":3524,"interventions":3525},[88],[975],[47,390,714,385,653,977,978,979,529,386,47,387,980],{"nctId":1078,"briefTitle":1079,"status":128,"phases":3527,"primaryCompletion":1081,"completion":1081,"start":1082,"enrollment":8,"conditions":3528,"interventions":3529},[87,88],[419,1084,1085],[653,1087,1088,1089,654,390,47],{"nctId":2867,"briefTitle":2868,"status":128,"phases":3531,"primaryCompletion":2870,"completion":2871,"start":2872,"enrollment":2873,"conditions":3532,"interventions":3533},[87,88],[789,790,791,792],[2876,387,794,327,955],{"nctId":3535,"briefTitle":3536,"status":128,"phases":3537,"primaryCompletion":3538,"completion":3539,"start":3540,"enrollment":3541,"conditions":3542,"interventions":3543},"NCT07286149","A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)",[87,88],"2031-08-11","2037-05-06","2026-04-30",190,[975],[500,1111,653,693,327],{"nctId":1256,"briefTitle":1257,"status":128,"phases":3545,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":1261,"conditions":3546,"interventions":3547},[87,88],[1263],[47,1265,435,796,797,434,653,842],{"nctId":1315,"briefTitle":1316,"status":128,"phases":3549,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1132,"conditions":3550,"interventions":3551},[87,88],[1263],[387,437,47,471,461,653,1323,1324,979,529,1325,654],{"nctId":1371,"briefTitle":1372,"status":139,"phases":3553,"primaryCompletion":1374,"completion":1374,"start":1375,"enrollment":312,"conditions":3554,"interventions":3555},[87,88],[1377,1378],[653,1136,47,654],{"nctId":3557,"briefTitle":3558,"status":128,"phases":3559,"primaryCompletion":645,"completion":3560,"start":3561,"enrollment":626,"conditions":3562,"interventions":3564},"NCT06637423","A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)",[87,88],"2028-07-31","2024-12-20",[3563],"Non-Muscle Invasive Bladder Cancer",[653,1089,654],{"trials":3566,"activeCount":3655,"soonestReadout":3073},[3567,3571,3575,3585,3589,3599,3608,3612,3616,3627,3631,3635,3639,3643,3647,3651],{"nctId":1628,"briefTitle":1629,"status":128,"phases":3568,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":3569,"interventions":3570},[89],[540],[653,47,842,387,388,714,386],{"nctId":1679,"briefTitle":1680,"status":128,"phases":3572,"primaryCompletion":1682,"completion":1683,"start":1684,"enrollment":1685,"conditions":3573,"interventions":3574},[89],[1687],[653,47,654],{"nctId":3576,"briefTitle":3577,"status":139,"phases":3578,"primaryCompletion":3579,"completion":3580,"start":3581,"enrollment":3582,"conditions":3583,"interventions":3584},"NCT06074588","Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)",[89],"2027-05-10","2030-03-11","2023-11-12",556,[1687],[653,967,385],{"nctId":1753,"briefTitle":1754,"status":128,"phases":3586,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":1759,"conditions":3587,"interventions":3588},[89],[1761],[47,653,795],{"nctId":3590,"briefTitle":3591,"status":128,"phases":3592,"primaryCompletion":3593,"completion":3594,"start":909,"enrollment":3595,"conditions":3596,"interventions":3598},"NCT06824467","A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022\u002FTroFuse-022\u002FENGOT-ov84\u002FGOG-3103)",[89],"2029-04-27","2032-11-09",770,[990,1930,3597],"Primary Peritoneal Cancer",[653,841,977,978,979,529,980],{"nctId":3600,"briefTitle":3601,"status":128,"phases":3602,"primaryCompletion":3603,"completion":3603,"start":3604,"enrollment":3605,"conditions":3606,"interventions":3607},"NCT07318558","A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)",[89],"2033-02-25","2026-02-16",900,[1288,990],[653,841,327],{"nctId":3005,"briefTitle":3006,"status":128,"phases":3609,"primaryCompletion":3008,"completion":3009,"start":3010,"enrollment":3011,"conditions":3610,"interventions":3611},[89],[1134],[653,3014,967,387,3015,3016],{"nctId":2198,"briefTitle":2199,"status":128,"phases":3613,"primaryCompletion":2201,"completion":2202,"start":2203,"enrollment":2204,"conditions":3614,"interventions":3615},[89],[1108],[653,47,387,388,795,2207],{"nctId":3617,"briefTitle":3618,"status":139,"phases":3619,"primaryCompletion":3620,"completion":3620,"start":477,"enrollment":3621,"conditions":3622,"interventions":3623},"NCT06459180","A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020\u002FTroFuse-020\u002FGog-3101\u002FENGOT-cx20)",[89],"2028-06-15",686,[863],[794,385,3624,3625,3626,714,437],"Tisotumab Vedotin","Topotecan","Vinorelbine",{"nctId":3030,"briefTitle":3031,"status":139,"phases":3628,"primaryCompletion":3033,"completion":3033,"start":1958,"enrollment":3034,"conditions":3629,"interventions":3630},[89],[861],[653,1069,387,388,3037],{"nctId":3070,"briefTitle":3071,"status":139,"phases":3632,"primaryCompletion":3073,"completion":3074,"start":3075,"enrollment":951,"conditions":3633,"interventions":3634},[89],[3077],[653,3079,437,387,967,3037,654],{"nctId":2426,"briefTitle":2427,"status":128,"phases":3636,"primaryCompletion":2429,"completion":2429,"start":2430,"enrollment":2431,"conditions":3637,"interventions":3638},[89],[861],[47,386,387,967,794],{"nctId":2435,"briefTitle":2436,"status":128,"phases":3640,"primaryCompletion":2438,"completion":2439,"start":2440,"enrollment":2441,"conditions":3641,"interventions":3642},[89],[1108,540,2443],[653,47,842,386,387,1069,1664,562,795,1114],{"nctId":3468,"briefTitle":3469,"status":139,"phases":3644,"primaryCompletion":3471,"completion":3472,"start":1776,"enrollment":2625,"conditions":3645,"interventions":3646},[89],[1687],[653,385,386,3475,1324,979,529,1325],{"nctId":2729,"briefTitle":2730,"status":128,"phases":3648,"primaryCompletion":2732,"completion":2733,"start":2734,"enrollment":2735,"conditions":3649,"interventions":3650},[89],[2737],[653,47,390,385,714,386,387,1089],{"nctId":2740,"briefTitle":2741,"status":128,"phases":3652,"primaryCompletion":2743,"completion":2743,"start":2744,"enrollment":2745,"conditions":3653,"interventions":3654},[89],[863],[47,794,841,387,390,386,327],16,{"trials":3657,"activeCount":99},[],{"trials":3659,"activeCount":99},[],{"intervention":390,"totalTrials":1621,"cells":3661},{"EARLY_PHASE1":3662,"PHASE1":3664,"PHASE2":3686,"PHASE3":3728,"PHASE4":3898,"NA":3900},{"trials":3663,"activeCount":99},[],{"trials":3665,"activeCount":224,"soonestReadout":378},[3666,3670,3674,3678,3682],{"nctId":3157,"briefTitle":3158,"status":105,"phases":3667,"primaryCompletion":3160,"completion":3160,"start":3161,"enrollment":3162,"conditions":3668,"interventions":3669},[87],[176],[2894,1885,486,484],{"nctId":375,"briefTitle":376,"status":139,"phases":3671,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":3672,"interventions":3673},[87],[382],[384,47,385,386,387,388,389,390],{"nctId":463,"briefTitle":464,"status":105,"phases":3675,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":3676,"interventions":3677},[87],[290],[471,47,386,385,461,387,390,472],{"nctId":474,"briefTitle":475,"status":105,"phases":3679,"primaryCompletion":477,"completion":477,"start":478,"enrollment":479,"conditions":3680,"interventions":3681},[87],[290],[482,42,483,484,485,486,487],{"nctId":564,"briefTitle":565,"status":105,"phases":3683,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":3684,"interventions":3685},[87],[571],[47,385,390],{"trials":3687,"activeCount":3197,"soonestReadout":1081},[3688,3692,3696,3700,3708,3712,3716,3720,3724],{"nctId":896,"briefTitle":897,"status":105,"phases":3689,"primaryCompletion":899,"completion":899,"start":900,"enrollment":901,"conditions":3690,"interventions":3691},[88],[903],[47,385,386,390],{"nctId":969,"briefTitle":970,"status":128,"phases":3693,"primaryCompletion":972,"completion":972,"start":973,"enrollment":558,"conditions":3694,"interventions":3695},[88],[975],[47,390,714,385,653,977,978,979,529,386,47,387,980],{"nctId":1078,"briefTitle":1079,"status":128,"phases":3697,"primaryCompletion":1081,"completion":1081,"start":1082,"enrollment":8,"conditions":3698,"interventions":3699},[87,88],[419,1084,1085],[653,1087,1088,1089,654,390,47],{"nctId":3701,"briefTitle":3702,"status":150,"phases":3703,"primaryCompletion":3704,"completion":3704,"start":3705,"enrollment":357,"conditions":3706,"interventions":3707},"NCT01076400","A Study of Adavosertib (MK-1775) in Combination With Topotecan\u002FCisplatin in Participants With Cervical Cancer (MK-1775-008)",[87,88],"2011-06-13","2010-05-31",[863],[2894,3625,390],{"nctId":1277,"briefTitle":1278,"status":105,"phases":3709,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":1282,"conditions":3710,"interventions":3711},[88],[1284,1285,965,1286,856,791,540,1014,1287,1288,1289],[74,47,461,797,390,387,714,386,967,841,795,434],{"nctId":2896,"briefTitle":2897,"status":150,"phases":3713,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":2901,"conditions":3714,"interventions":3715},[87,88],[290],[386,1664,1843,2904,714,2905,693,387,390,1444,1253,437,2906],{"nctId":1434,"briefTitle":1435,"status":105,"phases":3717,"primaryCompletion":1437,"completion":1437,"start":1438,"enrollment":1439,"conditions":3718,"interventions":3719},[88],[1441,1442],[42,486,1444,1445],{"nctId":1485,"briefTitle":1486,"status":105,"phases":3721,"primaryCompletion":1488,"completion":1488,"start":1489,"enrollment":920,"conditions":3722,"interventions":3723},[88],[991],[47,434,1492,390],{"nctId":1545,"briefTitle":1546,"status":105,"phases":3725,"primaryCompletion":1548,"completion":1548,"start":1549,"enrollment":1550,"conditions":3726,"interventions":3727},[88],[1552],[47,471,542,461,1073,390,386],{"trials":3729,"activeCount":3655,"soonestReadout":60},[3730,3734,3738,3742,3746,3750,3754,3758,3762,3766,3770,3774,3778,3782,3786,3790,3794,3798,3802,3806,3810,3814,3818,3822,3826,3830,3834,3838,3842,3846,3850,3854,3858,3862,3866,3870,3874,3878,3882,3886,3890,3894],{"nctId":1697,"briefTitle":1698,"status":105,"phases":3731,"primaryCompletion":1700,"completion":1701,"start":1702,"enrollment":1703,"conditions":3732,"interventions":3733},[89],[1705],[47,385,386,390,1114],{"nctId":1708,"briefTitle":1709,"status":105,"phases":3735,"primaryCompletion":1711,"completion":1712,"start":1713,"enrollment":1714,"conditions":3736,"interventions":3737},[89],[1716],[47,390,386,714],{"nctId":1732,"briefTitle":1733,"status":105,"phases":3739,"primaryCompletion":1735,"completion":1736,"start":1737,"enrollment":1738,"conditions":3740,"interventions":3741},[89],[1284],[47,390],{"nctId":1764,"briefTitle":1765,"status":1040,"phases":3743,"primaryCompletion":1767,"completion":1768,"start":1769,"enrollment":99,"conditions":3744,"interventions":3745},[89],[791],[47,390,1444],{"nctId":1791,"briefTitle":1792,"status":105,"phases":3747,"primaryCompletion":1794,"completion":1795,"start":1796,"enrollment":1797,"conditions":3748,"interventions":3749},[89],[1799],[1241,386,390,387,388,385,47],{"nctId":1822,"briefTitle":1823,"status":105,"phases":3751,"primaryCompletion":1539,"completion":1825,"start":1826,"enrollment":1827,"conditions":3752,"interventions":3753},[89],[1829],[47,714,390],{"nctId":1832,"briefTitle":1833,"status":105,"phases":3755,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":3756,"interventions":3757},[89],[1840,1442],[47,390,1444,434,795,1842,1843],{"nctId":63,"briefTitle":64,"status":139,"phases":3759,"primaryCompletion":65,"completion":1569,"start":1889,"enrollment":1890,"conditions":3760,"interventions":3761},[89],[314],[47,390,714,385],{"nctId":1904,"briefTitle":1905,"status":105,"phases":3763,"primaryCompletion":1907,"completion":65,"start":1908,"enrollment":1909,"conditions":3764,"interventions":3765},[89],[791],[47,390,1444],{"nctId":1913,"briefTitle":1914,"status":105,"phases":3767,"primaryCompletion":1916,"completion":1917,"start":1918,"enrollment":1919,"conditions":3768,"interventions":3769},[89],[1441],[47,390,1444,795],{"nctId":3332,"briefTitle":3333,"status":105,"phases":3771,"primaryCompletion":3335,"completion":3336,"start":3337,"enrollment":3338,"conditions":3772,"interventions":3773},[89],[2537],[84,390,386,385,3341,3342],{"nctId":2971,"briefTitle":2972,"status":139,"phases":3775,"primaryCompletion":2974,"completion":2974,"start":2975,"enrollment":987,"conditions":3776,"interventions":3777},[89],[369],[2978,2979,486,483,487,484,1654],{"nctId":2002,"briefTitle":2003,"status":105,"phases":3779,"primaryCompletion":2005,"completion":2006,"start":2007,"enrollment":2008,"conditions":3780,"interventions":3781},[89],[1289],[47,390,606,604,1445],{"nctId":2012,"briefTitle":2013,"status":1040,"phases":3783,"primaryCompletion":2015,"completion":2015,"start":2007,"enrollment":99,"conditions":3784,"interventions":3785},[89],[1289],[47,390,606,434,795],{"nctId":2019,"briefTitle":2020,"status":105,"phases":3787,"primaryCompletion":2022,"completion":730,"start":1406,"enrollment":2023,"conditions":3788,"interventions":3789},[89],[991,2025],[47,390,795,606,967,434,435],{"nctId":76,"briefTitle":77,"status":139,"phases":3791,"primaryCompletion":78,"completion":2070,"start":2071,"enrollment":2072,"conditions":3792,"interventions":3793},[89],[2074],[79,385,390,386,387,388,47,2076,2077],{"nctId":2102,"briefTitle":2103,"status":128,"phases":3795,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":2108,"conditions":3796,"interventions":3797},[89],[369],[47,390,386,385,714,387,885],{"nctId":2112,"briefTitle":2113,"status":105,"phases":3799,"primaryCompletion":2115,"completion":2116,"start":2117,"enrollment":2118,"conditions":3800,"interventions":3801},[89],[314],[42,483,484,486,2121],{"nctId":2123,"briefTitle":2124,"status":105,"phases":3803,"primaryCompletion":2126,"completion":2126,"start":2127,"enrollment":2128,"conditions":3804,"interventions":3805},[89],[1134],[47,2131,714,390],{"nctId":71,"briefTitle":72,"status":139,"phases":3807,"primaryCompletion":73,"completion":2398,"start":1796,"enrollment":836,"conditions":3808,"interventions":3809},[89],[866],[74,3375,1073,390,3267,386],{"nctId":2143,"briefTitle":2144,"status":105,"phases":3811,"primaryCompletion":2146,"completion":2147,"start":2148,"enrollment":2149,"conditions":3812,"interventions":3813},[89],[2151],[47,386,390,385,461],{"nctId":2176,"briefTitle":2177,"status":139,"phases":3815,"primaryCompletion":2179,"completion":2180,"start":2181,"enrollment":2182,"conditions":3816,"interventions":3817},[89],[2184,369],[47,1114,1073,386,390,387,385,2186],{"nctId":2218,"briefTitle":2219,"status":105,"phases":3819,"primaryCompletion":1539,"completion":2221,"start":2222,"enrollment":2223,"conditions":3820,"interventions":3821},[89],[1829],[47,714,390],{"nctId":3385,"briefTitle":3386,"status":105,"phases":3823,"primaryCompletion":3388,"completion":3336,"start":3389,"enrollment":3390,"conditions":3824,"interventions":3825},[89],[2537],[84,390,386,385,3341,3342],{"nctId":2318,"briefTitle":2319,"status":139,"phases":3827,"primaryCompletion":2321,"completion":2322,"start":2323,"enrollment":2324,"conditions":3828,"interventions":3829},[89],[2326],[47,461,390,1444,434,435,796,387],{"nctId":2339,"briefTitle":2340,"status":105,"phases":3831,"primaryCompletion":2022,"completion":730,"start":2342,"enrollment":2343,"conditions":3832,"interventions":3833},[89],[991,2025],[47,390,795,606,967,434,435],{"nctId":2347,"briefTitle":2348,"status":105,"phases":3835,"primaryCompletion":1736,"completion":1520,"start":2350,"enrollment":2351,"conditions":3836,"interventions":3837},[89],[1134],[47,714,390],{"nctId":2355,"briefTitle":2356,"status":105,"phases":3839,"primaryCompletion":2358,"completion":379,"start":2359,"enrollment":2335,"conditions":3840,"interventions":3841},[89],[867],[47,2362,386,390,1073],{"nctId":2364,"briefTitle":2365,"status":105,"phases":3843,"primaryCompletion":2005,"completion":73,"start":2367,"enrollment":2368,"conditions":3844,"interventions":3845},[89],[863],[47,387,390,386,841],{"nctId":58,"briefTitle":59,"status":139,"phases":3847,"primaryCompletion":60,"completion":3090,"start":3091,"enrollment":3092,"conditions":3848,"interventions":3849},[89],[903],[61,3095,387,3096,386,390,385],{"nctId":2456,"briefTitle":2457,"status":139,"phases":3851,"primaryCompletion":2459,"completion":2459,"start":2460,"enrollment":2461,"conditions":3852,"interventions":3853},[89],[1285],[42,484,1654,1677,486],{"nctId":3430,"briefTitle":3431,"status":128,"phases":3855,"primaryCompletion":3433,"completion":3434,"start":3435,"enrollment":3436,"conditions":3856,"interventions":3857},[89],[314],[602,384,385,390,386],{"nctId":2474,"briefTitle":2475,"status":105,"phases":3859,"primaryCompletion":2477,"completion":2478,"start":2479,"enrollment":2480,"conditions":3860,"interventions":3861},[89],[2482],[47,390],{"nctId":2492,"briefTitle":2493,"status":139,"phases":3863,"primaryCompletion":2495,"completion":2495,"start":2496,"enrollment":2497,"conditions":3864,"interventions":3865},[89],[1285],[47,386,387,967,390,390],{"nctId":2509,"briefTitle":2510,"status":105,"phases":3867,"primaryCompletion":2043,"completion":1807,"start":940,"enrollment":2512,"conditions":3868,"interventions":3869},[89],[2514,2515],[47,390,386,1444,693],{"nctId":2568,"briefTitle":2569,"status":105,"phases":3871,"primaryCompletion":2571,"completion":2572,"start":2573,"enrollment":2574,"conditions":3872,"interventions":3873},[89],[2576],[47,387,386,385,390,714],{"nctId":2619,"briefTitle":2620,"status":139,"phases":3875,"primaryCompletion":2622,"completion":2623,"start":2624,"enrollment":2625,"conditions":3876,"interventions":3877},[89],[1287],[47,390,1087,2628,714],{"nctId":2630,"briefTitle":2631,"status":139,"phases":3879,"primaryCompletion":2192,"completion":2633,"start":2634,"enrollment":2635,"conditions":3880,"interventions":3881},[89],[1230,2637,2638],[42,486,1444,605,2640,604],{"nctId":2660,"briefTitle":2661,"status":105,"phases":3883,"primaryCompletion":2146,"completion":2147,"start":2663,"enrollment":2664,"conditions":3884,"interventions":3885},[89],[2151],[47,386,390,385,461],{"nctId":2729,"briefTitle":2730,"status":128,"phases":3887,"primaryCompletion":2732,"completion":2733,"start":2734,"enrollment":2735,"conditions":3888,"interventions":3889},[89],[2737],[653,47,390,385,714,386,387,1089],{"nctId":2740,"briefTitle":2741,"status":128,"phases":3891,"primaryCompletion":2743,"completion":2743,"start":2744,"enrollment":2745,"conditions":3892,"interventions":3893},[89],[863],[47,794,841,387,390,386,327],{"nctId":2749,"briefTitle":2750,"status":139,"phases":3895,"primaryCompletion":2752,"completion":2070,"start":2753,"enrollment":2754,"conditions":3896,"interventions":3897},[89],[2074],[384,385,390,386,387,388,47,2076,2077],{"trials":3899,"activeCount":99},[],{"trials":3901,"activeCount":99},[],{"intervention":385,"totalTrials":3903,"cells":3904},35,{"EARLY_PHASE1":3905,"PHASE1":3907,"PHASE2":3937,"PHASE3":3964,"PHASE4":4054,"NA":4056},{"trials":3906,"activeCount":99},[],{"trials":3908,"activeCount":3197,"soonestReadout":378},[3909,3913,3917,3921,3925,3929,3933],{"nctId":375,"briefTitle":376,"status":139,"phases":3910,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":3911,"interventions":3912},[87],[382],[384,47,385,386,387,388,389,390],{"nctId":463,"briefTitle":464,"status":105,"phases":3914,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":3915,"interventions":3916},[87],[290],[471,47,386,385,461,387,390,472],{"nctId":474,"briefTitle":475,"status":105,"phases":3918,"primaryCompletion":477,"completion":477,"start":478,"enrollment":479,"conditions":3919,"interventions":3920},[87],[290],[482,42,483,484,485,486,487],{"nctId":532,"briefTitle":533,"status":105,"phases":3922,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":3923,"interventions":3924},[87],[539,279,369,540],[542,47,385,386,388],{"nctId":564,"briefTitle":565,"status":105,"phases":3926,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":3927,"interventions":3928},[87],[571],[47,385,390],{"nctId":594,"briefTitle":595,"status":128,"phases":3930,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":3931,"interventions":3932},[87],[497],[602,47,484,483,603,604,605,606],{"nctId":705,"briefTitle":706,"status":105,"phases":3934,"primaryCompletion":708,"completion":708,"start":709,"enrollment":710,"conditions":3935,"interventions":3936},[87],[290],[713,42,387,388,714,386,385],{"trials":3938,"activeCount":3963,"soonestReadout":972},[3939,3943,3947,3951,3955,3959],{"nctId":896,"briefTitle":897,"status":105,"phases":3940,"primaryCompletion":899,"completion":899,"start":900,"enrollment":901,"conditions":3941,"interventions":3942},[88],[903],[47,385,386,390],{"nctId":947,"briefTitle":948,"status":128,"phases":3944,"primaryCompletion":950,"completion":950,"start":891,"enrollment":951,"conditions":3945,"interventions":3946},[87,88],[369],[47,386,387,385,923,542,471,713,954,955],{"nctId":969,"briefTitle":970,"status":128,"phases":3948,"primaryCompletion":972,"completion":972,"start":973,"enrollment":558,"conditions":3949,"interventions":3950},[88],[975],[47,390,714,385,653,977,978,979,529,386,47,387,980],{"nctId":1138,"briefTitle":1139,"status":128,"phases":3952,"primaryCompletion":1141,"completion":1141,"start":1142,"enrollment":132,"conditions":3953,"interventions":3954},[88],[690],[500,47,693,386,385],{"nctId":1243,"briefTitle":1244,"status":105,"phases":3956,"primaryCompletion":1246,"completion":1247,"start":1248,"enrollment":1249,"conditions":3957,"interventions":3958},[87,88],[1251],[47,387,386,841,385,1100,1253,1254],{"nctId":1327,"briefTitle":1328,"status":128,"phases":3960,"primaryCompletion":1330,"completion":1330,"start":1331,"enrollment":397,"conditions":3961,"interventions":3962},[88],[314],[47,386,387,388,385,955],4,{"trials":3965,"activeCount":95,"soonestReadout":60},[3966,3970,3974,3978,3982,3986,3990,3994,3998,4002,4006,4010,4014,4018,4022,4026,4030,4034,4038,4042,4046,4050],{"nctId":1697,"briefTitle":1698,"status":105,"phases":3967,"primaryCompletion":1700,"completion":1701,"start":1702,"enrollment":1703,"conditions":3968,"interventions":3969},[89],[1705],[47,385,386,390,1114],{"nctId":3576,"briefTitle":3577,"status":139,"phases":3971,"primaryCompletion":3579,"completion":3580,"start":3581,"enrollment":3582,"conditions":3972,"interventions":3973},[89],[1687],[653,967,385],{"nctId":1791,"briefTitle":1792,"status":105,"phases":3975,"primaryCompletion":1794,"completion":1795,"start":1796,"enrollment":1797,"conditions":3976,"interventions":3977},[89],[1799],[1241,386,390,387,388,385,47],{"nctId":63,"briefTitle":64,"status":139,"phases":3979,"primaryCompletion":65,"completion":1569,"start":1889,"enrollment":1890,"conditions":3980,"interventions":3981},[89],[314],[47,390,714,385],{"nctId":3332,"briefTitle":3333,"status":105,"phases":3983,"primaryCompletion":3335,"completion":3336,"start":3337,"enrollment":3338,"conditions":3984,"interventions":3985},[89],[2537],[84,390,386,385,3341,3342],{"nctId":2971,"briefTitle":2972,"status":139,"phases":3987,"primaryCompletion":2974,"completion":2974,"start":2975,"enrollment":987,"conditions":3988,"interventions":3989},[89],[369],[2978,2979,486,483,487,484,1654],{"nctId":76,"briefTitle":77,"status":139,"phases":3991,"primaryCompletion":78,"completion":2070,"start":2071,"enrollment":2072,"conditions":3992,"interventions":3993},[89],[2074],[79,385,390,386,387,388,47,2076,2077],{"nctId":2102,"briefTitle":2103,"status":128,"phases":3995,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":2108,"conditions":3996,"interventions":3997},[89],[369],[47,390,386,385,714,387,885],{"nctId":2112,"briefTitle":2113,"status":105,"phases":3999,"primaryCompletion":2115,"completion":2116,"start":2117,"enrollment":2118,"conditions":4000,"interventions":4001},[89],[314],[42,483,484,486,2121],{"nctId":2143,"briefTitle":2144,"status":105,"phases":4003,"primaryCompletion":2146,"completion":2147,"start":2148,"enrollment":2149,"conditions":4004,"interventions":4005},[89],[2151],[47,386,390,385,461],{"nctId":2176,"briefTitle":2177,"status":139,"phases":4007,"primaryCompletion":2179,"completion":2180,"start":2181,"enrollment":2182,"conditions":4008,"interventions":4009},[89],[2184,369],[47,1114,1073,386,390,387,385,2186],{"nctId":3617,"briefTitle":3618,"status":139,"phases":4011,"primaryCompletion":3620,"completion":3620,"start":477,"enrollment":3621,"conditions":4012,"interventions":4013},[89],[863],[794,385,3624,3625,3626,714,437],{"nctId":3385,"briefTitle":3386,"status":105,"phases":4015,"primaryCompletion":3388,"completion":3336,"start":3389,"enrollment":3390,"conditions":4016,"interventions":4017},[89],[2537],[84,390,386,385,3341,3342],{"nctId":58,"briefTitle":59,"status":139,"phases":4019,"primaryCompletion":60,"completion":3090,"start":3091,"enrollment":3092,"conditions":4020,"interventions":4021},[89],[903],[61,3095,387,3096,386,390,385],{"nctId":3430,"briefTitle":3431,"status":128,"phases":4023,"primaryCompletion":3433,"completion":3434,"start":3435,"enrollment":3436,"conditions":4024,"interventions":4025},[89],[314],[602,384,385,390,386],{"nctId":2549,"briefTitle":2550,"status":105,"phases":4027,"primaryCompletion":2552,"completion":2553,"start":2554,"enrollment":2555,"conditions":4028,"interventions":4029},[89],[314],[42,484,1654,483],{"nctId":2559,"briefTitle":2560,"status":105,"phases":4031,"primaryCompletion":2552,"completion":2562,"start":2563,"enrollment":2564,"conditions":4032,"interventions":4033},[89],[314],[42,484,1654,483],{"nctId":2568,"briefTitle":2569,"status":105,"phases":4035,"primaryCompletion":2571,"completion":2572,"start":2573,"enrollment":2574,"conditions":4036,"interventions":4037},[89],[2576],[47,387,386,385,390,714],{"nctId":3468,"briefTitle":3469,"status":139,"phases":4039,"primaryCompletion":3471,"completion":3472,"start":1776,"enrollment":2625,"conditions":4040,"interventions":4041},[89],[1687],[653,385,386,3475,1324,979,529,1325],{"nctId":2660,"briefTitle":2661,"status":105,"phases":4043,"primaryCompletion":2146,"completion":2147,"start":2663,"enrollment":2664,"conditions":4044,"interventions":4045},[89],[2151],[47,386,390,385,461],{"nctId":2729,"briefTitle":2730,"status":128,"phases":4047,"primaryCompletion":2732,"completion":2733,"start":2734,"enrollment":2735,"conditions":4048,"interventions":4049},[89],[2737],[653,47,390,385,714,386,387,1089],{"nctId":2749,"briefTitle":2750,"status":139,"phases":4051,"primaryCompletion":2752,"completion":2070,"start":2753,"enrollment":2754,"conditions":4052,"interventions":4053},[89],[2074],[384,385,390,386,387,388,47,2076,2077],{"trials":4055,"activeCount":99},[],{"trials":4057,"activeCount":99},[],{"intervention":56,"totalTrials":4059,"cells":4060},22,{"EARLY_PHASE1":4061,"PHASE1":4063,"PHASE2":4115,"PHASE3":4179,"PHASE4":4237,"NA":4239},{"trials":4062,"activeCount":99},[],{"trials":4064,"activeCount":224,"soonestReadout":698},[4065,4076,4085,4095,4103,4107],{"nctId":4066,"briefTitle":4067,"status":105,"phases":4068,"primaryCompletion":4069,"completion":355,"start":4070,"enrollment":4071,"conditions":4072,"interventions":4075},"NCT04994522","A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)",[87],"2024-04-01","2022-07-12",14,[4073,4074],"End Stage Renal Disease","Renal Impairment",[56],{"nctId":4077,"briefTitle":4078,"status":105,"phases":4079,"primaryCompletion":4080,"completion":466,"start":4081,"enrollment":4071,"conditions":4082,"interventions":4083},"NCT07121959","A Study of Belzutifan (MK-6482) and Metformin in Healthy Adult Participants (MK-6482-039)",[87],"2025-09-13","2025-08-18",[18],[4084,56],"Metformin",{"nctId":4086,"briefTitle":4087,"status":105,"phases":4088,"primaryCompletion":4089,"completion":4090,"start":4091,"enrollment":3496,"conditions":4092,"interventions":4094},"NCT04995484","A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)",[87],"2023-12-25","2024-01-03","2022-06-24",[4093],"Moderate Hepatic Impairment",[56],{"nctId":4096,"briefTitle":4097,"status":105,"phases":4098,"primaryCompletion":4099,"completion":4099,"start":4100,"enrollment":31,"conditions":4101,"interventions":4102},"NCT04846920","A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)",[87],"2026-04-11","2021-06-14",[1035],[56],{"nctId":695,"briefTitle":696,"status":139,"phases":4104,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":4105,"interventions":4106},[87],[702],[56,47,461],{"nctId":4108,"briefTitle":4109,"status":105,"phases":4110,"primaryCompletion":2321,"completion":4111,"start":2286,"enrollment":4071,"conditions":4112,"interventions":4113},"NCT06903715","A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602\u002FMK-6482-035)",[87],"2025-05-27",[18],[56,4114],"Phenytoin",{"trials":4116,"activeCount":734,"soonestReadout":55},[4117,4124,4138,4142,4146,4157,4166,4170],{"nctId":53,"briefTitle":54,"status":139,"phases":4118,"primaryCompletion":55,"completion":4119,"start":4120,"enrollment":4121,"conditions":4122,"interventions":4123},[88],"2026-10-04","2020-09-13",154,[1035],[56],{"nctId":4125,"briefTitle":4126,"status":128,"phases":4127,"primaryCompletion":4128,"completion":4128,"start":4129,"enrollment":4130,"conditions":4131,"interventions":4137},"NCT04924075","Belzutifan\u002FMK-6482 for the Treatment of Advanced Pheochromocytoma\u002FParaganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)",[88],"2029-06-04","2021-08-12",322,[4132,4133,4134,4135,4136],"Pheochromocytoma\u002FParaganglioma","Pancreatic Neuroendocrine Tumor","Von Hippel-Lindau Disease","Advanced Gastrointestinal Stromal Tumor","HIF-2α Mutated Cancers",[56],{"nctId":997,"briefTitle":998,"status":139,"phases":4139,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":4140,"interventions":4141},[88],[1004],[47,56,461],{"nctId":1029,"briefTitle":1030,"status":139,"phases":4143,"primaryCompletion":1032,"completion":1032,"start":1033,"enrollment":941,"conditions":4144,"interventions":4145},[87,88],[1035],[47,471,56,461,818,460],{"nctId":4147,"briefTitle":4148,"status":128,"phases":4149,"primaryCompletion":2179,"completion":4150,"start":4151,"enrollment":2023,"conditions":4152,"interventions":4154},"NCT06428396","Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+\u002FHER2- Metastatic Breast Cancer (MK-6482-029\u002FLITESPARK-029)",[88],"2028-12-25","2024-11-27",[4153],"Metastatic Breast Cancer",[56,4155,2904,4156],"Fulvestrant","Exemestane",{"nctId":4158,"briefTitle":4159,"status":128,"phases":4160,"primaryCompletion":4161,"completion":4161,"start":4162,"enrollment":407,"conditions":4163,"interventions":4164},"NCT07049926","Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C\u002FKEYMAKER-U03)",[87,88],"2031-10-26","2025-07-20",[702],[56,4165],"Zanzalintinib",{"nctId":1146,"briefTitle":1147,"status":139,"phases":4167,"primaryCompletion":1032,"completion":1032,"start":1149,"enrollment":1150,"conditions":4168,"interventions":4169},[87,88],[1035],[47,460,56,461,818,1153],{"nctId":4171,"briefTitle":4172,"status":139,"phases":4173,"primaryCompletion":4174,"completion":4174,"start":4175,"enrollment":558,"conditions":4176,"interventions":4177},"NCT05468697","A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024\u002FLITESPARK-024)",[87,88],"2026-07-21","2022-08-10",[702],[56,4178],"Palbociclib",{"trials":4180,"activeCount":734,"soonestReadout":69},[4181,4190,4197,4206,4210,4214,4218,4228],{"nctId":4182,"briefTitle":4183,"status":128,"phases":4184,"primaryCompletion":4185,"completion":4185,"start":1540,"enrollment":4186,"conditions":4187,"interventions":4188},"NCT07227402","A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)",[89],"2032-02-27",904,[702],[56,4165,4189],"Cabozantinib",{"nctId":67,"briefTitle":68,"status":139,"phases":4191,"primaryCompletion":69,"completion":4192,"start":4193,"enrollment":4194,"conditions":4195,"interventions":4196},[89],"2026-09-17","2020-02-27",755,[1035],[56,2904],{"nctId":4198,"briefTitle":4199,"status":128,"phases":4200,"primaryCompletion":4201,"completion":4201,"start":4202,"enrollment":4203,"conditions":4204,"interventions":4205},"NCT07489495","A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034\u002FLS-034\u002FMK-6482-034)",[89],"2030-11-27","2026-04-09",758,[1035],[56,4165],{"nctId":2243,"briefTitle":2244,"status":139,"phases":4207,"primaryCompletion":2246,"completion":2247,"start":2248,"enrollment":2249,"conditions":4208,"interventions":4209},[89],[1035],[56,47],{"nctId":2395,"briefTitle":2396,"status":139,"phases":4211,"primaryCompletion":2398,"completion":2398,"start":1228,"enrollment":2399,"conditions":4212,"interventions":4213},[89],[1035],[47,56,818,461],{"nctId":2465,"briefTitle":2466,"status":139,"phases":4215,"primaryCompletion":2468,"completion":2468,"start":2469,"enrollment":2470,"conditions":4216,"interventions":4217},[89],[1035],[47,56,818,461],{"nctId":4219,"briefTitle":4220,"status":139,"phases":4221,"primaryCompletion":4222,"completion":4223,"start":4224,"enrollment":4225,"conditions":4226,"interventions":4227},"NCT04586231","A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)",[89],"2026-02-02","2027-02-11","2021-02-25",747,[1035],[56,461,4189],{"nctId":4229,"briefTitle":4230,"status":128,"phases":4231,"primaryCompletion":4232,"completion":4232,"start":4233,"enrollment":951,"conditions":4234,"interventions":4235},"NCT07405164","Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043\u002FLITESPARK-043)",[89],"2034-01-14","2026-03-23",[4134,1035],[56,4178,4236,461,4189,2904],"Nivolumab",{"trials":4238,"activeCount":99},[],{"trials":4240,"activeCount":99},[],{"intervention":842,"totalTrials":4242,"cells":4243},21,{"EARLY_PHASE1":4244,"PHASE1":4246,"PHASE2":4261,"PHASE3":4374,"PHASE4":4436,"NA":4438},{"trials":4245,"activeCount":99},[],{"trials":4247,"activeCount":99},[4248],{"nctId":4249,"briefTitle":4250,"status":105,"phases":4251,"primaryCompletion":4252,"completion":4252,"start":4253,"enrollment":193,"conditions":4254,"interventions":4256},"NCT02269735","A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001)",[87],"2016-07-29","2014-11-26",[4255],"Type 1 Diabetes Mellitus",[4257,4258,4259,4260,1089],"MK-2640","Regular Human Insulin","Dextrose","Insulin aspart",{"trials":4262,"activeCount":3308,"soonestReadout":645},[4263,4267,4280,4284,4296,4300,4311,4315,4324,4334,4338,4352,4364],{"nctId":831,"briefTitle":832,"status":128,"phases":4264,"primaryCompletion":834,"completion":834,"start":835,"enrollment":836,"conditions":4265,"interventions":4266},[87,88],[838],[840,386,387,841,842,47,714,843],{"nctId":4268,"briefTitle":4269,"status":128,"phases":4270,"primaryCompletion":4271,"completion":4271,"start":4272,"enrollment":4273,"conditions":4274,"interventions":4277},"NCT06863272","A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A\u002FIDeate-Prostate02)",[87,88],"2031-04-01","2025-07-03",360,[4275,4276],"Castration-Resistant Prostatic Cancer","Metastasis",[967,954,4278,4279,2382,842],"MK-5684","Abiraterone",{"nctId":1078,"briefTitle":1079,"status":128,"phases":4281,"primaryCompletion":1081,"completion":1081,"start":1082,"enrollment":8,"conditions":4282,"interventions":4283},[87,88],[419,1084,1085],[653,1087,1088,1089,654,390,47],{"nctId":4285,"briefTitle":4286,"status":150,"phases":4287,"primaryCompletion":4288,"completion":4288,"start":4289,"enrollment":417,"conditions":4290,"interventions":4293},"NCT01405924","Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)",[88],"2013-12-06","2011-10-25",[4291,4292],"Nausea","Vomiting",[4294,4295,529,1089],"Fosaprepitant dimeglumine","5-HT3 RA",{"nctId":1256,"briefTitle":1257,"status":128,"phases":4297,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":1261,"conditions":4298,"interventions":4299},[87,88],[1263],[47,1265,435,796,797,434,653,842],{"nctId":4301,"briefTitle":4302,"status":128,"phases":4303,"primaryCompletion":4304,"completion":4304,"start":1021,"enrollment":4305,"conditions":4306,"interventions":4308},"NCT06780098","Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I\u002FKEYMAKER-U01I)",[88],"2032-03-02",144,[4307],"Lung Neoplasm",[4309,4310,967,327,842],"R-DXD","I-DXD",{"nctId":1344,"briefTitle":1345,"status":128,"phases":4312,"primaryCompletion":1347,"completion":1347,"start":1348,"enrollment":1349,"conditions":4313,"interventions":4314},[87,88],[1134],[1059,1352,47,842],{"nctId":4316,"briefTitle":4317,"status":105,"phases":4318,"primaryCompletion":4319,"completion":4319,"start":4320,"enrollment":661,"conditions":4321,"interventions":4323},"NCT00632502","Neutrophilic Asthma Study With Navarixin (MK-7123, SCH 527123) (MK-7123-017)(COMPLETED)",[88],"2009-02-01","2008-05-01",[4322],"Neutrophilic Asthma",[1174,1089],{"nctId":4325,"briefTitle":4326,"status":150,"phases":4327,"primaryCompletion":4328,"completion":4329,"start":4330,"enrollment":3338,"conditions":4331,"interventions":4333},"NCT01006616","Long-Term Study of the Effects of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe COPD (MK-7123-019)",[88],"2011-03-01","2011-11-01","2009-10-01",[4332],"COPD",[1174,1089],{"nctId":3557,"briefTitle":3558,"status":128,"phases":4335,"primaryCompletion":645,"completion":3560,"start":3561,"enrollment":626,"conditions":4336,"interventions":4337},[87,88],[3563],[653,1089,654],{"nctId":4339,"briefTitle":4340,"status":128,"phases":4341,"primaryCompletion":4342,"completion":4343,"start":4344,"enrollment":4345,"conditions":4346,"interventions":4348},"NCT06890884","A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011\u002FwaveLINE-011)",[88],"2027-12-13","2032-12-16","2025-04-11",594,[4347],"Lymphoma, Large B-Cell, Diffuse",[1058,4349,562,1069,4350,1076,2413,4351,842],"Rituximab","Rituximab Biosimilar","Polatuzumab vedotin",{"nctId":4353,"briefTitle":4354,"status":150,"phases":4355,"primaryCompletion":4356,"completion":4356,"start":4357,"enrollment":4358,"conditions":4359,"interventions":4361},"NCT00441701","Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)",[88],"2008-10-01","2006-12-01",99,[4360],"Chronic Obstructive Pulmonary Disease",[4362,4363,1089],"Navarixin 1 mg","Navarixin 10 mg",{"nctId":4365,"briefTitle":4366,"status":128,"phases":4367,"primaryCompletion":4368,"completion":4369,"start":4370,"enrollment":558,"conditions":4371,"interventions":4373},"NCT07405151","A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)",[87,88],"2027-06-12","2028-06-12","2026-03-27",[4372],"Oesophageal Squamous Cell Carcinoma",[1265,842],{"trials":4375,"activeCount":174,"soonestReadout":4406},[4376,4380,4389,4402,4414,4428,4432],{"nctId":1628,"briefTitle":1629,"status":128,"phases":4377,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":4378,"interventions":4379},[89],[540],[653,47,842,387,388,714,386],{"nctId":4381,"briefTitle":4382,"status":128,"phases":4383,"primaryCompletion":762,"completion":4384,"start":1610,"enrollment":4385,"conditions":4386,"interventions":4387},"NCT06717347","A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)",[89],"2032-03-29",1046,[676],[1058,4349,562,1069,4350,1076,2413,1074,1089,4388],"Methylprednisolone",{"nctId":4390,"briefTitle":4391,"status":105,"phases":4392,"primaryCompletion":4393,"completion":4393,"start":4394,"enrollment":4395,"conditions":4396,"interventions":4398},"NCT00442936","Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)",[89],"2007-10-02","2007-02-15",1380,[4397],"Migraine",[4399,4400,4401,1089],"Telcagepant potassium 150 mg","Telcagepant potassium 300 mg","Zolmitriptan 5 mg",{"nctId":4403,"briefTitle":4404,"status":128,"phases":4405,"primaryCompletion":4406,"completion":4407,"start":4408,"enrollment":4409,"conditions":4410,"interventions":4412},"NCT06925737","A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)",[89],"2028-06-26","2031-01-06","2025-05-13",1440,[4411,2410],"Prostate Cancer",[4413,967,1076,842],"Ifinatamab deruxtecan",{"nctId":4415,"briefTitle":4416,"status":105,"phases":4417,"primaryCompletion":4418,"completion":4419,"start":4420,"enrollment":4421,"conditions":4422,"interventions":4423},"NCT00080444","Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)",[89],"2006-09","2007-03","2004-04",50,[4292],[4424,4425,4426,4427],"aprepitant","ondansetron","dexamethasone","rescue medication",{"nctId":2435,"briefTitle":2436,"status":128,"phases":4429,"primaryCompletion":2438,"completion":2439,"start":2440,"enrollment":2441,"conditions":4430,"interventions":4431},[89],[1108,540,2443],[653,47,842,386,387,1069,1664,562,795,1114],{"nctId":2729,"briefTitle":2730,"status":128,"phases":4433,"primaryCompletion":2732,"completion":2733,"start":2734,"enrollment":2735,"conditions":4434,"interventions":4435},[89],[2737],[653,47,390,385,714,386,387,1089],{"trials":4437,"activeCount":99},[],{"trials":4439,"activeCount":99},[],{"intervention":461,"totalTrials":700,"cells":4441},{"EARLY_PHASE1":4442,"PHASE1":4444,"PHASE2":4458,"PHASE3":4556,"PHASE4":4646,"NA":4648},{"trials":4443,"activeCount":99},[],{"trials":4445,"activeCount":224,"soonestReadout":698},[4446,4450,4454],{"nctId":450,"briefTitle":451,"status":105,"phases":4447,"primaryCompletion":453,"completion":453,"start":454,"enrollment":455,"conditions":4448,"interventions":4449},[87],[290],[458,47,434,437,435,459,460,461],{"nctId":463,"briefTitle":464,"status":105,"phases":4451,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":4452,"interventions":4453},[87],[290],[471,47,386,385,461,387,390,472],{"nctId":695,"briefTitle":696,"status":139,"phases":4455,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":4456,"interventions":4457},[87],[702],[56,47,461],{"trials":4459,"activeCount":4555,"soonestReadout":1032},[4460,4464,4468,4480,4484,4488,4492,4496,4500,4504,4508,4512,4516,4520,4524,4528,4539,4543,4547,4551],{"nctId":771,"briefTitle":772,"status":105,"phases":4461,"primaryCompletion":774,"completion":774,"start":775,"enrollment":776,"conditions":4462,"interventions":4463},[88],[778],[47,458,461,780],{"nctId":916,"briefTitle":917,"status":105,"phases":4465,"primaryCompletion":919,"completion":919,"start":356,"enrollment":920,"conditions":4466,"interventions":4467},[87,88],[35],[47,780,923,461,924],{"nctId":4469,"briefTitle":4470,"status":139,"phases":4471,"primaryCompletion":4472,"completion":4472,"start":4473,"enrollment":4474,"conditions":4475,"interventions":4476},"NCT04938817","Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98\u002FKEYNOTE-B98)",[87,88],"2029-12-10","2021-08-19",110,[866],[4477,1369,471,4478,4479],"coformulation pembrolizumab\u002Fquavonlimab","coformulation favezelimab\u002Fpembrolizumab","R-DXd",{"nctId":957,"briefTitle":958,"status":105,"phases":4481,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":4482,"interventions":4483},[88],[965],[461,47,967,795,387,693,461],{"nctId":982,"briefTitle":983,"status":105,"phases":4485,"primaryCompletion":985,"completion":985,"start":986,"enrollment":987,"conditions":4486,"interventions":4487},[88],[497,989,990,991,419,992,993,994],[47,461],{"nctId":997,"briefTitle":998,"status":139,"phases":4489,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":4490,"interventions":4491},[88],[1004],[47,56,461],{"nctId":1029,"briefTitle":1030,"status":139,"phases":4493,"primaryCompletion":1032,"completion":1032,"start":1033,"enrollment":941,"conditions":4494,"interventions":4495},[87,88],[1035],[47,471,56,461,818,460],{"nctId":1146,"briefTitle":1147,"status":139,"phases":4497,"primaryCompletion":1032,"completion":1032,"start":1149,"enrollment":1150,"conditions":4498,"interventions":4499},[87,88],[1035],[47,460,56,461,818,1153],{"nctId":3239,"briefTitle":3240,"status":128,"phases":4501,"primaryCompletion":3242,"completion":3243,"start":3244,"enrollment":2204,"conditions":4502,"interventions":4503},[87,88],[3246],[84,3248,3249,3250,3251,3252,3253,461,3254,386,1073,3255],{"nctId":1215,"briefTitle":1216,"status":105,"phases":4505,"primaryCompletion":1218,"completion":1218,"start":1219,"enrollment":429,"conditions":4506,"interventions":4507},[88],[1221],[818,461,47],{"nctId":1224,"briefTitle":1225,"status":105,"phases":4509,"primaryCompletion":1227,"completion":1227,"start":1228,"enrollment":397,"conditions":4510,"interventions":4511},[87,88],[1230],[47,1232,471,461,437,387],{"nctId":1277,"briefTitle":1278,"status":105,"phases":4513,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":1282,"conditions":4514,"interventions":4515},[88],[1284,1285,965,1286,856,791,540,1014,1287,1288,1289],[74,47,461,797,390,387,714,386,967,841,795,434],{"nctId":1315,"briefTitle":1316,"status":128,"phases":4517,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1132,"conditions":4518,"interventions":4519},[87,88],[1263],[387,437,47,471,461,653,1323,1324,979,529,1325,654],{"nctId":1363,"briefTitle":1364,"status":105,"phases":4521,"primaryCompletion":1064,"completion":1064,"start":1366,"enrollment":722,"conditions":4522,"interventions":4523},[88],[1161],[1369,42],{"nctId":1517,"briefTitle":1518,"status":105,"phases":4525,"primaryCompletion":1520,"completion":1520,"start":1521,"enrollment":1522,"conditions":4526,"interventions":4527},[87,88],[35],[47,923,818,461,460,924],{"nctId":4529,"briefTitle":4530,"status":105,"phases":4531,"primaryCompletion":4532,"completion":4533,"start":4534,"enrollment":4535,"conditions":4536,"interventions":4538},"NCT04447755","A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013\u002FE7080)",[88],"2022-09-16","2025-02-13","2020-07-30",127,[4537],"Relapsed or Refractory Solid Tumors",[461],{"nctId":1545,"briefTitle":1546,"status":105,"phases":4540,"primaryCompletion":1548,"completion":1548,"start":1549,"enrollment":1550,"conditions":4541,"interventions":4542},[88],[1552],[47,471,542,461,1073,390,386],{"nctId":1586,"briefTitle":1587,"status":105,"phases":4544,"primaryCompletion":1589,"completion":1589,"start":1011,"enrollment":1590,"conditions":4545,"interventions":4546},[88],[279,1592,861],[1594,42,1369],{"nctId":1607,"briefTitle":1608,"status":105,"phases":4548,"primaryCompletion":1610,"completion":1611,"start":1612,"enrollment":787,"conditions":4549,"interventions":4550},[88],[702],[47,461],{"nctId":1616,"briefTitle":1617,"status":105,"phases":4552,"primaryCompletion":1619,"completion":1619,"start":1620,"enrollment":1621,"conditions":4553,"interventions":4554},[87,88],[35],[47,818,461],6,{"trials":4557,"activeCount":4555,"soonestReadout":2321},[4558,4562,4566,4570,4574,4578,4582,4586,4590,4594,4598,4602,4606,4610,4614,4618,4622,4626,4630,4634,4638,4642],{"nctId":1719,"briefTitle":1720,"status":105,"phases":4559,"primaryCompletion":1722,"completion":1723,"start":1724,"enrollment":1725,"conditions":4560,"interventions":4561},[89],[1727],[461,47,1729,1730],{"nctId":1864,"briefTitle":1865,"status":105,"phases":4563,"primaryCompletion":1867,"completion":1868,"start":1869,"enrollment":1870,"conditions":4564,"interventions":4565},[89],[883],[47,461],{"nctId":1934,"briefTitle":1935,"status":105,"phases":4567,"primaryCompletion":1167,"completion":1937,"start":1938,"enrollment":1169,"conditions":4568,"interventions":4569},[89],[314],[47,461],{"nctId":2048,"briefTitle":2049,"status":105,"phases":4571,"primaryCompletion":2051,"completion":2052,"start":2053,"enrollment":2054,"conditions":4572,"interventions":4573},[89],[2056],[47,461,434,795,435,1444],{"nctId":2059,"briefTitle":2060,"status":105,"phases":4575,"primaryCompletion":535,"completion":535,"start":2062,"enrollment":2063,"conditions":4576,"interventions":4577},[89],[371],[42,1369,2066,2067],{"nctId":2143,"briefTitle":2144,"status":105,"phases":4579,"primaryCompletion":2146,"completion":2147,"start":2148,"enrollment":2149,"conditions":4580,"interventions":4581},[89],[2151],[47,386,390,385,461],{"nctId":2227,"briefTitle":2228,"status":105,"phases":4583,"primaryCompletion":1867,"completion":1868,"start":2230,"enrollment":2231,"conditions":4584,"interventions":4585},[89],[883],[47,461],{"nctId":2235,"briefTitle":2236,"status":105,"phases":4587,"primaryCompletion":2146,"completion":2238,"start":366,"enrollment":2239,"conditions":4588,"interventions":4589},[89],[1799],[47,461,967],{"nctId":2262,"briefTitle":2263,"status":105,"phases":4591,"primaryCompletion":2265,"completion":2266,"start":2267,"enrollment":2268,"conditions":4592,"interventions":4593},[89],[1056],[47,461],{"nctId":2282,"briefTitle":2283,"status":105,"phases":4595,"primaryCompletion":2285,"completion":2286,"start":2287,"enrollment":2288,"conditions":4596,"interventions":4597},[89],[1514],[461,47],{"nctId":2292,"briefTitle":2293,"status":105,"phases":4599,"primaryCompletion":2116,"completion":2295,"start":2296,"enrollment":132,"conditions":4600,"interventions":4601},[89],[1285],[461,47,387,386],{"nctId":2318,"briefTitle":2319,"status":139,"phases":4603,"primaryCompletion":2321,"completion":2322,"start":2323,"enrollment":2324,"conditions":4604,"interventions":4605},[89],[2326],[47,461,390,1444,434,435,796,387],{"nctId":2395,"briefTitle":2396,"status":139,"phases":4607,"primaryCompletion":2398,"completion":2398,"start":1228,"enrollment":2399,"conditions":4608,"interventions":4609},[89],[1035],[47,56,818,461],{"nctId":2465,"briefTitle":2466,"status":139,"phases":4611,"primaryCompletion":2468,"completion":2468,"start":2469,"enrollment":2470,"conditions":4612,"interventions":4613},[89],[1035],[47,56,818,461],{"nctId":2501,"briefTitle":2502,"status":105,"phases":4615,"primaryCompletion":2116,"completion":2504,"start":1877,"enrollment":2505,"conditions":4616,"interventions":4617},[89],[1285],[461,47,387,386],{"nctId":4219,"briefTitle":4220,"status":139,"phases":4619,"primaryCompletion":4222,"completion":4223,"start":4224,"enrollment":4225,"conditions":4620,"interventions":4621},[89],[1035],[56,461,4189],{"nctId":2579,"briefTitle":2580,"status":105,"phases":4623,"primaryCompletion":2582,"completion":2583,"start":2584,"enrollment":2585,"conditions":4624,"interventions":4625},[89],[1514],[461,47],{"nctId":4229,"briefTitle":4230,"status":128,"phases":4627,"primaryCompletion":4232,"completion":4232,"start":4233,"enrollment":951,"conditions":4628,"interventions":4629},[89],[4134,1035],[56,4178,4236,461,4189,2904],{"nctId":2598,"briefTitle":2599,"status":128,"phases":4631,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":2603,"conditions":4632,"interventions":4633},[89],[176,2605],[47,2607,461,1114,2608,2609,384],{"nctId":2660,"briefTitle":2661,"status":105,"phases":4635,"primaryCompletion":2146,"completion":2147,"start":2663,"enrollment":2664,"conditions":4636,"interventions":4637},[89],[2151],[47,386,390,385,461],{"nctId":2699,"briefTitle":2700,"status":105,"phases":4639,"primaryCompletion":1167,"completion":2702,"start":2703,"enrollment":2704,"conditions":4640,"interventions":4641},[89],[314],[47,461],{"nctId":2708,"briefTitle":2709,"status":105,"phases":4643,"primaryCompletion":2711,"completion":1794,"start":2712,"enrollment":2713,"conditions":4644,"interventions":4645},[89],[1727],[1369,42,2716],{"trials":4647,"activeCount":99},[],{"trials":4649,"activeCount":99},[],{"intervention":388,"totalTrials":569,"cells":4651},{"EARLY_PHASE1":4652,"PHASE1":4654,"PHASE2":4672,"PHASE3":4682,"PHASE4":4736,"NA":4738},{"trials":4653,"activeCount":99},[],{"trials":4655,"activeCount":224,"soonestReadout":378},[4656,4660,4664,4668],{"nctId":375,"briefTitle":376,"status":139,"phases":4657,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":4658,"interventions":4659},[87],[382],[384,47,385,386,387,388,389,390],{"nctId":532,"briefTitle":533,"status":105,"phases":4661,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":4662,"interventions":4663},[87],[539,279,369,540],[542,47,385,386,388],{"nctId":552,"briefTitle":553,"status":105,"phases":4665,"primaryCompletion":555,"completion":556,"start":557,"enrollment":558,"conditions":4666,"interventions":4667},[87],[540],[47,388,561,562,386,387],{"nctId":705,"briefTitle":706,"status":105,"phases":4669,"primaryCompletion":708,"completion":708,"start":709,"enrollment":710,"conditions":4670,"interventions":4671},[87],[290],[713,42,387,388,714,386,385],{"trials":4673,"activeCount":3197,"soonestReadout":762},[4674,4678],{"nctId":759,"briefTitle":760,"status":128,"phases":4675,"primaryCompletion":762,"completion":763,"start":764,"enrollment":765,"conditions":4676,"interventions":4677},[88],[767],[769,47,386,387,388],{"nctId":1327,"briefTitle":1328,"status":128,"phases":4679,"primaryCompletion":1330,"completion":1330,"start":1331,"enrollment":397,"conditions":4680,"interventions":4681},[88],[314],[47,386,387,388,385,955],{"trials":4683,"activeCount":3308,"soonestReadout":60},[4684,4688,4692,4696,4700,4704,4708,4712,4716,4720,4724,4728,4732],{"nctId":1628,"briefTitle":1629,"status":128,"phases":4685,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":4686,"interventions":4687},[89],[540],[653,47,842,387,388,714,386],{"nctId":2934,"briefTitle":2935,"status":128,"phases":4689,"primaryCompletion":2937,"completion":2937,"start":2938,"enrollment":1633,"conditions":4690,"interventions":4691},[89],[1108],[1111,387,388,795,2207,2941],{"nctId":1791,"briefTitle":1792,"status":105,"phases":4693,"primaryCompletion":1794,"completion":1795,"start":1796,"enrollment":1797,"conditions":4694,"interventions":4695},[89],[1799],[1241,386,390,387,388,385,47],{"nctId":1853,"briefTitle":1854,"status":139,"phases":4697,"primaryCompletion":1856,"completion":1856,"start":1510,"enrollment":1452,"conditions":4698,"interventions":4699},[89],[1108],[42,1654,1859,1860,1445,1861,1862],{"nctId":1942,"briefTitle":1943,"status":105,"phases":4701,"primaryCompletion":1945,"completion":1946,"start":1947,"enrollment":1948,"conditions":4702,"interventions":4703},[89],[314],[47,387,388,386,1951],{"nctId":76,"briefTitle":77,"status":139,"phases":4705,"primaryCompletion":78,"completion":2070,"start":2071,"enrollment":2072,"conditions":4706,"interventions":4707},[89],[2074],[79,385,390,386,387,388,47,2076,2077],{"nctId":2198,"briefTitle":2199,"status":128,"phases":4709,"primaryCompletion":2201,"completion":2202,"start":2203,"enrollment":2204,"conditions":4710,"interventions":4711},[89],[1108],[653,47,387,388,795,2207],{"nctId":3030,"briefTitle":3031,"status":139,"phases":4713,"primaryCompletion":3033,"completion":3033,"start":1958,"enrollment":3034,"conditions":4714,"interventions":4715},[89],[861],[653,1069,387,388,3037],{"nctId":2385,"briefTitle":2386,"status":105,"phases":4717,"primaryCompletion":2388,"completion":2389,"start":1702,"enrollment":2390,"conditions":4718,"interventions":4719},[89],[2392],[47,386,387,388,1114],{"nctId":58,"briefTitle":59,"status":139,"phases":4721,"primaryCompletion":60,"completion":3090,"start":3091,"enrollment":3092,"conditions":4722,"interventions":4723},[89],[903],[61,3095,387,3096,386,390,385],{"nctId":2518,"briefTitle":2519,"status":128,"phases":4725,"primaryCompletion":2521,"completion":2522,"start":2523,"enrollment":2390,"conditions":4726,"interventions":4727},[89],[314,2525],[47,2527,386,387,388],{"nctId":2718,"briefTitle":2719,"status":105,"phases":4729,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":2512,"conditions":4730,"interventions":4731},[89],[2725],[47,388,387,714,386,2727],{"nctId":2749,"briefTitle":2750,"status":139,"phases":4733,"primaryCompletion":2752,"completion":2070,"start":2753,"enrollment":2754,"conditions":4734,"interventions":4735},[89],[2074],[384,385,390,386,387,388,47,2076,2077],{"trials":4737,"activeCount":99},[],{"trials":4739,"activeCount":99},[],{"intervention":967,"totalTrials":4741,"cells":4742},31,{"EARLY_PHASE1":4743,"PHASE1":4745,"PHASE2":4761,"PHASE3":4814,"PHASE4":4900,"NA":4902},{"trials":4744,"activeCount":99},[],{"trials":4746,"activeCount":99},[4747,4751],{"nctId":2808,"briefTitle":2809,"status":105,"phases":4748,"primaryCompletion":2811,"completion":2812,"start":2813,"enrollment":22,"conditions":4749,"interventions":4750},[87],[2815],[2817,1677,2818,484,1654,2819],{"nctId":4752,"briefTitle":4753,"status":105,"phases":4754,"primaryCompletion":4755,"completion":4755,"start":4756,"enrollment":3903,"conditions":4757,"interventions":4759},"NCT00543387","Treatment of Participants With Advanced and\u002For Refractory Solid Tumors (MK-5108-001)",[87],"2011-04-04","2008-03-27",[4758],"Cancer, Neoplasms, Tumors",[4760,1677],"MK-5108",{"trials":4762,"activeCount":202,"soonestReadout":4771},[4763,4767,4778,4782,4791,4795,4799,4803],{"nctId":4268,"briefTitle":4269,"status":128,"phases":4764,"primaryCompletion":4271,"completion":4271,"start":4272,"enrollment":4273,"conditions":4765,"interventions":4766},[87,88],[4275,4276],[967,954,4278,4279,2382,842],{"nctId":4768,"briefTitle":4769,"status":128,"phases":4770,"primaryCompletion":4771,"completion":4771,"start":2266,"enrollment":8,"conditions":4772,"interventions":4774},"NCT06353386","Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)",[87,88],"2029-01-15",[4773],"Prostatic Neoplasms, Castration-Resistant",[4775,1114,967,4776,4777,529,1076],"Opevesostat","Cabazitaxel","Fludrocortisone acetate",{"nctId":957,"briefTitle":958,"status":105,"phases":4779,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":4780,"interventions":4781},[88],[965],[461,47,967,795,387,693,461],{"nctId":4783,"briefTitle":4784,"status":105,"phases":4785,"primaryCompletion":4786,"completion":4786,"start":4787,"enrollment":36,"conditions":4788,"interventions":4790},"NCT00687440","A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)",[88],"2008-10-24","2005-07-15",[4789],"Breast Neoplasm",[3229,967,1843],{"nctId":1277,"briefTitle":1278,"status":105,"phases":4792,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":1282,"conditions":4793,"interventions":4794},[88],[1284,1285,965,1286,856,791,540,1014,1287,1288,1289],[74,47,461,797,390,387,714,386,967,841,795,434],{"nctId":4301,"briefTitle":4302,"status":128,"phases":4796,"primaryCompletion":4304,"completion":4304,"start":1021,"enrollment":4305,"conditions":4797,"interventions":4798},[88],[4307],[4309,4310,967,327,842],{"nctId":1494,"briefTitle":1495,"status":105,"phases":4800,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":787,"conditions":4801,"interventions":4802},[88],[1501,1502],[47,387,386,1504,471,967],{"nctId":4804,"briefTitle":4805,"status":105,"phases":4806,"primaryCompletion":4807,"completion":4808,"start":4809,"enrollment":4810,"conditions":4811,"interventions":4813},"NCT04725188","Pembrolizumab\u002FVibostolimab Coformulation (MK-7684A) or Pembrolizumab\u002FVibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)",[88],"2023-01-26","2024-10-17","2021-04-20",255,[4812],"Metastatic Non Small Cell Lung Cancer",[3254,967],{"trials":4815,"activeCount":734,"soonestReadout":2167},[4816,4820,4824,4828,4832,4836,4840,4844,4848,4852,4856,4860,4864,4868,4872,4876,4880,4884,4888,4892,4896],{"nctId":1667,"briefTitle":1668,"status":105,"phases":4817,"primaryCompletion":1670,"completion":1671,"start":1672,"enrollment":1673,"conditions":4818,"interventions":4819},[89],[1563],[42,1654,1676,1677],{"nctId":3576,"briefTitle":3577,"status":139,"phases":4821,"primaryCompletion":3579,"completion":3580,"start":3581,"enrollment":3582,"conditions":4822,"interventions":4823},[89],[1687],[653,967,385],{"nctId":1845,"briefTitle":1846,"status":105,"phases":4825,"primaryCompletion":823,"completion":1848,"start":1670,"enrollment":1849,"conditions":4826,"interventions":4827},[89],[369],[47,967],{"nctId":1923,"briefTitle":1924,"status":105,"phases":4829,"primaryCompletion":1926,"completion":1927,"start":589,"enrollment":1928,"conditions":4830,"interventions":4831},[89],[990,1930,1931],[47,386,387,1114,841,967],{"nctId":2019,"briefTitle":2020,"status":105,"phases":4833,"primaryCompletion":2022,"completion":730,"start":1406,"enrollment":2023,"conditions":4834,"interventions":4835},[89],[991,2025],[47,390,795,606,967,434,435],{"nctId":2079,"briefTitle":2080,"status":105,"phases":4837,"primaryCompletion":2082,"completion":2083,"start":2084,"enrollment":2085,"conditions":4838,"interventions":4839},[89],[1603,1604],[42,1654,1677,2088],{"nctId":2090,"briefTitle":2091,"status":105,"phases":4841,"primaryCompletion":2093,"completion":2094,"start":2095,"enrollment":2096,"conditions":4842,"interventions":4843},[89],[2098],[47,2100,967,693],{"nctId":3005,"briefTitle":3006,"status":128,"phases":4845,"primaryCompletion":3008,"completion":3009,"start":3010,"enrollment":3011,"conditions":4846,"interventions":4847},[89],[1134],[653,3014,967,387,3015,3016],{"nctId":2154,"briefTitle":2155,"status":105,"phases":4849,"primaryCompletion":2157,"completion":1966,"start":2158,"enrollment":2159,"conditions":4850,"interventions":4851},[88,89],[2161],[47,967],{"nctId":2164,"briefTitle":2165,"status":139,"phases":4853,"primaryCompletion":2167,"completion":2168,"start":2169,"enrollment":2170,"conditions":4854,"interventions":4855},[89],[990,2172,2173],[47,387,841,967],{"nctId":2209,"briefTitle":2210,"status":105,"phases":4857,"primaryCompletion":2212,"completion":2083,"start":2213,"enrollment":2214,"conditions":4858,"interventions":4859},[89],[1603,1604],[42,1654,1677,2088],{"nctId":2235,"briefTitle":2236,"status":105,"phases":4861,"primaryCompletion":2146,"completion":2238,"start":366,"enrollment":2239,"conditions":4862,"interventions":4863},[89],[1799],[47,461,967],{"nctId":4403,"briefTitle":4404,"status":128,"phases":4865,"primaryCompletion":4406,"completion":4407,"start":4408,"enrollment":4409,"conditions":4866,"interventions":4867},[89],[4411,2410],[4413,967,1076,842],{"nctId":2339,"briefTitle":2340,"status":105,"phases":4869,"primaryCompletion":2022,"completion":730,"start":2342,"enrollment":2343,"conditions":4870,"interventions":4871},[89],[991,2025],[47,390,795,606,967,434,435],{"nctId":3070,"briefTitle":3071,"status":139,"phases":4873,"primaryCompletion":3073,"completion":3074,"start":3075,"enrollment":951,"conditions":4874,"interventions":4875},[89],[3077],[653,3079,437,387,967,3037,654],{"nctId":2426,"briefTitle":2427,"status":128,"phases":4877,"primaryCompletion":2429,"completion":2429,"start":2430,"enrollment":2431,"conditions":4878,"interventions":4879},[89],[861],[47,386,387,967,794],{"nctId":2446,"briefTitle":2447,"status":105,"phases":4881,"primaryCompletion":2449,"completion":929,"start":2450,"enrollment":2451,"conditions":4882,"interventions":4883},[89],[2453],[47,795,714,967],{"nctId":2456,"briefTitle":2457,"status":139,"phases":4885,"primaryCompletion":2459,"completion":2459,"start":2460,"enrollment":2461,"conditions":4886,"interventions":4887},[89],[1285],[42,484,1654,1677,486],{"nctId":2492,"briefTitle":2493,"status":139,"phases":4889,"primaryCompletion":2495,"completion":2495,"start":2496,"enrollment":2497,"conditions":4890,"interventions":4891},[89],[1285],[47,386,387,967,390,390],{"nctId":2652,"briefTitle":2653,"status":105,"phases":4893,"primaryCompletion":2655,"completion":427,"start":2407,"enrollment":2656,"conditions":4894,"interventions":4895},[89],[2410],[47,967,1076,529],{"nctId":2765,"briefTitle":2766,"status":150,"phases":4897,"primaryCompletion":2768,"completion":427,"start":2769,"enrollment":2770,"conditions":4898,"interventions":4899},[89],[2410],[47,967,1076,529],{"trials":4901,"activeCount":99},[],{"trials":4903,"activeCount":99},[],{"intervention":327,"totalTrials":335,"cells":4905},{"EARLY_PHASE1":4906,"PHASE1":4908,"PHASE2":4914,"PHASE3":4945,"PHASE4":4963,"NA":4965},{"trials":4907,"activeCount":99},[],{"trials":4909,"activeCount":224,"soonestReadout":320},[4910],{"nctId":317,"briefTitle":318,"status":139,"phases":4911,"primaryCompletion":320,"completion":320,"start":321,"enrollment":322,"conditions":4912,"interventions":4913},[87],[324],[326,47,327],{"trials":4915,"activeCount":174,"soonestReadout":4924},[4916,4920,4933,4937,4941],{"nctId":3257,"briefTitle":3258,"status":128,"phases":4917,"primaryCompletion":3260,"completion":3261,"start":1701,"enrollment":3262,"conditions":4918,"interventions":4919},[87,88],[3264],[3266,1265,3267,386,1073,327],{"nctId":4921,"briefTitle":4922,"status":128,"phases":4923,"primaryCompletion":4924,"completion":4924,"start":4925,"enrollment":688,"conditions":4926,"interventions":4927},"NCT06979596","A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015\u002FOMAHA-015)",[88],"2027-11-04","2025-08-11",[690],[4775,4928,4929,327,4155,4156,4930,4931,4932],"Fludrocortisone\u002F Fludrocortisone acetate","Dexamethasone\u002FDexamethasone acetate","Megestrol acetate\u002FMedroxyprogesterone acetate","Tamoxifen","Letrozole",{"nctId":2867,"briefTitle":2868,"status":128,"phases":4934,"primaryCompletion":2870,"completion":2871,"start":2872,"enrollment":2873,"conditions":4935,"interventions":4936},[87,88],[789,790,791,792],[2876,387,794,327,955],{"nctId":3535,"briefTitle":3536,"status":128,"phases":4938,"primaryCompletion":3538,"completion":3539,"start":3540,"enrollment":3541,"conditions":4939,"interventions":4940},[87,88],[975],[500,1111,653,693,327],{"nctId":4301,"briefTitle":4302,"status":128,"phases":4942,"primaryCompletion":4304,"completion":4304,"start":1021,"enrollment":4305,"conditions":4943,"interventions":4944},[88],[4307],[4309,4310,967,327,842],{"trials":4946,"activeCount":3963,"soonestReadout":3073},[4947,4951,4955,4959],{"nctId":3600,"briefTitle":3601,"status":128,"phases":4948,"primaryCompletion":3603,"completion":3603,"start":3604,"enrollment":3605,"conditions":4949,"interventions":4950},[89],[1288,990],[653,841,327],{"nctId":3030,"briefTitle":3031,"status":139,"phases":4952,"primaryCompletion":3033,"completion":3033,"start":1958,"enrollment":3034,"conditions":4953,"interventions":4954},[89],[861],[653,1069,387,388,3037],{"nctId":3070,"briefTitle":3071,"status":139,"phases":4956,"primaryCompletion":3073,"completion":3074,"start":3075,"enrollment":951,"conditions":4957,"interventions":4958},[89],[3077],[653,3079,437,387,967,3037,654],{"nctId":2740,"briefTitle":2741,"status":128,"phases":4960,"primaryCompletion":2743,"completion":2743,"start":2744,"enrollment":2745,"conditions":4961,"interventions":4962},[89],[863],[47,794,841,387,390,386,327],{"trials":4964,"activeCount":99},[],{"trials":4966,"activeCount":99},[],{"intervention":714,"totalTrials":3506,"cells":4968},{"EARLY_PHASE1":4969,"PHASE1":4971,"PHASE2":5000,"PHASE3":5033,"PHASE4":5107,"NA":5109},{"trials":4970,"activeCount":99},[],{"trials":4972,"activeCount":99},[4973,4982,4986,4996],{"nctId":4974,"briefTitle":4975,"status":105,"phases":4976,"primaryCompletion":4977,"completion":4977,"start":4978,"enrollment":700,"conditions":4979,"interventions":4980},"NCT00779584","A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002\u002FP05248)",[87],"2011-05-28","2008-10-17",[755,756,290],[4981,714],"MK-8776",{"nctId":3157,"briefTitle":3158,"status":105,"phases":4983,"primaryCompletion":3160,"completion":3160,"start":3161,"enrollment":3162,"conditions":4984,"interventions":4985},[87],[176],[2894,1885,486,484],{"nctId":4987,"briefTitle":4988,"status":105,"phases":4989,"primaryCompletion":4990,"completion":4990,"start":4419,"enrollment":4991,"conditions":4992,"interventions":4993},"NCT00423449","Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)",[87],"2010-04",61,[903],[4994,714,4995],"vorinostat","Platinum-based agent",{"nctId":705,"briefTitle":706,"status":105,"phases":4997,"primaryCompletion":708,"completion":708,"start":709,"enrollment":710,"conditions":4998,"interventions":4999},[87],[290],[713,42,387,388,714,386,385],{"trials":5001,"activeCount":3197,"soonestReadout":834},[5002,5006,5010,5021,5025,5029],{"nctId":831,"briefTitle":832,"status":128,"phases":5003,"primaryCompletion":834,"completion":834,"start":835,"enrollment":836,"conditions":5004,"interventions":5005},[87,88],[838],[840,386,387,841,842,47,714,843],{"nctId":969,"briefTitle":970,"status":128,"phases":5007,"primaryCompletion":972,"completion":972,"start":973,"enrollment":558,"conditions":5008,"interventions":5009},[88],[975],[47,390,714,385,653,977,978,979,529,386,47,387,980],{"nctId":5011,"briefTitle":5012,"status":105,"phases":5013,"primaryCompletion":5014,"completion":5015,"start":5016,"enrollment":5017,"conditions":5018,"interventions":5019},"NCT05508867","A Study of Coformulated Favezelimab\u002FPembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)",[88],"2025-09-03","2026-01-08","2022-10-18",203,[674],[1594,5020,1885],"bendamustine",{"nctId":1277,"briefTitle":1278,"status":105,"phases":5022,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":1282,"conditions":5023,"interventions":5024},[88],[1284,1285,965,1286,856,791,540,1014,1287,1288,1289],[74,47,461,797,390,387,714,386,967,841,795,434],{"nctId":2896,"briefTitle":2897,"status":150,"phases":5026,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":2901,"conditions":5027,"interventions":5028},[87,88],[290],[386,1664,1843,2904,714,2905,693,387,390,1444,1253,437,2906],{"nctId":1536,"briefTitle":1537,"status":105,"phases":5030,"primaryCompletion":1539,"completion":1540,"start":891,"enrollment":1541,"conditions":5031,"interventions":5032},[88],[540],[47,1114,386,714],{"trials":5034,"activeCount":357,"soonestReadout":65},[5035,5039,5043,5047,5051,5055,5059,5063,5067,5071,5083,5087,5091,5095,5099,5103],{"nctId":1628,"briefTitle":1629,"status":128,"phases":5036,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":5037,"interventions":5038},[89],[540],[653,47,842,387,388,714,386],{"nctId":1708,"briefTitle":1709,"status":105,"phases":5040,"primaryCompletion":1711,"completion":1712,"start":1713,"enrollment":1714,"conditions":5041,"interventions":5042},[89],[1716],[47,390,386,714],{"nctId":1822,"briefTitle":1823,"status":105,"phases":5044,"primaryCompletion":1539,"completion":1825,"start":1826,"enrollment":1827,"conditions":5045,"interventions":5046},[89],[1829],[47,714,390],{"nctId":1874,"briefTitle":1875,"status":105,"phases":5048,"primaryCompletion":1877,"completion":1878,"start":1879,"enrollment":1880,"conditions":5049,"interventions":5050},[89],[1882],[42,1445,1884,1885,1886],{"nctId":63,"briefTitle":64,"status":139,"phases":5052,"primaryCompletion":65,"completion":1569,"start":1889,"enrollment":1890,"conditions":5053,"interventions":5054},[89],[314],[47,390,714,385],{"nctId":2102,"briefTitle":2103,"status":128,"phases":5056,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":2108,"conditions":5057,"interventions":5058},[89],[369],[47,390,386,385,714,387,885],{"nctId":2123,"briefTitle":2124,"status":105,"phases":5060,"primaryCompletion":2126,"completion":2126,"start":2127,"enrollment":2128,"conditions":5061,"interventions":5062},[89],[1134],[47,2131,714,390],{"nctId":3617,"briefTitle":3618,"status":139,"phases":5064,"primaryCompletion":3620,"completion":3620,"start":477,"enrollment":3621,"conditions":5065,"interventions":5066},[89],[863],[794,385,3624,3625,3626,714,437],{"nctId":2218,"briefTitle":2219,"status":105,"phases":5068,"primaryCompletion":1539,"completion":2221,"start":2222,"enrollment":2223,"conditions":5069,"interventions":5070},[89],[1829],[47,714,390],{"nctId":5072,"briefTitle":5073,"status":128,"phases":5074,"primaryCompletion":5075,"completion":5075,"start":5076,"enrollment":5077,"conditions":5078,"interventions":5080},"NCT05139017","A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)",[88,89],"2027-09-24","2022-01-14",290,[5079,676],"DLBCL",[1058,4349,714,434,5081,5082],"Bendamustine","Granulocyte Colony-Stimulating Factor",{"nctId":2347,"briefTitle":2348,"status":105,"phases":5084,"primaryCompletion":1736,"completion":1520,"start":2350,"enrollment":2351,"conditions":5085,"interventions":5086},[89],[1134],[47,714,390],{"nctId":2446,"briefTitle":2447,"status":105,"phases":5088,"primaryCompletion":2449,"completion":929,"start":2450,"enrollment":2451,"conditions":5089,"interventions":5090},[89],[2453],[47,795,714,967],{"nctId":2568,"briefTitle":2569,"status":105,"phases":5092,"primaryCompletion":2571,"completion":2572,"start":2573,"enrollment":2574,"conditions":5093,"interventions":5094},[89],[2576],[47,387,386,385,390,714],{"nctId":2619,"briefTitle":2620,"status":139,"phases":5096,"primaryCompletion":2622,"completion":2623,"start":2624,"enrollment":2625,"conditions":5097,"interventions":5098},[89],[1287],[47,390,1087,2628,714],{"nctId":2718,"briefTitle":2719,"status":105,"phases":5100,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":2512,"conditions":5101,"interventions":5102},[89],[2725],[47,388,387,714,386,2727],{"nctId":2729,"briefTitle":2730,"status":128,"phases":5104,"primaryCompletion":2732,"completion":2733,"start":2734,"enrollment":2735,"conditions":5105,"interventions":5106},[89],[2737],[653,47,390,385,714,386,387,1089],{"trials":5108,"activeCount":99},[],{"trials":5110,"activeCount":99},[],{"intervention":529,"totalTrials":1624,"cells":5112},{"EARLY_PHASE1":5113,"PHASE1":5115,"PHASE2":5187,"PHASE3":5216,"PHASE4":5333,"NA":5354},{"trials":5114,"activeCount":99},[],{"trials":5116,"activeCount":99},[5117,5127,5138,5142,5155,5164,5175],{"nctId":5118,"briefTitle":5119,"status":105,"phases":5120,"primaryCompletion":5121,"completion":5121,"start":5122,"enrollment":4071,"conditions":5123,"interventions":5124},"NCT06136598","A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)",[87],"2026-03-09","2024-01-30",[2410,3246],[4775,529,5125,5126],"Fludrocortisone","Hydrocortisone",{"nctId":5128,"briefTitle":5129,"status":105,"phases":5130,"primaryCompletion":5131,"completion":5131,"start":5132,"enrollment":2770,"conditions":5133,"interventions":5134},"NCT00871910","Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)",[87],"2010-02-22","2006-10-11",[176,756,526],[5135,5135,5135,5135,5136,5137,529],"SCH 727965","Aprepitant","Ondansetron",{"nctId":520,"briefTitle":521,"status":150,"phases":5139,"primaryCompletion":523,"completion":523,"start":524,"enrollment":22,"conditions":5140,"interventions":5141},[87],[526],[47,528,529,530],{"nctId":5143,"briefTitle":5144,"status":150,"phases":5145,"primaryCompletion":5146,"completion":5146,"start":5147,"enrollment":5148,"conditions":5149,"interventions":5151},"NCT00818259","A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)",[87],"2014-01-20","2009-02-05",92,[5150],"Chemotherapy-Induced Nausea and Vomiting",[5152,5153,5154,5137,529],"Experimental: aprepitant","Experimental: fosaprepitant","Comparator: ondansetron",{"nctId":5156,"briefTitle":5157,"status":105,"phases":5158,"primaryCompletion":5159,"completion":5160,"start":5161,"enrollment":357,"conditions":5162,"interventions":5163},"NCT06104449","A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)",[87],"2026-02-20","2026-04-17","2023-11-14",[2410,3246],[4775,529,4777,5126],{"nctId":5165,"briefTitle":5166,"status":105,"phases":5167,"primaryCompletion":5168,"completion":5169,"start":5170,"enrollment":4741,"conditions":5171,"interventions":5173},"NCT00642954","Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)",[87],"2012-09-03","2013-08-20","2008-02-13",[5172],"Relapsed or Refractory Multiple Myeloma",[5174,528,529],"Vorinostat",{"nctId":5176,"briefTitle":5177,"status":105,"phases":5178,"primaryCompletion":5179,"completion":5179,"start":4990,"enrollment":3655,"conditions":5180,"interventions":5182},"NCT01111851","Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)",[87],"2010-10",[5181],"Chemotherapy-Induced Nausea and Vomiting (CINV)",[5183,5184,5185,529,529,5137,5186],"Fosaprepitant 150 mg","Aprepitant 165 mg","Aprepitant 250 mg","MK0999",{"trials":5188,"activeCount":202,"soonestReadout":1318},[5189,5200,5204,5208,5212],{"nctId":5190,"briefTitle":5191,"status":105,"phases":5192,"primaryCompletion":5193,"completion":5194,"start":5195,"enrollment":5196,"conditions":5197,"interventions":5198},"NCT00773838","Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)",[88],"2011-05-16","2012-04-09","2008-12-01",143,[5172],[5174,5199,529],"Bortezomib",{"nctId":4768,"briefTitle":4769,"status":128,"phases":5201,"primaryCompletion":4771,"completion":4771,"start":2266,"enrollment":8,"conditions":5202,"interventions":5203},[87,88],[4773],[4775,1114,967,4776,4777,529,1076],{"nctId":969,"briefTitle":970,"status":128,"phases":5205,"primaryCompletion":972,"completion":972,"start":973,"enrollment":558,"conditions":5206,"interventions":5207},[88],[975],[47,390,714,385,653,977,978,979,529,386,47,387,980],{"nctId":4285,"briefTitle":4286,"status":150,"phases":5209,"primaryCompletion":4288,"completion":4288,"start":4289,"enrollment":417,"conditions":5210,"interventions":5211},[88],[4291,4292],[4294,4295,529,1089],{"nctId":1315,"briefTitle":1316,"status":128,"phases":5213,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1132,"conditions":5214,"interventions":5215},[87,88],[1263],[387,437,47,471,461,653,1323,1324,979,529,1325,654],{"trials":5217,"activeCount":174,"soonestReadout":5260},[5218,5234,5245,5256,5268,5272,5276,5287,5300,5304,5317,5321,5325,5329],{"nctId":5219,"briefTitle":5220,"status":128,"phases":5221,"primaryCompletion":5222,"completion":5223,"start":1520,"enrollment":1452,"conditions":5224,"interventions":5226},"NCT07570173","A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)",[88,89],"2029-02-10","2029-10-02",[5225],"B-cell Acute Lymphoblastic Leukemia",[5227,5228,979,5229,529,5230,5231,5232,5233],"MK-1045","Blinatumomab","Diphenhydramine","Tocilizumab","Siltuximab","Avtozma","Tyenne",{"nctId":5235,"briefTitle":5236,"status":128,"phases":5237,"primaryCompletion":5238,"completion":5239,"start":5240,"enrollment":5241,"conditions":5242,"interventions":5244},"NCT06136624","Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)",[89],"2028-08-02","2030-02-15","2023-12-31",1310,[5243],"Prostate Cancer Metastatic",[4775,2412,2382,5126,4777,1076,529],{"nctId":5246,"briefTitle":5247,"status":150,"phases":5248,"primaryCompletion":5249,"completion":5249,"start":5250,"enrollment":613,"conditions":5251,"interventions":5253},"NCT02519842","Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)",[89],"2017-02-24","2015-09-14",[5252],"Chemotherapy-induced Nausea and Vomiting",[5254,5137,529,5255],"Fosaprepitant","5-HT3 antagonist",{"nctId":5257,"briefTitle":5258,"status":128,"phases":5259,"primaryCompletion":5260,"completion":5261,"start":5262,"enrollment":5263,"conditions":5264,"interventions":5266},"NCT06136650","A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)",[89],"2028-05-10","2030-12-02","2023-12-18",1314,[5265,2410],"Metastatic Castration-resistant Prostate Cancer (mCRPC)",[4775,529,4777,5126,2412,5267,2382],"Prednisone acetate",{"nctId":3590,"briefTitle":3591,"status":128,"phases":5269,"primaryCompletion":3593,"completion":3594,"start":909,"enrollment":3595,"conditions":5270,"interventions":5271},[89],[990,1930,3597],[653,841,977,978,979,529,980],{"nctId":2028,"briefTitle":2029,"status":150,"phases":5273,"primaryCompletion":2031,"completion":2032,"start":2033,"enrollment":2034,"conditions":5274,"interventions":5275},[89],[526],[47,528,529],{"nctId":5277,"briefTitle":5278,"status":105,"phases":5279,"primaryCompletion":5280,"completion":5280,"start":5281,"enrollment":5282,"conditions":5283,"interventions":5284},"NCT00619359","Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)",[89],"2009-06","2008-02",2322,[5181],[5285,5286,529,529,5137],"Comparator: fosaprepitant dimeglumine","Comparator: Aprepitant",{"nctId":5288,"briefTitle":5289,"status":105,"phases":5290,"primaryCompletion":5291,"completion":5292,"start":5293,"enrollment":5294,"conditions":5295,"interventions":5297},"NCT00952341","Aprepitant\u002FMK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)",[89],"2010-04-04","2010-05-05","2009-08-25",421,[5296],"Chemotherapy-induced Nausea and Vomiting (CINV)",[4424,5298,4426,5299,4426],"Comparator: Placebo to aprepitant","granisetron",{"nctId":4415,"briefTitle":4416,"status":105,"phases":5301,"primaryCompletion":4418,"completion":4419,"start":4420,"enrollment":4421,"conditions":5302,"interventions":5303},[89],[4292],[4424,4425,4426,4427],{"nctId":5305,"briefTitle":5306,"status":105,"phases":5307,"primaryCompletion":5308,"completion":5308,"start":5309,"enrollment":5310,"conditions":5311,"interventions":5312},"NCT01594749","Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)",[89],"2014-11-03","2012-09-24",1015,[5181],[4294,5313,529,5137,5314,5315,5316],"Fosaprepitant Placebo","Dexamethasone Placebo","Ondansetron Placebo","Rescue Therapy",{"nctId":2589,"briefTitle":2590,"status":150,"phases":5318,"primaryCompletion":2031,"completion":2592,"start":2033,"enrollment":2593,"conditions":5319,"interventions":5320},[89],[526],[47,2596,529],{"nctId":3468,"briefTitle":3469,"status":139,"phases":5322,"primaryCompletion":3471,"completion":3472,"start":1776,"enrollment":2625,"conditions":5323,"interventions":5324},[89],[1687],[653,385,386,3475,1324,979,529,1325],{"nctId":2652,"briefTitle":2653,"status":105,"phases":5326,"primaryCompletion":2655,"completion":427,"start":2407,"enrollment":2656,"conditions":5327,"interventions":5328},[89],[2410],[47,967,1076,529],{"nctId":2765,"briefTitle":2766,"status":150,"phases":5330,"primaryCompletion":2768,"completion":427,"start":2769,"enrollment":2770,"conditions":5331,"interventions":5332},[89],[2410],[47,967,1076,529],{"trials":5334,"activeCount":99},[5335,5343],{"nctId":5336,"briefTitle":5337,"status":105,"phases":5338,"primaryCompletion":5339,"completion":5339,"start":823,"enrollment":722,"conditions":5340,"interventions":5341},"NCT04054193","Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)",[90],"2021-02-11",[5252],[5342,5255,529],"Fosaprepitant Dimeglumine",{"nctId":5344,"briefTitle":5345,"status":105,"phases":5346,"primaryCompletion":5347,"completion":5347,"start":5348,"enrollment":5349,"conditions":5350,"interventions":5351},"NCT01636947","A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)",[90],"2014-08-04","2012-12-12",494,[4291,4292],[5136,5352,5137,529,5315,5353],"Aprepitant Placebo","Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).",{"trials":5355,"activeCount":99},[],{"intervention":434,"totalTrials":931,"cells":5357},{"EARLY_PHASE1":5358,"PHASE1":5360,"PHASE2":5374,"PHASE3":5392,"PHASE4":5447,"NA":5449},{"trials":5359,"activeCount":99},[],{"trials":5361,"activeCount":224,"soonestReadout":597},[5362,5366,5370],{"nctId":423,"briefTitle":424,"status":105,"phases":5363,"primaryCompletion":426,"completion":427,"start":428,"enrollment":429,"conditions":5364,"interventions":5365},[87],[431],[47,433,434,435,436,437],{"nctId":450,"briefTitle":451,"status":105,"phases":5367,"primaryCompletion":453,"completion":453,"start":454,"enrollment":455,"conditions":5368,"interventions":5369},[87],[290],[458,47,434,437,435,459,460,461],{"nctId":594,"briefTitle":595,"status":128,"phases":5371,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":5372,"interventions":5373},[87],[497],[602,47,484,483,603,604,605,606],{"trials":5375,"activeCount":3197,"soonestReadout":785},[5376,5380,5384,5388],{"nctId":782,"briefTitle":783,"status":128,"phases":5377,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":5378,"interventions":5379},[87,88],[789,790,791,792],[47,794,795,435,796,797,434,798],{"nctId":1256,"briefTitle":1257,"status":128,"phases":5381,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":1261,"conditions":5382,"interventions":5383},[87,88],[1263],[47,1265,435,796,797,434,653,842],{"nctId":1277,"briefTitle":1278,"status":105,"phases":5385,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":1282,"conditions":5386,"interventions":5387},[88],[1284,1285,965,1286,856,791,540,1014,1287,1288,1289],[74,47,461,797,390,387,714,386,967,841,795,434],{"nctId":1485,"briefTitle":1486,"status":105,"phases":5389,"primaryCompletion":1488,"completion":1488,"start":1489,"enrollment":920,"conditions":5390,"interventions":5391},[88],[991],[47,434,1492,390],{"trials":5393,"activeCount":174,"soonestReadout":2321},[5394,5407,5411,5415,5419,5423,5427,5431,5435,5439,5443],{"nctId":5395,"briefTitle":5396,"status":128,"phases":5397,"primaryCompletion":5398,"completion":5399,"start":5400,"enrollment":277,"conditions":5401,"interventions":5404},"NCT06997497","A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012\u002FKANDLELIT-012)",[89],"2029-03-28","2030-10-27","2025-07-16",[5402,5403],"Colon Adenocarcinoma","Rectal Adenocarcinoma",[602,434,5405,797,693,841,5406],"Leucovorin\u002Flevofolinate calcium","Bevacizumab biosimilar",{"nctId":1832,"briefTitle":1833,"status":105,"phases":5408,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":5409,"interventions":5410},[89],[1840,1442],[47,390,1444,434,795,1842,1843],{"nctId":2002,"briefTitle":2003,"status":105,"phases":5412,"primaryCompletion":2005,"completion":2006,"start":2007,"enrollment":2008,"conditions":5413,"interventions":5414},[89],[1289],[47,390,606,604,1445],{"nctId":2012,"briefTitle":2013,"status":1040,"phases":5416,"primaryCompletion":2015,"completion":2015,"start":2007,"enrollment":99,"conditions":5417,"interventions":5418},[89],[1289],[47,390,606,434,795],{"nctId":2019,"briefTitle":2020,"status":105,"phases":5420,"primaryCompletion":2022,"completion":730,"start":1406,"enrollment":2023,"conditions":5421,"interventions":5422},[89],[991,2025],[47,390,795,606,967,434,435],{"nctId":2048,"briefTitle":2049,"status":105,"phases":5424,"primaryCompletion":2051,"completion":2052,"start":2053,"enrollment":2054,"conditions":5425,"interventions":5426},[89],[2056],[47,461,434,795,435,1444],{"nctId":2318,"briefTitle":2319,"status":139,"phases":5428,"primaryCompletion":2321,"completion":2322,"start":2323,"enrollment":2324,"conditions":5429,"interventions":5430},[89],[2326],[47,461,390,1444,434,435,796,387],{"nctId":5072,"briefTitle":5073,"status":128,"phases":5432,"primaryCompletion":5075,"completion":5075,"start":5076,"enrollment":5077,"conditions":5433,"interventions":5434},[88,89],[5079,676],[1058,4349,714,434,5081,5082],{"nctId":2339,"briefTitle":2340,"status":105,"phases":5436,"primaryCompletion":2022,"completion":730,"start":2342,"enrollment":2343,"conditions":5437,"interventions":5438},[89],[991,2025],[47,390,795,606,967,434,435],{"nctId":2611,"briefTitle":2612,"status":139,"phases":5440,"primaryCompletion":2614,"completion":2614,"start":2615,"enrollment":920,"conditions":5441,"interventions":5442},[89],[371],[47,434,435,606,437,841,693],{"nctId":2630,"briefTitle":2631,"status":139,"phases":5444,"primaryCompletion":2192,"completion":2633,"start":2634,"enrollment":2635,"conditions":5445,"interventions":5446},[89],[1230,2637,2638],[42,486,1444,605,2640,604],{"trials":5448,"activeCount":99},[],{"trials":5450,"activeCount":99},[],{"intervention":562,"totalTrials":2901,"cells":5452},{"EARLY_PHASE1":5453,"PHASE1":5455,"PHASE2":5483,"PHASE3":5524,"PHASE4":5558,"NA":5560},{"trials":5454,"activeCount":99},[],{"trials":5456,"activeCount":99},[5457,5461,5473],{"nctId":552,"briefTitle":553,"status":105,"phases":5458,"primaryCompletion":555,"completion":556,"start":557,"enrollment":558,"conditions":5459,"interventions":5460},[87],[540],[47,388,561,562,386,387],{"nctId":5462,"briefTitle":5463,"status":150,"phases":5464,"primaryCompletion":5465,"completion":5465,"start":5466,"enrollment":3963,"conditions":5467,"interventions":5471},"NCT00960063","A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)",[87],"2010-12-22","2009-11-11",[290,176,5468,5469,5470],"Bone Cancer","Kidney Tumor","Neuroblastoma",[1390,1074,5472,437,2905,1069,562,1073],"Ifosfamide",{"nctId":5474,"briefTitle":5475,"status":150,"phases":5476,"primaryCompletion":5477,"completion":5477,"start":5478,"enrollment":357,"conditions":5479,"interventions":5480},"NCT01370694","Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)",[87],"2014-12-01","2011-08-19",[677],[5481,1458,1459,5482],"MK-8808","prednisolone",{"trials":5484,"activeCount":3963,"soonestReadout":1450},[5485,5489,5493,5503,5512,5516,5520],{"nctId":1061,"briefTitle":1062,"status":105,"phases":5486,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":110,"conditions":5487,"interventions":5488},[88],[943],[47,1069,1070,1071,1072,1073,562,1074,1075,1076],{"nctId":1102,"briefTitle":1103,"status":128,"phases":5490,"primaryCompletion":804,"completion":1105,"start":973,"enrollment":1106,"conditions":5491,"interventions":5492},[88],[1108,1109],[1111,47,387,386,1112,1113,562,795,1114],{"nctId":5494,"briefTitle":5495,"status":139,"phases":5496,"primaryCompletion":5497,"completion":5497,"start":5498,"enrollment":558,"conditions":5499,"interventions":5501},"NCT05406401","A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)",[88],"2029-04-26","2022-07-14",[5500],"Lymphoma, Large B-Cell, Diffuse (DLBCL)",[5502,562,1069,4349,4350,1076,2413],"Zilovertamab Vedotin",{"nctId":5504,"briefTitle":5505,"status":105,"phases":5506,"primaryCompletion":5507,"completion":5507,"start":5508,"enrollment":367,"conditions":5509,"interventions":5510},"NCT00779129","A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948)",[88],"2007-08","2003-03",[4789],[5511,562],"Pegylated Lyposomal Doxorubicin",{"nctId":1392,"briefTitle":1393,"status":1040,"phases":5513,"primaryCompletion":1395,"completion":1396,"start":1397,"enrollment":99,"conditions":5514,"interventions":5515},[88],[1399],[47,387,386,1069,542,1401,562,795,1114],{"nctId":1447,"briefTitle":1448,"status":139,"phases":5517,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":5518,"interventions":5519},[88],[674],[42,1455,1456,1457,1458,1459,1460,1461,487],{"nctId":4339,"briefTitle":4340,"status":128,"phases":5521,"primaryCompletion":4342,"completion":4343,"start":4344,"enrollment":4345,"conditions":5522,"interventions":5523},[88],[4347],[1058,4349,562,1069,4350,1076,2413,4351,842],{"trials":5525,"activeCount":3963,"soonestReadout":5534},[5526,5530,5546,5550,5554],{"nctId":1656,"briefTitle":1657,"status":105,"phases":5527,"primaryCompletion":1659,"completion":1659,"start":1660,"enrollment":1661,"conditions":5528,"interventions":5529},[89],[540],[47,386,387,1069,1664,562,1665],{"nctId":5531,"briefTitle":5532,"status":139,"phases":5533,"primaryCompletion":5534,"completion":5535,"start":5536,"enrollment":1570,"conditions":5537,"interventions":5540},"NCT05624554","A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)",[89],"2027-05-19","2031-03-17","2023-03-16",[5538,5539],"Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma",[5541,5542,562,5081,4349,5543,5544,5545],"Nemtabrutinib","Fludarabine","Truxima","Ruxience","Riabni",{"nctId":4381,"briefTitle":4382,"status":128,"phases":5547,"primaryCompletion":762,"completion":4384,"start":1610,"enrollment":4385,"conditions":5548,"interventions":5549},[89],[676],[1058,4349,562,1069,4350,1076,2413,1074,1089,4388],{"nctId":2133,"briefTitle":2134,"status":139,"phases":5551,"primaryCompletion":2136,"completion":2136,"start":2137,"enrollment":2138,"conditions":5552,"interventions":5553},[89],[1109],[47,387,1069,1664,562,2141],{"nctId":2435,"briefTitle":2436,"status":128,"phases":5555,"primaryCompletion":2438,"completion":2439,"start":2440,"enrollment":2441,"conditions":5556,"interventions":5557},[89],[1108,540,2443],[653,47,842,386,387,1069,1664,562,795,1114],{"trials":5559,"activeCount":99},[],{"trials":5561,"activeCount":99},[],{"intervention":602,"totalTrials":5563,"cells":5564},13,{"EARLY_PHASE1":5565,"PHASE1":5567,"PHASE2":5628,"PHASE3":5638,"PHASE4":5670,"NA":5672},{"trials":5566,"activeCount":99},[],{"trials":5568,"activeCount":3197,"soonestReadout":5592},[5569,5579,5588,5597,5605,5609,5619],{"nctId":5570,"briefTitle":5571,"status":105,"phases":5572,"primaryCompletion":5573,"completion":5574,"start":5575,"enrollment":3655,"conditions":5576,"interventions":5577},"NCT07222098","A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)",[87],"2025-12-14","2025-12-29","2025-11-19",[18],[5578,4084,602],"Rosuvastatin",{"nctId":5580,"briefTitle":5581,"status":105,"phases":5582,"primaryCompletion":5583,"completion":5583,"start":5584,"enrollment":1621,"conditions":5585,"interventions":5586},"NCT06619314","A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)",[87],"2023-11-25","2023-09-20",[18],[602,5587],"PPI",{"nctId":5589,"briefTitle":5590,"status":128,"phases":5591,"primaryCompletion":5592,"completion":5593,"start":1307,"enrollment":3226,"conditions":5594,"interventions":5596},"NCT07219550","A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)",[87],"2026-08-07","2026-08-14",[18,5595],"Hepatic Impairment",[602],{"nctId":5598,"briefTitle":5599,"status":105,"phases":5600,"primaryCompletion":5601,"completion":5601,"start":2266,"enrollment":1624,"conditions":5602,"interventions":5603},"NCT06719557","A Study of the Effect of Itraconazole and Phenytoin on Calderasib (MK-1084) in Healthy Adults (MK-1084-008)",[87],"2024-07-30",[18],[602,5604,4114],"Itraconazole",{"nctId":594,"briefTitle":595,"status":128,"phases":5606,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":5607,"interventions":5608},[87],[497],[602,47,484,483,603,604,605,606],{"nctId":5610,"briefTitle":5611,"status":105,"phases":5612,"primaryCompletion":5613,"completion":5614,"start":5615,"enrollment":5616,"conditions":5617,"interventions":5618},"NCT06814119","A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010)",[87],"2026-01-23","2026-02-06","2025-04-07",34,[18,4074],[602],{"nctId":5620,"briefTitle":5621,"status":105,"phases":5622,"primaryCompletion":985,"completion":985,"start":5623,"enrollment":1624,"conditions":5624,"interventions":5625},"NCT06575933","A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009)",[87],"2024-09-03",[314],[602,5626,5627],"Midazolam","Digoxin",{"trials":5629,"activeCount":224,"soonestReadout":5634},[5630],{"nctId":5631,"briefTitle":5632,"status":128,"phases":5633,"primaryCompletion":5634,"completion":5634,"start":5635,"enrollment":2779,"conditions":5636,"interventions":5637},"NCT07209111","A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)",[88],"2032-04-09","2025-12-04",[1004],[602,693],{"trials":5639,"activeCount":174,"soonestReadout":1815},[5640,5644,5648,5657,5666],{"nctId":5395,"briefTitle":5396,"status":128,"phases":5641,"primaryCompletion":5398,"completion":5399,"start":5400,"enrollment":277,"conditions":5642,"interventions":5643},[89],[5402,5403],[602,434,5405,797,693,841,5406],{"nctId":1812,"briefTitle":1813,"status":128,"phases":5645,"primaryCompletion":1815,"completion":1816,"start":1817,"enrollment":1818,"conditions":5646,"interventions":5647},[89],[314],[602,47],{"nctId":5649,"briefTitle":5650,"status":128,"phases":5651,"primaryCompletion":5652,"completion":5652,"start":5653,"enrollment":1150,"conditions":5654,"interventions":5655},"NCT07431827","MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)",[89],"2039-10-26","2026-03-18",[314],[602,5656],"MK-3475A",{"nctId":5658,"briefTitle":5659,"status":230,"phases":5660,"primaryCompletion":5661,"completion":5662,"start":5663,"enrollment":2034,"conditions":5664,"interventions":5665},"NCT07554339","A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015\u002FKANDLELIT-015)",[89],"2032-12-15","2037-08-17","2026-06-05",[314],[602,2186],{"nctId":3430,"briefTitle":3431,"status":128,"phases":5667,"primaryCompletion":3433,"completion":3434,"start":3435,"enrollment":3436,"conditions":5668,"interventions":5669},[89],[314],[602,384,385,390,386],{"trials":5671,"activeCount":99},[],{"trials":5673,"activeCount":99},[],{"intervention":885,"totalTrials":3308,"cells":5675},{"EARLY_PHASE1":5676,"PHASE1":5678,"PHASE2":5680,"PHASE3":5709,"PHASE4":5727,"NA":5729},{"trials":5677,"activeCount":99},[],{"trials":5679,"activeCount":99},[],{"trials":5681,"activeCount":174,"soonestReadout":1129},[5682,5686,5690,5694,5705],{"nctId":759,"briefTitle":760,"status":128,"phases":5683,"primaryCompletion":762,"completion":763,"start":764,"enrollment":765,"conditions":5684,"interventions":5685},[88],[767],[769,47,386,387,388],{"nctId":876,"briefTitle":877,"status":128,"phases":5687,"primaryCompletion":879,"completion":880,"start":881,"enrollment":787,"conditions":5688,"interventions":5689},[88],[883],[885,47],{"nctId":1126,"briefTitle":1127,"status":139,"phases":5691,"primaryCompletion":1129,"completion":1130,"start":1131,"enrollment":1132,"conditions":5692,"interventions":5693},[87,88],[1134],[47,885,1136],{"nctId":5695,"briefTitle":5696,"status":128,"phases":5697,"primaryCompletion":5698,"completion":5698,"start":5699,"enrollment":5700,"conditions":5701,"interventions":5704},"NCT06833073","A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011\u002FINTerpath-011)",[88],"2031-09-03","2025-03-11",308,[1287,5702,5703],"Non-Muscle Invasive Bladder Neoplasms","Carcinoma in Situ",[885,2424],{"nctId":1424,"briefTitle":1425,"status":139,"phases":5706,"primaryCompletion":1427,"completion":1428,"start":1429,"enrollment":1430,"conditions":5707,"interventions":5708},[88],[702],[885,47],{"trials":5710,"activeCount":202,"soonestReadout":1805},[5711,5715,5719,5723],{"nctId":1802,"briefTitle":1803,"status":139,"phases":5712,"primaryCompletion":1805,"completion":1806,"start":1807,"enrollment":1808,"conditions":5713,"interventions":5714},[89],[35],[885,47],{"nctId":1953,"briefTitle":1954,"status":128,"phases":5716,"primaryCompletion":1956,"completion":1957,"start":1958,"enrollment":1959,"conditions":5717,"interventions":5718},[89],[314],[885,47],{"nctId":2102,"briefTitle":2103,"status":128,"phases":5720,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":2108,"conditions":5721,"interventions":5722},[89],[369],[47,390,386,385,714,387,885],{"nctId":2253,"briefTitle":2254,"status":150,"phases":5724,"primaryCompletion":2256,"completion":2256,"start":2257,"enrollment":212,"conditions":5725,"interventions":5726},[88,89],[1901,2259],[47,885],{"trials":5728,"activeCount":99},[],{"trials":5730,"activeCount":99},[],{"intervention":384,"totalTrials":734,"cells":5732},{"EARLY_PHASE1":5733,"PHASE1":5735,"PHASE2":5741,"PHASE3":5766,"PHASE4":5784,"NA":5786},{"trials":5734,"activeCount":99},[],{"trials":5736,"activeCount":224,"soonestReadout":378},[5737],{"nctId":375,"briefTitle":376,"status":139,"phases":5738,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":5739,"interventions":5740},[87],[382],[384,47,385,386,387,388,389,390],{"trials":5742,"activeCount":202,"soonestReadout":909},[5743,5755,5759],{"nctId":5744,"briefTitle":5745,"status":139,"phases":5746,"primaryCompletion":5747,"completion":5747,"start":5748,"enrollment":12,"conditions":5749,"interventions":5754},"NCT06504394","A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)",[88],"2028-11-08","2024-10-14",[5750,5751,5752,5753],"Classical Hodgkin Lymphoma Recurrent","Classical Hodgkin Lymphoma Refractory","Primary Mediastinal Large B-cell Lymphoma Recurrent","Primary Mediastinal Large B-cell Lymphoma Refractory",[384],{"nctId":906,"briefTitle":907,"status":139,"phases":5756,"primaryCompletion":909,"completion":910,"start":911,"enrollment":912,"conditions":5757,"interventions":5758},[88],[903,702,35],[384,47],{"nctId":5760,"briefTitle":5761,"status":139,"phases":5762,"primaryCompletion":1374,"completion":1374,"start":5763,"enrollment":569,"conditions":5764,"interventions":5765},"NCT06041802","A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R\u002FM cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)",[88],"2023-10-20",[1411],[384],{"trials":5767,"activeCount":3963,"soonestReadout":2752},[5768,5772,5776,5780],{"nctId":3430,"briefTitle":3431,"status":128,"phases":5769,"primaryCompletion":3433,"completion":3434,"start":3435,"enrollment":3436,"conditions":5770,"interventions":5771},[89],[314],[602,384,385,390,386],{"nctId":2598,"briefTitle":2599,"status":128,"phases":5773,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":2603,"conditions":5774,"interventions":5775},[89],[176,2605],[47,2607,461,1114,2608,2609,384],{"nctId":2642,"briefTitle":2643,"status":139,"phases":5777,"primaryCompletion":1589,"completion":2645,"start":2646,"enrollment":2647,"conditions":5778,"interventions":5779},[89],[2649,903],[384,47],{"nctId":2749,"briefTitle":2750,"status":139,"phases":5781,"primaryCompletion":2752,"completion":2070,"start":2753,"enrollment":2754,"conditions":5782,"interventions":5783},[89],[2074],[384,385,390,386,387,388,47,2076,2077],{"trials":5785,"activeCount":99},[],{"trials":5787,"activeCount":99},[],{"intervention":795,"totalTrials":120,"cells":5789},{"EARLY_PHASE1":5790,"PHASE1":5792,"PHASE2":5794,"PHASE3":5839,"PHASE4":5916,"NA":5918},{"trials":5791,"activeCount":99},[],{"trials":5793,"activeCount":99},[],{"trials":5795,"activeCount":3197,"soonestReadout":785},[5796,5805,5809,5813,5817,5827,5831,5835],{"nctId":5797,"briefTitle":5798,"status":105,"phases":5799,"primaryCompletion":5800,"completion":5800,"start":5801,"enrollment":5802,"conditions":5803,"interventions":5804},"NCT00732810","SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)",[88],"2011-06","2008-07",97,[1108,369],[5135,795,1253],{"nctId":782,"briefTitle":783,"status":128,"phases":5806,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":5807,"interventions":5808},[87,88],[789,790,791,792],[47,794,795,435,796,797,434,798],{"nctId":957,"briefTitle":958,"status":105,"phases":5810,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":5811,"interventions":5812},[88],[965],[461,47,967,795,387,693,461],{"nctId":1102,"briefTitle":1103,"status":128,"phases":5814,"primaryCompletion":804,"completion":1105,"start":973,"enrollment":1106,"conditions":5815,"interventions":5816},[88],[1108,1109],[1111,47,387,386,1112,1113,562,795,1114],{"nctId":5818,"briefTitle":5819,"status":105,"phases":5820,"primaryCompletion":5821,"completion":5821,"start":5822,"enrollment":2647,"conditions":5823,"interventions":5824},"NCT00551213","A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)",[88],"2009-06-04","2007-11-21",[419],[2905,437,693,795,5825,5826,1751],"FOLFOX","CAPEOX\u002FXELOX",{"nctId":1277,"briefTitle":1278,"status":105,"phases":5828,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":1282,"conditions":5829,"interventions":5830},[88],[1284,1285,965,1286,856,791,540,1014,1287,1288,1289],[74,47,461,797,390,387,714,386,967,841,795,434],{"nctId":1392,"briefTitle":1393,"status":1040,"phases":5832,"primaryCompletion":1395,"completion":1396,"start":1397,"enrollment":99,"conditions":5833,"interventions":5834},[88],[1399],[47,387,386,1069,542,1401,562,795,1114],{"nctId":1434,"briefTitle":1435,"status":105,"phases":5836,"primaryCompletion":1437,"completion":1437,"start":1438,"enrollment":1439,"conditions":5837,"interventions":5838},[88],[1441,1442],[42,486,1444,1445],{"trials":5840,"activeCount":174,"soonestReadout":2201},[5841,5845,5849,5853,5857,5861,5865,5869,5873,5877,5881,5885,5889,5893,5897,5906],{"nctId":2934,"briefTitle":2935,"status":128,"phases":5842,"primaryCompletion":2937,"completion":2937,"start":2938,"enrollment":1633,"conditions":5843,"interventions":5844},[89],[1108],[1111,387,388,795,2207,2941],{"nctId":1753,"briefTitle":1754,"status":128,"phases":5846,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":1759,"conditions":5847,"interventions":5848},[89],[1761],[47,653,795],{"nctId":1832,"briefTitle":1833,"status":105,"phases":5850,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":5851,"interventions":5852},[89],[1840,1442],[47,390,1444,434,795,1842,1843],{"nctId":1853,"briefTitle":1854,"status":139,"phases":5854,"primaryCompletion":1856,"completion":1856,"start":1510,"enrollment":1452,"conditions":5855,"interventions":5856},[89],[1108],[42,1654,1859,1860,1445,1861,1862],{"nctId":1874,"briefTitle":1875,"status":105,"phases":5858,"primaryCompletion":1877,"completion":1878,"start":1879,"enrollment":1880,"conditions":5859,"interventions":5860},[89],[1882],[42,1445,1884,1885,1886],{"nctId":1913,"briefTitle":1914,"status":105,"phases":5862,"primaryCompletion":1916,"completion":1917,"start":1918,"enrollment":1919,"conditions":5863,"interventions":5864},[89],[1441],[47,390,1444,795],{"nctId":2002,"briefTitle":2003,"status":105,"phases":5866,"primaryCompletion":2005,"completion":2006,"start":2007,"enrollment":2008,"conditions":5867,"interventions":5868},[89],[1289],[47,390,606,604,1445],{"nctId":2012,"briefTitle":2013,"status":1040,"phases":5870,"primaryCompletion":2015,"completion":2015,"start":2007,"enrollment":99,"conditions":5871,"interventions":5872},[89],[1289],[47,390,606,434,795],{"nctId":2019,"briefTitle":2020,"status":105,"phases":5874,"primaryCompletion":2022,"completion":730,"start":1406,"enrollment":2023,"conditions":5875,"interventions":5876},[89],[991,2025],[47,390,795,606,967,434,435],{"nctId":2048,"briefTitle":2049,"status":105,"phases":5878,"primaryCompletion":2051,"completion":2052,"start":2053,"enrollment":2054,"conditions":5879,"interventions":5880},[89],[2056],[47,461,434,795,435,1444],{"nctId":2198,"briefTitle":2199,"status":128,"phases":5882,"primaryCompletion":2201,"completion":2202,"start":2203,"enrollment":2204,"conditions":5883,"interventions":5884},[89],[1108],[653,47,387,388,795,2207],{"nctId":2339,"briefTitle":2340,"status":105,"phases":5886,"primaryCompletion":2022,"completion":730,"start":2342,"enrollment":2343,"conditions":5887,"interventions":5888},[89],[991,2025],[47,390,795,606,967,434,435],{"nctId":2435,"briefTitle":2436,"status":128,"phases":5890,"primaryCompletion":2438,"completion":2439,"start":2440,"enrollment":2441,"conditions":5891,"interventions":5892},[89],[1108,540,2443],[653,47,842,386,387,1069,1664,562,795,1114],{"nctId":2446,"briefTitle":2447,"status":105,"phases":5894,"primaryCompletion":2449,"completion":929,"start":2450,"enrollment":2451,"conditions":5895,"interventions":5896},[89],[2453],[47,795,714,967],{"nctId":5898,"briefTitle":5899,"status":105,"phases":5900,"primaryCompletion":5901,"completion":5902,"start":5903,"enrollment":2873,"conditions":5904,"interventions":5905},"NCT00266799","The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445\u002FMK-2746-071)",[89],"2010-09-29","2010-10-18","2006-01-13",[1109],[843,795],{"nctId":5907,"briefTitle":5908,"status":105,"phases":5909,"primaryCompletion":5910,"completion":5911,"start":5912,"enrollment":1522,"conditions":5913,"interventions":5914},"NCT04456699","Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003\u002FLYNK-003)",[89],"2023-03-27","2023-11-06","2020-08-19",[431],[1114,1444,841,795,5915],"Leucovorin\u002F levoleucovorin",{"trials":5917,"activeCount":99},[],{"trials":5919,"activeCount":99},[],{"intervention":1076,"totalTrials":931,"cells":5921},{"EARLY_PHASE1":5922,"PHASE1":5924,"PHASE2":6003,"PHASE3":6021,"PHASE4":6047,"NA":6049},{"trials":5923,"activeCount":99},[],{"trials":5925,"activeCount":224,"soonestReadout":5972},[5926,5935,5947,5957,5968,5977,5987,5994],{"nctId":5927,"briefTitle":5928,"status":105,"phases":5929,"primaryCompletion":5930,"completion":4408,"start":5931,"enrollment":4071,"conditions":5932,"interventions":5933},"NCT06633419","A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)",[87],"2025-02-12","2024-12-18",[18],[4775,1076,4777,5934],"Carbamazepine",{"nctId":5936,"briefTitle":5937,"status":105,"phases":5938,"primaryCompletion":5939,"completion":1659,"start":5615,"enrollment":120,"conditions":5940,"interventions":5946},"NCT06814132","A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)",[87],"2025-10-04",[5941,5942,5943,5944,5945],"Kidney Failure, Chronic","End-Stage Kidney Disease","Renal Failure, Chronic","Renal Failure, End-Stage","Healthy Participants",[4278,1076,4777],{"nctId":5948,"briefTitle":5949,"status":105,"phases":5950,"primaryCompletion":5951,"completion":5952,"start":5953,"enrollment":95,"conditions":5954,"interventions":5955},"NCT06554639","A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)",[87],"2024-08-05","2024-08-29","2024-07-11",[2410],[4278,1076,4777,5956],"Diltiazem hydrocholoride",{"nctId":5958,"briefTitle":5959,"status":105,"phases":5960,"primaryCompletion":5961,"completion":5962,"start":5963,"enrollment":569,"conditions":5964,"interventions":5966},"NCT00828061","A Study of the Effects of Single Dose Corticosteroids on Response to Allergens",[87],"2009-05-07","2009-05-21","2009-02-04",[5965],"Allergic Rhinitis",[5967,5967],"prednisone",{"nctId":5969,"briefTitle":5970,"status":139,"phases":5971,"primaryCompletion":5972,"completion":5973,"start":5974,"enrollment":4071,"conditions":5975,"interventions":5976},"NCT07548606","A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)",[87],"2026-06-01","2026-06-14","2026-05-11",[18],[4775,1076,4777,5604],{"nctId":5978,"briefTitle":5979,"status":105,"phases":5980,"primaryCompletion":5981,"completion":5981,"start":5982,"enrollment":5983,"conditions":5984,"interventions":5986},"NCT01193049","A Study on the Effects of a Single Dose of Prednisone on Biomarkers of Allergen Responses in Asthmatics (MK-0000-175)",[87],"2011-05","2010-08",11,[5985],"Asthma",[1076],{"nctId":5988,"briefTitle":5989,"status":105,"phases":5990,"primaryCompletion":1348,"completion":5991,"start":4408,"enrollment":3655,"conditions":5992,"interventions":5993},"NCT06860243","A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)",[87],"2026-02-19",[5595,5945],[4775,1076,4777],{"nctId":5995,"briefTitle":5996,"status":105,"phases":5997,"primaryCompletion":4808,"completion":4808,"start":5998,"enrollment":734,"conditions":5999,"interventions":6001},"NCT06566989","A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)",[87],"2024-09-19",[6000],"Metastatic Prostate Cancer",[6002,1076,5125],"[¹⁴C]Opevesostat",{"trials":6004,"activeCount":202,"soonestReadout":4342},[6005,6009,6013,6017],{"nctId":4768,"briefTitle":4769,"status":128,"phases":6006,"primaryCompletion":4771,"completion":4771,"start":2266,"enrollment":8,"conditions":6007,"interventions":6008},[87,88],[4773],[4775,1114,967,4776,4777,529,1076],{"nctId":1061,"briefTitle":1062,"status":105,"phases":6010,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":110,"conditions":6011,"interventions":6012},[88],[943],[47,1069,1070,1071,1072,1073,562,1074,1075,1076],{"nctId":5494,"briefTitle":5495,"status":139,"phases":6014,"primaryCompletion":5497,"completion":5497,"start":5498,"enrollment":558,"conditions":6015,"interventions":6016},[88],[5500],[5502,562,1069,4349,4350,1076,2413],{"nctId":4339,"briefTitle":4340,"status":128,"phases":6018,"primaryCompletion":4342,"completion":4343,"start":4344,"enrollment":4345,"conditions":6019,"interventions":6020},[88],[4347],[1058,4349,562,1069,4350,1076,2413,4351,842],{"trials":6022,"activeCount":202,"soonestReadout":4406},[6023,6027,6031,6035,6039,6043],{"nctId":5235,"briefTitle":5236,"status":128,"phases":6024,"primaryCompletion":5238,"completion":5239,"start":5240,"enrollment":5241,"conditions":6025,"interventions":6026},[89],[5243],[4775,2412,2382,5126,4777,1076,529],{"nctId":4381,"briefTitle":4382,"status":128,"phases":6028,"primaryCompletion":762,"completion":4384,"start":1610,"enrollment":4385,"conditions":6029,"interventions":6030},[89],[676],[1058,4349,562,1069,4350,1076,2413,1074,1089,4388],{"nctId":4403,"briefTitle":4404,"status":128,"phases":6032,"primaryCompletion":4406,"completion":4407,"start":4408,"enrollment":4409,"conditions":6033,"interventions":6034},[89],[4411,2410],[4413,967,1076,842],{"nctId":2403,"briefTitle":2404,"status":105,"phases":6036,"primaryCompletion":2083,"completion":2406,"start":2407,"enrollment":2408,"conditions":6037,"interventions":6038},[89],[2410],[47,1114,2412,1076,2382,2413],{"nctId":2652,"briefTitle":2653,"status":105,"phases":6040,"primaryCompletion":2655,"completion":427,"start":2407,"enrollment":2656,"conditions":6041,"interventions":6042},[89],[2410],[47,967,1076,529],{"nctId":2765,"briefTitle":2766,"status":150,"phases":6044,"primaryCompletion":2768,"completion":427,"start":2769,"enrollment":2770,"conditions":6045,"interventions":6046},[89],[2410],[47,967,1076,529],{"trials":6048,"activeCount":99},[],{"trials":6050,"activeCount":99},[],{"intervention":693,"totalTrials":3655,"cells":6052},{"EARLY_PHASE1":6053,"PHASE1":6055,"PHASE2":6076,"PHASE3":6123,"PHASE4":6145,"NA":6147},{"trials":6054,"activeCount":99},[],{"trials":6056,"activeCount":3197,"soonestReadout":597},[6057,6068,6072],{"nctId":6058,"briefTitle":6059,"status":105,"phases":6060,"primaryCompletion":6061,"completion":6062,"start":6063,"enrollment":805,"conditions":6064,"interventions":6065},"NCT00925015","Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)",[87],"2010-07-28","2010-12-06","2009-06-17",[419],[6066,693,437,6067],"Dalotuzumab 10 mg\u002Fkg","Dalotuzumab 15\u002F7.5 mg\u002Fkg",{"nctId":594,"briefTitle":595,"status":128,"phases":6069,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":6070,"interventions":6071},[87],[497],[602,47,484,483,603,604,605,606],{"nctId":683,"briefTitle":684,"status":128,"phases":6073,"primaryCompletion":686,"completion":686,"start":687,"enrollment":688,"conditions":6074,"interventions":6075},[87],[690],[692,47,693],{"trials":6077,"activeCount":202,"soonestReadout":3538},[6078,6082,6093,6097,6107,6111,6115,6119],{"nctId":957,"briefTitle":958,"status":105,"phases":6079,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":6080,"interventions":6081},[88],[965],[461,47,967,795,387,693,461],{"nctId":6083,"briefTitle":6084,"status":105,"phases":6085,"primaryCompletion":173,"completion":6086,"start":6087,"enrollment":6088,"conditions":6089,"interventions":6090},"NCT00614393","Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)",[88],"2012-03-07","2007-12-24",558,[431],[6091,6092,603],"dalotuzumab","irinotecan hydrochloride",{"nctId":1138,"briefTitle":1139,"status":128,"phases":6094,"primaryCompletion":1141,"completion":1141,"start":1142,"enrollment":132,"conditions":6095,"interventions":6096},[88],[690],[500,47,693,386,385],{"nctId":6098,"briefTitle":6099,"status":150,"phases":6100,"primaryCompletion":6101,"completion":6101,"start":6102,"enrollment":5983,"conditions":6103,"interventions":6105},"NCT01609231","A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)",[88],"2014-12-09","2012-07-06",[6104],"Rectal Neoplasms",[6106,437,693],"Dalotuzumab",{"nctId":3535,"briefTitle":3536,"status":128,"phases":6108,"primaryCompletion":3538,"completion":3539,"start":3540,"enrollment":3541,"conditions":6109,"interventions":6110},[87,88],[975],[500,1111,653,693,327],{"nctId":5818,"briefTitle":5819,"status":105,"phases":6112,"primaryCompletion":5821,"completion":5821,"start":5822,"enrollment":2647,"conditions":6113,"interventions":6114},[88],[419],[2905,437,693,795,5825,5826,1751],{"nctId":2896,"briefTitle":2897,"status":150,"phases":6116,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":2901,"conditions":6117,"interventions":6118},[87,88],[290],[386,1664,1843,2904,714,2905,693,387,390,1444,1253,437,2906],{"nctId":5631,"briefTitle":5632,"status":128,"phases":6120,"primaryCompletion":5634,"completion":5634,"start":5635,"enrollment":2779,"conditions":6121,"interventions":6122},[88],[1004],[602,693],{"trials":6124,"activeCount":3197,"soonestReadout":2614},[6125,6129,6133,6137,6141],{"nctId":1742,"briefTitle":1743,"status":105,"phases":6126,"primaryCompletion":824,"completion":1745,"start":1746,"enrollment":1747,"conditions":6127,"interventions":6128},[89],[828],[1750,1751,47,841,693],{"nctId":5395,"briefTitle":5396,"status":128,"phases":6130,"primaryCompletion":5398,"completion":5399,"start":5400,"enrollment":277,"conditions":6131,"interventions":6132},[89],[5402,5403],[602,434,5405,797,693,841,5406],{"nctId":2090,"briefTitle":2091,"status":105,"phases":6134,"primaryCompletion":2093,"completion":2094,"start":2095,"enrollment":2096,"conditions":6135,"interventions":6136},[89],[2098],[47,2100,967,693],{"nctId":2509,"briefTitle":2510,"status":105,"phases":6138,"primaryCompletion":2043,"completion":1807,"start":940,"enrollment":2512,"conditions":6139,"interventions":6140},[89],[2514,2515],[47,390,386,1444,693],{"nctId":2611,"briefTitle":2612,"status":139,"phases":6142,"primaryCompletion":2614,"completion":2614,"start":2615,"enrollment":920,"conditions":6143,"interventions":6144},[89],[371],[47,434,435,606,437,841,693],{"trials":6146,"activeCount":99},[],{"trials":6148,"activeCount":99},[],{"intervention":5541,"totalTrials":2901,"cells":6150},{"EARLY_PHASE1":6151,"PHASE1":6153,"PHASE2":6236,"PHASE3":6261,"PHASE4":6294,"NA":6296},{"trials":6152,"activeCount":99},[],{"trials":6154,"activeCount":3197,"soonestReadout":6225},[6155,6164,6173,6182,6190,6198,6208,6214,6221,6229],{"nctId":6156,"briefTitle":6157,"status":105,"phases":6158,"primaryCompletion":6159,"completion":6159,"start":6160,"enrollment":3390,"conditions":6161,"interventions":6163},"NCT06586671","A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)",[87],"2023-11-13","2023-08-28",[6162],"Hematological Malignancy",[5541],{"nctId":6165,"briefTitle":6166,"status":105,"phases":6167,"primaryCompletion":6168,"completion":6169,"start":729,"enrollment":3506,"conditions":6170,"interventions":6171},"NCT07232589","A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)",[87],"2026-05-04","2026-05-16",[18],[5541,6172],"Diltiazem",{"nctId":6174,"briefTitle":6175,"status":105,"phases":6176,"primaryCompletion":6177,"completion":5014,"start":6178,"enrollment":357,"conditions":6179,"interventions":6181},"NCT05673460","A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)",[87],"2025-04-28","2023-02-13",[6180],"Mature B-cell Neoplasms",[5541],{"nctId":6183,"briefTitle":6184,"status":105,"phases":6185,"primaryCompletion":6186,"completion":6186,"start":6187,"enrollment":931,"conditions":6188,"interventions":6189},"NCT06772805","A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-016)",[87],"2023-12-12","2023-07-24",[18],[5541],{"nctId":6191,"briefTitle":6192,"status":105,"phases":6193,"primaryCompletion":6194,"completion":6194,"start":6195,"enrollment":120,"conditions":6196,"interventions":6197},"NCT06625827","A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012)",[87],"2024-01-22","2023-11-07",[18],[5627,5541],{"nctId":6199,"briefTitle":6200,"status":139,"phases":6201,"primaryCompletion":6202,"completion":6203,"start":6204,"enrollment":95,"conditions":6205,"interventions":6207},"NCT05347225","A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)",[87],"2027-04-30","2028-12-29","2022-06-09",[6206],"Hematological Malignancies",[5541],{"nctId":6209,"briefTitle":6210,"status":105,"phases":6211,"primaryCompletion":1497,"completion":2022,"start":2116,"enrollment":805,"conditions":6212,"interventions":6213},"NCT06772818","A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-017)",[87],[18],[5541],{"nctId":6215,"briefTitle":6216,"status":105,"phases":6217,"primaryCompletion":6218,"completion":6218,"start":2722,"enrollment":2901,"conditions":6219,"interventions":6220},"NCT06688045","A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013)",[87],"2024-01-06",[18],[5541,5604],{"nctId":6222,"briefTitle":6223,"status":128,"phases":6224,"primaryCompletion":6225,"completion":6225,"start":477,"enrollment":626,"conditions":6226,"interventions":6228},"NCT06442436","A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)",[87],"2026-09-14",[6227],"Hepatic Impairment (HI)",[5541],{"nctId":6230,"briefTitle":6231,"status":105,"phases":6232,"primaryCompletion":2722,"completion":2722,"start":1188,"enrollment":3655,"conditions":6233,"interventions":6234},"NCT06698016","A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)",[87],[18],[5541,6235],"Efavirenz",{"trials":6237,"activeCount":3197,"soonestReadout":6253},[6238,6249],{"nctId":6239,"briefTitle":6240,"status":139,"phases":6241,"primaryCompletion":6242,"completion":6242,"start":6243,"enrollment":6244,"conditions":6245,"interventions":6248},"NCT05458297","A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)",[88],"2029-05-17","2022-07-21",189,[5538,6246,677,6247],"Mantle Cell Lymphoma","Richter Transformation Lymphoma",[1058,5541],{"nctId":6250,"briefTitle":6251,"status":128,"phases":6252,"primaryCompletion":6253,"completion":6253,"start":6254,"enrollment":6255,"conditions":6256,"interventions":6260},"NCT04728893","Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)",[88],"2029-01-04","2021-04-05",490,[2605,6257,6258,6259],"Waldenstroms Macroglobulinaemia","Non-Hodgkins Lymphoma","Chronic Lymphocytic Leukaemia",[5541],{"trials":6262,"activeCount":202,"soonestReadout":5534},[6263,6267,6277],{"nctId":5531,"briefTitle":5532,"status":139,"phases":6264,"primaryCompletion":5534,"completion":5535,"start":5536,"enrollment":1570,"conditions":6265,"interventions":6266},[89],[5538,5539],[5541,5542,562,5081,4349,5543,5544,5545],{"nctId":6268,"briefTitle":6269,"status":128,"phases":6270,"primaryCompletion":6271,"completion":6271,"start":6272,"enrollment":2204,"conditions":6273,"interventions":6274},"NCT06136559","A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)\u002F Small Lymphocytic Lymphoma (SLL) (MK-1026-011\u002FBELLWAVE-011)",[89],"2032-09-07","2023-12-13",[5538,5539],[5541,6275,6276],"Ibrutinib","Acalabrutinib",{"nctId":6278,"briefTitle":6279,"status":128,"phases":6280,"primaryCompletion":6281,"completion":6282,"start":6283,"enrollment":6284,"conditions":6285,"interventions":6292},"NCT05947851","A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed\u002FRefractory (R\u002FR) Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL) (MK-1026-010\u002FBELLWAVE-010).",[89],"2032-06-01","2035-07-01","2023-08-08",735,[6286,6287,6288,6289,6290,6291],"Leukemia, Lymphocytic, Chronic, B-Cell","Leukemia, Chronic Lymphocytic","Small-Cell Lymphoma","Lymphoma, Small Lymphocytic","CLL","SLL",[5541,6293,4349],"Venetoclax",{"trials":6295,"activeCount":99},[],{"trials":6297,"activeCount":99},[],{"intervention":841,"totalTrials":4071,"cells":6299},{"EARLY_PHASE1":6300,"PHASE1":6302,"PHASE2":6314,"PHASE3":6328,"PHASE4":6370,"NA":6372},{"trials":6301,"activeCount":99},[],{"trials":6303,"activeCount":99},[6304],{"nctId":6305,"briefTitle":6306,"status":105,"phases":6307,"primaryCompletion":6308,"completion":6308,"start":6309,"enrollment":3496,"conditions":6310,"interventions":6311},"NCT00781846","Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)",[87],"2010-02","2008-10",[279],[6312,6313],"ridaforolimus","bevacizumab",{"trials":6315,"activeCount":224,"soonestReadout":834},[6316,6320,6324],{"nctId":831,"briefTitle":832,"status":128,"phases":6317,"primaryCompletion":834,"completion":834,"start":835,"enrollment":836,"conditions":6318,"interventions":6319},[87,88],[838],[840,386,387,841,842,47,714,843],{"nctId":1243,"briefTitle":1244,"status":105,"phases":6321,"primaryCompletion":1246,"completion":1247,"start":1248,"enrollment":1249,"conditions":6322,"interventions":6323},[87,88],[1251],[47,387,386,841,385,1100,1253,1254],{"nctId":1277,"briefTitle":1278,"status":105,"phases":6325,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":1282,"conditions":6326,"interventions":6327},[88],[1284,1285,965,1286,856,791,540,1014,1287,1288,1289],[74,47,461,797,390,387,714,386,967,841,795,434],{"trials":6329,"activeCount":4555,"soonestReadout":2167},[6330,6334,6338,6342,6346,6350,6354,6358,6362,6366],{"nctId":1742,"briefTitle":1743,"status":105,"phases":6331,"primaryCompletion":824,"completion":1745,"start":1746,"enrollment":1747,"conditions":6332,"interventions":6333},[89],[828],[1750,1751,47,841,693],{"nctId":5395,"briefTitle":5396,"status":128,"phases":6335,"primaryCompletion":5398,"completion":5399,"start":5400,"enrollment":277,"conditions":6336,"interventions":6337},[89],[5402,5403],[602,434,5405,797,693,841,5406],{"nctId":1923,"briefTitle":1924,"status":105,"phases":6339,"primaryCompletion":1926,"completion":1927,"start":589,"enrollment":1928,"conditions":6340,"interventions":6341},[89],[990,1930,1931],[47,386,387,1114,841,967],{"nctId":3590,"briefTitle":3591,"status":128,"phases":6343,"primaryCompletion":3593,"completion":3594,"start":909,"enrollment":3595,"conditions":6344,"interventions":6345},[89],[990,1930,3597],[653,841,977,978,979,529,980],{"nctId":3600,"briefTitle":3601,"status":128,"phases":6347,"primaryCompletion":3603,"completion":3603,"start":3604,"enrollment":3605,"conditions":6348,"interventions":6349},[89],[1288,990],[653,841,327],{"nctId":2164,"briefTitle":2165,"status":139,"phases":6351,"primaryCompletion":2167,"completion":2168,"start":2169,"enrollment":2170,"conditions":6352,"interventions":6353},[89],[990,2172,2173],[47,387,841,967],{"nctId":2364,"briefTitle":2365,"status":105,"phases":6355,"primaryCompletion":2005,"completion":73,"start":2367,"enrollment":2368,"conditions":6356,"interventions":6357},[89],[863],[47,387,390,386,841],{"nctId":2611,"briefTitle":2612,"status":139,"phases":6359,"primaryCompletion":2614,"completion":2614,"start":2615,"enrollment":920,"conditions":6360,"interventions":6361},[89],[371],[47,434,435,606,437,841,693],{"nctId":2740,"briefTitle":2741,"status":128,"phases":6363,"primaryCompletion":2743,"completion":2743,"start":2744,"enrollment":2745,"conditions":6364,"interventions":6365},[89],[863],[47,794,841,387,390,386,327],{"nctId":5907,"briefTitle":5908,"status":105,"phases":6367,"primaryCompletion":5910,"completion":5911,"start":5912,"enrollment":1522,"conditions":6368,"interventions":6369},[89],[431],[1114,1444,841,795,5915],{"trials":6371,"activeCount":99},[],{"trials":6373,"activeCount":99},[],{"intervention":1114,"totalTrials":4071,"cells":6375},{"EARLY_PHASE1":6376,"PHASE1":6378,"PHASE2":6380,"PHASE3":6412,"PHASE4":6446,"NA":6448},{"trials":6377,"activeCount":99},[],{"trials":6379,"activeCount":99},[],{"trials":6381,"activeCount":3963,"soonestReadout":6394},[6382,6386,6390,6400,6404,6408],{"nctId":4768,"briefTitle":4769,"status":128,"phases":6383,"primaryCompletion":4771,"completion":4771,"start":2266,"enrollment":8,"conditions":6384,"interventions":6385},[87,88],[4773],[4775,1114,967,4776,4777,529,1076],{"nctId":1102,"briefTitle":1103,"status":128,"phases":6387,"primaryCompletion":804,"completion":1105,"start":973,"enrollment":1106,"conditions":6388,"interventions":6389},[88],[1108,1109],[1111,47,387,386,1112,1113,562,795,1114],{"nctId":6391,"briefTitle":6392,"status":139,"phases":6393,"primaryCompletion":6394,"completion":645,"start":6395,"enrollment":6396,"conditions":6397,"interventions":6399},"NCT03742895","Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 \u002F LYNK-002)",[88],"2025-08-12","2018-12-12",329,[6398],"Advanced Solid Neoplasms",[1114],{"nctId":1392,"briefTitle":1393,"status":1040,"phases":6401,"primaryCompletion":1395,"completion":1396,"start":1397,"enrollment":99,"conditions":6402,"interventions":6403},[88],[1399],[47,387,386,1069,542,1401,562,795,1114],{"nctId":1536,"briefTitle":1537,"status":105,"phases":6405,"primaryCompletion":1539,"completion":1540,"start":891,"enrollment":1541,"conditions":6406,"interventions":6407},[88],[540],[47,1114,386,714],{"nctId":1566,"briefTitle":1567,"status":139,"phases":6409,"primaryCompletion":1569,"completion":1569,"start":556,"enrollment":1570,"conditions":6410,"interventions":6411},[88],[176],[1114,47],{"trials":6413,"activeCount":202,"soonestReadout":2179},[6414,6418,6422,6426,6430,6434,6438,6442],{"nctId":1697,"briefTitle":1698,"status":105,"phases":6415,"primaryCompletion":1700,"completion":1701,"start":1702,"enrollment":1703,"conditions":6416,"interventions":6417},[89],[1705],[47,385,386,390,1114],{"nctId":1923,"briefTitle":1924,"status":105,"phases":6419,"primaryCompletion":1926,"completion":1927,"start":589,"enrollment":1928,"conditions":6420,"interventions":6421},[89],[990,1930,1931],[47,386,387,1114,841,967],{"nctId":2176,"briefTitle":2177,"status":139,"phases":6423,"primaryCompletion":2179,"completion":2180,"start":2181,"enrollment":2182,"conditions":6424,"interventions":6425},[89],[2184,369],[47,1114,1073,386,390,387,385,2186],{"nctId":2385,"briefTitle":2386,"status":105,"phases":6427,"primaryCompletion":2388,"completion":2389,"start":1702,"enrollment":2390,"conditions":6428,"interventions":6429},[89],[2392],[47,386,387,388,1114],{"nctId":2403,"briefTitle":2404,"status":105,"phases":6431,"primaryCompletion":2083,"completion":2406,"start":2407,"enrollment":2408,"conditions":6432,"interventions":6433},[89],[2410],[47,1114,2412,1076,2382,2413],{"nctId":2435,"briefTitle":2436,"status":128,"phases":6435,"primaryCompletion":2438,"completion":2439,"start":2440,"enrollment":2441,"conditions":6436,"interventions":6437},[89],[1108,540,2443],[653,47,842,386,387,1069,1664,562,795,1114],{"nctId":2598,"briefTitle":2599,"status":128,"phases":6439,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":2603,"conditions":6440,"interventions":6441},[89],[176,2605],[47,2607,461,1114,2608,2609,384],{"nctId":5907,"briefTitle":5908,"status":105,"phases":6443,"primaryCompletion":5910,"completion":5911,"start":5912,"enrollment":1522,"conditions":6444,"interventions":6445},[89],[431],[1114,1444,841,795,5915],{"trials":6447,"activeCount":99},[],{"trials":6449,"activeCount":99},[],{"intervention":1069,"totalTrials":95,"cells":6451},{"EARLY_PHASE1":6452,"PHASE1":6454,"PHASE2":6468,"PHASE3":6490,"PHASE4":6512,"NA":6514},{"trials":6453,"activeCount":99},[],{"trials":6455,"activeCount":99},[6456,6460],{"nctId":5462,"briefTitle":5463,"status":150,"phases":6457,"primaryCompletion":5465,"completion":5465,"start":5466,"enrollment":3963,"conditions":6458,"interventions":6459},[87],[290,176,5468,5469,5470],[1390,1074,5472,437,2905,1069,562,1073],{"nctId":6461,"briefTitle":6462,"status":105,"phases":6463,"primaryCompletion":5801,"completion":5801,"start":6464,"enrollment":661,"conditions":6465,"interventions":6467},"NCT00288431","Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)",[87],"2006-02",[639,6466],"Sarcoma",[6312,1069],{"trials":6469,"activeCount":202,"soonestReadout":1450},[6470,6474,6478,6482,6486],{"nctId":1061,"briefTitle":1062,"status":105,"phases":6471,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":110,"conditions":6472,"interventions":6473},[88],[943],[47,1069,1070,1071,1072,1073,562,1074,1075,1076],{"nctId":5494,"briefTitle":5495,"status":139,"phases":6475,"primaryCompletion":5497,"completion":5497,"start":5498,"enrollment":558,"conditions":6476,"interventions":6477},[88],[5500],[5502,562,1069,4349,4350,1076,2413],{"nctId":1392,"briefTitle":1393,"status":1040,"phases":6479,"primaryCompletion":1395,"completion":1396,"start":1397,"enrollment":99,"conditions":6480,"interventions":6481},[88],[1399],[47,387,386,1069,542,1401,562,795,1114],{"nctId":1447,"briefTitle":1448,"status":139,"phases":6483,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":6484,"interventions":6485},[88],[674],[42,1455,1456,1457,1458,1459,1460,1461,487],{"nctId":4339,"briefTitle":4340,"status":128,"phases":6487,"primaryCompletion":4342,"completion":4343,"start":4344,"enrollment":4345,"conditions":6488,"interventions":6489},[88],[4347],[1058,4349,562,1069,4350,1076,2413,4351,842],{"trials":6491,"activeCount":3963,"soonestReadout":3033},[6492,6496,6500,6504,6508],{"nctId":1656,"briefTitle":1657,"status":105,"phases":6493,"primaryCompletion":1659,"completion":1659,"start":1660,"enrollment":1661,"conditions":6494,"interventions":6495},[89],[540],[47,386,387,1069,1664,562,1665],{"nctId":4381,"briefTitle":4382,"status":128,"phases":6497,"primaryCompletion":762,"completion":4384,"start":1610,"enrollment":4385,"conditions":6498,"interventions":6499},[89],[676],[1058,4349,562,1069,4350,1076,2413,1074,1089,4388],{"nctId":2133,"briefTitle":2134,"status":139,"phases":6501,"primaryCompletion":2136,"completion":2136,"start":2137,"enrollment":2138,"conditions":6502,"interventions":6503},[89],[1109],[47,387,1069,1664,562,2141],{"nctId":3030,"briefTitle":3031,"status":139,"phases":6505,"primaryCompletion":3033,"completion":3033,"start":1958,"enrollment":3034,"conditions":6506,"interventions":6507},[89],[861],[653,1069,387,388,3037],{"nctId":2435,"briefTitle":2436,"status":128,"phases":6509,"primaryCompletion":2438,"completion":2439,"start":2440,"enrollment":2441,"conditions":6510,"interventions":6511},[89],[1108,540,2443],[653,47,842,386,387,1069,1664,562,795,1114],{"trials":6513,"activeCount":99},[],{"trials":6515,"activeCount":99},[],{"intervention":1058,"totalTrials":734,"cells":6517},{"EARLY_PHASE1":6518,"PHASE1":6520,"PHASE2":6522,"PHASE3":6560,"PHASE4":6570,"NA":6572},{"trials":6519,"activeCount":99},[],{"trials":6521,"activeCount":99},[],{"trials":6523,"activeCount":174,"soonestReadout":4342},[6524,6528,6537,6541,6545,6556],{"nctId":6239,"briefTitle":6240,"status":139,"phases":6525,"primaryCompletion":6242,"completion":6242,"start":6243,"enrollment":6244,"conditions":6526,"interventions":6527},[88],[5538,6246,677,6247],[1058,5541],{"nctId":6529,"briefTitle":6530,"status":105,"phases":6531,"primaryCompletion":6532,"completion":6532,"start":6533,"enrollment":407,"conditions":6534,"interventions":6536},"NCT05144841","A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)",[88],"2026-04-21","2022-01-08",[6535],"Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[1058],{"nctId":1049,"briefTitle":1050,"status":128,"phases":6538,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":1054,"conditions":6539,"interventions":6540},[87,88],[1056],[1058,47,1059],{"nctId":5494,"briefTitle":5495,"status":139,"phases":6542,"primaryCompletion":5497,"completion":5497,"start":5498,"enrollment":558,"conditions":6543,"interventions":6544},[88],[5500],[5502,562,1069,4349,4350,1076,2413],{"nctId":6546,"briefTitle":6547,"status":128,"phases":6548,"primaryCompletion":6549,"completion":6549,"start":6550,"enrollment":397,"conditions":6551,"interventions":6555},"NCT06395103","Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A\u002FLIGHTBEAM-U01)",[87,88],"2029-03-31","2024-08-16",[5225,6552,6553,5470,6554],"Diffuse Large B-cell Lymphoma","Burkitt Lymphoma","Ewing Sarcoma",[1058],{"nctId":4339,"briefTitle":4340,"status":128,"phases":6557,"primaryCompletion":4342,"completion":4343,"start":4344,"enrollment":4345,"conditions":6558,"interventions":6559},[88],[4347],[1058,4349,562,1069,4350,1076,2413,4351,842],{"trials":6561,"activeCount":3197,"soonestReadout":5075},[6562,6566],{"nctId":4381,"briefTitle":4382,"status":128,"phases":6563,"primaryCompletion":762,"completion":4384,"start":1610,"enrollment":4385,"conditions":6564,"interventions":6565},[89],[676],[1058,4349,562,1069,4350,1076,2413,1074,1089,4388],{"nctId":5072,"briefTitle":5073,"status":128,"phases":6567,"primaryCompletion":5075,"completion":5075,"start":5076,"enrollment":5077,"conditions":6568,"interventions":6569},[88,89],[5079,676],[1058,4349,714,434,5081,5082],{"trials":6571,"activeCount":99},[],{"trials":6573,"activeCount":99},[],{"intervention":1111,"totalTrials":357,"cells":6575},{"EARLY_PHASE1":6576,"PHASE1":6578,"PHASE2":6580,"PHASE3":6620,"PHASE4":6626,"NA":6628},{"trials":6577,"activeCount":99},[],{"trials":6579,"activeCount":99},[],{"trials":6581,"activeCount":4555,"soonestReadout":219},[6582,6586,6593,6597,6601,6609],{"nctId":782,"briefTitle":783,"status":128,"phases":6583,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":6584,"interventions":6585},[87,88],[789,790,791,792],[47,794,795,435,796,797,434,798],{"nctId":6587,"briefTitle":6588,"status":128,"phases":6589,"primaryCompletion":3261,"completion":3261,"start":6590,"enrollment":4421,"conditions":6591,"interventions":6592},"NCT06941272","A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C\u002FLIGHTBEAM-U01)",[87,88],"2025-05-26",[690],[798],{"nctId":1102,"briefTitle":1103,"status":128,"phases":6594,"primaryCompletion":804,"completion":1105,"start":973,"enrollment":1106,"conditions":6595,"interventions":6596},[88],[1108,1109],[1111,47,387,386,1112,1113,562,795,1114],{"nctId":3535,"briefTitle":3536,"status":128,"phases":6598,"primaryCompletion":3538,"completion":3539,"start":3540,"enrollment":3541,"conditions":6599,"interventions":6600},[87,88],[975],[500,1111,653,693,327],{"nctId":6602,"briefTitle":6603,"status":128,"phases":6604,"primaryCompletion":219,"completion":219,"start":6605,"enrollment":765,"conditions":6606,"interventions":6608},"NCT06596694","Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)",[87,88],"2024-11-03",[6607],"Gastrointestinal Cancer",[1111],{"nctId":6610,"briefTitle":6611,"status":128,"phases":6612,"primaryCompletion":6613,"completion":6613,"start":6614,"enrollment":2770,"conditions":6615,"interventions":6616},"NCT06686394","Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)",[87,88],"2030-04-18","2025-02-26",[1108,1109],[1111,1843,6617,6618,6619],"Trastuzumab Biosimilar","Pertuzumab","Tucatinib",{"trials":6621,"activeCount":224,"soonestReadout":2937},[6622],{"nctId":2934,"briefTitle":2935,"status":128,"phases":6623,"primaryCompletion":2937,"completion":2937,"start":2938,"enrollment":1633,"conditions":6624,"interventions":6625},[89],[1108],[1111,387,388,795,2207,2941],{"trials":6627,"activeCount":99},[],{"trials":6629,"activeCount":99},[],{"intervention":654,"totalTrials":357,"cells":6631},{"EARLY_PHASE1":6632,"PHASE1":6634,"PHASE2":6640,"PHASE3":6658,"PHASE4":6668,"NA":6670},{"trials":6633,"activeCount":99},[],{"trials":6635,"activeCount":224,"soonestReadout":645},[6636],{"nctId":642,"briefTitle":643,"status":139,"phases":6637,"primaryCompletion":645,"completion":646,"start":647,"enrollment":154,"conditions":6638,"interventions":6639},[87],[314,176,649,650,651],[653,47,654],{"trials":6641,"activeCount":3963,"soonestReadout":645},[6642,6646,6650,6654],{"nctId":1078,"briefTitle":1079,"status":128,"phases":6643,"primaryCompletion":1081,"completion":1081,"start":1082,"enrollment":8,"conditions":6644,"interventions":6645},[87,88],[419,1084,1085],[653,1087,1088,1089,654,390,47],{"nctId":1315,"briefTitle":1316,"status":128,"phases":6647,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1132,"conditions":6648,"interventions":6649},[87,88],[1263],[387,437,47,471,461,653,1323,1324,979,529,1325,654],{"nctId":1371,"briefTitle":1372,"status":139,"phases":6651,"primaryCompletion":1374,"completion":1374,"start":1375,"enrollment":312,"conditions":6652,"interventions":6653},[87,88],[1377,1378],[653,1136,47,654],{"nctId":3557,"briefTitle":3558,"status":128,"phases":6655,"primaryCompletion":645,"completion":3560,"start":3561,"enrollment":626,"conditions":6656,"interventions":6657},[87,88],[3563],[653,1089,654],{"trials":6659,"activeCount":3197,"soonestReadout":3073},[6660,6664],{"nctId":1679,"briefTitle":1680,"status":128,"phases":6661,"primaryCompletion":1682,"completion":1683,"start":1684,"enrollment":1685,"conditions":6662,"interventions":6663},[89],[1687],[653,47,654],{"nctId":3070,"briefTitle":3071,"status":139,"phases":6665,"primaryCompletion":3073,"completion":3074,"start":3075,"enrollment":951,"conditions":6666,"interventions":6667},[89],[3077],[653,3079,437,387,967,3037,654],{"trials":6669,"activeCount":99},[],{"trials":6671,"activeCount":99},[],{"intervention":435,"totalTrials":5983,"cells":6673},{"EARLY_PHASE1":6674,"PHASE1":6676,"PHASE2":6690,"PHASE3":6700,"PHASE4":6726,"NA":6728},{"trials":6675,"activeCount":99},[],{"trials":6677,"activeCount":224,"soonestReadout":597},[6678,6682,6686],{"nctId":423,"briefTitle":424,"status":105,"phases":6679,"primaryCompletion":426,"completion":427,"start":428,"enrollment":429,"conditions":6680,"interventions":6681},[87],[431],[47,433,434,435,436,437],{"nctId":450,"briefTitle":451,"status":105,"phases":6683,"primaryCompletion":453,"completion":453,"start":454,"enrollment":455,"conditions":6684,"interventions":6685},[87],[290],[458,47,434,437,435,459,460,461],{"nctId":594,"briefTitle":595,"status":128,"phases":6687,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":6688,"interventions":6689},[87],[497],[602,47,484,483,603,604,605,606],{"trials":6691,"activeCount":3197,"soonestReadout":785},[6692,6696],{"nctId":782,"briefTitle":783,"status":128,"phases":6693,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":6694,"interventions":6695},[87,88],[789,790,791,792],[47,794,795,435,796,797,434,798],{"nctId":1256,"briefTitle":1257,"status":128,"phases":6697,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":1261,"conditions":6698,"interventions":6699},[87,88],[1263],[47,1265,435,796,797,434,653,842],{"trials":6701,"activeCount":202,"soonestReadout":2321},[6702,6706,6710,6714,6718,6722],{"nctId":2019,"briefTitle":2020,"status":105,"phases":6703,"primaryCompletion":2022,"completion":730,"start":1406,"enrollment":2023,"conditions":6704,"interventions":6705},[89],[991,2025],[47,390,795,606,967,434,435],{"nctId":2048,"briefTitle":2049,"status":105,"phases":6707,"primaryCompletion":2051,"completion":2052,"start":2053,"enrollment":2054,"conditions":6708,"interventions":6709},[89],[2056],[47,461,434,795,435,1444],{"nctId":2318,"briefTitle":2319,"status":139,"phases":6711,"primaryCompletion":2321,"completion":2322,"start":2323,"enrollment":2324,"conditions":6712,"interventions":6713},[89],[2326],[47,461,390,1444,434,435,796,387],{"nctId":2339,"briefTitle":2340,"status":105,"phases":6715,"primaryCompletion":2022,"completion":730,"start":2342,"enrollment":2343,"conditions":6716,"interventions":6717},[89],[991,2025],[47,390,795,606,967,434,435],{"nctId":2611,"briefTitle":2612,"status":139,"phases":6719,"primaryCompletion":2614,"completion":2614,"start":2615,"enrollment":920,"conditions":6720,"interventions":6721},[89],[371],[47,434,435,606,437,841,693],{"nctId":2630,"briefTitle":2631,"status":139,"phases":6723,"primaryCompletion":2192,"completion":2633,"start":2634,"enrollment":2635,"conditions":6724,"interventions":6725},[89],[1230,2637,2638],[42,486,1444,605,2640,604],{"trials":6727,"activeCount":99},[],{"trials":6729,"activeCount":99},[],{"intervention":1073,"totalTrials":5983,"cells":6731},{"EARLY_PHASE1":6732,"PHASE1":6734,"PHASE2":6744,"PHASE3":6766,"PHASE4":6784,"NA":6786},{"trials":6733,"activeCount":99},[],{"trials":6735,"activeCount":99},[6736,6740],{"nctId":474,"briefTitle":475,"status":105,"phases":6737,"primaryCompletion":477,"completion":477,"start":478,"enrollment":479,"conditions":6738,"interventions":6739},[87],[290],[482,42,483,484,485,486,487],{"nctId":5462,"briefTitle":5463,"status":150,"phases":6741,"primaryCompletion":5465,"completion":5465,"start":5466,"enrollment":3963,"conditions":6742,"interventions":6743},[87],[290,176,5468,5469,5470],[1390,1074,5472,437,2905,1069,562,1073],{"trials":6745,"activeCount":202,"soonestReadout":1450},[6746,6750,6754,6758,6762],{"nctId":1061,"briefTitle":1062,"status":105,"phases":6747,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":110,"conditions":6748,"interventions":6749},[88],[943],[47,1069,1070,1071,1072,1073,562,1074,1075,1076],{"nctId":3239,"briefTitle":3240,"status":128,"phases":6751,"primaryCompletion":3242,"completion":3243,"start":3244,"enrollment":2204,"conditions":6752,"interventions":6753},[87,88],[3246],[84,3248,3249,3250,3251,3252,3253,461,3254,386,1073,3255],{"nctId":3257,"briefTitle":3258,"status":128,"phases":6755,"primaryCompletion":3260,"completion":3261,"start":1701,"enrollment":3262,"conditions":6756,"interventions":6757},[87,88],[3264],[3266,1265,3267,386,1073,327],{"nctId":1447,"briefTitle":1448,"status":139,"phases":6759,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":6760,"interventions":6761},[88],[674],[42,1455,1456,1457,1458,1459,1460,1461,487],{"nctId":1545,"briefTitle":1546,"status":105,"phases":6763,"primaryCompletion":1548,"completion":1548,"start":1549,"enrollment":1550,"conditions":6764,"interventions":6765},[88],[1552],[47,471,542,461,1073,390,386],{"trials":6767,"activeCount":202,"soonestReadout":73},[6768,6772,6776,6780],{"nctId":2971,"briefTitle":2972,"status":139,"phases":6769,"primaryCompletion":2974,"completion":2974,"start":2975,"enrollment":987,"conditions":6770,"interventions":6771},[89],[369],[2978,2979,486,483,487,484,1654],{"nctId":71,"briefTitle":72,"status":139,"phases":6773,"primaryCompletion":73,"completion":2398,"start":1796,"enrollment":836,"conditions":6774,"interventions":6775},[89],[866],[74,3375,1073,390,3267,386],{"nctId":2176,"briefTitle":2177,"status":139,"phases":6777,"primaryCompletion":2179,"completion":2180,"start":2181,"enrollment":2182,"conditions":6778,"interventions":6779},[89],[2184,369],[47,1114,1073,386,390,387,385,2186],{"nctId":2355,"briefTitle":2356,"status":105,"phases":6781,"primaryCompletion":2358,"completion":379,"start":2359,"enrollment":2335,"conditions":6782,"interventions":6783},[89],[867],[47,2362,386,390,1073],{"trials":6785,"activeCount":99},[],{"trials":6787,"activeCount":99},[],{"intervention":4349,"totalTrials":357,"cells":6789},{"EARLY_PHASE1":6790,"PHASE1":6792,"PHASE2":6803,"PHASE3":6813,"PHASE4":6831,"NA":6833},{"trials":6791,"activeCount":99},[],{"trials":6793,"activeCount":99},[6794],{"nctId":6795,"briefTitle":6796,"status":105,"phases":6797,"primaryCompletion":6798,"completion":6798,"start":6799,"enrollment":174,"conditions":6800,"interventions":6801},"NCT01650727","A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)",[87],"2013-10","2012-10",[5538,5539],[6802,4349],"Dinaciclib",{"trials":6804,"activeCount":3197,"soonestReadout":4342},[6805,6809],{"nctId":5494,"briefTitle":5495,"status":139,"phases":6806,"primaryCompletion":5497,"completion":5497,"start":5498,"enrollment":558,"conditions":6807,"interventions":6808},[88],[5500],[5502,562,1069,4349,4350,1076,2413],{"nctId":4339,"briefTitle":4340,"status":128,"phases":6810,"primaryCompletion":4342,"completion":4343,"start":4344,"enrollment":4345,"conditions":6811,"interventions":6812},[88],[4347],[1058,4349,562,1069,4350,1076,2413,4351,842],{"trials":6814,"activeCount":3963,"soonestReadout":5534},[6815,6819,6823,6827],{"nctId":5531,"briefTitle":5532,"status":139,"phases":6816,"primaryCompletion":5534,"completion":5535,"start":5536,"enrollment":1570,"conditions":6817,"interventions":6818},[89],[5538,5539],[5541,5542,562,5081,4349,5543,5544,5545],{"nctId":4381,"briefTitle":4382,"status":128,"phases":6820,"primaryCompletion":762,"completion":4384,"start":1610,"enrollment":4385,"conditions":6821,"interventions":6822},[89],[676],[1058,4349,562,1069,4350,1076,2413,1074,1089,4388],{"nctId":5072,"briefTitle":5073,"status":128,"phases":6824,"primaryCompletion":5075,"completion":5075,"start":5076,"enrollment":5077,"conditions":6825,"interventions":6826},[88,89],[5079,676],[1058,4349,714,434,5081,5082],{"nctId":6278,"briefTitle":6279,"status":128,"phases":6828,"primaryCompletion":6281,"completion":6282,"start":6283,"enrollment":6284,"conditions":6829,"interventions":6830},[89],[6286,6287,6288,6289,6290,6291],[5541,6293,4349],{"trials":6832,"activeCount":99},[],{"trials":6834,"activeCount":99},[],{"intervention":606,"totalTrials":335,"cells":6836},{"EARLY_PHASE1":6837,"PHASE1":6839,"PHASE2":6845,"PHASE3":6859,"PHASE4":6885,"NA":6887},{"trials":6838,"activeCount":99},[],{"trials":6840,"activeCount":224,"soonestReadout":597},[6841],{"nctId":594,"briefTitle":595,"status":128,"phases":6842,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":6843,"interventions":6844},[87],[497],[602,47,484,483,603,604,605,606],{"trials":6846,"activeCount":3197,"soonestReadout":785},[6847,6851,6855],{"nctId":782,"briefTitle":783,"status":128,"phases":6848,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":6849,"interventions":6850},[87,88],[789,790,791,792],[47,794,795,435,796,797,434,798],{"nctId":1256,"briefTitle":1257,"status":128,"phases":6852,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":1261,"conditions":6853,"interventions":6854},[87,88],[1263],[47,1265,435,796,797,434,653,842],{"nctId":1277,"briefTitle":1278,"status":105,"phases":6856,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":1282,"conditions":6857,"interventions":6858},[88],[1284,1285,965,1286,856,791,540,1014,1287,1288,1289],[74,47,461,797,390,387,714,386,967,841,795,434],{"trials":6860,"activeCount":3197,"soonestReadout":2614},[6861,6865,6869,6873,6877,6881],{"nctId":5395,"briefTitle":5396,"status":128,"phases":6862,"primaryCompletion":5398,"completion":5399,"start":5400,"enrollment":277,"conditions":6863,"interventions":6864},[89],[5402,5403],[602,434,5405,797,693,841,5406],{"nctId":2002,"briefTitle":2003,"status":105,"phases":6866,"primaryCompletion":2005,"completion":2006,"start":2007,"enrollment":2008,"conditions":6867,"interventions":6868},[89],[1289],[47,390,606,604,1445],{"nctId":2012,"briefTitle":2013,"status":1040,"phases":6870,"primaryCompletion":2015,"completion":2015,"start":2007,"enrollment":99,"conditions":6871,"interventions":6872},[89],[1289],[47,390,606,434,795],{"nctId":2019,"briefTitle":2020,"status":105,"phases":6874,"primaryCompletion":2022,"completion":730,"start":1406,"enrollment":2023,"conditions":6875,"interventions":6876},[89],[991,2025],[47,390,795,606,967,434,435],{"nctId":2339,"briefTitle":2340,"status":105,"phases":6878,"primaryCompletion":2022,"completion":730,"start":2342,"enrollment":2343,"conditions":6879,"interventions":6880},[89],[991,2025],[47,390,795,606,967,434,435],{"nctId":2611,"briefTitle":2612,"status":139,"phases":6882,"primaryCompletion":2614,"completion":2614,"start":2615,"enrollment":920,"conditions":6883,"interventions":6884},[89],[371],[47,434,435,606,437,841,693],{"trials":6886,"activeCount":99},[],{"trials":6888,"activeCount":99},[],{"intervention":4775,"totalTrials":3308,"cells":6890},{"EARLY_PHASE1":6891,"PHASE1":6893,"PHASE2":6915,"PHASE3":6925,"PHASE4":6935,"NA":6937},{"trials":6892,"activeCount":99},[],{"trials":6894,"activeCount":224,"soonestReadout":5972},[6895,6899,6903,6907,6911],{"nctId":5927,"briefTitle":5928,"status":105,"phases":6896,"primaryCompletion":5930,"completion":4408,"start":5931,"enrollment":4071,"conditions":6897,"interventions":6898},[87],[18],[4775,1076,4777,5934],{"nctId":5118,"briefTitle":5119,"status":105,"phases":6900,"primaryCompletion":5121,"completion":5121,"start":5122,"enrollment":4071,"conditions":6901,"interventions":6902},[87],[2410,3246],[4775,529,5125,5126],{"nctId":5969,"briefTitle":5970,"status":139,"phases":6904,"primaryCompletion":5972,"completion":5973,"start":5974,"enrollment":4071,"conditions":6905,"interventions":6906},[87],[18],[4775,1076,4777,5604],{"nctId":5156,"briefTitle":5157,"status":105,"phases":6908,"primaryCompletion":5159,"completion":5160,"start":5161,"enrollment":357,"conditions":6909,"interventions":6910},[87],[2410,3246],[4775,529,4777,5126],{"nctId":5988,"briefTitle":5989,"status":105,"phases":6912,"primaryCompletion":1348,"completion":5991,"start":4408,"enrollment":3655,"conditions":6913,"interventions":6914},[87],[5595,5945],[4775,1076,4777],{"trials":6916,"activeCount":3197,"soonestReadout":4924},[6917,6921],{"nctId":4768,"briefTitle":4769,"status":128,"phases":6918,"primaryCompletion":4771,"completion":4771,"start":2266,"enrollment":8,"conditions":6919,"interventions":6920},[87,88],[4773],[4775,1114,967,4776,4777,529,1076],{"nctId":4921,"briefTitle":4922,"status":128,"phases":6922,"primaryCompletion":4924,"completion":4924,"start":4925,"enrollment":688,"conditions":6923,"interventions":6924},[88],[690],[4775,4928,4929,327,4155,4156,4930,4931,4932],{"trials":6926,"activeCount":3197,"soonestReadout":5260},[6927,6931],{"nctId":5235,"briefTitle":5236,"status":128,"phases":6928,"primaryCompletion":5238,"completion":5239,"start":5240,"enrollment":5241,"conditions":6929,"interventions":6930},[89],[5243],[4775,2412,2382,5126,4777,1076,529],{"nctId":5257,"briefTitle":5258,"status":128,"phases":6932,"primaryCompletion":5260,"completion":5261,"start":5262,"enrollment":5263,"conditions":6933,"interventions":6934},[89],[5265,2410],[4775,529,4777,5126,2412,5267,2382],{"trials":6936,"activeCount":99},[],{"trials":6938,"activeCount":99},[],{"intervention":818,"totalTrials":3308,"cells":6940},{"EARLY_PHASE1":6941,"PHASE1":6943,"PHASE2":6945,"PHASE3":6975,"PHASE4":6985,"NA":6987},{"trials":6942,"activeCount":99},[],{"trials":6944,"activeCount":99},[],{"trials":6946,"activeCount":202,"soonestReadout":395},[6947,6951,6955,6959,6963,6967,6971],{"nctId":810,"briefTitle":811,"status":105,"phases":6948,"primaryCompletion":813,"completion":813,"start":814,"enrollment":815,"conditions":6949,"interventions":6950},[87,88],[497],[780,47,818],{"nctId":1029,"briefTitle":1030,"status":139,"phases":6952,"primaryCompletion":1032,"completion":1032,"start":1033,"enrollment":941,"conditions":6953,"interventions":6954},[87,88],[1035],[47,471,56,461,818,460],{"nctId":1146,"briefTitle":1147,"status":139,"phases":6956,"primaryCompletion":1032,"completion":1032,"start":1149,"enrollment":1150,"conditions":6957,"interventions":6958},[87,88],[1035],[47,460,56,461,818,1153],{"nctId":1215,"briefTitle":1216,"status":105,"phases":6960,"primaryCompletion":1218,"completion":1218,"start":1219,"enrollment":429,"conditions":6961,"interventions":6962},[88],[1221],[818,461,47],{"nctId":1267,"briefTitle":1268,"status":139,"phases":6964,"primaryCompletion":395,"completion":1270,"start":1271,"enrollment":1272,"conditions":6965,"interventions":6966},[88],[419],[47,818,1275,1241,471],{"nctId":1517,"briefTitle":1518,"status":105,"phases":6968,"primaryCompletion":1520,"completion":1520,"start":1521,"enrollment":1522,"conditions":6969,"interventions":6970},[87,88],[35],[47,923,818,461,460,924],{"nctId":1616,"briefTitle":1617,"status":105,"phases":6972,"primaryCompletion":1619,"completion":1619,"start":1620,"enrollment":1621,"conditions":6973,"interventions":6974},[87,88],[35],[47,818,461],{"trials":6976,"activeCount":3197,"soonestReadout":2468},[6977,6981],{"nctId":2395,"briefTitle":2396,"status":139,"phases":6978,"primaryCompletion":2398,"completion":2398,"start":1228,"enrollment":2399,"conditions":6979,"interventions":6980},[89],[1035],[47,56,818,461],{"nctId":2465,"briefTitle":2466,"status":139,"phases":6982,"primaryCompletion":2468,"completion":2468,"start":2469,"enrollment":2470,"conditions":6983,"interventions":6984},[89],[1035],[47,56,818,461],{"trials":6986,"activeCount":99},[],{"trials":6988,"activeCount":99},[],{"intervention":979,"totalTrials":3308,"cells":6990},{"EARLY_PHASE1":6991,"PHASE1":6993,"PHASE2":7025,"PHASE3":7039,"PHASE4":7053,"NA":7055},{"trials":6992,"activeCount":99},[],{"trials":6994,"activeCount":99},[6995,7004,7013],{"nctId":6996,"briefTitle":6997,"status":105,"phases":6998,"primaryCompletion":6999,"completion":6999,"start":7000,"enrollment":31,"conditions":7001,"interventions":7002},"NCT03554005","Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C\u002FI97-349\u002FMK-4031-009)",[87],"2001-03-16","1997-12-29",[290],[7003,979],"PEG Interferon Alfa-2b",{"nctId":7005,"briefTitle":7006,"status":105,"phases":7007,"primaryCompletion":7008,"completion":7008,"start":7009,"enrollment":1054,"conditions":7010,"interventions":7011},"NCT06701305","A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)",[87],"2025-02-18","2024-06-13",[18],[7012,979],"Efinopegdutide",{"nctId":7014,"briefTitle":7015,"status":150,"phases":7016,"primaryCompletion":7017,"completion":7017,"start":7018,"enrollment":920,"conditions":7019,"interventions":7021},"NCT01390441","A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)",[87],"2014-04","2011-07",[7020],"Rheumatoid Arthritis",[5481,7022,2100,7023,4388,979,7024],"MabThera®","Rituxan®","Loratadine",{"trials":7026,"activeCount":3197,"soonestReadout":1318},[7027,7031,7035],{"nctId":969,"briefTitle":970,"status":128,"phases":7028,"primaryCompletion":972,"completion":972,"start":973,"enrollment":558,"conditions":7029,"interventions":7030},[88],[975],[47,390,714,385,653,977,978,979,529,386,47,387,980],{"nctId":1017,"briefTitle":1018,"status":105,"phases":7032,"primaryCompletion":1020,"completion":1021,"start":1022,"enrollment":1023,"conditions":7033,"interventions":7034},[88],[369],[47,542,471,1026,1027,713],{"nctId":1315,"briefTitle":1316,"status":128,"phases":7036,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1132,"conditions":7037,"interventions":7038},[87,88],[1263],[387,437,47,471,461,653,1323,1324,979,529,1325,654],{"trials":7040,"activeCount":202,"soonestReadout":3471},[7041,7045,7049],{"nctId":5219,"briefTitle":5220,"status":128,"phases":7042,"primaryCompletion":5222,"completion":5223,"start":1520,"enrollment":1452,"conditions":7043,"interventions":7044},[88,89],[5225],[5227,5228,979,5229,529,5230,5231,5232,5233],{"nctId":3590,"briefTitle":3591,"status":128,"phases":7046,"primaryCompletion":3593,"completion":3594,"start":909,"enrollment":3595,"conditions":7047,"interventions":7048},[89],[990,1930,3597],[653,841,977,978,979,529,980],{"nctId":3468,"briefTitle":3469,"status":139,"phases":7050,"primaryCompletion":3471,"completion":3472,"start":1776,"enrollment":2625,"conditions":7051,"interventions":7052},[89],[1687],[653,385,386,3475,1324,979,529,1325],{"trials":7054,"activeCount":99},[],{"trials":7056,"activeCount":99},[],{"intervention":7058,"totalTrials":3308,"cells":7059},"9vHPV vaccine",{"EARLY_PHASE1":7060,"PHASE1":7062,"PHASE2":7064,"PHASE3":7066,"PHASE4":7152,"NA":7154},{"trials":7061,"activeCount":99},[],{"trials":7063,"activeCount":99},[],{"trials":7065,"activeCount":99},[],{"trials":7067,"activeCount":174,"soonestReadout":7117},[7068,7078,7087,7096,7105,7113,7122,7132,7143],{"nctId":7069,"briefTitle":7070,"status":139,"phases":7071,"primaryCompletion":7072,"completion":7072,"start":7073,"enrollment":7074,"conditions":7075,"interventions":7077},"NCT04708041","Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)",[89],"2029-10-23","2021-03-15",700,[7076],"Papillomavirus Infections",[7058],{"nctId":7079,"briefTitle":7080,"status":139,"phases":7081,"primaryCompletion":1815,"completion":1815,"start":7082,"enrollment":7083,"conditions":7084,"interventions":7086},"NCT05314023","Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)",[89],"2022-05-07",1590,[7085],"Genital Warts",[7058],{"nctId":7088,"briefTitle":7089,"status":105,"phases":7090,"primaryCompletion":7091,"completion":7091,"start":7092,"enrollment":7093,"conditions":7094,"interventions":7095},"NCT04772534","Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)",[89],"2024-04-06","2021-05-17",314,[7076],[7058],{"nctId":7097,"briefTitle":7098,"status":105,"phases":7099,"primaryCompletion":5347,"completion":5347,"start":172,"enrollment":7100,"conditions":7101,"interventions":7103},"NCT01651949","Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)",[89],2520,[7085,854,7102],"Anal Intraepithelial Neoplasia",[7104],"9vHPV Vaccine",{"nctId":7106,"briefTitle":7107,"status":139,"phases":7108,"primaryCompletion":7109,"completion":7109,"start":1559,"enrollment":7110,"conditions":7111,"interventions":7112},"NCT05285826","Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)",[89],"2029-05-25",8100,[7076],[7104],{"nctId":7114,"briefTitle":7115,"status":139,"phases":7116,"primaryCompletion":7117,"completion":7118,"start":4193,"enrollment":7119,"conditions":7120,"interventions":7121},"NCT04199689","Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)",[89],"2027-08-27","2028-08-31",6033,[7076],[7104],{"nctId":7123,"briefTitle":7124,"status":105,"phases":7125,"primaryCompletion":6186,"completion":6186,"start":7126,"enrollment":7127,"conditions":7128,"interventions":7130},"NCT05119855","Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)",[89],"2022-03-28",165,[7076,7129],"Coronavirus Disease (COVID-19)",[7104,7131],"mRNA-1273 Vaccine",{"nctId":7133,"briefTitle":7134,"status":105,"phases":7135,"primaryCompletion":7136,"completion":7136,"start":2117,"enrollment":2149,"conditions":7137,"interventions":7142},"NCT03546842","Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)",[89],"2019-01-29",[7076,1284,7138,7139,7140,7141],"Vulvar Neoplasms","Vaginal Neoplasms","Adenocarcinoma in Situ","Condylomata Acuminata",[7058],{"nctId":7144,"briefTitle":7145,"status":139,"phases":7146,"primaryCompletion":7147,"completion":7147,"start":7148,"enrollment":7149,"conditions":7150,"interventions":7151},"NCT05450705","V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)",[89],"2029-08-03","2022-07-22",1500,[7076],[7058],{"trials":7153,"activeCount":99},[],{"trials":7155,"activeCount":99},[],{"intervention":7157,"totalTrials":357,"cells":7158},"Tulisokibart",{"EARLY_PHASE1":7159,"PHASE1":7161,"PHASE2":7178,"PHASE3":7218,"PHASE4":7229,"NA":7231},{"trials":7160,"activeCount":99},[],{"trials":7162,"activeCount":99},[7163,7171],{"nctId":7164,"briefTitle":7165,"status":105,"phases":7166,"primaryCompletion":7167,"completion":7167,"start":7009,"enrollment":1054,"conditions":7168,"interventions":7170},"NCT06829225","Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)",[87],"2024-11-11",[7169],"Colitis, Ulcerative",[7157],{"nctId":7172,"briefTitle":7173,"status":105,"phases":7174,"primaryCompletion":7175,"completion":7175,"start":1794,"enrollment":558,"conditions":7176,"interventions":7177},"NCT06575595","Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)",[87],"2025-01-31",[18],[7157],{"trials":7179,"activeCount":3963,"soonestReadout":7203},[7180,7190,7199,7208],{"nctId":7181,"briefTitle":7182,"status":128,"phases":7183,"primaryCompletion":7184,"completion":7185,"start":7186,"enrollment":407,"conditions":7187,"interventions":7189},"NCT07486960","Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)",[88],"2027-08-13","2030-01-11","2026-04-20",[7188],"Psoriatic Arthritis",[7157],{"nctId":7191,"briefTitle":7192,"status":128,"phases":7193,"primaryCompletion":7194,"completion":7195,"start":3435,"enrollment":537,"conditions":7196,"interventions":7198},"NCT07176390","A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)",[88],"2027-03-08","2029-09-03",[7197],"Arthritis, Rheumatoid",[7157,2100],{"nctId":7200,"briefTitle":7201,"status":139,"phases":7202,"primaryCompletion":7203,"completion":7204,"start":708,"enrollment":912,"conditions":7205,"interventions":7207},"NCT06956235","Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)",[88],"2026-11-16","2029-01-22",[7206],"Hidradenitis Suppurativa",[7157],{"nctId":7209,"briefTitle":7210,"status":128,"phases":7211,"primaryCompletion":7212,"completion":7213,"start":466,"enrollment":7214,"conditions":7215,"interventions":7217},"NCT07133633","A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)",[88],"2027-06-15","2030-02-05",315,[7216],"Radiographic Axial Spondyloarthritis",[7157],{"trials":7219,"activeCount":224,"soonestReadout":7224},[7220],{"nctId":7221,"briefTitle":7222,"status":128,"phases":7223,"primaryCompletion":7224,"completion":7224,"start":7225,"enrollment":4395,"conditions":7226,"interventions":7228},"NCT06651281","Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)",[89],"2037-12-17","2024-11-25",[7227,7169],"Crohn Disease",[7157],{"trials":7230,"activeCount":99},[],{"trials":7232,"activeCount":99},[],{"intervention":954,"totalTrials":174,"cells":7234},{"EARLY_PHASE1":7235,"PHASE1":7237,"PHASE2":7239,"PHASE3":7269,"PHASE4":7275,"NA":7277},{"trials":7236,"activeCount":99},[],{"trials":7238,"activeCount":99},[],{"trials":7240,"activeCount":3963,"soonestReadout":7264},[7241,7245,7249,7260],{"nctId":4268,"briefTitle":4269,"status":128,"phases":7242,"primaryCompletion":4271,"completion":4271,"start":4272,"enrollment":4273,"conditions":7243,"interventions":7244},[87,88],[4275,4276],[967,954,4278,4279,2382,842],{"nctId":947,"briefTitle":948,"status":128,"phases":7246,"primaryCompletion":950,"completion":950,"start":891,"enrollment":951,"conditions":7247,"interventions":7248},[87,88],[369],[47,386,387,385,923,542,471,713,954,955],{"nctId":7250,"briefTitle":7251,"status":128,"phases":7252,"primaryCompletion":1330,"completion":1330,"start":4408,"enrollment":7253,"conditions":7254,"interventions":7255},"NCT06780085","A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H\u002FKEYMAKER-U01)",[88],96,[369],[840,954,7256,7257,7258,7259],"Docetetaxel","5-hydroxytryptamine subtype 3 receptor antagonist","Neurokinin-1 receptor antagonist","Corticosteroid",{"nctId":7261,"briefTitle":7262,"status":128,"phases":7263,"primaryCompletion":7264,"completion":7265,"start":7266,"enrollment":2555,"conditions":7267,"interventions":7268},"NCT06780137","A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed\u002FRefractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)",[87,88],"2029-08-31","2030-01-17","2025-02-27",[1552],[3266,954,2186],{"trials":7270,"activeCount":224,"soonestReadout":4406},[7271],{"nctId":4403,"briefTitle":4404,"status":128,"phases":7272,"primaryCompletion":4406,"completion":4407,"start":4408,"enrollment":4409,"conditions":7273,"interventions":7274},[89],[4411,2410],[4413,967,1076,842],{"trials":7276,"activeCount":99},[],{"trials":7278,"activeCount":99},[],{"intervention":7280,"totalTrials":4071,"cells":7281},"MK-8527",{"EARLY_PHASE1":7282,"PHASE1":7284,"PHASE2":7380,"PHASE3":7392,"PHASE4":7413,"NA":7415},{"trials":7283,"activeCount":99},[],{"trials":7285,"activeCount":3197,"soonestReadout":7317},[7286,7296,7303,7313,7322,7328,7336,7346,7354,7363,7372],{"nctId":7287,"briefTitle":7288,"status":105,"phases":7289,"primaryCompletion":7290,"completion":7291,"start":7292,"enrollment":805,"conditions":7293,"interventions":7294},"NCT06816043","A Study of Emtricitabine\u002FTenofovir Disoproxil Fumarate (FTC\u002FTDF) and MK-8527 in Healthy Participants",[87],"2025-06-05","2025-06-17","2025-02-21",[18],[7280,7295],"FTC\u002FTDF",{"nctId":7297,"briefTitle":7298,"status":105,"phases":7299,"primaryCompletion":4370,"completion":4370,"start":835,"enrollment":5563,"conditions":7300,"interventions":7302},"NCT06580587","A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009)",[87],[18,7301],"HIV Pre-exposure Prophylaxis",[7280],{"nctId":7304,"briefTitle":7305,"status":105,"phases":7306,"primaryCompletion":7307,"completion":7307,"start":7308,"enrollment":3496,"conditions":7309,"interventions":7312},"NCT03615183","A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)",[87],"2019-09-26","2019-02-11",[7310,7311],"Human Immunodeficiency Virus","AIDS Virus",[7280],{"nctId":7314,"briefTitle":7315,"status":128,"phases":7316,"primaryCompletion":7317,"completion":7317,"start":7318,"enrollment":4071,"conditions":7319,"interventions":7320},"NCT07528508","A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527-020)",[87],"2026-08-10","2026-05-22",[18],[7280,7321],"Methadone",{"nctId":7323,"briefTitle":7324,"status":105,"phases":7325,"primaryCompletion":7175,"completion":7175,"start":1082,"enrollment":931,"conditions":7326,"interventions":7327},"NCT06295796","A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)",[87],[4074],[7280],{"nctId":7329,"briefTitle":7330,"status":105,"phases":7331,"primaryCompletion":7332,"completion":5574,"start":6394,"enrollment":184,"conditions":7333,"interventions":7334},"NCT07063238","A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014)",[87],"2025-12-06",[18],[7280,7335],"Moxifloxacin",{"nctId":7337,"briefTitle":7338,"status":105,"phases":7339,"primaryCompletion":1064,"completion":1064,"start":7340,"enrollment":4071,"conditions":7341,"interventions":7344},"NCT06783192","A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG\u002FEE)",[87],"2023-08-14",[7342,7343],"Human Immunodeficiency Virus (HIV)","HIV Pre-Exposure Prophylaxis",[7280,7345],"LNG\u002FEE",{"nctId":7347,"briefTitle":7348,"status":105,"phases":7349,"primaryCompletion":7350,"completion":7350,"start":7351,"enrollment":931,"conditions":7352,"interventions":7353},"NCT07025551","A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015)",[87],"2026-02-13","2025-09-19",[5595,5945],[7280],{"nctId":7355,"briefTitle":7356,"status":230,"phases":7357,"primaryCompletion":7358,"completion":7358,"start":7359,"enrollment":4071,"conditions":7360,"interventions":7361},"NCT07600775","A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)",[87],"2026-12-22","2026-06-22",[7342,7343],[7280,7362],"Rifampin",{"nctId":7364,"briefTitle":7365,"status":105,"phases":7366,"primaryCompletion":7367,"completion":7368,"start":6177,"enrollment":3655,"conditions":7369,"interventions":7370},"NCT06893081","A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012)",[87],"2025-06-19","2025-07-17",[18],[7280,7371],"CBZ",{"nctId":7373,"briefTitle":7374,"status":105,"phases":7375,"primaryCompletion":7376,"completion":7376,"start":7377,"enrollment":805,"conditions":7378,"interventions":7379},"NCT05494736","MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)",[87],"2024-01-31","2022-11-17",[7310],[7280],{"trials":7381,"activeCount":99},[7382],{"nctId":7383,"briefTitle":7384,"status":105,"phases":7385,"primaryCompletion":7386,"completion":5930,"start":7387,"enrollment":7388,"conditions":7389,"interventions":7391},"NCT06045507","Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)",[88],"2024-12-12","2023-11-08",352,[7390,7301],"HIV",[7280],{"trials":7393,"activeCount":3197,"soonestReadout":7398},[7394,7403],{"nctId":7395,"briefTitle":7396,"status":128,"phases":7397,"primaryCompletion":7398,"completion":7398,"start":7399,"enrollment":7400,"conditions":7401,"interventions":7402},"NCT07044297","A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)",[89],"2027-07-22","2025-07-31",4390,[7342,7343],[7280,7295],{"nctId":7404,"briefTitle":7405,"status":128,"phases":7406,"primaryCompletion":7407,"completion":7407,"start":7408,"enrollment":7409,"conditions":7410,"interventions":7411},"NCT07071623","A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)",[89],"2027-10-18","2025-11-10",4580,[7342,7343],[7280,7412],"Emtricitabine\u002Ftenofovir disoproxil",{"trials":7414,"activeCount":99},[],{"trials":7416,"activeCount":99},[],{"intervention":437,"totalTrials":4071,"cells":7418},{"EARLY_PHASE1":7419,"PHASE1":7421,"PHASE2":7439,"PHASE3":7461,"PHASE4":7483,"NA":7485},{"trials":7420,"activeCount":99},[],{"trials":7422,"activeCount":99},[7423,7427,7431,7435],{"nctId":423,"briefTitle":424,"status":105,"phases":7424,"primaryCompletion":426,"completion":427,"start":428,"enrollment":429,"conditions":7425,"interventions":7426},[87],[431],[47,433,434,435,436,437],{"nctId":450,"briefTitle":451,"status":105,"phases":7428,"primaryCompletion":453,"completion":453,"start":454,"enrollment":455,"conditions":7429,"interventions":7430},[87],[290],[458,47,434,437,435,459,460,461],{"nctId":5462,"briefTitle":5463,"status":150,"phases":7432,"primaryCompletion":5465,"completion":5465,"start":5466,"enrollment":3963,"conditions":7433,"interventions":7434},[87],[290,176,5468,5469,5470],[1390,1074,5472,437,2905,1069,562,1073],{"nctId":6058,"briefTitle":6059,"status":105,"phases":7436,"primaryCompletion":6061,"completion":6062,"start":6063,"enrollment":805,"conditions":7437,"interventions":7438},[87],[419],[6066,693,437,6067],{"trials":7440,"activeCount":224,"soonestReadout":1318},[7441,7445,7449,7453,7457],{"nctId":6098,"briefTitle":6099,"status":150,"phases":7442,"primaryCompletion":6101,"completion":6101,"start":6102,"enrollment":5983,"conditions":7443,"interventions":7444},[88],[6104],[6106,437,693],{"nctId":1224,"briefTitle":1225,"status":105,"phases":7446,"primaryCompletion":1227,"completion":1227,"start":1228,"enrollment":397,"conditions":7447,"interventions":7448},[87,88],[1230],[47,1232,471,461,437,387],{"nctId":5818,"briefTitle":5819,"status":105,"phases":7450,"primaryCompletion":5821,"completion":5821,"start":5822,"enrollment":2647,"conditions":7451,"interventions":7452},[88],[419],[2905,437,693,795,5825,5826,1751],{"nctId":2896,"briefTitle":2897,"status":150,"phases":7454,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":2901,"conditions":7455,"interventions":7456},[87,88],[290],[386,1664,1843,2904,714,2905,693,387,390,1444,1253,437,2906],{"nctId":1315,"briefTitle":1316,"status":128,"phases":7458,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1132,"conditions":7459,"interventions":7460},[87,88],[1263],[387,437,47,471,461,653,1323,1324,979,529,1325,654],{"trials":7462,"activeCount":202,"soonestReadout":3073},[7463,7467,7471,7475,7479],{"nctId":2079,"briefTitle":2080,"status":105,"phases":7464,"primaryCompletion":2082,"completion":2083,"start":2084,"enrollment":2085,"conditions":7465,"interventions":7466},[89],[1603,1604],[42,1654,1677,2088],{"nctId":3617,"briefTitle":3618,"status":139,"phases":7468,"primaryCompletion":3620,"completion":3620,"start":477,"enrollment":3621,"conditions":7469,"interventions":7470},[89],[863],[794,385,3624,3625,3626,714,437],{"nctId":2209,"briefTitle":2210,"status":105,"phases":7472,"primaryCompletion":2212,"completion":2083,"start":2213,"enrollment":2214,"conditions":7473,"interventions":7474},[89],[1603,1604],[42,1654,1677,2088],{"nctId":3070,"briefTitle":3071,"status":139,"phases":7476,"primaryCompletion":3073,"completion":3074,"start":3075,"enrollment":951,"conditions":7477,"interventions":7478},[89],[3077],[653,3079,437,387,967,3037,654],{"nctId":2611,"briefTitle":2612,"status":139,"phases":7480,"primaryCompletion":2614,"completion":2614,"start":2615,"enrollment":920,"conditions":7481,"interventions":7482},[89],[371],[47,434,435,606,437,841,693],{"trials":7484,"activeCount":99},[],{"trials":7486,"activeCount":99},[],{"intervention":7488,"totalTrials":5563,"cells":7489},"Enlicitide",{"EARLY_PHASE1":7490,"PHASE1":7492,"PHASE2":7576,"PHASE3":7588,"PHASE4":7612,"NA":7614},{"trials":7491,"activeCount":99},[],{"trials":7493,"activeCount":3197,"soonestReadout":7505},[7494,7501,7511,7519,7529,7537,7545,7553,7560,7568],{"nctId":7495,"briefTitle":7496,"status":105,"phases":7497,"primaryCompletion":1520,"completion":7498,"start":4233,"enrollment":154,"conditions":7499,"interventions":7500},"NCT07481708","A Clinical Study of the Effect of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-041)",[87],"2026-05-25",[18],[7488],{"nctId":7502,"briefTitle":7503,"status":230,"phases":7504,"primaryCompletion":7505,"completion":7506,"start":7507,"enrollment":154,"conditions":7508,"interventions":7509},"NCT07619443","A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)",[87],"2026-09-05","2026-09-12","2026-07-06",[18],[7510,7488],"MK-7262",{"nctId":7512,"briefTitle":7513,"status":105,"phases":7514,"primaryCompletion":7515,"completion":7516,"start":4272,"enrollment":558,"conditions":7517,"interventions":7518},"NCT07044479","A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040)",[87],"2025-08-13","2025-08-28",[18],[7488],{"nctId":7520,"briefTitle":7521,"status":105,"phases":7522,"primaryCompletion":1610,"completion":7523,"start":7524,"enrollment":3655,"conditions":7525,"interventions":7526},"NCT06719544","A Study of Lithium and Enlicitide in Healthy Adult Participants (MK-0616-034)",[87],"2025-02-06","2025-01-02",[18],[7527,7528],"lithium carbonate","enlicitide",{"nctId":7530,"briefTitle":7531,"status":105,"phases":7532,"primaryCompletion":109,"completion":7533,"start":7534,"enrollment":3390,"conditions":7535,"interventions":7536},"NCT06880874","A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)",[87],"2025-05-31","2025-04-02",[18],[7488],{"nctId":7538,"briefTitle":7539,"status":105,"phases":7540,"primaryCompletion":1868,"completion":7541,"start":7542,"enrollment":120,"conditions":7543,"interventions":7544},"NCT06597760","A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)",[87],"2024-11-15","2024-10-07",[18],[7488,5627],{"nctId":7546,"briefTitle":7547,"status":128,"phases":7548,"primaryCompletion":7549,"completion":3090,"start":5574,"enrollment":558,"conditions":7550,"interventions":7551},"NCT07300280","A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)",[87],"2026-10-07",[18],[7552,7488,5578],"MK-0616A",{"nctId":7554,"briefTitle":7555,"status":105,"phases":7556,"primaryCompletion":7557,"completion":7175,"start":2107,"enrollment":805,"conditions":7558,"interventions":7559},"NCT06609512","A Clinical Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033)",[87],"2025-01-13",[18],[7488],{"nctId":7561,"briefTitle":7562,"status":105,"phases":7563,"primaryCompletion":7564,"completion":7564,"start":7565,"enrollment":36,"conditions":7566,"interventions":7567},"NCT06643377","A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)",[87],"2025-06-25","2024-11-22",[18,4074],[7488],{"nctId":7569,"briefTitle":7570,"status":105,"phases":7571,"primaryCompletion":7572,"completion":2321,"start":786,"enrollment":805,"conditions":7573,"interventions":7575},"NCT06575959","A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)",[87],"2025-05-01",[7574,5595],"Hepatic Insufficiency",[7488],{"trials":7577,"activeCount":224,"soonestReadout":7582},[7578],{"nctId":7579,"briefTitle":7580,"status":230,"phases":7581,"primaryCompletion":7582,"completion":7582,"start":7583,"enrollment":7584,"conditions":7585,"interventions":7587},"NCT07614984","A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)",[88],"2027-10-12","2026-07-07",750,[7586],"Lipoprotein(a)",[7510,7488],{"trials":7589,"activeCount":224,"soonestReadout":7606},[7590,7602],{"nctId":7591,"briefTitle":7592,"status":105,"phases":7593,"primaryCompletion":7594,"completion":2286,"start":7595,"enrollment":7596,"conditions":7597,"interventions":7599},"NCT06450366","A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018\u002FCORALreef AddOn)",[89],"2025-02-14","2024-07-08",301,[7598],"Hypercholesterolemia",[7488,7600,7601],"Ezetimibe","Bempedoic Acid",{"nctId":7603,"briefTitle":7604,"status":128,"phases":7605,"primaryCompletion":7606,"completion":7607,"start":107,"enrollment":7608,"conditions":7609,"interventions":7611},"NCT07216482","A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)",[89],"2026-12-02","2027-03-01",975,[7610],"Hyperlipidemia",[7488,5578],{"trials":7613,"activeCount":99},[],{"trials":7615,"activeCount":99},[],{"intervention":7617,"totalTrials":335,"cells":7618},"DOR\u002FISL",{"EARLY_PHASE1":7619,"PHASE1":7621,"PHASE2":7629,"PHASE3":7641,"PHASE4":7718,"NA":7720},{"trials":7620,"activeCount":99},[],{"trials":7622,"activeCount":99},[7623],{"nctId":7624,"briefTitle":7625,"status":105,"phases":7626,"primaryCompletion":729,"completion":1641,"start":466,"enrollment":95,"conditions":7627,"interventions":7628},"NCT07086079","A Study of Doravirine\u002FIslatravir in Healthy Lactating Females (MK-8591A-061)",[87],[18],[7617],{"trials":7630,"activeCount":99},[7631],{"nctId":7632,"briefTitle":7633,"status":105,"phases":7634,"primaryCompletion":7635,"completion":7636,"start":7637,"enrollment":184,"conditions":7638,"interventions":7640},"NCT04295772","Doravirine\u002FIslatravir (DOR\u002FISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are \u003C18 Years of Age and Weigh ≥35 kg (MK-8591A-028)",[88],"2021-12-21","2023-01-25","2020-11-26",[7639],"HIV-1 Infection",[7617],{"trials":7642,"activeCount":3963,"soonestReadout":7703},[7643,7653,7664,7672,7681,7689,7699,7708],{"nctId":7644,"briefTitle":7645,"status":105,"phases":7646,"primaryCompletion":426,"completion":1926,"start":7647,"enrollment":7648,"conditions":7649,"interventions":7651},"NCT04223778","Safety and Efficacy of a Switch to Doravirine\u002FIslatravir in Participants With HIV-1 (MK-8591A-017)",[89],"2020-02-18",672,[7650],"HIV Infection",[7617,7652],"ART",{"nctId":7654,"briefTitle":7655,"status":105,"phases":7656,"primaryCompletion":7657,"completion":7658,"start":7659,"enrollment":3903,"conditions":7660,"interventions":7661},"NCT04233216","Doravirine\u002FIslatravir (DOR\u002FISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)",[89],"2022-11-21","2023-11-01","2020-03-18",[7639],[7662,7663,7617],"ISL","DOR",{"nctId":7665,"briefTitle":7666,"status":105,"phases":7667,"primaryCompletion":7668,"completion":7266,"start":7647,"enrollment":2170,"conditions":7669,"interventions":7670},"NCT04223791","Switch to Doravirine\u002FIslatravir (DOR\u002FISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide (BIC\u002FFTC\u002FTAF) (MK-8591A-018)",[89],"2021-08-26",[7650],[7617,7671],"BIC\u002FFTC\u002FTAF",{"nctId":7673,"briefTitle":7674,"status":139,"phases":7675,"primaryCompletion":1208,"completion":7676,"start":7677,"enrollment":7678,"conditions":7679,"interventions":7680},"NCT05705349","DOR\u002FISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)",[89],"2029-08-05","2023-03-08",537,[7639],[7617,7671],{"nctId":7682,"briefTitle":7683,"status":105,"phases":7684,"primaryCompletion":7377,"completion":7685,"start":2634,"enrollment":7686,"conditions":7687,"interventions":7688},"NCT04233879","Study of Doravirine\u002FIslatravir (DOR\u002FISL 100 mg\u002F0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)",[89],"2025-01-29",599,[7639],[7617,7671],{"nctId":7690,"briefTitle":7691,"status":139,"phases":7692,"primaryCompletion":7693,"completion":7694,"start":7695,"enrollment":7696,"conditions":7697,"interventions":7698},"NCT05630755","A Switch to Doravirine\u002FIslatravir (DOR\u002FISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide (BIC\u002FFTC\u002FTAF) (MK-8591A-052)",[89],"2024-10-25","2028-08-04","2023-02-17",514,[7639],[7617,7671],{"nctId":7700,"briefTitle":7701,"status":139,"phases":7702,"primaryCompletion":7703,"completion":7704,"start":2786,"enrollment":7705,"conditions":7706,"interventions":7707},"NCT05631093","A Switch to Doravirine\u002FIslatravir (DOR\u002FISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)",[89],"2024-10-10","2028-07-11",553,[7639],[7652,7617],{"nctId":7709,"briefTitle":7710,"status":139,"phases":7711,"primaryCompletion":7712,"completion":7713,"start":7714,"enrollment":7715,"conditions":7716,"interventions":7717},"NCT05766501","A Study of Doravirine\u002FIslatravir (DOR\u002FISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR\u002FISL (MK-8591A-054)",[89],"2025-10-16","2028-09-06","2023-03-17",641,[7650],[7617],{"trials":7719,"activeCount":99},[],{"trials":7721,"activeCount":99},[],{"intervention":4777,"totalTrials":3308,"cells":7723},{"EARLY_PHASE1":7724,"PHASE1":7726,"PHASE2":7752,"PHASE3":7758,"PHASE4":7768,"NA":7770},{"trials":7725,"activeCount":99},[],{"trials":7727,"activeCount":224,"soonestReadout":5972},[7728,7732,7736,7740,7744,7748],{"nctId":5927,"briefTitle":5928,"status":105,"phases":7729,"primaryCompletion":5930,"completion":4408,"start":5931,"enrollment":4071,"conditions":7730,"interventions":7731},[87],[18],[4775,1076,4777,5934],{"nctId":5936,"briefTitle":5937,"status":105,"phases":7733,"primaryCompletion":5939,"completion":1659,"start":5615,"enrollment":120,"conditions":7734,"interventions":7735},[87],[5941,5942,5943,5944,5945],[4278,1076,4777],{"nctId":5948,"briefTitle":5949,"status":105,"phases":7737,"primaryCompletion":5951,"completion":5952,"start":5953,"enrollment":95,"conditions":7738,"interventions":7739},[87],[2410],[4278,1076,4777,5956],{"nctId":5969,"briefTitle":5970,"status":139,"phases":7741,"primaryCompletion":5972,"completion":5973,"start":5974,"enrollment":4071,"conditions":7742,"interventions":7743},[87],[18],[4775,1076,4777,5604],{"nctId":5156,"briefTitle":5157,"status":105,"phases":7745,"primaryCompletion":5159,"completion":5160,"start":5161,"enrollment":357,"conditions":7746,"interventions":7747},[87],[2410,3246],[4775,529,4777,5126],{"nctId":5988,"briefTitle":5989,"status":105,"phases":7749,"primaryCompletion":1348,"completion":5991,"start":4408,"enrollment":3655,"conditions":7750,"interventions":7751},[87],[5595,5945],[4775,1076,4777],{"trials":7753,"activeCount":224,"soonestReadout":4771},[7754],{"nctId":4768,"briefTitle":4769,"status":128,"phases":7755,"primaryCompletion":4771,"completion":4771,"start":2266,"enrollment":8,"conditions":7756,"interventions":7757},[87,88],[4773],[4775,1114,967,4776,4777,529,1076],{"trials":7759,"activeCount":3197,"soonestReadout":5260},[7760,7764],{"nctId":5235,"briefTitle":5236,"status":128,"phases":7761,"primaryCompletion":5238,"completion":5239,"start":5240,"enrollment":5241,"conditions":7762,"interventions":7763},[89],[5243],[4775,2412,2382,5126,4777,1076,529],{"nctId":5257,"briefTitle":5258,"status":128,"phases":7765,"primaryCompletion":5260,"completion":5261,"start":5262,"enrollment":5263,"conditions":7766,"interventions":7767},[89],[5265,2410],[4775,529,4777,5126,2412,5267,2382],{"trials":7769,"activeCount":99},[],{"trials":7771,"activeCount":99},[],{"intervention":7671,"totalTrials":357,"cells":7773},{"EARLY_PHASE1":7774,"PHASE1":7776,"PHASE2":7778,"PHASE3":7802,"PHASE4":7831,"NA":7833},{"trials":7775,"activeCount":99},[],{"trials":7777,"activeCount":99},[],{"trials":7779,"activeCount":224,"soonestReadout":7784},[7780,7791],{"nctId":7781,"briefTitle":7782,"status":139,"phases":7783,"primaryCompletion":7784,"completion":7785,"start":7786,"enrollment":2779,"conditions":7787,"interventions":7789},"NCT06891066","A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)",[88],"2027-08-10","2031-09-30","2025-04-14",[7788],"Human Immunodeficiency Virus Type 1 (HIV-1) Infection",[7662,7790,7671],"ULO",{"nctId":7792,"briefTitle":7793,"status":105,"phases":7794,"primaryCompletion":7795,"completion":7795,"start":7796,"enrollment":7797,"conditions":7798,"interventions":7799},"NCT04564547","Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]",[88],"2025-01-30","2021-03-09",161,[7639],[7800,7801,7671],"Islatravir","Ulonivirine",{"trials":7803,"activeCount":202,"soonestReadout":7693},[7804,7808,7812,7816,7827],{"nctId":7665,"briefTitle":7666,"status":105,"phases":7805,"primaryCompletion":7668,"completion":7266,"start":7647,"enrollment":2170,"conditions":7806,"interventions":7807},[89],[7650],[7617,7671],{"nctId":7673,"briefTitle":7674,"status":139,"phases":7809,"primaryCompletion":1208,"completion":7676,"start":7677,"enrollment":7678,"conditions":7810,"interventions":7811},[89],[7639],[7617,7671],{"nctId":7682,"briefTitle":7683,"status":105,"phases":7813,"primaryCompletion":7377,"completion":7685,"start":2634,"enrollment":7686,"conditions":7814,"interventions":7815},[89],[7639],[7617,7671],{"nctId":7817,"briefTitle":7818,"status":128,"phases":7819,"primaryCompletion":7820,"completion":7821,"start":7822,"enrollment":7823,"conditions":7824,"interventions":7825},"NCT07266831","A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)",[88,89],"2029-03-21","2030-04-03","2025-12-18",570,[7788],[7662,7790,7671,7826],"ISL\u002FULO",{"nctId":7690,"briefTitle":7691,"status":139,"phases":7828,"primaryCompletion":7693,"completion":7694,"start":7695,"enrollment":7696,"conditions":7829,"interventions":7830},[89],[7639],[7617,7671],{"trials":7832,"activeCount":99},[],{"trials":7834,"activeCount":99},[],{"intervention":2382,"totalTrials":357,"cells":7836},{"EARLY_PHASE1":7837,"PHASE1":7839,"PHASE2":7841,"PHASE3":7847,"PHASE4":7873,"NA":7875},{"trials":7838,"activeCount":99},[],{"trials":7840,"activeCount":99},[],{"trials":7842,"activeCount":224,"soonestReadout":4271},[7843],{"nctId":4268,"briefTitle":4269,"status":128,"phases":7844,"primaryCompletion":4271,"completion":4271,"start":4272,"enrollment":4273,"conditions":7845,"interventions":7846},[87,88],[4275,4276],[967,954,4278,4279,2382,842],{"trials":7848,"activeCount":202,"soonestReadout":51},[7849,7853,7857,7861,7865,7869],{"nctId":5235,"briefTitle":5236,"status":128,"phases":7850,"primaryCompletion":5238,"completion":5239,"start":5240,"enrollment":5241,"conditions":7851,"interventions":7852},[89],[5243],[4775,2412,2382,5126,4777,1076,529],{"nctId":5257,"briefTitle":5258,"status":128,"phases":7854,"primaryCompletion":5260,"completion":5261,"start":5262,"enrollment":5263,"conditions":7855,"interventions":7856},[89],[5265,2410],[4775,529,4777,5126,2412,5267,2382],{"nctId":2372,"briefTitle":2373,"status":105,"phases":7858,"primaryCompletion":2375,"completion":2376,"start":2377,"enrollment":2378,"conditions":7859,"interventions":7860},[89],[2380],[47,2382,2383],{"nctId":2403,"briefTitle":2404,"status":105,"phases":7862,"primaryCompletion":2083,"completion":2406,"start":2407,"enrollment":2408,"conditions":7863,"interventions":7864},[89],[2410],[47,1114,2412,1076,2382,2413],{"nctId":2540,"briefTitle":2541,"status":105,"phases":7866,"primaryCompletion":2375,"completion":2543,"start":2544,"enrollment":2545,"conditions":7867,"interventions":7868},[89],[2380],[47,2382,2383],{"nctId":49,"briefTitle":50,"status":139,"phases":7870,"primaryCompletion":51,"completion":2759,"start":2760,"enrollment":2761,"conditions":7871,"interventions":7872},[89],[2410],[47,2382],{"trials":7874,"activeCount":99},[],{"trials":7876,"activeCount":99},[],{"intervention":796,"totalTrials":3963,"cells":7878},{"EARLY_PHASE1":7879,"PHASE1":7881,"PHASE2":7883,"PHASE3":7893,"PHASE4":7903,"NA":7905},{"trials":7880,"activeCount":99},[],{"trials":7882,"activeCount":99},[],{"trials":7884,"activeCount":3197,"soonestReadout":785},[7885,7889],{"nctId":782,"briefTitle":783,"status":128,"phases":7886,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":7887,"interventions":7888},[87,88],[789,790,791,792],[47,794,795,435,796,797,434,798],{"nctId":1256,"briefTitle":1257,"status":128,"phases":7890,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":1261,"conditions":7891,"interventions":7892},[87,88],[1263],[47,1265,435,796,797,434,653,842],{"trials":7894,"activeCount":3197,"soonestReadout":2321},[7895,7899],{"nctId":2318,"briefTitle":2319,"status":139,"phases":7896,"primaryCompletion":2321,"completion":2322,"start":2323,"enrollment":2324,"conditions":7897,"interventions":7898},[89],[2326],[47,461,390,1444,434,435,796,387],{"nctId":2630,"briefTitle":2631,"status":139,"phases":7900,"primaryCompletion":2192,"completion":2633,"start":2634,"enrollment":2635,"conditions":7901,"interventions":7902},[89],[1230,2637,2638],[42,486,1444,605,2640,604],{"trials":7904,"activeCount":99},[],{"trials":7906,"activeCount":99},[],{"intervention":978,"totalTrials":3963,"cells":7908},{"EARLY_PHASE1":7909,"PHASE1":7911,"PHASE2":7913,"PHASE3":7923,"PHASE4":7933,"NA":7935},{"trials":7910,"activeCount":99},[],{"trials":7912,"activeCount":99},[],{"trials":7914,"activeCount":3197,"soonestReadout":1318},[7915,7919],{"nctId":969,"briefTitle":970,"status":128,"phases":7916,"primaryCompletion":972,"completion":972,"start":973,"enrollment":558,"conditions":7917,"interventions":7918},[88],[975],[47,390,714,385,653,977,978,979,529,386,47,387,980],{"nctId":1315,"briefTitle":1316,"status":128,"phases":7920,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1132,"conditions":7921,"interventions":7922},[87,88],[1263],[387,437,47,471,461,653,1323,1324,979,529,1325,654],{"trials":7924,"activeCount":3197,"soonestReadout":3471},[7925,7929],{"nctId":3590,"briefTitle":3591,"status":128,"phases":7926,"primaryCompletion":3593,"completion":3594,"start":909,"enrollment":3595,"conditions":7927,"interventions":7928},[89],[990,1930,3597],[653,841,977,978,979,529,980],{"nctId":3468,"briefTitle":3469,"status":139,"phases":7930,"primaryCompletion":3471,"completion":3472,"start":1776,"enrollment":2625,"conditions":7931,"interventions":7932},[89],[1687],[653,385,386,3475,1324,979,529,1325],{"trials":7934,"activeCount":99},[],{"trials":7936,"activeCount":99},[],{"intervention":980,"totalTrials":3963,"cells":7938},{"EARLY_PHASE1":7939,"PHASE1":7941,"PHASE2":7943,"PHASE3":7953,"PHASE4":7963,"NA":7965},{"trials":7940,"activeCount":99},[],{"trials":7942,"activeCount":99},[],{"trials":7944,"activeCount":3197,"soonestReadout":1318},[7945,7949],{"nctId":969,"briefTitle":970,"status":128,"phases":7946,"primaryCompletion":972,"completion":972,"start":973,"enrollment":558,"conditions":7947,"interventions":7948},[88],[975],[47,390,714,385,653,977,978,979,529,386,47,387,980],{"nctId":1315,"briefTitle":1316,"status":128,"phases":7950,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1132,"conditions":7951,"interventions":7952},[87,88],[1263],[387,437,47,471,461,653,1323,1324,979,529,1325,654],{"trials":7954,"activeCount":3197,"soonestReadout":3471},[7955,7959],{"nctId":3590,"briefTitle":3591,"status":128,"phases":7956,"primaryCompletion":3593,"completion":3594,"start":909,"enrollment":3595,"conditions":7957,"interventions":7958},[89],[990,1930,3597],[653,841,977,978,979,529,980],{"nctId":3468,"briefTitle":3469,"status":139,"phases":7960,"primaryCompletion":3471,"completion":3472,"start":1776,"enrollment":2625,"conditions":7961,"interventions":7962},[89],[1687],[653,385,386,3475,1324,979,529,1325],{"trials":7964,"activeCount":99},[],{"trials":7966,"activeCount":99},[],{"intervention":2186,"totalTrials":3963,"cells":7968},{"EARLY_PHASE1":7969,"PHASE1":7971,"PHASE2":7973,"PHASE3":7979,"PHASE4":7993,"NA":7995},{"trials":7970,"activeCount":99},[],{"trials":7972,"activeCount":99},[],{"trials":7974,"activeCount":224,"soonestReadout":7264},[7975],{"nctId":7261,"briefTitle":7262,"status":128,"phases":7976,"primaryCompletion":7264,"completion":7265,"start":7266,"enrollment":2555,"conditions":7977,"interventions":7978},[87,88],[1552],[3266,954,2186],{"trials":7980,"activeCount":202,"soonestReadout":2974},[7981,7985,7989],{"nctId":2971,"briefTitle":2972,"status":139,"phases":7982,"primaryCompletion":2974,"completion":2974,"start":2975,"enrollment":987,"conditions":7983,"interventions":7984},[89],[369],[2978,2979,486,483,487,484,1654],{"nctId":5658,"briefTitle":5659,"status":230,"phases":7986,"primaryCompletion":5661,"completion":5662,"start":5663,"enrollment":2034,"conditions":7987,"interventions":7988},[89],[314],[602,2186],{"nctId":2176,"briefTitle":2177,"status":139,"phases":7990,"primaryCompletion":2179,"completion":2180,"start":2181,"enrollment":2182,"conditions":7991,"interventions":7992},[89],[2184,369],[47,1114,1073,386,390,387,385,2186],{"trials":7994,"activeCount":99},[],{"trials":7996,"activeCount":99},[],{"intervention":7998,"totalTrials":5563,"cells":7999},"Enlicitide Decanoate",{"EARLY_PHASE1":8000,"PHASE1":8002,"PHASE2":8071,"PHASE3":8073,"PHASE4":8122,"NA":8124},{"trials":8001,"activeCount":99},[],{"trials":8003,"activeCount":99},[8004,8012,8021,8028,8037,8045,8054,8062],{"nctId":8005,"briefTitle":8006,"status":105,"phases":8007,"primaryCompletion":8008,"completion":8008,"start":7387,"enrollment":931,"conditions":8009,"interventions":8010},"NCT06699355","A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024)",[87],"2023-12-29",[18],[7998,8011],"Atorvastatin",{"nctId":8013,"briefTitle":8014,"status":105,"phases":8015,"primaryCompletion":73,"completion":73,"start":4069,"enrollment":8016,"conditions":8017,"interventions":8018},"NCT06772779","A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026)",[87],36,[18],[8019,7998,8020],"Warfarin","Lisinopril",{"nctId":8022,"briefTitle":8023,"status":105,"phases":8024,"primaryCompletion":1817,"completion":1817,"start":6194,"enrollment":312,"conditions":8025,"interventions":8026},"NCT06699329","A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)",[87],[18],[7998,8027],"Semaglutide",{"nctId":8029,"briefTitle":8030,"status":105,"phases":8031,"primaryCompletion":8032,"completion":8032,"start":8033,"enrollment":444,"conditions":8034,"interventions":8036},"NCT05934292","Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)",[87],"2024-01-19","2023-07-20",[8035],"Hypercholesterolaemia",[7998],{"nctId":8038,"briefTitle":8039,"status":105,"phases":8040,"primaryCompletion":911,"completion":911,"start":8041,"enrollment":5616,"conditions":8042,"interventions":8043},"NCT06658652","The Effect of Food and Water Volume in Healthy Adult Participants Administered Enlicitide Decanoate (MK-0616) (MK-0616-022)",[87],"2023-10-24",[18],[8044],"Enlicitide decanoate",{"nctId":8046,"briefTitle":8047,"status":105,"phases":8048,"primaryCompletion":8049,"completion":8049,"start":8050,"enrollment":8016,"conditions":8051,"interventions":8052},"NCT06772792","A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)",[87],"2024-06-21","2024-04-23",[18],[8053,7998],"Alendronate",{"nctId":8055,"briefTitle":8056,"status":105,"phases":8057,"primaryCompletion":8058,"completion":8058,"start":8059,"enrollment":3390,"conditions":8060,"interventions":8061},"NCT06691906","A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)",[87],"2024-05-01","2024-03-18",[18],[8044],{"nctId":8063,"briefTitle":8064,"status":105,"phases":8065,"primaryCompletion":8066,"completion":8067,"start":7595,"enrollment":1624,"conditions":8068,"interventions":8069},"NCT06625814","A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)",[87],"2024-08-19","2024-09-11",[18],[8070,7998],"Levothyroxine",{"trials":8072,"activeCount":99},[],{"trials":8074,"activeCount":202,"soonestReadout":8090},[8075,8086,8094,8105,8115],{"nctId":8076,"briefTitle":8077,"status":139,"phases":8078,"primaryCompletion":8079,"completion":8080,"start":8081,"enrollment":8082,"conditions":8083,"interventions":8085},"NCT06008756","Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes",[89],"2029-11-29","2031-11-29","2023-10-09",14550,[8084,8035],"Arteriosclerosis",[7998],{"nctId":8087,"briefTitle":8088,"status":139,"phases":8089,"primaryCompletion":8090,"completion":8090,"start":5951,"enrollment":8091,"conditions":8092,"interventions":8093},"NCT06492291","Open-label Extension Study of Enlicitide Decanoate (MK-0616\u002FEnlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension",[89],"2028-10-13",3000,[7598],[7998],{"nctId":8095,"briefTitle":8096,"status":128,"phases":8097,"primaryCompletion":8098,"completion":8099,"start":8100,"enrollment":8101,"conditions":8102,"interventions":8104},"NCT07058077","A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)",[88,89],"2033-12-04","2037-01-23","2025-08-21",153,[8103],"Heterozygous Familial Hypercholesterolemia (HeFH)",[7998],{"nctId":8106,"briefTitle":8107,"status":105,"phases":8108,"primaryCompletion":8109,"completion":8109,"start":8110,"enrollment":8111,"conditions":8112,"interventions":8114},"NCT05952856","A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids",[89],"2025-07-28","2023-08-10",2912,[7598,8113],"Familial Hypercholesterolemia",[7998],{"nctId":8116,"briefTitle":8117,"status":105,"phases":8118,"primaryCompletion":5615,"completion":5615,"start":6283,"enrollment":8119,"conditions":8120,"interventions":8121},"NCT05952869","A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017\u002FCORALreef HeFH)",[89],303,[7598,8113],[7998],{"trials":8123,"activeCount":99},[],{"trials":8125,"activeCount":99},[],{"intervention":84,"totalTrials":734,"cells":8127},{"EARLY_PHASE1":8128,"PHASE1":8130,"PHASE2":8163,"PHASE3":8181,"PHASE4":8211,"NA":8213},{"trials":8129,"activeCount":99},[],{"trials":8131,"activeCount":99},[8132,8148],{"nctId":8133,"briefTitle":8134,"status":105,"phases":8135,"primaryCompletion":8136,"completion":8136,"start":8137,"enrollment":5616,"conditions":8138,"interventions":8139},"NCT02862457","Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)",[87],"2020-11-20","2016-08-23",[290,369],[8140,8141,8142,8143,8144,8145,8146,8147],"Epacadostat 25 mg","Epacadostat 100 mg","pembrolizumab 200 mg","Cisplatin 75 mg\u002Fm^2","Carboplatin Area Under the Curve (AUC) 5","Pemetrexed 500 mg\u002Fm^2","Paclitaxel 200 mg\u002Fm^2","Carboplatin AUC 6",{"nctId":8149,"briefTitle":8150,"status":105,"phases":8151,"primaryCompletion":2634,"completion":2634,"start":8152,"enrollment":28,"conditions":8153,"interventions":8154},"NCT01840579","Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer\u002F Extensive-disease Small Cell Lung Cancer (MK-3475-011\u002FKEYNOTE-011)",[87],"2013-04-26",[279,314,1552],[8155,8156,84,8143,8145,8157,8158,8146,8159,8160,8161,8162],"Pembrolizumab 2 mg\u002Fkg","Pembrolizumab 10 mg\u002Fkg","Carboplatin AUC 5 mg\u002FmL\u002Fmin","Carboplatin AUC 6 mg\u002FmL\u002Fmin","Nab-paclitaxel 100 mg\u002Fm^2","Ipilimumab 1 mg\u002Fkg","Etoposide 100 mg\u002Fm^2","G-CSF (pegfilgrastim) 3.6 mg",{"trials":8164,"activeCount":224,"soonestReadout":3242},[8165,8169],{"nctId":3239,"briefTitle":3240,"status":128,"phases":8166,"primaryCompletion":3242,"completion":3243,"start":3244,"enrollment":2204,"conditions":8167,"interventions":8168},[87,88],[3246],[84,3248,3249,3250,3251,3252,3253,461,3254,386,1073,3255],{"nctId":8170,"briefTitle":8171,"status":105,"phases":8172,"primaryCompletion":1247,"completion":8173,"start":8174,"enrollment":8175,"conditions":8176,"interventions":8177},"NCT03631784","A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)",[88],"2024-03-19","2018-10-19",216,[314],[84,8178,8179,8143,8145,8146,8180],"Paclitaxel 45 mg\u002Fm^2","Carboplatin AUC6","Carboplatin AUC2",{"trials":8182,"activeCount":3197,"soonestReadout":83},[8183,8195,8199,8207],{"nctId":8184,"briefTitle":8185,"status":139,"phases":8186,"primaryCompletion":8187,"completion":8187,"start":8188,"enrollment":7648,"conditions":8189,"interventions":8190},"NCT04624204","Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013\u002FKEYLYNK-013)",[89],"2027-10-28","2020-12-08",[1552],[84,8191,8192,8192,8193,8161,8194],"Pembrolizumab 400 mg","Pembrolizumab placebo","Olaparib 300 mg BID","Platinum, investigator's choice",{"nctId":3332,"briefTitle":3333,"status":105,"phases":8196,"primaryCompletion":3335,"completion":3336,"start":3337,"enrollment":3338,"conditions":8197,"interventions":8198},[89],[2537],[84,390,386,385,3341,3342],{"nctId":81,"briefTitle":82,"status":139,"phases":8200,"primaryCompletion":83,"completion":8201,"start":8202,"enrollment":8203,"conditions":8204,"interventions":8205},[89],"2026-09-10","2018-12-17",714,[2482],[84,8206],"Cisplatin 100 mg\u002Fm^2",{"nctId":3385,"briefTitle":3386,"status":105,"phases":8208,"primaryCompletion":3388,"completion":3336,"start":3389,"enrollment":3390,"conditions":8209,"interventions":8210},[89],[2537],[84,390,386,385,3341,3342],{"trials":8212,"activeCount":99},[],{"trials":8214,"activeCount":99},[],{"intervention":8216,"totalTrials":174,"cells":8217},"Bomedemstat",{"EARLY_PHASE1":8218,"PHASE1":8220,"PHASE2":8239,"PHASE3":8241,"PHASE4":8282,"NA":8284},{"trials":8219,"activeCount":99},[],{"trials":8221,"activeCount":99},[8222,8230],{"nctId":8223,"briefTitle":8224,"status":105,"phases":8225,"primaryCompletion":8226,"completion":8226,"start":8227,"enrollment":3308,"conditions":8228,"interventions":8229},"NCT07049939","A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)",[87],"2026-02-17","2025-08-20",[7574],[8216],{"nctId":8231,"briefTitle":8232,"status":105,"phases":8233,"primaryCompletion":2504,"completion":5699,"start":8234,"enrollment":3655,"conditions":8235,"interventions":8236},"NCT06596668","Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)",[87],"2024-10-02",[18],[8237,8238],"bomedemstat","carbamazepine",{"trials":8240,"activeCount":99},[],{"trials":8242,"activeCount":202,"soonestReadout":8247},[8243,8256,8268],{"nctId":8244,"briefTitle":8245,"status":128,"phases":8246,"primaryCompletion":8247,"completion":8248,"start":5240,"enrollment":1452,"conditions":8249,"interventions":8251},"NCT06079879","A Study of Bomedemstat (IMG-7289\u002FMK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)",[89],"2027-07-30","2028-08-18",[8250],"Essential Thrombocythemia",[8216,8252,8253,8254,8255],"Anagrelide","Busulfan","Interferon alfa\u002Fpegylated interferon alfa 2a\u002Fpegylated interferon alfa 2b","Ruxolitinib",{"nctId":8257,"briefTitle":8258,"status":128,"phases":8259,"primaryCompletion":8260,"completion":8261,"start":8262,"enrollment":1570,"conditions":8263,"interventions":8264},"NCT06456346","Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)",[89],"2027-09-28","2028-03-24","2024-07-16",[8250],[8216,8265,8266,8267],"Hydroxyurea","Bomedemstat placebo","Hydroxyurea placebo",{"nctId":8269,"briefTitle":8270,"status":128,"phases":8271,"primaryCompletion":8272,"completion":8272,"start":8273,"enrollment":1150,"conditions":8274,"interventions":8281},"NCT06351631","A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)",[89],"2034-12-04","2024-05-23",[8275,8276,8277,8278,8279,8280],"Thrombocythemia, Essential","Primary Myelofibrosis","Myelofibrosis","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis","Polycythemia Vera",[8216],{"trials":8283,"activeCount":99},[],{"trials":8285,"activeCount":99},[],{"intervention":5578,"totalTrials":174,"cells":8287},{"EARLY_PHASE1":8288,"PHASE1":8290,"PHASE2":8321,"PHASE3":8323,"PHASE4":8329,"NA":8331},{"trials":8289,"activeCount":99},[],{"trials":8291,"activeCount":3197,"soonestReadout":8316},[8292,8304,8308,8312],{"nctId":8293,"briefTitle":8294,"status":105,"phases":8295,"primaryCompletion":8296,"completion":8296,"start":8297,"enrollment":931,"conditions":8298,"interventions":8300},"NCT02477514","A Study to Evaluate the Effects of Tedizolid Phosphate on the Pharmacokinetics and Safety of Midazolam and Rosuvastatin (MK-1986-004)",[87],"2015-08","2015-06",[8299],"Skin Diseases, Bacterial",[8301,8302,8303],"midazolam","rosuvastatin","tedizolid phosphate",{"nctId":5570,"briefTitle":5571,"status":105,"phases":8305,"primaryCompletion":5573,"completion":5574,"start":5575,"enrollment":3655,"conditions":8306,"interventions":8307},[87],[18],[5578,4084,602],{"nctId":7546,"briefTitle":7547,"status":128,"phases":8309,"primaryCompletion":7549,"completion":3090,"start":5574,"enrollment":558,"conditions":8310,"interventions":8311},[87],[18],[7552,7488,5578],{"nctId":8313,"briefTitle":8314,"status":139,"phases":8315,"primaryCompletion":8316,"completion":8316,"start":5653,"enrollment":2754,"conditions":8317,"interventions":8318},"NCT07431866","A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)",[87],"2026-06-07",[18],[5578,8319,8320],"Furosemide","MK-2828",{"trials":8322,"activeCount":99},[],{"trials":8324,"activeCount":224,"soonestReadout":7606},[8325],{"nctId":7603,"briefTitle":7604,"status":128,"phases":8326,"primaryCompletion":7606,"completion":7607,"start":107,"enrollment":7608,"conditions":8327,"interventions":8328},[89],[7610],[7488,5578],{"trials":8330,"activeCount":99},[],{"trials":8332,"activeCount":99},[],{"intervention":2904,"totalTrials":3963,"cells":8334},{"EARLY_PHASE1":8335,"PHASE1":8337,"PHASE2":8339,"PHASE3":8349,"PHASE4":8359,"NA":8361},{"trials":8336,"activeCount":99},[],{"trials":8338,"activeCount":99},[],{"trials":8340,"activeCount":224,"soonestReadout":2179},[8341,8345],{"nctId":4147,"briefTitle":4148,"status":128,"phases":8342,"primaryCompletion":2179,"completion":4150,"start":4151,"enrollment":2023,"conditions":8343,"interventions":8344},[88],[4153],[56,4155,2904,4156],{"nctId":2896,"briefTitle":2897,"status":150,"phases":8346,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":2901,"conditions":8347,"interventions":8348},[87,88],[290],[386,1664,1843,2904,714,2905,693,387,390,1444,1253,437,2906],{"trials":8350,"activeCount":3197,"soonestReadout":69},[8351,8355],{"nctId":67,"briefTitle":68,"status":139,"phases":8352,"primaryCompletion":69,"completion":4192,"start":4193,"enrollment":4194,"conditions":8353,"interventions":8354},[89],[1035],[56,2904],{"nctId":4229,"briefTitle":4230,"status":128,"phases":8356,"primaryCompletion":4232,"completion":4232,"start":4233,"enrollment":951,"conditions":8357,"interventions":8358},[89],[4134,1035],[56,4178,4236,461,4189,2904],{"trials":8360,"activeCount":99},[],{"trials":8362,"activeCount":99},[],{"intervention":1136,"totalTrials":3963,"cells":8364},{"EARLY_PHASE1":8365,"PHASE1":8367,"PHASE2":8369,"PHASE3":8379,"PHASE4":8389,"NA":8391},{"trials":8366,"activeCount":99},[],{"trials":8368,"activeCount":99},[],{"trials":8370,"activeCount":3197,"soonestReadout":1129},[8371,8375],{"nctId":1126,"briefTitle":1127,"status":139,"phases":8372,"primaryCompletion":1129,"completion":1130,"start":1131,"enrollment":1132,"conditions":8373,"interventions":8374},[87,88],[1134],[47,885,1136],{"nctId":1371,"briefTitle":1372,"status":139,"phases":8376,"primaryCompletion":1374,"completion":1374,"start":1375,"enrollment":312,"conditions":8377,"interventions":8378},[87,88],[1377,1378],[653,1136,47,654],{"trials":8380,"activeCount":224,"soonestReadout":2671},[8381,8385],{"nctId":2123,"briefTitle":2124,"status":105,"phases":8382,"primaryCompletion":2126,"completion":2126,"start":2127,"enrollment":2128,"conditions":8383,"interventions":8384},[89],[1134],[47,2131,714,390],{"nctId":2668,"briefTitle":2669,"status":139,"phases":8386,"primaryCompletion":2671,"completion":2672,"start":2673,"enrollment":2674,"conditions":8387,"interventions":8388},[89],[2676],[47,1136],{"trials":8390,"activeCount":99},[],{"trials":8392,"activeCount":99},[],{"intervention":5227,"totalTrials":202,"cells":8394},{"EARLY_PHASE1":8395,"PHASE1":8397,"PHASE2":8407,"PHASE3":8420,"PHASE4":8426,"NA":8428},{"trials":8396,"activeCount":99},[],{"trials":8398,"activeCount":224,"soonestReadout":8403},[8399],{"nctId":8400,"briefTitle":8401,"status":128,"phases":8402,"primaryCompletion":8403,"completion":8403,"start":5991,"enrollment":4242,"conditions":8404,"interventions":8406},"NCT07363590","A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)",[87],"2029-07-16",[8405,7020],"Systemic Lupus Erythematosus",[5227],{"trials":8408,"activeCount":224,"soonestReadout":8413},[8409],{"nctId":8410,"briefTitle":8411,"status":128,"phases":8412,"primaryCompletion":8413,"completion":8414,"start":8415,"enrollment":8416,"conditions":8417,"interventions":8419},"NCT07519772","A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)",[87,88],"2030-01-20","2030-10-21","2026-05-03",200,[756,8418,4347],"Lymphoma, Follicular",[5227],{"trials":8421,"activeCount":224,"soonestReadout":5222},[8422],{"nctId":5219,"briefTitle":5220,"status":128,"phases":8423,"primaryCompletion":5222,"completion":5223,"start":1520,"enrollment":1452,"conditions":8424,"interventions":8425},[88,89],[5225],[5227,5228,979,5229,529,5230,5231,5232,5233],{"trials":8427,"activeCount":99},[],{"trials":8429,"activeCount":99},[],{"intervention":2207,"totalTrials":202,"cells":8431},{"EARLY_PHASE1":8432,"PHASE1":8434,"PHASE2":8436,"PHASE3":8438,"PHASE4":8452,"NA":8454},{"trials":8433,"activeCount":99},[],{"trials":8435,"activeCount":99},[],{"trials":8437,"activeCount":99},[],{"trials":8439,"activeCount":202,"soonestReadout":2201},[8440,8444,8448],{"nctId":2934,"briefTitle":2935,"status":128,"phases":8441,"primaryCompletion":2937,"completion":2937,"start":2938,"enrollment":1633,"conditions":8442,"interventions":8443},[89],[1108],[1111,387,388,795,2207,2941],{"nctId":1853,"briefTitle":1854,"status":139,"phases":8445,"primaryCompletion":1856,"completion":1856,"start":1510,"enrollment":1452,"conditions":8446,"interventions":8447},[89],[1108],[42,1654,1859,1860,1445,1861,1862],{"nctId":2198,"briefTitle":2199,"status":128,"phases":8449,"primaryCompletion":2201,"completion":2202,"start":2203,"enrollment":2204,"conditions":8450,"interventions":8451},[89],[1108],[653,47,387,388,795,2207],{"trials":8453,"activeCount":99},[],{"trials":8455,"activeCount":99},[],{"intervention":4165,"totalTrials":202,"cells":8457},{"EARLY_PHASE1":8458,"PHASE1":8460,"PHASE2":8462,"PHASE3":8468,"PHASE4":8478,"NA":8480},{"trials":8459,"activeCount":99},[],{"trials":8461,"activeCount":99},[],{"trials":8463,"activeCount":224,"soonestReadout":4161},[8464],{"nctId":4158,"briefTitle":4159,"status":128,"phases":8465,"primaryCompletion":4161,"completion":4161,"start":4162,"enrollment":407,"conditions":8466,"interventions":8467},[87,88],[702],[56,4165],{"trials":8469,"activeCount":3197,"soonestReadout":4201},[8470,8474],{"nctId":4182,"briefTitle":4183,"status":128,"phases":8471,"primaryCompletion":4185,"completion":4185,"start":1540,"enrollment":4186,"conditions":8472,"interventions":8473},[89],[702],[56,4165,4189],{"nctId":4198,"briefTitle":4199,"status":128,"phases":8475,"primaryCompletion":4201,"completion":4201,"start":4202,"enrollment":4203,"conditions":8476,"interventions":8477},[89],[1035],[56,4165],{"trials":8479,"activeCount":99},[],{"trials":8481,"activeCount":99},[],{"intervention":4189,"totalTrials":202,"cells":8483},{"EARLY_PHASE1":8484,"PHASE1":8486,"PHASE2":8488,"PHASE3":8490,"PHASE4":8504,"NA":8506},{"trials":8485,"activeCount":99},[],{"trials":8487,"activeCount":99},[],{"trials":8489,"activeCount":99},[],{"trials":8491,"activeCount":202,"soonestReadout":4222},[8492,8496,8500],{"nctId":4182,"briefTitle":4183,"status":128,"phases":8493,"primaryCompletion":4185,"completion":4185,"start":1540,"enrollment":4186,"conditions":8494,"interventions":8495},[89],[702],[56,4165,4189],{"nctId":4219,"briefTitle":4220,"status":139,"phases":8497,"primaryCompletion":4222,"completion":4223,"start":4224,"enrollment":4225,"conditions":8498,"interventions":8499},[89],[1035],[56,461,4189],{"nctId":4229,"briefTitle":4230,"status":128,"phases":8501,"primaryCompletion":4232,"completion":4232,"start":4233,"enrollment":951,"conditions":8502,"interventions":8503},[89],[4134,1035],[56,4178,4236,461,4189,2904],{"trials":8505,"activeCount":99},[],{"trials":8507,"activeCount":99},[],{"intervention":4350,"totalTrials":202,"cells":8509},{"EARLY_PHASE1":8510,"PHASE1":8512,"PHASE2":8514,"PHASE3":8524,"PHASE4":8530,"NA":8532},{"trials":8511,"activeCount":99},[],{"trials":8513,"activeCount":99},[],{"trials":8515,"activeCount":3197,"soonestReadout":4342},[8516,8520],{"nctId":5494,"briefTitle":5495,"status":139,"phases":8517,"primaryCompletion":5497,"completion":5497,"start":5498,"enrollment":558,"conditions":8518,"interventions":8519},[88],[5500],[5502,562,1069,4349,4350,1076,2413],{"nctId":4339,"briefTitle":4340,"status":128,"phases":8521,"primaryCompletion":4342,"completion":4343,"start":4344,"enrollment":4345,"conditions":8522,"interventions":8523},[88],[4347],[1058,4349,562,1069,4350,1076,2413,4351,842],{"trials":8525,"activeCount":224,"soonestReadout":762},[8526],{"nctId":4381,"briefTitle":4382,"status":128,"phases":8527,"primaryCompletion":762,"completion":4384,"start":1610,"enrollment":4385,"conditions":8528,"interventions":8529},[89],[676],[1058,4349,562,1069,4350,1076,2413,1074,1089,4388],{"trials":8531,"activeCount":99},[],{"trials":8533,"activeCount":99},[],{"intervention":977,"totalTrials":202,"cells":8535},{"EARLY_PHASE1":8536,"PHASE1":8538,"PHASE2":8540,"PHASE3":8546,"PHASE4":8556,"NA":8558},{"trials":8537,"activeCount":99},[],{"trials":8539,"activeCount":99},[],{"trials":8541,"activeCount":224,"soonestReadout":972},[8542],{"nctId":969,"briefTitle":970,"status":128,"phases":8543,"primaryCompletion":972,"completion":972,"start":973,"enrollment":558,"conditions":8544,"interventions":8545},[88],[975],[47,390,714,385,653,977,978,979,529,386,47,387,980],{"trials":8547,"activeCount":3197,"soonestReadout":3471},[8548,8552],{"nctId":3590,"briefTitle":3591,"status":128,"phases":8549,"primaryCompletion":3593,"completion":3594,"start":909,"enrollment":3595,"conditions":8550,"interventions":8551},[89],[990,1930,3597],[653,841,977,978,979,529,980],{"nctId":3468,"briefTitle":3469,"status":139,"phases":8553,"primaryCompletion":3471,"completion":3472,"start":1776,"enrollment":2625,"conditions":8554,"interventions":8555},[89],[1687],[653,385,386,3475,1324,979,529,1325],{"trials":8557,"activeCount":99},[],{"trials":8559,"activeCount":99},[],{"intervention":2413,"totalTrials":734,"cells":8561},{"EARLY_PHASE1":8562,"PHASE1":8564,"PHASE2":8570,"PHASE3":8580,"PHASE4":8611,"NA":8613},{"trials":8563,"activeCount":99},[],{"trials":8565,"activeCount":99},[8566],{"nctId":5474,"briefTitle":5475,"status":150,"phases":8567,"primaryCompletion":5477,"completion":5477,"start":5478,"enrollment":357,"conditions":8568,"interventions":8569},[87],[677],[5481,1458,1459,5482],{"trials":8571,"activeCount":3197,"soonestReadout":4342},[8572,8576],{"nctId":5494,"briefTitle":5495,"status":139,"phases":8573,"primaryCompletion":5497,"completion":5497,"start":5498,"enrollment":558,"conditions":8574,"interventions":8575},[88],[5500],[5502,562,1069,4349,4350,1076,2413],{"nctId":4339,"briefTitle":4340,"status":128,"phases":8577,"primaryCompletion":4342,"completion":4343,"start":4344,"enrollment":4345,"conditions":8578,"interventions":8579},[88],[4347],[1058,4349,562,1069,4350,1076,2413,4351,842],{"trials":8581,"activeCount":224,"soonestReadout":762},[8582,8586,8597,8607],{"nctId":4381,"briefTitle":4382,"status":128,"phases":8583,"primaryCompletion":762,"completion":4384,"start":1610,"enrollment":4385,"conditions":8584,"interventions":8585},[89],[676],[1058,4349,562,1069,4350,1076,2413,1074,1089,4388],{"nctId":8587,"briefTitle":8588,"status":150,"phases":8589,"primaryCompletion":8590,"completion":8590,"start":8591,"enrollment":1624,"conditions":8592,"interventions":8593},"NCT00984568","Conventional Step-Up Versus Infliximab Monotherapy in Patients With Ulcerative Colitis (P05553)",[89],"2012-03","2009-11",[7169],[8594,2413,8595,8596],"Infliximab","5-aminosalicylic acid","Azathioprine",{"nctId":8598,"briefTitle":8599,"status":150,"phases":8600,"primaryCompletion":8601,"completion":8601,"start":8602,"enrollment":3308,"conditions":8603,"interventions":8605},"NCT00796250","Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732)",[89],"2005-01-01","2003-11-01",[8604],"Crohn's Disease",[8594,8606,2413,8606],"AZA",{"nctId":2403,"briefTitle":2404,"status":105,"phases":8608,"primaryCompletion":2083,"completion":2406,"start":2407,"enrollment":2408,"conditions":8609,"interventions":8610},[89],[2410],[47,1114,2412,1076,2382,2413],{"trials":8612,"activeCount":99},[],{"trials":8614,"activeCount":99},[8615],{"nctId":8616,"briefTitle":8617,"status":105,"phases":8618,"primaryCompletion":8619,"completion":8620,"start":8621,"enrollment":380,"conditions":8622,"interventions":8626},"NCT00971724","Biomarkers of Prednisolone Treatment (P05888)",[91],"2006-10","2008-03","2006-05",[8623,8624,8625],"Insulin Resistance","Hyperglycemia","Glucose Intolerance",[2413],{"intervention":1444,"totalTrials":5983,"cells":8628},{"EARLY_PHASE1":8629,"PHASE1":8631,"PHASE2":8633,"PHASE3":8643,"PHASE4":8681,"NA":8683},{"trials":8630,"activeCount":99},[],{"trials":8632,"activeCount":99},[],{"trials":8634,"activeCount":99},[8635,8639],{"nctId":2896,"briefTitle":2897,"status":150,"phases":8636,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":2901,"conditions":8637,"interventions":8638},[87,88],[290],[386,1664,1843,2904,714,2905,693,387,390,1444,1253,437,2906],{"nctId":1434,"briefTitle":1435,"status":105,"phases":8640,"primaryCompletion":1437,"completion":1437,"start":1438,"enrollment":1439,"conditions":8641,"interventions":8642},[88],[1441,1442],[42,486,1444,1445],{"trials":8644,"activeCount":3197,"soonestReadout":2321},[8645,8649,8653,8657,8661,8665,8669,8673,8677],{"nctId":1764,"briefTitle":1765,"status":1040,"phases":8646,"primaryCompletion":1767,"completion":1768,"start":1769,"enrollment":99,"conditions":8647,"interventions":8648},[89],[791],[47,390,1444],{"nctId":1832,"briefTitle":1833,"status":105,"phases":8650,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":8651,"interventions":8652},[89],[1840,1442],[47,390,1444,434,795,1842,1843],{"nctId":1904,"briefTitle":1905,"status":105,"phases":8654,"primaryCompletion":1907,"completion":65,"start":1908,"enrollment":1909,"conditions":8655,"interventions":8656},[89],[791],[47,390,1444],{"nctId":1913,"briefTitle":1914,"status":105,"phases":8658,"primaryCompletion":1916,"completion":1917,"start":1918,"enrollment":1919,"conditions":8659,"interventions":8660},[89],[1441],[47,390,1444,795],{"nctId":2048,"briefTitle":2049,"status":105,"phases":8662,"primaryCompletion":2051,"completion":2052,"start":2053,"enrollment":2054,"conditions":8663,"interventions":8664},[89],[2056],[47,461,434,795,435,1444],{"nctId":2318,"briefTitle":2319,"status":139,"phases":8666,"primaryCompletion":2321,"completion":2322,"start":2323,"enrollment":2324,"conditions":8667,"interventions":8668},[89],[2326],[47,461,390,1444,434,435,796,387],{"nctId":2509,"briefTitle":2510,"status":105,"phases":8670,"primaryCompletion":2043,"completion":1807,"start":940,"enrollment":2512,"conditions":8671,"interventions":8672},[89],[2514,2515],[47,390,386,1444,693],{"nctId":2630,"briefTitle":2631,"status":139,"phases":8674,"primaryCompletion":2192,"completion":2633,"start":2634,"enrollment":2635,"conditions":8675,"interventions":8676},[89],[1230,2637,2638],[42,486,1444,605,2640,604],{"nctId":5907,"briefTitle":5908,"status":105,"phases":8678,"primaryCompletion":5910,"completion":5911,"start":5912,"enrollment":1522,"conditions":8679,"interventions":8680},[89],[431],[1114,1444,841,795,5915],{"trials":8682,"activeCount":99},[],{"trials":8684,"activeCount":99},[],{"intervention":1241,"totalTrials":4555,"cells":8686},{"EARLY_PHASE1":8687,"PHASE1":8689,"PHASE2":8691,"PHASE3":8701,"PHASE4":8719,"NA":8721},{"trials":8688,"activeCount":99},[],{"trials":8690,"activeCount":99},[],{"trials":8692,"activeCount":224,"soonestReadout":395},[8693,8697],{"nctId":1234,"briefTitle":1235,"status":1040,"phases":8694,"primaryCompletion":1237,"completion":1237,"start":1238,"enrollment":99,"conditions":8695,"interventions":8696},[87,88],[324],[47,458,460,923,1241],{"nctId":1267,"briefTitle":1268,"status":139,"phases":8698,"primaryCompletion":395,"completion":1270,"start":1271,"enrollment":1272,"conditions":8699,"interventions":8700},[88],[419],[47,818,1275,1241,471],{"trials":8702,"activeCount":224,"soonestReadout":2974},[8703,8707,8711,8715],{"nctId":1791,"briefTitle":1792,"status":105,"phases":8704,"primaryCompletion":1794,"completion":1795,"start":1796,"enrollment":1797,"conditions":8705,"interventions":8706},[89],[1799],[1241,386,390,387,388,385,47],{"nctId":2971,"briefTitle":2972,"status":139,"phases":8708,"primaryCompletion":2974,"completion":2974,"start":2975,"enrollment":987,"conditions":8709,"interventions":8710},[89],[369],[2978,2979,486,483,487,484,1654],{"nctId":2310,"briefTitle":2311,"status":105,"phases":8712,"primaryCompletion":2313,"completion":466,"start":183,"enrollment":2314,"conditions":8713,"interventions":8714},[89],[35],[1241,47],{"nctId":2529,"briefTitle":2530,"status":105,"phases":8716,"primaryCompletion":2532,"completion":2533,"start":2534,"enrollment":2535,"conditions":8717,"interventions":8718},[89],[2184,2537],[1241,47],{"trials":8720,"activeCount":99},[],{"trials":8722,"activeCount":99},[],{"intervention":1074,"totalTrials":174,"cells":8724},{"EARLY_PHASE1":8725,"PHASE1":8727,"PHASE2":8737,"PHASE3":8747,"PHASE4":8753,"NA":8755},{"trials":8726,"activeCount":99},[],{"trials":8728,"activeCount":99},[8729,8733],{"nctId":5462,"briefTitle":5463,"status":150,"phases":8730,"primaryCompletion":5465,"completion":5465,"start":5466,"enrollment":3963,"conditions":8731,"interventions":8732},[87],[290,176,5468,5469,5470],[1390,1074,5472,437,2905,1069,562,1073],{"nctId":5474,"briefTitle":5475,"status":150,"phases":8734,"primaryCompletion":5477,"completion":5477,"start":5478,"enrollment":357,"conditions":8735,"interventions":8736},[87],[677],[5481,1458,1459,5482],{"trials":8738,"activeCount":224,"soonestReadout":1450},[8739,8743],{"nctId":1061,"briefTitle":1062,"status":105,"phases":8740,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":110,"conditions":8741,"interventions":8742},[88],[943],[47,1069,1070,1071,1072,1073,562,1074,1075,1076],{"nctId":1447,"briefTitle":1448,"status":139,"phases":8744,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":8745,"interventions":8746},[88],[674],[42,1455,1456,1457,1458,1459,1460,1461,487],{"trials":8748,"activeCount":224,"soonestReadout":762},[8749],{"nctId":4381,"briefTitle":4382,"status":128,"phases":8750,"primaryCompletion":762,"completion":4384,"start":1610,"enrollment":4385,"conditions":8751,"interventions":8752},[89],[676],[1058,4349,562,1069,4350,1076,2413,1074,1089,4388],{"trials":8754,"activeCount":99},[],{"trials":8756,"activeCount":99},[],{"intervention":7662,"totalTrials":3963,"cells":8758},{"EARLY_PHASE1":8759,"PHASE1":8761,"PHASE2":8763,"PHASE3":8769,"PHASE4":8788,"NA":8790},{"trials":8760,"activeCount":99},[],{"trials":8762,"activeCount":99},[],{"trials":8764,"activeCount":224,"soonestReadout":7784},[8765],{"nctId":7781,"briefTitle":7782,"status":139,"phases":8766,"primaryCompletion":7784,"completion":7785,"start":7786,"enrollment":2779,"conditions":8767,"interventions":8768},[88],[7788],[7662,7790,7671],{"trials":8770,"activeCount":224,"soonestReadout":7820},[8771,8775,8784],{"nctId":7654,"briefTitle":7655,"status":105,"phases":8772,"primaryCompletion":7657,"completion":7658,"start":7659,"enrollment":3903,"conditions":8773,"interventions":8774},[89],[7639],[7662,7663,7617],{"nctId":8776,"briefTitle":8777,"status":150,"phases":8778,"primaryCompletion":8779,"completion":8779,"start":7073,"enrollment":5349,"conditions":8780,"interventions":8782},"NCT04652700","Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)",[89],"2023-08-04",[8781],"HIV Preexposure Prophylaxis",[7662,7295,8783],"FTC\u002FTAF",{"nctId":7817,"briefTitle":7818,"status":128,"phases":8785,"primaryCompletion":7820,"completion":7821,"start":7822,"enrollment":7823,"conditions":8786,"interventions":8787},[88,89],[7788],[7662,7790,7671,7826],{"trials":8789,"activeCount":99},[],{"trials":8791,"activeCount":99},[],{"intervention":1664,"totalTrials":3963,"cells":8793},{"EARLY_PHASE1":8794,"PHASE1":8796,"PHASE2":8798,"PHASE3":8804,"PHASE4":8818,"NA":8820},{"trials":8795,"activeCount":99},[],{"trials":8797,"activeCount":99},[],{"trials":8799,"activeCount":99},[8800],{"nctId":2896,"briefTitle":2897,"status":150,"phases":8801,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":2901,"conditions":8802,"interventions":8803},[87,88],[290],[386,1664,1843,2904,714,2905,693,387,390,1444,1253,437,2906],{"trials":8805,"activeCount":3197,"soonestReadout":2136},[8806,8810,8814],{"nctId":1656,"briefTitle":1657,"status":105,"phases":8807,"primaryCompletion":1659,"completion":1659,"start":1660,"enrollment":1661,"conditions":8808,"interventions":8809},[89],[540],[47,386,387,1069,1664,562,1665],{"nctId":2133,"briefTitle":2134,"status":139,"phases":8811,"primaryCompletion":2136,"completion":2136,"start":2137,"enrollment":2138,"conditions":8812,"interventions":8813},[89],[1109],[47,387,1069,1664,562,2141],{"nctId":2435,"briefTitle":2436,"status":128,"phases":8815,"primaryCompletion":2438,"completion":2439,"start":2440,"enrollment":2441,"conditions":8816,"interventions":8817},[89],[1108,540,2443],[653,47,842,386,387,1069,1664,562,795,1114],{"trials":8819,"activeCount":99},[],{"trials":8821,"activeCount":99},[],{"intervention":5126,"totalTrials":3963,"cells":8823},{"EARLY_PHASE1":8824,"PHASE1":8826,"PHASE2":8836,"PHASE3":8838,"PHASE4":8848,"NA":8850},{"trials":8825,"activeCount":99},[],{"trials":8827,"activeCount":99},[8828,8832],{"nctId":5118,"briefTitle":5119,"status":105,"phases":8829,"primaryCompletion":5121,"completion":5121,"start":5122,"enrollment":4071,"conditions":8830,"interventions":8831},[87],[2410,3246],[4775,529,5125,5126],{"nctId":5156,"briefTitle":5157,"status":105,"phases":8833,"primaryCompletion":5159,"completion":5160,"start":5161,"enrollment":357,"conditions":8834,"interventions":8835},[87],[2410,3246],[4775,529,4777,5126],{"trials":8837,"activeCount":99},[],{"trials":8839,"activeCount":3197,"soonestReadout":5260},[8840,8844],{"nctId":5235,"briefTitle":5236,"status":128,"phases":8841,"primaryCompletion":5238,"completion":5239,"start":5240,"enrollment":5241,"conditions":8842,"interventions":8843},[89],[5243],[4775,2412,2382,5126,4777,1076,529],{"nctId":5257,"briefTitle":5258,"status":128,"phases":8845,"primaryCompletion":5260,"completion":5261,"start":5262,"enrollment":5263,"conditions":8846,"interventions":8847},[89],[5265,2410],[4775,529,4777,5126,2412,5267,2382],{"trials":8849,"activeCount":99},[],{"trials":8851,"activeCount":99},[],{"intervention":5081,"totalTrials":202,"cells":8853},{"EARLY_PHASE1":8854,"PHASE1":8856,"PHASE2":8858,"PHASE3":8864,"PHASE4":8874,"NA":8876},{"trials":8855,"activeCount":99},[],{"trials":8857,"activeCount":99},[],{"trials":8859,"activeCount":99},[8860],{"nctId":5011,"briefTitle":5012,"status":105,"phases":8861,"primaryCompletion":5014,"completion":5015,"start":5016,"enrollment":5017,"conditions":8862,"interventions":8863},[88],[674],[1594,5020,1885],{"trials":8865,"activeCount":3197,"soonestReadout":5534},[8866,8870],{"nctId":5531,"briefTitle":5532,"status":139,"phases":8867,"primaryCompletion":5534,"completion":5535,"start":5536,"enrollment":1570,"conditions":8868,"interventions":8869},[89],[5538,5539],[5541,5542,562,5081,4349,5543,5544,5545],{"nctId":5072,"briefTitle":5073,"status":128,"phases":8871,"primaryCompletion":5075,"completion":5075,"start":5076,"enrollment":5077,"conditions":8872,"interventions":8873},[88,89],[5079,676],[1058,4349,714,434,5081,5082],{"trials":8875,"activeCount":99},[],{"trials":8877,"activeCount":99},[],{"intervention":2412,"totalTrials":202,"cells":8879},{"EARLY_PHASE1":8880,"PHASE1":8882,"PHASE2":8884,"PHASE3":8886,"PHASE4":8900,"NA":8902},{"trials":8881,"activeCount":99},[],{"trials":8883,"activeCount":99},[],{"trials":8885,"activeCount":99},[],{"trials":8887,"activeCount":3197,"soonestReadout":5260},[8888,8892,8896],{"nctId":5235,"briefTitle":5236,"status":128,"phases":8889,"primaryCompletion":5238,"completion":5239,"start":5240,"enrollment":5241,"conditions":8890,"interventions":8891},[89],[5243],[4775,2412,2382,5126,4777,1076,529],{"nctId":5257,"briefTitle":5258,"status":128,"phases":8893,"primaryCompletion":5260,"completion":5261,"start":5262,"enrollment":5263,"conditions":8894,"interventions":8895},[89],[5265,2410],[4775,529,4777,5126,2412,5267,2382],{"nctId":2403,"briefTitle":2404,"status":105,"phases":8897,"primaryCompletion":2083,"completion":2406,"start":2407,"enrollment":2408,"conditions":8898,"interventions":8899},[89],[2410],[47,1114,2412,1076,2382,2413],{"trials":8901,"activeCount":99},[],{"trials":8903,"activeCount":99},[],{"intervention":7790,"totalTrials":3197,"cells":8905},{"EARLY_PHASE1":8906,"PHASE1":8908,"PHASE2":8910,"PHASE3":8916,"PHASE4":8922,"NA":8924},{"trials":8907,"activeCount":99},[],{"trials":8909,"activeCount":99},[],{"trials":8911,"activeCount":224,"soonestReadout":7784},[8912],{"nctId":7781,"briefTitle":7782,"status":139,"phases":8913,"primaryCompletion":7784,"completion":7785,"start":7786,"enrollment":2779,"conditions":8914,"interventions":8915},[88],[7788],[7662,7790,7671],{"trials":8917,"activeCount":224,"soonestReadout":7820},[8918],{"nctId":7817,"briefTitle":7818,"status":128,"phases":8919,"primaryCompletion":7820,"completion":7821,"start":7822,"enrollment":7823,"conditions":8920,"interventions":8921},[88,89],[7788],[7662,7790,7671,7826],{"trials":8923,"activeCount":99},[],{"trials":8925,"activeCount":99},[],{"intervention":1087,"totalTrials":3197,"cells":8927},{"EARLY_PHASE1":8928,"PHASE1":8930,"PHASE2":8932,"PHASE3":8938,"PHASE4":8944,"NA":8946},{"trials":8929,"activeCount":99},[],{"trials":8931,"activeCount":99},[],{"trials":8933,"activeCount":224,"soonestReadout":1081},[8934],{"nctId":1078,"briefTitle":1079,"status":128,"phases":8935,"primaryCompletion":1081,"completion":1081,"start":1082,"enrollment":8,"conditions":8936,"interventions":8937},[87,88],[419,1084,1085],[653,1087,1088,1089,654,390,47],{"trials":8939,"activeCount":224,"soonestReadout":2622},[8940],{"nctId":2619,"briefTitle":2620,"status":139,"phases":8941,"primaryCompletion":2622,"completion":2623,"start":2624,"enrollment":2625,"conditions":8942,"interventions":8943},[89],[1287],[47,390,1087,2628,714],{"trials":8945,"activeCount":99},[],{"trials":8947,"activeCount":99},[],{"intervention":2076,"totalTrials":3197,"cells":8949},{"EARLY_PHASE1":8950,"PHASE1":8952,"PHASE2":8954,"PHASE3":8956,"PHASE4":8966,"NA":8968},{"trials":8951,"activeCount":99},[],{"trials":8953,"activeCount":99},[],{"trials":8955,"activeCount":99},[],{"trials":8957,"activeCount":3197,"soonestReadout":78},[8958,8962],{"nctId":76,"briefTitle":77,"status":139,"phases":8959,"primaryCompletion":78,"completion":2070,"start":2071,"enrollment":2072,"conditions":8960,"interventions":8961},[89],[2074],[79,385,390,386,387,388,47,2076,2077],{"nctId":2749,"briefTitle":2750,"status":139,"phases":8963,"primaryCompletion":2752,"completion":2070,"start":2753,"enrollment":2754,"conditions":8964,"interventions":8965},[89],[2074],[384,385,390,386,387,388,47,2076,2077],{"trials":8967,"activeCount":99},[],{"trials":8969,"activeCount":99},[],{"intervention":2077,"totalTrials":3197,"cells":8971},{"EARLY_PHASE1":8972,"PHASE1":8974,"PHASE2":8976,"PHASE3":8978,"PHASE4":8988,"NA":8990},{"trials":8973,"activeCount":99},[],{"trials":8975,"activeCount":99},[],{"trials":8977,"activeCount":99},[],{"trials":8979,"activeCount":3197,"soonestReadout":78},[8980,8984],{"nctId":76,"briefTitle":77,"status":139,"phases":8981,"primaryCompletion":78,"completion":2070,"start":2071,"enrollment":2072,"conditions":8982,"interventions":8983},[89],[2074],[79,385,390,386,387,388,47,2076,2077],{"nctId":2749,"briefTitle":2750,"status":139,"phases":8985,"primaryCompletion":2752,"completion":2070,"start":2753,"enrollment":2754,"conditions":8986,"interventions":8987},[89],[2074],[384,385,390,386,387,388,47,2076,2077],{"trials":8989,"activeCount":99},[],{"trials":8991,"activeCount":99},[],{"intervention":3267,"totalTrials":3197,"cells":8993},{"EARLY_PHASE1":8994,"PHASE1":8996,"PHASE2":8998,"PHASE3":9004,"PHASE4":9010,"NA":9012},{"trials":8995,"activeCount":99},[],{"trials":8997,"activeCount":99},[],{"trials":8999,"activeCount":224,"soonestReadout":3260},[9000],{"nctId":3257,"briefTitle":3258,"status":128,"phases":9001,"primaryCompletion":3260,"completion":3261,"start":1701,"enrollment":3262,"conditions":9002,"interventions":9003},[87,88],[3264],[3266,1265,3267,386,1073,327],{"trials":9005,"activeCount":224,"soonestReadout":73},[9006],{"nctId":71,"briefTitle":72,"status":139,"phases":9007,"primaryCompletion":73,"completion":2398,"start":1796,"enrollment":836,"conditions":9008,"interventions":9009},[89],[866],[74,3375,1073,390,3267,386],{"trials":9011,"activeCount":99},[],{"trials":9013,"activeCount":99},[],{"intervention":2424,"totalTrials":3197,"cells":9015},{"EARLY_PHASE1":9016,"PHASE1":9018,"PHASE2":9020,"PHASE3":9026,"PHASE4":9032,"NA":9034},{"trials":9017,"activeCount":99},[],{"trials":9019,"activeCount":99},[],{"trials":9021,"activeCount":224,"soonestReadout":5698},[9022],{"nctId":5695,"briefTitle":5696,"status":128,"phases":9023,"primaryCompletion":5698,"completion":5698,"start":5699,"enrollment":5700,"conditions":9024,"interventions":9025},[88],[1287,5702,5703],[885,2424],{"trials":9027,"activeCount":224,"soonestReadout":505},[9028],{"nctId":2415,"briefTitle":2416,"status":139,"phases":9029,"primaryCompletion":505,"completion":2418,"start":2419,"enrollment":2420,"conditions":9030,"interventions":9031},[89],[2422],[47,2424],{"trials":9033,"activeCount":99},[],{"trials":9035,"activeCount":99},[],{"intervention":9037,"totalTrials":3197,"cells":9038},"IV Tulisokibart",{"EARLY_PHASE1":9039,"PHASE1":9041,"PHASE2":9043,"PHASE3":9045,"PHASE4":9069,"NA":9071},{"trials":9040,"activeCount":99},[],{"trials":9042,"activeCount":99},[],{"trials":9044,"activeCount":99},[],{"trials":9046,"activeCount":3197,"soonestReadout":9061},[9047,9057],{"nctId":9048,"briefTitle":9049,"status":128,"phases":9050,"primaryCompletion":9051,"completion":9052,"start":9053,"enrollment":2204,"conditions":9054,"interventions":9055},"NCT06430801","A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)",[89],"2028-10-30","2029-11-12","2024-06-05",[8604],[9037,9056],"SC Tulisokibart",{"nctId":9058,"briefTitle":9059,"status":139,"phases":9060,"primaryCompletion":9061,"completion":9062,"start":9063,"enrollment":9064,"conditions":9065,"interventions":9067},"NCT06052059","A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)",[89],"2026-08-01","2029-08-01","2023-10-25",1020,[9066],"Ulcerative Colitis",[9037,1730,9056,9068],"SC Placebo",{"trials":9070,"activeCount":99},[],{"trials":9072,"activeCount":99},[],{"intervention":9056,"totalTrials":3197,"cells":9074},{"EARLY_PHASE1":9075,"PHASE1":9077,"PHASE2":9079,"PHASE3":9081,"PHASE4":9091,"NA":9093},{"trials":9076,"activeCount":99},[],{"trials":9078,"activeCount":99},[],{"trials":9080,"activeCount":99},[],{"trials":9082,"activeCount":3197,"soonestReadout":9061},[9083,9087],{"nctId":9048,"briefTitle":9049,"status":128,"phases":9084,"primaryCompletion":9051,"completion":9052,"start":9053,"enrollment":2204,"conditions":9085,"interventions":9086},[89],[8604],[9037,9056],{"nctId":9058,"briefTitle":9059,"status":139,"phases":9088,"primaryCompletion":9061,"completion":9062,"start":9063,"enrollment":9064,"conditions":9089,"interventions":9090},[89],[9066],[9037,1730,9056,9068],{"trials":9092,"activeCount":99},[],{"trials":9094,"activeCount":99},[],{"intervention":4178,"totalTrials":3197,"cells":9096},{"EARLY_PHASE1":9097,"PHASE1":9099,"PHASE2":9101,"PHASE3":9107,"PHASE4":9113,"NA":9115},{"trials":9098,"activeCount":99},[],{"trials":9100,"activeCount":99},[],{"trials":9102,"activeCount":224,"soonestReadout":4174},[9103],{"nctId":4171,"briefTitle":4172,"status":139,"phases":9104,"primaryCompletion":4174,"completion":4174,"start":4175,"enrollment":558,"conditions":9105,"interventions":9106},[87,88],[702],[56,4178],{"trials":9108,"activeCount":224,"soonestReadout":4232},[9109],{"nctId":4229,"briefTitle":4230,"status":128,"phases":9110,"primaryCompletion":4232,"completion":4232,"start":4233,"enrollment":951,"conditions":9111,"interventions":9112},[89],[4134,1035],[56,4178,4236,461,4189,2904],{"trials":9114,"activeCount":99},[],{"trials":9116,"activeCount":99},[],{"intervention":9118,"totalTrials":95,"cells":9119},"V503",{"EARLY_PHASE1":9120,"PHASE1":9122,"PHASE2":9124,"PHASE3":9126,"PHASE4":9241,"NA":9243},{"trials":9121,"activeCount":99},[],{"trials":9123,"activeCount":99},[],{"trials":9125,"activeCount":99},[],{"trials":9127,"activeCount":224,"soonestReadout":1374},[9128,9137,9150,9160,9171,9182,9191,9199,9210,9219,9228],{"nctId":9129,"briefTitle":9130,"status":105,"phases":9131,"primaryCompletion":9132,"completion":9132,"start":9133,"enrollment":9134,"conditions":9135,"interventions":9136},"NCT03903562","Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)",[89],"2025-02-28","2019-04-27",1990,[7076],[9118],{"nctId":9138,"briefTitle":9139,"status":105,"phases":9140,"primaryCompletion":9141,"completion":9142,"start":9143,"enrollment":9144,"conditions":9145,"interventions":9149},"NCT01047345","A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)",[89],"2011-06-10","2015-11-28","2010-02-24",924,[9146,9147,9148,7085],"Cervical Cancers","Vulvar Cancers","Vaginal Cancers",[9118],{"nctId":9151,"briefTitle":9152,"status":105,"phases":9153,"primaryCompletion":5240,"completion":9154,"start":2449,"enrollment":9155,"conditions":9156,"interventions":9159},"NCT04635423","Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064)",[89],"2025-07-23",1059,[9157,9158],"Warts, Genital","Neoplasms, Anal",[9118],{"nctId":9161,"briefTitle":9162,"status":105,"phases":9163,"primaryCompletion":9164,"completion":9165,"start":9166,"enrollment":9167,"conditions":9168,"interventions":9170},"NCT01984697","A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)",[89],"2015-06-19","2017-07-24","2013-12-12",1518,[9169],"Human Papillomavirus Infection",[9118],{"nctId":9172,"briefTitle":9173,"status":105,"phases":9174,"primaryCompletion":9175,"completion":9175,"start":9176,"enrollment":9177,"conditions":9178,"interventions":9180},"NCT02114385","A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)",[89],"2015-04-22","2014-03-24",500,[9179],"Papilloma Viral Infection",[9118,9181],"GARDASIL",{"nctId":9183,"briefTitle":9184,"status":105,"phases":9185,"primaryCompletion":9186,"completion":9186,"start":9187,"enrollment":1818,"conditions":9188,"interventions":9190},"NCT01304498","Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)",[89],"2011-12-20","2011-02-23",[9189],"Human Papillomavirus",[9118,9181],{"nctId":9192,"briefTitle":9193,"status":105,"phases":9194,"primaryCompletion":9195,"completion":9195,"start":9196,"enrollment":920,"conditions":9197,"interventions":9198},"NCT01254643","A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).",[89],"2013-08-10","2011-01-12",[7076],[9118],{"nctId":9200,"briefTitle":9201,"status":105,"phases":9202,"primaryCompletion":9203,"completion":9203,"start":9204,"enrollment":9205,"conditions":9206,"interventions":9207},"NCT00988884","A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)",[89],"2011-02-22","2009-10-21",1241,[9169],[9118,9208,9209,9208,9209],"Comparator: Menactra™","Comparator: Adacel™",{"nctId":9211,"briefTitle":9212,"status":105,"phases":9213,"primaryCompletion":9214,"completion":9214,"start":406,"enrollment":9215,"conditions":9216,"interventions":9218},"NCT03158220","Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)",[89],"2018-11-19",1212,[863,865,9217,7085,9169],"Vaginal Cancer",[9118],{"nctId":9220,"briefTitle":9221,"status":139,"phases":9222,"primaryCompletion":1374,"completion":9223,"start":366,"enrollment":9224,"conditions":9225,"interventions":9226},"NCT03998254","Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)",[89],"2029-11-30",6000,[7076],[9118,9227],"Gardasil",{"nctId":9229,"briefTitle":9230,"status":105,"phases":9231,"primaryCompletion":9232,"completion":9233,"start":9234,"enrollment":9235,"conditions":9236,"interventions":9240},"NCT00943722","A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)",[89],"2011-04-30","2021-04-22","2009-08-27",3074,[9146,865,9217,9237,9238,9239],"Genital Lesions","PAP Test Abnormalities","HPV Infections",[9118],{"trials":9242,"activeCount":99},[],{"trials":9244,"activeCount":224,"soonestReadout":9249},[9245],{"nctId":9246,"briefTitle":9247,"status":139,"phases":9248,"primaryCompletion":9249,"completion":9249,"start":9250,"enrollment":9251,"conditions":9252,"interventions":9253},"NCT02653118","Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)",[],"2040-01-01","2016-01-22",4453,[863,865,9217,7085,9169],[9118,9181],{"intervention":9181,"totalTrials":3963,"cells":9255},{"EARLY_PHASE1":9256,"PHASE1":9258,"PHASE2":9260,"PHASE3":9262,"PHASE4":9276,"NA":9278},{"trials":9257,"activeCount":99},[],{"trials":9259,"activeCount":99},[],{"trials":9261,"activeCount":99},[],{"trials":9263,"activeCount":224,"soonestReadout":1374},[9264,9268,9272],{"nctId":9172,"briefTitle":9173,"status":105,"phases":9265,"primaryCompletion":9175,"completion":9175,"start":9176,"enrollment":9177,"conditions":9266,"interventions":9267},[89],[9179],[9118,9181],{"nctId":9183,"briefTitle":9184,"status":105,"phases":9269,"primaryCompletion":9186,"completion":9186,"start":9187,"enrollment":1818,"conditions":9270,"interventions":9271},[89],[9189],[9118,9181],{"nctId":9220,"briefTitle":9221,"status":139,"phases":9273,"primaryCompletion":1374,"completion":9223,"start":366,"enrollment":9224,"conditions":9274,"interventions":9275},[89],[7076],[9118,9227],{"trials":9277,"activeCount":99},[],{"trials":9279,"activeCount":224,"soonestReadout":9249},[9280],{"nctId":9246,"briefTitle":9247,"status":139,"phases":9281,"primaryCompletion":9249,"completion":9249,"start":9250,"enrollment":9251,"conditions":9282,"interventions":9283},[],[863,865,9217,7085,9169],[9118,9181],{"intervention":9285,"totalTrials":3308,"cells":9286},"Suvorexant",{"EARLY_PHASE1":9287,"PHASE1":9289,"PHASE2":9327,"PHASE3":9339,"PHASE4":9379,"NA":9381},{"trials":9288,"activeCount":99},[],{"trials":9290,"activeCount":99},[9291,9300,9309,9316],{"nctId":9292,"briefTitle":9293,"status":105,"phases":9294,"primaryCompletion":9295,"completion":9295,"start":9296,"enrollment":3506,"conditions":9297,"interventions":9299},"NCT01300455","Effects of Suvorexant in Participants With Obstructive Sleep Apnea (MK-4305-036)",[87],"2011-08-11","2011-03-19",[9298],"Sleep Apnea",[9285],{"nctId":9301,"briefTitle":9302,"status":105,"phases":9303,"primaryCompletion":9304,"completion":9304,"start":9305,"enrollment":3655,"conditions":9306,"interventions":9308},"NCT01059851","Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)",[87],"2010-07-15","2010-05-24",[9307],"Insomnia",[9285],{"nctId":9310,"briefTitle":9311,"status":105,"phases":9312,"primaryCompletion":9313,"completion":9313,"start":5131,"enrollment":3655,"conditions":9314,"interventions":9315},"NCT01043926","Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)",[87],"2010-04-14",[9307,7574],[9285],{"nctId":9317,"briefTitle":9318,"status":105,"phases":9319,"primaryCompletion":9320,"completion":9321,"start":9322,"enrollment":9323,"conditions":9324,"interventions":9325},"NCT01293006","Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)",[87],"2012-01-20","2012-02-22","2011-03-25",25,[9307],[9326],"suvorexant",{"trials":9328,"activeCount":99},[9329],{"nctId":9330,"briefTitle":9331,"status":105,"phases":9332,"primaryCompletion":9333,"completion":9333,"start":9334,"enrollment":1122,"conditions":9335,"interventions":9337},"NCT00792298","Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)",[88],"2009-12-26","2008-11-05",[9336],"Primary Insomnia",[9285,9338],"Dose-matched Placebo to Suvorexant",{"trials":9340,"activeCount":224,"soonestReadout":9375},[9341,9351,9361,9371],{"nctId":9342,"briefTitle":9343,"status":105,"phases":9344,"primaryCompletion":9345,"completion":9346,"start":9347,"enrollment":9348,"conditions":9349,"interventions":9350},"NCT01021813","A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)",[89],"2011-05-17","2011-08-01","2009-12-10",781,[9307],[9285,9338],{"nctId":9352,"briefTitle":9353,"status":105,"phases":9354,"primaryCompletion":9355,"completion":9355,"start":9356,"enrollment":9357,"conditions":9358,"interventions":9360},"NCT04571944","Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085)",[89],"2022-12-23","2020-10-22",207,[9359],"Delirium",[9285],{"nctId":9362,"briefTitle":9363,"status":105,"phases":9364,"primaryCompletion":9365,"completion":9365,"start":1996,"enrollment":9366,"conditions":9367,"interventions":9370},"NCT02750306","Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)",[89],"2018-09-30",285,[9368,9369],"Sleep Initiation and Maintenance Disorders","Alzheimer Disease",[9285],{"nctId":9372,"briefTitle":9373,"status":128,"phases":9374,"primaryCompletion":9375,"completion":9375,"start":9376,"enrollment":1570,"conditions":9377,"interventions":9378},"NCT06655883","A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)",[89],"2027-06-24","2025-10-09",[9307],[9285],{"trials":9380,"activeCount":99},[],{"trials":9382,"activeCount":99},[],{"intervention":9384,"totalTrials":3308,"cells":9385},"Molnupiravir",{"EARLY_PHASE1":9386,"PHASE1":9388,"PHASE2":9427,"PHASE3":9440,"PHASE4":9473,"NA":9475},{"trials":9387,"activeCount":99},[],{"trials":9389,"activeCount":99},[9390,9400,9409,9418],{"nctId":9391,"briefTitle":9392,"status":105,"phases":9393,"primaryCompletion":1897,"completion":1897,"start":9394,"enrollment":7797,"conditions":9395,"interventions":9397},"NCT05818124","Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)",[87],"2023-08-21",[9396],"Influenza Infection",[9384,9398,9399],"Oseltamivir","Influenza A Virus",{"nctId":9401,"briefTitle":9402,"status":105,"phases":9403,"primaryCompletion":9404,"completion":9405,"start":9406,"enrollment":287,"conditions":9407,"interventions":9408},"NCT06615869","A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011)",[87],"2023-02-27","2023-03-15","2023-01-20",[18],[9384],{"nctId":9410,"briefTitle":9411,"status":105,"phases":9412,"primaryCompletion":9413,"completion":9414,"start":9415,"enrollment":3655,"conditions":9416,"interventions":9417},"NCT05386758","A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)",[87],"2023-02-04","2023-03-01","2022-06-29",[4074],[9384],{"nctId":9419,"briefTitle":9420,"status":105,"phases":9421,"primaryCompletion":9422,"completion":9423,"start":9424,"enrollment":4071,"conditions":9425,"interventions":9426},"NCT05386589","A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)",[87],"2022-12-18","2023-01-05","2022-06-14",[5595],[9384],{"trials":9428,"activeCount":99},[9429],{"nctId":9430,"briefTitle":9431,"status":105,"phases":9432,"primaryCompletion":9433,"completion":9434,"start":9435,"enrollment":429,"conditions":9436,"interventions":9438},"NCT05559905","Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)",[88],"2023-04-18","2023-06-08","2022-11-02",[9437],"Respiratory Syncytial Virus",[9384,9439],"RSV A Memphis 37b",{"trials":9441,"activeCount":224,"soonestReadout":9454},[9442,9450,9459,9466],{"nctId":9443,"briefTitle":9444,"status":105,"phases":9445,"primaryCompletion":9446,"completion":9446,"start":442,"enrollment":9447,"conditions":9448,"interventions":9449},"NCT04575597","Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)",[88,89],"2022-05-05",1735,[7129],[9384],{"nctId":9451,"briefTitle":9452,"status":128,"phases":9453,"primaryCompletion":9454,"completion":9454,"start":9455,"enrollment":9456,"conditions":9457,"interventions":9458},"NCT06667700","A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)",[89],"2031-01-26","2024-12-02",3082,[7129],[9384],{"nctId":9460,"briefTitle":9461,"status":150,"phases":9462,"primaryCompletion":9463,"completion":9463,"start":442,"enrollment":1997,"conditions":9464,"interventions":9465},"NCT04575584","Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)",[88,89],"2021-08-11",[7129],[9384],{"nctId":9467,"briefTitle":9468,"status":105,"phases":9469,"primaryCompletion":1053,"completion":1053,"start":9463,"enrollment":9470,"conditions":9471,"interventions":9472},"NCT04939428","Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)",[89],2441,[7129],[9384],{"trials":9474,"activeCount":99},[],{"trials":9476,"activeCount":99},[],{"intervention":7295,"totalTrials":3963,"cells":9478},{"EARLY_PHASE1":9479,"PHASE1":9481,"PHASE2":9487,"PHASE3":9489,"PHASE4":9509,"NA":9511},{"trials":9480,"activeCount":99},[],{"trials":9482,"activeCount":99},[9483],{"nctId":7287,"briefTitle":7288,"status":105,"phases":9484,"primaryCompletion":7290,"completion":7291,"start":7292,"enrollment":805,"conditions":9485,"interventions":9486},[87],[18],[7280,7295],{"trials":9488,"activeCount":99},[],{"trials":9490,"activeCount":224,"soonestReadout":7398},[9491,9495,9505],{"nctId":7395,"briefTitle":7396,"status":128,"phases":9492,"primaryCompletion":7398,"completion":7398,"start":7399,"enrollment":7400,"conditions":9493,"interventions":9494},[89],[7342,7343],[7280,7295],{"nctId":9496,"briefTitle":9497,"status":150,"phases":9498,"primaryCompletion":427,"completion":1776,"start":9499,"enrollment":1002,"conditions":9500,"interventions":9504},"NCT04644029","Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)",[89],"2021-02-24",[9501,9502,9503],"HIV-I","Human Immunodeficiency Virus Type 1","Prophylaxis",[7800,7295],{"nctId":8776,"briefTitle":8777,"status":150,"phases":9506,"primaryCompletion":8779,"completion":8779,"start":7073,"enrollment":5349,"conditions":9507,"interventions":9508},[89],[8781],[7662,7295,8783],{"trials":9510,"activeCount":99},[],{"trials":9512,"activeCount":99},[],{"intervention":9514,"totalTrials":202,"cells":9515},"Vericiguat",{"EARLY_PHASE1":9516,"PHASE1":9518,"PHASE2":9520,"PHASE3":9522,"PHASE4":9556,"NA":9558},{"trials":9517,"activeCount":99},[],{"trials":9519,"activeCount":99},[],{"trials":9521,"activeCount":99},[],{"trials":9523,"activeCount":224,"soonestReadout":9549},[9524,9534,9545],{"nctId":9525,"briefTitle":9526,"status":105,"phases":9527,"primaryCompletion":9528,"completion":2504,"start":9529,"enrollment":9530,"conditions":9531,"interventions":9533},"NCT05093933","A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)",[89],"2024-11-20","2021-11-02",6106,[9532],"Chronic Heart Failure With Reduced Ejection Fraction",[9514],{"nctId":9535,"briefTitle":9536,"status":105,"phases":9537,"primaryCompletion":9538,"completion":9539,"start":9540,"enrollment":9541,"conditions":9542,"interventions":9544},"NCT02861534","A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)",[89],"2019-06-18","2019-09-02","2016-09-20",5050,[9543,9532],"Heart Failure",[9514],{"nctId":9546,"briefTitle":9547,"status":128,"phases":9548,"primaryCompletion":9549,"completion":9549,"start":9550,"enrollment":9551,"conditions":9552,"interventions":9554},"NCT05714085","Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)",[88,89],"2032-04-15","2023-05-31",342,[9543,9553],"Left Ventricular Systolic Dysfunction",[9514,9555],"Vericiguat suspension",{"trials":9557,"activeCount":99},[],{"trials":9559,"activeCount":99},[],{"intervention":4259,"totalTrials":202,"cells":9561},{"EARLY_PHASE1":9562,"PHASE1":9564,"PHASE2":9583,"PHASE3":9585,"PHASE4":9591,"NA":9593},{"trials":9563,"activeCount":99},[],{"trials":9565,"activeCount":99},[9566,9570],{"nctId":4249,"briefTitle":4250,"status":105,"phases":9567,"primaryCompletion":4252,"completion":4252,"start":4253,"enrollment":193,"conditions":9568,"interventions":9569},[87],[4255],[4257,4258,4259,4260,1089],{"nctId":9571,"briefTitle":9572,"status":105,"phases":9573,"primaryCompletion":9574,"completion":9574,"start":9575,"enrollment":444,"conditions":9576,"interventions":9577},"NCT03095651","Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)",[87],"2018-01-30","2017-04-12",[4255,15],[9578,9579,9580,9581,4259,9582],"MK-5160 16 nmol\u002Fkg","MK-5160 32 nmol\u002Fkg","MK-5160 64 nmol\u002Fkg","Glargine 0.4 U\u002Fkg","Glargine 0.6 U\u002Fkg",{"trials":9584,"activeCount":99},[],{"trials":9586,"activeCount":224,"soonestReadout":1856},[9587],{"nctId":1853,"briefTitle":1854,"status":139,"phases":9588,"primaryCompletion":1856,"completion":1856,"start":1510,"enrollment":1452,"conditions":9589,"interventions":9590},[89],[1108],[42,1654,1859,1860,1445,1861,1862],{"trials":9592,"activeCount":99},[],{"trials":9594,"activeCount":99},[],{"intervention":9596,"totalTrials":3197,"cells":9597},"Normal Saline",{"EARLY_PHASE1":9598,"PHASE1":9600,"PHASE2":9602,"PHASE3":9604,"PHASE4":9624,"NA":9626},{"trials":9599,"activeCount":99},[],{"trials":9601,"activeCount":99},[],{"trials":9603,"activeCount":99},[],{"trials":9605,"activeCount":224,"soonestReadout":1856},[9606,9620],{"nctId":9607,"briefTitle":9608,"status":150,"phases":9609,"primaryCompletion":5179,"completion":5179,"start":9610,"enrollment":9611,"conditions":9612,"interventions":9618},"NCT00872001","The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633 AM1)(TERMINATED)",[89],"2009-04",3080,[9613,9614,9615,9616,9617],"Coronary Artery Bypass","Myocardial Infarction","Ventricular Dysfunction, Left","Stroke","Cardiopulmonary Bypass",[9619,9596],"Acadesine",{"nctId":1853,"briefTitle":1854,"status":139,"phases":9621,"primaryCompletion":1856,"completion":1856,"start":1510,"enrollment":1452,"conditions":9622,"interventions":9623},[89],[1108],[42,1654,1859,1860,1445,1861,1862],{"trials":9625,"activeCount":99},[],{"trials":9627,"activeCount":99},[],{"intervention":7652,"totalTrials":3197,"cells":9629},{"EARLY_PHASE1":9630,"PHASE1":9632,"PHASE2":9634,"PHASE3":9636,"PHASE4":9646,"NA":9648},{"trials":9631,"activeCount":99},[],{"trials":9633,"activeCount":99},[],{"trials":9635,"activeCount":99},[],{"trials":9637,"activeCount":224,"soonestReadout":7703},[9638,9642],{"nctId":7644,"briefTitle":7645,"status":105,"phases":9639,"primaryCompletion":426,"completion":1926,"start":7647,"enrollment":7648,"conditions":9640,"interventions":9641},[89],[7650],[7617,7652],{"nctId":7700,"briefTitle":7701,"status":139,"phases":9643,"primaryCompletion":7703,"completion":7704,"start":2786,"enrollment":7705,"conditions":9644,"interventions":9645},[89],[7639],[7652,7617],{"trials":9647,"activeCount":99},[],{"trials":9649,"activeCount":99},[],{"intervention":1676,"totalTrials":3197,"cells":9651},{"EARLY_PHASE1":9652,"PHASE1":9654,"PHASE2":9656,"PHASE3":9658,"PHASE4":9668,"NA":9670},{"trials":9653,"activeCount":99},[],{"trials":9655,"activeCount":99},[],{"trials":9657,"activeCount":99},[],{"trials":9659,"activeCount":224,"soonestReadout":3008},[9660,9664],{"nctId":1667,"briefTitle":1668,"status":105,"phases":9661,"primaryCompletion":1670,"completion":1671,"start":1672,"enrollment":1673,"conditions":9662,"interventions":9663},[89],[1563],[42,1654,1676,1677],{"nctId":3005,"briefTitle":3006,"status":128,"phases":9665,"primaryCompletion":3008,"completion":3009,"start":3010,"enrollment":3011,"conditions":9666,"interventions":9667},[89],[1134],[653,3014,967,387,3015,3016],{"trials":9669,"activeCount":99},[],{"trials":9671,"activeCount":99},[],{"intervention":5229,"totalTrials":3197,"cells":9673},{"EARLY_PHASE1":9674,"PHASE1":9676,"PHASE2":9678,"PHASE3":9684,"PHASE4":9690,"NA":9692},{"trials":9675,"activeCount":99},[],{"trials":9677,"activeCount":99},[],{"trials":9679,"activeCount":99},[9680],{"nctId":1017,"briefTitle":1018,"status":105,"phases":9681,"primaryCompletion":1020,"completion":1021,"start":1022,"enrollment":1023,"conditions":9682,"interventions":9683},[88],[369],[47,542,471,1026,1027,713],{"trials":9685,"activeCount":224,"soonestReadout":5222},[9686],{"nctId":5219,"briefTitle":5220,"status":128,"phases":9687,"primaryCompletion":5222,"completion":5223,"start":1520,"enrollment":1452,"conditions":9688,"interventions":9689},[88,89],[5225],[5227,5228,979,5229,529,5230,5231,5232,5233],{"trials":9691,"activeCount":99},[],{"trials":9693,"activeCount":99},[],{"intervention":1730,"totalTrials":3197,"cells":9695},{"EARLY_PHASE1":9696,"PHASE1":9698,"PHASE2":9700,"PHASE3":9702,"PHASE4":9712,"NA":9714},{"trials":9697,"activeCount":99},[],{"trials":9699,"activeCount":99},[],{"trials":9701,"activeCount":99},[],{"trials":9703,"activeCount":224,"soonestReadout":9061},[9704,9708],{"nctId":1719,"briefTitle":1720,"status":105,"phases":9705,"primaryCompletion":1722,"completion":1723,"start":1724,"enrollment":1725,"conditions":9706,"interventions":9707},[89],[1727],[461,47,1729,1730],{"nctId":9058,"briefTitle":9059,"status":139,"phases":9709,"primaryCompletion":9061,"completion":9062,"start":9063,"enrollment":9064,"conditions":9710,"interventions":9711},[89],[9066],[9037,1730,9056,9068],{"trials":9713,"activeCount":99},[],{"trials":9715,"activeCount":99},[],{"intervention":8161,"totalTrials":3197,"cells":9717},{"EARLY_PHASE1":9718,"PHASE1":9720,"PHASE2":9726,"PHASE3":9728,"PHASE4":9734,"NA":9736},{"trials":9719,"activeCount":99},[],{"trials":9721,"activeCount":99},[9722],{"nctId":8149,"briefTitle":8150,"status":105,"phases":9723,"primaryCompletion":2634,"completion":2634,"start":8152,"enrollment":28,"conditions":9724,"interventions":9725},[87],[279,314,1552],[8155,8156,84,8143,8145,8157,8158,8146,8159,8160,8161,8162],{"trials":9727,"activeCount":99},[],{"trials":9729,"activeCount":224,"soonestReadout":8187},[9730],{"nctId":8184,"briefTitle":8185,"status":139,"phases":9731,"primaryCompletion":8187,"completion":8187,"start":8188,"enrollment":7648,"conditions":9732,"interventions":9733},[89],[1552],[84,8191,8192,8192,8193,8161,8194],{"trials":9735,"activeCount":99},[],{"trials":9737,"activeCount":99},[],{"intervention":4388,"totalTrials":3197,"cells":9739},{"EARLY_PHASE1":9740,"PHASE1":9742,"PHASE2":9748,"PHASE3":9750,"PHASE4":9756,"NA":9758},{"trials":9741,"activeCount":99},[],{"trials":9743,"activeCount":99},[9744],{"nctId":7014,"briefTitle":7015,"status":150,"phases":9745,"primaryCompletion":7017,"completion":7017,"start":7018,"enrollment":920,"conditions":9746,"interventions":9747},[87],[7020],[5481,7022,2100,7023,4388,979,7024],{"trials":9749,"activeCount":99},[],{"trials":9751,"activeCount":224,"soonestReadout":762},[9752],{"nctId":4381,"briefTitle":4382,"status":128,"phases":9753,"primaryCompletion":762,"completion":4384,"start":1610,"enrollment":4385,"conditions":9754,"interventions":9755},[89],[676],[1058,4349,562,1069,4350,1076,2413,1074,1089,4388],{"trials":9757,"activeCount":99},[],{"trials":9759,"activeCount":99},[],{"intervention":1886,"totalTrials":3197,"cells":9761},{"EARLY_PHASE1":9762,"PHASE1":9764,"PHASE2":9766,"PHASE3":9768,"PHASE4":9778,"NA":9780},{"trials":9763,"activeCount":99},[],{"trials":9765,"activeCount":99},[],{"trials":9767,"activeCount":99},[],{"trials":9769,"activeCount":224,"soonestReadout":3620},[9770,9774],{"nctId":1874,"briefTitle":1875,"status":105,"phases":9771,"primaryCompletion":1877,"completion":1878,"start":1879,"enrollment":1880,"conditions":9772,"interventions":9773},[89],[1882],[42,1445,1884,1885,1886],{"nctId":3617,"briefTitle":3618,"status":139,"phases":9775,"primaryCompletion":3620,"completion":3620,"start":477,"enrollment":3621,"conditions":9776,"interventions":9777},[89],[863],[794,385,3624,3625,3626,714,437],{"trials":9779,"activeCount":99},[],{"trials":9781,"activeCount":99},[],{"intervention":3625,"totalTrials":3197,"cells":9783},{"EARLY_PHASE1":9784,"PHASE1":9786,"PHASE2":9788,"PHASE3":9794,"PHASE4":9800,"NA":9802},{"trials":9785,"activeCount":99},[],{"trials":9787,"activeCount":99},[],{"trials":9789,"activeCount":99},[9790],{"nctId":3701,"briefTitle":3702,"status":150,"phases":9791,"primaryCompletion":3704,"completion":3704,"start":3705,"enrollment":357,"conditions":9792,"interventions":9793},[87,88],[863],[2894,3625,390],{"trials":9795,"activeCount":224,"soonestReadout":3620},[9796],{"nctId":3617,"briefTitle":3618,"status":139,"phases":9797,"primaryCompletion":3620,"completion":3620,"start":477,"enrollment":3621,"conditions":9798,"interventions":9799},[89],[863],[794,385,3624,3625,3626,714,437],{"trials":9801,"activeCount":99},[],{"trials":9803,"activeCount":99},[],{"intervention":74,"totalTrials":3197,"cells":9805},{"EARLY_PHASE1":9806,"PHASE1":9808,"PHASE2":9810,"PHASE3":9816,"PHASE4":9822,"NA":9824},{"trials":9807,"activeCount":99},[],{"trials":9809,"activeCount":99},[],{"trials":9811,"activeCount":99},[9812],{"nctId":1277,"briefTitle":1278,"status":105,"phases":9813,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":1282,"conditions":9814,"interventions":9815},[88],[1284,1285,965,1286,856,791,540,1014,1287,1288,1289],[74,47,461,797,390,387,714,386,967,841,795,434],{"trials":9817,"activeCount":224,"soonestReadout":73},[9818],{"nctId":71,"briefTitle":72,"status":139,"phases":9819,"primaryCompletion":73,"completion":2398,"start":1796,"enrollment":836,"conditions":9820,"interventions":9821},[89],[866],[74,3375,1073,390,3267,386],{"trials":9823,"activeCount":99},[],{"trials":9825,"activeCount":99},[],{"intervention":3375,"totalTrials":3197,"cells":9827},{"EARLY_PHASE1":9828,"PHASE1":9830,"PHASE2":9832,"PHASE3":9834,"PHASE4":9844,"NA":9846},{"trials":9829,"activeCount":99},[],{"trials":9831,"activeCount":99},[],{"trials":9833,"activeCount":99},[],{"trials":9835,"activeCount":224,"soonestReadout":73},[9836,9840],{"nctId":71,"briefTitle":72,"status":139,"phases":9837,"primaryCompletion":73,"completion":2398,"start":1796,"enrollment":836,"conditions":9838,"interventions":9839},[89],[866],[74,3375,1073,390,3267,386],{"nctId":2708,"briefTitle":2709,"status":105,"phases":9841,"primaryCompletion":2711,"completion":1794,"start":2712,"enrollment":2713,"conditions":9842,"interventions":9843},[89],[1727],[1369,42,2716],{"trials":9845,"activeCount":99},[],{"trials":9847,"activeCount":99},[],{"intervention":9849,"totalTrials":3197,"cells":9850},"MK-8591A",{"EARLY_PHASE1":9851,"PHASE1":9853,"PHASE2":9863,"PHASE3":9865,"PHASE4":9876,"NA":9878},{"trials":9852,"activeCount":99},[],{"trials":9854,"activeCount":99},[9855],{"nctId":9856,"briefTitle":9857,"status":105,"phases":9858,"primaryCompletion":453,"completion":453,"start":9859,"enrollment":120,"conditions":9860,"interventions":9861},"NCT06719570","A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)",[87],"2024-01-23",[18],[9849,7800,9862],"Doravine",{"trials":9864,"activeCount":99},[],{"trials":9866,"activeCount":224,"soonestReadout":9871},[9867],{"nctId":9868,"briefTitle":9869,"status":139,"phases":9870,"primaryCompletion":9871,"completion":9871,"start":9872,"enrollment":9873,"conditions":9874,"interventions":9875},"NCT04776252","Open-label, Follow-up of Doravirine\u002FIslatravir (DOR\u002FISL 100 mg\u002F0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)",[89],"2029-05-29","2021-09-15",2000,[7639],[9849],{"trials":9877,"activeCount":99},[],{"trials":9879,"activeCount":99},[],{"intervention":2941,"totalTrials":224,"cells":9881},{"EARLY_PHASE1":9882,"PHASE1":9884,"PHASE2":9886,"PHASE3":9888,"PHASE4":9894,"NA":9896},{"trials":9883,"activeCount":99},[],{"trials":9885,"activeCount":99},[],{"trials":9887,"activeCount":99},[],{"trials":9889,"activeCount":224,"soonestReadout":2937},[9890],{"nctId":2934,"briefTitle":2935,"status":128,"phases":9891,"primaryCompletion":2937,"completion":2937,"start":2938,"enrollment":1633,"conditions":9892,"interventions":9893},[89],[1108],[1111,387,388,795,2207,2941],{"trials":9895,"activeCount":99},[],{"trials":9897,"activeCount":99},[],{"intervention":5228,"totalTrials":224,"cells":9899},{"EARLY_PHASE1":9900,"PHASE1":9902,"PHASE2":9904,"PHASE3":9906,"PHASE4":9912,"NA":9914},{"trials":9901,"activeCount":99},[],{"trials":9903,"activeCount":99},[],{"trials":9905,"activeCount":99},[],{"trials":9907,"activeCount":224,"soonestReadout":5222},[9908],{"nctId":5219,"briefTitle":5220,"status":128,"phases":9909,"primaryCompletion":5222,"completion":5223,"start":1520,"enrollment":1452,"conditions":9910,"interventions":9911},[88,89],[5225],[5227,5228,979,5229,529,5230,5231,5232,5233],{"trials":9913,"activeCount":99},[],{"trials":9915,"activeCount":99},[],{"intervention":5230,"totalTrials":224,"cells":9917},{"EARLY_PHASE1":9918,"PHASE1":9920,"PHASE2":9922,"PHASE3":9924,"PHASE4":9930,"NA":9932},{"trials":9919,"activeCount":99},[],{"trials":9921,"activeCount":99},[],{"trials":9923,"activeCount":99},[],{"trials":9925,"activeCount":224,"soonestReadout":5222},[9926],{"nctId":5219,"briefTitle":5220,"status":128,"phases":9927,"primaryCompletion":5222,"completion":5223,"start":1520,"enrollment":1452,"conditions":9928,"interventions":9929},[88,89],[5225],[5227,5228,979,5229,529,5230,5231,5232,5233],{"trials":9931,"activeCount":99},[],{"trials":9933,"activeCount":99},[],{"intervention":5231,"totalTrials":224,"cells":9935},{"EARLY_PHASE1":9936,"PHASE1":9938,"PHASE2":9940,"PHASE3":9942,"PHASE4":9948,"NA":9950},{"trials":9937,"activeCount":99},[],{"trials":9939,"activeCount":99},[],{"trials":9941,"activeCount":99},[],{"trials":9943,"activeCount":224,"soonestReadout":5222},[9944],{"nctId":5219,"briefTitle":5220,"status":128,"phases":9945,"primaryCompletion":5222,"completion":5223,"start":1520,"enrollment":1452,"conditions":9946,"interventions":9947},[88,89],[5225],[5227,5228,979,5229,529,5230,5231,5232,5233],{"trials":9949,"activeCount":99},[],{"trials":9951,"activeCount":99},[],{"intervention":5232,"totalTrials":224,"cells":9953},{"EARLY_PHASE1":9954,"PHASE1":9956,"PHASE2":9958,"PHASE3":9960,"PHASE4":9966,"NA":9968},{"trials":9955,"activeCount":99},[],{"trials":9957,"activeCount":99},[],{"trials":9959,"activeCount":99},[],{"trials":9961,"activeCount":224,"soonestReadout":5222},[9962],{"nctId":5219,"briefTitle":5220,"status":128,"phases":9963,"primaryCompletion":5222,"completion":5223,"start":1520,"enrollment":1452,"conditions":9964,"interventions":9965},[88,89],[5225],[5227,5228,979,5229,529,5230,5231,5232,5233],{"trials":9967,"activeCount":99},[],{"trials":9969,"activeCount":99},[],{"intervention":5233,"totalTrials":224,"cells":9971},{"EARLY_PHASE1":9972,"PHASE1":9974,"PHASE2":9976,"PHASE3":9978,"PHASE4":9984,"NA":9986},{"trials":9973,"activeCount":99},[],{"trials":9975,"activeCount":99},[],{"trials":9977,"activeCount":99},[],{"trials":9979,"activeCount":224,"soonestReadout":5222},[9980],{"nctId":5219,"briefTitle":5220,"status":128,"phases":9981,"primaryCompletion":5222,"completion":5223,"start":1520,"enrollment":1452,"conditions":9982,"interventions":9983},[88,89],[5225],[5227,5228,979,5229,529,5230,5231,5232,5233],{"trials":9985,"activeCount":99},[],{"trials":9987,"activeCount":99},[],{"intervention":8191,"totalTrials":224,"cells":9989},{"EARLY_PHASE1":9990,"PHASE1":9992,"PHASE2":9994,"PHASE3":9996,"PHASE4":10002,"NA":10004},{"trials":9991,"activeCount":99},[],{"trials":9993,"activeCount":99},[],{"trials":9995,"activeCount":99},[],{"trials":9997,"activeCount":224,"soonestReadout":8187},[9998],{"nctId":8184,"briefTitle":8185,"status":139,"phases":9999,"primaryCompletion":8187,"completion":8187,"start":8188,"enrollment":7648,"conditions":10000,"interventions":10001},[89],[1552],[84,8191,8192,8192,8193,8161,8194],{"trials":10003,"activeCount":99},[],{"trials":10005,"activeCount":99},[],{"intervention":8192,"totalTrials":224,"cells":10007},{"EARLY_PHASE1":10008,"PHASE1":10010,"PHASE2":10012,"PHASE3":10014,"PHASE4":10020,"NA":10022},{"trials":10009,"activeCount":99},[],{"trials":10011,"activeCount":99},[],{"trials":10013,"activeCount":99},[],{"trials":10015,"activeCount":224,"soonestReadout":8187},[10016],{"nctId":8184,"briefTitle":8185,"status":139,"phases":10017,"primaryCompletion":8187,"completion":8187,"start":8188,"enrollment":7648,"conditions":10018,"interventions":10019},[89],[1552],[84,8191,8192,8192,8193,8161,8194],{"trials":10021,"activeCount":99},[],{"trials":10023,"activeCount":99},[],{"intervention":8193,"totalTrials":224,"cells":10025},{"EARLY_PHASE1":10026,"PHASE1":10028,"PHASE2":10030,"PHASE3":10032,"PHASE4":10038,"NA":10040},{"trials":10027,"activeCount":99},[],{"trials":10029,"activeCount":99},[],{"trials":10031,"activeCount":99},[],{"trials":10033,"activeCount":224,"soonestReadout":8187},[10034],{"nctId":8184,"briefTitle":8185,"status":139,"phases":10035,"primaryCompletion":8187,"completion":8187,"start":8188,"enrollment":7648,"conditions":10036,"interventions":10037},[89],[1552],[84,8191,8192,8192,8193,8161,8194],{"trials":10039,"activeCount":99},[],{"trials":10041,"activeCount":99},[],{"intervention":8194,"totalTrials":224,"cells":10043},{"EARLY_PHASE1":10044,"PHASE1":10046,"PHASE2":10048,"PHASE3":10050,"PHASE4":10056,"NA":10058},{"trials":10045,"activeCount":99},[],{"trials":10047,"activeCount":99},[],{"trials":10049,"activeCount":99},[],{"trials":10051,"activeCount":224,"soonestReadout":8187},[10052],{"nctId":8184,"briefTitle":8185,"status":139,"phases":10053,"primaryCompletion":8187,"completion":8187,"start":8188,"enrollment":7648,"conditions":10054,"interventions":10055},[89],[1552],[84,8191,8192,8192,8193,8161,8194],{"trials":10057,"activeCount":99},[],{"trials":10059,"activeCount":99},[],{"intervention":5542,"totalTrials":224,"cells":10061},{"EARLY_PHASE1":10062,"PHASE1":10064,"PHASE2":10066,"PHASE3":10068,"PHASE4":10074,"NA":10076},{"trials":10063,"activeCount":99},[],{"trials":10065,"activeCount":99},[],{"trials":10067,"activeCount":99},[],{"trials":10069,"activeCount":224,"soonestReadout":5534},[10070],{"nctId":5531,"briefTitle":5532,"status":139,"phases":10071,"primaryCompletion":5534,"completion":5535,"start":5536,"enrollment":1570,"conditions":10072,"interventions":10073},[89],[5538,5539],[5541,5542,562,5081,4349,5543,5544,5545],{"trials":10075,"activeCount":99},[],{"trials":10077,"activeCount":99},[],{"intervention":5543,"totalTrials":224,"cells":10079},{"EARLY_PHASE1":10080,"PHASE1":10082,"PHASE2":10084,"PHASE3":10086,"PHASE4":10092,"NA":10094},{"trials":10081,"activeCount":99},[],{"trials":10083,"activeCount":99},[],{"trials":10085,"activeCount":99},[],{"trials":10087,"activeCount":224,"soonestReadout":5534},[10088],{"nctId":5531,"briefTitle":5532,"status":139,"phases":10089,"primaryCompletion":5534,"completion":5535,"start":5536,"enrollment":1570,"conditions":10090,"interventions":10091},[89],[5538,5539],[5541,5542,562,5081,4349,5543,5544,5545],{"trials":10093,"activeCount":99},[],{"trials":10095,"activeCount":99},[],{"intervention":5544,"totalTrials":224,"cells":10097},{"EARLY_PHASE1":10098,"PHASE1":10100,"PHASE2":10102,"PHASE3":10104,"PHASE4":10110,"NA":10112},{"trials":10099,"activeCount":99},[],{"trials":10101,"activeCount":99},[],{"trials":10103,"activeCount":99},[],{"trials":10105,"activeCount":224,"soonestReadout":5534},[10106],{"nctId":5531,"briefTitle":5532,"status":139,"phases":10107,"primaryCompletion":5534,"completion":5535,"start":5536,"enrollment":1570,"conditions":10108,"interventions":10109},[89],[5538,5539],[5541,5542,562,5081,4349,5543,5544,5545],{"trials":10111,"activeCount":99},[],{"trials":10113,"activeCount":99},[],{"intervention":5545,"totalTrials":224,"cells":10115},{"EARLY_PHASE1":10116,"PHASE1":10118,"PHASE2":10120,"PHASE3":10122,"PHASE4":10128,"NA":10130},{"trials":10117,"activeCount":99},[],{"trials":10119,"activeCount":99},[],{"trials":10121,"activeCount":99},[],{"trials":10123,"activeCount":224,"soonestReadout":5534},[10124],{"nctId":5531,"briefTitle":5532,"status":139,"phases":10125,"primaryCompletion":5534,"completion":5535,"start":5536,"enrollment":1570,"conditions":10126,"interventions":10127},[89],[5538,5539],[5541,5542,562,5081,4349,5543,5544,5545],{"trials":10129,"activeCount":99},[],{"trials":10131,"activeCount":99},[],{"intervention":5405,"totalTrials":224,"cells":10133},{"EARLY_PHASE1":10134,"PHASE1":10136,"PHASE2":10138,"PHASE3":10140,"PHASE4":10146,"NA":10148},{"trials":10135,"activeCount":99},[],{"trials":10137,"activeCount":99},[],{"trials":10139,"activeCount":99},[],{"trials":10141,"activeCount":224,"soonestReadout":5398},[10142],{"nctId":5395,"briefTitle":5396,"status":128,"phases":10143,"primaryCompletion":5398,"completion":5399,"start":5400,"enrollment":277,"conditions":10144,"interventions":10145},[89],[5402,5403],[602,434,5405,797,693,841,5406],{"trials":10147,"activeCount":99},[],{"trials":10149,"activeCount":99},[],{"intervention":5406,"totalTrials":224,"cells":10151},{"EARLY_PHASE1":10152,"PHASE1":10154,"PHASE2":10156,"PHASE3":10158,"PHASE4":10164,"NA":10166},{"trials":10153,"activeCount":99},[],{"trials":10155,"activeCount":99},[],{"trials":10157,"activeCount":99},[],{"trials":10159,"activeCount":224,"soonestReadout":5398},[10160],{"nctId":5395,"briefTitle":5396,"status":128,"phases":10161,"primaryCompletion":5398,"completion":5399,"start":5400,"enrollment":277,"conditions":10162,"interventions":10163},[89],[5402,5403],[602,434,5405,797,693,841,5406],{"trials":10165,"activeCount":99},[],{"trials":10167,"activeCount":99},[],{"intervention":5267,"totalTrials":224,"cells":10169},{"EARLY_PHASE1":10170,"PHASE1":10172,"PHASE2":10174,"PHASE3":10176,"PHASE4":10182,"NA":10184},{"trials":10171,"activeCount":99},[],{"trials":10173,"activeCount":99},[],{"trials":10175,"activeCount":99},[],{"trials":10177,"activeCount":224,"soonestReadout":5260},[10178],{"nctId":5257,"briefTitle":5258,"status":128,"phases":10179,"primaryCompletion":5260,"completion":5261,"start":5262,"enrollment":5263,"conditions":10180,"interventions":10181},[89],[5265,2410],[4775,529,4777,5126,2412,5267,2382],{"trials":10183,"activeCount":99},[],{"trials":10185,"activeCount":99},[],{"intervention":8252,"totalTrials":224,"cells":10187},{"EARLY_PHASE1":10188,"PHASE1":10190,"PHASE2":10192,"PHASE3":10194,"PHASE4":10200,"NA":10202},{"trials":10189,"activeCount":99},[],{"trials":10191,"activeCount":99},[],{"trials":10193,"activeCount":99},[],{"trials":10195,"activeCount":224,"soonestReadout":8247},[10196],{"nctId":8244,"briefTitle":8245,"status":128,"phases":10197,"primaryCompletion":8247,"completion":8248,"start":5240,"enrollment":1452,"conditions":10198,"interventions":10199},[89],[8250],[8216,8252,8253,8254,8255],{"trials":10201,"activeCount":99},[],{"trials":10203,"activeCount":99},[],{"intervention":8253,"totalTrials":224,"cells":10205},{"EARLY_PHASE1":10206,"PHASE1":10208,"PHASE2":10210,"PHASE3":10212,"PHASE4":10218,"NA":10220},{"trials":10207,"activeCount":99},[],{"trials":10209,"activeCount":99},[],{"trials":10211,"activeCount":99},[],{"trials":10213,"activeCount":224,"soonestReadout":8247},[10214],{"nctId":8244,"briefTitle":8245,"status":128,"phases":10215,"primaryCompletion":8247,"completion":8248,"start":5240,"enrollment":1452,"conditions":10216,"interventions":10217},[89],[8250],[8216,8252,8253,8254,8255],{"trials":10219,"activeCount":99},[],{"trials":10221,"activeCount":99},[],{"intervention":8254,"totalTrials":224,"cells":10223},{"EARLY_PHASE1":10224,"PHASE1":10226,"PHASE2":10228,"PHASE3":10230,"PHASE4":10236,"NA":10238},{"trials":10225,"activeCount":99},[],{"trials":10227,"activeCount":99},[],{"trials":10229,"activeCount":99},[],{"trials":10231,"activeCount":224,"soonestReadout":8247},[10232],{"nctId":8244,"briefTitle":8245,"status":128,"phases":10233,"primaryCompletion":8247,"completion":8248,"start":5240,"enrollment":1452,"conditions":10234,"interventions":10235},[89],[8250],[8216,8252,8253,8254,8255],{"trials":10237,"activeCount":99},[],{"trials":10239,"activeCount":99},[],{"intervention":8255,"totalTrials":224,"cells":10241},{"EARLY_PHASE1":10242,"PHASE1":10244,"PHASE2":10246,"PHASE3":10248,"PHASE4":10254,"NA":10256},{"trials":10243,"activeCount":99},[],{"trials":10245,"activeCount":99},[],{"trials":10247,"activeCount":99},[],{"trials":10249,"activeCount":224,"soonestReadout":8247},[10250],{"nctId":8244,"briefTitle":8245,"status":128,"phases":10251,"primaryCompletion":8247,"completion":8248,"start":5240,"enrollment":1452,"conditions":10252,"interventions":10253},[89],[8250],[8216,8252,8253,8254,8255],{"trials":10255,"activeCount":99},[],{"trials":10257,"activeCount":99},[],{"intervention":5656,"totalTrials":224,"cells":10259},{"EARLY_PHASE1":10260,"PHASE1":10262,"PHASE2":10264,"PHASE3":10266,"PHASE4":10272,"NA":10274},{"trials":10261,"activeCount":99},[],{"trials":10263,"activeCount":99},[],{"trials":10265,"activeCount":99},[],{"trials":10267,"activeCount":224,"soonestReadout":5652},[10268],{"nctId":5649,"briefTitle":5650,"status":128,"phases":10269,"primaryCompletion":5652,"completion":5652,"start":5653,"enrollment":1150,"conditions":10270,"interventions":10271},[89],[314],[602,5656],{"trials":10273,"activeCount":99},[],{"trials":10275,"activeCount":99},[],{"intervention":8206,"totalTrials":224,"cells":10277},{"EARLY_PHASE1":10278,"PHASE1":10280,"PHASE2":10282,"PHASE3":10284,"PHASE4":10290,"NA":10292},{"trials":10279,"activeCount":99},[],{"trials":10281,"activeCount":99},[],{"trials":10283,"activeCount":99},[],{"trials":10285,"activeCount":224,"soonestReadout":83},[10286],{"nctId":81,"briefTitle":82,"status":139,"phases":10287,"primaryCompletion":83,"completion":8201,"start":8202,"enrollment":8203,"conditions":10288,"interventions":10289},[89],[2482],[84,8206],{"trials":10291,"activeCount":99},[],{"trials":10293,"activeCount":99},[],{"intervention":79,"totalTrials":224,"cells":10295},{"EARLY_PHASE1":10296,"PHASE1":10298,"PHASE2":10300,"PHASE3":10302,"PHASE4":10308,"NA":10310},{"trials":10297,"activeCount":99},[],{"trials":10299,"activeCount":99},[],{"trials":10301,"activeCount":99},[],{"trials":10303,"activeCount":224,"soonestReadout":78},[10304],{"nctId":76,"briefTitle":77,"status":139,"phases":10305,"primaryCompletion":78,"completion":2070,"start":2071,"enrollment":2072,"conditions":10306,"interventions":10307},[89],[2074],[79,385,390,386,387,388,47,2076,2077],{"trials":10309,"activeCount":99},[],{"trials":10311,"activeCount":99},[],{"intervention":8265,"totalTrials":224,"cells":10313},{"EARLY_PHASE1":10314,"PHASE1":10316,"PHASE2":10318,"PHASE3":10320,"PHASE4":10326,"NA":10328},{"trials":10315,"activeCount":99},[],{"trials":10317,"activeCount":99},[],{"trials":10319,"activeCount":99},[],{"trials":10321,"activeCount":224,"soonestReadout":8260},[10322],{"nctId":8257,"briefTitle":8258,"status":128,"phases":10323,"primaryCompletion":8260,"completion":8261,"start":8262,"enrollment":1570,"conditions":10324,"interventions":10325},[89],[8250],[8216,8265,8266,8267],{"trials":10327,"activeCount":99},[],{"trials":10329,"activeCount":99},[],{"intervention":8266,"totalTrials":224,"cells":10331},{"EARLY_PHASE1":10332,"PHASE1":10334,"PHASE2":10336,"PHASE3":10338,"PHASE4":10344,"NA":10346},{"trials":10333,"activeCount":99},[],{"trials":10335,"activeCount":99},[],{"trials":10337,"activeCount":99},[],{"trials":10339,"activeCount":224,"soonestReadout":8260},[10340],{"nctId":8257,"briefTitle":8258,"status":128,"phases":10341,"primaryCompletion":8260,"completion":8261,"start":8262,"enrollment":1570,"conditions":10342,"interventions":10343},[89],[8250],[8216,8265,8266,8267],{"trials":10345,"activeCount":99},[],{"trials":10347,"activeCount":99},[],{"intervention":8267,"totalTrials":224,"cells":10349},{"EARLY_PHASE1":10350,"PHASE1":10352,"PHASE2":10354,"PHASE3":10356,"PHASE4":10362,"NA":10364},{"trials":10351,"activeCount":99},[],{"trials":10353,"activeCount":99},[],{"trials":10355,"activeCount":99},[],{"trials":10357,"activeCount":224,"soonestReadout":8260},[10358],{"nctId":8257,"briefTitle":8258,"status":128,"phases":10359,"primaryCompletion":8260,"completion":8261,"start":8262,"enrollment":1570,"conditions":10360,"interventions":10361},[89],[8250],[8216,8265,8266,8267],{"trials":10363,"activeCount":99},[],{"trials":10365,"activeCount":99},[],{"intervention":7412,"totalTrials":224,"cells":10367},{"EARLY_PHASE1":10368,"PHASE1":10370,"PHASE2":10372,"PHASE3":10374,"PHASE4":10380,"NA":10382},{"trials":10369,"activeCount":99},[],{"trials":10371,"activeCount":99},[],{"trials":10373,"activeCount":99},[],{"trials":10375,"activeCount":224,"soonestReadout":7407},[10376],{"nctId":7404,"briefTitle":7405,"status":128,"phases":10377,"primaryCompletion":7407,"completion":7407,"start":7408,"enrollment":7409,"conditions":10378,"interventions":10379},[89],[7342,7343],[7280,7412],{"trials":10381,"activeCount":99},[],{"trials":10383,"activeCount":99},[],{"intervention":2141,"totalTrials":224,"cells":10385},{"EARLY_PHASE1":10386,"PHASE1":10388,"PHASE2":10390,"PHASE3":10392,"PHASE4":10398,"NA":10400},{"trials":10387,"activeCount":99},[],{"trials":10389,"activeCount":99},[],{"trials":10391,"activeCount":99},[],{"trials":10393,"activeCount":224,"soonestReadout":2136},[10394],{"nctId":2133,"briefTitle":2134,"status":139,"phases":10395,"primaryCompletion":2136,"completion":2136,"start":2137,"enrollment":2138,"conditions":10396,"interventions":10397},[89],[1109],[47,387,1069,1664,562,2141],{"trials":10399,"activeCount":99},[],{"trials":10401,"activeCount":99},[],{"intervention":3015,"totalTrials":224,"cells":10403},{"EARLY_PHASE1":10404,"PHASE1":10406,"PHASE2":10408,"PHASE3":10410,"PHASE4":10416,"NA":10418},{"trials":10405,"activeCount":99},[],{"trials":10407,"activeCount":99},[],{"trials":10409,"activeCount":99},[],{"trials":10411,"activeCount":224,"soonestReadout":3008},[10412],{"nctId":3005,"briefTitle":3006,"status":128,"phases":10413,"primaryCompletion":3008,"completion":3009,"start":3010,"enrollment":3011,"conditions":10414,"interventions":10415},[89],[1134],[653,3014,967,387,3015,3016],{"trials":10417,"activeCount":99},[],{"trials":10419,"activeCount":99},[],{"intervention":3016,"totalTrials":224,"cells":10421},{"EARLY_PHASE1":10422,"PHASE1":10424,"PHASE2":10426,"PHASE3":10428,"PHASE4":10434,"NA":10436},{"trials":10423,"activeCount":99},[],{"trials":10425,"activeCount":99},[],{"trials":10427,"activeCount":99},[],{"trials":10429,"activeCount":224,"soonestReadout":3008},[10430],{"nctId":3005,"briefTitle":3006,"status":128,"phases":10431,"primaryCompletion":3008,"completion":3009,"start":3010,"enrollment":3011,"conditions":10432,"interventions":10433},[89],[1134],[653,3014,967,387,3015,3016],{"trials":10435,"activeCount":99},[],{"trials":10437,"activeCount":99},[],{"intervention":3624,"totalTrials":224,"cells":10439},{"EARLY_PHASE1":10440,"PHASE1":10442,"PHASE2":10444,"PHASE3":10446,"PHASE4":10452,"NA":10454},{"trials":10441,"activeCount":99},[],{"trials":10443,"activeCount":99},[],{"trials":10445,"activeCount":99},[],{"trials":10447,"activeCount":224,"soonestReadout":3620},[10448],{"nctId":3617,"briefTitle":3618,"status":139,"phases":10449,"primaryCompletion":3620,"completion":3620,"start":477,"enrollment":3621,"conditions":10450,"interventions":10451},[89],[863],[794,385,3624,3625,3626,714,437],{"trials":10453,"activeCount":99},[],{"trials":10455,"activeCount":99},[],{"intervention":6275,"totalTrials":224,"cells":10457},{"EARLY_PHASE1":10458,"PHASE1":10460,"PHASE2":10462,"PHASE3":10464,"PHASE4":10470,"NA":10472},{"trials":10459,"activeCount":99},[],{"trials":10461,"activeCount":99},[],{"trials":10463,"activeCount":99},[],{"trials":10465,"activeCount":224,"soonestReadout":6271},[10466],{"nctId":6268,"briefTitle":6269,"status":128,"phases":10467,"primaryCompletion":6271,"completion":6271,"start":6272,"enrollment":2204,"conditions":10468,"interventions":10469},[89],[5538,5539],[5541,6275,6276],{"trials":10471,"activeCount":99},[],{"trials":10473,"activeCount":99},[],{"intervention":6276,"totalTrials":224,"cells":10475},{"EARLY_PHASE1":10476,"PHASE1":10478,"PHASE2":10480,"PHASE3":10482,"PHASE4":10488,"NA":10490},{"trials":10477,"activeCount":99},[],{"trials":10479,"activeCount":99},[],{"trials":10481,"activeCount":99},[],{"trials":10483,"activeCount":224,"soonestReadout":6271},[10484],{"nctId":6268,"briefTitle":6269,"status":128,"phases":10485,"primaryCompletion":6271,"completion":6271,"start":6272,"enrollment":2204,"conditions":10486,"interventions":10487},[89],[5538,5539],[5541,6275,6276],{"trials":10489,"activeCount":99},[],{"trials":10491,"activeCount":99},[],{"intervention":10493,"totalTrials":224,"cells":10494},"V181",{"EARLY_PHASE1":10495,"PHASE1":10497,"PHASE2":10499,"PHASE3":10501,"PHASE4":10512,"NA":10514},{"trials":10496,"activeCount":99},[],{"trials":10498,"activeCount":99},[],{"trials":10500,"activeCount":99},[],{"trials":10502,"activeCount":224,"soonestReadout":10507},[10503],{"nctId":10504,"briefTitle":10505,"status":128,"phases":10506,"primaryCompletion":10507,"completion":10507,"start":10508,"enrollment":10509,"conditions":10510,"interventions":10511},"NCT07013487","A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005\u002FMOBILIZE-1)",[89],"2031-10-24","2025-06-11",12000,[18],[10493],{"trials":10513,"activeCount":99},[],{"trials":10515,"activeCount":99},[],{"intervention":2308,"totalTrials":224,"cells":10517},{"EARLY_PHASE1":10518,"PHASE1":10520,"PHASE2":10522,"PHASE3":10524,"PHASE4":10530,"NA":10532},{"trials":10519,"activeCount":99},[],{"trials":10521,"activeCount":99},[],{"trials":10523,"activeCount":99},[],{"trials":10525,"activeCount":224,"soonestReadout":2303},[10526],{"nctId":2300,"briefTitle":2301,"status":139,"phases":10527,"primaryCompletion":2303,"completion":2304,"start":2305,"enrollment":1685,"conditions":10528,"interventions":10529},[89],[369],[2308,47],{"trials":10531,"activeCount":99},[],{"trials":10533,"activeCount":99},[],{"intervention":5082,"totalTrials":224,"cells":10535},{"EARLY_PHASE1":10536,"PHASE1":10538,"PHASE2":10540,"PHASE3":10542,"PHASE4":10548,"NA":10550},{"trials":10537,"activeCount":99},[],{"trials":10539,"activeCount":99},[],{"trials":10541,"activeCount":99},[],{"trials":10543,"activeCount":224,"soonestReadout":5075},[10544],{"nctId":5072,"briefTitle":5073,"status":128,"phases":10545,"primaryCompletion":5075,"completion":5075,"start":5076,"enrollment":5077,"conditions":10546,"interventions":10547},[88,89],[5079,676],[1058,4349,714,434,5081,5082],{"trials":10549,"activeCount":99},[],{"trials":10551,"activeCount":99},[],{"intervention":10553,"totalTrials":224,"cells":10554},"Intismeran",{"EARLY_PHASE1":10555,"PHASE1":10557,"PHASE2":10559,"PHASE3":10561,"PHASE4":10573,"NA":10575},{"trials":10556,"activeCount":99},[],{"trials":10558,"activeCount":99},[],{"trials":10560,"activeCount":99},[],{"trials":10562,"activeCount":224,"soonestReadout":10567},[10563],{"nctId":10564,"briefTitle":10565,"status":128,"phases":10566,"primaryCompletion":10567,"completion":10568,"start":6168,"enrollment":10569,"conditions":10570,"interventions":10571},"NCT07513376","A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)",[89],"2034-08-22","2038-05-11",876,[314],[10553,10572],"Pembrolizumab coformulated with berahyaluronidase alfa",{"trials":10574,"activeCount":99},[],{"trials":10576,"activeCount":99},[],{"intervention":10572,"totalTrials":224,"cells":10578},{"EARLY_PHASE1":10579,"PHASE1":10581,"PHASE2":10583,"PHASE3":10585,"PHASE4":10591,"NA":10593},{"trials":10580,"activeCount":99},[],{"trials":10582,"activeCount":99},[],{"trials":10584,"activeCount":99},[],{"trials":10586,"activeCount":224,"soonestReadout":10567},[10587],{"nctId":10564,"briefTitle":10565,"status":128,"phases":10588,"primaryCompletion":10567,"completion":10568,"start":6168,"enrollment":10569,"conditions":10589,"interventions":10590},[89],[314],[10553,10572],{"trials":10592,"activeCount":99},[],{"trials":10594,"activeCount":99},[],{"intervention":3079,"totalTrials":224,"cells":10596},{"EARLY_PHASE1":10597,"PHASE1":10599,"PHASE2":10601,"PHASE3":10603,"PHASE4":10609,"NA":10611},{"trials":10598,"activeCount":99},[],{"trials":10600,"activeCount":99},[],{"trials":10602,"activeCount":99},[],{"trials":10604,"activeCount":224,"soonestReadout":3073},[10605],{"nctId":3070,"briefTitle":3071,"status":139,"phases":10606,"primaryCompletion":3073,"completion":3074,"start":3075,"enrollment":951,"conditions":10607,"interventions":10608},[89],[3077],[653,3079,437,387,967,3037,654],{"trials":10610,"activeCount":99},[],{"trials":10612,"activeCount":99},[],{"intervention":7826,"totalTrials":224,"cells":10614},{"EARLY_PHASE1":10615,"PHASE1":10617,"PHASE2":10619,"PHASE3":10621,"PHASE4":10627,"NA":10629},{"trials":10616,"activeCount":99},[],{"trials":10618,"activeCount":99},[],{"trials":10620,"activeCount":99},[],{"trials":10622,"activeCount":224,"soonestReadout":7820},[10623],{"nctId":7817,"briefTitle":7818,"status":128,"phases":10624,"primaryCompletion":7820,"completion":7821,"start":7822,"enrollment":7823,"conditions":10625,"interventions":10626},[88,89],[7788],[7662,7790,7671,7826],{"trials":10628,"activeCount":99},[],{"trials":10630,"activeCount":99},[],{"intervention":61,"totalTrials":224,"cells":10632},{"EARLY_PHASE1":10633,"PHASE1":10635,"PHASE2":10637,"PHASE3":10639,"PHASE4":10645,"NA":10647},{"trials":10634,"activeCount":99},[],{"trials":10636,"activeCount":99},[],{"trials":10638,"activeCount":99},[],{"trials":10640,"activeCount":224,"soonestReadout":60},[10641],{"nctId":58,"briefTitle":59,"status":139,"phases":10642,"primaryCompletion":60,"completion":3090,"start":3091,"enrollment":3092,"conditions":10643,"interventions":10644},[89],[903],[61,3095,387,3096,386,390,385],{"trials":10646,"activeCount":99},[],{"trials":10648,"activeCount":99},[],{"intervention":3095,"totalTrials":224,"cells":10650},{"EARLY_PHASE1":10651,"PHASE1":10653,"PHASE2":10655,"PHASE3":10657,"PHASE4":10663,"NA":10665},{"trials":10652,"activeCount":99},[],{"trials":10654,"activeCount":99},[],{"trials":10656,"activeCount":99},[],{"trials":10658,"activeCount":224,"soonestReadout":60},[10659],{"nctId":58,"briefTitle":59,"status":139,"phases":10660,"primaryCompletion":60,"completion":3090,"start":3091,"enrollment":3092,"conditions":10661,"interventions":10662},[89],[903],[61,3095,387,3096,386,390,385],{"trials":10664,"activeCount":99},[],{"trials":10666,"activeCount":99},[],{"intervention":2527,"totalTrials":224,"cells":10668},{"EARLY_PHASE1":10669,"PHASE1":10671,"PHASE2":10673,"PHASE3":10675,"PHASE4":10681,"NA":10683},{"trials":10670,"activeCount":99},[],{"trials":10672,"activeCount":99},[],{"trials":10674,"activeCount":99},[],{"trials":10676,"activeCount":224,"soonestReadout":2521},[10677],{"nctId":2518,"briefTitle":2519,"status":128,"phases":10678,"primaryCompletion":2521,"completion":2522,"start":2523,"enrollment":2390,"conditions":10679,"interventions":10680},[89],[314,2525],[47,2527,386,387,388],{"trials":10682,"activeCount":99},[],{"trials":10684,"activeCount":99},[],{"intervention":9068,"totalTrials":224,"cells":10686},{"EARLY_PHASE1":10687,"PHASE1":10689,"PHASE2":10691,"PHASE3":10693,"PHASE4":10699,"NA":10701},{"trials":10688,"activeCount":99},[],{"trials":10690,"activeCount":99},[],{"trials":10692,"activeCount":99},[],{"trials":10694,"activeCount":224,"soonestReadout":9061},[10695],{"nctId":9058,"briefTitle":9059,"status":139,"phases":10696,"primaryCompletion":9061,"completion":9062,"start":9063,"enrollment":9064,"conditions":10697,"interventions":10698},[89],[9066],[9037,1730,9056,9068],{"trials":10700,"activeCount":99},[],{"trials":10702,"activeCount":99},[],{"intervention":9555,"totalTrials":224,"cells":10704},{"EARLY_PHASE1":10705,"PHASE1":10707,"PHASE2":10709,"PHASE3":10711,"PHASE4":10717,"NA":10719},{"trials":10706,"activeCount":99},[],{"trials":10708,"activeCount":99},[],{"trials":10710,"activeCount":99},[],{"trials":10712,"activeCount":224,"soonestReadout":9549},[10713],{"nctId":9546,"briefTitle":9547,"status":128,"phases":10714,"primaryCompletion":9549,"completion":9549,"start":9550,"enrollment":9551,"conditions":10715,"interventions":10716},[88,89],[9543,9553],[9514,9555],{"trials":10718,"activeCount":99},[],{"trials":10720,"activeCount":99},[],{"intervention":4236,"totalTrials":224,"cells":10722},{"EARLY_PHASE1":10723,"PHASE1":10725,"PHASE2":10727,"PHASE3":10729,"PHASE4":10735,"NA":10737},{"trials":10724,"activeCount":99},[],{"trials":10726,"activeCount":99},[],{"trials":10728,"activeCount":99},[],{"trials":10730,"activeCount":224,"soonestReadout":4232},[10731],{"nctId":4229,"briefTitle":4230,"status":128,"phases":10732,"primaryCompletion":4232,"completion":4232,"start":4233,"enrollment":951,"conditions":10733,"interventions":10734},[89],[4134,1035],[56,4178,4236,461,4189,2904],{"trials":10736,"activeCount":99},[],{"trials":10738,"activeCount":99},[],{"intervention":2607,"totalTrials":224,"cells":10740},{"EARLY_PHASE1":10741,"PHASE1":10743,"PHASE2":10745,"PHASE3":10747,"PHASE4":10753,"NA":10755},{"trials":10742,"activeCount":99},[],{"trials":10744,"activeCount":99},[],{"trials":10746,"activeCount":99},[],{"trials":10748,"activeCount":224,"soonestReadout":2601},[10749],{"nctId":2598,"briefTitle":2599,"status":128,"phases":10750,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":2603,"conditions":10751,"interventions":10752},[89],[176,2605],[47,2607,461,1114,2608,2609,384],{"trials":10754,"activeCount":99},[],{"trials":10756,"activeCount":99},[],{"intervention":2608,"totalTrials":224,"cells":10758},{"EARLY_PHASE1":10759,"PHASE1":10761,"PHASE2":10763,"PHASE3":10765,"PHASE4":10771,"NA":10773},{"trials":10760,"activeCount":99},[],{"trials":10762,"activeCount":99},[],{"trials":10764,"activeCount":99},[],{"trials":10766,"activeCount":224,"soonestReadout":2601},[10767],{"nctId":2598,"briefTitle":2599,"status":128,"phases":10768,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":2603,"conditions":10769,"interventions":10770},[89],[176,2605],[47,2607,461,1114,2608,2609,384],{"trials":10772,"activeCount":99},[],{"trials":10774,"activeCount":99},[],{"intervention":2609,"totalTrials":224,"cells":10776},{"EARLY_PHASE1":10777,"PHASE1":10779,"PHASE2":10781,"PHASE3":10783,"PHASE4":10789,"NA":10791},{"trials":10778,"activeCount":99},[],{"trials":10780,"activeCount":99},[],{"trials":10782,"activeCount":99},[],{"trials":10784,"activeCount":224,"soonestReadout":2601},[10785],{"nctId":2598,"briefTitle":2599,"status":128,"phases":10786,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":2603,"conditions":10787,"interventions":10788},[89],[176,2605],[47,2607,461,1114,2608,2609,384],{"trials":10790,"activeCount":99},[],{"trials":10792,"activeCount":99},[],{"intervention":2628,"totalTrials":224,"cells":10794},{"EARLY_PHASE1":10795,"PHASE1":10797,"PHASE2":10799,"PHASE3":10801,"PHASE4":10807,"NA":10809},{"trials":10796,"activeCount":99},[],{"trials":10798,"activeCount":99},[],{"trials":10800,"activeCount":99},[],{"trials":10802,"activeCount":224,"soonestReadout":2622},[10803],{"nctId":2619,"briefTitle":2620,"status":139,"phases":10804,"primaryCompletion":2622,"completion":2623,"start":2624,"enrollment":2625,"conditions":10805,"interventions":10806},[89],[1287],[47,390,1087,2628,714],{"trials":10808,"activeCount":99},[],{"trials":10810,"activeCount":99},[],{"intervention":6293,"totalTrials":224,"cells":10812},{"EARLY_PHASE1":10813,"PHASE1":10815,"PHASE2":10817,"PHASE3":10819,"PHASE4":10825,"NA":10827},{"trials":10814,"activeCount":99},[],{"trials":10816,"activeCount":99},[],{"trials":10818,"activeCount":99},[],{"trials":10820,"activeCount":224,"soonestReadout":6281},[10821],{"nctId":6278,"briefTitle":6279,"status":128,"phases":10822,"primaryCompletion":6281,"completion":6282,"start":6283,"enrollment":6284,"conditions":10823,"interventions":10824},[89],[6286,6287,6288,6289,6290,6291],[5541,6293,4349],{"trials":10826,"activeCount":99},[],{"trials":10828,"activeCount":99},[],{"intervention":471,"totalTrials":95,"cells":10830},{"EARLY_PHASE1":10831,"PHASE1":10833,"PHASE2":10839,"PHASE3":10885,"PHASE4":10887,"NA":10889},{"trials":10832,"activeCount":99},[],{"trials":10834,"activeCount":99},[10835],{"nctId":463,"briefTitle":464,"status":105,"phases":10836,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":10837,"interventions":10838},[87],[290],[471,47,386,385,461,387,390,472],{"trials":10840,"activeCount":174,"soonestReadout":395},[10841,10845,10849,10853,10857,10861,10865,10869,10873,10877,10881],{"nctId":887,"briefTitle":888,"status":105,"phases":10842,"primaryCompletion":890,"completion":890,"start":891,"enrollment":892,"conditions":10843,"interventions":10844},[88],[369],[47,471,713],{"nctId":947,"briefTitle":948,"status":128,"phases":10846,"primaryCompletion":950,"completion":950,"start":891,"enrollment":951,"conditions":10847,"interventions":10848},[87,88],[369],[47,386,387,385,923,542,471,713,954,955],{"nctId":4469,"briefTitle":4470,"status":139,"phases":10850,"primaryCompletion":4472,"completion":4472,"start":4473,"enrollment":4474,"conditions":10851,"interventions":10852},[87,88],[866],[4477,1369,471,4478,4479],{"nctId":1017,"briefTitle":1018,"status":105,"phases":10854,"primaryCompletion":1020,"completion":1021,"start":1022,"enrollment":1023,"conditions":10855,"interventions":10856},[88],[369],[47,542,471,1026,1027,713],{"nctId":1029,"briefTitle":1030,"status":139,"phases":10858,"primaryCompletion":1032,"completion":1032,"start":1033,"enrollment":941,"conditions":10859,"interventions":10860},[87,88],[1035],[47,471,56,461,818,460],{"nctId":1176,"briefTitle":1177,"status":105,"phases":10862,"primaryCompletion":1179,"completion":1179,"start":356,"enrollment":110,"conditions":10863,"interventions":10864},[87,88],[35],[47,923,1182,471,1183,924],{"nctId":1224,"briefTitle":1225,"status":105,"phases":10866,"primaryCompletion":1227,"completion":1227,"start":1228,"enrollment":397,"conditions":10867,"interventions":10868},[87,88],[1230],[47,1232,471,461,437,387],{"nctId":1267,"briefTitle":1268,"status":139,"phases":10870,"primaryCompletion":395,"completion":1270,"start":1271,"enrollment":1272,"conditions":10871,"interventions":10872},[88],[419],[47,818,1275,1241,471],{"nctId":1315,"briefTitle":1316,"status":128,"phases":10874,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1132,"conditions":10875,"interventions":10876},[87,88],[1263],[387,437,47,471,461,653,1323,1324,979,529,1325,654],{"nctId":1494,"briefTitle":1495,"status":105,"phases":10878,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":787,"conditions":10879,"interventions":10880},[88],[1501,1502],[47,387,386,1504,471,967],{"nctId":1545,"briefTitle":1546,"status":105,"phases":10882,"primaryCompletion":1548,"completion":1548,"start":1549,"enrollment":1550,"conditions":10883,"interventions":10884},[88],[1552],[47,471,542,461,1073,390,386],{"trials":10886,"activeCount":99},[],{"trials":10888,"activeCount":99},[],{"trials":10890,"activeCount":99},[],{"intervention":1059,"totalTrials":3963,"cells":10892},{"EARLY_PHASE1":10893,"PHASE1":10895,"PHASE2":10897,"PHASE3":10924,"PHASE4":10926,"NA":10928},{"trials":10894,"activeCount":99},[],{"trials":10896,"activeCount":99},[],{"trials":10898,"activeCount":3963,"soonestReadout":10915},[10899,10903,10911,10920],{"nctId":1049,"briefTitle":1050,"status":128,"phases":10900,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":1054,"conditions":10901,"interventions":10902},[87,88],[1056],[1058,47,1059],{"nctId":10904,"briefTitle":10905,"status":128,"phases":10906,"primaryCompletion":10907,"completion":10907,"start":10908,"enrollment":700,"conditions":10909,"interventions":10910},"NCT07222488","A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)",[87,88],"2029-02-28","2025-12-09",[1134,1287],[1059],{"nctId":10912,"briefTitle":10913,"status":128,"phases":10914,"primaryCompletion":10915,"completion":10916,"start":1825,"enrollment":10917,"conditions":10918,"interventions":10919},"NCT06818643","A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)",[87,88],"2028-10-25","2031-03-25",270,[497,690],[1059],{"nctId":1344,"briefTitle":1345,"status":128,"phases":10921,"primaryCompletion":1347,"completion":1347,"start":1348,"enrollment":1349,"conditions":10922,"interventions":10923},[87,88],[1134],[1059,1352,47,842],{"trials":10925,"activeCount":99},[],{"trials":10927,"activeCount":99},[],{"trials":10929,"activeCount":99},[],{"intervention":1265,"totalTrials":3963,"cells":10931},{"EARLY_PHASE1":10932,"PHASE1":10934,"PHASE2":10936,"PHASE3":10954,"PHASE4":10956,"NA":10958},{"trials":10933,"activeCount":99},[],{"trials":10935,"activeCount":99},[],{"trials":10937,"activeCount":3963,"soonestReadout":4368},[10938,10942,10946,10950],{"nctId":3257,"briefTitle":3258,"status":128,"phases":10939,"primaryCompletion":3260,"completion":3261,"start":1701,"enrollment":3262,"conditions":10940,"interventions":10941},[87,88],[3264],[3266,1265,3267,386,1073,327],{"nctId":1256,"briefTitle":1257,"status":128,"phases":10943,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":1261,"conditions":10944,"interventions":10945},[87,88],[1263],[47,1265,435,796,797,434,653,842],{"nctId":4301,"briefTitle":4302,"status":128,"phases":10947,"primaryCompletion":4304,"completion":4304,"start":1021,"enrollment":4305,"conditions":10948,"interventions":10949},[88],[4307],[4309,4310,967,327,842],{"nctId":4365,"briefTitle":4366,"status":128,"phases":10951,"primaryCompletion":4368,"completion":4369,"start":4370,"enrollment":558,"conditions":10952,"interventions":10953},[87,88],[4372],[1265,842],{"trials":10955,"activeCount":99},[],{"trials":10957,"activeCount":99},[],{"trials":10959,"activeCount":99},[],{"intervention":840,"totalTrials":202,"cells":10961},{"EARLY_PHASE1":10962,"PHASE1":10964,"PHASE2":10966,"PHASE3":10983,"PHASE4":10985,"NA":10987},{"trials":10963,"activeCount":99},[],{"trials":10965,"activeCount":99},[],{"trials":10967,"activeCount":202,"soonestReadout":10980},[10968,10972,10976],{"nctId":831,"briefTitle":832,"status":128,"phases":10969,"primaryCompletion":834,"completion":834,"start":835,"enrollment":836,"conditions":10970,"interventions":10971},[87,88],[838],[840,386,387,841,842,47,714,843],{"nctId":7250,"briefTitle":7251,"status":128,"phases":10973,"primaryCompletion":1330,"completion":1330,"start":4408,"enrollment":7253,"conditions":10974,"interventions":10975},[88],[369],[840,954,7256,7257,7258,7259],{"nctId":10977,"briefTitle":10978,"status":139,"phases":10979,"primaryCompletion":10980,"completion":6253,"start":2221,"enrollment":787,"conditions":10981,"interventions":10982},"NCT06864169","A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)",[88],"2026-08-18",[6607],[840],{"trials":10984,"activeCount":99},[],{"trials":10986,"activeCount":99},[],{"trials":10988,"activeCount":99},[],{"intervention":955,"totalTrials":202,"cells":10990},{"EARLY_PHASE1":10991,"PHASE1":10993,"PHASE2":10995,"PHASE3":11009,"PHASE4":11011,"NA":11013},{"trials":10992,"activeCount":99},[],{"trials":10994,"activeCount":99},[],{"trials":10996,"activeCount":202,"soonestReadout":2870},[10997,11001,11005],{"nctId":947,"briefTitle":948,"status":128,"phases":10998,"primaryCompletion":950,"completion":950,"start":891,"enrollment":951,"conditions":10999,"interventions":11000},[87,88],[369],[47,386,387,385,923,542,471,713,954,955],{"nctId":2867,"briefTitle":2868,"status":128,"phases":11002,"primaryCompletion":2870,"completion":2871,"start":2872,"enrollment":2873,"conditions":11003,"interventions":11004},[87,88],[789,790,791,792],[2876,387,794,327,955],{"nctId":1327,"briefTitle":1328,"status":128,"phases":11006,"primaryCompletion":1330,"completion":1330,"start":1331,"enrollment":397,"conditions":11007,"interventions":11008},[88],[314],[47,386,387,388,385,955],{"trials":11010,"activeCount":99},[],{"trials":11012,"activeCount":99},[],{"trials":11014,"activeCount":99},[],{"intervention":500,"totalTrials":202,"cells":11016},{"EARLY_PHASE1":11017,"PHASE1":11019,"PHASE2":11025,"PHASE3":11035,"PHASE4":11037,"NA":11039},{"trials":11018,"activeCount":99},[],{"trials":11020,"activeCount":224,"soonestReadout":492},[11021],{"nctId":489,"briefTitle":490,"status":128,"phases":11022,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":11023,"interventions":11024},[87],[496,497],[499,47,500],{"trials":11026,"activeCount":3197,"soonestReadout":3538},[11027,11031],{"nctId":1138,"briefTitle":1139,"status":128,"phases":11028,"primaryCompletion":1141,"completion":1141,"start":1142,"enrollment":132,"conditions":11029,"interventions":11030},[88],[690],[500,47,693,386,385],{"nctId":3535,"briefTitle":3536,"status":128,"phases":11032,"primaryCompletion":3538,"completion":3539,"start":3540,"enrollment":3541,"conditions":11033,"interventions":11034},[87,88],[975],[500,1111,653,693,327],{"trials":11036,"activeCount":99},[],{"trials":11038,"activeCount":99},[],{"trials":11040,"activeCount":99},[],{"intervention":11042,"totalTrials":202,"cells":11043},"GARDASIL®9",{"EARLY_PHASE1":11044,"PHASE1":11046,"PHASE2":11065,"PHASE3":11078,"PHASE4":11080,"NA":11082},{"trials":11045,"activeCount":99},[],{"trials":11047,"activeCount":3197,"soonestReadout":11052},[11048,11057],{"nctId":11049,"briefTitle":11050,"status":139,"phases":11051,"primaryCompletion":11052,"completion":11052,"start":11053,"enrollment":380,"conditions":11054,"interventions":11055},"NCT06623409","Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).",[87],"2026-11-20","2024-11-12",[18],[11042,11056],"V540B",{"nctId":11058,"briefTitle":11059,"status":139,"phases":11060,"primaryCompletion":11061,"completion":11061,"start":3561,"enrollment":380,"conditions":11062,"interventions":11063},"NCT06688058","A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)",[87],"2026-11-30",[18],[11064,11042],"V540D",{"trials":11066,"activeCount":224,"soonestReadout":11071},[11067],{"nctId":11068,"briefTitle":11069,"status":230,"phases":11070,"primaryCompletion":11071,"completion":11071,"start":11072,"enrollment":11073,"conditions":11074,"interventions":11075},"NCT07224477","A Clinical Study of V540A in Healthy Female Participants (V540A-005)",[88],"2028-04-04","2026-07-20",525,[18],[11076,11077,11042],"V540A-2","V540A-3",{"trials":11079,"activeCount":99},[],{"trials":11081,"activeCount":99},[],{"trials":11083,"activeCount":99},[],{"intervention":460,"totalTrials":3308,"cells":11085},{"EARLY_PHASE1":11086,"PHASE1":11088,"PHASE2":11094,"PHASE3":11120,"PHASE4":11137,"NA":11139},{"trials":11087,"activeCount":99},[],{"trials":11089,"activeCount":99},[11090],{"nctId":450,"briefTitle":451,"status":105,"phases":11091,"primaryCompletion":453,"completion":453,"start":454,"enrollment":455,"conditions":11092,"interventions":11093},[87],[290],[458,47,434,437,435,459,460,461],{"trials":11095,"activeCount":3197,"soonestReadout":1032},[11096,11100,11104,11108,11112,11116],{"nctId":1029,"briefTitle":1030,"status":139,"phases":11097,"primaryCompletion":1032,"completion":1032,"start":1033,"enrollment":941,"conditions":11098,"interventions":11099},[87,88],[1035],[47,471,56,461,818,460],{"nctId":1146,"briefTitle":1147,"status":139,"phases":11101,"primaryCompletion":1032,"completion":1032,"start":1149,"enrollment":1150,"conditions":11102,"interventions":11103},[87,88],[1035],[47,460,56,461,818,1153],{"nctId":5011,"briefTitle":5012,"status":105,"phases":11105,"primaryCompletion":5014,"completion":5015,"start":5016,"enrollment":5017,"conditions":11106,"interventions":11107},[88],[674],[1594,5020,1885],{"nctId":1234,"briefTitle":1235,"status":1040,"phases":11109,"primaryCompletion":1237,"completion":1237,"start":1238,"enrollment":99,"conditions":11110,"interventions":11111},[87,88],[324],[47,458,460,923,1241],{"nctId":1517,"briefTitle":1518,"status":105,"phases":11113,"primaryCompletion":1520,"completion":1520,"start":1521,"enrollment":1522,"conditions":11114,"interventions":11115},[87,88],[35],[47,923,818,461,460,924],{"nctId":1586,"briefTitle":1587,"status":105,"phases":11117,"primaryCompletion":1589,"completion":1589,"start":1011,"enrollment":1590,"conditions":11118,"interventions":11119},[88],[279,1592,861],[1594,42,1369],{"trials":11121,"activeCount":99},[11122,11131],{"nctId":11123,"briefTitle":11124,"status":105,"phases":11125,"primaryCompletion":11126,"completion":7292,"start":11127,"enrollment":11128,"conditions":11129,"interventions":11130},"NCT05064059","A Study of Coformulated Favezelimab\u002FPembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)",[89],"2024-08-15","2021-11-10",441,[419],[1594,2066,2067],{"nctId":11132,"briefTitle":11133,"status":105,"phases":11134,"primaryCompletion":11126,"completion":7292,"start":9424,"enrollment":1977,"conditions":11135,"interventions":11136},"NCT05600309","A Study of Coformulated Favezelimab\u002FPembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study",[89],[419],[1594,2066,2067],{"trials":11138,"activeCount":99},[],{"trials":11140,"activeCount":99},[],{"intervention":11142,"totalTrials":4555,"cells":11143},"MK-1167",{"EARLY_PHASE1":11144,"PHASE1":11146,"PHASE2":11185,"PHASE3":11197,"PHASE4":11199,"NA":11201},{"trials":11145,"activeCount":99},[],{"trials":11147,"activeCount":224,"soonestReadout":11152},[11148,11155,11161,11168,11177],{"nctId":11149,"briefTitle":11150,"status":139,"phases":11151,"primaryCompletion":11152,"completion":11152,"start":5614,"enrollment":3655,"conditions":11153,"interventions":11154},"NCT07334860","A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011)",[87],"2026-05-28",[18],[11142],{"nctId":11156,"briefTitle":11157,"status":105,"phases":11158,"primaryCompletion":4202,"completion":4202,"start":7822,"enrollment":154,"conditions":11159,"interventions":11160},"NCT07266818","A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010)",[87],[18],[11142],{"nctId":11162,"briefTitle":11163,"status":105,"phases":11164,"primaryCompletion":11165,"completion":11165,"start":1338,"enrollment":3655,"conditions":11166,"interventions":11167},"NCT06625840","A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004)",[87],"2024-05-08",[18],[11142],{"nctId":11169,"briefTitle":11170,"status":105,"phases":11171,"primaryCompletion":11172,"completion":11172,"start":1131,"enrollment":1624,"conditions":11173,"interventions":11175},"NCT06285240","Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)",[87],"2024-09-23",[11174],"Alzheimer's Disease",[11142,11176],"Donepezil",{"nctId":11178,"briefTitle":11179,"status":105,"phases":11180,"primaryCompletion":11181,"completion":11181,"start":11182,"enrollment":3655,"conditions":11183,"interventions":11184},"NCT06703463","A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006)",[87],"2024-02-02","2023-10-17",[18],[11142,6172],{"trials":11186,"activeCount":224,"soonestReadout":11191},[11187],{"nctId":11188,"briefTitle":11189,"status":139,"phases":11190,"primaryCompletion":11191,"completion":11191,"start":11192,"enrollment":11193,"conditions":11194,"interventions":11196},"NCT06721156","A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)",[88],"2026-12-31","2024-12-16",350,[9369,11195],"Dementia",[11142],{"trials":11198,"activeCount":99},[],{"trials":11200,"activeCount":99},[],{"trials":11202,"activeCount":99},[],{"intervention":4156,"totalTrials":3963,"cells":11204},{"EARLY_PHASE1":11205,"PHASE1":11207,"PHASE2":11209,"PHASE3":11240,"PHASE4":11242,"NA":11244},{"trials":11206,"activeCount":99},[],{"trials":11208,"activeCount":99},[],{"trials":11210,"activeCount":3197,"soonestReadout":2179},[11211,11215,11219,11230],{"nctId":4147,"briefTitle":4148,"status":128,"phases":11212,"primaryCompletion":2179,"completion":4150,"start":4151,"enrollment":2023,"conditions":11213,"interventions":11214},[88],[4153],[56,4155,2904,4156],{"nctId":4921,"briefTitle":4922,"status":128,"phases":11216,"primaryCompletion":4924,"completion":4924,"start":4925,"enrollment":688,"conditions":11217,"interventions":11218},[88],[690],[4775,4928,4929,327,4155,4156,4930,4931,4932],{"nctId":11220,"briefTitle":11221,"status":105,"phases":11222,"primaryCompletion":11223,"completion":11223,"start":11224,"enrollment":11225,"conditions":11226,"interventions":11227},"NCT01234857","A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)",[88],"2013-10-15","2010-09-17",115,[1109],[11228,11229,6312,6091],"ridaforolimus + dalotuzumab","exemestane",{"nctId":11231,"briefTitle":11232,"status":105,"phases":11233,"primaryCompletion":11234,"completion":11235,"start":11236,"enrollment":1479,"conditions":11237,"interventions":11238},"NCT01605396","A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)",[88],"2014-02-19","2018-03-15","2012-07-04",[1108],[11239,6106,4156],"Ridaforolimus",{"trials":11241,"activeCount":99},[],{"trials":11243,"activeCount":99},[],{"trials":11245,"activeCount":99},[],{"intervention":4479,"totalTrials":3197,"cells":11247},{"EARLY_PHASE1":11248,"PHASE1":11250,"PHASE2":11252,"PHASE3":11262,"PHASE4":11264,"NA":11266},{"trials":11249,"activeCount":99},[],{"trials":11251,"activeCount":99},[],{"trials":11253,"activeCount":3197,"soonestReadout":4472},[11254,11258],{"nctId":4469,"briefTitle":4470,"status":139,"phases":11255,"primaryCompletion":4472,"completion":4472,"start":4473,"enrollment":4474,"conditions":11256,"interventions":11257},[87,88],[866],[4477,1369,471,4478,4479],{"nctId":4301,"briefTitle":4302,"status":128,"phases":11259,"primaryCompletion":4304,"completion":4304,"start":1021,"enrollment":4305,"conditions":11260,"interventions":11261},[88],[4307],[4309,4310,967,327,842],{"trials":11263,"activeCount":99},[],{"trials":11265,"activeCount":99},[],{"trials":11267,"activeCount":99},[],{"intervention":7510,"totalTrials":3197,"cells":11269},{"EARLY_PHASE1":11270,"PHASE1":11272,"PHASE2":11278,"PHASE3":11284,"PHASE4":11286,"NA":11288},{"trials":11271,"activeCount":99},[],{"trials":11273,"activeCount":224,"soonestReadout":7505},[11274],{"nctId":7502,"briefTitle":7503,"status":230,"phases":11275,"primaryCompletion":7505,"completion":7506,"start":7507,"enrollment":154,"conditions":11276,"interventions":11277},[87],[18],[7510,7488],{"trials":11279,"activeCount":224,"soonestReadout":7582},[11280],{"nctId":7579,"briefTitle":7580,"status":230,"phases":11281,"primaryCompletion":7582,"completion":7582,"start":7583,"enrollment":7584,"conditions":11282,"interventions":11283},[88],[7586],[7510,7488],{"trials":11285,"activeCount":99},[],{"trials":11287,"activeCount":99},[],{"trials":11289,"activeCount":99},[],{"intervention":4155,"totalTrials":3197,"cells":11291},{"EARLY_PHASE1":11292,"PHASE1":11294,"PHASE2":11296,"PHASE3":11306,"PHASE4":11308,"NA":11310},{"trials":11293,"activeCount":99},[],{"trials":11295,"activeCount":99},[],{"trials":11297,"activeCount":3197,"soonestReadout":2179},[11298,11302],{"nctId":4147,"briefTitle":4148,"status":128,"phases":11299,"primaryCompletion":2179,"completion":4150,"start":4151,"enrollment":2023,"conditions":11300,"interventions":11301},[88],[4153],[56,4155,2904,4156],{"nctId":4921,"briefTitle":4922,"status":128,"phases":11303,"primaryCompletion":4924,"completion":4924,"start":4925,"enrollment":688,"conditions":11304,"interventions":11305},[88],[690],[4775,4928,4929,327,4155,4156,4930,4931,4932],{"trials":11307,"activeCount":99},[],{"trials":11309,"activeCount":99},[],{"trials":11311,"activeCount":99},[],{"intervention":3266,"totalTrials":3197,"cells":11313},{"EARLY_PHASE1":11314,"PHASE1":11316,"PHASE2":11318,"PHASE3":11328,"PHASE4":11330,"NA":11332},{"trials":11315,"activeCount":99},[],{"trials":11317,"activeCount":99},[],{"trials":11319,"activeCount":3197,"soonestReadout":7264},[11320,11324],{"nctId":3257,"briefTitle":3258,"status":128,"phases":11321,"primaryCompletion":3260,"completion":3261,"start":1701,"enrollment":3262,"conditions":11322,"interventions":11323},[87,88],[3264],[3266,1265,3267,386,1073,327],{"nctId":7261,"briefTitle":7262,"status":128,"phases":11325,"primaryCompletion":7264,"completion":7265,"start":7266,"enrollment":2555,"conditions":11326,"interventions":11327},[87,88],[1552],[3266,954,2186],{"trials":11329,"activeCount":99},[],{"trials":11331,"activeCount":99},[],{"trials":11333,"activeCount":99},[],{"intervention":1352,"totalTrials":3197,"cells":11335},{"EARLY_PHASE1":11336,"PHASE1":11338,"PHASE2":11340,"PHASE3":11350,"PHASE4":11352,"NA":11354},{"trials":11337,"activeCount":99},[],{"trials":11339,"activeCount":99},[],{"trials":11341,"activeCount":3197,"soonestReadout":1577},[11342,11346],{"nctId":1344,"briefTitle":1345,"status":128,"phases":11343,"primaryCompletion":1347,"completion":1347,"start":1348,"enrollment":1349,"conditions":11344,"interventions":11345},[87,88],[1134],[1059,1352,47,842],{"nctId":1574,"briefTitle":1575,"status":139,"phases":11347,"primaryCompletion":1577,"completion":1577,"start":1578,"enrollment":1579,"conditions":11348,"interventions":11349},[87,88],[1377,1581],[1583,1584,1352,47],{"trials":11351,"activeCount":99},[],{"trials":11353,"activeCount":99},[],{"trials":11355,"activeCount":99},[],{"intervention":11357,"totalTrials":734,"cells":11358},"Doravirine",{"EARLY_PHASE1":11359,"PHASE1":11361,"PHASE2":11398,"PHASE3":11434,"PHASE4":11449,"NA":11451},{"trials":11360,"activeCount":99},[],{"trials":11362,"activeCount":99},[11363,11371,11379,11388],{"nctId":11364,"briefTitle":11365,"status":105,"phases":11366,"primaryCompletion":11367,"completion":11367,"start":11368,"enrollment":931,"conditions":11369,"interventions":11370},"NCT01466985","A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)",[87],"2012-04-10","2011-10-21",[7639],[11357],{"nctId":11372,"briefTitle":11373,"status":105,"phases":11374,"primaryCompletion":11375,"completion":11375,"start":11376,"enrollment":3655,"conditions":11377,"interventions":11378},"NCT02089659","A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)",[87],"2014-05-12","2014-03-26",[7639],[11357],{"nctId":11380,"briefTitle":11381,"status":105,"phases":11382,"primaryCompletion":11383,"completion":11384,"start":11385,"enrollment":3655,"conditions":11386,"interventions":11387},"NCT02641067","A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)",[87],"2016-05-14","2016-05-25","2016-01-26",[4074],[11357],{"nctId":11389,"briefTitle":11390,"status":105,"phases":11391,"primaryCompletion":11392,"completion":11393,"start":11394,"enrollment":4071,"conditions":11395,"interventions":11397},"NCT02715700","Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045)",[87],"2016-06-13","2016-08-15","2015-09-28",[11396],"Human Immunodeficiency Virus (HIV) Infection",[7321,11357],{"trials":11399,"activeCount":224,"soonestReadout":11404},[11400,11412,11424],{"nctId":11401,"briefTitle":11402,"status":128,"phases":11403,"primaryCompletion":11404,"completion":11405,"start":11406,"enrollment":11407,"conditions":11408,"interventions":11409},"NCT04375800","Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to \u003C12 Years and \u003C45 kg (MK-1439-066)",[88],"2028-11-12","2034-04-11","2021-02-03",84,[11396],[11357,11410,11411],"2 NRTIs","DOR\u002F3TC\u002FTDF",{"nctId":11413,"briefTitle":11414,"status":105,"phases":11415,"primaryCompletion":11416,"completion":11417,"start":11418,"enrollment":2085,"conditions":11419,"interventions":11420},"NCT03272347","Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)",[88],"2021-03-08","2022-03-09","2017-11-27",[7639],[7800,11357,11421,11422,11423],"Lamivudine","Doravirine\u002FLamivudine\u002FTenofovir Disoproxil Fumarate","Doravirine\u002FIslatravir",{"nctId":11425,"briefTitle":11426,"status":105,"phases":11427,"primaryCompletion":11428,"completion":11429,"start":11430,"enrollment":9551,"conditions":11431,"interventions":11432},"NCT01632345","A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)",[88],"2014-12-03","2016-03-21","2012-10-12",[27],[11357,6235,11433],"TRUVADA®",{"trials":11435,"activeCount":99},[11436],{"nctId":11437,"briefTitle":11438,"status":105,"phases":11439,"primaryCompletion":11440,"completion":11441,"start":5477,"enrollment":11442,"conditions":11443,"interventions":11445},"NCT02275780","Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)",[89],"2016-09-29","2023-03-06",769,[11444],"HIV-1",[11357,11446,11447,11448],"Darunavir","Ritonavir","TRUVADA™ or EPZICOM™\u002FKIVEXA™",{"trials":11450,"activeCount":99},[],{"trials":11452,"activeCount":99},[],{"intervention":1843,"totalTrials":4555,"cells":11454},{"EARLY_PHASE1":11455,"PHASE1":11457,"PHASE2":11469,"PHASE3":11491,"PHASE4":11497,"NA":11499},{"trials":11456,"activeCount":99},[],{"trials":11458,"activeCount":99},[11459],{"nctId":11460,"briefTitle":11461,"status":150,"phases":11462,"primaryCompletion":11463,"completion":11464,"start":11465,"enrollment":444,"conditions":11466,"interventions":11467},"NCT00963547","A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)",[87],"2011-08-09","2011-12-22","2009-09-15",[497,1109],[2817,1843,11468],"Lapatinib",{"trials":11470,"activeCount":224,"soonestReadout":6613},[11471,11475,11483,11487],{"nctId":4783,"briefTitle":4784,"status":105,"phases":11472,"primaryCompletion":4786,"completion":4786,"start":4787,"enrollment":36,"conditions":11473,"interventions":11474},[88],[4789],[3229,967,1843],{"nctId":11476,"briefTitle":11477,"status":105,"phases":11478,"primaryCompletion":11479,"completion":5981,"start":5801,"enrollment":5616,"conditions":11480,"interventions":11481},"NCT00736970","Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)",[88],"2011-01",[1109,1108],[6312,11482],"trastuzumab",{"nctId":2896,"briefTitle":2897,"status":150,"phases":11484,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":2901,"conditions":11485,"interventions":11486},[87,88],[290],[386,1664,1843,2904,714,2905,693,387,390,1444,1253,437,2906],{"nctId":6610,"briefTitle":6611,"status":128,"phases":11488,"primaryCompletion":6613,"completion":6613,"start":6614,"enrollment":2770,"conditions":11489,"interventions":11490},[87,88],[1108,1109],[1111,1843,6617,6618,6619],{"trials":11492,"activeCount":99},[11493],{"nctId":1832,"briefTitle":1833,"status":105,"phases":11494,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":11495,"interventions":11496},[89],[1840,1442],[47,390,1444,434,795,1842,1843],{"trials":11498,"activeCount":99},[],{"trials":11500,"activeCount":99},[],{"intervention":11502,"totalTrials":174,"cells":11503},"Frespaciguat",{"EARLY_PHASE1":11504,"PHASE1":11506,"PHASE2":11534,"PHASE3":11544,"PHASE4":11554,"NA":11556},{"trials":11505,"activeCount":99},[],{"trials":11507,"activeCount":99},[11508,11516,11526],{"nctId":11509,"briefTitle":11510,"status":105,"phases":11511,"primaryCompletion":11512,"completion":11512,"start":11513,"enrollment":9323,"conditions":11514,"interventions":11515},"NCT03744637","A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002)",[87],"2020-12-11","2019-01-18",[144],[11502],{"nctId":11517,"briefTitle":11518,"status":1040,"phases":11519,"primaryCompletion":1878,"completion":1878,"start":11520,"enrollment":99,"conditions":11521,"interventions":11525},"NCT04425733","Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)",[87],"2020-07-07",[11522,11523,11524],"Coronavirus Disease 2019 (COVID-19)","Pneumonia","Hypoxemia",[11502],{"nctId":11527,"briefTitle":11528,"status":105,"phases":11529,"primaryCompletion":11530,"completion":11530,"start":1296,"enrollment":4059,"conditions":11531,"interventions":11533},"NCT04370873","Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)",[87],"2022-01-12",[11532],"Pulmonary Hypertension",[11502],{"trials":11535,"activeCount":224,"soonestReadout":4202},[11536],{"nctId":11537,"briefTitle":11538,"status":139,"phases":11539,"primaryCompletion":4202,"completion":11540,"start":5536,"enrollment":11541,"conditions":11542,"interventions":11543},"NCT05612035","Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD",[88],"2029-10-08",129,[11532,4360],[11502],{"trials":11545,"activeCount":99},[11546],{"nctId":11547,"briefTitle":11548,"status":105,"phases":11549,"primaryCompletion":11550,"completion":11551,"start":1167,"enrollment":322,"conditions":11552,"interventions":11553},"NCT04732221","A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2\u002F3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)",[88,89],"2024-01-04","2024-07-02",[144,134],[11502],{"trials":11555,"activeCount":99},[],{"trials":11557,"activeCount":99},[],{"intervention":1071,"totalTrials":3963,"cells":11559},{"EARLY_PHASE1":11560,"PHASE1":11562,"PHASE2":11564,"PHASE3":11578,"PHASE4":11589,"NA":11591},{"trials":11561,"activeCount":99},[],{"trials":11563,"activeCount":99},[],{"trials":11565,"activeCount":224,"soonestReadout":1450},[11566,11570,11574],{"nctId":1061,"briefTitle":1062,"status":105,"phases":11567,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":110,"conditions":11568,"interventions":11569},[88],[943],[47,1069,1070,1071,1072,1073,562,1074,1075,1076],{"nctId":1381,"briefTitle":1382,"status":105,"phases":11571,"primaryCompletion":1384,"completion":1385,"start":1386,"enrollment":1387,"conditions":11572,"interventions":11573},[88],[883],[47,386,387,1071,1390],{"nctId":1447,"briefTitle":1448,"status":139,"phases":11575,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":11576,"interventions":11577},[88],[674],[42,1455,1456,1457,1458,1459,1460,1461,487],{"trials":11579,"activeCount":99},[11580],{"nctId":11581,"briefTitle":11582,"status":105,"phases":11583,"primaryCompletion":11584,"completion":11584,"start":11585,"enrollment":11586,"conditions":11587,"interventions":11588},"NCT00091572","Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)",[89],"2007-12-31","2004-10-20",859,[35],[1390,1071],{"trials":11590,"activeCount":99},[],{"trials":11592,"activeCount":99},[],{"intervention":7012,"totalTrials":4555,"cells":11594},{"EARLY_PHASE1":11595,"PHASE1":11597,"PHASE2":11620,"PHASE3":11653,"PHASE4":11655,"NA":11657},{"trials":11596,"activeCount":99},[],{"trials":11598,"activeCount":99},[11599,11608,11616],{"nctId":11600,"briefTitle":11601,"status":105,"phases":11602,"primaryCompletion":11603,"completion":11603,"start":11604,"enrollment":4059,"conditions":11605,"interventions":11607},"NCT06052566","A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)",[87],"2024-12-05","2023-11-21",[11606,5595],"Non-alcoholic Steatohepatitis",[7012],{"nctId":11609,"briefTitle":11610,"status":105,"phases":11611,"primaryCompletion":11612,"completion":11612,"start":11613,"enrollment":1621,"conditions":11614,"interventions":11615},"NCT06836037","A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)",[87],"2023-02-02","2022-09-05",[18],[7012],{"nctId":7005,"briefTitle":7006,"status":105,"phases":11617,"primaryCompletion":7008,"completion":7008,"start":7009,"enrollment":1054,"conditions":11618,"interventions":11619},[87],[18],[7012,979],{"trials":11621,"activeCount":224,"soonestReadout":11638},[11622,11634,11645],{"nctId":11623,"briefTitle":11624,"status":105,"phases":11625,"primaryCompletion":11626,"completion":11626,"start":11627,"enrollment":826,"conditions":11628,"interventions":11633},"NCT06482112","Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)",[88],"2025-06-27","2024-07-29",[11629,11630,11631,11632],"Metabolic Dysfunction-Associated Steatotic Liver Disease","Non-alcoholic Fatty Liver Disease","Nonalcoholic Fatty Liver Disease","Liver Disease",[7012],{"nctId":11635,"briefTitle":11636,"status":139,"phases":11637,"primaryCompletion":11638,"completion":11638,"start":78,"enrollment":1479,"conditions":11639,"interventions":11644},"NCT06465186","A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)",[88],"2026-08-06",[11630,11640,11641,11642,11643],"Nonalcoholic Steatohepatitis","NAFLD","Metabolic Dysfunction-associated Steatotic Liver Disease","Metabolic Dysfunction-associated Steatohepatitis",[7012],{"nctId":11646,"briefTitle":11647,"status":105,"phases":11648,"primaryCompletion":5574,"completion":5574,"start":1578,"enrollment":11649,"conditions":11650,"interventions":11652},"NCT05877547","A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)",[88],381,[11630,11651,11641,11631,11640],"Fatty Liver, Nonalcoholic",[7012,8027],{"trials":11654,"activeCount":99},[],{"trials":11656,"activeCount":99},[],{"trials":11658,"activeCount":99},[],{"intervention":923,"totalTrials":4555,"cells":11660},{"EARLY_PHASE1":11661,"PHASE1":11663,"PHASE2":11669,"PHASE3":11691,"PHASE4":11693,"NA":11695},{"trials":11662,"activeCount":99},[],{"trials":11664,"activeCount":99},[11665],{"nctId":474,"briefTitle":475,"status":105,"phases":11666,"primaryCompletion":477,"completion":477,"start":478,"enrollment":479,"conditions":11667,"interventions":11668},[87],[290],[482,42,483,484,485,486,487],{"trials":11670,"activeCount":224,"soonestReadout":950},[11671,11675,11679,11683,11687],{"nctId":916,"briefTitle":917,"status":105,"phases":11672,"primaryCompletion":919,"completion":919,"start":356,"enrollment":920,"conditions":11673,"interventions":11674},[87,88],[35],[47,780,923,461,924],{"nctId":947,"briefTitle":948,"status":128,"phases":11676,"primaryCompletion":950,"completion":950,"start":891,"enrollment":951,"conditions":11677,"interventions":11678},[87,88],[369],[47,386,387,385,923,542,471,713,954,955],{"nctId":1176,"briefTitle":1177,"status":105,"phases":11680,"primaryCompletion":1179,"completion":1179,"start":356,"enrollment":110,"conditions":11681,"interventions":11682},[87,88],[35],[47,923,1182,471,1183,924],{"nctId":1234,"briefTitle":1235,"status":1040,"phases":11684,"primaryCompletion":1237,"completion":1237,"start":1238,"enrollment":99,"conditions":11685,"interventions":11686},[87,88],[324],[47,458,460,923,1241],{"nctId":1517,"briefTitle":1518,"status":105,"phases":11688,"primaryCompletion":1520,"completion":1520,"start":1521,"enrollment":1522,"conditions":11689,"interventions":11690},[87,88],[35],[47,923,818,461,460,924],{"trials":11692,"activeCount":99},[],{"trials":11694,"activeCount":99},[],{"trials":11696,"activeCount":99},[],{"intervention":713,"totalTrials":174,"cells":11698},{"EARLY_PHASE1":11699,"PHASE1":11701,"PHASE2":11717,"PHASE3":11731,"PHASE4":11733,"NA":11735},{"trials":11700,"activeCount":99},[],{"trials":11702,"activeCount":99},[11703,11713],{"nctId":11704,"briefTitle":11705,"status":150,"phases":11706,"primaryCompletion":11707,"completion":11707,"start":11708,"enrollment":5563,"conditions":11709,"interventions":11712},"NCT05038800","A Study to Evaluate MK-0482 for Relapsed\u002FRefractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)",[87],"2023-12-11","2021-09-26",[11710,11711],"Relapsed or Refractory Acute Myeloid Leukemia","Relapsed or Refractory Chronic Myelomonocytic Leukemia",[713],{"nctId":705,"briefTitle":706,"status":105,"phases":11714,"primaryCompletion":708,"completion":708,"start":709,"enrollment":710,"conditions":11715,"interventions":11716},[87],[290],[713,42,387,388,714,386,385],{"trials":11718,"activeCount":224,"soonestReadout":950},[11719,11723,11727],{"nctId":887,"briefTitle":888,"status":105,"phases":11720,"primaryCompletion":890,"completion":890,"start":891,"enrollment":892,"conditions":11721,"interventions":11722},[88],[369],[47,471,713],{"nctId":947,"briefTitle":948,"status":128,"phases":11724,"primaryCompletion":950,"completion":950,"start":891,"enrollment":951,"conditions":11725,"interventions":11726},[87,88],[369],[47,386,387,385,923,542,471,713,954,955],{"nctId":1017,"briefTitle":1018,"status":105,"phases":11728,"primaryCompletion":1020,"completion":1021,"start":1022,"enrollment":1023,"conditions":11729,"interventions":11730},[88],[369],[47,542,471,1026,1027,713],{"trials":11732,"activeCount":99},[],{"trials":11734,"activeCount":99},[],{"trials":11736,"activeCount":99},[],{"intervention":542,"totalTrials":174,"cells":11738},{"EARLY_PHASE1":11739,"PHASE1":11741,"PHASE2":11747,"PHASE3":11765,"PHASE4":11767,"NA":11769},{"trials":11740,"activeCount":99},[],{"trials":11742,"activeCount":99},[11743],{"nctId":532,"briefTitle":533,"status":105,"phases":11744,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":11745,"interventions":11746},[87],[539,279,369,540],[542,47,385,386,388],{"trials":11748,"activeCount":224,"soonestReadout":950},[11749,11753,11757,11761],{"nctId":947,"briefTitle":948,"status":128,"phases":11750,"primaryCompletion":950,"completion":950,"start":891,"enrollment":951,"conditions":11751,"interventions":11752},[87,88],[369],[47,386,387,385,923,542,471,713,954,955],{"nctId":1017,"briefTitle":1018,"status":105,"phases":11754,"primaryCompletion":1020,"completion":1021,"start":1022,"enrollment":1023,"conditions":11755,"interventions":11756},[88],[369],[47,542,471,1026,1027,713],{"nctId":1392,"briefTitle":1393,"status":1040,"phases":11758,"primaryCompletion":1395,"completion":1396,"start":1397,"enrollment":99,"conditions":11759,"interventions":11760},[88],[1399],[47,387,386,1069,542,1401,562,795,1114],{"nctId":1545,"briefTitle":1546,"status":105,"phases":11762,"primaryCompletion":1548,"completion":1548,"start":1549,"enrollment":1550,"conditions":11763,"interventions":11764},[88],[1552],[47,471,542,461,1073,390,386],{"trials":11766,"activeCount":99},[],{"trials":11768,"activeCount":99},[],{"trials":11770,"activeCount":99},[],{"intervention":3254,"totalTrials":174,"cells":11772},{"EARLY_PHASE1":11773,"PHASE1":11775,"PHASE2":11781,"PHASE3":11804,"PHASE4":11806,"NA":11808},{"trials":11774,"activeCount":99},[],{"trials":11776,"activeCount":99},[11777],{"nctId":474,"briefTitle":475,"status":105,"phases":11778,"primaryCompletion":477,"completion":477,"start":478,"enrollment":479,"conditions":11779,"interventions":11780},[87],[290],[482,42,483,484,485,486,487],{"trials":11782,"activeCount":224,"soonestReadout":3242},[11783,11787,11791,11795],{"nctId":3239,"briefTitle":3240,"status":128,"phases":11784,"primaryCompletion":3242,"completion":3243,"start":3244,"enrollment":2204,"conditions":11785,"interventions":11786},[87,88],[3246],[84,3248,3249,3250,3251,3252,3253,461,3254,386,1073,3255],{"nctId":1304,"briefTitle":1305,"status":105,"phases":11788,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1309,"conditions":11789,"interventions":11790},[88],[1134],[47,1312,1313],{"nctId":4804,"briefTitle":4805,"status":105,"phases":11792,"primaryCompletion":4807,"completion":4808,"start":4809,"enrollment":4810,"conditions":11793,"interventions":11794},[88],[4812],[3254,967],{"nctId":11796,"briefTitle":11797,"status":105,"phases":11798,"primaryCompletion":11799,"completion":11799,"start":11800,"enrollment":11801,"conditions":11802,"interventions":11803},"NCT05005442","A Study of Pembrolizumab\u002FVibostolimab (MK-7684A) in Relapsed\u002FRefractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)",[88],"2024-12-10","2021-09-28",192,[6206],[1312],{"trials":11805,"activeCount":99},[],{"trials":11807,"activeCount":99},[],{"trials":11809,"activeCount":99},[],{"intervention":4278,"totalTrials":202,"cells":11811},{"EARLY_PHASE1":11812,"PHASE1":11814,"PHASE2":11824,"PHASE3":11830,"PHASE4":11832,"NA":11834},{"trials":11813,"activeCount":99},[],{"trials":11815,"activeCount":99},[11816,11820],{"nctId":5936,"briefTitle":5937,"status":105,"phases":11817,"primaryCompletion":5939,"completion":1659,"start":5615,"enrollment":120,"conditions":11818,"interventions":11819},[87],[5941,5942,5943,5944,5945],[4278,1076,4777],{"nctId":5948,"briefTitle":5949,"status":105,"phases":11821,"primaryCompletion":5951,"completion":5952,"start":5953,"enrollment":95,"conditions":11822,"interventions":11823},[87],[2410],[4278,1076,4777,5956],{"trials":11825,"activeCount":224,"soonestReadout":4271},[11826],{"nctId":4268,"briefTitle":4269,"status":128,"phases":11827,"primaryCompletion":4271,"completion":4271,"start":4272,"enrollment":4273,"conditions":11828,"interventions":11829},[87,88],[4275,4276],[967,954,4278,4279,2382,842],{"trials":11831,"activeCount":99},[],{"trials":11833,"activeCount":99},[],{"trials":11835,"activeCount":99},[],{"intervention":2819,"totalTrials":3197,"cells":11837},{"EARLY_PHASE1":11838,"PHASE1":11840,"PHASE2":11846,"PHASE3":11852,"PHASE4":11854,"NA":11856},{"trials":11839,"activeCount":99},[],{"trials":11841,"activeCount":99},[11842],{"nctId":2808,"briefTitle":2809,"status":105,"phases":11843,"primaryCompletion":2811,"completion":2812,"start":2813,"enrollment":22,"conditions":11844,"interventions":11845},[87],[2815],[2817,1677,2818,484,1654,2819],{"trials":11847,"activeCount":224,"soonestReadout":1330},[11848],{"nctId":7250,"briefTitle":7251,"status":128,"phases":11849,"primaryCompletion":1330,"completion":1330,"start":4408,"enrollment":7253,"conditions":11850,"interventions":11851},[88],[369],[840,954,7256,7257,7258,7259],{"trials":11853,"activeCount":99},[],{"trials":11855,"activeCount":99},[],{"trials":11857,"activeCount":99},[],{"intervention":11859,"totalTrials":3197,"cells":11860},"MK-2214",{"EARLY_PHASE1":11861,"PHASE1":11863,"PHASE2":11872,"PHASE3":11882,"PHASE4":11884,"NA":11886},{"trials":11862,"activeCount":99},[],{"trials":11864,"activeCount":99},[11865],{"nctId":11866,"briefTitle":11867,"status":105,"phases":11868,"primaryCompletion":4272,"completion":4272,"start":11869,"enrollment":5616,"conditions":11870,"interventions":11871},"NCT05466422","A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)",[87],"2022-09-20",[9369],[11859],{"trials":11873,"activeCount":224,"soonestReadout":11878},[11874],{"nctId":11875,"briefTitle":11876,"status":128,"phases":11877,"primaryCompletion":11878,"completion":11878,"start":5400,"enrollment":1452,"conditions":11879,"interventions":11881},"NCT07033494","A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)",[88],"2029-04-30",[11880],"Early Alzheimer's Disease",[11859],{"trials":11883,"activeCount":99},[],{"trials":11885,"activeCount":99},[],{"trials":11887,"activeCount":99},[],{"intervention":4478,"totalTrials":3197,"cells":11889},{"EARLY_PHASE1":11890,"PHASE1":11892,"PHASE2":11894,"PHASE3":11904,"PHASE4":11906,"NA":11908},{"trials":11891,"activeCount":99},[],{"trials":11893,"activeCount":99},[],{"trials":11895,"activeCount":224,"soonestReadout":4472},[11896,11900],{"nctId":4469,"briefTitle":4470,"status":139,"phases":11897,"primaryCompletion":4472,"completion":4472,"start":4473,"enrollment":4474,"conditions":11898,"interventions":11899},[87,88],[866],[4477,1369,471,4478,4479],{"nctId":1224,"briefTitle":1225,"status":105,"phases":11901,"primaryCompletion":1227,"completion":1227,"start":1228,"enrollment":397,"conditions":11902,"interventions":11903},[87,88],[1230],[47,1232,471,461,437,387],{"trials":11905,"activeCount":99},[],{"trials":11907,"activeCount":99},[],{"trials":11909,"activeCount":99},[],{"intervention":1070,"totalTrials":3197,"cells":11911},{"EARLY_PHASE1":11912,"PHASE1":11914,"PHASE2":11916,"PHASE3":11926,"PHASE4":11928,"NA":11930},{"trials":11913,"activeCount":99},[],{"trials":11915,"activeCount":99},[],{"trials":11917,"activeCount":224,"soonestReadout":1450},[11918,11922],{"nctId":1061,"briefTitle":1062,"status":105,"phases":11919,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":110,"conditions":11920,"interventions":11921},[88],[943],[47,1069,1070,1071,1072,1073,562,1074,1075,1076],{"nctId":1447,"briefTitle":1448,"status":139,"phases":11923,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":11924,"interventions":11925},[88],[674],[42,1455,1456,1457,1458,1459,1460,1461,487],{"trials":11927,"activeCount":99},[],{"trials":11929,"activeCount":99},[],{"trials":11931,"activeCount":99},[],{"intervention":1072,"totalTrials":3197,"cells":11933},{"EARLY_PHASE1":11934,"PHASE1":11936,"PHASE2":11938,"PHASE3":11948,"PHASE4":11950,"NA":11952},{"trials":11935,"activeCount":99},[],{"trials":11937,"activeCount":99},[],{"trials":11939,"activeCount":224,"soonestReadout":1450},[11940,11944],{"nctId":1061,"briefTitle":1062,"status":105,"phases":11941,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":110,"conditions":11942,"interventions":11943},[88],[943],[47,1069,1070,1071,1072,1073,562,1074,1075,1076],{"nctId":1447,"briefTitle":1448,"status":139,"phases":11945,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":11946,"interventions":11947},[88],[674],[42,1455,1456,1457,1458,1459,1460,1461,487],{"trials":11949,"activeCount":99},[],{"trials":11951,"activeCount":99},[],{"trials":11953,"activeCount":99},[],{"intervention":1113,"totalTrials":3197,"cells":11955},{"EARLY_PHASE1":11956,"PHASE1":11958,"PHASE2":11960,"PHASE3":11970,"PHASE4":11972,"NA":11974},{"trials":11957,"activeCount":99},[],{"trials":11959,"activeCount":99},[],{"trials":11961,"activeCount":224,"soonestReadout":804},[11962,11966],{"nctId":1102,"briefTitle":1103,"status":128,"phases":11963,"primaryCompletion":804,"completion":1105,"start":973,"enrollment":1106,"conditions":11964,"interventions":11965},[88],[1108,1109],[1111,47,387,386,1112,1113,562,795,1114],{"nctId":1392,"briefTitle":1393,"status":1040,"phases":11967,"primaryCompletion":1395,"completion":1396,"start":1397,"enrollment":99,"conditions":11968,"interventions":11969},[88],[1399],[47,387,386,1069,542,1401,562,795,1114],{"trials":11971,"activeCount":99},[],{"trials":11973,"activeCount":99},[],{"trials":11975,"activeCount":99},[],{"intervention":11410,"totalTrials":224,"cells":11977},{"EARLY_PHASE1":11978,"PHASE1":11980,"PHASE2":11982,"PHASE3":11988,"PHASE4":11990,"NA":11992},{"trials":11979,"activeCount":99},[],{"trials":11981,"activeCount":99},[],{"trials":11983,"activeCount":224,"soonestReadout":11404},[11984],{"nctId":11401,"briefTitle":11402,"status":128,"phases":11985,"primaryCompletion":11404,"completion":11405,"start":11406,"enrollment":11407,"conditions":11986,"interventions":11987},[88],[11396],[11357,11410,11411],{"trials":11989,"activeCount":99},[],{"trials":11991,"activeCount":99},[],{"trials":11993,"activeCount":99},[],{"intervention":11411,"totalTrials":224,"cells":11995},{"EARLY_PHASE1":11996,"PHASE1":11998,"PHASE2":12000,"PHASE3":12006,"PHASE4":12008,"NA":12010},{"trials":11997,"activeCount":99},[],{"trials":11999,"activeCount":99},[],{"trials":12001,"activeCount":224,"soonestReadout":11404},[12002],{"nctId":11401,"briefTitle":11402,"status":128,"phases":12003,"primaryCompletion":11404,"completion":11405,"start":11406,"enrollment":11407,"conditions":12004,"interventions":12005},[88],[11396],[11357,11410,11411],{"trials":12007,"activeCount":99},[],{"trials":12009,"activeCount":99},[],{"trials":12011,"activeCount":99},[],{"intervention":4279,"totalTrials":224,"cells":12013},{"EARLY_PHASE1":12014,"PHASE1":12016,"PHASE2":12018,"PHASE3":12024,"PHASE4":12026,"NA":12028},{"trials":12015,"activeCount":99},[],{"trials":12017,"activeCount":99},[],{"trials":12019,"activeCount":224,"soonestReadout":4271},[12020],{"nctId":4268,"briefTitle":4269,"status":128,"phases":12021,"primaryCompletion":4271,"completion":4271,"start":4272,"enrollment":4273,"conditions":12022,"interventions":12023},[87,88],[4275,4276],[967,954,4278,4279,2382,842],{"trials":12025,"activeCount":99},[],{"trials":12027,"activeCount":99},[],{"trials":12029,"activeCount":99},[],{"intervention":4477,"totalTrials":224,"cells":12031},{"EARLY_PHASE1":12032,"PHASE1":12034,"PHASE2":12036,"PHASE3":12042,"PHASE4":12044,"NA":12046},{"trials":12033,"activeCount":99},[],{"trials":12035,"activeCount":99},[],{"trials":12037,"activeCount":224,"soonestReadout":4472},[12038],{"nctId":4469,"briefTitle":4470,"status":139,"phases":12039,"primaryCompletion":4472,"completion":4472,"start":4473,"enrollment":4474,"conditions":12040,"interventions":12041},[87,88],[866],[4477,1369,471,4478,4479],{"trials":12043,"activeCount":99},[],{"trials":12045,"activeCount":99},[],{"trials":12047,"activeCount":99},[],{"intervention":4776,"totalTrials":224,"cells":12049},{"EARLY_PHASE1":12050,"PHASE1":12052,"PHASE2":12054,"PHASE3":12060,"PHASE4":12062,"NA":12064},{"trials":12051,"activeCount":99},[],{"trials":12053,"activeCount":99},[],{"trials":12055,"activeCount":224,"soonestReadout":4771},[12056],{"nctId":4768,"briefTitle":4769,"status":128,"phases":12057,"primaryCompletion":4771,"completion":4771,"start":2266,"enrollment":8,"conditions":12058,"interventions":12059},[87,88],[4773],[4775,1114,967,4776,4777,529,1076],{"trials":12061,"activeCount":99},[],{"trials":12063,"activeCount":99},[],{"trials":12065,"activeCount":99},[],{"intervention":12067,"totalTrials":224,"cells":12068},"Posaconazole IV 6 mg\u002Fkg",{"EARLY_PHASE1":12069,"PHASE1":12071,"PHASE2":12073,"PHASE3":12085,"PHASE4":12087,"NA":12089},{"trials":12070,"activeCount":99},[],{"trials":12072,"activeCount":99},[],{"trials":12074,"activeCount":224,"soonestReadout":12079},[12075],{"nctId":12076,"briefTitle":12077,"status":128,"phases":12078,"primaryCompletion":12079,"completion":11191,"start":12080,"enrollment":3390,"conditions":12081,"interventions":12083},"NCT04665037","Posaconazole (MK-5592) Intravenous and Oral in Children (\u003C2 Years) With Invasive Fungal Infection (MK-5592-127)",[88],"2026-12-16","2022-02-22",[12082],"Invasive Fungal Infection",[12067,12084],"Posaconazole PFS 6 mg\u002Fkg",{"trials":12086,"activeCount":99},[],{"trials":12088,"activeCount":99},[],{"trials":12090,"activeCount":99},[],{"intervention":12084,"totalTrials":224,"cells":12092},{"EARLY_PHASE1":12093,"PHASE1":12095,"PHASE2":12097,"PHASE3":12103,"PHASE4":12105,"NA":12107},{"trials":12094,"activeCount":99},[],{"trials":12096,"activeCount":99},[],{"trials":12098,"activeCount":224,"soonestReadout":12079},[12099],{"nctId":12076,"briefTitle":12077,"status":128,"phases":12100,"primaryCompletion":12079,"completion":11191,"start":12080,"enrollment":3390,"conditions":12101,"interventions":12102},[88],[12082],[12067,12084],{"trials":12104,"activeCount":99},[],{"trials":12106,"activeCount":99},[],{"trials":12108,"activeCount":99},[],{"intervention":12110,"totalTrials":224,"cells":12111},"Miransertib",{"EARLY_PHASE1":12112,"PHASE1":12114,"PHASE2":12116,"PHASE3":12126,"PHASE4":12128,"NA":12130},{"trials":12113,"activeCount":99},[],{"trials":12115,"activeCount":99},[],{"trials":12117,"activeCount":224,"soonestReadout":12122},[12118],{"nctId":12119,"briefTitle":12120,"status":139,"phases":12121,"primaryCompletion":12122,"completion":12122,"start":9529,"enrollment":558,"conditions":12123,"interventions":12125},"NCT04980872","A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)",[88],"2030-02-07",[12124],"PIK3CA-Related Overgrowth Spectrum (PROS)\u002FProteus Syndrome (PS)",[12110],{"trials":12127,"activeCount":99},[],{"trials":12129,"activeCount":99},[],{"trials":12131,"activeCount":99},[],{"intervention":1088,"totalTrials":224,"cells":12133},{"EARLY_PHASE1":12134,"PHASE1":12136,"PHASE2":12138,"PHASE3":12144,"PHASE4":12146,"NA":12148},{"trials":12135,"activeCount":99},[],{"trials":12137,"activeCount":99},[],{"trials":12139,"activeCount":224,"soonestReadout":1081},[12140],{"nctId":1078,"briefTitle":1079,"status":128,"phases":12141,"primaryCompletion":1081,"completion":1081,"start":1082,"enrollment":8,"conditions":12142,"interventions":12143},[87,88],[419,1084,1085],[653,1087,1088,1089,654,390,47],{"trials":12145,"activeCount":99},[],{"trials":12147,"activeCount":99},[],{"trials":12149,"activeCount":99},[],{"intervention":1112,"totalTrials":224,"cells":12151},{"EARLY_PHASE1":12152,"PHASE1":12154,"PHASE2":12156,"PHASE3":12162,"PHASE4":12164,"NA":12166},{"trials":12153,"activeCount":99},[],{"trials":12155,"activeCount":99},[],{"trials":12157,"activeCount":224,"soonestReadout":804},[12158],{"nctId":1102,"briefTitle":1103,"status":128,"phases":12159,"primaryCompletion":804,"completion":1105,"start":973,"enrollment":1106,"conditions":12160,"interventions":12161},[88],[1108,1109],[1111,47,387,386,1112,1113,562,795,1114],{"trials":12163,"activeCount":99},[],{"trials":12165,"activeCount":99},[],{"trials":12167,"activeCount":99},[],{"intervention":7256,"totalTrials":224,"cells":12169},{"EARLY_PHASE1":12170,"PHASE1":12172,"PHASE2":12174,"PHASE3":12180,"PHASE4":12182,"NA":12184},{"trials":12171,"activeCount":99},[],{"trials":12173,"activeCount":99},[],{"trials":12175,"activeCount":224,"soonestReadout":1330},[12176],{"nctId":7250,"briefTitle":7251,"status":128,"phases":12177,"primaryCompletion":1330,"completion":1330,"start":4408,"enrollment":7253,"conditions":12178,"interventions":12179},[88],[369],[840,954,7256,7257,7258,7259],{"trials":12181,"activeCount":99},[],{"trials":12183,"activeCount":99},[],{"trials":12185,"activeCount":99},[],{"intervention":7257,"totalTrials":224,"cells":12187},{"EARLY_PHASE1":12188,"PHASE1":12190,"PHASE2":12192,"PHASE3":12198,"PHASE4":12200,"NA":12202},{"trials":12189,"activeCount":99},[],{"trials":12191,"activeCount":99},[],{"trials":12193,"activeCount":224,"soonestReadout":1330},[12194],{"nctId":7250,"briefTitle":7251,"status":128,"phases":12195,"primaryCompletion":1330,"completion":1330,"start":4408,"enrollment":7253,"conditions":12196,"interventions":12197},[88],[369],[840,954,7256,7257,7258,7259],{"trials":12199,"activeCount":99},[],{"trials":12201,"activeCount":99},[],{"trials":12203,"activeCount":99},[],{"intervention":7258,"totalTrials":224,"cells":12205},{"EARLY_PHASE1":12206,"PHASE1":12208,"PHASE2":12210,"PHASE3":12216,"PHASE4":12218,"NA":12220},{"trials":12207,"activeCount":99},[],{"trials":12209,"activeCount":99},[],{"trials":12211,"activeCount":224,"soonestReadout":1330},[12212],{"nctId":7250,"briefTitle":7251,"status":128,"phases":12213,"primaryCompletion":1330,"completion":1330,"start":4408,"enrollment":7253,"conditions":12214,"interventions":12215},[88],[369],[840,954,7256,7257,7258,7259],{"trials":12217,"activeCount":99},[],{"trials":12219,"activeCount":99},[],{"trials":12221,"activeCount":99},[],{"intervention":1153,"totalTrials":224,"cells":12223},{"EARLY_PHASE1":12224,"PHASE1":12226,"PHASE2":12228,"PHASE3":12234,"PHASE4":12236,"NA":12238},{"trials":12225,"activeCount":99},[],{"trials":12227,"activeCount":99},[],{"trials":12229,"activeCount":224,"soonestReadout":1032},[12230],{"nctId":1146,"briefTitle":1147,"status":139,"phases":12231,"primaryCompletion":1032,"completion":1032,"start":1149,"enrollment":1150,"conditions":12232,"interventions":12233},[87,88],[1035],[47,460,56,461,818,1153],{"trials":12235,"activeCount":99},[],{"trials":12237,"activeCount":99},[],{"trials":12239,"activeCount":99},[],{"intervention":3248,"totalTrials":224,"cells":12241},{"EARLY_PHASE1":12242,"PHASE1":12244,"PHASE2":12246,"PHASE3":12252,"PHASE4":12254,"NA":12256},{"trials":12243,"activeCount":99},[],{"trials":12245,"activeCount":99},[],{"trials":12247,"activeCount":224,"soonestReadout":3242},[12248],{"nctId":3239,"briefTitle":3240,"status":128,"phases":12249,"primaryCompletion":3242,"completion":3243,"start":3244,"enrollment":2204,"conditions":12250,"interventions":12251},[87,88],[3246],[84,3248,3249,3250,3251,3252,3253,461,3254,386,1073,3255],{"trials":12253,"activeCount":99},[],{"trials":12255,"activeCount":99},[],{"trials":12257,"activeCount":99},[],{"intervention":3249,"totalTrials":224,"cells":12259},{"EARLY_PHASE1":12260,"PHASE1":12262,"PHASE2":12264,"PHASE3":12270,"PHASE4":12272,"NA":12274},{"trials":12261,"activeCount":99},[],{"trials":12263,"activeCount":99},[],{"trials":12265,"activeCount":224,"soonestReadout":3242},[12266],{"nctId":3239,"briefTitle":3240,"status":128,"phases":12267,"primaryCompletion":3242,"completion":3243,"start":3244,"enrollment":2204,"conditions":12268,"interventions":12269},[87,88],[3246],[84,3248,3249,3250,3251,3252,3253,461,3254,386,1073,3255],{"trials":12271,"activeCount":99},[],{"trials":12273,"activeCount":99},[],{"trials":12275,"activeCount":99},[],{"intervention":3250,"totalTrials":224,"cells":12277},{"EARLY_PHASE1":12278,"PHASE1":12280,"PHASE2":12282,"PHASE3":12288,"PHASE4":12290,"NA":12292},{"trials":12279,"activeCount":99},[],{"trials":12281,"activeCount":99},[],{"trials":12283,"activeCount":224,"soonestReadout":3242},[12284],{"nctId":3239,"briefTitle":3240,"status":128,"phases":12285,"primaryCompletion":3242,"completion":3243,"start":3244,"enrollment":2204,"conditions":12286,"interventions":12287},[87,88],[3246],[84,3248,3249,3250,3251,3252,3253,461,3254,386,1073,3255],{"trials":12289,"activeCount":99},[],{"trials":12291,"activeCount":99},[],{"trials":12293,"activeCount":99},[],{"intervention":3251,"totalTrials":224,"cells":12295},{"EARLY_PHASE1":12296,"PHASE1":12298,"PHASE2":12300,"PHASE3":12306,"PHASE4":12308,"NA":12310},{"trials":12297,"activeCount":99},[],{"trials":12299,"activeCount":99},[],{"trials":12301,"activeCount":224,"soonestReadout":3242},[12302],{"nctId":3239,"briefTitle":3240,"status":128,"phases":12303,"primaryCompletion":3242,"completion":3243,"start":3244,"enrollment":2204,"conditions":12304,"interventions":12305},[87,88],[3246],[84,3248,3249,3250,3251,3252,3253,461,3254,386,1073,3255],{"trials":12307,"activeCount":99},[],{"trials":12309,"activeCount":99},[],{"trials":12311,"activeCount":99},[],{"intervention":3252,"totalTrials":224,"cells":12313},{"EARLY_PHASE1":12314,"PHASE1":12316,"PHASE2":12318,"PHASE3":12324,"PHASE4":12326,"NA":12328},{"trials":12315,"activeCount":99},[],{"trials":12317,"activeCount":99},[],{"trials":12319,"activeCount":224,"soonestReadout":3242},[12320],{"nctId":3239,"briefTitle":3240,"status":128,"phases":12321,"primaryCompletion":3242,"completion":3243,"start":3244,"enrollment":2204,"conditions":12322,"interventions":12323},[87,88],[3246],[84,3248,3249,3250,3251,3252,3253,461,3254,386,1073,3255],{"trials":12325,"activeCount":99},[],{"trials":12327,"activeCount":99},[],{"trials":12329,"activeCount":99},[],{"intervention":3253,"totalTrials":224,"cells":12331},{"EARLY_PHASE1":12332,"PHASE1":12334,"PHASE2":12336,"PHASE3":12342,"PHASE4":12344,"NA":12346},{"trials":12333,"activeCount":99},[],{"trials":12335,"activeCount":99},[],{"trials":12337,"activeCount":224,"soonestReadout":3242},[12338],{"nctId":3239,"briefTitle":3240,"status":128,"phases":12339,"primaryCompletion":3242,"completion":3243,"start":3244,"enrollment":2204,"conditions":12340,"interventions":12341},[87,88],[3246],[84,3248,3249,3250,3251,3252,3253,461,3254,386,1073,3255],{"trials":12343,"activeCount":99},[],{"trials":12345,"activeCount":99},[],{"trials":12347,"activeCount":99},[],{"intervention":3255,"totalTrials":224,"cells":12349},{"EARLY_PHASE1":12350,"PHASE1":12352,"PHASE2":12354,"PHASE3":12360,"PHASE4":12362,"NA":12364},{"trials":12351,"activeCount":99},[],{"trials":12353,"activeCount":99},[],{"trials":12355,"activeCount":224,"soonestReadout":3242},[12356],{"nctId":3239,"briefTitle":3240,"status":128,"phases":12357,"primaryCompletion":3242,"completion":3243,"start":3244,"enrollment":2204,"conditions":12358,"interventions":12359},[87,88],[3246],[84,3248,3249,3250,3251,3252,3253,461,3254,386,1073,3255],{"trials":12361,"activeCount":99},[],{"trials":12363,"activeCount":99},[],{"trials":12365,"activeCount":99},[],{"intervention":4928,"totalTrials":224,"cells":12367},{"EARLY_PHASE1":12368,"PHASE1":12370,"PHASE2":12372,"PHASE3":12378,"PHASE4":12380,"NA":12382},{"trials":12369,"activeCount":99},[],{"trials":12371,"activeCount":99},[],{"trials":12373,"activeCount":224,"soonestReadout":4924},[12374],{"nctId":4921,"briefTitle":4922,"status":128,"phases":12375,"primaryCompletion":4924,"completion":4924,"start":4925,"enrollment":688,"conditions":12376,"interventions":12377},[88],[690],[4775,4928,4929,327,4155,4156,4930,4931,4932],{"trials":12379,"activeCount":99},[],{"trials":12381,"activeCount":99},[],{"trials":12383,"activeCount":99},[],{"intervention":4929,"totalTrials":224,"cells":12385},{"EARLY_PHASE1":12386,"PHASE1":12388,"PHASE2":12390,"PHASE3":12396,"PHASE4":12398,"NA":12400},{"trials":12387,"activeCount":99},[],{"trials":12389,"activeCount":99},[],{"trials":12391,"activeCount":224,"soonestReadout":4924},[12392],{"nctId":4921,"briefTitle":4922,"status":128,"phases":12393,"primaryCompletion":4924,"completion":4924,"start":4925,"enrollment":688,"conditions":12394,"interventions":12395},[88],[690],[4775,4928,4929,327,4155,4156,4930,4931,4932],{"trials":12397,"activeCount":99},[],{"trials":12399,"activeCount":99},[],{"trials":12401,"activeCount":99},[],{"intervention":4930,"totalTrials":224,"cells":12403},{"EARLY_PHASE1":12404,"PHASE1":12406,"PHASE2":12408,"PHASE3":12414,"PHASE4":12416,"NA":12418},{"trials":12405,"activeCount":99},[],{"trials":12407,"activeCount":99},[],{"trials":12409,"activeCount":224,"soonestReadout":4924},[12410],{"nctId":4921,"briefTitle":4922,"status":128,"phases":12411,"primaryCompletion":4924,"completion":4924,"start":4925,"enrollment":688,"conditions":12412,"interventions":12413},[88],[690],[4775,4928,4929,327,4155,4156,4930,4931,4932],{"trials":12415,"activeCount":99},[],{"trials":12417,"activeCount":99},[],{"trials":12419,"activeCount":99},[],{"intervention":4931,"totalTrials":224,"cells":12421},{"EARLY_PHASE1":12422,"PHASE1":12424,"PHASE2":12426,"PHASE3":12432,"PHASE4":12434,"NA":12436},{"trials":12423,"activeCount":99},[],{"trials":12425,"activeCount":99},[],{"trials":12427,"activeCount":224,"soonestReadout":4924},[12428],{"nctId":4921,"briefTitle":4922,"status":128,"phases":12429,"primaryCompletion":4924,"completion":4924,"start":4925,"enrollment":688,"conditions":12430,"interventions":12431},[88],[690],[4775,4928,4929,327,4155,4156,4930,4931,4932],{"trials":12433,"activeCount":99},[],{"trials":12435,"activeCount":99},[],{"trials":12437,"activeCount":99},[],{"intervention":4932,"totalTrials":224,"cells":12439},{"EARLY_PHASE1":12440,"PHASE1":12442,"PHASE2":12444,"PHASE3":12450,"PHASE4":12452,"NA":12454},{"trials":12441,"activeCount":99},[],{"trials":12443,"activeCount":99},[],{"trials":12445,"activeCount":224,"soonestReadout":4924},[12446],{"nctId":4921,"briefTitle":4922,"status":128,"phases":12447,"primaryCompletion":4924,"completion":4924,"start":4925,"enrollment":688,"conditions":12448,"interventions":12449},[88],[690],[4775,4928,4929,327,4155,4156,4930,4931,4932],{"trials":12451,"activeCount":99},[],{"trials":12453,"activeCount":99},[],{"trials":12455,"activeCount":99},[],{"intervention":2876,"totalTrials":224,"cells":12457},{"EARLY_PHASE1":12458,"PHASE1":12460,"PHASE2":12462,"PHASE3":12468,"PHASE4":12470,"NA":12472},{"trials":12459,"activeCount":99},[],{"trials":12461,"activeCount":99},[],{"trials":12463,"activeCount":224,"soonestReadout":2870},[12464],{"nctId":2867,"briefTitle":2868,"status":128,"phases":12465,"primaryCompletion":2870,"completion":2871,"start":2872,"enrollment":2873,"conditions":12466,"interventions":12467},[87,88],[789,790,791,792],[2876,387,794,327,955],{"trials":12469,"activeCount":99},[],{"trials":12471,"activeCount":99},[],{"trials":12473,"activeCount":99},[],{"intervention":1275,"totalTrials":224,"cells":12475},{"EARLY_PHASE1":12476,"PHASE1":12478,"PHASE2":12480,"PHASE3":12486,"PHASE4":12488,"NA":12490},{"trials":12477,"activeCount":99},[],{"trials":12479,"activeCount":99},[],{"trials":12481,"activeCount":224,"soonestReadout":395},[12482],{"nctId":1267,"briefTitle":1268,"status":139,"phases":12483,"primaryCompletion":395,"completion":1270,"start":1271,"enrollment":1272,"conditions":12484,"interventions":12485},[88],[419],[47,818,1275,1241,471],{"trials":12487,"activeCount":99},[],{"trials":12489,"activeCount":99},[],{"trials":12491,"activeCount":99},[],{"intervention":1323,"totalTrials":224,"cells":12493},{"EARLY_PHASE1":12494,"PHASE1":12496,"PHASE2":12498,"PHASE3":12504,"PHASE4":12506,"NA":12508},{"trials":12495,"activeCount":99},[],{"trials":12497,"activeCount":99},[],{"trials":12499,"activeCount":224,"soonestReadout":1318},[12500],{"nctId":1315,"briefTitle":1316,"status":128,"phases":12501,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1132,"conditions":12502,"interventions":12503},[87,88],[1263],[387,437,47,471,461,653,1323,1324,979,529,1325,654],{"trials":12505,"activeCount":99},[],{"trials":12507,"activeCount":99},[],{"trials":12509,"activeCount":99},[],{"intervention":12511,"totalTrials":224,"cells":12512},"MK-8690",{"EARLY_PHASE1":12513,"PHASE1":12515,"PHASE2":12517,"PHASE3":12528,"PHASE4":12530,"NA":12532},{"trials":12514,"activeCount":99},[],{"trials":12516,"activeCount":99},[],{"trials":12518,"activeCount":224,"soonestReadout":8187},[12519],{"nctId":12520,"briefTitle":12521,"status":128,"phases":12522,"primaryCompletion":8187,"completion":12523,"start":12524,"enrollment":920,"conditions":12525,"interventions":12527},"NCT07463183","A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)",[88],"2028-12-21","2026-03-24",[12526,9066],"Colitis Ulcerative",[12511],{"trials":12529,"activeCount":99},[],{"trials":12531,"activeCount":99},[],{"trials":12533,"activeCount":99},[],{"intervention":1460,"totalTrials":224,"cells":12535},{"EARLY_PHASE1":12536,"PHASE1":12538,"PHASE2":12540,"PHASE3":12546,"PHASE4":12548,"NA":12550},{"trials":12537,"activeCount":99},[],{"trials":12539,"activeCount":99},[],{"trials":12541,"activeCount":224,"soonestReadout":1450},[12542],{"nctId":1447,"briefTitle":1448,"status":139,"phases":12543,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":12544,"interventions":12545},[88],[674],[42,1455,1456,1457,1458,1459,1460,1461,487],{"trials":12547,"activeCount":99},[],{"trials":12549,"activeCount":99},[],{"trials":12551,"activeCount":99},[],{"intervention":1583,"totalTrials":224,"cells":12553},{"EARLY_PHASE1":12554,"PHASE1":12556,"PHASE2":12558,"PHASE3":12564,"PHASE4":12566,"NA":12568},{"trials":12555,"activeCount":99},[],{"trials":12557,"activeCount":99},[],{"trials":12559,"activeCount":224,"soonestReadout":1577},[12560],{"nctId":1574,"briefTitle":1575,"status":139,"phases":12561,"primaryCompletion":1577,"completion":1577,"start":1578,"enrollment":1579,"conditions":12562,"interventions":12563},[87,88],[1377,1581],[1583,1584,1352,47],{"trials":12565,"activeCount":99},[],{"trials":12567,"activeCount":99},[],{"trials":12569,"activeCount":99},[],{"intervention":1584,"totalTrials":224,"cells":12571},{"EARLY_PHASE1":12572,"PHASE1":12574,"PHASE2":12576,"PHASE3":12582,"PHASE4":12584,"NA":12586},{"trials":12573,"activeCount":99},[],{"trials":12575,"activeCount":99},[],{"trials":12577,"activeCount":224,"soonestReadout":1577},[12578],{"nctId":1574,"briefTitle":1575,"status":139,"phases":12579,"primaryCompletion":1577,"completion":1577,"start":1578,"enrollment":1579,"conditions":12580,"interventions":12581},[87,88],[1377,1581],[1583,1584,1352,47],{"trials":12583,"activeCount":99},[],{"trials":12585,"activeCount":99},[],{"trials":12587,"activeCount":99},[],{"intervention":6617,"totalTrials":224,"cells":12589},{"EARLY_PHASE1":12590,"PHASE1":12592,"PHASE2":12594,"PHASE3":12600,"PHASE4":12602,"NA":12604},{"trials":12591,"activeCount":99},[],{"trials":12593,"activeCount":99},[],{"trials":12595,"activeCount":224,"soonestReadout":6613},[12596],{"nctId":6610,"briefTitle":6611,"status":128,"phases":12597,"primaryCompletion":6613,"completion":6613,"start":6614,"enrollment":2770,"conditions":12598,"interventions":12599},[87,88],[1108,1109],[1111,1843,6617,6618,6619],{"trials":12601,"activeCount":99},[],{"trials":12603,"activeCount":99},[],{"trials":12605,"activeCount":99},[],{"intervention":6618,"totalTrials":224,"cells":12607},{"EARLY_PHASE1":12608,"PHASE1":12610,"PHASE2":12612,"PHASE3":12618,"PHASE4":12620,"NA":12622},{"trials":12609,"activeCount":99},[],{"trials":12611,"activeCount":99},[],{"trials":12613,"activeCount":224,"soonestReadout":6613},[12614],{"nctId":6610,"briefTitle":6611,"status":128,"phases":12615,"primaryCompletion":6613,"completion":6613,"start":6614,"enrollment":2770,"conditions":12616,"interventions":12617},[87,88],[1108,1109],[1111,1843,6617,6618,6619],{"trials":12619,"activeCount":99},[],{"trials":12621,"activeCount":99},[],{"trials":12623,"activeCount":99},[],{"intervention":6619,"totalTrials":224,"cells":12625},{"EARLY_PHASE1":12626,"PHASE1":12628,"PHASE2":12630,"PHASE3":12636,"PHASE4":12638,"NA":12640},{"trials":12627,"activeCount":99},[],{"trials":12629,"activeCount":99},[],{"trials":12631,"activeCount":224,"soonestReadout":6613},[12632],{"nctId":6610,"briefTitle":6611,"status":128,"phases":12633,"primaryCompletion":6613,"completion":6613,"start":6614,"enrollment":2770,"conditions":12634,"interventions":12635},[87,88],[1108,1109],[1111,1843,6617,6618,6619],{"trials":12637,"activeCount":99},[],{"trials":12639,"activeCount":99},[],{"trials":12641,"activeCount":99},[],{"intervention":11076,"totalTrials":224,"cells":12643},{"EARLY_PHASE1":12644,"PHASE1":12646,"PHASE2":12648,"PHASE3":12654,"PHASE4":12656,"NA":12658},{"trials":12645,"activeCount":99},[],{"trials":12647,"activeCount":99},[],{"trials":12649,"activeCount":224,"soonestReadout":11071},[12650],{"nctId":11068,"briefTitle":11069,"status":230,"phases":12651,"primaryCompletion":11071,"completion":11071,"start":11072,"enrollment":11073,"conditions":12652,"interventions":12653},[88],[18],[11076,11077,11042],{"trials":12655,"activeCount":99},[],{"trials":12657,"activeCount":99},[],{"trials":12659,"activeCount":99},[],{"intervention":11077,"totalTrials":224,"cells":12661},{"EARLY_PHASE1":12662,"PHASE1":12664,"PHASE2":12666,"PHASE3":12672,"PHASE4":12674,"NA":12676},{"trials":12663,"activeCount":99},[],{"trials":12665,"activeCount":99},[],{"trials":12667,"activeCount":224,"soonestReadout":11071},[12668],{"nctId":11068,"briefTitle":11069,"status":230,"phases":12669,"primaryCompletion":11071,"completion":11071,"start":11072,"enrollment":11073,"conditions":12670,"interventions":12671},[88],[18],[11076,11077,11042],{"trials":12673,"activeCount":99},[],{"trials":12675,"activeCount":99},[],{"trials":12677,"activeCount":99},[],{"intervention":4351,"totalTrials":224,"cells":12679},{"EARLY_PHASE1":12680,"PHASE1":12682,"PHASE2":12684,"PHASE3":12690,"PHASE4":12692,"NA":12694},{"trials":12681,"activeCount":99},[],{"trials":12683,"activeCount":99},[],{"trials":12685,"activeCount":224,"soonestReadout":4342},[12686],{"nctId":4339,"briefTitle":4340,"status":128,"phases":12687,"primaryCompletion":4342,"completion":4343,"start":4344,"enrollment":4345,"conditions":12688,"interventions":12689},[88],[4347],[1058,4349,562,1069,4350,1076,2413,4351,842],{"trials":12691,"activeCount":99},[],{"trials":12693,"activeCount":99},[],{"trials":12695,"activeCount":99},[],{"intervention":2100,"totalTrials":734,"cells":12697},{"EARLY_PHASE1":12698,"PHASE1":12700,"PHASE2":12706,"PHASE3":12733,"PHASE4":12758,"NA":12760},{"trials":12699,"activeCount":99},[],{"trials":12701,"activeCount":99},[12702],{"nctId":7014,"briefTitle":7015,"status":150,"phases":12703,"primaryCompletion":7017,"completion":7017,"start":7018,"enrollment":920,"conditions":12704,"interventions":12705},[87],[7020],[5481,7022,2100,7023,4388,979,7024],{"trials":12707,"activeCount":224,"soonestReadout":7194},[12708,12718,12722],{"nctId":12709,"briefTitle":12710,"status":150,"phases":12711,"primaryCompletion":12712,"completion":12712,"start":12713,"enrollment":1621,"conditions":12714,"interventions":12715},"NCT01651936","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)",[88],"2013-10-08","2012-08-29",[7020],[12716,2100,12717],"MK-8457 100 mg","Dose-match placebo",{"nctId":7191,"briefTitle":7192,"status":128,"phases":12719,"primaryCompletion":7194,"completion":7195,"start":3435,"enrollment":537,"conditions":12720,"interventions":12721},[88],[7197],[7157,2100],{"nctId":12723,"briefTitle":12724,"status":150,"phases":12725,"primaryCompletion":12726,"completion":12726,"start":12727,"enrollment":12728,"conditions":12729,"interventions":12731},"NCT01569152","Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)",[88],"2013-10-03","2012-05-22",82,[12730],"Rheumatoid Arthritis (RA)",[12716,12732,2100],"Dose-Matched Placebo",{"trials":12734,"activeCount":99},[12735,12739,12747],{"nctId":2090,"briefTitle":2091,"status":105,"phases":12736,"primaryCompletion":2093,"completion":2094,"start":2095,"enrollment":2096,"conditions":12737,"interventions":12738},[89],[2098],[47,2100,967,693],{"nctId":12740,"briefTitle":12741,"status":105,"phases":12742,"primaryCompletion":8620,"completion":8620,"start":8621,"enrollment":11225,"conditions":12743,"interventions":12745},"NCT00367237","Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)",[89],[12744],"Arthritis, Psoriatic",[12746,2100],"Infliximab + methotrexate",{"nctId":12748,"briefTitle":12749,"status":105,"phases":12750,"primaryCompletion":12751,"completion":12751,"start":12752,"enrollment":1959,"conditions":12753,"interventions":12755},"NCT00251641","The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)",[89],"2008-06-01","2005-09-01",[12754],"Psoriasis",[12756,12757],"infliximab","methotrexate",{"trials":12759,"activeCount":99},[],{"trials":12761,"activeCount":99},[12762],{"nctId":12763,"briefTitle":12764,"status":105,"phases":12765,"primaryCompletion":12766,"completion":12766,"start":4990,"enrollment":12767,"conditions":12768,"interventions":12770},"NCT01313858","A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)",[],"2015-09",1613,[7197,12744,12769],"Spondylitis, Ankylosing",[12771,2100],"Simponi®",{"intervention":3229,"totalTrials":4555,"cells":12773},{"EARLY_PHASE1":12774,"PHASE1":12776,"PHASE2":12778,"PHASE3":12792,"PHASE4":12798,"NA":12807},{"trials":12775,"activeCount":99},[],{"trials":12777,"activeCount":99},[],{"trials":12779,"activeCount":224,"soonestReadout":834},[12780,12784,12788],{"nctId":831,"briefTitle":832,"status":128,"phases":12781,"primaryCompletion":834,"completion":834,"start":835,"enrollment":836,"conditions":12782,"interventions":12783},[87,88],[838],[840,386,387,841,842,47,714,843],{"nctId":3221,"briefTitle":3222,"status":105,"phases":12785,"primaryCompletion":3224,"completion":3224,"start":3225,"enrollment":3226,"conditions":12786,"interventions":12787},[88],[1288],[3229,386],{"nctId":4783,"briefTitle":4784,"status":105,"phases":12789,"primaryCompletion":4786,"completion":4786,"start":4787,"enrollment":36,"conditions":12790,"interventions":12791},[88],[4789],[3229,967,1843],{"trials":12793,"activeCount":99},[12794],{"nctId":5898,"briefTitle":5899,"status":105,"phases":12795,"primaryCompletion":5901,"completion":5902,"start":5903,"enrollment":2873,"conditions":12796,"interventions":12797},[89],[1109],[843,795],{"trials":12799,"activeCount":99},[12800],{"nctId":12801,"briefTitle":12802,"status":150,"phases":12803,"primaryCompletion":12804,"completion":12804,"start":6464,"enrollment":224,"conditions":12805,"interventions":12806},"NCT00779285","Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)",[90],"2006-08",[4789],[3229],{"trials":12808,"activeCount":99},[12809],{"nctId":12810,"briefTitle":12811,"status":105,"phases":12812,"primaryCompletion":12813,"completion":12813,"start":12814,"enrollment":12815,"conditions":12816,"interventions":12817},"NCT00736333","A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)",[],"2010-06","2006-11",167,[4789],[3229],{"intervention":7801,"totalTrials":4555,"cells":12819},{"EARLY_PHASE1":12820,"PHASE1":12822,"PHASE2":12863,"PHASE3":12869,"PHASE4":12871,"NA":12873},{"trials":12821,"activeCount":99},[],{"trials":12823,"activeCount":202,"soonestReadout":12844},[12824,12833,12840,12848,12856],{"nctId":12825,"briefTitle":12826,"status":105,"phases":12827,"primaryCompletion":4202,"completion":4202,"start":12828,"enrollment":25,"conditions":12829,"interventions":12830},"NCT07305831","A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)",[87],"2026-01-22",[18],[7801,7335,12831,12832],"Ulonivirine Placebo","Moxifloxacin Placebo",{"nctId":12834,"briefTitle":12835,"status":230,"phases":12836,"primaryCompletion":12837,"completion":12837,"start":645,"enrollment":4071,"conditions":12838,"interventions":12839},"NCT07595263","A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019)",[87],"2027-01-15",[18],[7801,7321],{"nctId":12841,"briefTitle":12842,"status":139,"phases":12843,"primaryCompletion":12844,"completion":12844,"start":12845,"enrollment":95,"conditions":12846,"interventions":12847},"NCT07530289","A Clinical Study of Ulonivirine (MK-8507) With Atorvastatin and Metformin in Healthy Adults (MK-8507-018)",[87],"2026-06-03","2026-04-29",[18],[8011,4084,7801],{"nctId":12849,"briefTitle":12850,"status":105,"phases":12851,"primaryCompletion":1692,"completion":12852,"start":12853,"enrollment":931,"conditions":12854,"interventions":12855},"NCT02174159","Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)",[87],"2015-07-23","2014-09-15",[7639],[7801],{"nctId":12857,"briefTitle":12858,"status":230,"phases":12859,"primaryCompletion":8201,"completion":8201,"start":12860,"enrollment":4059,"conditions":12861,"interventions":12862},"NCT05093972","Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)",[87],"2026-04-07",[7574],[7801],{"trials":12864,"activeCount":99},[12865],{"nctId":7792,"briefTitle":7793,"status":105,"phases":12866,"primaryCompletion":7795,"completion":7795,"start":7796,"enrollment":7797,"conditions":12867,"interventions":12868},[88],[7639],[7800,7801,7671],{"trials":12870,"activeCount":99},[],{"trials":12872,"activeCount":99},[],{"trials":12874,"activeCount":99},[],{"intervention":8320,"totalTrials":3963,"cells":12876},{"EARLY_PHASE1":12877,"PHASE1":12879,"PHASE2":12909,"PHASE3":12911,"PHASE4":12913,"NA":12915},{"trials":12878,"activeCount":99},[],{"trials":12880,"activeCount":202,"soonestReadout":8316},[12881,12888,12897,12905],{"nctId":12882,"briefTitle":12883,"status":105,"phases":12884,"primaryCompletion":6168,"completion":6168,"start":12885,"enrollment":212,"conditions":12886,"interventions":12887},"NCT07089784","Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)",[87],"2025-09-22",[33],[8320],{"nctId":12889,"briefTitle":12890,"status":128,"phases":12891,"primaryCompletion":11072,"completion":11072,"start":12892,"enrollment":120,"conditions":12893,"interventions":12896},"NCT07348237","A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)",[87],"2026-03-02",[12894,12895,4074],"Chronic Kidney Failure","End-Stage Renal Disease",[8320],{"nctId":12898,"briefTitle":12899,"status":128,"phases":12900,"primaryCompletion":12901,"completion":12901,"start":12902,"enrollment":1624,"conditions":12903,"interventions":12904},"NCT07435194","A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007)",[87],"2026-08-12","2026-03-06",[18],[8320,5604,5626],{"nctId":8313,"briefTitle":8314,"status":139,"phases":12906,"primaryCompletion":8316,"completion":8316,"start":5653,"enrollment":2754,"conditions":12907,"interventions":12908},[87],[18],[5578,8319,8320],{"trials":12910,"activeCount":99},[],{"trials":12912,"activeCount":99},[],{"trials":12914,"activeCount":99},[],{"trials":12916,"activeCount":99},[],{"intervention":5604,"totalTrials":4555,"cells":12918},{"EARLY_PHASE1":12919,"PHASE1":12921,"PHASE2":12947,"PHASE3":12960,"PHASE4":12962,"NA":12964},{"trials":12920,"activeCount":99},[],{"trials":12922,"activeCount":3197,"soonestReadout":5972},[12923,12927,12931,12935,12939],{"nctId":6215,"briefTitle":6216,"status":105,"phases":12924,"primaryCompletion":6218,"completion":6218,"start":2722,"enrollment":2901,"conditions":12925,"interventions":12926},[87],[18],[5541,5604],{"nctId":5598,"briefTitle":5599,"status":105,"phases":12928,"primaryCompletion":5601,"completion":5601,"start":2266,"enrollment":1624,"conditions":12929,"interventions":12930},[87],[18],[602,5604,4114],{"nctId":5969,"briefTitle":5970,"status":139,"phases":12932,"primaryCompletion":5972,"completion":5973,"start":5974,"enrollment":4071,"conditions":12933,"interventions":12934},[87],[18],[4775,1076,4777,5604],{"nctId":12898,"briefTitle":12899,"status":128,"phases":12936,"primaryCompletion":12901,"completion":12901,"start":12902,"enrollment":1624,"conditions":12937,"interventions":12938},[87],[18],[8320,5604,5626],{"nctId":12940,"briefTitle":12941,"status":105,"phases":12942,"primaryCompletion":11799,"completion":11799,"start":12943,"enrollment":95,"conditions":12944,"interventions":12945},"NCT06586606","A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003)",[87],"2024-10-03",[11174],[12946,5604],"MK-1708",{"trials":12948,"activeCount":99},[12949],{"nctId":12950,"briefTitle":12951,"status":105,"phases":12952,"primaryCompletion":12953,"completion":12954,"start":12955,"enrollment":494,"conditions":12956,"interventions":12958},"NCT01974687","Single and Multiple Dose Study of Uprifosbuvir (MK-3682\u002FIDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)",[87,88],"2015-09-02","2015-09-11","2013-10-31",[12957],"Chronic Hepatitis C",[12959,5604],"Uprifosbuvir",{"trials":12961,"activeCount":99},[],{"trials":12963,"activeCount":99},[],{"trials":12965,"activeCount":99},[],{"intervention":7321,"totalTrials":3963,"cells":12967},{"EARLY_PHASE1":12968,"PHASE1":12970,"PHASE2":12996,"PHASE3":12998,"PHASE4":13000,"NA":13002},{"trials":12969,"activeCount":99},[],{"trials":12971,"activeCount":3197,"soonestReadout":7317},[12972,12976,12980,12992],{"nctId":7314,"briefTitle":7315,"status":128,"phases":12973,"primaryCompletion":7317,"completion":7317,"start":7318,"enrollment":4071,"conditions":12974,"interventions":12975},[87],[18],[7280,7321],{"nctId":12834,"briefTitle":12835,"status":230,"phases":12977,"primaryCompletion":12837,"completion":12837,"start":645,"enrollment":4071,"conditions":12978,"interventions":12979},[87],[18],[7801,7321],{"nctId":12981,"briefTitle":12982,"status":105,"phases":12983,"primaryCompletion":12984,"completion":12984,"start":12985,"enrollment":4242,"conditions":12986,"interventions":12988},"NCT01396005","A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine\u002FNaloxone Plasma Concentrations (P08123)",[87],"2011-12","2011-09",[12987],"Hepatitis C Virus",[12989,12990,12991],"boceprevir","methadone","buprenorphine\u002Fnaloxone",{"nctId":11389,"briefTitle":11390,"status":105,"phases":12993,"primaryCompletion":11392,"completion":11393,"start":11394,"enrollment":4071,"conditions":12994,"interventions":12995},[87],[11396],[7321,11357],{"trials":12997,"activeCount":99},[],{"trials":12999,"activeCount":99},[],{"trials":13001,"activeCount":99},[],{"trials":13003,"activeCount":99},[],{"intervention":13005,"totalTrials":357,"cells":13006},"Letermovir",{"EARLY_PHASE1":13007,"PHASE1":13009,"PHASE2":13020,"PHASE3":13033,"PHASE4":13083,"NA":13085},{"trials":13008,"activeCount":99},[],{"trials":13010,"activeCount":224,"soonestReadout":13015},[13011],{"nctId":13012,"briefTitle":13013,"status":128,"phases":13014,"primaryCompletion":13015,"completion":13016,"start":2052,"enrollment":3390,"conditions":13017,"interventions":13019},"NCT07199465","A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)",[87],"2028-04-14","2028-05-19",[13018],"Cytomegalovirus Prophylaxis",[13005],{"trials":13021,"activeCount":99},[13022],{"nctId":13023,"briefTitle":13024,"status":105,"phases":13025,"primaryCompletion":13026,"completion":2285,"start":13027,"enrollment":2801,"conditions":13028,"interventions":13030},"NCT03940586","Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)",[88],"2023-01-04","2019-08-08",[13029],"Cytomegalovirus (CMV) Infection",[13031,13005,13032],"Letermovir oral granules","Letermovir intravenous",{"trials":13034,"activeCount":99},[13035,13044,13054,13066,13076],{"nctId":13036,"briefTitle":13037,"status":105,"phases":13038,"primaryCompletion":2889,"completion":13039,"start":13040,"enrollment":7823,"conditions":13041,"interventions":13043},"NCT02137772","Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)",[89],"2016-11-21","2014-06-06",[13042],"Prevention of CMV Infection or Disease",[13005],{"nctId":13045,"briefTitle":13046,"status":105,"phases":13047,"primaryCompletion":13048,"completion":13049,"start":13050,"enrollment":8,"conditions":13051,"interventions":13053},"NCT03930615","Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)",[89],"2021-10-27","2022-03-16","2019-06-21",[13052],"Cytomegalovirus Infection",[13005],{"nctId":13055,"briefTitle":13056,"status":105,"phases":13057,"primaryCompletion":13058,"completion":13058,"start":13059,"enrollment":13060,"conditions":13061,"interventions":13063},"NCT03443869","Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)",[89],"2022-04-05","2018-05-03",601,[13062],"CMV Disease",[13005,13064,13065],"Valganciclovir","Acyclovir",{"nctId":13067,"briefTitle":13068,"status":105,"phases":13069,"primaryCompletion":13070,"completion":13070,"start":13071,"enrollment":4059,"conditions":13072,"interventions":13074},"NCT04129398","MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)",[89],"2022-10-06","2019-12-27",[13052,13073],"Cytomegalovirus Disease",[13005,13075],"Letermovir IV",{"nctId":13077,"briefTitle":13078,"status":105,"phases":13079,"primaryCompletion":2257,"completion":2257,"start":13080,"enrollment":2023,"conditions":13081,"interventions":13082},"NCT05763823","A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)",[89],"2023-03-24",[13052],[13005],{"trials":13084,"activeCount":99},[],{"trials":13086,"activeCount":99},[],{"intervention":8011,"totalTrials":4555,"cells":13088},{"EARLY_PHASE1":13089,"PHASE1":13091,"PHASE2":13112,"PHASE3":13123,"PHASE4":13147,"NA":13149},{"trials":13090,"activeCount":99},[],{"trials":13092,"activeCount":224,"soonestReadout":12844},[13093,13097,13108],{"nctId":8005,"briefTitle":8006,"status":105,"phases":13094,"primaryCompletion":8008,"completion":8008,"start":7387,"enrollment":931,"conditions":13095,"interventions":13096},[87],[18],[7998,8011],{"nctId":13098,"briefTitle":13099,"status":105,"phases":13100,"primaryCompletion":13101,"completion":13101,"start":13102,"enrollment":13103,"conditions":13104,"interventions":13106},"NCT00703261","Evaluate the Utility of 18FDG-PET as a Tool to Quantify Atherosclerotic Plaque (MK-0000-081 AM3)(COMPLETED)",[87],"2009-12","2008-08",83,[13105],"Atherosclerotic Vascular Disease",[13107],"atorvastatin",{"nctId":12841,"briefTitle":12842,"status":139,"phases":13109,"primaryCompletion":12844,"completion":12844,"start":12845,"enrollment":95,"conditions":13110,"interventions":13111},[87],[18],[8011,4084,7801],{"trials":13113,"activeCount":99},[13114],{"nctId":13115,"briefTitle":13116,"status":105,"phases":13117,"primaryCompletion":5179,"completion":5179,"start":9610,"enrollment":920,"conditions":13118,"interventions":13120},"NCT00804843","Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED)",[88],[13119],"Carotid Atherosclerosis",[13121,8011,13122,13122],"Atorvastatin\u002Fniacin extended-release","Simvastatin",{"trials":13124,"activeCount":99},[13125,13136],{"nctId":13126,"briefTitle":13127,"status":105,"phases":13128,"primaryCompletion":13129,"completion":13129,"start":13130,"enrollment":13131,"conditions":13132,"interventions":13134},"NCT00289900","Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)",[89],"2010-08-06","2006-01-24",2340,[13133],"Mixed Hyperlipidemia",[13135,8011,13122],"MK-0524A",{"nctId":13137,"briefTitle":13138,"status":150,"phases":13139,"primaryCompletion":13140,"completion":13140,"start":13141,"enrollment":13142,"conditions":13143,"interventions":13144},"NCT01477853","A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)",[89],"2012-12-04","2011-10-24",166,[15],[13145,8011,4084,13146,13146],"Sitagliptin","Glimepiride",{"trials":13148,"activeCount":99},[],{"trials":13150,"activeCount":99},[],{"intervention":389,"totalTrials":3197,"cells":13152},{"EARLY_PHASE1":13153,"PHASE1":13155,"PHASE2":13161,"PHASE3":13163,"PHASE4":13169,"NA":13171},{"trials":13154,"activeCount":99},[],{"trials":13156,"activeCount":224,"soonestReadout":378},[13157],{"nctId":375,"briefTitle":376,"status":139,"phases":13158,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":13159,"interventions":13160},[87],[382],[384,47,385,386,387,388,389,390],{"trials":13162,"activeCount":99},[],{"trials":13164,"activeCount":99},[13165],{"nctId":1981,"briefTitle":1982,"status":105,"phases":13166,"primaryCompletion":1984,"completion":1985,"start":1986,"enrollment":1987,"conditions":13167,"interventions":13168},[89],[702],[47,389,1990],{"trials":13170,"activeCount":99},[],{"trials":13172,"activeCount":99},[],{"intervention":13174,"totalTrials":3197,"cells":13175},"PCV20",{"EARLY_PHASE1":13176,"PHASE1":13178,"PHASE2":13190,"PHASE3":13192,"PHASE4":13204,"NA":13206},{"trials":13177,"activeCount":99},[],{"trials":13179,"activeCount":224,"soonestReadout":13184},[13180],{"nctId":13181,"briefTitle":13182,"status":128,"phases":13183,"primaryCompletion":13184,"completion":7109,"start":13185,"enrollment":2873,"conditions":13186,"interventions":13188},"NCT07300267","A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)",[87],"2028-10-24","2026-01-13",[13187],"Pneumococcal Infection",[13189,13189,13174,13174],"V118C",{"trials":13191,"activeCount":99},[],{"trials":13193,"activeCount":99},[13194],{"nctId":13195,"briefTitle":13196,"status":105,"phases":13197,"primaryCompletion":13198,"completion":13198,"start":13199,"enrollment":13200,"conditions":13201,"interventions":13202},"NCT05425732","Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)",[89],"2023-05-18","2022-07-13",2663,[13187],[13203,13174],"V116",{"trials":13205,"activeCount":99},[],{"trials":13207,"activeCount":99},[],{"intervention":5626,"totalTrials":174,"cells":13209},{"EARLY_PHASE1":13210,"PHASE1":13212,"PHASE2":13250,"PHASE3":13252,"PHASE4":13254,"NA":13256},{"trials":13211,"activeCount":99},[],{"trials":13213,"activeCount":224,"soonestReadout":12901},[13214,13218,13228,13242,13246],{"nctId":8293,"briefTitle":8294,"status":105,"phases":13215,"primaryCompletion":8296,"completion":8296,"start":8297,"enrollment":931,"conditions":13216,"interventions":13217},[87],[8299],[8301,8302,8303],{"nctId":13219,"briefTitle":13220,"status":105,"phases":13221,"primaryCompletion":13222,"completion":13223,"start":13224,"enrollment":3655,"conditions":13225,"interventions":13227},"NCT01071304","Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)",[87],"2010-09","2012-02","2010-03",[13226],"Relapsed or Refractory Advanced Cancer",[5626,11239],{"nctId":13229,"briefTitle":13230,"status":105,"phases":13231,"primaryCompletion":13232,"completion":13232,"start":13233,"enrollment":13234,"conditions":13235,"interventions":13237},"NCT01275170","A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)",[87],"2012-03-05","2011-01-28",49,[13236],"Infectious Disease",[13238,13239,13240,5626,13241],"MK-7655","Imipenem + Cilastatin","Caffeine","Omeprazole",{"nctId":12898,"briefTitle":12899,"status":128,"phases":13243,"primaryCompletion":12901,"completion":12901,"start":12902,"enrollment":1624,"conditions":13244,"interventions":13245},[87],[18],[8320,5604,5626],{"nctId":5620,"briefTitle":5621,"status":105,"phases":13247,"primaryCompletion":985,"completion":985,"start":5623,"enrollment":1624,"conditions":13248,"interventions":13249},[87],[314],[602,5626,5627],{"trials":13251,"activeCount":99},[],{"trials":13253,"activeCount":99},[],{"trials":13255,"activeCount":99},[],{"trials":13257,"activeCount":99},[],{"intervention":8319,"totalTrials":3197,"cells":13259},{"EARLY_PHASE1":13260,"PHASE1":13262,"PHASE2":13278,"PHASE3":13280,"PHASE4":13282,"NA":13284},{"trials":13261,"activeCount":99},[],{"trials":13263,"activeCount":224,"soonestReadout":8316},[13264,13274],{"nctId":13265,"briefTitle":13266,"status":150,"phases":13267,"primaryCompletion":13268,"completion":13268,"start":13269,"enrollment":5983,"conditions":13270,"interventions":13271},"NCT01558674","A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) (MK-7145-011)",[87],"2014-12-17","2014-05-23",[4074,9543],[13272,8319,13273],"MK-7145","Torsemide",{"nctId":8313,"briefTitle":8314,"status":139,"phases":13275,"primaryCompletion":8316,"completion":8316,"start":5653,"enrollment":2754,"conditions":13276,"interventions":13277},[87],[18],[5578,8319,8320],{"trials":13279,"activeCount":99},[],{"trials":13281,"activeCount":99},[],{"trials":13283,"activeCount":99},[],{"trials":13285,"activeCount":99},[],{"intervention":13189,"totalTrials":3197,"cells":13287},{"EARLY_PHASE1":13288,"PHASE1":13290,"PHASE2":13306,"PHASE3":13308,"PHASE4":13310,"NA":13312},{"trials":13289,"activeCount":99},[],{"trials":13291,"activeCount":224,"soonestReadout":13184},[13292,13302],{"nctId":13293,"briefTitle":13294,"status":105,"phases":13295,"primaryCompletion":1795,"completion":1795,"start":13296,"enrollment":2801,"conditions":13297,"interventions":13298},"NCT06611033","A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)",[87],"2024-09-25",[18],[13189,13299,13300,13301],"V118","PREVNAR 20™","Saline",{"nctId":13181,"briefTitle":13182,"status":128,"phases":13303,"primaryCompletion":13184,"completion":7109,"start":13185,"enrollment":2873,"conditions":13304,"interventions":13305},[87],[13187],[13189,13189,13174,13174],{"trials":13307,"activeCount":99},[],{"trials":13309,"activeCount":99},[],{"trials":13311,"activeCount":99},[],{"trials":13313,"activeCount":99},[],{"intervention":13300,"totalTrials":3197,"cells":13315},{"EARLY_PHASE1":13316,"PHASE1":13318,"PHASE2":13332,"PHASE3":13334,"PHASE4":13336,"NA":13338},{"trials":13317,"activeCount":99},[],{"trials":13319,"activeCount":224,"soonestReadout":13328},[13320,13324],{"nctId":13293,"briefTitle":13294,"status":105,"phases":13321,"primaryCompletion":1795,"completion":1795,"start":13296,"enrollment":2801,"conditions":13322,"interventions":13323},[87],[18],[13189,13299,13300,13301],{"nctId":13325,"briefTitle":13326,"status":128,"phases":13327,"primaryCompletion":13328,"completion":13328,"start":3435,"enrollment":1550,"conditions":13329,"interventions":13330},"NCT07168915","A Study of V118E in Healthy Participants (V118E-003)",[87],"2027-11-12",[18],[13331,13300,13301],"V118E",{"trials":13333,"activeCount":99},[],{"trials":13335,"activeCount":99},[],{"trials":13337,"activeCount":99},[],{"trials":13339,"activeCount":99},[],{"intervention":13301,"totalTrials":3197,"cells":13341},{"EARLY_PHASE1":13342,"PHASE1":13344,"PHASE2":13354,"PHASE3":13356,"PHASE4":13358,"NA":13360},{"trials":13343,"activeCount":99},[],{"trials":13345,"activeCount":224,"soonestReadout":13328},[13346,13350],{"nctId":13293,"briefTitle":13294,"status":105,"phases":13347,"primaryCompletion":1795,"completion":1795,"start":13296,"enrollment":2801,"conditions":13348,"interventions":13349},[87],[18],[13189,13299,13300,13301],{"nctId":13325,"briefTitle":13326,"status":128,"phases":13351,"primaryCompletion":13328,"completion":13328,"start":3435,"enrollment":1550,"conditions":13352,"interventions":13353},[87],[18],[13331,13300,13301],{"trials":13355,"activeCount":99},[],{"trials":13357,"activeCount":99},[],{"trials":13359,"activeCount":99},[],{"trials":13361,"activeCount":99},[],{"intervention":13363,"totalTrials":3197,"cells":13364},"MK-4646",{"EARLY_PHASE1":13365,"PHASE1":13367,"PHASE2":13388,"PHASE3":13390,"PHASE4":13392,"NA":13394},{"trials":13366,"activeCount":99},[],{"trials":13368,"activeCount":224,"soonestReadout":13373},[13369,13378],{"nctId":13370,"briefTitle":13371,"status":128,"phases":13372,"primaryCompletion":13373,"completion":13374,"start":13375,"enrollment":1624,"conditions":13376,"interventions":13377},"NCT07042945","MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)",[87],"2026-07-08","2026-08-17","2025-07-09",[7650],[13363],{"nctId":13379,"briefTitle":13380,"status":105,"phases":13381,"primaryCompletion":13382,"completion":13383,"start":13384,"enrollment":931,"conditions":13385,"interventions":13386},"NCT07199452","A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)",[87],"2025-12-27","2026-01-07","2025-10-28",[18],[13363,13387],"Rifabutin",{"trials":13389,"activeCount":99},[],{"trials":13391,"activeCount":99},[],{"trials":13393,"activeCount":99},[],{"trials":13395,"activeCount":99},[],{"intervention":7362,"totalTrials":3197,"cells":13397},{"EARLY_PHASE1":13398,"PHASE1":13400,"PHASE2":13418,"PHASE3":13420,"PHASE4":13422,"NA":13424},{"trials":13399,"activeCount":99},[],{"trials":13401,"activeCount":224,"soonestReadout":7358},[13402,13414],{"nctId":13403,"briefTitle":13404,"status":105,"phases":13405,"primaryCompletion":13406,"completion":13406,"start":13407,"enrollment":626,"conditions":13408,"interventions":13410},"NCT03311841","Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)",[87],"2018-08-02","2018-03-01",[13409],"Renal Insufficiency",[13411,13412,13413,7362],"Midazolam oral solution","Dabigatran and pitavastatin oral solution","Atorvastatin and rosuvastatin oral solution",{"nctId":7355,"briefTitle":7356,"status":230,"phases":13415,"primaryCompletion":7358,"completion":7358,"start":7359,"enrollment":4071,"conditions":13416,"interventions":13417},[87],[7342,7343],[7280,7362],{"trials":13419,"activeCount":99},[],{"trials":13421,"activeCount":99},[],{"trials":13423,"activeCount":99},[],{"trials":13425,"activeCount":99},[],{"intervention":13427,"totalTrials":224,"cells":13428},"MK-1403 + additive coformulation",{"EARLY_PHASE1":13429,"PHASE1":13431,"PHASE2":13442,"PHASE3":13444,"PHASE4":13446,"NA":13448},{"trials":13430,"activeCount":99},[],{"trials":13432,"activeCount":224,"soonestReadout":13437},[13433],{"nctId":13434,"briefTitle":13435,"status":128,"phases":13436,"primaryCompletion":13437,"completion":13437,"start":13438,"enrollment":13439,"conditions":13440,"interventions":13441},"NCT07242469","A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)",[87],"2026-08-28","2025-12-22",52,[33],[13427],{"trials":13443,"activeCount":99},[],{"trials":13445,"activeCount":99},[],{"trials":13447,"activeCount":99},[],{"trials":13449,"activeCount":99},[],{"intervention":13451,"totalTrials":224,"cells":13452},"V350A",{"EARLY_PHASE1":13453,"PHASE1":13455,"PHASE2":13465,"PHASE3":13467,"PHASE4":13469,"NA":13471},{"trials":13454,"activeCount":99},[],{"trials":13456,"activeCount":224,"soonestReadout":13461},[13457],{"nctId":13458,"briefTitle":13459,"status":128,"phases":13460,"primaryCompletion":13461,"completion":13461,"start":11603,"enrollment":688,"conditions":13462,"interventions":13463},"NCT06655324","A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).",[87],"2028-07-17",[18],[13451,13464],"V350B",{"trials":13466,"activeCount":99},[],{"trials":13468,"activeCount":99},[],{"trials":13470,"activeCount":99},[],{"trials":13472,"activeCount":99},[],{"intervention":13464,"totalTrials":224,"cells":13474},{"EARLY_PHASE1":13475,"PHASE1":13477,"PHASE2":13483,"PHASE3":13485,"PHASE4":13487,"NA":13489},{"trials":13476,"activeCount":99},[],{"trials":13478,"activeCount":224,"soonestReadout":13461},[13479],{"nctId":13458,"briefTitle":13459,"status":128,"phases":13480,"primaryCompletion":13461,"completion":13461,"start":11603,"enrollment":688,"conditions":13481,"interventions":13482},[87],[18],[13451,13464],{"trials":13484,"activeCount":99},[],{"trials":13486,"activeCount":99},[],{"trials":13488,"activeCount":99},[],{"trials":13490,"activeCount":99},[],{"intervention":326,"totalTrials":224,"cells":13492},{"EARLY_PHASE1":13493,"PHASE1":13495,"PHASE2":13501,"PHASE3":13503,"PHASE4":13505,"NA":13507},{"trials":13494,"activeCount":99},[],{"trials":13496,"activeCount":224,"soonestReadout":320},[13497],{"nctId":317,"briefTitle":318,"status":139,"phases":13498,"primaryCompletion":320,"completion":320,"start":321,"enrollment":322,"conditions":13499,"interventions":13500},[87],[324],[326,47,327],{"trials":13502,"activeCount":99},[],{"trials":13504,"activeCount":99},[],{"trials":13506,"activeCount":99},[],{"trials":13508,"activeCount":99},[],{"intervention":13510,"totalTrials":224,"cells":13511},"MK-4082",{"EARLY_PHASE1":13512,"PHASE1":13514,"PHASE2":13523,"PHASE3":13525,"PHASE4":13527,"NA":13529},{"trials":13513,"activeCount":99},[],{"trials":13515,"activeCount":224,"soonestReadout":2974},[13516],{"nctId":13517,"briefTitle":13518,"status":139,"phases":13519,"primaryCompletion":2974,"completion":2974,"start":13520,"enrollment":2023,"conditions":13521,"interventions":13522},"NCT07388667","A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)",[87],"2026-03-04",[18],[13510],{"trials":13524,"activeCount":99},[],{"trials":13526,"activeCount":99},[],{"trials":13528,"activeCount":99},[],{"trials":13530,"activeCount":99},[],{"intervention":13331,"totalTrials":224,"cells":13532},{"EARLY_PHASE1":13533,"PHASE1":13535,"PHASE2":13541,"PHASE3":13543,"PHASE4":13545,"NA":13547},{"trials":13534,"activeCount":99},[],{"trials":13536,"activeCount":224,"soonestReadout":13328},[13537],{"nctId":13325,"briefTitle":13326,"status":128,"phases":13538,"primaryCompletion":13328,"completion":13328,"start":3435,"enrollment":1550,"conditions":13539,"interventions":13540},[87],[18],[13331,13300,13301],{"trials":13542,"activeCount":99},[],{"trials":13544,"activeCount":99},[],{"trials":13546,"activeCount":99},[],{"trials":13548,"activeCount":99},[],{"intervention":499,"totalTrials":224,"cells":13550},{"EARLY_PHASE1":13551,"PHASE1":13553,"PHASE2":13559,"PHASE3":13561,"PHASE4":13563,"NA":13565},{"trials":13552,"activeCount":99},[],{"trials":13554,"activeCount":224,"soonestReadout":492},[13555],{"nctId":489,"briefTitle":490,"status":128,"phases":13556,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":13557,"interventions":13558},[87],[496,497],[499,47,500],{"trials":13560,"activeCount":99},[],{"trials":13562,"activeCount":99},[],{"trials":13564,"activeCount":99},[],{"trials":13566,"activeCount":99},[],{"intervention":509,"totalTrials":224,"cells":13568},{"EARLY_PHASE1":13569,"PHASE1":13571,"PHASE2":13577,"PHASE3":13579,"PHASE4":13581,"NA":13583},{"trials":13570,"activeCount":99},[],{"trials":13572,"activeCount":224,"soonestReadout":505},[13573],{"nctId":502,"briefTitle":503,"status":139,"phases":13574,"primaryCompletion":505,"completion":505,"start":506,"enrollment":367,"conditions":13575,"interventions":13576},[87],[382],[509,47],{"trials":13578,"activeCount":99},[],{"trials":13580,"activeCount":99},[],{"trials":13582,"activeCount":99},[],{"trials":13584,"activeCount":99},[],{"intervention":7552,"totalTrials":224,"cells":13586},{"EARLY_PHASE1":13587,"PHASE1":13589,"PHASE2":13595,"PHASE3":13597,"PHASE4":13599,"NA":13601},{"trials":13588,"activeCount":99},[],{"trials":13590,"activeCount":224,"soonestReadout":7549},[13591],{"nctId":7546,"briefTitle":7547,"status":128,"phases":13592,"primaryCompletion":7549,"completion":3090,"start":5574,"enrollment":558,"conditions":13593,"interventions":13594},[87],[18],[7552,7488,5578],{"trials":13596,"activeCount":99},[],{"trials":13598,"activeCount":99},[],{"trials":13600,"activeCount":99},[],{"trials":13602,"activeCount":99},[],{"intervention":13604,"totalTrials":224,"cells":13605},"Bictegravir\u002Femtricitabine\u002Ftenofovir alafenamide",{"EARLY_PHASE1":13606,"PHASE1":13608,"PHASE2":13618,"PHASE3":13620,"PHASE4":13622,"NA":13624},{"trials":13607,"activeCount":99},[],{"trials":13609,"activeCount":224,"soonestReadout":4174},[13610],{"nctId":13611,"briefTitle":13612,"status":128,"phases":13613,"primaryCompletion":4174,"completion":4174,"start":5974,"enrollment":3655,"conditions":13614,"interventions":13615},"NCT07532304","A Clinical Trial of MK-4646 With Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)",[87],[18],[13604,13616,13617],"Dolutegravir","MK4646",{"trials":13619,"activeCount":99},[],{"trials":13621,"activeCount":99},[],{"trials":13623,"activeCount":99},[],{"trials":13625,"activeCount":99},[],{"intervention":13616,"totalTrials":224,"cells":13627},{"EARLY_PHASE1":13628,"PHASE1":13630,"PHASE2":13636,"PHASE3":13638,"PHASE4":13640,"NA":13642},{"trials":13629,"activeCount":99},[],{"trials":13631,"activeCount":224,"soonestReadout":4174},[13632],{"nctId":13611,"briefTitle":13612,"status":128,"phases":13633,"primaryCompletion":4174,"completion":4174,"start":5974,"enrollment":3655,"conditions":13634,"interventions":13635},[87],[18],[13604,13616,13617],{"trials":13637,"activeCount":99},[],{"trials":13639,"activeCount":99},[],{"trials":13641,"activeCount":99},[],{"trials":13643,"activeCount":99},[],{"intervention":13617,"totalTrials":224,"cells":13645},{"EARLY_PHASE1":13646,"PHASE1":13648,"PHASE2":13654,"PHASE3":13656,"PHASE4":13658,"NA":13660},{"trials":13647,"activeCount":99},[],{"trials":13649,"activeCount":224,"soonestReadout":4174},[13650],{"nctId":13611,"briefTitle":13612,"status":128,"phases":13651,"primaryCompletion":4174,"completion":4174,"start":5974,"enrollment":3655,"conditions":13652,"interventions":13653},[87],[18],[13604,13616,13617],{"trials":13655,"activeCount":99},[],{"trials":13657,"activeCount":99},[],{"trials":13659,"activeCount":99},[],{"trials":13661,"activeCount":99},[],{"intervention":11056,"totalTrials":224,"cells":13663},{"EARLY_PHASE1":13664,"PHASE1":13666,"PHASE2":13672,"PHASE3":13674,"PHASE4":13676,"NA":13678},{"trials":13665,"activeCount":99},[],{"trials":13667,"activeCount":224,"soonestReadout":11052},[13668],{"nctId":11049,"briefTitle":11050,"status":139,"phases":13669,"primaryCompletion":11052,"completion":11052,"start":11053,"enrollment":380,"conditions":13670,"interventions":13671},[87],[18],[11042,11056],{"trials":13673,"activeCount":99},[],{"trials":13675,"activeCount":99},[],{"trials":13677,"activeCount":99},[],{"trials":13679,"activeCount":99},[],{"intervention":13681,"totalTrials":224,"cells":13682},"MK-8294",{"EARLY_PHASE1":13683,"PHASE1":13685,"PHASE2":13695,"PHASE3":13697,"PHASE4":13699,"NA":13701},{"trials":13684,"activeCount":99},[],{"trials":13686,"activeCount":224,"soonestReadout":13691},[13687],{"nctId":13688,"briefTitle":13689,"status":128,"phases":13690,"primaryCompletion":13691,"completion":13691,"start":9154,"enrollment":2647,"conditions":13692,"interventions":13694},"NCT07030712","A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)",[87],"2027-08-23",[13693],"Metastatic Neoplasm",[13681,13681,13681,13681,13681,13681,13681,13681],{"trials":13696,"activeCount":99},[],{"trials":13698,"activeCount":99},[],{"trials":13700,"activeCount":99},[],{"trials":13702,"activeCount":99},[],{"intervention":13704,"totalTrials":224,"cells":13705},"Tulisokibart Form 1",{"EARLY_PHASE1":13706,"PHASE1":13708,"PHASE2":13719,"PHASE3":13721,"PHASE4":13723,"NA":13725},{"trials":13707,"activeCount":99},[],{"trials":13709,"activeCount":224,"soonestReadout":13714},[13710],{"nctId":13711,"briefTitle":13712,"status":128,"phases":13713,"primaryCompletion":13714,"completion":13714,"start":2256,"enrollment":13715,"conditions":13716,"interventions":13717},"NCT07405177","A Study of MK-7240 in Healthy Participants (MK-7240-009)",[87],"2026-09-03",330,[18],[13704,13718],"Tulisokibart Form 2",{"trials":13720,"activeCount":99},[],{"trials":13722,"activeCount":99},[],{"trials":13724,"activeCount":99},[],{"trials":13726,"activeCount":99},[],{"intervention":13718,"totalTrials":224,"cells":13728},{"EARLY_PHASE1":13729,"PHASE1":13731,"PHASE2":13737,"PHASE3":13739,"PHASE4":13741,"NA":13743},{"trials":13730,"activeCount":99},[],{"trials":13732,"activeCount":224,"soonestReadout":13714},[13733],{"nctId":13711,"briefTitle":13712,"status":128,"phases":13734,"primaryCompletion":13714,"completion":13714,"start":2256,"enrollment":13715,"conditions":13735,"interventions":13736},[87],[18],[13704,13718],{"trials":13738,"activeCount":99},[],{"trials":13740,"activeCount":99},[],{"trials":13742,"activeCount":99},[],{"trials":13744,"activeCount":99},[],{"intervention":13746,"totalTrials":224,"cells":13747},"MK-4884",{"EARLY_PHASE1":13748,"PHASE1":13750,"PHASE2":13760,"PHASE3":13762,"PHASE4":13764,"NA":13766},{"trials":13749,"activeCount":99},[],{"trials":13751,"activeCount":224,"soonestReadout":13756},[13752],{"nctId":13753,"briefTitle":13754,"status":230,"phases":13755,"primaryCompletion":13756,"completion":13756,"start":13757,"enrollment":2023,"conditions":13758,"interventions":13759},"NCT07600749","Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)",[87],"2029-10-04","2026-06-15",[690],[13746],{"trials":13761,"activeCount":99},[],{"trials":13763,"activeCount":99},[],{"trials":13765,"activeCount":99},[],{"trials":13767,"activeCount":99},[],{"intervention":11064,"totalTrials":224,"cells":13769},{"EARLY_PHASE1":13770,"PHASE1":13772,"PHASE2":13778,"PHASE3":13780,"PHASE4":13782,"NA":13784},{"trials":13771,"activeCount":99},[],{"trials":13773,"activeCount":224,"soonestReadout":11061},[13774],{"nctId":11058,"briefTitle":11059,"status":139,"phases":13775,"primaryCompletion":11061,"completion":11061,"start":3561,"enrollment":380,"conditions":13776,"interventions":13777},[87],[18],[11064,11042],{"trials":13779,"activeCount":99},[],{"trials":13781,"activeCount":99},[],{"trials":13783,"activeCount":99},[],{"trials":13785,"activeCount":99},[],{"intervention":692,"totalTrials":224,"cells":13787},{"EARLY_PHASE1":13788,"PHASE1":13790,"PHASE2":13796,"PHASE3":13798,"PHASE4":13800,"NA":13802},{"trials":13789,"activeCount":99},[],{"trials":13791,"activeCount":224,"soonestReadout":686},[13792],{"nctId":683,"briefTitle":684,"status":128,"phases":13793,"primaryCompletion":686,"completion":686,"start":687,"enrollment":688,"conditions":13794,"interventions":13795},[87],[690],[692,47,693],{"trials":13797,"activeCount":99},[],{"trials":13799,"activeCount":99},[],{"trials":13801,"activeCount":99},[],{"trials":13803,"activeCount":99},[],{"intervention":4084,"totalTrials":13805,"cells":13806},51,{"EARLY_PHASE1":13807,"PHASE1":13809,"PHASE2":13842,"PHASE3":13942,"PHASE4":14267,"NA":14291},{"trials":13808,"activeCount":99},[],{"trials":13810,"activeCount":224,"soonestReadout":12844},[13811,13821,13830,13834,13838],{"nctId":13812,"briefTitle":13813,"status":105,"phases":13814,"primaryCompletion":13815,"completion":13815,"start":13816,"enrollment":9323,"conditions":13817,"interventions":13818},"NCT01557504","A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)",[87],"2014-04-29","2012-07-18",[15],[13819,4084,13820],"Sitagliptin\u002Fmetformin XR","Thyroid hormone",{"nctId":13822,"briefTitle":13823,"status":105,"phases":13824,"primaryCompletion":13825,"completion":13825,"start":13826,"enrollment":3496,"conditions":13827,"interventions":13828},"NCT00673465","Effect of SCH 497079 on Metabolic Parameters and Influence of Race\u002FEthnic Origin on Therapeutic Response (Study P05338)(COMPLETED)",[87],"2008-12-11","2008-04-17",[15],[13829,4084],"SCH 497079",{"nctId":4077,"briefTitle":4078,"status":105,"phases":13831,"primaryCompletion":4080,"completion":466,"start":4081,"enrollment":4071,"conditions":13832,"interventions":13833},[87],[18],[4084,56],{"nctId":5570,"briefTitle":5571,"status":105,"phases":13835,"primaryCompletion":5573,"completion":5574,"start":5575,"enrollment":3655,"conditions":13836,"interventions":13837},[87],[18],[5578,4084,602],{"nctId":12841,"briefTitle":12842,"status":139,"phases":13839,"primaryCompletion":12844,"completion":12844,"start":12845,"enrollment":95,"conditions":13840,"interventions":13841},[87],[18],[8011,4084,7801],{"trials":13843,"activeCount":99},[13844,13856,13866,13874,13886,13895,13903,13915,13921,13932],{"nctId":13845,"briefTitle":13846,"status":105,"phases":13847,"primaryCompletion":13848,"completion":13849,"start":13850,"enrollment":13851,"conditions":13852,"interventions":13854},"NCT00481663","A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)",[88],"2004-07-21","2006-05-14","2003-08-19",555,[13853],"Type II Diabetes Mellitus",[13145,4084,13855],"Rescue",{"nctId":13857,"briefTitle":13858,"status":150,"phases":13859,"primaryCompletion":4990,"completion":12813,"start":6309,"enrollment":13860,"conditions":13861,"interventions":13862},"NCT00767000","Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)",[88],813,[33],[13863,13864,13865,4084],"MK-0941","Comparator: Placebo","Lantus",{"nctId":13867,"briefTitle":13868,"status":105,"phases":13869,"primaryCompletion":13870,"completion":13870,"start":5281,"enrollment":110,"conditions":13871,"interventions":13872},"NCT00631488","A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)",[88],"2009-01",[33],[13873,13145,4084],"MK-0893",{"nctId":13875,"briefTitle":13876,"status":105,"phases":13877,"primaryCompletion":13878,"completion":13878,"start":9143,"enrollment":13879,"conditions":13880,"interventions":13881},"NCT01059825","Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)",[88],"2011-01-20",375,[33],[13882,13883,13884,13885,4084],"Ertugliflozin 1 mg","Ertugliflozin 5 mg","Ertugliflozin 25 mg","Sitagliptin 100 mg",{"nctId":13887,"briefTitle":13888,"status":150,"phases":13889,"primaryCompletion":13890,"completion":13890,"start":13891,"enrollment":9551,"conditions":13892,"interventions":13893},"NCT00479466","Dose-Range Finding Study for MK0893 (0893-008)",[88],"2008-05","2007-07",[33],[13894,4084],"MK0893",{"nctId":13896,"briefTitle":13897,"status":105,"phases":13898,"primaryCompletion":13899,"completion":13899,"start":13900,"enrollment":193,"conditions":13901,"interventions":13902},"NCT02004886","A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)",[88],"2007-02-07","2006-08-11",[15],[13873,4084],{"nctId":13904,"briefTitle":13905,"status":105,"phases":13906,"primaryCompletion":13907,"completion":13908,"start":13909,"enrollment":13910,"conditions":13911,"interventions":13912},"NCT01217073","A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)",[88],"2012-01-03","2013-04-01","2010-10-08",685,[15],[13913,13914,4084],"Omarigliptin","Pioglitazone",{"nctId":13916,"briefTitle":13917,"status":105,"phases":13918,"primaryCompletion":6308,"completion":6308,"start":13870,"enrollment":5196,"conditions":13919,"interventions":13920},"NCT00792935","A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017)",[88],[15],[13863,13146,4084],{"nctId":13922,"briefTitle":13923,"status":150,"phases":13924,"primaryCompletion":13925,"completion":13925,"start":13926,"enrollment":13927,"conditions":13928,"interventions":13929},"NCT02492763","A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)",[88],"2017-04-18","2015-07-27",176,[13853],[13930,13931,4084],"MK-8521","Liraglutide",{"nctId":13933,"briefTitle":13934,"status":150,"phases":13935,"primaryCompletion":13936,"completion":13937,"start":13938,"enrollment":901,"conditions":13939,"interventions":13940},"NCT00868790","A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)",[88],"2010-07-12","2010-07-13","2009-03-24",[15],[13941,4084],"MK-3577",{"trials":13943,"activeCount":99},[13944,13952,13962,13972,13988,13999,14009,14019,14029,14041,14050,14060,14068,14080,14088,14099,14108,14117,14129,14139,14149,14160,14171,14181,14188,14199,14209,14217,14224,14235,14243,14247,14258],{"nctId":13945,"briefTitle":13946,"status":105,"phases":13947,"primaryCompletion":5250,"completion":5250,"start":13948,"enrollment":5017,"conditions":13949,"interventions":13951},"NCT01814748","A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and \u003C45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)",[89],"2013-05-03",[13950],"Diabetes Mellitus",[13913,4084],{"nctId":13953,"briefTitle":13954,"status":105,"phases":13955,"primaryCompletion":13956,"completion":13956,"start":13957,"enrollment":13958,"conditions":13959,"interventions":13960},"NCT00885352","Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)",[89],"2010-11-10","2009-04-15",313,[15],[13145,13864,13914,4084,13961],"Glipizide",{"nctId":13963,"briefTitle":13964,"status":105,"phases":13965,"primaryCompletion":13966,"completion":13966,"start":13967,"enrollment":13968,"conditions":13969,"interventions":13970},"NCT01755156","A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)",[89],"2016-03-16","2013-01-11",402,[15],[13913,13146,13971,4084],"Insulin glargine",{"nctId":13973,"briefTitle":13974,"status":105,"phases":13975,"primaryCompletion":13976,"completion":13977,"start":13978,"enrollment":13979,"conditions":13980,"interventions":13981},"NCT01076075","A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)",[89],"2011-07-11","2012-01-19","2010-06-03",427,[15],[13982,13983,13984,13985,13986,4084,13987],"Sitagliptin phosphate","Comparator: placebo to pioglitazone","Comparator: placebo to Sitagliptin","Comparator: pioglitazone","Glimepiride or gliclazide","Pioglitazone rescue therapy",{"nctId":13989,"briefTitle":13990,"status":105,"phases":13991,"primaryCompletion":13992,"completion":13993,"start":13994,"enrollment":13995,"conditions":13996,"interventions":13997},"NCT01462266","Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)",[89],"2013-06-06","2013-06-07","2012-01-13",660,[15],[13145,13864,13998,4084],"Insulin Glargine",{"nctId":14000,"briefTitle":14001,"status":105,"phases":14002,"primaryCompletion":14003,"completion":14003,"start":14004,"enrollment":14005,"conditions":14006,"interventions":14007},"NCT01682759","A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)",[89],"2015-01-26","2012-09-10",751,[15],[13913,13146,14008,4084,13998],"Glimepiride Placebo",{"nctId":14010,"briefTitle":14011,"status":105,"phases":14012,"primaryCompletion":14013,"completion":14013,"start":14014,"enrollment":1685,"conditions":14015,"interventions":14016},"NCT02532855","A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)",[89],"2017-10-10","2015-10-20",[15],[13145,14017,4084,14018],"Dapagliflozin","Sulfonylurea",{"nctId":14020,"briefTitle":14021,"status":105,"phases":14022,"primaryCompletion":14023,"completion":9322,"start":14024,"enrollment":14025,"conditions":14026,"interventions":14027},"NCT00722371","MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)",[89],"2010-10-26","2008-09-05",1615,[15],[13982,14028,4084],"Pioglitazone hydrochloride",{"nctId":14030,"briefTitle":14031,"status":105,"phases":14032,"primaryCompletion":14033,"completion":14034,"start":14035,"enrollment":14036,"conditions":14037,"interventions":14038},"NCT00482729","MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)",[89],"2008-11-03","2009-04-27","2007-06-19",1246,[15],[14039,14040],"sitagliptin phosphate (+) metformin hydrochloride","metformin",{"nctId":14042,"briefTitle":14043,"status":105,"phases":14044,"primaryCompletion":719,"completion":719,"start":14045,"enrollment":14046,"conditions":14047,"interventions":14048},"NCT02630706","A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)",[89],"2015-12-16",506,[15],[13883,14049,4084,13146],"Ertugliflozin 15 mg",{"nctId":14051,"briefTitle":14052,"status":105,"phases":14053,"primaryCompletion":14054,"completion":14054,"start":14055,"enrollment":14056,"conditions":14057,"interventions":14058},"NCT02036515","Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)",[89],"2016-06-06","2014-03-12",464,[15],[13883,14049,4084,13145,13146,14059],"Insulin",{"nctId":14061,"briefTitle":14062,"status":105,"phases":14063,"primaryCompletion":14064,"completion":14064,"start":14065,"enrollment":2182,"conditions":14066,"interventions":14067},"NCT01340768","Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)",[89],"2011-09-21","2010-06-22",[15],[13145,14018,4084],{"nctId":14069,"briefTitle":14070,"status":105,"phases":14071,"primaryCompletion":14072,"completion":14072,"start":14073,"enrollment":14074,"conditions":14075,"interventions":14076},"NCT01760447","A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170\u002FMK-0431A-289)",[89],"2019-09-17","2011-12-07",223,[15],[14077,4084,14078,14059,14079],"Sitagliptin plus metformin","Sitagliptin plus metformin XR","Metformin XR",{"nctId":14081,"briefTitle":14082,"status":105,"phases":14083,"primaryCompletion":14084,"completion":14084,"start":14085,"enrollment":1747,"conditions":14086,"interventions":14087},"NCT01704261","Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)",[89],"2014-12-23","2012-10-18",[15],[13913,13146,4084],{"nctId":14089,"briefTitle":14090,"status":105,"phases":14091,"primaryCompletion":14092,"completion":14093,"start":14094,"enrollment":14095,"conditions":14096,"interventions":14098},"NCT00086515","Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)",[89],"2005-07-20","2007-02-02","2004-06-30",701,[14097],"Diabetes Mellitus, Type II",[13145,4084,13914],{"nctId":14100,"briefTitle":14101,"status":105,"phases":14102,"primaryCompletion":14103,"completion":14103,"start":14104,"enrollment":184,"conditions":14105,"interventions":14106},"NCT01702298","A Study to Assess the Safety and Tolerability of Sitagliptin\u002FSimvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)",[89],"2013-05-29","2012-12-07",[15],[14107,4084],"Sitagliptin 100 mg\u002Fsimvastatin 40 mg FDC",{"nctId":14109,"briefTitle":14110,"status":105,"phases":14111,"primaryCompletion":14112,"completion":14112,"start":14113,"enrollment":14114,"conditions":14115,"interventions":14116},"NCT01545388","Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)",[89],"2013-03-12","2012-02-23",337,[15],[13145,4084,4084],{"nctId":14118,"briefTitle":14119,"status":105,"phases":14120,"primaryCompletion":14121,"completion":14122,"start":14123,"enrollment":2555,"conditions":14124,"interventions":14125},"NCT00350779","Sitagliptin Metformin\u002FPPARg Agonist Combination Therapy Add-on (0431-052)",[89],"2007-09-25","2008-06-11","2006-06-12",[15],[14126,13864,14127,14040,14128],"sitagliptin","rosiglitazone","glipizide",{"nctId":14130,"briefTitle":14131,"status":150,"phases":14132,"primaryCompletion":14133,"completion":14133,"start":14134,"enrollment":14135,"conditions":14136,"interventions":14137},"NCT01678820","A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)",[89],"2013-11-01","2012-10-10",299,[15],[14138,13145,13122,4084,13146],"Sitagliptin\u002FSimvastatin FDC",{"nctId":14140,"briefTitle":14141,"status":105,"phases":14142,"primaryCompletion":13925,"completion":13925,"start":14143,"enrollment":14144,"conditions":14145,"interventions":14146},"NCT01999218","Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)",[89],"2013-12-16",1326,[15],[13883,14147,14148,4084,13145],"Ertugliflozin 10 mg","Glimerpiride",{"nctId":14150,"briefTitle":14151,"status":105,"phases":14152,"primaryCompletion":14153,"completion":14153,"start":14154,"enrollment":8416,"conditions":14155,"interventions":14157},"NCT01485614","Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)",[89],"2019-10-09","2012-02-10",[13950,14156],"Type 2 Diabetes",[13145,4084,14158,14159],"Glycemic Rescue 1","Glycemic Rescue 2",{"nctId":14161,"briefTitle":14162,"status":105,"phases":14163,"primaryCompletion":14164,"completion":14164,"start":14165,"enrollment":14166,"conditions":14167,"interventions":14168},"NCT01296412","Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)",[89],"2012-02-29","2011-03-11",653,[33],[14126,14169,14170,14040],"liraglutide","glimepiride",{"nctId":14172,"briefTitle":14173,"status":105,"phases":14174,"primaryCompletion":14175,"completion":14175,"start":14176,"enrollment":14177,"conditions":14178,"interventions":14179},"NCT02033889","A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).",[89],"2017-08-03","2013-12-13",621,[15],[13883,14049,14180,4084],"Basal Insulin",{"nctId":14182,"briefTitle":14183,"status":105,"phases":14184,"primaryCompletion":9164,"completion":9164,"start":14185,"enrollment":6396,"conditions":14186,"interventions":14187},"NCT01717313","A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)",[89],"2012-12-05",[15],[13913,4084,13146],{"nctId":14189,"briefTitle":14190,"status":105,"phases":14191,"primaryCompletion":14192,"completion":14193,"start":14194,"enrollment":14195,"conditions":14196,"interventions":14197},"NCT01590771","A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)",[89],"2014-06-10","2014-06-24","2012-07-09",498,[15],[13145,14198,13146,4084],"Gliclazide",{"nctId":14200,"briefTitle":14201,"status":105,"phases":14202,"primaryCompletion":14203,"completion":14204,"start":14205,"enrollment":14206,"conditions":14207,"interventions":14208},"NCT01590797","A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)",[89],"2014-06-11","2014-06-25","2012-07-10",467,[15],[13145,14059,4084],{"nctId":14210,"briefTitle":14211,"status":105,"phases":14212,"primaryCompletion":14213,"completion":14213,"start":14214,"enrollment":154,"conditions":14215,"interventions":14216},"NCT01034111","A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)",[89],"2010-10-04","2010-03-01",[14156],[13982,4084],{"nctId":14218,"briefTitle":14219,"status":105,"phases":14220,"primaryCompletion":4344,"completion":4344,"start":14221,"enrollment":13142,"conditions":14222,"interventions":14223},"NCT04029480","Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835\u002FPF-04971729) (MK-8835-059)",[89],"2019-10-08",[15],[13883,14049,14059,4084],{"nctId":14225,"briefTitle":14226,"status":105,"phases":14227,"primaryCompletion":14228,"completion":14228,"start":14229,"enrollment":14230,"conditions":14231,"interventions":14232},"NCT00086502","Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus",[89],"2005-11","2004-06",353,[33],[14233,13864,14234,4084],"Comparator: Sitagliptin","Comparator: Pioglitazone",{"nctId":14236,"briefTitle":14237,"status":105,"phases":14238,"primaryCompletion":14239,"completion":9574,"start":2571,"enrollment":14240,"conditions":14241,"interventions":14242},"NCT02738879","Randomized Sitagliptin Withdrawal Study (MK-0431-845)",[89],"2018-01-22",746,[15],[13145,4084,14079,13971],{"nctId":13137,"briefTitle":13138,"status":150,"phases":14244,"primaryCompletion":13140,"completion":13140,"start":13141,"enrollment":13142,"conditions":14245,"interventions":14246},[89],[15],[13145,8011,4084,13146,13146],{"nctId":14248,"briefTitle":14249,"status":105,"phases":14250,"primaryCompletion":14251,"completion":14251,"start":14252,"enrollment":14253,"conditions":14254,"interventions":14255},"NCT01028391","30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)",[89],"2009-01-01","2007-09-01",317,[15],[14256,14257,4084],"Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.","Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.",{"nctId":14259,"briefTitle":14260,"status":105,"phases":14261,"primaryCompletion":14262,"completion":14262,"start":14263,"enrollment":14264,"conditions":14265,"interventions":14266},"NCT01958671","A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)",[89],"2016-07-28","2013-10-09",461,[15],[13883,14147,4084,13146],{"trials":14268,"activeCount":99},[14269,14280],{"nctId":14270,"briefTitle":14271,"status":105,"phases":14272,"primaryCompletion":14273,"completion":14273,"start":14274,"enrollment":14275,"conditions":14276,"interventions":14278},"NCT01131182","Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)",[90],"2010-11-04","2010-06-13",1147,[14277],"Type 2 Diabetes Mellitus (T2DM)",[13982,14279,4084],"Comparator: Sulfonylurea",{"nctId":14281,"briefTitle":14282,"status":105,"phases":14283,"primaryCompletion":14284,"completion":14284,"start":14285,"enrollment":14286,"conditions":14287,"interventions":14288},"NCT01709305","A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)",[90],"2015-04-17","2012-11-08",5570,[15],[4084,13145,14289,14290,13146,14198],"Acarbose","Repaglinide",{"trials":14292,"activeCount":99},[14293],{"nctId":14294,"briefTitle":14295,"status":105,"phases":14296,"primaryCompletion":14297,"completion":14297,"start":14298,"enrollment":14299,"conditions":14300,"interventions":14301},"NCT01357135","An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®\u002FXelevia®, MK-0431-201)",[],"2013-08-31","2009-07-15",3453,[15],[4084,13145,14018,14302],"Antihyperglycemic Medication",{"intervention":13864,"totalTrials":110,"cells":14304},{"EARLY_PHASE1":14305,"PHASE1":14307,"PHASE2":14739,"PHASE3":15088,"PHASE4":15600,"NA":15609},{"trials":14306,"activeCount":99},[],{"trials":14308,"activeCount":99},[14309,14320,14332,14340,14348,14359,14368,14378,14388,14398,14404,14413,14424,14433,14441,14450,14459,14471,14479,14490,14500,14510,14519,14527,14536,14544,14555,14562,14572,14580,14589,14600,14610,14619,14629,14637,14648,14658,14667,14674,14683,14693,14701,14709,14720,14726,14733],{"nctId":14310,"briefTitle":14311,"status":105,"phases":14312,"primaryCompletion":14313,"completion":14314,"start":14315,"enrollment":36,"conditions":14316,"interventions":14318},"NCT00782418","A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED)",[87],"2009-02","2009-03","2008-09",[14317],"The Methodology Assessment of Glucose Dependent Insulin Secretion",[14319,14319,13864],"Comparator: exenatide",{"nctId":14321,"briefTitle":14322,"status":105,"phases":14323,"primaryCompletion":13102,"completion":13102,"start":14324,"enrollment":14325,"conditions":14326,"interventions":14327},"NCT01017458","Safety and Tolerability of MK0773 in Healthy Older Men (0773-004)",[87],"2007-06",68,[18],[14328,14329,14330,14331],"MK0773","Comparator: testosterone enanthate","Comparator: placebo oral","Comparator: placebo",{"nctId":14333,"briefTitle":14334,"status":105,"phases":14335,"primaryCompletion":5982,"completion":13222,"start":6308,"enrollment":661,"conditions":14336,"interventions":14338},"NCT01071291","Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)",[87],[14337],"Dyslipidemia",[14339,13864],"Niaspan",{"nctId":14341,"briefTitle":14342,"status":105,"phases":14343,"primaryCompletion":5179,"completion":5179,"start":12813,"enrollment":9323,"conditions":14344,"interventions":14345},"NCT01110616","EEG (Electroencephalogram) Platform Standardization in Healthy Male Subjects (3134-010)",[87],[11195],[14346,14347,13864],"MK3134","Comparator: Lorazepam",{"nctId":14349,"briefTitle":14350,"status":105,"phases":14351,"primaryCompletion":14352,"completion":14352,"start":14353,"enrollment":31,"conditions":14354,"interventions":14356},"NCT00820664","A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women",[87],"2009-05","2008-12",[14355],"Postmenopausal Symptoms",[14357,14358,13864],"Comparator: Estrace 0.5 mg","Comparator: Estrace 2 mg",{"nctId":14360,"briefTitle":14361,"status":105,"phases":14362,"primaryCompletion":14363,"completion":14363,"start":14364,"enrollment":120,"conditions":14365,"interventions":14366},"NCT01104545","A Study of Single Dose MK-3614 (MK-3614-001)(COMPLETED)",[87],"2009-05-01","2008-11-01",[30],[14367,13864],"MK-3614",{"nctId":14369,"briefTitle":14370,"status":105,"phases":14371,"primaryCompletion":14372,"completion":14372,"start":14373,"enrollment":154,"conditions":14374,"interventions":14375},"NCT01033318","A Study of the Pharmacokinetics and Pharmacodynamics of MK1809 (1809-001)(COMPLETED)",[87],"2008-06-19","2007-09-11",[30],[14376,14377,13864],"MK1809","Comparator: Losartan",{"nctId":14379,"briefTitle":14380,"status":105,"phases":14381,"primaryCompletion":14382,"completion":14383,"start":14384,"enrollment":1621,"conditions":14385,"interventions":14386},"NCT00972322","Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)",[87],"2010-01-12","2010-01-26","2009-08-24",[15],[14387,14331],"MK-8245",{"nctId":14389,"briefTitle":14390,"status":105,"phases":14391,"primaryCompletion":14392,"completion":14392,"start":14393,"enrollment":5077,"conditions":14394,"interventions":14396},"NCT00696709","A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)",[87],"2009-11-16","2008-12-12",[14395],"Herpes Zoster",[14397,13864],"Comparator: V212",{"nctId":14399,"briefTitle":14400,"status":105,"phases":14401,"primaryCompletion":5801,"completion":5801,"start":8620,"enrollment":95,"conditions":14402,"interventions":14403},"NCT01104519","A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093)",[87],[14337],[14339,13864],{"nctId":14405,"briefTitle":14406,"status":105,"phases":14407,"primaryCompletion":14408,"completion":14408,"start":14409,"enrollment":367,"conditions":14410,"interventions":14411},"NCT00511667","A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)",[87],"2008-04","2007-05",[15],[14412,13864],"MK0941",{"nctId":14414,"briefTitle":14415,"status":105,"phases":14416,"primaryCompletion":13224,"completion":4990,"start":8591,"enrollment":8016,"conditions":14417,"interventions":14419},"NCT01012219","A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)",[87],[14418,13133],"Primary Hypercholesterolemia",[14420,14421,14422,14423,14331],"niacin (+) laropiprant","Comparator: aspirin","Comparator: clopidogrel","Comparator: laropiprant",{"nctId":14425,"briefTitle":14426,"status":105,"phases":14427,"primaryCompletion":5982,"completion":5982,"start":12813,"enrollment":2901,"conditions":14428,"interventions":14430},"NCT01108588","Reproducibility and Comparison of Platelet Function Assays With Aspirin and Clopidogrel (MK-0000-167)",[87],[14429],"Healthy Volunteers",[14431,14432,13864],"Aspirin","Clopidogrel",{"nctId":14434,"briefTitle":14435,"status":105,"phases":14436,"primaryCompletion":13890,"completion":9610,"start":13891,"enrollment":9323,"conditions":14437,"interventions":14440},"NCT00632931","A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)",[87],[14438,14439],"Advanced Cancer Relapsed","Advanced Cancer Refractory",[4994,14331],{"nctId":14442,"briefTitle":14443,"status":105,"phases":14444,"primaryCompletion":13224,"completion":13224,"start":14445,"enrollment":4305,"conditions":14446,"interventions":14448},"NCT00953056","A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED)",[87],"2009-09",[14447],"Rotavirus Gastroenteritis",[14449,13864,14449,13864],"Rotavirus Vaccine, Live, Oral, Pentavalent",{"nctId":14451,"briefTitle":14452,"status":105,"phases":14453,"primaryCompletion":14454,"completion":14454,"start":5507,"enrollment":3506,"conditions":14455,"interventions":14456},"NCT00618995","A Study to Evaluate the Effects of ER Niacin\u002FLaropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)",[87],"2007-12",[15],[14457,14458,14423,14331],"Comparator: ER niacin (+) laropiprant","Comparator: ER niacin",{"nctId":14460,"briefTitle":14461,"status":105,"phases":14462,"primaryCompletion":14315,"completion":14315,"start":14454,"enrollment":14463,"conditions":14464,"interventions":14469},"NCT00570310","Neuropathic Pain Syndrome Patient Study (MK-0000-072)",[87],104,[14465,14466,14467,14468],"Neuralgia, Postherpetic","Diabetic Neuropathy","Painful Small-Fiber Neuropathy","Idiopathic Distal Sensory Polyneuropathy",[14470,13864],"Comparator: pregabalin",{"nctId":14472,"briefTitle":14473,"status":105,"phases":14474,"primaryCompletion":13101,"completion":13101,"start":14314,"enrollment":2023,"conditions":14475,"interventions":14476},"NCT00886613","A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)",[87],[14395],[14477,14478,13864],"V212","Comparator: Zostavax™",{"nctId":14480,"briefTitle":14481,"status":105,"phases":14482,"primaryCompletion":14483,"completion":14483,"start":14484,"enrollment":3655,"conditions":14485,"interventions":14486},"NCT00975052","A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)",[87],"2006-03","2006-01",[14156],[14487,14488,14489,14331],"sitagliptin phosphate","Comparator: metformin","Comparator: sitagliptin and metformin",{"nctId":14491,"briefTitle":14492,"status":105,"phases":14493,"primaryCompletion":14484,"completion":14494,"start":14495,"enrollment":3496,"conditions":14496,"interventions":14497},"NCT00857311","MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)",[87],"2010-05","2004-05",[24],[14498,13864,14499,14498],"MRKAd5 HIV-1 gag vaccine","Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed",{"nctId":14501,"briefTitle":14502,"status":105,"phases":14503,"primaryCompletion":5281,"completion":5281,"start":14504,"enrollment":154,"conditions":14505,"interventions":14507},"NCT00812396","Biomarkers of Muscle Anabolism (MK-0000-082)",[87],"2007-11",[14506],"Muscle Anabolism",[14508,14509,14331],"Comparator: low dose testosterone","Comparator: high dose testosterone",{"nctId":14511,"briefTitle":14512,"status":105,"phases":14513,"primaryCompletion":14514,"completion":14515,"start":14516,"enrollment":722,"conditions":14517,"interventions":14518},"NCT00541229","Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)",[87],"2008-06-17","2008-07-01","2007-08-24",[14156],[14487,14487,13864],{"nctId":14520,"briefTitle":14521,"status":105,"phases":14522,"primaryCompletion":14408,"completion":6308,"start":5507,"enrollment":4059,"conditions":14523,"interventions":14525},"NCT00548353","A Study of Gastric Delay in Migraine Patients (3207-003)",[87],[14524],"Migraine Disorders",[14526,13864],"MK3207",{"nctId":14528,"briefTitle":14529,"status":105,"phases":14530,"primaryCompletion":14531,"completion":14531,"start":14228,"enrollment":826,"conditions":14532,"interventions":14534},"NCT00303069","V710 First-In-Man (FIM) Study (V710-001)",[87],"2006-07",[14533],"Staphylococcal Infections",[14535,13864],"V710",{"nctId":14537,"briefTitle":14538,"status":105,"phases":14539,"primaryCompletion":14540,"completion":14454,"start":5507,"enrollment":13805,"conditions":14541,"interventions":14542},"NCT00822757","Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004)",[87],"2007-10",[18],[14543,14331],"Comparator: V710",{"nctId":14545,"briefTitle":14546,"status":105,"phases":14547,"primaryCompletion":14548,"completion":14549,"start":14550,"enrollment":347,"conditions":14551,"interventions":14553},"NCT01068262","Safety and Tolerability of Odanacatib (0822-059)",[87],"2010-04-26","2010-05-02","2009-12-08",[14552],"Osteoporosis",[14554,13864],"Odanacatib",{"nctId":14556,"briefTitle":14557,"status":105,"phases":14558,"primaryCompletion":14445,"completion":14445,"start":6309,"enrollment":4071,"conditions":14559,"interventions":14560},"NCT00790556","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245 (8245-004)(COMPLETED)",[87],[14156],[14561,13864],"MK8245",{"nctId":14563,"briefTitle":14564,"status":105,"phases":14565,"primaryCompletion":8619,"completion":14566,"start":14567,"enrollment":4273,"conditions":14568,"interventions":14569},"NCT00849732","A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)",[87],"2011-02","2003-06",[11444,27],[14570,14571,14571,13864],"V520","Comparator: V520",{"nctId":14573,"briefTitle":14574,"status":105,"phases":14575,"primaryCompletion":14313,"completion":14314,"start":5801,"enrollment":14576,"conditions":14577,"interventions":14578},"NCT00789321","A Study to Evaluate Methodologies for Measuring Swelling of the Leg and Ankle (MK-0000-106)(COMPLETED)",[87],47,[30],[14579,13864],"Comparator: amlodipine besylate",{"nctId":14581,"briefTitle":14582,"status":105,"phases":14583,"primaryCompletion":14584,"completion":14584,"start":14585,"enrollment":28,"conditions":14586,"interventions":14587},"NCT00704132","Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)",[87],"2010-04-28","2007-02-14",[14277],[14588,14331],"Comparator: sitagliptin phosphate",{"nctId":14590,"briefTitle":14591,"status":105,"phases":14592,"primaryCompletion":14593,"completion":14594,"start":14595,"enrollment":154,"conditions":14596,"interventions":14598},"NCT00969163","A Study to Investigate Biomarkers of Skin Androgenization Following Testosterone Administration (0000-015)(COMPLETED).",[87],"2005-04","2005-06","2004-10",[14597],"Skin Androgenization",[14599,14331],"testosterone gel",{"nctId":14601,"briefTitle":14602,"status":105,"phases":14603,"primaryCompletion":5281,"completion":5281,"start":14409,"enrollment":931,"conditions":14604,"interventions":14606},"NCT00505843","A Study of MK0657 in Parkinson's Disease Patients (0657-006)",[87],[14605],"Parkinson's Disease",[14607,13864,14608,14609],"MK0657","Comparator: levodopa","Comparator: carbidopa",{"nctId":14611,"briefTitle":14612,"status":150,"phases":14613,"primaryCompletion":14614,"completion":14614,"start":14615,"enrollment":931,"conditions":14616,"interventions":14617},"NCT01152255","MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2)",[87],"2011-06-30","2010-10-10",[7639],[14618,13864],"MK6186",{"nctId":14620,"briefTitle":14621,"status":150,"phases":14622,"primaryCompletion":14623,"completion":14623,"start":13870,"enrollment":12,"conditions":14624,"interventions":14626},"NCT00836498","A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)",[87],"2010-01",[14625],"Rotavirus",[14627,13864,14628],"Comparator: RotaTeq","Comparator: RotaTeq + Placebo",{"nctId":14630,"briefTitle":14631,"status":105,"phases":14632,"primaryCompletion":6309,"completion":6309,"start":13890,"enrollment":36,"conditions":14633,"interventions":14635},"NCT00799708","A Study of the Effect of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women (0000-094)(COMPLETED)",[87],[14634],"Postmenopause",[14331,14636],"Comparator: Estrace",{"nctId":14638,"briefTitle":14639,"status":105,"phases":14640,"primaryCompletion":14641,"completion":14642,"start":14643,"enrollment":3506,"conditions":14644,"interventions":14645},"NCT00769132","A Study to Evaluate the Effects of Extended Release (ER) Niacin\u002FLaropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)",[87],"2007-10-13","2007-11-06","2007-08-03",[7598],[14646,14647,14423,14331],"Comparator: niacin + laropiprant","Comparator: niacin",{"nctId":14649,"briefTitle":14650,"status":150,"phases":14651,"primaryCompletion":14652,"completion":14652,"start":14653,"enrollment":4071,"conditions":14654,"interventions":14656},"NCT00679055","A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)",[87],"2008-08-26","2007-03-31",[14655],"Peripheral Vascular Diseases",[14657,14331],"MK-0736",{"nctId":14659,"briefTitle":14660,"status":105,"phases":14661,"primaryCompletion":14662,"completion":14663,"start":14664,"enrollment":95,"conditions":14665,"interventions":14666},"NCT00888238","A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)",[87],"2009-06-10","2009-07-21","2009-05-12",[15],[14126,13864],{"nctId":14668,"briefTitle":14669,"status":105,"phases":14670,"primaryCompletion":14315,"completion":14315,"start":13891,"enrollment":3390,"conditions":14671,"interventions":14672},"NCT00518622","Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)",[87],[24],[14673,13864],"Comparator: MK7009",{"nctId":14675,"briefTitle":14676,"status":105,"phases":14677,"primaryCompletion":14678,"completion":4418,"start":14679,"enrollment":25,"conditions":14680,"interventions":14681},"NCT00769418","Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)",[87],"2004-12","2004-09",[14552],[14682,13864],"odanacatib",{"nctId":14684,"briefTitle":14685,"status":105,"phases":14686,"primaryCompletion":14687,"completion":14687,"start":13891,"enrollment":920,"conditions":14688,"interventions":14690},"NCT00601458","Bunionectomy Study (0000-063)",[87],"2008-01",[14689],"Acute Pain",[14691,14692,13864],"pregabalin","naproxen sodium",{"nctId":14694,"briefTitle":14695,"status":105,"phases":14696,"primaryCompletion":13870,"completion":13870,"start":14353,"enrollment":154,"conditions":14697,"interventions":14698},"NCT00803894","A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor",[87],[18],[14699,14700,13864],"MK0752","Comparator: MK0752.",{"nctId":14702,"briefTitle":14703,"status":105,"phases":14704,"primaryCompletion":14678,"completion":14705,"start":14706,"enrollment":734,"conditions":14707,"interventions":14708},"NCT00863525","A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822)",[87],"2006-06","2004-11",[14552],[14682,13864],{"nctId":14710,"briefTitle":14711,"status":105,"phases":14712,"primaryCompletion":13101,"completion":13101,"start":14713,"enrollment":2901,"conditions":14714,"interventions":14716},"NCT00934466","Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)",[87],"2009-07",[14715],"Schizophrenia",[14717,14718,13864,14719,14719],"MK2637","Comparator: MK2637","Comparator: Dextromethorphan",{"nctId":14721,"briefTitle":14722,"status":105,"phases":14723,"primaryCompletion":13890,"completion":13890,"start":5507,"enrollment":626,"conditions":14724,"interventions":14725},"NCT00887601","BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)",[87],[11195],[14346,13864,11176,14346],{"nctId":14727,"briefTitle":14728,"status":105,"phases":14729,"primaryCompletion":14623,"completion":13224,"start":14730,"enrollment":5563,"conditions":14731,"interventions":14732},"NCT01106287","Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)",[87],"2009-10",[14156],[13863,13864],{"nctId":14734,"briefTitle":14735,"status":105,"phases":14736,"primaryCompletion":14352,"completion":14352,"start":14353,"enrollment":347,"conditions":14737,"interventions":14738},"NCT00873821","A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED)",[87],[33],[13863,13864],{"trials":14740,"activeCount":99},[14741,14749,14757,14768,14778,14782,14791,14798,14811,14819,14827,14835,14845,14854,14863,14871,14883,14892,14899,14908,14916,14926,14936,14947,14955,14964,14972,14980,14988,14997,15008,15016,15025,15034,15042,15050,15059,15067,15074,15080],{"nctId":14742,"briefTitle":14743,"status":105,"phases":14744,"primaryCompletion":14730,"completion":14730,"start":14540,"enrollment":3262,"conditions":14745,"interventions":14747},"NCT00529659","A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(MK-0773-005)",[88],[14746],"Sarcopenia",[14748,13864],"Comparator: MK-0773",{"nctId":14750,"briefTitle":14751,"status":150,"phases":14752,"primaryCompletion":13870,"completion":13870,"start":13891,"enrollment":2779,"conditions":14753,"interventions":14755},"NCT00401310","The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)",[88],[14754],"Middle Cerebral Artery Stroke",[13864,14756],"Comparator: MK0724",{"nctId":14758,"briefTitle":14759,"status":150,"phases":14760,"primaryCompletion":14313,"completion":14313,"start":5281,"enrollment":1968,"conditions":14761,"interventions":14765},"NCT00620659","Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea\u002FHypopnea Syndrome (OSA\u002FHS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015)",[88],[14762,14763,14764],"Sleep Apnea, Obstructive","Hypopnea Syndrome","Excessive Daytime Sleepiness",[14766,14331,14767],"Comparator: MK0249","Comparator: modafinil",{"nctId":14769,"briefTitle":14770,"status":105,"phases":14771,"primaryCompletion":14772,"completion":14531,"start":14773,"enrollment":765,"conditions":14774,"interventions":14776},"NCT00109122","Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)",[88],"2003-02","2001-11",[14775],"Shingles",[14777,14331],"zoster vaccine live",{"nctId":13857,"briefTitle":13858,"status":150,"phases":14779,"primaryCompletion":4990,"completion":12813,"start":6309,"enrollment":13860,"conditions":14780,"interventions":14781},[88],[33],[13863,13864,13865,4084],{"nctId":14783,"briefTitle":14784,"status":105,"phases":14785,"primaryCompletion":14786,"completion":14786,"start":14123,"enrollment":14787,"conditions":14788,"interventions":14789},"NCT00378560","V501 Efficacy Study in Women Aged 18 to 26 (V501-027)",[88],"2009-09-16",1021,[9239],[14790,13864],"Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine",{"nctId":14792,"briefTitle":14793,"status":150,"phases":14794,"primaryCompletion":14504,"completion":14504,"start":12814,"enrollment":120,"conditions":14795,"interventions":14796},"NCT00362024","MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)",[88],[11174],[14797,13864],"MK0952",{"nctId":14799,"briefTitle":14800,"status":105,"phases":14801,"primaryCompletion":13870,"completion":13870,"start":5801,"enrollment":14802,"conditions":14803,"interventions":14804},"NCT00712725","MK3207 for Treatment of Acute Migraines (3207-005)",[88],676,[4397],[14805,14806,14807,14808,14809,14810,14331],"MK3207- 2.5 mg","MK3207- 5 mg","MK3207- 10 mg","MK3207- 20 mg","MK3207- 50 mg","MK3207- 100 mg",{"nctId":14812,"briefTitle":14813,"status":150,"phases":14814,"primaryCompletion":13224,"completion":12813,"start":14353,"enrollment":14815,"conditions":14816,"interventions":14817},"NCT00806585","Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)",[88],620,[15,30],[14657,13864,14818],"Comparator: HCTZ",{"nctId":14820,"briefTitle":14821,"status":105,"phases":14822,"primaryCompletion":14314,"completion":14314,"start":14823,"enrollment":558,"conditions":14824,"interventions":14825},"NCT00729222","Hemodynamic Effects of Rolofylline in the Treatment of Patients With Heart Failure (7418-503)",[88],"2008-11",[9543],[13864,14826],"rolofylline",{"nctId":14828,"briefTitle":14829,"status":105,"phases":14830,"primaryCompletion":14352,"completion":14352,"start":14540,"enrollment":14815,"conditions":14831,"interventions":14832},"NCT00551187","A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)",[88],[863,865,9217,7085,9169],[14833,14834,13864],"V504","Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine",{"nctId":14836,"briefTitle":14837,"status":105,"phases":14838,"primaryCompletion":5981,"completion":5981,"start":14540,"enrollment":2585,"conditions":14839,"interventions":14840},"NCT00520598","Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)",[88],[863,865,9217,7085,9169],[14841,14842,14842,14843,14844,13864],"Comparator: V505 formulation 1","Comparator: V505 formulation 2","Comparator: V505 formulation 3","Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant",{"nctId":14846,"briefTitle":14847,"status":150,"phases":14848,"primaryCompletion":5507,"completion":5507,"start":14705,"enrollment":14849,"conditions":14850,"interventions":14852},"NCT00543959","Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)",[88],346,[14851],"Diabetes Mellitus Type 2",[14853,13864,13985],"MK0533",{"nctId":14855,"briefTitle":14856,"status":105,"phases":14857,"primaryCompletion":14445,"completion":14445,"start":14858,"enrollment":14859,"conditions":14860,"interventions":14861},"NCT00847197","A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004)",[88],"2008-06",191,[14337],[14862,13864],"MK1903",{"nctId":14864,"briefTitle":14865,"status":105,"phases":14866,"primaryCompletion":14858,"completion":14858,"start":14540,"enrollment":787,"conditions":14867,"interventions":14868},"NCT00543413","A Study to Determine the Effectiveness and Tolerability of MK8141 in Patients With High Blood Pressure (MK-8141-006)",[88],[30],[14869,14331,14870],"MK8141","Enalapril",{"nctId":14872,"briefTitle":14873,"status":150,"phases":14874,"primaryCompletion":14875,"completion":14875,"start":14876,"enrollment":14877,"conditions":14878,"interventions":14880},"NCT00703690","MK0767 in Metabolic Syndrome-Dyslipidemia (0767-016)",[88],"2003-12","2002-01",436,[14879],"Metabolic X Syndrome Dyslipidemia",[14881,14882,13864],"MK0767","Comparator: fenofibrate",{"nctId":14884,"briefTitle":14885,"status":150,"phases":14886,"primaryCompletion":14887,"completion":14445,"start":14706,"enrollment":8091,"conditions":14888,"interventions":14890},"NCT00095576","Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)",[88],"2007-09",[14889,27],"AIDS",[14891,14331],"Trivalent MRKAd5 HIV-1 gag\u002Fpol\u002Fnef",{"nctId":14893,"briefTitle":14894,"status":105,"phases":14895,"primaryCompletion":5981,"completion":5800,"start":6309,"enrollment":4059,"conditions":14896,"interventions":14897},"NCT00777959","Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)",[88],[4411],[6312,13864,14898],"open-label ridaforolimus",{"nctId":14900,"briefTitle":14901,"status":105,"phases":14902,"primaryCompletion":14228,"completion":14228,"start":14903,"enrollment":14904,"conditions":14905,"interventions":14906},"NCT00132769","A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED)",[88],"2005-01",106,[7020],[14907,13864],"MK-0873",{"nctId":14909,"briefTitle":14910,"status":150,"phases":14911,"primaryCompletion":5280,"completion":5280,"start":14687,"enrollment":14912,"conditions":14913,"interventions":14914},"NCT00404313","The Effect of MK0633 in Patients With Chronic Asthma (0633-007)",[88],688,[5985],[14915,14331],"MK0633",{"nctId":14917,"briefTitle":14918,"status":105,"phases":14919,"primaryCompletion":13978,"completion":14113,"start":14920,"enrollment":397,"conditions":14921,"interventions":14922},"NCT00880763","A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)",[88],"2009-04-20",[24],[14923,14924,14925,13864],"Vaniprevir","Pegylated Interferon","Ribavirin",{"nctId":14927,"briefTitle":14928,"status":105,"phases":14929,"primaryCompletion":14930,"completion":14930,"start":14595,"enrollment":132,"conditions":14931,"interventions":14932},"NCT00783601","MK0524 Asthma POC Study (0524-008)(COMPLETED)",[88],"2005-05",[5985],[14933,14934,14935,13864],"Comparator: MK0524 + placebo","Comparator: MK0524 + montelukast","Comparator: placebo + montelukast",{"nctId":14937,"briefTitle":14938,"status":105,"phases":14939,"primaryCompletion":14393,"completion":9313,"start":14940,"enrollment":14941,"conditions":14942,"interventions":14943},"NCT00704184","Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)",[88],"2008-07-25",95,[24],[14944,14945,14946,14331],"Comparator: Vaniprevir","Comparator: Pegylated-Interferon","Comparator: Ribavirin",{"nctId":14948,"briefTitle":14949,"status":105,"phases":14950,"primaryCompletion":5280,"completion":5280,"start":6309,"enrollment":14951,"conditions":14952,"interventions":14953},"NCT00848484","Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)",[88],54,[14715],[14954,13864],"MK5757",{"nctId":14956,"briefTitle":14957,"status":105,"phases":14958,"primaryCompletion":14959,"completion":14959,"start":14960,"enrollment":1169,"conditions":14961,"interventions":14962},"NCT00411749","V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)",[88],"2009-09-18","2006-12-11",[9239],[14963,13864],"Quadrivalent Human Papillomavirus",{"nctId":14965,"briefTitle":14966,"status":105,"phases":14967,"primaryCompletion":13224,"completion":7017,"start":14445,"enrollment":963,"conditions":14968,"interventions":14969},"NCT00977288","A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)",[88],[14337],[14970,14971,13864],"anacetrapib","Comparator: atorvastatin",{"nctId":14973,"briefTitle":14974,"status":105,"phases":14975,"primaryCompletion":14483,"completion":14483,"start":14976,"enrollment":14977,"conditions":14978,"interventions":14979},"NCT00127192","A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)",[88],"2005-07",363,[15],[14487,14331],{"nctId":14981,"briefTitle":14982,"status":105,"phases":14983,"primaryCompletion":4990,"completion":4990,"start":14314,"enrollment":8175,"conditions":14984,"interventions":14985},"NCT00827918","A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)",[88],[14715],[14986,14987,13864],"MK-8998","Comparator: Olanzapine",{"nctId":14989,"briefTitle":14990,"status":105,"phases":14991,"primaryCompletion":14314,"completion":14314,"start":14687,"enrollment":14992,"conditions":14993,"interventions":14995},"NCT00418613","A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED)",[88],266,[14994],"Chronic Obstructive Pulmonary Disease (COPD)",[14996,13864],"MK633",{"nctId":14998,"briefTitle":14999,"status":105,"phases":15000,"primaryCompletion":15001,"completion":14713,"start":15002,"enrollment":15003,"conditions":15004,"interventions":15006},"NCT00365378","Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)",[88],"2004-03","1999-09",2409,[15005],"HPV 16 Infection",[15007,13864],"Comparator: HPV 16 L1 Vaccine",{"nctId":15009,"briefTitle":15010,"status":105,"phases":15011,"primaryCompletion":14623,"completion":14623,"start":13102,"enrollment":3162,"conditions":15012,"interventions":15014},"NCT00572910","A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED)",[88],[15013],"Staphylococcus Aureus Infection",[13864,15015,15015,15015,15015,15015],"V710 Comparator: Placebo",{"nctId":15017,"briefTitle":15018,"status":105,"phases":15019,"primaryCompletion":15020,"completion":15020,"start":15021,"enrollment":1479,"conditions":15022,"interventions":15024},"NCT00758069","Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)",[88],"2006-02-13","2005-07-03",[15023],"Diabetes Mellitus, Non-Insulin-Dependent",[14487,13864,14233],{"nctId":15026,"briefTitle":15027,"status":105,"phases":15028,"primaryCompletion":8621,"completion":8621,"start":14228,"enrollment":15029,"conditions":15030,"interventions":15031},"NCT00246337","A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)",[88],420,[4397],[13864,15032,15032,15032,15032,15032,15032,15032,15033],"MK0974","Rizatriptan",{"nctId":15035,"briefTitle":15036,"status":150,"phases":15037,"primaryCompletion":14713,"completion":14713,"start":15038,"enrollment":95,"conditions":15039,"interventions":15040},"NCT00387036","Exercise Study in Patient With Chronic Obstructive Pulmonary Disease (0000-036)",[88],"2006-12",[14994],[15041,13864],"Fluticasone",{"nctId":15043,"briefTitle":15044,"status":105,"phases":15045,"primaryCompletion":6309,"completion":6309,"start":14887,"enrollment":4421,"conditions":15046,"interventions":15048},"NCT00482430","MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)",[88],[15047,14715],"Paranoid Schizophrenia",[15049,13864],"MK0557",{"nctId":15051,"briefTitle":15052,"status":105,"phases":15053,"primaryCompletion":14772,"completion":14772,"start":15054,"enrollment":10917,"conditions":15055,"interventions":15057},"NCT00539578","Treatment of Patients With Anxiety Disorder (0777-022)",[88],"2002-09",[15056],"Generalized Anxiety Disorder",[15058,14331],"MK0777",{"nctId":15060,"briefTitle":15061,"status":105,"phases":15062,"primaryCompletion":15063,"completion":15063,"start":14594,"enrollment":15064,"conditions":15065,"interventions":15066},"NCT00111891","An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)",[88],"2005-08",575,[14337],[14420,14331],{"nctId":15068,"briefTitle":15069,"status":105,"phases":15070,"primaryCompletion":13102,"completion":13102,"start":12814,"enrollment":4305,"conditions":15071,"interventions":15072},"NCT00420420","MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)",[88],[11174],[15073,13864],"MK0249",{"nctId":15075,"briefTitle":15076,"status":105,"phases":15077,"primaryCompletion":6309,"completion":6309,"start":14454,"enrollment":1349,"conditions":15078,"interventions":15079},"NCT00506077","MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)",[88],[15047],[15073,13864],{"nctId":15081,"briefTitle":15082,"status":105,"phases":15083,"primaryCompletion":5982,"completion":5982,"start":14540,"enrollment":15084,"conditions":15085,"interventions":15086},"NCT00546819","ZOSTAVAX™ in Patients on Chronic\u002FMaintenance Corticosteroids (V211-017) (COMPLETED)",[88],309,[14395],[15087,13864],"Zoster Vaccine, Live",{"trials":15089,"activeCount":99},[15090,15094,15103,15114,15122,15131,15139,15151,15161,15165,15174,15186,15194,15206,15214,15221,15233,15239,15247,15254,15261,15270,15278,15284,15291,15300,15316,15325,15334,15338,15346,15356,15364,15374,15384,15394,15401,15412,15422,15434,15440,15450,15457,15468,15475,15484,15493,15501,15510,15519,15525,15540,15548,15557,15567,15576,15580,15590],{"nctId":13953,"briefTitle":13954,"status":105,"phases":15091,"primaryCompletion":13956,"completion":13956,"start":13957,"enrollment":13958,"conditions":15092,"interventions":15093},[89],[15],[13145,13864,13914,4084,13961],{"nctId":15095,"briefTitle":15096,"status":105,"phases":15097,"primaryCompletion":15098,"completion":1468,"start":15099,"enrollment":15100,"conditions":15101,"interventions":15102},"NCT00834106","Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)",[89],"2012-05-11","2008-12-31",3006,[9239],[14790,14331],{"nctId":15104,"briefTitle":15105,"status":105,"phases":15106,"primaryCompletion":15107,"completion":15107,"start":15108,"enrollment":15109,"conditions":15110,"interventions":15112},"NCT00042029","Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)",[89],"2003-10-03","2002-06-18",324,[15111],"Major Depressive Disorder",[15113,14331],"MK0869, aprepitant",{"nctId":15115,"briefTitle":15116,"status":150,"phases":15117,"primaryCompletion":14875,"completion":14875,"start":15118,"enrollment":15119,"conditions":15120,"interventions":15121},"NCT00543361","Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020)",[89],"2003-05",382,[33],[14881,14331,14488],{"nctId":15123,"briefTitle":15124,"status":105,"phases":15125,"primaryCompletion":15126,"completion":15126,"start":15127,"enrollment":15128,"conditions":15129,"interventions":15130},"NCT01177384","Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)",[89],"2013-03-25","2011-01-25",380,[15],[13982,13864,14289,13146],{"nctId":15132,"briefTitle":15133,"status":105,"phases":15134,"primaryCompletion":14540,"completion":5981,"start":6464,"enrollment":15135,"conditions":15136,"interventions":15137},"NCT00293254","A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)",[89],351,[27],[15138,14331],"raltegravir potassium",{"nctId":15140,"briefTitle":15141,"status":105,"phases":15142,"primaryCompletion":15143,"completion":15144,"start":15145,"enrollment":15146,"conditions":15147,"interventions":15148},"NCT00094757","An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)",[89],"2005-08-17","2006-04-28","2004-10-06",521,[33],[15149,15150,14331,13985],"Comparator: sitagliptin 100 mg","Comparator: sitagliptin 200 mg",{"nctId":15152,"briefTitle":15153,"status":150,"phases":15154,"primaryCompletion":15155,"completion":14353,"start":15156,"enrollment":2441,"conditions":15157,"interventions":15159},"NCT00131404","A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED)",[89],"2007-02","2005-09",[15158],"Obesity",[15160,13864],"taranabant",{"nctId":13989,"briefTitle":13990,"status":105,"phases":15162,"primaryCompletion":13992,"completion":13993,"start":13994,"enrollment":13995,"conditions":15163,"interventions":15164},[89],[15],[13145,13864,13998,4084],{"nctId":15166,"briefTitle":15167,"status":150,"phases":15168,"primaryCompletion":6309,"completion":9610,"start":14409,"enrollment":15169,"conditions":15170,"interventions":15171},"NCT00443729","MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)",[89],355,[7650],[15172,14331,15173,14331],"Comparator: raltegravir","Comparator: lopinavir (+) ritonavir",{"nctId":15175,"briefTitle":15176,"status":105,"phases":15177,"primaryCompletion":5962,"completion":660,"start":15178,"enrollment":15179,"conditions":15180,"interventions":15185},"NCT00090220","A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)",[89],"2004-06-16",3819,[15181,15182,15183,15184],"Healthy Adult Female Participants","Prevention","Papillomavirus Infection","Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18",[14790,13864],{"nctId":15187,"briefTitle":15188,"status":150,"phases":15189,"primaryCompletion":14687,"completion":14823,"start":12814,"enrollment":1818,"conditions":15190,"interventions":15192},"NCT00430742","An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED)",[89],[15191,15],"Obesity Type 2 Diabetes Mellitus",[15193,13864],"Taranabant",{"nctId":15195,"briefTitle":15196,"status":105,"phases":15197,"primaryCompletion":15198,"completion":15199,"start":15200,"enrollment":15201,"conditions":15202,"interventions":15204},"NCT00092547","A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)",[89],"2005-11-03","2015-06-01","2003-10-08",1781,[15203,7076],"Human",[15205,13864],"V501",{"nctId":15207,"briefTitle":15208,"status":105,"phases":15209,"primaryCompletion":14705,"completion":15210,"start":15211,"enrollment":11128,"conditions":15212,"interventions":15213},"NCT00106704","Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)",[89],"2007-01","2005-03",[33],[14233,13864,14234],{"nctId":15215,"briefTitle":15216,"status":1040,"phases":15217,"primaryCompletion":14315,"completion":14315,"start":14315,"enrollment":99,"conditions":15218,"interventions":15219},"NCT00692458","A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)",[89],[1109],[15220,14331],"Comparator: odanacatib",{"nctId":15222,"briefTitle":15223,"status":105,"phases":15224,"primaryCompletion":15225,"completion":15226,"start":15227,"enrollment":15228,"conditions":15229,"interventions":15230},"NCT00887250","A Study to Investigate the Antihypertensive Efficacy of MK0954",[89],"1992-08","1992-11","1991-12",366,[30],[15231,15232,13864],"losartan potassium","Comparator: losartan",{"nctId":15234,"briefTitle":15235,"status":105,"phases":15236,"primaryCompletion":5507,"completion":5981,"start":6464,"enrollment":7388,"conditions":15237,"interventions":15238},"NCT00293267","A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)",[89],[27],[15138,13864],{"nctId":15240,"briefTitle":15241,"status":150,"phases":15242,"primaryCompletion":9610,"completion":9610,"start":14409,"enrollment":7388,"conditions":15243,"interventions":15244},"NCT00443703","MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)",[89],[7650],[15245,15246,14331,14331],"MK0518","Comparator: KALETRA™",{"nctId":15248,"briefTitle":15249,"status":105,"phases":15250,"primaryCompletion":14623,"completion":14623,"start":14540,"enrollment":15251,"conditions":15252,"interventions":15253},"NCT00534248","Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)",[89],22439,[14775],[15087,13864],{"nctId":15255,"briefTitle":15256,"status":105,"phases":15257,"primaryCompletion":14875,"completion":14875,"start":15258,"enrollment":951,"conditions":15259,"interventions":15260},"NCT00035282","Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)",[89],"2001-09",[15111],[4424,14331],{"nctId":15262,"briefTitle":15263,"status":105,"phases":15264,"primaryCompletion":15265,"completion":15265,"start":15266,"enrollment":15267,"conditions":15268,"interventions":15269},"NCT00372060","MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)",[89],"2008-02-05","2006-08-21",134,[15],[14487,14588,13985,14331],{"nctId":15271,"briefTitle":15272,"status":105,"phases":15273,"primaryCompletion":15274,"completion":15274,"start":15275,"enrollment":3162,"conditions":15276,"interventions":15277},"NCT00305604","Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)",[89],"2008-03-12","2006-03-08",[14156],[14487,13864],{"nctId":15279,"briefTitle":15280,"status":105,"phases":15281,"primaryCompletion":14531,"completion":14531,"start":15063,"enrollment":494,"conditions":15282,"interventions":15283},"NCT00166517","V260 Registration Study (V260-013)(COMPLETED)",[89],[14625],[14449,13864],{"nctId":15285,"briefTitle":15286,"status":150,"phases":15287,"primaryCompletion":5281,"completion":14353,"start":14976,"enrollment":2441,"conditions":15288,"interventions":15289},"NCT00131391","A Study of MK0364 in Obese Patients (0364-014)",[89],[15158],[15290,14331],"Comparator: taranabant",{"nctId":15292,"briefTitle":15293,"status":105,"phases":15294,"primaryCompletion":13891,"completion":13870,"start":15295,"enrollment":15296,"conditions":15297,"interventions":15298},"NCT00092521","Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)",[89],"2001-12",5759,[863,7085],[15205,13864,15299],"Human Papillomavirus (HPV) 16 Monovalent",{"nctId":15301,"briefTitle":15302,"status":105,"phases":15303,"primaryCompletion":15304,"completion":15118,"start":15305,"enrollment":15306,"conditions":15307,"interventions":15312},"NCT00985166","A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)",[89],"2002-05","2000-08",801,[15308,15309,15310,15311],"Measles","Mumps","Rubella","Varicella",[15313,15314,15315,13864],"ProQuad","Comparator: M-M-R II","Comparator: Varivax",{"nctId":15317,"briefTitle":15318,"status":105,"phases":15319,"primaryCompletion":15320,"completion":15320,"start":5147,"enrollment":15321,"conditions":15322,"interventions":15323},"NCT00837577","MK0431\u002FONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)",[89],"2010-08-11",133,[15023],[13864,13145,15324],"Voglibose",{"nctId":15326,"briefTitle":15327,"status":105,"phases":15328,"primaryCompletion":15329,"completion":15330,"start":15331,"enrollment":1387,"conditions":15332,"interventions":15333},"NCT00035048","Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)",[89],"2003-12-29","2003-12-31","2001-11-21",[15111],[4424,14331],{"nctId":14118,"briefTitle":14119,"status":105,"phases":15335,"primaryCompletion":14121,"completion":14122,"start":14123,"enrollment":2555,"conditions":15336,"interventions":15337},[89],[15],[14126,13864,14127,14040,14128],{"nctId":15339,"briefTitle":15340,"status":105,"phases":15341,"primaryCompletion":15342,"completion":15342,"start":15343,"enrollment":2096,"conditions":15344,"interventions":15345},"NCT00034944","Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)",[89],"2003-12-17","2002-01-24",[15111],[15113,14331],{"nctId":15347,"briefTitle":15348,"status":105,"phases":15349,"primaryCompletion":15350,"completion":15351,"start":15352,"enrollment":15353,"conditions":15354,"interventions":15355},"NCT00048594","Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)",[89],"2003-12-18","2003-12-22","2002-01-03",800,[15111],[4424,14331],{"nctId":15357,"briefTitle":15358,"status":105,"phases":15359,"primaryCompletion":15330,"completion":15330,"start":15360,"enrollment":1818,"conditions":15361,"interventions":15362},"NCT00048607","Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)",[89],"2002-07-30",[15111],[4424,15363,13864],"Comparator: paroxetine HCL",{"nctId":15365,"briefTitle":15366,"status":105,"phases":15367,"primaryCompletion":15368,"completion":15368,"start":15369,"enrollment":9064,"conditions":15370,"interventions":15371},"NCT01097629","Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)",[89],"2011-11-08","2010-05-03",[9336],[15372,15373,13864],"Suvorexant High Dose","Suvorexant Low Dose",{"nctId":15375,"briefTitle":15376,"status":105,"phases":15377,"primaryCompletion":14454,"completion":14454,"start":4419,"enrollment":15378,"conditions":15379,"interventions":15380},"NCT00432237","Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)",[89],1703,[4397],[15381,15382,15383,13864],"MK0974 50 mg","MK0974 150 mg","MK0974 300 mg",{"nctId":15385,"briefTitle":15386,"status":105,"phases":15387,"primaryCompletion":15388,"completion":15389,"start":15390,"enrollment":15391,"conditions":15392,"interventions":15393},"NCT00888355","MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension",[89],"1993-01","1993-02","1992-05",428,[30],[15231,14331],{"nctId":15395,"briefTitle":15396,"status":105,"phases":15397,"primaryCompletion":4419,"completion":4419,"start":14483,"enrollment":15398,"conditions":15399,"interventions":15400},"NCT00289848","MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)",[89],530,[15],[14487,14331],{"nctId":15402,"briefTitle":15403,"status":105,"phases":15404,"primaryCompletion":15405,"completion":15406,"start":15407,"enrollment":15408,"conditions":15409,"interventions":15410},"NCT00090285","An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)",[89],"2009-07-31","2017-04-03","2004-09-03",4065,[7141],[15411,14331],"(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine",{"nctId":15413,"briefTitle":15414,"status":150,"phases":15415,"primaryCompletion":14353,"completion":14353,"start":14409,"enrollment":15416,"conditions":15417,"interventions":15419},"NCT00473889","A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)",[88,89],253,[15418],"Stage IIIB or IV Non-Small Cell Lung Cancer",[4994,15420,15421,14331],"Comparator: paclitaxel","Comparator: carboplatin",{"nctId":15423,"briefTitle":15424,"status":105,"phases":15425,"primaryCompletion":15426,"completion":15427,"start":15428,"enrollment":15429,"conditions":15430,"interventions":15433},"NCT00685776","Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)",[89],"2009-07-02","2017-11-23","2008-03-24",1623,[15431,15432],"Coronary Heart Disease (CHD)","CHD Risk-Equivalent Disease",[14970,14331],{"nctId":15435,"briefTitle":15436,"status":150,"phases":15437,"primaryCompletion":5281,"completion":14823,"start":8619,"enrollment":1633,"conditions":15438,"interventions":15439},"NCT00420589","A Weight Maintenance Study in Obese Patients (0364-012)(TERMINATED)",[89],[15158],[15160,14331],{"nctId":15441,"briefTitle":15442,"status":105,"phases":15443,"primaryCompletion":15444,"completion":15444,"start":15445,"enrollment":15446,"conditions":15447,"interventions":15448},"NCT00813995","A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)",[89],"2010-08-09","2008-12-09",395,[15],[15449,13864],"Comparator: Sitagliptin phosphate",{"nctId":15451,"briefTitle":15452,"status":150,"phases":15453,"primaryCompletion":14228,"completion":14228,"start":15156,"enrollment":1818,"conditions":15454,"interventions":15455},"NCT00130806","An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)",[89],[15],[15456,14331],"MK0478",{"nctId":15458,"briefTitle":15459,"status":105,"phases":15460,"primaryCompletion":15461,"completion":15462,"start":15463,"enrollment":15464,"conditions":15465,"interventions":15466},"NCT00975507","ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)",[89],"1999-01","1999-06","1998-03",480,[15308,15309,15310,15311],[15467,13864,15315,15314],"Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live",{"nctId":15469,"briefTitle":15470,"status":105,"phases":15471,"primaryCompletion":15472,"completion":14073,"start":5292,"enrollment":2745,"conditions":15473,"interventions":15474},"NCT01097616","Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)",[89],"2011-09-09",[9336],[15372,15373,13864],{"nctId":15476,"briefTitle":15477,"status":105,"phases":15478,"primaryCompletion":5281,"completion":5281,"start":14324,"enrollment":15479,"conditions":15480,"interventions":15481},"NCT00535730","ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)",[89],473,[14395,13187],[15482,14331,15483],"Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™","Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23",{"nctId":15485,"briefTitle":15486,"status":105,"phases":15487,"primaryCompletion":15390,"completion":15225,"start":15488,"enrollment":15489,"conditions":15490,"interventions":15491},"NCT00886600","A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)",[89],"1991-05",122,[30],[15231,14331,15492],"hydrochlorothiazide",{"nctId":15494,"briefTitle":15495,"status":105,"phases":15496,"primaryCompletion":15497,"completion":15497,"start":15498,"enrollment":1818,"conditions":15499,"interventions":15500},"NCT00496626","An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)",[89],"2009-02-28","2008-07-20",[7076],[14963,13864],{"nctId":15502,"briefTitle":15503,"status":105,"phases":15504,"primaryCompletion":8620,"completion":8620,"start":15505,"enrollment":15506,"conditions":15507,"interventions":15508},"NCT00536510","Effect of MK0524A on Cholesterol Levels (0524A-048)",[89],"2007-04",646,[7598,7610],[15509,14331],"laropiprant\u002Fniacin",{"nctId":15511,"briefTitle":15512,"status":105,"phases":15513,"primaryCompletion":15514,"completion":15514,"start":15515,"enrollment":15516,"conditions":15517,"interventions":15518},"NCT00035295","Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)",[89],"2003-12-05","2001-11-08",584,[15111],[15113,14331],{"nctId":15520,"briefTitle":15521,"status":105,"phases":15522,"primaryCompletion":13891,"completion":13891,"start":8621,"enrollment":2788,"conditions":15523,"interventions":15524},"NCT00322231","A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)",[89],[14395],[14777,13864],{"nctId":15526,"briefTitle":15527,"status":105,"phases":15528,"primaryCompletion":15529,"completion":15530,"start":15531,"enrollment":15532,"conditions":15533,"interventions":15534},"NCT00103857","MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)",[89],"2006-07-25","2008-02-21","2005-03-17",1208,[15],[15535,15536,13864,15537,15538,15539],"Comparator: MK0431 50 mg b.i.d.","Comparator: MK0431 100 mg q.d.","Comparator: Metformin 500 mg b.i.d.","Comparator: Open-Label MK0431\u002FMetformin 50\u002F1000 mg b.i.d.","Comparator: Metformin 1000 mg b.i.d.",{"nctId":15541,"briefTitle":15542,"status":150,"phases":15543,"primaryCompletion":13102,"completion":13102,"start":4418,"enrollment":15544,"conditions":15545,"interventions":15547},"NCT00384293","Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED)",[89],937,[15546],"Hypercholesterolemia, Familial",[14647,14331],{"nctId":15549,"briefTitle":15550,"status":105,"phases":15551,"primaryCompletion":12814,"completion":12814,"start":6464,"enrollment":15552,"conditions":15553,"interventions":15555},"NCT00258154","V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)",[89],403,[15554],"Rotavirus Disease",[14449,14331,15556],"Comparator: Infanrix(tm) Hexa",{"nctId":15558,"briefTitle":15559,"status":105,"phases":15560,"primaryCompletion":15561,"completion":15561,"start":15562,"enrollment":15563,"conditions":15564,"interventions":15565},"NCT00060476","Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)",[89],"2004-12-08","2003-01-08",15000,[4411],[15566,14331],"rofecoxib",{"nctId":15568,"briefTitle":15569,"status":105,"phases":15570,"primaryCompletion":4419,"completion":4419,"start":14705,"enrollment":15571,"conditions":15572,"interventions":15573},"NCT00541775","Safety\u002FEfficacy of Sitagliptin in Patient w\u002F Type 2 Diabetes (0431-801)",[89],273,[15],[13145,15574,13864,15575],"Comparator: Rosiglitazone","Comparator: Metformin",{"nctId":14225,"briefTitle":14226,"status":105,"phases":15577,"primaryCompletion":14228,"completion":14228,"start":14229,"enrollment":14230,"conditions":15578,"interventions":15579},[89],[33],[14233,13864,14234,4084],{"nctId":15581,"briefTitle":15582,"status":105,"phases":15583,"primaryCompletion":14595,"completion":14595,"start":15584,"enrollment":15585,"conditions":15586,"interventions":15588},"NCT00090233","Rotavirus Efficacy and Safety Trial (REST)(V260-006)",[89],"2001-01",69274,[15587],"Rotavirus Infections",[15589,13864],"Rotateq™",{"nctId":15591,"briefTitle":15592,"status":105,"phases":15593,"primaryCompletion":14314,"completion":14314,"start":4419,"enrollment":15594,"conditions":15595,"interventions":15598},"NCT00362648","Developing World Study for RotaTeq™ (V260-015)(COMPLETED)",[89],7504,[4292,15596,15597],"Diarrhea","Fever",[15599,13864],"RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent",{"trials":15601,"activeCount":99},[15602],{"nctId":15603,"briefTitle":15604,"status":105,"phases":15605,"primaryCompletion":13870,"completion":13870,"start":14887,"enrollment":15606,"conditions":15607,"interventions":15608},"NCT00550745","ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)",[90],11999,[14395],[15087,14331],{"trials":15610,"activeCount":99},[],{"intervention":14487,"totalTrials":9323,"cells":15612},{"EARLY_PHASE1":15613,"PHASE1":15615,"PHASE2":15668,"PHASE3":15678,"PHASE4":15759,"NA":15781},{"trials":15614,"activeCount":99},[],{"trials":15616,"activeCount":99},[15617,15629,15636,15640,15648,15652,15661],{"nctId":15618,"briefTitle":15619,"status":105,"phases":15620,"primaryCompletion":15621,"completion":15622,"start":15623,"enrollment":931,"conditions":15624,"interventions":15625},"NCT00830076","A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)",[87],"2009-04-30","2009-05-14","2008-12-02",[15],[14487,15626,15627,15628],"metformin hydrochloride","Comparator: placebo sitagliptin","Comparator: placebo metformin",{"nctId":15630,"briefTitle":15631,"status":105,"phases":15632,"primaryCompletion":14495,"completion":14495,"start":4420,"enrollment":805,"conditions":15633,"interventions":15635},"NCT00696826","A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)",[87],[15634],"Liver Insufficiency",[14487],{"nctId":14480,"briefTitle":14481,"status":105,"phases":15637,"primaryCompletion":14483,"completion":14483,"start":14484,"enrollment":3655,"conditions":15638,"interventions":15639},[87],[14156],[14487,14488,14489,14331],{"nctId":15641,"briefTitle":15642,"status":105,"phases":15643,"primaryCompletion":8620,"completion":13890,"start":14687,"enrollment":4991,"conditions":15644,"interventions":15645},"NCT00929201","Sitagliptin\u002FMetformin Fed Bioequivalence Study (0431A-080)",[87],[15],[15646,13982,15647],"Sitagliptin phosphate\u002Fmetformin hydrochloride FDC","Metformin hydrochloride",{"nctId":14511,"briefTitle":14512,"status":105,"phases":15649,"primaryCompletion":14514,"completion":14515,"start":14516,"enrollment":722,"conditions":15650,"interventions":15651},[87],[14156],[14487,14487,13864],{"nctId":15653,"briefTitle":15654,"status":105,"phases":15655,"primaryCompletion":15656,"completion":15657,"start":15658,"enrollment":3903,"conditions":15659,"interventions":15660},"NCT00730275","A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)",[87],"2010-12-30","2011-02-14","2008-07-18",[14156],[13982],{"nctId":15662,"briefTitle":15663,"status":105,"phases":15664,"primaryCompletion":8620,"completion":8620,"start":8620,"enrollment":3655,"conditions":15665,"interventions":15667},"NCT00642798","An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED)",[87],[15666],"Diabetes Mellitus Non-insulin-dependent",[14487],{"trials":15669,"activeCount":99},[15670,15674],{"nctId":14973,"briefTitle":14974,"status":105,"phases":15671,"primaryCompletion":14483,"completion":14483,"start":14976,"enrollment":14977,"conditions":15672,"interventions":15673},[88],[15],[14487,14331],{"nctId":15017,"briefTitle":15018,"status":105,"phases":15675,"primaryCompletion":15020,"completion":15020,"start":15021,"enrollment":1479,"conditions":15676,"interventions":15677},[88],[15023],[14487,13864,14233],{"trials":15679,"activeCount":99},[15680,15688,15692,15696,15700,15704,15708,15717,15726,15730,15734,15742,15751],{"nctId":15681,"briefTitle":15682,"status":105,"phases":15683,"primaryCompletion":5507,"completion":5507,"start":15210,"enrollment":15684,"conditions":15685,"interventions":15686},"NCT00411554","A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet\u002FExercise Therapy (0431-054)(COMPLETED)",[89],319,[15023],[14487,15687],"Comparator: voglibose",{"nctId":15123,"briefTitle":15124,"status":105,"phases":15689,"primaryCompletion":15126,"completion":15126,"start":15127,"enrollment":15128,"conditions":15690,"interventions":15691},[89],[15],[13982,13864,14289,13146],{"nctId":13973,"briefTitle":13974,"status":105,"phases":15693,"primaryCompletion":13976,"completion":13977,"start":13978,"enrollment":13979,"conditions":15694,"interventions":15695},[89],[15],[13982,13983,13984,13985,13986,4084,13987],{"nctId":14020,"briefTitle":14021,"status":105,"phases":15697,"primaryCompletion":14023,"completion":9322,"start":14024,"enrollment":14025,"conditions":15698,"interventions":15699},[89],[15],[13982,14028,4084],{"nctId":15262,"briefTitle":15263,"status":105,"phases":15701,"primaryCompletion":15265,"completion":15265,"start":15266,"enrollment":15267,"conditions":15702,"interventions":15703},[89],[15],[14487,14588,13985,14331],{"nctId":15271,"briefTitle":15272,"status":105,"phases":15705,"primaryCompletion":15274,"completion":15274,"start":15275,"enrollment":3162,"conditions":15706,"interventions":15707},[89],[14156],[14487,13864],{"nctId":15709,"briefTitle":15710,"status":105,"phases":15711,"primaryCompletion":15712,"completion":15712,"start":15713,"enrollment":15714,"conditions":15715,"interventions":15716},"NCT00545584","Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)",[89],"2009-11-19","2007-04-01",1512,[15023],[14487],{"nctId":15718,"briefTitle":15719,"status":105,"phases":15720,"primaryCompletion":14940,"completion":14940,"start":15721,"enrollment":15722,"conditions":15723,"interventions":15724},"NCT00449930","Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)",[89],"2007-03-01",1050,[15],[14487,15725],"Comparator: metformin hydrochloride",{"nctId":15395,"briefTitle":15396,"status":105,"phases":15727,"primaryCompletion":4419,"completion":4419,"start":14483,"enrollment":15398,"conditions":15728,"interventions":15729},[89],[15],[14487,14331],{"nctId":14210,"briefTitle":14211,"status":105,"phases":15731,"primaryCompletion":14213,"completion":14213,"start":14214,"enrollment":154,"conditions":15732,"interventions":15733},[89],[14156],[13982,4084],{"nctId":15735,"briefTitle":15736,"status":105,"phases":15737,"primaryCompletion":15738,"completion":15738,"start":14960,"enrollment":7715,"conditions":15739,"interventions":15740},"NCT00395343","Sitagliptin Added-on to Insulin Study (0431-051)",[89],"2008-10-13",[15],[14487,15741],"Comparator : placebo",{"nctId":15743,"briefTitle":15744,"status":105,"phases":15745,"primaryCompletion":15746,"completion":15746,"start":15747,"enrollment":14325,"conditions":15748,"interventions":15749},"NCT00875394","Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)",[89],"2008-06-27","2007-02-01",[15023],[14487,14488,14488,15750],"Comparator: Antidiabetic Standard of Care",{"nctId":15752,"briefTitle":15753,"status":105,"phases":15754,"primaryCompletion":15755,"completion":15755,"start":15756,"enrollment":15464,"conditions":15757,"interventions":15758},"NCT01189890","Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)",[89],"2012-10-31","2010-08-16",[15],[14487,13146],{"trials":15760,"activeCount":99},[15761,15765,15774],{"nctId":14270,"briefTitle":14271,"status":105,"phases":15762,"primaryCompletion":14273,"completion":14273,"start":14274,"enrollment":14275,"conditions":15763,"interventions":15764},[90],[14277],[13982,14279,4084],{"nctId":15766,"briefTitle":15767,"status":105,"phases":15768,"primaryCompletion":15769,"completion":15769,"start":15770,"enrollment":15771,"conditions":15772,"interventions":15773},"NCT00833027","ALPHA Sitagliptin Add on to Metformin (0431-103)",[90],"2009-10-30","2008-03-01",608,[13950],[14487],{"nctId":15775,"briefTitle":15776,"status":105,"phases":15777,"primaryCompletion":15778,"completion":15778,"start":14585,"enrollment":31,"conditions":15779,"interventions":15780},"NCT00832390","Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)",[90],"2008-07-11",[13950],[14487],{"trials":15782,"activeCount":99},[],{"intervention":15784,"totalTrials":4059,"cells":15785},"Boceprevir",{"EARLY_PHASE1":15786,"PHASE1":15788,"PHASE2":15810,"PHASE3":15850,"PHASE4":15971,"NA":15989},{"trials":15787,"activeCount":99},[],{"trials":15789,"activeCount":99},[15790,15798,15802],{"nctId":15791,"briefTitle":15792,"status":105,"phases":15793,"primaryCompletion":15794,"completion":15794,"start":12813,"enrollment":15795,"conditions":15796,"interventions":15797},"NCT01181804","Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED)",[87],"2010-12",177,[24],[12989,12989,12989,12989],{"nctId":12981,"briefTitle":12982,"status":105,"phases":15799,"primaryCompletion":12984,"completion":12984,"start":12985,"enrollment":4242,"conditions":15800,"interventions":15801},[87],[12987],[12989,12990,12991],{"nctId":15803,"briefTitle":15804,"status":150,"phases":15805,"primaryCompletion":15806,"completion":15806,"start":15807,"enrollment":3655,"conditions":15808,"interventions":15809},"NCT01425190","Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)",[87],"2013-03-20","2012-01-04",[21],[15784],{"trials":15811,"activeCount":99},[15812,15821,15829,15841],{"nctId":15813,"briefTitle":15814,"status":105,"phases":15815,"primaryCompletion":13102,"completion":14823,"start":15210,"enrollment":15816,"conditions":15817,"interventions":15818},"NCT00423670","Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)",[88],765,[12957],[12989,15819,15820,15820],"peginterferon-alfa 2b","ribavirin",{"nctId":15822,"briefTitle":15823,"status":105,"phases":15824,"primaryCompletion":13891,"completion":13891,"start":15156,"enrollment":15825,"conditions":15826,"interventions":15827},"NCT00160251","Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)",[88],357,[12957],[15784,15828,14925],"PegIntron",{"nctId":15830,"briefTitle":15831,"status":105,"phases":15832,"primaryCompletion":15833,"completion":15834,"start":15835,"enrollment":15836,"conditions":15837,"interventions":15838},"NCT01353911","Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)",[88],"2013-01-20","2015-03-10","2011-06-27",368,[21],[15839,15784,15840,14925],"Grazoprevir","Peg-interferon alfa-2b",{"nctId":15842,"briefTitle":15843,"status":105,"phases":15844,"primaryCompletion":15845,"completion":6799,"start":8591,"enrollment":4358,"conditions":15846,"interventions":15848},"NCT00959699","A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)",[88],"2012-05",[27,24,15847],"HCV Infection",[1099,15849,15784],"RBV",{"trials":15851,"activeCount":99},[15852,15860,15871,15879,15887,15897,15907,15916,15927,15936,15943,15953,15963],{"nctId":15853,"briefTitle":15854,"status":105,"phases":15855,"primaryCompletion":14104,"completion":14104,"start":15856,"enrollment":322,"conditions":15857,"interventions":15858},"NCT00910624","Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon\u002FRibavirin (P05514)",[89],"2009-06-22",[21],[15784,15859,14925],"Peginterferon alfa-2b",{"nctId":15861,"briefTitle":15862,"status":105,"phases":15863,"primaryCompletion":15864,"completion":15864,"start":15865,"enrollment":15866,"conditions":15867,"interventions":15869},"NCT01425203","The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)",[89],"2013-10-21","2011-11-23",238,[15868],"Chronic Hepatitis C Genotype 1",[15784,15870,14925],"peginterferon alfa-2b",{"nctId":15872,"briefTitle":15873,"status":1040,"phases":15874,"primaryCompletion":1001,"completion":1001,"start":15875,"enrollment":99,"conditions":15876,"interventions":15877},"NCT01590225","Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)",[89],"2013-01-28",[12957],[15784,15878,14925,15784,15859,14925],"Peginterferon alpha-2b",{"nctId":15880,"briefTitle":15881,"status":105,"phases":15882,"primaryCompletion":5179,"completion":5179,"start":14313,"enrollment":15883,"conditions":15884,"interventions":15885},"NCT00845065","Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon\u002FRibavirin (Study P05685AM2)(COMPLETED)",[89],202,[21],[15784,15886,14925],"Peginterferon alfa-2a",{"nctId":15888,"briefTitle":15889,"status":105,"phases":15890,"primaryCompletion":15891,"completion":15891,"start":15892,"enrollment":15893,"conditions":15894,"interventions":15895},"NCT01544920","Safety and Efficacy of Boceprevir\u002FPeginterferon Alfa-2a\u002FRibavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)",[89],"2015-05-19","2012-05-30",737,[21],[15896,14925,15784],"peg-Interferon alfa-2a",{"nctId":15898,"briefTitle":15899,"status":105,"phases":15900,"primaryCompletion":15901,"completion":15901,"start":15902,"enrollment":15903,"conditions":15904,"interventions":15905},"NCT01023035","Boceprevir\u002FPeginterferon\u002FRibavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)",[89],"2011-10-26","2009-12-07",687,[21],[15784,15859,14925,15906],"Erythropoietin",{"nctId":15908,"briefTitle":15909,"status":1040,"phases":15910,"primaryCompletion":15911,"completion":15911,"start":15912,"enrollment":99,"conditions":15913,"interventions":15914},"NCT01641666","Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)",[89],"2016-09","2014-05",[12957],[15784,15915,14925],"Peginterferon Alfa-2b 1.5 mcg\u002Fkg\u002Fweek",{"nctId":15917,"briefTitle":15918,"status":150,"phases":15919,"primaryCompletion":15920,"completion":15920,"start":15921,"enrollment":15922,"conditions":15923,"interventions":15925},"NCT00689390","Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)",[88,89],"2014-10-13","2007-02-20",1954,[21,15924],"Hepacivirus",[15784,15926,15859,14925],"Narlaprevir",{"nctId":15928,"briefTitle":15929,"status":105,"phases":15930,"primaryCompletion":4990,"completion":4990,"start":13102,"enrollment":15931,"conditions":15932,"interventions":15933},"NCT00708500","Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon\u002FRibavirin (Study P05101AM3)(COMPLETED)",[89],404,[21],[15784,15934,14925,15935],"Pegylated interferon alfa-2b","Boceprevir placebo",{"nctId":15937,"briefTitle":15938,"status":105,"phases":15939,"primaryCompletion":14494,"completion":14494,"start":13102,"enrollment":15940,"conditions":15941,"interventions":15942},"NCT00705432","Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)",[89],1472,[21],[15859,14925,15784],{"nctId":15944,"briefTitle":15945,"status":1040,"phases":15946,"primaryCompletion":15947,"completion":15911,"start":15948,"enrollment":99,"conditions":15949,"interventions":15950},"NCT02204475","Grazoprevir (MK-5172)\u002FElbasvir (MK-8742) Versus Boceprevir\u002FPegylated Interferon\u002FRibavarin for Chronic Hepatitis C Infection (MK-5172-066)",[89],"2016-06","2014-11",[24],[15951,15784,15828,15952],"Grazoprevir\u002FElbasvir","Ribavarin",{"nctId":15954,"briefTitle":15955,"status":105,"phases":15956,"primaryCompletion":15957,"completion":15958,"start":15959,"enrollment":15960,"conditions":15961,"interventions":15962},"NCT01945294","Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)",[89],"2015-08-05","2015-11-04","2013-10-10",257,[21],[15784,15840,14925],{"nctId":15964,"briefTitle":15965,"status":105,"phases":15966,"primaryCompletion":9164,"completion":9164,"start":11368,"enrollment":15967,"conditions":15968,"interventions":15969},"NCT01390844","Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)",[89],282,[21],[15784,15859,14925,15970],"Cross-Over Boceprevir Treatment",{"trials":15972,"activeCount":99},[15973,15981],{"nctId":15974,"briefTitle":15975,"status":1040,"phases":15976,"primaryCompletion":15977,"completion":15977,"start":15978,"enrollment":99,"conditions":15979,"interventions":15980},"NCT01770223","A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)",[90],"2015-12","2014-01",[24],[12989,1099,15849],{"nctId":15982,"briefTitle":15983,"status":105,"phases":15984,"primaryCompletion":15985,"completion":15985,"start":15986,"enrollment":3226,"conditions":15987,"interventions":15988},"NCT01756079","A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)",[90],"2015-11-17","2013-02-06",[24],[12989,1099,15849],{"trials":15990,"activeCount":99},[],{"intervention":13146,"totalTrials":3496,"cells":15992},{"EARLY_PHASE1":15993,"PHASE1":15995,"PHASE2":15997,"PHASE3":16003,"PHASE4":16076,"NA":16082},{"trials":15994,"activeCount":99},[],{"trials":15996,"activeCount":99},[],{"trials":15998,"activeCount":99},[15999],{"nctId":13916,"briefTitle":13917,"status":105,"phases":16000,"primaryCompletion":6308,"completion":6308,"start":13870,"enrollment":5196,"conditions":16001,"interventions":16002},[88],[15],[13863,13146,4084],{"trials":16004,"activeCount":99},[16005,16015,16019,16023,16027,16031,16035,16039,16043,16052,16056,16060,16064,16068,16072],{"nctId":16006,"briefTitle":16007,"status":105,"phases":16008,"primaryCompletion":16009,"completion":16009,"start":16010,"enrollment":16011,"conditions":16012,"interventions":16013},"NCT02226003","Efficacy and Safety of Ertugliflozin (MK-8835\u002FPF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)",[89],"2016-02-23","2014-09-23",291,[15],[16014,13145,13146],"Ertugliflozin",{"nctId":13963,"briefTitle":13964,"status":105,"phases":16016,"primaryCompletion":13966,"completion":13966,"start":13967,"enrollment":13968,"conditions":16017,"interventions":16018},[89],[15],[13913,13146,13971,4084],{"nctId":15123,"briefTitle":15124,"status":105,"phases":16020,"primaryCompletion":15126,"completion":15126,"start":15127,"enrollment":15128,"conditions":16021,"interventions":16022},[89],[15],[13982,13864,14289,13146],{"nctId":14000,"briefTitle":14001,"status":105,"phases":16024,"primaryCompletion":14003,"completion":14003,"start":14004,"enrollment":14005,"conditions":16025,"interventions":16026},[89],[15],[13913,13146,14008,4084,13998],{"nctId":14042,"briefTitle":14043,"status":105,"phases":16028,"primaryCompletion":719,"completion":719,"start":14045,"enrollment":14046,"conditions":16029,"interventions":16030},[89],[15],[13883,14049,4084,13146],{"nctId":14051,"briefTitle":14052,"status":105,"phases":16032,"primaryCompletion":14054,"completion":14054,"start":14055,"enrollment":14056,"conditions":16033,"interventions":16034},[89],[15],[13883,14049,4084,13145,13146,14059],{"nctId":14081,"briefTitle":14082,"status":105,"phases":16036,"primaryCompletion":14084,"completion":14084,"start":14085,"enrollment":1747,"conditions":16037,"interventions":16038},[89],[15],[13913,13146,4084],{"nctId":14130,"briefTitle":14131,"status":150,"phases":16040,"primaryCompletion":14133,"completion":14133,"start":14134,"enrollment":14135,"conditions":16041,"interventions":16042},[89],[15],[14138,13145,13122,4084,13146],{"nctId":16044,"briefTitle":16045,"status":150,"phases":16046,"primaryCompletion":16047,"completion":16047,"start":16048,"enrollment":2801,"conditions":16049,"interventions":16050},"NCT01863667","A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)",[89],"2014-04-03","2013-07-08",[15],[13913,13146,16051,14008],"Omarigliptin Placebo",{"nctId":14161,"briefTitle":14162,"status":105,"phases":16053,"primaryCompletion":14164,"completion":14164,"start":14165,"enrollment":14166,"conditions":16054,"interventions":16055},[89],[33],[14126,14169,14170,14040],{"nctId":14182,"briefTitle":14183,"status":105,"phases":16057,"primaryCompletion":9164,"completion":9164,"start":14185,"enrollment":6396,"conditions":16058,"interventions":16059},[89],[15],[13913,4084,13146],{"nctId":14189,"briefTitle":14190,"status":105,"phases":16061,"primaryCompletion":14192,"completion":14193,"start":14194,"enrollment":14195,"conditions":16062,"interventions":16063},[89],[15],[13145,14198,13146,4084],{"nctId":13137,"briefTitle":13138,"status":150,"phases":16065,"primaryCompletion":13140,"completion":13140,"start":13141,"enrollment":13142,"conditions":16066,"interventions":16067},[89],[15],[13145,8011,4084,13146,13146],{"nctId":15752,"briefTitle":15753,"status":105,"phases":16069,"primaryCompletion":15755,"completion":15755,"start":15756,"enrollment":15464,"conditions":16070,"interventions":16071},[89],[15],[14487,13146],{"nctId":14259,"briefTitle":14260,"status":105,"phases":16073,"primaryCompletion":14262,"completion":14262,"start":14263,"enrollment":14264,"conditions":16074,"interventions":16075},[89],[15],[13883,14147,4084,13146],{"trials":16077,"activeCount":99},[16078],{"nctId":14281,"briefTitle":14282,"status":105,"phases":16079,"primaryCompletion":14284,"completion":14284,"start":14285,"enrollment":14286,"conditions":16080,"interventions":16081},[90],[15],[4084,13145,14289,14290,13146,14198],{"trials":16083,"activeCount":99},[],{"intervention":13913,"totalTrials":2901,"cells":16085},{"EARLY_PHASE1":16086,"PHASE1":16088,"PHASE2":16108,"PHASE3":16114,"PHASE4":16186,"NA":16195},{"trials":16087,"activeCount":99},[],{"trials":16089,"activeCount":99},[16090,16099],{"nctId":16091,"briefTitle":16092,"status":105,"phases":16093,"primaryCompletion":16094,"completion":16094,"start":16095,"enrollment":626,"conditions":16096,"interventions":16098},"NCT01088711","Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)",[87],"2010-05-11","2010-03-11",[16097],"Type 2 Diabetes (T2D)",[13913],{"nctId":16100,"briefTitle":16101,"status":105,"phases":16102,"primaryCompletion":16103,"completion":16103,"start":16104,"enrollment":13234,"conditions":16105,"interventions":16107},"NCT01407276","A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)",[87],"2012-03-23","2011-08-08",[16106,15],"Chronic Renal Insufficiency",[13913],{"trials":16109,"activeCount":99},[16110],{"nctId":13904,"briefTitle":13905,"status":105,"phases":16111,"primaryCompletion":13907,"completion":13908,"start":13909,"enrollment":13910,"conditions":16112,"interventions":16113},[88],[15],[13913,13914,4084],{"trials":16115,"activeCount":99},[16116,16120,16129,16133,16137,16145,16155,16159,16168,16172,16182],{"nctId":13945,"briefTitle":13946,"status":105,"phases":16117,"primaryCompletion":5250,"completion":5250,"start":13948,"enrollment":5017,"conditions":16118,"interventions":16119},[89],[13950],[13913,4084],{"nctId":16121,"briefTitle":16122,"status":105,"phases":16123,"primaryCompletion":16124,"completion":16124,"start":16125,"enrollment":16126,"conditions":16127,"interventions":16128},"NCT01703221","Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)",[89],"2014-04-25","2012-10-24",414,[15],[13913,13145],{"nctId":13963,"briefTitle":13964,"status":105,"phases":16130,"primaryCompletion":13966,"completion":13966,"start":13967,"enrollment":13968,"conditions":16131,"interventions":16132},[89],[15],[13913,13146,13971,4084],{"nctId":14000,"briefTitle":14001,"status":105,"phases":16134,"primaryCompletion":14003,"completion":14003,"start":14004,"enrollment":14005,"conditions":16135,"interventions":16136},[89],[15],[13913,13146,14008,4084,13998],{"nctId":16138,"briefTitle":16139,"status":105,"phases":16140,"primaryCompletion":16141,"completion":16141,"start":16125,"enrollment":16142,"conditions":16143,"interventions":16144},"NCT01697592","Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)",[89],"2014-05-08",585,[15],[13913],{"nctId":16146,"briefTitle":16147,"status":150,"phases":16148,"primaryCompletion":16149,"completion":16150,"start":16151,"enrollment":16152,"conditions":16153,"interventions":16154},"NCT01703208","A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)",[89],"2016-05-13","2017-03-22","2012-10-05",4202,[15],[13913],{"nctId":14081,"briefTitle":14082,"status":105,"phases":16156,"primaryCompletion":14084,"completion":14084,"start":14085,"enrollment":1747,"conditions":16157,"interventions":16158},[89],[15],[13913,13146,4084],{"nctId":16160,"briefTitle":16161,"status":105,"phases":16162,"primaryCompletion":16163,"completion":16163,"start":16164,"enrollment":16165,"conditions":16166,"interventions":16167},"NCT01698775","A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)",[89],"2016-01-19","2012-10-02",213,[15],[13913,13961,14059],{"nctId":16044,"briefTitle":16045,"status":150,"phases":16169,"primaryCompletion":16047,"completion":16047,"start":16048,"enrollment":2801,"conditions":16170,"interventions":16171},[89],[15],[13913,13146,16051,14008],{"nctId":16173,"briefTitle":16174,"status":105,"phases":16175,"primaryCompletion":2095,"completion":2095,"start":16176,"enrollment":16177,"conditions":16178,"interventions":16179},"NCT01841697","Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)",[89],"2013-06-13",642,[14156],[13913,13145,16180,16181],"Open-label Metformin","Open-label Glimepiride",{"nctId":14182,"briefTitle":14183,"status":105,"phases":16183,"primaryCompletion":9164,"completion":9164,"start":14185,"enrollment":6396,"conditions":16184,"interventions":16185},[89],[15],[13913,4084,13146],{"trials":16187,"activeCount":99},[16188],{"nctId":16189,"briefTitle":16190,"status":105,"phases":16191,"primaryCompletion":2602,"completion":2602,"start":16192,"enrollment":743,"conditions":16193,"interventions":16194},"NCT02906709","Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)",[90],"2016-10-17",[15],[13913,14059],{"trials":16196,"activeCount":99},[],{"intervention":5137,"totalTrials":5563,"cells":16198},{"EARLY_PHASE1":16199,"PHASE1":16201,"PHASE2":16224,"PHASE3":16257,"PHASE4":16289,"NA":16295},{"trials":16200,"activeCount":99},[],{"trials":16202,"activeCount":99},[16203,16212,16216,16220],{"nctId":16204,"briefTitle":16205,"status":105,"phases":16206,"primaryCompletion":14112,"completion":14112,"start":16207,"enrollment":16208,"conditions":16209,"interventions":16211},"NCT00819039","A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)",[87],"2009-01-26",98,[16210],"Postoperative Nausea and Vomiting",[5136,5137],{"nctId":5128,"briefTitle":5129,"status":105,"phases":16213,"primaryCompletion":5131,"completion":5131,"start":5132,"enrollment":2770,"conditions":16214,"interventions":16215},[87],[176,756,526],[5135,5135,5135,5135,5136,5137,529],{"nctId":5143,"briefTitle":5144,"status":150,"phases":16217,"primaryCompletion":5146,"completion":5146,"start":5147,"enrollment":5148,"conditions":16218,"interventions":16219},[87],[5150],[5152,5153,5154,5137,529],{"nctId":5176,"briefTitle":5177,"status":105,"phases":16221,"primaryCompletion":5179,"completion":5179,"start":4990,"enrollment":3655,"conditions":16222,"interventions":16223},[87],[5181],[5183,5184,5185,529,529,5137,5186],{"trials":16225,"activeCount":99},[16226,16235,16246],{"nctId":16227,"briefTitle":16228,"status":105,"phases":16229,"primaryCompletion":13039,"completion":13039,"start":16230,"enrollment":16231,"conditions":16232,"interventions":16233},"NCT01697579","Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)",[88],"2012-12-13",240,[5252],[5254,5313,5137,16234],"5-hydroxytryptamine 3 antagonist",{"nctId":16236,"briefTitle":16237,"status":105,"phases":16238,"primaryCompletion":16239,"completion":16239,"start":16240,"enrollment":16241,"conditions":16242,"interventions":16245},"NCT01732458","A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)",[88],"2016-09-26","2013-02-12",229,[16243,16244],"Post-operative Nausea","Post-operative Vomiting",[5136,5137],{"nctId":16247,"briefTitle":16248,"status":105,"phases":16249,"primaryCompletion":5801,"completion":5801,"start":14540,"enrollment":16250,"conditions":16251,"interventions":16252},"NCT00539721","A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED)",[88],619,[16210],[16253,16254,16255,16256,5137],"Rolapitant Dose 1","Rolapitant Dose 2","Rolapitant Dose 3","Rolapitant Dose 4",{"trials":16258,"activeCount":99},[16259,16263,16267,16271,16275],{"nctId":5246,"briefTitle":5247,"status":150,"phases":16260,"primaryCompletion":5249,"completion":5249,"start":5250,"enrollment":613,"conditions":16261,"interventions":16262},[89],[5252],[5254,5137,529,5255],{"nctId":5277,"briefTitle":5278,"status":105,"phases":16264,"primaryCompletion":5280,"completion":5280,"start":5281,"enrollment":5282,"conditions":16265,"interventions":16266},[89],[5181],[5285,5286,529,529,5137],{"nctId":4415,"briefTitle":4416,"status":105,"phases":16268,"primaryCompletion":4418,"completion":4419,"start":4420,"enrollment":4421,"conditions":16269,"interventions":16270},[89],[4292],[4424,4425,4426,4427],{"nctId":5305,"briefTitle":5306,"status":105,"phases":16272,"primaryCompletion":5308,"completion":5308,"start":5309,"enrollment":5310,"conditions":16273,"interventions":16274},[89],[5181],[4294,5313,529,5137,5314,5315,5316],{"nctId":16276,"briefTitle":16277,"status":105,"phases":16278,"primaryCompletion":16279,"completion":16280,"start":16281,"enrollment":1747,"conditions":16282,"interventions":16284},"NCT01362530","A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)",[89],"2013-03-14","2013-08-16","2011-09-13",[16283],"Chemotherapy Induced Nausea and Vomiting",[16285,16286,16287,5137,16288],"Aprepitant 125 mg","Aprepitant 80 mg","Aprepitant powder for suspension","Emetogenic chemotherapy",{"trials":16290,"activeCount":99},[16291],{"nctId":5344,"briefTitle":5345,"status":105,"phases":16292,"primaryCompletion":5347,"completion":5347,"start":5348,"enrollment":5349,"conditions":16293,"interventions":16294},[90],[4291,4292],[5136,5352,5137,529,5315,5353],{"trials":16296,"activeCount":99},[],{"intervention":4424,"totalTrials":95,"cells":16298},{"EARLY_PHASE1":16299,"PHASE1":16301,"PHASE2":16311,"PHASE3":16317,"PHASE4":16362,"NA":16368},{"trials":16300,"activeCount":99},[],{"trials":16302,"activeCount":99},[16303,16307],{"nctId":16204,"briefTitle":16205,"status":105,"phases":16304,"primaryCompletion":14112,"completion":14112,"start":16207,"enrollment":16208,"conditions":16305,"interventions":16306},[87],[16210],[5136,5137],{"nctId":5128,"briefTitle":5129,"status":105,"phases":16308,"primaryCompletion":5131,"completion":5131,"start":5132,"enrollment":2770,"conditions":16309,"interventions":16310},[87],[176,756,526],[5135,5135,5135,5135,5136,5137,529],{"trials":16312,"activeCount":99},[16313],{"nctId":16236,"briefTitle":16237,"status":105,"phases":16314,"primaryCompletion":16239,"completion":16239,"start":16240,"enrollment":16241,"conditions":16315,"interventions":16316},[88],[16243,16244],[5136,5137],{"trials":16318,"activeCount":99},[16319,16326,16330,16334,16338,16342,16346,16350],{"nctId":16320,"briefTitle":16321,"status":105,"phases":16322,"primaryCompletion":15329,"completion":15329,"start":16323,"enrollment":3605,"conditions":16324,"interventions":16325},"NCT00034983","Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)",[89],"2001-10-29",[15111],[4424,15363],{"nctId":15255,"briefTitle":15256,"status":105,"phases":16327,"primaryCompletion":14875,"completion":14875,"start":15258,"enrollment":951,"conditions":16328,"interventions":16329},[89],[15111],[4424,14331],{"nctId":15326,"briefTitle":15327,"status":105,"phases":16331,"primaryCompletion":15329,"completion":15330,"start":15331,"enrollment":1387,"conditions":16332,"interventions":16333},[89],[15111],[4424,14331],{"nctId":15347,"briefTitle":15348,"status":105,"phases":16335,"primaryCompletion":15350,"completion":15351,"start":15352,"enrollment":15353,"conditions":16336,"interventions":16337},[89],[15111],[4424,14331],{"nctId":15357,"briefTitle":15358,"status":105,"phases":16339,"primaryCompletion":15330,"completion":15330,"start":15360,"enrollment":1818,"conditions":16340,"interventions":16341},[89],[15111],[4424,15363,13864],{"nctId":5288,"briefTitle":5289,"status":105,"phases":16343,"primaryCompletion":5291,"completion":5292,"start":5293,"enrollment":5294,"conditions":16344,"interventions":16345},[89],[5296],[4424,5298,4426,5299,4426],{"nctId":4415,"briefTitle":4416,"status":105,"phases":16347,"primaryCompletion":4418,"completion":4419,"start":4420,"enrollment":4421,"conditions":16348,"interventions":16349},[89],[4292],[4424,4425,4426,4427],{"nctId":16351,"briefTitle":16352,"status":105,"phases":16353,"primaryCompletion":16354,"completion":16355,"start":16356,"enrollment":16357,"conditions":16358,"interventions":16359},"NCT00337727","Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)",[89],"2008-10-28","2008-11-19","2007-01-01",848,[5150],[4424,5154,16360,5285,16361,16361],"Comparator: dexamethasone","Comparator; Placebo",{"trials":16363,"activeCount":99},[16364],{"nctId":5344,"briefTitle":5345,"status":105,"phases":16365,"primaryCompletion":5347,"completion":5347,"start":5348,"enrollment":5349,"conditions":16366,"interventions":16367},[90],[4291,4292],[5136,5352,5137,529,5315,5353],{"trials":16369,"activeCount":99},[],{"intervention":13122,"totalTrials":734,"cells":16371},{"EARLY_PHASE1":16372,"PHASE1":16374,"PHASE2":16391,"PHASE3":16397,"PHASE4":16429,"NA":16438},{"trials":16373,"activeCount":99},[],{"trials":16375,"activeCount":99},[16376,16383],{"nctId":16377,"briefTitle":16378,"status":105,"phases":16379,"primaryCompletion":14730,"completion":14730,"start":14713,"enrollment":4741,"conditions":16380,"interventions":16382},"NCT00935259","Lipid Biomarker Study in Men With Dyslipidemia After Simvastatin Treatment (Study MK-0000-140)(COMPLETED)",[87],[16381],"Hypercholesterolemia, Dyslipidemia",[13122],{"nctId":16384,"briefTitle":16385,"status":105,"phases":16386,"primaryCompletion":5507,"completion":5507,"start":13891,"enrollment":8,"conditions":16387,"interventions":16388},"NCT00943124","MK0524B Bioequivalence Study (0524B-070)",[87],[14337],[16389,16390,13122],"MK0524B","MK0524A",{"trials":16392,"activeCount":99},[16393],{"nctId":13115,"briefTitle":13116,"status":105,"phases":16394,"primaryCompletion":5179,"completion":5179,"start":9610,"enrollment":920,"conditions":16395,"interventions":16396},[88],[13119],[13121,8011,13122,13122],{"trials":16398,"activeCount":99},[16399,16409,16421,16425],{"nctId":16400,"briefTitle":16401,"status":150,"phases":16402,"primaryCompletion":16403,"completion":16403,"start":16404,"enrollment":16405,"conditions":16406,"interventions":16407},"NCT01294683","A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)",[89],"2012-01-17","2011-02-04",977,[14418,14337],[13122,16408,16408],"Extended Release",{"nctId":16410,"briefTitle":16411,"status":150,"phases":16412,"primaryCompletion":16413,"completion":16413,"start":16414,"enrollment":16415,"conditions":16416,"interventions":16418},"NCT01335997","Efficacy and Safety of Extended-Release Niacin\u002F Laropiprant\u002FSimvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)",[89],"2012-01-01","2011-05-01",1139,[14418,16417],"Mixed Dyslipidemia",[16419,16420,13122],"ER niacin\u002Flaropiprant","ER niacin\u002Flaropiprant\u002Fsimvastatin",{"nctId":14130,"briefTitle":14131,"status":150,"phases":16422,"primaryCompletion":14133,"completion":14133,"start":14134,"enrollment":14135,"conditions":16423,"interventions":16424},[89],[15],[14138,13145,13122,4084,13146],{"nctId":13126,"briefTitle":13127,"status":105,"phases":16426,"primaryCompletion":13129,"completion":13129,"start":13130,"enrollment":13131,"conditions":16427,"interventions":16428},[89],[13133],[13135,8011,13122],{"trials":16430,"activeCount":99},[16431],{"nctId":16432,"briefTitle":16433,"status":105,"phases":16434,"primaryCompletion":13890,"start":14531,"enrollment":3390,"conditions":16435,"interventions":16436},"NCT00753883","Ezetrol Post-Marketing Study",[90],[7610],[16437,7600],"simvastatin",{"trials":16439,"activeCount":99},[],{"intervention":16441,"totalTrials":4555,"cells":16442},"RotaTeq™",{"EARLY_PHASE1":16443,"PHASE1":16445,"PHASE2":16447,"PHASE3":16449,"PHASE4":16507,"NA":16517},{"trials":16444,"activeCount":99},[],{"trials":16446,"activeCount":99},[],{"trials":16448,"activeCount":99},[],{"trials":16450,"activeCount":99},[16451,16467,16480,16491,16503],{"nctId":16452,"briefTitle":16453,"status":105,"phases":16454,"primaryCompletion":16455,"completion":16456,"start":16457,"enrollment":16458,"conditions":16459,"interventions":16462},"NCT01340937","A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)",[89],"2012-12-18","2013-07-26","2011-05-10",2808,[16460,16461],"Bacterial Infections","Virus Diseases",[16463,16464,16465,16441,16466],"V419","PENTACEL™","Prevnar 13™","Recombivax HB vaccine",{"nctId":16468,"briefTitle":16469,"status":105,"phases":16470,"primaryCompletion":1640,"completion":1640,"start":1984,"enrollment":3605,"conditions":16471,"interventions":16473},"NCT03620162","A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027\u002FPNEU-DIRECTION)",[89],[16472],"Pneumococcal Infections",[16465,16474,16441,16475,16476,16477,16478,16479],"V114","Pentacel™","RECOMBIVAX HB™","HIBERIX™","M-M-R™ II","VARIVAX™",{"nctId":16481,"briefTitle":16482,"status":105,"phases":16483,"primaryCompletion":16484,"completion":16484,"start":709,"enrollment":16485,"conditions":16486,"interventions":16488},"NCT03893448","Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)",[89],"2021-05-24",1720,[16472,16487],"Pneumococcal Vaccines",[16474,16465,16441,16475,16476,16489,16490,16479,16477],"VAQTA™","MMR II™",{"nctId":16492,"briefTitle":16493,"status":105,"phases":16494,"primaryCompletion":16495,"completion":16495,"start":16496,"enrollment":16497,"conditions":16498,"interventions":16499},"NCT01337167","Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)",[89],"2013-05-09","2011-04-19",1473,[16460,16461],[16463,16500,16501,16465,16441,16464,16466,16502],"DAPTACEL™","PedvaxHIB™","ActHIB™",{"nctId":15581,"briefTitle":15582,"status":105,"phases":16504,"primaryCompletion":14595,"completion":14595,"start":15584,"enrollment":15585,"conditions":16505,"interventions":16506},[89],[15587],[15589,13864],{"trials":16508,"activeCount":99},[16509],{"nctId":16510,"briefTitle":16511,"status":105,"phases":16512,"primaryCompletion":13040,"completion":13040,"start":16513,"enrollment":11801,"conditions":16514,"interventions":16515},"NCT01926015","Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)",[90],"2013-09-19",[15554],[16441,16516],"DTP-IPV",{"trials":16518,"activeCount":99},[],{"intervention":15205,"totalTrials":4555,"cells":16520},{"EARLY_PHASE1":16521,"PHASE1":16523,"PHASE2":16525,"PHASE3":16527,"PHASE4":16565,"NA":16576},{"trials":16522,"activeCount":99},[],{"trials":16524,"activeCount":99},[],{"trials":16526,"activeCount":99},[],{"trials":16528,"activeCount":99},[16529,16538,16542,16552,16556],{"nctId":16530,"briefTitle":16531,"status":105,"phases":16532,"primaryCompletion":2722,"completion":2722,"start":16533,"enrollment":16534,"conditions":16535,"interventions":16537},"NCT03493542","A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)",[89],"2018-08-31",766,[16536],"Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1\u002F2\u002F3, and Cervical Adenocarcinoma in Situ",[15205],{"nctId":15195,"briefTitle":15196,"status":105,"phases":16539,"primaryCompletion":15198,"completion":15199,"start":15200,"enrollment":15201,"conditions":16540,"interventions":16541},[89],[15203,7076],[15205,13864],{"nctId":16543,"briefTitle":16544,"status":105,"phases":16545,"primaryCompletion":16546,"completion":16546,"start":16547,"enrollment":2788,"conditions":16548,"interventions":16551},"NCT02576054","Safety and Tolerability Study of V501 in Japanese Boys (V501-200)",[89],"2018-08-08","2015-11-20",[16549,16550],"Anogenital Human Papilloma Virus Infection","Condyloma Acuminata",[15205],{"nctId":15292,"briefTitle":15293,"status":105,"phases":16553,"primaryCompletion":13891,"completion":13870,"start":15295,"enrollment":15296,"conditions":16554,"interventions":16555},[89],[863,7085],[15205,13864,15299],{"nctId":16557,"briefTitle":16558,"status":105,"phases":16559,"primaryCompletion":16560,"completion":16560,"start":16561,"enrollment":16562,"conditions":16563,"interventions":16564},"NCT01862874","Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)",[89],"2017-08-30","2013-06-27",1124,[16549,16550],[15205],{"trials":16566,"activeCount":99},[16567],{"nctId":16568,"briefTitle":16569,"status":105,"phases":16570,"primaryCompletion":16571,"completion":16571,"start":16572,"enrollment":2656,"conditions":16573,"interventions":16575},"NCT01544478","V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)",[90],"2016-08-27","2011-11-25",[863,16574,7140],"Cervical Intraepithelial Neoplasia",[15205],{"trials":16577,"activeCount":99},[],{"intervention":16579,"totalTrials":4555,"cells":16580},"Azithromycin ophthalmic solution, 1%",{"EARLY_PHASE1":16581,"PHASE1":16583,"PHASE2":16585,"PHASE3":16616,"PHASE4":16618,"NA":16637},{"trials":16582,"activeCount":99},[],{"trials":16584,"activeCount":99},[],{"trials":16586,"activeCount":99},[16587,16596,16604,16610],{"nctId":16588,"briefTitle":16589,"status":150,"phases":16590,"primaryCompletion":16591,"completion":16591,"start":16592,"enrollment":31,"conditions":16593,"interventions":16595},"NCT01220258","A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)",[88],"2011-08","2010-11",[16594],"Posterior Blepharoconjunctivitis",[16579],{"nctId":16597,"briefTitle":16598,"status":150,"phases":16599,"primaryCompletion":5800,"completion":5800,"start":15794,"enrollment":3390,"conditions":16600,"interventions":16602},"NCT01269658","A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis (P08636)",[88],[16601],"Blepharitis",[16579,16603],"Vehicle",{"nctId":16605,"briefTitle":16606,"status":105,"phases":16607,"primaryCompletion":13101,"completion":13101,"start":14352,"enrollment":7093,"conditions":16608,"interventions":16609},"NCT00894530","The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)",[88],[16601],[16579],{"nctId":16611,"briefTitle":16612,"status":105,"phases":16613,"primaryCompletion":14623,"completion":14623,"start":9610,"enrollment":13958,"conditions":16614,"interventions":16615},"NCT00892970","The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period",[88],[16601],[16579],{"trials":16617,"activeCount":99},[],{"trials":16619,"activeCount":99},[16620,16628],{"nctId":16621,"briefTitle":16622,"status":105,"phases":16623,"primaryCompletion":13224,"completion":13224,"start":14730,"enrollment":2288,"conditions":16624,"interventions":16626},"NCT01014078","A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease",[90],[16625],"Dry Eye Disease",[16627],"Azithromycin Ophthalmic Solution, 1%",{"nctId":16629,"briefTitle":16630,"status":105,"phases":16631,"primaryCompletion":16592,"completion":16592,"start":13224,"enrollment":4421,"conditions":16632,"interventions":16634},"NCT01105624","A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)",[90],[16633],"Contact Lens Dry Eye",[16635,16636],"azithromycin ophthalmic solution, 1%","Visine® for Contacts®",{"trials":16638,"activeCount":99},[],{"intervention":16640,"totalTrials":174,"cells":16641},"Sugammadex 4 mg\u002Fkg",{"EARLY_PHASE1":16642,"PHASE1":16644,"PHASE2":16656,"PHASE3":16658,"PHASE4":16674,"NA":16708},{"trials":16643,"activeCount":99},[],{"trials":16645,"activeCount":99},[16646],{"nctId":16647,"briefTitle":16648,"status":105,"phases":16649,"primaryCompletion":16650,"completion":16650,"start":16651,"enrollment":1779,"conditions":16652,"interventions":16654},"NCT00988065","Sugammadex Hypersensitivity Study (Study P06042)",[87],"2010-04-13","2009-09-06",[16653],"Hypersensitivity",[16640,16655],"Sugammadex 16 mg\u002Fkg",{"trials":16657,"activeCount":99},[],{"trials":16659,"activeCount":99},[16660],{"nctId":16661,"briefTitle":16662,"status":105,"phases":16663,"primaryCompletion":16664,"completion":16665,"start":16666,"enrollment":1977,"conditions":16667,"interventions":16669},"NCT00421148","Dose-Finding Pediatric and Adult Trial With Sugammadex (Org 25969, MK-8616, SCH 900616) (19.4.306) (MK-8616-034) (P05961)",[89],"2006-05-31","2006-06-02","2005-05-30",[16668],"Anesthesia",[16670,16671,16672,16640,16673],"Sugammadex 0.5 mg\u002Fkg","Sugammadex 1 mg\u002Fkg","Sugammadex 2 mg\u002Fkg","Rocuronium bromide",{"trials":16675,"activeCount":99},[16676,16689,16699],{"nctId":16677,"briefTitle":16678,"status":105,"phases":16679,"primaryCompletion":16680,"completion":16680,"start":16681,"enrollment":16682,"conditions":16683,"interventions":16685},"NCT03346057","Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)",[90],"2019-09-04","2017-12-20",344,[16684],"Reversal of Neuromuscular Blockade",[16672,16640,16655,16686,16687,16688],"Neostigmine + Glycopyrrolate","Rocuronium","Vecuronium",{"nctId":16690,"briefTitle":16691,"status":105,"phases":16692,"primaryCompletion":2388,"completion":2388,"start":16693,"enrollment":16694,"conditions":16695,"interventions":16697},"NCT03909165","Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to \u003C2 Years (MK-8616-169)",[90],"2019-07-23",145,[16696],"Neuromuscular Blockade",[16672,16640,16686,16698],"Neostigmine + Atropine",{"nctId":16700,"briefTitle":16701,"status":105,"phases":16702,"primaryCompletion":16703,"completion":16703,"start":16704,"enrollment":16705,"conditions":16706,"interventions":16707},"NCT03351608","Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)",[90],"2020-01-28","2018-02-12",288,[16696],[16672,16640,16686,16698],{"trials":16709,"activeCount":99},[],{"intervention":16711,"totalTrials":174,"cells":16712},"Golimumab",{"EARLY_PHASE1":16713,"PHASE1":16715,"PHASE2":16717,"PHASE3":16719,"PHASE4":16731,"NA":16768},{"trials":16714,"activeCount":99},[],{"trials":16716,"activeCount":99},[],{"trials":16718,"activeCount":99},[],{"trials":16720,"activeCount":99},[16721],{"nctId":16722,"briefTitle":16723,"status":105,"phases":16724,"primaryCompletion":16725,"completion":16726,"start":16727,"enrollment":16728,"conditions":16729,"interventions":16730},"NCT01453725","Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006)",[89],"2014-03-11","2015-01-15","2012-02-13",198,[12769],[16711],{"trials":16732,"activeCount":99},[16733,16741,16751,16759],{"nctId":16734,"briefTitle":16735,"status":105,"phases":16736,"primaryCompletion":16737,"completion":16737,"start":5168,"enrollment":2788,"conditions":16738,"interventions":16740},"NCT01668004","The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)",[90],"2015-04-30",[16739],"Ankylosing Spondylitis",[16711],{"nctId":16742,"briefTitle":16743,"status":105,"phases":16744,"primaryCompletion":16745,"completion":16745,"start":16746,"enrollment":16747,"conditions":16748,"interventions":16750},"NCT03253796","Golimumab (MK-8259 \u002F SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)",[90],"2021-03-17","2017-11-07",323,[16749],"Spondyloarthritis",[16711],{"nctId":16752,"briefTitle":16753,"status":105,"phases":16754,"primaryCompletion":11384,"completion":11384,"start":16755,"enrollment":16756,"conditions":16757,"interventions":16758},"NCT02092285","Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)",[90],"2014-05-09",205,[9066],[16711],{"nctId":16760,"briefTitle":16761,"status":105,"phases":16762,"primaryCompletion":16763,"completion":16764,"start":16765,"enrollment":312,"conditions":16766,"interventions":16767},"NCT02318667","Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).",[90],"2017-06-21","2017-09-05","2015-02-27",[7169],[16711],{"trials":16769,"activeCount":99},[],{"intervention":15087,"totalTrials":174,"cells":16771},{"EARLY_PHASE1":16772,"PHASE1":16774,"PHASE2":16776,"PHASE3":16782,"PHASE4":16806,"NA":16812},{"trials":16773,"activeCount":99},[],{"trials":16775,"activeCount":99},[],{"trials":16777,"activeCount":99},[16778],{"nctId":15081,"briefTitle":15082,"status":105,"phases":16779,"primaryCompletion":5982,"completion":5982,"start":14540,"enrollment":15084,"conditions":16780,"interventions":16781},[88],[14395],[15087,13864],{"trials":16783,"activeCount":99},[16784,16788,16797],{"nctId":15248,"briefTitle":15249,"status":105,"phases":16785,"primaryCompletion":14623,"completion":14623,"start":14540,"enrollment":15251,"conditions":16786,"interventions":16787},[89],[14775],[15087,13864],{"nctId":16789,"briefTitle":16790,"status":105,"phases":16791,"primaryCompletion":16792,"completion":16793,"start":16794,"enrollment":14195,"conditions":16795,"interventions":16796},"NCT01505647","Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)",[89],"2012-07","2012-11","2012-04",[14395,14775],[15087,15087],{"nctId":16798,"briefTitle":16799,"status":105,"phases":16800,"primaryCompletion":16792,"completion":16801,"start":16802,"enrollment":1818,"conditions":16803,"interventions":16805},"NCT01245751","Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)",[89],"2015-05","2011-04",[14395,16804],"Varicella-zoster Vaccine",[15087],{"trials":16807,"activeCount":99},[16808],{"nctId":15603,"briefTitle":15604,"status":105,"phases":16809,"primaryCompletion":13870,"completion":13870,"start":14887,"enrollment":15606,"conditions":16810,"interventions":16811},[90],[14395],[15087,14331],{"trials":16813,"activeCount":99},[],{"intervention":16672,"totalTrials":3963,"cells":16815},{"EARLY_PHASE1":16816,"PHASE1":16818,"PHASE2":16820,"PHASE3":16822,"PHASE4":16828,"NA":16842},{"trials":16817,"activeCount":99},[],{"trials":16819,"activeCount":99},[],{"trials":16821,"activeCount":99},[],{"trials":16823,"activeCount":99},[16824],{"nctId":16661,"briefTitle":16662,"status":105,"phases":16825,"primaryCompletion":16664,"completion":16665,"start":16666,"enrollment":1977,"conditions":16826,"interventions":16827},[89],[16668],[16670,16671,16672,16640,16673],{"trials":16829,"activeCount":99},[16830,16834,16838],{"nctId":16677,"briefTitle":16678,"status":105,"phases":16831,"primaryCompletion":16680,"completion":16680,"start":16681,"enrollment":16682,"conditions":16832,"interventions":16833},[90],[16684],[16672,16640,16655,16686,16687,16688],{"nctId":16690,"briefTitle":16691,"status":105,"phases":16835,"primaryCompletion":2388,"completion":2388,"start":16693,"enrollment":16694,"conditions":16836,"interventions":16837},[90],[16696],[16672,16640,16686,16698],{"nctId":16700,"briefTitle":16701,"status":105,"phases":16839,"primaryCompletion":16703,"completion":16703,"start":16704,"enrollment":16705,"conditions":16840,"interventions":16841},[90],[16696],[16672,16640,16686,16698],{"trials":16843,"activeCount":99},[],{"intervention":16686,"totalTrials":3963,"cells":16845},{"EARLY_PHASE1":16846,"PHASE1":16848,"PHASE2":16850,"PHASE3":16852,"PHASE4":16854,"NA":16880},{"trials":16847,"activeCount":99},[],{"trials":16849,"activeCount":99},[],{"trials":16851,"activeCount":99},[],{"trials":16853,"activeCount":99},[],{"trials":16855,"activeCount":99},[16856,16860,16872,16876],{"nctId":16677,"briefTitle":16678,"status":105,"phases":16857,"primaryCompletion":16680,"completion":16680,"start":16681,"enrollment":16682,"conditions":16858,"interventions":16859},[90],[16684],[16672,16640,16655,16686,16687,16688],{"nctId":16861,"briefTitle":16862,"status":105,"phases":16863,"primaryCompletion":7136,"completion":7136,"start":16864,"enrollment":9357,"conditions":16865,"interventions":16866},"NCT03346070","Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)",[90],"2018-01-01",[16696],[16867,16868,16869,16870,16686,16871],"Sugammadex 2 mg\u002Fkg ABW","Sugammadex 2 mg\u002Fkg IBW","Sugammadex 4 mg\u002Fkg ABW","Sugammadex 4 mg\u002Fkg IBW","Rocuronium or Vecuronium",{"nctId":16690,"briefTitle":16691,"status":105,"phases":16873,"primaryCompletion":2388,"completion":2388,"start":16693,"enrollment":16694,"conditions":16874,"interventions":16875},[90],[16696],[16672,16640,16686,16698],{"nctId":16700,"briefTitle":16701,"status":105,"phases":16877,"primaryCompletion":16703,"completion":16703,"start":16704,"enrollment":16705,"conditions":16878,"interventions":16879},[90],[16696],[16672,16640,16686,16698],{"trials":16881,"activeCount":99},[],{"intervention":14777,"totalTrials":3963,"cells":16883},{"EARLY_PHASE1":16884,"PHASE1":16886,"PHASE2":16888,"PHASE3":16894,"PHASE4":16908,"NA":16916},{"trials":16885,"activeCount":99},[],{"trials":16887,"activeCount":99},[],{"trials":16889,"activeCount":99},[16890],{"nctId":14769,"briefTitle":14770,"status":105,"phases":16891,"primaryCompletion":14772,"completion":14531,"start":14773,"enrollment":765,"conditions":16892,"interventions":16893},[88],[14775],[14777,14331],{"trials":16895,"activeCount":99},[16896,16904],{"nctId":16897,"briefTitle":16898,"status":105,"phases":16899,"primaryCompletion":16900,"completion":16900,"start":15755,"enrollment":688,"conditions":16901,"interventions":16902},"NCT01527370","Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)",[89],"2013-04-09",[14395,14775],[16903],"Zoster Vaccine Live",{"nctId":15520,"briefTitle":15521,"status":105,"phases":16905,"primaryCompletion":13891,"completion":13891,"start":8621,"enrollment":2788,"conditions":16906,"interventions":16907},[89],[14395],[14777,13864],{"trials":16909,"activeCount":99},[16910],{"nctId":16911,"briefTitle":16912,"status":105,"phases":16913,"primaryCompletion":6799,"completion":6799,"start":16794,"enrollment":765,"conditions":16914,"interventions":16915},"NCT01556451","ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)",[90],[14395,14775],[16903],{"trials":16917,"activeCount":99},[],{"intervention":7335,"totalTrials":3963,"cells":16919},{"EARLY_PHASE1":16920,"PHASE1":16922,"PHASE2":16941,"PHASE3":16943,"PHASE4":16945,"NA":16955},{"trials":16921,"activeCount":99},[],{"trials":16923,"activeCount":99},[16924,16933,16937],{"nctId":16925,"briefTitle":16926,"status":105,"phases":16927,"primaryCompletion":16928,"completion":16928,"start":16929,"enrollment":1169,"conditions":16930,"interventions":16931},"NCT05893862","A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)",[87],"2024-02-22","2023-06-26",[14715],[16932,7335],"Elpipodect",{"nctId":12825,"briefTitle":12826,"status":105,"phases":16934,"primaryCompletion":4202,"completion":4202,"start":12828,"enrollment":25,"conditions":16935,"interventions":16936},[87],[18],[7801,7335,12831,12832],{"nctId":7329,"briefTitle":7330,"status":105,"phases":16938,"primaryCompletion":7332,"completion":5574,"start":6394,"enrollment":184,"conditions":16939,"interventions":16940},[87],[18],[7280,7335],{"trials":16942,"activeCount":99},[],{"trials":16944,"activeCount":99},[],{"trials":16946,"activeCount":99},[16947],{"nctId":16948,"briefTitle":16949,"status":105,"phases":16950,"primaryCompletion":14454,"start":14454,"enrollment":1054,"conditions":16951,"interventions":16953},"NCT00564447","Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers",[90],[16460,16952],"Eye Infections",[16954,7335],"Azithromycin",{"trials":16956,"activeCount":99},[],{"intervention":16958,"totalTrials":3963,"cells":16959},"AzaSite®",{"EARLY_PHASE1":16960,"PHASE1":16962,"PHASE2":16964,"PHASE3":16966,"PHASE4":16968,"NA":16994},{"trials":16961,"activeCount":99},[],{"trials":16963,"activeCount":99},[],{"trials":16965,"activeCount":99},[],{"trials":16967,"activeCount":99},[],{"trials":16969,"activeCount":99},[16970,16976,16982,16988],{"nctId":16971,"briefTitle":16972,"status":105,"phases":16973,"primaryCompletion":13102,"start":8620,"enrollment":9323,"conditions":16974,"interventions":16975},"NCT00629941","Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis",[90],[16601],[16958],{"nctId":16977,"briefTitle":16978,"status":105,"phases":16979,"primaryCompletion":14823,"start":14408,"enrollment":805,"conditions":16980,"interventions":16981},"NCT00656539","Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis",[90],[16601],[16958],{"nctId":16983,"briefTitle":16984,"status":105,"phases":16985,"primaryCompletion":14315,"start":5281,"enrollment":558,"conditions":16986,"interventions":16987},"NCT00629980","Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis",[90],[16601],[16958],{"nctId":16989,"briefTitle":16990,"status":105,"phases":16991,"primaryCompletion":5801,"start":8620,"enrollment":805,"conditions":16992,"interventions":16993},"NCT00629590","Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis",[90],[16601],[16958],{"trials":16995,"activeCount":99},[],{"intervention":16688,"totalTrials":202,"cells":16997},{"EARLY_PHASE1":16998,"PHASE1":17000,"PHASE2":17002,"PHASE3":17014,"PHASE4":17030,"NA":17036},{"trials":16999,"activeCount":99},[],{"trials":17001,"activeCount":99},[],{"trials":17003,"activeCount":99},[17004],{"nctId":17005,"briefTitle":17006,"status":105,"phases":17007,"primaryCompletion":17008,"completion":17008,"start":17009,"enrollment":920,"conditions":17010,"interventions":17012},"NCT00552617","A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)",[88],"2006-08-31","2005-09-20",[17011],"Anesthesia, General",[17013,16687,16688],"Sugammadex",{"trials":17015,"activeCount":99},[17016],{"nctId":17017,"briefTitle":17018,"status":105,"phases":17019,"primaryCompletion":17020,"completion":17021,"start":17022,"enrollment":537,"conditions":17023,"interventions":17024},"NCT00473694","Comparison of Sugammadex (MK-8616\u002FOrg 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302\u002FP05945\u002FMK-8616-025)",[89],"2006-11-06","2007-01-29","2005-11-28",[17011],[17025,17026,17027,17028,17029],"sugammadex","neostigmine","vecuronium","rocuronium","glycopyrrolate",{"trials":17031,"activeCount":99},[17032],{"nctId":16677,"briefTitle":16678,"status":105,"phases":17033,"primaryCompletion":16680,"completion":16680,"start":16681,"enrollment":16682,"conditions":17034,"interventions":17035},[90],[16684],[16672,16640,16655,16686,16687,16688],{"trials":17037,"activeCount":99},[],{"intervention":17039,"totalTrials":202,"cells":17040},"Pneumovax™ 23",{"EARLY_PHASE1":17041,"PHASE1":17043,"PHASE2":17045,"PHASE3":17047,"PHASE4":17066,"NA":17078},{"trials":17042,"activeCount":99},[],{"trials":17044,"activeCount":99},[],{"trials":17046,"activeCount":99},[],{"trials":17048,"activeCount":99},[17049,17057],{"nctId":17050,"briefTitle":17051,"status":105,"phases":17052,"primaryCompletion":17053,"completion":17053,"start":17054,"enrollment":1150,"conditions":17055,"interventions":17056},"NCT02225587","Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)",[89],"2015-07-06","2014-08-28",[16472],[16465,17039],{"nctId":17058,"briefTitle":17059,"status":105,"phases":17060,"primaryCompletion":17061,"completion":17061,"start":17062,"enrollment":892,"conditions":17063,"interventions":17065},"NCT01734239","A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)",[89],"2013-10-22","2013-06-03",[17064],"Pneumococcal Disease",[17039],{"trials":17067,"activeCount":99},[17068],{"nctId":17069,"briefTitle":17070,"status":105,"phases":17071,"primaryCompletion":17072,"completion":17072,"start":17073,"enrollment":17074,"conditions":17075,"interventions":17076},"NCT02260882","Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)",[90],"2015-04-09","2014-10-31",243,[13187],[17077],"PNEUMOVAX™ 23",{"trials":17079,"activeCount":99},[],{"intervention":17081,"totalTrials":202,"cells":17082},"AzaSite",{"EARLY_PHASE1":17083,"PHASE1":17085,"PHASE2":17087,"PHASE3":17089,"PHASE4":17108,"NA":17117},{"trials":17084,"activeCount":99},[],{"trials":17086,"activeCount":99},[],{"trials":17088,"activeCount":99},[],{"trials":17090,"activeCount":99},[17091,17102],{"nctId":17092,"briefTitle":17093,"status":105,"phases":17094,"primaryCompletion":17095,"completion":17095,"start":17096,"enrollment":17097,"conditions":17098,"interventions":17100},"NCT00105469","Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)",[89],"2005-10","2004-07",743,[17099],"Bacterial Conjunctivitis",[17081,17101],"Tobramycin",{"nctId":17103,"briefTitle":17104,"status":105,"phases":17105,"primaryCompletion":14484,"completion":14484,"start":17096,"enrollment":13910,"conditions":17106,"interventions":17107},"NCT00105534","Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)",[89],[17099],[17081],{"trials":17109,"activeCount":99},[17110],{"nctId":17111,"briefTitle":17112,"status":105,"phases":17113,"primaryCompletion":6309,"start":8620,"enrollment":661,"conditions":17114,"interventions":17115},"NCT00575367","Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers",[90],[16460,16952],[17081,17116],"Vigamox",{"trials":17118,"activeCount":99},[],{"intervention":17120,"totalTrials":202,"cells":17121},"dorzolamide hydrochloride (+) timolol maleate",{"EARLY_PHASE1":17122,"PHASE1":17124,"PHASE2":17126,"PHASE3":17128,"PHASE4":17150,"NA":17161},{"trials":17123,"activeCount":99},[],{"trials":17125,"activeCount":99},[],{"trials":17127,"activeCount":99},[],{"trials":17129,"activeCount":99},[17130,17141],{"nctId":17131,"briefTitle":17132,"status":105,"phases":17133,"primaryCompletion":17134,"completion":17134,"start":17135,"enrollment":479,"conditions":17136,"interventions":17138},"NCT00449956","MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)",[89],"2008-02-16","2007-03-12",[17137],"Glaucoma",[17120,17139,17140],"Comparator: timolol maleate","Comparator: dorzolamide hydrochloride",{"nctId":17142,"briefTitle":17143,"status":105,"phases":17144,"primaryCompletion":17145,"completion":17145,"start":16664,"enrollment":3262,"conditions":17146,"interventions":17148},"NCT00546286","A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153)",[89],"2007-08-23",[17137,17147],"Ocular Hypertension",[17120,17149],"Comparator: dorzolamide HCl\u002Ftimolol maleate + prostaglandin",{"trials":17151,"activeCount":99},[17152],{"nctId":17153,"briefTitle":17154,"status":105,"phases":17155,"primaryCompletion":17156,"completion":17156,"start":17157,"enrollment":13927,"conditions":17158,"interventions":17160},"NCT00545064","Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED)",[90],"2008-09-15","2007-05-23",[17147,17159],"Open Angle Glaucoma",[17120],{"trials":17162,"activeCount":99},[],{"intervention":17164,"totalTrials":202,"cells":17165},"MK0869, aprepitant \u002F Duration of Treatment: 3 days",{"EARLY_PHASE1":17166,"PHASE1":17168,"PHASE2":17170,"PHASE3":17172,"PHASE4":17183,"NA":17205},{"trials":17167,"activeCount":99},[],{"trials":17169,"activeCount":99},[],{"trials":17171,"activeCount":99},[],{"trials":17173,"activeCount":99},[17174],{"nctId":17175,"briefTitle":17176,"status":105,"phases":17177,"primaryCompletion":17178,"completion":17178,"start":17179,"enrollment":17180,"conditions":17181,"interventions":17182},"NCT00092196","Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)",[89],"2004-12-01","2002-12-01",820,[4291,4292,1108],[17164],{"trials":17184,"activeCount":99},[17185,17194],{"nctId":17186,"briefTitle":17187,"status":105,"phases":17188,"primaryCompletion":17189,"completion":17189,"start":17190,"enrollment":277,"conditions":17191,"interventions":17192},"NCT00090207","Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)",[90],"2004-09-30","2004-01-13",[4291,4292],[17164,17193],"Comparator: ondansetron \u002F Duration of Treatment: 4 days",{"nctId":17195,"briefTitle":17196,"status":105,"phases":17197,"primaryCompletion":17198,"completion":17199,"start":17200,"enrollment":17201,"conditions":17202,"interventions":17203},"NCT00092183","An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)",[90],"2003-12-01","2004-02-11","2002-10-10",866,[4291,4292,1108],[17164,17204],"Comparator: ondansetron \u002F Duration of Treatment: 3 days",{"trials":17206,"activeCount":99},[],{"intervention":4294,"totalTrials":202,"cells":17208},{"EARLY_PHASE1":17209,"PHASE1":17211,"PHASE2":17213,"PHASE3":17219,"PHASE4":17225,"NA":17231},{"trials":17210,"activeCount":99},[],{"trials":17212,"activeCount":99},[],{"trials":17214,"activeCount":99},[17215],{"nctId":4285,"briefTitle":4286,"status":150,"phases":17216,"primaryCompletion":4288,"completion":4288,"start":4289,"enrollment":417,"conditions":17217,"interventions":17218},[88],[4291,4292],[4294,4295,529,1089],{"trials":17220,"activeCount":99},[17221],{"nctId":5305,"briefTitle":5306,"status":105,"phases":17222,"primaryCompletion":5308,"completion":5308,"start":5309,"enrollment":5310,"conditions":17223,"interventions":17224},[89],[5181],[4294,5313,529,5137,5314,5315,5316],{"trials":17226,"activeCount":99},[17227],{"nctId":5336,"briefTitle":5337,"status":105,"phases":17228,"primaryCompletion":5339,"completion":5339,"start":823,"enrollment":722,"conditions":17229,"interventions":17230},[90],[5252],[5342,5255,529],{"trials":17232,"activeCount":99},[],{"intervention":17234,"totalTrials":202,"cells":17235},"MK0966; rofecoxib",{"EARLY_PHASE1":17236,"PHASE1":17238,"PHASE2":17240,"PHASE3":17242,"PHASE4":17254,"NA":17275},{"trials":17237,"activeCount":99},[],{"trials":17239,"activeCount":99},[],{"trials":17241,"activeCount":99},[],{"trials":17243,"activeCount":99},[17244],{"nctId":17245,"briefTitle":17246,"status":150,"phases":17247,"start":17248,"enrollment":17249,"conditions":17250,"interventions":17252},"NCT00140933","A Study to Evaluate Rofecoxib Versus Placebo and Diclofenac in Patients With Acute Painful Rotator Cuff Syndrome",[89],"2003-04",274,[17251],"Pain",[17234,17253],"Comparator: diclofenac, placebo",{"trials":17255,"activeCount":99},[17256,17266],{"nctId":17257,"briefTitle":17258,"status":105,"phases":17259,"primaryCompletion":17260,"completion":17261,"start":17262,"enrollment":2779,"conditions":17263,"interventions":17264},"NCT00157872","A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)",[90],"2004-07-05","2004-09-19","2004-01-07",[7020],[17234,17265],"Comparator: naproxen tablet 500 mg",{"nctId":17267,"briefTitle":17268,"status":150,"phases":17269,"primaryCompletion":17270,"completion":17270,"start":17271,"enrollment":5983,"conditions":17272,"interventions":17273},"NCT00140920","A Study of Rofecoxib in the Treatment of Post-Operative Pain After Total Knee Joint Replacement (0966-259)",[90],"2004-09-27","2004-05-25",[17251],[17234,17274],"Comparator: diclofenac 2x 75 mg",{"trials":17276,"activeCount":99},[],{"intervention":17278,"totalTrials":202,"cells":17279},"Succinylcholine",{"EARLY_PHASE1":17280,"PHASE1":17282,"PHASE2":17284,"PHASE3":17286,"PHASE4":17304,"NA":17316},{"trials":17281,"activeCount":99},[],{"trials":17283,"activeCount":99},[],{"trials":17285,"activeCount":99},[],{"trials":17287,"activeCount":99},[17288,17295],{"nctId":17289,"briefTitle":17290,"status":105,"phases":17291,"primaryCompletion":13101,"completion":13101,"start":14823,"enrollment":7797,"conditions":17292,"interventions":17293},"NCT00751179","Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)",[89],[16696],[17028,17025,17294],"succinylcholine",{"nctId":17296,"briefTitle":17297,"status":105,"phases":17298,"primaryCompletion":17299,"completion":17300,"start":17301,"enrollment":11225,"conditions":17302,"interventions":17303},"NCT00474253","Comparison of Recovery From Rocuronium 1.2 mg\u002Fkg Followed by Sugammadex (Org 25969) 16 mg\u002Fkg at 3 Minutes With Recovery From Succinylcholine 1.0 mg\u002Fkg (19.4.303)(P05946)(MK-8616-026)",[89],"2006-08-22","2006-09-09","2006-02-10",[17011],[17013,17278,16687],{"trials":17305,"activeCount":99},[17306],{"nctId":17307,"briefTitle":17308,"status":1040,"phases":17309,"primaryCompletion":17310,"completion":17310,"start":17311,"enrollment":99,"conditions":17312,"interventions":17313},"NCT02410590","Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine\u002FAtropine in Obese Participants (MK-8616-104)",[90],"2016-10","2015-07",[16696],[16687,17013,17314,17315,17278],"Cisatracurium","Neostigmine\u002FAtropine",{"trials":17317,"activeCount":99},[],{"intervention":16655,"totalTrials":3197,"cells":17319},{"EARLY_PHASE1":17320,"PHASE1":17322,"PHASE2":17328,"PHASE3":17330,"PHASE4":17332,"NA":17338},{"trials":17321,"activeCount":99},[],{"trials":17323,"activeCount":99},[17324],{"nctId":16647,"briefTitle":16648,"status":105,"phases":17325,"primaryCompletion":16650,"completion":16650,"start":16651,"enrollment":1779,"conditions":17326,"interventions":17327},[87],[16653],[16640,16655],{"trials":17329,"activeCount":99},[],{"trials":17331,"activeCount":99},[],{"trials":17333,"activeCount":99},[17334],{"nctId":16677,"briefTitle":16678,"status":105,"phases":17335,"primaryCompletion":16680,"completion":16680,"start":16681,"enrollment":16682,"conditions":17336,"interventions":17337},[90],[16684],[16672,16640,16655,16686,16687,16688],{"trials":17339,"activeCount":99},[],{"intervention":14289,"totalTrials":3197,"cells":17341},{"EARLY_PHASE1":17342,"PHASE1":17344,"PHASE2":17346,"PHASE3":17348,"PHASE4":17354,"NA":17360},{"trials":17343,"activeCount":99},[],{"trials":17345,"activeCount":99},[],{"trials":17347,"activeCount":99},[],{"trials":17349,"activeCount":99},[17350],{"nctId":15123,"briefTitle":15124,"status":105,"phases":17351,"primaryCompletion":15126,"completion":15126,"start":15127,"enrollment":15128,"conditions":17352,"interventions":17353},[89],[15],[13982,13864,14289,13146],{"trials":17355,"activeCount":99},[17356],{"nctId":14281,"briefTitle":14282,"status":105,"phases":17357,"primaryCompletion":14284,"completion":14284,"start":14285,"enrollment":14286,"conditions":17358,"interventions":17359},[90],[15],[4084,13145,14289,14290,13146,14198],{"trials":17361,"activeCount":99},[],{"intervention":17363,"totalTrials":3197,"cells":17364},"MK-5172A",{"EARLY_PHASE1":17365,"PHASE1":17367,"PHASE2":17369,"PHASE3":17371,"PHASE4":17382,"NA":17391},{"trials":17366,"activeCount":99},[],{"trials":17368,"activeCount":99},[],{"trials":17370,"activeCount":99},[],{"trials":17372,"activeCount":99},[17373],{"nctId":17374,"briefTitle":17375,"status":105,"phases":17376,"primaryCompletion":17377,"completion":17378,"start":16755,"enrollment":3390,"conditions":17379,"interventions":17380},"NCT02115321","Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)",[88,89],"2015-03-05","2015-06-16",[12957],[15839,17381,17363],"Elbasvir",{"trials":17383,"activeCount":99},[17384],{"nctId":17385,"briefTitle":17386,"status":1040,"phases":17387,"primaryCompletion":17388,"completion":17388,"start":16704,"enrollment":99,"conditions":17389,"interventions":17390},"NCT03143998","Efficacy and Safety of Elbasvir\u002FGrazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)",[90],"2019-01-12",[24],[17363],{"trials":17392,"activeCount":99},[],{"intervention":15313,"totalTrials":3197,"cells":17394},{"EARLY_PHASE1":17395,"PHASE1":17397,"PHASE2":17399,"PHASE3":17401,"PHASE4":17407,"NA":17420},{"trials":17396,"activeCount":99},[],{"trials":17398,"activeCount":99},[],{"trials":17400,"activeCount":99},[],{"trials":17402,"activeCount":99},[17403],{"nctId":15301,"briefTitle":15302,"status":105,"phases":17404,"primaryCompletion":15304,"completion":15118,"start":15305,"enrollment":15306,"conditions":17405,"interventions":17406},[89],[15308,15309,15310,15311],[15313,15314,15315,13864],{"trials":17408,"activeCount":99},[17409],{"nctId":17410,"briefTitle":17411,"status":105,"phases":17412,"primaryCompletion":17413,"completion":17413,"start":17414,"enrollment":2249,"conditions":17415,"interventions":17418},"NCT00326183","Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)",[90],"2008-01-15","2007-03-26",[17416,15308,15309,15310,17417],"Hepatitis A","Chickenpox",[17419,15313],"VAQTA®",{"trials":17421,"activeCount":99},[],{"intervention":5255,"totalTrials":3197,"cells":17423},{"EARLY_PHASE1":17424,"PHASE1":17426,"PHASE2":17428,"PHASE3":17430,"PHASE4":17436,"NA":17442},{"trials":17425,"activeCount":99},[],{"trials":17427,"activeCount":99},[],{"trials":17429,"activeCount":99},[],{"trials":17431,"activeCount":99},[17432],{"nctId":5246,"briefTitle":5247,"status":150,"phases":17433,"primaryCompletion":5249,"completion":5249,"start":5250,"enrollment":613,"conditions":17434,"interventions":17435},[89],[5252],[5254,5137,529,5255],{"trials":17437,"activeCount":99},[17438],{"nctId":5336,"briefTitle":5337,"status":105,"phases":17439,"primaryCompletion":5339,"completion":5339,"start":823,"enrollment":722,"conditions":17440,"interventions":17441},[90],[5252],[5342,5255,529],{"trials":17443,"activeCount":99},[],{"intervention":17445,"totalTrials":3197,"cells":17446},"Comparator: VAQTA™",{"EARLY_PHASE1":17447,"PHASE1":17449,"PHASE2":17451,"PHASE3":17453,"PHASE4":17455,"NA":17475},{"trials":17448,"activeCount":99},[],{"trials":17450,"activeCount":99},[],{"trials":17452,"activeCount":99},[],{"trials":17454,"activeCount":99},[],{"trials":17456,"activeCount":99},[17457,17467],{"nctId":17458,"briefTitle":17459,"status":105,"phases":17460,"primaryCompletion":12813,"completion":12813,"start":17461,"enrollment":2564,"conditions":17462,"interventions":17464},"NCT00289913","Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)",[90],"2006-04",[17463],"Hepatitis A Virus",[17445,17465,17466],"Comparator: Infanrix™","Comparator: PedvaxHIB™",{"nctId":17468,"briefTitle":17469,"status":105,"phases":17470,"primaryCompletion":8620,"completion":8620,"start":17461,"enrollment":14166,"conditions":17471,"interventions":17472},"NCT00312858","Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)",[90],[17463],[17445,17473,17474],"Comparator: ProQuad™","Comparator: Prevnar™",{"trials":17476,"activeCount":99},[],{"intervention":17473,"totalTrials":3197,"cells":17478},{"EARLY_PHASE1":17479,"PHASE1":17481,"PHASE2":17483,"PHASE3":17485,"PHASE4":17495,"NA":17501},{"trials":17480,"activeCount":99},[],{"trials":17482,"activeCount":99},[],{"trials":17484,"activeCount":99},[],{"trials":17486,"activeCount":99},[17487],{"nctId":17488,"briefTitle":17489,"status":105,"phases":17490,"primaryCompletion":14887,"completion":14887,"start":14483,"enrollment":17491,"conditions":17492,"interventions":17493},"NCT00109343","V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)",[89],1027,[15308,15309,15310,15311],[17473,17494],"Comparator: PREVNAR™",{"trials":17496,"activeCount":99},[17497],{"nctId":17468,"briefTitle":17469,"status":105,"phases":17498,"primaryCompletion":8620,"completion":8620,"start":17461,"enrollment":14166,"conditions":17499,"interventions":17500},[90],[17463],[17445,17473,17474],{"trials":17502,"activeCount":99},[],{"intervention":17474,"totalTrials":3197,"cells":17504},{"EARLY_PHASE1":17505,"PHASE1":17507,"PHASE2":17509,"PHASE3":17511,"PHASE4":17517,"NA":17523},{"trials":17506,"activeCount":99},[],{"trials":17508,"activeCount":99},[],{"trials":17510,"activeCount":99},[],{"trials":17512,"activeCount":99},[17513],{"nctId":17488,"briefTitle":17489,"status":105,"phases":17514,"primaryCompletion":14887,"completion":14887,"start":14483,"enrollment":17491,"conditions":17515,"interventions":17516},[89],[15308,15309,15310,15311],[17473,17494],{"trials":17518,"activeCount":99},[17519],{"nctId":17468,"briefTitle":17469,"status":105,"phases":17520,"primaryCompletion":8620,"completion":8620,"start":17461,"enrollment":14166,"conditions":17521,"interventions":17522},[90],[17463],[17445,17473,17474],{"trials":17524,"activeCount":99},[],{"intervention":17526,"totalTrials":3197,"cells":17527},"Comparator: Glimepiride",{"EARLY_PHASE1":17528,"PHASE1":17530,"PHASE2":17532,"PHASE3":17534,"PHASE4":17546,"NA":17558},{"trials":17529,"activeCount":99},[],{"trials":17531,"activeCount":99},[],{"trials":17533,"activeCount":99},[],{"trials":17535,"activeCount":99},[17536],{"nctId":17537,"briefTitle":17538,"status":105,"phases":17539,"primaryCompletion":14730,"completion":14730,"start":13890,"enrollment":17540,"conditions":17541,"interventions":17543},"NCT00701090","A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)",[89],1035,[17542,15023],"Type 2 Diabetes Mellitus, Non Insulin Dependent",[14126,17544,17545],"Comparator: glimepiride","open-label metformin",{"trials":17547,"activeCount":99},[17548],{"nctId":17549,"briefTitle":17550,"status":105,"phases":17551,"primaryCompletion":17552,"completion":17552,"start":17553,"enrollment":17554,"conditions":17555,"interventions":17556},"NCT00993187","Efficacy and Safety of Sitagliptin\u002FMetformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)",[90],"2013-10-29","2010-05-04",292,[15],[17557,17526],"Sitagliptin\u002FMetformin FDC",{"trials":17559,"activeCount":99},[],{"intervention":17561,"totalTrials":3197,"cells":17562},"Tenofovir",{"EARLY_PHASE1":17563,"PHASE1":17565,"PHASE2":17567,"PHASE3":17582,"PHASE4":17584,"NA":17596},{"trials":17564,"activeCount":99},[],{"trials":17566,"activeCount":99},[],{"trials":17568,"activeCount":99},[17569],{"nctId":17570,"briefTitle":17571,"status":150,"phases":17572,"primaryCompletion":17573,"completion":17573,"start":17574,"enrollment":5983,"conditions":17575,"interventions":17576},"NCT02116660","Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir\u002FEmtricitabine Plus a Protease Inhibitor\u002FRitonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)",[88],"2017-07-10","2014-09-03",[27],[17577,17578,11421,17561,17579,17580,11447,17581,11446],"Raltegravir","Nevirapine","Emtricitabine","Lopinavir","Atazanavir",{"trials":17583,"activeCount":99},[],{"trials":17585,"activeCount":99},[17586],{"nctId":17587,"briefTitle":17588,"status":1040,"phases":17589,"primaryCompletion":17590,"completion":17590,"start":17591,"enrollment":99,"conditions":17592,"interventions":17594},"NCT01727271","A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)",[90],"2017-08","2013-08",[17593],"Hepatitis B",[17561,17595],"Pegylated interferon alpha-2b",{"trials":17597,"activeCount":99},[],{"intervention":17595,"totalTrials":3197,"cells":17599},{"EARLY_PHASE1":17600,"PHASE1":17602,"PHASE2":17604,"PHASE3":17606,"PHASE4":17617,"NA":17623},{"trials":17601,"activeCount":99},[],{"trials":17603,"activeCount":99},[],{"trials":17605,"activeCount":99},[],{"trials":17607,"activeCount":99},[17608],{"nctId":17609,"briefTitle":17610,"status":105,"phases":17611,"primaryCompletion":8591,"completion":8591,"start":14887,"enrollment":17612,"conditions":17613,"interventions":17615},"NCT00536263","PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170\u002FMK-4031-327)",[89],671,[17614],"Hepatitis B, Chronic",[17616,17616,17616],"pegylated interferon alpha-2b",{"trials":17618,"activeCount":99},[17619],{"nctId":17587,"briefTitle":17588,"status":1040,"phases":17620,"primaryCompletion":17590,"completion":17590,"start":17591,"enrollment":99,"conditions":17621,"interventions":17622},[90],[17593],[17561,17595],{"trials":17624,"activeCount":99},[],{"intervention":16698,"totalTrials":3197,"cells":17626},{"EARLY_PHASE1":17627,"PHASE1":17629,"PHASE2":17631,"PHASE3":17633,"PHASE4":17635,"NA":17645},{"trials":17628,"activeCount":99},[],{"trials":17630,"activeCount":99},[],{"trials":17632,"activeCount":99},[],{"trials":17634,"activeCount":99},[],{"trials":17636,"activeCount":99},[17637,17641],{"nctId":16690,"briefTitle":16691,"status":105,"phases":17638,"primaryCompletion":2388,"completion":2388,"start":16693,"enrollment":16694,"conditions":17639,"interventions":17640},[90],[16696],[16672,16640,16686,16698],{"nctId":16700,"briefTitle":16701,"status":105,"phases":17642,"primaryCompletion":16703,"completion":16703,"start":16704,"enrollment":16705,"conditions":17643,"interventions":17644},[90],[16696],[16672,16640,16686,16698],{"trials":17646,"activeCount":99},[],{"intervention":17648,"totalTrials":3197,"cells":17649},"Combination of pegylated interferon alfa-2b and ribavirin",{"EARLY_PHASE1":17650,"PHASE1":17652,"PHASE2":17654,"PHASE3":17656,"PHASE4":17666,"NA":17675},{"trials":17651,"activeCount":99},[],{"trials":17653,"activeCount":99},[],{"trials":17655,"activeCount":99},[],{"trials":17657,"activeCount":99},[17658],{"nctId":17659,"briefTitle":17660,"status":105,"phases":17661,"primaryCompletion":13890,"completion":13890,"start":14678,"enrollment":17662,"conditions":17663,"interventions":17664},"NCT00265395","Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)",[89],1428,[21],[17665,17648],"Combination of pegylated interferon alfa-2b",{"trials":17667,"activeCount":99},[17668],{"nctId":17669,"briefTitle":17670,"status":150,"phases":17671,"primaryCompletion":14730,"completion":14730,"start":15505,"enrollment":17672,"conditions":17673,"interventions":17674},"NCT00493805","Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823\u002FMK-4031-303)",[90],59,[21,8623],[17648,17648],{"trials":17676,"activeCount":99},[],{"intervention":7600,"totalTrials":3197,"cells":17678},{"EARLY_PHASE1":17679,"PHASE1":17681,"PHASE2":17683,"PHASE3":17685,"PHASE4":17691,"NA":17697},{"trials":17680,"activeCount":99},[],{"trials":17682,"activeCount":99},[],{"trials":17684,"activeCount":99},[],{"trials":17686,"activeCount":99},[17687],{"nctId":7591,"briefTitle":7592,"status":105,"phases":17688,"primaryCompletion":7594,"completion":2286,"start":7595,"enrollment":7596,"conditions":17689,"interventions":17690},[89],[7598],[7488,7600,7601],{"trials":17692,"activeCount":99},[17693],{"nctId":16432,"briefTitle":16433,"status":105,"phases":17694,"primaryCompletion":13890,"start":14531,"enrollment":3390,"conditions":17695,"interventions":17696},[90],[7610],[16437,7600],{"trials":17698,"activeCount":99},[],{"intervention":17700,"totalTrials":3197,"cells":17701},"Vaxelis™",{"EARLY_PHASE1":17702,"PHASE1":17704,"PHASE2":17706,"PHASE3":17708,"PHASE4":17720,"NA":17732},{"trials":17703,"activeCount":99},[],{"trials":17705,"activeCount":99},[],{"trials":17707,"activeCount":99},[],{"trials":17709,"activeCount":99},[17710],{"nctId":17711,"briefTitle":17712,"status":105,"phases":17713,"primaryCompletion":1600,"completion":1600,"start":17714,"enrollment":17715,"conditions":17716,"interventions":17717},"NCT04016714","Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2\u002FV114-026)",[89],"2019-08-28",1191,[16472],[16474,17718,17700,17719,16479],"Prevenar 13™","M-M-R®II",{"trials":17721,"activeCount":99},[17722],{"nctId":17723,"briefTitle":17724,"status":105,"phases":17725,"primaryCompletion":17726,"completion":17726,"start":17727,"enrollment":322,"conditions":17728,"interventions":17731},"NCT05289271","Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016)",[90],"2022-08-30","2022-03-25",[17729,17730],"Vaccines, Combined","Hexavalent Vaccine",[17700],{"trials":17733,"activeCount":99},[],{"intervention":17735,"totalTrials":3197,"cells":17736},"Didanosine",{"EARLY_PHASE1":17737,"PHASE1":17739,"PHASE2":17741,"PHASE3":17743,"PHASE4":17745,"NA":17764},{"trials":17738,"activeCount":99},[],{"trials":17740,"activeCount":99},[],{"trials":17742,"activeCount":99},[],{"trials":17744,"activeCount":99},[],{"trials":17746,"activeCount":99},[17747,17758],{"nctId":17748,"briefTitle":17749,"status":105,"phases":17750,"enrollment":1349,"conditions":17751,"interventions":17753},"NCT00002386","Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia",[90],[27,17752],"Hemophilia A",[17754,11421,17755,17756,17757,17735],"Indinavir sulfate","Stavudine","Zidovudine","Zalcitabine",{"nctId":17759,"briefTitle":17760,"status":105,"phases":17761,"enrollment":1387,"conditions":17762,"interventions":17763},"NCT00002376","The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients",[90],[27],[17754,11421,17755,17756,17735],{"trials":17765,"activeCount":99},[],{"intervention":14198,"totalTrials":3197,"cells":17767},{"EARLY_PHASE1":17768,"PHASE1":17770,"PHASE2":17772,"PHASE3":17774,"PHASE4":17780,"NA":17786},{"trials":17769,"activeCount":99},[],{"trials":17771,"activeCount":99},[],{"trials":17773,"activeCount":99},[],{"trials":17775,"activeCount":99},[17776],{"nctId":14189,"briefTitle":14190,"status":105,"phases":17777,"primaryCompletion":14192,"completion":14193,"start":14194,"enrollment":14195,"conditions":17778,"interventions":17779},[89],[15],[13145,14198,13146,4084],{"trials":17781,"activeCount":99},[17782],{"nctId":14281,"briefTitle":14282,"status":105,"phases":17783,"primaryCompletion":14284,"completion":14284,"start":14285,"enrollment":14286,"conditions":17784,"interventions":17785},[90],[15],[4084,13145,14289,14290,13146,14198],{"trials":17787,"activeCount":99},[],{"intervention":5315,"totalTrials":3197,"cells":17789},{"EARLY_PHASE1":17790,"PHASE1":17792,"PHASE2":17794,"PHASE3":17796,"PHASE4":17802,"NA":17808},{"trials":17791,"activeCount":99},[],{"trials":17793,"activeCount":99},[],{"trials":17795,"activeCount":99},[],{"trials":17797,"activeCount":99},[17798],{"nctId":5305,"briefTitle":5306,"status":105,"phases":17799,"primaryCompletion":5308,"completion":5308,"start":5309,"enrollment":5310,"conditions":17800,"interventions":17801},[89],[5181],[4294,5313,529,5137,5314,5315,5316],{"trials":17803,"activeCount":99},[17804],{"nctId":5344,"briefTitle":5345,"status":105,"phases":17805,"primaryCompletion":5347,"completion":5347,"start":5348,"enrollment":5349,"conditions":17806,"interventions":17807},[90],[4291,4292],[5136,5352,5137,529,5315,5353],{"trials":17809,"activeCount":99},[],{"intervention":17811,"totalTrials":224,"cells":17812},"Calogen®",{"EARLY_PHASE1":17813,"PHASE1":17815,"PHASE2":17817,"PHASE3":17819,"PHASE4":17821,"NA":17833},{"trials":17814,"activeCount":99},[],{"trials":17816,"activeCount":99},[],{"trials":17818,"activeCount":99},[],{"trials":17820,"activeCount":99},[],{"trials":17822,"activeCount":99},[17823],{"nctId":17824,"briefTitle":17825,"status":150,"phases":17826,"primaryCompletion":17827,"completion":17827,"start":17828,"enrollment":3506,"conditions":17829,"interventions":17831},"NCT01667107","A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105)",[90],"2014-01-16","2013-01-23",[17830],"Fungal Infection",[17832,17811],"Posaconazole",{"trials":17834,"activeCount":99},[],{"intervention":17836,"totalTrials":224,"cells":17837},"Palonosetron and Dexamethasone",{"EARLY_PHASE1":17838,"PHASE1":17840,"PHASE2":17842,"PHASE3":17844,"PHASE4":17846,"NA":17856},{"trials":17839,"activeCount":99},[],{"trials":17841,"activeCount":99},[],{"trials":17843,"activeCount":99},[],{"trials":17845,"activeCount":99},[],{"trials":17847,"activeCount":99},[17848],{"nctId":17849,"briefTitle":17850,"status":105,"phases":17851,"primaryCompletion":17852,"completion":17852,"start":17853,"enrollment":901,"conditions":17854,"interventions":17855},"NCT00687011","Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)",[90],"2008-10-27","2006-10-10",[290,4291,4292],[17836],{"trials":17857,"activeCount":99},[],{"intervention":17419,"totalTrials":224,"cells":17859},{"EARLY_PHASE1":17860,"PHASE1":17862,"PHASE2":17864,"PHASE3":17866,"PHASE4":17868,"NA":17874},{"trials":17861,"activeCount":99},[],{"trials":17863,"activeCount":99},[],{"trials":17865,"activeCount":99},[],{"trials":17867,"activeCount":99},[],{"trials":17869,"activeCount":99},[17870],{"nctId":17410,"briefTitle":17411,"status":105,"phases":17871,"primaryCompletion":17413,"completion":17413,"start":17414,"enrollment":2249,"conditions":17872,"interventions":17873},[90],[17416,15308,15309,15310,17417],[17419,15313],{"trials":17875,"activeCount":99},[],{"intervention":17877,"totalTrials":224,"cells":17878},"MK0966; rofecoxib \u002F Duration of Treatment: 24 weeks",{"EARLY_PHASE1":17879,"PHASE1":17881,"PHASE2":17883,"PHASE3":17885,"PHASE4":17887,"NA":17899},{"trials":17880,"activeCount":99},[],{"trials":17882,"activeCount":99},[],{"trials":17884,"activeCount":99},[],{"trials":17886,"activeCount":99},[],{"trials":17888,"activeCount":99},[17889],{"nctId":17890,"briefTitle":17891,"status":150,"phases":17892,"completion":17893,"start":17894,"enrollment":25,"conditions":17895,"interventions":17897},"NCT00140894","A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)",[90],"2004-10-11","2002-08-06",[17896],"Adenomatous Polyposis Coli",[17877,17898],"Comparator: placebo \u002F Duration of Treatment: 24 weeks",{"trials":17900,"activeCount":99},[],{"intervention":17898,"totalTrials":224,"cells":17902},{"EARLY_PHASE1":17903,"PHASE1":17905,"PHASE2":17907,"PHASE3":17909,"PHASE4":17911,"NA":17917},{"trials":17904,"activeCount":99},[],{"trials":17906,"activeCount":99},[],{"trials":17908,"activeCount":99},[],{"trials":17910,"activeCount":99},[],{"trials":17912,"activeCount":99},[17913],{"nctId":17890,"briefTitle":17891,"status":150,"phases":17914,"completion":17893,"start":17894,"enrollment":25,"conditions":17915,"interventions":17916},[90],[17896],[17877,17898],{"trials":17918,"activeCount":99},[],{"intervention":17465,"totalTrials":224,"cells":17920},{"EARLY_PHASE1":17921,"PHASE1":17923,"PHASE2":17925,"PHASE3":17927,"PHASE4":17929,"NA":17935},{"trials":17922,"activeCount":99},[],{"trials":17924,"activeCount":99},[],{"trials":17926,"activeCount":99},[],{"trials":17928,"activeCount":99},[],{"trials":17930,"activeCount":99},[17931],{"nctId":17458,"briefTitle":17459,"status":105,"phases":17932,"primaryCompletion":12813,"completion":12813,"start":17461,"enrollment":2564,"conditions":17933,"interventions":17934},[90],[17463],[17445,17465,17466],{"trials":17936,"activeCount":99},[],{"intervention":17466,"totalTrials":224,"cells":17938},{"EARLY_PHASE1":17939,"PHASE1":17941,"PHASE2":17943,"PHASE3":17945,"PHASE4":17947,"NA":17953},{"trials":17940,"activeCount":99},[],{"trials":17942,"activeCount":99},[],{"trials":17944,"activeCount":99},[],{"trials":17946,"activeCount":99},[],{"trials":17948,"activeCount":99},[17949],{"nctId":17458,"briefTitle":17459,"status":105,"phases":17950,"primaryCompletion":12813,"completion":12813,"start":17461,"enrollment":2564,"conditions":17951,"interventions":17952},[90],[17463],[17445,17465,17466],{"trials":17954,"activeCount":99},[],{"intervention":16867,"totalTrials":224,"cells":17956},{"EARLY_PHASE1":17957,"PHASE1":17959,"PHASE2":17961,"PHASE3":17963,"PHASE4":17965,"NA":17971},{"trials":17958,"activeCount":99},[],{"trials":17960,"activeCount":99},[],{"trials":17962,"activeCount":99},[],{"trials":17964,"activeCount":99},[],{"trials":17966,"activeCount":99},[17967],{"nctId":16861,"briefTitle":16862,"status":105,"phases":17968,"primaryCompletion":7136,"completion":7136,"start":16864,"enrollment":9357,"conditions":17969,"interventions":17970},[90],[16696],[16867,16868,16869,16870,16686,16871],{"trials":17972,"activeCount":99},[],{"intervention":16868,"totalTrials":224,"cells":17974},{"EARLY_PHASE1":17975,"PHASE1":17977,"PHASE2":17979,"PHASE3":17981,"PHASE4":17983,"NA":17989},{"trials":17976,"activeCount":99},[],{"trials":17978,"activeCount":99},[],{"trials":17980,"activeCount":99},[],{"trials":17982,"activeCount":99},[],{"trials":17984,"activeCount":99},[17985],{"nctId":16861,"briefTitle":16862,"status":105,"phases":17986,"primaryCompletion":7136,"completion":7136,"start":16864,"enrollment":9357,"conditions":17987,"interventions":17988},[90],[16696],[16867,16868,16869,16870,16686,16871],{"trials":17990,"activeCount":99},[],{"intervention":16869,"totalTrials":224,"cells":17992},{"EARLY_PHASE1":17993,"PHASE1":17995,"PHASE2":17997,"PHASE3":17999,"PHASE4":18001,"NA":18007},{"trials":17994,"activeCount":99},[],{"trials":17996,"activeCount":99},[],{"trials":17998,"activeCount":99},[],{"trials":18000,"activeCount":99},[],{"trials":18002,"activeCount":99},[18003],{"nctId":16861,"briefTitle":16862,"status":105,"phases":18004,"primaryCompletion":7136,"completion":7136,"start":16864,"enrollment":9357,"conditions":18005,"interventions":18006},[90],[16696],[16867,16868,16869,16870,16686,16871],{"trials":18008,"activeCount":99},[],{"intervention":16870,"totalTrials":224,"cells":18010},{"EARLY_PHASE1":18011,"PHASE1":18013,"PHASE2":18015,"PHASE3":18017,"PHASE4":18019,"NA":18025},{"trials":18012,"activeCount":99},[],{"trials":18014,"activeCount":99},[],{"trials":18016,"activeCount":99},[],{"trials":18018,"activeCount":99},[],{"trials":18020,"activeCount":99},[18021],{"nctId":16861,"briefTitle":16862,"status":105,"phases":18022,"primaryCompletion":7136,"completion":7136,"start":16864,"enrollment":9357,"conditions":18023,"interventions":18024},[90],[16696],[16867,16868,16869,16870,16686,16871],{"trials":18026,"activeCount":99},[],{"intervention":16871,"totalTrials":224,"cells":18028},{"EARLY_PHASE1":18029,"PHASE1":18031,"PHASE2":18033,"PHASE3":18035,"PHASE4":18037,"NA":18043},{"trials":18030,"activeCount":99},[],{"trials":18032,"activeCount":99},[],{"trials":18034,"activeCount":99},[],{"trials":18036,"activeCount":99},[],{"trials":18038,"activeCount":99},[18039],{"nctId":16861,"briefTitle":16862,"status":105,"phases":18040,"primaryCompletion":7136,"completion":7136,"start":16864,"enrollment":9357,"conditions":18041,"interventions":18042},[90],[16696],[16867,16868,16869,16870,16686,16871],{"trials":18044,"activeCount":99},[],{"intervention":17557,"totalTrials":224,"cells":18046},{"EARLY_PHASE1":18047,"PHASE1":18049,"PHASE2":18051,"PHASE3":18053,"PHASE4":18055,"NA":18061},{"trials":18048,"activeCount":99},[],{"trials":18050,"activeCount":99},[],{"trials":18052,"activeCount":99},[],{"trials":18054,"activeCount":99},[],{"trials":18056,"activeCount":99},[18057],{"nctId":17549,"briefTitle":17550,"status":105,"phases":18058,"primaryCompletion":17552,"completion":17552,"start":17553,"enrollment":17554,"conditions":18059,"interventions":18060},[90],[15],[17557,17526],{"trials":18062,"activeCount":99},[],{"intervention":16954,"totalTrials":224,"cells":18064},{"EARLY_PHASE1":18065,"PHASE1":18067,"PHASE2":18069,"PHASE3":18071,"PHASE4":18073,"NA":18079},{"trials":18066,"activeCount":99},[],{"trials":18068,"activeCount":99},[],{"trials":18070,"activeCount":99},[],{"trials":18072,"activeCount":99},[],{"trials":18074,"activeCount":99},[18075],{"nctId":16948,"briefTitle":16949,"status":105,"phases":18076,"primaryCompletion":14454,"start":14454,"enrollment":1054,"conditions":18077,"interventions":18078},[90],[16460,16952],[16954,7335],{"trials":18080,"activeCount":99},[],{"intervention":18082,"totalTrials":224,"cells":18083},"ZOSTAVAX®",{"EARLY_PHASE1":18084,"PHASE1":18086,"PHASE2":18088,"PHASE3":18090,"PHASE4":18092,"NA":18102},{"trials":18085,"activeCount":99},[],{"trials":18087,"activeCount":99},[],{"trials":18089,"activeCount":99},[],{"trials":18091,"activeCount":99},[],{"trials":18093,"activeCount":99},[18094],{"nctId":18095,"briefTitle":18096,"status":105,"phases":18097,"primaryCompletion":18098,"completion":18098,"start":18099,"enrollment":7253,"conditions":18100,"interventions":18101},"NCT00681031","Zostavax® at Minimum Release Specification Approaching Expiry (V211-044)",[90],"2008-06-25","2008-05-14",[14395],[18082],{"trials":18103,"activeCount":99},[],{"intervention":18105,"totalTrials":224,"cells":18106},"Infliximab 5 mg\u002Fkg",{"EARLY_PHASE1":18107,"PHASE1":18109,"PHASE2":18111,"PHASE3":18113,"PHASE4":18115,"NA":18125},{"trials":18108,"activeCount":99},[],{"trials":18110,"activeCount":99},[],{"trials":18112,"activeCount":99},[],{"trials":18114,"activeCount":99},[],{"trials":18116,"activeCount":99},[18117],{"nctId":18118,"briefTitle":18119,"status":150,"phases":18120,"primaryCompletion":12813,"completion":12813,"start":14823,"enrollment":920,"conditions":18121,"interventions":18122},"NCT00752622","Treatment With Infliximab in a Medical Setting (Study P05587)",[90],[8604],[18105,18123,18124],"Infliximab 5 mg\u002Fkg every 6 weeks","Infliximab 7 mg\u002Fkg every 8 weeks",{"trials":18126,"activeCount":99},[],{"intervention":18123,"totalTrials":224,"cells":18128},{"EARLY_PHASE1":18129,"PHASE1":18131,"PHASE2":18133,"PHASE3":18135,"PHASE4":18137,"NA":18143},{"trials":18130,"activeCount":99},[],{"trials":18132,"activeCount":99},[],{"trials":18134,"activeCount":99},[],{"trials":18136,"activeCount":99},[],{"trials":18138,"activeCount":99},[18139],{"nctId":18118,"briefTitle":18119,"status":150,"phases":18140,"primaryCompletion":12813,"completion":12813,"start":14823,"enrollment":920,"conditions":18141,"interventions":18142},[90],[8604],[18105,18123,18124],{"trials":18144,"activeCount":99},[],{"intervention":18124,"totalTrials":224,"cells":18146},{"EARLY_PHASE1":18147,"PHASE1":18149,"PHASE2":18151,"PHASE3":18153,"PHASE4":18155,"NA":18161},{"trials":18148,"activeCount":99},[],{"trials":18150,"activeCount":99},[],{"trials":18152,"activeCount":99},[],{"trials":18154,"activeCount":99},[],{"trials":18156,"activeCount":99},[18157],{"nctId":18118,"briefTitle":18119,"status":150,"phases":18158,"primaryCompletion":12813,"completion":12813,"start":14823,"enrollment":920,"conditions":18159,"interventions":18160},[90],[8604],[18105,18123,18124],{"trials":18162,"activeCount":99},[],{"intervention":16516,"totalTrials":224,"cells":18164},{"EARLY_PHASE1":18165,"PHASE1":18167,"PHASE2":18169,"PHASE3":18171,"PHASE4":18173,"NA":18179},{"trials":18166,"activeCount":99},[],{"trials":18168,"activeCount":99},[],{"trials":18170,"activeCount":99},[],{"trials":18172,"activeCount":99},[],{"trials":18174,"activeCount":99},[18175],{"nctId":16510,"briefTitle":16511,"status":105,"phases":18176,"primaryCompletion":13040,"completion":13040,"start":16513,"enrollment":11801,"conditions":18177,"interventions":18178},[90],[15554],[16441,16516],{"trials":18180,"activeCount":99},[],{"intervention":18182,"totalTrials":224,"cells":18183},"sisomicin",{"EARLY_PHASE1":18184,"PHASE1":18186,"PHASE2":18188,"PHASE3":18190,"PHASE4":18192,"NA":18201},{"trials":18185,"activeCount":99},[],{"trials":18187,"activeCount":99},[],{"trials":18189,"activeCount":99},[],{"trials":18191,"activeCount":99},[],{"trials":18193,"activeCount":99},[18194],{"nctId":18195,"briefTitle":18196,"status":1040,"phases":18197,"completion":14887,"start":14409,"enrollment":99,"conditions":18198,"interventions":18200},"NCT00202891","Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460)",[90],[18199],"Pyoderma",[18182],{"trials":18202,"activeCount":99},[],{"intervention":18204,"totalTrials":224,"cells":18205},"Suboxone",{"EARLY_PHASE1":18206,"PHASE1":18208,"PHASE2":18210,"PHASE3":18212,"PHASE4":18214,"NA":18228},{"trials":18207,"activeCount":99},[],{"trials":18209,"activeCount":99},[],{"trials":18211,"activeCount":99},[],{"trials":18213,"activeCount":99},[],{"trials":18215,"activeCount":99},[18216],{"nctId":18217,"briefTitle":18218,"status":105,"phases":18219,"primaryCompletion":9347,"completion":9347,"start":18220,"enrollment":18221,"conditions":18222,"interventions":18226},"NCT00604188","A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED)",[90],"2008-02-22",188,[18223,18224,18225],"Opiate Dependence","Drug Dependence","Substance Dependence",[18204,18227],"Subutex",{"trials":18229,"activeCount":99},[],{"intervention":18227,"totalTrials":224,"cells":18231},{"EARLY_PHASE1":18232,"PHASE1":18234,"PHASE2":18236,"PHASE3":18238,"PHASE4":18240,"NA":18246},{"trials":18233,"activeCount":99},[],{"trials":18235,"activeCount":99},[],{"trials":18237,"activeCount":99},[],{"trials":18239,"activeCount":99},[],{"trials":18241,"activeCount":99},[18242],{"nctId":18217,"briefTitle":18218,"status":105,"phases":18243,"primaryCompletion":9347,"completion":9347,"start":18220,"enrollment":18221,"conditions":18244,"interventions":18245},[90],[18223,18224,18225],[18204,18227],{"trials":18247,"activeCount":99},[],{"intervention":18249,"totalTrials":224,"cells":18250},"formoterol fumarate",{"EARLY_PHASE1":18251,"PHASE1":18253,"PHASE2":18255,"PHASE3":18257,"PHASE4":18259,"NA":18269},{"trials":18252,"activeCount":99},[],{"trials":18254,"activeCount":99},[],{"trials":18256,"activeCount":99},[],{"trials":18258,"activeCount":99},[],{"trials":18260,"activeCount":99},[18261],{"nctId":18262,"briefTitle":18263,"status":105,"phases":18264,"primaryCompletion":18265,"completion":18265,"start":12752,"enrollment":4810,"conditions":18266,"interventions":18268},"NCT00139932","Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)",[90],"2006-11-21",[18267],"Pulmonary Disease, Chronic Obstructive",[18249],{"trials":18270,"activeCount":99},[],{"intervention":17265,"totalTrials":224,"cells":18272},{"EARLY_PHASE1":18273,"PHASE1":18275,"PHASE2":18277,"PHASE3":18279,"PHASE4":18281,"NA":18287},{"trials":18274,"activeCount":99},[],{"trials":18276,"activeCount":99},[],{"trials":18278,"activeCount":99},[],{"trials":18280,"activeCount":99},[],{"trials":18282,"activeCount":99},[18283],{"nctId":17257,"briefTitle":17258,"status":105,"phases":18284,"primaryCompletion":17260,"completion":17261,"start":17262,"enrollment":2779,"conditions":18285,"interventions":18286},[90],[7020],[17234,17265],{"trials":18288,"activeCount":99},[],{"intervention":14279,"totalTrials":224,"cells":18290},{"EARLY_PHASE1":18291,"PHASE1":18293,"PHASE2":18295,"PHASE3":18297,"PHASE4":18299,"NA":18305},{"trials":18292,"activeCount":99},[],{"trials":18294,"activeCount":99},[],{"trials":18296,"activeCount":99},[],{"trials":18298,"activeCount":99},[],{"trials":18300,"activeCount":99},[18301],{"nctId":14270,"briefTitle":14271,"status":105,"phases":18302,"primaryCompletion":14273,"completion":14273,"start":14274,"enrollment":14275,"conditions":18303,"interventions":18304},[90],[14277],[13982,14279,4084],{"trials":18306,"activeCount":99},[],{"intervention":18308,"totalTrials":224,"cells":18309},"Elestat",{"EARLY_PHASE1":18310,"PHASE1":18312,"PHASE2":18314,"PHASE3":18316,"PHASE4":18318,"NA":18329},{"trials":18311,"activeCount":99},[],{"trials":18313,"activeCount":99},[],{"trials":18315,"activeCount":99},[],{"trials":18317,"activeCount":99},[],{"trials":18319,"activeCount":99},[18320],{"nctId":18321,"briefTitle":18322,"status":105,"phases":18323,"primaryCompletion":14687,"start":14540,"enrollment":18324,"conditions":18325,"interventions":18327},"NCT00534794","Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis",[90],79,[18326],"Allergic Conjunctivitis",[18308,18328],"Pataday",{"trials":18330,"activeCount":99},[],{"intervention":18328,"totalTrials":224,"cells":18332},{"EARLY_PHASE1":18333,"PHASE1":18335,"PHASE2":18337,"PHASE3":18339,"PHASE4":18341,"NA":18347},{"trials":18334,"activeCount":99},[],{"trials":18336,"activeCount":99},[],{"trials":18338,"activeCount":99},[],{"trials":18340,"activeCount":99},[],{"trials":18342,"activeCount":99},[18343],{"nctId":18321,"briefTitle":18322,"status":105,"phases":18344,"primaryCompletion":14687,"start":14540,"enrollment":18324,"conditions":18345,"interventions":18346},[90],[18326],[18308,18328],{"trials":18348,"activeCount":99},[],{"intervention":18350,"totalTrials":224,"cells":18351},"Prefilled Syringe delivery of Golimumab",{"EARLY_PHASE1":18352,"PHASE1":18354,"PHASE2":18356,"PHASE3":18358,"PHASE4":18360,"NA":18371},{"trials":18353,"activeCount":99},[],{"trials":18355,"activeCount":99},[],{"trials":18357,"activeCount":99},[],{"trials":18359,"activeCount":99},[],{"trials":18361,"activeCount":99},[18362],{"nctId":18363,"briefTitle":18364,"status":105,"phases":18365,"primaryCompletion":18366,"completion":18366,"start":18367,"enrollment":920,"conditions":18368,"interventions":18369},"NCT02155335","Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)",[90],"2015-10-05","2014-07-01",[9066],[18350,18370],"Smartject Device delivery of Golimumab",{"trials":18372,"activeCount":99},[],{"intervention":18370,"totalTrials":224,"cells":18374},{"EARLY_PHASE1":18375,"PHASE1":18377,"PHASE2":18379,"PHASE3":18381,"PHASE4":18383,"NA":18389},{"trials":18376,"activeCount":99},[],{"trials":18378,"activeCount":99},[],{"trials":18380,"activeCount":99},[],{"trials":18382,"activeCount":99},[],{"trials":18384,"activeCount":99},[18385],{"nctId":18363,"briefTitle":18364,"status":105,"phases":18386,"primaryCompletion":18366,"completion":18366,"start":18367,"enrollment":920,"conditions":18387,"interventions":18388},[90],[9066],[18350,18370],{"trials":18390,"activeCount":99},[],{"intervention":16636,"totalTrials":224,"cells":18392},{"EARLY_PHASE1":18393,"PHASE1":18395,"PHASE2":18397,"PHASE3":18399,"PHASE4":18401,"NA":18407},{"trials":18394,"activeCount":99},[],{"trials":18396,"activeCount":99},[],{"trials":18398,"activeCount":99},[],{"trials":18400,"activeCount":99},[],{"trials":18402,"activeCount":99},[18403],{"nctId":16629,"briefTitle":16630,"status":105,"phases":18404,"primaryCompletion":16592,"completion":16592,"start":13224,"enrollment":4421,"conditions":18405,"interventions":18406},[90],[16633],[16635,16636],{"trials":18408,"activeCount":99},[],{"intervention":18410,"totalTrials":224,"cells":18411},"Betamethasone",{"EARLY_PHASE1":18412,"PHASE1":18414,"PHASE2":18416,"PHASE3":18418,"PHASE4":18420,"NA":18430},{"trials":18413,"activeCount":99},[],{"trials":18415,"activeCount":99},[],{"trials":18417,"activeCount":99},[],{"trials":18419,"activeCount":99},[],{"trials":18421,"activeCount":99},[18422],{"nctId":18423,"briefTitle":18424,"status":105,"phases":18425,"primaryCompletion":12814,"completion":12814,"start":18426,"enrollment":920,"conditions":18427,"interventions":18429},"NCT00963573","Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428)",[90],"2003-09",[18428],"Rhinitis",[7024,18410],{"trials":18431,"activeCount":99},[],{"intervention":18433,"totalTrials":224,"cells":18434},"MK0787B, imipenem\u002Fcilastatin sodium \u002F Duration of Treatment: 7 Days",{"EARLY_PHASE1":18435,"PHASE1":18437,"PHASE2":18439,"PHASE3":18441,"PHASE4":18443,"NA":18455},{"trials":18436,"activeCount":99},[],{"trials":18438,"activeCount":99},[],{"trials":18440,"activeCount":99},[],{"trials":18442,"activeCount":99},[],{"trials":18444,"activeCount":99},[18445],{"nctId":18446,"briefTitle":18447,"status":105,"phases":18448,"primaryCompletion":15210,"completion":15210,"start":12814,"enrollment":2023,"conditions":18449,"interventions":18451},"NCT00445094","A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)",[90],[18450,11523],"Infection",[18433,18452,18453,18454],"Comparator: amikacin \u002F Duration of Treatment: 3 Days","Comparator: tazocin \u002F Duration of Treatment: 3 Days","Comparator: vancomycin \u002F Duration of Treatment: 3 Days",{"trials":18456,"activeCount":99},[],{"intervention":18452,"totalTrials":224,"cells":18458},{"EARLY_PHASE1":18459,"PHASE1":18461,"PHASE2":18463,"PHASE3":18465,"PHASE4":18467,"NA":18473},{"trials":18460,"activeCount":99},[],{"trials":18462,"activeCount":99},[],{"trials":18464,"activeCount":99},[],{"trials":18466,"activeCount":99},[],{"trials":18468,"activeCount":99},[18469],{"nctId":18446,"briefTitle":18447,"status":105,"phases":18470,"primaryCompletion":15210,"completion":15210,"start":12814,"enrollment":2023,"conditions":18471,"interventions":18472},[90],[18450,11523],[18433,18452,18453,18454],{"trials":18474,"activeCount":99},[],{"intervention":18453,"totalTrials":224,"cells":18476},{"EARLY_PHASE1":18477,"PHASE1":18479,"PHASE2":18481,"PHASE3":18483,"PHASE4":18485,"NA":18491},{"trials":18478,"activeCount":99},[],{"trials":18480,"activeCount":99},[],{"trials":18482,"activeCount":99},[],{"trials":18484,"activeCount":99},[],{"trials":18486,"activeCount":99},[18487],{"nctId":18446,"briefTitle":18447,"status":105,"phases":18488,"primaryCompletion":15210,"completion":15210,"start":12814,"enrollment":2023,"conditions":18489,"interventions":18490},[90],[18450,11523],[18433,18452,18453,18454],{"trials":18492,"activeCount":99},[],{"intervention":18454,"totalTrials":224,"cells":18494},{"EARLY_PHASE1":18495,"PHASE1":18497,"PHASE2":18499,"PHASE3":18501,"PHASE4":18503,"NA":18509},{"trials":18496,"activeCount":99},[],{"trials":18498,"activeCount":99},[],{"trials":18500,"activeCount":99},[],{"trials":18502,"activeCount":99},[],{"trials":18504,"activeCount":99},[18505],{"nctId":18446,"briefTitle":18447,"status":105,"phases":18506,"primaryCompletion":15210,"completion":15210,"start":12814,"enrollment":2023,"conditions":18507,"interventions":18508},[90],[18450,11523],[18433,18452,18453,18454],{"trials":18510,"activeCount":99},[],{"intervention":17116,"totalTrials":224,"cells":18512},{"EARLY_PHASE1":18513,"PHASE1":18515,"PHASE2":18517,"PHASE3":18519,"PHASE4":18521,"NA":18527},{"trials":18514,"activeCount":99},[],{"trials":18516,"activeCount":99},[],{"trials":18518,"activeCount":99},[],{"trials":18520,"activeCount":99},[],{"trials":18522,"activeCount":99},[18523],{"nctId":17111,"briefTitle":17112,"status":105,"phases":18524,"primaryCompletion":6309,"start":8620,"enrollment":661,"conditions":18525,"interventions":18526},[90],[16460,16952],[17081,17116],{"trials":18528,"activeCount":99},[],{"intervention":17193,"totalTrials":224,"cells":18530},{"EARLY_PHASE1":18531,"PHASE1":18533,"PHASE2":18535,"PHASE3":18537,"PHASE4":18539,"NA":18545},{"trials":18532,"activeCount":99},[],{"trials":18534,"activeCount":99},[],{"trials":18536,"activeCount":99},[],{"trials":18538,"activeCount":99},[],{"trials":18540,"activeCount":99},[18541],{"nctId":17186,"briefTitle":17187,"status":105,"phases":18542,"primaryCompletion":17189,"completion":17189,"start":17190,"enrollment":277,"conditions":18543,"interventions":18544},[90],[4291,4292],[17164,17193],{"trials":18546,"activeCount":99},[],{"intervention":17757,"totalTrials":224,"cells":18548},{"EARLY_PHASE1":18549,"PHASE1":18551,"PHASE2":18553,"PHASE3":18555,"PHASE4":18557,"NA":18563},{"trials":18550,"activeCount":99},[],{"trials":18552,"activeCount":99},[],{"trials":18554,"activeCount":99},[],{"trials":18556,"activeCount":99},[],{"trials":18558,"activeCount":99},[18559],{"nctId":17748,"briefTitle":17749,"status":105,"phases":18560,"enrollment":1349,"conditions":18561,"interventions":18562},[90],[27,17752],[17754,11421,17755,17756,17757,17735],{"trials":18564,"activeCount":99},[],{"intervention":18566,"totalTrials":224,"cells":18567},"Glibenclamide",{"EARLY_PHASE1":18568,"PHASE1":18570,"PHASE2":18572,"PHASE3":18574,"PHASE4":18576,"NA":18587},{"trials":18569,"activeCount":99},[],{"trials":18571,"activeCount":99},[],{"trials":18573,"activeCount":99},[],{"trials":18575,"activeCount":99},[],{"trials":18577,"activeCount":99},[18578],{"nctId":18579,"briefTitle":18580,"status":105,"phases":18581,"primaryCompletion":18582,"completion":18582,"start":18583,"enrollment":18584,"conditions":18585,"interventions":18586},"NCT02318693","Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)",[90],"2015-12-15","2015-02-04",53,[15],[13145,18566],{"trials":18588,"activeCount":99},[],{"intervention":17274,"totalTrials":224,"cells":18590},{"EARLY_PHASE1":18591,"PHASE1":18593,"PHASE2":18595,"PHASE3":18597,"PHASE4":18599,"NA":18605},{"trials":18592,"activeCount":99},[],{"trials":18594,"activeCount":99},[],{"trials":18596,"activeCount":99},[],{"trials":18598,"activeCount":99},[],{"trials":18600,"activeCount":99},[18601],{"nctId":17267,"briefTitle":17268,"status":150,"phases":18602,"primaryCompletion":17270,"completion":17270,"start":17271,"enrollment":5983,"conditions":18603,"interventions":18604},[90],[17251],[17234,17274],{"trials":18606,"activeCount":99},[],{"intervention":18608,"totalTrials":224,"cells":18609},"EBR\u002FGZR (50 mg\u002F100 mg) FDC",{"EARLY_PHASE1":18610,"PHASE1":18612,"PHASE2":18614,"PHASE3":18616,"PHASE4":18618,"NA":18629},{"trials":18611,"activeCount":99},[],{"trials":18613,"activeCount":99},[],{"trials":18615,"activeCount":99},[],{"trials":18617,"activeCount":99},[],{"trials":18619,"activeCount":99},[18620],{"nctId":18621,"briefTitle":18622,"status":105,"phases":18623,"primaryCompletion":2212,"completion":2212,"start":18624,"enrollment":18625,"conditions":18626,"interventions":18628},"NCT03111108","Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve\u002FTreatment-Experienced (TN\u002FTE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)",[90],"2017-06-20",117,[18627],"Hepatitis C Virus (HCV) Infection",[18608],{"trials":18630,"activeCount":99},[],{"intervention":18632,"totalTrials":224,"cells":18633},"Palonosetron",{"EARLY_PHASE1":18634,"PHASE1":18636,"PHASE2":18638,"PHASE3":18640,"PHASE4":18642,"NA":18651},{"trials":18635,"activeCount":99},[],{"trials":18637,"activeCount":99},[],{"trials":18639,"activeCount":99},[],{"trials":18641,"activeCount":99},[],{"trials":18643,"activeCount":99},[18644],{"nctId":18645,"briefTitle":18646,"status":105,"phases":18647,"primaryCompletion":18220,"completion":18220,"start":18648,"enrollment":17672,"conditions":18649,"interventions":18650},"NCT00684463","Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)",[90],"2007-04-11",[290,4291,4292],[18632],{"trials":18652,"activeCount":99},[],{"intervention":17204,"totalTrials":224,"cells":18654},{"EARLY_PHASE1":18655,"PHASE1":18657,"PHASE2":18659,"PHASE3":18661,"PHASE4":18663,"NA":18669},{"trials":18656,"activeCount":99},[],{"trials":18658,"activeCount":99},[],{"trials":18660,"activeCount":99},[],{"trials":18662,"activeCount":99},[],{"trials":18664,"activeCount":99},[18665],{"nctId":17195,"briefTitle":17196,"status":105,"phases":18666,"primaryCompletion":17198,"completion":17199,"start":17200,"enrollment":17201,"conditions":18667,"interventions":18668},[90],[4291,4292,1108],[17164,17204],{"trials":18670,"activeCount":99},[],{"intervention":14290,"totalTrials":224,"cells":18672},{"EARLY_PHASE1":18673,"PHASE1":18675,"PHASE2":18677,"PHASE3":18679,"PHASE4":18681,"NA":18687},{"trials":18674,"activeCount":99},[],{"trials":18676,"activeCount":99},[],{"trials":18678,"activeCount":99},[],{"trials":18680,"activeCount":99},[],{"trials":18682,"activeCount":99},[18683],{"nctId":14281,"briefTitle":14282,"status":105,"phases":18684,"primaryCompletion":14284,"completion":14284,"start":14285,"enrollment":14286,"conditions":18685,"interventions":18686},[90],[15],[4084,13145,14289,14290,13146,14198],{"trials":18688,"activeCount":99},[],{"intervention":18690,"totalTrials":224,"cells":18691},"AzaSite Eye Drops",{"EARLY_PHASE1":18692,"PHASE1":18694,"PHASE2":18696,"PHASE3":18698,"PHASE4":18700,"NA":18710},{"trials":18693,"activeCount":99},[],{"trials":18695,"activeCount":99},[],{"trials":18697,"activeCount":99},[],{"trials":18699,"activeCount":99},[],{"trials":18701,"activeCount":99},[18702],{"nctId":18703,"briefTitle":18704,"status":105,"phases":18705,"primaryCompletion":14858,"start":14454,"enrollment":429,"conditions":18706,"interventions":18708},"NCT00575380","Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery",[90],[16460,16952,18707],"Cataract Extraction",[18690,18709],"Vigamox Eye Drops",{"trials":18711,"activeCount":99},[],{"intervention":18709,"totalTrials":224,"cells":18713},{"EARLY_PHASE1":18714,"PHASE1":18716,"PHASE2":18718,"PHASE3":18720,"PHASE4":18722,"NA":18728},{"trials":18715,"activeCount":99},[],{"trials":18717,"activeCount":99},[],{"trials":18719,"activeCount":99},[],{"trials":18721,"activeCount":99},[],{"trials":18723,"activeCount":99},[18724],{"nctId":18703,"briefTitle":18704,"status":105,"phases":18725,"primaryCompletion":14858,"start":14454,"enrollment":429,"conditions":18726,"interventions":18727},[90],[16460,16952,18707],[18690,18709],{"trials":18729,"activeCount":99},[],{"intervention":17314,"totalTrials":224,"cells":18731},{"EARLY_PHASE1":18732,"PHASE1":18734,"PHASE2":18736,"PHASE3":18738,"PHASE4":18740,"NA":18746},{"trials":18733,"activeCount":99},[],{"trials":18735,"activeCount":99},[],{"trials":18737,"activeCount":99},[],{"trials":18739,"activeCount":99},[],{"trials":18741,"activeCount":99},[18742],{"nctId":17307,"briefTitle":17308,"status":1040,"phases":18743,"primaryCompletion":17310,"completion":17310,"start":17311,"enrollment":99,"conditions":18744,"interventions":18745},[90],[16696],[16687,17013,17314,17315,17278],{"trials":18747,"activeCount":99},[],{"intervention":17315,"totalTrials":224,"cells":18749},{"EARLY_PHASE1":18750,"PHASE1":18752,"PHASE2":18754,"PHASE3":18756,"PHASE4":18758,"NA":18764},{"trials":18751,"activeCount":99},[],{"trials":18753,"activeCount":99},[],{"trials":18755,"activeCount":99},[],{"trials":18757,"activeCount":99},[],{"trials":18759,"activeCount":99},[18760],{"nctId":17307,"briefTitle":17308,"status":1040,"phases":18761,"primaryCompletion":17310,"completion":17310,"start":17311,"enrollment":99,"conditions":18762,"interventions":18763},[90],[16696],[16687,17013,17314,17315,17278],{"trials":18765,"activeCount":99},[],{"intervention":18767,"totalTrials":224,"cells":18768},"Pegylated Liposomal Doxorubicin hydrochloride",{"EARLY_PHASE1":18769,"PHASE1":18771,"PHASE2":18773,"PHASE3":18775,"PHASE4":18777,"NA":18787},{"trials":18770,"activeCount":99},[],{"trials":18772,"activeCount":99},[],{"trials":18774,"activeCount":99},[],{"trials":18776,"activeCount":99},[],{"trials":18778,"activeCount":99},[18779],{"nctId":18780,"briefTitle":18781,"status":105,"phases":18782,"primaryCompletion":18783,"completion":18783,"start":18784,"enrollment":3226,"conditions":18785,"interventions":18786},"NCT00727961","A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)",[90],"2008-01-10","2004-11-09",[1288],[18767],{"trials":18788,"activeCount":99},[],{"intervention":18790,"totalTrials":224,"cells":18791},"MK0826; ertapenem sodium",{"EARLY_PHASE1":18792,"PHASE1":18794,"PHASE2":18796,"PHASE3":18798,"PHASE4":18800,"NA":18812},{"trials":18793,"activeCount":99},[],{"trials":18795,"activeCount":99},[],{"trials":18797,"activeCount":99},[],{"trials":18799,"activeCount":99},[],{"trials":18801,"activeCount":99},[18802],{"nctId":18803,"briefTitle":18804,"status":105,"phases":18805,"primaryCompletion":18806,"completion":14679,"start":18807,"enrollment":15267,"conditions":18808,"interventions":18810},"NCT00157898","A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED)",[90],"2004-08","2004-01",[18809],"Complicated Intra-abdominal Infection",[18790,18811],"Comparator: ceftriaxone + metronidazole",{"trials":18813,"activeCount":99},[],{"intervention":18811,"totalTrials":224,"cells":18815},{"EARLY_PHASE1":18816,"PHASE1":18818,"PHASE2":18820,"PHASE3":18822,"PHASE4":18824,"NA":18830},{"trials":18817,"activeCount":99},[],{"trials":18819,"activeCount":99},[],{"trials":18821,"activeCount":99},[],{"trials":18823,"activeCount":99},[],{"trials":18825,"activeCount":99},[18826],{"nctId":18803,"briefTitle":18804,"status":105,"phases":18827,"primaryCompletion":18806,"completion":14679,"start":18807,"enrollment":15267,"conditions":18828,"interventions":18829},[90],[18809],[18790,18811],{"trials":18831,"activeCount":99},[],{"intervention":5352,"totalTrials":224,"cells":18833},{"EARLY_PHASE1":18834,"PHASE1":18836,"PHASE2":18838,"PHASE3":18840,"PHASE4":18842,"NA":18848},{"trials":18835,"activeCount":99},[],{"trials":18837,"activeCount":99},[],{"trials":18839,"activeCount":99},[],{"trials":18841,"activeCount":99},[],{"trials":18843,"activeCount":99},[18844],{"nctId":5344,"briefTitle":5345,"status":105,"phases":18845,"primaryCompletion":5347,"completion":5347,"start":5348,"enrollment":5349,"conditions":18846,"interventions":18847},[90],[4291,4292],[5136,5352,5137,529,5315,5353],{"trials":18849,"activeCount":99},[],{"intervention":5353,"totalTrials":224,"cells":18851},{"EARLY_PHASE1":18852,"PHASE1":18854,"PHASE2":18856,"PHASE3":18858,"PHASE4":18860,"NA":18866},{"trials":18853,"activeCount":99},[],{"trials":18855,"activeCount":99},[],{"trials":18857,"activeCount":99},[],{"trials":18859,"activeCount":99},[],{"trials":18861,"activeCount":99},[18862],{"nctId":5344,"briefTitle":5345,"status":105,"phases":18863,"primaryCompletion":5347,"completion":5347,"start":5348,"enrollment":5349,"conditions":18864,"interventions":18865},[90],[4291,4292],[5136,5352,5137,529,5315,5353],{"trials":18867,"activeCount":99},[],{"intervention":18869,"totalTrials":224,"cells":18870},"VARIVAX®",{"EARLY_PHASE1":18871,"PHASE1":18873,"PHASE2":18875,"PHASE3":18877,"PHASE4":18879,"NA":18888},{"trials":18872,"activeCount":99},[],{"trials":18874,"activeCount":99},[],{"trials":18876,"activeCount":99},[],{"trials":18878,"activeCount":99},[],{"trials":18880,"activeCount":99},[18881],{"nctId":18882,"briefTitle":18883,"status":105,"phases":18884,"primaryCompletion":15156,"completion":15156,"start":14678,"enrollment":9177,"conditions":18885,"interventions":18886},"NCT00432731","Safety Study of a Refrigerator-stable Formulation of VARIVAX®",[90],[15311,15308,15309,15310],[18869,18887],"M-M-RTM II",{"trials":18889,"activeCount":99},[],{"intervention":18887,"totalTrials":224,"cells":18891},{"EARLY_PHASE1":18892,"PHASE1":18894,"PHASE2":18896,"PHASE3":18898,"PHASE4":18900,"NA":18906},{"trials":18893,"activeCount":99},[],{"trials":18895,"activeCount":99},[],{"trials":18897,"activeCount":99},[],{"trials":18899,"activeCount":99},[],{"trials":18901,"activeCount":99},[18902],{"nctId":18882,"briefTitle":18883,"status":105,"phases":18903,"primaryCompletion":15156,"completion":15156,"start":14678,"enrollment":9177,"conditions":18904,"interventions":18905},[90],[15311,15308,15309,15310],[18869,18887],{"trials":18907,"activeCount":99},[],{"intervention":6312,"totalTrials":36,"cells":18909},{"EARLY_PHASE1":18910,"PHASE1":18912,"PHASE2":19014,"PHASE3":19087,"PHASE4":19098,"NA":19100},{"trials":18911,"activeCount":99},[],{"trials":18913,"activeCount":99},[18914,18921,18927,18936,18943,18949,18953,18963,18969,18976,18982,18990,18994,19003,19007],{"nctId":18915,"briefTitle":18916,"status":105,"phases":18917,"primaryCompletion":16651,"completion":16651,"start":18918,"enrollment":5563,"conditions":18919,"interventions":18920},"NCT00694083","Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)",[87],"2008-06-10",[337],[11239],{"nctId":18922,"briefTitle":18923,"status":105,"phases":18924,"primaryCompletion":12813,"completion":12813,"start":14687,"enrollment":2901,"conditions":18925,"interventions":18926},"NCT00704054","A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)",[87],[176],[6312],{"nctId":18928,"briefTitle":18929,"status":150,"phases":18930,"primaryCompletion":13140,"completion":15126,"start":18931,"enrollment":14576,"conditions":18932,"interventions":18934},"NCT01243762","A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)",[87],"2010-11-22",[18933],"Neoplasms Malignant",[6091,18935,6312,2817],"MK-0752",{"nctId":18937,"briefTitle":18938,"status":105,"phases":18939,"primaryCompletion":8621,"completion":14313,"start":15118,"enrollment":444,"conditions":18940,"interventions":18942},"NCT00060645","Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)",[87],[18941,302,526],"Tumors",[6312],{"nctId":18944,"briefTitle":18945,"status":105,"phases":18946,"primaryCompletion":17095,"completion":17095,"start":17248,"enrollment":212,"conditions":18947,"interventions":18948},"NCT00060632","Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)",[87],[18941,302,526],[6312],{"nctId":13219,"briefTitle":13220,"status":105,"phases":18950,"primaryCompletion":13222,"completion":13223,"start":13224,"enrollment":3655,"conditions":18951,"interventions":18952},[87],[13226],[5626,11239],{"nctId":18954,"briefTitle":18955,"status":105,"phases":18956,"primaryCompletion":18957,"completion":18958,"start":18959,"enrollment":2901,"conditions":18960,"interventions":18962},"NCT01380184","Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059)",[87],"2011-10-20","2012-04-05","2011-07-05",[18961],"Cancer, Advanced",[6312],{"nctId":18964,"briefTitle":18965,"status":105,"phases":18966,"primaryCompletion":14353,"completion":14314,"start":14930,"enrollment":912,"conditions":18967,"interventions":18968},"NCT00112372","Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)",[87],[639],[11239],{"nctId":18970,"briefTitle":18971,"status":105,"phases":18972,"primaryCompletion":18973,"completion":8296,"start":14566,"enrollment":2801,"conditions":18974,"interventions":18975},"NCT01295632","Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)",[87],"2013-12",[852],[6312,18935,2817],{"nctId":18977,"briefTitle":18978,"status":105,"phases":18979,"primaryCompletion":4990,"completion":4990,"start":14623,"enrollment":569,"conditions":18980,"interventions":18981},"NCT01043887","Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046)",[87],[14429,7574],[6312],{"nctId":18983,"briefTitle":18984,"status":150,"phases":18985,"primaryCompletion":5169,"completion":18986,"start":18987,"enrollment":805,"conditions":18988,"interventions":18989},"NCT01431534","A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)",[87],"2018-05-25","2012-01-30",[176],[11239],{"nctId":6305,"briefTitle":6306,"status":105,"phases":18991,"primaryCompletion":6308,"completion":6308,"start":6309,"enrollment":3496,"conditions":18992,"interventions":18993},[87],[279],[6312,6313],{"nctId":18995,"briefTitle":18996,"status":105,"phases":18997,"primaryCompletion":18998,"completion":18998,"start":13222,"enrollment":18999,"conditions":19000,"interventions":19001},"NCT01220570","The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)",[87],"2012-12",63,[1109],[19002,11239,6106],"Ridaforolimus + Dalotuzumab",{"nctId":6461,"briefTitle":6462,"status":105,"phases":19004,"primaryCompletion":5801,"completion":5801,"start":6464,"enrollment":661,"conditions":19005,"interventions":19006},[87],[639,6466],[6312,1069],{"nctId":19008,"briefTitle":19009,"status":105,"phases":19010,"primaryCompletion":19011,"completion":19011,"start":13223,"enrollment":4242,"conditions":19012,"interventions":19013},"NCT01431547","Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)",[87],"2013-09",[176],[6091,6091,6312],{"trials":19015,"activeCount":99},[19016,19023,19029,19038,19049,19053,19061,19065,19071,19075,19083],{"nctId":19017,"briefTitle":19018,"status":105,"phases":19019,"primaryCompletion":12985,"completion":19020,"start":8591,"enrollment":4421,"conditions":19021,"interventions":19022},"NCT01010672","Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)",[88],"2013-01",[6466],[11239],{"nctId":19024,"briefTitle":19025,"status":105,"phases":19026,"primaryCompletion":14687,"completion":14687,"start":15063,"enrollment":700,"conditions":19027,"interventions":19028},"NCT00122343","AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)",[88],[861],[6312],{"nctId":19030,"briefTitle":19031,"status":150,"phases":19032,"primaryCompletion":15406,"completion":19033,"start":4319,"enrollment":357,"conditions":19034,"interventions":19036},"NCT00836927","Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)",[88],"2018-02-04",[19035],"Advanced Cancers",[11239,19037],"Ridaforolimus Intravenous (IV)",{"nctId":19039,"briefTitle":19040,"status":105,"phases":19041,"primaryCompletion":14823,"completion":14823,"start":14595,"enrollment":8175,"conditions":19042,"interventions":19048},"NCT00093080","Study of AP23573\u002FMK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)",[88],[19043,19044,19045,19046,19047],"Leiomyosarcoma","Liposarcoma","Osteosarcoma","Sarcoma, Soft Tissue","Metastases",[6312],{"nctId":14893,"briefTitle":14894,"status":105,"phases":19050,"primaryCompletion":5981,"completion":5800,"start":6309,"enrollment":4059,"conditions":19051,"interventions":19052},[88],[4411],[6312,13864,14898],{"nctId":19054,"briefTitle":19055,"status":105,"phases":19056,"primaryCompletion":14566,"completion":16792,"start":13102,"enrollment":132,"conditions":19057,"interventions":19058},"NCT00739830","Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)",[88],[861],[6312,19059,19060],"medroxyprogesterone acetate tablets OR megestrol acetate","chemotherapy",{"nctId":11220,"briefTitle":11221,"status":105,"phases":19062,"primaryCompletion":11223,"completion":11223,"start":11224,"enrollment":11225,"conditions":19063,"interventions":19064},[88],[1109],[11228,11229,6312,6091],{"nctId":19066,"briefTitle":19067,"status":105,"phases":19068,"primaryCompletion":15505,"completion":5507,"start":14930,"enrollment":2754,"conditions":19069,"interventions":19070},"NCT00110188","Ridaforolimus (AP23573\u002FMK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)",[88],[4411],[6312],{"nctId":11476,"briefTitle":11477,"status":105,"phases":19072,"primaryCompletion":11479,"completion":5981,"start":5801,"enrollment":5616,"conditions":19073,"interventions":19074},[88],[1109,1108],[6312,11482],{"nctId":19076,"briefTitle":19077,"status":105,"phases":19078,"primaryCompletion":14705,"completion":14705,"start":14229,"enrollment":28,"conditions":19079,"interventions":19082},"NCT00086125","Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)",[88],[2605,19080,196,19081,302],"Leukemia","Myeloid Metaplasia",[6312],{"nctId":11231,"briefTitle":11232,"status":105,"phases":19084,"primaryCompletion":11234,"completion":11235,"start":11236,"enrollment":1479,"conditions":19085,"interventions":19086},[88],[1108],[11239,6106,4156],{"trials":19088,"activeCount":99},[19089],{"nctId":19090,"briefTitle":19091,"status":105,"phases":19092,"primaryCompletion":5179,"completion":18998,"start":14540,"enrollment":19093,"conditions":19094,"interventions":19097},"NCT00538239","Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)",[89],711,[19095,19096],"Metastatic Soft-Tissue Sarcomas","Metastatic Bone Sarcomas",[6312],{"trials":19099,"activeCount":99},[],{"trials":19101,"activeCount":99},[],{"intervention":16474,"totalTrials":4242,"cells":19103},{"EARLY_PHASE1":19104,"PHASE1":19106,"PHASE2":19118,"PHASE3":19128,"PHASE4":19281,"NA":19283},{"trials":19105,"activeCount":99},[],{"trials":19107,"activeCount":99},[19108],{"nctId":19109,"briefTitle":19110,"status":105,"phases":19111,"primaryCompletion":19112,"completion":19112,"start":19113,"enrollment":15321,"conditions":19114,"interventions":19115},"NCT03848065","Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)",[87],"2020-06-24","2019-04-02",[16472],[16474,19116,19117],"Pneumococcal 13-valent Conjugate Vaccine","Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio",{"trials":19119,"activeCount":99},[19120],{"nctId":19121,"briefTitle":19122,"status":105,"phases":19123,"primaryCompletion":19124,"completion":19124,"start":19125,"enrollment":15416,"conditions":19126,"interventions":19127},"NCT02573181","Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)",[88],"2016-01-28","2015-10-30",[16472],[16474,16465],{"trials":19129,"activeCount":99},[19130,19139,19148,19155,19164,19172,19176,19185,19194,19203,19211,19221,19230,19239,19243,19251,19260,19264,19273],{"nctId":19131,"briefTitle":19132,"status":105,"phases":19133,"primaryCompletion":19134,"completion":19134,"start":2487,"enrollment":19135,"conditions":19136,"interventions":19137},"NCT03565900","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022\u002FPNEU-STEM)",[89],"2021-11-04",277,[16472],[16474,16465,19138],"PNEUMOVAX™23",{"nctId":19140,"briefTitle":19141,"status":105,"phases":19142,"primaryCompletion":19143,"completion":19143,"start":19144,"enrollment":13131,"conditions":19145,"interventions":19147},"NCT03950856","Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)",[89],"2020-04-03","2019-06-12",[16472,19146],"Pneumonia, Pneumococcal",[16474,16465],{"nctId":19149,"briefTitle":19150,"status":105,"phases":19151,"primaryCompletion":1620,"completion":1620,"start":2148,"enrollment":19152,"conditions":19153,"interventions":19154},"NCT03921424","Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030\u002FPNEU-WAY PED)",[89],407,[16472],[16474,16465,19138],{"nctId":19156,"briefTitle":19157,"status":105,"phases":19158,"primaryCompletion":19159,"completion":19160,"start":19161,"enrollment":1272,"conditions":19162,"interventions":19163},"NCT03480802","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",[89],"2019-09-16","2020-01-17","2018-07-06",[16472],[16474,16465,19138],{"nctId":19165,"briefTitle":19166,"status":105,"phases":19167,"primaryCompletion":19168,"completion":19168,"start":19169,"enrollment":3226,"conditions":19170,"interventions":19171},"NCT04633226","Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)",[89],"2022-11-04","2021-02-10",[17064],[16474],{"nctId":16468,"briefTitle":16469,"status":105,"phases":19173,"primaryCompletion":1640,"completion":1640,"start":1984,"enrollment":3605,"conditions":19174,"interventions":19175},[89],[16472],[16465,16474,16441,16475,16476,16477,16478,16479],{"nctId":19177,"briefTitle":19178,"status":105,"phases":19179,"primaryCompletion":3091,"completion":3091,"start":16680,"enrollment":19180,"conditions":19181,"interventions":19182},"NCT04031846","Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)",[89],1184,[16472],[19183,19184,16474,17718],"Rotarix™","Infanrix™ hexa",{"nctId":19186,"briefTitle":19187,"status":105,"phases":19188,"primaryCompletion":13438,"completion":13438,"start":19189,"enrollment":19190,"conditions":19191,"interventions":19193},"NCT04193215","V114 and Acute Otitis Media (V114-032\u002FPNEU-ERA)",[89],"2020-09-12",7119,[19192],"Acute Otitis Media (AOM)",[16474],{"nctId":19195,"briefTitle":19196,"status":105,"phases":19197,"primaryCompletion":19198,"completion":19198,"start":1521,"enrollment":19199,"conditions":19200,"interventions":19201},"NCT04384107","Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)",[89],"2021-12-01",694,[16472],[16474,19202],"PCV13",{"nctId":19204,"briefTitle":19205,"status":105,"phases":19206,"primaryCompletion":19207,"completion":19207,"start":19208,"enrollment":14463,"conditions":19209,"interventions":19210},"NCT03731182","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023\u002FPNEU-SICKLE)",[89],"2020-06-08","2019-01-23",[16472],[16474,16465],{"nctId":19212,"briefTitle":19213,"status":105,"phases":19214,"primaryCompletion":19215,"completion":19215,"start":11530,"enrollment":19216,"conditions":19217,"interventions":19218},"NCT05158140","Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)",[89],"2023-02-21",850,[13187],[19219,16474,19220],"V110","mRNA-1273",{"nctId":19222,"briefTitle":19223,"status":105,"phases":19224,"primaryCompletion":19225,"completion":19225,"start":19226,"enrollment":2204,"conditions":19227,"interventions":19228},"NCT03615482","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021\u002FPNEU-FLU)",[89],"2019-06-24","2018-09-14",[16472],[16474,19229],"QIV",{"nctId":19231,"briefTitle":19232,"status":105,"phases":19233,"primaryCompletion":19234,"completion":19234,"start":19235,"enrollment":19236,"conditions":19237,"interventions":19238},"NCT03547167","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017\u002FPNEU-DAY)",[89],"2020-01-20","2018-07-16",1515,[16472],[16474,16465,19138],{"nctId":17711,"briefTitle":17712,"status":105,"phases":19240,"primaryCompletion":1600,"completion":1600,"start":17714,"enrollment":17715,"conditions":19241,"interventions":19242},[89],[16472],[16474,17718,17700,17719,16479],{"nctId":19244,"briefTitle":19245,"status":105,"phases":19246,"primaryCompletion":19247,"completion":19247,"start":19248,"enrollment":15003,"conditions":19249,"interventions":19250},"NCT03692871","A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031\u002FPNEU-LINK)",[89],"2021-03-26","2018-12-14",[16472],[16474,16465],{"nctId":19252,"briefTitle":19253,"status":105,"phases":19254,"primaryCompletion":19255,"completion":19255,"start":19256,"enrollment":19257,"conditions":19258,"interventions":19259},"NCT03480763","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016\u002FPNEU-PATH)",[89],"2019-12-23","2018-06-22",652,[16472],[16474,16465,19138],{"nctId":16481,"briefTitle":16482,"status":105,"phases":19261,"primaryCompletion":16484,"completion":16484,"start":709,"enrollment":16485,"conditions":19262,"interventions":19263},[89],[16472,16487],[16474,16465,16441,16475,16476,16489,16490,16479,16477],{"nctId":19265,"briefTitle":19266,"status":105,"phases":19267,"primaryCompletion":19268,"completion":19268,"start":2350,"enrollment":19269,"conditions":19270,"interventions":19271},"NCT03950622","Safety and Immunogenicity of V114 in Healthy Adults (V114-019\u002FPNEU-AGE)",[89],"2020-03-30",1205,[16472],[16474,19272],"Prevnar 13®",{"nctId":19274,"briefTitle":19275,"status":105,"phases":19276,"primaryCompletion":19277,"completion":19277,"start":1778,"enrollment":19278,"conditions":19279,"interventions":19280},"NCT03885934","Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)",[89],"2020-12-09",606,[16472],[16474,19272],{"trials":19282,"activeCount":99},[],{"trials":19284,"activeCount":99},[],{"intervention":4994,"totalTrials":805,"cells":19286},{"EARLY_PHASE1":19287,"PHASE1":19289,"PHASE2":19370,"PHASE3":19404,"PHASE4":19429,"NA":19431},{"trials":19288,"activeCount":99},[],{"trials":19290,"activeCount":99},[19291,19295,19302,19308,19312,19319,19327,19333,19339,19348,19352,19361],{"nctId":4987,"briefTitle":4988,"status":105,"phases":19292,"primaryCompletion":4990,"completion":4990,"start":4419,"enrollment":4991,"conditions":19293,"interventions":19294},[87],[903],[4994,714,4995],{"nctId":19296,"briefTitle":19297,"status":150,"phases":19298,"primaryCompletion":6309,"completion":6309,"start":15156,"enrollment":3141,"conditions":19299,"interventions":19300},"NCT00127101","An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)",[87],[302],[4994,19301],"Comparator: bexarotene",{"nctId":19303,"briefTitle":19304,"status":105,"phases":19305,"primaryCompletion":14540,"completion":14540,"start":14531,"enrollment":3655,"conditions":19306,"interventions":19307},"NCT00373490","A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)",[87],[18941],[5174,5174],{"nctId":14434,"briefTitle":14435,"status":105,"phases":19309,"primaryCompletion":13890,"completion":9610,"start":13891,"enrollment":9323,"conditions":19310,"interventions":19311},[87],[14438,14439],[4994,14331],{"nctId":19313,"briefTitle":19314,"status":105,"phases":19315,"primaryCompletion":13101,"completion":5981,"start":15156,"enrollment":5616,"conditions":19316,"interventions":19317},"NCT00111813","Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))",[87],[526],[4994,19318],"bortezomib",{"nctId":19320,"briefTitle":19321,"status":105,"phases":19322,"primaryCompletion":19323,"completion":19323,"start":19324,"enrollment":931,"conditions":19325,"interventions":19326},"NCT00127127","A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)",[87],"2009-08-21","2005-06-10",[18941],[4994],{"nctId":19328,"briefTitle":19329,"status":105,"phases":19330,"primaryCompletion":7018,"completion":7018,"start":13102,"enrollment":335,"conditions":19331,"interventions":19332},"NCT00771472","Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)",[87],[302],[4994],{"nctId":19334,"briefTitle":19335,"status":105,"phases":19336,"primaryCompletion":16794,"completion":16794,"start":14594,"enrollment":335,"conditions":19337,"interventions":19338},"NCT00127140","A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)",[87],[302],[4994],{"nctId":19340,"briefTitle":19341,"status":105,"phases":19342,"primaryCompletion":19343,"completion":19344,"start":19345,"enrollment":154,"conditions":19346,"interventions":19347},"NCT00750178","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)",[87],"2005-08-01","2005-11-01","2004-11-01",[18961],[4994],{"nctId":5165,"briefTitle":5166,"status":105,"phases":19349,"primaryCompletion":5168,"completion":5169,"start":5170,"enrollment":4741,"conditions":19350,"interventions":19351},[87],[5172],[5174,528,529],{"nctId":19353,"briefTitle":19354,"status":105,"phases":19355,"primaryCompletion":4990,"completion":8590,"start":14324,"enrollment":19356,"conditions":19357,"interventions":19359},"NCT00479232","Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)",[87],71,[19358,196],"Leukemia, Myelocytic, Acute Myelodysplastic Syndromes",[4994,19360],"decitabine",{"nctId":19362,"briefTitle":19363,"status":105,"phases":19364,"primaryCompletion":19365,"completion":19366,"start":19367,"enrollment":3308,"conditions":19368,"interventions":19369},"NCT00858234","Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)",[87],"2010-06-11","2012-04-19","2009-02-13",[526],[5174,5199],{"trials":19371,"activeCount":99},[19372,19376,19382,19388,19396],{"nctId":5190,"briefTitle":5191,"status":105,"phases":19373,"primaryCompletion":5193,"completion":5194,"start":5195,"enrollment":5196,"conditions":19374,"interventions":19375},[88],[5172],[5174,5199,529],{"nctId":19377,"briefTitle":19378,"status":105,"phases":19379,"primaryCompletion":12813,"completion":12813,"start":15063,"enrollment":36,"conditions":19380,"interventions":19381},"NCT00907738","A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)",[88],[852],[4994],{"nctId":19383,"briefTitle":19384,"status":150,"phases":19385,"primaryCompletion":14540,"completion":14540,"start":14484,"enrollment":3141,"conditions":19386,"interventions":19387},"NCT00251589","A Phase I\u002FII Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed\u002FRefractory Non-Small-Cell Lung Cancer (0683-025)",[87,88],[369],[5174,5174,5174,5174,2818],{"nctId":19389,"briefTitle":19390,"status":105,"phases":19391,"primaryCompletion":19392,"completion":19393,"start":13957,"enrollment":1621,"conditions":19394,"interventions":19395},"NCT00875056","Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)",[88],"2011-09-06","2019-02-08",[302],[5174],{"nctId":19397,"briefTitle":19398,"status":150,"phases":19399,"primaryCompletion":14713,"completion":14713,"start":14324,"enrollment":4059,"conditions":19400,"interventions":19403},"NCT00486720","Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)",[88],[196,19401,19402],"Blood Disease","Bone Marrow Disease",[4994,4994],{"trials":19405,"activeCount":99},[19406,19415,19419],{"nctId":19407,"briefTitle":19408,"status":105,"phases":19409,"primaryCompletion":19410,"completion":19411,"start":5195,"enrollment":19412,"conditions":19413,"interventions":19414},"NCT00773747","Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)",[89],"2011-09-08","2015-06-30",637,[526],[5174,19318],{"nctId":15413,"briefTitle":15414,"status":150,"phases":19416,"primaryCompletion":14353,"completion":14353,"start":14409,"enrollment":15416,"conditions":19417,"interventions":19418},[88,89],[15418],[4994,15420,15421,14331],{"nctId":19420,"briefTitle":19421,"status":105,"phases":19422,"primaryCompletion":19423,"completion":19424,"start":19425,"enrollment":19426,"conditions":19427,"interventions":19428},"NCT00128102","Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)",[89],"2011-07-15","2011-11-21","2005-06-30",661,[571,2649],[5174],{"trials":19430,"activeCount":99},[],{"trials":19432,"activeCount":99},[],{"intervention":16465,"totalTrials":3655,"cells":19434},{"EARLY_PHASE1":19435,"PHASE1":19437,"PHASE2":19439,"PHASE3":19469,"PHASE4":19523,"NA":19525},{"trials":19436,"activeCount":99},[],{"trials":19438,"activeCount":99},[],{"trials":19440,"activeCount":99},[19441,19452,19456],{"nctId":19442,"briefTitle":19443,"status":105,"phases":19444,"primaryCompletion":19445,"completion":19445,"start":19446,"enrollment":19447,"conditions":19448,"interventions":19449},"NCT02987972","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)",[88],"2018-10-04","2017-03-21",1051,[16472],[19450,19451,16465],"V114 Lot 1","V114 Lot 2",{"nctId":19121,"briefTitle":19122,"status":105,"phases":19453,"primaryCompletion":19124,"completion":19124,"start":19125,"enrollment":15416,"conditions":19454,"interventions":19455},[88],[16472],[16474,16465],{"nctId":19457,"briefTitle":19458,"status":105,"phases":19459,"primaryCompletion":19460,"completion":19460,"start":19461,"enrollment":19462,"conditions":19463,"interventions":19464},"NCT02531373","A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)",[87,88],"2017-04-14","2015-09-15",338,[16472],[19465,19466,19467,19468,16465],"V114 Medium Dose","V114 High Dose","V114 Medium Dose with Alternative Carrier Protein","V114 High Dose with Alternative Carrier Protein",{"trials":19470,"activeCount":99},[19471,19475,19479,19483,19487,19491,19495,19499,19503,19507,19511,19515,19519],{"nctId":17050,"briefTitle":17051,"status":105,"phases":19472,"primaryCompletion":17053,"completion":17053,"start":17054,"enrollment":1150,"conditions":19473,"interventions":19474},[89],[16472],[16465,17039],{"nctId":19131,"briefTitle":19132,"status":105,"phases":19476,"primaryCompletion":19134,"completion":19134,"start":2487,"enrollment":19135,"conditions":19477,"interventions":19478},[89],[16472],[16474,16465,19138],{"nctId":19140,"briefTitle":19141,"status":105,"phases":19480,"primaryCompletion":19143,"completion":19143,"start":19144,"enrollment":13131,"conditions":19481,"interventions":19482},[89],[16472,19146],[16474,16465],{"nctId":16452,"briefTitle":16453,"status":105,"phases":19484,"primaryCompletion":16455,"completion":16456,"start":16457,"enrollment":16458,"conditions":19485,"interventions":19486},[89],[16460,16461],[16463,16464,16465,16441,16466],{"nctId":19149,"briefTitle":19150,"status":105,"phases":19488,"primaryCompletion":1620,"completion":1620,"start":2148,"enrollment":19152,"conditions":19489,"interventions":19490},[89],[16472],[16474,16465,19138],{"nctId":19156,"briefTitle":19157,"status":105,"phases":19492,"primaryCompletion":19159,"completion":19160,"start":19161,"enrollment":1272,"conditions":19493,"interventions":19494},[89],[16472],[16474,16465,19138],{"nctId":16468,"briefTitle":16469,"status":105,"phases":19496,"primaryCompletion":1640,"completion":1640,"start":1984,"enrollment":3605,"conditions":19497,"interventions":19498},[89],[16472],[16465,16474,16441,16475,16476,16477,16478,16479],{"nctId":19204,"briefTitle":19205,"status":105,"phases":19500,"primaryCompletion":19207,"completion":19207,"start":19208,"enrollment":14463,"conditions":19501,"interventions":19502},[89],[16472],[16474,16465],{"nctId":19231,"briefTitle":19232,"status":105,"phases":19504,"primaryCompletion":19234,"completion":19234,"start":19235,"enrollment":19236,"conditions":19505,"interventions":19506},[89],[16472],[16474,16465,19138],{"nctId":19244,"briefTitle":19245,"status":105,"phases":19508,"primaryCompletion":19247,"completion":19247,"start":19248,"enrollment":15003,"conditions":19509,"interventions":19510},[89],[16472],[16474,16465],{"nctId":19252,"briefTitle":19253,"status":105,"phases":19512,"primaryCompletion":19255,"completion":19255,"start":19256,"enrollment":19257,"conditions":19513,"interventions":19514},[89],[16472],[16474,16465,19138],{"nctId":16481,"briefTitle":16482,"status":105,"phases":19516,"primaryCompletion":16484,"completion":16484,"start":709,"enrollment":16485,"conditions":19517,"interventions":19518},[89],[16472,16487],[16474,16465,16441,16475,16476,16489,16490,16479,16477],{"nctId":16492,"briefTitle":16493,"status":105,"phases":19520,"primaryCompletion":16495,"completion":16495,"start":16496,"enrollment":16497,"conditions":19521,"interventions":19522},[89],[16460,16461],[16463,16500,16501,16465,16441,16464,16466,16502],{"trials":19524,"activeCount":99},[],{"trials":19526,"activeCount":99},[],{"intervention":14554,"totalTrials":3655,"cells":19528},{"EARLY_PHASE1":19529,"PHASE1":19531,"PHASE2":19567,"PHASE3":19609,"PHASE4":19664,"NA":19666},{"trials":19530,"activeCount":99},[],{"trials":19532,"activeCount":99},[19533,19540,19548,19552,19556,19560],{"nctId":19534,"briefTitle":19535,"status":105,"phases":19536,"primaryCompletion":19537,"completion":13102,"start":14229,"enrollment":120,"conditions":19538,"interventions":19539},"NCT00863590","A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers",[87],"2005-02",[14552],[14682,15220,15220,15220],{"nctId":19541,"briefTitle":19542,"status":105,"phases":19543,"primaryCompletion":14594,"completion":14228,"start":14706,"enrollment":19544,"conditions":19545,"interventions":19546},"NCT00770159","A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)",[87],78,[14552],[14682,19547],"Comparator: placebo to MK0822",{"nctId":14545,"briefTitle":14546,"status":105,"phases":19549,"primaryCompletion":14548,"completion":14549,"start":14550,"enrollment":347,"conditions":19550,"interventions":19551},[87],[14552],[14554,13864],{"nctId":14675,"briefTitle":14676,"status":105,"phases":19553,"primaryCompletion":14678,"completion":4418,"start":14679,"enrollment":25,"conditions":19554,"interventions":19555},[87],[14552],[14682,13864],{"nctId":14702,"briefTitle":14703,"status":105,"phases":19557,"primaryCompletion":14678,"completion":14705,"start":14706,"enrollment":734,"conditions":19558,"interventions":19559},[87],[14552],[14682,13864],{"nctId":19561,"briefTitle":19562,"status":150,"phases":19563,"primaryCompletion":19564,"completion":19564,"start":14112,"enrollment":569,"conditions":19565,"interventions":19566},"NCT01630616","A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066)",[87],"2016-07-14",[14552],[14554],{"trials":19568,"activeCount":99},[19569,19580,19590,19600],{"nctId":19570,"briefTitle":19571,"status":105,"phases":19572,"primaryCompletion":19573,"completion":19573,"start":19574,"enrollment":19575,"conditions":19576,"interventions":19578},"NCT00399802","A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)",[88],"2007-12-05","2006-11-16",43,[1109,19577],"Metastatic Bone Disease",[19579,14554],"ZA",{"nctId":19581,"briefTitle":19582,"status":105,"phases":19583,"primaryCompletion":19584,"completion":19585,"start":19586,"enrollment":19587,"conditions":19588,"interventions":19589},"NCT00112437","A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)",[88],"2007-12-26","2016-01-20","2005-06-24",399,[14552],[14554,14554,14554,14554],{"nctId":19591,"briefTitle":19592,"status":105,"phases":19593,"primaryCompletion":19594,"completion":19594,"start":19595,"enrollment":19596,"conditions":19597,"interventions":19599},"NCT00620113","Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)",[88],"2009-05-29","2007-12-03",287,[19598],"Osteoporosis Postmenopausal",[14554],{"nctId":19601,"briefTitle":19602,"status":105,"phases":19603,"primaryCompletion":19604,"completion":19604,"start":19605,"enrollment":19606,"conditions":19607,"interventions":19608},"NCT00885170","A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)",[88],"2011-09-15","2009-04-13",246,[14552],[14554],{"trials":19610,"activeCount":99},[19611,19622,19631,19638,19646,19652],{"nctId":19612,"briefTitle":19613,"status":150,"phases":19614,"primaryCompletion":19615,"completion":19616,"start":19617,"enrollment":19618,"conditions":19619,"interventions":19621},"NCT00529373","A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)",[89],"2012-11-14","2017-02-01","2007-09-13",16071,[19620],"Postmenopausal Osteoporosis",[14554],{"nctId":19623,"briefTitle":19624,"status":105,"phases":19625,"primaryCompletion":19626,"completion":19626,"start":19627,"enrollment":19628,"conditions":19629,"interventions":19630},"NCT01120600","A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)",[89],"2013-07-22","2010-06-09",294,[14552],[14554],{"nctId":19632,"briefTitle":19633,"status":1040,"phases":19634,"primaryCompletion":19635,"completion":19635,"start":15845,"enrollment":99,"conditions":19636,"interventions":19637},"NCT01552122","Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)",[89],"2015-02",[14552,19620],[14554,8053],{"nctId":19639,"briefTitle":19640,"status":150,"phases":19641,"primaryCompletion":19642,"completion":19642,"start":16279,"enrollment":19643,"conditions":19644,"interventions":19645},"NCT01803607","Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)",[89],"2014-11-11",135,[14552],[14682],{"nctId":19647,"briefTitle":19648,"status":1040,"phases":19649,"primaryCompletion":14315,"completion":14315,"start":14315,"enrollment":99,"conditions":19650,"interventions":19651},"NCT00691899","A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)",[89],[4411],[14682],{"nctId":19653,"briefTitle":19654,"status":105,"phases":19655,"primaryCompletion":19656,"completion":19657,"start":19658,"enrollment":19659,"conditions":19660,"interventions":19661},"NCT00729183","Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)",[89],"2010-03-23","2011-03-21","2008-10-02",214,[14552],[14554,19662,19663],"Vitamin D3","Calcium supplement",{"trials":19665,"activeCount":99},[],{"trials":19667,"activeCount":99},[],{"intervention":7800,"totalTrials":95,"cells":19669},{"EARLY_PHASE1":19670,"PHASE1":19672,"PHASE2":19716,"PHASE3":19752,"PHASE4":19758,"NA":19760},{"trials":19671,"activeCount":99},[],{"trials":19673,"activeCount":99},[19674,19682,19688,19692,19700,19709],{"nctId":19675,"briefTitle":19676,"status":105,"phases":19677,"primaryCompletion":19678,"completion":19678,"start":19679,"enrollment":4071,"conditions":19680,"interventions":19681},"NCT04568603","Islatravir and Methadone Pharmacokinetics (MK-8591-029)",[87],"2021-07-09","2020-10-16",[7639],[7800],{"nctId":19683,"briefTitle":19684,"status":105,"phases":19685,"primaryCompletion":321,"completion":321,"start":1700,"enrollment":805,"conditions":19686,"interventions":19687},"NCT06811246","A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)",[87],[18],[7800,11421],{"nctId":9856,"briefTitle":9857,"status":105,"phases":19689,"primaryCompletion":453,"completion":453,"start":9859,"enrollment":120,"conditions":19690,"interventions":19691},[87],[18],[9849,7800,9862],{"nctId":19693,"briefTitle":19694,"status":105,"phases":19695,"primaryCompletion":19696,"completion":19696,"start":19697,"enrollment":95,"conditions":19698,"interventions":19699},"NCT04515641","Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)",[87],"2021-09-13","2020-11-05",[11396],[7800],{"nctId":19701,"briefTitle":19702,"status":105,"phases":19703,"primaryCompletion":19704,"completion":19704,"start":19705,"enrollment":8016,"conditions":19706,"interventions":19707},"NCT06619678","A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)",[87],"2024-06-23","2024-01-17",[18],[19708,7800],"MK-8507",{"nctId":19710,"briefTitle":19711,"status":105,"phases":19712,"primaryCompletion":442,"completion":442,"start":19713,"enrollment":95,"conditions":19714,"interventions":19715},"NCT04303156","Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)",[87],"2020-06-18",[11396],[7800],{"trials":19717,"activeCount":99},[19718,19728,19737,19741,19745],{"nctId":19719,"briefTitle":19720,"status":105,"phases":19721,"primaryCompletion":19722,"completion":19723,"start":19724,"enrollment":19725,"conditions":19726,"interventions":19727},"NCT04003103","Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)",[88],"2022-03-18","2022-11-24","2019-09-19",242,[7639],[7800],{"nctId":19729,"briefTitle":19730,"status":1040,"phases":19731,"primaryCompletion":19732,"completion":19732,"start":19733,"enrollment":99,"conditions":19734,"interventions":19736},"NCT05130086","A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)",[88],"2024-03-25","2022-10-17",[19735],"Human Immunodeficiency Virus (HIV) Infections",[7800],{"nctId":11413,"briefTitle":11414,"status":105,"phases":19738,"primaryCompletion":11416,"completion":11417,"start":11418,"enrollment":2085,"conditions":19739,"interventions":19740},[88],[7639],[7800,11357,11421,11422,11423],{"nctId":7792,"briefTitle":7793,"status":105,"phases":19742,"primaryCompletion":7795,"completion":7795,"start":7796,"enrollment":7797,"conditions":19743,"interventions":19744},[88],[7639],[7800,7801,7671],{"nctId":19746,"briefTitle":19747,"status":1040,"phases":19748,"primaryCompletion":19749,"completion":19749,"start":11550,"enrollment":99,"conditions":19750,"interventions":19751},"NCT05115838","Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)",[88],"2025-10-02",[7310,7390],[7800],{"trials":19753,"activeCount":99},[19754],{"nctId":9496,"briefTitle":9497,"status":150,"phases":19755,"primaryCompletion":427,"completion":1776,"start":9499,"enrollment":1002,"conditions":19756,"interventions":19757},[89],[9501,9502,9503],[7800,7295],{"trials":19759,"activeCount":99},[],{"trials":19761,"activeCount":99},[],{"intervention":17381,"totalTrials":95,"cells":19763},{"EARLY_PHASE1":19764,"PHASE1":19766,"PHASE2":19793,"PHASE3":19851,"PHASE4":19874,"NA":19876},{"trials":19765,"activeCount":99},[],{"trials":19767,"activeCount":99},[19768,19776,19785],{"nctId":19769,"briefTitle":19770,"status":105,"phases":19771,"primaryCompletion":19772,"completion":19772,"start":19773,"enrollment":120,"conditions":19774,"interventions":19775},"NCT01937975","The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)",[87],"2013-12-17","2013-09-06",[12957,4074],[15839,17381],{"nctId":19777,"briefTitle":19778,"status":105,"phases":19779,"primaryCompletion":19780,"completion":19780,"start":19781,"enrollment":1054,"conditions":19782,"interventions":19784},"NCT01532973","Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002)",[87],"2013-05-17","2012-02-16",[19783],"Hepatitis, Viral, Human",[17381],{"nctId":19786,"briefTitle":19787,"status":105,"phases":19788,"primaryCompletion":19789,"completion":19789,"start":19790,"enrollment":4741,"conditions":19791,"interventions":19792},"NCT01797536","The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)",[87],"2014-08-20","2013-03-06",[7574],[17381],{"trials":19794,"activeCount":99},[19795,19805,19813,19824,19834,19844],{"nctId":19796,"briefTitle":19797,"status":105,"phases":19798,"primaryCompletion":19799,"completion":19800,"start":19801,"enrollment":19802,"conditions":19803,"interventions":19804},"NCT01717326","A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)",[88],"2015-02-23","2015-05-06","2013-02-07",573,[24],[15839,17381,14925],{"nctId":19806,"briefTitle":19807,"status":105,"phases":19808,"primaryCompletion":19809,"completion":19809,"start":19810,"enrollment":16208,"conditions":19811,"interventions":19812},"NCT01932762","Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)",[88],"2014-12-04","2013-10-01",[24],[15839,17381,14925],{"nctId":19814,"briefTitle":19815,"status":105,"phases":19816,"primaryCompletion":1986,"completion":19817,"start":19818,"enrollment":19819,"conditions":19820,"interventions":19821},"NCT02332707","Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)",[88],"2016-12-06","2015-01-22",443,[24],[15839,12959,17381,19822,19823,14925],"Ruzasvir","Uprifosbuvir (+) Grazoprevir (+) Ruzasvir",{"nctId":19825,"briefTitle":19826,"status":105,"phases":19827,"primaryCompletion":19828,"completion":19829,"start":19830,"enrollment":2788,"conditions":19831,"interventions":19832},"NCT02601573","Elbasvir\u002FGrazoprevir (EBR\u002FGZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)",[88],"2016-10-18","2017-01-06","2016-01-05",[24],[15839,17381,14925,19833],"Sofosbuvir",{"nctId":19835,"briefTitle":19836,"status":105,"phases":19837,"primaryCompletion":19838,"completion":19839,"start":19840,"enrollment":2695,"conditions":19841,"interventions":19842},"NCT02332720","Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)",[88],"2016-09-19","2017-05-03","2015-01-28",[24],[15839,12959,17381,19822,19843,14925],"MK-3682B",{"nctId":19845,"briefTitle":19846,"status":105,"phases":19847,"primaryCompletion":19848,"completion":19848,"start":13269,"enrollment":18324,"conditions":19849,"interventions":19850},"NCT02105454","Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)",[88],"2015-05-04",[12987],[15839,17381,14925],{"trials":19852,"activeCount":99},[19853,19862,19866],{"nctId":19854,"briefTitle":19855,"status":105,"phases":19856,"primaryCompletion":19857,"completion":19858,"start":19859,"enrollment":19587,"conditions":19860,"interventions":19861},"NCT02203149","Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)",[88,89],"2015-10-02","2016-05-16","2014-08-01",[24],[15839,17381],{"nctId":17374,"briefTitle":17375,"status":105,"phases":19863,"primaryCompletion":17377,"completion":17378,"start":16755,"enrollment":3390,"conditions":19864,"interventions":19865},[88,89],[12957],[15839,17381,17363],{"nctId":19867,"briefTitle":19868,"status":105,"phases":19869,"primaryCompletion":19870,"completion":12953,"start":1095,"enrollment":19871,"conditions":19872,"interventions":19873},"NCT02092350","Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)",[88,89],"2015-03-11",237,[12987],[15839,17381],{"trials":19875,"activeCount":99},[],{"trials":19877,"activeCount":99},[],{"intervention":13203,"totalTrials":5983,"cells":19879},{"EARLY_PHASE1":19880,"PHASE1":19882,"PHASE2":19892,"PHASE3":19903,"PHASE4":19976,"NA":19978},{"trials":19881,"activeCount":99},[],{"trials":19883,"activeCount":99},[19884],{"nctId":19885,"briefTitle":19886,"status":105,"phases":19887,"primaryCompletion":19888,"completion":19888,"start":19889,"enrollment":892,"conditions":19890,"interventions":19891},"NCT04665050","Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)",[87],"2021-04-06","2021-02-04",[13187],[13203,19138],{"trials":19893,"activeCount":99},[19894],{"nctId":19895,"briefTitle":19896,"status":105,"phases":19897,"primaryCompletion":19898,"completion":19898,"start":19899,"enrollment":1818,"conditions":19900,"interventions":19901},"NCT04168190","A Phase 1\u002FPhase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)",[87,88],"2021-07-12","2019-12-06",[19146],[13203,19902],"Pneumovax™23",{"trials":19904,"activeCount":99},[19905,19916,19923,19931,19940,19947,19954,19958,19967],{"nctId":19906,"briefTitle":19907,"status":105,"phases":19908,"primaryCompletion":19909,"completion":19910,"start":13199,"enrollment":13958,"conditions":19911,"interventions":19912},"NCT05393037","Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)",[89],"2023-07-13","2024-01-25",[17064],[13203,19913,19914,19915],"PCV15","PPSV23","PCV15 - Part B",{"nctId":19917,"briefTitle":19918,"status":105,"phases":19919,"primaryCompletion":1320,"completion":1320,"start":4070,"enrollment":19920,"conditions":19921,"interventions":19922},"NCT05420961","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)",[89],717,[19146],[13203,19913,19914],{"nctId":19924,"briefTitle":19925,"status":105,"phases":19926,"primaryCompletion":19927,"completion":19927,"start":19928,"enrollment":951,"conditions":19929,"interventions":19930},"NCT05633992","Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)",[89],"2023-05-24","2023-01-10",[17064],[13203,19914],{"nctId":19932,"briefTitle":19933,"status":105,"phases":19934,"primaryCompletion":19935,"completion":19935,"start":19936,"enrollment":19937,"conditions":19938,"interventions":19939},"NCT05464420","A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)",[89],"2023-05-25","2022-08-12",2162,[17064],[13203,19914],{"nctId":19941,"briefTitle":19942,"status":105,"phases":19943,"primaryCompletion":2022,"completion":2022,"start":6178,"enrollment":19944,"conditions":19945,"interventions":19946},"NCT05696080","Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)",[89],518,[13187],[13203,19913,19914],{"nctId":19948,"briefTitle":19949,"status":105,"phases":19950,"primaryCompletion":6614,"completion":6614,"start":19951,"enrollment":2512,"conditions":19952,"interventions":19953},"NCT06177912","A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)",[89],"2024-01-18",[13187],[13203,19914],{"nctId":13195,"briefTitle":13196,"status":105,"phases":19955,"primaryCompletion":13198,"completion":13198,"start":13199,"enrollment":13200,"conditions":19956,"interventions":19957},[89],[13187],[13203,13174],{"nctId":19959,"briefTitle":19960,"status":105,"phases":19961,"primaryCompletion":19962,"completion":19962,"start":19963,"enrollment":19964,"conditions":19965,"interventions":19966},"NCT05526716","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)",[89],"2023-06-21","2022-09-23",1080,[19146],[13203,19229],{"nctId":19968,"briefTitle":19969,"status":105,"phases":19970,"primaryCompletion":2722,"completion":19971,"start":19972,"enrollment":19973,"conditions":19974,"interventions":19975},"NCT05569954","Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)",[89],"2025-02-07","2022-11-07",1484,[17064],[13203,19914],{"trials":19977,"activeCount":99},[],{"trials":19979,"activeCount":99},[],{"intervention":19981,"totalTrials":335,"cells":19982},"Preladenant",{"EARLY_PHASE1":19983,"PHASE1":19985,"PHASE2":20009,"PHASE3":20062,"PHASE4":20085,"NA":20087},{"trials":19984,"activeCount":99},[],{"trials":19986,"activeCount":99},[19987,19991,20000],{"nctId":329,"briefTitle":330,"status":150,"phases":19988,"primaryCompletion":332,"completion":333,"start":334,"enrollment":335,"conditions":19989,"interventions":19990},[87],[337],[339,42],{"nctId":19992,"briefTitle":19993,"status":105,"phases":19994,"primaryCompletion":19995,"completion":19995,"start":19996,"enrollment":212,"conditions":19997,"interventions":19999},"NCT01323855","A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)",[87],"2011-11-29","2011-03-28",[19998],"Parkinson Disease",[19981],{"nctId":20001,"briefTitle":20002,"status":105,"phases":20003,"primaryCompletion":20004,"completion":20004,"start":20005,"enrollment":184,"conditions":20006,"interventions":20008},"NCT01465412","A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)",[87],"2012-06-14","2011-11-10",[20007],"Chronic Hepatic Impairment",[19981],{"trials":20010,"activeCount":99},[20011,20025,20037,20044,20052],{"nctId":20012,"briefTitle":20013,"status":105,"phases":20014,"primaryCompletion":20015,"completion":14033,"start":20016,"enrollment":15416,"conditions":20017,"interventions":20022},"NCT00406029","Dyskinesia in Parkinson's Disease (Study P04501)",[88],"2008-10-05","2006-11-20",[19998,20018,20019,20020,20021],"Movement Disorders","Central Nervous System Diseases","Neurodegenerative Diseases","Brain Diseases",[19981,19981,19981,19981,20023,20024],"L-dopa","Other Parkinson's Disease treatments",{"nctId":20026,"briefTitle":20027,"status":150,"phases":20028,"primaryCompletion":14393,"completion":20029,"start":20030,"enrollment":212,"conditions":20031,"interventions":20034},"NCT00693472","Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)",[88],"2009-01-09","2007-08-15",[20032,20033,20018],"Akathisia, Drug-Induced","Antipsychotic Agents",[19981,20035,20036],"Anticholinergic agents or propanolol","Haloperidol",{"nctId":20038,"briefTitle":20039,"status":105,"phases":20040,"primaryCompletion":15712,"completion":15712,"start":20041,"enrollment":407,"conditions":20042,"interventions":20043},"NCT00537017","Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)",[88],"2007-11-23",[19998,20020,20019,20018,20021],[19981,20023,20024],{"nctId":20045,"briefTitle":20046,"status":105,"phases":20047,"primaryCompletion":20048,"completion":20048,"start":20049,"enrollment":951,"conditions":20050,"interventions":20051},"NCT01294800","A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)",[88],"2013-06-01","2011-02-25",[14605],[19981],{"nctId":20053,"briefTitle":20054,"status":150,"phases":20055,"primaryCompletion":20056,"completion":20056,"start":20057,"enrollment":5983,"conditions":20058,"interventions":20061},"NCT00686699","Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)",[88],"2008-03-06","2006-07-10",[20032,20059,20060],"Dyskinesia, Drug-Induced","Parkinsonian Disorders",[19981],{"trials":20063,"activeCount":99},[20064,20076],{"nctId":20065,"briefTitle":20066,"status":105,"phases":20067,"primaryCompletion":20068,"completion":20069,"start":20070,"enrollment":20071,"conditions":20072,"interventions":20075},"NCT01227265","Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)",[89],"2013-04-04","2013-04-16","2010-11-19",476,[19998,20073,20074],"Idiopathic Parkinson Disease","Idiopathic Parkinson's Disease",[19981],{"nctId":20077,"briefTitle":20078,"status":150,"phases":20079,"primaryCompletion":20080,"completion":20080,"start":152,"enrollment":20081,"conditions":20082,"interventions":20083},"NCT01215227","An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)",[89],"2013-07-16",839,[19998,20073],[19981,20084],"Rasagiline",{"trials":20086,"activeCount":99},[],{"trials":20088,"activeCount":99},[],{"intervention":13985,"totalTrials":335,"cells":20090},{"EARLY_PHASE1":20091,"PHASE1":20093,"PHASE2":20112,"PHASE3":20118,"PHASE4":20157,"NA":20159},{"trials":20092,"activeCount":99},[],{"trials":20094,"activeCount":99},[20095,20103],{"nctId":20096,"briefTitle":20097,"status":105,"phases":20098,"primaryCompletion":13222,"completion":13222,"start":14494,"enrollment":3903,"conditions":20099,"interventions":20101},"NCT01115712","Effects of Pioglitazone on Insulin Sensitivity in Healthy Overweight and Obese Males (MK-0000-170)",[87],[18,20100,15158],"Overweight",[14234,20102],"Comparator: Hyperinsulinemic Euglycemic Clamp",{"nctId":20104,"briefTitle":20105,"status":105,"phases":20106,"primaryCompletion":20107,"completion":20107,"start":20108,"enrollment":1340,"conditions":20109,"interventions":20110},"NCT00511108","Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)",[87],"2009-02-24","2007-07-11",[14277],[14588,13985,13983,20111],"Comparator: placebo to sitagliptin",{"trials":20113,"activeCount":99},[20114],{"nctId":14846,"briefTitle":14847,"status":150,"phases":20115,"primaryCompletion":5507,"completion":5507,"start":14705,"enrollment":14849,"conditions":20116,"interventions":20117},[88],[14851],[14853,13864,13985],{"trials":20119,"activeCount":99},[20120,20124,20128,20136,20140,20149,20153],{"nctId":15140,"briefTitle":15141,"status":105,"phases":20121,"primaryCompletion":15143,"completion":15144,"start":15145,"enrollment":15146,"conditions":20122,"interventions":20123},[89],[33],[15149,15150,14331,13985],{"nctId":13973,"briefTitle":13974,"status":105,"phases":20125,"primaryCompletion":13976,"completion":13977,"start":13978,"enrollment":13979,"conditions":20126,"interventions":20127},[89],[15],[13982,13983,13984,13985,13986,4084,13987],{"nctId":20129,"briefTitle":20130,"status":105,"phases":20131,"primaryCompletion":20132,"completion":20133,"start":17413,"enrollment":2118,"conditions":20134,"interventions":20135},"NCT00541450","A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)",[89],"2010-01-08","2010-01-16",[15],[14588,14039,13985],{"nctId":15207,"briefTitle":15208,"status":105,"phases":20137,"primaryCompletion":14705,"completion":15210,"start":15211,"enrollment":11128,"conditions":20138,"interventions":20139},[89],[33],[14233,13864,14234],{"nctId":20141,"briefTitle":20142,"status":105,"phases":20143,"primaryCompletion":20144,"completion":20144,"start":20145,"enrollment":20146,"conditions":20147,"interventions":20148},"NCT00532935","MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)",[89],"2009-10-23","2008-01-26",517,[15],[14039,13985],{"nctId":15262,"briefTitle":15263,"status":105,"phases":20150,"primaryCompletion":15265,"completion":15265,"start":15266,"enrollment":15267,"conditions":20151,"interventions":20152},[89],[15],[14487,14588,13985,14331],{"nctId":14225,"briefTitle":14226,"status":105,"phases":20154,"primaryCompletion":14228,"completion":14228,"start":14229,"enrollment":14230,"conditions":20155,"interventions":20156},[89],[33],[14233,13864,14234,4084],{"trials":20158,"activeCount":99},[],{"trials":20160,"activeCount":99},[],{"intervention":14881,"totalTrials":335,"cells":20162},{"EARLY_PHASE1":20163,"PHASE1":20165,"PHASE2":20167,"PHASE3":20181,"PHASE4":20236,"NA":20238},{"trials":20164,"activeCount":99},[],{"trials":20166,"activeCount":99},[],{"trials":20168,"activeCount":99},[20169,20177],{"nctId":20170,"briefTitle":20171,"status":150,"phases":20172,"primaryCompletion":20173,"completion":20173,"start":20174,"enrollment":7696,"conditions":20175,"interventions":20176},"NCT00543556","MK0767 in Type 2 Diabetes (0767-012)",[88],"2003-11","2001-10",[15],[14881],{"nctId":14872,"briefTitle":14873,"status":150,"phases":20178,"primaryCompletion":14875,"completion":14875,"start":14876,"enrollment":14877,"conditions":20179,"interventions":20180},[88],[14879],[14881,14882,13864],{"trials":20182,"activeCount":99},[20183,20187,20193,20201,20209,20215,20222,20229],{"nctId":15115,"briefTitle":15116,"status":150,"phases":20184,"primaryCompletion":14875,"completion":14875,"start":15118,"enrollment":15119,"conditions":20185,"interventions":20186},[89],[33],[14881,14331,14488],{"nctId":20188,"briefTitle":20189,"status":150,"phases":20190,"primaryCompletion":14875,"completion":14875,"start":15118,"enrollment":11541,"conditions":20191,"interventions":20192},"NCT00543491","MK0767 and Sulfonylurea Combination Study (0767-027)",[89],[33],[14881],{"nctId":20194,"briefTitle":20195,"status":150,"phases":20196,"primaryCompletion":20173,"completion":20173,"start":20197,"enrollment":20198,"conditions":20199,"interventions":20200},"NCT00543751","Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes (0767-025)",[89],"2003-01",610,[33],[14881],{"nctId":20202,"briefTitle":20203,"status":150,"phases":20204,"primaryCompletion":20173,"completion":20173,"start":20205,"enrollment":20206,"conditions":20207,"interventions":20208},"NCT00543010","MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)",[89],"2002-11",247,[33],[14881],{"nctId":20210,"briefTitle":20211,"status":150,"phases":20212,"primaryCompletion":20173,"completion":20173,"start":14772,"enrollment":4358,"conditions":20213,"interventions":20214},"NCT00543517","Study A - MK0767 Monotherapy Study",[89],[33],[14881],{"nctId":20216,"briefTitle":20217,"status":150,"phases":20218,"primaryCompletion":20173,"completion":20173,"start":20219,"enrollment":920,"conditions":20220,"interventions":20221},"NCT00543816","MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)",[89],"2003-08",[33],[14881],{"nctId":20223,"briefTitle":20224,"status":150,"phases":20225,"primaryCompletion":20173,"completion":20173,"start":20226,"enrollment":417,"conditions":20227,"interventions":20228},"NCT00547274","Dyslipidemia in Type 2 Diabetes (0767-034)",[89],"2003-07",[14097,14337],[14881],{"nctId":20230,"briefTitle":20231,"status":150,"phases":20232,"primaryCompletion":14875,"completion":14875,"start":14567,"enrollment":20233,"conditions":20234,"interventions":20235},"NCT00543738","MK0767 and Metformin Combination Study (0767-028)",[89],114,[13950],[14881],{"trials":20237,"activeCount":99},[],{"trials":20239,"activeCount":99},[],{"intervention":14970,"totalTrials":335,"cells":20241},{"EARLY_PHASE1":20242,"PHASE1":20244,"PHASE2":20267,"PHASE3":20273,"PHASE4":20324,"NA":20326},{"trials":20243,"activeCount":99},[],{"trials":20245,"activeCount":99},[20246,20254,20261],{"nctId":20247,"briefTitle":20248,"status":105,"phases":20249,"primaryCompletion":5800,"completion":7018,"start":8591,"enrollment":212,"conditions":20250,"interventions":20251},"NCT00990808","The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)",[87],[14337],[14970,14971,20252,20253],"Comparator: placebo to MK0859","Comparator: placebo to atorvastatin",{"nctId":20255,"briefTitle":20256,"status":105,"phases":20257,"primaryCompletion":20258,"completion":20258,"start":14494,"enrollment":120,"conditions":20259,"interventions":20260},"NCT01114490","Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)",[87],"2010-07",[14337],[14970],{"nctId":20262,"briefTitle":20263,"status":105,"phases":20264,"primaryCompletion":5800,"completion":5800,"start":12813,"enrollment":120,"conditions":20265,"interventions":20266},"NCT01122667","Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)",[87],[14337],[14970],{"trials":20268,"activeCount":99},[20269],{"nctId":14965,"briefTitle":14966,"status":105,"phases":20270,"primaryCompletion":13224,"completion":7017,"start":14445,"enrollment":963,"conditions":20271,"interventions":20272},[88],[14337],[14970,14971,13864],{"trials":20274,"activeCount":99},[20275,20283,20294,20301,20311,20315],{"nctId":20276,"briefTitle":20277,"status":105,"phases":20278,"primaryCompletion":15912,"completion":15912,"start":20279,"enrollment":14325,"conditions":20280,"interventions":20281},"NCT01824238","A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)",[89],"2013-05",[8103],[20282],"Anacetrapib",{"nctId":20284,"briefTitle":20285,"status":105,"phases":20286,"primaryCompletion":20287,"completion":20288,"start":20289,"enrollment":20290,"conditions":20291,"interventions":20293},"NCT01524289","Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)",[89],"2014-02-12","2018-11-13","2012-02-03",306,[20292,15546],"Hyperlipoproteinemia Type II",[20282],{"nctId":20295,"briefTitle":20296,"status":105,"phases":20297,"primaryCompletion":20298,"completion":20298,"start":16279,"enrollment":1747,"conditions":20299,"interventions":20300},"NCT01760460","A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)",[89],"2015-03-04",[14337],[20282],{"nctId":20302,"briefTitle":20303,"status":105,"phases":20304,"primaryCompletion":20305,"completion":20306,"start":20307,"enrollment":20308,"conditions":20309,"interventions":20310},"NCT01860729","A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)",[89],"2015-05-29","2015-08-20","2013-05-13",589,[7598],[20282],{"nctId":15423,"briefTitle":15424,"status":105,"phases":20312,"primaryCompletion":15426,"completion":15427,"start":15428,"enrollment":15429,"conditions":20313,"interventions":20314},[89],[15431,15432],[14970,14331],{"nctId":20316,"briefTitle":20317,"status":150,"phases":20318,"primaryCompletion":20319,"completion":20319,"start":20320,"enrollment":3197,"conditions":20321,"interventions":20323},"NCT01841684","Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)",[89],"2014-06","2013-06",[20292,20322],"Homozygous Familial Hypercholesterolemia",[20282],{"trials":20325,"activeCount":99},[],{"trials":20327,"activeCount":99},[],{"intervention":13883,"totalTrials":335,"cells":20329},{"EARLY_PHASE1":20330,"PHASE1":20332,"PHASE2":20334,"PHASE3":20350,"PHASE4":20396,"NA":20398},{"trials":20331,"activeCount":99},[],{"trials":20333,"activeCount":99},[],{"trials":20335,"activeCount":99},[20336,20340],{"nctId":13875,"briefTitle":13876,"status":105,"phases":20337,"primaryCompletion":13878,"completion":13878,"start":9143,"enrollment":13879,"conditions":20338,"interventions":20339},[88],[33],[13882,13883,13884,13885,4084],{"nctId":20341,"briefTitle":20342,"status":105,"phases":20343,"primaryCompletion":20344,"completion":20049,"start":20345,"enrollment":20346,"conditions":20347,"interventions":20348},"NCT01096667","Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)",[88],"2011-02-09","2010-05-17",194,[33,30],[13882,13883,13884,20349],"HCTZ 12.5mg",{"trials":20351,"activeCount":99},[20352,20356,20360,20369,20373,20384,20388,20392],{"nctId":14042,"briefTitle":14043,"status":105,"phases":20353,"primaryCompletion":719,"completion":719,"start":14045,"enrollment":14046,"conditions":20354,"interventions":20355},[89],[15],[13883,14049,4084,13146],{"nctId":14051,"briefTitle":14052,"status":105,"phases":20357,"primaryCompletion":14054,"completion":14054,"start":14055,"enrollment":14056,"conditions":20358,"interventions":20359},[89],[15],[13883,14049,4084,13145,13146,14059],{"nctId":20361,"briefTitle":20362,"status":105,"phases":20363,"primaryCompletion":20364,"completion":20364,"start":20365,"enrollment":20366,"conditions":20367,"interventions":20368},"NCT01986855","A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)",[89],"2016-09-28","2013-12-02",468,[15],[13883,14147],{"nctId":14140,"briefTitle":14141,"status":105,"phases":20370,"primaryCompletion":13925,"completion":13925,"start":14143,"enrollment":14144,"conditions":20371,"interventions":20372},[89],[15],[13883,14147,14148,4084,13145],{"nctId":20374,"briefTitle":20375,"status":105,"phases":20376,"primaryCompletion":2694,"completion":2694,"start":20377,"enrollment":20378,"conditions":20379,"interventions":20380},"NCT02099110","Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)",[89],"2014-04-22",1233,[15],[13883,14147,13885,20381,20382,20383],"Metformin >= 1500 mg\u002Fday","Insulin Glargine Rescue Medication","Glimepiride Rescue Medication",{"nctId":14172,"briefTitle":14173,"status":105,"phases":20385,"primaryCompletion":14175,"completion":14175,"start":14176,"enrollment":14177,"conditions":20386,"interventions":20387},[89],[15],[13883,14049,14180,4084],{"nctId":14218,"briefTitle":14219,"status":105,"phases":20389,"primaryCompletion":4344,"completion":4344,"start":14221,"enrollment":13142,"conditions":20390,"interventions":20391},[89],[15],[13883,14049,14059,4084],{"nctId":14259,"briefTitle":14260,"status":105,"phases":20393,"primaryCompletion":14262,"completion":14262,"start":14263,"enrollment":14264,"conditions":20394,"interventions":20395},[89],[15],[13883,14147,4084,13146],{"trials":20397,"activeCount":99},[],{"trials":20399,"activeCount":99},[],{"intervention":11447,"totalTrials":3308,"cells":20401},{"EARLY_PHASE1":20402,"PHASE1":20404,"PHASE2":20416,"PHASE3":20467,"PHASE4":20473,"NA":20475},{"trials":20403,"activeCount":99},[],{"trials":20405,"activeCount":99},[20406],{"nctId":20407,"briefTitle":20408,"status":105,"phases":20409,"primaryCompletion":20410,"completion":20410,"start":20411,"enrollment":120,"conditions":20412,"interventions":20414},"NCT01813552","To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)",[87],"2013-03","2013-02",[20413],"Chronic Hepatitis C Infection",[20415,13241,11447],"Samatasvir",{"trials":20417,"activeCount":99},[20418,20427,20438,20445,20451,20455,20461],{"nctId":20419,"briefTitle":20420,"status":105,"phases":20421,"primaryCompletion":14713,"completion":13222,"start":14823,"enrollment":417,"conditions":20422,"interventions":20423},"NCT00797745","A Pharmacokinetics\u002FPharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)",[88],[21],[20424,15820,20425,20426],"peginterferon alfa 2b","SCH 900518","ritonavir",{"nctId":20428,"briefTitle":20429,"status":105,"phases":20430,"primaryCompletion":20431,"completion":20431,"start":20410,"enrollment":5196,"conditions":20432,"interventions":20434},"NCT01852604","Samatasvir (IDX719) in Combinations With Simeprevir and\u002For TMC647055\u002FRitonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)",[88],"2015-04",[20433],"Chronic Hepatitis C Virus",[20415,20435,14925,20436,11447,20437],"Simeprevir","TMC647055","Pegylated interferon",{"nctId":20439,"briefTitle":20440,"status":20441,"phases":20442,"enrollment":734,"conditions":20443,"interventions":20444},"NCT00002451","Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs","UNKNOWN",[88],[27],[17754,11447,11421,17755],{"nctId":20446,"briefTitle":20447,"status":20441,"phases":20448,"enrollment":920,"conditions":20449,"interventions":20450},"NCT00005118","The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment",[88],[27],[17754,11447],{"nctId":17570,"briefTitle":17571,"status":150,"phases":20452,"primaryCompletion":17573,"completion":17573,"start":17574,"enrollment":5983,"conditions":20453,"interventions":20454},[88],[27],[17577,17578,11421,17561,17579,17580,11447,17581,11446],{"nctId":20456,"briefTitle":20457,"status":105,"phases":20458,"enrollment":154,"conditions":20459,"interventions":20460},"NCT00002361","Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors",[88],[27],[17754,11447],{"nctId":20462,"briefTitle":20463,"status":20441,"phases":20464,"enrollment":1479,"conditions":20465,"interventions":20466},"NCT00002241","Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily",[88],[27],[17754,11447,11421,17755],{"trials":20468,"activeCount":99},[20469],{"nctId":11437,"briefTitle":11438,"status":105,"phases":20470,"primaryCompletion":11440,"completion":11441,"start":5477,"enrollment":11442,"conditions":20471,"interventions":20472},[89],[11444],[11357,11446,11447,11448],{"trials":20474,"activeCount":99},[],{"trials":20476,"activeCount":99},[],{"intervention":20478,"totalTrials":3308,"cells":20479},"caspofungin acetate",{"EARLY_PHASE1":20480,"PHASE1":20482,"PHASE2":20484,"PHASE3":20522,"PHASE4":20550,"NA":20552},{"trials":20481,"activeCount":99},[],{"trials":20483,"activeCount":99},[],{"trials":20485,"activeCount":99},[20486,20493,20500,20508,20516],{"nctId":20487,"briefTitle":20488,"status":105,"phases":20489,"primaryCompletion":8619,"completion":8619,"start":8621,"enrollment":3655,"conditions":20490,"interventions":20492},"NCT00330395","Open, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058)",[88],[20491],"Candidiasis",[20478],{"nctId":20494,"briefTitle":20495,"status":105,"phases":20496,"primaryCompletion":13891,"completion":13891,"start":4420,"enrollment":4421,"conditions":20497,"interventions":20499},"NCT00082524","Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)",[88],[20498,20491],"Aspergillosis",[20478],{"nctId":20501,"briefTitle":20502,"status":105,"phases":20503,"primaryCompletion":8619,"completion":8619,"start":4420,"enrollment":920,"conditions":20504,"interventions":20506},"NCT00082537","MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)",[88],[20505,15597],"Neutropenia",[20478,20507],"Comparator: AmBisome",{"nctId":20509,"briefTitle":20510,"status":150,"phases":20511,"primaryCompletion":16794,"completion":16794,"start":15794,"enrollment":2901,"conditions":20512,"interventions":20514},"NCT01045798","Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)",[88],[20513],"Invasive Candidiasis",[20515],"Caspofungin acetate",{"nctId":20517,"briefTitle":20518,"status":105,"phases":20519,"primaryCompletion":14531,"completion":14531,"start":14495,"enrollment":3655,"conditions":20520,"interventions":20521},"NCT00292071","Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)",[88],[17830],[20478],{"trials":20523,"activeCount":99},[20524,20531,20537,20544],{"nctId":20525,"briefTitle":20526,"status":105,"phases":20527,"primaryCompletion":14687,"completion":8620,"start":14484,"enrollment":20528,"conditions":20529,"interventions":20530},"NCT00250432","A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)",[89],204,[20513],[20478],{"nctId":20532,"briefTitle":20533,"status":105,"phases":20534,"primaryCompletion":8621,"completion":8621,"start":14594,"enrollment":4421,"conditions":20535,"interventions":20536},"NCT00379964","A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED)",[89],[17830],[20478],{"nctId":20538,"briefTitle":20539,"status":105,"phases":20540,"primaryCompletion":20258,"completion":20258,"start":13102,"enrollment":1601,"conditions":20541,"interventions":20542},"NCT00717860","A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)",[89],[17830],[20478,20543],"Comparator: Micafungin sodium",{"nctId":20545,"briefTitle":20546,"status":105,"phases":20547,"primaryCompletion":5981,"completion":5981,"start":14687,"enrollment":18999,"conditions":20548,"interventions":20549},"NCT00635648","A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)",[89],[17830],[20478],{"trials":20551,"activeCount":99},[],{"trials":20553,"activeCount":99},[],{"intervention":14449,"totalTrials":734,"cells":20555},{"EARLY_PHASE1":20556,"PHASE1":20558,"PHASE2":20564,"PHASE3":20566,"PHASE4":20617,"NA":20619},{"trials":20557,"activeCount":99},[],{"trials":20559,"activeCount":99},[20560],{"nctId":14442,"briefTitle":14443,"status":105,"phases":20561,"primaryCompletion":13224,"completion":13224,"start":14445,"enrollment":4305,"conditions":20562,"interventions":20563},[87],[14447],[14449,13864,14449,13864],{"trials":20565,"activeCount":99},[],{"trials":20567,"activeCount":99},[20568,20579,20586,20593,20597,20604,20613],{"nctId":20569,"briefTitle":20570,"status":1040,"phases":20571,"primaryCompletion":5982,"completion":13222,"start":13101,"enrollment":99,"conditions":20572,"interventions":20576},"NCT01003431","A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)",[89],[14447,20573,20574,20575],"Diphtheria","Tetanus","Pertussis",[14449,20577,20578],"Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB","Comparator: RotaTeq™ administered concomitantly with INFANRIX™",{"nctId":20580,"briefTitle":20581,"status":105,"phases":20582,"primaryCompletion":6309,"completion":6309,"start":13890,"enrollment":4474,"conditions":20583,"interventions":20585},"NCT00496054","Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)",[89],[20584,14625],"Gastroenteritis",[14449],{"nctId":20587,"briefTitle":20588,"status":105,"phases":20589,"primaryCompletion":14531,"completion":14531,"start":17095,"enrollment":6284,"conditions":20590,"interventions":20591},"NCT00130832","Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)",[89],[15587,20584],[14449,20592,20592],"Comparator: Oral Poliovirus Vaccine",{"nctId":15279,"briefTitle":15280,"status":105,"phases":20594,"primaryCompletion":14531,"completion":14531,"start":15063,"enrollment":494,"conditions":20595,"interventions":20596},[89],[14625],[14449,13864],{"nctId":20598,"briefTitle":20599,"status":105,"phases":20600,"primaryCompletion":18806,"completion":18806,"start":15118,"enrollment":2408,"conditions":20601,"interventions":20602},"NCT00092456","Consistency Lots Vaccine Study (V260-009)",[89],[15587],[20603],"rotavirus vaccine, live, oral, pentavalent",{"nctId":20605,"briefTitle":20606,"status":105,"phases":20607,"primaryCompletion":20608,"completion":20608,"start":13102,"enrollment":20609,"conditions":20610,"interventions":20611},"NCT00718237","Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)",[89],"2009-08",762,[14625,20584],[14449,20612],"Comparator: Comparator: Placebo",{"nctId":15549,"briefTitle":15550,"status":105,"phases":20614,"primaryCompletion":12814,"completion":12814,"start":6464,"enrollment":15552,"conditions":20615,"interventions":20616},[89],[15554],[14449,14331,15556],{"trials":20618,"activeCount":99},[],{"trials":20620,"activeCount":99},[],{"intervention":20622,"totalTrials":734,"cells":20623},"Esmirtazapine",{"EARLY_PHASE1":20624,"PHASE1":20626,"PHASE2":20628,"PHASE3":20630,"PHASE4":20709,"NA":20711},{"trials":20625,"activeCount":99},[],{"trials":20627,"activeCount":99},[],{"trials":20629,"activeCount":99},[],{"trials":20631,"activeCount":99},[20632,20641,20649,20661,20673,20685,20694,20701],{"nctId":20633,"briefTitle":20634,"status":105,"phases":20635,"primaryCompletion":20636,"completion":20636,"start":20637,"enrollment":20638,"conditions":20639,"interventions":20640},"NCT00482612","Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)",[89],"2008-08-11","2006-12-07",526,[9307],[20622],{"nctId":20642,"briefTitle":20643,"status":105,"phases":20644,"primaryCompletion":5170,"completion":5170,"start":20645,"enrollment":20646,"conditions":20647,"interventions":20648},"NCT00506389","A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)",[89],"2007-06-06",419,[9307],[20622],{"nctId":20650,"briefTitle":20651,"status":105,"phases":20652,"primaryCompletion":20653,"completion":20653,"start":20654,"enrollment":20655,"conditions":20656,"interventions":20660},"NCT00561821","Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)",[89],"2009-12-21","2007-11-20",538,[9307,9368,20657,20658,20659],"Mental Disorders","Dyssomnias","Sleep Disorders",[20622],{"nctId":20662,"briefTitle":20663,"status":105,"phases":20664,"primaryCompletion":20665,"completion":20665,"start":20666,"enrollment":20667,"conditions":20668,"interventions":20672},"NCT00561574","A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005\u002FP05697\u002FMK-8265-001)",[89],"2010-02-14","2008-01-09",259,[20669,20670,20658,20659,20671],"Sleep Initiation and Maintenance Disorder; Elderly","Mental Disorder","Sleep Disorder, Intrinsic",[20622],{"nctId":20674,"briefTitle":20675,"status":105,"phases":20676,"primaryCompletion":20677,"completion":20677,"start":20678,"enrollment":20679,"conditions":20680,"interventions":20683},"NCT00560833","Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101\u002FP06459\u002FMK-8265-012)",[89],"2006-01-15","2004-10-15",943,[20681,20682],"Menopause","Vasomotor Symptoms",[20684],"esmirtazapine",{"nctId":20686,"briefTitle":20687,"status":150,"phases":20688,"primaryCompletion":20689,"completion":20689,"start":20690,"enrollment":743,"conditions":20691,"interventions":20693},"NCT00750919","Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003\u002FP05721\u002FMK-8265-007)",[89],"2010-03-10","2008-10-07",[9368,20657,20658,20659,20692],"Sleep Disorders, Intrinsic",[20684],{"nctId":20695,"briefTitle":20696,"status":105,"phases":20697,"primaryCompletion":15712,"completion":15712,"start":20698,"enrollment":836,"conditions":20699,"interventions":20700},"NCT00631657","A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106\u002FP05701\u002FMK-8265-002)",[89],"2008-03-04",[9368,20657,20658,20659,20671],[20622],{"nctId":20702,"briefTitle":20703,"status":105,"phases":20704,"primaryCompletion":20677,"completion":20677,"start":20705,"enrollment":20706,"conditions":20707,"interventions":20708},"NCT00535288","Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001\u002FP06472\u002FMK-8265-013)",[89],"2004-09-15",946,[14355,20681,20682],[20622],{"trials":20710,"activeCount":99},[],{"trials":20712,"activeCount":99},[],{"intervention":20714,"totalTrials":734,"cells":20715},"Gefapixant",{"EARLY_PHASE1":20716,"PHASE1":20718,"PHASE2":20736,"PHASE3":20757,"PHASE4":20795,"NA":20797},{"trials":20717,"activeCount":99},[],{"trials":20719,"activeCount":99},[20720,20728],{"nctId":20721,"briefTitle":20722,"status":105,"phases":20723,"primaryCompletion":20724,"completion":20725,"start":19460,"enrollment":120,"conditions":20726,"interventions":20727},"NCT03108924","The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)",[87],"2017-09-03","2017-09-13",[13409],[20714],{"nctId":20729,"briefTitle":20730,"status":105,"phases":20731,"primaryCompletion":2296,"completion":2296,"start":20732,"enrollment":120,"conditions":20733,"interventions":20735},"NCT03882801","Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)",[87],"2019-04-10",[20734],"Obstructive Sleep Apnea (OSA)",[20714],{"trials":20737,"activeCount":99},[20738,20748],{"nctId":20739,"briefTitle":20740,"status":105,"phases":20741,"primaryCompletion":635,"completion":635,"start":20742,"enrollment":20743,"conditions":20744,"interventions":20746},"NCT03654326","A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034)",[88],"2018-09-11",187,[20745],"Endometriosis-related Pain",[20714,20747],"Naproxen",{"nctId":20749,"briefTitle":20750,"status":150,"phases":20751,"primaryCompletion":20752,"completion":9214,"start":20753,"enrollment":212,"conditions":20754,"interventions":20756},"NCT03569033","Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)",[88],"2018-10-31","2018-07-04",[20755],"Acute Cough",[20714],{"trials":20758,"activeCount":99},[20759,20769,20777,20786],{"nctId":20760,"briefTitle":20761,"status":105,"phases":20762,"primaryCompletion":1296,"completion":20763,"start":20764,"enrollment":20765,"conditions":20766,"interventions":20768},"NCT03449134","A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)",[89],"2020-08-17","2018-03-14",732,[20767],"Chronic Cough",[20714],{"nctId":20770,"briefTitle":20771,"status":105,"phases":20772,"primaryCompletion":20773,"completion":20773,"start":20752,"enrollment":20774,"conditions":20775,"interventions":20776},"NCT03696108","A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)",[89],"2020-10-07",175,[20767],[20714],{"nctId":20778,"briefTitle":20779,"status":105,"phases":20780,"primaryCompletion":20781,"completion":20782,"start":20783,"enrollment":1532,"conditions":20784,"interventions":20785},"NCT04193176","Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)",[89],"2022-08-18","2022-09-02","2020-05-10",[20767],[20714],{"nctId":20787,"briefTitle":20788,"status":105,"phases":20789,"primaryCompletion":20790,"completion":20791,"start":20792,"enrollment":20646,"conditions":20793,"interventions":20794},"NCT04193202","Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043)",[89],"2021-10-19","2021-11-03","2020-05-21",[20767],[20714],{"trials":20796,"activeCount":99},[],{"trials":20798,"activeCount":99},[],{"intervention":17026,"totalTrials":734,"cells":20800},{"EARLY_PHASE1":20801,"PHASE1":20803,"PHASE2":20805,"PHASE3":20807,"PHASE4":20872,"NA":20874},{"trials":20802,"activeCount":99},[],{"trials":20804,"activeCount":99},[],{"trials":20806,"activeCount":99},[],{"trials":20808,"activeCount":99},[20809,20815,20826,20837,20846,20854,20862,20866],{"nctId":20810,"briefTitle":20811,"status":105,"phases":20812,"primaryCompletion":13222,"completion":13222,"start":14623,"enrollment":5700,"conditions":20813,"interventions":20814},"NCT00825812","Comparison of 2.0 mg\u002Fkg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED)",[89],[17011,16696],[17013,17026],{"nctId":20816,"briefTitle":20817,"status":105,"phases":20818,"primaryCompletion":20819,"completion":20820,"start":20821,"enrollment":407,"conditions":20822,"interventions":20823},"NCT00724932","Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699)",[89],"2009-04-01","2009-05-03","2008-07-16",[17011],[16687,17013,20824,20825],"Neostigmine","Atropine",{"nctId":20827,"briefTitle":20828,"status":105,"phases":20829,"primaryCompletion":20830,"completion":20831,"start":20832,"enrollment":4121,"conditions":20833,"interventions":20835},"NCT01479764","Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)",[89],"2012-10-26","2012-11-05","2011-12-02",[20834],"Surgical Procedures, Elective",[17013,20824,20836],"Glycopyrrolate",{"nctId":20838,"briefTitle":20839,"status":105,"phases":20840,"primaryCompletion":20841,"completion":20842,"start":20843,"enrollment":11407,"conditions":20844,"interventions":20845},"NCT00451100","Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)",[89],"2006-05-22","2006-08-29","2005-11-10",[17011],[17013,17026],{"nctId":20847,"briefTitle":20848,"status":105,"phases":20849,"primaryCompletion":20850,"completion":20850,"start":20851,"enrollment":1023,"conditions":20852,"interventions":20853},"NCT01050543","Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101)",[89],"2010-08-20","2010-02-01",[16696],[17025,17026],{"nctId":20855,"briefTitle":20856,"status":105,"phases":20857,"primaryCompletion":20858,"completion":20858,"start":20859,"enrollment":16728,"conditions":20860,"interventions":20861},"NCT00451217","Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)",[89],"2006-03-06","2005-11-17",[17011],[17013,20824],{"nctId":17017,"briefTitle":17018,"status":105,"phases":20863,"primaryCompletion":17020,"completion":17021,"start":17022,"enrollment":537,"conditions":20864,"interventions":20865},[89],[17011],[17025,17026,17027,17028,17029],{"nctId":20867,"briefTitle":20868,"status":105,"phases":20869,"primaryCompletion":14315,"completion":14315,"start":13890,"enrollment":920,"conditions":20870,"interventions":20871},"NCT00675792","Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)",[89],[16668],[17013,20824,16687],{"trials":20873,"activeCount":99},[],{"trials":20875,"activeCount":99},[],{"intervention":16014,"totalTrials":357,"cells":20877},{"EARLY_PHASE1":20878,"PHASE1":20880,"PHASE2":20919,"PHASE3":20921,"PHASE4":20936,"NA":20938},{"trials":20879,"activeCount":99},[],{"trials":20881,"activeCount":99},[20882,20890,20896,20905,20911],{"nctId":20883,"briefTitle":20884,"status":105,"phases":20885,"primaryCompletion":20886,"completion":20886,"start":20887,"enrollment":120,"conditions":20888,"interventions":20889},"NCT00989079","A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)",[87],"2009-12-11","2009-10-16",[15],[16014],{"nctId":20891,"briefTitle":20892,"status":105,"phases":20893,"primaryCompletion":20258,"completion":20258,"start":12813,"enrollment":4555,"conditions":20894,"interventions":20895},"NCT01127308","A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)",[87],[14277],[16014],{"nctId":20897,"briefTitle":20898,"status":105,"phases":20899,"primaryCompletion":20900,"completion":20900,"start":20901,"enrollment":3390,"conditions":20902,"interventions":20904},"NCT01018823","A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)",[87],"2010-03-18","2009-12-14",[20903],"Healthy Volunteer",[16014],{"nctId":20906,"briefTitle":20907,"status":105,"phases":20908,"primaryCompletion":14566,"completion":14566,"start":5179,"enrollment":120,"conditions":20909,"interventions":20910},"NCT01223339","Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)",[87],[33],[16014,16014],{"nctId":20912,"briefTitle":20913,"status":105,"phases":20914,"primaryCompletion":20915,"completion":20916,"start":19810,"enrollment":8016,"conditions":20917,"interventions":20918},"NCT01948986","Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)",[87],"2014-10-06","2014-10-16",[4074,15],[16014],{"trials":20920,"activeCount":99},[],{"trials":20922,"activeCount":99},[20923,20927],{"nctId":16006,"briefTitle":16007,"status":105,"phases":20924,"primaryCompletion":16009,"completion":16009,"start":16010,"enrollment":16011,"conditions":20925,"interventions":20926},[89],[15],[16014,13145,13146],{"nctId":20928,"briefTitle":20929,"status":105,"phases":20930,"primaryCompletion":13071,"completion":13071,"start":20931,"enrollment":20932,"conditions":20933,"interventions":20934},"NCT01986881","Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)",[89],"2013-11-04",8246,[15],[16014,20935],"Glycemic Rescue",{"trials":20937,"activeCount":99},[],{"trials":20939,"activeCount":99},[],{"intervention":19138,"totalTrials":357,"cells":20941},{"EARLY_PHASE1":20942,"PHASE1":20944,"PHASE2":20950,"PHASE3":20956,"PHASE4":20978,"NA":20980},{"trials":20943,"activeCount":99},[],{"trials":20945,"activeCount":99},[20946],{"nctId":19885,"briefTitle":19886,"status":105,"phases":20947,"primaryCompletion":19888,"completion":19888,"start":19889,"enrollment":892,"conditions":20948,"interventions":20949},[87],[13187],[13203,19138],{"trials":20951,"activeCount":99},[20952],{"nctId":19895,"briefTitle":19896,"status":105,"phases":20953,"primaryCompletion":19898,"completion":19898,"start":19899,"enrollment":1818,"conditions":20954,"interventions":20955},[87,88],[19146],[13203,19902],{"trials":20957,"activeCount":99},[20958,20962,20966,20970,20974],{"nctId":19131,"briefTitle":19132,"status":105,"phases":20959,"primaryCompletion":19134,"completion":19134,"start":2487,"enrollment":19135,"conditions":20960,"interventions":20961},[89],[16472],[16474,16465,19138],{"nctId":19149,"briefTitle":19150,"status":105,"phases":20963,"primaryCompletion":1620,"completion":1620,"start":2148,"enrollment":19152,"conditions":20964,"interventions":20965},[89],[16472],[16474,16465,19138],{"nctId":19156,"briefTitle":19157,"status":105,"phases":20967,"primaryCompletion":19159,"completion":19160,"start":19161,"enrollment":1272,"conditions":20968,"interventions":20969},[89],[16472],[16474,16465,19138],{"nctId":19231,"briefTitle":19232,"status":105,"phases":20971,"primaryCompletion":19234,"completion":19234,"start":19235,"enrollment":19236,"conditions":20972,"interventions":20973},[89],[16472],[16474,16465,19138],{"nctId":19252,"briefTitle":19253,"status":105,"phases":20975,"primaryCompletion":19255,"completion":19255,"start":19256,"enrollment":19257,"conditions":20976,"interventions":20977},[89],[16472],[16474,16465,19138],{"trials":20979,"activeCount":99},[],{"trials":20981,"activeCount":99},[],{"intervention":14923,"totalTrials":357,"cells":20983},{"EARLY_PHASE1":20984,"PHASE1":20986,"PHASE2":20995,"PHASE3":21020,"PHASE4":21047,"NA":21049},{"trials":20985,"activeCount":99},[],{"trials":20987,"activeCount":99},[20988],{"nctId":20989,"briefTitle":20990,"status":150,"phases":20991,"primaryCompletion":579,"completion":579,"start":20992,"enrollment":202,"conditions":20993,"interventions":20994},"NCT00954993","Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029)",[87],"2010-01-13",[20413],[14923],{"trials":20996,"activeCount":99},[20997,21005,21009],{"nctId":20998,"briefTitle":20999,"status":105,"phases":21000,"primaryCompletion":21001,"completion":14004,"start":21002,"enrollment":9366,"conditions":21003,"interventions":21004},"NCT00704405","Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)",[88],"2012-03-26","2009-03-27",[21],[14923,14924,14925],{"nctId":14917,"briefTitle":14918,"status":105,"phases":21006,"primaryCompletion":13978,"completion":14113,"start":14920,"enrollment":397,"conditions":21007,"interventions":21008},[88],[24],[14923,14924,14925,13864],{"nctId":21010,"briefTitle":21011,"status":1040,"phases":21012,"primaryCompletion":19020,"completion":19020,"start":16592,"enrollment":99,"conditions":21013,"interventions":21015},"NCT00895882","Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)",[88],[21014],"Chronic Genotype 1 Hepatitis C Virus Infection",[21016,21017,21018,14946,21019],"vaniprevir","Comparator: vaniprevir","Comparator: Pegylated Interferon (peg-IFN) alfa-2a","Comparator: Placebo to vaniprevir",{"trials":21021,"activeCount":99},[21022,21030,21039],{"nctId":21023,"briefTitle":21024,"status":105,"phases":21025,"primaryCompletion":21026,"completion":1095,"start":15835,"enrollment":19628,"conditions":21027,"interventions":21028},"NCT01370642","Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)",[89],"2013-07-31",[21],[21016,21029,15820],"Peg-IFN",{"nctId":21031,"briefTitle":21032,"status":105,"phases":21033,"primaryCompletion":21034,"completion":21034,"start":21035,"enrollment":184,"conditions":21036,"interventions":21037},"NCT01405560","Vaniprevir Plus PegIntron®\u002FRibavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)",[89],"2013-03-29","2011-09-02",[21],[14923,21038,15820],"peg-IFN",{"nctId":21040,"briefTitle":21041,"status":105,"phases":21042,"primaryCompletion":21043,"completion":14112,"start":21044,"enrollment":13805,"conditions":21045,"interventions":21046},"NCT01405937","Study of Vaniprevir Plus PegIntron®\u002FRibavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)",[89],"2013-02-26","2011-08-29",[21],[21016,21038,15820],{"trials":21048,"activeCount":99},[],{"trials":21050,"activeCount":99},[],{"intervention":19914,"totalTrials":357,"cells":21052},{"EARLY_PHASE1":21053,"PHASE1":21055,"PHASE2":21057,"PHASE3":21059,"PHASE4":21089,"NA":21091},{"trials":21054,"activeCount":99},[],{"trials":21056,"activeCount":99},[],{"trials":21058,"activeCount":99},[],{"trials":21060,"activeCount":99},[21061,21065,21069,21073,21077,21081,21085],{"nctId":19906,"briefTitle":19907,"status":105,"phases":21062,"primaryCompletion":19909,"completion":19910,"start":13199,"enrollment":13958,"conditions":21063,"interventions":21064},[89],[17064],[13203,19913,19914,19915],{"nctId":19917,"briefTitle":19918,"status":105,"phases":21066,"primaryCompletion":1320,"completion":1320,"start":4070,"enrollment":19920,"conditions":21067,"interventions":21068},[89],[19146],[13203,19913,19914],{"nctId":19924,"briefTitle":19925,"status":105,"phases":21070,"primaryCompletion":19927,"completion":19927,"start":19928,"enrollment":951,"conditions":21071,"interventions":21072},[89],[17064],[13203,19914],{"nctId":19932,"briefTitle":19933,"status":105,"phases":21074,"primaryCompletion":19935,"completion":19935,"start":19936,"enrollment":19937,"conditions":21075,"interventions":21076},[89],[17064],[13203,19914],{"nctId":19941,"briefTitle":19942,"status":105,"phases":21078,"primaryCompletion":2022,"completion":2022,"start":6178,"enrollment":19944,"conditions":21079,"interventions":21080},[89],[13187],[13203,19913,19914],{"nctId":19948,"briefTitle":19949,"status":105,"phases":21082,"primaryCompletion":6614,"completion":6614,"start":19951,"enrollment":2512,"conditions":21083,"interventions":21084},[89],[13187],[13203,19914],{"nctId":19968,"briefTitle":19969,"status":105,"phases":21086,"primaryCompletion":2722,"completion":19971,"start":19972,"enrollment":19973,"conditions":21087,"interventions":21088},[89],[17064],[13203,19914],{"trials":21090,"activeCount":99},[],{"trials":21092,"activeCount":99},[],{"intervention":1422,"totalTrials":357,"cells":21094},{"EARLY_PHASE1":21095,"PHASE1":21097,"PHASE2":21105,"PHASE3":21126,"PHASE4":21148,"NA":21150},{"trials":21096,"activeCount":99},[],{"trials":21098,"activeCount":99},[21099],{"nctId":21100,"briefTitle":21101,"status":105,"phases":21102,"primaryCompletion":14713,"completion":13224,"start":8620,"enrollment":5563,"conditions":21103,"interventions":21104},"NCT00632073","Effect of Vicriviroc on HIV Ribonucleic Acid (RNA) Levels in Cerebrospinal Fluid (Study P05241)",[87],[27],[1422],{"trials":21106,"activeCount":99},[21107,21115,21119],{"nctId":21108,"briefTitle":21109,"status":105,"phases":21110,"primaryCompletion":14494,"completion":5179,"start":14454,"enrollment":21111,"conditions":21112,"interventions":21113},"NCT00551018","Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)",[88],218,[27],[1422,21114],"emtricitabine and tenofovir disoproxil fumarate",{"nctId":1414,"briefTitle":1415,"status":105,"phases":21116,"primaryCompletion":1417,"completion":1417,"start":1418,"enrollment":1419,"conditions":21117,"interventions":21118},[88],[371],[1422,47],{"nctId":21120,"briefTitle":21121,"status":105,"phases":21122,"primaryCompletion":6308,"completion":14494,"start":14887,"enrollment":417,"conditions":21123,"interventions":21125},"NCT00551330","Vicriviroc in HIV(R5\u002FX4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)",[88],[27,21124],"Acquired Immunodeficiency Syndrome",[1422],{"trials":21127,"activeCount":99},[21128,21135,21141],{"nctId":21129,"briefTitle":21130,"status":105,"phases":21131,"primaryCompletion":14384,"completion":14023,"start":21132,"enrollment":1150,"conditions":21133,"interventions":21134},"NCT00474370","Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)",[89],"2007-05-15",[27,21124],[1422],{"nctId":21136,"briefTitle":21137,"status":1040,"phases":21138,"start":12752,"enrollment":99,"conditions":21139,"interventions":21140},"NCT00243568","Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285",[89],[27,21124],[1422],{"nctId":21142,"briefTitle":21143,"status":105,"phases":21144,"primaryCompletion":5280,"completion":21145,"start":13891,"enrollment":14046,"conditions":21146,"interventions":21147},"NCT00523211","Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)",[89],"2011-03",[27,21124],[1422],{"trials":21149,"activeCount":99},[],{"trials":21151,"activeCount":99},[],{"intervention":21153,"totalTrials":357,"cells":21154},"MK0966, rofecoxib",{"EARLY_PHASE1":21155,"PHASE1":21157,"PHASE2":21159,"PHASE3":21161,"PHASE4":21221,"NA":21223},{"trials":21156,"activeCount":99},[],{"trials":21158,"activeCount":99},[],{"trials":21160,"activeCount":99},[],{"trials":21162,"activeCount":99},[21163,21173,21180,21189,21198,21206,21213],{"nctId":21164,"briefTitle":21165,"status":105,"phases":21166,"primaryCompletion":15054,"completion":15054,"start":21167,"enrollment":21168,"conditions":21169,"interventions":21171},"NCT00092313","A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-182)",[89],"2002-06",271,[21170],"Postoperative Pain",[21153,21172],"Comparator: oxycodone and acetaminophen",{"nctId":21174,"briefTitle":21175,"status":105,"phases":21176,"primaryCompletion":15054,"start":15304,"enrollment":951,"conditions":21177,"interventions":21178},"NCT00092300","A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-181)(COMPLETED)",[89],[21170],[21153,21179],"Comparator: valdecoxib",{"nctId":21181,"briefTitle":21182,"status":105,"phases":21183,"primaryCompletion":21184,"completion":21184,"start":21185,"enrollment":1968,"conditions":21186,"interventions":21187},"NCT00092339","A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED)",[89],"2002-09-15","2002-08-01",[21170],[21153,21188],"Comparator: valdecoxib, placebo",{"nctId":21190,"briefTitle":21191,"status":105,"phases":21192,"primaryCompletion":17198,"completion":17198,"start":21193,"enrollment":15446,"conditions":21194,"interventions":21196},"NCT00092352","A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)",[89],"2003-04-29",[21195],"Osteoarthritis",[21153,21197],"Comparator: celecoxib, placebo",{"nctId":21199,"briefTitle":21200,"status":105,"phases":21201,"primaryCompletion":17198,"completion":17198,"start":21202,"enrollment":2593,"conditions":21203,"interventions":21204},"NCT00092378","A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED)",[89],"2003-09-01",[21170],[21153,21205],"Comparator: diclofenac sodium, placebo",{"nctId":21207,"briefTitle":21208,"status":105,"phases":21209,"primaryCompletion":8602,"completion":8602,"start":21210,"enrollment":2695,"conditions":21211,"interventions":21212},"NCT00092365","A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-220)(COMPLETED)",[89],"2003-04-01",[21195],[21153,21197],{"nctId":21214,"briefTitle":21215,"status":105,"phases":21216,"primaryCompletion":15054,"completion":15054,"start":21167,"enrollment":21217,"conditions":21218,"interventions":21219},"NCT00092326","A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-183)",[89],269,[21170],[21153,21220],"Comparator: oxycodone with acetaminophen, placebo",{"trials":21222,"activeCount":99},[],{"trials":21224,"activeCount":99},[],{"intervention":13961,"totalTrials":4555,"cells":21226},{"EARLY_PHASE1":21227,"PHASE1":21229,"PHASE2":21231,"PHASE3":21233,"PHASE4":21272,"NA":21274},{"trials":21228,"activeCount":99},[],{"trials":21230,"activeCount":99},[],{"trials":21232,"activeCount":99},[],{"trials":21234,"activeCount":99},[21235,21239,21243,21251,21255,21262],{"nctId":13953,"briefTitle":13954,"status":105,"phases":21236,"primaryCompletion":13956,"completion":13956,"start":13957,"enrollment":13958,"conditions":21237,"interventions":21238},[89],[15],[13145,13864,13914,4084,13961],{"nctId":16160,"briefTitle":16161,"status":105,"phases":21240,"primaryCompletion":16163,"completion":16163,"start":16164,"enrollment":16165,"conditions":21241,"interventions":21242},[89],[15],[13913,13961,14059],{"nctId":21244,"briefTitle":21245,"status":105,"phases":21246,"primaryCompletion":21247,"completion":21247,"start":21248,"enrollment":11541,"conditions":21249,"interventions":21250},"NCT00509236","Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)",[89],"2011-03-14","2007-10-19",[33,5942],[13145,13961],{"nctId":14118,"briefTitle":14119,"status":105,"phases":21252,"primaryCompletion":14121,"completion":14122,"start":14123,"enrollment":2555,"conditions":21253,"interventions":21254},[89],[15],[14126,13864,14127,14040,14128],{"nctId":21256,"briefTitle":21257,"status":105,"phases":21258,"primaryCompletion":14531,"completion":14531,"start":14595,"enrollment":21259,"conditions":21260,"interventions":21261},"NCT00095056","An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)",[89],91,[33,16106],[14126,14128],{"nctId":21263,"briefTitle":21264,"status":105,"phases":21265,"primaryCompletion":21266,"completion":21266,"start":21267,"enrollment":21268,"conditions":21269,"interventions":21271},"NCT00509262","Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)",[89],"2011-03-16","2007-10-09",426,[33,21270],"Renal Insufficiency, Chronic",[13145,13961],{"trials":21273,"activeCount":99},[],{"trials":21275,"activeCount":99},[],{"intervention":19272,"totalTrials":4555,"cells":21277},{"EARLY_PHASE1":21278,"PHASE1":21280,"PHASE2":21282,"PHASE3":21331,"PHASE4":21341,"NA":21343},{"trials":21279,"activeCount":99},[],{"trials":21281,"activeCount":99},[],{"trials":21283,"activeCount":99},[21284,21298,21309,21321],{"nctId":21285,"briefTitle":21286,"status":105,"phases":21287,"primaryCompletion":1198,"completion":1198,"start":21288,"enrollment":21289,"conditions":21290,"interventions":21292},"NCT02037984","Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)",[87,88],"2014-01-28",341,[21291,16472],"Streptococcus Pneumoniae Infection",[19272,21293,21294,21295,21296,21297],"V114 1x:1x:1x","V114 2x:2x:2x","V114 2x:1x:2x","V114 1x:1x:2x","V114 0.5x:0.5x:2x",{"nctId":21299,"briefTitle":21300,"status":105,"phases":21301,"primaryCompletion":21302,"completion":21302,"start":21303,"enrollment":21304,"conditions":21305,"interventions":21306},"NCT01215188","A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)",[88],"2012-07-31","2010-10-14",1152,[16472],[21307,21308,19272],"V114 Aluminum-adjuvanted","V114 Non-adjuvanted",{"nctId":21310,"briefTitle":21311,"status":105,"phases":21312,"primaryCompletion":21313,"completion":21313,"start":21314,"enrollment":21315,"conditions":21316,"interventions":21317},"NCT01513551","The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)",[88],"2013-02-15","2012-03-13",692,[16472],[21318,21319,21320],"Pneumococcal Conjugate Vaccine","PNEUMOVAX® 23","PREVNAR 13®",{"nctId":21322,"briefTitle":21323,"status":105,"phases":21324,"primaryCompletion":19585,"completion":19585,"start":21325,"enrollment":21326,"conditions":21327,"interventions":21328},"NCT02547649","Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)",[88],"2015-10-08",690,[16472],[21329,21330,19272],"V114-A","V114-B",{"trials":21332,"activeCount":99},[21333,21337],{"nctId":19265,"briefTitle":19266,"status":105,"phases":21334,"primaryCompletion":19268,"completion":19268,"start":2350,"enrollment":19269,"conditions":21335,"interventions":21336},[89],[16472],[16474,19272],{"nctId":19274,"briefTitle":19275,"status":105,"phases":21338,"primaryCompletion":19277,"completion":19277,"start":1778,"enrollment":19278,"conditions":21339,"interventions":21340},[89],[16472],[16474,19272],{"trials":21342,"activeCount":99},[],{"trials":21344,"activeCount":99},[],{"intervention":14790,"totalTrials":4555,"cells":21346},{"EARLY_PHASE1":21347,"PHASE1":21349,"PHASE2":21357,"PHASE3":21363,"PHASE4":21387,"NA":21389},{"trials":21348,"activeCount":99},[],{"trials":21350,"activeCount":99},[21351],{"nctId":21352,"briefTitle":21353,"status":105,"phases":21354,"primaryCompletion":14408,"completion":14408,"start":8620,"enrollment":3390,"conditions":21355,"interventions":21356},"NCT00635830","An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)",[87],[9239],[14790],{"trials":21358,"activeCount":99},[21359],{"nctId":14783,"briefTitle":14784,"status":105,"phases":21360,"primaryCompletion":14786,"completion":14786,"start":14123,"enrollment":14787,"conditions":21361,"interventions":21362},[88],[9239],[14790,13864],{"trials":21364,"activeCount":99},[21365,21369,21375,21379],{"nctId":15095,"briefTitle":15096,"status":105,"phases":21366,"primaryCompletion":15098,"completion":1468,"start":15099,"enrollment":15100,"conditions":21367,"interventions":21368},[89],[9239],[14790,14331],{"nctId":21370,"briefTitle":21371,"status":1040,"phases":21372,"primaryCompletion":19810,"completion":19810,"start":4330,"enrollment":99,"conditions":21373,"interventions":21374},"NCT00733122","Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)",[89],[9239],[14790],{"nctId":15175,"briefTitle":15176,"status":105,"phases":21376,"primaryCompletion":5962,"completion":660,"start":15178,"enrollment":15179,"conditions":21377,"interventions":21378},[89],[15181,15182,15183,15184],[14790,13864],{"nctId":21380,"briefTitle":21381,"status":105,"phases":21382,"primaryCompletion":21383,"completion":21383,"start":21384,"enrollment":4474,"conditions":21385,"interventions":21386},"NCT00380367","Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)",[89],"2008-02-04","2007-05-03",[7076],[14790],{"trials":21388,"activeCount":99},[],{"trials":21390,"activeCount":99},[],{"intervention":15113,"totalTrials":4555,"cells":21392},{"EARLY_PHASE1":21393,"PHASE1":21395,"PHASE2":21397,"PHASE3":21399,"PHASE4":21441,"NA":21443},{"trials":21394,"activeCount":99},[],{"trials":21396,"activeCount":99},[],{"trials":21398,"activeCount":99},[],{"trials":21400,"activeCount":99},[21401,21405,21415,21419,21427,21431],{"nctId":15104,"briefTitle":15105,"status":105,"phases":21402,"primaryCompletion":15107,"completion":15107,"start":15108,"enrollment":15109,"conditions":21403,"interventions":21404},[89],[15111],[15113,14331],{"nctId":21406,"briefTitle":21407,"status":105,"phases":21408,"primaryCompletion":21409,"completion":21409,"start":21410,"enrollment":21411,"conditions":21412,"interventions":21413},"NCT00090155","2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)",[89],"2004-11-24","2003-09-26",805,[16210],[15113,21414],"Comparator: ondansetron IV",{"nctId":15339,"briefTitle":15340,"status":105,"phases":21416,"primaryCompletion":15342,"completion":15342,"start":15343,"enrollment":2096,"conditions":21417,"interventions":21418},[89],[15111],[15113,14331],{"nctId":21420,"briefTitle":21421,"status":105,"phases":21422,"primaryCompletion":15351,"completion":21423,"start":21424,"enrollment":20366,"conditions":21425,"interventions":21426},"NCT00035009","Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)",[89],"2004-03-24","2001-09-20",[15111],[15113,15363],{"nctId":15511,"briefTitle":15512,"status":105,"phases":21428,"primaryCompletion":15514,"completion":15514,"start":15515,"enrollment":15516,"conditions":21429,"interventions":21430},[89],[15111],[15113,14331],{"nctId":21432,"briefTitle":21433,"status":105,"phases":21434,"primaryCompletion":21435,"completion":21436,"start":21437,"enrollment":21438,"conditions":21439,"interventions":21440},"NCT00090246","2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)",[89],"2005-04-06","2005-04-20","2004-05-13",922,[16210],[15113,21414],{"trials":21442,"activeCount":99},[],{"trials":21444,"activeCount":99},[],{"intervention":14477,"totalTrials":4555,"cells":21446},{"EARLY_PHASE1":21447,"PHASE1":21449,"PHASE2":21472,"PHASE3":21482,"PHASE4":21502,"NA":21504},{"trials":21448,"activeCount":99},[],{"trials":21450,"activeCount":99},[21451,21459,21468],{"nctId":21452,"briefTitle":21453,"status":105,"phases":21454,"primaryCompletion":21455,"completion":21455,"start":21456,"enrollment":1479,"conditions":21457,"interventions":21458},"NCT01460719","A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013)",[87],"2012-09-25","2012-01-24",[14395],[14477],{"nctId":21460,"briefTitle":21461,"status":105,"phases":21462,"primaryCompletion":21463,"completion":14383,"start":21464,"enrollment":21289,"conditions":21465,"interventions":21467},"NCT00535236","A Study of an Investigational V212\u002FHeat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)",[87],"2010-01-25","2007-11-02",[14395,21466],"Herpes Zoster-related Complications",[14477],{"nctId":14472,"briefTitle":14473,"status":105,"phases":21469,"primaryCompletion":13101,"completion":13101,"start":14314,"enrollment":2023,"conditions":21470,"interventions":21471},[87],[14395],[14477,14478,13864],{"trials":21473,"activeCount":99},[21474],{"nctId":21475,"briefTitle":21476,"status":105,"phases":21477,"primaryCompletion":21043,"completion":21043,"start":21478,"enrollment":21479,"conditions":21480,"interventions":21481},"NCT01527383","A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)",[88],"2012-02-21",354,[14395],[14477],{"trials":21483,"activeCount":99},[21484,21493],{"nctId":21485,"briefTitle":21486,"status":105,"phases":21487,"primaryCompletion":21488,"completion":21488,"start":21489,"enrollment":21490,"conditions":21491,"interventions":21492},"NCT01254630","A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)",[89],"2017-04-11","2011-06-24",5305,[14395],[14477],{"nctId":21494,"briefTitle":21495,"status":105,"phases":21496,"primaryCompletion":21497,"completion":21497,"start":21498,"enrollment":21499,"conditions":21500,"interventions":21501},"NCT01229267","A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001)",[89],"2015-12-23","2010-11-30",1257,[14395],[14477],{"trials":21503,"activeCount":99},[],{"trials":21505,"activeCount":99},[],{"intervention":15160,"totalTrials":4555,"cells":21507},{"EARLY_PHASE1":21508,"PHASE1":21510,"PHASE2":21512,"PHASE3":21521,"PHASE4":21548,"NA":21550},{"trials":21509,"activeCount":99},[],{"trials":21511,"activeCount":99},[],{"trials":21513,"activeCount":99},[21514],{"nctId":21515,"briefTitle":21516,"status":105,"phases":21517,"primaryCompletion":14594,"completion":14594,"start":14903,"enrollment":1570,"conditions":21518,"interventions":21520},"NCT00109135","A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007)",[88],[21519],"Smoking",[15160],{"trials":21522,"activeCount":99},[21523,21527,21531,21538,21544],{"nctId":15152,"briefTitle":15153,"status":150,"phases":21524,"primaryCompletion":15155,"completion":14353,"start":15156,"enrollment":2441,"conditions":21525,"interventions":21526},[89],[15158],[15160,13864],{"nctId":15187,"briefTitle":15188,"status":150,"phases":21528,"primaryCompletion":14687,"completion":14823,"start":12814,"enrollment":1818,"conditions":21529,"interventions":21530},[89],[15191,15],[15193,13864],{"nctId":21532,"briefTitle":21533,"status":105,"phases":21534,"primaryCompletion":14409,"completion":14409,"start":15063,"enrollment":9177,"conditions":21535,"interventions":21537},"NCT00131430","An Eighteen Month Efficacy and Safety Study in Obese Patients (0364-020)(COMPLETED)",[88,89],[21536],"Obesity and Obesity-related Medical Conditions",[15160],{"nctId":21539,"briefTitle":21540,"status":150,"phases":21541,"primaryCompletion":14687,"completion":14353,"start":8619,"enrollment":1633,"conditions":21542,"interventions":21543},"NCT00384605","An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Patients (0364-037)(TERMINATED)",[89],[15158],[15160],{"nctId":15435,"briefTitle":15436,"status":150,"phases":21545,"primaryCompletion":5281,"completion":14823,"start":8619,"enrollment":1633,"conditions":21546,"interventions":21547},[89],[15158],[15160,14331],{"trials":21549,"activeCount":99},[],{"trials":21551,"activeCount":99},[],{"intervention":5199,"totalTrials":174,"cells":21553},{"EARLY_PHASE1":21554,"PHASE1":21556,"PHASE2":21566,"PHASE3":21580,"PHASE4":21586,"NA":21588},{"trials":21555,"activeCount":99},[],{"trials":21557,"activeCount":99},[21558,21562],{"nctId":19313,"briefTitle":19314,"status":105,"phases":21559,"primaryCompletion":13101,"completion":5981,"start":15156,"enrollment":5616,"conditions":21560,"interventions":21561},[87],[526],[4994,19318],{"nctId":19362,"briefTitle":19363,"status":105,"phases":21563,"primaryCompletion":19365,"completion":19366,"start":19367,"enrollment":3308,"conditions":21564,"interventions":21565},[87],[526],[5174,5199],{"trials":21567,"activeCount":99},[21568,21572],{"nctId":5190,"briefTitle":5191,"status":105,"phases":21569,"primaryCompletion":5193,"completion":5194,"start":5195,"enrollment":5196,"conditions":21570,"interventions":21571},[88],[5172],[5174,5199,529],{"nctId":21573,"briefTitle":21574,"status":150,"phases":21575,"primaryCompletion":15794,"completion":15794,"start":14314,"enrollment":734,"conditions":21576,"interventions":21578},"NCT00871546","SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)",[88],[21577,6286],"Lymphoma, Mantle-Cell",[5135,5199,21579],"Alemtuzumab",{"trials":21581,"activeCount":99},[21582],{"nctId":19407,"briefTitle":19408,"status":105,"phases":21583,"primaryCompletion":19410,"completion":19411,"start":5195,"enrollment":19412,"conditions":21584,"interventions":21585},[89],[526],[5174,19318],{"trials":21587,"activeCount":99},[],{"trials":21589,"activeCount":99},[],{"intervention":15314,"totalTrials":174,"cells":21591},{"EARLY_PHASE1":21592,"PHASE1":21594,"PHASE2":21596,"PHASE3":21609,"PHASE4":21638,"NA":21640},{"trials":21593,"activeCount":99},[],{"trials":21595,"activeCount":99},[],{"trials":21597,"activeCount":99},[21598],{"nctId":21599,"briefTitle":21600,"status":105,"phases":21601,"primaryCompletion":21602,"completion":21603,"start":21604,"enrollment":21605,"conditions":21606,"interventions":21607},"NCT00986232","ProQuad Dose Selection Study (V221-011)(COMPLETED)",[88],"2000-04","2000-09","1999-04",1551,[15308,15309,15310,15311],[15467,15314,21608],"Comparator: PUVV",{"trials":21610,"activeCount":99},[21611,21615,21624,21628],{"nctId":15301,"briefTitle":15302,"status":105,"phases":21612,"primaryCompletion":15304,"completion":15118,"start":15305,"enrollment":15306,"conditions":21613,"interventions":21614},[89],[15308,15309,15310,15311],[15313,15314,15315,13864],{"nctId":21616,"briefTitle":21617,"status":105,"phases":21618,"primaryCompletion":21619,"completion":21619,"start":21620,"enrollment":21621,"conditions":21622,"interventions":21623},"NCT00985153","Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)",[89],"2001-05","2000-03",3927,[15308,15309,15310,15311],[15467,15315,15314],{"nctId":15458,"briefTitle":15459,"status":105,"phases":21625,"primaryCompletion":15461,"completion":15462,"start":15463,"enrollment":15464,"conditions":21626,"interventions":21627},[89],[15308,15309,15310,15311],[15467,13864,15315,15314],{"nctId":21629,"briefTitle":21630,"status":105,"phases":21631,"primaryCompletion":20174,"completion":15295,"start":21632,"enrollment":21633,"conditions":21634,"interventions":21635},"NCT00984295","Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines",[89],"2000-06",1913,[15308,15309,15310,15311],[15467,21636,21637,15315,15314],"Comparator: Tripedia","Comparator: Comvax",{"trials":21639,"activeCount":99},[],{"trials":21641,"activeCount":99},[],{"intervention":16464,"totalTrials":174,"cells":21643},{"EARLY_PHASE1":21644,"PHASE1":21646,"PHASE2":21648,"PHASE3":21660,"PHASE4":21678,"NA":21680},{"trials":21645,"activeCount":99},[],{"trials":21647,"activeCount":99},[],{"trials":21649,"activeCount":99},[21650],{"nctId":21651,"briefTitle":21652,"status":105,"phases":21653,"primaryCompletion":20197,"completion":20197,"start":21619,"enrollment":21654,"conditions":21655,"interventions":21657},"NCT00551915","A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003)",[88],756,[21656],"Bacterial Infections; Virus Diseases",[21658,21659,21659,16464,16476],"AR51","PR51",{"trials":21661,"activeCount":99},[21662,21666,21670,21674],{"nctId":16452,"briefTitle":16453,"status":105,"phases":21663,"primaryCompletion":16455,"completion":16456,"start":16457,"enrollment":16458,"conditions":21664,"interventions":21665},[89],[16460,16461],[16463,16464,16465,16441,16466],{"nctId":16468,"briefTitle":16469,"status":105,"phases":21667,"primaryCompletion":1640,"completion":1640,"start":1984,"enrollment":3605,"conditions":21668,"interventions":21669},[89],[16472],[16465,16474,16441,16475,16476,16477,16478,16479],{"nctId":16481,"briefTitle":16482,"status":105,"phases":21671,"primaryCompletion":16484,"completion":16484,"start":709,"enrollment":16485,"conditions":21672,"interventions":21673},[89],[16472,16487],[16474,16465,16441,16475,16476,16489,16490,16479,16477],{"nctId":16492,"briefTitle":16493,"status":105,"phases":21675,"primaryCompletion":16495,"completion":16495,"start":16496,"enrollment":16497,"conditions":21676,"interventions":21677},[89],[16460,16461],[16463,16500,16501,16465,16441,16464,16466,16502],{"trials":21679,"activeCount":99},[],{"trials":21681,"activeCount":99},[],{"intervention":14588,"totalTrials":174,"cells":21683},{"EARLY_PHASE1":21684,"PHASE1":21686,"PHASE2":21696,"PHASE3":21698,"PHASE4":21712,"NA":21714},{"trials":21685,"activeCount":99},[],{"trials":21687,"activeCount":99},[21688,21692],{"nctId":14581,"briefTitle":14582,"status":105,"phases":21689,"primaryCompletion":14584,"completion":14584,"start":14585,"enrollment":28,"conditions":21690,"interventions":21691},[87],[14277],[14588,14331],{"nctId":20104,"briefTitle":20105,"status":105,"phases":21693,"primaryCompletion":20107,"completion":20107,"start":20108,"enrollment":1340,"conditions":21694,"interventions":21695},[87],[14277],[14588,13985,13983,20111],{"trials":21697,"activeCount":99},[],{"trials":21699,"activeCount":99},[21700,21704,21708],{"nctId":20129,"briefTitle":20130,"status":105,"phases":21701,"primaryCompletion":20132,"completion":20133,"start":17413,"enrollment":2118,"conditions":21702,"interventions":21703},[89],[15],[14588,14039,13985],{"nctId":15262,"briefTitle":15263,"status":105,"phases":21705,"primaryCompletion":15265,"completion":15265,"start":15266,"enrollment":15267,"conditions":21706,"interventions":21707},[89],[15],[14487,14588,13985,14331],{"nctId":15441,"briefTitle":15442,"status":105,"phases":21709,"primaryCompletion":15444,"completion":15444,"start":15445,"enrollment":15446,"conditions":21710,"interventions":21711},[89],[15],[15449,13864],{"trials":21713,"activeCount":99},[],{"trials":21715,"activeCount":99},[],{"intervention":14039,"totalTrials":174,"cells":21717},{"EARLY_PHASE1":21718,"PHASE1":21720,"PHASE2":21745,"PHASE3":21747,"PHASE4":21761,"NA":21763},{"trials":21719,"activeCount":99},[],{"trials":21721,"activeCount":99},[21722,21735],{"nctId":21723,"briefTitle":21724,"status":105,"phases":21725,"primaryCompletion":14504,"completion":14504,"start":14540,"enrollment":120,"conditions":21726,"interventions":21727},"NCT00961480","A Study to Demonstrate the Bioequivalence of Sitagliptin\u002FMetformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)",[87],[14156],[14039,21728,21729,21730,21731,21732,21733,21734],"Comparator: metformin 500mg","Comparator: sitagliptin","Comparator: FMI sitagliptin \u002F metformin 50 mg\u002F500 mg FDC","Comparator: FMI sitagliptin\u002Fmetformin 50 mg\u002F1000 mg FDC","Comparator: FMI sitagliptin\u002Fmetformin 50 mg\u002F850 mg FDC","Comparator: metformin 1000 mg","Comparator: metformin 850 mg",{"nctId":21736,"briefTitle":21737,"status":105,"phases":21738,"primaryCompletion":21739,"completion":21740,"start":21739,"enrollment":1054,"conditions":21741,"interventions":21742},"NCT00961857","A Study to Demonstrate the Bioequivalence of Sitagliptin\u002FMetformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)",[87],"2005-12-01","2006-01-01",[14156],[14039,21743,21729,21744,21731,21733],"Comparator: metformin 500 mg","Comparator: FMI sitagliptin\u002Fmetformin 50 mg\u002F500 mg FDC",{"trials":21746,"activeCount":99},[],{"trials":21748,"activeCount":99},[21749,21753,21757],{"nctId":20129,"briefTitle":20130,"status":105,"phases":21750,"primaryCompletion":20132,"completion":20133,"start":17413,"enrollment":2118,"conditions":21751,"interventions":21752},[89],[15],[14588,14039,13985],{"nctId":14030,"briefTitle":14031,"status":105,"phases":21754,"primaryCompletion":14033,"completion":14034,"start":14035,"enrollment":14036,"conditions":21755,"interventions":21756},[89],[15],[14039,14040],{"nctId":20141,"briefTitle":20142,"status":105,"phases":21758,"primaryCompletion":20144,"completion":20144,"start":20145,"enrollment":20146,"conditions":21759,"interventions":21760},[89],[15],[14039,13985],{"trials":21762,"activeCount":99},[],{"trials":21764,"activeCount":99},[],{"intervention":14233,"totalTrials":174,"cells":21766},{"EARLY_PHASE1":21767,"PHASE1":21769,"PHASE2":21779,"PHASE3":21785,"PHASE4":21795,"NA":21797},{"trials":21768,"activeCount":99},[],{"trials":21770,"activeCount":99},[21771,21775],{"nctId":21723,"briefTitle":21724,"status":105,"phases":21772,"primaryCompletion":14504,"completion":14504,"start":14540,"enrollment":120,"conditions":21773,"interventions":21774},[87],[14156],[14039,21728,21729,21730,21731,21732,21733,21734],{"nctId":21736,"briefTitle":21737,"status":105,"phases":21776,"primaryCompletion":21739,"completion":21740,"start":21739,"enrollment":1054,"conditions":21777,"interventions":21778},[87],[14156],[14039,21743,21729,21744,21731,21733],{"trials":21780,"activeCount":99},[21781],{"nctId":15017,"briefTitle":15018,"status":105,"phases":21782,"primaryCompletion":15020,"completion":15020,"start":15021,"enrollment":1479,"conditions":21783,"interventions":21784},[88],[15023],[14487,13864,14233],{"trials":21786,"activeCount":99},[21787,21791],{"nctId":15207,"briefTitle":15208,"status":105,"phases":21788,"primaryCompletion":14705,"completion":15210,"start":15211,"enrollment":11128,"conditions":21789,"interventions":21790},[89],[33],[14233,13864,14234],{"nctId":14225,"briefTitle":14226,"status":105,"phases":21792,"primaryCompletion":14228,"completion":14228,"start":14229,"enrollment":14230,"conditions":21793,"interventions":21794},[89],[33],[14233,13864,14234,4084],{"trials":21796,"activeCount":99},[],{"trials":21798,"activeCount":99},[],{"intervention":14049,"totalTrials":174,"cells":21800},{"EARLY_PHASE1":21801,"PHASE1":21803,"PHASE2":21814,"PHASE3":21816,"PHASE4":21834,"NA":21836},{"trials":21802,"activeCount":99},[],{"trials":21804,"activeCount":99},[21805],{"nctId":21806,"briefTitle":21807,"status":105,"phases":21808,"primaryCompletion":21809,"completion":21810,"start":21811,"enrollment":3655,"conditions":21812,"interventions":21813},"NCT02115347","Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835\u002FPF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)",[87],"2015-01-10","2015-01-19","2014-09-19",[15,5595],[14049],{"trials":21815,"activeCount":99},[],{"trials":21817,"activeCount":99},[21818,21822,21826,21830],{"nctId":14042,"briefTitle":14043,"status":105,"phases":21819,"primaryCompletion":719,"completion":719,"start":14045,"enrollment":14046,"conditions":21820,"interventions":21821},[89],[15],[13883,14049,4084,13146],{"nctId":14051,"briefTitle":14052,"status":105,"phases":21823,"primaryCompletion":14054,"completion":14054,"start":14055,"enrollment":14056,"conditions":21824,"interventions":21825},[89],[15],[13883,14049,4084,13145,13146,14059],{"nctId":14172,"briefTitle":14173,"status":105,"phases":21827,"primaryCompletion":14175,"completion":14175,"start":14176,"enrollment":14177,"conditions":21828,"interventions":21829},[89],[15],[13883,14049,14180,4084],{"nctId":14218,"briefTitle":14219,"status":105,"phases":21831,"primaryCompletion":4344,"completion":4344,"start":14221,"enrollment":13142,"conditions":21832,"interventions":21833},[89],[15],[13883,14049,14059,4084],{"trials":21835,"activeCount":99},[],{"trials":21837,"activeCount":99},[],{"intervention":15049,"totalTrials":174,"cells":21839},{"EARLY_PHASE1":21840,"PHASE1":21842,"PHASE2":21844,"PHASE3":21864,"PHASE4":21879,"NA":21881},{"trials":21841,"activeCount":99},[],{"trials":21843,"activeCount":99},[],{"trials":21845,"activeCount":99},[21846,21854,21860],{"nctId":21847,"briefTitle":21848,"status":105,"phases":21849,"primaryCompletion":14678,"completion":14678,"start":21850,"enrollment":21851,"conditions":21852,"interventions":21853},"NCT00533481","Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)",[88],"2004-02",497,[15158],[15049],{"nctId":21855,"briefTitle":21856,"status":105,"phases":21857,"primaryCompletion":14567,"completion":14567,"start":15054,"conditions":21858,"interventions":21859},"NCT00533598","A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)",[88],[15158],[15049],{"nctId":15043,"briefTitle":15044,"status":105,"phases":21861,"primaryCompletion":6309,"completion":6309,"start":14887,"enrollment":4421,"conditions":21862,"interventions":21863},[88],[15047,14715],[15049,13864],{"trials":21865,"activeCount":99},[21866,21872],{"nctId":21867,"briefTitle":21868,"status":105,"phases":21869,"primaryCompletion":14594,"completion":14594,"start":20219,"enrollment":7149,"conditions":21870,"interventions":21871},"NCT00092859","A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)",[89],[15158],[15049],{"nctId":21873,"briefTitle":21874,"status":105,"phases":21875,"primaryCompletion":19537,"completion":19537,"start":20173,"enrollment":21876,"conditions":21877,"interventions":21878},"NCT00092872","A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)",[89],359,[15158],[15049],{"trials":21880,"activeCount":99},[],{"trials":21882,"activeCount":99},[],{"intervention":21884,"totalTrials":174,"cells":21885},"telcagepant",{"EARLY_PHASE1":21886,"PHASE1":21888,"PHASE2":21909,"PHASE3":21921,"PHASE4":21945,"NA":21947},{"trials":21887,"activeCount":99},[],{"trials":21889,"activeCount":99},[21890,21901],{"nctId":21891,"briefTitle":21892,"status":105,"phases":21893,"primaryCompletion":15497,"completion":21894,"start":21895,"enrollment":287,"conditions":21896,"interventions":21900},"NCT01294709","A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)",[87],"2009-03-13","2008-02-12",[21897,21898,21899],"Angina Pectoris","Coronary Heart Disease","Calcitonin Gene-related Peptide Receptor",[21884],{"nctId":21902,"briefTitle":21903,"status":105,"phases":21904,"primaryCompletion":2890,"completion":2890,"start":21905,"enrollment":335,"conditions":21906,"interventions":21907},"NCT01315847","Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067)",[87],"2010-01-14",[4397],[21884,21908],"[11C]MK-4232",{"trials":21910,"activeCount":99},[21911],{"nctId":21912,"briefTitle":21913,"status":105,"phases":21914,"primaryCompletion":14384,"completion":14384,"start":21915,"enrollment":21916,"conditions":21917,"interventions":21918},"NCT00758836","A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046)",[88],"2008-12-03",683,[4397],[21919,21920,21884],"ibuprofen","acetominophen",{"trials":21922,"activeCount":99},[21923,21932],{"nctId":21924,"briefTitle":21925,"status":105,"phases":21926,"primaryCompletion":21927,"completion":21927,"start":173,"enrollment":21928,"conditions":21929,"interventions":21930},"NCT01125774","Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)",[88,89],"2011-04-08",4548,[4397],[21931],"Telcagepant",{"nctId":21933,"briefTitle":21934,"status":105,"phases":21935,"primaryCompletion":21936,"completion":21936,"start":21937,"enrollment":7127,"conditions":21938,"interventions":21943},"NCT00662818","Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)",[89],"2009-09-02","2008-03-17",[14524,21939,21940,21941,21942,14655],"Heart Disease","Cerebrovascular Accident","TIA (Transient Ischemic Attack)","Vascular Diseases",[21931,21944],"Acetaminophen\u002FParacetamol",{"trials":21946,"activeCount":99},[],{"trials":21948,"activeCount":99},[],{"intervention":14147,"totalTrials":174,"cells":21950},{"EARLY_PHASE1":21951,"PHASE1":21953,"PHASE2":21963,"PHASE3":21965,"PHASE4":21983,"NA":21985},{"trials":21952,"activeCount":99},[],{"trials":21954,"activeCount":99},[21955],{"nctId":21956,"briefTitle":21957,"status":105,"phases":21958,"primaryCompletion":12813,"completion":12813,"start":14494,"enrollment":95,"conditions":21959,"interventions":21960},"NCT01114568","Study To Estimate The Relative Bioavailability of Ertugliflozin (PF-04971729, MK-8835) in Healthy Adult Participants (MK-8835-039)",[87],[18],[14147,21961,21962],"Ertugliflozin OC Fast","Ertugliflozin OC Slow",{"trials":21964,"activeCount":99},[],{"trials":21966,"activeCount":99},[21967,21971,21975,21979],{"nctId":20361,"briefTitle":20362,"status":105,"phases":21968,"primaryCompletion":20364,"completion":20364,"start":20365,"enrollment":20366,"conditions":21969,"interventions":21970},[89],[15],[13883,14147],{"nctId":14140,"briefTitle":14141,"status":105,"phases":21972,"primaryCompletion":13925,"completion":13925,"start":14143,"enrollment":14144,"conditions":21973,"interventions":21974},[89],[15],[13883,14147,14148,4084,13145],{"nctId":20374,"briefTitle":20375,"status":105,"phases":21976,"primaryCompletion":2694,"completion":2694,"start":20377,"enrollment":20378,"conditions":21977,"interventions":21978},[89],[15],[13883,14147,13885,20381,20382,20383],{"nctId":14259,"briefTitle":14260,"status":105,"phases":21980,"primaryCompletion":14262,"completion":14262,"start":14263,"enrollment":14264,"conditions":21981,"interventions":21982},[89],[15],[13883,14147,4084,13146],{"trials":21984,"activeCount":99},[],{"trials":21986,"activeCount":99},[],{"intervention":15315,"totalTrials":174,"cells":21988},{"EARLY_PHASE1":21989,"PHASE1":21991,"PHASE2":21993,"PHASE3":21995,"PHASE4":22023,"NA":22025},{"trials":21990,"activeCount":99},[],{"trials":21992,"activeCount":99},[],{"trials":21994,"activeCount":99},[],{"trials":21996,"activeCount":99},[21997,22001,22005,22015,22019],{"nctId":15301,"briefTitle":15302,"status":105,"phases":21998,"primaryCompletion":15304,"completion":15118,"start":15305,"enrollment":15306,"conditions":21999,"interventions":22000},[89],[15308,15309,15310,15311],[15313,15314,15315,13864],{"nctId":21616,"briefTitle":21617,"status":105,"phases":22002,"primaryCompletion":21619,"completion":21619,"start":21620,"enrollment":21621,"conditions":22003,"interventions":22004},[89],[15308,15309,15310,15311],[15467,15315,15314],{"nctId":22006,"briefTitle":22007,"status":105,"phases":22008,"primaryCompletion":22009,"completion":22009,"start":3047,"enrollment":22010,"conditions":22011,"interventions":22012},"NCT00092391","A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)",[89],"2001-07",1997,[15308,15309,15310,15311],[22013,22014],"Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live","Comparator: VARIVAX",{"nctId":15458,"briefTitle":15459,"status":105,"phases":22016,"primaryCompletion":15461,"completion":15462,"start":15463,"enrollment":15464,"conditions":22017,"interventions":22018},[89],[15308,15309,15310,15311],[15467,13864,15315,15314],{"nctId":21629,"briefTitle":21630,"status":105,"phases":22020,"primaryCompletion":20174,"completion":15295,"start":21632,"enrollment":21633,"conditions":22021,"interventions":22022},[89],[15308,15309,15310,15311],[15467,21636,21637,15315,15314],{"trials":22024,"activeCount":99},[],{"trials":22026,"activeCount":99},[],{"intervention":22028,"totalTrials":3963,"cells":22029},"diquafosol tetrasodium (INS365) Ophthalmic Solution",{"EARLY_PHASE1":22030,"PHASE1":22032,"PHASE2":22034,"PHASE3":22052,"PHASE4":22067,"NA":22069},{"trials":22031,"activeCount":99},[],{"trials":22033,"activeCount":99},[],{"trials":22035,"activeCount":99},[22036,22045],{"nctId":22037,"briefTitle":22038,"status":105,"phases":22039,"primaryCompletion":22040,"completion":22040,"start":22041,"enrollment":2779,"conditions":22042,"interventions":22043},"NCT00679718","A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease",[88],"2000-07","2000-01",[16625],[22044],"diquafosol tetrasodium (INS365) ophthalmic solution",{"nctId":22046,"briefTitle":22047,"status":105,"phases":22048,"primaryCompletion":22049,"completion":22049,"start":15002,"enrollment":25,"conditions":22050,"interventions":22051},"NCT00680108","A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution",[88],"2000-05",[16625],[22044],{"trials":22053,"activeCount":99},[22054,22061],{"nctId":22055,"briefTitle":22056,"status":105,"phases":22057,"primaryCompletion":15054,"completion":15054,"start":22058,"enrollment":9177,"conditions":22059,"interventions":22060},"NCT00403715","Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease",[89],"2001-02",[16625],[22028],{"nctId":22062,"briefTitle":22056,"status":105,"phases":22063,"primaryCompletion":15295,"completion":15295,"start":22064,"enrollment":9177,"conditions":22065,"interventions":22066},"NCT00404131",[89],"2001-03",[16625],[22028],{"trials":22068,"activeCount":99},[],{"trials":22070,"activeCount":99},[],{"intervention":16673,"totalTrials":3963,"cells":22072},{"EARLY_PHASE1":22073,"PHASE1":22075,"PHASE2":22077,"PHASE3":22079,"PHASE4":22106,"NA":22108},{"trials":22074,"activeCount":99},[],{"trials":22076,"activeCount":99},[],{"trials":22078,"activeCount":99},[],{"trials":22080,"activeCount":99},[22081,22089,22093,22099],{"nctId":22082,"briefTitle":22083,"status":105,"phases":22084,"primaryCompletion":18426,"completion":18426,"start":15118,"enrollment":312,"conditions":22085,"interventions":22086},"NCT00988520","Study of Efficacy, Pharmacokinetics and Safety of Continuous Intravenous Infusion of Org 9426 (Study P05977)",[89],[16668],[16673,16673,16673,22087,22088],"Sevoflurane","Propofol",{"nctId":16661,"briefTitle":16662,"status":105,"phases":22090,"primaryCompletion":16664,"completion":16665,"start":16666,"enrollment":1977,"conditions":22091,"interventions":22092},[89],[16668],[16670,16671,16672,16640,16673],{"nctId":22094,"briefTitle":22095,"status":105,"phases":22096,"primaryCompletion":13891,"completion":13891,"start":14678,"enrollment":9357,"conditions":22097,"interventions":22098},"NCT00124722","A Study to Compare Different Intubating Doses of Zemuron in Pediatric and Adolescent Subjects Under General Anesthesia",[89],[16668],[16673,16673,16673],{"nctId":22100,"briefTitle":22101,"status":105,"phases":22102,"primaryCompletion":14875,"completion":14875,"start":14567,"enrollment":3390,"conditions":22103,"interventions":22105},"NCT00984633","Study of Efficacy, Pharmacokinetics, and Safety of Bolus Maintenance Doses of Org 9426 (Study P05976)(COMPLETED)",[89],[22104],"Muscle Relaxation",[16673,16673,22087,22088],{"trials":22107,"activeCount":99},[],{"trials":22109,"activeCount":99},[],{"intervention":15467,"totalTrials":3963,"cells":22111},{"EARLY_PHASE1":22112,"PHASE1":22114,"PHASE2":22116,"PHASE3":22122,"PHASE4":22136,"NA":22138},{"trials":22113,"activeCount":99},[],{"trials":22115,"activeCount":99},[],{"trials":22117,"activeCount":99},[22118],{"nctId":21599,"briefTitle":21600,"status":105,"phases":22119,"primaryCompletion":21602,"completion":21603,"start":21604,"enrollment":21605,"conditions":22120,"interventions":22121},[88],[15308,15309,15310,15311],[15467,15314,21608],{"trials":22123,"activeCount":99},[22124,22128,22132],{"nctId":21616,"briefTitle":21617,"status":105,"phases":22125,"primaryCompletion":21619,"completion":21619,"start":21620,"enrollment":21621,"conditions":22126,"interventions":22127},[89],[15308,15309,15310,15311],[15467,15315,15314],{"nctId":15458,"briefTitle":15459,"status":105,"phases":22129,"primaryCompletion":15461,"completion":15462,"start":15463,"enrollment":15464,"conditions":22130,"interventions":22131},[89],[15308,15309,15310,15311],[15467,13864,15315,15314],{"nctId":21629,"briefTitle":21630,"status":105,"phases":22133,"primaryCompletion":20174,"completion":15295,"start":21632,"enrollment":21633,"conditions":22134,"interventions":22135},[89],[15308,15309,15310,15311],[15467,21636,21637,15315,15314],{"trials":22137,"activeCount":99},[],{"trials":22139,"activeCount":99},[],{"intervention":22141,"totalTrials":3963,"cells":22142},"Ceftolozane\u002FTazobactam",{"EARLY_PHASE1":22143,"PHASE1":22145,"PHASE2":22156,"PHASE3":22178,"PHASE4":22189,"NA":22191},{"trials":22144,"activeCount":99},[],{"trials":22146,"activeCount":99},[22147],{"nctId":22148,"briefTitle":22149,"status":105,"phases":22150,"primaryCompletion":22151,"completion":22151,"start":22152,"enrollment":1419,"conditions":22153,"interventions":22155},"NCT04223752","Safety and Pharmacokinetics of Ceftolozane\u002FTazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)",[87],"2024-09-14","2020-04-17",[22154],"Nosocomial Pneumonia",[22141],{"trials":22157,"activeCount":99},[22158,22168],{"nctId":22159,"briefTitle":22160,"status":105,"phases":22161,"primaryCompletion":22162,"completion":22162,"start":1945,"enrollment":1977,"conditions":22163,"interventions":22165},"NCT03217136","MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)",[88],"2020-03-16",[22164],"Complicated Intra-Abdominal Infection",[22141,22166,22167],"Metronidazole","Meropenem",{"nctId":22169,"briefTitle":22170,"status":105,"phases":22171,"primaryCompletion":22172,"completion":22172,"start":22173,"enrollment":15267,"conditions":22174,"interventions":22177},"NCT03230838","MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)",[88],"2020-12-03","2018-04-26",[22175,22176],"Complicated Urinary Tract Infection","Pyelonephritis",[22141,22167],{"trials":22179,"activeCount":99},[22180],{"nctId":22181,"briefTitle":22182,"status":105,"phases":22183,"primaryCompletion":22184,"completion":22184,"start":1042,"enrollment":22185,"conditions":22186,"interventions":22188},"NCT03830333","Ceftolozane\u002FTazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)",[89],"2020-10-14",268,[22187],"Complicated Intra-abdominal Infections",[22141,22166,22167],{"trials":22190,"activeCount":99},[],{"trials":22192,"activeCount":99},[],{"intervention":22194,"totalTrials":3963,"cells":22195},"ertapenem sodium",{"EARLY_PHASE1":22196,"PHASE1":22198,"PHASE2":22200,"PHASE3":22202,"PHASE4":22240,"NA":22242},{"trials":22197,"activeCount":99},[],{"trials":22199,"activeCount":99},[],{"trials":22201,"activeCount":99},[],{"trials":22203,"activeCount":99},[22204,22211,22218,22227],{"nctId":22205,"briefTitle":22206,"status":105,"phases":22207,"primaryCompletion":8621,"completion":8621,"start":14594,"enrollment":1169,"conditions":22208,"interventions":22210},"NCT00379951","A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048)",[89],[22209],"Urinary Tract Infection",[22194],{"nctId":22212,"briefTitle":22213,"status":105,"phases":22214,"primaryCompletion":14313,"completion":14313,"start":14408,"enrollment":21168,"conditions":22215,"interventions":22216},"NCT01014013","Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)",[89],[22209],[22194,22217],"Comparator: ceftriaxone sodium",{"nctId":22219,"briefTitle":22220,"status":105,"phases":22221,"primaryCompletion":12984,"completion":12984,"start":15794,"enrollment":7686,"conditions":22222,"interventions":22224},"NCT01254344","Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)",[89],[18450,22223],"Surgical Site Infection",[22194,22225,22226],"ceftriaxone sodium","metronidazole",{"nctId":22228,"briefTitle":22229,"status":105,"phases":22230,"primaryCompletion":22231,"completion":22232,"start":21035,"enrollment":22233,"conditions":22234,"interventions":22236},"NCT01370616","Ertapenem Sodium (MK-0826) Versus Piperacillin\u002FTazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061)",[89],"2013-12-08","2013-12-18",565,[22235],"Infection; Diabetic Foot",[22237,22238,22239],"Ertapenem sodium","Piperacillin\u002Ftazobactam sodium","Amoxicillin\u002Fclavulunate potassium",{"trials":22241,"activeCount":99},[],{"trials":22243,"activeCount":99},[],{"intervention":14488,"totalTrials":3963,"cells":22245},{"EARLY_PHASE1":22246,"PHASE1":22248,"PHASE2":22254,"PHASE3":22256,"PHASE4":22270,"NA":22272},{"trials":22247,"activeCount":99},[],{"trials":22249,"activeCount":99},[22250],{"nctId":14480,"briefTitle":14481,"status":105,"phases":22251,"primaryCompletion":14483,"completion":14483,"start":14484,"enrollment":3655,"conditions":22252,"interventions":22253},[87],[14156],[14487,14488,14489,14331],{"trials":22255,"activeCount":99},[],{"trials":22257,"activeCount":99},[22258,22262,22266],{"nctId":15115,"briefTitle":15116,"status":150,"phases":22259,"primaryCompletion":14875,"completion":14875,"start":15118,"enrollment":15119,"conditions":22260,"interventions":22261},[89],[33],[14881,14331,14488],{"nctId":15568,"briefTitle":15569,"status":105,"phases":22263,"primaryCompletion":4419,"completion":4419,"start":14705,"enrollment":15571,"conditions":22264,"interventions":22265},[89],[15],[13145,15574,13864,15575],{"nctId":15743,"briefTitle":15744,"status":105,"phases":22267,"primaryCompletion":15746,"completion":15746,"start":15747,"enrollment":14325,"conditions":22268,"interventions":22269},[89],[15023],[14487,14488,14488,15750],{"trials":22271,"activeCount":99},[],{"trials":22273,"activeCount":99},[],{"intervention":13971,"totalTrials":3963,"cells":22275},{"EARLY_PHASE1":22276,"PHASE1":22278,"PHASE2":22280,"PHASE3":22282,"PHASE4":22300,"NA":22302},{"trials":22277,"activeCount":99},[],{"trials":22279,"activeCount":99},[],{"trials":22281,"activeCount":99},[],{"trials":22283,"activeCount":99},[22284,22288,22292,22296],{"nctId":13963,"briefTitle":13964,"status":105,"phases":22285,"primaryCompletion":13966,"completion":13966,"start":13967,"enrollment":13968,"conditions":22286,"interventions":22287},[89],[15],[13913,13146,13971,4084],{"nctId":13989,"briefTitle":13990,"status":105,"phases":22289,"primaryCompletion":13992,"completion":13993,"start":13994,"enrollment":13995,"conditions":22290,"interventions":22291},[89],[15],[13145,13864,13998,4084],{"nctId":14000,"briefTitle":14001,"status":105,"phases":22293,"primaryCompletion":14003,"completion":14003,"start":14004,"enrollment":14005,"conditions":22294,"interventions":22295},[89],[15],[13913,13146,14008,4084,13998],{"nctId":14236,"briefTitle":14237,"status":105,"phases":22297,"primaryCompletion":14239,"completion":9574,"start":2571,"enrollment":14240,"conditions":22298,"interventions":22299},[89],[15],[13145,4084,14079,13971],{"trials":22301,"activeCount":99},[],{"trials":22303,"activeCount":99},[],{"intervention":22305,"totalTrials":3963,"cells":22306},"Posaconazole oral suspension",{"EARLY_PHASE1":22307,"PHASE1":22309,"PHASE2":22311,"PHASE3":22321,"PHASE4":22345,"NA":22347},{"trials":22308,"activeCount":99},[],{"trials":22310,"activeCount":99},[],{"trials":22312,"activeCount":99},[22313],{"nctId":22314,"briefTitle":22315,"status":105,"phases":22316,"primaryCompletion":14773,"completion":22317,"start":15584,"enrollment":16208,"conditions":22318,"interventions":22320},"NCT00034671","PK\u002FPD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)",[88],"2002-03",[22319],"Mycoses",[22305],{"trials":22322,"activeCount":99},[22323,22329,22338],{"nctId":22324,"briefTitle":22325,"status":105,"phases":22326,"primaryCompletion":14772,"completion":14772,"start":15461,"enrollment":1818,"conditions":22327,"interventions":22328},"NCT00034645","Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host Disease",[89],[22319],[22305],{"nctId":22330,"briefTitle":22331,"status":105,"phases":22332,"primaryCompletion":14678,"completion":14593,"start":22333,"enrollment":22334,"conditions":22335,"interventions":22337},"NCT00044486","Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)",[89],"2002-07",602,[22336,196,20505],"Leukemia, Myelocytic, Acute",[22305],{"nctId":22339,"briefTitle":22340,"status":105,"phases":22341,"primaryCompletion":4419,"completion":4419,"start":22342,"conditions":22343,"interventions":22344},"NCT00034632","Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)",[89],"2001-04",[22319],[22305],{"trials":22346,"activeCount":99},[],{"trials":22348,"activeCount":99},[],{"intervention":13135,"totalTrials":3963,"cells":22350},{"EARLY_PHASE1":22351,"PHASE1":22353,"PHASE2":22363,"PHASE3":22365,"PHASE4":22391,"NA":22393},{"trials":22352,"activeCount":99},[],{"trials":22354,"activeCount":99},[22355],{"nctId":22356,"briefTitle":22357,"status":150,"phases":22358,"primaryCompletion":18998,"completion":18998,"start":22359,"enrollment":335,"conditions":22360,"interventions":22362},"NCT01583647","A Study of Extended-release (ER) Niacin\u002FLaropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)",[87],"2012-06",[15546,22361],"Heterozygous Familial Hypercholesterolemia",[13135,13135],{"trials":22364,"activeCount":99},[],{"trials":22366,"activeCount":99},[22367,22376,22387],{"nctId":22368,"briefTitle":22369,"status":105,"phases":22370,"primaryCompletion":15210,"completion":15210,"start":14531,"enrollment":22371,"conditions":22372,"interventions":22374},"NCT00376584","Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)",[89],825,[22373,7610],"Hypercholesteremia",[13135,22375],"ER Niacin",{"nctId":22377,"briefTitle":22378,"status":105,"phases":22379,"primaryCompletion":22380,"completion":22380,"start":22381,"enrollment":22382,"conditions":22383,"interventions":22384},"NCT00479882","MK-0524B Lipid Study (MK-0524B-063)",[89],"2008-06-16","2007-06-15",2414,[14418,16417],[22385,13135,22386],"Comparator: simvastatin","MK-0524B",{"nctId":13126,"briefTitle":13127,"status":105,"phases":22388,"primaryCompletion":13129,"completion":13129,"start":13130,"enrollment":13131,"conditions":22389,"interventions":22390},[89],[13133],[13135,8011,13122],{"trials":22392,"activeCount":99},[],{"trials":22394,"activeCount":99},[],{"intervention":22396,"totalTrials":3963,"cells":22397},"Comparator: Modified Process Hepatitis B Vaccine",{"EARLY_PHASE1":22398,"PHASE1":22400,"PHASE2":22402,"PHASE3":22413,"PHASE4":22439,"NA":22441},{"trials":22399,"activeCount":99},[],{"trials":22401,"activeCount":99},[],{"trials":22403,"activeCount":99},[22404],{"nctId":22405,"briefTitle":22406,"status":105,"phases":22407,"primaryCompletion":13891,"completion":13891,"start":8621,"enrollment":22408,"conditions":22409,"interventions":22410},"NCT00322361","Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056)",[88],566,[17593,1014],[22411,22412],"Comparator: RECOMBIVAX HB™","Comparator: Modified process Hepatitis B Vaccine",{"trials":22414,"activeCount":99},[22415,22423,22432],{"nctId":22416,"briefTitle":22417,"status":105,"phases":22418,"primaryCompletion":14858,"completion":14858,"start":4418,"enrollment":22419,"conditions":22420,"interventions":22421},"NCT00393523","Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED)",[89],1478,[17593],[22396,22422],"Comparator: Comparator: ENGERIX-B",{"nctId":22424,"briefTitle":22425,"status":105,"phases":22426,"primaryCompletion":13890,"completion":13890,"start":15038,"enrollment":19135,"conditions":22427,"interventions":22429},"NCT00440297","Hepatitis B Vaccine Predialysis\u002FDialysis Study (V232-060)",[89],[22428],"Hepatitis B Virus Infection",[22430,22431],"Comparator: modified process hepatitis B vaccine","Comparator: ENGERIX-B™",{"nctId":22433,"briefTitle":22434,"status":105,"phases":22435,"primaryCompletion":14504,"completion":14504,"start":12814,"enrollment":1387,"conditions":22436,"interventions":22437},"NCT00440531","Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)",[89],[17593],[22438,22396,22431],"Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine",{"trials":22440,"activeCount":99},[],{"trials":22442,"activeCount":99},[],{"intervention":22444,"totalTrials":3963,"cells":22445},"PEG-Intron",{"EARLY_PHASE1":22446,"PHASE1":22448,"PHASE2":22458,"PHASE3":22460,"PHASE4":22488,"NA":22490},{"trials":22447,"activeCount":99},[],{"trials":22449,"activeCount":99},[22450],{"nctId":22451,"briefTitle":22452,"status":105,"phases":22453,"primaryCompletion":22454,"completion":22455,"start":15921,"enrollment":626,"conditions":22456,"interventions":22457},"NCT00457418","High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)",[87],"2008-05-27","2012-07-11",[35],[22444],{"trials":22459,"activeCount":99},[],{"trials":22461,"activeCount":99},[22462,22472,22479],{"nctId":22463,"briefTitle":22464,"status":105,"phases":22465,"primaryCompletion":22466,"completion":22466,"start":22467,"enrollment":22468,"conditions":22469,"interventions":22470},"NCT03537274","Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)",[88,89],"1999-07-23","1997-08-05",1224,[24],[22444,22471],"Interferon Alfa-2B",{"nctId":22473,"briefTitle":22474,"status":105,"phases":22475,"primaryCompletion":22476,"completion":22476,"start":22317,"enrollment":13234,"conditions":22477,"interventions":22478},"NCT00035360","Phase III PEG-Intron in HIV-infected Patients (Study P00738)",[89],"2003-10",[27,14889],[22444],{"nctId":22480,"briefTitle":22481,"status":150,"phases":22482,"primaryCompletion":22483,"completion":22483,"start":22484,"enrollment":1550,"conditions":22485,"interventions":22486},"NCT03552549","SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)",[88,89],"2001-02-19","1998-08-05",[35],[22444,22487],"INTRON A",{"trials":22489,"activeCount":99},[],{"trials":22491,"activeCount":99},[],{"intervention":1100,"totalTrials":3963,"cells":22493},{"EARLY_PHASE1":22494,"PHASE1":22496,"PHASE2":22498,"PHASE3":22508,"PHASE4":22518,"NA":22520},{"trials":22495,"activeCount":99},[],{"trials":22497,"activeCount":99},[],{"trials":22499,"activeCount":99},[22500,22504],{"nctId":1091,"briefTitle":1092,"status":105,"phases":22501,"primaryCompletion":1094,"completion":1094,"start":1095,"enrollment":1096,"conditions":22502,"interventions":22503},[87,88],[702,35],[47,1099,1100],{"nctId":1243,"briefTitle":1244,"status":105,"phases":22505,"primaryCompletion":1246,"completion":1247,"start":1248,"enrollment":1249,"conditions":22506,"interventions":22507},[87,88],[1251],[47,387,386,841,385,1100,1253,1254],{"trials":22509,"activeCount":99},[22510,22514],{"nctId":2272,"briefTitle":2273,"status":105,"phases":22511,"primaryCompletion":2275,"completion":2276,"start":2277,"enrollment":2278,"conditions":22512,"interventions":22513},[89],[35],[47,1100],{"nctId":2679,"briefTitle":2680,"status":105,"phases":22515,"primaryCompletion":2682,"completion":2683,"start":2684,"enrollment":2685,"conditions":22516,"interventions":22517},[89],[369],[47,1100],{"trials":22519,"activeCount":99},[],{"trials":22521,"activeCount":99},[],{"intervention":13885,"totalTrials":3963,"cells":22523},{"EARLY_PHASE1":22524,"PHASE1":22526,"PHASE2":22539,"PHASE3":22545,"PHASE4":22563,"NA":22565},{"trials":22525,"activeCount":99},[],{"trials":22527,"activeCount":99},[22528],{"nctId":22529,"briefTitle":22530,"status":105,"phases":22531,"primaryCompletion":13140,"completion":22532,"start":22533,"enrollment":4059,"conditions":22534,"interventions":22535},"NCT01582308","A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)",[87],"2012-12-14","2012-06-21",[15],[13885,22536,22537,22538],"Saxagliptin 5 mg","Vildagliptin 50 mg","Vildagliptin 50 mg BID",{"trials":22540,"activeCount":99},[22541],{"nctId":13875,"briefTitle":13876,"status":105,"phases":22542,"primaryCompletion":13878,"completion":13878,"start":9143,"enrollment":13879,"conditions":22543,"interventions":22544},[88],[33],[13882,13883,13884,13885,4084],{"trials":22546,"activeCount":99},[22547,22551],{"nctId":20374,"briefTitle":20375,"status":105,"phases":22548,"primaryCompletion":2694,"completion":2694,"start":20377,"enrollment":20378,"conditions":22549,"interventions":22550},[89],[15],[13883,14147,13885,20381,20382,20383],{"nctId":22552,"briefTitle":22553,"status":105,"phases":22554,"primaryCompletion":22555,"completion":22555,"start":22556,"enrollment":22557,"conditions":22558,"interventions":22559},"NCT01076088","Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)",[89],"2012-12-24","2010-11-15",744,[15],[22560,22561,13885,22562],"Sitagliptin 50 mg","Metformin 500 mg","Metformin 850 mg",{"trials":22564,"activeCount":99},[],{"trials":22566,"activeCount":99},[],{"intervention":22568,"totalTrials":3963,"cells":22569},"Clesrovimab",{"EARLY_PHASE1":22570,"PHASE1":22572,"PHASE2":22574,"PHASE3":22597,"PHASE4":22618,"NA":22620},{"trials":22571,"activeCount":99},[],{"trials":22573,"activeCount":99},[],{"trials":22575,"activeCount":99},[22576,22587],{"nctId":22577,"briefTitle":22578,"status":105,"phases":22579,"primaryCompletion":22580,"completion":22581,"start":22582,"enrollment":1479,"conditions":22583,"interventions":22585},"NCT04086472","Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005)",[88],"2020-03-22","2020-08-14","2019-10-28",[22584],"Respiratory Syncytial Viruses",[22568,22586],"RSV-A Memphis 37b",{"nctId":22588,"briefTitle":22589,"status":105,"phases":22590,"primaryCompletion":22591,"completion":22591,"start":22592,"enrollment":22593,"conditions":22594,"interventions":22596},"NCT03524118","Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)",[87,88],"2022-09-14","2018-09-20",183,[22595,9437],"Respiratory Tract Infection",[22568],{"trials":22598,"activeCount":99},[22599,22608],{"nctId":22600,"briefTitle":22601,"status":105,"phases":22602,"primaryCompletion":22603,"completion":22603,"start":2534,"enrollment":22604,"conditions":22605,"interventions":22607},"NCT04767373","Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)",[88,89],"2024-07-09",3632,[22606],"Respiratory Syncytial Virus Infection",[22568],{"nctId":22609,"briefTitle":22610,"status":105,"phases":22611,"primaryCompletion":6177,"completion":22612,"start":22613,"enrollment":1703,"conditions":22614,"interventions":22616},"NCT04938830","Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)",[89],"2025-08-01","2021-11-30",[22615],"RSV Infection",[22568,22617],"Palivizumab",{"trials":22619,"activeCount":99},[],{"trials":22621,"activeCount":99},[],{"intervention":22623,"totalTrials":3963,"cells":22624},"denufosol tetrasodium (INS37217) Inhalation Solution",{"EARLY_PHASE1":22625,"PHASE1":22627,"PHASE2":22629,"PHASE3":22646,"PHASE4":22662,"NA":22664},{"trials":22626,"activeCount":99},[],{"trials":22628,"activeCount":99},[],{"trials":22630,"activeCount":99},[22631,22640],{"nctId":22632,"briefTitle":22633,"status":105,"phases":22634,"primaryCompletion":22635,"completion":22635,"start":22636,"enrollment":18999,"conditions":22637,"interventions":22639},"NCT00034515","A Study in Adult and Pediatric Patients With Cystic Fibrosis",[87,88],"2002-08","2001-06",[22638],"Cystic Fibrosis",[22623],{"nctId":22641,"briefTitle":22642,"status":150,"phases":22643,"primaryCompletion":13890,"completion":13890,"start":5507,"enrollment":4555,"conditions":22644,"interventions":22645},"NCT00425165","Study of Denufosol Inhalation Solution in Patients With Mild to Moderate Cystic Fibrosis Lung Disease",[88],[22638],[22623],{"trials":22647,"activeCount":99},[22648,22654],{"nctId":22649,"briefTitle":22650,"status":105,"phases":22651,"primaryCompletion":14315,"completion":14315,"start":14531,"enrollment":7388,"conditions":22652,"interventions":22653},"NCT00357279","Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease",[89],[22638],[22623],{"nctId":22655,"briefTitle":22656,"status":105,"phases":22657,"primaryCompletion":5179,"completion":5179,"start":5281,"enrollment":22658,"conditions":22659,"interventions":22660},"NCT00625612","Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease",[89],466,[22638],[22661],"Denufosol Tetrasodium (INS37217) Inhalation Solution",{"trials":22663,"activeCount":99},[],{"trials":22665,"activeCount":99},[],{"intervention":13914,"totalTrials":202,"cells":22667},{"EARLY_PHASE1":22668,"PHASE1":22670,"PHASE2":22672,"PHASE3":22678,"PHASE4":22688,"NA":22690},{"trials":22669,"activeCount":99},[],{"trials":22671,"activeCount":99},[],{"trials":22673,"activeCount":99},[22674],{"nctId":13904,"briefTitle":13905,"status":105,"phases":22675,"primaryCompletion":13907,"completion":13908,"start":13909,"enrollment":13910,"conditions":22676,"interventions":22677},[88],[15],[13913,13914,4084],{"trials":22679,"activeCount":99},[22680,22684],{"nctId":13953,"briefTitle":13954,"status":105,"phases":22681,"primaryCompletion":13956,"completion":13956,"start":13957,"enrollment":13958,"conditions":22682,"interventions":22683},[89],[15],[13145,13864,13914,4084,13961],{"nctId":14089,"briefTitle":14090,"status":105,"phases":22685,"primaryCompletion":14092,"completion":14093,"start":14094,"enrollment":14095,"conditions":22686,"interventions":22687},[89],[14097],[13145,4084,13914],{"trials":22689,"activeCount":99},[],{"trials":22691,"activeCount":99},[],{"intervention":22087,"totalTrials":202,"cells":22693},{"EARLY_PHASE1":22694,"PHASE1":22696,"PHASE2":22698,"PHASE3":22700,"PHASE4":22717,"NA":22719},{"trials":22695,"activeCount":99},[],{"trials":22697,"activeCount":99},[],{"trials":22699,"activeCount":99},[],{"trials":22701,"activeCount":99},[22702,22706,22713],{"nctId":22082,"briefTitle":22083,"status":105,"phases":22703,"primaryCompletion":18426,"completion":18426,"start":15118,"enrollment":312,"conditions":22704,"interventions":22705},[89],[16668],[16673,16673,16673,22087,22088],{"nctId":22707,"briefTitle":22708,"status":105,"phases":22709,"primaryCompletion":22710,"completion":22710,"start":20637,"enrollment":13439,"conditions":22711,"interventions":22712},"NCT00559468","Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028)",[89],"2007-03-02",[17011],[17013,16687,22087,22088],{"nctId":22100,"briefTitle":22101,"status":105,"phases":22714,"primaryCompletion":14875,"completion":14875,"start":14567,"enrollment":3390,"conditions":22715,"interventions":22716},[89],[22104],[16673,16673,22087,22088],{"trials":22718,"activeCount":99},[],{"trials":22720,"activeCount":99},[],{"intervention":22088,"totalTrials":202,"cells":22722},{"EARLY_PHASE1":22723,"PHASE1":22725,"PHASE2":22727,"PHASE3":22729,"PHASE4":22743,"NA":22745},{"trials":22724,"activeCount":99},[],{"trials":22726,"activeCount":99},[],{"trials":22728,"activeCount":99},[],{"trials":22730,"activeCount":99},[22731,22735,22739],{"nctId":22082,"briefTitle":22083,"status":105,"phases":22732,"primaryCompletion":18426,"completion":18426,"start":15118,"enrollment":312,"conditions":22733,"interventions":22734},[89],[16668],[16673,16673,16673,22087,22088],{"nctId":22707,"briefTitle":22708,"status":105,"phases":22736,"primaryCompletion":22710,"completion":22710,"start":20637,"enrollment":13439,"conditions":22737,"interventions":22738},[89],[17011],[17013,16687,22087,22088],{"nctId":22100,"briefTitle":22101,"status":105,"phases":22740,"primaryCompletion":14875,"completion":14875,"start":14567,"enrollment":3390,"conditions":22741,"interventions":22742},[89],[22104],[16673,16673,22087,22088],{"trials":22744,"activeCount":99},[],{"trials":22746,"activeCount":99},[],{"intervention":22166,"totalTrials":202,"cells":22748},{"EARLY_PHASE1":22749,"PHASE1":22751,"PHASE2":22753,"PHASE3":22759,"PHASE4":22769,"NA":22771},{"trials":22750,"activeCount":99},[],{"trials":22752,"activeCount":99},[],{"trials":22754,"activeCount":99},[22755],{"nctId":22159,"briefTitle":22160,"status":105,"phases":22756,"primaryCompletion":22162,"completion":22162,"start":1945,"enrollment":1977,"conditions":22757,"interventions":22758},[88],[22164],[22141,22166,22167],{"trials":22760,"activeCount":99},[22761,22765],{"nctId":22181,"briefTitle":22182,"status":105,"phases":22762,"primaryCompletion":22184,"completion":22184,"start":1042,"enrollment":22185,"conditions":22763,"interventions":22764},[89],[22187],[22141,22166,22167],{"nctId":22219,"briefTitle":22220,"status":105,"phases":22766,"primaryCompletion":12984,"completion":12984,"start":15794,"enrollment":7686,"conditions":22767,"interventions":22768},[89],[18450,22223],[22194,22225,22226],{"trials":22770,"activeCount":99},[],{"trials":22772,"activeCount":99},[],{"intervention":22167,"totalTrials":202,"cells":22774},{"EARLY_PHASE1":22775,"PHASE1":22777,"PHASE2":22779,"PHASE3":22789,"PHASE4":22795,"NA":22797},{"trials":22776,"activeCount":99},[],{"trials":22778,"activeCount":99},[],{"trials":22780,"activeCount":99},[22781,22785],{"nctId":22159,"briefTitle":22160,"status":105,"phases":22782,"primaryCompletion":22162,"completion":22162,"start":1945,"enrollment":1977,"conditions":22783,"interventions":22784},[88],[22164],[22141,22166,22167],{"nctId":22169,"briefTitle":22170,"status":105,"phases":22786,"primaryCompletion":22172,"completion":22172,"start":22173,"enrollment":15267,"conditions":22787,"interventions":22788},[88],[22175,22176],[22141,22167],{"trials":22790,"activeCount":99},[22791],{"nctId":22181,"briefTitle":22182,"status":105,"phases":22792,"primaryCompletion":22184,"completion":22184,"start":1042,"enrollment":22185,"conditions":22793,"interventions":22794},[89],[22187],[22141,22166,22167],{"trials":22796,"activeCount":99},[],{"trials":22798,"activeCount":99},[],{"intervention":19913,"totalTrials":202,"cells":22800},{"EARLY_PHASE1":22801,"PHASE1":22803,"PHASE2":22805,"PHASE3":22807,"PHASE4":22821,"NA":22823},{"trials":22802,"activeCount":99},[],{"trials":22804,"activeCount":99},[],{"trials":22806,"activeCount":99},[],{"trials":22808,"activeCount":99},[22809,22813,22817],{"nctId":19906,"briefTitle":19907,"status":105,"phases":22810,"primaryCompletion":19909,"completion":19910,"start":13199,"enrollment":13958,"conditions":22811,"interventions":22812},[89],[17064],[13203,19913,19914,19915],{"nctId":19917,"briefTitle":19918,"status":105,"phases":22814,"primaryCompletion":1320,"completion":1320,"start":4070,"enrollment":19920,"conditions":22815,"interventions":22816},[89],[19146],[13203,19913,19914],{"nctId":19941,"briefTitle":19942,"status":105,"phases":22818,"primaryCompletion":2022,"completion":2022,"start":6178,"enrollment":19944,"conditions":22819,"interventions":22820},[89],[13187],[13203,19913,19914],{"trials":22822,"activeCount":99},[],{"trials":22824,"activeCount":99},[],{"intervention":14377,"totalTrials":202,"cells":22826},{"EARLY_PHASE1":22827,"PHASE1":22829,"PHASE2":22844,"PHASE3":22846,"PHASE4":22852,"NA":22854},{"trials":22828,"activeCount":99},[],{"trials":22830,"activeCount":99},[22831,22835],{"nctId":14369,"briefTitle":14370,"status":105,"phases":22832,"primaryCompletion":14372,"completion":14372,"start":14373,"enrollment":154,"conditions":22833,"interventions":22834},[87],[30],[14376,14377,13864],{"nctId":22836,"briefTitle":22837,"status":105,"phases":22838,"primaryCompletion":13224,"completion":4990,"start":14623,"enrollment":95,"conditions":22839,"interventions":22840},"NCT00856960","The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males (MK-0000-127)",[87],[30],[22841,22841,14377,22842,22843],"Aliskiren","Comparator: Placebo to Aliskiren","Comparator: Placebo to Losartan",{"trials":22845,"activeCount":99},[],{"trials":22847,"activeCount":99},[22848],{"nctId":15222,"briefTitle":15223,"status":105,"phases":22849,"primaryCompletion":15225,"completion":15226,"start":15227,"enrollment":15228,"conditions":22850,"interventions":22851},[89],[30],[15231,15232,13864],{"trials":22853,"activeCount":99},[],{"trials":22855,"activeCount":99},[],{"intervention":22857,"totalTrials":202,"cells":22858},"Lonafarnib",{"EARLY_PHASE1":22859,"PHASE1":22861,"PHASE2":22863,"PHASE3":22872,"PHASE4":22893,"NA":22895},{"trials":22860,"activeCount":99},[],{"trials":22862,"activeCount":99},[],{"trials":22864,"activeCount":99},[22865],{"nctId":22866,"briefTitle":22867,"status":105,"phases":22868,"primaryCompletion":14352,"completion":14352,"start":14875,"enrollment":4474,"conditions":22869,"interventions":22870},"NCT00081510","Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)",[88],[1109],[22857,22871],"anastrozole",{"trials":22873,"activeCount":99},[22874,22884],{"nctId":22875,"briefTitle":22876,"status":150,"phases":22877,"primaryCompletion":21850,"completion":15001,"start":22878,"enrollment":22879,"conditions":22880,"interventions":22883},"NCT00050336","Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)",[89],"2002-12",702,[22881,22882],"Carcinoma, Non-small-cell Lung","Metastases, Neoplasm",[22857],{"nctId":22885,"briefTitle":22886,"status":150,"phases":22887,"primaryCompletion":13102,"completion":13102,"start":14930,"enrollment":14576,"conditions":22888,"interventions":22892},"NCT00109538","Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)",[89],[196,22889,22890,22891],"Leukemia, Myelomonocytic, Chronic","Myelodysplasia","Myelomonocytic",[22857],{"trials":22894,"activeCount":99},[],{"trials":22896,"activeCount":99},[],{"intervention":22898,"totalTrials":202,"cells":22899},"Hydrochlorothiazide",{"EARLY_PHASE1":22900,"PHASE1":22902,"PHASE2":22922,"PHASE3":22924,"PHASE4":22930,"NA":22932},{"trials":22901,"activeCount":99},[],{"trials":22903,"activeCount":99},[22904,22913],{"nctId":22905,"briefTitle":22906,"status":105,"phases":22907,"primaryCompletion":6308,"completion":13224,"start":14314,"enrollment":287,"conditions":22908,"interventions":22909},"NCT00871871","Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis (MK-0000-117)(Completed)",[87],[30],[22898,22910,22911,22912],"Comparator: Placebo to HCTZ","Isosorbide mononitrate","Comparator: Placebo to ISMN",{"nctId":22914,"briefTitle":22915,"status":105,"phases":22916,"primaryCompletion":22917,"completion":22918,"start":22919,"enrollment":212,"conditions":22920,"interventions":22921},"NCT01370655","A Study of MK-7145 Compared to Placebo and Hydrochlorothiazide for Lowering Blood Pressure in Male Participants With Hypertension (MK-7145-009)",[87],"2011-12-19","2012-01-26","2011-06-15",[30],[13272,22898],{"trials":22923,"activeCount":99},[],{"trials":22925,"activeCount":99},[22926],{"nctId":15485,"briefTitle":15486,"status":105,"phases":22927,"primaryCompletion":15390,"completion":15225,"start":15488,"enrollment":15489,"conditions":22928,"interventions":22929},[89],[30],[15231,14331,15492],{"trials":22931,"activeCount":99},[],{"trials":22933,"activeCount":99},[],{"intervention":21038,"totalTrials":202,"cells":22935},{"EARLY_PHASE1":22936,"PHASE1":22938,"PHASE2":22940,"PHASE3":22942,"PHASE4":22956,"NA":22958},{"trials":22937,"activeCount":99},[],{"trials":22939,"activeCount":99},[],{"trials":22941,"activeCount":99},[],{"trials":22943,"activeCount":99},[22944,22948,22952],{"nctId":21023,"briefTitle":21024,"status":105,"phases":22945,"primaryCompletion":21026,"completion":1095,"start":15835,"enrollment":19628,"conditions":22946,"interventions":22947},[89],[21],[21016,21029,15820],{"nctId":21031,"briefTitle":21032,"status":105,"phases":22949,"primaryCompletion":21034,"completion":21034,"start":21035,"enrollment":184,"conditions":22950,"interventions":22951},[89],[21],[14923,21038,15820],{"nctId":21040,"briefTitle":21041,"status":105,"phases":22953,"primaryCompletion":21043,"completion":14112,"start":21044,"enrollment":13805,"conditions":22954,"interventions":22955},[89],[21],[21016,21038,15820],{"trials":22957,"activeCount":99},[],{"trials":22959,"activeCount":99},[],{"intervention":8303,"totalTrials":202,"cells":22961},{"EARLY_PHASE1":22962,"PHASE1":22964,"PHASE2":22980,"PHASE3":22982,"PHASE4":22994,"NA":22996},{"trials":22963,"activeCount":99},[],{"trials":22965,"activeCount":99},[22966,22970],{"nctId":8293,"briefTitle":8294,"status":105,"phases":22967,"primaryCompletion":8296,"completion":8296,"start":8297,"enrollment":931,"conditions":22968,"interventions":22969},[87],[8299],[8301,8302,8303],{"nctId":22971,"briefTitle":22972,"status":105,"phases":22973,"primaryCompletion":22974,"completion":22975,"start":454,"enrollment":626,"conditions":22976,"interventions":22978},"NCT02750761","A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to \u003C12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)",[87],"2018-12-16","2018-12-21",[22977],"Gram-Positive Bacterial Infections",[22979,22979],"Tedizolid Phosphate",{"trials":22981,"activeCount":99},[],{"trials":22983,"activeCount":99},[22984],{"nctId":22985,"briefTitle":22986,"status":105,"phases":22987,"primaryCompletion":493,"completion":493,"start":22988,"enrollment":920,"conditions":22989,"interventions":22991},"NCT03176134","A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)",[89],"2019-01-20",[22990],"Acute Bacterial Skin and Skin Structure Infections",[22992,22993],"Tedizolid phosphate","Comparator",{"trials":22995,"activeCount":99},[],{"trials":22997,"activeCount":99},[],{"intervention":22999,"totalTrials":202,"cells":23000},"ProQuad®",{"EARLY_PHASE1":23001,"PHASE1":23003,"PHASE2":23005,"PHASE3":23007,"PHASE4":23038,"NA":23040},{"trials":23002,"activeCount":99},[],{"trials":23004,"activeCount":99},[],{"trials":23006,"activeCount":99},[],{"trials":23008,"activeCount":99},[23009,23018,23029],{"nctId":23010,"briefTitle":23011,"status":105,"phases":23012,"primaryCompletion":23013,"completion":23013,"start":23014,"enrollment":23015,"conditions":23016,"interventions":23017},"NCT00402831","ProQuad® Intramuscular vs Subcutaneous",[89],"2007-05-11","2006-10-06",405,[15308,15309,15310,15311],[22999],{"nctId":23019,"briefTitle":23020,"status":105,"phases":23021,"primaryCompletion":4756,"completion":4756,"start":23022,"enrollment":23023,"conditions":23024,"interventions":23027},"NCT00432042","Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)",[89],"2007-01-12",955,[15311,15308,15309,15310,20573,20574,20575,23025,17593,23026],"Poliomyelitis","Haemophilus Infections",[22999,23028],"Infanrix® hexa",{"nctId":23030,"briefTitle":23031,"status":105,"phases":23032,"primaryCompletion":23033,"completion":23033,"start":23034,"enrollment":23035,"conditions":23036,"interventions":23037},"NCT00560755","Safety Study of ProQuad® rHA in Infants (V221-037)",[89],"2008-11-24","2007-10-24",3388,[15308,15309,15310,15311],[22999],{"trials":23039,"activeCount":99},[],{"trials":23041,"activeCount":99},[],{"intervention":15363,"totalTrials":202,"cells":23043},{"EARLY_PHASE1":23044,"PHASE1":23046,"PHASE2":23048,"PHASE3":23050,"PHASE4":23064,"NA":23066},{"trials":23045,"activeCount":99},[],{"trials":23047,"activeCount":99},[],{"trials":23049,"activeCount":99},[],{"trials":23051,"activeCount":99},[23052,23056,23060],{"nctId":16320,"briefTitle":16321,"status":105,"phases":23053,"primaryCompletion":15329,"completion":15329,"start":16323,"enrollment":3605,"conditions":23054,"interventions":23055},[89],[15111],[4424,15363],{"nctId":15357,"briefTitle":15358,"status":105,"phases":23057,"primaryCompletion":15330,"completion":15330,"start":15360,"enrollment":1818,"conditions":23058,"interventions":23059},[89],[15111],[4424,15363,13864],{"nctId":21420,"briefTitle":21421,"status":105,"phases":23061,"primaryCompletion":15351,"completion":21423,"start":21424,"enrollment":20366,"conditions":23062,"interventions":23063},[89],[15111],[15113,15363],{"trials":23065,"activeCount":99},[],{"trials":23067,"activeCount":99},[],{"intervention":6802,"totalTrials":202,"cells":23069},{"EARLY_PHASE1":23070,"PHASE1":23072,"PHASE2":23082,"PHASE3":23084,"PHASE4":23096,"NA":23098},{"trials":23071,"activeCount":99},[],{"trials":23073,"activeCount":99},[23074,23078],{"nctId":6795,"briefTitle":6796,"status":105,"phases":23075,"primaryCompletion":6798,"completion":6798,"start":6799,"enrollment":174,"conditions":23076,"interventions":23077},[87],[5538,5539],[6802,4349],{"nctId":608,"briefTitle":609,"status":150,"phases":23079,"primaryCompletion":611,"completion":611,"start":612,"enrollment":613,"conditions":23080,"interventions":23081},[87],[615,616,617],[42,619],{"trials":23083,"activeCount":99},[],{"trials":23085,"activeCount":99},[23086],{"nctId":23087,"briefTitle":23088,"status":105,"phases":23089,"primaryCompletion":23090,"completion":23090,"start":23091,"enrollment":347,"conditions":23092,"interventions":23094},"NCT01580228","A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)",[89],"2014-12","2012-08",[23093],"Chronic Lymphocytic Leukemia (CLL)",[6802,23095],"Ofatumumab",{"trials":23097,"activeCount":99},[],{"trials":23099,"activeCount":99},[],{"intervention":15245,"totalTrials":202,"cells":23101},{"EARLY_PHASE1":23102,"PHASE1":23104,"PHASE2":23114,"PHASE3":23124,"PHASE4":23130,"NA":23132},{"trials":23103,"activeCount":99},[],{"trials":23105,"activeCount":99},[23106],{"nctId":23107,"briefTitle":23108,"status":105,"phases":23109,"primaryCompletion":14314,"completion":14314,"start":14858,"enrollment":931,"conditions":23110,"interventions":23111},"NCT01000818","A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)",[87],[7639,27],[15245,23112,23113],"famotidine","omeprazole",{"trials":23115,"activeCount":99},[23116],{"nctId":23117,"briefTitle":23118,"status":105,"phases":23119,"primaryCompletion":8619,"completion":14713,"start":15211,"enrollment":23120,"conditions":23121,"interventions":23122},"NCT00105157","Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)",[88],179,[27,21124],[23123,15245,15245],"Comparator: MK0518",{"trials":23125,"activeCount":99},[23126],{"nctId":15240,"briefTitle":15241,"status":150,"phases":23127,"primaryCompletion":9610,"completion":9610,"start":14409,"enrollment":7388,"conditions":23128,"interventions":23129},[89],[7650],[15245,15246,14331,14331],{"trials":23131,"activeCount":99},[],{"trials":23133,"activeCount":99},[],{"intervention":3342,"totalTrials":202,"cells":23135},{"EARLY_PHASE1":23136,"PHASE1":23138,"PHASE2":23140,"PHASE3":23142,"PHASE4":23156,"NA":23158},{"trials":23137,"activeCount":99},[],{"trials":23139,"activeCount":99},[],{"trials":23141,"activeCount":99},[],{"trials":23143,"activeCount":99},[23144,23148,23152],{"nctId":3332,"briefTitle":3333,"status":105,"phases":23145,"primaryCompletion":3335,"completion":3336,"start":3337,"enrollment":3338,"conditions":23146,"interventions":23147},[89],[2537],[84,390,386,385,3341,3342],{"nctId":2112,"briefTitle":2113,"status":105,"phases":23149,"primaryCompletion":2115,"completion":2116,"start":2117,"enrollment":2118,"conditions":23150,"interventions":23151},[89],[314],[42,483,484,486,2121],{"nctId":3385,"briefTitle":3386,"status":105,"phases":23153,"primaryCompletion":3388,"completion":3336,"start":3389,"enrollment":3390,"conditions":23154,"interventions":23155},[89],[2537],[84,390,386,385,3341,3342],{"trials":23157,"activeCount":99},[],{"trials":23159,"activeCount":99},[],{"intervention":14535,"totalTrials":202,"cells":23161},{"EARLY_PHASE1":23162,"PHASE1":23164,"PHASE2":23177,"PHASE3":23179,"PHASE4":23191,"NA":23193},{"trials":23163,"activeCount":99},[],{"trials":23165,"activeCount":99},[23166,23170],{"nctId":14528,"briefTitle":14529,"status":105,"phases":23167,"primaryCompletion":14531,"completion":14531,"start":14228,"enrollment":826,"conditions":23168,"interventions":23169},[87],[14533],[14535,13864],{"nctId":23171,"briefTitle":23172,"status":105,"phases":23173,"primaryCompletion":14858,"completion":14858,"start":8620,"enrollment":3390,"conditions":23174,"interventions":23176},"NCT00735839","V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)",[87],[23175],"Staphylococcal Infection",[14535],{"trials":23178,"activeCount":99},[],{"trials":23180,"activeCount":99},[23181],{"nctId":23182,"briefTitle":23183,"status":150,"phases":23184,"primaryCompletion":16591,"completion":16591,"start":14454,"enrollment":23185,"conditions":23186,"interventions":23190},"NCT00518687","Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)",[88,89],8031,[23187,23188,23189],"Staphylococcus Aureus","Bacteremia","Mediastinitis",[14535],{"trials":23192,"activeCount":99},[],{"trials":23194,"activeCount":99},[],{"intervention":16476,"totalTrials":202,"cells":23196},{"EARLY_PHASE1":23197,"PHASE1":23199,"PHASE2":23201,"PHASE3":23207,"PHASE4":23217,"NA":23219},{"trials":23198,"activeCount":99},[],{"trials":23200,"activeCount":99},[],{"trials":23202,"activeCount":99},[23203],{"nctId":21651,"briefTitle":21652,"status":105,"phases":23204,"primaryCompletion":20197,"completion":20197,"start":21619,"enrollment":21654,"conditions":23205,"interventions":23206},[88],[21656],[21658,21659,21659,16464,16476],{"trials":23208,"activeCount":99},[23209,23213],{"nctId":16468,"briefTitle":16469,"status":105,"phases":23210,"primaryCompletion":1640,"completion":1640,"start":1984,"enrollment":3605,"conditions":23211,"interventions":23212},[89],[16472],[16465,16474,16441,16475,16476,16477,16478,16479],{"nctId":16481,"briefTitle":16482,"status":105,"phases":23214,"primaryCompletion":16484,"completion":16484,"start":709,"enrollment":16485,"conditions":23215,"interventions":23216},[89],[16472,16487],[16474,16465,16441,16475,16476,16489,16490,16479,16477],{"trials":23218,"activeCount":99},[],{"trials":23220,"activeCount":99},[],{"intervention":19833,"totalTrials":202,"cells":23222},{"EARLY_PHASE1":23223,"PHASE1":23225,"PHASE2":23227,"PHASE3":23243,"PHASE4":23254,"NA":23256},{"trials":23224,"activeCount":99},[],{"trials":23226,"activeCount":99},[],{"trials":23228,"activeCount":99},[23229,23239],{"nctId":23230,"briefTitle":23231,"status":105,"phases":23232,"primaryCompletion":23233,"completion":23234,"start":23235,"enrollment":5196,"conditions":23236,"interventions":23237},"NCT02133131","Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)",[88],"2015-11-02","2016-02-01","2014-06-13",[24],[23238,19833],"Grazoprevir\u002FElbasvir FDC",{"nctId":19825,"briefTitle":19826,"status":105,"phases":23240,"primaryCompletion":19828,"completion":19829,"start":19830,"enrollment":2788,"conditions":23241,"interventions":23242},[88],[24],[15839,17381,14925,19833],{"trials":23244,"activeCount":99},[23245],{"nctId":23246,"briefTitle":23247,"status":105,"phases":23248,"primaryCompletion":23249,"completion":23250,"start":16765,"enrollment":15960,"conditions":23251,"interventions":23252},"NCT02358044","Efficacy and Safety of Combination Grazoprevir (MK-5172)\u002FElbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)",[89],"2015-11-26","2016-02-16",[24],[19833,15828,14925,23253],"Grazoprevir\u002FElbasvir (100 mg\u002F50 mg) FDC",{"trials":23255,"activeCount":99},[],{"trials":23257,"activeCount":99},[],{"intervention":14963,"totalTrials":202,"cells":23259},{"EARLY_PHASE1":23260,"PHASE1":23262,"PHASE2":23264,"PHASE3":23270,"PHASE4":23283,"NA":23285},{"trials":23261,"activeCount":99},[],{"trials":23263,"activeCount":99},[],{"trials":23265,"activeCount":99},[23266],{"nctId":14956,"briefTitle":14957,"status":105,"phases":23267,"primaryCompletion":14959,"completion":14959,"start":14960,"enrollment":1169,"conditions":23268,"interventions":23269},[88],[9239],[14963,13864],{"trials":23271,"activeCount":99},[23272,23279],{"nctId":23273,"briefTitle":23274,"status":105,"phases":23275,"primaryCompletion":23276,"completion":23276,"start":19657,"enrollment":688,"conditions":23277,"interventions":23278},"NCT01245764","GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)",[89],"2013-04-15",[7076],[14963],{"nctId":15494,"briefTitle":15495,"status":105,"phases":23280,"primaryCompletion":15497,"completion":15497,"start":15498,"enrollment":1818,"conditions":23281,"interventions":23282},[89],[7076],[14963,13864],{"trials":23284,"activeCount":99},[],{"trials":23286,"activeCount":99},[],{"intervention":528,"totalTrials":202,"cells":23288},{"EARLY_PHASE1":23289,"PHASE1":23291,"PHASE2":23301,"PHASE3":23303,"PHASE4":23309,"NA":23311},{"trials":23290,"activeCount":99},[],{"trials":23292,"activeCount":99},[23293,23297],{"nctId":520,"briefTitle":521,"status":150,"phases":23294,"primaryCompletion":523,"completion":523,"start":524,"enrollment":22,"conditions":23295,"interventions":23296},[87],[526],[47,528,529,530],{"nctId":5165,"briefTitle":5166,"status":105,"phases":23298,"primaryCompletion":5168,"completion":5169,"start":5170,"enrollment":4741,"conditions":23299,"interventions":23300},[87],[5172],[5174,528,529],{"trials":23302,"activeCount":99},[],{"trials":23304,"activeCount":99},[23305],{"nctId":2028,"briefTitle":2029,"status":150,"phases":23306,"primaryCompletion":2031,"completion":2032,"start":2033,"enrollment":2034,"conditions":23307,"interventions":23308},[89],[526],[47,528,529],{"trials":23310,"activeCount":99},[],{"trials":23312,"activeCount":99},[],{"intervention":22385,"totalTrials":202,"cells":23314},{"EARLY_PHASE1":23315,"PHASE1":23317,"PHASE2":23319,"PHASE3":23321,"PHASE4":23344,"NA":23346},{"trials":23316,"activeCount":99},[],{"trials":23318,"activeCount":99},[],{"trials":23320,"activeCount":99},[],{"trials":23322,"activeCount":99},[23323,23332,23336],{"nctId":23324,"briefTitle":23325,"status":105,"phases":23326,"primaryCompletion":15210,"completion":15210,"start":14484,"enrollment":23327,"conditions":23328,"interventions":23329},"NCT00269217","Lipid Efficacy Study (0524B-022)(COMPLETED)",[89],1400,[14418,13133],[23330,23331,22385],"niacin (+) laropiprant (+) simvastatin","Comparator: niacin (+) laropiprant",{"nctId":22377,"briefTitle":22378,"status":105,"phases":23333,"primaryCompletion":22380,"completion":22380,"start":22381,"enrollment":22382,"conditions":23334,"interventions":23335},[89],[14418,16417],[22385,13135,22386],{"nctId":23337,"briefTitle":23338,"status":105,"phases":23339,"primaryCompletion":5801,"completion":6309,"start":13891,"enrollment":23340,"conditions":23341,"interventions":23342},"NCT00479388","Study of Extended Release Niacin\u002FLaropiprant on Lipids (0524A-067)",[89],1216,[14418,16417],[22385,14420,23343],"Comparator: atorvastatin calcium",{"trials":23345,"activeCount":99},[],{"trials":23347,"activeCount":99},[],{"intervention":2066,"totalTrials":202,"cells":23349},{"EARLY_PHASE1":23350,"PHASE1":23352,"PHASE2":23354,"PHASE3":23356,"PHASE4":23370,"NA":23372},{"trials":23351,"activeCount":99},[],{"trials":23353,"activeCount":99},[],{"trials":23355,"activeCount":99},[],{"trials":23357,"activeCount":99},[23358,23362,23366],{"nctId":2059,"briefTitle":2060,"status":105,"phases":23359,"primaryCompletion":535,"completion":535,"start":2062,"enrollment":2063,"conditions":23360,"interventions":23361},[89],[371],[42,1369,2066,2067],{"nctId":11123,"briefTitle":11124,"status":105,"phases":23363,"primaryCompletion":11126,"completion":7292,"start":11127,"enrollment":11128,"conditions":23364,"interventions":23365},[89],[419],[1594,2066,2067],{"nctId":11132,"briefTitle":11133,"status":105,"phases":23367,"primaryCompletion":11126,"completion":7292,"start":9424,"enrollment":1977,"conditions":23368,"interventions":23369},[89],[419],[1594,2066,2067],{"trials":23371,"activeCount":99},[],{"trials":23373,"activeCount":99},[],{"intervention":2067,"totalTrials":202,"cells":23375},{"EARLY_PHASE1":23376,"PHASE1":23378,"PHASE2":23380,"PHASE3":23382,"PHASE4":23396,"NA":23398},{"trials":23377,"activeCount":99},[],{"trials":23379,"activeCount":99},[],{"trials":23381,"activeCount":99},[],{"trials":23383,"activeCount":99},[23384,23388,23392],{"nctId":2059,"briefTitle":2060,"status":105,"phases":23385,"primaryCompletion":535,"completion":535,"start":2062,"enrollment":2063,"conditions":23386,"interventions":23387},[89],[371],[42,1369,2066,2067],{"nctId":11123,"briefTitle":11124,"status":105,"phases":23389,"primaryCompletion":11126,"completion":7292,"start":11127,"enrollment":11128,"conditions":23390,"interventions":23391},[89],[419],[1594,2066,2067],{"nctId":11132,"briefTitle":11133,"status":105,"phases":23393,"primaryCompletion":11126,"completion":7292,"start":9424,"enrollment":1977,"conditions":23394,"interventions":23395},[89],[419],[1594,2066,2067],{"trials":23397,"activeCount":99},[],{"trials":23399,"activeCount":99},[],{"intervention":23401,"totalTrials":202,"cells":23402},"Vorapaxar",{"EARLY_PHASE1":23403,"PHASE1":23405,"PHASE2":23407,"PHASE3":23418,"PHASE4":23439,"NA":23441},{"trials":23404,"activeCount":99},[],{"trials":23406,"activeCount":99},[],{"trials":23408,"activeCount":99},[23409],{"nctId":23410,"briefTitle":23411,"status":105,"phases":23412,"primaryCompletion":23413,"completion":23413,"start":4357,"enrollment":2023,"conditions":23414,"interventions":23417},"NCT00684203","Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)",[88],"2007-10-01",[23415,23416,9614],"Atherosclerosis","Myocardial Ischemia",[23401,14431,14432],{"trials":23419,"activeCount":99},[23420,23429],{"nctId":23421,"briefTitle":23422,"status":150,"phases":23423,"primaryCompletion":23424,"completion":23424,"start":23425,"enrollment":23426,"conditions":23427,"interventions":23428},"NCT00527943","Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)",[89],"2011-07-01","2007-12-01",12944,[23415,23416,9614],[23401],{"nctId":23430,"briefTitle":23431,"status":105,"phases":23432,"primaryCompletion":23433,"completion":23433,"start":14252,"enrollment":23434,"conditions":23435,"interventions":23438},"NCT00526474","Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)",[89],"2011-12-01",26449,[23415,23436,9614,21940,23437],"Ischemia","Peripheral Arterial Disease",[23401],{"trials":23440,"activeCount":99},[],{"trials":23442,"activeCount":99},[],{"intervention":23444,"totalTrials":202,"cells":23445},"Ipragliflozin",{"EARLY_PHASE1":23446,"PHASE1":23448,"PHASE2":23450,"PHASE3":23452,"PHASE4":23478,"NA":23480},{"trials":23447,"activeCount":99},[],{"trials":23449,"activeCount":99},[],{"trials":23451,"activeCount":99},[],{"trials":23453,"activeCount":99},[23454,23461,23469],{"nctId":23455,"briefTitle":23456,"status":105,"phases":23457,"primaryCompletion":1660,"completion":1660,"start":23458,"enrollment":22,"conditions":23459,"interventions":23460},"NCT02564211","Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)",[89],"2015-10-26",[15],[23444,13145],{"nctId":23462,"briefTitle":23463,"status":105,"phases":23464,"primaryCompletion":23465,"completion":23465,"start":23466,"enrollment":5196,"conditions":23467,"interventions":23468},"NCT02577003","Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)",[89],"2016-11-25","2015-11-09",[15],[23444,13145],{"nctId":23470,"briefTitle":23471,"status":105,"phases":23472,"primaryCompletion":23473,"completion":23473,"start":23474,"enrollment":23475,"conditions":23476,"interventions":23477},"NCT02577016","Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)",[89],"2016-11-18","2015-11-05",141,[15],[13145,23444],{"trials":23479,"activeCount":99},[],{"trials":23481,"activeCount":99},[],{"intervention":5154,"totalTrials":202,"cells":23483},{"EARLY_PHASE1":23484,"PHASE1":23486,"PHASE2":23492,"PHASE3":23494,"PHASE4":23508,"NA":23510},{"trials":23485,"activeCount":99},[],{"trials":23487,"activeCount":99},[23488],{"nctId":5143,"briefTitle":5144,"status":150,"phases":23489,"primaryCompletion":5146,"completion":5146,"start":5147,"enrollment":5148,"conditions":23490,"interventions":23491},[87],[5150],[5152,5153,5154,5137,529],{"trials":23493,"activeCount":99},[],{"trials":23495,"activeCount":99},[23496,23504],{"nctId":23497,"briefTitle":23498,"status":105,"phases":23499,"primaryCompletion":14228,"completion":14228,"start":14976,"enrollment":8175,"conditions":23500,"interventions":23502},"NCT00231777","A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)",[89],[23501],"Post-Operative Nausea and Vomiting",[23503,5154],"Comparator: MK0517",{"nctId":16351,"briefTitle":16352,"status":105,"phases":23505,"primaryCompletion":16354,"completion":16355,"start":16356,"enrollment":16357,"conditions":23506,"interventions":23507},[89],[5150],[4424,5154,16360,5285,16361,16361],{"trials":23509,"activeCount":99},[],{"trials":23511,"activeCount":99},[],{"intervention":20747,"totalTrials":202,"cells":23513},{"EARLY_PHASE1":23514,"PHASE1":23516,"PHASE2":23525,"PHASE3":23531,"PHASE4":23540,"NA":23542},{"trials":23515,"activeCount":99},[],{"trials":23517,"activeCount":99},[23518],{"nctId":23519,"briefTitle":23520,"status":105,"phases":23521,"primaryCompletion":14823,"completion":14823,"start":14858,"enrollment":4059,"conditions":23522,"interventions":23523},"NCT00772967","A Study to Evaluate the Effect of Analgesics on a Walking Model of Knee Pain (0000-105)(COMPLETED)",[87],[21195],[20747,23524],"Ultracet",{"trials":23526,"activeCount":99},[23527],{"nctId":20739,"briefTitle":20740,"status":105,"phases":23528,"primaryCompletion":635,"completion":635,"start":20742,"enrollment":20743,"conditions":23529,"interventions":23530},[88],[20745],[20714,20747],{"trials":23532,"activeCount":99},[23533],{"nctId":23534,"briefTitle":23535,"status":105,"phases":23536,"primaryCompletion":16802,"completion":12985,"start":14445,"enrollment":1827,"conditions":23537,"interventions":23539},"NCT00844805","Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)",[89],[16739,23538],"Axial Spondyloarthritis",[8594,20747],{"trials":23541,"activeCount":99},[],{"trials":23543,"activeCount":99},[],{"intervention":14647,"totalTrials":202,"cells":23545},{"EARLY_PHASE1":23546,"PHASE1":23548,"PHASE2":23561,"PHASE3":23563,"PHASE4":23569,"NA":23571},{"trials":23547,"activeCount":99},[],{"trials":23549,"activeCount":99},[23550,23557],{"nctId":23551,"briefTitle":23552,"status":105,"phases":23553,"primaryCompletion":15210,"completion":15210,"start":8619,"enrollment":18221,"conditions":23554,"interventions":23555},"NCT00944645","MK0524A Bioequivalence Study (0524A-059)",[87],[14337],[23556,14647],"niacin",{"nctId":14638,"briefTitle":14639,"status":105,"phases":23558,"primaryCompletion":14641,"completion":14642,"start":14643,"enrollment":3506,"conditions":23559,"interventions":23560},[87],[7598],[14646,14647,14423,14331],{"trials":23562,"activeCount":99},[],{"trials":23564,"activeCount":99},[23565],{"nctId":15541,"briefTitle":15542,"status":150,"phases":23566,"primaryCompletion":13102,"completion":13102,"start":4418,"enrollment":15544,"conditions":23567,"interventions":23568},[89],[15546],[14647,14331],{"trials":23570,"activeCount":99},[],{"trials":23572,"activeCount":99},[],{"intervention":23574,"totalTrials":202,"cells":23575},"MK-1293",{"EARLY_PHASE1":23576,"PHASE1":23578,"PHASE2":23591,"PHASE3":23593,"PHASE4":23613,"NA":23615},{"trials":23577,"activeCount":99},[],{"trials":23579,"activeCount":99},[23580],{"nctId":23581,"briefTitle":23582,"status":105,"phases":23583,"primaryCompletion":23584,"completion":23585,"start":23586,"enrollment":1190,"conditions":23587,"interventions":23588},"NCT02059174","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)",[87],"2015-03-30","2015-04-27","2014-02-10",[4255],[23574,23589,23590],"EU-Lantus™","Novolog™",{"trials":23592,"activeCount":99},[],{"trials":23594,"activeCount":99},[23595,23604],{"nctId":23596,"briefTitle":23597,"status":105,"phases":23598,"primaryCompletion":19870,"completion":19870,"start":23599,"enrollment":3092,"conditions":23600,"interventions":23601},"NCT02059187","The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)",[89],"2014-02-11",[15],[23574,23602,23603],"Lantus™","Prandial insulin",{"nctId":23605,"briefTitle":23606,"status":105,"phases":23607,"primaryCompletion":19848,"completion":660,"start":23608,"enrollment":23609,"conditions":23610,"interventions":23611},"NCT02059161","A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)",[89],"2013-10-17",508,[4255],[23574,23602,23612],"Prandial Insulin",{"trials":23614,"activeCount":99},[],{"trials":23616,"activeCount":99},[],{"intervention":13931,"totalTrials":202,"cells":23618},{"EARLY_PHASE1":23619,"PHASE1":23621,"PHASE2":23632,"PHASE3":23638,"PHASE4":23644,"NA":23646},{"trials":23620,"activeCount":99},[],{"trials":23622,"activeCount":99},[23623],{"nctId":23624,"briefTitle":23625,"status":105,"phases":23626,"primaryCompletion":23627,"completion":23627,"start":23628,"enrollment":23629,"conditions":23630,"interventions":23631},"NCT01982630","Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)",[87],"2014-10-03","2013-11-07",87,[13950],[13930,13931],{"trials":23633,"activeCount":99},[23634],{"nctId":13922,"briefTitle":13923,"status":150,"phases":23635,"primaryCompletion":13925,"completion":13925,"start":13926,"enrollment":13927,"conditions":23636,"interventions":23637},[88],[13853],[13930,13931,4084],{"trials":23639,"activeCount":99},[23640],{"nctId":14161,"briefTitle":14162,"status":105,"phases":23641,"primaryCompletion":14164,"completion":14164,"start":14165,"enrollment":14166,"conditions":23642,"interventions":23643},[89],[33],[14126,14169,14170,14040],{"trials":23645,"activeCount":99},[],{"trials":23647,"activeCount":99},[],{"intervention":23649,"totalTrials":202,"cells":23650},"Diquafosol tetrasodium ophthalmic solution, 2%",{"EARLY_PHASE1":23651,"PHASE1":23653,"PHASE2":23655,"PHASE3":23657,"PHASE4":23682,"NA":23684},{"trials":23652,"activeCount":99},[],{"trials":23654,"activeCount":99},[],{"trials":23656,"activeCount":99},[],{"trials":23658,"activeCount":99},[23659,23665,23673],{"nctId":23660,"briefTitle":23661,"status":105,"phases":23662,"primaryCompletion":13101,"completion":13101,"start":13870,"enrollment":6255,"conditions":23663,"interventions":23664},"NCT00831662","The Effects of Diquafosol Tetrasodium Ophthalmic Solution, 2% in Subjects With Dry Eye Disease (P08637)",[89],[16625],[23649],{"nctId":23666,"briefTitle":23667,"status":105,"phases":23668,"primaryCompletion":14706,"completion":14706,"start":14229,"enrollment":23669,"conditions":23670,"interventions":23671},"NCT00403975","Study of Diquafosol Tetrasodium Ophthalmic Solution in Subjects With Dry Eye Disease",[89],640,[16625],[23672],"diquafosol tetrasodium ophthalmic solution, 2%",{"nctId":23674,"briefTitle":23675,"status":105,"phases":23676,"primaryCompletion":13890,"completion":13890,"start":14687,"enrollment":23677,"conditions":23678,"interventions":23679},"NCT00600288","Study of the Effect of Diquafosol Tetrasodium Ophthalmic Solution, 2% Versus Placebo in Dry Eye Subjects (P08634)",[89],261,[16625],[23680,23681],"diquafosol tetrasodium Ophthalmic Solution, 2%","Non-preserved saline solution",{"trials":23683,"activeCount":99},[],{"trials":23685,"activeCount":99},[],{"intervention":9338,"totalTrials":3197,"cells":23687},{"EARLY_PHASE1":23688,"PHASE1":23690,"PHASE2":23692,"PHASE3":23698,"PHASE4":23704,"NA":23706},{"trials":23689,"activeCount":99},[],{"trials":23691,"activeCount":99},[],{"trials":23693,"activeCount":99},[23694],{"nctId":9330,"briefTitle":9331,"status":105,"phases":23695,"primaryCompletion":9333,"completion":9333,"start":9334,"enrollment":1122,"conditions":23696,"interventions":23697},[88],[9336],[9285,9338],{"trials":23699,"activeCount":99},[23700],{"nctId":9342,"briefTitle":9343,"status":105,"phases":23701,"primaryCompletion":9345,"completion":9346,"start":9347,"enrollment":9348,"conditions":23702,"interventions":23703},[89],[9307],[9285,9338],{"trials":23705,"activeCount":99},[],{"trials":23707,"activeCount":99},[],{"intervention":23709,"totalTrials":3197,"cells":23710},"Org 50081",{"EARLY_PHASE1":23711,"PHASE1":23713,"PHASE2":23722,"PHASE3":23724,"PHASE4":23733,"NA":23735},{"trials":23712,"activeCount":99},[],{"trials":23714,"activeCount":99},[23715],{"nctId":23716,"briefTitle":23717,"status":105,"phases":23718,"primaryCompletion":14315,"completion":14315,"start":14540,"enrollment":626,"conditions":23719,"interventions":23720},"NCT00798395","A Study to Assess the Effect of Single and Multiple Doses Org 50081 and a Single Dose of Zopiclone on Next-day Driving Ability and Psychomotor Performance in Healthy Volunteers. (P05794) (COMPLETED)",[87],[9368,20657],[23709,23709,23721],"zopiclone",{"trials":23723,"activeCount":99},[],{"trials":23725,"activeCount":99},[23726],{"nctId":23727,"briefTitle":23728,"status":105,"phases":23729,"primaryCompletion":23730,"completion":23730,"start":20637,"enrollment":14849,"conditions":23731,"interventions":23732},"NCT00610675","Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708)",[89],"2009-08-17",[9307],[23709],{"trials":23734,"activeCount":99},[],{"trials":23736,"activeCount":99},[],{"intervention":19662,"totalTrials":3197,"cells":23738},{"EARLY_PHASE1":23739,"PHASE1":23741,"PHASE2":23743,"PHASE3":23754,"PHASE4":23760,"NA":23762},{"trials":23740,"activeCount":99},[],{"trials":23742,"activeCount":99},[],{"trials":23744,"activeCount":99},[23745],{"nctId":23746,"briefTitle":23747,"status":105,"phases":23748,"primaryCompletion":5800,"completion":5800,"start":8591,"enrollment":20638,"conditions":23749,"interventions":23750},"NCT00996801","MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)",[88],[14552,19620],[23751,23752,19662,23753],"MK-5442","Alendronate Sodium","Calcium carbonate",{"trials":23755,"activeCount":99},[23756],{"nctId":19653,"briefTitle":19654,"status":105,"phases":23757,"primaryCompletion":19656,"completion":19657,"start":19658,"enrollment":19659,"conditions":23758,"interventions":23759},[89],[14552],[14554,19662,19663],{"trials":23761,"activeCount":99},[],{"trials":23763,"activeCount":99},[],{"intervention":23765,"totalTrials":3197,"cells":23766},"ER niacin",{"EARLY_PHASE1":23767,"PHASE1":23769,"PHASE2":23771,"PHASE3":23773,"PHASE4":23786,"NA":23788},{"trials":23768,"activeCount":99},[],{"trials":23770,"activeCount":99},[],{"trials":23772,"activeCount":99},[],{"trials":23774,"activeCount":99},[23775,23782],{"nctId":23776,"briefTitle":23777,"status":105,"phases":23778,"primaryCompletion":11479,"completion":11479,"start":14730,"enrollment":21304,"conditions":23779,"interventions":23780},"NCT00961636","A Long-term Study of ERN\u002FLRPT (Extended Release Niacin\u002FLaropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)",[89],[14337],[23765,23765,23781],"Extended-release niacin",{"nctId":22368,"briefTitle":22369,"status":105,"phases":23783,"primaryCompletion":15210,"completion":15210,"start":14531,"enrollment":22371,"conditions":23784,"interventions":23785},[89],[22373,7610],[13135,22375],{"trials":23787,"activeCount":99},[],{"trials":23789,"activeCount":99},[],{"intervention":15172,"totalTrials":3197,"cells":23791},{"EARLY_PHASE1":23792,"PHASE1":23794,"PHASE2":23796,"PHASE3":23798,"PHASE4":23811,"NA":23813},{"trials":23793,"activeCount":99},[],{"trials":23795,"activeCount":99},[],{"trials":23797,"activeCount":99},[],{"trials":23799,"activeCount":99},[23800,23807],{"nctId":23801,"briefTitle":23802,"status":105,"phases":23803,"primaryCompletion":14566,"completion":14566,"start":6309,"enrollment":23804,"conditions":23805,"interventions":23806},"NCT00764946","A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)",[89],209,[7310],[15172],{"nctId":15166,"briefTitle":15167,"status":150,"phases":23808,"primaryCompletion":6309,"completion":9610,"start":14409,"enrollment":15169,"conditions":23809,"interventions":23810},[89],[7650],[15172,14331,15173,14331],{"trials":23812,"activeCount":99},[],{"trials":23814,"activeCount":99},[],{"intervention":23816,"totalTrials":3197,"cells":23817},"Modified Process Hepatitis B Vaccine",{"EARLY_PHASE1":23818,"PHASE1":23820,"PHASE2":23822,"PHASE3":23824,"PHASE4":23842,"NA":23844},{"trials":23819,"activeCount":99},[],{"trials":23821,"activeCount":99},[],{"trials":23823,"activeCount":99},[],{"trials":23825,"activeCount":99},[23826,23835],{"nctId":23827,"briefTitle":23828,"status":105,"phases":23829,"primaryCompletion":23830,"completion":23034,"start":23014,"enrollment":23831,"conditions":23832,"interventions":23833},"NCT00414050","A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)",[89],"2007-10-22",1718,[17593],[23816,23834,23834],"Hepatitis B Vaccine",{"nctId":23836,"briefTitle":23837,"status":105,"phases":23838,"primaryCompletion":23839,"completion":23839,"start":21498,"enrollment":20528,"conditions":23840,"interventions":23841},"NCT01251276","Hepatitis B Challenge Dose in Adults (V232-059-10)",[89],"2011-04-12",[17593],[23816],{"trials":23843,"activeCount":99},[],{"trials":23845,"activeCount":99},[],{"intervention":5254,"totalTrials":3197,"cells":23847},{"EARLY_PHASE1":23848,"PHASE1":23850,"PHASE2":23852,"PHASE3":23858,"PHASE4":23864,"NA":23866},{"trials":23849,"activeCount":99},[],{"trials":23851,"activeCount":99},[],{"trials":23853,"activeCount":99},[23854],{"nctId":16227,"briefTitle":16228,"status":105,"phases":23855,"primaryCompletion":13039,"completion":13039,"start":16230,"enrollment":16231,"conditions":23856,"interventions":23857},[88],[5252],[5254,5313,5137,16234],{"trials":23859,"activeCount":99},[23860],{"nctId":5246,"briefTitle":5247,"status":150,"phases":23861,"primaryCompletion":5249,"completion":5249,"start":5250,"enrollment":613,"conditions":23862,"interventions":23863},[89],[5252],[5254,5137,529,5255],{"trials":23865,"activeCount":99},[],{"trials":23867,"activeCount":99},[],{"intervention":5313,"totalTrials":3197,"cells":23869},{"EARLY_PHASE1":23870,"PHASE1":23872,"PHASE2":23874,"PHASE3":23880,"PHASE4":23886,"NA":23888},{"trials":23871,"activeCount":99},[],{"trials":23873,"activeCount":99},[],{"trials":23875,"activeCount":99},[23876],{"nctId":16227,"briefTitle":16228,"status":105,"phases":23877,"primaryCompletion":13039,"completion":13039,"start":16230,"enrollment":16231,"conditions":23878,"interventions":23879},[88],[5252],[5254,5313,5137,16234],{"trials":23881,"activeCount":99},[23882],{"nctId":5305,"briefTitle":5306,"status":105,"phases":23883,"primaryCompletion":5308,"completion":5308,"start":5309,"enrollment":5310,"conditions":23884,"interventions":23885},[89],[5181],[4294,5313,529,5137,5314,5315,5316],{"trials":23887,"activeCount":99},[],{"trials":23889,"activeCount":99},[],{"intervention":23891,"totalTrials":3197,"cells":23892},"Varicella Virus Vaccine Live",{"EARLY_PHASE1":23893,"PHASE1":23895,"PHASE2":23897,"PHASE3":23899,"PHASE4":23918,"NA":23920},{"trials":23894,"activeCount":99},[],{"trials":23896,"activeCount":99},[],{"trials":23898,"activeCount":99},[],{"trials":23900,"activeCount":99},[23901,23909],{"nctId":23902,"briefTitle":23903,"status":105,"phases":23904,"primaryCompletion":23905,"completion":23905,"start":23906,"enrollment":920,"conditions":23907,"interventions":23908},"NCT00496327","Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056)",[89],"2005-10-06","2005-06-22",[15311],[23891],{"nctId":23910,"briefTitle":23911,"status":105,"phases":23912,"primaryCompletion":14730,"completion":13101,"start":13870,"enrollment":23913,"conditions":23914,"interventions":23915},"NCT00822237","Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)",[89],598,[15311],[23891,23916,23917],"Comparator: Varicella Virus Vaccine Live","Measles, Mumps, and Rubella Virus Vaccine Live",{"trials":23919,"activeCount":99},[],{"trials":23921,"activeCount":99},[],{"intervention":1751,"totalTrials":3197,"cells":23923},{"EARLY_PHASE1":23924,"PHASE1":23926,"PHASE2":23928,"PHASE3":23934,"PHASE4":23940,"NA":23942},{"trials":23925,"activeCount":99},[],{"trials":23927,"activeCount":99},[],{"trials":23929,"activeCount":99},[23930],{"nctId":5818,"briefTitle":5819,"status":105,"phases":23931,"primaryCompletion":5821,"completion":5821,"start":5822,"enrollment":2647,"conditions":23932,"interventions":23933},[88],[419],[2905,437,693,795,5825,5826,1751],{"trials":23935,"activeCount":99},[23936],{"nctId":1742,"briefTitle":1743,"status":105,"phases":23937,"primaryCompletion":824,"completion":1745,"start":1746,"enrollment":1747,"conditions":23938,"interventions":23939},[89],[828],[1750,1751,47,841,693],{"trials":23941,"activeCount":99},[],{"trials":23943,"activeCount":99},[],{"intervention":15138,"totalTrials":3197,"cells":23945},{"EARLY_PHASE1":23946,"PHASE1":23948,"PHASE2":23950,"PHASE3":23952,"PHASE4":23962,"NA":23964},{"trials":23947,"activeCount":99},[],{"trials":23949,"activeCount":99},[],{"trials":23951,"activeCount":99},[],{"trials":23953,"activeCount":99},[23954,23958],{"nctId":15132,"briefTitle":15133,"status":105,"phases":23955,"primaryCompletion":14540,"completion":5981,"start":6464,"enrollment":15135,"conditions":23956,"interventions":23957},[89],[27],[15138,14331],{"nctId":15234,"briefTitle":15235,"status":105,"phases":23959,"primaryCompletion":5507,"completion":5981,"start":6464,"enrollment":7388,"conditions":23960,"interventions":23961},[89],[27],[15138,13864],{"trials":23963,"activeCount":99},[],{"trials":23965,"activeCount":99},[],{"intervention":16463,"totalTrials":3197,"cells":23967},{"EARLY_PHASE1":23968,"PHASE1":23970,"PHASE2":23972,"PHASE3":23974,"PHASE4":23984,"NA":23986},{"trials":23969,"activeCount":99},[],{"trials":23971,"activeCount":99},[],{"trials":23973,"activeCount":99},[],{"trials":23975,"activeCount":99},[23976,23980],{"nctId":16452,"briefTitle":16453,"status":105,"phases":23977,"primaryCompletion":16455,"completion":16456,"start":16457,"enrollment":16458,"conditions":23978,"interventions":23979},[89],[16460,16461],[16463,16464,16465,16441,16466],{"nctId":16492,"briefTitle":16493,"status":105,"phases":23981,"primaryCompletion":16495,"completion":16495,"start":16496,"enrollment":16497,"conditions":23982,"interventions":23983},[89],[16460,16461],[16463,16500,16501,16465,16441,16464,16466,16502],{"trials":23985,"activeCount":99},[],{"trials":23987,"activeCount":99},[],{"intervention":16466,"totalTrials":3197,"cells":23989},{"EARLY_PHASE1":23990,"PHASE1":23992,"PHASE2":23994,"PHASE3":23996,"PHASE4":24006,"NA":24008},{"trials":23991,"activeCount":99},[],{"trials":23993,"activeCount":99},[],{"trials":23995,"activeCount":99},[],{"trials":23997,"activeCount":99},[23998,24002],{"nctId":16452,"briefTitle":16453,"status":105,"phases":23999,"primaryCompletion":16455,"completion":16456,"start":16457,"enrollment":16458,"conditions":24000,"interventions":24001},[89],[16460,16461],[16463,16464,16465,16441,16466],{"nctId":16492,"briefTitle":16493,"status":105,"phases":24003,"primaryCompletion":16495,"completion":16495,"start":16496,"enrollment":16497,"conditions":24004,"interventions":24005},[89],[16460,16461],[16463,16500,16501,16465,16441,16464,16466,16502],{"trials":24007,"activeCount":99},[],{"trials":24009,"activeCount":99},[],{"intervention":24011,"totalTrials":3197,"cells":24012},"MK0826, \u002FDuration of Treatment : 8 Weeks",{"EARLY_PHASE1":24013,"PHASE1":24015,"PHASE2":24017,"PHASE3":24019,"PHASE4":24038,"NA":24040},{"trials":24014,"activeCount":99},[],{"trials":24016,"activeCount":99},[],{"trials":24018,"activeCount":99},[],{"trials":24020,"activeCount":99},[24021,24030],{"nctId":24022,"briefTitle":24023,"status":105,"phases":24024,"primaryCompletion":14567,"completion":14567,"start":15295,"enrollment":1570,"conditions":24025,"interventions":24027},"NCT00481702","A Study to Evaluate the Safety and Effectiveness of Ertapenem Versus Ceftriaxone\u002FMetronidazole in the Treatment of Intra-abdominal Infections in Adults (0826-802)",[89],[24026],"Intra-abdominal Infection",[24028,24011,24029],"Comparator: ceftriaxone sodium \u002F Duration of Treatment: 8 Weeks","Comparator: metronidazole \u002F Duration of Treatment: 8 Weeks",{"nctId":24031,"briefTitle":24032,"status":105,"phases":24033,"primaryCompletion":14495,"completion":14495,"start":15258,"enrollment":1570,"conditions":24034,"interventions":24036},"NCT00389987","Ertapenem Sodium vs. Piperacillin\u002FTazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)",[89],[24035],"Complicated Intra-Abdominal Infections",[24011,24037],"Comparator : piperacillin sodium (+) tazobactam sodium \u002FDuration of Treatment : 8 Weeks",{"trials":24039,"activeCount":99},[],{"trials":24041,"activeCount":99},[],{"intervention":13983,"totalTrials":3197,"cells":24043},{"EARLY_PHASE1":24044,"PHASE1":24046,"PHASE2":24052,"PHASE3":24054,"PHASE4":24060,"NA":24062},{"trials":24045,"activeCount":99},[],{"trials":24047,"activeCount":99},[24048],{"nctId":20104,"briefTitle":20105,"status":105,"phases":24049,"primaryCompletion":20107,"completion":20107,"start":20108,"enrollment":1340,"conditions":24050,"interventions":24051},[87],[14277],[14588,13985,13983,20111],{"trials":24053,"activeCount":99},[],{"trials":24055,"activeCount":99},[24056],{"nctId":13973,"briefTitle":13974,"status":105,"phases":24057,"primaryCompletion":13976,"completion":13977,"start":13978,"enrollment":13979,"conditions":24058,"interventions":24059},[89],[15],[13982,13983,13984,13985,13986,4084,13987],{"trials":24061,"activeCount":99},[],{"trials":24063,"activeCount":99},[],{"intervention":13984,"totalTrials":3197,"cells":24065},{"EARLY_PHASE1":24066,"PHASE1":24068,"PHASE2":24074,"PHASE3":24076,"PHASE4":24082,"NA":24084},{"trials":24067,"activeCount":99},[],{"trials":24069,"activeCount":99},[24070],{"nctId":20104,"briefTitle":20105,"status":105,"phases":24071,"primaryCompletion":20107,"completion":20107,"start":20108,"enrollment":1340,"conditions":24072,"interventions":24073},[87],[14277],[14588,13985,13983,20111],{"trials":24075,"activeCount":99},[],{"trials":24077,"activeCount":99},[24078],{"nctId":13973,"briefTitle":13974,"status":105,"phases":24079,"primaryCompletion":13976,"completion":13977,"start":13978,"enrollment":13979,"conditions":24080,"interventions":24081},[89],[15],[13982,13983,13984,13985,13986,4084,13987],{"trials":24083,"activeCount":99},[],{"trials":24085,"activeCount":99},[],{"intervention":24087,"totalTrials":3197,"cells":24088},"Telcagepant 280 mg",{"EARLY_PHASE1":24089,"PHASE1":24091,"PHASE2":24093,"PHASE3":24106,"PHASE4":24119,"NA":24121},{"trials":24090,"activeCount":99},[],{"trials":24092,"activeCount":99},[],{"trials":24094,"activeCount":99},[24095],{"nctId":24096,"briefTitle":24097,"status":150,"phases":24098,"primaryCompletion":24099,"completion":24099,"start":24100,"enrollment":13995,"conditions":24101,"interventions":24102},"NCT00797667","MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)",[88],"2009-05-20","2008-11-12",[4397],[24103,24087,24104,24105],"Telcagepant 140 mg","140 mg telcagepant placebo","280 mg telcagepant placebo",{"trials":24107,"activeCount":99},[24108],{"nctId":24109,"briefTitle":24110,"status":105,"phases":24111,"primaryCompletion":24112,"completion":24112,"start":24113,"enrollment":24114,"conditions":24115,"interventions":24116},"NCT00443209","Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)",[89],"2009-01-22","2007-02-21",1068,[4397],[24117,24087,24118],"Telcagepant 300 mg soft gel","Rizatriptan 10 mg",{"trials":24120,"activeCount":99},[],{"trials":24122,"activeCount":99},[],{"intervention":24124,"totalTrials":3197,"cells":24125},"VARIVAX™ 2007 process",{"EARLY_PHASE1":24126,"PHASE1":24128,"PHASE2":24130,"PHASE3":24132,"PHASE4":24153,"NA":24155},{"trials":24127,"activeCount":99},[],{"trials":24129,"activeCount":99},[],{"trials":24131,"activeCount":99},[],{"trials":24133,"activeCount":99},[24134,24143],{"nctId":24135,"briefTitle":24136,"status":105,"phases":24137,"primaryCompletion":1560,"completion":1879,"start":24138,"enrollment":987,"conditions":24139,"interventions":24140},"NCT02062502","Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)",[89],"2014-03-07",[15311],[24141,24124,24142],"VARIVAX™ New Seed Process","M-M-R II™",{"nctId":24144,"briefTitle":24145,"status":1040,"phases":24146,"primaryCompletion":24147,"completion":24147,"start":24148,"enrollment":99,"conditions":24149,"interventions":24150},"NCT01626794","A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062)",[89],"2015-10","2014-07",[15311],[24151,24152,16478],"VARIVAX™ VEP","VARIVAX™ 2007 Process",{"trials":24154,"activeCount":99},[],{"trials":24156,"activeCount":99},[],{"intervention":24158,"totalTrials":3197,"cells":24159},"MK0826, ertapenem sodium",{"EARLY_PHASE1":24160,"PHASE1":24162,"PHASE2":24164,"PHASE3":24175,"PHASE4":24187,"NA":24189},{"trials":24161,"activeCount":99},[],{"trials":24163,"activeCount":99},[],{"trials":24165,"activeCount":99},[24166],{"nctId":24167,"briefTitle":24168,"status":105,"phases":24169,"primaryCompletion":18807,"completion":18807,"start":22317,"enrollment":920,"conditions":24170,"interventions":24173},"NCT00092170","An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038)",[88],[24171,24172],"Infections","Pelvic Infections",[24158,24174],"Comparator: Ticarcillin\u002FClavulanate",{"trials":24176,"activeCount":99},[24177],{"nctId":24178,"briefTitle":24179,"status":105,"phases":24180,"primaryCompletion":15211,"completion":15211,"start":24181,"enrollment":24182,"conditions":24183,"interventions":24185},"NCT00090272","A Single Dose of a Marketed Drug Being Studied for a New Indication to Treat Surgical Site Infection Following Colorectal Surgery as Compared to a Marketed Drug Approved for This Indication (0826-039)",[89],"2002-04",952,[24184],"Colorectal Surgery",[24158,24186],"Comparator: cefotetan",{"trials":24188,"activeCount":99},[],{"trials":24190,"activeCount":99},[],{"intervention":24192,"totalTrials":3197,"cells":24193},"Imipenem+Cilastatin\u002FRelebactam",{"EARLY_PHASE1":24194,"PHASE1":24196,"PHASE2":24198,"PHASE3":24200,"PHASE4":24219,"NA":24221},{"trials":24195,"activeCount":99},[],{"trials":24197,"activeCount":99},[],{"trials":24199,"activeCount":99},[],{"trials":24201,"activeCount":99},[24202,24209],{"nctId":24203,"briefTitle":24204,"status":105,"phases":24205,"primaryCompletion":19226,"completion":19226,"start":24206,"enrollment":13103,"conditions":24207,"interventions":24208},"NCT03293485","Efficacy and Safety of Imipenem+Cilastatin\u002FRelebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)",[89],"2017-10-04",[18809,22175],[24192],{"nctId":24210,"briefTitle":24211,"status":105,"phases":24212,"primaryCompletion":24213,"completion":24213,"start":24214,"enrollment":4421,"conditions":24215,"interventions":24216},"NCT02452047","Efficacy and Safety of Imipenem+Cilastatin\u002FRelebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)",[89],"2017-09-18","2015-08-21",[16460],[24192,24217,24218],"Colistimethate sodium","Imipenem+Cilastatin",{"trials":24220,"activeCount":99},[],{"trials":24222,"activeCount":99},[],{"intervention":17139,"totalTrials":3197,"cells":24224},{"EARLY_PHASE1":24225,"PHASE1":24227,"PHASE2":24229,"PHASE3":24231,"PHASE4":24246,"NA":24248},{"trials":24226,"activeCount":99},[],{"trials":24228,"activeCount":99},[],{"trials":24230,"activeCount":99},[],{"trials":24232,"activeCount":99},[24233,24237],{"nctId":17131,"briefTitle":17132,"status":105,"phases":24234,"primaryCompletion":17134,"completion":17134,"start":17135,"enrollment":479,"conditions":24235,"interventions":24236},[89],[17137],[17120,17139,17140],{"nctId":24238,"briefTitle":24239,"status":105,"phases":24240,"primaryCompletion":14531,"completion":14531,"start":14593,"enrollment":13715,"conditions":24241,"interventions":24242},"NCT00108017","Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)",[89],[17137,17147],[24243,17139,24244,24245],"MK0507A, dorzolamide hydrochloride (+) timolol maleate","Duration of Treatment: Part 1) 6 wk timolol maleate run in","Part 2) 6 wk washout pd Part 3) two 8 wk active tx pds",{"trials":24247,"activeCount":99},[],{"trials":24249,"activeCount":99},[],{"intervention":24103,"totalTrials":3197,"cells":24251},{"EARLY_PHASE1":24252,"PHASE1":24254,"PHASE2":24256,"PHASE3":24262,"PHASE4":24275,"NA":24277},{"trials":24253,"activeCount":99},[],{"trials":24255,"activeCount":99},[],{"trials":24257,"activeCount":99},[24258],{"nctId":24096,"briefTitle":24097,"status":150,"phases":24259,"primaryCompletion":24099,"completion":24099,"start":24100,"enrollment":13995,"conditions":24260,"interventions":24261},[88],[4397],[24103,24087,24104,24105],{"trials":24263,"activeCount":99},[24264],{"nctId":24265,"briefTitle":24266,"status":105,"phases":24267,"primaryCompletion":24268,"completion":24268,"start":24269,"enrollment":24270,"conditions":24271,"interventions":24273},"NCT00483704","Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)",[89],"2009-03-25","2008-08-14",1935,[24272],"Migraines",[24103,24274],"Talcagepant 280 mg",{"trials":24276,"activeCount":99},[],{"trials":24278,"activeCount":99},[],{"intervention":24280,"totalTrials":3197,"cells":24281},"ZOSTAVAX",{"EARLY_PHASE1":24282,"PHASE1":24284,"PHASE2":24286,"PHASE3":24288,"PHASE4":24309,"NA":24311},{"trials":24283,"activeCount":99},[],{"trials":24285,"activeCount":99},[],{"trials":24287,"activeCount":99},[],{"trials":24289,"activeCount":99},[24290,24298],{"nctId":24291,"briefTitle":24292,"status":105,"phases":24293,"primaryCompletion":24294,"completion":24294,"start":24295,"enrollment":21479,"conditions":24296,"interventions":24297},"NCT01391546","Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045)",[89],"2012-10-15","2011-06-20",[14395],[24280],{"nctId":24299,"briefTitle":24300,"status":105,"phases":24301,"primaryCompletion":24302,"completion":24302,"start":24303,"enrollment":24304,"conditions":24305,"interventions":24307},"NCT00561080","Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)",[89],"2009-06-03","2007-10-26",759,[24306],"Prevention of : Herpes-Zoster",[24308],"Zostavax",{"trials":24310,"activeCount":99},[],{"trials":24312,"activeCount":99},[],{"intervention":14008,"totalTrials":3197,"cells":24314},{"EARLY_PHASE1":24315,"PHASE1":24317,"PHASE2":24319,"PHASE3":24321,"PHASE4":24331,"NA":24333},{"trials":24316,"activeCount":99},[],{"trials":24318,"activeCount":99},[],{"trials":24320,"activeCount":99},[],{"trials":24322,"activeCount":99},[24323,24327],{"nctId":14000,"briefTitle":14001,"status":105,"phases":24324,"primaryCompletion":14003,"completion":14003,"start":14004,"enrollment":14005,"conditions":24325,"interventions":24326},[89],[15],[13913,13146,14008,4084,13998],{"nctId":16044,"briefTitle":16045,"status":150,"phases":24328,"primaryCompletion":16047,"completion":16047,"start":16048,"enrollment":2801,"conditions":24329,"interventions":24330},[89],[15],[13913,13146,16051,14008],{"trials":24332,"activeCount":99},[],{"trials":24334,"activeCount":99},[],{"intervention":24336,"totalTrials":3197,"cells":24337},"Grazoprevir + Elbasvir",{"EARLY_PHASE1":24338,"PHASE1":24340,"PHASE2":24342,"PHASE3":24344,"PHASE4":24363,"NA":24365},{"trials":24339,"activeCount":99},[],{"trials":24341,"activeCount":99},[],{"trials":24343,"activeCount":99},[],{"trials":24345,"activeCount":99},[24346,24355],{"nctId":24347,"briefTitle":24348,"status":105,"phases":24349,"primaryCompletion":24350,"completion":9164,"start":24351,"enrollment":15029,"conditions":24352,"interventions":24354},"NCT02105701","Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)",[89],"2015-03-24","2014-06-05",[24353],"Hepatitis C Infection",[24336,14925],{"nctId":24356,"briefTitle":24357,"status":105,"phases":24358,"primaryCompletion":24359,"completion":24360,"start":1672,"enrollment":1409,"conditions":24361,"interventions":24362},"NCT02252016","Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)",[89],"2015-12-07","2016-06-14",[24],[24336],{"trials":24364,"activeCount":99},[],{"trials":24366,"activeCount":99},[],{"intervention":24368,"totalTrials":3197,"cells":24369},"MK-7625A 1.5 g",{"EARLY_PHASE1":24370,"PHASE1":24372,"PHASE2":24374,"PHASE3":24376,"PHASE4":24396,"NA":24398},{"trials":24371,"activeCount":99},[],{"trials":24373,"activeCount":99},[],{"trials":24375,"activeCount":99},[],{"trials":24377,"activeCount":99},[24378,24387],{"nctId":24379,"briefTitle":24380,"status":105,"phases":24381,"primaryCompletion":16764,"completion":16764,"start":24382,"enrollment":11225,"conditions":24383,"interventions":24386},"NCT02728089","Study of Ceftolozane\u002FTazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)",[89],"2016-04-14",[24384,22175,22176,24385],"Urinary Tract Infection (UTI)","Uncomplicated Pyelonephritis",[24368],{"nctId":24388,"briefTitle":24389,"status":105,"phases":24390,"primaryCompletion":24391,"completion":24391,"start":24392,"enrollment":920,"conditions":24393,"interventions":24394},"NCT02739997","Study of Ceftolozane\u002FTazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)",[89],"2017-07-28","2016-04-08",[24026,18809],[24368,24395],"metronidazole 500 mg",{"trials":24397,"activeCount":99},[],{"trials":24399,"activeCount":99},[],{"intervention":22471,"totalTrials":3197,"cells":24401},{"EARLY_PHASE1":24402,"PHASE1":24404,"PHASE2":24406,"PHASE3":24408,"PHASE4":24424,"NA":24426},{"trials":24403,"activeCount":99},[],{"trials":24405,"activeCount":99},[],{"trials":24407,"activeCount":99},[],{"trials":24409,"activeCount":99},[24410,24414],{"nctId":22463,"briefTitle":22464,"status":105,"phases":24411,"primaryCompletion":22466,"completion":22466,"start":22467,"enrollment":22468,"conditions":24412,"interventions":24413},[88,89],[24],[22444,22471],{"nctId":24415,"briefTitle":24416,"status":150,"phases":24417,"primaryCompletion":24418,"completion":24418,"start":24419,"enrollment":16682,"conditions":24420,"interventions":24422},"NCT03547154","Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)",[88,89],"2001-02-20","1998-10-22",[24421],"Chronic Myelogenous Leukemia",[15934,24423],"Interferon alfa-2b",{"trials":24425,"activeCount":99},[],{"trials":24427,"activeCount":99},[],{"intervention":24429,"totalTrials":3197,"cells":24430},"Adefovir dipivoxil",{"EARLY_PHASE1":24431,"PHASE1":24433,"PHASE2":24435,"PHASE3":24437,"PHASE4":24453,"NA":24455},{"trials":24432,"activeCount":99},[],{"trials":24434,"activeCount":99},[],{"trials":24436,"activeCount":99},[],{"trials":24438,"activeCount":99},[24439,24446],{"nctId":24440,"briefTitle":24441,"status":105,"phases":24442,"enrollment":2023,"conditions":24443,"interventions":24444},"NCT00002220","Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir",[89],[27],[17754,6235,24445,24429],"Levocarnitine",{"nctId":24447,"briefTitle":24448,"status":105,"phases":24449,"primaryCompletion":14313,"completion":14313,"start":4418,"enrollment":9323,"conditions":24450,"interventions":24452},"NCT00371761","PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498\u002FMK-4031-278)",[89],[24451],"Hepatitis B, Chronic (CHB)",[15934,24429],{"trials":24454,"activeCount":99},[],{"trials":24456,"activeCount":99},[],{"intervention":24458,"totalTrials":3197,"cells":24459},"Voriconazole",{"EARLY_PHASE1":24460,"PHASE1":24462,"PHASE2":24464,"PHASE3":24466,"PHASE4":24487,"NA":24489},{"trials":24461,"activeCount":99},[],{"trials":24463,"activeCount":99},[],{"trials":24465,"activeCount":99},[],{"trials":24467,"activeCount":99},[24468,24479],{"nctId":24469,"briefTitle":24470,"status":105,"phases":24471,"primaryCompletion":24472,"completion":24473,"start":24474,"enrollment":16142,"conditions":24475,"interventions":24478},"NCT01782131","A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)",[89],"2019-07-10","2019-09-10","2013-09-25",[24476,24477],"Fungal Infections","Invasive Pulmonary Aspergillosis",[17832,24458],{"nctId":24480,"briefTitle":24481,"status":105,"phases":24482,"primaryCompletion":24483,"completion":24483,"start":24484,"enrollment":429,"conditions":24485,"interventions":24486},"NCT02180165","Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)",[89],"2018-01-24","2014-07-29",[20498],[17832,24458],{"trials":24488,"activeCount":99},[],{"trials":24490,"activeCount":99},[],{"intervention":24492,"totalTrials":3197,"cells":24493},"Comparator: Gardasil",{"EARLY_PHASE1":24494,"PHASE1":24496,"PHASE2":24498,"PHASE3":24512,"PHASE4":24526,"NA":24528},{"trials":24495,"activeCount":99},[],{"trials":24497,"activeCount":99},[],{"trials":24499,"activeCount":99},[24500],{"nctId":24501,"briefTitle":24502,"status":105,"phases":24503,"primaryCompletion":5507,"completion":5507,"start":24504,"enrollment":2108,"conditions":24505,"interventions":24508},"NCT00260039","Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)",[88],"2005-12",[24506,863,24507],"HPV","Premalignancy Anogenital Warts",[24492,24509,24510,24511],"Comparator: octavalent HPV Vaccine - dose formulation 1","Comparator: octavalent HPV Vaccine - dose formulation 2","Comparator: octavalent HPV Vaccine - dose formulation 3",{"trials":24513,"activeCount":99},[24514],{"nctId":24515,"briefTitle":24516,"status":105,"phases":24517,"primaryCompletion":24518,"completion":24519,"start":24520,"enrollment":24521,"conditions":24522,"interventions":24523},"NCT00543543","Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)",[89],"2013-04-10","2016-07-07","2007-09-24",14840,[863,865,9217,7085,9169],[24524,24525],"Comparator: GARDASIL","Experimental: V503",{"trials":24527,"activeCount":99},[],{"trials":24529,"activeCount":99},[],{"intervention":24531,"totalTrials":3197,"cells":24532},"Comparator: efavirenz",{"EARLY_PHASE1":24533,"PHASE1":24535,"PHASE2":24537,"PHASE3":24549,"PHASE4":24561,"NA":24563},{"trials":24534,"activeCount":99},[],{"trials":24536,"activeCount":99},[],{"trials":24538,"activeCount":99},[24539],{"nctId":24540,"briefTitle":24541,"status":105,"phases":24542,"primaryCompletion":8619,"completion":20258,"start":14903,"enrollment":3162,"conditions":24543,"interventions":24544},"NCT00100048","A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)",[88],[27,21124],[24545,24546,24531,24547,24548],"Comparator: MK0518 monotherapy","Comparator: MK0518 combination therapy","Comparator: tenofovir","Comparator: lamivudine",{"trials":24550,"activeCount":99},[24551],{"nctId":24552,"briefTitle":24553,"status":105,"phases":24554,"primaryCompletion":14352,"completion":13223,"start":12804,"enrollment":22408,"conditions":24555,"interventions":24556},"NCT00369941","A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)",[89],[27],[24557,24531,24558,24559,24560],"MK-0518","Comparator: Truvada","Comparator: Placebo to MK-0518","Comparator: Placebo to efavirenz",{"trials":24562,"activeCount":99},[],{"trials":24564,"activeCount":99},[],{"intervention":15220,"totalTrials":3197,"cells":24566},{"EARLY_PHASE1":24567,"PHASE1":24569,"PHASE2":24575,"PHASE3":24577,"PHASE4":24583,"NA":24585},{"trials":24568,"activeCount":99},[],{"trials":24570,"activeCount":99},[24571],{"nctId":19534,"briefTitle":19535,"status":105,"phases":24572,"primaryCompletion":19537,"completion":13102,"start":14229,"enrollment":120,"conditions":24573,"interventions":24574},[87],[14552],[14682,15220,15220,15220],{"trials":24576,"activeCount":99},[],{"trials":24578,"activeCount":99},[24579],{"nctId":15215,"briefTitle":15216,"status":1040,"phases":24580,"primaryCompletion":14315,"completion":14315,"start":14315,"enrollment":99,"conditions":24581,"interventions":24582},[89],[1109],[15220,14331],{"trials":24584,"activeCount":99},[],{"trials":24586,"activeCount":99},[],{"intervention":24588,"totalTrials":3197,"cells":24589},"Denufosol tetrasodium Inhalation Solution",{"EARLY_PHASE1":24590,"PHASE1":24592,"PHASE2":24594,"PHASE3":24604,"PHASE4":24612,"NA":24614},{"trials":24591,"activeCount":99},[],{"trials":24593,"activeCount":99},[],{"trials":24595,"activeCount":99},[24596],{"nctId":24597,"briefTitle":24598,"status":105,"phases":24599,"primaryCompletion":5179,"completion":5179,"start":5982,"enrollment":9323,"conditions":24600,"interventions":24601},"NCT01181622","A Safety and Tolerability Study of Denufosol in 2-4 Year Olds",[88],[22638],[24602,24603],"denufosol tetrasodium Inhalation Solution","0.9% w\u002Fv sodium chloride solution",{"trials":24605,"activeCount":99},[24606],{"nctId":24607,"briefTitle":24608,"status":150,"phases":24609,"primaryCompletion":14566,"completion":14566,"start":14313,"enrollment":5700,"conditions":24610,"interventions":24611},"NCT00846781","Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease (P08642)",[89],[22638],[24588],{"trials":24613,"activeCount":99},[],{"trials":24615,"activeCount":99},[],{"intervention":23556,"totalTrials":3197,"cells":24617},{"EARLY_PHASE1":24618,"PHASE1":24620,"PHASE2":24626,"PHASE3":24628,"PHASE4":24637,"NA":24639},{"trials":24619,"activeCount":99},[],{"trials":24621,"activeCount":99},[24622],{"nctId":23551,"briefTitle":23552,"status":105,"phases":24623,"primaryCompletion":15210,"completion":15210,"start":8619,"enrollment":18221,"conditions":24624,"interventions":24625},[87],[14337],[23556,14647],{"trials":24627,"activeCount":99},[],{"trials":24629,"activeCount":99},[24630],{"nctId":24631,"briefTitle":24632,"status":105,"phases":24633,"primaryCompletion":4419,"completion":4419,"start":14531,"enrollment":24634,"conditions":24635,"interventions":24636},"NCT00378833","Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)",[89],1300,[7598,7610],[14420,23556],{"trials":24638,"activeCount":99},[],{"trials":24640,"activeCount":99},[],{"intervention":14079,"totalTrials":3197,"cells":24642},{"EARLY_PHASE1":24643,"PHASE1":24645,"PHASE2":24647,"PHASE3":24649,"PHASE4":24659,"NA":24661},{"trials":24644,"activeCount":99},[],{"trials":24646,"activeCount":99},[],{"trials":24648,"activeCount":99},[],{"trials":24650,"activeCount":99},[24651,24655],{"nctId":14069,"briefTitle":14070,"status":105,"phases":24652,"primaryCompletion":14072,"completion":14072,"start":14073,"enrollment":14074,"conditions":24653,"interventions":24654},[89],[15],[14077,4084,14078,14059,14079],{"nctId":14236,"briefTitle":14237,"status":105,"phases":24656,"primaryCompletion":14239,"completion":9574,"start":2571,"enrollment":14240,"conditions":24657,"interventions":24658},[89],[15],[13145,4084,14079,13971],{"trials":24660,"activeCount":99},[],{"trials":24662,"activeCount":99},[],{"intervention":3341,"totalTrials":3197,"cells":24664},{"EARLY_PHASE1":24665,"PHASE1":24667,"PHASE2":24669,"PHASE3":24671,"PHASE4":24681,"NA":24683},{"trials":24666,"activeCount":99},[],{"trials":24668,"activeCount":99},[],{"trials":24670,"activeCount":99},[],{"trials":24672,"activeCount":99},[24673,24677],{"nctId":3332,"briefTitle":3333,"status":105,"phases":24674,"primaryCompletion":3335,"completion":3336,"start":3337,"enrollment":3338,"conditions":24675,"interventions":24676},[89],[2537],[84,390,386,385,3341,3342],{"nctId":3385,"briefTitle":3386,"status":105,"phases":24678,"primaryCompletion":3388,"completion":3336,"start":3389,"enrollment":3390,"conditions":24679,"interventions":24680},[89],[2537],[84,390,386,385,3341,3342],{"trials":24682,"activeCount":99},[],{"trials":24684,"activeCount":99},[],{"intervention":1951,"totalTrials":3197,"cells":24686},{"EARLY_PHASE1":24687,"PHASE1":24689,"PHASE2":24691,"PHASE3":24693,"PHASE4":24703,"NA":24705},{"trials":24688,"activeCount":99},[],{"trials":24690,"activeCount":99},[],{"trials":24692,"activeCount":99},[],{"trials":24694,"activeCount":99},[24695,24699],{"nctId":1942,"briefTitle":1943,"status":105,"phases":24696,"primaryCompletion":1945,"completion":1946,"start":1947,"enrollment":1948,"conditions":24697,"interventions":24698},[89],[314],[47,387,388,386,1951],{"nctId":1963,"briefTitle":1964,"status":105,"phases":24700,"primaryCompletion":1966,"completion":1946,"start":1967,"enrollment":1968,"conditions":24701,"interventions":24702},[89],[314],[47,387,386,1951],{"trials":24704,"activeCount":99},[],{"trials":24706,"activeCount":99},[],{"intervention":16477,"totalTrials":3197,"cells":24708},{"EARLY_PHASE1":24709,"PHASE1":24711,"PHASE2":24713,"PHASE3":24715,"PHASE4":24725,"NA":24727},{"trials":24710,"activeCount":99},[],{"trials":24712,"activeCount":99},[],{"trials":24714,"activeCount":99},[],{"trials":24716,"activeCount":99},[24717,24721],{"nctId":16468,"briefTitle":16469,"status":105,"phases":24718,"primaryCompletion":1640,"completion":1640,"start":1984,"enrollment":3605,"conditions":24719,"interventions":24720},[89],[16472],[16465,16474,16441,16475,16476,16477,16478,16479],{"nctId":16481,"briefTitle":16482,"status":105,"phases":24722,"primaryCompletion":16484,"completion":16484,"start":709,"enrollment":16485,"conditions":24723,"interventions":24724},[89],[16472,16487],[16474,16465,16441,16475,16476,16489,16490,16479,16477],{"trials":24726,"activeCount":99},[],{"trials":24728,"activeCount":99},[],{"intervention":16478,"totalTrials":3197,"cells":24730},{"EARLY_PHASE1":24731,"PHASE1":24733,"PHASE2":24735,"PHASE3":24737,"PHASE4":24747,"NA":24749},{"trials":24732,"activeCount":99},[],{"trials":24734,"activeCount":99},[],{"trials":24736,"activeCount":99},[],{"trials":24738,"activeCount":99},[24739,24743],{"nctId":16468,"briefTitle":16469,"status":105,"phases":24740,"primaryCompletion":1640,"completion":1640,"start":1984,"enrollment":3605,"conditions":24741,"interventions":24742},[89],[16472],[16465,16474,16441,16475,16476,16477,16478,16479],{"nctId":24144,"briefTitle":24145,"status":1040,"phases":24744,"primaryCompletion":24147,"completion":24147,"start":24148,"enrollment":99,"conditions":24745,"interventions":24746},[89],[15311],[24151,24152,16478],{"trials":24748,"activeCount":99},[],{"trials":24750,"activeCount":99},[],{"intervention":16419,"totalTrials":3197,"cells":24752},{"EARLY_PHASE1":24753,"PHASE1":24755,"PHASE2":24757,"PHASE3":24759,"PHASE4":24772,"NA":24774},{"trials":24754,"activeCount":99},[],{"trials":24756,"activeCount":99},[],{"trials":24758,"activeCount":99},[],{"trials":24760,"activeCount":99},[24761,24765],{"nctId":16410,"briefTitle":16411,"status":150,"phases":24762,"primaryCompletion":16413,"completion":16413,"start":16414,"enrollment":16415,"conditions":24763,"interventions":24764},[89],[14418,16417],[16419,16420,13122],{"nctId":24766,"briefTitle":24767,"status":105,"phases":24768,"primaryCompletion":13102,"completion":13102,"start":13891,"enrollment":24769,"conditions":24770,"interventions":24771},"NCT00485758","Extended Niacin\u002FLaropiprant in Patients With Type 2 Diabetes (0524A-069)",[89],796,[14851],[16419,15741],{"trials":24773,"activeCount":99},[],{"trials":24775,"activeCount":99},[],{"intervention":21414,"totalTrials":3197,"cells":24777},{"EARLY_PHASE1":24778,"PHASE1":24780,"PHASE2":24782,"PHASE3":24784,"PHASE4":24794,"NA":24796},{"trials":24779,"activeCount":99},[],{"trials":24781,"activeCount":99},[],{"trials":24783,"activeCount":99},[],{"trials":24785,"activeCount":99},[24786,24790],{"nctId":21406,"briefTitle":21407,"status":105,"phases":24787,"primaryCompletion":21409,"completion":21409,"start":21410,"enrollment":21411,"conditions":24788,"interventions":24789},[89],[16210],[15113,21414],{"nctId":21432,"briefTitle":21433,"status":105,"phases":24791,"primaryCompletion":21435,"completion":21436,"start":21437,"enrollment":21438,"conditions":24792,"interventions":24793},[89],[16210],[15113,21414],{"trials":24795,"activeCount":99},[],{"trials":24797,"activeCount":99},[],{"intervention":17718,"totalTrials":3197,"cells":24799},{"EARLY_PHASE1":24800,"PHASE1":24802,"PHASE2":24804,"PHASE3":24806,"PHASE4":24816,"NA":24818},{"trials":24801,"activeCount":99},[],{"trials":24803,"activeCount":99},[],{"trials":24805,"activeCount":99},[],{"trials":24807,"activeCount":99},[24808,24812],{"nctId":19177,"briefTitle":19178,"status":105,"phases":24809,"primaryCompletion":3091,"completion":3091,"start":16680,"enrollment":19180,"conditions":24810,"interventions":24811},[89],[16472],[19183,19184,16474,17718],{"nctId":17711,"briefTitle":17712,"status":105,"phases":24813,"primaryCompletion":1600,"completion":1600,"start":17714,"enrollment":17715,"conditions":24814,"interventions":24815},[89],[16472],[16474,17718,17700,17719,16479],{"trials":24817,"activeCount":99},[],{"trials":24819,"activeCount":99},[],{"intervention":14870,"totalTrials":3197,"cells":24821},{"EARLY_PHASE1":24822,"PHASE1":24824,"PHASE2":24826,"PHASE3":24832,"PHASE4":24844,"NA":24846},{"trials":24823,"activeCount":99},[],{"trials":24825,"activeCount":99},[],{"trials":24827,"activeCount":99},[24828],{"nctId":14864,"briefTitle":14865,"status":105,"phases":24829,"primaryCompletion":14858,"completion":14858,"start":14540,"enrollment":787,"conditions":24830,"interventions":24831},[88],[30],[14869,14331,14870],{"trials":24833,"activeCount":99},[24834],{"nctId":24835,"briefTitle":24836,"status":105,"phases":24837,"primaryCompletion":24838,"completion":24839,"start":24840,"enrollment":24841,"conditions":24842,"interventions":24843},"NCT00882440","A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)",[89],"1991-08","1992-01","1990-12",576,[30],[15231,14870],{"trials":24845,"activeCount":99},[],{"trials":24847,"activeCount":99},[],{"intervention":24849,"totalTrials":3197,"cells":24850},"Preladenant 2 mg",{"EARLY_PHASE1":24851,"PHASE1":24853,"PHASE2":24855,"PHASE3":24857,"PHASE4":24879,"NA":24881},{"trials":24852,"activeCount":99},[],{"trials":24854,"activeCount":99},[],{"trials":24856,"activeCount":99},[],{"trials":24858,"activeCount":99},[24859,24870],{"nctId":24860,"briefTitle":24861,"status":150,"phases":24862,"primaryCompletion":20080,"completion":20080,"start":24863,"enrollment":24864,"conditions":24865,"interventions":24866},"NCT01155479","A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)",[89],"2010-07-06",1022,[19998],[24849,24867,24868,24869],"Preladenant 5 mg","Preladenant 10 mg","Rasagiline 1 mg",{"nctId":24871,"briefTitle":24872,"status":105,"phases":24873,"primaryCompletion":24874,"completion":24874,"start":24875,"enrollment":24876,"conditions":24877,"interventions":24878},"NCT01155466","A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)",[89],"2012-12-20","2010-07-14",778,[19998],[24849,24867,24868,24869],{"trials":24880,"activeCount":99},[],{"trials":24882,"activeCount":99},[],{"intervention":24867,"totalTrials":3197,"cells":24884},{"EARLY_PHASE1":24885,"PHASE1":24887,"PHASE2":24889,"PHASE3":24891,"PHASE4":24901,"NA":24903},{"trials":24886,"activeCount":99},[],{"trials":24888,"activeCount":99},[],{"trials":24890,"activeCount":99},[],{"trials":24892,"activeCount":99},[24893,24897],{"nctId":24860,"briefTitle":24861,"status":150,"phases":24894,"primaryCompletion":20080,"completion":20080,"start":24863,"enrollment":24864,"conditions":24895,"interventions":24896},[89],[19998],[24849,24867,24868,24869],{"nctId":24871,"briefTitle":24872,"status":105,"phases":24898,"primaryCompletion":24874,"completion":24874,"start":24875,"enrollment":24876,"conditions":24899,"interventions":24900},[89],[19998],[24849,24867,24868,24869],{"trials":24902,"activeCount":99},[],{"trials":24904,"activeCount":99},[],{"intervention":24868,"totalTrials":3197,"cells":24906},{"EARLY_PHASE1":24907,"PHASE1":24909,"PHASE2":24911,"PHASE3":24913,"PHASE4":24923,"NA":24925},{"trials":24908,"activeCount":99},[],{"trials":24910,"activeCount":99},[],{"trials":24912,"activeCount":99},[],{"trials":24914,"activeCount":99},[24915,24919],{"nctId":24860,"briefTitle":24861,"status":150,"phases":24916,"primaryCompletion":20080,"completion":20080,"start":24863,"enrollment":24864,"conditions":24917,"interventions":24918},[89],[19998],[24849,24867,24868,24869],{"nctId":24871,"briefTitle":24872,"status":105,"phases":24920,"primaryCompletion":24874,"completion":24874,"start":24875,"enrollment":24876,"conditions":24921,"interventions":24922},[89],[19998],[24849,24867,24868,24869],{"trials":24924,"activeCount":99},[],{"trials":24926,"activeCount":99},[],{"intervention":24869,"totalTrials":3197,"cells":24928},{"EARLY_PHASE1":24929,"PHASE1":24931,"PHASE2":24933,"PHASE3":24935,"PHASE4":24945,"NA":24947},{"trials":24930,"activeCount":99},[],{"trials":24932,"activeCount":99},[],{"trials":24934,"activeCount":99},[],{"trials":24936,"activeCount":99},[24937,24941],{"nctId":24860,"briefTitle":24861,"status":150,"phases":24938,"primaryCompletion":20080,"completion":20080,"start":24863,"enrollment":24864,"conditions":24939,"interventions":24940},[89],[19998],[24849,24867,24868,24869],{"nctId":24871,"briefTitle":24872,"status":105,"phases":24942,"primaryCompletion":24874,"completion":24874,"start":24875,"enrollment":24876,"conditions":24943,"interventions":24944},[89],[19998],[24849,24867,24868,24869],{"trials":24946,"activeCount":99},[],{"trials":24948,"activeCount":99},[],{"intervention":12746,"totalTrials":3197,"cells":24950},{"EARLY_PHASE1":24951,"PHASE1":24953,"PHASE2":24955,"PHASE3":24957,"PHASE4":24969,"NA":24971},{"trials":24952,"activeCount":99},[],{"trials":24954,"activeCount":99},[],{"trials":24956,"activeCount":99},[],{"trials":24958,"activeCount":99},[24959,24963],{"nctId":12740,"briefTitle":12741,"status":105,"phases":24960,"primaryCompletion":8620,"completion":8620,"start":8621,"enrollment":11225,"conditions":24961,"interventions":24962},[89],[12744],[12746,2100],{"nctId":24964,"briefTitle":24965,"status":105,"phases":24966,"primaryCompletion":13890,"completion":13890,"start":12804,"enrollment":5148,"conditions":24967,"interventions":24968},"NCT00732875","A Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methorexate (Extension Part)(Study P05645)(COMPLETED)",[89],[7197],[12746],{"trials":24970,"activeCount":99},[],{"trials":24972,"activeCount":99},[],{"intervention":24974,"totalTrials":3197,"cells":24975},"Vorapaxar 2.5 mg",{"EARLY_PHASE1":24976,"PHASE1":24978,"PHASE2":24980,"PHASE3":24993,"PHASE4":25003,"NA":25005},{"trials":24977,"activeCount":99},[],{"trials":24979,"activeCount":99},[],{"trials":24981,"activeCount":99},[24982],{"nctId":24983,"briefTitle":24984,"status":105,"phases":24985,"primaryCompletion":24986,"completion":24986,"start":24987,"enrollment":397,"conditions":24988,"interventions":24990},"NCT00684515","Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)",[88],"2007-11-08","2006-09-21",[24989],"Cerebral Infarction",[24974,24991,24992],"Vorapaxar 1 mg","Aspirin 75-150 mg",{"trials":24994,"activeCount":99},[24995],{"nctId":24996,"briefTitle":24997,"status":105,"phases":24998,"primaryCompletion":24999,"completion":24999,"start":14515,"enrollment":25000,"conditions":25001,"interventions":25002},"NCT00617123","Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)",[89],"2010-10-01",258,[23415,23436,9614,21940],[24974],{"trials":25004,"activeCount":99},[],{"trials":25006,"activeCount":99},[],{"intervention":5285,"totalTrials":3197,"cells":25008},{"EARLY_PHASE1":25009,"PHASE1":25011,"PHASE2":25013,"PHASE3":25015,"PHASE4":25025,"NA":25027},{"trials":25010,"activeCount":99},[],{"trials":25012,"activeCount":99},[],{"trials":25014,"activeCount":99},[],{"trials":25016,"activeCount":99},[25017,25021],{"nctId":5277,"briefTitle":5278,"status":105,"phases":25018,"primaryCompletion":5280,"completion":5280,"start":5281,"enrollment":5282,"conditions":25019,"interventions":25020},[89],[5181],[5285,5286,529,529,5137],{"nctId":16351,"briefTitle":16352,"status":105,"phases":25022,"primaryCompletion":16354,"completion":16355,"start":16356,"enrollment":16357,"conditions":25023,"interventions":25024},[89],[5150],[4424,5154,16360,5285,16361,16361],{"trials":25026,"activeCount":99},[],{"trials":25028,"activeCount":99},[],{"intervention":20836,"totalTrials":3197,"cells":25030},{"EARLY_PHASE1":25031,"PHASE1":25033,"PHASE2":25035,"PHASE3":25037,"PHASE4":25047,"NA":25049},{"trials":25032,"activeCount":99},[],{"trials":25034,"activeCount":99},[],{"trials":25036,"activeCount":99},[],{"trials":25038,"activeCount":99},[25039,25043],{"nctId":20827,"briefTitle":20828,"status":105,"phases":25040,"primaryCompletion":20830,"completion":20831,"start":20832,"enrollment":4121,"conditions":25041,"interventions":25042},[89],[20834],[17013,20824,20836],{"nctId":17017,"briefTitle":17018,"status":105,"phases":25044,"primaryCompletion":17020,"completion":17021,"start":17022,"enrollment":537,"conditions":25045,"interventions":25046},[89],[17011],[17025,17026,17027,17028,17029],{"trials":25048,"activeCount":99},[],{"trials":25050,"activeCount":99},[],{"intervention":17665,"totalTrials":3197,"cells":25052},{"EARLY_PHASE1":25053,"PHASE1":25055,"PHASE2":25057,"PHASE3":25059,"PHASE4":25071,"NA":25073},{"trials":25054,"activeCount":99},[],{"trials":25056,"activeCount":99},[],{"trials":25058,"activeCount":99},[],{"trials":25060,"activeCount":99},[25061,25065],{"nctId":17659,"briefTitle":17660,"status":105,"phases":25062,"primaryCompletion":13890,"completion":13890,"start":14678,"enrollment":17662,"conditions":25063,"interventions":25064},[89],[21],[17665,17648],{"nctId":25066,"briefTitle":25067,"status":150,"phases":25068,"primaryCompletion":14730,"completion":14730,"start":15038,"enrollment":1621,"conditions":25069,"interventions":25070},"NCT00423800","Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)",[89],[21],[17665],{"trials":25072,"activeCount":99},[],{"trials":25074,"activeCount":99},[],{"intervention":16180,"totalTrials":3197,"cells":25076},{"EARLY_PHASE1":25077,"PHASE1":25079,"PHASE2":25081,"PHASE3":25083,"PHASE4":25093,"NA":25095},{"trials":25078,"activeCount":99},[],{"trials":25080,"activeCount":99},[],{"trials":25082,"activeCount":99},[],{"trials":25084,"activeCount":99},[25085,25089],{"nctId":16173,"briefTitle":16174,"status":105,"phases":25086,"primaryCompletion":2095,"completion":2095,"start":16176,"enrollment":16177,"conditions":25087,"interventions":25088},[89],[14156],[13913,13145,16180,16181],{"nctId":17537,"briefTitle":17538,"status":105,"phases":25090,"primaryCompletion":14730,"completion":14730,"start":13890,"enrollment":17540,"conditions":25091,"interventions":25092},[89],[17542,15023],[14126,17544,17545],{"trials":25094,"activeCount":99},[],{"trials":25096,"activeCount":99},[],{"intervention":8596,"totalTrials":3197,"cells":25098},{"EARLY_PHASE1":25099,"PHASE1":25101,"PHASE2":25103,"PHASE3":25105,"PHASE4":25117,"NA":25119},{"trials":25100,"activeCount":99},[],{"trials":25102,"activeCount":99},[],{"trials":25104,"activeCount":99},[],{"trials":25106,"activeCount":99},[25107,25111],{"nctId":8587,"briefTitle":8588,"status":150,"phases":25108,"primaryCompletion":8590,"completion":8590,"start":8591,"enrollment":1624,"conditions":25109,"interventions":25110},[89],[7169],[8594,2413,8595,8596],{"nctId":25112,"briefTitle":25113,"status":150,"phases":25114,"primaryCompletion":6308,"completion":6308,"start":13891,"enrollment":19725,"conditions":25115,"interventions":25116},"NCT00537316","Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807)",[89],[9066],[8594,8596],{"trials":25118,"activeCount":99},[],{"trials":25120,"activeCount":99},[],{"intervention":25122,"totalTrials":3197,"cells":25123},"TRUVADA™",{"EARLY_PHASE1":25124,"PHASE1":25126,"PHASE2":25128,"PHASE3":25130,"PHASE4":25151,"NA":25153},{"trials":25125,"activeCount":99},[],{"trials":25127,"activeCount":99},[],{"trials":25129,"activeCount":99},[],{"trials":25131,"activeCount":99},[25132,25142],{"nctId":25133,"briefTitle":25134,"status":105,"phases":25135,"primaryCompletion":25136,"completion":25137,"start":13269,"enrollment":25138,"conditions":25139,"interventions":25140},"NCT02131233","Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)",[89],"2015-12-21","2016-12-19",802,[7650],[25141,17577,25122],"Reformulated Raltegravir",{"nctId":25143,"briefTitle":25144,"status":150,"phases":25145,"primaryCompletion":5179,"completion":5981,"start":14315,"enrollment":25146,"conditions":25147,"interventions":25148},"NCT00745823","A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)",[89],775,[7390],[25149,25150,25122],"Comparator: Raltegravir 400 mg b.i.d.","Experimental: Raltegravir 800 mg q.d.",{"trials":25152,"activeCount":99},[],{"trials":25154,"activeCount":99},[],{"intervention":15372,"totalTrials":3197,"cells":25156},{"EARLY_PHASE1":25157,"PHASE1":25159,"PHASE2":25161,"PHASE3":25163,"PHASE4":25173,"NA":25175},{"trials":25158,"activeCount":99},[],{"trials":25160,"activeCount":99},[],{"trials":25162,"activeCount":99},[],{"trials":25164,"activeCount":99},[25165,25169],{"nctId":15365,"briefTitle":15366,"status":105,"phases":25166,"primaryCompletion":15368,"completion":15368,"start":15369,"enrollment":9064,"conditions":25167,"interventions":25168},[89],[9336],[15372,15373,13864],{"nctId":15469,"briefTitle":15470,"status":105,"phases":25170,"primaryCompletion":15472,"completion":14073,"start":5292,"enrollment":2745,"conditions":25171,"interventions":25172},[89],[9336],[15372,15373,13864],{"trials":25174,"activeCount":99},[],{"trials":25176,"activeCount":99},[],{"intervention":15373,"totalTrials":3197,"cells":25178},{"EARLY_PHASE1":25179,"PHASE1":25181,"PHASE2":25183,"PHASE3":25185,"PHASE4":25195,"NA":25197},{"trials":25180,"activeCount":99},[],{"trials":25182,"activeCount":99},[],{"trials":25184,"activeCount":99},[],{"trials":25186,"activeCount":99},[25187,25191],{"nctId":15365,"briefTitle":15366,"status":105,"phases":25188,"primaryCompletion":15368,"completion":15368,"start":15369,"enrollment":9064,"conditions":25189,"interventions":25190},[89],[9336],[15372,15373,13864],{"nctId":15469,"briefTitle":15470,"status":105,"phases":25192,"primaryCompletion":15472,"completion":14073,"start":5292,"enrollment":2745,"conditions":25193,"interventions":25194},[89],[9336],[15372,15373,13864],{"trials":25196,"activeCount":99},[],{"trials":25198,"activeCount":99},[],{"intervention":19229,"totalTrials":3197,"cells":25200},{"EARLY_PHASE1":25201,"PHASE1":25203,"PHASE2":25205,"PHASE3":25207,"PHASE4":25217,"NA":25219},{"trials":25202,"activeCount":99},[],{"trials":25204,"activeCount":99},[],{"trials":25206,"activeCount":99},[],{"trials":25208,"activeCount":99},[25209,25213],{"nctId":19222,"briefTitle":19223,"status":105,"phases":25210,"primaryCompletion":19225,"completion":19225,"start":19226,"enrollment":2204,"conditions":25211,"interventions":25212},[89],[16472],[16474,19229],{"nctId":19959,"briefTitle":19960,"status":105,"phases":25214,"primaryCompletion":19962,"completion":19962,"start":19963,"enrollment":19964,"conditions":25215,"interventions":25216},[89],[19146],[13203,19229],{"trials":25218,"activeCount":99},[],{"trials":25220,"activeCount":99},[],{"intervention":3052,"totalTrials":3197,"cells":25222},{"EARLY_PHASE1":25223,"PHASE1":25225,"PHASE2":25234,"PHASE3":25236,"PHASE4":25242,"NA":25244},{"trials":25224,"activeCount":99},[],{"trials":25226,"activeCount":99},[25227],{"nctId":25228,"briefTitle":25229,"status":105,"phases":25230,"primaryCompletion":22040,"completion":22040,"start":15462,"enrollment":17672,"conditions":25231,"interventions":25233},"NCT00002960","SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)",[87],[1930,25232,990,3050],"Metastatic Cancer",[3052],{"trials":25235,"activeCount":99},[],{"trials":25237,"activeCount":99},[25238],{"nctId":3043,"briefTitle":3044,"status":150,"phases":25239,"primaryCompletion":3046,"completion":3046,"start":3047,"enrollment":3048,"conditions":25240,"interventions":25241},[88,89],[990,3050],[3052,484,1654],{"trials":25243,"activeCount":99},[],{"trials":25245,"activeCount":99},[],{"intervention":22560,"totalTrials":3197,"cells":25247},{"EARLY_PHASE1":25248,"PHASE1":25250,"PHASE2":25252,"PHASE3":25262,"PHASE4":25268,"NA":25270},{"trials":25249,"activeCount":99},[],{"trials":25251,"activeCount":99},[],{"trials":25253,"activeCount":99},[25254],{"nctId":25255,"briefTitle":25256,"status":105,"phases":25257,"primaryCompletion":5194,"completion":5194,"start":25258,"enrollment":19725,"conditions":25259,"interventions":25260},"NCT01405911","Dose Response Finding Study of MK-0431\u002FONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)",[88],"2011-08-16",[8625],[25261,22560],"Sitagliptin 25 mg",{"trials":25263,"activeCount":99},[25264],{"nctId":22552,"briefTitle":22553,"status":105,"phases":25265,"primaryCompletion":22555,"completion":22555,"start":22556,"enrollment":22557,"conditions":25266,"interventions":25267},[89],[15],[22560,22561,13885,22562],{"trials":25269,"activeCount":99},[],{"trials":25271,"activeCount":99},[],{"intervention":25273,"totalTrials":3197,"cells":25274},"MK0826, ertapenem sodium \u002F Duration of Treatment: 14 Days",{"EARLY_PHASE1":25275,"PHASE1":25277,"PHASE2":25279,"PHASE3":25281,"PHASE4":25296,"NA":25298},{"trials":25276,"activeCount":99},[],{"trials":25278,"activeCount":99},[],{"trials":25280,"activeCount":99},[],{"trials":25282,"activeCount":99},[25283,25290],{"nctId":25284,"briefTitle":25285,"status":105,"phases":25286,"primaryCompletion":24504,"completion":24504,"start":14679,"enrollment":154,"conditions":25287,"interventions":25289},"NCT00397956","To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053)",[89],[25288],"Sepsis",[25273],{"nctId":25291,"briefTitle":25292,"status":105,"phases":25293,"primaryCompletion":14484,"completion":14484,"start":14976,"enrollment":154,"conditions":25294,"interventions":25295},"NCT00398099","To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052)",[89],[18450,11523,22209],[25273],{"trials":25297,"activeCount":99},[],{"trials":25299,"activeCount":99},[],{"intervention":15951,"totalTrials":3197,"cells":25301},{"EARLY_PHASE1":25302,"PHASE1":25304,"PHASE2":25306,"PHASE3":25308,"PHASE4":25323,"NA":25325},{"trials":25303,"activeCount":99},[],{"trials":25305,"activeCount":99},[],{"trials":25307,"activeCount":99},[],{"trials":25309,"activeCount":99},[25310,25319],{"nctId":25311,"briefTitle":25312,"status":105,"phases":25313,"primaryCompletion":25314,"completion":25315,"start":19840,"enrollment":25316,"conditions":25317,"interventions":25318},"NCT02251990","Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)",[89],"2016-09-27","2017-04-10",489,[24],[15951],{"nctId":15944,"briefTitle":15945,"status":1040,"phases":25320,"primaryCompletion":15947,"completion":15911,"start":15948,"enrollment":99,"conditions":25321,"interventions":25322},[89],[24],[15951,15784,15828,15952],{"trials":25324,"activeCount":99},[],{"trials":25326,"activeCount":99},[],{"intervention":25328,"totalTrials":3197,"cells":25329},"Fluconazole",{"EARLY_PHASE1":25330,"PHASE1":25332,"PHASE2":25334,"PHASE3":25336,"PHASE4":25353,"NA":25355},{"trials":25331,"activeCount":99},[],{"trials":25333,"activeCount":99},[],{"trials":25335,"activeCount":99},[],{"trials":25337,"activeCount":99},[25338,25345],{"nctId":25339,"briefTitle":25340,"status":105,"phases":25341,"primaryCompletion":14352,"completion":14352,"start":14409,"enrollment":3655,"conditions":25342,"interventions":25344},"NCT00423267","POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)",[89],[25343],"Coccidioidomycosis",[17832,25328],{"nctId":25346,"briefTitle":25347,"status":105,"phases":25348,"primaryCompletion":14494,"completion":14494,"start":14823,"enrollment":25349,"conditions":25350,"interventions":25352},"NCT00811928","Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED)",[89],252,[25351],"Leukopenia",[17832,25328],{"trials":25354,"activeCount":99},[],{"trials":25356,"activeCount":99},[],{"intervention":25358,"totalTrials":3197,"cells":25359},"Doravirine, Tenofovir, Lamivudine",{"EARLY_PHASE1":25360,"PHASE1":25362,"PHASE2":25364,"PHASE3":25366,"PHASE4":25392,"NA":25394},{"trials":25361,"activeCount":99},[],{"trials":25363,"activeCount":99},[],{"trials":25365,"activeCount":99},[],{"trials":25367,"activeCount":99},[25368,25378],{"nctId":25369,"briefTitle":25370,"status":105,"phases":25371,"primaryCompletion":25372,"completion":1357,"start":25373,"enrollment":25374,"conditions":25375,"interventions":25376},"NCT02403674","Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)",[89],"2017-03-20","2015-06-05",734,[7342],[25358,25377],"ATRIPLA™",{"nctId":25379,"briefTitle":25380,"status":105,"phases":25381,"primaryCompletion":25382,"completion":25383,"start":25384,"enrollment":25385,"conditions":25386,"interventions":25387},"NCT02397096","Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)",[89],"2018-02-22","2023-09-05","2015-06-09",673,[7639],[25358,25388,25389,25390,25391],"Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor","Baseline regimen of cobicistat-boosted elvitegravir","Baseline regimen of a non-nucleoside reverse transcriptase inhibitor","Baseline regimen of two nucleoside reverse transcriptase inhibitors",{"trials":25393,"activeCount":99},[],{"trials":25395,"activeCount":99},[],{"intervention":11446,"totalTrials":3197,"cells":25397},{"EARLY_PHASE1":25398,"PHASE1":25400,"PHASE2":25402,"PHASE3":25408,"PHASE4":25414,"NA":25416},{"trials":25399,"activeCount":99},[],{"trials":25401,"activeCount":99},[],{"trials":25403,"activeCount":99},[25404],{"nctId":17570,"briefTitle":17571,"status":150,"phases":25405,"primaryCompletion":17573,"completion":17573,"start":17574,"enrollment":5983,"conditions":25406,"interventions":25407},[88],[27],[17577,17578,11421,17561,17579,17580,11447,17581,11446],{"trials":25409,"activeCount":99},[25410],{"nctId":11437,"briefTitle":11438,"status":105,"phases":25411,"primaryCompletion":11440,"completion":11441,"start":5477,"enrollment":11442,"conditions":25412,"interventions":25413},[89],[11444],[11357,11446,11447,11448],{"trials":25415,"activeCount":99},[],{"trials":25417,"activeCount":99},[],{"intervention":8053,"totalTrials":3197,"cells":25419},{"EARLY_PHASE1":25420,"PHASE1":25422,"PHASE2":25428,"PHASE3":25430,"PHASE4":25436,"NA":25438},{"trials":25421,"activeCount":99},[],{"trials":25423,"activeCount":99},[25424],{"nctId":8046,"briefTitle":8047,"status":105,"phases":25425,"primaryCompletion":8049,"completion":8049,"start":8050,"enrollment":8016,"conditions":25426,"interventions":25427},[87],[18],[8053,7998],{"trials":25429,"activeCount":99},[],{"trials":25431,"activeCount":99},[25432],{"nctId":19632,"briefTitle":19633,"status":1040,"phases":25433,"primaryCompletion":19635,"completion":19635,"start":15845,"enrollment":99,"conditions":25434,"interventions":25435},[89],[14552,19620],[14554,8053],{"trials":25437,"activeCount":99},[],{"trials":25439,"activeCount":99},[],{"intervention":25441,"totalTrials":3197,"cells":25442},"IMI\u002FREL FDC",{"EARLY_PHASE1":25443,"PHASE1":25445,"PHASE2":25457,"PHASE3":25459,"PHASE4":25472,"NA":25474},{"trials":25444,"activeCount":99},[],{"trials":25446,"activeCount":99},[25447],{"nctId":25448,"briefTitle":25449,"status":105,"phases":25450,"primaryCompletion":25451,"completion":25452,"start":25453,"enrollment":14576,"conditions":25454,"interventions":25456},"NCT03230916","A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)",[87],"2020-07-28","2020-08-11","2017-11-06",[25455],"Suspected or Documented Gram-negative Bacterial Infection",[25441],{"trials":25458,"activeCount":99},[],{"trials":25460,"activeCount":99},[25461],{"nctId":25462,"briefTitle":25463,"status":105,"phases":25464,"primaryCompletion":4070,"completion":4070,"start":25465,"enrollment":17249,"conditions":25466,"interventions":25469},"NCT03583333","Imipenem\u002FCilastatin\u002FRelebactam (MK-7655A) Versus Piperacillin\u002FTazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)",[89],"2018-09-18",[25467,25468],"Hospital-Acquired Bacterial Pneumonia","Ventilator-Associated Bacterial Pneumonia",[25441,25470,25471],"PIP\u002FTAZ FDC","Linezolid",{"trials":25473,"activeCount":99},[],{"trials":25475,"activeCount":99},[],{"intervention":15840,"totalTrials":3197,"cells":25477},{"EARLY_PHASE1":25478,"PHASE1":25480,"PHASE2":25482,"PHASE3":25488,"PHASE4":25494,"NA":25496},{"trials":25479,"activeCount":99},[],{"trials":25481,"activeCount":99},[],{"trials":25483,"activeCount":99},[25484],{"nctId":15830,"briefTitle":15831,"status":105,"phases":25485,"primaryCompletion":15833,"completion":15834,"start":15835,"enrollment":15836,"conditions":25486,"interventions":25487},[88],[21],[15839,15784,15840,14925],{"trials":25489,"activeCount":99},[25490],{"nctId":15954,"briefTitle":15955,"status":105,"phases":25491,"primaryCompletion":15957,"completion":15958,"start":15959,"enrollment":15960,"conditions":25492,"interventions":25493},[89],[21],[15784,15840,14925],{"trials":25495,"activeCount":99},[],{"trials":25497,"activeCount":99},[],{"intervention":2383,"totalTrials":3197,"cells":25499},{"EARLY_PHASE1":25500,"PHASE1":25502,"PHASE2":25504,"PHASE3":25506,"PHASE4":25516,"NA":25518},{"trials":25501,"activeCount":99},[],{"trials":25503,"activeCount":99},[],{"trials":25505,"activeCount":99},[],{"trials":25507,"activeCount":99},[25508,25512],{"nctId":2372,"briefTitle":2373,"status":105,"phases":25509,"primaryCompletion":2375,"completion":2376,"start":2377,"enrollment":2378,"conditions":25510,"interventions":25511},[89],[2380],[47,2382,2383],{"nctId":2540,"briefTitle":2541,"status":105,"phases":25513,"primaryCompletion":2375,"completion":2543,"start":2544,"enrollment":2545,"conditions":25514,"interventions":25515},[89],[2380],[47,2382,2383],{"trials":25517,"activeCount":99},[],{"trials":25519,"activeCount":99},[],{"intervention":25521,"totalTrials":3197,"cells":25522},"Gefapixant 15 mg BID",{"EARLY_PHASE1":25523,"PHASE1":25525,"PHASE2":25527,"PHASE3":25529,"PHASE4":25548,"NA":25550},{"trials":25524,"activeCount":99},[],{"trials":25526,"activeCount":99},[],{"trials":25528,"activeCount":99},[],{"trials":25530,"activeCount":99},[25531,25540],{"nctId":25532,"briefTitle":25533,"status":105,"phases":25534,"primaryCompletion":25535,"completion":2287,"start":11235,"enrollment":25536,"conditions":25537,"interventions":25538},"NCT03449147","A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)",[89],"2020-08-20",1317,[20767],[25521,25539],"Gefapixant 45 mg BID",{"nctId":25541,"briefTitle":25542,"status":105,"phases":25543,"primaryCompletion":1712,"completion":1712,"start":25544,"enrollment":7797,"conditions":25545,"interventions":25546},"NCT04525885","A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension",[89],"2019-05-17",[20767],[25547,25521,25539],"Gefapixant 45 mg twice daily",{"trials":25549,"activeCount":99},[],{"trials":25551,"activeCount":99},[],{"intervention":25539,"totalTrials":3197,"cells":25553},{"EARLY_PHASE1":25554,"PHASE1":25556,"PHASE2":25558,"PHASE3":25560,"PHASE4":25570,"NA":25572},{"trials":25555,"activeCount":99},[],{"trials":25557,"activeCount":99},[],{"trials":25559,"activeCount":99},[],{"trials":25561,"activeCount":99},[25562,25566],{"nctId":25532,"briefTitle":25533,"status":105,"phases":25563,"primaryCompletion":25535,"completion":2287,"start":11235,"enrollment":25536,"conditions":25564,"interventions":25565},[89],[20767],[25521,25539],{"nctId":25541,"briefTitle":25542,"status":105,"phases":25567,"primaryCompletion":1712,"completion":1712,"start":25544,"enrollment":7797,"conditions":25568,"interventions":25569},[89],[20767],[25547,25521,25539],{"trials":25571,"activeCount":99},[],{"trials":25573,"activeCount":99},[],{"intervention":25575,"totalTrials":3197,"cells":25576},"measles, mumps, and rubella virus vaccine live",{"EARLY_PHASE1":25577,"PHASE1":25579,"PHASE2":25581,"PHASE3":25591,"PHASE4":25597,"NA":25599},{"trials":25578,"activeCount":99},[],{"trials":25580,"activeCount":99},[],{"trials":25582,"activeCount":99},[25583],{"nctId":25584,"briefTitle":25585,"status":105,"phases":25586,"primaryCompletion":14594,"completion":14594,"start":15295,"enrollment":25587,"conditions":25588,"interventions":25589},"NCT00092404","Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)",[88],1210,[15308,15309,15310,15311],[25575,25590],"Comparator: Measles, Mumps, and Rubella Virus Vaccine Live",{"trials":25592,"activeCount":99},[25593],{"nctId":23910,"briefTitle":23911,"status":105,"phases":25594,"primaryCompletion":14730,"completion":13101,"start":13870,"enrollment":23913,"conditions":25595,"interventions":25596},[89],[15311],[23891,23916,23917],{"trials":25598,"activeCount":99},[],{"trials":25600,"activeCount":99},[],{"intervention":25471,"totalTrials":3197,"cells":25602},{"EARLY_PHASE1":25603,"PHASE1":25605,"PHASE2":25607,"PHASE3":25609,"PHASE4":25629,"NA":25631},{"trials":25604,"activeCount":99},[],{"trials":25606,"activeCount":99},[],{"trials":25608,"activeCount":99},[],{"trials":25610,"activeCount":99},[25611,25625],{"nctId":25612,"briefTitle":25613,"status":105,"phases":25614,"primaryCompletion":25615,"completion":25615,"start":25616,"enrollment":7678,"conditions":25617,"interventions":25619},"NCT02493764","Imipenem\u002FRelebactam\u002FCilastatin Versus Piperacillin\u002FTazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)",[89],"2019-04-03","2015-11-24",[25618],"Bacterial Pneumonia",[25620,25621,25622,25623,25624,25471],"Imipenem","Relebactam","Cilastatin","Piperacillin","Tazobactam",{"nctId":25462,"briefTitle":25463,"status":105,"phases":25626,"primaryCompletion":4070,"completion":4070,"start":25465,"enrollment":17249,"conditions":25627,"interventions":25628},[89],[25467,25468],[25441,25470,25471],{"trials":25630,"activeCount":99},[],{"trials":25632,"activeCount":99},[],{"intervention":25634,"totalTrials":3197,"cells":25635},"MK-6072",{"EARLY_PHASE1":25636,"PHASE1":25638,"PHASE2":25640,"PHASE3":25642,"PHASE4":25665,"NA":25667},{"trials":25637,"activeCount":99},[],{"trials":25639,"activeCount":99},[],{"trials":25641,"activeCount":99},[],{"trials":25643,"activeCount":99},[25644,25656],{"nctId":25645,"briefTitle":25646,"status":105,"phases":25647,"primaryCompletion":6101,"completion":6101,"start":25648,"enrollment":25649,"conditions":25650,"interventions":25652},"NCT01241552","A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",[89],"2011-10-10",1452,[25651],"Clostridium Difficile Infection",[25653,25634,25654,25655],"MK-3415","MK-3415A","SOC",{"nctId":25657,"briefTitle":25658,"status":105,"phases":25659,"primaryCompletion":25660,"completion":25660,"start":25661,"enrollment":25662,"conditions":25663,"interventions":25664},"NCT01513239","A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)",[89],"2015-05-22","2012-02-01",1203,[25651],[25634,25654,25655],{"trials":25666,"activeCount":99},[],{"trials":25668,"activeCount":99},[],{"intervention":25654,"totalTrials":3197,"cells":25670},{"EARLY_PHASE1":25671,"PHASE1":25673,"PHASE2":25675,"PHASE3":25677,"PHASE4":25687,"NA":25689},{"trials":25672,"activeCount":99},[],{"trials":25674,"activeCount":99},[],{"trials":25676,"activeCount":99},[],{"trials":25678,"activeCount":99},[25679,25683],{"nctId":25645,"briefTitle":25646,"status":105,"phases":25680,"primaryCompletion":6101,"completion":6101,"start":25648,"enrollment":25649,"conditions":25681,"interventions":25682},[89],[25651],[25653,25634,25654,25655],{"nctId":25657,"briefTitle":25658,"status":105,"phases":25684,"primaryCompletion":25660,"completion":25660,"start":25661,"enrollment":25662,"conditions":25685,"interventions":25686},[89],[25651],[25634,25654,25655],{"trials":25688,"activeCount":99},[],{"trials":25690,"activeCount":99},[],{"intervention":25655,"totalTrials":3197,"cells":25692},{"EARLY_PHASE1":25693,"PHASE1":25695,"PHASE2":25697,"PHASE3":25699,"PHASE4":25709,"NA":25711},{"trials":25694,"activeCount":99},[],{"trials":25696,"activeCount":99},[],{"trials":25698,"activeCount":99},[],{"trials":25700,"activeCount":99},[25701,25705],{"nctId":25645,"briefTitle":25646,"status":105,"phases":25702,"primaryCompletion":6101,"completion":6101,"start":25648,"enrollment":25649,"conditions":25703,"interventions":25704},[89],[25651],[25653,25634,25654,25655],{"nctId":25657,"briefTitle":25658,"status":105,"phases":25706,"primaryCompletion":25660,"completion":25660,"start":25661,"enrollment":25662,"conditions":25707,"interventions":25708},[89],[25651],[25634,25654,25655],{"trials":25710,"activeCount":99},[],{"trials":25712,"activeCount":99},[],{"intervention":15741,"totalTrials":3197,"cells":25714},{"EARLY_PHASE1":25715,"PHASE1":25717,"PHASE2":25719,"PHASE3":25721,"PHASE4":25731,"NA":25733},{"trials":25716,"activeCount":99},[],{"trials":25718,"activeCount":99},[],{"trials":25720,"activeCount":99},[],{"trials":25722,"activeCount":99},[25723,25727],{"nctId":15735,"briefTitle":15736,"status":105,"phases":25724,"primaryCompletion":15738,"completion":15738,"start":14960,"enrollment":7715,"conditions":25725,"interventions":25726},[89],[15],[14487,15741],{"nctId":24766,"briefTitle":24767,"status":105,"phases":25728,"primaryCompletion":13102,"completion":13102,"start":13891,"enrollment":24769,"conditions":25729,"interventions":25730},[89],[14851],[16419,15741],{"trials":25732,"activeCount":99},[],{"trials":25734,"activeCount":99},[],{"intervention":22431,"totalTrials":3197,"cells":25736},{"EARLY_PHASE1":25737,"PHASE1":25739,"PHASE2":25741,"PHASE3":25743,"PHASE4":25753,"NA":25755},{"trials":25738,"activeCount":99},[],{"trials":25740,"activeCount":99},[],{"trials":25742,"activeCount":99},[],{"trials":25744,"activeCount":99},[25745,25749],{"nctId":22424,"briefTitle":22425,"status":105,"phases":25746,"primaryCompletion":13890,"completion":13890,"start":15038,"enrollment":19135,"conditions":25747,"interventions":25748},[89],[22428],[22430,22431],{"nctId":22433,"briefTitle":22434,"status":105,"phases":25750,"primaryCompletion":14504,"completion":14504,"start":12814,"enrollment":1387,"conditions":25751,"interventions":25752},[89],[17593],[22438,22396,22431],{"trials":25754,"activeCount":99},[],{"trials":25756,"activeCount":99},[],{"intervention":9208,"totalTrials":3197,"cells":25758},{"EARLY_PHASE1":25759,"PHASE1":25761,"PHASE2":25763,"PHASE3":25765,"PHASE4":25782,"NA":25784},{"trials":25760,"activeCount":99},[],{"trials":25762,"activeCount":99},[],{"trials":25764,"activeCount":99},[],{"trials":25766,"activeCount":99},[25767,25771],{"nctId":9200,"briefTitle":9201,"status":105,"phases":25768,"primaryCompletion":9203,"completion":9203,"start":9204,"enrollment":9205,"conditions":25769,"interventions":25770},[89],[9169],[9118,9208,9209,9208,9209],{"nctId":25772,"briefTitle":25773,"status":105,"phases":25774,"primaryCompletion":15505,"completion":15505,"start":17461,"enrollment":25775,"conditions":25776,"interventions":25780},"NCT00325130","Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)",[89],1042,[25777,20573,20574,25778,25779],"Neoplasms, Glandular and Epithelial","Whooping Cough","Meningitis",[25781,9208,9209,9208,9209],"Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine",{"trials":25783,"activeCount":99},[],{"trials":25785,"activeCount":99},[],{"intervention":9209,"totalTrials":3197,"cells":25787},{"EARLY_PHASE1":25788,"PHASE1":25790,"PHASE2":25792,"PHASE3":25794,"PHASE4":25804,"NA":25806},{"trials":25789,"activeCount":99},[],{"trials":25791,"activeCount":99},[],{"trials":25793,"activeCount":99},[],{"trials":25795,"activeCount":99},[25796,25800],{"nctId":9200,"briefTitle":9201,"status":105,"phases":25797,"primaryCompletion":9203,"completion":9203,"start":9204,"enrollment":9205,"conditions":25798,"interventions":25799},[89],[9169],[9118,9208,9209,9208,9209],{"nctId":25772,"briefTitle":25773,"status":105,"phases":25801,"primaryCompletion":15505,"completion":15505,"start":17461,"enrollment":25775,"conditions":25802,"interventions":25803},[89],[25777,20573,20574,25778,25779],[25781,9208,9209,9208,9209],{"trials":25805,"activeCount":99},[],{"trials":25807,"activeCount":99},[],{"intervention":23602,"totalTrials":3197,"cells":25809},{"EARLY_PHASE1":25810,"PHASE1":25812,"PHASE2":25814,"PHASE3":25816,"PHASE4":25826,"NA":25828},{"trials":25811,"activeCount":99},[],{"trials":25813,"activeCount":99},[],{"trials":25815,"activeCount":99},[],{"trials":25817,"activeCount":99},[25818,25822],{"nctId":23596,"briefTitle":23597,"status":105,"phases":25819,"primaryCompletion":19870,"completion":19870,"start":23599,"enrollment":3092,"conditions":25820,"interventions":25821},[89],[15],[23574,23602,23603],{"nctId":23605,"briefTitle":23606,"status":105,"phases":25823,"primaryCompletion":19848,"completion":660,"start":23608,"enrollment":23609,"conditions":25824,"interventions":25825},[89],[4255],[23574,23602,23612],{"trials":25827,"activeCount":99},[],{"trials":25829,"activeCount":99},[],{"intervention":23603,"totalTrials":3197,"cells":25831},{"EARLY_PHASE1":25832,"PHASE1":25834,"PHASE2":25836,"PHASE3":25838,"PHASE4":25848,"NA":25850},{"trials":25833,"activeCount":99},[],{"trials":25835,"activeCount":99},[],{"trials":25837,"activeCount":99},[],{"trials":25839,"activeCount":99},[25840,25844],{"nctId":23596,"briefTitle":23597,"status":105,"phases":25841,"primaryCompletion":19870,"completion":19870,"start":23599,"enrollment":3092,"conditions":25842,"interventions":25843},[89],[15],[23574,23602,23603],{"nctId":23605,"briefTitle":23606,"status":105,"phases":25845,"primaryCompletion":19848,"completion":660,"start":23608,"enrollment":23609,"conditions":25846,"interventions":25847},[89],[4255],[23574,23602,23612],{"trials":25849,"activeCount":99},[],{"trials":25851,"activeCount":99},[],{"intervention":21197,"totalTrials":3197,"cells":25853},{"EARLY_PHASE1":25854,"PHASE1":25856,"PHASE2":25858,"PHASE3":25860,"PHASE4":25870,"NA":25872},{"trials":25855,"activeCount":99},[],{"trials":25857,"activeCount":99},[],{"trials":25859,"activeCount":99},[],{"trials":25861,"activeCount":99},[25862,25866],{"nctId":21190,"briefTitle":21191,"status":105,"phases":25863,"primaryCompletion":17198,"completion":17198,"start":21193,"enrollment":15446,"conditions":25864,"interventions":25865},[89],[21195],[21153,21197],{"nctId":21207,"briefTitle":21208,"status":105,"phases":25867,"primaryCompletion":8602,"completion":8602,"start":21210,"enrollment":2695,"conditions":25868,"interventions":25869},[89],[21195],[21153,21197],{"trials":25871,"activeCount":99},[],{"trials":25873,"activeCount":99},[],{"intervention":25875,"totalTrials":224,"cells":25876},"V441, diptheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant), & Haemophilus influenza type b conjugate vaccine",{"EARLY_PHASE1":25877,"PHASE1":25879,"PHASE2":25881,"PHASE3":25883,"PHASE4":25892,"NA":25894},{"trials":25878,"activeCount":99},[],{"trials":25880,"activeCount":99},[],{"trials":25882,"activeCount":99},[],{"trials":25884,"activeCount":99},[25885],{"nctId":25886,"briefTitle":25887,"status":105,"phases":25888,"primaryCompletion":20219,"completion":20219,"start":22317,"enrollment":25889,"conditions":25890,"interventions":25891},"NCT00092469","Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED)",[89],151,[20573,20574,20575,17593,23025],[25875],{"trials":25893,"activeCount":99},[],{"trials":25895,"activeCount":99},[],{"intervention":9619,"totalTrials":224,"cells":25897},{"EARLY_PHASE1":25898,"PHASE1":25900,"PHASE2":25902,"PHASE3":25904,"PHASE4":25910,"NA":25912},{"trials":25899,"activeCount":99},[],{"trials":25901,"activeCount":99},[],{"trials":25903,"activeCount":99},[],{"trials":25905,"activeCount":99},[25906],{"nctId":9607,"briefTitle":9608,"status":150,"phases":25907,"primaryCompletion":5179,"completion":5179,"start":9610,"enrollment":9611,"conditions":25908,"interventions":25909},[89],[9613,9614,9615,9616,9617],[9619,9596],{"trials":25911,"activeCount":99},[],{"trials":25913,"activeCount":99},[],{"intervention":23781,"totalTrials":224,"cells":25915},{"EARLY_PHASE1":25916,"PHASE1":25918,"PHASE2":25920,"PHASE3":25922,"PHASE4":25928,"NA":25930},{"trials":25917,"activeCount":99},[],{"trials":25919,"activeCount":99},[],{"trials":25921,"activeCount":99},[],{"trials":25923,"activeCount":99},[25924],{"nctId":23776,"briefTitle":23777,"status":105,"phases":25925,"primaryCompletion":11479,"completion":11479,"start":14730,"enrollment":21304,"conditions":25926,"interventions":25927},[89],[14337],[23765,23765,23781],{"trials":25929,"activeCount":99},[],{"trials":25931,"activeCount":99},[],{"intervention":1665,"totalTrials":224,"cells":25933},{"EARLY_PHASE1":25934,"PHASE1":25936,"PHASE2":25938,"PHASE3":25940,"PHASE4":25946,"NA":25948},{"trials":25935,"activeCount":99},[],{"trials":25937,"activeCount":99},[],{"trials":25939,"activeCount":99},[],{"trials":25941,"activeCount":99},[25942],{"nctId":1656,"briefTitle":1657,"status":105,"phases":25943,"primaryCompletion":1659,"completion":1659,"start":1660,"enrollment":1661,"conditions":25944,"interventions":25945},[89],[540],[47,386,387,1069,1664,562,1665],{"trials":25947,"activeCount":99},[],{"trials":25949,"activeCount":99},[],{"intervention":25951,"totalTrials":224,"cells":25952},"ER-niacin",{"EARLY_PHASE1":25953,"PHASE1":25955,"PHASE2":25957,"PHASE3":25959,"PHASE4":25970,"NA":25972},{"trials":25954,"activeCount":99},[],{"trials":25956,"activeCount":99},[],{"trials":25958,"activeCount":99},[],{"trials":25960,"activeCount":99},[25961],{"nctId":25962,"briefTitle":25963,"status":105,"phases":25964,"primaryCompletion":15038,"completion":15038,"start":24504,"enrollment":25965,"conditions":25966,"interventions":25969},"NCT00269204","Lipid Efficacy\u002FTolerability Study (0524A-020)",[89],1620,[25967,25968],"Primary Hypercholesterolaemia","Mixed Hyperlipidaemia",[14420,25951],{"trials":25971,"activeCount":99},[],{"trials":25973,"activeCount":99},[],{"intervention":20577,"totalTrials":224,"cells":25975},{"EARLY_PHASE1":25976,"PHASE1":25978,"PHASE2":25980,"PHASE3":25982,"PHASE4":25988,"NA":25990},{"trials":25977,"activeCount":99},[],{"trials":25979,"activeCount":99},[],{"trials":25981,"activeCount":99},[],{"trials":25983,"activeCount":99},[25984],{"nctId":20569,"briefTitle":20570,"status":1040,"phases":25985,"primaryCompletion":5982,"completion":13222,"start":13101,"enrollment":99,"conditions":25986,"interventions":25987},[89],[14447,20573,20574,20575],[14449,20577,20578],{"trials":25989,"activeCount":99},[],{"trials":25991,"activeCount":99},[],{"intervention":20578,"totalTrials":224,"cells":25993},{"EARLY_PHASE1":25994,"PHASE1":25996,"PHASE2":25998,"PHASE3":26000,"PHASE4":26006,"NA":26008},{"trials":25995,"activeCount":99},[],{"trials":25997,"activeCount":99},[],{"trials":25999,"activeCount":99},[],{"trials":26001,"activeCount":99},[26002],{"nctId":20569,"briefTitle":20570,"status":1040,"phases":26003,"primaryCompletion":5982,"completion":13222,"start":13101,"enrollment":99,"conditions":26004,"interventions":26005},[89],[14447,20573,20574,20575],[14449,20577,20578],{"trials":26007,"activeCount":99},[],{"trials":26009,"activeCount":99},[],{"intervention":26011,"totalTrials":224,"cells":26012},"V110, pneumococcal vaccine polyvalent",{"EARLY_PHASE1":26013,"PHASE1":26015,"PHASE2":26017,"PHASE3":26019,"PHASE4":26027,"NA":26029},{"trials":26014,"activeCount":99},[],{"trials":26016,"activeCount":99},[],{"trials":26018,"activeCount":99},[],{"trials":26020,"activeCount":99},[26021],{"nctId":26022,"briefTitle":26023,"status":105,"phases":26024,"primaryCompletion":14930,"completion":14930,"start":15211,"enrollment":132,"conditions":26025,"interventions":26026},"NCT00127153","A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)",[89],[18,16472],[26011],{"trials":26028,"activeCount":99},[],{"trials":26030,"activeCount":99},[],{"intervention":23834,"totalTrials":224,"cells":26032},{"EARLY_PHASE1":26033,"PHASE1":26035,"PHASE2":26037,"PHASE3":26039,"PHASE4":26045,"NA":26047},{"trials":26034,"activeCount":99},[],{"trials":26036,"activeCount":99},[],{"trials":26038,"activeCount":99},[],{"trials":26040,"activeCount":99},[26041],{"nctId":23827,"briefTitle":23828,"status":105,"phases":26042,"primaryCompletion":23830,"completion":23034,"start":23014,"enrollment":23831,"conditions":26043,"interventions":26044},[89],[17593],[23816,23834,23834],{"trials":26046,"activeCount":99},[],{"trials":26048,"activeCount":99},[],{"intervention":15687,"totalTrials":224,"cells":26050},{"EARLY_PHASE1":26051,"PHASE1":26053,"PHASE2":26055,"PHASE3":26057,"PHASE4":26063,"NA":26065},{"trials":26052,"activeCount":99},[],{"trials":26054,"activeCount":99},[],{"trials":26056,"activeCount":99},[],{"trials":26058,"activeCount":99},[26059],{"nctId":15681,"briefTitle":15682,"status":105,"phases":26060,"primaryCompletion":5507,"completion":5507,"start":15210,"enrollment":15684,"conditions":26061,"interventions":26062},[89],[15023],[14487,15687],{"trials":26064,"activeCount":99},[],{"trials":26066,"activeCount":99},[],{"intervention":26068,"totalTrials":224,"cells":26069},"MK-0663B",{"EARLY_PHASE1":26070,"PHASE1":26072,"PHASE2":26074,"PHASE3":26076,"PHASE4":26088,"NA":26090},{"trials":26071,"activeCount":99},[],{"trials":26073,"activeCount":99},[],{"trials":26075,"activeCount":99},[],{"trials":26077,"activeCount":99},[26078],{"nctId":26079,"briefTitle":26080,"status":1040,"phases":26081,"primaryCompletion":15912,"completion":15912,"start":26082,"enrollment":99,"conditions":26083,"interventions":26085},"NCT01979510","Safety and Efficacy Study of an Etoricoxib and Tizanidine Fixed Dose Combination in Participants With Moderate to Severe Acute Low Back Pain (MK-0663B-164)",[89],"2013-11",[26084],"Low Back Pain",[26068,26086,26087],"DOLOCAM PLUS®","Acetaminophen 500 mg",{"trials":26089,"activeCount":99},[],{"trials":26091,"activeCount":99},[],{"intervention":26086,"totalTrials":224,"cells":26093},{"EARLY_PHASE1":26094,"PHASE1":26096,"PHASE2":26098,"PHASE3":26100,"PHASE4":26106,"NA":26108},{"trials":26095,"activeCount":99},[],{"trials":26097,"activeCount":99},[],{"trials":26099,"activeCount":99},[],{"trials":26101,"activeCount":99},[26102],{"nctId":26079,"briefTitle":26080,"status":1040,"phases":26103,"primaryCompletion":15912,"completion":15912,"start":26082,"enrollment":99,"conditions":26104,"interventions":26105},[89],[26084],[26068,26086,26087],{"trials":26107,"activeCount":99},[],{"trials":26109,"activeCount":99},[],{"intervention":26087,"totalTrials":224,"cells":26111},{"EARLY_PHASE1":26112,"PHASE1":26114,"PHASE2":26116,"PHASE3":26118,"PHASE4":26124,"NA":26126},{"trials":26113,"activeCount":99},[],{"trials":26115,"activeCount":99},[],{"trials":26117,"activeCount":99},[],{"trials":26119,"activeCount":99},[26120],{"nctId":26079,"briefTitle":26080,"status":1040,"phases":26121,"primaryCompletion":15912,"completion":15912,"start":26082,"enrollment":99,"conditions":26122,"interventions":26123},[89],[26084],[26068,26086,26087],{"trials":26125,"activeCount":99},[],{"trials":26127,"activeCount":99},[],{"intervention":17101,"totalTrials":224,"cells":26129},{"EARLY_PHASE1":26130,"PHASE1":26132,"PHASE2":26134,"PHASE3":26136,"PHASE4":26142,"NA":26144},{"trials":26131,"activeCount":99},[],{"trials":26133,"activeCount":99},[],{"trials":26135,"activeCount":99},[],{"trials":26137,"activeCount":99},[26138],{"nctId":17092,"briefTitle":17093,"status":105,"phases":26139,"primaryCompletion":17095,"completion":17095,"start":17096,"enrollment":17097,"conditions":26140,"interventions":26141},[89],[17099],[17081,17101],{"trials":26143,"activeCount":99},[],{"trials":26145,"activeCount":99},[],{"intervention":26147,"totalTrials":224,"cells":26148},"VARIVAX® PE34 Process",{"EARLY_PHASE1":26149,"PHASE1":26151,"PHASE2":26153,"PHASE3":26155,"PHASE4":26167,"NA":26169},{"trials":26150,"activeCount":99},[],{"trials":26152,"activeCount":99},[],{"trials":26154,"activeCount":99},[],{"trials":26156,"activeCount":99},[26157],{"nctId":26158,"briefTitle":26159,"status":105,"phases":26160,"primaryCompletion":26161,"completion":19113,"start":26162,"enrollment":1818,"conditions":26163,"interventions":26164},"NCT03239873","Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)",[89],"2018-08-14","2017-10-17",[15311],[26147,26165,26166],"VARIVAX® 2016 Commercial Process","M-M-R II®",{"trials":26168,"activeCount":99},[],{"trials":26170,"activeCount":99},[],{"intervention":26165,"totalTrials":224,"cells":26172},{"EARLY_PHASE1":26173,"PHASE1":26175,"PHASE2":26177,"PHASE3":26179,"PHASE4":26185,"NA":26187},{"trials":26174,"activeCount":99},[],{"trials":26176,"activeCount":99},[],{"trials":26178,"activeCount":99},[],{"trials":26180,"activeCount":99},[26181],{"nctId":26158,"briefTitle":26159,"status":105,"phases":26182,"primaryCompletion":26161,"completion":19113,"start":26162,"enrollment":1818,"conditions":26183,"interventions":26184},[89],[15311],[26147,26165,26166],{"trials":26186,"activeCount":99},[],{"trials":26188,"activeCount":99},[],{"intervention":26166,"totalTrials":224,"cells":26190},{"EARLY_PHASE1":26191,"PHASE1":26193,"PHASE2":26195,"PHASE3":26197,"PHASE4":26203,"NA":26205},{"trials":26192,"activeCount":99},[],{"trials":26194,"activeCount":99},[],{"trials":26196,"activeCount":99},[],{"trials":26198,"activeCount":99},[26199],{"nctId":26158,"briefTitle":26159,"status":105,"phases":26200,"primaryCompletion":26161,"completion":19113,"start":26162,"enrollment":1818,"conditions":26201,"interventions":26202},[89],[15311],[26147,26165,26166],{"trials":26204,"activeCount":99},[],{"trials":26206,"activeCount":99},[],{"intervention":26208,"totalTrials":224,"cells":26209},"Grazoprevir 100 mg\u002FElbasvir 50 mg FDC",{"EARLY_PHASE1":26210,"PHASE1":26212,"PHASE2":26214,"PHASE3":26216,"PHASE4":26226,"NA":26228},{"trials":26211,"activeCount":99},[],{"trials":26213,"activeCount":99},[],{"trials":26215,"activeCount":99},[],{"trials":26217,"activeCount":99},[26218],{"nctId":26219,"briefTitle":26220,"status":105,"phases":26221,"primaryCompletion":1339,"completion":26222,"start":26223,"enrollment":7596,"conditions":26224,"interventions":26225},"NCT02105688","An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)",[89],"2018-12-04","2014-09-02",[12957],[26208],{"trials":26227,"activeCount":99},[],{"trials":26229,"activeCount":99},[],{"intervention":26231,"totalTrials":224,"cells":26232},"Metformin IR",{"EARLY_PHASE1":26233,"PHASE1":26235,"PHASE2":26237,"PHASE3":26239,"PHASE4":26250,"NA":26252},{"trials":26234,"activeCount":99},[],{"trials":26236,"activeCount":99},[],{"trials":26238,"activeCount":99},[],{"trials":26240,"activeCount":99},[26241],{"nctId":26242,"briefTitle":26243,"status":105,"phases":26244,"primaryCompletion":26245,"completion":26245,"start":26246,"enrollment":26247,"conditions":26248,"interventions":26249},"NCT02791490","A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)",[89],"2018-02-01","2016-06-16",458,[15],[13145,26231],{"trials":26251,"activeCount":99},[],{"trials":26253,"activeCount":99},[],{"intervention":26255,"totalTrials":224,"cells":26256},"Comparator: Influenza Vaccine",{"EARLY_PHASE1":26257,"PHASE1":26259,"PHASE2":26261,"PHASE3":26263,"PHASE4":26272,"NA":26274},{"trials":26258,"activeCount":99},[],{"trials":26260,"activeCount":99},[],{"trials":26262,"activeCount":99},[],{"trials":26264,"activeCount":99},[26265],{"nctId":26266,"briefTitle":26267,"status":105,"phases":26268,"primaryCompletion":14483,"completion":14483,"start":15156,"enrollment":1919,"conditions":26269,"interventions":26270},"NCT00231816","A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)",[89],[14395],[26271,26255,26271],"ZOSTAVAX™",{"trials":26273,"activeCount":99},[],{"trials":26275,"activeCount":99},[],{"intervention":26277,"totalTrials":224,"cells":26278},"Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine",{"EARLY_PHASE1":26279,"PHASE1":26281,"PHASE2":26283,"PHASE3":26285,"PHASE4":26296,"NA":26298},{"trials":26280,"activeCount":99},[],{"trials":26282,"activeCount":99},[],{"trials":26284,"activeCount":99},[],{"trials":26286,"activeCount":99},[26287],{"nctId":26288,"briefTitle":26289,"status":105,"phases":26290,"primaryCompletion":26291,"completion":774,"start":26292,"enrollment":26293,"conditions":26294,"interventions":26295},"NCT00092534","Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)",[89],"2007-07-31","2002-06-14",12167,[863,7085],[26277],{"trials":26297,"activeCount":99},[],{"trials":26299,"activeCount":99},[],{"intervention":26301,"totalTrials":224,"cells":26302},"Influenza Vaccine",{"EARLY_PHASE1":26303,"PHASE1":26305,"PHASE2":26307,"PHASE3":26309,"PHASE4":26317,"NA":26319},{"trials":26304,"activeCount":99},[],{"trials":26306,"activeCount":99},[],{"trials":26308,"activeCount":99},[],{"trials":26310,"activeCount":99},[26311],{"nctId":26312,"briefTitle":26313,"status":105,"phases":26314,"primaryCompletion":11385,"completion":11385,"start":12954,"enrollment":2512,"conditions":26315,"interventions":26316},"NCT02519855","Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)",[89],[14395],[26271,26301],{"trials":26318,"activeCount":99},[],{"trials":26320,"activeCount":99},[],{"intervention":1729,"totalTrials":224,"cells":26322},{"EARLY_PHASE1":26323,"PHASE1":26325,"PHASE2":26327,"PHASE3":26329,"PHASE4":26335,"NA":26337},{"trials":26324,"activeCount":99},[],{"trials":26326,"activeCount":99},[],{"trials":26328,"activeCount":99},[],{"trials":26330,"activeCount":99},[26331],{"nctId":1719,"briefTitle":1720,"status":105,"phases":26332,"primaryCompletion":1722,"completion":1723,"start":1724,"enrollment":1725,"conditions":26333,"interventions":26334},[89],[1727],[461,47,1729,1730],{"trials":26336,"activeCount":99},[],{"trials":26338,"activeCount":99},[],{"intervention":1750,"totalTrials":224,"cells":26340},{"EARLY_PHASE1":26341,"PHASE1":26343,"PHASE2":26345,"PHASE3":26347,"PHASE4":26353,"NA":26355},{"trials":26342,"activeCount":99},[],{"trials":26344,"activeCount":99},[],{"trials":26346,"activeCount":99},[],{"trials":26348,"activeCount":99},[26349],{"nctId":1742,"briefTitle":1743,"status":105,"phases":26350,"primaryCompletion":824,"completion":1745,"start":1746,"enrollment":1747,"conditions":26351,"interventions":26352},[89],[828],[1750,1751,47,841,693],{"trials":26354,"activeCount":99},[],{"trials":26356,"activeCount":99},[],{"intervention":26358,"totalTrials":224,"cells":26359},"V232 Modified Process Hepatitis B Vaccine: Lot A",{"EARLY_PHASE1":26360,"PHASE1":26362,"PHASE2":26364,"PHASE3":26366,"PHASE4":26379,"NA":26381},{"trials":26361,"activeCount":99},[],{"trials":26363,"activeCount":99},[],{"trials":26365,"activeCount":99},[],{"trials":26367,"activeCount":99},[26368],{"nctId":26369,"briefTitle":26370,"status":105,"phases":26371,"primaryCompletion":8621,"completion":8621,"start":14594,"enrollment":26372,"conditions":26373,"interventions":26375},"NCT00489099","A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054)",[89],860,[26374],"Hepatitis B Infection",[26358,26376,26377,26378],"V232 Modified Process Hepatitis B Vaccine: Lot B","V232 Modified Process Hepatitis B Vaccine: Lot C","V232 Current Process Hepatitis B Vaccine",{"trials":26380,"activeCount":99},[],{"trials":26382,"activeCount":99},[],{"intervention":26376,"totalTrials":224,"cells":26384},{"EARLY_PHASE1":26385,"PHASE1":26387,"PHASE2":26389,"PHASE3":26391,"PHASE4":26397,"NA":26399},{"trials":26386,"activeCount":99},[],{"trials":26388,"activeCount":99},[],{"trials":26390,"activeCount":99},[],{"trials":26392,"activeCount":99},[26393],{"nctId":26369,"briefTitle":26370,"status":105,"phases":26394,"primaryCompletion":8621,"completion":8621,"start":14594,"enrollment":26372,"conditions":26395,"interventions":26396},[89],[26374],[26358,26376,26377,26378],{"trials":26398,"activeCount":99},[],{"trials":26400,"activeCount":99},[],{"intervention":26377,"totalTrials":224,"cells":26402},{"EARLY_PHASE1":26403,"PHASE1":26405,"PHASE2":26407,"PHASE3":26409,"PHASE4":26415,"NA":26417},{"trials":26404,"activeCount":99},[],{"trials":26406,"activeCount":99},[],{"trials":26408,"activeCount":99},[],{"trials":26410,"activeCount":99},[26411],{"nctId":26369,"briefTitle":26370,"status":105,"phases":26412,"primaryCompletion":8621,"completion":8621,"start":14594,"enrollment":26372,"conditions":26413,"interventions":26414},[89],[26374],[26358,26376,26377,26378],{"trials":26416,"activeCount":99},[],{"trials":26418,"activeCount":99},[],{"intervention":26378,"totalTrials":224,"cells":26420},{"EARLY_PHASE1":26421,"PHASE1":26423,"PHASE2":26425,"PHASE3":26427,"PHASE4":26433,"NA":26435},{"trials":26422,"activeCount":99},[],{"trials":26424,"activeCount":99},[],{"trials":26426,"activeCount":99},[],{"trials":26428,"activeCount":99},[26429],{"nctId":26369,"briefTitle":26370,"status":105,"phases":26430,"primaryCompletion":8621,"completion":8621,"start":14594,"enrollment":26372,"conditions":26431,"interventions":26432},[89],[26374],[26358,26376,26377,26378],{"trials":26434,"activeCount":99},[],{"trials":26436,"activeCount":99},[],{"intervention":24028,"totalTrials":224,"cells":26438},{"EARLY_PHASE1":26439,"PHASE1":26441,"PHASE2":26443,"PHASE3":26445,"PHASE4":26451,"NA":26453},{"trials":26440,"activeCount":99},[],{"trials":26442,"activeCount":99},[],{"trials":26444,"activeCount":99},[],{"trials":26446,"activeCount":99},[26447],{"nctId":24022,"briefTitle":24023,"status":105,"phases":26448,"primaryCompletion":14567,"completion":14567,"start":15295,"enrollment":1570,"conditions":26449,"interventions":26450},[89],[24026],[24028,24011,24029],{"trials":26452,"activeCount":99},[],{"trials":26454,"activeCount":99},[],{"intervention":24029,"totalTrials":224,"cells":26456},{"EARLY_PHASE1":26457,"PHASE1":26459,"PHASE2":26461,"PHASE3":26463,"PHASE4":26469,"NA":26471},{"trials":26458,"activeCount":99},[],{"trials":26460,"activeCount":99},[],{"trials":26462,"activeCount":99},[],{"trials":26464,"activeCount":99},[26465],{"nctId":24022,"briefTitle":24023,"status":105,"phases":26466,"primaryCompletion":14567,"completion":14567,"start":15295,"enrollment":1570,"conditions":26467,"interventions":26468},[89],[24026],[24028,24011,24029],{"trials":26470,"activeCount":99},[],{"trials":26472,"activeCount":99},[],{"intervention":15149,"totalTrials":224,"cells":26474},{"EARLY_PHASE1":26475,"PHASE1":26477,"PHASE2":26479,"PHASE3":26481,"PHASE4":26487,"NA":26489},{"trials":26476,"activeCount":99},[],{"trials":26478,"activeCount":99},[],{"trials":26480,"activeCount":99},[],{"trials":26482,"activeCount":99},[26483],{"nctId":15140,"briefTitle":15141,"status":105,"phases":26484,"primaryCompletion":15143,"completion":15144,"start":15145,"enrollment":15146,"conditions":26485,"interventions":26486},[89],[33],[15149,15150,14331,13985],{"trials":26488,"activeCount":99},[],{"trials":26490,"activeCount":99},[],{"intervention":15150,"totalTrials":224,"cells":26492},{"EARLY_PHASE1":26493,"PHASE1":26495,"PHASE2":26497,"PHASE3":26499,"PHASE4":26505,"NA":26507},{"trials":26494,"activeCount":99},[],{"trials":26496,"activeCount":99},[],{"trials":26498,"activeCount":99},[],{"trials":26500,"activeCount":99},[26501],{"nctId":15140,"briefTitle":15141,"status":105,"phases":26502,"primaryCompletion":15143,"completion":15144,"start":15145,"enrollment":15146,"conditions":26503,"interventions":26504},[89],[33],[15149,15150,14331,13985],{"trials":26506,"activeCount":99},[],{"trials":26508,"activeCount":99},[],{"intervention":19915,"totalTrials":224,"cells":26510},{"EARLY_PHASE1":26511,"PHASE1":26513,"PHASE2":26515,"PHASE3":26517,"PHASE4":26523,"NA":26525},{"trials":26512,"activeCount":99},[],{"trials":26514,"activeCount":99},[],{"trials":26516,"activeCount":99},[],{"trials":26518,"activeCount":99},[26519],{"nctId":19906,"briefTitle":19907,"status":105,"phases":26520,"primaryCompletion":19909,"completion":19910,"start":13199,"enrollment":13958,"conditions":26521,"interventions":26522},[89],[17064],[13203,19913,19914,19915],{"trials":26524,"activeCount":99},[],{"trials":26526,"activeCount":99},[],{"intervention":26528,"totalTrials":224,"cells":26529},"Infliximab Increased Frequency",{"EARLY_PHASE1":26530,"PHASE1":26532,"PHASE2":26534,"PHASE3":26536,"PHASE4":26546,"NA":26548},{"trials":26531,"activeCount":99},[],{"trials":26533,"activeCount":99},[],{"trials":26535,"activeCount":99},[],{"trials":26537,"activeCount":99},[26538],{"nctId":26539,"briefTitle":26540,"status":150,"phases":26541,"primaryCompletion":6309,"completion":6309,"start":14483,"enrollment":19575,"conditions":26542,"interventions":26543},"NCT00394589","Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)",[89],[7020],[26528,26544,26545],"Infliximab Increased Dose","Infliximab Control",{"trials":26547,"activeCount":99},[],{"trials":26549,"activeCount":99},[],{"intervention":26544,"totalTrials":224,"cells":26551},{"EARLY_PHASE1":26552,"PHASE1":26554,"PHASE2":26556,"PHASE3":26558,"PHASE4":26564,"NA":26566},{"trials":26553,"activeCount":99},[],{"trials":26555,"activeCount":99},[],{"trials":26557,"activeCount":99},[],{"trials":26559,"activeCount":99},[26560],{"nctId":26539,"briefTitle":26540,"status":150,"phases":26561,"primaryCompletion":6309,"completion":6309,"start":14483,"enrollment":19575,"conditions":26562,"interventions":26563},[89],[7020],[26528,26544,26545],{"trials":26565,"activeCount":99},[],{"trials":26567,"activeCount":99},[],{"intervention":26545,"totalTrials":224,"cells":26569},{"EARLY_PHASE1":26570,"PHASE1":26572,"PHASE2":26574,"PHASE3":26576,"PHASE4":26582,"NA":26584},{"trials":26571,"activeCount":99},[],{"trials":26573,"activeCount":99},[],{"trials":26575,"activeCount":99},[],{"trials":26577,"activeCount":99},[26578],{"nctId":26539,"briefTitle":26540,"status":150,"phases":26579,"primaryCompletion":6309,"completion":6309,"start":14483,"enrollment":19575,"conditions":26580,"interventions":26581},[89],[7020],[26528,26544,26545],{"trials":26583,"activeCount":99},[],{"trials":26585,"activeCount":99},[],{"intervention":13986,"totalTrials":224,"cells":26587},{"EARLY_PHASE1":26588,"PHASE1":26590,"PHASE2":26592,"PHASE3":26594,"PHASE4":26600,"NA":26602},{"trials":26589,"activeCount":99},[],{"trials":26591,"activeCount":99},[],{"trials":26593,"activeCount":99},[],{"trials":26595,"activeCount":99},[26596],{"nctId":13973,"briefTitle":13974,"status":105,"phases":26597,"primaryCompletion":13976,"completion":13977,"start":13978,"enrollment":13979,"conditions":26598,"interventions":26599},[89],[15],[13982,13983,13984,13985,13986,4084,13987],{"trials":26601,"activeCount":99},[],{"trials":26603,"activeCount":99},[],{"intervention":13987,"totalTrials":224,"cells":26605},{"EARLY_PHASE1":26606,"PHASE1":26608,"PHASE2":26610,"PHASE3":26612,"PHASE4":26618,"NA":26620},{"trials":26607,"activeCount":99},[],{"trials":26609,"activeCount":99},[],{"trials":26611,"activeCount":99},[],{"trials":26613,"activeCount":99},[26614],{"nctId":13973,"briefTitle":13974,"status":105,"phases":26615,"primaryCompletion":13976,"completion":13977,"start":13978,"enrollment":13979,"conditions":26616,"interventions":26617},[89],[15],[13982,13983,13984,13985,13986,4084,13987],{"trials":26619,"activeCount":99},[],{"trials":26621,"activeCount":99},[],{"intervention":24117,"totalTrials":224,"cells":26623},{"EARLY_PHASE1":26624,"PHASE1":26626,"PHASE2":26628,"PHASE3":26630,"PHASE4":26636,"NA":26638},{"trials":26625,"activeCount":99},[],{"trials":26627,"activeCount":99},[],{"trials":26629,"activeCount":99},[],{"trials":26631,"activeCount":99},[26632],{"nctId":24109,"briefTitle":24110,"status":105,"phases":26633,"primaryCompletion":24112,"completion":24112,"start":24113,"enrollment":24114,"conditions":26634,"interventions":26635},[89],[4397],[24117,24087,24118],{"trials":26637,"activeCount":99},[],{"trials":26639,"activeCount":99},[],{"intervention":24118,"totalTrials":224,"cells":26641},{"EARLY_PHASE1":26642,"PHASE1":26644,"PHASE2":26646,"PHASE3":26648,"PHASE4":26654,"NA":26656},{"trials":26643,"activeCount":99},[],{"trials":26645,"activeCount":99},[],{"trials":26647,"activeCount":99},[],{"trials":26649,"activeCount":99},[26650],{"nctId":24109,"briefTitle":24110,"status":105,"phases":26651,"primaryCompletion":24112,"completion":24112,"start":24113,"enrollment":24114,"conditions":26652,"interventions":26653},[89],[4397],[24117,24087,24118],{"trials":26655,"activeCount":99},[],{"trials":26657,"activeCount":99},[],{"intervention":7663,"totalTrials":224,"cells":26659},{"EARLY_PHASE1":26660,"PHASE1":26662,"PHASE2":26664,"PHASE3":26666,"PHASE4":26672,"NA":26674},{"trials":26661,"activeCount":99},[],{"trials":26663,"activeCount":99},[],{"trials":26665,"activeCount":99},[],{"trials":26667,"activeCount":99},[26668],{"nctId":7654,"briefTitle":7655,"status":105,"phases":26669,"primaryCompletion":7657,"completion":7658,"start":7659,"enrollment":3903,"conditions":26670,"interventions":26671},[89],[7639],[7662,7663,7617],{"trials":26673,"activeCount":99},[],{"trials":26675,"activeCount":99},[],{"intervention":24141,"totalTrials":224,"cells":26677},{"EARLY_PHASE1":26678,"PHASE1":26680,"PHASE2":26682,"PHASE3":26684,"PHASE4":26690,"NA":26692},{"trials":26679,"activeCount":99},[],{"trials":26681,"activeCount":99},[],{"trials":26683,"activeCount":99},[],{"trials":26685,"activeCount":99},[26686],{"nctId":24135,"briefTitle":24136,"status":105,"phases":26687,"primaryCompletion":1560,"completion":1879,"start":24138,"enrollment":987,"conditions":26688,"interventions":26689},[89],[15311],[24141,24124,24142],{"trials":26691,"activeCount":99},[],{"trials":26693,"activeCount":99},[],{"intervention":24142,"totalTrials":224,"cells":26695},{"EARLY_PHASE1":26696,"PHASE1":26698,"PHASE2":26700,"PHASE3":26702,"PHASE4":26708,"NA":26710},{"trials":26697,"activeCount":99},[],{"trials":26699,"activeCount":99},[],{"trials":26701,"activeCount":99},[],{"trials":26703,"activeCount":99},[26704],{"nctId":24135,"briefTitle":24136,"status":105,"phases":26705,"primaryCompletion":1560,"completion":1879,"start":24138,"enrollment":987,"conditions":26706,"interventions":26707},[89],[15311],[24141,24124,24142],{"trials":26709,"activeCount":99},[],{"trials":26711,"activeCount":99},[],{"intervention":26713,"totalTrials":224,"cells":26714},"MK0966; Rofecoxib \u002F Duration of Treatment: 156 weeks",{"EARLY_PHASE1":26715,"PHASE1":26717,"PHASE2":26719,"PHASE3":26721,"PHASE4":26733,"NA":26735},{"trials":26716,"activeCount":99},[],{"trials":26718,"activeCount":99},[],{"trials":26720,"activeCount":99},[],{"trials":26722,"activeCount":99},[26723],{"nctId":26724,"briefTitle":26725,"status":105,"phases":26726,"primaryCompletion":26727,"completion":26727,"start":26728,"enrollment":26729,"conditions":26730,"interventions":26732},"NCT00282386","A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)",[89],"2004-09-01","1999-12-23",2586,[26731],"Colorectal Adenoma",[26713],{"trials":26734,"activeCount":99},[],{"trials":26736,"activeCount":99},[],{"intervention":26738,"totalTrials":224,"cells":26739},"Verubecestat",{"EARLY_PHASE1":26740,"PHASE1":26742,"PHASE2":26744,"PHASE3":26746,"PHASE4":26756,"NA":26758},{"trials":26741,"activeCount":99},[],{"trials":26743,"activeCount":99},[],{"trials":26745,"activeCount":99},[],{"trials":26747,"activeCount":99},[26748],{"nctId":26749,"briefTitle":26750,"status":150,"phases":26751,"primaryCompletion":19460,"completion":19460,"start":26752,"enrollment":26753,"conditions":26754,"interventions":26755},"NCT01739348","An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)",[88,89],"2012-11-30",2211,[11174],[26738,26738,26738,26738],{"trials":26757,"activeCount":99},[],{"trials":26759,"activeCount":99},[],{"intervention":15878,"totalTrials":224,"cells":26761},{"EARLY_PHASE1":26762,"PHASE1":26764,"PHASE2":26766,"PHASE3":26768,"PHASE4":26774,"NA":26776},{"trials":26763,"activeCount":99},[],{"trials":26765,"activeCount":99},[],{"trials":26767,"activeCount":99},[],{"trials":26769,"activeCount":99},[26770],{"nctId":15872,"briefTitle":15873,"status":1040,"phases":26771,"primaryCompletion":1001,"completion":1001,"start":15875,"enrollment":99,"conditions":26772,"interventions":26773},[89],[12957],[15784,15878,14925,15784,15859,14925],{"trials":26775,"activeCount":99},[],{"trials":26777,"activeCount":99},[],{"intervention":26779,"totalTrials":224,"cells":26780},"HBVAXPRO™",{"EARLY_PHASE1":26781,"PHASE1":26783,"PHASE2":26785,"PHASE3":26787,"PHASE4":26797,"NA":26799},{"trials":26782,"activeCount":99},[],{"trials":26784,"activeCount":99},[],{"trials":26786,"activeCount":99},[],{"trials":26788,"activeCount":99},[26789],{"nctId":26790,"briefTitle":26791,"status":105,"phases":26792,"primaryCompletion":26793,"completion":26793,"start":26794,"enrollment":9357,"conditions":26795,"interventions":26796},"NCT04490499","A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)",[89],"2020-12-29","2020-09-02",[17593],[26779],{"trials":26798,"activeCount":99},[],{"trials":26800,"activeCount":99},[],{"intervention":17140,"totalTrials":224,"cells":26802},{"EARLY_PHASE1":26803,"PHASE1":26805,"PHASE2":26807,"PHASE3":26809,"PHASE4":26815,"NA":26817},{"trials":26804,"activeCount":99},[],{"trials":26806,"activeCount":99},[],{"trials":26808,"activeCount":99},[],{"trials":26810,"activeCount":99},[26811],{"nctId":17131,"briefTitle":17132,"status":105,"phases":26812,"primaryCompletion":17134,"completion":17134,"start":17135,"enrollment":479,"conditions":26813,"interventions":26814},[89],[17137],[17120,17139,17140],{"trials":26816,"activeCount":99},[],{"trials":26818,"activeCount":99},[],{"intervention":26820,"totalTrials":224,"cells":26821},"IMI\u002FREL",{"EARLY_PHASE1":26822,"PHASE1":26824,"PHASE2":26826,"PHASE3":26828,"PHASE4":26839,"NA":26841},{"trials":26823,"activeCount":99},[],{"trials":26825,"activeCount":99},[],{"trials":26827,"activeCount":99},[],{"trials":26829,"activeCount":99},[26830],{"nctId":26831,"briefTitle":26832,"status":105,"phases":26833,"primaryCompletion":26834,"completion":26834,"start":14221,"enrollment":11225,"conditions":26835,"interventions":26836},"NCT03969901","Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem\u002FCilastatin\u002FRelebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)",[88,89],"2024-05-07",[25455],[26820,26837,26838],"Active Control","Oral Switch",{"trials":26840,"activeCount":99},[],{"trials":26842,"activeCount":99},[],{"intervention":26837,"totalTrials":224,"cells":26844},{"EARLY_PHASE1":26845,"PHASE1":26847,"PHASE2":26849,"PHASE3":26851,"PHASE4":26857,"NA":26859},{"trials":26846,"activeCount":99},[],{"trials":26848,"activeCount":99},[],{"trials":26850,"activeCount":99},[],{"trials":26852,"activeCount":99},[26853],{"nctId":26831,"briefTitle":26832,"status":105,"phases":26854,"primaryCompletion":26834,"completion":26834,"start":14221,"enrollment":11225,"conditions":26855,"interventions":26856},[88,89],[25455],[26820,26837,26838],{"trials":26858,"activeCount":99},[],{"trials":26860,"activeCount":99},[],{"intervention":26838,"totalTrials":224,"cells":26862},{"EARLY_PHASE1":26863,"PHASE1":26865,"PHASE2":26867,"PHASE3":26869,"PHASE4":26875,"NA":26877},{"trials":26864,"activeCount":99},[],{"trials":26866,"activeCount":99},[],{"trials":26868,"activeCount":99},[],{"trials":26870,"activeCount":99},[26871],{"nctId":26831,"briefTitle":26832,"status":105,"phases":26872,"primaryCompletion":26834,"completion":26834,"start":14221,"enrollment":11225,"conditions":26873,"interventions":26874},[88,89],[25455],[26820,26837,26838],{"trials":26876,"activeCount":99},[],{"trials":26878,"activeCount":99},[],{"intervention":26880,"totalTrials":224,"cells":26881},"MK0803, lovastatin",{"EARLY_PHASE1":26882,"PHASE1":26884,"PHASE2":26886,"PHASE3":26888,"PHASE4":26897,"NA":26899},{"trials":26883,"activeCount":99},[],{"trials":26885,"activeCount":99},[],{"trials":26887,"activeCount":99},[],{"trials":26889,"activeCount":99},[26890],{"nctId":26891,"briefTitle":26892,"status":105,"phases":26893,"primaryCompletion":21202,"start":26894,"enrollment":1633,"conditions":26895,"interventions":26896},"NCT00092846","A 6-Month Consumer Behavior Study of a Self-Management System (0803-084)(COMPLETED)",[89],"2002-12-04",[7598],[26880],{"trials":26898,"activeCount":99},[],{"trials":26900,"activeCount":99},[],{"intervention":26902,"totalTrials":224,"cells":26903},"MK0217A, alendronate sodium (+) cholecalciferol \u002F Duration of Treatment: 24 weeks",{"EARLY_PHASE1":26904,"PHASE1":26906,"PHASE2":26908,"PHASE3":26910,"PHASE4":26919,"NA":26921},{"trials":26905,"activeCount":99},[],{"trials":26907,"activeCount":99},[],{"trials":26909,"activeCount":99},[],{"trials":26911,"activeCount":99},[26912],{"nctId":26913,"briefTitle":26914,"status":105,"phases":26915,"primaryCompletion":14706,"completion":14706,"start":18807,"enrollment":19257,"conditions":26916,"interventions":26918},"NCT00092079","A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)",[89],[14552,26917],"Vitamin D Deficiency",[26902],{"trials":26920,"activeCount":99},[],{"trials":26922,"activeCount":99},[],{"intervention":15173,"totalTrials":224,"cells":26924},{"EARLY_PHASE1":26925,"PHASE1":26927,"PHASE2":26929,"PHASE3":26931,"PHASE4":26937,"NA":26939},{"trials":26926,"activeCount":99},[],{"trials":26928,"activeCount":99},[],{"trials":26930,"activeCount":99},[],{"trials":26932,"activeCount":99},[26933],{"nctId":15166,"briefTitle":15167,"status":150,"phases":26934,"primaryCompletion":6309,"completion":9610,"start":14409,"enrollment":15169,"conditions":26935,"interventions":26936},[89],[7650],[15172,14331,15173,14331],{"trials":26938,"activeCount":99},[],{"trials":26940,"activeCount":99},[],{"intervention":15896,"totalTrials":224,"cells":26942},{"EARLY_PHASE1":26943,"PHASE1":26945,"PHASE2":26947,"PHASE3":26949,"PHASE4":26955,"NA":26957},{"trials":26944,"activeCount":99},[],{"trials":26946,"activeCount":99},[],{"trials":26948,"activeCount":99},[],{"trials":26950,"activeCount":99},[26951],{"nctId":15888,"briefTitle":15889,"status":105,"phases":26952,"primaryCompletion":15891,"completion":15891,"start":15892,"enrollment":15893,"conditions":26953,"interventions":26954},[89],[21],[15896,14925,15784],{"trials":26956,"activeCount":99},[],{"trials":26958,"activeCount":99},[],{"intervention":14017,"totalTrials":224,"cells":26960},{"EARLY_PHASE1":26961,"PHASE1":26963,"PHASE2":26965,"PHASE3":26967,"PHASE4":26973,"NA":26975},{"trials":26962,"activeCount":99},[],{"trials":26964,"activeCount":99},[],{"trials":26966,"activeCount":99},[],{"trials":26968,"activeCount":99},[26969],{"nctId":14010,"briefTitle":14011,"status":105,"phases":26970,"primaryCompletion":14013,"completion":14013,"start":14014,"enrollment":1685,"conditions":26971,"interventions":26972},[89],[15],[13145,14017,4084,14018],{"trials":26974,"activeCount":99},[],{"trials":26976,"activeCount":99},[],{"intervention":21172,"totalTrials":224,"cells":26978},{"EARLY_PHASE1":26979,"PHASE1":26981,"PHASE2":26983,"PHASE3":26985,"PHASE4":26991,"NA":26993},{"trials":26980,"activeCount":99},[],{"trials":26982,"activeCount":99},[],{"trials":26984,"activeCount":99},[],{"trials":26986,"activeCount":99},[26987],{"nctId":21164,"briefTitle":21165,"status":105,"phases":26988,"primaryCompletion":15054,"completion":15054,"start":21167,"enrollment":21168,"conditions":26989,"interventions":26990},[89],[21170],[21153,21172],{"trials":26992,"activeCount":99},[],{"trials":26994,"activeCount":99},[],{"intervention":26996,"totalTrials":224,"cells":26997},"INS365 Ophthalmic Solution",{"EARLY_PHASE1":26998,"PHASE1":27000,"PHASE2":27002,"PHASE3":27004,"PHASE4":27013,"NA":27015},{"trials":26999,"activeCount":99},[],{"trials":27001,"activeCount":99},[],{"trials":27003,"activeCount":99},[],{"trials":27005,"activeCount":99},[27006],{"nctId":27007,"briefTitle":27008,"status":105,"phases":27009,"primaryCompletion":5508,"completion":5508,"start":24181,"enrollment":710,"conditions":27010,"interventions":27012},"NCT00037661","Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye",[89],[27011],"Keratoconjunctivitis Sicca",[26996],{"trials":27014,"activeCount":99},[],{"trials":27016,"activeCount":99},[],{"intervention":1842,"totalTrials":224,"cells":27018},{"EARLY_PHASE1":27019,"PHASE1":27021,"PHASE2":27023,"PHASE3":27025,"PHASE4":27031,"NA":27033},{"trials":27020,"activeCount":99},[],{"trials":27022,"activeCount":99},[],{"trials":27024,"activeCount":99},[],{"trials":27026,"activeCount":99},[27027],{"nctId":1832,"briefTitle":1833,"status":105,"phases":27028,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":27029,"interventions":27030},[89],[1840,1442],[47,390,1444,434,795,1842,1843],{"trials":27032,"activeCount":99},[],{"trials":27034,"activeCount":99},[],{"intervention":27036,"totalTrials":224,"cells":27037},"sitagliptin 100 mg q.d.\u002Fmetformin ≥ 1500 mg\u002Fday",{"EARLY_PHASE1":27038,"PHASE1":27040,"PHASE2":27042,"PHASE3":27044,"PHASE4":27053,"NA":27055},{"trials":27039,"activeCount":99},[],{"trials":27041,"activeCount":99},[],{"trials":27043,"activeCount":99},[],{"trials":27045,"activeCount":99},[27046],{"nctId":27047,"briefTitle":27048,"status":105,"phases":27049,"primaryCompletion":14409,"completion":5507,"start":14705,"enrollment":3541,"conditions":27050,"interventions":27051},"NCT00337610","Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus",[89],[14277],[27036,27052],"comparator: placebo to match sitagliptin 100 mg q.d.\u002Fmetformin ≥ 1500 mg\u002Fday",{"trials":27054,"activeCount":99},[],{"trials":27056,"activeCount":99},[],{"intervention":27052,"totalTrials":224,"cells":27058},{"EARLY_PHASE1":27059,"PHASE1":27061,"PHASE2":27063,"PHASE3":27065,"PHASE4":27071,"NA":27073},{"trials":27060,"activeCount":99},[],{"trials":27062,"activeCount":99},[],{"trials":27064,"activeCount":99},[],{"trials":27066,"activeCount":99},[27067],{"nctId":27047,"briefTitle":27048,"status":105,"phases":27068,"primaryCompletion":14409,"completion":5507,"start":14705,"enrollment":3541,"conditions":27069,"interventions":27070},[89],[14277],[27036,27052],{"trials":27072,"activeCount":99},[],{"trials":27074,"activeCount":99},[],{"intervention":24445,"totalTrials":224,"cells":27076},{"EARLY_PHASE1":27077,"PHASE1":27079,"PHASE2":27081,"PHASE3":27083,"PHASE4":27089,"NA":27091},{"trials":27078,"activeCount":99},[],{"trials":27080,"activeCount":99},[],{"trials":27082,"activeCount":99},[],{"trials":27084,"activeCount":99},[27085],{"nctId":24440,"briefTitle":24441,"status":105,"phases":27086,"enrollment":2023,"conditions":27087,"interventions":27088},[89],[27],[17754,6235,24445,24429],{"trials":27090,"activeCount":99},[],{"trials":27092,"activeCount":99},[],{"intervention":23028,"totalTrials":224,"cells":27094},{"EARLY_PHASE1":27095,"PHASE1":27097,"PHASE2":27099,"PHASE3":27101,"PHASE4":27107,"NA":27109},{"trials":27096,"activeCount":99},[],{"trials":27098,"activeCount":99},[],{"trials":27100,"activeCount":99},[],{"trials":27102,"activeCount":99},[27103],{"nctId":23019,"briefTitle":23020,"status":105,"phases":27104,"primaryCompletion":4756,"completion":4756,"start":23022,"enrollment":23023,"conditions":27105,"interventions":27106},[89],[15311,15308,15309,15310,20573,20574,20575,23025,17593,23026],[22999,23028],{"trials":27108,"activeCount":99},[],{"trials":27110,"activeCount":99},[],{"intervention":14028,"totalTrials":224,"cells":27112},{"EARLY_PHASE1":27113,"PHASE1":27115,"PHASE2":27117,"PHASE3":27119,"PHASE4":27125,"NA":27127},{"trials":27114,"activeCount":99},[],{"trials":27116,"activeCount":99},[],{"trials":27118,"activeCount":99},[],{"trials":27120,"activeCount":99},[27121],{"nctId":14020,"briefTitle":14021,"status":105,"phases":27122,"primaryCompletion":14023,"completion":9322,"start":14024,"enrollment":14025,"conditions":27123,"interventions":27124},[89],[15],[13982,14028,4084],{"trials":27126,"activeCount":99},[],{"trials":27128,"activeCount":99},[],{"intervention":27130,"totalTrials":224,"cells":27131},"V503 Vaccine",{"EARLY_PHASE1":27132,"PHASE1":27134,"PHASE2":27136,"PHASE3":27138,"PHASE4":27150,"NA":27152},{"trials":27133,"activeCount":99},[],{"trials":27135,"activeCount":99},[],{"trials":27137,"activeCount":99},[],{"trials":27139,"activeCount":99},[27140],{"nctId":27141,"briefTitle":27142,"status":105,"phases":27143,"primaryCompletion":27144,"completion":27144,"start":27145,"enrollment":27146,"conditions":27147,"interventions":27148},"NCT01073293","A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)",[89],"2011-06-16","2010-04-22",1054,[7076],[27130,27149,27149],"REPEVAX™",{"trials":27151,"activeCount":99},[],{"trials":27153,"activeCount":99},[],{"intervention":27149,"totalTrials":224,"cells":27155},{"EARLY_PHASE1":27156,"PHASE1":27158,"PHASE2":27160,"PHASE3":27162,"PHASE4":27168,"NA":27170},{"trials":27157,"activeCount":99},[],{"trials":27159,"activeCount":99},[],{"trials":27161,"activeCount":99},[],{"trials":27163,"activeCount":99},[27164],{"nctId":27141,"briefTitle":27142,"status":105,"phases":27165,"primaryCompletion":27144,"completion":27144,"start":27145,"enrollment":27146,"conditions":27166,"interventions":27167},[89],[7076],[27130,27149,27149],{"trials":27169,"activeCount":99},[],{"trials":27171,"activeCount":99},[],{"intervention":27173,"totalTrials":224,"cells":27174},"MK0966 \u002F Duration of Treatment: 1 Days",{"EARLY_PHASE1":27175,"PHASE1":27177,"PHASE2":27179,"PHASE3":27181,"PHASE4":27193,"NA":27195},{"trials":27176,"activeCount":99},[],{"trials":27178,"activeCount":99},[],{"trials":27180,"activeCount":99},[],{"trials":27182,"activeCount":99},[27183],{"nctId":27184,"briefTitle":27185,"status":105,"phases":27186,"primaryCompletion":14772,"completion":14772,"start":27187,"enrollment":15029,"conditions":27188,"interventions":27190},"NCT00390260","Effect of Rofecoxib and a Narcotic Analgesic to Treat Pain Following Arthroscopic Surgery (0966-179)(COMPLETED)",[89],"2002-02",[27189],"Pain, Postoperative Arthroscopy",[27173,27191,27192],"Comparator: acetaminophen (+) hydrocodone bitartrate \u002F Duration of Treatment: 1 Days","Comparator: placebo (unspecified) \u002F Duration of Treatment: 1 Days",{"trials":27194,"activeCount":99},[],{"trials":27196,"activeCount":99},[],{"intervention":27191,"totalTrials":224,"cells":27198},{"EARLY_PHASE1":27199,"PHASE1":27201,"PHASE2":27203,"PHASE3":27205,"PHASE4":27211,"NA":27213},{"trials":27200,"activeCount":99},[],{"trials":27202,"activeCount":99},[],{"trials":27204,"activeCount":99},[],{"trials":27206,"activeCount":99},[27207],{"nctId":27184,"briefTitle":27185,"status":105,"phases":27208,"primaryCompletion":14772,"completion":14772,"start":27187,"enrollment":15029,"conditions":27209,"interventions":27210},[89],[27189],[27173,27191,27192],{"trials":27212,"activeCount":99},[],{"trials":27214,"activeCount":99},[],{"intervention":27192,"totalTrials":224,"cells":27216},{"EARLY_PHASE1":27217,"PHASE1":27219,"PHASE2":27221,"PHASE3":27223,"PHASE4":27229,"NA":27231},{"trials":27218,"activeCount":99},[],{"trials":27220,"activeCount":99},[],{"trials":27222,"activeCount":99},[],{"trials":27224,"activeCount":99},[27225],{"nctId":27184,"briefTitle":27185,"status":105,"phases":27226,"primaryCompletion":14772,"completion":14772,"start":27187,"enrollment":15029,"conditions":27227,"interventions":27228},[89],[27189],[27173,27191,27192],{"trials":27230,"activeCount":99},[],{"trials":27232,"activeCount":99},[],{"intervention":27234,"totalTrials":224,"cells":27235},"Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin",{"EARLY_PHASE1":27236,"PHASE1":27238,"PHASE2":27240,"PHASE3":27242,"PHASE4":27253,"NA":27255},{"trials":27237,"activeCount":99},[],{"trials":27239,"activeCount":99},[],{"trials":27241,"activeCount":99},[],{"trials":27243,"activeCount":99},[27244],{"nctId":27245,"briefTitle":27246,"status":105,"phases":27247,"primaryCompletion":14614,"completion":14614,"start":27248,"enrollment":27249,"conditions":27250,"interventions":27251},"NCT00237484","Effect of Infliximab on the Efficacy of Peg-Intron\u002FRibavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)",[89],"2005-07-18",89,[21],[27234,27252],"Combination of (a) pegylated interferon alfa-2b and (b) ribavirin",{"trials":27254,"activeCount":99},[],{"trials":27256,"activeCount":99},[],{"intervention":27252,"totalTrials":224,"cells":27258},{"EARLY_PHASE1":27259,"PHASE1":27261,"PHASE2":27263,"PHASE3":27265,"PHASE4":27271,"NA":27273},{"trials":27260,"activeCount":99},[],{"trials":27262,"activeCount":99},[],{"trials":27264,"activeCount":99},[],{"trials":27266,"activeCount":99},[27267],{"nctId":27245,"briefTitle":27246,"status":105,"phases":27268,"primaryCompletion":14614,"completion":14614,"start":27248,"enrollment":27249,"conditions":27269,"interventions":27270},[89],[21],[27234,27252],{"trials":27272,"activeCount":99},[],{"trials":27274,"activeCount":99},[],{"intervention":27276,"totalTrials":224,"cells":27277},"V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine \u002F Duration of Treatment: 4 years",{"EARLY_PHASE1":27278,"PHASE1":27280,"PHASE2":27282,"PHASE3":27284,"PHASE4":27295,"NA":27297},{"trials":27279,"activeCount":99},[],{"trials":27281,"activeCount":99},[],{"trials":27283,"activeCount":99},[],{"trials":27285,"activeCount":99},[27286],{"nctId":27287,"briefTitle":27288,"status":105,"phases":27289,"primaryCompletion":14094,"completion":27290,"start":27291,"enrollment":27292,"conditions":27293,"interventions":27294},"NCT00092482","Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)",[89],"2008-08-15","2002-06-28",3882,[863,7085],[27276],{"trials":27296,"activeCount":99},[],{"trials":27298,"activeCount":99},[],{"intervention":27300,"totalTrials":224,"cells":27301},"Verubecestat 12 mg",{"EARLY_PHASE1":27302,"PHASE1":27304,"PHASE2":27306,"PHASE3":27308,"PHASE4":27322,"NA":27324},{"trials":27303,"activeCount":99},[],{"trials":27305,"activeCount":99},[],{"trials":27307,"activeCount":99},[],{"trials":27309,"activeCount":99},[27310],{"nctId":27311,"briefTitle":27312,"status":150,"phases":27313,"primaryCompletion":27314,"completion":27314,"start":27315,"enrollment":27316,"conditions":27317,"interventions":27320},"NCT01953601","Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)",[89],"2018-04-17","2013-11-05",1454,[27318,11174,27319],"Amnestic Mild Cognitive Impairment","Prodromal Alzheimer's Disease",[27300,27321],"Verubecestat 40 mg",{"trials":27323,"activeCount":99},[],{"trials":27325,"activeCount":99},[],{"intervention":27321,"totalTrials":224,"cells":27327},{"EARLY_PHASE1":27328,"PHASE1":27330,"PHASE2":27332,"PHASE3":27334,"PHASE4":27340,"NA":27342},{"trials":27329,"activeCount":99},[],{"trials":27331,"activeCount":99},[],{"trials":27333,"activeCount":99},[],{"trials":27335,"activeCount":99},[27336],{"nctId":27311,"briefTitle":27312,"status":150,"phases":27337,"primaryCompletion":27314,"completion":27314,"start":27315,"enrollment":27316,"conditions":27338,"interventions":27339},[89],[27318,11174,27319],[27300,27321],{"trials":27341,"activeCount":99},[],{"trials":27343,"activeCount":99},[],{"intervention":24557,"totalTrials":224,"cells":27345},{"EARLY_PHASE1":27346,"PHASE1":27348,"PHASE2":27350,"PHASE3":27352,"PHASE4":27358,"NA":27360},{"trials":27347,"activeCount":99},[],{"trials":27349,"activeCount":99},[],{"trials":27351,"activeCount":99},[],{"trials":27353,"activeCount":99},[27354],{"nctId":24552,"briefTitle":24553,"status":105,"phases":27355,"primaryCompletion":14352,"completion":13223,"start":12804,"enrollment":22408,"conditions":27356,"interventions":27357},[89],[27],[24557,24531,24558,24559,24560],{"trials":27359,"activeCount":99},[],{"trials":27361,"activeCount":99},[],{"intervention":24558,"totalTrials":224,"cells":27363},{"EARLY_PHASE1":27364,"PHASE1":27366,"PHASE2":27368,"PHASE3":27370,"PHASE4":27376,"NA":27378},{"trials":27365,"activeCount":99},[],{"trials":27367,"activeCount":99},[],{"trials":27369,"activeCount":99},[],{"trials":27371,"activeCount":99},[27372],{"nctId":24552,"briefTitle":24553,"status":105,"phases":27373,"primaryCompletion":14352,"completion":13223,"start":12804,"enrollment":22408,"conditions":27374,"interventions":27375},[89],[27],[24557,24531,24558,24559,24560],{"trials":27377,"activeCount":99},[],{"trials":27379,"activeCount":99},[],{"intervention":24559,"totalTrials":224,"cells":27381},{"EARLY_PHASE1":27382,"PHASE1":27384,"PHASE2":27386,"PHASE3":27388,"PHASE4":27394,"NA":27396},{"trials":27383,"activeCount":99},[],{"trials":27385,"activeCount":99},[],{"trials":27387,"activeCount":99},[],{"trials":27389,"activeCount":99},[27390],{"nctId":24552,"briefTitle":24553,"status":105,"phases":27391,"primaryCompletion":14352,"completion":13223,"start":12804,"enrollment":22408,"conditions":27392,"interventions":27393},[89],[27],[24557,24531,24558,24559,24560],{"trials":27395,"activeCount":99},[],{"trials":27397,"activeCount":99},[],{"intervention":24560,"totalTrials":224,"cells":27399},{"EARLY_PHASE1":27400,"PHASE1":27402,"PHASE2":27404,"PHASE3":27406,"PHASE4":27412,"NA":27414},{"trials":27401,"activeCount":99},[],{"trials":27403,"activeCount":99},[],{"trials":27405,"activeCount":99},[],{"trials":27407,"activeCount":99},[27408],{"nctId":24552,"briefTitle":24553,"status":105,"phases":27409,"primaryCompletion":14352,"completion":13223,"start":12804,"enrollment":22408,"conditions":27410,"interventions":27411},[89],[27],[24557,24531,24558,24559,24560],{"trials":27413,"activeCount":99},[],{"trials":27415,"activeCount":99},[],{"intervention":27417,"totalTrials":224,"cells":27418},"PEGASYS",{"EARLY_PHASE1":27419,"PHASE1":27421,"PHASE2":27423,"PHASE3":27425,"PHASE4":27436,"NA":27438},{"trials":27420,"activeCount":99},[],{"trials":27422,"activeCount":99},[],{"trials":27424,"activeCount":99},[],{"trials":27426,"activeCount":99},[27427],{"nctId":27428,"briefTitle":27429,"status":105,"phases":27430,"primaryCompletion":14504,"completion":14504,"start":15001,"enrollment":27431,"conditions":27432,"interventions":27433},"NCT00081770","Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)",[89],4469,[21],[15828,15828,27434,27417,27435],"REBETOL","COPEGUS",{"trials":27437,"activeCount":99},[],{"trials":27439,"activeCount":99},[],{"intervention":27435,"totalTrials":224,"cells":27441},{"EARLY_PHASE1":27442,"PHASE1":27444,"PHASE2":27446,"PHASE3":27448,"PHASE4":27454,"NA":27456},{"trials":27443,"activeCount":99},[],{"trials":27445,"activeCount":99},[],{"trials":27447,"activeCount":99},[],{"trials":27449,"activeCount":99},[27450],{"nctId":27428,"briefTitle":27429,"status":105,"phases":27451,"primaryCompletion":14504,"completion":14504,"start":15001,"enrollment":27431,"conditions":27452,"interventions":27453},[89],[21],[15828,15828,27434,27417,27435],{"trials":27455,"activeCount":99},[],{"trials":27457,"activeCount":99},[],{"intervention":16670,"totalTrials":224,"cells":27459},{"EARLY_PHASE1":27460,"PHASE1":27462,"PHASE2":27464,"PHASE3":27466,"PHASE4":27472,"NA":27474},{"trials":27461,"activeCount":99},[],{"trials":27463,"activeCount":99},[],{"trials":27465,"activeCount":99},[],{"trials":27467,"activeCount":99},[27468],{"nctId":16661,"briefTitle":16662,"status":105,"phases":27469,"primaryCompletion":16664,"completion":16665,"start":16666,"enrollment":1977,"conditions":27470,"interventions":27471},[89],[16668],[16670,16671,16672,16640,16673],{"trials":27473,"activeCount":99},[],{"trials":27475,"activeCount":99},[],{"intervention":16671,"totalTrials":224,"cells":27477},{"EARLY_PHASE1":27478,"PHASE1":27480,"PHASE2":27482,"PHASE3":27484,"PHASE4":27490,"NA":27492},{"trials":27479,"activeCount":99},[],{"trials":27481,"activeCount":99},[],{"trials":27483,"activeCount":99},[],{"trials":27485,"activeCount":99},[27486],{"nctId":16661,"briefTitle":16662,"status":105,"phases":27487,"primaryCompletion":16664,"completion":16665,"start":16666,"enrollment":1977,"conditions":27488,"interventions":27489},[89],[16668],[16670,16671,16672,16640,16673],{"trials":27491,"activeCount":99},[],{"trials":27493,"activeCount":99},[],{"intervention":27495,"totalTrials":224,"cells":27496},"Peginterferon",{"EARLY_PHASE1":27497,"PHASE1":27499,"PHASE2":27501,"PHASE3":27503,"PHASE4":27513,"NA":27515},{"trials":27498,"activeCount":99},[],{"trials":27500,"activeCount":99},[],{"trials":27502,"activeCount":99},[],{"trials":27504,"activeCount":99},[27505],{"nctId":27506,"briefTitle":27507,"status":105,"phases":27508,"primaryCompletion":16592,"completion":16592,"start":27509,"enrollment":27510,"conditions":27511,"interventions":27512},"NCT00732641","Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)",[89],"2000-12",244,[526],[27495],{"trials":27514,"activeCount":99},[],{"trials":27516,"activeCount":99},[],{"intervention":1884,"totalTrials":224,"cells":27518},{"EARLY_PHASE1":27519,"PHASE1":27521,"PHASE2":27523,"PHASE3":27525,"PHASE4":27531,"NA":27533},{"trials":27520,"activeCount":99},[],{"trials":27522,"activeCount":99},[],{"trials":27524,"activeCount":99},[],{"trials":27526,"activeCount":99},[27527],{"nctId":1874,"briefTitle":1875,"status":105,"phases":27528,"primaryCompletion":1877,"completion":1878,"start":1879,"enrollment":1880,"conditions":27529,"interventions":27530},[89],[1882],[42,1445,1884,1885,1886],{"trials":27532,"activeCount":99},[],{"trials":27534,"activeCount":99},[],{"intervention":22217,"totalTrials":224,"cells":27536},{"EARLY_PHASE1":27537,"PHASE1":27539,"PHASE2":27541,"PHASE3":27543,"PHASE4":27549,"NA":27551},{"trials":27538,"activeCount":99},[],{"trials":27540,"activeCount":99},[],{"trials":27542,"activeCount":99},[],{"trials":27544,"activeCount":99},[27545],{"nctId":22212,"briefTitle":22213,"status":105,"phases":27546,"primaryCompletion":14313,"completion":14313,"start":14408,"enrollment":21168,"conditions":27547,"interventions":27548},[89],[22209],[22194,22217],{"trials":27550,"activeCount":99},[],{"trials":27552,"activeCount":99},[],{"intervention":27554,"totalTrials":224,"cells":27555},"simvastatin 20 mg\u002Fezetimibe",{"EARLY_PHASE1":27556,"PHASE1":27558,"PHASE2":27560,"PHASE3":27562,"PHASE4":27570,"NA":27572},{"trials":27557,"activeCount":99},[],{"trials":27559,"activeCount":99},[],{"trials":27561,"activeCount":99},[],{"trials":27563,"activeCount":99},[27564],{"nctId":27565,"briefTitle":27566,"status":105,"phases":27567,"completion":14504,"start":17461,"enrollment":3226,"conditions":27568,"interventions":27569},"NCT00566267","A Randomized, Double-Blinded Study of Simvastatin 20 mg\u002FDay Versus Vytorin 10\u002F20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet",[88,89],[7610],[27554],{"trials":27571,"activeCount":99},[],{"trials":27573,"activeCount":99},[],{"intervention":16408,"totalTrials":224,"cells":27575},{"EARLY_PHASE1":27576,"PHASE1":27578,"PHASE2":27580,"PHASE3":27582,"PHASE4":27588,"NA":27590},{"trials":27577,"activeCount":99},[],{"trials":27579,"activeCount":99},[],{"trials":27581,"activeCount":99},[],{"trials":27583,"activeCount":99},[27584],{"nctId":16400,"briefTitle":16401,"status":150,"phases":27585,"primaryCompletion":16403,"completion":16403,"start":16404,"enrollment":16405,"conditions":27586,"interventions":27587},[89],[14418,14337],[13122,16408,16408],{"trials":27589,"activeCount":99},[],{"trials":27591,"activeCount":99},[],{"intervention":27593,"totalTrials":224,"cells":27594},"RotaTeq®",{"EARLY_PHASE1":27595,"PHASE1":27597,"PHASE2":27599,"PHASE3":27601,"PHASE4":27614,"NA":27616},{"trials":27596,"activeCount":99},[],{"trials":27598,"activeCount":99},[],{"trials":27600,"activeCount":99},[],{"trials":27602,"activeCount":99},[27603],{"nctId":27604,"briefTitle":27605,"status":105,"phases":27606,"primaryCompletion":27607,"completion":27608,"start":27609,"enrollment":20206,"conditions":27610,"interventions":27612},"NCT00443846","RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)",[89],"2007-09-04","2007-10-23","2007-02-13",[27611,15587],"Meningitis, Meningococcal",[27593,27613],"NeisVac-C®",{"trials":27615,"activeCount":99},[],{"trials":27617,"activeCount":99},[],{"intervention":27613,"totalTrials":224,"cells":27619},{"EARLY_PHASE1":27620,"PHASE1":27622,"PHASE2":27624,"PHASE3":27626,"PHASE4":27632,"NA":27634},{"trials":27621,"activeCount":99},[],{"trials":27623,"activeCount":99},[],{"trials":27625,"activeCount":99},[],{"trials":27627,"activeCount":99},[27628],{"nctId":27604,"briefTitle":27605,"status":105,"phases":27629,"primaryCompletion":27607,"completion":27608,"start":27609,"enrollment":20206,"conditions":27630,"interventions":27631},[89],[27611,15587],[27593,27613],{"trials":27633,"activeCount":99},[],{"trials":27635,"activeCount":99},[],{"intervention":27637,"totalTrials":224,"cells":27638},"Pneumococcal Vaccine, Polyvalent",{"EARLY_PHASE1":27639,"PHASE1":27641,"PHASE2":27643,"PHASE3":27645,"PHASE4":27653,"NA":27655},{"trials":27640,"activeCount":99},[],{"trials":27642,"activeCount":99},[],{"trials":27644,"activeCount":99},[],{"trials":27646,"activeCount":99},[27647],{"nctId":27648,"briefTitle":27649,"status":105,"phases":27650,"primaryCompletion":14484,"completion":14484,"start":17095,"enrollment":15321,"conditions":27651,"interventions":27652},"NCT00496093","Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)",[89],[13187],[27637],{"trials":27654,"activeCount":99},[],{"trials":27656,"activeCount":99},[],{"intervention":14077,"totalTrials":224,"cells":27658},{"EARLY_PHASE1":27659,"PHASE1":27661,"PHASE2":27663,"PHASE3":27665,"PHASE4":27671,"NA":27673},{"trials":27660,"activeCount":99},[],{"trials":27662,"activeCount":99},[],{"trials":27664,"activeCount":99},[],{"trials":27666,"activeCount":99},[27667],{"nctId":14069,"briefTitle":14070,"status":105,"phases":27668,"primaryCompletion":14072,"completion":14072,"start":14073,"enrollment":14074,"conditions":27669,"interventions":27670},[89],[15],[14077,4084,14078,14059,14079],{"trials":27672,"activeCount":99},[],{"trials":27674,"activeCount":99},[],{"intervention":14078,"totalTrials":224,"cells":27676},{"EARLY_PHASE1":27677,"PHASE1":27679,"PHASE2":27681,"PHASE3":27683,"PHASE4":27689,"NA":27691},{"trials":27678,"activeCount":99},[],{"trials":27680,"activeCount":99},[],{"trials":27682,"activeCount":99},[],{"trials":27684,"activeCount":99},[27685],{"nctId":14069,"briefTitle":14070,"status":105,"phases":27686,"primaryCompletion":14072,"completion":14072,"start":14073,"enrollment":14074,"conditions":27687,"interventions":27688},[89],[15],[14077,4084,14078,14059,14079],{"trials":27690,"activeCount":99},[],{"trials":27692,"activeCount":99},[],{"intervention":21179,"totalTrials":224,"cells":27694},{"EARLY_PHASE1":27695,"PHASE1":27697,"PHASE2":27699,"PHASE3":27701,"PHASE4":27707,"NA":27709},{"trials":27696,"activeCount":99},[],{"trials":27698,"activeCount":99},[],{"trials":27700,"activeCount":99},[],{"trials":27702,"activeCount":99},[27703],{"nctId":21174,"briefTitle":21175,"status":105,"phases":27704,"primaryCompletion":15054,"start":15304,"enrollment":951,"conditions":27705,"interventions":27706},[89],[21170],[21153,21179],{"trials":27708,"activeCount":99},[],{"trials":27710,"activeCount":99},[],{"intervention":27712,"totalTrials":224,"cells":27713},"V212 Lot 1",{"EARLY_PHASE1":27714,"PHASE1":27716,"PHASE2":27718,"PHASE3":27720,"PHASE4":27731,"NA":27733},{"trials":27715,"activeCount":99},[],{"trials":27717,"activeCount":99},[],{"trials":27719,"activeCount":99},[],{"trials":27721,"activeCount":99},[27722],{"nctId":27723,"briefTitle":27724,"status":1040,"phases":27725,"primaryCompletion":27726,"completion":27726,"start":24148,"enrollment":99,"conditions":27727,"interventions":27728},"NCT02180295","A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Healthy Adults (V212-014)",[89],"2015-03",[14395],[27712,27729,27730],"V212 Lot 2","V212 Lot 3",{"trials":27732,"activeCount":99},[],{"trials":27734,"activeCount":99},[],{"intervention":27729,"totalTrials":224,"cells":27736},{"EARLY_PHASE1":27737,"PHASE1":27739,"PHASE2":27741,"PHASE3":27743,"PHASE4":27749,"NA":27751},{"trials":27738,"activeCount":99},[],{"trials":27740,"activeCount":99},[],{"trials":27742,"activeCount":99},[],{"trials":27744,"activeCount":99},[27745],{"nctId":27723,"briefTitle":27724,"status":1040,"phases":27746,"primaryCompletion":27726,"completion":27726,"start":24148,"enrollment":99,"conditions":27747,"interventions":27748},[89],[14395],[27712,27729,27730],{"trials":27750,"activeCount":99},[],{"trials":27752,"activeCount":99},[],{"intervention":27730,"totalTrials":224,"cells":27754},{"EARLY_PHASE1":27755,"PHASE1":27757,"PHASE2":27759,"PHASE3":27761,"PHASE4":27767,"NA":27769},{"trials":27756,"activeCount":99},[],{"trials":27758,"activeCount":99},[],{"trials":27760,"activeCount":99},[],{"trials":27762,"activeCount":99},[27763],{"nctId":27723,"briefTitle":27724,"status":1040,"phases":27764,"primaryCompletion":27726,"completion":27726,"start":24148,"enrollment":99,"conditions":27765,"interventions":27766},[89],[14395],[27712,27729,27730],{"trials":27768,"activeCount":99},[],{"trials":27770,"activeCount":99},[],{"intervention":27772,"totalTrials":224,"cells":27773},"ProQuad® manufactured with recombinant Human Albumin",{"EARLY_PHASE1":27774,"PHASE1":27776,"PHASE2":27778,"PHASE3":27780,"PHASE4":27790,"NA":27792},{"trials":27775,"activeCount":99},[],{"trials":27777,"activeCount":99},[],{"trials":27779,"activeCount":99},[],{"trials":27781,"activeCount":99},[27782],{"nctId":27783,"briefTitle":27784,"status":105,"phases":27785,"primaryCompletion":27786,"completion":27786,"start":27787,"enrollment":25965,"conditions":27788,"interventions":27789},"NCT00566527","Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)",[89],"2008-12-29","2007-11-29",[15308,15309,15310,15311],[27772],{"trials":27791,"activeCount":99},[],{"trials":27793,"activeCount":99},[],{"intervention":20592,"totalTrials":224,"cells":27795},{"EARLY_PHASE1":27796,"PHASE1":27798,"PHASE2":27800,"PHASE3":27802,"PHASE4":27808,"NA":27810},{"trials":27797,"activeCount":99},[],{"trials":27799,"activeCount":99},[],{"trials":27801,"activeCount":99},[],{"trials":27803,"activeCount":99},[27804],{"nctId":20587,"briefTitle":20588,"status":105,"phases":27805,"primaryCompletion":14531,"completion":14531,"start":17095,"enrollment":6284,"conditions":27806,"interventions":27807},[89],[15587,20584],[14449,20592,20592],{"trials":27809,"activeCount":99},[],{"trials":27811,"activeCount":99},[],{"intervention":27813,"totalTrials":224,"cells":27814},"Short ragweed pollen allergen extract",{"EARLY_PHASE1":27815,"PHASE1":27817,"PHASE2":27819,"PHASE3":27821,"PHASE4":27837,"NA":27839},{"trials":27816,"activeCount":99},[],{"trials":27818,"activeCount":99},[],{"trials":27820,"activeCount":99},[],{"trials":27822,"activeCount":99},[27823],{"nctId":27824,"briefTitle":27825,"status":105,"phases":27826,"primaryCompletion":27827,"completion":9214,"start":27828,"enrollment":27829,"conditions":27830,"interventions":27832},"NCT02478398","Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)",[89],"2018-11-09","2015-07-20",1025,[27831],"Rhinitis, Allergic, Seasonal",[27813,27833,27834,7024,27835,27836],"Self-injectable epinephrine","Albuterol\u002FSalbutamol","Olopatadine","Mometasone furoate monohydrate",{"trials":27838,"activeCount":99},[],{"trials":27840,"activeCount":99},[],{"intervention":27833,"totalTrials":224,"cells":27842},{"EARLY_PHASE1":27843,"PHASE1":27845,"PHASE2":27847,"PHASE3":27849,"PHASE4":27855,"NA":27857},{"trials":27844,"activeCount":99},[],{"trials":27846,"activeCount":99},[],{"trials":27848,"activeCount":99},[],{"trials":27850,"activeCount":99},[27851],{"nctId":27824,"briefTitle":27825,"status":105,"phases":27852,"primaryCompletion":27827,"completion":9214,"start":27828,"enrollment":27829,"conditions":27853,"interventions":27854},[89],[27831],[27813,27833,27834,7024,27835,27836],{"trials":27856,"activeCount":99},[],{"trials":27858,"activeCount":99},[],{"intervention":27834,"totalTrials":224,"cells":27860},{"EARLY_PHASE1":27861,"PHASE1":27863,"PHASE2":27865,"PHASE3":27867,"PHASE4":27873,"NA":27875},{"trials":27862,"activeCount":99},[],{"trials":27864,"activeCount":99},[],{"trials":27866,"activeCount":99},[],{"trials":27868,"activeCount":99},[27869],{"nctId":27824,"briefTitle":27825,"status":105,"phases":27870,"primaryCompletion":27827,"completion":9214,"start":27828,"enrollment":27829,"conditions":27871,"interventions":27872},[89],[27831],[27813,27833,27834,7024,27835,27836],{"trials":27874,"activeCount":99},[],{"trials":27876,"activeCount":99},[],{"intervention":27835,"totalTrials":224,"cells":27878},{"EARLY_PHASE1":27879,"PHASE1":27881,"PHASE2":27883,"PHASE3":27885,"PHASE4":27891,"NA":27893},{"trials":27880,"activeCount":99},[],{"trials":27882,"activeCount":99},[],{"trials":27884,"activeCount":99},[],{"trials":27886,"activeCount":99},[27887],{"nctId":27824,"briefTitle":27825,"status":105,"phases":27888,"primaryCompletion":27827,"completion":9214,"start":27828,"enrollment":27829,"conditions":27889,"interventions":27890},[89],[27831],[27813,27833,27834,7024,27835,27836],{"trials":27892,"activeCount":99},[],{"trials":27894,"activeCount":99},[],{"intervention":27836,"totalTrials":224,"cells":27896},{"EARLY_PHASE1":27897,"PHASE1":27899,"PHASE2":27901,"PHASE3":27903,"PHASE4":27909,"NA":27911},{"trials":27898,"activeCount":99},[],{"trials":27900,"activeCount":99},[],{"trials":27902,"activeCount":99},[],{"trials":27904,"activeCount":99},[27905],{"nctId":27824,"briefTitle":27825,"status":105,"phases":27906,"primaryCompletion":27827,"completion":9214,"start":27828,"enrollment":27829,"conditions":27907,"interventions":27908},[89],[27831],[27813,27833,27834,7024,27835,27836],{"trials":27910,"activeCount":99},[],{"trials":27912,"activeCount":99},[],{"intervention":27914,"totalTrials":224,"cells":27915},"Metformin - Rescue",{"EARLY_PHASE1":27916,"PHASE1":27918,"PHASE2":27920,"PHASE3":27922,"PHASE4":27931,"NA":27933},{"trials":27917,"activeCount":99},[],{"trials":27919,"activeCount":99},[],{"trials":27921,"activeCount":99},[],{"trials":27923,"activeCount":99},[27924],{"nctId":27925,"briefTitle":27926,"status":105,"phases":27927,"primaryCompletion":14976,"completion":15155,"start":14229,"enrollment":27928,"conditions":27929,"interventions":27930},"NCT00087516","Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)",[89],741,[33],[13145,13145,27914],{"trials":27932,"activeCount":99},[],{"trials":27934,"activeCount":99},[],{"intervention":27936,"totalTrials":224,"cells":27937},"Peg interferon alpha-2b",{"EARLY_PHASE1":27938,"PHASE1":27940,"PHASE2":27942,"PHASE3":27944,"PHASE4":27953,"NA":27955},{"trials":27939,"activeCount":99},[],{"trials":27941,"activeCount":99},[],{"trials":27943,"activeCount":99},[],{"trials":27945,"activeCount":99},[27946],{"nctId":27947,"briefTitle":27948,"status":1040,"phases":27949,"start":4418,"enrollment":99,"conditions":27950,"interventions":27952},"NCT00381017","Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371)",[89],[24,27951,27],"Liver Cirrhosis",[27936],{"trials":27954,"activeCount":99},[],{"trials":27956,"activeCount":99},[],{"intervention":27958,"totalTrials":224,"cells":27959},"100 mg clindamycin \u002F800 mg ketoconazole vaginal ovule",{"EARLY_PHASE1":27960,"PHASE1":27962,"PHASE2":27964,"PHASE3":27966,"PHASE4":27977,"NA":27979},{"trials":27961,"activeCount":99},[],{"trials":27963,"activeCount":99},[],{"trials":27965,"activeCount":99},[],{"trials":27967,"activeCount":99},[27968],{"nctId":27969,"briefTitle":27970,"status":105,"phases":27971,"primaryCompletion":11479,"completion":11479,"start":14494,"enrollment":4358,"conditions":27972,"interventions":27975},"NCT01293643","A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline\u002FAmphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)",[89],[27973,27974],"Vaginosis, Bacterial","Candidiasis, Vulvovaginal",[27958,27976],"100 mg tetracycline hydrochloride \u002F50 mg amphotericin B cream",{"trials":27978,"activeCount":99},[],{"trials":27980,"activeCount":99},[],{"intervention":27976,"totalTrials":224,"cells":27982},{"EARLY_PHASE1":27983,"PHASE1":27985,"PHASE2":27987,"PHASE3":27989,"PHASE4":27995,"NA":27997},{"trials":27984,"activeCount":99},[],{"trials":27986,"activeCount":99},[],{"trials":27988,"activeCount":99},[],{"trials":27990,"activeCount":99},[27991],{"nctId":27969,"briefTitle":27970,"status":105,"phases":27992,"primaryCompletion":11479,"completion":11479,"start":14494,"enrollment":4358,"conditions":27993,"interventions":27994},[89],[27973,27974],[27958,27976],{"trials":27996,"activeCount":99},[],{"trials":27998,"activeCount":99},[],{"intervention":28000,"totalTrials":224,"cells":28001},"Rocuronium 0.6 mg\u002Fkg intubating dose",{"EARLY_PHASE1":28002,"PHASE1":28004,"PHASE2":28006,"PHASE3":28008,"PHASE4":28022,"NA":28024},{"trials":28003,"activeCount":99},[],{"trials":28005,"activeCount":99},[],{"trials":28007,"activeCount":99},[],{"trials":28009,"activeCount":99},[28010],{"nctId":28011,"briefTitle":28012,"status":105,"phases":28013,"primaryCompletion":21850,"completion":21850,"start":14772,"enrollment":397,"conditions":28014,"interventions":28015},"NCT00970762","Comparative Study of Rocuronium With Vecuronium (Study 71101)(COMPLETED)",[89],[16668],[28000,28016,28017,28018,28019,28020,28021],"Rocuronium 0.9 mg\u002Fkg intubating dose","Rocuronium 0.1 mg\u002Fkg maintenance dose","Rocuronium 0.15 mg\u002Fkg maintenance dose","Rocuronium 0.2 mg\u002Fkg maintenance","Vecuronium 0.1 mg\u002Fkg intubating dose","Vecuronium 0.025 mg\u002Fkg maintenance dose",{"trials":28023,"activeCount":99},[],{"trials":28025,"activeCount":99},[],{"intervention":28016,"totalTrials":224,"cells":28027},{"EARLY_PHASE1":28028,"PHASE1":28030,"PHASE2":28032,"PHASE3":28034,"PHASE4":28040,"NA":28042},{"trials":28029,"activeCount":99},[],{"trials":28031,"activeCount":99},[],{"trials":28033,"activeCount":99},[],{"trials":28035,"activeCount":99},[28036],{"nctId":28011,"briefTitle":28012,"status":105,"phases":28037,"primaryCompletion":21850,"completion":21850,"start":14772,"enrollment":397,"conditions":28038,"interventions":28039},[89],[16668],[28000,28016,28017,28018,28019,28020,28021],{"trials":28041,"activeCount":99},[],{"trials":28043,"activeCount":99},[],{"intervention":28017,"totalTrials":224,"cells":28045},{"EARLY_PHASE1":28046,"PHASE1":28048,"PHASE2":28050,"PHASE3":28052,"PHASE4":28058,"NA":28060},{"trials":28047,"activeCount":99},[],{"trials":28049,"activeCount":99},[],{"trials":28051,"activeCount":99},[],{"trials":28053,"activeCount":99},[28054],{"nctId":28011,"briefTitle":28012,"status":105,"phases":28055,"primaryCompletion":21850,"completion":21850,"start":14772,"enrollment":397,"conditions":28056,"interventions":28057},[89],[16668],[28000,28016,28017,28018,28019,28020,28021],{"trials":28059,"activeCount":99},[],{"trials":28061,"activeCount":99},[],{"intervention":28018,"totalTrials":224,"cells":28063},{"EARLY_PHASE1":28064,"PHASE1":28066,"PHASE2":28068,"PHASE3":28070,"PHASE4":28076,"NA":28078},{"trials":28065,"activeCount":99},[],{"trials":28067,"activeCount":99},[],{"trials":28069,"activeCount":99},[],{"trials":28071,"activeCount":99},[28072],{"nctId":28011,"briefTitle":28012,"status":105,"phases":28073,"primaryCompletion":21850,"completion":21850,"start":14772,"enrollment":397,"conditions":28074,"interventions":28075},[89],[16668],[28000,28016,28017,28018,28019,28020,28021],{"trials":28077,"activeCount":99},[],{"trials":28079,"activeCount":99},[],{"intervention":28019,"totalTrials":224,"cells":28081},{"EARLY_PHASE1":28082,"PHASE1":28084,"PHASE2":28086,"PHASE3":28088,"PHASE4":28094,"NA":28096},{"trials":28083,"activeCount":99},[],{"trials":28085,"activeCount":99},[],{"trials":28087,"activeCount":99},[],{"trials":28089,"activeCount":99},[28090],{"nctId":28011,"briefTitle":28012,"status":105,"phases":28091,"primaryCompletion":21850,"completion":21850,"start":14772,"enrollment":397,"conditions":28092,"interventions":28093},[89],[16668],[28000,28016,28017,28018,28019,28020,28021],{"trials":28095,"activeCount":99},[],{"trials":28097,"activeCount":99},[],{"intervention":28020,"totalTrials":224,"cells":28099},{"EARLY_PHASE1":28100,"PHASE1":28102,"PHASE2":28104,"PHASE3":28106,"PHASE4":28112,"NA":28114},{"trials":28101,"activeCount":99},[],{"trials":28103,"activeCount":99},[],{"trials":28105,"activeCount":99},[],{"trials":28107,"activeCount":99},[28108],{"nctId":28011,"briefTitle":28012,"status":105,"phases":28109,"primaryCompletion":21850,"completion":21850,"start":14772,"enrollment":397,"conditions":28110,"interventions":28111},[89],[16668],[28000,28016,28017,28018,28019,28020,28021],{"trials":28113,"activeCount":99},[],{"trials":28115,"activeCount":99},[],{"intervention":28021,"totalTrials":224,"cells":28117},{"EARLY_PHASE1":28118,"PHASE1":28120,"PHASE2":28122,"PHASE3":28124,"PHASE4":28130,"NA":28132},{"trials":28119,"activeCount":99},[],{"trials":28121,"activeCount":99},[],{"trials":28123,"activeCount":99},[],{"trials":28125,"activeCount":99},[28126],{"nctId":28011,"briefTitle":28012,"status":105,"phases":28127,"primaryCompletion":21850,"completion":21850,"start":14772,"enrollment":397,"conditions":28128,"interventions":28129},[89],[16668],[28000,28016,28017,28018,28019,28020,28021],{"trials":28131,"activeCount":99},[],{"trials":28133,"activeCount":99},[],{"intervention":15246,"totalTrials":224,"cells":28135},{"EARLY_PHASE1":28136,"PHASE1":28138,"PHASE2":28140,"PHASE3":28142,"PHASE4":28148,"NA":28150},{"trials":28137,"activeCount":99},[],{"trials":28139,"activeCount":99},[],{"trials":28141,"activeCount":99},[],{"trials":28143,"activeCount":99},[28144],{"nctId":15240,"briefTitle":15241,"status":150,"phases":28145,"primaryCompletion":9610,"completion":9610,"start":14409,"enrollment":7388,"conditions":28146,"interventions":28147},[89],[7650],[15245,15246,14331,14331],{"trials":28149,"activeCount":99},[],{"trials":28151,"activeCount":99},[],{"intervention":13064,"totalTrials":224,"cells":28153},{"EARLY_PHASE1":28154,"PHASE1":28156,"PHASE2":28158,"PHASE3":28160,"PHASE4":28166,"NA":28168},{"trials":28155,"activeCount":99},[],{"trials":28157,"activeCount":99},[],{"trials":28159,"activeCount":99},[],{"trials":28161,"activeCount":99},[28162],{"nctId":13055,"briefTitle":13056,"status":105,"phases":28163,"primaryCompletion":13058,"completion":13058,"start":13059,"enrollment":13060,"conditions":28164,"interventions":28165},[89],[13062],[13005,13064,13065],{"trials":28167,"activeCount":99},[],{"trials":28169,"activeCount":99},[],{"intervention":13065,"totalTrials":224,"cells":28171},{"EARLY_PHASE1":28172,"PHASE1":28174,"PHASE2":28176,"PHASE3":28178,"PHASE4":28184,"NA":28186},{"trials":28173,"activeCount":99},[],{"trials":28175,"activeCount":99},[],{"trials":28177,"activeCount":99},[],{"trials":28179,"activeCount":99},[28180],{"nctId":13055,"briefTitle":13056,"status":105,"phases":28181,"primaryCompletion":13058,"completion":13058,"start":13059,"enrollment":13060,"conditions":28182,"interventions":28183},[89],[13062],[13005,13064,13065],{"trials":28185,"activeCount":99},[],{"trials":28187,"activeCount":99},[],{"intervention":28189,"totalTrials":224,"cells":28190},"Comparator: zoster vaccine live (Oka\u002FMerck) refrigerated formulation",{"EARLY_PHASE1":28191,"PHASE1":28193,"PHASE2":28195,"PHASE3":28197,"PHASE4":28206,"NA":28208},{"trials":28192,"activeCount":99},[],{"trials":28194,"activeCount":99},[],{"trials":28196,"activeCount":99},[],{"trials":28198,"activeCount":99},[28199],{"nctId":28200,"briefTitle":28201,"status":105,"phases":28202,"primaryCompletion":14228,"completion":14228,"start":15063,"enrollment":15836,"conditions":28203,"interventions":28204},"NCT00130793","A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED)",[89],[14395],[28189,28205],"Comparator: zoster vaccine live (Oka\u002FMerck) frozen formulation",{"trials":28207,"activeCount":99},[],{"trials":28209,"activeCount":99},[],{"intervention":28205,"totalTrials":224,"cells":28211},{"EARLY_PHASE1":28212,"PHASE1":28214,"PHASE2":28216,"PHASE3":28218,"PHASE4":28224,"NA":28226},{"trials":28213,"activeCount":99},[],{"trials":28215,"activeCount":99},[],{"trials":28217,"activeCount":99},[],{"trials":28219,"activeCount":99},[28220],{"nctId":28200,"briefTitle":28201,"status":105,"phases":28221,"primaryCompletion":14228,"completion":14228,"start":15063,"enrollment":15836,"conditions":28222,"interventions":28223},[89],[14395],[28189,28205],{"trials":28225,"activeCount":99},[],{"trials":28227,"activeCount":99},[],{"intervention":28229,"totalTrials":224,"cells":28230},"Rocurium",{"EARLY_PHASE1":28231,"PHASE1":28233,"PHASE2":28235,"PHASE3":28237,"PHASE4":28248,"NA":28250},{"trials":28232,"activeCount":99},[],{"trials":28234,"activeCount":99},[],{"trials":28236,"activeCount":99},[],{"trials":28238,"activeCount":99},[28239],{"nctId":28240,"briefTitle":28241,"status":105,"phases":28242,"primaryCompletion":28243,"completion":28243,"start":28244,"enrollment":28245,"conditions":28246,"interventions":28247},"NCT00474617","Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029)",[89],"2006-10-20","2005-12-29",162,[17011],[17013,28229],{"trials":28249,"activeCount":99},[],{"trials":28251,"activeCount":99},[],{"intervention":24525,"totalTrials":224,"cells":28253},{"EARLY_PHASE1":28254,"PHASE1":28256,"PHASE2":28258,"PHASE3":28260,"PHASE4":28266,"NA":28268},{"trials":28255,"activeCount":99},[],{"trials":28257,"activeCount":99},[],{"trials":28259,"activeCount":99},[],{"trials":28261,"activeCount":99},[28262],{"nctId":24515,"briefTitle":24516,"status":105,"phases":28263,"primaryCompletion":24518,"completion":24519,"start":24520,"enrollment":24521,"conditions":28264,"interventions":28265},[89],[863,865,9217,7085,9169],[24524,24525],{"trials":28267,"activeCount":99},[],{"trials":28269,"activeCount":99},[],{"intervention":1990,"totalTrials":224,"cells":28271},{"EARLY_PHASE1":28272,"PHASE1":28274,"PHASE2":28276,"PHASE3":28278,"PHASE4":28284,"NA":28286},{"trials":28273,"activeCount":99},[],{"trials":28275,"activeCount":99},[],{"trials":28277,"activeCount":99},[],{"trials":28279,"activeCount":99},[28280],{"nctId":1981,"briefTitle":1982,"status":105,"phases":28281,"primaryCompletion":1984,"completion":1985,"start":1986,"enrollment":1987,"conditions":28282,"interventions":28283},[89],[702],[47,389,1990],{"trials":28285,"activeCount":99},[],{"trials":28287,"activeCount":99},[],{"intervention":23253,"totalTrials":224,"cells":28289},{"EARLY_PHASE1":28290,"PHASE1":28292,"PHASE2":28294,"PHASE3":28296,"PHASE4":28302,"NA":28304},{"trials":28291,"activeCount":99},[],{"trials":28293,"activeCount":99},[],{"trials":28295,"activeCount":99},[],{"trials":28297,"activeCount":99},[28298],{"nctId":23246,"briefTitle":23247,"status":105,"phases":28299,"primaryCompletion":23249,"completion":23250,"start":16765,"enrollment":15960,"conditions":28300,"interventions":28301},[89],[24],[19833,15828,14925,23253],{"trials":28303,"activeCount":99},[],{"trials":28305,"activeCount":99},[],{"intervention":2000,"totalTrials":224,"cells":28307},{"EARLY_PHASE1":28308,"PHASE1":28310,"PHASE2":28312,"PHASE3":28314,"PHASE4":28320,"NA":28322},{"trials":28309,"activeCount":99},[],{"trials":28311,"activeCount":99},[],{"trials":28313,"activeCount":99},[],{"trials":28315,"activeCount":99},[28316],{"nctId":1992,"briefTitle":1993,"status":105,"phases":28317,"primaryCompletion":1995,"completion":1995,"start":1996,"enrollment":1997,"conditions":28318,"interventions":28319},[89],[674],[42,2000],{"trials":28321,"activeCount":99},[],{"trials":28323,"activeCount":99},[],{"intervention":24037,"totalTrials":224,"cells":28325},{"EARLY_PHASE1":28326,"PHASE1":28328,"PHASE2":28330,"PHASE3":28332,"PHASE4":28338,"NA":28340},{"trials":28327,"activeCount":99},[],{"trials":28329,"activeCount":99},[],{"trials":28331,"activeCount":99},[],{"trials":28333,"activeCount":99},[28334],{"nctId":24031,"briefTitle":24032,"status":105,"phases":28335,"primaryCompletion":14495,"completion":14495,"start":15258,"enrollment":1570,"conditions":28336,"interventions":28337},[89],[24035],[24011,24037],{"trials":28339,"activeCount":99},[],{"trials":28341,"activeCount":99},[],{"intervention":28343,"totalTrials":224,"cells":28344},"Extended-release niacin\u002Flaropiprant",{"EARLY_PHASE1":28345,"PHASE1":28347,"PHASE2":28349,"PHASE3":28351,"PHASE4":28360,"NA":28362},{"trials":28346,"activeCount":99},[],{"trials":28348,"activeCount":99},[],{"trials":28350,"activeCount":99},[],{"trials":28352,"activeCount":99},[28353],{"nctId":28354,"briefTitle":28355,"status":150,"phases":28356,"primaryCompletion":21043,"completion":21043,"start":4328,"enrollment":28357,"conditions":28358,"interventions":28359},"NCT01274559","Efficacy and Safety of Extended Release (ER) Niacin\u002FLaropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)",[89],1173,[14418,16417],[28343],{"trials":28361,"activeCount":99},[],{"trials":28363,"activeCount":99},[],{"intervention":22422,"totalTrials":224,"cells":28365},{"EARLY_PHASE1":28366,"PHASE1":28368,"PHASE2":28370,"PHASE3":28372,"PHASE4":28378,"NA":28380},{"trials":28367,"activeCount":99},[],{"trials":28369,"activeCount":99},[],{"trials":28371,"activeCount":99},[],{"trials":28373,"activeCount":99},[28374],{"nctId":22416,"briefTitle":22417,"status":105,"phases":28375,"primaryCompletion":14858,"completion":14858,"start":4418,"enrollment":22419,"conditions":28376,"interventions":28377},[89],[17593],[22396,22422],{"trials":28379,"activeCount":99},[],{"trials":28381,"activeCount":99},[],{"intervention":28383,"totalTrials":224,"cells":28384},"Preservative-Free Tafluprost",{"EARLY_PHASE1":28385,"PHASE1":28387,"PHASE2":28389,"PHASE3":28391,"PHASE4":28402,"NA":28404},{"trials":28386,"activeCount":99},[],{"trials":28388,"activeCount":99},[],{"trials":28390,"activeCount":99},[],{"trials":28392,"activeCount":99},[28393],{"nctId":28394,"briefTitle":28395,"status":105,"phases":28396,"primaryCompletion":11224,"completion":11224,"start":28397,"enrollment":2170,"conditions":28398,"interventions":28400},"NCT01026831","Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma\u002FOcular Hypertension (MK2452-001)(COMPLETED)",[89],"2010-01-06",[28399,17147],"Open-angle Glaucoma",[28383,28401],"Comparator: timolol",{"trials":28403,"activeCount":99},[],{"trials":28405,"activeCount":99},[],{"intervention":28401,"totalTrials":224,"cells":28407},{"EARLY_PHASE1":28408,"PHASE1":28410,"PHASE2":28412,"PHASE3":28414,"PHASE4":28420,"NA":28422},{"trials":28409,"activeCount":99},[],{"trials":28411,"activeCount":99},[],{"trials":28413,"activeCount":99},[],{"trials":28415,"activeCount":99},[28416],{"nctId":28394,"briefTitle":28395,"status":105,"phases":28417,"primaryCompletion":11224,"completion":11224,"start":28397,"enrollment":2170,"conditions":28418,"interventions":28419},[89],[28399,17147],[28383,28401],{"trials":28421,"activeCount":99},[],{"trials":28423,"activeCount":99},[],{"intervention":28425,"totalTrials":224,"cells":28426},"Comparator: glipizide",{"EARLY_PHASE1":28427,"PHASE1":28429,"PHASE2":28431,"PHASE3":28433,"PHASE4":28442,"NA":28444},{"trials":28428,"activeCount":99},[],{"trials":28430,"activeCount":99},[],{"trials":28432,"activeCount":99},[],{"trials":28434,"activeCount":99},[28435],{"nctId":28436,"briefTitle":28437,"status":105,"phases":28438,"primaryCompletion":8621,"completion":14409,"start":14679,"enrollment":28439,"conditions":28440,"interventions":28441},"NCT00094770","An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)",[89],1172,[33],[14126,28425],{"trials":28443,"activeCount":99},[],{"trials":28445,"activeCount":99},[],{"intervention":16420,"totalTrials":224,"cells":28447},{"EARLY_PHASE1":28448,"PHASE1":28450,"PHASE2":28452,"PHASE3":28454,"PHASE4":28460,"NA":28462},{"trials":28449,"activeCount":99},[],{"trials":28451,"activeCount":99},[],{"trials":28453,"activeCount":99},[],{"trials":28455,"activeCount":99},[28456],{"nctId":16410,"briefTitle":16411,"status":150,"phases":28457,"primaryCompletion":16413,"completion":16413,"start":16414,"enrollment":16415,"conditions":28458,"interventions":28459},[89],[14418,16417],[16419,16420,13122],{"trials":28461,"activeCount":99},[],{"trials":28463,"activeCount":99},[],{"intervention":19183,"totalTrials":224,"cells":28465},{"EARLY_PHASE1":28466,"PHASE1":28468,"PHASE2":28470,"PHASE3":28472,"PHASE4":28478,"NA":28480},{"trials":28467,"activeCount":99},[],{"trials":28469,"activeCount":99},[],{"trials":28471,"activeCount":99},[],{"trials":28473,"activeCount":99},[28474],{"nctId":19177,"briefTitle":19178,"status":105,"phases":28475,"primaryCompletion":3091,"completion":3091,"start":16680,"enrollment":19180,"conditions":28476,"interventions":28477},[89],[16472],[19183,19184,16474,17718],{"trials":28479,"activeCount":99},[],{"trials":28481,"activeCount":99},[],{"intervention":19184,"totalTrials":224,"cells":28483},{"EARLY_PHASE1":28484,"PHASE1":28486,"PHASE2":28488,"PHASE3":28490,"PHASE4":28496,"NA":28498},{"trials":28485,"activeCount":99},[],{"trials":28487,"activeCount":99},[],{"trials":28489,"activeCount":99},[],{"trials":28491,"activeCount":99},[28492],{"nctId":19177,"briefTitle":19178,"status":105,"phases":28493,"primaryCompletion":3091,"completion":3091,"start":16680,"enrollment":19180,"conditions":28494,"interventions":28495},[89],[16472],[19183,19184,16474,17718],{"trials":28497,"activeCount":99},[],{"trials":28499,"activeCount":99},[],{"intervention":28501,"totalTrials":224,"cells":28502},"Prulifloxacin",{"EARLY_PHASE1":28503,"PHASE1":28505,"PHASE2":28507,"PHASE3":28509,"PHASE4":28518,"NA":28520},{"trials":28504,"activeCount":99},[],{"trials":28506,"activeCount":99},[],{"trials":28508,"activeCount":99},[],{"trials":28510,"activeCount":99},[28511],{"nctId":28512,"briefTitle":28513,"status":105,"phases":28514,"primaryCompletion":5281,"completion":8620,"start":12804,"enrollment":15967,"conditions":28515,"interventions":28517},"NCT00392574","Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea",[89],[28516],"Acute Gastroenteritis in Adult Travelers",[28501],{"trials":28519,"activeCount":99},[],{"trials":28521,"activeCount":99},[],{"intervention":23330,"totalTrials":224,"cells":28523},{"EARLY_PHASE1":28524,"PHASE1":28526,"PHASE2":28528,"PHASE3":28530,"PHASE4":28536,"NA":28538},{"trials":28525,"activeCount":99},[],{"trials":28527,"activeCount":99},[],{"trials":28529,"activeCount":99},[],{"trials":28531,"activeCount":99},[28532],{"nctId":23324,"briefTitle":23325,"status":105,"phases":28533,"primaryCompletion":15210,"completion":15210,"start":14484,"enrollment":23327,"conditions":28534,"interventions":28535},[89],[14418,13133],[23330,23331,22385],{"trials":28537,"activeCount":99},[],{"trials":28539,"activeCount":99},[],{"intervention":23331,"totalTrials":224,"cells":28541},{"EARLY_PHASE1":28542,"PHASE1":28544,"PHASE2":28546,"PHASE3":28548,"PHASE4":28554,"NA":28556},{"trials":28543,"activeCount":99},[],{"trials":28545,"activeCount":99},[],{"trials":28547,"activeCount":99},[],{"trials":28549,"activeCount":99},[28550],{"nctId":23324,"briefTitle":23325,"status":105,"phases":28551,"primaryCompletion":15210,"completion":15210,"start":14484,"enrollment":23327,"conditions":28552,"interventions":28553},[89],[14418,13133],[23330,23331,22385],{"trials":28555,"activeCount":99},[],{"trials":28557,"activeCount":99},[],{"intervention":28559,"totalTrials":224,"cells":28560},"pneumococcal 23v polysaccharide vaccine",{"EARLY_PHASE1":28561,"PHASE1":28563,"PHASE2":28565,"PHASE3":28567,"PHASE4":28575,"NA":28577},{"trials":28562,"activeCount":99},[],{"trials":28564,"activeCount":99},[],{"trials":28566,"activeCount":99},[],{"trials":28568,"activeCount":99},[28569],{"nctId":28570,"briefTitle":28571,"status":105,"phases":28572,"primaryCompletion":13890,"completion":13890,"start":13891,"enrollment":5196,"conditions":28573,"interventions":28574},"NCT00560950","Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)",[89],[13187],[28559],{"trials":28576,"activeCount":99},[],{"trials":28578,"activeCount":99},[],{"intervention":28580,"totalTrials":224,"cells":28581},"Measles, Mumps, Rubella and Varicella",{"EARLY_PHASE1":28582,"PHASE1":28584,"PHASE2":28586,"PHASE3":28588,"PHASE4":28597,"NA":28599},{"trials":28583,"activeCount":99},[],{"trials":28585,"activeCount":99},[],{"trials":28587,"activeCount":99},[],{"trials":28589,"activeCount":99},[28590],{"nctId":28591,"briefTitle":28592,"status":150,"phases":28593,"primaryCompletion":13890,"completion":13890,"start":5281,"enrollment":154,"conditions":28594,"interventions":28595},"NCT00839917","A Study of ProQuad™ in Healthy Children in Korea (V221-023)",[89],[15308,15309,15310,15311],[28580,28596],"M-M-R™ II and Varivax™",{"trials":28598,"activeCount":99},[],{"trials":28600,"activeCount":99},[],{"intervention":28596,"totalTrials":224,"cells":28602},{"EARLY_PHASE1":28603,"PHASE1":28605,"PHASE2":28607,"PHASE3":28609,"PHASE4":28615,"NA":28617},{"trials":28604,"activeCount":99},[],{"trials":28606,"activeCount":99},[],{"trials":28608,"activeCount":99},[],{"trials":28610,"activeCount":99},[28611],{"nctId":28591,"briefTitle":28592,"status":150,"phases":28612,"primaryCompletion":13890,"completion":13890,"start":5281,"enrollment":154,"conditions":28613,"interventions":28614},[89],[15308,15309,15310,15311],[28580,28596],{"trials":28616,"activeCount":99},[],{"trials":28618,"activeCount":99},[],{"intervention":15290,"totalTrials":224,"cells":28620},{"EARLY_PHASE1":28621,"PHASE1":28623,"PHASE2":28625,"PHASE3":28627,"PHASE4":28633,"NA":28635},{"trials":28622,"activeCount":99},[],{"trials":28624,"activeCount":99},[],{"trials":28626,"activeCount":99},[],{"trials":28628,"activeCount":99},[28629],{"nctId":15285,"briefTitle":15286,"status":150,"phases":28630,"primaryCompletion":5281,"completion":14353,"start":14976,"enrollment":2441,"conditions":28631,"interventions":28632},[89],[15158],[15290,14331],{"trials":28634,"activeCount":99},[],{"trials":28636,"activeCount":99},[],{"intervention":8783,"totalTrials":224,"cells":28638},{"EARLY_PHASE1":28639,"PHASE1":28641,"PHASE2":28643,"PHASE3":28645,"PHASE4":28651,"NA":28653},{"trials":28640,"activeCount":99},[],{"trials":28642,"activeCount":99},[],{"trials":28644,"activeCount":99},[],{"trials":28646,"activeCount":99},[28647],{"nctId":8776,"briefTitle":8777,"status":150,"phases":28648,"primaryCompletion":8779,"completion":8779,"start":7073,"enrollment":5349,"conditions":28649,"interventions":28650},[89],[8781],[7662,7295,8783],{"trials":28652,"activeCount":99},[],{"trials":28654,"activeCount":99},[],{"intervention":28656,"totalTrials":224,"cells":28657},"Uridine 5'-Triphosphate (UTP) Solution for Inhalation",{"EARLY_PHASE1":28658,"PHASE1":28660,"PHASE2":28662,"PHASE3":28664,"PHASE4":28672,"NA":28674},{"trials":28659,"activeCount":99},[],{"trials":28661,"activeCount":99},[],{"trials":28663,"activeCount":99},[],{"trials":28665,"activeCount":99},[28666],{"nctId":28667,"briefTitle":28668,"status":105,"phases":28669,"primaryCompletion":14875,"completion":14875,"start":22342,"enrollment":7074,"conditions":28670,"interventions":28671},"NCT00210080","A Study to Diagnose Lung Cancer by Sputum Cytology (01-312)",[89],[2649],[28656],{"trials":28673,"activeCount":99},[],{"trials":28675,"activeCount":99},[],{"intervention":15299,"totalTrials":224,"cells":28677},{"EARLY_PHASE1":28678,"PHASE1":28680,"PHASE2":28682,"PHASE3":28684,"PHASE4":28690,"NA":28692},{"trials":28679,"activeCount":99},[],{"trials":28681,"activeCount":99},[],{"trials":28683,"activeCount":99},[],{"trials":28685,"activeCount":99},[28686],{"nctId":15292,"briefTitle":15293,"status":105,"phases":28687,"primaryCompletion":13891,"completion":13870,"start":15295,"enrollment":15296,"conditions":28688,"interventions":28689},[89],[863,7085],[15205,13864,15299],{"trials":28691,"activeCount":99},[],{"trials":28693,"activeCount":99},[],{"intervention":14107,"totalTrials":224,"cells":28695},{"EARLY_PHASE1":28696,"PHASE1":28698,"PHASE2":28700,"PHASE3":28702,"PHASE4":28708,"NA":28710},{"trials":28697,"activeCount":99},[],{"trials":28699,"activeCount":99},[],{"trials":28701,"activeCount":99},[],{"trials":28703,"activeCount":99},[28704],{"nctId":14100,"briefTitle":14101,"status":105,"phases":28705,"primaryCompletion":14103,"completion":14103,"start":14104,"enrollment":184,"conditions":28706,"interventions":28707},[89],[15],[14107,4084],{"trials":28709,"activeCount":99},[],{"trials":28711,"activeCount":99},[],{"intervention":4399,"totalTrials":224,"cells":28713},{"EARLY_PHASE1":28714,"PHASE1":28716,"PHASE2":28718,"PHASE3":28720,"PHASE4":28726,"NA":28728},{"trials":28715,"activeCount":99},[],{"trials":28717,"activeCount":99},[],{"trials":28719,"activeCount":99},[],{"trials":28721,"activeCount":99},[28722],{"nctId":4390,"briefTitle":4391,"status":105,"phases":28723,"primaryCompletion":4393,"completion":4393,"start":4394,"enrollment":4395,"conditions":28724,"interventions":28725},[89],[4397],[4399,4400,4401,1089],{"trials":28727,"activeCount":99},[],{"trials":28729,"activeCount":99},[],{"intervention":4400,"totalTrials":224,"cells":28731},{"EARLY_PHASE1":28732,"PHASE1":28734,"PHASE2":28736,"PHASE3":28738,"PHASE4":28744,"NA":28746},{"trials":28733,"activeCount":99},[],{"trials":28735,"activeCount":99},[],{"trials":28737,"activeCount":99},[],{"trials":28739,"activeCount":99},[28740],{"nctId":4390,"briefTitle":4391,"status":105,"phases":28741,"primaryCompletion":4393,"completion":4393,"start":4394,"enrollment":4395,"conditions":28742,"interventions":28743},[89],[4397],[4399,4400,4401,1089],{"trials":28745,"activeCount":99},[],{"trials":28747,"activeCount":99},[],{"intervention":4401,"totalTrials":224,"cells":28749},{"EARLY_PHASE1":28750,"PHASE1":28752,"PHASE2":28754,"PHASE3":28756,"PHASE4":28762,"NA":28764},{"trials":28751,"activeCount":99},[],{"trials":28753,"activeCount":99},[],{"trials":28755,"activeCount":99},[],{"trials":28757,"activeCount":99},[28758],{"nctId":4390,"briefTitle":4391,"status":105,"phases":28759,"primaryCompletion":4393,"completion":4393,"start":4394,"enrollment":4395,"conditions":28760,"interventions":28761},[89],[4397],[4399,4400,4401,1089],{"trials":28763,"activeCount":99},[],{"trials":28765,"activeCount":99},[],{"intervention":28767,"totalTrials":224,"cells":28768},"Investigational drug",{"EARLY_PHASE1":28769,"PHASE1":28771,"PHASE2":28773,"PHASE3":28775,"PHASE4":28783,"NA":28785},{"trials":28770,"activeCount":99},[],{"trials":28772,"activeCount":99},[],{"trials":28774,"activeCount":99},[],{"trials":28776,"activeCount":99},[28777],{"nctId":28778,"briefTitle":28779,"status":150,"phases":28780,"primaryCompletion":14594,"completion":14594,"conditions":28781,"interventions":28782},"NCT00006187","The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease",[89],[9369],[28767],{"trials":28784,"activeCount":99},[],{"trials":28786,"activeCount":99},[],{"intervention":20825,"totalTrials":224,"cells":28788},{"EARLY_PHASE1":28789,"PHASE1":28791,"PHASE2":28793,"PHASE3":28795,"PHASE4":28801,"NA":28803},{"trials":28790,"activeCount":99},[],{"trials":28792,"activeCount":99},[],{"trials":28794,"activeCount":99},[],{"trials":28796,"activeCount":99},[28797],{"nctId":20816,"briefTitle":20817,"status":105,"phases":28798,"primaryCompletion":20819,"completion":20820,"start":20821,"enrollment":407,"conditions":28799,"interventions":28800},[89],[17011],[16687,17013,20824,20825],{"trials":28802,"activeCount":99},[],{"trials":28804,"activeCount":99},[],{"intervention":28806,"totalTrials":224,"cells":28807},"lovastatin",{"EARLY_PHASE1":28808,"PHASE1":28810,"PHASE2":28812,"PHASE3":28814,"PHASE4":28825,"NA":28827},{"trials":28809,"activeCount":99},[],{"trials":28811,"activeCount":99},[],{"trials":28813,"activeCount":99},[],{"trials":28815,"activeCount":99},[28816],{"nctId":28817,"briefTitle":28818,"status":105,"phases":28819,"primaryCompletion":28820,"completion":28820,"start":28821,"enrollment":10917,"conditions":28822,"interventions":28824},"NCT00116870","MARS - Monitored Atherosclerosis Regression Study",[88,89],"1992-02","1985-06",[23415,28823],"Coronary Artery Disease",[28806],{"trials":28826,"activeCount":99},[],{"trials":28828,"activeCount":99},[],{"intervention":24395,"totalTrials":224,"cells":28830},{"EARLY_PHASE1":28831,"PHASE1":28833,"PHASE2":28835,"PHASE3":28837,"PHASE4":28843,"NA":28845},{"trials":28832,"activeCount":99},[],{"trials":28834,"activeCount":99},[],{"trials":28836,"activeCount":99},[],{"trials":28838,"activeCount":99},[28839],{"nctId":24388,"briefTitle":24389,"status":105,"phases":28840,"primaryCompletion":24391,"completion":24391,"start":24392,"enrollment":920,"conditions":28841,"interventions":28842},[89],[24026,18809],[24368,24395],{"trials":28844,"activeCount":99},[],{"trials":28846,"activeCount":99},[],{"intervention":28848,"totalTrials":224,"cells":28849},"Grazoprevir 100 mg\u002FElbasvir 50 mg fixed-dose combination",{"EARLY_PHASE1":28850,"PHASE1":28852,"PHASE2":28854,"PHASE3":28856,"PHASE4":28866,"NA":28868},{"trials":28851,"activeCount":99},[],{"trials":28853,"activeCount":99},[],{"trials":28855,"activeCount":99},[],{"trials":28857,"activeCount":99},[28858],{"nctId":28859,"briefTitle":28860,"status":105,"phases":28861,"primaryCompletion":28862,"completion":25660,"start":28863,"enrollment":21111,"conditions":28864,"interventions":28865},"NCT02105662","An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)",[89],"2015-02-20","2014-06-03",[12957],[28848],{"trials":28867,"activeCount":99},[],{"trials":28869,"activeCount":99},[],{"intervention":28871,"totalTrials":224,"cells":28872},"Finasteride",{"EARLY_PHASE1":28873,"PHASE1":28875,"PHASE2":28877,"PHASE3":28879,"PHASE4":28891,"NA":28893},{"trials":28874,"activeCount":99},[],{"trials":28876,"activeCount":99},[],{"trials":28878,"activeCount":99},[],{"trials":28880,"activeCount":99},[28881],{"nctId":28882,"briefTitle":28883,"status":150,"phases":28884,"primaryCompletion":28885,"completion":28885,"start":28886,"enrollment":224,"conditions":28887,"interventions":28889},"NCT01534351","Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)",[89],"2013-11-18","2013-08-01",[28888],"Benign Prostatic Hyperplasia",[28871,28890],"Tamsulosin",{"trials":28892,"activeCount":99},[],{"trials":28894,"activeCount":99},[],{"intervention":28890,"totalTrials":224,"cells":28896},{"EARLY_PHASE1":28897,"PHASE1":28899,"PHASE2":28901,"PHASE3":28903,"PHASE4":28909,"NA":28911},{"trials":28898,"activeCount":99},[],{"trials":28900,"activeCount":99},[],{"trials":28902,"activeCount":99},[],{"trials":28904,"activeCount":99},[28905],{"nctId":28882,"briefTitle":28883,"status":150,"phases":28906,"primaryCompletion":28885,"completion":28885,"start":28886,"enrollment":224,"conditions":28907,"interventions":28908},[89],[28888],[28871,28890],{"trials":28910,"activeCount":99},[],{"trials":28912,"activeCount":99},[],{"intervention":7601,"totalTrials":224,"cells":28914},{"EARLY_PHASE1":28915,"PHASE1":28917,"PHASE2":28919,"PHASE3":28921,"PHASE4":28927,"NA":28929},{"trials":28916,"activeCount":99},[],{"trials":28918,"activeCount":99},[],{"trials":28920,"activeCount":99},[],{"trials":28922,"activeCount":99},[28923],{"nctId":7591,"briefTitle":7592,"status":105,"phases":28924,"primaryCompletion":7594,"completion":2286,"start":7595,"enrollment":7596,"conditions":28925,"interventions":28926},[89],[7598],[7488,7600,7601],{"trials":28928,"activeCount":99},[],{"trials":28930,"activeCount":99},[],{"intervention":15324,"totalTrials":224,"cells":28932},{"EARLY_PHASE1":28933,"PHASE1":28935,"PHASE2":28937,"PHASE3":28939,"PHASE4":28945,"NA":28947},{"trials":28934,"activeCount":99},[],{"trials":28936,"activeCount":99},[],{"trials":28938,"activeCount":99},[],{"trials":28940,"activeCount":99},[28941],{"nctId":15317,"briefTitle":15318,"status":105,"phases":28942,"primaryCompletion":15320,"completion":15320,"start":5147,"enrollment":15321,"conditions":28943,"interventions":28944},[89],[15023],[13864,13145,15324],{"trials":28946,"activeCount":99},[],{"trials":28948,"activeCount":99},[],{"intervention":17253,"totalTrials":224,"cells":28950},{"EARLY_PHASE1":28951,"PHASE1":28953,"PHASE2":28955,"PHASE3":28957,"PHASE4":28963,"NA":28965},{"trials":28952,"activeCount":99},[],{"trials":28954,"activeCount":99},[],{"trials":28956,"activeCount":99},[],{"trials":28958,"activeCount":99},[28959],{"nctId":17245,"briefTitle":17246,"status":150,"phases":28960,"start":17248,"enrollment":17249,"conditions":28961,"interventions":28962},[89],[17251],[17234,17253],{"trials":28964,"activeCount":99},[],{"trials":28966,"activeCount":99},[],{"intervention":14127,"totalTrials":224,"cells":28968},{"EARLY_PHASE1":28969,"PHASE1":28971,"PHASE2":28973,"PHASE3":28975,"PHASE4":28981,"NA":28983},{"trials":28970,"activeCount":99},[],{"trials":28972,"activeCount":99},[],{"trials":28974,"activeCount":99},[],{"trials":28976,"activeCount":99},[28977],{"nctId":14118,"briefTitle":14119,"status":105,"phases":28978,"primaryCompletion":14121,"completion":14122,"start":14123,"enrollment":2555,"conditions":28979,"interventions":28980},[89],[15],[14126,13864,14127,14040,14128],{"trials":28982,"activeCount":99},[],{"trials":28984,"activeCount":99},[],{"intervention":28986,"totalTrials":224,"cells":28987},"M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®",{"EARLY_PHASE1":28988,"PHASE1":28990,"PHASE2":28992,"PHASE3":28994,"PHASE4":29005,"NA":29007},{"trials":28989,"activeCount":99},[],{"trials":28991,"activeCount":99},[],{"trials":28993,"activeCount":99},[],{"trials":28995,"activeCount":99},[28996],{"nctId":28997,"briefTitle":28998,"status":105,"phases":28999,"primaryCompletion":29000,"completion":29000,"start":29001,"enrollment":29002,"conditions":29003,"interventions":29004},"NCT00432523","Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)",[89],"2005-09-05","2005-01-20",752,[15308,15309,15311],[28986],{"trials":29006,"activeCount":99},[],{"trials":29008,"activeCount":99},[],{"intervention":5286,"totalTrials":224,"cells":29010},{"EARLY_PHASE1":29011,"PHASE1":29013,"PHASE2":29015,"PHASE3":29017,"PHASE4":29023,"NA":29025},{"trials":29012,"activeCount":99},[],{"trials":29014,"activeCount":99},[],{"trials":29016,"activeCount":99},[],{"trials":29018,"activeCount":99},[29019],{"nctId":5277,"briefTitle":5278,"status":105,"phases":29020,"primaryCompletion":5280,"completion":5280,"start":5281,"enrollment":5282,"conditions":29021,"interventions":29022},[89],[5181],[5285,5286,529,529,5137],{"trials":29024,"activeCount":99},[],{"trials":29026,"activeCount":99},[],{"intervention":20543,"totalTrials":224,"cells":29028},{"EARLY_PHASE1":29029,"PHASE1":29031,"PHASE2":29033,"PHASE3":29035,"PHASE4":29041,"NA":29043},{"trials":29030,"activeCount":99},[],{"trials":29032,"activeCount":99},[],{"trials":29034,"activeCount":99},[],{"trials":29036,"activeCount":99},[29037],{"nctId":20538,"briefTitle":20539,"status":105,"phases":29038,"primaryCompletion":20258,"completion":20258,"start":13102,"enrollment":1601,"conditions":29039,"interventions":29040},[89],[17830],[20478,20543],{"trials":29042,"activeCount":99},[],{"trials":29044,"activeCount":99},[],{"intervention":24151,"totalTrials":224,"cells":29046},{"EARLY_PHASE1":29047,"PHASE1":29049,"PHASE2":29051,"PHASE3":29053,"PHASE4":29059,"NA":29061},{"trials":29048,"activeCount":99},[],{"trials":29050,"activeCount":99},[],{"trials":29052,"activeCount":99},[],{"trials":29054,"activeCount":99},[29055],{"nctId":24144,"briefTitle":24145,"status":1040,"phases":29056,"primaryCompletion":24147,"completion":24147,"start":24148,"enrollment":99,"conditions":29057,"interventions":29058},[89],[15311],[24151,24152,16478],{"trials":29060,"activeCount":99},[],{"trials":29062,"activeCount":99},[],{"intervention":29064,"totalTrials":224,"cells":29065},"Comparator: Stronger neo minophagen C",{"EARLY_PHASE1":29066,"PHASE1":29068,"PHASE2":29070,"PHASE3":29072,"PHASE4":29080,"NA":29082},{"trials":29067,"activeCount":99},[],{"trials":29069,"activeCount":99},[],{"trials":29071,"activeCount":99},[],{"trials":29073,"activeCount":99},[29074],{"nctId":29075,"briefTitle":29076,"status":150,"phases":29077,"primaryCompletion":14566,"completion":14566,"start":15038,"enrollment":23677,"conditions":29078,"interventions":29079},"NCT00686881","Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2\u002FF3 Liver Fibrosis (P04773)",[89],[21],[15859,29064],{"trials":29081,"activeCount":99},[],{"trials":29083,"activeCount":99},[],{"intervention":29085,"totalTrials":224,"cells":29086},"V221, measles, mumps, rubella and varicella (Oka\u002FMerck) virus vaccine live \u002F Duration of Treatment: 12 weeks",{"EARLY_PHASE1":29087,"PHASE1":29089,"PHASE2":29091,"PHASE3":29093,"PHASE4":29103,"NA":29105},{"trials":29088,"activeCount":99},[],{"trials":29090,"activeCount":99},[],{"trials":29092,"activeCount":99},[],{"trials":29094,"activeCount":99},[29095],{"nctId":29096,"briefTitle":29097,"status":105,"phases":29098,"primaryCompletion":29099,"completion":29099,"start":29100,"enrollment":2204,"conditions":29101,"interventions":29102},"NCT00092430","Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)",[89],"2003-06-09","2002-09-26",[15308,15309,15310,15311],[29085],{"trials":29104,"activeCount":99},[],{"trials":29106,"activeCount":99},[],{"intervention":22993,"totalTrials":224,"cells":29108},{"EARLY_PHASE1":29109,"PHASE1":29111,"PHASE2":29113,"PHASE3":29115,"PHASE4":29121,"NA":29123},{"trials":29110,"activeCount":99},[],{"trials":29112,"activeCount":99},[],{"trials":29114,"activeCount":99},[],{"trials":29116,"activeCount":99},[29117],{"nctId":22985,"briefTitle":22986,"status":105,"phases":29118,"primaryCompletion":493,"completion":493,"start":22988,"enrollment":920,"conditions":29119,"interventions":29120},[89],[22990],[22992,22993],{"trials":29122,"activeCount":99},[],{"trials":29124,"activeCount":99},[],{"intervention":13075,"totalTrials":224,"cells":29126},{"EARLY_PHASE1":29127,"PHASE1":29129,"PHASE2":29131,"PHASE3":29133,"PHASE4":29139,"NA":29141},{"trials":29128,"activeCount":99},[],{"trials":29130,"activeCount":99},[],{"trials":29132,"activeCount":99},[],{"trials":29134,"activeCount":99},[29135],{"nctId":13067,"briefTitle":13068,"status":105,"phases":29136,"primaryCompletion":13070,"completion":13070,"start":13071,"enrollment":4059,"conditions":29137,"interventions":29138},[89],[13052,13073],[13005,13075],{"trials":29140,"activeCount":99},[],{"trials":29142,"activeCount":99},[],{"intervention":29144,"totalTrials":224,"cells":29145},"MK0524A, \u002FDuration of Treatment : 4 Weeks",{"EARLY_PHASE1":29146,"PHASE1":29148,"PHASE2":29150,"PHASE3":29152,"PHASE4":29162,"NA":29164},{"trials":29147,"activeCount":99},[],{"trials":29149,"activeCount":99},[],{"trials":29151,"activeCount":99},[],{"trials":29153,"activeCount":99},[29154],{"nctId":29155,"briefTitle":29156,"status":105,"phases":29157,"primaryCompletion":5507,"completion":5507,"start":15505,"enrollment":13715,"conditions":29158,"interventions":29160},"NCT00533611","Effect of MK0524A on Flushing Caused by Niacin (0524A-056)",[89],[29159],"Flushing",[29144,29161],"Comparator : niacin \u002FDuration of Treatment : 1 Weeks",{"trials":29163,"activeCount":99},[],{"trials":29165,"activeCount":99},[],{"intervention":29161,"totalTrials":224,"cells":29167},{"EARLY_PHASE1":29168,"PHASE1":29170,"PHASE2":29172,"PHASE3":29174,"PHASE4":29180,"NA":29182},{"trials":29169,"activeCount":99},[],{"trials":29171,"activeCount":99},[],{"trials":29173,"activeCount":99},[],{"trials":29175,"activeCount":99},[29176],{"nctId":29155,"briefTitle":29156,"status":105,"phases":29177,"primaryCompletion":5507,"completion":5507,"start":15505,"enrollment":13715,"conditions":29178,"interventions":29179},[89],[29159],[29144,29161],{"trials":29181,"activeCount":99},[],{"trials":29183,"activeCount":99},[],{"intervention":29185,"totalTrials":224,"cells":29186},"epinastine nasal spray, low concentration, low dose volume",{"EARLY_PHASE1":29187,"PHASE1":29189,"PHASE2":29191,"PHASE3":29193,"PHASE4":29208,"NA":29210},{"trials":29188,"activeCount":99},[],{"trials":29190,"activeCount":99},[],{"trials":29192,"activeCount":99},[],{"trials":29194,"activeCount":99},[29195],{"nctId":29196,"briefTitle":29197,"status":105,"phases":29198,"primaryCompletion":29199,"completion":29199,"start":29200,"enrollment":29201,"conditions":29202,"interventions":29204},"NCT00564421","Safety and Efficacy Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis (P08648)",[89],"2008-02-14","2007-12-18",798,[29203],"Seasonal Allergic Rhinitis",[29185,29205,29206,29207],"epinastine nasal spray, low concentration, high dose volume","epinastine nasal spray, high concentration, low dose volume","epinastine nasal spray, high concentration, high dose volume",{"trials":29209,"activeCount":99},[],{"trials":29211,"activeCount":99},[],{"intervention":29205,"totalTrials":224,"cells":29213},{"EARLY_PHASE1":29214,"PHASE1":29216,"PHASE2":29218,"PHASE3":29220,"PHASE4":29226,"NA":29228},{"trials":29215,"activeCount":99},[],{"trials":29217,"activeCount":99},[],{"trials":29219,"activeCount":99},[],{"trials":29221,"activeCount":99},[29222],{"nctId":29196,"briefTitle":29197,"status":105,"phases":29223,"primaryCompletion":29199,"completion":29199,"start":29200,"enrollment":29201,"conditions":29224,"interventions":29225},[89],[29203],[29185,29205,29206,29207],{"trials":29227,"activeCount":99},[],{"trials":29229,"activeCount":99},[],{"intervention":29206,"totalTrials":224,"cells":29231},{"EARLY_PHASE1":29232,"PHASE1":29234,"PHASE2":29236,"PHASE3":29238,"PHASE4":29244,"NA":29246},{"trials":29233,"activeCount":99},[],{"trials":29235,"activeCount":99},[],{"trials":29237,"activeCount":99},[],{"trials":29239,"activeCount":99},[29240],{"nctId":29196,"briefTitle":29197,"status":105,"phases":29241,"primaryCompletion":29199,"completion":29199,"start":29200,"enrollment":29201,"conditions":29242,"interventions":29243},[89],[29203],[29185,29205,29206,29207],{"trials":29245,"activeCount":99},[],{"trials":29247,"activeCount":99},[],{"intervention":29207,"totalTrials":224,"cells":29249},{"EARLY_PHASE1":29250,"PHASE1":29252,"PHASE2":29254,"PHASE3":29256,"PHASE4":29262,"NA":29264},{"trials":29251,"activeCount":99},[],{"trials":29253,"activeCount":99},[],{"trials":29255,"activeCount":99},[],{"trials":29257,"activeCount":99},[29258],{"nctId":29196,"briefTitle":29197,"status":105,"phases":29259,"primaryCompletion":29199,"completion":29199,"start":29200,"enrollment":29201,"conditions":29260,"interventions":29261},[89],[29203],[29185,29205,29206,29207],{"trials":29263,"activeCount":99},[],{"trials":29265,"activeCount":99},[],{"intervention":14138,"totalTrials":224,"cells":29267},{"EARLY_PHASE1":29268,"PHASE1":29270,"PHASE2":29272,"PHASE3":29274,"PHASE4":29280,"NA":29282},{"trials":29269,"activeCount":99},[],{"trials":29271,"activeCount":99},[],{"trials":29273,"activeCount":99},[],{"trials":29275,"activeCount":99},[29276],{"nctId":14130,"briefTitle":14131,"status":150,"phases":29277,"primaryCompletion":14133,"completion":14133,"start":14134,"enrollment":14135,"conditions":29278,"interventions":29279},[89],[15],[14138,13145,13122,4084,13146],{"trials":29281,"activeCount":99},[],{"trials":29283,"activeCount":99},[],{"intervention":16051,"totalTrials":224,"cells":29285},{"EARLY_PHASE1":29286,"PHASE1":29288,"PHASE2":29290,"PHASE3":29292,"PHASE4":29298,"NA":29300},{"trials":29287,"activeCount":99},[],{"trials":29289,"activeCount":99},[],{"trials":29291,"activeCount":99},[],{"trials":29293,"activeCount":99},[29294],{"nctId":16044,"briefTitle":16045,"status":150,"phases":29295,"primaryCompletion":16047,"completion":16047,"start":16048,"enrollment":2801,"conditions":29296,"interventions":29297},[89],[15],[13913,13146,16051,14008],{"trials":29299,"activeCount":99},[],{"trials":29301,"activeCount":99},[],{"intervention":19202,"totalTrials":224,"cells":29303},{"EARLY_PHASE1":29304,"PHASE1":29306,"PHASE2":29308,"PHASE3":29310,"PHASE4":29316,"NA":29318},{"trials":29305,"activeCount":99},[],{"trials":29307,"activeCount":99},[],{"trials":29309,"activeCount":99},[],{"trials":29311,"activeCount":99},[29312],{"nctId":19195,"briefTitle":19196,"status":105,"phases":29313,"primaryCompletion":19198,"completion":19198,"start":1521,"enrollment":19199,"conditions":29314,"interventions":29315},[89],[16472],[16474,19202],{"trials":29317,"activeCount":99},[],{"trials":29319,"activeCount":99},[],{"intervention":17149,"totalTrials":224,"cells":29321},{"EARLY_PHASE1":29322,"PHASE1":29324,"PHASE2":29326,"PHASE3":29328,"PHASE4":29334,"NA":29336},{"trials":29323,"activeCount":99},[],{"trials":29325,"activeCount":99},[],{"trials":29327,"activeCount":99},[],{"trials":29329,"activeCount":99},[29330],{"nctId":17142,"briefTitle":17143,"status":105,"phases":29331,"primaryCompletion":17145,"completion":17145,"start":16664,"enrollment":3262,"conditions":29332,"interventions":29333},[89],[17137,17147],[17120,17149],{"trials":29335,"activeCount":99},[],{"trials":29337,"activeCount":99},[],{"intervention":29339,"totalTrials":224,"cells":29340},"Infliximab and methotrexate",{"EARLY_PHASE1":29341,"PHASE1":29343,"PHASE2":29345,"PHASE3":29347,"PHASE4":29355,"NA":29357},{"trials":29342,"activeCount":99},[],{"trials":29344,"activeCount":99},[],{"trials":29346,"activeCount":99},[],{"trials":29348,"activeCount":99},[29349],{"nctId":29350,"briefTitle":29351,"status":150,"phases":29352,"primaryCompletion":16802,"completion":16802,"start":14730,"enrollment":2754,"conditions":29353,"interventions":29354},"NCT00833053","Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)",[89],[12754],[8594,29339],{"trials":29356,"activeCount":99},[],{"trials":29358,"activeCount":99},[],{"intervention":22013,"totalTrials":224,"cells":29360},{"EARLY_PHASE1":29361,"PHASE1":29363,"PHASE2":29365,"PHASE3":29367,"PHASE4":29373,"NA":29375},{"trials":29362,"activeCount":99},[],{"trials":29364,"activeCount":99},[],{"trials":29366,"activeCount":99},[],{"trials":29368,"activeCount":99},[29369],{"nctId":22006,"briefTitle":22007,"status":105,"phases":29370,"primaryCompletion":22009,"completion":22009,"start":3047,"enrollment":22010,"conditions":29371,"interventions":29372},[89],[15308,15309,15310,15311],[22013,22014],{"trials":29374,"activeCount":99},[],{"trials":29376,"activeCount":99},[],{"intervention":16181,"totalTrials":224,"cells":29378},{"EARLY_PHASE1":29379,"PHASE1":29381,"PHASE2":29383,"PHASE3":29385,"PHASE4":29391,"NA":29393},{"trials":29380,"activeCount":99},[],{"trials":29382,"activeCount":99},[],{"trials":29384,"activeCount":99},[],{"trials":29386,"activeCount":99},[29387],{"nctId":16173,"briefTitle":16174,"status":105,"phases":29388,"primaryCompletion":2095,"completion":2095,"start":16176,"enrollment":16177,"conditions":29389,"interventions":29390},[89],[14156],[13913,13145,16180,16181],{"trials":29392,"activeCount":99},[],{"trials":29394,"activeCount":99},[],{"intervention":8595,"totalTrials":224,"cells":29396},{"EARLY_PHASE1":29397,"PHASE1":29399,"PHASE2":29401,"PHASE3":29403,"PHASE4":29409,"NA":29411},{"trials":29398,"activeCount":99},[],{"trials":29400,"activeCount":99},[],{"trials":29402,"activeCount":99},[],{"trials":29404,"activeCount":99},[29405],{"nctId":8587,"briefTitle":8588,"status":150,"phases":29406,"primaryCompletion":8590,"completion":8590,"start":8591,"enrollment":1624,"conditions":29407,"interventions":29408},[89],[7169],[8594,2413,8595,8596],{"trials":29410,"activeCount":99},[],{"trials":29412,"activeCount":99},[],{"intervention":29414,"totalTrials":224,"cells":29415},"losartan potassium + hydrochlorothiazide + amlodipine besylate",{"EARLY_PHASE1":29416,"PHASE1":29418,"PHASE2":29420,"PHASE3":29422,"PHASE4":29435,"NA":29437},{"trials":29417,"activeCount":99},[],{"trials":29419,"activeCount":99},[],{"trials":29421,"activeCount":99},[],{"trials":29423,"activeCount":99},[29424],{"nctId":29425,"briefTitle":29426,"status":105,"phases":29427,"primaryCompletion":29428,"completion":29428,"start":29429,"enrollment":29430,"conditions":29431,"interventions":29432},"NCT01302691","MK-0954E Study in Participants With Hypertension (MK-0954E-357)",[89],"2012-04-01","2011-01-01",327,[30],[29414,29433,29434],"Losartan potassium","Amlodipine besylate",{"trials":29436,"activeCount":99},[],{"trials":29438,"activeCount":99},[],{"intervention":29434,"totalTrials":224,"cells":29440},{"EARLY_PHASE1":29441,"PHASE1":29443,"PHASE2":29445,"PHASE3":29447,"PHASE4":29453,"NA":29455},{"trials":29442,"activeCount":99},[],{"trials":29444,"activeCount":99},[],{"trials":29446,"activeCount":99},[],{"trials":29448,"activeCount":99},[29449],{"nctId":29425,"briefTitle":29426,"status":105,"phases":29450,"primaryCompletion":29428,"completion":29428,"start":29429,"enrollment":29430,"conditions":29451,"interventions":29452},[89],[30],[29414,29433,29434],{"trials":29454,"activeCount":99},[],{"trials":29456,"activeCount":99},[],{"intervention":25141,"totalTrials":224,"cells":29458},{"EARLY_PHASE1":29459,"PHASE1":29461,"PHASE2":29463,"PHASE3":29465,"PHASE4":29471,"NA":29473},{"trials":29460,"activeCount":99},[],{"trials":29462,"activeCount":99},[],{"trials":29464,"activeCount":99},[],{"trials":29466,"activeCount":99},[29467],{"nctId":25133,"briefTitle":25134,"status":105,"phases":29468,"primaryCompletion":25136,"completion":25137,"start":13269,"enrollment":25138,"conditions":29469,"interventions":29470},[89],[7650],[25141,17577,25122],{"trials":29472,"activeCount":99},[],{"trials":29474,"activeCount":99},[],{"intervention":19219,"totalTrials":224,"cells":29476},{"EARLY_PHASE1":29477,"PHASE1":29479,"PHASE2":29481,"PHASE3":29483,"PHASE4":29489,"NA":29491},{"trials":29478,"activeCount":99},[],{"trials":29480,"activeCount":99},[],{"trials":29482,"activeCount":99},[],{"trials":29484,"activeCount":99},[29485],{"nctId":19212,"briefTitle":19213,"status":105,"phases":29486,"primaryCompletion":19215,"completion":19215,"start":11530,"enrollment":19216,"conditions":29487,"interventions":29488},[89],[13187],[19219,16474,19220],{"trials":29490,"activeCount":99},[],{"trials":29492,"activeCount":99},[],{"intervention":19220,"totalTrials":224,"cells":29494},{"EARLY_PHASE1":29495,"PHASE1":29497,"PHASE2":29499,"PHASE3":29501,"PHASE4":29507,"NA":29509},{"trials":29496,"activeCount":99},[],{"trials":29498,"activeCount":99},[],{"trials":29500,"activeCount":99},[],{"trials":29502,"activeCount":99},[29503],{"nctId":19212,"briefTitle":19213,"status":105,"phases":29504,"primaryCompletion":19215,"completion":19215,"start":11530,"enrollment":19216,"conditions":29505,"interventions":29506},[89],[13187],[19219,16474,19220],{"trials":29508,"activeCount":99},[],{"trials":29510,"activeCount":99},[],{"intervention":15906,"totalTrials":224,"cells":29512},{"EARLY_PHASE1":29513,"PHASE1":29515,"PHASE2":29517,"PHASE3":29519,"PHASE4":29525,"NA":29527},{"trials":29514,"activeCount":99},[],{"trials":29516,"activeCount":99},[],{"trials":29518,"activeCount":99},[],{"trials":29520,"activeCount":99},[29521],{"nctId":15898,"briefTitle":15899,"status":105,"phases":29522,"primaryCompletion":15901,"completion":15901,"start":15902,"enrollment":15903,"conditions":29523,"interventions":29524},[89],[21],[15784,15859,14925,15906],{"trials":29526,"activeCount":99},[],{"trials":29528,"activeCount":99},[],{"intervention":25149,"totalTrials":224,"cells":29530},{"EARLY_PHASE1":29531,"PHASE1":29533,"PHASE2":29535,"PHASE3":29537,"PHASE4":29543,"NA":29545},{"trials":29532,"activeCount":99},[],{"trials":29534,"activeCount":99},[],{"trials":29536,"activeCount":99},[],{"trials":29538,"activeCount":99},[29539],{"nctId":25143,"briefTitle":25144,"status":150,"phases":29540,"primaryCompletion":5179,"completion":5981,"start":14315,"enrollment":25146,"conditions":29541,"interventions":29542},[89],[7390],[25149,25150,25122],{"trials":29544,"activeCount":99},[],{"trials":29546,"activeCount":99},[],{"intervention":25150,"totalTrials":224,"cells":29548},{"EARLY_PHASE1":29549,"PHASE1":29551,"PHASE2":29553,"PHASE3":29555,"PHASE4":29561,"NA":29563},{"trials":29550,"activeCount":99},[],{"trials":29552,"activeCount":99},[],{"trials":29554,"activeCount":99},[],{"trials":29556,"activeCount":99},[29557],{"nctId":25143,"briefTitle":25144,"status":150,"phases":29558,"primaryCompletion":5179,"completion":5981,"start":14315,"enrollment":25146,"conditions":29559,"interventions":29560},[89],[7390],[25149,25150,25122],{"trials":29562,"activeCount":99},[],{"trials":29564,"activeCount":99},[],{"intervention":29566,"totalTrials":224,"cells":29567},"V920 Consistency Lot A",{"EARLY_PHASE1":29568,"PHASE1":29570,"PHASE2":29572,"PHASE3":29574,"PHASE4":29589,"NA":29591},{"trials":29569,"activeCount":99},[],{"trials":29571,"activeCount":99},[],{"trials":29573,"activeCount":99},[],{"trials":29575,"activeCount":99},[29576],{"nctId":29577,"briefTitle":29578,"status":105,"phases":29579,"primaryCompletion":454,"completion":29580,"start":29581,"enrollment":29582,"conditions":29583,"interventions":29585},"NCT02503202","Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)",[89],"2017-09-29","2015-08-17",1197,[29584],"Prevention of Ebola Infection",[29566,29586,29587,29588],"V920 Consistency Lot B","V920 Consistency Lot C","V920 High-dose Lot",{"trials":29590,"activeCount":99},[],{"trials":29592,"activeCount":99},[],{"intervention":29586,"totalTrials":224,"cells":29594},{"EARLY_PHASE1":29595,"PHASE1":29597,"PHASE2":29599,"PHASE3":29601,"PHASE4":29607,"NA":29609},{"trials":29596,"activeCount":99},[],{"trials":29598,"activeCount":99},[],{"trials":29600,"activeCount":99},[],{"trials":29602,"activeCount":99},[29603],{"nctId":29577,"briefTitle":29578,"status":105,"phases":29604,"primaryCompletion":454,"completion":29580,"start":29581,"enrollment":29582,"conditions":29605,"interventions":29606},[89],[29584],[29566,29586,29587,29588],{"trials":29608,"activeCount":99},[],{"trials":29610,"activeCount":99},[],{"intervention":29587,"totalTrials":224,"cells":29612},{"EARLY_PHASE1":29613,"PHASE1":29615,"PHASE2":29617,"PHASE3":29619,"PHASE4":29625,"NA":29627},{"trials":29614,"activeCount":99},[],{"trials":29616,"activeCount":99},[],{"trials":29618,"activeCount":99},[],{"trials":29620,"activeCount":99},[29621],{"nctId":29577,"briefTitle":29578,"status":105,"phases":29622,"primaryCompletion":454,"completion":29580,"start":29581,"enrollment":29582,"conditions":29623,"interventions":29624},[89],[29584],[29566,29586,29587,29588],{"trials":29626,"activeCount":99},[],{"trials":29628,"activeCount":99},[],{"intervention":29588,"totalTrials":224,"cells":29630},{"EARLY_PHASE1":29631,"PHASE1":29633,"PHASE2":29635,"PHASE3":29637,"PHASE4":29643,"NA":29645},{"trials":29632,"activeCount":99},[],{"trials":29634,"activeCount":99},[],{"trials":29636,"activeCount":99},[],{"trials":29638,"activeCount":99},[29639],{"nctId":29577,"briefTitle":29578,"status":105,"phases":29640,"primaryCompletion":454,"completion":29580,"start":29581,"enrollment":29582,"conditions":29641,"interventions":29642},[89],[29584],[29566,29586,29587,29588],{"trials":29644,"activeCount":99},[],{"trials":29646,"activeCount":99},[],{"intervention":15725,"totalTrials":224,"cells":29648},{"EARLY_PHASE1":29649,"PHASE1":29651,"PHASE2":29653,"PHASE3":29655,"PHASE4":29661,"NA":29663},{"trials":29650,"activeCount":99},[],{"trials":29652,"activeCount":99},[],{"trials":29654,"activeCount":99},[],{"trials":29656,"activeCount":99},[29657],{"nctId":15718,"briefTitle":15719,"status":105,"phases":29658,"primaryCompletion":14940,"completion":14940,"start":15721,"enrollment":15722,"conditions":29659,"interventions":29660},[89],[15],[14487,15725],{"trials":29662,"activeCount":99},[],{"trials":29664,"activeCount":99},[],{"intervention":29666,"totalTrials":224,"cells":29667},"Bezlotoxumab",{"EARLY_PHASE1":29668,"PHASE1":29670,"PHASE2":29672,"PHASE3":29674,"PHASE4":29686,"NA":29688},{"trials":29669,"activeCount":99},[],{"trials":29671,"activeCount":99},[],{"trials":29673,"activeCount":99},[],{"trials":29675,"activeCount":99},[29676],{"nctId":29677,"briefTitle":29678,"status":105,"phases":29679,"primaryCompletion":29680,"completion":29680,"start":29681,"enrollment":29682,"conditions":29683,"interventions":29684},"NCT03182907","Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)",[89],"2022-05-12","2018-03-27",148,[25651],[29666,29685],"Antibacterial drug treatment",{"trials":29687,"activeCount":99},[],{"trials":29689,"activeCount":99},[],{"intervention":29685,"totalTrials":224,"cells":29691},{"EARLY_PHASE1":29692,"PHASE1":29694,"PHASE2":29696,"PHASE3":29698,"PHASE4":29704,"NA":29706},{"trials":29693,"activeCount":99},[],{"trials":29695,"activeCount":99},[],{"trials":29697,"activeCount":99},[],{"trials":29699,"activeCount":99},[29700],{"nctId":29677,"briefTitle":29678,"status":105,"phases":29701,"primaryCompletion":29680,"completion":29680,"start":29681,"enrollment":29682,"conditions":29702,"interventions":29703},[89],[25651],[29666,29685],{"trials":29705,"activeCount":99},[],{"trials":29707,"activeCount":99},[],{"intervention":29709,"totalTrials":224,"cells":29710},"MK0826, ertapenem sodium \u002F Duration of Treatment - 24 weeks",{"EARLY_PHASE1":29711,"PHASE1":29713,"PHASE2":29715,"PHASE3":29717,"PHASE4":29727,"NA":29729},{"trials":29712,"activeCount":99},[],{"trials":29714,"activeCount":99},[],{"trials":29716,"activeCount":99},[],{"trials":29718,"activeCount":99},[29719],{"nctId":29720,"briefTitle":29721,"status":105,"phases":29722,"primaryCompletion":4420,"completion":4420,"start":22342,"enrollment":1150,"conditions":29723,"interventions":29725},"NCT00229112","Comparative Study of Ertapenem Versus Another Antibiotic in the Treatment of Diabetic Foot Infections in Adults (0826-034)",[89],[29724],"Foot Infections in Diabetic Patients",[29709,29726],"Comparator: Piperacillin\u002FTazobactam \u002F Duration of Treatment - 24 weeks",{"trials":29728,"activeCount":99},[],{"trials":29730,"activeCount":99},[],{"intervention":29726,"totalTrials":224,"cells":29732},{"EARLY_PHASE1":29733,"PHASE1":29735,"PHASE2":29737,"PHASE3":29739,"PHASE4":29745,"NA":29747},{"trials":29734,"activeCount":99},[],{"trials":29736,"activeCount":99},[],{"trials":29738,"activeCount":99},[],{"trials":29740,"activeCount":99},[29741],{"nctId":29720,"briefTitle":29721,"status":105,"phases":29742,"primaryCompletion":4420,"completion":4420,"start":22342,"enrollment":1150,"conditions":29743,"interventions":29744},[89],[29724],[29709,29726],{"trials":29746,"activeCount":99},[],{"trials":29748,"activeCount":99},[],{"intervention":15381,"totalTrials":224,"cells":29750},{"EARLY_PHASE1":29751,"PHASE1":29753,"PHASE2":29755,"PHASE3":29757,"PHASE4":29763,"NA":29765},{"trials":29752,"activeCount":99},[],{"trials":29754,"activeCount":99},[],{"trials":29756,"activeCount":99},[],{"trials":29758,"activeCount":99},[29759],{"nctId":15375,"briefTitle":15376,"status":105,"phases":29760,"primaryCompletion":14454,"completion":14454,"start":4419,"enrollment":15378,"conditions":29761,"interventions":29762},[89],[4397],[15381,15382,15383,13864],{"trials":29764,"activeCount":99},[],{"trials":29766,"activeCount":99},[],{"intervention":15382,"totalTrials":224,"cells":29768},{"EARLY_PHASE1":29769,"PHASE1":29771,"PHASE2":29773,"PHASE3":29775,"PHASE4":29781,"NA":29783},{"trials":29770,"activeCount":99},[],{"trials":29772,"activeCount":99},[],{"trials":29774,"activeCount":99},[],{"trials":29776,"activeCount":99},[29777],{"nctId":15375,"briefTitle":15376,"status":105,"phases":29778,"primaryCompletion":14454,"completion":14454,"start":4419,"enrollment":15378,"conditions":29779,"interventions":29780},[89],[4397],[15381,15382,15383,13864],{"trials":29782,"activeCount":99},[],{"trials":29784,"activeCount":99},[],{"intervention":15383,"totalTrials":224,"cells":29786},{"EARLY_PHASE1":29787,"PHASE1":29789,"PHASE2":29791,"PHASE3":29793,"PHASE4":29799,"NA":29801},{"trials":29788,"activeCount":99},[],{"trials":29790,"activeCount":99},[],{"trials":29792,"activeCount":99},[],{"trials":29794,"activeCount":99},[29795],{"nctId":15375,"briefTitle":15376,"status":105,"phases":29796,"primaryCompletion":14454,"completion":14454,"start":4419,"enrollment":15378,"conditions":29797,"interventions":29798},[89],[4397],[15381,15382,15383,13864],{"trials":29800,"activeCount":99},[],{"trials":29802,"activeCount":99},[],{"intervention":15915,"totalTrials":224,"cells":29804},{"EARLY_PHASE1":29805,"PHASE1":29807,"PHASE2":29809,"PHASE3":29811,"PHASE4":29817,"NA":29819},{"trials":29806,"activeCount":99},[],{"trials":29808,"activeCount":99},[],{"trials":29810,"activeCount":99},[],{"trials":29812,"activeCount":99},[29813],{"nctId":15908,"briefTitle":15909,"status":1040,"phases":29814,"primaryCompletion":15911,"completion":15911,"start":15912,"enrollment":99,"conditions":29815,"interventions":29816},[89],[12957],[15784,15915,14925],{"trials":29818,"activeCount":99},[],{"trials":29820,"activeCount":99},[],{"intervention":29822,"totalTrials":224,"cells":29823},"V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine",{"EARLY_PHASE1":29824,"PHASE1":29826,"PHASE2":29828,"PHASE3":29830,"PHASE4":29839,"NA":29841},{"trials":29825,"activeCount":99},[],{"trials":29827,"activeCount":99},[],{"trials":29829,"activeCount":99},[],{"trials":29831,"activeCount":99},[29832],{"nctId":29833,"briefTitle":29834,"status":105,"phases":29835,"primaryCompletion":14679,"completion":14313,"start":22878,"enrollment":29836,"conditions":29837,"interventions":29838},"NCT00092495","Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)",[89],3055,[863,7085],[29822],{"trials":29840,"activeCount":99},[],{"trials":29842,"activeCount":99},[],{"intervention":14148,"totalTrials":224,"cells":29844},{"EARLY_PHASE1":29845,"PHASE1":29847,"PHASE2":29849,"PHASE3":29851,"PHASE4":29857,"NA":29859},{"trials":29846,"activeCount":99},[],{"trials":29848,"activeCount":99},[],{"trials":29850,"activeCount":99},[],{"trials":29852,"activeCount":99},[29853],{"nctId":14140,"briefTitle":14141,"status":105,"phases":29854,"primaryCompletion":13925,"completion":13925,"start":14143,"enrollment":14144,"conditions":29855,"interventions":29856},[89],[15],[13883,14147,14148,4084,13145],{"trials":29858,"activeCount":99},[],{"trials":29860,"activeCount":99},[],{"intervention":29862,"totalTrials":224,"cells":29863},"DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.",{"EARLY_PHASE1":29864,"PHASE1":29866,"PHASE2":29868,"PHASE3":29870,"PHASE4":29878,"NA":29880},{"trials":29865,"activeCount":99},[],{"trials":29867,"activeCount":99},[],{"trials":29869,"activeCount":99},[],{"trials":29871,"activeCount":99},[29872],{"nctId":29873,"briefTitle":29874,"status":150,"phases":29875,"primaryCompletion":14408,"completion":14408,"start":14324,"enrollment":734,"conditions":29876,"interventions":29877},"NCT00521924","Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)",[89],[7020],[12756,29862],{"trials":29879,"activeCount":99},[],{"trials":29881,"activeCount":99},[],{"intervention":29883,"totalTrials":224,"cells":29884},"Zoster Vaccine, Live,",{"EARLY_PHASE1":29885,"PHASE1":29887,"PHASE2":29889,"PHASE3":29891,"PHASE4":29900,"NA":29902},{"trials":29886,"activeCount":99},[],{"trials":29888,"activeCount":99},[],{"trials":29890,"activeCount":99},[],{"trials":29892,"activeCount":99},[29893],{"nctId":29894,"briefTitle":29895,"status":105,"phases":29896,"primaryCompletion":14409,"completion":14409,"start":4419,"enrollment":2779,"conditions":29897,"interventions":29899},"NCT00444860","ZOSTAVAX(R) Local Registration Trial (V211-019)",[89],[29898],"Varicella Virus Infection",[29883],{"trials":29901,"activeCount":99},[],{"trials":29903,"activeCount":99},[],{"intervention":29905,"totalTrials":224,"cells":29906},"Preservative-Free Tafluprost or vehicle",{"EARLY_PHASE1":29907,"PHASE1":29909,"PHASE2":29911,"PHASE3":29913,"PHASE4":29922,"NA":29924},{"trials":29908,"activeCount":99},[],{"trials":29910,"activeCount":99},[],{"trials":29912,"activeCount":99},[],{"trials":29914,"activeCount":99},[29915],{"nctId":29916,"briefTitle":29917,"status":105,"phases":29918,"primaryCompletion":16495,"completion":16495,"start":23433,"enrollment":3541,"conditions":29919,"interventions":29920},"NCT01254604","Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)",[89],[17137,17147],[29905,29921],"Preservative-Free Timolol maleate",{"trials":29923,"activeCount":99},[],{"trials":29925,"activeCount":99},[],{"intervention":29921,"totalTrials":224,"cells":29927},{"EARLY_PHASE1":29928,"PHASE1":29930,"PHASE2":29932,"PHASE3":29934,"PHASE4":29940,"NA":29942},{"trials":29929,"activeCount":99},[],{"trials":29931,"activeCount":99},[],{"trials":29933,"activeCount":99},[],{"trials":29935,"activeCount":99},[29936],{"nctId":29916,"briefTitle":29917,"status":105,"phases":29937,"primaryCompletion":16495,"completion":16495,"start":23433,"enrollment":3541,"conditions":29938,"interventions":29939},[89],[17137,17147],[29905,29921],{"trials":29941,"activeCount":99},[],{"trials":29943,"activeCount":99},[],{"intervention":14158,"totalTrials":224,"cells":29945},{"EARLY_PHASE1":29946,"PHASE1":29948,"PHASE2":29950,"PHASE3":29952,"PHASE4":29958,"NA":29960},{"trials":29947,"activeCount":99},[],{"trials":29949,"activeCount":99},[],{"trials":29951,"activeCount":99},[],{"trials":29953,"activeCount":99},[29954],{"nctId":14150,"briefTitle":14151,"status":105,"phases":29955,"primaryCompletion":14153,"completion":14153,"start":14154,"enrollment":8416,"conditions":29956,"interventions":29957},[89],[13950,14156],[13145,4084,14158,14159],{"trials":29959,"activeCount":99},[],{"trials":29961,"activeCount":99},[],{"intervention":14159,"totalTrials":224,"cells":29963},{"EARLY_PHASE1":29964,"PHASE1":29966,"PHASE2":29968,"PHASE3":29970,"PHASE4":29976,"NA":29978},{"trials":29965,"activeCount":99},[],{"trials":29967,"activeCount":99},[],{"trials":29969,"activeCount":99},[],{"trials":29971,"activeCount":99},[29972],{"nctId":14150,"briefTitle":14151,"status":105,"phases":29973,"primaryCompletion":14153,"completion":14153,"start":14154,"enrollment":8416,"conditions":29974,"interventions":29975},[89],[13950,14156],[13145,4084,14158,14159],{"trials":29977,"activeCount":99},[],{"trials":29979,"activeCount":99},[],{"intervention":29981,"totalTrials":224,"cells":29982},"L50\u002FH12.5\u002FA5",{"EARLY_PHASE1":29983,"PHASE1":29985,"PHASE2":29987,"PHASE3":29989,"PHASE4":30002,"NA":30004},{"trials":29984,"activeCount":99},[],{"trials":29986,"activeCount":99},[],{"trials":29988,"activeCount":99},[],{"trials":29990,"activeCount":99},[29991],{"nctId":29992,"briefTitle":29993,"status":105,"phases":29994,"primaryCompletion":29995,"completion":29996,"start":29997,"enrollment":29998,"conditions":29999,"interventions":30000},"NCT01299376","MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)",[89],"2011-11-16","2012-09-20","2011-01-24",286,[30],[29981,30001],"L50\u002FH12.5",{"trials":30003,"activeCount":99},[],{"trials":30005,"activeCount":99},[],{"intervention":30001,"totalTrials":224,"cells":30007},{"EARLY_PHASE1":30008,"PHASE1":30010,"PHASE2":30012,"PHASE3":30014,"PHASE4":30020,"NA":30022},{"trials":30009,"activeCount":99},[],{"trials":30011,"activeCount":99},[],{"trials":30013,"activeCount":99},[],{"trials":30015,"activeCount":99},[30016],{"nctId":29992,"briefTitle":29993,"status":105,"phases":30017,"primaryCompletion":29995,"completion":29996,"start":29997,"enrollment":29998,"conditions":30018,"interventions":30019},[89],[30],[29981,30001],{"trials":30021,"activeCount":99},[],{"trials":30023,"activeCount":99},[],{"intervention":24186,"totalTrials":224,"cells":30025},{"EARLY_PHASE1":30026,"PHASE1":30028,"PHASE2":30030,"PHASE3":30032,"PHASE4":30038,"NA":30040},{"trials":30027,"activeCount":99},[],{"trials":30029,"activeCount":99},[],{"trials":30031,"activeCount":99},[],{"trials":30033,"activeCount":99},[30034],{"nctId":24178,"briefTitle":24179,"status":105,"phases":30035,"primaryCompletion":15211,"completion":15211,"start":24181,"enrollment":24182,"conditions":30036,"interventions":30037},[89],[24184],[24158,24186],{"trials":30039,"activeCount":99},[],{"trials":30041,"activeCount":99},[],{"intervention":30043,"totalTrials":224,"cells":30044},"Rocuronium bolus maintenance",{"EARLY_PHASE1":30045,"PHASE1":30047,"PHASE2":30049,"PHASE3":30051,"PHASE4":30061,"NA":30063},{"trials":30046,"activeCount":99},[],{"trials":30048,"activeCount":99},[],{"trials":30050,"activeCount":99},[],{"trials":30052,"activeCount":99},[30053],{"nctId":30054,"briefTitle":30055,"status":105,"phases":30056,"primaryCompletion":5507,"completion":14887,"start":14595,"enrollment":30057,"conditions":30058,"interventions":30059},"NCT00124735","A Study to Determine the Dose Requirements of Rocuronium Bromide (Zemuron®) in Pediatric and Adolescent Subjects (21048)(COMPLETED)(P05797)",[89],149,[16668],[30043,30060],"rocuronium continuous infusion maintenance",{"trials":30062,"activeCount":99},[],{"trials":30064,"activeCount":99},[],{"intervention":30060,"totalTrials":224,"cells":30066},{"EARLY_PHASE1":30067,"PHASE1":30069,"PHASE2":30071,"PHASE3":30073,"PHASE4":30079,"NA":30081},{"trials":30068,"activeCount":99},[],{"trials":30070,"activeCount":99},[],{"trials":30072,"activeCount":99},[],{"trials":30074,"activeCount":99},[30075],{"nctId":30054,"briefTitle":30055,"status":105,"phases":30076,"primaryCompletion":5507,"completion":14887,"start":14595,"enrollment":30057,"conditions":30077,"interventions":30078},[89],[16668],[30043,30060],{"trials":30080,"activeCount":99},[],{"trials":30082,"activeCount":99},[],{"intervention":15411,"totalTrials":224,"cells":30084},{"EARLY_PHASE1":30085,"PHASE1":30087,"PHASE2":30089,"PHASE3":30091,"PHASE4":30097,"NA":30099},{"trials":30086,"activeCount":99},[],{"trials":30088,"activeCount":99},[],{"trials":30090,"activeCount":99},[],{"trials":30092,"activeCount":99},[30093],{"nctId":15402,"briefTitle":15403,"status":105,"phases":30094,"primaryCompletion":15405,"completion":15406,"start":15407,"enrollment":15408,"conditions":30095,"interventions":30096},[89],[7141],[15411,14331],{"trials":30098,"activeCount":99},[],{"trials":30100,"activeCount":99},[],{"intervention":30102,"totalTrials":224,"cells":30103},"MK0831",{"EARLY_PHASE1":30104,"PHASE1":30106,"PHASE2":30108,"PHASE3":30110,"PHASE4":30118,"NA":30120},{"trials":30105,"activeCount":99},[],{"trials":30107,"activeCount":99},[],{"trials":30109,"activeCount":99},[],{"trials":30111,"activeCount":99},[30112],{"nctId":30113,"briefTitle":30114,"status":105,"phases":30115,"primaryCompletion":22878,"completion":22878,"start":22064,"conditions":30116,"interventions":30117},"NCT00543530","Pediatric Expanded Access Program-Oral Solution (0831-908)",[89],[27],[30102],{"trials":30119,"activeCount":99},[],{"trials":30121,"activeCount":99},[],{"intervention":17719,"totalTrials":224,"cells":30123},{"EARLY_PHASE1":30124,"PHASE1":30126,"PHASE2":30128,"PHASE3":30130,"PHASE4":30136,"NA":30138},{"trials":30125,"activeCount":99},[],{"trials":30127,"activeCount":99},[],{"trials":30129,"activeCount":99},[],{"trials":30131,"activeCount":99},[30132],{"nctId":17711,"briefTitle":17712,"status":105,"phases":30133,"primaryCompletion":1600,"completion":1600,"start":17714,"enrollment":17715,"conditions":30134,"interventions":30135},[89],[16472],[16474,17718,17700,17719,16479],{"trials":30137,"activeCount":99},[],{"trials":30139,"activeCount":99},[],{"intervention":30141,"totalTrials":224,"cells":30142},"Comparator: Quadrivalent Human Papillomavirus",{"EARLY_PHASE1":30143,"PHASE1":30145,"PHASE2":30147,"PHASE3":30149,"PHASE4":30159,"NA":30161},{"trials":30144,"activeCount":99},[],{"trials":30146,"activeCount":99},[],{"trials":30148,"activeCount":99},[],{"trials":30150,"activeCount":99},[30151],{"nctId":30152,"briefTitle":30153,"status":105,"phases":30154,"primaryCompletion":14409,"completion":14409,"start":8621,"enrollment":30155,"conditions":30156,"interventions":30157},"NCT00337428","Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)",[89],843,[25777,20573,20574,25778,23025],[30141,30141,30158,30158],"Comparator: REPEVAX™",{"trials":30160,"activeCount":99},[],{"trials":30162,"activeCount":99},[],{"intervention":30158,"totalTrials":224,"cells":30164},{"EARLY_PHASE1":30165,"PHASE1":30167,"PHASE2":30169,"PHASE3":30171,"PHASE4":30177,"NA":30179},{"trials":30166,"activeCount":99},[],{"trials":30168,"activeCount":99},[],{"trials":30170,"activeCount":99},[],{"trials":30172,"activeCount":99},[30173],{"nctId":30152,"briefTitle":30153,"status":105,"phases":30174,"primaryCompletion":14409,"completion":14409,"start":8621,"enrollment":30155,"conditions":30175,"interventions":30176},[89],[25777,20573,20574,25778,23025],[30141,30141,30158,30158],{"trials":30178,"activeCount":99},[],{"trials":30180,"activeCount":99},[],{"intervention":5298,"totalTrials":224,"cells":30182},{"EARLY_PHASE1":30183,"PHASE1":30185,"PHASE2":30187,"PHASE3":30189,"PHASE4":30195,"NA":30197},{"trials":30184,"activeCount":99},[],{"trials":30186,"activeCount":99},[],{"trials":30188,"activeCount":99},[],{"trials":30190,"activeCount":99},[30191],{"nctId":5288,"briefTitle":5289,"status":105,"phases":30192,"primaryCompletion":5291,"completion":5292,"start":5293,"enrollment":5294,"conditions":30193,"interventions":30194},[89],[5296],[4424,5298,4426,5299,4426],{"trials":30196,"activeCount":99},[],{"trials":30198,"activeCount":99},[],{"intervention":5299,"totalTrials":224,"cells":30200},{"EARLY_PHASE1":30201,"PHASE1":30203,"PHASE2":30205,"PHASE3":30207,"PHASE4":30213,"NA":30215},{"trials":30202,"activeCount":99},[],{"trials":30204,"activeCount":99},[],{"trials":30206,"activeCount":99},[],{"trials":30208,"activeCount":99},[30209],{"nctId":5288,"briefTitle":5289,"status":105,"phases":30210,"primaryCompletion":5291,"completion":5292,"start":5293,"enrollment":5294,"conditions":30211,"interventions":30212},[89],[5296],[4424,5298,4426,5299,4426],{"trials":30214,"activeCount":99},[],{"trials":30216,"activeCount":99},[],{"intervention":30218,"totalTrials":224,"cells":30219},"Gardasil™",{"EARLY_PHASE1":30220,"PHASE1":30222,"PHASE2":30224,"PHASE3":30226,"PHASE4":30234,"NA":30236},{"trials":30221,"activeCount":99},[],{"trials":30223,"activeCount":99},[],{"trials":30225,"activeCount":99},[],{"trials":30227,"activeCount":99},[30228],{"nctId":30229,"briefTitle":30230,"status":105,"phases":30231,"primaryCompletion":14705,"completion":14705,"start":17095,"enrollment":13927,"conditions":30232,"interventions":30233},"NCT00157950","Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)",[89],[7076],[30218],{"trials":30235,"activeCount":99},[],{"trials":30237,"activeCount":99},[],{"intervention":15420,"totalTrials":224,"cells":30239},{"EARLY_PHASE1":30240,"PHASE1":30242,"PHASE2":30244,"PHASE3":30246,"PHASE4":30252,"NA":30254},{"trials":30241,"activeCount":99},[],{"trials":30243,"activeCount":99},[],{"trials":30245,"activeCount":99},[],{"trials":30247,"activeCount":99},[30248],{"nctId":15413,"briefTitle":15414,"status":150,"phases":30249,"primaryCompletion":14353,"completion":14353,"start":14409,"enrollment":15416,"conditions":30250,"interventions":30251},[88,89],[15418],[4994,15420,15421,14331],{"trials":30253,"activeCount":99},[],{"trials":30255,"activeCount":99},[],{"intervention":15421,"totalTrials":224,"cells":30257},{"EARLY_PHASE1":30258,"PHASE1":30260,"PHASE2":30262,"PHASE3":30264,"PHASE4":30270,"NA":30272},{"trials":30259,"activeCount":99},[],{"trials":30261,"activeCount":99},[],{"trials":30263,"activeCount":99},[],{"trials":30265,"activeCount":99},[30266],{"nctId":15413,"briefTitle":15414,"status":150,"phases":30267,"primaryCompletion":14353,"completion":14353,"start":14409,"enrollment":15416,"conditions":30268,"interventions":30269},[88,89],[15418],[4994,15420,15421,14331],{"trials":30271,"activeCount":99},[],{"trials":30273,"activeCount":99},[],{"intervention":24243,"totalTrials":224,"cells":30275},{"EARLY_PHASE1":30276,"PHASE1":30278,"PHASE2":30280,"PHASE3":30282,"PHASE4":30288,"NA":30290},{"trials":30277,"activeCount":99},[],{"trials":30279,"activeCount":99},[],{"trials":30281,"activeCount":99},[],{"trials":30283,"activeCount":99},[30284],{"nctId":24238,"briefTitle":24239,"status":105,"phases":30285,"primaryCompletion":14531,"completion":14531,"start":14593,"enrollment":13715,"conditions":30286,"interventions":30287},[89],[17137,17147],[24243,17139,24244,24245],{"trials":30289,"activeCount":99},[],{"trials":30291,"activeCount":99},[],{"intervention":24244,"totalTrials":224,"cells":30293},{"EARLY_PHASE1":30294,"PHASE1":30296,"PHASE2":30298,"PHASE3":30300,"PHASE4":30306,"NA":30308},{"trials":30295,"activeCount":99},[],{"trials":30297,"activeCount":99},[],{"trials":30299,"activeCount":99},[],{"trials":30301,"activeCount":99},[30302],{"nctId":24238,"briefTitle":24239,"status":105,"phases":30303,"primaryCompletion":14531,"completion":14531,"start":14593,"enrollment":13715,"conditions":30304,"interventions":30305},[89],[17137,17147],[24243,17139,24244,24245],{"trials":30307,"activeCount":99},[],{"trials":30309,"activeCount":99},[],{"intervention":24245,"totalTrials":224,"cells":30311},{"EARLY_PHASE1":30312,"PHASE1":30314,"PHASE2":30316,"PHASE3":30318,"PHASE4":30324,"NA":30326},{"trials":30313,"activeCount":99},[],{"trials":30315,"activeCount":99},[],{"trials":30317,"activeCount":99},[],{"trials":30319,"activeCount":99},[30320],{"nctId":24238,"briefTitle":24239,"status":105,"phases":30321,"primaryCompletion":14531,"completion":14531,"start":14593,"enrollment":13715,"conditions":30322,"interventions":30323},[89],[17137,17147],[24243,17139,24244,24245],{"trials":30325,"activeCount":99},[],{"trials":30327,"activeCount":99},[],{"intervention":15926,"totalTrials":224,"cells":30329},{"EARLY_PHASE1":30330,"PHASE1":30332,"PHASE2":30334,"PHASE3":30336,"PHASE4":30342,"NA":30344},{"trials":30331,"activeCount":99},[],{"trials":30333,"activeCount":99},[],{"trials":30335,"activeCount":99},[],{"trials":30337,"activeCount":99},[30338],{"nctId":15917,"briefTitle":15918,"status":150,"phases":30339,"primaryCompletion":15920,"completion":15920,"start":15921,"enrollment":15922,"conditions":30340,"interventions":30341},[88,89],[21,15924],[15784,15926,15859,14925],{"trials":30343,"activeCount":99},[],{"trials":30345,"activeCount":99},[],{"intervention":20381,"totalTrials":224,"cells":30347},{"EARLY_PHASE1":30348,"PHASE1":30350,"PHASE2":30352,"PHASE3":30354,"PHASE4":30360,"NA":30362},{"trials":30349,"activeCount":99},[],{"trials":30351,"activeCount":99},[],{"trials":30353,"activeCount":99},[],{"trials":30355,"activeCount":99},[30356],{"nctId":20374,"briefTitle":20375,"status":105,"phases":30357,"primaryCompletion":2694,"completion":2694,"start":20377,"enrollment":20378,"conditions":30358,"interventions":30359},[89],[15],[13883,14147,13885,20381,20382,20383],{"trials":30361,"activeCount":99},[],{"trials":30363,"activeCount":99},[],{"intervention":20382,"totalTrials":224,"cells":30365},{"EARLY_PHASE1":30366,"PHASE1":30368,"PHASE2":30370,"PHASE3":30372,"PHASE4":30378,"NA":30380},{"trials":30367,"activeCount":99},[],{"trials":30369,"activeCount":99},[],{"trials":30371,"activeCount":99},[],{"trials":30373,"activeCount":99},[30374],{"nctId":20374,"briefTitle":20375,"status":105,"phases":30375,"primaryCompletion":2694,"completion":2694,"start":20377,"enrollment":20378,"conditions":30376,"interventions":30377},[89],[15],[13883,14147,13885,20381,20382,20383],{"trials":30379,"activeCount":99},[],{"trials":30381,"activeCount":99},[],{"intervention":20383,"totalTrials":224,"cells":30383},{"EARLY_PHASE1":30384,"PHASE1":30386,"PHASE2":30388,"PHASE3":30390,"PHASE4":30396,"NA":30398},{"trials":30385,"activeCount":99},[],{"trials":30387,"activeCount":99},[],{"trials":30389,"activeCount":99},[],{"trials":30391,"activeCount":99},[30392],{"nctId":20374,"briefTitle":20375,"status":105,"phases":30393,"primaryCompletion":2694,"completion":2694,"start":20377,"enrollment":20378,"conditions":30394,"interventions":30395},[89],[15],[13883,14147,13885,20381,20382,20383],{"trials":30397,"activeCount":99},[],{"trials":30399,"activeCount":99},[],{"intervention":30401,"totalTrials":224,"cells":30402},"Hepatitis A Vaccine, Purified Inactivated",{"EARLY_PHASE1":30403,"PHASE1":30405,"PHASE2":30407,"PHASE3":30409,"PHASE4":30418,"NA":30420},{"trials":30404,"activeCount":99},[],{"trials":30406,"activeCount":99},[],{"trials":30408,"activeCount":99},[],{"trials":30410,"activeCount":99},[30411],{"nctId":30412,"briefTitle":30413,"status":105,"phases":30414,"primaryCompletion":6309,"completion":6309,"start":8620,"enrollment":1479,"conditions":30415,"interventions":30417},"NCT00835380","A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069)",[89],[30416],"Hepatitis A Virus Infection",[30401],{"trials":30419,"activeCount":99},[],{"trials":30421,"activeCount":99},[],{"intervention":30423,"totalTrials":224,"cells":30424},"ERN\u002FLRPT",{"EARLY_PHASE1":30425,"PHASE1":30427,"PHASE2":30429,"PHASE3":30431,"PHASE4":30439,"NA":30441},{"trials":30426,"activeCount":99},[],{"trials":30428,"activeCount":99},[],{"trials":30430,"activeCount":99},[],{"trials":30432,"activeCount":99},[30433],{"nctId":30434,"briefTitle":30435,"status":150,"phases":30436,"primaryCompletion":20411,"completion":20411,"start":12985,"enrollment":27510,"conditions":30437,"interventions":30438},"NCT01414166","Niacin\u002FLaropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)",[89],[14337],[30423],{"trials":30440,"activeCount":99},[],{"trials":30442,"activeCount":99},[],{"intervention":22561,"totalTrials":224,"cells":30444},{"EARLY_PHASE1":30445,"PHASE1":30447,"PHASE2":30449,"PHASE3":30451,"PHASE4":30457,"NA":30459},{"trials":30446,"activeCount":99},[],{"trials":30448,"activeCount":99},[],{"trials":30450,"activeCount":99},[],{"trials":30452,"activeCount":99},[30453],{"nctId":22552,"briefTitle":22553,"status":105,"phases":30454,"primaryCompletion":22555,"completion":22555,"start":22556,"enrollment":22557,"conditions":30455,"interventions":30456},[89],[15],[22560,22561,13885,22562],{"trials":30458,"activeCount":99},[],{"trials":30460,"activeCount":99},[],{"intervention":22562,"totalTrials":224,"cells":30462},{"EARLY_PHASE1":30463,"PHASE1":30465,"PHASE2":30467,"PHASE3":30469,"PHASE4":30475,"NA":30477},{"trials":30464,"activeCount":99},[],{"trials":30466,"activeCount":99},[],{"trials":30468,"activeCount":99},[],{"trials":30470,"activeCount":99},[30471],{"nctId":22552,"briefTitle":22553,"status":105,"phases":30472,"primaryCompletion":22555,"completion":22555,"start":22556,"enrollment":22557,"conditions":30473,"interventions":30474},[89],[15],[22560,22561,13885,22562],{"trials":30476,"activeCount":99},[],{"trials":30478,"activeCount":99},[],{"intervention":21188,"totalTrials":224,"cells":30480},{"EARLY_PHASE1":30481,"PHASE1":30483,"PHASE2":30485,"PHASE3":30487,"PHASE4":30493,"NA":30495},{"trials":30482,"activeCount":99},[],{"trials":30484,"activeCount":99},[],{"trials":30486,"activeCount":99},[],{"trials":30488,"activeCount":99},[30489],{"nctId":21181,"briefTitle":21182,"status":105,"phases":30490,"primaryCompletion":21184,"completion":21184,"start":21185,"enrollment":1968,"conditions":30491,"interventions":30492},[89],[21170],[21153,21188],{"trials":30494,"activeCount":99},[],{"trials":30496,"activeCount":99},[],{"intervention":30498,"totalTrials":224,"cells":30499},"Semustine",{"EARLY_PHASE1":30500,"PHASE1":30502,"PHASE2":30504,"PHASE3":30506,"PHASE4":30517,"NA":30519},{"trials":30501,"activeCount":99},[],{"trials":30503,"activeCount":99},[],{"trials":30505,"activeCount":99},[],{"trials":30507,"activeCount":99},[30508],{"nctId":30509,"briefTitle":30510,"status":105,"phases":30511,"primaryCompletion":30512,"completion":30512,"start":30513,"enrollment":25889,"conditions":30514,"interventions":30516},"NCT00335075","Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)",[89],"2006-02-23","2005-03-02",[992,30515],"Astrocytoma",[1390,30498],{"trials":30518,"activeCount":99},[],{"trials":30520,"activeCount":99},[],{"intervention":20935,"totalTrials":224,"cells":30522},{"EARLY_PHASE1":30523,"PHASE1":30525,"PHASE2":30527,"PHASE3":30529,"PHASE4":30535,"NA":30537},{"trials":30524,"activeCount":99},[],{"trials":30526,"activeCount":99},[],{"trials":30528,"activeCount":99},[],{"trials":30530,"activeCount":99},[30531],{"nctId":20928,"briefTitle":20929,"status":105,"phases":30532,"primaryCompletion":13071,"completion":13071,"start":20931,"enrollment":20932,"conditions":30533,"interventions":30534},[89],[15],[16014,20935],{"trials":30536,"activeCount":99},[],{"trials":30538,"activeCount":99},[],{"intervention":23095,"totalTrials":224,"cells":30540},{"EARLY_PHASE1":30541,"PHASE1":30543,"PHASE2":30545,"PHASE3":30547,"PHASE4":30553,"NA":30555},{"trials":30542,"activeCount":99},[],{"trials":30544,"activeCount":99},[],{"trials":30546,"activeCount":99},[],{"trials":30548,"activeCount":99},[30549],{"nctId":23087,"briefTitle":23088,"status":105,"phases":30550,"primaryCompletion":23090,"completion":23090,"start":23091,"enrollment":347,"conditions":30551,"interventions":30552},[89],[23093],[6802,23095],{"trials":30554,"activeCount":99},[],{"trials":30556,"activeCount":99},[],{"intervention":30558,"totalTrials":224,"cells":30559},"MK0991, caspofungin acetate \u002F Duration of Treatment:",{"EARLY_PHASE1":30560,"PHASE1":30562,"PHASE2":30564,"PHASE3":30566,"PHASE4":30574,"NA":30576},{"trials":30561,"activeCount":99},[],{"trials":30563,"activeCount":99},[],{"trials":30565,"activeCount":99},[],{"trials":30567,"activeCount":99},[30568],{"nctId":30569,"briefTitle":30570,"status":105,"phases":30571,"primaryCompletion":12814,"completion":12814,"start":14483,"enrollment":2231,"conditions":30572,"interventions":30573},"NCT00548080","Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia (0991-055)",[89],[17830],[30558],{"trials":30575,"activeCount":99},[],{"trials":30577,"activeCount":99},[],{"intervention":30579,"totalTrials":224,"cells":30580},"V260",{"EARLY_PHASE1":30581,"PHASE1":30583,"PHASE2":30585,"PHASE3":30587,"PHASE4":30599,"NA":30601},{"trials":30582,"activeCount":99},[],{"trials":30584,"activeCount":99},[],{"trials":30586,"activeCount":99},[],{"trials":30588,"activeCount":99},[30589],{"nctId":30590,"briefTitle":30591,"status":105,"phases":30592,"primaryCompletion":1121,"completion":1121,"start":30593,"enrollment":30594,"conditions":30595,"interventions":30596},"NCT02062385","Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)",[89],"2014-05-30",4040,[14447],[30579,30597,30598],"OPV","DTaP",{"trials":30600,"activeCount":99},[],{"trials":30602,"activeCount":99},[],{"intervention":30597,"totalTrials":224,"cells":30604},{"EARLY_PHASE1":30605,"PHASE1":30607,"PHASE2":30609,"PHASE3":30611,"PHASE4":30617,"NA":30619},{"trials":30606,"activeCount":99},[],{"trials":30608,"activeCount":99},[],{"trials":30610,"activeCount":99},[],{"trials":30612,"activeCount":99},[30613],{"nctId":30590,"briefTitle":30591,"status":105,"phases":30614,"primaryCompletion":1121,"completion":1121,"start":30593,"enrollment":30594,"conditions":30615,"interventions":30616},[89],[14447],[30579,30597,30598],{"trials":30618,"activeCount":99},[],{"trials":30620,"activeCount":99},[],{"intervention":30598,"totalTrials":224,"cells":30622},{"EARLY_PHASE1":30623,"PHASE1":30625,"PHASE2":30627,"PHASE3":30629,"PHASE4":30635,"NA":30637},{"trials":30624,"activeCount":99},[],{"trials":30626,"activeCount":99},[],{"trials":30628,"activeCount":99},[],{"trials":30630,"activeCount":99},[30631],{"nctId":30590,"briefTitle":30591,"status":105,"phases":30632,"primaryCompletion":1121,"completion":1121,"start":30593,"enrollment":30594,"conditions":30633,"interventions":30634},[89],[14447],[30579,30597,30598],{"trials":30636,"activeCount":99},[],{"trials":30638,"activeCount":99},[],{"intervention":30640,"totalTrials":224,"cells":30641},"MTX",{"EARLY_PHASE1":30642,"PHASE1":30644,"PHASE2":30646,"PHASE3":30648,"PHASE4":30658,"NA":30660},{"trials":30643,"activeCount":99},[],{"trials":30645,"activeCount":99},[],{"trials":30647,"activeCount":99},[],{"trials":30649,"activeCount":99},[30650],{"nctId":30651,"briefTitle":30652,"status":105,"phases":30653,"primaryCompletion":30654,"completion":30654,"start":30655,"enrollment":5196,"conditions":30656,"interventions":30657},"NCT00202852","A Placebo-Controlled, Double-Blinded, Randomized Trial of Remicade in Korean Patients With Rheumatoid Arthritis Despite Methotrexate (Study P04280)(COMPLETED)",[89],"2006-03-01","2005-06-01",[7197],[30640,8594,30640],{"trials":30659,"activeCount":99},[],{"trials":30661,"activeCount":99},[],{"intervention":30663,"totalTrials":224,"cells":30664},"RotaTeq",{"EARLY_PHASE1":30665,"PHASE1":30667,"PHASE2":30669,"PHASE3":30671,"PHASE4":30683,"NA":30685},{"trials":30666,"activeCount":99},[],{"trials":30668,"activeCount":99},[],{"trials":30670,"activeCount":99},[],{"trials":30672,"activeCount":99},[30673],{"nctId":30674,"briefTitle":30675,"status":105,"phases":30676,"primaryCompletion":30677,"completion":30677,"start":30678,"enrollment":1150,"conditions":30679,"interventions":30681},"NCT04481191","Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)",[89],"2021-05-08","2020-08-25",[30680],"Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9",[30663,30682],"IPV",{"trials":30684,"activeCount":99},[],{"trials":30686,"activeCount":99},[],{"intervention":30682,"totalTrials":224,"cells":30688},{"EARLY_PHASE1":30689,"PHASE1":30691,"PHASE2":30693,"PHASE3":30695,"PHASE4":30701,"NA":30703},{"trials":30690,"activeCount":99},[],{"trials":30692,"activeCount":99},[],{"trials":30694,"activeCount":99},[],{"trials":30696,"activeCount":99},[30697],{"nctId":30674,"briefTitle":30675,"status":105,"phases":30698,"primaryCompletion":30677,"completion":30677,"start":30678,"enrollment":1150,"conditions":30699,"interventions":30700},[89],[30680],[30663,30682],{"trials":30702,"activeCount":99},[],{"trials":30704,"activeCount":99},[],{"intervention":25377,"totalTrials":224,"cells":30706},{"EARLY_PHASE1":30707,"PHASE1":30709,"PHASE2":30711,"PHASE3":30713,"PHASE4":30719,"NA":30721},{"trials":30708,"activeCount":99},[],{"trials":30710,"activeCount":99},[],{"trials":30712,"activeCount":99},[],{"trials":30714,"activeCount":99},[30715],{"nctId":25369,"briefTitle":25370,"status":105,"phases":30716,"primaryCompletion":25372,"completion":1357,"start":25373,"enrollment":25374,"conditions":30717,"interventions":30718},[89],[7342],[25358,25377],{"trials":30720,"activeCount":99},[],{"trials":30722,"activeCount":99},[],{"intervention":14180,"totalTrials":224,"cells":30724},{"EARLY_PHASE1":30725,"PHASE1":30727,"PHASE2":30729,"PHASE3":30731,"PHASE4":30737,"NA":30739},{"trials":30726,"activeCount":99},[],{"trials":30728,"activeCount":99},[],{"trials":30730,"activeCount":99},[],{"trials":30732,"activeCount":99},[30733],{"nctId":14172,"briefTitle":14173,"status":105,"phases":30734,"primaryCompletion":14175,"completion":14175,"start":14176,"enrollment":14177,"conditions":30735,"interventions":30736},[89],[15],[13883,14049,14180,4084],{"trials":30738,"activeCount":99},[],{"trials":30740,"activeCount":99},[],{"intervention":30742,"totalTrials":224,"cells":30743},"Comparator: Modified Process Vaccine",{"EARLY_PHASE1":30744,"PHASE1":30746,"PHASE2":30748,"PHASE3":30750,"PHASE4":30761,"NA":30763},{"trials":30745,"activeCount":99},[],{"trials":30747,"activeCount":99},[],{"trials":30749,"activeCount":99},[],{"trials":30751,"activeCount":99},[30752],{"nctId":30753,"briefTitle":30754,"status":105,"phases":30755,"primaryCompletion":14858,"completion":14858,"start":15038,"enrollment":30756,"conditions":30757,"interventions":30759},"NCT00441012","Study of Modified Process Hib\u002FHep B Vaccine in Infants (V121-019)(COMPLETED)",[89],546,[30758,17593],"Haemophilus Influenzae Type B",[30742,30760],"Comparator: COMVAX™",{"trials":30762,"activeCount":99},[],{"trials":30764,"activeCount":99},[],{"intervention":30760,"totalTrials":224,"cells":30766},{"EARLY_PHASE1":30767,"PHASE1":30769,"PHASE2":30771,"PHASE3":30773,"PHASE4":30779,"NA":30781},{"trials":30768,"activeCount":99},[],{"trials":30770,"activeCount":99},[],{"trials":30772,"activeCount":99},[],{"trials":30774,"activeCount":99},[30775],{"nctId":30753,"briefTitle":30754,"status":105,"phases":30776,"primaryCompletion":14858,"completion":14858,"start":15038,"enrollment":30756,"conditions":30777,"interventions":30778},[89],[30758,17593],[30742,30760],{"trials":30780,"activeCount":99},[],{"trials":30782,"activeCount":99},[],{"intervention":22386,"totalTrials":224,"cells":30784},{"EARLY_PHASE1":30785,"PHASE1":30787,"PHASE2":30789,"PHASE3":30791,"PHASE4":30797,"NA":30799},{"trials":30786,"activeCount":99},[],{"trials":30788,"activeCount":99},[],{"trials":30790,"activeCount":99},[],{"trials":30792,"activeCount":99},[30793],{"nctId":22377,"briefTitle":22378,"status":105,"phases":30794,"primaryCompletion":22380,"completion":22380,"start":22381,"enrollment":22382,"conditions":30795,"interventions":30796},[89],[14418,16417],[22385,13135,22386],{"trials":30798,"activeCount":99},[],{"trials":30800,"activeCount":99},[],{"intervention":15456,"totalTrials":224,"cells":30802},{"EARLY_PHASE1":30803,"PHASE1":30805,"PHASE2":30807,"PHASE3":30809,"PHASE4":30815,"NA":30817},{"trials":30804,"activeCount":99},[],{"trials":30806,"activeCount":99},[],{"trials":30808,"activeCount":99},[],{"trials":30810,"activeCount":99},[30811],{"nctId":15451,"briefTitle":15452,"status":150,"phases":30812,"primaryCompletion":14228,"completion":14228,"start":15156,"enrollment":1818,"conditions":30813,"interventions":30814},[89],[15],[15456,14331],{"trials":30816,"activeCount":99},[],{"trials":30818,"activeCount":99},[],{"intervention":2362,"totalTrials":224,"cells":30820},{"EARLY_PHASE1":30821,"PHASE1":30823,"PHASE2":30825,"PHASE3":30827,"PHASE4":30833,"NA":30835},{"trials":30822,"activeCount":99},[],{"trials":30824,"activeCount":99},[],{"trials":30826,"activeCount":99},[],{"trials":30828,"activeCount":99},[30829],{"nctId":2355,"briefTitle":2356,"status":105,"phases":30830,"primaryCompletion":2358,"completion":379,"start":2359,"enrollment":2335,"conditions":30831,"interventions":30832},[89],[867],[47,2362,386,390,1073],{"trials":30834,"activeCount":99},[],{"trials":30836,"activeCount":99},[],{"intervention":8606,"totalTrials":224,"cells":30838},{"EARLY_PHASE1":30839,"PHASE1":30841,"PHASE2":30843,"PHASE3":30845,"PHASE4":30851,"NA":30853},{"trials":30840,"activeCount":99},[],{"trials":30842,"activeCount":99},[],{"trials":30844,"activeCount":99},[],{"trials":30846,"activeCount":99},[30847],{"nctId":8598,"briefTitle":8599,"status":150,"phases":30848,"primaryCompletion":8601,"completion":8601,"start":8602,"enrollment":3308,"conditions":30849,"interventions":30850},[89],[8604],[8594,8606,2413,8606],{"trials":30852,"activeCount":99},[],{"trials":30854,"activeCount":99},[],{"intervention":30856,"totalTrials":224,"cells":30857},"RotaTeq™, rotavirus vaccine, live, oral, pentavalent",{"EARLY_PHASE1":30858,"PHASE1":30860,"PHASE2":30862,"PHASE3":30864,"PHASE4":30874,"NA":30876},{"trials":30859,"activeCount":99},[],{"trials":30861,"activeCount":99},[],{"trials":30863,"activeCount":99},[],{"trials":30865,"activeCount":99},[30866],{"nctId":30867,"briefTitle":30868,"status":105,"phases":30869,"primaryCompletion":14229,"completion":14229,"start":15054,"enrollment":30870,"conditions":30871,"interventions":30872},"NCT00092443","Dose Confirmation Efficacy Study (V260-007)",[89],1312,[15587],[30856,30873],"Comparator: Placebo matching RotaTeq™",{"trials":30875,"activeCount":99},[],{"trials":30877,"activeCount":99},[],{"intervention":30873,"totalTrials":224,"cells":30879},{"EARLY_PHASE1":30880,"PHASE1":30882,"PHASE2":30884,"PHASE3":30886,"PHASE4":30892,"NA":30894},{"trials":30881,"activeCount":99},[],{"trials":30883,"activeCount":99},[],{"trials":30885,"activeCount":99},[],{"trials":30887,"activeCount":99},[30888],{"nctId":30867,"briefTitle":30868,"status":105,"phases":30889,"primaryCompletion":14229,"completion":14229,"start":15054,"enrollment":30870,"conditions":30890,"interventions":30891},[89],[15587],[30856,30873],{"trials":30893,"activeCount":99},[],{"trials":30895,"activeCount":99},[],{"intervention":23681,"totalTrials":224,"cells":30897},{"EARLY_PHASE1":30898,"PHASE1":30900,"PHASE2":30902,"PHASE3":30904,"PHASE4":30910,"NA":30912},{"trials":30899,"activeCount":99},[],{"trials":30901,"activeCount":99},[],{"trials":30903,"activeCount":99},[],{"trials":30905,"activeCount":99},[30906],{"nctId":23674,"briefTitle":23675,"status":105,"phases":30907,"primaryCompletion":13890,"completion":13890,"start":14687,"enrollment":23677,"conditions":30908,"interventions":30909},[89],[16625],[23680,23681],{"trials":30911,"activeCount":99},[],{"trials":30913,"activeCount":99},[],{"intervention":30915,"totalTrials":224,"cells":30916},"Comparator: Varicella Zoster Virus Vaccine",{"EARLY_PHASE1":30917,"PHASE1":30919,"PHASE2":30921,"PHASE3":30923,"PHASE4":30932,"NA":30934},{"trials":30918,"activeCount":99},[],{"trials":30920,"activeCount":99},[],{"trials":30922,"activeCount":99},[],{"trials":30924,"activeCount":99},[30925],{"nctId":30926,"briefTitle":30927,"status":105,"phases":30928,"primaryCompletion":14229,"completion":14229,"start":22476,"enrollment":30929,"conditions":30930,"interventions":30931},"NCT00092417","Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)",[89],695,[18],[30915,30915],{"trials":30933,"activeCount":99},[],{"trials":30935,"activeCount":99},[],{"intervention":7131,"totalTrials":224,"cells":30937},{"EARLY_PHASE1":30938,"PHASE1":30940,"PHASE2":30942,"PHASE3":30944,"PHASE4":30950,"NA":30952},{"trials":30939,"activeCount":99},[],{"trials":30941,"activeCount":99},[],{"trials":30943,"activeCount":99},[],{"trials":30945,"activeCount":99},[30946],{"nctId":7123,"briefTitle":7124,"status":105,"phases":30947,"primaryCompletion":6186,"completion":6186,"start":7126,"enrollment":7127,"conditions":30948,"interventions":30949},[89],[7076,7129],[7104,7131],{"trials":30951,"activeCount":99},[],{"trials":30953,"activeCount":99},[],{"intervention":30955,"totalTrials":224,"cells":30956},"PEG-Intron™",{"EARLY_PHASE1":30957,"PHASE1":30959,"PHASE2":30961,"PHASE3":30963,"PHASE4":30974,"NA":30976},{"trials":30958,"activeCount":99},[],{"trials":30960,"activeCount":99},[],{"trials":30962,"activeCount":99},[],{"trials":30964,"activeCount":99},[30965],{"nctId":30966,"briefTitle":30967,"status":150,"phases":30968,"primaryCompletion":30969,"completion":30969,"start":30970,"enrollment":13968,"conditions":30971,"interventions":30972},"NCT01641926","A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)",[89],"2016-01-21","2012-11-26",[17614],[30955,30973],"PEGASYS™",{"trials":30975,"activeCount":99},[],{"trials":30977,"activeCount":99},[],{"intervention":30973,"totalTrials":224,"cells":30979},{"EARLY_PHASE1":30980,"PHASE1":30982,"PHASE2":30984,"PHASE3":30986,"PHASE4":30992,"NA":30994},{"trials":30981,"activeCount":99},[],{"trials":30983,"activeCount":99},[],{"trials":30985,"activeCount":99},[],{"trials":30987,"activeCount":99},[30988],{"nctId":30966,"briefTitle":30967,"status":150,"phases":30989,"primaryCompletion":30969,"completion":30969,"start":30970,"enrollment":13968,"conditions":30990,"interventions":30991},[89],[17614],[30955,30973],{"trials":30993,"activeCount":99},[],{"trials":30995,"activeCount":99},[],{"intervention":22225,"totalTrials":224,"cells":30997},{"EARLY_PHASE1":30998,"PHASE1":31000,"PHASE2":31002,"PHASE3":31004,"PHASE4":31010,"NA":31012},{"trials":30999,"activeCount":99},[],{"trials":31001,"activeCount":99},[],{"trials":31003,"activeCount":99},[],{"trials":31005,"activeCount":99},[31006],{"nctId":22219,"briefTitle":22220,"status":105,"phases":31007,"primaryCompletion":12984,"completion":12984,"start":15794,"enrollment":7686,"conditions":31008,"interventions":31009},[89],[18450,22223],[22194,22225,22226],{"trials":31011,"activeCount":99},[],{"trials":31013,"activeCount":99},[],{"intervention":20084,"totalTrials":224,"cells":31015},{"EARLY_PHASE1":31016,"PHASE1":31018,"PHASE2":31020,"PHASE3":31022,"PHASE4":31028,"NA":31030},{"trials":31017,"activeCount":99},[],{"trials":31019,"activeCount":99},[],{"trials":31021,"activeCount":99},[],{"trials":31023,"activeCount":99},[31024],{"nctId":20077,"briefTitle":20078,"status":150,"phases":31025,"primaryCompletion":20080,"completion":20080,"start":152,"enrollment":20081,"conditions":31026,"interventions":31027},[89],[19998,20073],[19981,20084],{"trials":31029,"activeCount":99},[],{"trials":31031,"activeCount":99},[],{"intervention":25620,"totalTrials":224,"cells":31033},{"EARLY_PHASE1":31034,"PHASE1":31036,"PHASE2":31038,"PHASE3":31040,"PHASE4":31046,"NA":31048},{"trials":31035,"activeCount":99},[],{"trials":31037,"activeCount":99},[],{"trials":31039,"activeCount":99},[],{"trials":31041,"activeCount":99},[31042],{"nctId":25612,"briefTitle":25613,"status":105,"phases":31043,"primaryCompletion":25615,"completion":25615,"start":25616,"enrollment":7678,"conditions":31044,"interventions":31045},[89],[25618],[25620,25621,25622,25623,25624,25471],{"trials":31047,"activeCount":99},[],{"trials":31049,"activeCount":99},[],{"intervention":25621,"totalTrials":224,"cells":31051},{"EARLY_PHASE1":31052,"PHASE1":31054,"PHASE2":31056,"PHASE3":31058,"PHASE4":31064,"NA":31066},{"trials":31053,"activeCount":99},[],{"trials":31055,"activeCount":99},[],{"trials":31057,"activeCount":99},[],{"trials":31059,"activeCount":99},[31060],{"nctId":25612,"briefTitle":25613,"status":105,"phases":31061,"primaryCompletion":25615,"completion":25615,"start":25616,"enrollment":7678,"conditions":31062,"interventions":31063},[89],[25618],[25620,25621,25622,25623,25624,25471],{"trials":31065,"activeCount":99},[],{"trials":31067,"activeCount":99},[],{"intervention":25622,"totalTrials":224,"cells":31069},{"EARLY_PHASE1":31070,"PHASE1":31072,"PHASE2":31074,"PHASE3":31076,"PHASE4":31082,"NA":31084},{"trials":31071,"activeCount":99},[],{"trials":31073,"activeCount":99},[],{"trials":31075,"activeCount":99},[],{"trials":31077,"activeCount":99},[31078],{"nctId":25612,"briefTitle":25613,"status":105,"phases":31079,"primaryCompletion":25615,"completion":25615,"start":25616,"enrollment":7678,"conditions":31080,"interventions":31081},[89],[25618],[25620,25621,25622,25623,25624,25471],{"trials":31083,"activeCount":99},[],{"trials":31085,"activeCount":99},[],{"intervention":25623,"totalTrials":224,"cells":31087},{"EARLY_PHASE1":31088,"PHASE1":31090,"PHASE2":31092,"PHASE3":31094,"PHASE4":31100,"NA":31102},{"trials":31089,"activeCount":99},[],{"trials":31091,"activeCount":99},[],{"trials":31093,"activeCount":99},[],{"trials":31095,"activeCount":99},[31096],{"nctId":25612,"briefTitle":25613,"status":105,"phases":31097,"primaryCompletion":25615,"completion":25615,"start":25616,"enrollment":7678,"conditions":31098,"interventions":31099},[89],[25618],[25620,25621,25622,25623,25624,25471],{"trials":31101,"activeCount":99},[],{"trials":31103,"activeCount":99},[],{"intervention":25624,"totalTrials":224,"cells":31105},{"EARLY_PHASE1":31106,"PHASE1":31108,"PHASE2":31110,"PHASE3":31112,"PHASE4":31118,"NA":31120},{"trials":31107,"activeCount":99},[],{"trials":31109,"activeCount":99},[],{"trials":31111,"activeCount":99},[],{"trials":31113,"activeCount":99},[31114],{"nctId":25612,"briefTitle":25613,"status":105,"phases":31115,"primaryCompletion":25615,"completion":25615,"start":25616,"enrollment":7678,"conditions":31116,"interventions":31117},[89],[25618],[25620,25621,25622,25623,25624,25471],{"trials":31119,"activeCount":99},[],{"trials":31121,"activeCount":99},[],{"intervention":15482,"totalTrials":224,"cells":31123},{"EARLY_PHASE1":31124,"PHASE1":31126,"PHASE2":31128,"PHASE3":31130,"PHASE4":31136,"NA":31138},{"trials":31125,"activeCount":99},[],{"trials":31127,"activeCount":99},[],{"trials":31129,"activeCount":99},[],{"trials":31131,"activeCount":99},[31132],{"nctId":15476,"briefTitle":15477,"status":105,"phases":31133,"primaryCompletion":5281,"completion":5281,"start":14324,"enrollment":15479,"conditions":31134,"interventions":31135},[89],[14395,13187],[15482,14331,15483],{"trials":31137,"activeCount":99},[],{"trials":31139,"activeCount":99},[],{"intervention":15483,"totalTrials":224,"cells":31141},{"EARLY_PHASE1":31142,"PHASE1":31144,"PHASE2":31146,"PHASE3":31148,"PHASE4":31154,"NA":31156},{"trials":31143,"activeCount":99},[],{"trials":31145,"activeCount":99},[],{"trials":31147,"activeCount":99},[],{"trials":31149,"activeCount":99},[31150],{"nctId":15476,"briefTitle":15477,"status":105,"phases":31151,"primaryCompletion":5281,"completion":5281,"start":14324,"enrollment":15479,"conditions":31152,"interventions":31153},[89],[14395,13187],[15482,14331,15483],{"trials":31155,"activeCount":99},[],{"trials":31157,"activeCount":99},[],{"intervention":25653,"totalTrials":224,"cells":31159},{"EARLY_PHASE1":31160,"PHASE1":31162,"PHASE2":31164,"PHASE3":31166,"PHASE4":31172,"NA":31174},{"trials":31161,"activeCount":99},[],{"trials":31163,"activeCount":99},[],{"trials":31165,"activeCount":99},[],{"trials":31167,"activeCount":99},[31168],{"nctId":25645,"briefTitle":25646,"status":105,"phases":31169,"primaryCompletion":6101,"completion":6101,"start":25648,"enrollment":25649,"conditions":31170,"interventions":31171},[89],[25651],[25653,25634,25654,25655],{"trials":31173,"activeCount":99},[],{"trials":31175,"activeCount":99},[],{"intervention":31177,"totalTrials":224,"cells":31178},"Grazoprevir 100mg \u002F Elbasvir 50 mg FDC",{"EARLY_PHASE1":31179,"PHASE1":31181,"PHASE2":31183,"PHASE3":31185,"PHASE4":31195,"NA":31197},{"trials":31180,"activeCount":99},[],{"trials":31182,"activeCount":99},[],{"trials":31184,"activeCount":99},[],{"trials":31186,"activeCount":99},[31187],{"nctId":31188,"briefTitle":31189,"status":105,"phases":31190,"primaryCompletion":31191,"completion":31192,"start":24351,"enrollment":5294,"conditions":31193,"interventions":31194},"NCT02105467","Study of Efficacy and Safety of Grazoprevir (MK-5172)\u002FElbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)",[89],"2015-02-26","2015-09-06",[20433],[31177],{"trials":31196,"activeCount":99},[],{"trials":31198,"activeCount":99},[],{"intervention":25547,"totalTrials":224,"cells":31200},{"EARLY_PHASE1":31201,"PHASE1":31203,"PHASE2":31205,"PHASE3":31207,"PHASE4":31213,"NA":31215},{"trials":31202,"activeCount":99},[],{"trials":31204,"activeCount":99},[],{"trials":31206,"activeCount":99},[],{"trials":31208,"activeCount":99},[31209],{"nctId":25541,"briefTitle":25542,"status":105,"phases":31210,"primaryCompletion":1712,"completion":1712,"start":25544,"enrollment":7797,"conditions":31211,"interventions":31212},[89],[20767],[25547,25521,25539],{"trials":31214,"activeCount":99},[],{"trials":31216,"activeCount":99},[],{"intervention":20612,"totalTrials":224,"cells":31218},{"EARLY_PHASE1":31219,"PHASE1":31221,"PHASE2":31223,"PHASE3":31225,"PHASE4":31231,"NA":31233},{"trials":31220,"activeCount":99},[],{"trials":31222,"activeCount":99},[],{"trials":31224,"activeCount":99},[],{"trials":31226,"activeCount":99},[31227],{"nctId":20605,"briefTitle":20606,"status":105,"phases":31228,"primaryCompletion":20608,"completion":20608,"start":13102,"enrollment":20609,"conditions":31229,"interventions":31230},[89],[14625,20584],[14449,20612],{"trials":31232,"activeCount":99},[],{"trials":31234,"activeCount":99},[],{"intervention":23503,"totalTrials":224,"cells":31236},{"EARLY_PHASE1":31237,"PHASE1":31239,"PHASE2":31241,"PHASE3":31243,"PHASE4":31249,"NA":31251},{"trials":31238,"activeCount":99},[],{"trials":31240,"activeCount":99},[],{"trials":31242,"activeCount":99},[],{"trials":31244,"activeCount":99},[31245],{"nctId":23497,"briefTitle":23498,"status":105,"phases":31246,"primaryCompletion":14228,"completion":14228,"start":14976,"enrollment":8175,"conditions":31247,"interventions":31248},[89],[23501],[23503,5154],{"trials":31250,"activeCount":99},[],{"trials":31252,"activeCount":99},[],{"intervention":15935,"totalTrials":224,"cells":31254},{"EARLY_PHASE1":31255,"PHASE1":31257,"PHASE2":31259,"PHASE3":31261,"PHASE4":31267,"NA":31269},{"trials":31256,"activeCount":99},[],{"trials":31258,"activeCount":99},[],{"trials":31260,"activeCount":99},[],{"trials":31262,"activeCount":99},[31263],{"nctId":15928,"briefTitle":15929,"status":105,"phases":31264,"primaryCompletion":4990,"completion":4990,"start":13102,"enrollment":15931,"conditions":31265,"interventions":31266},[89],[21],[15784,15934,14925,15935],{"trials":31268,"activeCount":99},[],{"trials":31270,"activeCount":99},[],{"intervention":25470,"totalTrials":224,"cells":31272},{"EARLY_PHASE1":31273,"PHASE1":31275,"PHASE2":31277,"PHASE3":31279,"PHASE4":31285,"NA":31287},{"trials":31274,"activeCount":99},[],{"trials":31276,"activeCount":99},[],{"trials":31278,"activeCount":99},[],{"trials":31280,"activeCount":99},[31281],{"nctId":25462,"briefTitle":25463,"status":105,"phases":31282,"primaryCompletion":4070,"completion":4070,"start":25465,"enrollment":17249,"conditions":31283,"interventions":31284},[89],[25467,25468],[25441,25470,25471],{"trials":31286,"activeCount":99},[],{"trials":31288,"activeCount":99},[],{"intervention":15509,"totalTrials":224,"cells":31290},{"EARLY_PHASE1":31291,"PHASE1":31293,"PHASE2":31295,"PHASE3":31297,"PHASE4":31303,"NA":31305},{"trials":31292,"activeCount":99},[],{"trials":31294,"activeCount":99},[],{"trials":31296,"activeCount":99},[],{"trials":31298,"activeCount":99},[31299],{"nctId":15502,"briefTitle":15503,"status":105,"phases":31300,"primaryCompletion":8620,"completion":8620,"start":15505,"enrollment":15506,"conditions":31301,"interventions":31302},[89],[7598,7610],[15509,14331],{"trials":31304,"activeCount":99},[],{"trials":31306,"activeCount":99},[],{"intervention":31308,"totalTrials":224,"cells":31309},"MK0826",{"EARLY_PHASE1":31310,"PHASE1":31312,"PHASE2":31314,"PHASE3":31316,"PHASE4":31326,"NA":31328},{"trials":31311,"activeCount":99},[],{"trials":31313,"activeCount":99},[],{"trials":31315,"activeCount":99},[],{"trials":31317,"activeCount":99},[31318],{"nctId":31319,"briefTitle":31320,"status":150,"phases":31321,"primaryCompletion":5280,"completion":5280,"start":14353,"enrollment":4555,"conditions":31322,"interventions":31324},"NCT00771316","Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection (0826-054)",[89],[31323],"Urinary Tract Infections",[31308,31325],"Comparator: meropenem",{"trials":31327,"activeCount":99},[],{"trials":31329,"activeCount":99},[],{"intervention":31325,"totalTrials":224,"cells":31331},{"EARLY_PHASE1":31332,"PHASE1":31334,"PHASE2":31336,"PHASE3":31338,"PHASE4":31344,"NA":31346},{"trials":31333,"activeCount":99},[],{"trials":31335,"activeCount":99},[],{"trials":31337,"activeCount":99},[],{"trials":31339,"activeCount":99},[31340],{"nctId":31319,"briefTitle":31320,"status":150,"phases":31341,"primaryCompletion":5280,"completion":5280,"start":14353,"enrollment":4555,"conditions":31342,"interventions":31343},[89],[31323],[31308,31325],{"trials":31345,"activeCount":99},[],{"trials":31347,"activeCount":99},[],{"intervention":11448,"totalTrials":224,"cells":31349},{"EARLY_PHASE1":31350,"PHASE1":31352,"PHASE2":31354,"PHASE3":31356,"PHASE4":31362,"NA":31364},{"trials":31351,"activeCount":99},[],{"trials":31353,"activeCount":99},[],{"trials":31355,"activeCount":99},[],{"trials":31357,"activeCount":99},[31358],{"nctId":11437,"briefTitle":11438,"status":105,"phases":31359,"primaryCompletion":11440,"completion":11441,"start":5477,"enrollment":11442,"conditions":31360,"interventions":31361},[89],[11444],[11357,11446,11447,11448],{"trials":31363,"activeCount":99},[],{"trials":31365,"activeCount":99},[],{"intervention":31367,"totalTrials":224,"cells":31368},"MK0217, alendronate sodium \u002F Duration of Treatment: 1 Month",{"EARLY_PHASE1":31369,"PHASE1":31371,"PHASE2":31373,"PHASE3":31375,"PHASE4":31384,"NA":31386},{"trials":31370,"activeCount":99},[],{"trials":31372,"activeCount":99},[],{"trials":31374,"activeCount":99},[],{"trials":31376,"activeCount":99},[31377],{"nctId":31378,"briefTitle":31379,"status":105,"phases":31380,"start":24504,"enrollment":9323,"conditions":31381,"interventions":31382},"NCT00400530","Upper GI Handling of Branded vs. Generic Alendronate",[89],[14552],[31367,31383],"Comparator: Alendronate-Teva \u002F Duration of Treatment: 1 Month",{"trials":31385,"activeCount":99},[],{"trials":31387,"activeCount":99},[],{"intervention":31383,"totalTrials":224,"cells":31389},{"EARLY_PHASE1":31390,"PHASE1":31392,"PHASE2":31394,"PHASE3":31396,"PHASE4":31402,"NA":31404},{"trials":31391,"activeCount":99},[],{"trials":31393,"activeCount":99},[],{"trials":31395,"activeCount":99},[],{"trials":31397,"activeCount":99},[31398],{"nctId":31378,"briefTitle":31379,"status":105,"phases":31399,"start":24504,"enrollment":9323,"conditions":31400,"interventions":31401},[89],[14552],[31367,31383],{"trials":31403,"activeCount":99},[],{"trials":31405,"activeCount":99},[],{"intervention":24274,"totalTrials":224,"cells":31407},{"EARLY_PHASE1":31408,"PHASE1":31410,"PHASE2":31412,"PHASE3":31414,"PHASE4":31420,"NA":31422},{"trials":31409,"activeCount":99},[],{"trials":31411,"activeCount":99},[],{"trials":31413,"activeCount":99},[],{"trials":31415,"activeCount":99},[31416],{"nctId":24265,"briefTitle":24266,"status":105,"phases":31417,"primaryCompletion":24268,"completion":24268,"start":24269,"enrollment":24270,"conditions":31418,"interventions":31419},[89],[24272],[24103,24274],{"trials":31421,"activeCount":99},[],{"trials":31423,"activeCount":99},[],{"intervention":5314,"totalTrials":224,"cells":31425},{"EARLY_PHASE1":31426,"PHASE1":31428,"PHASE2":31430,"PHASE3":31432,"PHASE4":31438,"NA":31440},{"trials":31427,"activeCount":99},[],{"trials":31429,"activeCount":99},[],{"trials":31431,"activeCount":99},[],{"trials":31433,"activeCount":99},[31434],{"nctId":5305,"briefTitle":5306,"status":105,"phases":31435,"primaryCompletion":5308,"completion":5308,"start":5309,"enrollment":5310,"conditions":31436,"interventions":31437},[89],[5181],[4294,5313,529,5137,5314,5315,5316],{"trials":31439,"activeCount":99},[],{"trials":31441,"activeCount":99},[],{"intervention":5316,"totalTrials":224,"cells":31443},{"EARLY_PHASE1":31444,"PHASE1":31446,"PHASE2":31448,"PHASE3":31450,"PHASE4":31456,"NA":31458},{"trials":31445,"activeCount":99},[],{"trials":31447,"activeCount":99},[],{"trials":31449,"activeCount":99},[],{"trials":31451,"activeCount":99},[31452],{"nctId":5305,"briefTitle":5306,"status":105,"phases":31453,"primaryCompletion":5308,"completion":5308,"start":5309,"enrollment":5310,"conditions":31454,"interventions":31455},[89],[5181],[4294,5313,529,5137,5314,5315,5316],{"trials":31457,"activeCount":99},[],{"trials":31459,"activeCount":99},[],{"intervention":16489,"totalTrials":224,"cells":31461},{"EARLY_PHASE1":31462,"PHASE1":31464,"PHASE2":31466,"PHASE3":31468,"PHASE4":31474,"NA":31476},{"trials":31463,"activeCount":99},[],{"trials":31465,"activeCount":99},[],{"trials":31467,"activeCount":99},[],{"trials":31469,"activeCount":99},[31470],{"nctId":16481,"briefTitle":16482,"status":105,"phases":31471,"primaryCompletion":16484,"completion":16484,"start":709,"enrollment":16485,"conditions":31472,"interventions":31473},[89],[16472,16487],[16474,16465,16441,16475,16476,16489,16490,16479,16477],{"trials":31475,"activeCount":99},[],{"trials":31477,"activeCount":99},[],{"intervention":16490,"totalTrials":224,"cells":31479},{"EARLY_PHASE1":31480,"PHASE1":31482,"PHASE2":31484,"PHASE3":31486,"PHASE4":31492,"NA":31494},{"trials":31481,"activeCount":99},[],{"trials":31483,"activeCount":99},[],{"trials":31485,"activeCount":99},[],{"trials":31487,"activeCount":99},[31488],{"nctId":16481,"briefTitle":16482,"status":105,"phases":31489,"primaryCompletion":16484,"completion":16484,"start":709,"enrollment":16485,"conditions":31490,"interventions":31491},[89],[16472,16487],[16474,16465,16441,16475,16476,16489,16490,16479,16477],{"trials":31493,"activeCount":99},[],{"trials":31495,"activeCount":99},[],{"intervention":22438,"totalTrials":224,"cells":31497},{"EARLY_PHASE1":31498,"PHASE1":31500,"PHASE2":31502,"PHASE3":31504,"PHASE4":31510,"NA":31512},{"trials":31499,"activeCount":99},[],{"trials":31501,"activeCount":99},[],{"trials":31503,"activeCount":99},[],{"trials":31505,"activeCount":99},[31506],{"nctId":22433,"briefTitle":22434,"status":105,"phases":31507,"primaryCompletion":14504,"completion":14504,"start":12814,"enrollment":1387,"conditions":31508,"interventions":31509},[89],[17593],[22438,22396,22431],{"trials":31511,"activeCount":99},[],{"trials":31513,"activeCount":99},[],{"intervention":31515,"totalTrials":224,"cells":31516},"2XP HEPTAVAX™-II SC",{"EARLY_PHASE1":31517,"PHASE1":31519,"PHASE2":31521,"PHASE3":31523,"PHASE4":31535,"NA":31537},{"trials":31518,"activeCount":99},[],{"trials":31520,"activeCount":99},[],{"trials":31522,"activeCount":99},[],{"trials":31524,"activeCount":99},[31525],{"nctId":31526,"briefTitle":31527,"status":105,"phases":31528,"primaryCompletion":31529,"completion":31529,"start":19995,"enrollment":31530,"conditions":31531,"interventions":31532},"NCT01463683","Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)",[89],"2012-11-06",722,[17593],[31515,31533,31534],"1XP HEPTAVAX™-II SC","2XP HEPTAVAX™-II IM",{"trials":31536,"activeCount":99},[],{"trials":31538,"activeCount":99},[],{"intervention":31533,"totalTrials":224,"cells":31540},{"EARLY_PHASE1":31541,"PHASE1":31543,"PHASE2":31545,"PHASE3":31547,"PHASE4":31553,"NA":31555},{"trials":31542,"activeCount":99},[],{"trials":31544,"activeCount":99},[],{"trials":31546,"activeCount":99},[],{"trials":31548,"activeCount":99},[31549],{"nctId":31526,"briefTitle":31527,"status":105,"phases":31550,"primaryCompletion":31529,"completion":31529,"start":19995,"enrollment":31530,"conditions":31551,"interventions":31552},[89],[17593],[31515,31533,31534],{"trials":31554,"activeCount":99},[],{"trials":31556,"activeCount":99},[],{"intervention":31534,"totalTrials":224,"cells":31558},{"EARLY_PHASE1":31559,"PHASE1":31561,"PHASE2":31563,"PHASE3":31565,"PHASE4":31571,"NA":31573},{"trials":31560,"activeCount":99},[],{"trials":31562,"activeCount":99},[],{"trials":31564,"activeCount":99},[],{"trials":31566,"activeCount":99},[31567],{"nctId":31526,"briefTitle":31527,"status":105,"phases":31568,"primaryCompletion":31529,"completion":31529,"start":19995,"enrollment":31530,"conditions":31569,"interventions":31570},[89],[17593],[31515,31533,31534],{"trials":31572,"activeCount":99},[],{"trials":31574,"activeCount":99},[],{"intervention":22617,"totalTrials":224,"cells":31576},{"EARLY_PHASE1":31577,"PHASE1":31579,"PHASE2":31581,"PHASE3":31583,"PHASE4":31589,"NA":31591},{"trials":31578,"activeCount":99},[],{"trials":31580,"activeCount":99},[],{"trials":31582,"activeCount":99},[],{"trials":31584,"activeCount":99},[31585],{"nctId":22609,"briefTitle":22610,"status":105,"phases":31586,"primaryCompletion":6177,"completion":22612,"start":22613,"enrollment":1703,"conditions":31587,"interventions":31588},[89],[22615],[22568,22617],{"trials":31590,"activeCount":99},[],{"trials":31592,"activeCount":99},[],{"intervention":23343,"totalTrials":224,"cells":31594},{"EARLY_PHASE1":31595,"PHASE1":31597,"PHASE2":31599,"PHASE3":31601,"PHASE4":31607,"NA":31609},{"trials":31596,"activeCount":99},[],{"trials":31598,"activeCount":99},[],{"trials":31600,"activeCount":99},[],{"trials":31602,"activeCount":99},[31603],{"nctId":23337,"briefTitle":23338,"status":105,"phases":31604,"primaryCompletion":5801,"completion":6309,"start":13891,"enrollment":23340,"conditions":31605,"interventions":31606},[89],[14418,16417],[22385,14420,23343],{"trials":31608,"activeCount":99},[],{"trials":31610,"activeCount":99},[],{"intervention":15952,"totalTrials":224,"cells":31612},{"EARLY_PHASE1":31613,"PHASE1":31615,"PHASE2":31617,"PHASE3":31619,"PHASE4":31625,"NA":31627},{"trials":31614,"activeCount":99},[],{"trials":31616,"activeCount":99},[],{"trials":31618,"activeCount":99},[],{"trials":31620,"activeCount":99},[31621],{"nctId":15944,"briefTitle":15945,"status":1040,"phases":31622,"primaryCompletion":15947,"completion":15911,"start":15948,"enrollment":99,"conditions":31623,"interventions":31624},[89],[24],[15951,15784,15828,15952],{"trials":31626,"activeCount":99},[],{"trials":31628,"activeCount":99},[],{"intervention":15535,"totalTrials":224,"cells":31630},{"EARLY_PHASE1":31631,"PHASE1":31633,"PHASE2":31635,"PHASE3":31637,"PHASE4":31643,"NA":31645},{"trials":31632,"activeCount":99},[],{"trials":31634,"activeCount":99},[],{"trials":31636,"activeCount":99},[],{"trials":31638,"activeCount":99},[31639],{"nctId":15526,"briefTitle":15527,"status":105,"phases":31640,"primaryCompletion":15529,"completion":15530,"start":15531,"enrollment":15532,"conditions":31641,"interventions":31642},[89],[15],[15535,15536,13864,15537,15538,15539],{"trials":31644,"activeCount":99},[],{"trials":31646,"activeCount":99},[],{"intervention":15536,"totalTrials":224,"cells":31648},{"EARLY_PHASE1":31649,"PHASE1":31651,"PHASE2":31653,"PHASE3":31655,"PHASE4":31661,"NA":31663},{"trials":31650,"activeCount":99},[],{"trials":31652,"activeCount":99},[],{"trials":31654,"activeCount":99},[],{"trials":31656,"activeCount":99},[31657],{"nctId":15526,"briefTitle":15527,"status":105,"phases":31658,"primaryCompletion":15529,"completion":15530,"start":15531,"enrollment":15532,"conditions":31659,"interventions":31660},[89],[15],[15535,15536,13864,15537,15538,15539],{"trials":31662,"activeCount":99},[],{"trials":31664,"activeCount":99},[],{"intervention":15537,"totalTrials":224,"cells":31666},{"EARLY_PHASE1":31667,"PHASE1":31669,"PHASE2":31671,"PHASE3":31673,"PHASE4":31679,"NA":31681},{"trials":31668,"activeCount":99},[],{"trials":31670,"activeCount":99},[],{"trials":31672,"activeCount":99},[],{"trials":31674,"activeCount":99},[31675],{"nctId":15526,"briefTitle":15527,"status":105,"phases":31676,"primaryCompletion":15529,"completion":15530,"start":15531,"enrollment":15532,"conditions":31677,"interventions":31678},[89],[15],[15535,15536,13864,15537,15538,15539],{"trials":31680,"activeCount":99},[],{"trials":31682,"activeCount":99},[],{"intervention":15538,"totalTrials":224,"cells":31684},{"EARLY_PHASE1":31685,"PHASE1":31687,"PHASE2":31689,"PHASE3":31691,"PHASE4":31697,"NA":31699},{"trials":31686,"activeCount":99},[],{"trials":31688,"activeCount":99},[],{"trials":31690,"activeCount":99},[],{"trials":31692,"activeCount":99},[31693],{"nctId":15526,"briefTitle":15527,"status":105,"phases":31694,"primaryCompletion":15529,"completion":15530,"start":15531,"enrollment":15532,"conditions":31695,"interventions":31696},[89],[15],[15535,15536,13864,15537,15538,15539],{"trials":31698,"activeCount":99},[],{"trials":31700,"activeCount":99},[],{"intervention":15539,"totalTrials":224,"cells":31702},{"EARLY_PHASE1":31703,"PHASE1":31705,"PHASE2":31707,"PHASE3":31709,"PHASE4":31715,"NA":31717},{"trials":31704,"activeCount":99},[],{"trials":31706,"activeCount":99},[],{"trials":31708,"activeCount":99},[],{"trials":31710,"activeCount":99},[31711],{"nctId":15526,"briefTitle":15527,"status":105,"phases":31712,"primaryCompletion":15529,"completion":15530,"start":15531,"enrollment":15532,"conditions":31713,"interventions":31714},[89],[15],[15535,15536,13864,15537,15538,15539],{"trials":31716,"activeCount":99},[],{"trials":31718,"activeCount":99},[],{"intervention":16500,"totalTrials":224,"cells":31720},{"EARLY_PHASE1":31721,"PHASE1":31723,"PHASE2":31725,"PHASE3":31727,"PHASE4":31733,"NA":31735},{"trials":31722,"activeCount":99},[],{"trials":31724,"activeCount":99},[],{"trials":31726,"activeCount":99},[],{"trials":31728,"activeCount":99},[31729],{"nctId":16492,"briefTitle":16493,"status":105,"phases":31730,"primaryCompletion":16495,"completion":16495,"start":16496,"enrollment":16497,"conditions":31731,"interventions":31732},[89],[16460,16461],[16463,16500,16501,16465,16441,16464,16466,16502],{"trials":31734,"activeCount":99},[],{"trials":31736,"activeCount":99},[],{"intervention":16501,"totalTrials":224,"cells":31738},{"EARLY_PHASE1":31739,"PHASE1":31741,"PHASE2":31743,"PHASE3":31745,"PHASE4":31751,"NA":31753},{"trials":31740,"activeCount":99},[],{"trials":31742,"activeCount":99},[],{"trials":31744,"activeCount":99},[],{"trials":31746,"activeCount":99},[31747],{"nctId":16492,"briefTitle":16493,"status":105,"phases":31748,"primaryCompletion":16495,"completion":16495,"start":16496,"enrollment":16497,"conditions":31749,"interventions":31750},[89],[16460,16461],[16463,16500,16501,16465,16441,16464,16466,16502],{"trials":31752,"activeCount":99},[],{"trials":31754,"activeCount":99},[],{"intervention":16502,"totalTrials":224,"cells":31756},{"EARLY_PHASE1":31757,"PHASE1":31759,"PHASE2":31761,"PHASE3":31763,"PHASE4":31769,"NA":31771},{"trials":31758,"activeCount":99},[],{"trials":31760,"activeCount":99},[],{"trials":31762,"activeCount":99},[],{"trials":31764,"activeCount":99},[31765],{"nctId":16492,"briefTitle":16493,"status":105,"phases":31766,"primaryCompletion":16495,"completion":16495,"start":16496,"enrollment":16497,"conditions":31767,"interventions":31768},[89],[16460,16461],[16463,16500,16501,16465,16441,16464,16466,16502],{"trials":31770,"activeCount":99},[],{"trials":31772,"activeCount":99},[],{"intervention":31774,"totalTrials":224,"cells":31775},"Anacetrapib 100 mg",{"EARLY_PHASE1":31776,"PHASE1":31778,"PHASE2":31780,"PHASE3":31782,"PHASE4":31793,"NA":31795},{"trials":31777,"activeCount":99},[],{"trials":31779,"activeCount":99},[],{"trials":31781,"activeCount":99},[],{"trials":31783,"activeCount":99},[31784],{"nctId":31785,"briefTitle":31786,"status":105,"phases":31787,"primaryCompletion":31788,"completion":31788,"start":31529,"enrollment":31789,"conditions":31790,"interventions":31791},"NCT01717300","A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)",[89],"2014-10-29",459,[7598],[31774,31792],"Anacetrapib 25 mg",{"trials":31794,"activeCount":99},[],{"trials":31796,"activeCount":99},[],{"intervention":31792,"totalTrials":224,"cells":31798},{"EARLY_PHASE1":31799,"PHASE1":31801,"PHASE2":31803,"PHASE3":31805,"PHASE4":31811,"NA":31813},{"trials":31800,"activeCount":99},[],{"trials":31802,"activeCount":99},[],{"trials":31804,"activeCount":99},[],{"trials":31806,"activeCount":99},[31807],{"nctId":31785,"briefTitle":31786,"status":105,"phases":31808,"primaryCompletion":31788,"completion":31788,"start":31529,"enrollment":31789,"conditions":31809,"interventions":31810},[89],[7598],[31774,31792],{"trials":31812,"activeCount":99},[],{"trials":31814,"activeCount":99},[],{"intervention":15556,"totalTrials":224,"cells":31816},{"EARLY_PHASE1":31817,"PHASE1":31819,"PHASE2":31821,"PHASE3":31823,"PHASE4":31829,"NA":31831},{"trials":31818,"activeCount":99},[],{"trials":31820,"activeCount":99},[],{"trials":31822,"activeCount":99},[],{"trials":31824,"activeCount":99},[31825],{"nctId":15549,"briefTitle":15550,"status":105,"phases":31826,"primaryCompletion":12814,"completion":12814,"start":6464,"enrollment":15552,"conditions":31827,"interventions":31828},[89],[15554],[14449,14331,15556],{"trials":31830,"activeCount":99},[],{"trials":31832,"activeCount":99},[],{"intervention":15566,"totalTrials":224,"cells":31834},{"EARLY_PHASE1":31835,"PHASE1":31837,"PHASE2":31839,"PHASE3":31841,"PHASE4":31847,"NA":31849},{"trials":31836,"activeCount":99},[],{"trials":31838,"activeCount":99},[],{"trials":31840,"activeCount":99},[],{"trials":31842,"activeCount":99},[31843],{"nctId":15558,"briefTitle":15559,"status":105,"phases":31844,"primaryCompletion":15561,"completion":15561,"start":15562,"enrollment":15563,"conditions":31845,"interventions":31846},[89],[4411],[15566,14331],{"trials":31848,"activeCount":99},[],{"trials":31850,"activeCount":99},[],{"intervention":31852,"totalTrials":224,"cells":31853},"0.9% sodium chloride",{"EARLY_PHASE1":31854,"PHASE1":31856,"PHASE2":31858,"PHASE3":31860,"PHASE4":31868,"NA":31870},{"trials":31855,"activeCount":99},[],{"trials":31857,"activeCount":99},[],{"trials":31859,"activeCount":99},[],{"trials":31861,"activeCount":99},[31862],{"nctId":31863,"briefTitle":31864,"status":105,"phases":31865,"primaryCompletion":14352,"completion":5280,"start":6309,"enrollment":407,"conditions":31866,"interventions":31867},"NCT00758485","Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767)",[89],[16668,16696],[17013,31852],{"trials":31869,"activeCount":99},[],{"trials":31871,"activeCount":99},[],{"intervention":25388,"totalTrials":224,"cells":31873},{"EARLY_PHASE1":31874,"PHASE1":31876,"PHASE2":31878,"PHASE3":31880,"PHASE4":31886,"NA":31888},{"trials":31875,"activeCount":99},[],{"trials":31877,"activeCount":99},[],{"trials":31879,"activeCount":99},[],{"trials":31881,"activeCount":99},[31882],{"nctId":25379,"briefTitle":25380,"status":105,"phases":31883,"primaryCompletion":25382,"completion":25383,"start":25384,"enrollment":25385,"conditions":31884,"interventions":31885},[89],[7639],[25358,25388,25389,25390,25391],{"trials":31887,"activeCount":99},[],{"trials":31889,"activeCount":99},[],{"intervention":25389,"totalTrials":224,"cells":31891},{"EARLY_PHASE1":31892,"PHASE1":31894,"PHASE2":31896,"PHASE3":31898,"PHASE4":31904,"NA":31906},{"trials":31893,"activeCount":99},[],{"trials":31895,"activeCount":99},[],{"trials":31897,"activeCount":99},[],{"trials":31899,"activeCount":99},[31900],{"nctId":25379,"briefTitle":25380,"status":105,"phases":31901,"primaryCompletion":25382,"completion":25383,"start":25384,"enrollment":25385,"conditions":31902,"interventions":31903},[89],[7639],[25358,25388,25389,25390,25391],{"trials":31905,"activeCount":99},[],{"trials":31907,"activeCount":99},[],{"intervention":25390,"totalTrials":224,"cells":31909},{"EARLY_PHASE1":31910,"PHASE1":31912,"PHASE2":31914,"PHASE3":31916,"PHASE4":31922,"NA":31924},{"trials":31911,"activeCount":99},[],{"trials":31913,"activeCount":99},[],{"trials":31915,"activeCount":99},[],{"trials":31917,"activeCount":99},[31918],{"nctId":25379,"briefTitle":25380,"status":105,"phases":31919,"primaryCompletion":25382,"completion":25383,"start":25384,"enrollment":25385,"conditions":31920,"interventions":31921},[89],[7639],[25358,25388,25389,25390,25391],{"trials":31923,"activeCount":99},[],{"trials":31925,"activeCount":99},[],{"intervention":25391,"totalTrials":224,"cells":31927},{"EARLY_PHASE1":31928,"PHASE1":31930,"PHASE2":31932,"PHASE3":31934,"PHASE4":31940,"NA":31942},{"trials":31929,"activeCount":99},[],{"trials":31931,"activeCount":99},[],{"trials":31933,"activeCount":99},[],{"trials":31935,"activeCount":99},[31936],{"nctId":25379,"briefTitle":25380,"status":105,"phases":31937,"primaryCompletion":25382,"completion":25383,"start":25384,"enrollment":25385,"conditions":31938,"interventions":31939},[89],[7639],[25358,25388,25389,25390,25391],{"trials":31941,"activeCount":99},[],{"trials":31943,"activeCount":99},[],{"intervention":21205,"totalTrials":224,"cells":31945},{"EARLY_PHASE1":31946,"PHASE1":31948,"PHASE2":31950,"PHASE3":31952,"PHASE4":31958,"NA":31960},{"trials":31947,"activeCount":99},[],{"trials":31949,"activeCount":99},[],{"trials":31951,"activeCount":99},[],{"trials":31953,"activeCount":99},[31954],{"nctId":21199,"briefTitle":21200,"status":105,"phases":31955,"primaryCompletion":17198,"completion":17198,"start":21202,"enrollment":2593,"conditions":31956,"interventions":31957},[89],[21170],[21153,21205],{"trials":31959,"activeCount":99},[],{"trials":31961,"activeCount":99},[],{"intervention":15574,"totalTrials":224,"cells":31963},{"EARLY_PHASE1":31964,"PHASE1":31966,"PHASE2":31968,"PHASE3":31970,"PHASE4":31976,"NA":31978},{"trials":31965,"activeCount":99},[],{"trials":31967,"activeCount":99},[],{"trials":31969,"activeCount":99},[],{"trials":31971,"activeCount":99},[31972],{"nctId":15568,"briefTitle":15569,"status":105,"phases":31973,"primaryCompletion":4419,"completion":4419,"start":14705,"enrollment":15571,"conditions":31974,"interventions":31975},[89],[15],[13145,15574,13864,15575],{"trials":31977,"activeCount":99},[],{"trials":31979,"activeCount":99},[],{"intervention":23916,"totalTrials":224,"cells":31981},{"EARLY_PHASE1":31982,"PHASE1":31984,"PHASE2":31986,"PHASE3":31988,"PHASE4":31994,"NA":31996},{"trials":31983,"activeCount":99},[],{"trials":31985,"activeCount":99},[],{"trials":31987,"activeCount":99},[],{"trials":31989,"activeCount":99},[31990],{"nctId":23910,"briefTitle":23911,"status":105,"phases":31991,"primaryCompletion":14730,"completion":13101,"start":13870,"enrollment":23913,"conditions":31992,"interventions":31993},[89],[15311],[23891,23916,23917],{"trials":31995,"activeCount":99},[],{"trials":31997,"activeCount":99},[],{"intervention":24217,"totalTrials":224,"cells":31999},{"EARLY_PHASE1":32000,"PHASE1":32002,"PHASE2":32004,"PHASE3":32006,"PHASE4":32012,"NA":32014},{"trials":32001,"activeCount":99},[],{"trials":32003,"activeCount":99},[],{"trials":32005,"activeCount":99},[],{"trials":32007,"activeCount":99},[32008],{"nctId":24210,"briefTitle":24211,"status":105,"phases":32009,"primaryCompletion":24213,"completion":24213,"start":24214,"enrollment":4421,"conditions":32010,"interventions":32011},[89],[16460],[24192,24217,24218],{"trials":32013,"activeCount":99},[],{"trials":32015,"activeCount":99},[],{"intervention":24218,"totalTrials":224,"cells":32017},{"EARLY_PHASE1":32018,"PHASE1":32020,"PHASE2":32022,"PHASE3":32024,"PHASE4":32030,"NA":32032},{"trials":32019,"activeCount":99},[],{"trials":32021,"activeCount":99},[],{"trials":32023,"activeCount":99},[],{"trials":32025,"activeCount":99},[32026],{"nctId":24210,"briefTitle":24211,"status":105,"phases":32027,"primaryCompletion":24213,"completion":24213,"start":24214,"enrollment":4421,"conditions":32028,"interventions":32029},[89],[16460],[24192,24217,24218],{"trials":32031,"activeCount":99},[],{"trials":32033,"activeCount":99},[],{"intervention":16285,"totalTrials":224,"cells":32035},{"EARLY_PHASE1":32036,"PHASE1":32038,"PHASE2":32040,"PHASE3":32042,"PHASE4":32048,"NA":32050},{"trials":32037,"activeCount":99},[],{"trials":32039,"activeCount":99},[],{"trials":32041,"activeCount":99},[],{"trials":32043,"activeCount":99},[32044],{"nctId":16276,"briefTitle":16277,"status":105,"phases":32045,"primaryCompletion":16279,"completion":16280,"start":16281,"enrollment":1747,"conditions":32046,"interventions":32047},[89],[16283],[16285,16286,16287,5137,16288],{"trials":32049,"activeCount":99},[],{"trials":32051,"activeCount":99},[],{"intervention":16286,"totalTrials":224,"cells":32053},{"EARLY_PHASE1":32054,"PHASE1":32056,"PHASE2":32058,"PHASE3":32060,"PHASE4":32066,"NA":32068},{"trials":32055,"activeCount":99},[],{"trials":32057,"activeCount":99},[],{"trials":32059,"activeCount":99},[],{"trials":32061,"activeCount":99},[32062],{"nctId":16276,"briefTitle":16277,"status":105,"phases":32063,"primaryCompletion":16279,"completion":16280,"start":16281,"enrollment":1747,"conditions":32064,"interventions":32065},[89],[16283],[16285,16286,16287,5137,16288],{"trials":32067,"activeCount":99},[],{"trials":32069,"activeCount":99},[],{"intervention":16287,"totalTrials":224,"cells":32071},{"EARLY_PHASE1":32072,"PHASE1":32074,"PHASE2":32076,"PHASE3":32078,"PHASE4":32084,"NA":32086},{"trials":32073,"activeCount":99},[],{"trials":32075,"activeCount":99},[],{"trials":32077,"activeCount":99},[],{"trials":32079,"activeCount":99},[32080],{"nctId":16276,"briefTitle":16277,"status":105,"phases":32081,"primaryCompletion":16279,"completion":16280,"start":16281,"enrollment":1747,"conditions":32082,"interventions":32083},[89],[16283],[16285,16286,16287,5137,16288],{"trials":32085,"activeCount":99},[],{"trials":32087,"activeCount":99},[],{"intervention":16288,"totalTrials":224,"cells":32089},{"EARLY_PHASE1":32090,"PHASE1":32092,"PHASE2":32094,"PHASE3":32096,"PHASE4":32102,"NA":32104},{"trials":32091,"activeCount":99},[],{"trials":32093,"activeCount":99},[],{"trials":32095,"activeCount":99},[],{"trials":32097,"activeCount":99},[32098],{"nctId":16276,"briefTitle":16277,"status":105,"phases":32099,"primaryCompletion":16279,"completion":16280,"start":16281,"enrollment":1747,"conditions":32100,"interventions":32101},[89],[16283],[16285,16286,16287,5137,16288],{"trials":32103,"activeCount":99},[],{"trials":32105,"activeCount":99},[],{"intervention":32107,"totalTrials":224,"cells":32108},"SC golimumab",{"EARLY_PHASE1":32109,"PHASE1":32111,"PHASE2":32113,"PHASE3":32115,"PHASE4":32125,"NA":32127},{"trials":32110,"activeCount":99},[],{"trials":32112,"activeCount":99},[],{"trials":32114,"activeCount":99},[],{"trials":32116,"activeCount":99},[32117],{"nctId":32118,"briefTitle":32119,"status":105,"phases":32120,"primaryCompletion":16591,"completion":13223,"start":14445,"enrollment":32121,"conditions":32122,"interventions":32123},"NCT00975130","Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous\u002FSubcutaneous GLM Strategy (P06129 AM2)",[89],3366,[7197],[32107,32124],"IV golimumab",{"trials":32126,"activeCount":99},[],{"trials":32128,"activeCount":99},[],{"intervention":32124,"totalTrials":224,"cells":32130},{"EARLY_PHASE1":32131,"PHASE1":32133,"PHASE2":32135,"PHASE3":32137,"PHASE4":32143,"NA":32145},{"trials":32132,"activeCount":99},[],{"trials":32134,"activeCount":99},[],{"trials":32136,"activeCount":99},[],{"trials":32138,"activeCount":99},[32139],{"nctId":32118,"briefTitle":32119,"status":105,"phases":32140,"primaryCompletion":16591,"completion":13223,"start":14445,"enrollment":32121,"conditions":32141,"interventions":32142},[89],[7197],[32107,32124],{"trials":32144,"activeCount":99},[],{"trials":32146,"activeCount":99},[],{"intervention":32148,"totalTrials":224,"cells":32149},"MMRV",{"EARLY_PHASE1":32150,"PHASE1":32152,"PHASE2":32154,"PHASE3":32156,"PHASE4":32168,"NA":32170},{"trials":32151,"activeCount":99},[],{"trials":32153,"activeCount":99},[],{"trials":32155,"activeCount":99},[],{"trials":32157,"activeCount":99},[32158],{"nctId":32159,"briefTitle":32160,"status":105,"phases":32161,"primaryCompletion":32162,"completion":32163,"start":32164,"enrollment":32165,"conditions":32166,"interventions":32167},"NCT01536405","Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)",[89],"2013-07-02","2014-01-27","2012-06-05",1412,[15308,15309,15310,15311],[32148,32148],{"trials":32169,"activeCount":99},[],{"trials":32171,"activeCount":99},[],{"intervention":2596,"totalTrials":224,"cells":32173},{"EARLY_PHASE1":32174,"PHASE1":32176,"PHASE2":32178,"PHASE3":32180,"PHASE4":32186,"NA":32188},{"trials":32175,"activeCount":99},[],{"trials":32177,"activeCount":99},[],{"trials":32179,"activeCount":99},[],{"trials":32181,"activeCount":99},[32182],{"nctId":2589,"briefTitle":2590,"status":150,"phases":32183,"primaryCompletion":2031,"completion":2592,"start":2033,"enrollment":2593,"conditions":32184,"interventions":32185},[89],[526],[47,2596,529],{"trials":32187,"activeCount":99},[],{"trials":32189,"activeCount":99},[],{"intervention":32191,"totalTrials":224,"cells":32192},"losartan potassium (+) hydrochlorothiazide",{"EARLY_PHASE1":32193,"PHASE1":32195,"PHASE2":32197,"PHASE3":32199,"PHASE4":32209,"NA":32211},{"trials":32194,"activeCount":99},[],{"trials":32196,"activeCount":99},[],{"trials":32198,"activeCount":99},[],{"trials":32200,"activeCount":99},[32201],{"nctId":32202,"briefTitle":32203,"status":105,"phases":32204,"primaryCompletion":15713,"completion":15713,"start":32205,"enrollment":32206,"conditions":32207,"interventions":32208},"NCT00354991","Hyzaar Asia HEAALTH (0954A-950)",[89],"2006-06-01",437,[30],[32191],{"trials":32210,"activeCount":99},[],{"trials":32212,"activeCount":99},[],{"intervention":32214,"totalTrials":224,"cells":32215},"RotaTeq™ experimental formulation",{"EARLY_PHASE1":32216,"PHASE1":32218,"PHASE2":32220,"PHASE3":32222,"PHASE4":32233,"NA":32235},{"trials":32217,"activeCount":99},[],{"trials":32219,"activeCount":99},[],{"trials":32221,"activeCount":99},[],{"trials":32223,"activeCount":99},[32224],{"nctId":32225,"briefTitle":32226,"status":105,"phases":32227,"primaryCompletion":32228,"completion":32228,"start":32229,"enrollment":9064,"conditions":32230,"interventions":32231},"NCT01600092","A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035)",[89],"2014-03-25","2013-04-29",[14447],[32214,32232],"RotaTeq™ existing formulation",{"trials":32234,"activeCount":99},[],{"trials":32236,"activeCount":99},[],{"intervention":32232,"totalTrials":224,"cells":32238},{"EARLY_PHASE1":32239,"PHASE1":32241,"PHASE2":32243,"PHASE3":32245,"PHASE4":32251,"NA":32253},{"trials":32240,"activeCount":99},[],{"trials":32242,"activeCount":99},[],{"trials":32244,"activeCount":99},[],{"trials":32246,"activeCount":99},[32247],{"nctId":32225,"briefTitle":32226,"status":105,"phases":32248,"primaryCompletion":32228,"completion":32228,"start":32229,"enrollment":9064,"conditions":32249,"interventions":32250},[89],[14447],[32214,32232],{"trials":32252,"activeCount":99},[],{"trials":32254,"activeCount":99},[],{"intervention":15750,"totalTrials":224,"cells":32256},{"EARLY_PHASE1":32257,"PHASE1":32259,"PHASE2":32261,"PHASE3":32263,"PHASE4":32269,"NA":32271},{"trials":32258,"activeCount":99},[],{"trials":32260,"activeCount":99},[],{"trials":32262,"activeCount":99},[],{"trials":32264,"activeCount":99},[32265],{"nctId":15743,"briefTitle":15744,"status":105,"phases":32266,"primaryCompletion":15746,"completion":15746,"start":15747,"enrollment":14325,"conditions":32267,"interventions":32268},[89],[15023],[14487,14488,14488,15750],{"trials":32270,"activeCount":99},[],{"trials":32272,"activeCount":99},[],{"intervention":21220,"totalTrials":224,"cells":32274},{"EARLY_PHASE1":32275,"PHASE1":32277,"PHASE2":32279,"PHASE3":32281,"PHASE4":32287,"NA":32289},{"trials":32276,"activeCount":99},[],{"trials":32278,"activeCount":99},[],{"trials":32280,"activeCount":99},[],{"trials":32282,"activeCount":99},[32283],{"nctId":21214,"briefTitle":21215,"status":105,"phases":32284,"primaryCompletion":15054,"completion":15054,"start":21167,"enrollment":21217,"conditions":32285,"interventions":32286},[89],[21170],[21153,21220],{"trials":32288,"activeCount":99},[],{"trials":32290,"activeCount":99},[],{"intervention":21944,"totalTrials":224,"cells":32292},{"EARLY_PHASE1":32293,"PHASE1":32295,"PHASE2":32297,"PHASE3":32299,"PHASE4":32305,"NA":32307},{"trials":32294,"activeCount":99},[],{"trials":32296,"activeCount":99},[],{"trials":32298,"activeCount":99},[],{"trials":32300,"activeCount":99},[32301],{"nctId":21933,"briefTitle":21934,"status":105,"phases":32302,"primaryCompletion":21936,"completion":21936,"start":21937,"enrollment":7127,"conditions":32303,"interventions":32304},[89],[14524,21939,21940,21941,21942,14655],[21931,21944],{"trials":32306,"activeCount":99},[],{"trials":32308,"activeCount":99},[],{"intervention":14256,"totalTrials":224,"cells":32310},{"EARLY_PHASE1":32311,"PHASE1":32313,"PHASE2":32315,"PHASE3":32317,"PHASE4":32323,"NA":32325},{"trials":32312,"activeCount":99},[],{"trials":32314,"activeCount":99},[],{"trials":32316,"activeCount":99},[],{"trials":32318,"activeCount":99},[32319],{"nctId":14248,"briefTitle":14249,"status":105,"phases":32320,"primaryCompletion":14251,"completion":14251,"start":14252,"enrollment":14253,"conditions":32321,"interventions":32322},[89],[15],[14256,14257,4084],{"trials":32324,"activeCount":99},[],{"trials":32326,"activeCount":99},[],{"intervention":14257,"totalTrials":224,"cells":32328},{"EARLY_PHASE1":32329,"PHASE1":32331,"PHASE2":32333,"PHASE3":32335,"PHASE4":32341,"NA":32343},{"trials":32330,"activeCount":99},[],{"trials":32332,"activeCount":99},[],{"trials":32334,"activeCount":99},[],{"trials":32336,"activeCount":99},[32337],{"nctId":14248,"briefTitle":14249,"status":105,"phases":32338,"primaryCompletion":14251,"completion":14251,"start":14252,"enrollment":14253,"conditions":32339,"interventions":32340},[89],[15],[14256,14257,4084],{"trials":32342,"activeCount":99},[],{"trials":32344,"activeCount":99},[],{"intervention":32346,"totalTrials":224,"cells":32347},"Combination of (a) pegylated interferon alfa-2b and (b) rebetol",{"EARLY_PHASE1":32348,"PHASE1":32350,"PHASE2":32352,"PHASE3":32354,"PHASE4":32363,"NA":32365},{"trials":32349,"activeCount":99},[],{"trials":32351,"activeCount":99},[],{"trials":32353,"activeCount":99},[],{"trials":32355,"activeCount":99},[32356],{"nctId":32357,"briefTitle":32358,"status":105,"phases":32359,"primaryCompletion":14713,"completion":14713,"start":8621,"enrollment":1968,"conditions":32360,"interventions":32362},"NCT00378599","Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)",[89],[32361,21,27951],"Liver Transplantation",[32346],{"trials":32364,"activeCount":99},[],{"trials":32366,"activeCount":99},[],{"intervention":32368,"totalTrials":224,"cells":32369},"V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine \u002F Duration of Treatment : 4 Years",{"EARLY_PHASE1":32370,"PHASE1":32372,"PHASE2":32374,"PHASE3":32376,"PHASE4":32389,"NA":32391},{"trials":32371,"activeCount":99},[],{"trials":32373,"activeCount":99},[],{"trials":32375,"activeCount":99},[],{"trials":32377,"activeCount":99},[32378],{"nctId":32379,"briefTitle":32380,"status":105,"phases":32381,"primaryCompletion":32382,"completion":32383,"start":32384,"enrollment":32385,"conditions":32386,"interventions":32387},"NCT00517309","Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)",[89],"2004-06-08","2004-06-11","2001-12-28",1877,[863,7085],[32368,32388],"Comparator: placebo (concomitant-vaccine matched) \u002F Duration of Treatment : 4 Years",{"trials":32390,"activeCount":99},[],{"trials":32392,"activeCount":99},[],{"intervention":32388,"totalTrials":224,"cells":32394},{"EARLY_PHASE1":32395,"PHASE1":32397,"PHASE2":32399,"PHASE3":32401,"PHASE4":32407,"NA":32409},{"trials":32396,"activeCount":99},[],{"trials":32398,"activeCount":99},[],{"trials":32400,"activeCount":99},[],{"trials":32402,"activeCount":99},[32403],{"nctId":32379,"briefTitle":32380,"status":105,"phases":32404,"primaryCompletion":32382,"completion":32383,"start":32384,"enrollment":32385,"conditions":32405,"interventions":32406},[89],[863,7085],[32368,32388],{"trials":32408,"activeCount":99},[],{"trials":32410,"activeCount":99},[],{"intervention":15970,"totalTrials":224,"cells":32412},{"EARLY_PHASE1":32413,"PHASE1":32415,"PHASE2":32417,"PHASE3":32419,"PHASE4":32425,"NA":32427},{"trials":32414,"activeCount":99},[],{"trials":32416,"activeCount":99},[],{"trials":32418,"activeCount":99},[],{"trials":32420,"activeCount":99},[32421],{"nctId":15964,"briefTitle":15965,"status":105,"phases":32422,"primaryCompletion":9164,"completion":9164,"start":11368,"enrollment":15967,"conditions":32423,"interventions":32424},[89],[21],[15784,15859,14925,15970],{"trials":32426,"activeCount":99},[],{"trials":32428,"activeCount":99},[],{"intervention":25781,"totalTrials":224,"cells":32430},{"EARLY_PHASE1":32431,"PHASE1":32433,"PHASE2":32435,"PHASE3":32437,"PHASE4":32443,"NA":32445},{"trials":32432,"activeCount":99},[],{"trials":32434,"activeCount":99},[],{"trials":32436,"activeCount":99},[],{"trials":32438,"activeCount":99},[32439],{"nctId":25772,"briefTitle":25773,"status":105,"phases":32440,"primaryCompletion":15505,"completion":15505,"start":17461,"enrollment":25775,"conditions":32441,"interventions":32442},[89],[25777,20573,20574,25778,25779],[25781,9208,9209,9208,9209],{"trials":32444,"activeCount":99},[],{"trials":32446,"activeCount":99},[],{"intervention":19663,"totalTrials":224,"cells":32448},{"EARLY_PHASE1":32449,"PHASE1":32451,"PHASE2":32453,"PHASE3":32455,"PHASE4":32461,"NA":32463},{"trials":32450,"activeCount":99},[],{"trials":32452,"activeCount":99},[],{"trials":32454,"activeCount":99},[],{"trials":32456,"activeCount":99},[32457],{"nctId":19653,"briefTitle":19654,"status":105,"phases":32458,"primaryCompletion":19656,"completion":19657,"start":19658,"enrollment":19659,"conditions":32459,"interventions":32460},[89],[14552],[14554,19662,19663],{"trials":32462,"activeCount":99},[],{"trials":32464,"activeCount":99},[],{"intervention":2727,"totalTrials":224,"cells":32466},{"EARLY_PHASE1":32467,"PHASE1":32469,"PHASE2":32471,"PHASE3":32473,"PHASE4":32479,"NA":32481},{"trials":32468,"activeCount":99},[],{"trials":32470,"activeCount":99},[],{"trials":32472,"activeCount":99},[],{"trials":32474,"activeCount":99},[32475],{"nctId":2718,"briefTitle":2719,"status":105,"phases":32476,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":2512,"conditions":32477,"interventions":32478},[89],[2725],[47,388,387,714,386,2727],{"trials":32480,"activeCount":99},[],{"trials":32482,"activeCount":99},[],{"intervention":16360,"totalTrials":224,"cells":32484},{"EARLY_PHASE1":32485,"PHASE1":32487,"PHASE2":32489,"PHASE3":32491,"PHASE4":32497,"NA":32499},{"trials":32486,"activeCount":99},[],{"trials":32488,"activeCount":99},[],{"trials":32490,"activeCount":99},[],{"trials":32492,"activeCount":99},[32493],{"nctId":16351,"briefTitle":16352,"status":105,"phases":32494,"primaryCompletion":16354,"completion":16355,"start":16356,"enrollment":16357,"conditions":32495,"interventions":32496},[89],[5150],[4424,5154,16360,5285,16361,16361],{"trials":32498,"activeCount":99},[],{"trials":32500,"activeCount":99},[],{"intervention":16361,"totalTrials":224,"cells":32502},{"EARLY_PHASE1":32503,"PHASE1":32505,"PHASE2":32507,"PHASE3":32509,"PHASE4":32515,"NA":32517},{"trials":32504,"activeCount":99},[],{"trials":32506,"activeCount":99},[],{"trials":32508,"activeCount":99},[],{"trials":32510,"activeCount":99},[32511],{"nctId":16351,"briefTitle":16352,"status":105,"phases":32512,"primaryCompletion":16354,"completion":16355,"start":16356,"enrollment":16357,"conditions":32513,"interventions":32514},[89],[5150],[4424,5154,16360,5285,16361,16361],{"trials":32516,"activeCount":99},[],{"trials":32518,"activeCount":99},[],{"intervention":32520,"totalTrials":224,"cells":32521},"Daptomycin 4 mg\u002Fkg",{"EARLY_PHASE1":32522,"PHASE1":32524,"PHASE2":32526,"PHASE3":32528,"PHASE4":32538,"NA":32540},{"trials":32523,"activeCount":99},[],{"trials":32525,"activeCount":99},[],{"trials":32527,"activeCount":99},[],{"trials":32529,"activeCount":99},[32530],{"nctId":32531,"briefTitle":32532,"status":105,"phases":32533,"primaryCompletion":6308,"completion":6308,"start":14315,"enrollment":15489,"conditions":32534,"interventions":32535},"NCT00770341","A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)",[89],[23175],[32520,32536,32537],"Comparator: vancomycin","Daptomycin 6 mg\u002Fkg",{"trials":32539,"activeCount":99},[],{"trials":32541,"activeCount":99},[],{"intervention":32536,"totalTrials":224,"cells":32543},{"EARLY_PHASE1":32544,"PHASE1":32546,"PHASE2":32548,"PHASE3":32550,"PHASE4":32556,"NA":32558},{"trials":32545,"activeCount":99},[],{"trials":32547,"activeCount":99},[],{"trials":32549,"activeCount":99},[],{"trials":32551,"activeCount":99},[32552],{"nctId":32531,"briefTitle":32532,"status":105,"phases":32553,"primaryCompletion":6308,"completion":6308,"start":14315,"enrollment":15489,"conditions":32554,"interventions":32555},[89],[23175],[32520,32536,32537],{"trials":32557,"activeCount":99},[],{"trials":32559,"activeCount":99},[],{"intervention":32537,"totalTrials":224,"cells":32561},{"EARLY_PHASE1":32562,"PHASE1":32564,"PHASE2":32566,"PHASE3":32568,"PHASE4":32574,"NA":32576},{"trials":32563,"activeCount":99},[],{"trials":32565,"activeCount":99},[],{"trials":32567,"activeCount":99},[],{"trials":32569,"activeCount":99},[32570],{"nctId":32531,"briefTitle":32532,"status":105,"phases":32571,"primaryCompletion":6308,"completion":6308,"start":14315,"enrollment":15489,"conditions":32572,"interventions":32573},[89],[23175],[32520,32536,32537],{"trials":32575,"activeCount":99},[],{"trials":32577,"activeCount":99},[],{"intervention":15599,"totalTrials":224,"cells":32579},{"EARLY_PHASE1":32580,"PHASE1":32582,"PHASE2":32584,"PHASE3":32586,"PHASE4":32592,"NA":32594},{"trials":32581,"activeCount":99},[],{"trials":32583,"activeCount":99},[],{"trials":32585,"activeCount":99},[],{"trials":32587,"activeCount":99},[32588],{"nctId":15591,"briefTitle":15592,"status":105,"phases":32589,"primaryCompletion":14314,"completion":14314,"start":4419,"enrollment":15594,"conditions":32590,"interventions":32591},[89],[4292,15596,15597],[15599,13864],{"trials":32593,"activeCount":99},[],{"trials":32595,"activeCount":99},[],{"intervention":22238,"totalTrials":224,"cells":32597},{"EARLY_PHASE1":32598,"PHASE1":32600,"PHASE2":32602,"PHASE3":32604,"PHASE4":32610,"NA":32612},{"trials":32599,"activeCount":99},[],{"trials":32601,"activeCount":99},[],{"trials":32603,"activeCount":99},[],{"trials":32605,"activeCount":99},[32606],{"nctId":22228,"briefTitle":22229,"status":105,"phases":32607,"primaryCompletion":22231,"completion":22232,"start":21035,"enrollment":22233,"conditions":32608,"interventions":32609},[89],[22235],[22237,22238,22239],{"trials":32611,"activeCount":99},[],{"trials":32613,"activeCount":99},[],{"intervention":22239,"totalTrials":224,"cells":32615},{"EARLY_PHASE1":32616,"PHASE1":32618,"PHASE2":32620,"PHASE3":32622,"PHASE4":32628,"NA":32630},{"trials":32617,"activeCount":99},[],{"trials":32619,"activeCount":99},[],{"trials":32621,"activeCount":99},[],{"trials":32623,"activeCount":99},[32624],{"nctId":22228,"briefTitle":22229,"status":105,"phases":32625,"primaryCompletion":22231,"completion":22232,"start":21035,"enrollment":22233,"conditions":32626,"interventions":32627},[89],[22235],[22237,22238,22239],{"trials":32629,"activeCount":99},[],{"trials":32631,"activeCount":99},[],{"intervention":21636,"totalTrials":224,"cells":32633},{"EARLY_PHASE1":32634,"PHASE1":32636,"PHASE2":32638,"PHASE3":32640,"PHASE4":32646,"NA":32648},{"trials":32635,"activeCount":99},[],{"trials":32637,"activeCount":99},[],{"trials":32639,"activeCount":99},[],{"trials":32641,"activeCount":99},[32642],{"nctId":21629,"briefTitle":21630,"status":105,"phases":32643,"primaryCompletion":20174,"completion":15295,"start":21632,"enrollment":21633,"conditions":32644,"interventions":32645},[89],[15308,15309,15310,15311],[15467,21636,21637,15315,15314],{"trials":32647,"activeCount":99},[],{"trials":32649,"activeCount":99},[],{"intervention":21637,"totalTrials":224,"cells":32651},{"EARLY_PHASE1":32652,"PHASE1":32654,"PHASE2":32656,"PHASE3":32658,"PHASE4":32664,"NA":32666},{"trials":32653,"activeCount":99},[],{"trials":32655,"activeCount":99},[],{"trials":32657,"activeCount":99},[],{"trials":32659,"activeCount":99},[32660],{"nctId":21629,"briefTitle":21630,"status":105,"phases":32661,"primaryCompletion":20174,"completion":15295,"start":21632,"enrollment":21633,"conditions":32662,"interventions":32663},[89],[15308,15309,15310,15311],[15467,21636,21637,15315,15314],{"trials":32665,"activeCount":99},[],{"trials":32667,"activeCount":99},[],{"intervention":32669,"totalTrials":224,"cells":32670},"neostigmine and glycopyrrolate or atropine",{"EARLY_PHASE1":32671,"PHASE1":32673,"PHASE2":32675,"PHASE3":32677,"PHASE4":32692,"NA":32694},{"trials":32672,"activeCount":99},[],{"trials":32674,"activeCount":99},[],{"trials":32676,"activeCount":99},[],{"trials":32678,"activeCount":99},[32679],{"nctId":32680,"briefTitle":32681,"status":105,"phases":32682,"primaryCompletion":32683,"completion":32683,"start":32684,"enrollment":32685,"conditions":32686,"interventions":32691},"NCT01422304","Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip\u002FKnee) Replacement (P07038)",[89],"2012-09-26","2011-10-12",1198,[16696,32687,32688,32689,32690],"Arthroplasty, Replacement, Hip","Arthroplasty, Replacement, Knee","Blood Coagulation","Antithrombotic Agents",[17013,32669],{"trials":32693,"activeCount":99},[],{"trials":32695,"activeCount":99},[],{"intervention":5915,"totalTrials":224,"cells":32697},{"EARLY_PHASE1":32698,"PHASE1":32700,"PHASE2":32702,"PHASE3":32704,"PHASE4":32710,"NA":32712},{"trials":32699,"activeCount":99},[],{"trials":32701,"activeCount":99},[],{"trials":32703,"activeCount":99},[],{"trials":32705,"activeCount":99},[32706],{"nctId":5907,"briefTitle":5908,"status":105,"phases":32707,"primaryCompletion":5910,"completion":5911,"start":5912,"enrollment":1522,"conditions":32708,"interventions":32709},[89],[431],[1114,1444,841,795,5915],{"trials":32711,"activeCount":99},[],{"trials":32713,"activeCount":99},[],{"intervention":32715,"totalTrials":224,"cells":32716},"sitagliptin 100 mg q.d.\u002Fpioglitazone 30 mg q.d",{"EARLY_PHASE1":32717,"PHASE1":32719,"PHASE2":32721,"PHASE3":32723,"PHASE4":32734,"NA":32736},{"trials":32718,"activeCount":99},[],{"trials":32720,"activeCount":99},[],{"trials":32722,"activeCount":99},[],{"trials":32724,"activeCount":99},[32725],{"nctId":32726,"briefTitle":32727,"status":105,"phases":32728,"primaryCompletion":32729,"completion":32729,"start":32730,"enrollment":2625,"conditions":32731,"interventions":32732},"NCT00397631","Initial Combination With Pioglitazone Study (0431-064)",[89],"2008-06-28","2006-12-19",[15],[32715,32733],"Comparator: placebo to match sitagliptin 100 mg q.d.\u002Fpioglitazone 30 mg q.d.",{"trials":32735,"activeCount":99},[],{"trials":32737,"activeCount":99},[],{"intervention":32733,"totalTrials":224,"cells":32739},{"EARLY_PHASE1":32740,"PHASE1":32742,"PHASE2":32744,"PHASE3":32746,"PHASE4":32752,"NA":32754},{"trials":32741,"activeCount":99},[],{"trials":32743,"activeCount":99},[],{"trials":32745,"activeCount":99},[],{"trials":32747,"activeCount":99},[32748],{"nctId":32726,"briefTitle":32727,"status":105,"phases":32749,"primaryCompletion":32729,"completion":32729,"start":32730,"enrollment":2625,"conditions":32750,"interventions":32751},[89],[15],[32715,32733],{"trials":32753,"activeCount":99},[],{"trials":32755,"activeCount":99},[],{"intervention":6106,"totalTrials":95,"cells":32757},{"EARLY_PHASE1":32758,"PHASE1":32760,"PHASE2":32806,"PHASE3":32832,"PHASE4":32834,"NA":32836},{"trials":32759,"activeCount":99},[],{"trials":32761,"activeCount":99},[32762,32771,32779,32783,32790,32798,32802],{"nctId":32763,"briefTitle":32764,"status":105,"phases":32765,"primaryCompletion":32766,"completion":32767,"start":32768,"enrollment":2901,"conditions":32769,"interventions":32770},"NCT00694356","Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)",[87],"2009-03-18","2009-04-28","2008-08-04",[337],[6106],{"nctId":32772,"briefTitle":32773,"status":105,"phases":32774,"primaryCompletion":32775,"completion":32775,"start":32776,"enrollment":1479,"conditions":32777,"interventions":32778},"NCT00701103","Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)",[87],"2009-12-01","2006-01-12",[279,526],[6106],{"nctId":18928,"briefTitle":18929,"status":150,"phases":32780,"primaryCompletion":13140,"completion":15126,"start":18931,"enrollment":14576,"conditions":32781,"interventions":32782},[87],[18933],[6091,18935,6312,2817],{"nctId":32784,"briefTitle":32785,"status":105,"phases":32786,"primaryCompletion":9334,"completion":9334,"start":32787,"enrollment":4421,"conditions":32788,"interventions":32789},"NCT00635778","A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002)",[87],"2006-08-07",[497],[6091],{"nctId":32791,"briefTitle":32792,"status":105,"phases":32793,"primaryCompletion":32794,"completion":32794,"start":32795,"enrollment":1054,"conditions":32796,"interventions":32797},"NCT00759785","A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013)",[87],"2010-02-17","2008-09-30",[1109],[6091],{"nctId":18995,"briefTitle":18996,"status":105,"phases":32799,"primaryCompletion":18998,"completion":18998,"start":13222,"enrollment":18999,"conditions":32800,"interventions":32801},[87],[1109],[19002,11239,6106],{"nctId":19008,"briefTitle":19009,"status":105,"phases":32803,"primaryCompletion":19011,"completion":19011,"start":13223,"enrollment":4242,"conditions":32804,"interventions":32805},[87],[176],[6091,6091,6312],{"trials":32807,"activeCount":99},[32808,32812,32816,32824,32828],{"nctId":6083,"briefTitle":6084,"status":105,"phases":32809,"primaryCompletion":173,"completion":6086,"start":6087,"enrollment":6088,"conditions":32810,"interventions":32811},[88],[431],[6091,6092,603],{"nctId":6098,"briefTitle":6099,"status":150,"phases":32813,"primaryCompletion":6101,"completion":6101,"start":6102,"enrollment":5983,"conditions":32814,"interventions":32815},[88],[6104],[6106,437,693],{"nctId":32817,"briefTitle":32818,"status":105,"phases":32819,"primaryCompletion":32820,"completion":16727,"start":32821,"enrollment":14941,"conditions":32822,"interventions":32823},"NCT00654420","A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)",[88],"2009-11-25","2008-03-19",[22881],[6106,1253],{"nctId":11220,"briefTitle":11221,"status":105,"phases":32825,"primaryCompletion":11223,"completion":11223,"start":11224,"enrollment":11225,"conditions":32826,"interventions":32827},[88],[1109],[11228,11229,6312,6091],{"nctId":11231,"briefTitle":11232,"status":105,"phases":32829,"primaryCompletion":11234,"completion":11235,"start":11236,"enrollment":1479,"conditions":32830,"interventions":32831},[88],[1108],[11239,6106,4156],{"trials":32833,"activeCount":99},[],{"trials":32835,"activeCount":99},[],{"trials":32837,"activeCount":99},[],{"intervention":16932,"totalTrials":3308,"cells":32839},{"EARLY_PHASE1":32840,"PHASE1":32842,"PHASE2":32894,"PHASE3":32915,"PHASE4":32917,"NA":32919},{"trials":32841,"activeCount":99},[],{"trials":32843,"activeCount":99},[32844,32848,32857,32865,32872,32879,32886],{"nctId":16925,"briefTitle":16926,"status":105,"phases":32845,"primaryCompletion":16928,"completion":16928,"start":16929,"enrollment":1169,"conditions":32846,"interventions":32847},[87],[14715],[16932,7335],{"nctId":32849,"briefTitle":32850,"status":105,"phases":32851,"primaryCompletion":32852,"completion":32852,"start":32853,"enrollment":1349,"conditions":32854,"interventions":32855},"NCT02181803","Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)",[87],"2015-04-23","2014-08-05",[14715],[16932,32856],"Base Monotherapy",{"nctId":32858,"briefTitle":32859,"status":105,"phases":32860,"primaryCompletion":32861,"completion":32862,"start":16745,"enrollment":4071,"conditions":32863,"interventions":32864},"NCT04676425","A Study to Investigate the Influence of Hepatic Impairment on Elpipodect (MK-8189) Treatment (MK-8189-012)",[87],"2022-01-16","2022-01-25",[5595],[16932],{"nctId":32866,"briefTitle":32867,"status":105,"phases":32868,"primaryCompletion":2478,"completion":2478,"start":813,"enrollment":5616,"conditions":32869,"interventions":32871},"NCT06273774","A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020)",[87],[32870],"Bipolar I Disorder",[16932],{"nctId":32873,"briefTitle":32874,"status":105,"phases":32875,"primaryCompletion":19928,"completion":19928,"start":32876,"enrollment":31,"conditions":32877,"interventions":32878},"NCT05227118","Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and\u002For Psychosis (MK-8189-017)",[87],"2022-07-01",[11174],[16932],{"nctId":32880,"briefTitle":32881,"status":105,"phases":32882,"primaryCompletion":32883,"completion":32883,"start":4070,"enrollment":18584,"conditions":32884,"interventions":32885},"NCT05406440","A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)",[87],"2023-02-24",[14715],[16932],{"nctId":32887,"briefTitle":32888,"status":105,"phases":32889,"primaryCompletion":32890,"completion":32890,"start":32891,"enrollment":18999,"conditions":32892,"interventions":32893},"NCT04506905","Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)",[87],"2022-03-22","2020-08-28",[14715],[16932],{"trials":32895,"activeCount":99},[32896,32907],{"nctId":32897,"briefTitle":32898,"status":105,"phases":32899,"primaryCompletion":32900,"completion":32900,"start":32901,"enrollment":32902,"conditions":32903,"interventions":32905},"NCT03055338","An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)",[88],"2018-01-09","2017-03-08",224,[32904],"Schizophrenia, Acute Episode",[16932,32906],"Risperidone",{"nctId":32908,"briefTitle":32909,"status":105,"phases":32910,"primaryCompletion":8049,"completion":8049,"start":32911,"enrollment":32912,"conditions":32913,"interventions":32914},"NCT04624243","Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)",[88],"2020-12-15",499,[14715],[16932,32906],{"trials":32916,"activeCount":99},[],{"trials":32918,"activeCount":99},[],{"trials":32920,"activeCount":99},[],{"intervention":13863,"totalTrials":734,"cells":32922},{"EARLY_PHASE1":32923,"PHASE1":32925,"PHASE2":32954,"PHASE3":32970,"PHASE4":32972,"NA":32974},{"trials":32924,"activeCount":99},[],{"trials":32926,"activeCount":99},[32927,32933,32939,32946,32950],{"nctId":32928,"briefTitle":32929,"status":105,"phases":32930,"primaryCompletion":6309,"completion":6309,"start":14315,"enrollment":3655,"conditions":32931,"interventions":32932},"NCT00754130","MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011).",[87],[15023],[13863],{"nctId":32934,"briefTitle":32935,"status":105,"phases":32936,"primaryCompletion":14823,"completion":13870,"start":6309,"enrollment":4555,"conditions":32937,"interventions":32938},"NCT00912002","A Study of Absorption, Metabolism, Excretion and Mass Balance After a Single Dose Administration of MK-0941 (MK-0941-016)(COMPLETED)",[87],[14156],[13863],{"nctId":32940,"briefTitle":32941,"status":105,"phases":32942,"primaryCompletion":14408,"completion":14408,"start":13891,"enrollment":367,"conditions":32943,"interventions":32944},"NCT00511472","An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)",[87],[15],[13863,32945],"LANTUS insulin",{"nctId":14727,"briefTitle":14728,"status":105,"phases":32947,"primaryCompletion":14623,"completion":13224,"start":14730,"enrollment":5563,"conditions":32948,"interventions":32949},[87],[14156],[13863,13864],{"nctId":14734,"briefTitle":14735,"status":105,"phases":32951,"primaryCompletion":14352,"completion":14352,"start":14353,"enrollment":347,"conditions":32952,"interventions":32953},[87],[33],[13863,13864],{"trials":32955,"activeCount":99},[32956,32960,32966],{"nctId":13857,"briefTitle":13858,"status":150,"phases":32957,"primaryCompletion":4990,"completion":12813,"start":6309,"enrollment":13860,"conditions":32958,"interventions":32959},[88],[33],[13863,13864,13865,4084],{"nctId":32961,"briefTitle":32962,"status":105,"phases":32963,"primaryCompletion":14494,"completion":14494,"start":13870,"enrollment":14325,"conditions":32964,"interventions":32965},"NCT00824616","A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)",[88],[15],[13863,14059],{"nctId":13916,"briefTitle":13917,"status":105,"phases":32967,"primaryCompletion":6308,"completion":6308,"start":13870,"enrollment":5196,"conditions":32968,"interventions":32969},[88],[15],[13863,13146,4084],{"trials":32971,"activeCount":99},[],{"trials":32973,"activeCount":99},[],{"trials":32975,"activeCount":99},[],{"intervention":32977,"totalTrials":357,"cells":32978},"MK-2060",{"EARLY_PHASE1":32979,"PHASE1":32981,"PHASE2":33031,"PHASE3":33041,"PHASE4":33043,"NA":33045},{"trials":32980,"activeCount":99},[],{"trials":32982,"activeCount":99},[32983,32992,33000,33008,33015,33024],{"nctId":32984,"briefTitle":32985,"status":105,"phases":32986,"primaryCompletion":32987,"completion":32987,"start":32988,"enrollment":312,"conditions":32989,"interventions":32991},"NCT03873038","Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)",[87],"2021-12-20","2019-04-29",[32990,5941],"Renal Dialysis",[32977],{"nctId":32993,"briefTitle":32994,"status":105,"phases":32995,"primaryCompletion":32996,"completion":32996,"start":32997,"enrollment":4071,"conditions":32998,"interventions":32999},"NCT05656040","A Study of MK-2060 in Participants With Chronic and\u002For End-Stage Kidney Disease (MK-2060-011)",[87],"2024-08-12","2023-02-08",[12895,5942,5941],[32977],{"nctId":33001,"briefTitle":33002,"status":105,"phases":33003,"primaryCompletion":33004,"completion":33004,"start":2333,"enrollment":3141,"conditions":33005,"interventions":33007},"NCT06582602","A Study of MK-2060 in Healthy Participants (MK-2060-016)",[87],"2025-04-18",[33006],"Venous Thrombosis",[32977],{"nctId":33009,"briefTitle":33010,"status":105,"phases":33011,"primaryCompletion":33012,"completion":33012,"start":9414,"enrollment":8016,"conditions":33013,"interventions":33014},"NCT06843993","Single-Ascending Dose Study of MK-2060 in Healthy Chinese Male Adult Participants (MK-2060-009)",[87],"2023-10-27",[18],[32977],{"nctId":33016,"briefTitle":33017,"status":105,"phases":33018,"primaryCompletion":2042,"completion":2042,"start":33019,"enrollment":3496,"conditions":33020,"interventions":33023},"NCT05769595","Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)",[87],"2023-06-14",[33021,33022,5941],"End-Stage Renal Disease (ESRD)","End-Stage Kidney Disease (ESKD)",[32977],{"nctId":33025,"briefTitle":33026,"status":105,"phases":33027,"primaryCompletion":2071,"completion":2071,"start":33028,"enrollment":95,"conditions":33029,"interventions":33030},"NCT05335005","MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)",[87],"2022-05-30",[12895,5941],[32977],{"trials":33032,"activeCount":99},[33033],{"nctId":33034,"briefTitle":33035,"status":105,"phases":33036,"primaryCompletion":33037,"completion":4533,"start":33038,"enrollment":14046,"conditions":33039,"interventions":33040},"NCT05027074","Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)",[88],"2024-10-30","2021-09-17",[12895,5942,5941],[32977],{"trials":33042,"activeCount":99},[],{"trials":33044,"activeCount":99},[],{"trials":33046,"activeCount":99},[],{"intervention":1253,"totalTrials":4555,"cells":33048},{"EARLY_PHASE1":33049,"PHASE1":33051,"PHASE2":33057,"PHASE3":33079,"PHASE4":33081,"NA":33083},{"trials":33050,"activeCount":99},[],{"trials":33052,"activeCount":99},[33053],{"nctId":2808,"briefTitle":2809,"status":105,"phases":33054,"primaryCompletion":2811,"completion":2812,"start":2813,"enrollment":22,"conditions":33055,"interventions":33056},[87],[2815],[2817,1677,2818,484,1654,2819],{"trials":33058,"activeCount":99},[33059,33063,33067,33071,33075],{"nctId":5797,"briefTitle":5798,"status":105,"phases":33060,"primaryCompletion":5800,"completion":5800,"start":5801,"enrollment":5802,"conditions":33061,"interventions":33062},[88],[1108,369],[5135,795,1253],{"nctId":32817,"briefTitle":32818,"status":105,"phases":33064,"primaryCompletion":32820,"completion":16727,"start":32821,"enrollment":14941,"conditions":33065,"interventions":33066},[88],[22881],[6106,1253],{"nctId":1243,"briefTitle":1244,"status":105,"phases":33068,"primaryCompletion":1246,"completion":1247,"start":1248,"enrollment":1249,"conditions":33069,"interventions":33070},[87,88],[1251],[47,387,386,841,385,1100,1253,1254],{"nctId":19383,"briefTitle":19384,"status":150,"phases":33072,"primaryCompletion":14540,"completion":14540,"start":14484,"enrollment":3141,"conditions":33073,"interventions":33074},[87,88],[369],[5174,5174,5174,5174,2818],{"nctId":2896,"briefTitle":2897,"status":150,"phases":33076,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":2901,"conditions":33077,"interventions":33078},[87,88],[290],[386,1664,1843,2904,714,2905,693,387,390,1444,1253,437,2906],{"trials":33080,"activeCount":99},[],{"trials":33082,"activeCount":99},[],{"trials":33084,"activeCount":99},[],{"intervention":33086,"totalTrials":4555,"cells":33087},"MK-6194",{"EARLY_PHASE1":33088,"PHASE1":33090,"PHASE2":33124,"PHASE3":33142,"PHASE4":33144,"NA":33146},{"trials":33089,"activeCount":99},[],{"trials":33091,"activeCount":99},[33092,33101,33108,33115],{"nctId":33093,"briefTitle":33094,"status":105,"phases":33095,"primaryCompletion":33096,"completion":33096,"start":33097,"enrollment":380,"conditions":33098,"interventions":33100},"NCT05450198","Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)",[87],"2024-05-22","2022-08-08",[33099],"Dermatitis, Atopic",[33086],{"nctId":33102,"briefTitle":33103,"status":105,"phases":33104,"primaryCompletion":33105,"completion":33105,"start":8050,"enrollment":661,"conditions":33106,"interventions":33107},"NCT06821334","A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)",[87],"2024-08-09",[18],[33086],{"nctId":33109,"briefTitle":33110,"status":105,"phases":33111,"primaryCompletion":19909,"completion":19909,"start":33112,"enrollment":3655,"conditions":33113,"interventions":33114},"NCT06649877","MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013)",[87],"2023-03-20",[18],[33086],{"nctId":33116,"briefTitle":33117,"status":105,"phases":33118,"primaryCompletion":33119,"completion":33120,"start":33121,"enrollment":28,"conditions":33122,"interventions":33123},"NCT04924114","A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)",[87],"2024-01-08","2024-07-15","2021-10-14",[9066],[33086],{"trials":33125,"activeCount":99},[33126,33135],{"nctId":33127,"briefTitle":33128,"status":150,"phases":33129,"primaryCompletion":973,"completion":1260,"start":33130,"enrollment":33131,"conditions":33132,"interventions":33134},"NCT06113328","A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)",[88],"2023-11-27",169,[33133],"Non-segmental Vitiligo",[33086],{"nctId":33136,"briefTitle":33137,"status":150,"phases":33138,"primaryCompletion":1260,"completion":1260,"start":33139,"enrollment":30057,"conditions":33140,"interventions":33141},"NCT06161116","Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)",[88],"2023-12-27",[8405],[33086],{"trials":33143,"activeCount":99},[],{"trials":33145,"activeCount":99},[],{"trials":33147,"activeCount":99},[],{"intervention":5135,"totalTrials":174,"cells":33149},{"EARLY_PHASE1":33150,"PHASE1":33152,"PHASE2":33165,"PHASE3":33184,"PHASE4":33186,"NA":33188},{"trials":33151,"activeCount":99},[],{"trials":33153,"activeCount":99},[33154,33158],{"nctId":5128,"briefTitle":5129,"status":105,"phases":33155,"primaryCompletion":5131,"completion":5131,"start":5132,"enrollment":2770,"conditions":33156,"interventions":33157},[87],[176,756,526],[5135,5135,5135,5135,5136,5137,529],{"nctId":33159,"briefTitle":33160,"status":105,"phases":33161,"primaryCompletion":6799,"completion":6799,"start":12804,"enrollment":2085,"conditions":33162,"interventions":33164},"NCT00871663","Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)",[87],[176,756,526,33163],"Leukemia, Lymphocytic, Chronic. B-Cell",[5135],{"trials":33166,"activeCount":99},[33167,33171,33175],{"nctId":5797,"briefTitle":5798,"status":105,"phases":33168,"primaryCompletion":5800,"completion":5800,"start":5801,"enrollment":5802,"conditions":33169,"interventions":33170},[88],[1108,369],[5135,795,1253],{"nctId":21573,"briefTitle":21574,"status":150,"phases":33172,"primaryCompletion":15794,"completion":15794,"start":14314,"enrollment":734,"conditions":33173,"interventions":33174},[88],[21577,6286],[5135,5199,21579],{"nctId":33176,"briefTitle":33177,"status":150,"phases":33178,"primaryCompletion":4990,"completion":4990,"start":13870,"enrollment":31,"conditions":33179,"interventions":33182},"NCT00798213","SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)",[88],[33180,33181],"Leukemia, Myeloid, Acute","Lymphoblastic Leukemia, Acute",[5135,33183],"Gemtuzumab ozogamicin",{"trials":33185,"activeCount":99},[],{"trials":33187,"activeCount":99},[],{"trials":33189,"activeCount":99},[],{"intervention":11176,"totalTrials":174,"cells":33191},{"EARLY_PHASE1":33192,"PHASE1":33194,"PHASE2":33221,"PHASE3":33230,"PHASE4":33232,"NA":33234},{"trials":33193,"activeCount":99},[],{"trials":33195,"activeCount":99},[33196,33204,33208,33217],{"nctId":33197,"briefTitle":33198,"status":105,"phases":33199,"primaryCompletion":9406,"completion":2305,"start":33200,"enrollment":347,"conditions":33201,"interventions":33203},"NCT04730635","Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)",[87],"2021-03-23",[11174,33202],"Mild Cognitive Impairment",[11176],{"nctId":11169,"briefTitle":11170,"status":105,"phases":33205,"primaryCompletion":11172,"completion":11172,"start":1131,"enrollment":1624,"conditions":33206,"interventions":33207},[87],[11174],[11142,11176],{"nctId":33209,"briefTitle":33210,"status":105,"phases":33211,"primaryCompletion":33212,"completion":33212,"start":33213,"enrollment":36,"conditions":33214,"interventions":33215},"NCT04308304","MK-1942\u002FDonepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)",[87],"2022-05-18","2021-02-16",[11174],[33216,11176],"MK-1942",{"nctId":14721,"briefTitle":14722,"status":105,"phases":33218,"primaryCompletion":13890,"completion":13890,"start":5507,"enrollment":626,"conditions":33219,"interventions":33220},[87],[11195],[14346,13864,11176,14346],{"trials":33222,"activeCount":99},[33223],{"nctId":33224,"briefTitle":33225,"status":105,"phases":33226,"primaryCompletion":33227,"completion":33227,"start":20377,"enrollment":8016,"conditions":33228,"interventions":33229},"NCT02064920","Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)",[88],"2016-07-13",[11174],[11176,11176],{"trials":33231,"activeCount":99},[],{"trials":33233,"activeCount":99},[],{"trials":33235,"activeCount":99},[],{"intervention":12959,"totalTrials":174,"cells":33237},{"EARLY_PHASE1":33238,"PHASE1":33240,"PHASE2":33249,"PHASE3":33272,"PHASE4":33274,"NA":33276},{"trials":33239,"activeCount":99},[],{"trials":33241,"activeCount":99},[33242],{"nctId":33243,"briefTitle":33244,"status":105,"phases":33245,"primaryCompletion":33246,"completion":33246,"start":9250,"enrollment":120,"conditions":33247,"interventions":33248},"NCT02666352","A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)",[87],"2017-01-16",[21],[12959,19822],{"trials":33250,"activeCount":99},[33251,33255,33259,33263],{"nctId":12950,"briefTitle":12951,"status":105,"phases":33252,"primaryCompletion":12953,"completion":12954,"start":12955,"enrollment":494,"conditions":33253,"interventions":33254},[87,88],[12957],[12959,5604],{"nctId":19814,"briefTitle":19815,"status":105,"phases":33256,"primaryCompletion":1986,"completion":19817,"start":19818,"enrollment":19819,"conditions":33257,"interventions":33258},[88],[24],[15839,12959,17381,19822,19823,14925],{"nctId":19835,"briefTitle":19836,"status":105,"phases":33260,"primaryCompletion":19838,"completion":19839,"start":19840,"enrollment":2695,"conditions":33261,"interventions":33262},[88],[24],[15839,12959,17381,19822,19843,14925],{"nctId":33264,"briefTitle":33265,"status":150,"phases":33266,"primaryCompletion":33267,"completion":33268,"start":33269,"enrollment":15967,"conditions":33270,"interventions":33271},"NCT02956629","Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)",[88],"2017-12-22","2018-03-05","2016-11-16",[24],[12959,19822,14925],{"trials":33273,"activeCount":99},[],{"trials":33275,"activeCount":99},[],{"trials":33277,"activeCount":99},[],{"intervention":19822,"totalTrials":174,"cells":33279},{"EARLY_PHASE1":33280,"PHASE1":33282,"PHASE2":33296,"PHASE3":33310,"PHASE4":33312,"NA":33314},{"trials":33281,"activeCount":99},[],{"trials":33283,"activeCount":99},[33284,33288],{"nctId":33243,"briefTitle":33244,"status":105,"phases":33285,"primaryCompletion":33246,"completion":33246,"start":9250,"enrollment":120,"conditions":33286,"interventions":33287},[87],[21],[12959,19822],{"nctId":33289,"briefTitle":33290,"status":105,"phases":33291,"primaryCompletion":33292,"completion":33292,"start":33293,"enrollment":4059,"conditions":33294,"interventions":33295},"NCT02076100","Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)",[87],"2015-11-15","2014-03-27",[24353],[19822],{"trials":33297,"activeCount":99},[33298,33302,33306],{"nctId":19814,"briefTitle":19815,"status":105,"phases":33299,"primaryCompletion":1986,"completion":19817,"start":19818,"enrollment":19819,"conditions":33300,"interventions":33301},[88],[24],[15839,12959,17381,19822,19823,14925],{"nctId":19835,"briefTitle":19836,"status":105,"phases":33303,"primaryCompletion":19838,"completion":19839,"start":19840,"enrollment":2695,"conditions":33304,"interventions":33305},[88],[24],[15839,12959,17381,19822,19843,14925],{"nctId":33264,"briefTitle":33265,"status":150,"phases":33307,"primaryCompletion":33267,"completion":33268,"start":33269,"enrollment":15967,"conditions":33308,"interventions":33309},[88],[24],[12959,19822,14925],{"trials":33311,"activeCount":99},[],{"trials":33313,"activeCount":99},[],{"trials":33315,"activeCount":99},[],{"intervention":33317,"totalTrials":174,"cells":33318},"denufosol tetrasodium",{"EARLY_PHASE1":33319,"PHASE1":33321,"PHASE2":33334,"PHASE3":33354,"PHASE4":33356,"NA":33358},{"trials":33320,"activeCount":99},[],{"trials":33322,"activeCount":99},[33323,33329],{"nctId":33324,"briefTitle":33325,"status":105,"phases":33326,"primaryCompletion":15118,"completion":15118,"start":17248,"enrollment":95,"conditions":33327,"interventions":33328},"NCT00210093","A Pharmacokinetic Evaluation Study in Healthy Volunteers",[87],[18],[33317],{"nctId":33330,"briefTitle":33325,"status":105,"phases":33331,"primaryCompletion":22878,"completion":22878,"start":20205,"enrollment":3963,"conditions":33332,"interventions":33333},"NCT00210054",[87],[18],[33317],{"trials":33335,"activeCount":99},[33336,33342,33348],{"nctId":33337,"briefTitle":33338,"status":105,"phases":33339,"primaryCompletion":15063,"completion":15063,"start":14903,"enrollment":380,"conditions":33340,"interventions":33341},"NCT00103714","Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease",[88],[22638],[33317],{"nctId":33343,"briefTitle":33344,"status":105,"phases":33345,"primaryCompletion":21850,"completion":21850,"start":17248,"enrollment":397,"conditions":33346,"interventions":33347},"NCT00056147","Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease",[88],[22638],[33317],{"nctId":33349,"briefTitle":33350,"status":105,"phases":33351,"primaryCompletion":4418,"start":15063,"enrollment":5563,"conditions":33352,"interventions":33353},"NCT00130182","A Study in Pediatric Patients With Cystic Fibrosis Lung Disease",[88],[22638],[33317],{"trials":33355,"activeCount":99},[],{"trials":33357,"activeCount":99},[],{"trials":33359,"activeCount":99},[],{"intervention":33361,"totalTrials":174,"cells":33362},"IDX184",{"EARLY_PHASE1":33363,"PHASE1":33365,"PHASE2":33382,"PHASE3":33404,"PHASE4":33406,"NA":33408},{"trials":33364,"activeCount":99},[],{"trials":33366,"activeCount":99},[33367,33373],{"nctId":33368,"briefTitle":33369,"status":105,"phases":33370,"primaryCompletion":6309,"completion":6309,"start":5801,"enrollment":1054,"conditions":33371,"interventions":33372},"NCT00730431","Single-Dose Escalation Study of IDX184 in Healthy Volunteers (MK-2355-002)",[87],[24],[33361],{"nctId":33374,"briefTitle":33375,"status":105,"phases":33376,"primaryCompletion":20258,"completion":5982,"start":12813,"enrollment":805,"conditions":33377,"interventions":33378},"NCT01157104","A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002)",[87],[12957],[33379,33361,33380,33381],"IDX320","IDX184 placebo","IDX320 placebo",{"trials":33383,"activeCount":99},[33384,33390,33397],{"nctId":33385,"briefTitle":33386,"status":105,"phases":33387,"primaryCompletion":20258,"completion":20258,"start":8591,"enrollment":2770,"conditions":33388,"interventions":33389},"NCT01011166","Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)",[88],[20413],[33361,15886,14925],{"nctId":33391,"briefTitle":33392,"status":105,"phases":33393,"primaryCompletion":14713,"completion":14713,"start":14353,"enrollment":1419,"conditions":33394,"interventions":33396},"NCT00807001","Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects",[87,88],[33395],"Chronic Hepatitis C (HCV)",[33361],{"nctId":33398,"briefTitle":33399,"status":105,"phases":33400,"primaryCompletion":20410,"completion":33401,"start":7018,"enrollment":14325,"conditions":33402,"interventions":33403},"NCT01371604","Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)",[88],"2014-10",[21],[33361,15886,14925],{"trials":33405,"activeCount":99},[],{"trials":33407,"activeCount":99},[],{"trials":33409,"activeCount":99},[],{"intervention":458,"totalTrials":3963,"cells":33411},{"EARLY_PHASE1":33412,"PHASE1":33414,"PHASE2":33420,"PHASE3":33434,"PHASE4":33436,"NA":33438},{"trials":33413,"activeCount":99},[],{"trials":33415,"activeCount":99},[33416],{"nctId":450,"briefTitle":451,"status":105,"phases":33417,"primaryCompletion":453,"completion":453,"start":454,"enrollment":455,"conditions":33418,"interventions":33419},[87],[290],[458,47,434,437,435,459,460,461],{"trials":33421,"activeCount":99},[33422,33426,33430],{"nctId":749,"briefTitle":750,"status":105,"phases":33423,"primaryCompletion":752,"completion":752,"start":659,"enrollment":753,"conditions":33424,"interventions":33425},[87,88],[755,756,359],[42,458],{"nctId":771,"briefTitle":772,"status":105,"phases":33427,"primaryCompletion":774,"completion":774,"start":775,"enrollment":776,"conditions":33428,"interventions":33429},[88],[778],[47,458,461,780],{"nctId":1234,"briefTitle":1235,"status":1040,"phases":33431,"primaryCompletion":1237,"completion":1237,"start":1238,"enrollment":99,"conditions":33432,"interventions":33433},[87,88],[324],[47,458,460,923,1241],{"trials":33435,"activeCount":99},[],{"trials":33437,"activeCount":99},[],{"trials":33439,"activeCount":99},[],{"intervention":33441,"totalTrials":3963,"cells":33442},"MK-6096",{"EARLY_PHASE1":33443,"PHASE1":33445,"PHASE2":33457,"PHASE3":33486,"PHASE4":33488,"NA":33490},{"trials":33444,"activeCount":99},[],{"trials":33446,"activeCount":99},[33447],{"nctId":33448,"briefTitle":33449,"status":105,"phases":33450,"primaryCompletion":33451,"completion":33451,"start":33452,"enrollment":805,"conditions":33453,"interventions":33455},"NCT02549027","A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)",[87],"2010-04-06","2009-11-06",[33454],"Polysomnography",[33456,33441],"MK-1064",{"trials":33458,"activeCount":99},[33459,33467,33477],{"nctId":33460,"briefTitle":33461,"status":105,"phases":33462,"primaryCompletion":33463,"completion":33463,"start":21001,"enrollment":3262,"conditions":33464,"interventions":33466},"NCT01564459","Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)",[88],"2013-04-18",[33465],"Diabetic Neuropathy, Painful",[33441],{"nctId":33468,"briefTitle":33469,"status":105,"phases":33470,"primaryCompletion":33471,"completion":33471,"start":33472,"enrollment":33473,"conditions":33474,"interventions":33475},"NCT01021852","Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)",[88],"2011-02-01","2009-11-30",326,[9336],[33441,33476],"Dose-matched Placebo to MK-6096",{"nctId":33478,"briefTitle":33479,"status":105,"phases":33480,"primaryCompletion":33481,"completion":33481,"start":33482,"enrollment":19871,"conditions":33483,"interventions":33485},"NCT01513291","A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)",[88],"2012-10-03","2012-02-06",[4397,33484],"Headache",[33441],{"trials":33487,"activeCount":99},[],{"trials":33489,"activeCount":99},[],{"trials":33491,"activeCount":99},[],{"intervention":33493,"totalTrials":3963,"cells":33494},"MK0457",{"EARLY_PHASE1":33495,"PHASE1":33497,"PHASE2":33516,"PHASE3":33530,"PHASE4":33532,"NA":33534},{"trials":33496,"activeCount":99},[],{"trials":33498,"activeCount":99},[33499,33507],{"nctId":33500,"briefTitle":33501,"status":150,"phases":33502,"primaryCompletion":14504,"completion":14504,"start":14540,"enrollment":202,"conditions":33503,"interventions":33505},"NCT00500006","A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)",[87],[24421,33504],"Leukemia, Lymphoblastic, Acute, Philadelphia-Positive",[33493,33506],"dasatinib",{"nctId":33508,"briefTitle":33509,"status":105,"phases":33510,"primaryCompletion":13890,"completion":13890,"start":14594,"enrollment":1624,"conditions":33511,"interventions":33515},"NCT00111683","MK0457 in Patients With Leukemia (0457-003)",[87],[33512,33513,196,33514],"Chronic Myelogenous Leukemia in Blast Crisis","Lymphocytic Leukemia, B Cell, Acute","Myelogenous Leukemia, Chronic",[33493],{"trials":33517,"activeCount":99},[33518,33524],{"nctId":33519,"briefTitle":33520,"status":150,"phases":33521,"primaryCompletion":5280,"completion":5280,"start":15038,"enrollment":13439,"conditions":33522,"interventions":33523},"NCT00405054","A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)",[88],[19080],[33493],{"nctId":33525,"briefTitle":33526,"status":150,"phases":33527,"primaryCompletion":14409,"completion":14409,"start":14705,"enrollment":4059,"conditions":33528,"interventions":33529},"NCT00290550","A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)",[88],[369],[33493],{"trials":33531,"activeCount":99},[],{"trials":33533,"activeCount":99},[],{"trials":33535,"activeCount":99},[],{"intervention":33537,"totalTrials":3963,"cells":33538},"IDX719",{"EARLY_PHASE1":33539,"PHASE1":33541,"PHASE2":33564,"PHASE3":33573,"PHASE4":33575,"NA":33577},{"trials":33540,"activeCount":99},[],{"trials":33542,"activeCount":99},[33543,33550,33557],{"nctId":33544,"briefTitle":33545,"status":105,"phases":33546,"primaryCompletion":33547,"completion":33547,"start":19020,"enrollment":184,"conditions":33548,"interventions":33549},"NCT01813513","Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)",[87],"2013-07",[20413],[33537,20435],{"nctId":33551,"briefTitle":33552,"status":105,"phases":33553,"primaryCompletion":17591,"completion":17591,"start":20279,"enrollment":5616,"conditions":33554,"interventions":33555},"NCT01907724","Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)",[87],[21],[33537,20435,20436,33556],"RTV",{"nctId":33558,"briefTitle":33559,"status":105,"phases":33560,"primaryCompletion":33561,"completion":33561,"start":17591,"enrollment":8016,"conditions":33562,"interventions":33563},"NCT01919125","Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)",[87],"2014-02",[21],[33537],{"trials":33565,"activeCount":99},[33566],{"nctId":33567,"briefTitle":33568,"status":105,"phases":33569,"primaryCompletion":16792,"completion":16792,"start":33570,"enrollment":132,"conditions":33571,"interventions":33572},"NCT01508156","Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)",[87,88],"2012-01",[21],[33537],{"trials":33574,"activeCount":99},[],{"trials":33576,"activeCount":99},[],{"trials":33578,"activeCount":99},[],{"intervention":1174,"totalTrials":3963,"cells":33580},{"EARLY_PHASE1":33581,"PHASE1":33583,"PHASE2":33585,"PHASE3":33606,"PHASE4":33608,"NA":33610},{"trials":33582,"activeCount":99},[],{"trials":33584,"activeCount":99},[],{"trials":33586,"activeCount":99},[33587,33594,33598,33602],{"nctId":33588,"briefTitle":33589,"status":105,"phases":33590,"primaryCompletion":33591,"completion":33591,"start":12751,"enrollment":569,"conditions":33592,"interventions":33593},"NCT00688467","Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363)",[88],"2009-03-01",[5985],[1174],{"nctId":1164,"briefTitle":1165,"status":105,"phases":33595,"primaryCompletion":1167,"completion":1167,"start":1168,"enrollment":1169,"conditions":33596,"interventions":33597},[88],[176,314,1171,1172],[1174,47],{"nctId":4316,"briefTitle":4317,"status":105,"phases":33599,"primaryCompletion":4319,"completion":4319,"start":4320,"enrollment":661,"conditions":33600,"interventions":33601},[88],[4322],[1174,1089],{"nctId":4325,"briefTitle":4326,"status":150,"phases":33603,"primaryCompletion":4328,"completion":4329,"start":4330,"enrollment":3338,"conditions":33604,"interventions":33605},[88],[4332],[1174,1089],{"trials":33607,"activeCount":99},[],{"trials":33609,"activeCount":99},[],{"trials":33611,"activeCount":99},[],{"intervention":33613,"totalTrials":3963,"cells":33614},"denufosol tetrasodium (INS37217) Intravitreal",{"EARLY_PHASE1":33615,"PHASE1":33617,"PHASE2":33626,"PHASE3":33649,"PHASE4":33651,"NA":33653},{"trials":33616,"activeCount":99},[],{"trials":33618,"activeCount":99},[33619],{"nctId":33620,"briefTitle":33621,"status":105,"phases":33622,"primaryCompletion":21167,"completion":21167,"start":21619,"enrollment":4071,"conditions":33623,"interventions":33625},"NCT00210067","A Study in Subjects With Retinal Detachment",[87],[33624],"Retinal Detachment",[33613],{"trials":33627,"activeCount":99},[33628,33635,33641],{"nctId":33629,"briefTitle":33630,"status":1040,"phases":33631,"start":15063,"enrollment":99,"conditions":33632,"interventions":33634},"NCT00135655","A Study of Denufosol Tetrasodium Intravitreal Injection in Subjects With Post Cataract Extraction Macular Edema",[88],[33633],"Macular Edema, Cystoid",[33613],{"nctId":33636,"briefTitle":33637,"status":150,"phases":33638,"primaryCompletion":17461,"completion":17461,"start":14229,"enrollment":3141,"conditions":33639,"interventions":33640},"NCT00083967","Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment",[88],[33624],[33613],{"nctId":33642,"briefTitle":33643,"status":150,"phases":33644,"primaryCompletion":15038,"completion":15038,"start":15156,"enrollment":2901,"conditions":33645,"interventions":33648},"NCT00114062","Study to Treat Uveitis Associated Macular Edema",[88],[33646,33647],"Cystoid Macular Edema","Uveitis",[33613],{"trials":33650,"activeCount":99},[],{"trials":33652,"activeCount":99},[],{"trials":33654,"activeCount":99},[],{"intervention":33656,"totalTrials":3963,"cells":33657},"Farnesyl Protein Transferase Inhibitor",{"EARLY_PHASE1":33658,"PHASE1":33660,"PHASE2":33674,"PHASE3":33691,"PHASE4":33693,"NA":33695},{"trials":33659,"activeCount":99},[],{"trials":33661,"activeCount":99},[33662,33668],{"nctId":33663,"briefTitle":33664,"status":150,"phases":33665,"primaryCompletion":17096,"completion":17096,"start":15584,"enrollment":4059,"conditions":33666,"interventions":33667},"NCT00040534","Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)",[87],[290],[33656],{"nctId":33669,"briefTitle":33670,"status":105,"phases":33671,"primaryCompletion":21850,"completion":21850,"start":22636,"enrollment":31,"conditions":33672,"interventions":33673},"NCT00040547","Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED)",[87],[290],[33656],{"trials":33675,"activeCount":99},[33676,33685],{"nctId":33677,"briefTitle":33678,"status":105,"phases":33679,"primaryCompletion":22476,"completion":22476,"start":22009,"enrollment":3048,"conditions":33680,"interventions":33684},"NCT00034684","Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)",[87,88],[19080,196,33681,33682,33683],"Leukemia, Myeloid, Chronic","Blast Crisis","Leukemia, Lymphocytic",[33656],{"nctId":33686,"briefTitle":33687,"status":150,"phases":33688,"primaryCompletion":14229,"completion":14229,"start":18426,"enrollment":2901,"conditions":33689,"interventions":33690},"NCT00073450","Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)",[88],[1901,2482],[33656],{"trials":33692,"activeCount":99},[],{"trials":33694,"activeCount":99},[],{"trials":33696,"activeCount":99},[],{"intervention":15058,"totalTrials":3963,"cells":33698},{"EARLY_PHASE1":33699,"PHASE1":33701,"PHASE2":33703,"PHASE3":33729,"PHASE4":33731,"NA":33733},{"trials":33700,"activeCount":99},[],{"trials":33702,"activeCount":99},[],{"trials":33704,"activeCount":99},[33705,33711,33718,33722],{"nctId":33706,"briefTitle":33707,"status":105,"phases":33708,"primaryCompletion":14772,"completion":14772,"start":15054,"enrollment":13805,"conditions":33709,"interventions":33710},"NCT00703833","A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)",[88],[15056],[15058],{"nctId":33712,"briefTitle":33713,"status":105,"phases":33714,"primaryCompletion":14772,"completion":14772,"start":20205,"enrollment":312,"conditions":33715,"interventions":33717},"NCT00546624","GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)",[88],[33716],"Anxiety Disorder",[15058],{"nctId":15051,"briefTitle":15052,"status":105,"phases":33719,"primaryCompletion":14772,"completion":14772,"start":15054,"enrollment":10917,"conditions":33720,"interventions":33721},[88],[15056],[15058,14331],{"nctId":33723,"briefTitle":33724,"status":105,"phases":33725,"primaryCompletion":14772,"completion":14772,"start":22635,"enrollment":558,"conditions":33726,"interventions":33728},"NCT00543920","A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)",[88],[33727],"Anxiety Disorders",[15058],{"trials":33730,"activeCount":99},[],{"trials":33732,"activeCount":99},[],{"trials":33734,"activeCount":99},[],{"intervention":2905,"totalTrials":3963,"cells":33736},{"EARLY_PHASE1":33737,"PHASE1":33739,"PHASE2":33745,"PHASE3":33767,"PHASE4":33769,"NA":33771},{"trials":33738,"activeCount":99},[],{"trials":33740,"activeCount":99},[33741],{"nctId":5462,"briefTitle":5463,"status":150,"phases":33742,"primaryCompletion":5465,"completion":5465,"start":5466,"enrollment":3963,"conditions":33743,"interventions":33744},[87],[290,176,5468,5469,5470],[1390,1074,5472,437,2905,1069,562,1073],{"trials":33746,"activeCount":99},[33747,33751,33763],{"nctId":5818,"briefTitle":5819,"status":105,"phases":33748,"primaryCompletion":5821,"completion":5821,"start":5822,"enrollment":2647,"conditions":33749,"interventions":33750},[88],[419],[2905,437,693,795,5825,5826,1751],{"nctId":33752,"briefTitle":33753,"status":150,"phases":33754,"primaryCompletion":33755,"completion":14297,"start":33756,"enrollment":33757,"conditions":33758,"interventions":33761},"NCT00617890","A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002\u002FP04720)",[88],"2011-08-31","2008-02-01",219,[19045,33759,33760],"Sarcoma, Ewing's","Peripheral Neuroectodermal Tumor",[33762],"robatumumab",{"nctId":2896,"briefTitle":2897,"status":150,"phases":33764,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":2901,"conditions":33765,"interventions":33766},[87,88],[290],[386,1664,1843,2904,714,2905,693,387,390,1444,1253,437,2906],{"trials":33768,"activeCount":99},[],{"trials":33770,"activeCount":99},[],{"trials":33772,"activeCount":99},[],{"intervention":8143,"totalTrials":202,"cells":33774},{"EARLY_PHASE1":33775,"PHASE1":33777,"PHASE2":33787,"PHASE3":33793,"PHASE4":33795,"NA":33797},{"trials":33776,"activeCount":99},[],{"trials":33778,"activeCount":99},[33779,33783],{"nctId":8133,"briefTitle":8134,"status":105,"phases":33780,"primaryCompletion":8136,"completion":8136,"start":8137,"enrollment":5616,"conditions":33781,"interventions":33782},[87],[290,369],[8140,8141,8142,8143,8144,8145,8146,8147],{"nctId":8149,"briefTitle":8150,"status":105,"phases":33784,"primaryCompletion":2634,"completion":2634,"start":8152,"enrollment":28,"conditions":33785,"interventions":33786},[87],[279,314,1552],[8155,8156,84,8143,8145,8157,8158,8146,8159,8160,8161,8162],{"trials":33788,"activeCount":99},[33789],{"nctId":8170,"briefTitle":8171,"status":105,"phases":33790,"primaryCompletion":1247,"completion":8173,"start":8174,"enrollment":8175,"conditions":33791,"interventions":33792},[88],[314],[84,8178,8179,8143,8145,8146,8180],{"trials":33794,"activeCount":99},[],{"trials":33796,"activeCount":99},[],{"trials":33798,"activeCount":99},[],{"intervention":8145,"totalTrials":202,"cells":33800},{"EARLY_PHASE1":33801,"PHASE1":33803,"PHASE2":33813,"PHASE3":33819,"PHASE4":33821,"NA":33823},{"trials":33802,"activeCount":99},[],{"trials":33804,"activeCount":99},[33805,33809],{"nctId":8133,"briefTitle":8134,"status":105,"phases":33806,"primaryCompletion":8136,"completion":8136,"start":8137,"enrollment":5616,"conditions":33807,"interventions":33808},[87],[290,369],[8140,8141,8142,8143,8144,8145,8146,8147],{"nctId":8149,"briefTitle":8150,"status":105,"phases":33810,"primaryCompletion":2634,"completion":2634,"start":8152,"enrollment":28,"conditions":33811,"interventions":33812},[87],[279,314,1552],[8155,8156,84,8143,8145,8157,8158,8146,8159,8160,8161,8162],{"trials":33814,"activeCount":99},[33815],{"nctId":8170,"briefTitle":8171,"status":105,"phases":33816,"primaryCompletion":1247,"completion":8173,"start":8174,"enrollment":8175,"conditions":33817,"interventions":33818},[88],[314],[84,8178,8179,8143,8145,8146,8180],{"trials":33820,"activeCount":99},[],{"trials":33822,"activeCount":99},[],{"trials":33824,"activeCount":99},[],{"intervention":8146,"totalTrials":202,"cells":33826},{"EARLY_PHASE1":33827,"PHASE1":33829,"PHASE2":33839,"PHASE3":33845,"PHASE4":33847,"NA":33849},{"trials":33828,"activeCount":99},[],{"trials":33830,"activeCount":99},[33831,33835],{"nctId":8133,"briefTitle":8134,"status":105,"phases":33832,"primaryCompletion":8136,"completion":8136,"start":8137,"enrollment":5616,"conditions":33833,"interventions":33834},[87],[290,369],[8140,8141,8142,8143,8144,8145,8146,8147],{"nctId":8149,"briefTitle":8150,"status":105,"phases":33836,"primaryCompletion":2634,"completion":2634,"start":8152,"enrollment":28,"conditions":33837,"interventions":33838},[87],[279,314,1552],[8155,8156,84,8143,8145,8157,8158,8146,8159,8160,8161,8162],{"trials":33840,"activeCount":99},[33841],{"nctId":8170,"briefTitle":8171,"status":105,"phases":33842,"primaryCompletion":1247,"completion":8173,"start":8174,"enrollment":8175,"conditions":33843,"interventions":33844},[88],[314],[84,8178,8179,8143,8145,8146,8180],{"trials":33846,"activeCount":99},[],{"trials":33848,"activeCount":99},[],{"trials":33850,"activeCount":99},[],{"intervention":2894,"totalTrials":202,"cells":33852},{"EARLY_PHASE1":33853,"PHASE1":33855,"PHASE2":33861,"PHASE3":33871,"PHASE4":33873,"NA":33875},{"trials":33854,"activeCount":99},[],{"trials":33856,"activeCount":99},[33857],{"nctId":3157,"briefTitle":3158,"status":105,"phases":33858,"primaryCompletion":3160,"completion":3160,"start":3161,"enrollment":3162,"conditions":33859,"interventions":33860},[87],[176],[2894,1885,486,484],{"trials":33862,"activeCount":99},[33863,33867],{"nctId":3701,"briefTitle":3702,"status":150,"phases":33864,"primaryCompletion":3704,"completion":3704,"start":3705,"enrollment":357,"conditions":33865,"interventions":33866},[87,88],[863],[2894,3625,390],{"nctId":2886,"briefTitle":2887,"status":105,"phases":33868,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":2891,"conditions":33869,"interventions":33870},[88],[990],[2894,1654,484],{"trials":33872,"activeCount":99},[],{"trials":33874,"activeCount":99},[],{"trials":33876,"activeCount":99},[],{"intervention":780,"totalTrials":202,"cells":33878},{"EARLY_PHASE1":33879,"PHASE1":33881,"PHASE2":33883,"PHASE3":33897,"PHASE4":33899,"NA":33901},{"trials":33880,"activeCount":99},[],{"trials":33882,"activeCount":99},[],{"trials":33884,"activeCount":99},[33885,33889,33893],{"nctId":771,"briefTitle":772,"status":105,"phases":33886,"primaryCompletion":774,"completion":774,"start":775,"enrollment":776,"conditions":33887,"interventions":33888},[88],[778],[47,458,461,780],{"nctId":810,"briefTitle":811,"status":105,"phases":33890,"primaryCompletion":813,"completion":813,"start":814,"enrollment":815,"conditions":33891,"interventions":33892},[87,88],[497],[780,47,818],{"nctId":916,"briefTitle":917,"status":105,"phases":33894,"primaryCompletion":919,"completion":919,"start":356,"enrollment":920,"conditions":33895,"interventions":33896},[87,88],[35],[47,780,923,461,924],{"trials":33898,"activeCount":99},[],{"trials":33900,"activeCount":99},[],{"trials":33902,"activeCount":99},[],{"intervention":33216,"totalTrials":202,"cells":33904},{"EARLY_PHASE1":33905,"PHASE1":33907,"PHASE2":33913,"PHASE3":33931,"PHASE4":33933,"NA":33935},{"trials":33906,"activeCount":99},[],{"trials":33908,"activeCount":99},[33909],{"nctId":33209,"briefTitle":33210,"status":105,"phases":33910,"primaryCompletion":33212,"completion":33212,"start":33213,"enrollment":36,"conditions":33911,"interventions":33912},[87],[11174],[33216,11176],{"trials":33914,"activeCount":99},[33915,33922],{"nctId":33916,"briefTitle":33917,"status":150,"phases":33918,"primaryCompletion":33919,"completion":33919,"start":415,"enrollment":4358,"conditions":33920,"interventions":33921},"NCT05602727","Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)",[88],"2023-09-27",[11174],[33216],{"nctId":33923,"briefTitle":33924,"status":150,"phases":33925,"primaryCompletion":33926,"completion":33926,"start":33927,"enrollment":4358,"conditions":33928,"interventions":33930},"NCT04663321","Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)",[88],"2023-09-08","2021-05-20",[33929],"Treatment Resistant Depression",[33216],{"trials":33932,"activeCount":99},[],{"trials":33934,"activeCount":99},[],{"trials":33936,"activeCount":99},[],{"intervention":20435,"totalTrials":202,"cells":33938},{"EARLY_PHASE1":33939,"PHASE1":33941,"PHASE2":33951,"PHASE3":33957,"PHASE4":33959,"NA":33961},{"trials":33940,"activeCount":99},[],{"trials":33942,"activeCount":99},[33943,33947],{"nctId":33544,"briefTitle":33545,"status":105,"phases":33944,"primaryCompletion":33547,"completion":33547,"start":19020,"enrollment":184,"conditions":33945,"interventions":33946},[87],[20413],[33537,20435],{"nctId":33551,"briefTitle":33552,"status":105,"phases":33948,"primaryCompletion":17591,"completion":17591,"start":20279,"enrollment":5616,"conditions":33949,"interventions":33950},[87],[21],[33537,20435,20436,33556],{"trials":33952,"activeCount":99},[33953],{"nctId":20428,"briefTitle":20429,"status":105,"phases":33954,"primaryCompletion":20431,"completion":20431,"start":20410,"enrollment":5196,"conditions":33955,"interventions":33956},[88],[20433],[20415,20435,14925,20436,11447,20437],{"trials":33958,"activeCount":99},[],{"trials":33960,"activeCount":99},[],{"trials":33962,"activeCount":99},[],{"intervention":33964,"totalTrials":202,"cells":33965},"MK0359",{"EARLY_PHASE1":33966,"PHASE1":33968,"PHASE2":33970,"PHASE3":33990,"PHASE4":33992,"NA":33994},{"trials":33967,"activeCount":99},[],{"trials":33969,"activeCount":99},[],{"trials":33971,"activeCount":99},[33972,33978,33984],{"nctId":33973,"briefTitle":33974,"status":105,"phases":33975,"primaryCompletion":17248,"completion":17248,"start":15054,"enrollment":1621,"conditions":33976,"interventions":33977},"NCT00482898","A Study of MK0359 in Patients With Chronic Asthma (0359-013)",[88],[5985],[33964],{"nctId":33979,"briefTitle":33980,"status":105,"phases":33981,"primaryCompletion":15118,"completion":15118,"start":22878,"enrollment":5983,"conditions":33982,"interventions":33983},"NCT00482417","Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)",[88],[7020],[33964],{"nctId":33985,"briefTitle":33986,"status":105,"phases":33987,"primaryCompletion":17248,"completion":17248,"start":22878,"enrollment":700,"conditions":33988,"interventions":33989},"NCT00482235","A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)",[88],[18267],[33964],{"trials":33991,"activeCount":99},[],{"trials":33993,"activeCount":99},[],{"trials":33995,"activeCount":99},[],{"intervention":33997,"totalTrials":202,"cells":33998},"MK-1029",{"EARLY_PHASE1":33999,"PHASE1":34001,"PHASE2":34011,"PHASE3":34031,"PHASE4":34033,"NA":34035},{"trials":34000,"activeCount":99},[],{"trials":34002,"activeCount":99},[34003],{"nctId":34004,"briefTitle":34005,"status":105,"phases":34006,"primaryCompletion":34007,"completion":34007,"start":34008,"enrollment":36,"conditions":34009,"interventions":34010},"NCT01370317","Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma",[87],"2011-12-27","2011-06-01",[5985],[33997],{"trials":34012,"activeCount":99},[34013,34022],{"nctId":34014,"briefTitle":34015,"status":150,"phases":34016,"primaryCompletion":14192,"completion":34017,"start":34018,"enrollment":24841,"conditions":34019,"interventions":34020},"NCT01656395","A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012)",[88],"2014-07-08","2012-08-23",[5985],[33997,34021],"Montelukast 10 mg",{"nctId":34023,"briefTitle":34024,"status":105,"phases":34025,"primaryCompletion":34026,"completion":34026,"start":34027,"enrollment":1169,"conditions":34028,"interventions":34029},"NCT01624974","Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011)",[88],"2014-05-05","2012-08-09",[5985],[33997,34030],"Montelukast",{"trials":34032,"activeCount":99},[],{"trials":34034,"activeCount":99},[],{"trials":34036,"activeCount":99},[],{"intervention":19843,"totalTrials":202,"cells":34038},{"EARLY_PHASE1":34039,"PHASE1":34041,"PHASE2":34050,"PHASE3":34070,"PHASE4":34072,"NA":34074},{"trials":34040,"activeCount":99},[],{"trials":34042,"activeCount":99},[34043],{"nctId":34044,"briefTitle":34045,"status":105,"phases":34046,"primaryCompletion":34047,"completion":34047,"start":16163,"enrollment":3655,"conditions":34048,"interventions":34049},"NCT02661126","Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030)",[87],"2016-08-26",[24],[19843],{"trials":34051,"activeCount":99},[34052,34066],{"nctId":34053,"briefTitle":34054,"status":150,"phases":34055,"primaryCompletion":34056,"completion":34057,"start":34058,"enrollment":1977,"conditions":34059,"interventions":34065},"NCT02613403","Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)",[88],"2017-01-09","2017-03-27","2015-12-10",[34060,24,34061,34062,19783,34063,34064,16461],"Hepatitis","Digestive System Diseases","Flaviviridae Infections","Liver Diseases","RNA Virus Infections",[19843,14925],{"nctId":19835,"briefTitle":19836,"status":105,"phases":34067,"primaryCompletion":19838,"completion":19839,"start":19840,"enrollment":2695,"conditions":34068,"interventions":34069},[88],[24],[15839,12959,17381,19822,19843,14925],{"trials":34071,"activeCount":99},[],{"trials":34073,"activeCount":99},[],{"trials":34075,"activeCount":99},[],{"intervention":924,"totalTrials":202,"cells":34077},{"EARLY_PHASE1":34078,"PHASE1":34080,"PHASE2":34082,"PHASE3":34096,"PHASE4":34098,"NA":34100},{"trials":34079,"activeCount":99},[],{"trials":34081,"activeCount":99},[],{"trials":34083,"activeCount":99},[34084,34088,34092],{"nctId":916,"briefTitle":917,"status":105,"phases":34085,"primaryCompletion":919,"completion":919,"start":356,"enrollment":920,"conditions":34086,"interventions":34087},[87,88],[35],[47,780,923,461,924],{"nctId":1176,"briefTitle":1177,"status":105,"phases":34089,"primaryCompletion":1179,"completion":1179,"start":356,"enrollment":110,"conditions":34090,"interventions":34091},[87,88],[35],[47,923,1182,471,1183,924],{"nctId":1517,"briefTitle":1518,"status":105,"phases":34093,"primaryCompletion":1520,"completion":1520,"start":1521,"enrollment":1522,"conditions":34094,"interventions":34095},[87,88],[35],[47,923,818,461,460,924],{"trials":34097,"activeCount":99},[],{"trials":34099,"activeCount":99},[],{"trials":34101,"activeCount":99},[],{"intervention":34103,"totalTrials":202,"cells":34104},"valopicitabine",{"EARLY_PHASE1":34105,"PHASE1":34107,"PHASE2":34109,"PHASE3":34131,"PHASE4":34133,"NA":34135},{"trials":34106,"activeCount":99},[],{"trials":34108,"activeCount":99},[],{"trials":34110,"activeCount":99},[34111,34118,34124],{"nctId":34112,"briefTitle":34113,"status":105,"phases":34114,"start":17096,"conditions":34115,"interventions":34116},"NCT00120835","Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C",[87,88],[12957],[34103,34117],"pegylated interferon",{"nctId":34119,"briefTitle":34120,"status":105,"phases":34121,"start":14903,"conditions":34122,"interventions":34123},"NCT00120861","Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy",[88],[12957],[34103,34117,15820],{"nctId":34125,"briefTitle":34126,"status":105,"phases":34127,"start":15063,"enrollment":20774,"conditions":34128,"interventions":34129},"NCT00118768","A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C",[88],[12957],[34103,34130],"Pegylated Interferon Alfa",{"trials":34132,"activeCount":99},[],{"trials":34134,"activeCount":99},[],{"trials":34136,"activeCount":99},[],{"intervention":20415,"totalTrials":202,"cells":34138},{"EARLY_PHASE1":34139,"PHASE1":34141,"PHASE2":34153,"PHASE3":34159,"PHASE4":34161,"NA":34163},{"trials":34140,"activeCount":99},[],{"trials":34142,"activeCount":99},[34143,34149],{"nctId":34144,"briefTitle":34145,"status":105,"phases":34146,"primaryCompletion":5981,"completion":5981,"start":16802,"enrollment":95,"conditions":34147,"interventions":34148},"NCT01335607","A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006)",[87],[24],[20415,20415],{"nctId":20407,"briefTitle":20408,"status":105,"phases":34150,"primaryCompletion":20410,"completion":20410,"start":20411,"enrollment":120,"conditions":34151,"interventions":34152},[87],[20413],[20415,13241,11447],{"trials":34154,"activeCount":99},[34155],{"nctId":20428,"briefTitle":20429,"status":105,"phases":34156,"primaryCompletion":20431,"completion":20431,"start":20410,"enrollment":5196,"conditions":34157,"interventions":34158},[88],[20433],[20415,20435,14925,20436,11447,20437],{"trials":34160,"activeCount":99},[],{"trials":34162,"activeCount":99},[],{"trials":34164,"activeCount":99},[],{"intervention":34166,"totalTrials":202,"cells":34167},"MK0859",{"EARLY_PHASE1":34168,"PHASE1":34170,"PHASE2":34185,"PHASE3":34194,"PHASE4":34196,"NA":34198},{"trials":34169,"activeCount":99},[],{"trials":34171,"activeCount":99},[34172,34178],{"nctId":34173,"briefTitle":34174,"status":105,"phases":34175,"primaryCompletion":12804,"completion":12804,"start":14531,"enrollment":4421,"conditions":34176,"interventions":34177},"NCT00565292","A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)",[87],[7598,7610],[34166],{"nctId":34179,"briefTitle":34180,"status":105,"phases":34181,"primaryCompletion":4418,"completion":4418,"start":14531,"enrollment":4059,"conditions":34182,"interventions":34184},"NCT00565006","A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED)",[87],[34183],"Ambulatory Blood Pressure",[34166],{"trials":34186,"activeCount":99},[34187],{"nctId":34188,"briefTitle":34189,"status":150,"phases":34190,"primaryCompletion":15155,"completion":4419,"start":14705,"enrollment":9177,"conditions":34191,"interventions":34193},"NCT00325455","MK0859 Dose-Ranging Study (0859-003)",[88],[7598,34192],"Mixed Hyperlipemia",[34166],{"trials":34195,"activeCount":99},[],{"trials":34197,"activeCount":99},[],{"trials":34199,"activeCount":99},[],{"intervention":15073,"totalTrials":202,"cells":34201},{"EARLY_PHASE1":34202,"PHASE1":34204,"PHASE2":34206,"PHASE3":34224,"PHASE4":34226,"NA":34228},{"trials":34203,"activeCount":99},[],{"trials":34205,"activeCount":99},[],{"trials":34207,"activeCount":99},[34208,34216,34220],{"nctId":34209,"briefTitle":34210,"status":105,"phases":34211,"primaryCompletion":14408,"completion":14408,"start":13891,"enrollment":380,"conditions":34212,"interventions":34214},"NCT00475735","A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)",[88],[34213],"Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[15073,34215],"Concerta",{"nctId":15068,"briefTitle":15069,"status":105,"phases":34217,"primaryCompletion":13102,"completion":13102,"start":12814,"enrollment":4305,"conditions":34218,"interventions":34219},[88],[11174],[15073,13864],{"nctId":15075,"briefTitle":15076,"status":105,"phases":34221,"primaryCompletion":6309,"completion":6309,"start":14454,"enrollment":1349,"conditions":34222,"interventions":34223},[88],[15047],[15073,13864],{"trials":34225,"activeCount":99},[],{"trials":34227,"activeCount":99},[],{"trials":34229,"activeCount":99},[],{"intervention":34231,"totalTrials":202,"cells":34232},"Vibegron",{"EARLY_PHASE1":34233,"PHASE1":34235,"PHASE2":34257,"PHASE3":34269,"PHASE4":34271,"NA":34273},{"trials":34234,"activeCount":99},[],{"trials":34236,"activeCount":99},[34237,34249],{"nctId":34238,"briefTitle":34239,"status":150,"phases":34240,"primaryCompletion":34241,"completion":34241,"start":34242,"enrollment":3963,"conditions":34243,"interventions":34246},"NCT01500382","A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)",[87],"2013-01-02","2012-02-27",[34244,34245],"Overactive Bladder","Overactive Urinary Bladder",[34231,34247,34248],"Tolterodine ER","Prophylactic Antibiotic",{"nctId":34250,"briefTitle":34251,"status":105,"phases":34252,"primaryCompletion":34253,"completion":34253,"start":34254,"enrollment":3655,"conditions":34255,"interventions":34256},"NCT01737684","A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)",[87],"2013-06-14","2013-01-15",[34244],[34231],{"trials":34258,"activeCount":99},[34259],{"nctId":34260,"briefTitle":34261,"status":105,"phases":34262,"primaryCompletion":34263,"completion":15959,"start":34264,"enrollment":34265,"conditions":34266,"interventions":34268},"NCT01314872","A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)",[88],"2012-10-22","2011-03-31",1395,[34267],"Urinary Bladder, Overactive",[34231,34247],{"trials":34270,"activeCount":99},[],{"trials":34272,"activeCount":99},[],{"trials":34274,"activeCount":99},[],{"intervention":34276,"totalTrials":202,"cells":34277},"MK0686",{"EARLY_PHASE1":34278,"PHASE1":34280,"PHASE2":34282,"PHASE3":34303,"PHASE4":34305,"NA":34307},{"trials":34279,"activeCount":99},[],{"trials":34281,"activeCount":99},[],{"trials":34283,"activeCount":99},[34284,34290,34297],{"nctId":34285,"briefTitle":34286,"status":150,"phases":34287,"primaryCompletion":12804,"completion":12804,"start":24504,"enrollment":95,"conditions":34288,"interventions":34289},"NCT00282763","A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005)",[88],[14465],[34276],{"nctId":34291,"briefTitle":34292,"status":105,"phases":34293,"primaryCompletion":14706,"completion":14706,"start":17096,"enrollment":20233,"conditions":34294,"interventions":34296},"NCT00533403","MK0686 in Postsurgery Dental Pain (0686-002)",[88],[34295],"Pain, Postoperative",[34276],{"nctId":34298,"briefTitle":34299,"status":105,"phases":34300,"primaryCompletion":8621,"completion":8621,"start":15156,"enrollment":2779,"conditions":34301,"interventions":34302},"NCT00296569","A Study to Assess the Safety and Efficacy of an Investigational Drug (MK-686) in Patients With Osteoarthritis (0686-006)",[88],[21195],[34276],{"trials":34304,"activeCount":99},[],{"trials":34306,"activeCount":99},[],{"trials":34308,"activeCount":99},[],{"intervention":14915,"totalTrials":202,"cells":34310},{"EARLY_PHASE1":34311,"PHASE1":34313,"PHASE2":34321,"PHASE3":34333,"PHASE4":34335,"NA":34337},{"trials":34312,"activeCount":99},[],{"trials":34314,"activeCount":99},[34315],{"nctId":34316,"briefTitle":34317,"status":105,"phases":34318,"primaryCompletion":14352,"completion":14352,"start":14315,"enrollment":335,"conditions":34319,"interventions":34320},"NCT00768170","MK0633 Single Dose Study in Japanese Asthmatic Children Aged 12 to Less Than 16 Years (0633-028)",[87],[5985],[14915],{"trials":34322,"activeCount":99},[34323,34327],{"nctId":14909,"briefTitle":14910,"status":150,"phases":34324,"primaryCompletion":5280,"completion":5280,"start":14687,"enrollment":14912,"conditions":34325,"interventions":34326},[88],[5985],[14915,14331],{"nctId":34328,"briefTitle":34329,"status":105,"phases":34330,"primaryCompletion":15038,"completion":15210,"start":12814,"enrollment":765,"conditions":34331,"interventions":34332},"NCT00421278","The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED)",[88],[23415],[14915],{"trials":34334,"activeCount":99},[],{"trials":34336,"activeCount":99},[],{"trials":34338,"activeCount":99},[],{"intervention":20023,"totalTrials":3197,"cells":34340},{"EARLY_PHASE1":34341,"PHASE1":34343,"PHASE2":34345,"PHASE3":34355,"PHASE4":34357,"NA":34359},{"trials":34342,"activeCount":99},[],{"trials":34344,"activeCount":99},[],{"trials":34346,"activeCount":99},[34347,34351],{"nctId":20012,"briefTitle":20013,"status":105,"phases":34348,"primaryCompletion":20015,"completion":14033,"start":20016,"enrollment":15416,"conditions":34349,"interventions":34350},[88],[19998,20018,20019,20020,20021],[19981,19981,19981,19981,20023,20024],{"nctId":20038,"briefTitle":20039,"status":105,"phases":34352,"primaryCompletion":15712,"completion":15712,"start":20041,"enrollment":407,"conditions":34353,"interventions":34354},[88],[19998,20020,20019,20018,20021],[19981,20023,20024],{"trials":34356,"activeCount":99},[],{"trials":34358,"activeCount":99},[],{"trials":34360,"activeCount":99},[],{"intervention":20024,"totalTrials":3197,"cells":34362},{"EARLY_PHASE1":34363,"PHASE1":34365,"PHASE2":34367,"PHASE3":34377,"PHASE4":34379,"NA":34381},{"trials":34364,"activeCount":99},[],{"trials":34366,"activeCount":99},[],{"trials":34368,"activeCount":99},[34369,34373],{"nctId":20012,"briefTitle":20013,"status":105,"phases":34370,"primaryCompletion":20015,"completion":14033,"start":20016,"enrollment":15416,"conditions":34371,"interventions":34372},[88],[19998,20018,20019,20020,20021],[19981,19981,19981,19981,20023,20024],{"nctId":20038,"briefTitle":20039,"status":105,"phases":34374,"primaryCompletion":15712,"completion":15712,"start":20041,"enrollment":407,"conditions":34375,"interventions":34376},[88],[19998,20020,20019,20018,20021],[19981,20023,20024],{"trials":34378,"activeCount":99},[],{"trials":34380,"activeCount":99},[],{"trials":34382,"activeCount":99},[],{"intervention":34384,"totalTrials":3197,"cells":34385},"MK0493",{"EARLY_PHASE1":34386,"PHASE1":34388,"PHASE2":34390,"PHASE3":34407,"PHASE4":34409,"NA":34411},{"trials":34387,"activeCount":99},[],{"trials":34389,"activeCount":99},[],{"trials":34391,"activeCount":99},[34392,34399],{"nctId":34393,"briefTitle":34394,"status":105,"phases":34395,"primaryCompletion":14483,"completion":14483,"start":14976,"enrollment":34396,"conditions":34397,"interventions":34398},"NCT00482196","To Study Different Levels of MK0493 for Safety, Efficacy, and Tolerability in Obese Patients (0493-017)(COMPLETED)",[88],173,[15158],[34384],{"nctId":34400,"briefTitle":34401,"status":105,"phases":34402,"primaryCompletion":34403,"completion":34403,"start":34404,"conditions":34405,"interventions":34406},"NCT00482638","Study of Safety, Tolerability and Efficacy of MK0493 in Obese Patients (0493-008)(COMPLETED)",[88],"2004-10-29","2004-05-12",[15158],[34384],{"trials":34408,"activeCount":99},[],{"trials":34410,"activeCount":99},[],{"trials":34412,"activeCount":99},[],{"intervention":21658,"totalTrials":3197,"cells":34414},{"EARLY_PHASE1":34415,"PHASE1":34417,"PHASE2":34419,"PHASE3":34432,"PHASE4":34434,"NA":34436},{"trials":34416,"activeCount":99},[],{"trials":34418,"activeCount":99},[],{"trials":34420,"activeCount":99},[34421,34428],{"nctId":34422,"briefTitle":34423,"status":105,"phases":34424,"primaryCompletion":5508,"completion":5508,"start":21619,"enrollment":34425,"conditions":34426,"interventions":34427},"NCT00551629","A Study to Test the Safety and Effectiveness of an Investigational Vaccine in Infants (V419-002)",[88],708,[21656],[21658,21659,21659,21659],{"nctId":21651,"briefTitle":21652,"status":105,"phases":34429,"primaryCompletion":20197,"completion":20197,"start":21619,"enrollment":21654,"conditions":34430,"interventions":34431},[88],[21656],[21658,21659,21659,16464,16476],{"trials":34433,"activeCount":99},[],{"trials":34435,"activeCount":99},[],{"trials":34437,"activeCount":99},[],{"intervention":21659,"totalTrials":3197,"cells":34439},{"EARLY_PHASE1":34440,"PHASE1":34442,"PHASE2":34444,"PHASE3":34454,"PHASE4":34456,"NA":34458},{"trials":34441,"activeCount":99},[],{"trials":34443,"activeCount":99},[],{"trials":34445,"activeCount":99},[34446,34450],{"nctId":34422,"briefTitle":34423,"status":105,"phases":34447,"primaryCompletion":5508,"completion":5508,"start":21619,"enrollment":34425,"conditions":34448,"interventions":34449},[88],[21656],[21658,21659,21659,21659],{"nctId":21651,"briefTitle":21652,"status":105,"phases":34451,"primaryCompletion":20197,"completion":20197,"start":21619,"enrollment":21654,"conditions":34452,"interventions":34453},[88],[21656],[21658,21659,21659,16464,16476],{"trials":34455,"activeCount":99},[],{"trials":34457,"activeCount":99},[],{"trials":34459,"activeCount":99},[],{"intervention":23751,"totalTrials":3197,"cells":34461},{"EARLY_PHASE1":34462,"PHASE1":34464,"PHASE2":34466,"PHASE3":34479,"PHASE4":34481,"NA":34483},{"trials":34463,"activeCount":99},[],{"trials":34465,"activeCount":99},[],{"trials":34467,"activeCount":99},[34468,34472],{"nctId":23746,"briefTitle":23747,"status":105,"phases":34469,"primaryCompletion":5800,"completion":5800,"start":8591,"enrollment":20638,"conditions":34470,"interventions":34471},[88],[14552,19620],[23751,23752,19662,23753],{"nctId":34473,"briefTitle":34474,"status":150,"phases":34475,"primaryCompletion":15794,"completion":15794,"start":14730,"enrollment":34476,"conditions":34477,"interventions":34478},"NCT00960934","A Dose-Ranging Study of MK-5442 in Postmenopausal Women With Osteoporosis (MK-5442-001)",[88],383,[14552],[23751],{"trials":34480,"activeCount":99},[],{"trials":34482,"activeCount":99},[],{"trials":34484,"activeCount":99},[],{"intervention":12716,"totalTrials":3197,"cells":34486},{"EARLY_PHASE1":34487,"PHASE1":34489,"PHASE2":34491,"PHASE3":34501,"PHASE4":34503,"NA":34505},{"trials":34488,"activeCount":99},[],{"trials":34490,"activeCount":99},[],{"trials":34492,"activeCount":99},[34493,34497],{"nctId":12709,"briefTitle":12710,"status":150,"phases":34494,"primaryCompletion":12712,"completion":12712,"start":12713,"enrollment":1621,"conditions":34495,"interventions":34496},[88],[7020],[12716,2100,12717],{"nctId":12723,"briefTitle":12724,"status":150,"phases":34498,"primaryCompletion":12726,"completion":12726,"start":12727,"enrollment":12728,"conditions":34499,"interventions":34500},[88],[12730],[12716,12732,2100],{"trials":34502,"activeCount":99},[],{"trials":34504,"activeCount":99},[],{"trials":34506,"activeCount":99},[],{"intervention":34508,"totalTrials":3197,"cells":34509},"SCH 527123",{"EARLY_PHASE1":34510,"PHASE1":34512,"PHASE2":34520,"PHASE3":34528,"PHASE4":34530,"NA":34532},{"trials":34511,"activeCount":99},[],{"trials":34513,"activeCount":99},[34514],{"nctId":34515,"briefTitle":34516,"status":150,"phases":34517,"primaryCompletion":21145,"completion":21145,"start":6308,"enrollment":931,"conditions":34518,"interventions":34519},"NCT01068145","Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7)",[87],[4360],[34508,34508,34508,34508,34508,34508,34508],{"trials":34521,"activeCount":99},[34522],{"nctId":34523,"briefTitle":34524,"status":1040,"phases":34525,"primaryCompletion":23091,"completion":23091,"start":14623,"enrollment":99,"conditions":34526,"interventions":34527},"NCT01006161","Study of SCH 527123 in Subjects With Severe Asthma (Study P05109AM1)",[88],[5985],[34508,34508,34508,34508],{"trials":34529,"activeCount":99},[],{"trials":34531,"activeCount":99},[],{"trials":34533,"activeCount":99},[],{"intervention":304,"totalTrials":3197,"cells":34535},{"EARLY_PHASE1":34536,"PHASE1":34538,"PHASE2":34544,"PHASE3":34550,"PHASE4":34552,"NA":34554},{"trials":34537,"activeCount":99},[],{"trials":34539,"activeCount":99},[34540],{"nctId":295,"briefTitle":296,"status":105,"phases":34541,"primaryCompletion":298,"completion":298,"start":299,"enrollment":300,"conditions":34542,"interventions":34543},[87],[176,302],[304,47],{"trials":34545,"activeCount":99},[34546],{"nctId":926,"briefTitle":927,"status":105,"phases":34547,"primaryCompletion":929,"completion":929,"start":930,"enrollment":931,"conditions":34548,"interventions":34549},[88],[933],[304,47],{"trials":34551,"activeCount":99},[],{"trials":34553,"activeCount":99},[],{"trials":34555,"activeCount":99},[],{"intervention":34557,"totalTrials":3197,"cells":34558},"Relebactam 250 mg",{"EARLY_PHASE1":34559,"PHASE1":34561,"PHASE2":34563,"PHASE3":34586,"PHASE4":34588,"NA":34590},{"trials":34560,"activeCount":99},[],{"trials":34562,"activeCount":99},[],{"trials":34564,"activeCount":99},[34565,34576],{"nctId":34566,"briefTitle":34567,"status":105,"phases":34568,"primaryCompletion":34569,"completion":34569,"start":34570,"enrollment":15135,"conditions":34571,"interventions":34573},"NCT01506271","Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem\u002FCilastatin Versus Imipenem\u002FCilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)",[88],"2014-08-12","2012-06-01",[34572],"Intra-abdominal Infections",[34557,34574,34575],"Relebactam 125 mg","Imipenem\u002Fcilastatin",{"nctId":34577,"briefTitle":34578,"status":105,"phases":34579,"primaryCompletion":34580,"completion":34580,"start":34581,"enrollment":1272,"conditions":34582,"interventions":34583},"NCT01505634","Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem\u002FCilastatin Versus Imipenem\u002FCilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)",[88],"2015-07-28","2012-05-16",[31323,22176],[34557,34574,34584,34585],"imipenem\u002Fcilastatin 500 mg","Ciprofloxacin",{"trials":34587,"activeCount":99},[],{"trials":34589,"activeCount":99},[],{"trials":34591,"activeCount":99},[],{"intervention":34574,"totalTrials":3197,"cells":34593},{"EARLY_PHASE1":34594,"PHASE1":34596,"PHASE2":34598,"PHASE3":34608,"PHASE4":34610,"NA":34612},{"trials":34595,"activeCount":99},[],{"trials":34597,"activeCount":99},[],{"trials":34599,"activeCount":99},[34600,34604],{"nctId":34566,"briefTitle":34567,"status":105,"phases":34601,"primaryCompletion":34569,"completion":34569,"start":34570,"enrollment":15135,"conditions":34602,"interventions":34603},[88],[34572],[34557,34574,34575],{"nctId":34577,"briefTitle":34578,"status":105,"phases":34605,"primaryCompletion":34580,"completion":34580,"start":34581,"enrollment":1272,"conditions":34606,"interventions":34607},[88],[31323,22176],[34557,34574,34584,34585],{"trials":34609,"activeCount":99},[],{"trials":34611,"activeCount":99},[],{"trials":34613,"activeCount":99},[],{"intervention":34615,"totalTrials":3197,"cells":34616},"MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) \u002F Duration of Treatment 6 Months",{"EARLY_PHASE1":34617,"PHASE1":34619,"PHASE2":34621,"PHASE3":34644,"PHASE4":34646,"NA":34648},{"trials":34618,"activeCount":99},[],{"trials":34620,"activeCount":99},[],{"trials":34622,"activeCount":99},[34623,34632],{"nctId":34624,"briefTitle":34625,"status":105,"phases":34626,"primaryCompletion":34627,"completion":34627,"start":34628,"enrollment":931,"conditions":34629,"interventions":34631},"NCT00097929","An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)",[88],"2006-07-31","2005-05-01",[34630],"B-cell Lymphoma",[34615],{"nctId":34633,"briefTitle":34634,"status":105,"phases":34635,"primaryCompletion":34636,"completion":34637,"start":34638,"enrollment":193,"conditions":34639,"interventions":34643},"NCT00091559","Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)",[88],"2005-11-23","2006-03-13","2005-02-03",[34640,34641,34642],"Cutaneous T-cell Lymphoma","Sezary Syndrome","Mycosis Fungoides",[34615],{"trials":34645,"activeCount":99},[],{"trials":34647,"activeCount":99},[],{"trials":34649,"activeCount":99},[],{"intervention":34651,"totalTrials":3197,"cells":34652},"SCH 530348",{"EARLY_PHASE1":34653,"PHASE1":34655,"PHASE2":34665,"PHASE3":34677,"PHASE4":34679,"NA":34681},{"trials":34654,"activeCount":99},[],{"trials":34656,"activeCount":99},[34657],{"nctId":34658,"briefTitle":34659,"status":105,"phases":34660,"primaryCompletion":15794,"completion":15794,"start":5982,"enrollment":34396,"conditions":34661,"interventions":34663},"NCT01358344","A Bioequivalence Study of SCH 530348 2.5 mg Tablets (P06558)",[87],[34662],"Acute Coronary Syndrome",[34664,34651,34651],"Pantoprazole",{"trials":34666,"activeCount":99},[34667],{"nctId":34668,"briefTitle":34669,"status":105,"phases":34670,"primaryCompletion":34671,"completion":34671,"start":34672,"enrollment":2656,"conditions":34673,"interventions":34676},"NCT00132912","Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573)",[88],"2007-01-28","2005-08-30",[34674,34675],"Arterial Obstructive Diseases","Coronary Disease",[34651],{"trials":34678,"activeCount":99},[],{"trials":34680,"activeCount":99},[],{"trials":34682,"activeCount":99},[],{"intervention":14971,"totalTrials":3197,"cells":34684},{"EARLY_PHASE1":34685,"PHASE1":34687,"PHASE2":34693,"PHASE3":34699,"PHASE4":34701,"NA":34703},{"trials":34686,"activeCount":99},[],{"trials":34688,"activeCount":99},[34689],{"nctId":20247,"briefTitle":20248,"status":105,"phases":34690,"primaryCompletion":5800,"completion":7018,"start":8591,"enrollment":212,"conditions":34691,"interventions":34692},[87],[14337],[14970,14971,20252,20253],{"trials":34694,"activeCount":99},[34695],{"nctId":14965,"briefTitle":14966,"status":105,"phases":34696,"primaryCompletion":13224,"completion":7017,"start":14445,"enrollment":963,"conditions":34697,"interventions":34698},[88],[14337],[14970,14971,13864],{"trials":34700,"activeCount":99},[],{"trials":34702,"activeCount":99},[],{"trials":34704,"activeCount":99},[],{"intervention":34706,"totalTrials":3197,"cells":34707},"MK0916",{"EARLY_PHASE1":34708,"PHASE1":34710,"PHASE2":34712,"PHASE3":34728,"PHASE4":34730,"NA":34732},{"trials":34709,"activeCount":99},[],{"trials":34711,"activeCount":99},[],{"trials":34713,"activeCount":99},[34714,34721],{"nctId":34715,"briefTitle":34716,"status":105,"phases":34717,"primaryCompletion":15210,"completion":15210,"start":14228,"enrollment":2399,"conditions":34718,"interventions":34719},"NCT00274716","Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension (High Blood Pressure)(0736-003)(COMPLETED)",[88],[30],[34720,34706],"MK0736",{"nctId":34722,"briefTitle":34723,"status":105,"phases":34724,"primaryCompletion":14930,"completion":14930,"start":18806,"enrollment":4121,"conditions":34725,"interventions":34727},"NCT00543595","MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)",[88],[33,34726],"Metabolic Syndrome",[34706],{"trials":34729,"activeCount":99},[],{"trials":34731,"activeCount":99},[],{"trials":34733,"activeCount":99},[],{"intervention":13829,"totalTrials":3197,"cells":34735},{"EARLY_PHASE1":34736,"PHASE1":34738,"PHASE2":34744,"PHASE3":34756,"PHASE4":34758,"NA":34760},{"trials":34737,"activeCount":99},[],{"trials":34739,"activeCount":99},[34740],{"nctId":13822,"briefTitle":13823,"status":105,"phases":34741,"primaryCompletion":13825,"completion":13825,"start":13826,"enrollment":3496,"conditions":34742,"interventions":34743},[87],[15],[13829,4084],{"trials":34745,"activeCount":99},[34746],{"nctId":34747,"briefTitle":34748,"status":105,"phases":34749,"primaryCompletion":34750,"completion":34750,"start":34751,"enrollment":34752,"conditions":34753,"interventions":34755},"NCT00642993","Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Participants (Study P05483)(COMPLETED)",[88],"2009-01-30","2008-06-09",401,[15158,20100,34754],"Body Weight",[13829],{"trials":34757,"activeCount":99},[],{"trials":34759,"activeCount":99},[],{"trials":34761,"activeCount":99},[],{"intervention":13894,"totalTrials":3197,"cells":34763},{"EARLY_PHASE1":34764,"PHASE1":34766,"PHASE2":34776,"PHASE3":34782,"PHASE4":34784,"NA":34786},{"trials":34765,"activeCount":99},[],{"trials":34767,"activeCount":99},[34768],{"nctId":34769,"briefTitle":34770,"status":105,"phases":34771,"primaryCompletion":14730,"completion":8591,"start":14352,"enrollment":4059,"conditions":34772,"interventions":34773},"NCT00902161","A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)",[87],[15],[13894,34774,34775],"MK0893-matched Placebo","Propranolol Hydrochloride",{"trials":34777,"activeCount":99},[34778],{"nctId":13887,"briefTitle":13888,"status":150,"phases":34779,"primaryCompletion":13890,"completion":13890,"start":13891,"enrollment":9551,"conditions":34780,"interventions":34781},[88],[33],[13894,4084],{"trials":34783,"activeCount":99},[],{"trials":34785,"activeCount":99},[],{"trials":34787,"activeCount":99},[],{"intervention":34021,"totalTrials":3197,"cells":34789},{"EARLY_PHASE1":34790,"PHASE1":34792,"PHASE2":34794,"PHASE3":34813,"PHASE4":34815,"NA":34817},{"trials":34791,"activeCount":99},[],{"trials":34793,"activeCount":99},[],{"trials":34795,"activeCount":99},[34796,34800],{"nctId":34014,"briefTitle":34015,"status":150,"phases":34797,"primaryCompletion":14192,"completion":34017,"start":34018,"enrollment":24841,"conditions":34798,"interventions":34799},[88],[5985],[33997,34021],{"nctId":34801,"briefTitle":34802,"status":105,"phases":34803,"primaryCompletion":34804,"completion":34805,"start":34806,"enrollment":34807,"conditions":34808,"interventions":34809},"NCT02720081","Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015)",[88],"2017-08-16","2017-09-06","2016-05-11",142,[5985],[34810,34811,34021,34812],"MK-1029 150 mg","MK-1029 Matching-image Placebo","Albuterol\u002FSalbutamol 90 mcg - 100 mcg per inhalation",{"trials":34814,"activeCount":99},[],{"trials":34816,"activeCount":99},[],{"trials":34818,"activeCount":99},[],{"intervention":14431,"totalTrials":3197,"cells":34820},{"EARLY_PHASE1":34821,"PHASE1":34823,"PHASE2":34829,"PHASE3":34835,"PHASE4":34837,"NA":34839},{"trials":34822,"activeCount":99},[],{"trials":34824,"activeCount":99},[34825],{"nctId":14425,"briefTitle":14426,"status":105,"phases":34826,"primaryCompletion":5982,"completion":5982,"start":12813,"enrollment":2901,"conditions":34827,"interventions":34828},[87],[14429],[14431,14432,13864],{"trials":34830,"activeCount":99},[34831],{"nctId":23410,"briefTitle":23411,"status":105,"phases":34832,"primaryCompletion":23413,"completion":23413,"start":4357,"enrollment":2023,"conditions":34833,"interventions":34834},[88],[23415,23416,9614],[23401,14431,14432],{"trials":34836,"activeCount":99},[],{"trials":34838,"activeCount":99},[],{"trials":34840,"activeCount":99},[],{"intervention":14432,"totalTrials":3197,"cells":34842},{"EARLY_PHASE1":34843,"PHASE1":34845,"PHASE2":34851,"PHASE3":34857,"PHASE4":34859,"NA":34861},{"trials":34844,"activeCount":99},[],{"trials":34846,"activeCount":99},[34847],{"nctId":14425,"briefTitle":14426,"status":105,"phases":34848,"primaryCompletion":5982,"completion":5982,"start":12813,"enrollment":2901,"conditions":34849,"interventions":34850},[87],[14429],[14431,14432,13864],{"trials":34852,"activeCount":99},[34853],{"nctId":23410,"briefTitle":23411,"status":105,"phases":34854,"primaryCompletion":23413,"completion":23413,"start":4357,"enrollment":2023,"conditions":34855,"interventions":34856},[88],[23415,23416,9614],[23401,14431,14432],{"trials":34858,"activeCount":99},[],{"trials":34860,"activeCount":99},[],{"trials":34862,"activeCount":99},[],{"intervention":8027,"totalTrials":3197,"cells":34864},{"EARLY_PHASE1":34865,"PHASE1":34867,"PHASE2":34873,"PHASE3":34879,"PHASE4":34881,"NA":34883},{"trials":34866,"activeCount":99},[],{"trials":34868,"activeCount":99},[34869],{"nctId":8022,"briefTitle":8023,"status":105,"phases":34870,"primaryCompletion":1817,"completion":1817,"start":6194,"enrollment":312,"conditions":34871,"interventions":34872},[87],[18],[7998,8027],{"trials":34874,"activeCount":99},[34875],{"nctId":11646,"briefTitle":11647,"status":105,"phases":34876,"primaryCompletion":5574,"completion":5574,"start":1578,"enrollment":11649,"conditions":34877,"interventions":34878},[88],[11630,11651,11641,11631,11640],[7012,8027],{"trials":34880,"activeCount":99},[],{"trials":34882,"activeCount":99},[],{"trials":34884,"activeCount":99},[],{"intervention":13873,"totalTrials":3197,"cells":34886},{"EARLY_PHASE1":34887,"PHASE1":34889,"PHASE2":34891,"PHASE3":34901,"PHASE4":34903,"NA":34905},{"trials":34888,"activeCount":99},[],{"trials":34890,"activeCount":99},[],{"trials":34892,"activeCount":99},[34893,34897],{"nctId":13867,"briefTitle":13868,"status":105,"phases":34894,"primaryCompletion":13870,"completion":13870,"start":5281,"enrollment":110,"conditions":34895,"interventions":34896},[88],[33],[13873,13145,4084],{"nctId":13896,"briefTitle":13897,"status":105,"phases":34898,"primaryCompletion":13899,"completion":13899,"start":13900,"enrollment":193,"conditions":34899,"interventions":34900},[88],[15],[13873,4084],{"trials":34902,"activeCount":99},[],{"trials":34904,"activeCount":99},[],{"trials":34906,"activeCount":99},[],{"intervention":34908,"totalTrials":3197,"cells":34909},"Esmeron®",{"EARLY_PHASE1":34910,"PHASE1":34912,"PHASE2":34914,"PHASE3":34932,"PHASE4":34934,"NA":34936},{"trials":34911,"activeCount":99},[],{"trials":34913,"activeCount":99},[],{"trials":34915,"activeCount":99},[34916,34925],{"nctId":34917,"briefTitle":34918,"status":105,"phases":34919,"primaryCompletion":34920,"completion":34920,"start":34921,"enrollment":34922,"conditions":34923,"interventions":34924},"NCT00535743","Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg\u002Fkg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024)",[88],"2004-07-20","2004-03-04",174,[17011],[17013,34908],{"nctId":34926,"briefTitle":34927,"status":105,"phases":34928,"primaryCompletion":34929,"completion":34929,"start":17179,"enrollment":4358,"conditions":34930,"interventions":34931},"NCT03519854","Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg\u002Fkg Esmeron® in Male Participants (P05940; MK-8616-020).",[88],"2003-06-01",[16696],[17013,34908],{"trials":34933,"activeCount":99},[],{"trials":34935,"activeCount":99},[],{"trials":34937,"activeCount":99},[],{"intervention":34939,"totalTrials":3197,"cells":34940},"MK0677",{"EARLY_PHASE1":34941,"PHASE1":34943,"PHASE2":34945,"PHASE3":34961,"PHASE4":34963,"NA":34965},{"trials":34942,"activeCount":99},[],{"trials":34944,"activeCount":99},[],{"trials":34946,"activeCount":99},[34947,34954],{"nctId":34948,"briefTitle":34949,"status":150,"phases":34950,"primaryCompletion":5507,"completion":5507,"start":15156,"enrollment":13103,"conditions":34951,"interventions":34953},"NCT00128115","Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)",[88],[34952],"Hip Fracture",[34939],{"nctId":34955,"briefTitle":34956,"status":105,"phases":34957,"primaryCompletion":14484,"completion":14484,"start":22476,"enrollment":34958,"conditions":34959,"interventions":34960},"NCT00074529","Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)",[88],512,[11174],[34939],{"trials":34962,"activeCount":99},[],{"trials":34964,"activeCount":99},[],{"trials":34966,"activeCount":99},[],{"intervention":20436,"totalTrials":3197,"cells":34968},{"EARLY_PHASE1":34969,"PHASE1":34971,"PHASE2":34977,"PHASE3":34983,"PHASE4":34985,"NA":34987},{"trials":34970,"activeCount":99},[],{"trials":34972,"activeCount":99},[34973],{"nctId":33551,"briefTitle":33552,"status":105,"phases":34974,"primaryCompletion":17591,"completion":17591,"start":20279,"enrollment":5616,"conditions":34975,"interventions":34976},[87],[21],[33537,20435,20436,33556],{"trials":34978,"activeCount":99},[34979],{"nctId":20428,"briefTitle":20429,"status":105,"phases":34980,"primaryCompletion":20431,"completion":20431,"start":20410,"enrollment":5196,"conditions":34981,"interventions":34982},[88],[20433],[20415,20435,14925,20436,11447,20437],{"trials":34984,"activeCount":99},[],{"trials":34986,"activeCount":99},[],{"trials":34988,"activeCount":99},[],{"intervention":34990,"totalTrials":3197,"cells":34991},"V160",{"EARLY_PHASE1":34992,"PHASE1":34994,"PHASE2":35005,"PHASE3":35015,"PHASE4":35017,"NA":35019},{"trials":34993,"activeCount":99},[],{"trials":34995,"activeCount":99},[34996],{"nctId":34997,"briefTitle":34998,"status":105,"phases":34999,"primaryCompletion":35000,"completion":35000,"start":35001,"enrollment":931,"conditions":35002,"interventions":35004},"NCT03840174","Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003)",[87],"2019-11-07","2019-03-08",[35003],"Cytomegalovirus Infections",[34990],{"trials":35006,"activeCount":99},[35007],{"nctId":35008,"briefTitle":35009,"status":105,"phases":35010,"primaryCompletion":2287,"completion":2332,"start":191,"enrollment":35011,"conditions":35012,"interventions":35014},"NCT03486834","V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)",[88],2200,[35013],"Cytomegalovirus (CMV) Infections",[34990],{"trials":35016,"activeCount":99},[],{"trials":35018,"activeCount":99},[],{"trials":35020,"activeCount":99},[],{"intervention":11422,"totalTrials":3197,"cells":35022},{"EARLY_PHASE1":35023,"PHASE1":35025,"PHASE2":35027,"PHASE3":35042,"PHASE4":35044,"NA":35046},{"trials":35024,"activeCount":99},[],{"trials":35026,"activeCount":99},[],{"trials":35028,"activeCount":99},[35029,35033],{"nctId":11413,"briefTitle":11414,"status":105,"phases":35030,"primaryCompletion":11416,"completion":11417,"start":11418,"enrollment":2085,"conditions":35031,"interventions":35032},[88],[7639],[7800,11357,11421,11422,11423],{"nctId":35034,"briefTitle":35035,"status":105,"phases":35036,"primaryCompletion":35037,"completion":1189,"start":35038,"enrollment":335,"conditions":35039,"interventions":35040},"NCT02629822","Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)",[88],"2018-11-28","2016-01-14",[7639],[35041],"Doravirine\u002Flamivudine\u002Ftenofovir disoproxil fumarate",{"trials":35043,"activeCount":99},[],{"trials":35045,"activeCount":99},[],{"trials":35047,"activeCount":99},[],{"intervention":35049,"totalTrials":3197,"cells":35050},"Caspofungin",{"EARLY_PHASE1":35051,"PHASE1":35053,"PHASE2":35055,"PHASE3":35076,"PHASE4":35078,"NA":35080},{"trials":35052,"activeCount":99},[],{"trials":35054,"activeCount":99},[],{"trials":35056,"activeCount":99},[35057,35066],{"nctId":35058,"briefTitle":35059,"status":105,"phases":35060,"primaryCompletion":35061,"completion":35061,"start":24863,"enrollment":805,"conditions":35062,"interventions":35065},"NCT01165320","A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)",[88],"2013-09-17",[35063,35064,20498],"Candidiasis, Esophageal","Candidiasis, Invasive",[35049],{"nctId":35067,"briefTitle":35068,"status":150,"phases":35069,"primaryCompletion":35070,"completion":35071,"start":35072,"enrollment":13805,"conditions":35073,"interventions":35074},"NCT01945281","Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)",[88],"2018-01-02","2018-02-28","2014-01-15",[35064],[35049,35075],"Amphotericin B Deoxycholate",{"trials":35077,"activeCount":99},[],{"trials":35079,"activeCount":99},[],{"trials":35081,"activeCount":99},[],{"intervention":13882,"totalTrials":3197,"cells":35083},{"EARLY_PHASE1":35084,"PHASE1":35086,"PHASE2":35088,"PHASE3":35098,"PHASE4":35100,"NA":35102},{"trials":35085,"activeCount":99},[],{"trials":35087,"activeCount":99},[],{"trials":35089,"activeCount":99},[35090,35094],{"nctId":13875,"briefTitle":13876,"status":105,"phases":35091,"primaryCompletion":13878,"completion":13878,"start":9143,"enrollment":13879,"conditions":35092,"interventions":35093},[88],[33],[13882,13883,13884,13885,4084],{"nctId":20341,"briefTitle":20342,"status":105,"phases":35095,"primaryCompletion":20344,"completion":20049,"start":20345,"enrollment":20346,"conditions":35096,"interventions":35097},[88],[33,30],[13882,13883,13884,20349],{"trials":35099,"activeCount":99},[],{"trials":35101,"activeCount":99},[],{"trials":35103,"activeCount":99},[],{"intervention":13884,"totalTrials":3197,"cells":35105},{"EARLY_PHASE1":35106,"PHASE1":35108,"PHASE2":35110,"PHASE3":35120,"PHASE4":35122,"NA":35124},{"trials":35107,"activeCount":99},[],{"trials":35109,"activeCount":99},[],{"trials":35111,"activeCount":99},[35112,35116],{"nctId":13875,"briefTitle":13876,"status":105,"phases":35113,"primaryCompletion":13878,"completion":13878,"start":9143,"enrollment":13879,"conditions":35114,"interventions":35115},[88],[33],[13882,13883,13884,13885,4084],{"nctId":20341,"briefTitle":20342,"status":105,"phases":35117,"primaryCompletion":20344,"completion":20049,"start":20345,"enrollment":20346,"conditions":35118,"interventions":35119},[88],[33,30],[13882,13883,13884,20349],{"trials":35121,"activeCount":99},[],{"trials":35123,"activeCount":99},[],{"trials":35125,"activeCount":99},[],{"intervention":14657,"totalTrials":3197,"cells":35127},{"EARLY_PHASE1":35128,"PHASE1":35130,"PHASE2":35136,"PHASE3":35142,"PHASE4":35144,"NA":35146},{"trials":35129,"activeCount":99},[],{"trials":35131,"activeCount":99},[35132],{"nctId":14649,"briefTitle":14650,"status":150,"phases":35133,"primaryCompletion":14652,"completion":14652,"start":14653,"enrollment":4071,"conditions":35134,"interventions":35135},[87],[14655],[14657,14331],{"trials":35137,"activeCount":99},[35138],{"nctId":14812,"briefTitle":14813,"status":150,"phases":35139,"primaryCompletion":13224,"completion":12813,"start":14353,"enrollment":14815,"conditions":35140,"interventions":35141},[88],[15,30],[14657,13864,14818],{"trials":35143,"activeCount":99},[],{"trials":35145,"activeCount":99},[],{"trials":35147,"activeCount":99},[],{"intervention":34247,"totalTrials":3197,"cells":35149},{"EARLY_PHASE1":35150,"PHASE1":35152,"PHASE2":35158,"PHASE3":35164,"PHASE4":35166,"NA":35168},{"trials":35151,"activeCount":99},[],{"trials":35153,"activeCount":99},[35154],{"nctId":34238,"briefTitle":34239,"status":150,"phases":35155,"primaryCompletion":34241,"completion":34241,"start":34242,"enrollment":3963,"conditions":35156,"interventions":35157},[87],[34244,34245],[34231,34247,34248],{"trials":35159,"activeCount":99},[35160],{"nctId":34260,"briefTitle":34261,"status":105,"phases":35161,"primaryCompletion":34263,"completion":15959,"start":34264,"enrollment":34265,"conditions":35162,"interventions":35163},[88],[34267],[34231,34247],{"trials":35165,"activeCount":99},[],{"trials":35167,"activeCount":99},[],{"trials":35169,"activeCount":99},[],{"intervention":32906,"totalTrials":3197,"cells":35171},{"EARLY_PHASE1":35172,"PHASE1":35174,"PHASE2":35176,"PHASE3":35186,"PHASE4":35188,"NA":35190},{"trials":35173,"activeCount":99},[],{"trials":35175,"activeCount":99},[],{"trials":35177,"activeCount":99},[35178,35182],{"nctId":32897,"briefTitle":32898,"status":105,"phases":35179,"primaryCompletion":32900,"completion":32900,"start":32901,"enrollment":32902,"conditions":35180,"interventions":35181},[88],[32904],[16932,32906],{"nctId":32908,"briefTitle":32909,"status":105,"phases":35183,"primaryCompletion":8049,"completion":8049,"start":32911,"enrollment":32912,"conditions":35184,"interventions":35185},[88],[14715],[16932,32906],{"trials":35187,"activeCount":99},[],{"trials":35189,"activeCount":99},[],{"trials":35191,"activeCount":99},[],{"intervention":35193,"totalTrials":3197,"cells":35194},"L-756423",{"EARLY_PHASE1":35195,"PHASE1":35197,"PHASE2":35199,"PHASE3":35214,"PHASE4":35216,"NA":35218},{"trials":35196,"activeCount":99},[],{"trials":35198,"activeCount":99},[],{"trials":35200,"activeCount":99},[35201,35207],{"nctId":35202,"briefTitle":35203,"status":105,"phases":35204,"enrollment":154,"conditions":35205,"interventions":35206},"NCT00002452","A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir",[88],[27],[35193,17754],{"nctId":35208,"briefTitle":35209,"status":35210,"phases":35211,"enrollment":2545,"conditions":35212,"interventions":35213},"NCT00002424","A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine","SUSPENDED",[88],[27],[35193,17754,11421,17755],{"trials":35215,"activeCount":99},[],{"trials":35217,"activeCount":99},[],{"trials":35219,"activeCount":99},[],{"intervention":25590,"totalTrials":3197,"cells":35221},{"EARLY_PHASE1":35222,"PHASE1":35224,"PHASE2":35226,"PHASE3":35240,"PHASE4":35242,"NA":35244},{"trials":35223,"activeCount":99},[],{"trials":35225,"activeCount":99},[],{"trials":35227,"activeCount":99},[35228,35236],{"nctId":35229,"briefTitle":35230,"status":105,"phases":35231,"primaryCompletion":14930,"completion":14930,"start":14595,"enrollment":35232,"conditions":35233,"interventions":35234},"NCT00109278","A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)",[88],1100,[15308],[35235,25590],"V205C, measles, mumps, and rubella virus vaccine live",{"nctId":25584,"briefTitle":25585,"status":105,"phases":35237,"primaryCompletion":14594,"completion":14594,"start":15295,"enrollment":25587,"conditions":35238,"interventions":35239},[88],[15308,15309,15310,15311],[25575,25590],{"trials":35241,"activeCount":99},[],{"trials":35243,"activeCount":99},[],{"trials":35245,"activeCount":99},[],{"intervention":35247,"totalTrials":3197,"cells":35248},"MK0782",{"EARLY_PHASE1":35249,"PHASE1":35251,"PHASE2":35253,"PHASE3":35269,"PHASE4":35271,"NA":35273},{"trials":35250,"activeCount":99},[],{"trials":35252,"activeCount":99},[],{"trials":35254,"activeCount":99},[35255,35261],{"nctId":35256,"briefTitle":35257,"status":150,"phases":35258,"primaryCompletion":14706,"completion":14706,"start":18806,"enrollment":13234,"conditions":35259,"interventions":35260},"NCT00543465","12-Week No-Rofecoxib Plus Aspirin Endoscopy Study (0782-003)",[88],[7197,21195],[35247],{"nctId":35262,"briefTitle":35263,"status":105,"phases":35264,"primaryCompletion":18806,"completion":18806,"start":14229,"enrollment":1541,"conditions":35265,"interventions":35268},"NCT00543868","MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001)",[88],[35266,35267],"Stomach Ulcer","Duodenal Ulcer",[35247],{"trials":35270,"activeCount":99},[],{"trials":35272,"activeCount":99},[],{"trials":35274,"activeCount":99},[],{"intervention":21919,"totalTrials":3197,"cells":35276},{"EARLY_PHASE1":35277,"PHASE1":35279,"PHASE2":35288,"PHASE3":35294,"PHASE4":35296,"NA":35298},{"trials":35278,"activeCount":99},[],{"trials":35280,"activeCount":99},[35281],{"nctId":35282,"briefTitle":35283,"status":105,"phases":35284,"primaryCompletion":14454,"completion":14454,"start":4419,"enrollment":444,"conditions":35285,"interventions":35287},"NCT00565084","Tolerability and Efficacy of Ibuprofen 800 mg in a Walking Model of Osteoarthritis Pain (0000-057)",[87],[35286],"Osteoarthritis, Knee",[21919],{"trials":35289,"activeCount":99},[35290],{"nctId":21912,"briefTitle":21913,"status":105,"phases":35291,"primaryCompletion":14384,"completion":14384,"start":21915,"enrollment":21916,"conditions":35292,"interventions":35293},[88],[4397],[21919,21920,21884],{"trials":35295,"activeCount":99},[],{"trials":35297,"activeCount":99},[],{"trials":35299,"activeCount":99},[],{"intervention":35301,"totalTrials":3197,"cells":35302},"MK-8777",{"EARLY_PHASE1":35303,"PHASE1":35305,"PHASE2":35307,"PHASE3":35329,"PHASE4":35331,"NA":35333},{"trials":35304,"activeCount":99},[],{"trials":35306,"activeCount":99},[],{"trials":35308,"activeCount":99},[35309,35319],{"nctId":35310,"briefTitle":35311,"status":105,"phases":35312,"primaryCompletion":35313,"completion":35314,"start":35315,"enrollment":14951,"conditions":35316,"interventions":35318},"NCT00610649","Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001\u002FP05704\u002FMK-8777-001)",[88],"2008-11-18","2008-12-10","2007-09-20",[35317],"Depression",[35301],{"nctId":35320,"briefTitle":35321,"status":105,"phases":35322,"primaryCompletion":35323,"completion":35324,"start":35325,"enrollment":2647,"conditions":35326,"interventions":35328},"NCT00610441","Dose Finding Study in Adults With Attention-Deficit\u002FHyperactivity Disorder (ADHD)(174007\u002FP05805\u002FMK-8777-003)",[88],"2009-03-02","2009-03-09","2008-04-01",[35327],"Attention Deficit Hyperactivity Disorder",[35301],{"trials":35330,"activeCount":99},[],{"trials":35332,"activeCount":99},[],{"trials":35334,"activeCount":99},[],{"intervention":1182,"totalTrials":3197,"cells":35336},{"EARLY_PHASE1":35337,"PHASE1":35339,"PHASE2":35341,"PHASE3":35351,"PHASE4":35353,"NA":35355},{"trials":35338,"activeCount":99},[],{"trials":35340,"activeCount":99},[],{"trials":35342,"activeCount":99},[35343,35347],{"nctId":1176,"briefTitle":1177,"status":105,"phases":35344,"primaryCompletion":1179,"completion":1179,"start":356,"enrollment":110,"conditions":35345,"interventions":35346},[87,88],[35],[47,923,1182,471,1183,924],{"nctId":1185,"briefTitle":1186,"status":150,"phases":35348,"primaryCompletion":1188,"completion":1188,"start":1189,"enrollment":1190,"conditions":35349,"interventions":35350},[87,88],[324],[1182,47],{"trials":35352,"activeCount":99},[],{"trials":35354,"activeCount":99},[],{"trials":35356,"activeCount":99},[],{"intervention":35358,"totalTrials":3197,"cells":35359},"INS50589 Intravenous",{"EARLY_PHASE1":35360,"PHASE1":35362,"PHASE2":35371,"PHASE3":35379,"PHASE4":35381,"NA":35383},{"trials":35361,"activeCount":99},[],{"trials":35363,"activeCount":99},[35364],{"nctId":35365,"briefTitle":35366,"status":105,"phases":35367,"primaryCompletion":15211,"completion":15211,"start":14678,"enrollment":1054,"conditions":35368,"interventions":35370},"NCT00099450","Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers",[87],[35369],"Cardiovascular Disease",[35358],{"trials":35372,"activeCount":99},[35373],{"nctId":35374,"briefTitle":35375,"status":150,"phases":35376,"primaryCompletion":12804,"start":17461,"enrollment":787,"conditions":35377,"interventions":35378},"NCT00316212","Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Grafting (CABG) Involving Cardiopulmonary Bypass",[88],[34675],[35358],{"trials":35380,"activeCount":99},[],{"trials":35382,"activeCount":99},[],{"trials":35384,"activeCount":99},[],{"intervention":35386,"totalTrials":3197,"cells":35387},"MK2461",{"EARLY_PHASE1":35388,"PHASE1":35390,"PHASE2":35398,"PHASE3":35406,"PHASE4":35408,"NA":35410},{"trials":35389,"activeCount":99},[],{"trials":35391,"activeCount":99},[35392],{"nctId":35393,"briefTitle":35394,"status":105,"phases":35395,"primaryCompletion":14353,"completion":14353,"start":15155,"enrollment":9323,"conditions":35396,"interventions":35397},"NCT00518739","MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED)",[87],[852],[35386],{"trials":35399,"activeCount":99},[35400],{"nctId":35401,"briefTitle":35402,"status":105,"phases":35403,"primaryCompletion":6309,"completion":14823,"start":14324,"enrollment":3506,"conditions":35404,"interventions":35405},"NCT00496353","MK2461 Phase I\u002FII Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)",[87,88],[337],[35386],{"trials":35407,"activeCount":99},[],{"trials":35409,"activeCount":99},[],{"trials":35411,"activeCount":99},[],{"intervention":11228,"totalTrials":3197,"cells":35413},{"EARLY_PHASE1":35414,"PHASE1":35416,"PHASE2":35422,"PHASE3":35428,"PHASE4":35430,"NA":35432},{"trials":35415,"activeCount":99},[],{"trials":35417,"activeCount":99},[35418],{"nctId":18995,"briefTitle":18996,"status":105,"phases":35419,"primaryCompletion":18998,"completion":18998,"start":13222,"enrollment":18999,"conditions":35420,"interventions":35421},[87],[1109],[19002,11239,6106],{"trials":35423,"activeCount":99},[35424],{"nctId":11220,"briefTitle":11221,"status":105,"phases":35425,"primaryCompletion":11223,"completion":11223,"start":11224,"enrollment":11225,"conditions":35426,"interventions":35427},[88],[1109],[11228,11229,6312,6091],{"trials":35429,"activeCount":99},[],{"trials":35431,"activeCount":99},[],{"trials":35433,"activeCount":99},[],{"intervention":14944,"totalTrials":3197,"cells":35435},{"EARLY_PHASE1":35436,"PHASE1":35438,"PHASE2":35440,"PHASE3":35450,"PHASE4":35452,"NA":35454},{"trials":35437,"activeCount":99},[],{"trials":35439,"activeCount":99},[],{"trials":35441,"activeCount":99},[35442,35446],{"nctId":14937,"briefTitle":14938,"status":105,"phases":35443,"primaryCompletion":14393,"completion":9313,"start":14940,"enrollment":14941,"conditions":35444,"interventions":35445},[88],[24],[14944,14945,14946,14331],{"nctId":21010,"briefTitle":21011,"status":1040,"phases":35447,"primaryCompletion":19020,"completion":19020,"start":16592,"enrollment":99,"conditions":35448,"interventions":35449},[88],[21014],[21016,21017,21018,14946,21019],{"trials":35451,"activeCount":99},[],{"trials":35453,"activeCount":99},[],{"trials":35455,"activeCount":99},[],{"intervention":14946,"totalTrials":3197,"cells":35457},{"EARLY_PHASE1":35458,"PHASE1":35460,"PHASE2":35462,"PHASE3":35472,"PHASE4":35474,"NA":35476},{"trials":35459,"activeCount":99},[],{"trials":35461,"activeCount":99},[],{"trials":35463,"activeCount":99},[35464,35468],{"nctId":14937,"briefTitle":14938,"status":105,"phases":35465,"primaryCompletion":14393,"completion":9313,"start":14940,"enrollment":14941,"conditions":35466,"interventions":35467},[88],[24],[14944,14945,14946,14331],{"nctId":21010,"briefTitle":21011,"status":1040,"phases":35469,"primaryCompletion":19020,"completion":19020,"start":16592,"enrollment":99,"conditions":35470,"interventions":35471},[88],[21014],[21016,21017,21018,14946,21019],{"trials":35473,"activeCount":99},[],{"trials":35475,"activeCount":99},[],{"trials":35477,"activeCount":99},[],{"intervention":592,"totalTrials":3197,"cells":35479},{"EARLY_PHASE1":35480,"PHASE1":35482,"PHASE2":35488,"PHASE3":35498,"PHASE4":35500,"NA":35502},{"trials":35481,"activeCount":99},[],{"trials":35483,"activeCount":99},[35484],{"nctId":585,"briefTitle":586,"status":150,"phases":35485,"primaryCompletion":588,"completion":588,"start":589,"enrollment":154,"conditions":35486,"interventions":35487},[87],[497],[592,47],{"trials":35489,"activeCount":99},[35490],{"nctId":35491,"briefTitle":35492,"status":150,"phases":35493,"primaryCompletion":35494,"completion":35494,"start":35495,"enrollment":2901,"conditions":35496,"interventions":35497},"NCT03065023","Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001\u002FRGT100-001)",[87,88],"2018-05-18","2017-04-25",[497],[592],{"trials":35499,"activeCount":99},[],{"trials":35501,"activeCount":99},[],{"trials":35503,"activeCount":99},[],{"intervention":35505,"totalTrials":3197,"cells":35506},"SCH 900435",{"EARLY_PHASE1":35507,"PHASE1":35509,"PHASE2":35511,"PHASE3":35529,"PHASE4":35531,"NA":35533},{"trials":35508,"activeCount":99},[],{"trials":35510,"activeCount":99},[],{"trials":35512,"activeCount":99},[35513,35522],{"nctId":35514,"briefTitle":35515,"status":150,"phases":35516,"primaryCompletion":35517,"completion":35518,"start":19367,"enrollment":23475,"conditions":35519,"interventions":35521},"NCT00764660","Trial Investigating the Efficacy and Safety of SCH 900435 (Org 25935) in Relapse Prevention in Participants With Alcohol Dependence (P05718)",[88],"2010-05-28","2010-07-08",[35520],"Alcoholism",[35505],{"nctId":35523,"briefTitle":35524,"status":1040,"phases":35525,"primaryCompletion":16792,"completion":16792,"start":14566,"enrollment":99,"conditions":35526,"interventions":35527},"NCT00988728","Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)",[88],[14715],[35505,35528],"Olanzapine",{"trials":35530,"activeCount":99},[],{"trials":35532,"activeCount":99},[],{"trials":35534,"activeCount":99},[],{"intervention":35536,"totalTrials":3197,"cells":35537},"SCH 486757",{"EARLY_PHASE1":35538,"PHASE1":35540,"PHASE2":35542,"PHASE3":35557,"PHASE4":35559,"NA":35561},{"trials":35539,"activeCount":99},[],{"trials":35541,"activeCount":99},[],{"trials":35543,"activeCount":99},[35544,35551],{"nctId":35545,"briefTitle":35546,"status":105,"phases":35547,"primaryCompletion":14504,"completion":14504,"start":15210,"enrollment":4741,"conditions":35548,"interventions":35550},"NCT00506987","Study of the Efficacy and Safety of SCH 486757 in Subjects With Chronic Cough (Study P04887)",[88],[35549],"Cough",[35536],{"nctId":35552,"briefTitle":35553,"status":105,"phases":35554,"primaryCompletion":15505,"completion":15505,"start":17095,"enrollment":21259,"conditions":35555,"interventions":35556},"NCT00230230","Comparison of SCH 486757 to Codeine and Placebo in Subjects With Persistent Postviral Cough (Study P03069AM2)(COMPLETED)",[88],[35549],[35536],{"trials":35558,"activeCount":99},[],{"trials":35560,"activeCount":99},[],{"trials":35562,"activeCount":99},[],{"intervention":13930,"totalTrials":3197,"cells":35564},{"EARLY_PHASE1":35565,"PHASE1":35567,"PHASE2":35573,"PHASE3":35579,"PHASE4":35581,"NA":35583},{"trials":35566,"activeCount":99},[],{"trials":35568,"activeCount":99},[35569],{"nctId":23624,"briefTitle":23625,"status":105,"phases":35570,"primaryCompletion":23627,"completion":23627,"start":23628,"enrollment":23629,"conditions":35571,"interventions":35572},[87],[13950],[13930,13931],{"trials":35574,"activeCount":99},[35575],{"nctId":13922,"briefTitle":13923,"status":150,"phases":35576,"primaryCompletion":13925,"completion":13925,"start":13926,"enrollment":13927,"conditions":35577,"interventions":35578},[88],[13853],[13930,13931,4084],{"trials":35580,"activeCount":99},[],{"trials":35582,"activeCount":99},[],{"trials":35584,"activeCount":99},[],{"intervention":4363,"totalTrials":3197,"cells":35586},{"EARLY_PHASE1":35587,"PHASE1":35589,"PHASE2":35591,"PHASE3":35604,"PHASE4":35606,"NA":35608},{"trials":35588,"activeCount":99},[],{"trials":35590,"activeCount":99},[],{"trials":35592,"activeCount":99},[35593,35600],{"nctId":35594,"briefTitle":35595,"status":105,"phases":35596,"primaryCompletion":23413,"completion":23413,"start":35597,"enrollment":4741,"conditions":35598,"interventions":35599},"NCT00684593","A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009)",[88],"2007-06-01",[12754],[4363],{"nctId":4353,"briefTitle":4354,"status":150,"phases":35601,"primaryCompletion":4356,"completion":4356,"start":4357,"enrollment":4358,"conditions":35602,"interventions":35603},[88],[4360],[4362,4363,1089],{"trials":35605,"activeCount":99},[],{"trials":35607,"activeCount":99},[],{"trials":35609,"activeCount":99},[],{"intervention":15032,"totalTrials":3197,"cells":35611},{"EARLY_PHASE1":35612,"PHASE1":35614,"PHASE2":35623,"PHASE3":35629,"PHASE4":35631,"NA":35633},{"trials":35613,"activeCount":99},[],{"trials":35615,"activeCount":99},[35616],{"nctId":35617,"briefTitle":35618,"status":105,"phases":35619,"primaryCompletion":13890,"completion":13890,"start":8620,"enrollment":4421,"conditions":35620,"interventions":35621},"NCT00966030","Bioequivalence of the Tablet and Liquid-Filled Capsule Forms of MK0974 (0974-042)",[87],[4397],[15032,35622],"Comparator: MK0974 liquid filled",{"trials":35624,"activeCount":99},[35625],{"nctId":15026,"briefTitle":15027,"status":105,"phases":35626,"primaryCompletion":8621,"completion":8621,"start":14228,"enrollment":15029,"conditions":35627,"interventions":35628},[88],[4397],[13864,15032,15032,15032,15032,15032,15032,15032,15033],{"trials":35630,"activeCount":99},[],{"trials":35632,"activeCount":99},[],{"trials":35634,"activeCount":99},[],{"intervention":746,"totalTrials":224,"cells":35636},{"EARLY_PHASE1":35637,"PHASE1":35639,"PHASE2":35641,"PHASE3":35647,"PHASE4":35649,"NA":35651},{"trials":35638,"activeCount":99},[],{"trials":35640,"activeCount":99},[],{"trials":35642,"activeCount":99},[35643],{"nctId":738,"briefTitle":739,"status":105,"phases":35644,"primaryCompletion":741,"completion":741,"start":742,"enrollment":743,"conditions":35645,"interventions":35646},[87,88],[35,176],[47,746,747],{"trials":35648,"activeCount":99},[],{"trials":35650,"activeCount":99},[],{"trials":35652,"activeCount":99},[],{"intervention":747,"totalTrials":224,"cells":35654},{"EARLY_PHASE1":35655,"PHASE1":35657,"PHASE2":35659,"PHASE3":35665,"PHASE4":35667,"NA":35669},{"trials":35656,"activeCount":99},[],{"trials":35658,"activeCount":99},[],{"trials":35660,"activeCount":99},[35661],{"nctId":738,"briefTitle":739,"status":105,"phases":35662,"primaryCompletion":741,"completion":741,"start":742,"enrollment":743,"conditions":35663,"interventions":35664},[87,88],[35,176],[47,746,747],{"trials":35666,"activeCount":99},[],{"trials":35668,"activeCount":99},[],{"trials":35670,"activeCount":99},[],{"intervention":35672,"totalTrials":224,"cells":35673},"MRKAd5 HIV-1 gag\u002Fpol\u002Fnef 4 x 10^9 Ad5 vg\u002Fdose",{"EARLY_PHASE1":35674,"PHASE1":35676,"PHASE2":35678,"PHASE3":35688,"PHASE4":35690,"NA":35692},{"trials":35675,"activeCount":99},[],{"trials":35677,"activeCount":99},[],{"trials":35679,"activeCount":99},[35680],{"nctId":35681,"briefTitle":35682,"status":150,"phases":35683,"primaryCompletion":13890,"completion":13890,"start":8619,"enrollment":2873,"conditions":35684,"interventions":35685},"NCT00350623","Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)",[88],[27],[35672,35686,35687],"MRKAd5 HIV-1 gag\u002Fpol\u002Fnef 8 x 10^9 Ad5 vg\u002Fdose","MRKAd5 HIV-1 gag\u002Fpol\u002Fnef 1.5 x 10^10 Ad5 vg\u002Fdose",{"trials":35689,"activeCount":99},[],{"trials":35691,"activeCount":99},[],{"trials":35693,"activeCount":99},[],{"intervention":35686,"totalTrials":224,"cells":35695},{"EARLY_PHASE1":35696,"PHASE1":35698,"PHASE2":35700,"PHASE3":35706,"PHASE4":35708,"NA":35710},{"trials":35697,"activeCount":99},[],{"trials":35699,"activeCount":99},[],{"trials":35701,"activeCount":99},[35702],{"nctId":35681,"briefTitle":35682,"status":150,"phases":35703,"primaryCompletion":13890,"completion":13890,"start":8619,"enrollment":2873,"conditions":35704,"interventions":35705},[88],[27],[35672,35686,35687],{"trials":35707,"activeCount":99},[],{"trials":35709,"activeCount":99},[],{"trials":35711,"activeCount":99},[],{"intervention":35687,"totalTrials":224,"cells":35713},{"EARLY_PHASE1":35714,"PHASE1":35716,"PHASE2":35718,"PHASE3":35724,"PHASE4":35726,"NA":35728},{"trials":35715,"activeCount":99},[],{"trials":35717,"activeCount":99},[],{"trials":35719,"activeCount":99},[35720],{"nctId":35681,"briefTitle":35682,"status":150,"phases":35721,"primaryCompletion":13890,"completion":13890,"start":8619,"enrollment":2873,"conditions":35722,"interventions":35723},[88],[27],[35672,35686,35687],{"trials":35725,"activeCount":99},[],{"trials":35727,"activeCount":99},[],{"trials":35729,"activeCount":99},[],{"intervention":35731,"totalTrials":224,"cells":35732},"V181 High-Potency Level",{"EARLY_PHASE1":35733,"PHASE1":35735,"PHASE2":35737,"PHASE3":35751,"PHASE4":35753,"NA":35755},{"trials":35734,"activeCount":99},[],{"trials":35736,"activeCount":99},[],{"trials":35738,"activeCount":99},[35739],{"nctId":35740,"briefTitle":35741,"status":105,"phases":35742,"primaryCompletion":35743,"completion":26834,"start":2683,"enrollment":35744,"conditions":35745,"interventions":35748},"NCT05507450","Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)",[88],"2023-06-05",1271,[35746,35747],"Dengue Disease","Dengue Virus",[35731,35749,35750],"V181 Mid-Potency Level","V181 Low-Potency Level",{"trials":35752,"activeCount":99},[],{"trials":35754,"activeCount":99},[],{"trials":35756,"activeCount":99},[],{"intervention":35749,"totalTrials":224,"cells":35758},{"EARLY_PHASE1":35759,"PHASE1":35761,"PHASE2":35763,"PHASE3":35769,"PHASE4":35771,"NA":35773},{"trials":35760,"activeCount":99},[],{"trials":35762,"activeCount":99},[],{"trials":35764,"activeCount":99},[35765],{"nctId":35740,"briefTitle":35741,"status":105,"phases":35766,"primaryCompletion":35743,"completion":26834,"start":2683,"enrollment":35744,"conditions":35767,"interventions":35768},[88],[35746,35747],[35731,35749,35750],{"trials":35770,"activeCount":99},[],{"trials":35772,"activeCount":99},[],{"trials":35774,"activeCount":99},[],{"intervention":35750,"totalTrials":224,"cells":35776},{"EARLY_PHASE1":35777,"PHASE1":35779,"PHASE2":35781,"PHASE3":35787,"PHASE4":35789,"NA":35791},{"trials":35778,"activeCount":99},[],{"trials":35780,"activeCount":99},[],{"trials":35782,"activeCount":99},[35783],{"nctId":35740,"briefTitle":35741,"status":105,"phases":35784,"primaryCompletion":35743,"completion":26834,"start":2683,"enrollment":35744,"conditions":35785,"interventions":35786},[88],[35746,35747],[35731,35749,35750],{"trials":35788,"activeCount":99},[],{"trials":35790,"activeCount":99},[],{"trials":35792,"activeCount":99},[],{"intervention":14748,"totalTrials":224,"cells":35794},{"EARLY_PHASE1":35795,"PHASE1":35797,"PHASE2":35799,"PHASE3":35805,"PHASE4":35807,"NA":35809},{"trials":35796,"activeCount":99},[],{"trials":35798,"activeCount":99},[],{"trials":35800,"activeCount":99},[35801],{"nctId":14742,"briefTitle":14743,"status":105,"phases":35802,"primaryCompletion":14730,"completion":14730,"start":14540,"enrollment":3262,"conditions":35803,"interventions":35804},[88],[14746],[14748,13864],{"trials":35806,"activeCount":99},[],{"trials":35808,"activeCount":99},[],{"trials":35810,"activeCount":99},[],{"intervention":14756,"totalTrials":224,"cells":35812},{"EARLY_PHASE1":35813,"PHASE1":35815,"PHASE2":35817,"PHASE3":35823,"PHASE4":35825,"NA":35827},{"trials":35814,"activeCount":99},[],{"trials":35816,"activeCount":99},[],{"trials":35818,"activeCount":99},[35819],{"nctId":14750,"briefTitle":14751,"status":150,"phases":35820,"primaryCompletion":13870,"completion":13870,"start":13891,"enrollment":2779,"conditions":35821,"interventions":35822},[88],[14754],[13864,14756],{"trials":35824,"activeCount":99},[],{"trials":35826,"activeCount":99},[],{"trials":35828,"activeCount":99},[],{"intervention":35830,"totalTrials":224,"cells":35831},"Daptomycin for",{"EARLY_PHASE1":35832,"PHASE1":35834,"PHASE2":35836,"PHASE3":35848,"PHASE4":35850,"NA":35852},{"trials":35833,"activeCount":99},[],{"trials":35835,"activeCount":99},[],{"trials":35837,"activeCount":99},[35838],{"nctId":35839,"briefTitle":35840,"status":105,"phases":35841,"primaryCompletion":35842,"completion":35842,"start":35843,"enrollment":931,"conditions":35844,"interventions":35847},"NCT03643952","Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)",[88],"2020-04-07","2018-12-06",[23188,35845,35846],"Soft Tissue Infections","Skin Diseases, Infectious",[35830],{"trials":35849,"activeCount":99},[],{"trials":35851,"activeCount":99},[],{"trials":35853,"activeCount":99},[],{"intervention":35855,"totalTrials":224,"cells":35856},"timolol\u002Fdorzolamide combination",{"EARLY_PHASE1":35857,"PHASE1":35859,"PHASE2":35861,"PHASE3":35872,"PHASE4":35874,"NA":35876},{"trials":35858,"activeCount":99},[],{"trials":35860,"activeCount":99},[],{"trials":35862,"activeCount":99},[35863],{"nctId":35864,"briefTitle":35865,"status":105,"phases":35866,"primaryCompletion":35867,"completion":35868,"start":35869,"enrollment":661,"conditions":35870,"interventions":35871},"NCT00832377","COSOPT (Timolol\u002FDorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED)",[88],"2010-03-12","2010-03-26","2009-04-24",[17137],[35855],{"trials":35873,"activeCount":99},[],{"trials":35875,"activeCount":99},[],{"trials":35877,"activeCount":99},[],{"intervention":23752,"totalTrials":224,"cells":35879},{"EARLY_PHASE1":35880,"PHASE1":35882,"PHASE2":35884,"PHASE3":35890,"PHASE4":35892,"NA":35894},{"trials":35881,"activeCount":99},[],{"trials":35883,"activeCount":99},[],{"trials":35885,"activeCount":99},[35886],{"nctId":23746,"briefTitle":23747,"status":105,"phases":35887,"primaryCompletion":5800,"completion":5800,"start":8591,"enrollment":20638,"conditions":35888,"interventions":35889},[88],[14552,19620],[23751,23752,19662,23753],{"trials":35891,"activeCount":99},[],{"trials":35893,"activeCount":99},[],{"trials":35895,"activeCount":99},[],{"intervention":23753,"totalTrials":224,"cells":35897},{"EARLY_PHASE1":35898,"PHASE1":35900,"PHASE2":35902,"PHASE3":35908,"PHASE4":35910,"NA":35912},{"trials":35899,"activeCount":99},[],{"trials":35901,"activeCount":99},[],{"trials":35903,"activeCount":99},[35904],{"nctId":23746,"briefTitle":23747,"status":105,"phases":35905,"primaryCompletion":5800,"completion":5800,"start":8591,"enrollment":20638,"conditions":35906,"interventions":35907},[88],[14552,19620],[23751,23752,19662,23753],{"trials":35909,"activeCount":99},[],{"trials":35911,"activeCount":99},[],{"trials":35913,"activeCount":99},[],{"intervention":13855,"totalTrials":224,"cells":35915},{"EARLY_PHASE1":35916,"PHASE1":35918,"PHASE2":35920,"PHASE3":35926,"PHASE4":35928,"NA":35930},{"trials":35917,"activeCount":99},[],{"trials":35919,"activeCount":99},[],{"trials":35921,"activeCount":99},[35922],{"nctId":13845,"briefTitle":13846,"status":105,"phases":35923,"primaryCompletion":13848,"completion":13849,"start":13850,"enrollment":13851,"conditions":35924,"interventions":35925},[88],[13853],[13145,4084,13855],{"trials":35927,"activeCount":99},[],{"trials":35929,"activeCount":99},[],{"trials":35931,"activeCount":99},[],{"intervention":21293,"totalTrials":224,"cells":35933},{"EARLY_PHASE1":35934,"PHASE1":35936,"PHASE2":35938,"PHASE3":35944,"PHASE4":35946,"NA":35948},{"trials":35935,"activeCount":99},[],{"trials":35937,"activeCount":99},[],{"trials":35939,"activeCount":99},[35940],{"nctId":21285,"briefTitle":21286,"status":105,"phases":35941,"primaryCompletion":1198,"completion":1198,"start":21288,"enrollment":21289,"conditions":35942,"interventions":35943},[87,88],[21291,16472],[19272,21293,21294,21295,21296,21297],{"trials":35945,"activeCount":99},[],{"trials":35947,"activeCount":99},[],{"trials":35949,"activeCount":99},[],{"intervention":21294,"totalTrials":224,"cells":35951},{"EARLY_PHASE1":35952,"PHASE1":35954,"PHASE2":35956,"PHASE3":35962,"PHASE4":35964,"NA":35966},{"trials":35953,"activeCount":99},[],{"trials":35955,"activeCount":99},[],{"trials":35957,"activeCount":99},[35958],{"nctId":21285,"briefTitle":21286,"status":105,"phases":35959,"primaryCompletion":1198,"completion":1198,"start":21288,"enrollment":21289,"conditions":35960,"interventions":35961},[87,88],[21291,16472],[19272,21293,21294,21295,21296,21297],{"trials":35963,"activeCount":99},[],{"trials":35965,"activeCount":99},[],{"trials":35967,"activeCount":99},[],{"intervention":21295,"totalTrials":224,"cells":35969},{"EARLY_PHASE1":35970,"PHASE1":35972,"PHASE2":35974,"PHASE3":35980,"PHASE4":35982,"NA":35984},{"trials":35971,"activeCount":99},[],{"trials":35973,"activeCount":99},[],{"trials":35975,"activeCount":99},[35976],{"nctId":21285,"briefTitle":21286,"status":105,"phases":35977,"primaryCompletion":1198,"completion":1198,"start":21288,"enrollment":21289,"conditions":35978,"interventions":35979},[87,88],[21291,16472],[19272,21293,21294,21295,21296,21297],{"trials":35981,"activeCount":99},[],{"trials":35983,"activeCount":99},[],{"trials":35985,"activeCount":99},[],{"intervention":21296,"totalTrials":224,"cells":35987},{"EARLY_PHASE1":35988,"PHASE1":35990,"PHASE2":35992,"PHASE3":35998,"PHASE4":36000,"NA":36002},{"trials":35989,"activeCount":99},[],{"trials":35991,"activeCount":99},[],{"trials":35993,"activeCount":99},[35994],{"nctId":21285,"briefTitle":21286,"status":105,"phases":35995,"primaryCompletion":1198,"completion":1198,"start":21288,"enrollment":21289,"conditions":35996,"interventions":35997},[87,88],[21291,16472],[19272,21293,21294,21295,21296,21297],{"trials":35999,"activeCount":99},[],{"trials":36001,"activeCount":99},[],{"trials":36003,"activeCount":99},[],{"intervention":21297,"totalTrials":224,"cells":36005},{"EARLY_PHASE1":36006,"PHASE1":36008,"PHASE2":36010,"PHASE3":36016,"PHASE4":36018,"NA":36020},{"trials":36007,"activeCount":99},[],{"trials":36009,"activeCount":99},[],{"trials":36011,"activeCount":99},[36012],{"nctId":21285,"briefTitle":21286,"status":105,"phases":36013,"primaryCompletion":1198,"completion":1198,"start":21288,"enrollment":21289,"conditions":36014,"interventions":36015},[87,88],[21291,16472],[19272,21293,21294,21295,21296,21297],{"trials":36017,"activeCount":99},[],{"trials":36019,"activeCount":99},[],{"trials":36021,"activeCount":99},[],{"intervention":21307,"totalTrials":224,"cells":36023},{"EARLY_PHASE1":36024,"PHASE1":36026,"PHASE2":36028,"PHASE3":36034,"PHASE4":36036,"NA":36038},{"trials":36025,"activeCount":99},[],{"trials":36027,"activeCount":99},[],{"trials":36029,"activeCount":99},[36030],{"nctId":21299,"briefTitle":21300,"status":105,"phases":36031,"primaryCompletion":21302,"completion":21302,"start":21303,"enrollment":21304,"conditions":36032,"interventions":36033},[88],[16472],[21307,21308,19272],{"trials":36035,"activeCount":99},[],{"trials":36037,"activeCount":99},[],{"trials":36039,"activeCount":99},[],{"intervention":21308,"totalTrials":224,"cells":36041},{"EARLY_PHASE1":36042,"PHASE1":36044,"PHASE2":36046,"PHASE3":36052,"PHASE4":36054,"NA":36056},{"trials":36043,"activeCount":99},[],{"trials":36045,"activeCount":99},[],{"trials":36047,"activeCount":99},[36048],{"nctId":21299,"briefTitle":21300,"status":105,"phases":36049,"primaryCompletion":21302,"completion":21302,"start":21303,"enrollment":21304,"conditions":36050,"interventions":36051},[88],[16472],[21307,21308,19272],{"trials":36053,"activeCount":99},[],{"trials":36055,"activeCount":99},[],{"trials":36057,"activeCount":99},[],{"intervention":14766,"totalTrials":224,"cells":36059},{"EARLY_PHASE1":36060,"PHASE1":36062,"PHASE2":36064,"PHASE3":36070,"PHASE4":36072,"NA":36074},{"trials":36061,"activeCount":99},[],{"trials":36063,"activeCount":99},[],{"trials":36065,"activeCount":99},[36066],{"nctId":14758,"briefTitle":14759,"status":150,"phases":36067,"primaryCompletion":14313,"completion":14313,"start":5281,"enrollment":1968,"conditions":36068,"interventions":36069},[88],[14762,14763,14764],[14766,14331,14767],{"trials":36071,"activeCount":99},[],{"trials":36073,"activeCount":99},[],{"trials":36075,"activeCount":99},[],{"intervention":14767,"totalTrials":224,"cells":36077},{"EARLY_PHASE1":36078,"PHASE1":36080,"PHASE2":36082,"PHASE3":36088,"PHASE4":36090,"NA":36092},{"trials":36079,"activeCount":99},[],{"trials":36081,"activeCount":99},[],{"trials":36083,"activeCount":99},[36084],{"nctId":14758,"briefTitle":14759,"status":150,"phases":36085,"primaryCompletion":14313,"completion":14313,"start":5281,"enrollment":1968,"conditions":36086,"interventions":36087},[88],[14762,14763,14764],[14766,14331,14767],{"trials":36089,"activeCount":99},[],{"trials":36091,"activeCount":99},[],{"trials":36093,"activeCount":99},[],{"intervention":12717,"totalTrials":224,"cells":36095},{"EARLY_PHASE1":36096,"PHASE1":36098,"PHASE2":36100,"PHASE3":36106,"PHASE4":36108,"NA":36110},{"trials":36097,"activeCount":99},[],{"trials":36099,"activeCount":99},[],{"trials":36101,"activeCount":99},[36102],{"nctId":12709,"briefTitle":12710,"status":150,"phases":36103,"primaryCompletion":12712,"completion":12712,"start":12713,"enrollment":1621,"conditions":36104,"interventions":36105},[88],[7020],[12716,2100,12717],{"trials":36107,"activeCount":99},[],{"trials":36109,"activeCount":99},[],{"trials":36111,"activeCount":99},[],{"intervention":21608,"totalTrials":224,"cells":36113},{"EARLY_PHASE1":36114,"PHASE1":36116,"PHASE2":36118,"PHASE3":36124,"PHASE4":36126,"NA":36128},{"trials":36115,"activeCount":99},[],{"trials":36117,"activeCount":99},[],{"trials":36119,"activeCount":99},[36120],{"nctId":21599,"briefTitle":21600,"status":105,"phases":36121,"primaryCompletion":21602,"completion":21603,"start":21604,"enrollment":21605,"conditions":36122,"interventions":36123},[88],[15308,15309,15310,15311],[15467,15314,21608],{"trials":36125,"activeCount":99},[],{"trials":36127,"activeCount":99},[],{"trials":36129,"activeCount":99},[],{"intervention":36131,"totalTrials":224,"cells":36132},"Raltegravir Film-coated",{"EARLY_PHASE1":36133,"PHASE1":36135,"PHASE2":36137,"PHASE3":36149,"PHASE4":36151,"NA":36153},{"trials":36134,"activeCount":99},[],{"trials":36136,"activeCount":99},[],{"trials":36138,"activeCount":99},[36139],{"nctId":36140,"briefTitle":36141,"status":105,"phases":36142,"primaryCompletion":36143,"completion":36143,"start":36144,"enrollment":626,"conditions":36145,"interventions":36146},"NCT01717287","A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)",[88],"2013-12-11","2012-11-16",[7650],[36131,36147,36148],"Raltegravir Chewable","Other Anti-Retroviral Therapy",{"trials":36150,"activeCount":99},[],{"trials":36152,"activeCount":99},[],{"trials":36154,"activeCount":99},[],{"intervention":36147,"totalTrials":224,"cells":36156},{"EARLY_PHASE1":36157,"PHASE1":36159,"PHASE2":36161,"PHASE3":36167,"PHASE4":36169,"NA":36171},{"trials":36158,"activeCount":99},[],{"trials":36160,"activeCount":99},[],{"trials":36162,"activeCount":99},[36163],{"nctId":36140,"briefTitle":36141,"status":105,"phases":36164,"primaryCompletion":36143,"completion":36143,"start":36144,"enrollment":626,"conditions":36165,"interventions":36166},[88],[7650],[36131,36147,36148],{"trials":36168,"activeCount":99},[],{"trials":36170,"activeCount":99},[],{"trials":36172,"activeCount":99},[],{"intervention":36148,"totalTrials":224,"cells":36174},{"EARLY_PHASE1":36175,"PHASE1":36177,"PHASE2":36179,"PHASE3":36185,"PHASE4":36187,"NA":36189},{"trials":36176,"activeCount":99},[],{"trials":36178,"activeCount":99},[],{"trials":36180,"activeCount":99},[36181],{"nctId":36140,"briefTitle":36141,"status":105,"phases":36182,"primaryCompletion":36143,"completion":36143,"start":36144,"enrollment":626,"conditions":36183,"interventions":36184},[88],[7650],[36131,36147,36148],{"trials":36186,"activeCount":99},[],{"trials":36188,"activeCount":99},[],{"trials":36190,"activeCount":99},[],{"intervention":36192,"totalTrials":224,"cells":36193},"MK0822",{"EARLY_PHASE1":36194,"PHASE1":36196,"PHASE2":36198,"PHASE3":36206,"PHASE4":36208,"NA":36210},{"trials":36195,"activeCount":99},[],{"trials":36197,"activeCount":99},[],{"trials":36199,"activeCount":99},[36200],{"nctId":36201,"briefTitle":36202,"status":150,"phases":36203,"primaryCompletion":15505,"completion":15505,"start":8619,"enrollment":3197,"conditions":36204,"interventions":36205},"NCT00397683","A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011)",[88],[21195],[36192],{"trials":36207,"activeCount":99},[],{"trials":36209,"activeCount":99},[],{"trials":36211,"activeCount":99},[],{"intervention":15819,"totalTrials":224,"cells":36213},{"EARLY_PHASE1":36214,"PHASE1":36216,"PHASE2":36218,"PHASE3":36224,"PHASE4":36226,"NA":36228},{"trials":36215,"activeCount":99},[],{"trials":36217,"activeCount":99},[],{"trials":36219,"activeCount":99},[36220],{"nctId":15813,"briefTitle":15814,"status":105,"phases":36221,"primaryCompletion":13102,"completion":14823,"start":15210,"enrollment":15816,"conditions":36222,"interventions":36223},[88],[12957],[12989,15819,15820,15820],{"trials":36225,"activeCount":99},[],{"trials":36227,"activeCount":99},[],{"trials":36229,"activeCount":99},[],{"intervention":36231,"totalTrials":224,"cells":36232},"MK0683, vorinostat, Suberoylanilide Hydroxamic Acid",{"EARLY_PHASE1":36233,"PHASE1":36235,"PHASE2":36237,"PHASE3":36248,"PHASE4":36250,"NA":36252},{"trials":36234,"activeCount":99},[],{"trials":36236,"activeCount":99},[],{"trials":36238,"activeCount":99},[36239],{"nctId":36240,"briefTitle":36241,"status":150,"phases":36242,"primaryCompletion":36243,"completion":36243,"start":17178,"enrollment":3655,"conditions":36244,"interventions":36246},"NCT00126451","A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)",[88],"2005-10-11",[1109,419,36245],"Non-small-cell Lung Carcinoma",[36231,36247],"Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles",{"trials":36249,"activeCount":99},[],{"trials":36251,"activeCount":99},[],{"trials":36253,"activeCount":99},[],{"intervention":36247,"totalTrials":224,"cells":36255},{"EARLY_PHASE1":36256,"PHASE1":36258,"PHASE2":36260,"PHASE3":36266,"PHASE4":36268,"NA":36270},{"trials":36257,"activeCount":99},[],{"trials":36259,"activeCount":99},[],{"trials":36261,"activeCount":99},[36262],{"nctId":36240,"briefTitle":36241,"status":150,"phases":36263,"primaryCompletion":36243,"completion":36243,"start":17178,"enrollment":3655,"conditions":36264,"interventions":36265},[88],[1109,419,36245],[36231,36247],{"trials":36267,"activeCount":99},[],{"trials":36269,"activeCount":99},[],{"trials":36271,"activeCount":99},[],{"intervention":36273,"totalTrials":224,"cells":36274},"MK0719",{"EARLY_PHASE1":36275,"PHASE1":36277,"PHASE2":36279,"PHASE3":36287,"PHASE4":36289,"NA":36291},{"trials":36276,"activeCount":99},[],{"trials":36278,"activeCount":99},[],{"trials":36280,"activeCount":99},[36281],{"nctId":36282,"briefTitle":36283,"status":150,"phases":36284,"primaryCompletion":15210,"completion":15210,"start":12804,"enrollment":2770,"conditions":36285,"interventions":36286},"NCT00424424","A Study to Evaluate the Efficacy of MK0719 in the Prevention of Postoperative Dental Pain (0719-002)",[88],[34295],[36273],{"trials":36288,"activeCount":99},[],{"trials":36290,"activeCount":99},[],{"trials":36292,"activeCount":99},[],{"intervention":16234,"totalTrials":224,"cells":36294},{"EARLY_PHASE1":36295,"PHASE1":36297,"PHASE2":36299,"PHASE3":36305,"PHASE4":36307,"NA":36309},{"trials":36296,"activeCount":99},[],{"trials":36298,"activeCount":99},[],{"trials":36300,"activeCount":99},[36301],{"nctId":16227,"briefTitle":16228,"status":105,"phases":36302,"primaryCompletion":13039,"completion":13039,"start":16230,"enrollment":16231,"conditions":36303,"interventions":36304},[88],[5252],[5254,5313,5137,16234],{"trials":36306,"activeCount":99},[],{"trials":36308,"activeCount":99},[],{"trials":36310,"activeCount":99},[],{"intervention":34575,"totalTrials":224,"cells":36312},{"EARLY_PHASE1":36313,"PHASE1":36315,"PHASE2":36317,"PHASE3":36323,"PHASE4":36325,"NA":36327},{"trials":36314,"activeCount":99},[],{"trials":36316,"activeCount":99},[],{"trials":36318,"activeCount":99},[36319],{"nctId":34566,"briefTitle":34567,"status":105,"phases":36320,"primaryCompletion":34569,"completion":34569,"start":34570,"enrollment":15135,"conditions":36321,"interventions":36322},[88],[34572],[34557,34574,34575],{"trials":36324,"activeCount":99},[],{"trials":36326,"activeCount":99},[],{"trials":36328,"activeCount":99},[],{"intervention":36330,"totalTrials":224,"cells":36331},"val-mCyd",{"EARLY_PHASE1":36332,"PHASE1":36334,"PHASE2":36336,"PHASE3":36344,"PHASE4":36346,"NA":36348},{"trials":36333,"activeCount":99},[],{"trials":36335,"activeCount":99},[],{"trials":36337,"activeCount":99},[36338],{"nctId":36339,"briefTitle":36340,"status":105,"phases":36341,"primaryCompletion":17096,"completion":17096,"start":14772,"conditions":36342,"interventions":36343},"NCT00227435","Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C",[87,88],[12957],[36330],{"trials":36345,"activeCount":99},[],{"trials":36347,"activeCount":99},[],{"trials":36349,"activeCount":99},[],{"intervention":36351,"totalTrials":224,"cells":36352},"Sotatercept 15 mg",{"EARLY_PHASE1":36353,"PHASE1":36355,"PHASE2":36357,"PHASE3":36370,"PHASE4":36372,"NA":36374},{"trials":36354,"activeCount":99},[],{"trials":36356,"activeCount":99},[],{"trials":36358,"activeCount":99},[36359],{"nctId":36360,"briefTitle":36361,"status":150,"phases":36362,"primaryCompletion":36363,"completion":36363,"start":9322,"enrollment":3506,"conditions":36364,"interventions":36368},"NCT01284348","To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer",[88],"2012-09-21",[195,369,36365,1134,36366,36367],"Carcinoma, Small-Cell Lung","Cancer of Head and Neck","Uterine Cervical Cancer",[36351,36369],"Sotatercept 30 mg",{"trials":36371,"activeCount":99},[],{"trials":36373,"activeCount":99},[],{"trials":36375,"activeCount":99},[],{"intervention":36369,"totalTrials":224,"cells":36377},{"EARLY_PHASE1":36378,"PHASE1":36380,"PHASE2":36382,"PHASE3":36388,"PHASE4":36390,"NA":36392},{"trials":36379,"activeCount":99},[],{"trials":36381,"activeCount":99},[],{"trials":36383,"activeCount":99},[36384],{"nctId":36360,"briefTitle":36361,"status":150,"phases":36385,"primaryCompletion":36363,"completion":36363,"start":9322,"enrollment":3506,"conditions":36386,"interventions":36387},[88],[195,369,36365,1134,36366,36367],[36351,36369],{"trials":36389,"activeCount":99},[],{"trials":36391,"activeCount":99},[],{"trials":36393,"activeCount":99},[],{"intervention":36395,"totalTrials":224,"cells":36396},"Lead-In Ridaforolimus",{"EARLY_PHASE1":36397,"PHASE1":36399,"PHASE2":36401,"PHASE3":36411,"PHASE4":36413,"NA":36415},{"trials":36398,"activeCount":99},[],{"trials":36400,"activeCount":99},[],{"trials":36402,"activeCount":99},[36403],{"nctId":36404,"briefTitle":36405,"status":150,"phases":36406,"primaryCompletion":23091,"completion":23091,"start":14314,"enrollment":1479,"conditions":36407,"interventions":36408},"NCT00818675","A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)",[88],[903],[36395,36409,36410],"Comparator: Blinded Ridaforolimus","Comparator: Blinded Placebo",{"trials":36412,"activeCount":99},[],{"trials":36414,"activeCount":99},[],{"trials":36416,"activeCount":99},[],{"intervention":36409,"totalTrials":224,"cells":36418},{"EARLY_PHASE1":36419,"PHASE1":36421,"PHASE2":36423,"PHASE3":36429,"PHASE4":36431,"NA":36433},{"trials":36420,"activeCount":99},[],{"trials":36422,"activeCount":99},[],{"trials":36424,"activeCount":99},[36425],{"nctId":36404,"briefTitle":36405,"status":150,"phases":36426,"primaryCompletion":23091,"completion":23091,"start":14314,"enrollment":1479,"conditions":36427,"interventions":36428},[88],[903],[36395,36409,36410],{"trials":36430,"activeCount":99},[],{"trials":36432,"activeCount":99},[],{"trials":36434,"activeCount":99},[],{"intervention":36410,"totalTrials":224,"cells":36436},{"EARLY_PHASE1":36437,"PHASE1":36439,"PHASE2":36441,"PHASE3":36447,"PHASE4":36449,"NA":36451},{"trials":36438,"activeCount":99},[],{"trials":36440,"activeCount":99},[],{"trials":36442,"activeCount":99},[36443],{"nctId":36404,"briefTitle":36405,"status":150,"phases":36444,"primaryCompletion":23091,"completion":23091,"start":14314,"enrollment":1479,"conditions":36445,"interventions":36446},[88],[903],[36395,36409,36410],{"trials":36448,"activeCount":99},[],{"trials":36450,"activeCount":99},[],{"trials":36452,"activeCount":99},[],{"intervention":36454,"totalTrials":224,"cells":36455},"Temozolomide and radiotherapy",{"EARLY_PHASE1":36456,"PHASE1":36458,"PHASE2":36460,"PHASE3":36470,"PHASE4":36472,"NA":36474},{"trials":36457,"activeCount":99},[],{"trials":36459,"activeCount":99},[],{"trials":36461,"activeCount":99},[36462],{"nctId":36463,"briefTitle":36464,"status":150,"phases":36465,"primaryCompletion":36466,"completion":36466,"start":36467,"enrollment":3903,"conditions":36468,"interventions":36469},"NCT00266812","Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)",[88],"2008-01-16","2005-03-08",[369],[36454],{"trials":36471,"activeCount":99},[],{"trials":36473,"activeCount":99},[],{"trials":36475,"activeCount":99},[],{"intervention":36477,"totalTrials":224,"cells":36478},"MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline",{"EARLY_PHASE1":36479,"PHASE1":36481,"PHASE2":36483,"PHASE3":36494,"PHASE4":36496,"NA":36498},{"trials":36480,"activeCount":99},[],{"trials":36482,"activeCount":99},[],{"trials":36484,"activeCount":99},[36485],{"nctId":36486,"briefTitle":36487,"status":150,"phases":36488,"primaryCompletion":4990,"completion":14494,"start":5280,"enrollment":2754,"conditions":36489,"interventions":36491},"NCT00924781","A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12)",[88],[195,36490],"Chronic Kidney Disease",[36477,36492,36493],"MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline","MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline",{"trials":36495,"activeCount":99},[],{"trials":36497,"activeCount":99},[],{"trials":36499,"activeCount":99},[],{"intervention":36492,"totalTrials":224,"cells":36501},{"EARLY_PHASE1":36502,"PHASE1":36504,"PHASE2":36506,"PHASE3":36512,"PHASE4":36514,"NA":36516},{"trials":36503,"activeCount":99},[],{"trials":36505,"activeCount":99},[],{"trials":36507,"activeCount":99},[36508],{"nctId":36486,"briefTitle":36487,"status":150,"phases":36509,"primaryCompletion":4990,"completion":14494,"start":5280,"enrollment":2754,"conditions":36510,"interventions":36511},[88],[195,36490],[36477,36492,36493],{"trials":36513,"activeCount":99},[],{"trials":36515,"activeCount":99},[],{"trials":36517,"activeCount":99},[],{"intervention":36493,"totalTrials":224,"cells":36519},{"EARLY_PHASE1":36520,"PHASE1":36522,"PHASE2":36524,"PHASE3":36530,"PHASE4":36532,"NA":36534},{"trials":36521,"activeCount":99},[],{"trials":36523,"activeCount":99},[],{"trials":36525,"activeCount":99},[36526],{"nctId":36486,"briefTitle":36487,"status":150,"phases":36527,"primaryCompletion":4990,"completion":14494,"start":5280,"enrollment":2754,"conditions":36528,"interventions":36529},[88],[195,36490],[36477,36492,36493],{"trials":36531,"activeCount":99},[],{"trials":36533,"activeCount":99},[],{"trials":36535,"activeCount":99},[],{"intervention":13865,"totalTrials":224,"cells":36537},{"EARLY_PHASE1":36538,"PHASE1":36540,"PHASE2":36542,"PHASE3":36548,"PHASE4":36550,"NA":36552},{"trials":36539,"activeCount":99},[],{"trials":36541,"activeCount":99},[],{"trials":36543,"activeCount":99},[36544],{"nctId":13857,"briefTitle":13858,"status":150,"phases":36545,"primaryCompletion":4990,"completion":12813,"start":6309,"enrollment":13860,"conditions":36546,"interventions":36547},[88],[33],[13863,13864,13865,4084],{"trials":36549,"activeCount":99},[],{"trials":36551,"activeCount":99},[],{"trials":36553,"activeCount":99},[],{"intervention":34720,"totalTrials":224,"cells":36555},{"EARLY_PHASE1":36556,"PHASE1":36558,"PHASE2":36560,"PHASE3":36566,"PHASE4":36568,"NA":36570},{"trials":36557,"activeCount":99},[],{"trials":36559,"activeCount":99},[],{"trials":36561,"activeCount":99},[36562],{"nctId":34715,"briefTitle":34716,"status":105,"phases":36563,"primaryCompletion":15210,"completion":15210,"start":14228,"enrollment":2399,"conditions":36564,"interventions":36565},[88],[30],[34720,34706],{"trials":36567,"activeCount":99},[],{"trials":36569,"activeCount":99},[],{"trials":36571,"activeCount":99},[],{"intervention":24174,"totalTrials":224,"cells":36573},{"EARLY_PHASE1":36574,"PHASE1":36576,"PHASE2":36578,"PHASE3":36584,"PHASE4":36586,"NA":36588},{"trials":36575,"activeCount":99},[],{"trials":36577,"activeCount":99},[],{"trials":36579,"activeCount":99},[36580],{"nctId":24167,"briefTitle":24168,"status":105,"phases":36581,"primaryCompletion":18807,"completion":18807,"start":22317,"enrollment":920,"conditions":36582,"interventions":36583},[88],[24171,24172],[24158,24174],{"trials":36585,"activeCount":99},[],{"trials":36587,"activeCount":99},[],{"trials":36589,"activeCount":99},[],{"intervention":21318,"totalTrials":224,"cells":36591},{"EARLY_PHASE1":36592,"PHASE1":36594,"PHASE2":36596,"PHASE3":36602,"PHASE4":36604,"NA":36606},{"trials":36593,"activeCount":99},[],{"trials":36595,"activeCount":99},[],{"trials":36597,"activeCount":99},[36598],{"nctId":21310,"briefTitle":21311,"status":105,"phases":36599,"primaryCompletion":21313,"completion":21313,"start":21314,"enrollment":21315,"conditions":36600,"interventions":36601},[88],[16472],[21318,21319,21320],{"trials":36603,"activeCount":99},[],{"trials":36605,"activeCount":99},[],{"trials":36607,"activeCount":99},[],{"intervention":21319,"totalTrials":224,"cells":36609},{"EARLY_PHASE1":36610,"PHASE1":36612,"PHASE2":36614,"PHASE3":36620,"PHASE4":36622,"NA":36624},{"trials":36611,"activeCount":99},[],{"trials":36613,"activeCount":99},[],{"trials":36615,"activeCount":99},[36616],{"nctId":21310,"briefTitle":21311,"status":105,"phases":36617,"primaryCompletion":21313,"completion":21313,"start":21314,"enrollment":21315,"conditions":36618,"interventions":36619},[88],[16472],[21318,21319,21320],{"trials":36621,"activeCount":99},[],{"trials":36623,"activeCount":99},[],{"trials":36625,"activeCount":99},[],{"intervention":36627,"totalTrials":224,"cells":36628},"triamcinolone acetonide",{"EARLY_PHASE1":36629,"PHASE1":36631,"PHASE2":36633,"PHASE3":36642,"PHASE4":36644,"NA":36646},{"trials":36630,"activeCount":99},[],{"trials":36632,"activeCount":99},[],{"trials":36634,"activeCount":99},[36635],{"nctId":36636,"briefTitle":36637,"status":150,"phases":36638,"primaryCompletion":14823,"completion":14823,"start":14858,"enrollment":3197,"conditions":36639,"interventions":36641},"NCT00692614","A Study of MK0140 in Diabetic Patients With Macular Edema (0140-001)",[88],[36640],"Macular Edema",[36627],{"trials":36643,"activeCount":99},[],{"trials":36645,"activeCount":99},[],{"trials":36647,"activeCount":99},[],{"intervention":22411,"totalTrials":224,"cells":36649},{"EARLY_PHASE1":36650,"PHASE1":36652,"PHASE2":36654,"PHASE3":36660,"PHASE4":36662,"NA":36664},{"trials":36651,"activeCount":99},[],{"trials":36653,"activeCount":99},[],{"trials":36655,"activeCount":99},[36656],{"nctId":22405,"briefTitle":22406,"status":105,"phases":36657,"primaryCompletion":13891,"completion":13891,"start":8621,"enrollment":22408,"conditions":36658,"interventions":36659},[88],[17593,1014],[22411,22412],{"trials":36661,"activeCount":99},[],{"trials":36663,"activeCount":99},[],{"trials":36665,"activeCount":99},[],{"intervention":24104,"totalTrials":224,"cells":36667},{"EARLY_PHASE1":36668,"PHASE1":36670,"PHASE2":36672,"PHASE3":36678,"PHASE4":36680,"NA":36682},{"trials":36669,"activeCount":99},[],{"trials":36671,"activeCount":99},[],{"trials":36673,"activeCount":99},[36674],{"nctId":24096,"briefTitle":24097,"status":150,"phases":36675,"primaryCompletion":24099,"completion":24099,"start":24100,"enrollment":13995,"conditions":36676,"interventions":36677},[88],[4397],[24103,24087,24104,24105],{"trials":36679,"activeCount":99},[],{"trials":36681,"activeCount":99},[],{"trials":36683,"activeCount":99},[],{"intervention":24105,"totalTrials":224,"cells":36685},{"EARLY_PHASE1":36686,"PHASE1":36688,"PHASE2":36690,"PHASE3":36696,"PHASE4":36698,"NA":36700},{"trials":36687,"activeCount":99},[],{"trials":36689,"activeCount":99},[],{"trials":36691,"activeCount":99},[36692],{"nctId":24096,"briefTitle":24097,"status":150,"phases":36693,"primaryCompletion":24099,"completion":24099,"start":24100,"enrollment":13995,"conditions":36694,"interventions":36695},[88],[4397],[24103,24087,24104,24105],{"trials":36697,"activeCount":99},[],{"trials":36699,"activeCount":99},[],{"trials":36701,"activeCount":99},[],{"intervention":36703,"totalTrials":224,"cells":36704},"Vicriviroc 30 mg",{"EARLY_PHASE1":36705,"PHASE1":36707,"PHASE2":36709,"PHASE3":36721,"PHASE4":36723,"NA":36725},{"trials":36706,"activeCount":99},[],{"trials":36708,"activeCount":99},[],{"trials":36710,"activeCount":99},[36711],{"nctId":36712,"briefTitle":36713,"status":105,"phases":36714,"primaryCompletion":21248,"completion":36715,"start":36716,"enrollment":429,"conditions":36717,"interventions":36718},"NCT00243230","Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020\u002FP03672)",[88],"2011-03-17","2005-09-19",[27],[36703,36719,36720],"Vicriviroc 20 mg","Background ART Regimen",{"trials":36722,"activeCount":99},[],{"trials":36724,"activeCount":99},[],{"trials":36726,"activeCount":99},[],{"intervention":36719,"totalTrials":224,"cells":36728},{"EARLY_PHASE1":36729,"PHASE1":36731,"PHASE2":36733,"PHASE3":36739,"PHASE4":36741,"NA":36743},{"trials":36730,"activeCount":99},[],{"trials":36732,"activeCount":99},[],{"trials":36734,"activeCount":99},[36735],{"nctId":36712,"briefTitle":36713,"status":105,"phases":36736,"primaryCompletion":21248,"completion":36715,"start":36716,"enrollment":429,"conditions":36737,"interventions":36738},[88],[27],[36703,36719,36720],{"trials":36740,"activeCount":99},[],{"trials":36742,"activeCount":99},[],{"trials":36744,"activeCount":99},[],{"intervention":36720,"totalTrials":224,"cells":36746},{"EARLY_PHASE1":36747,"PHASE1":36749,"PHASE2":36751,"PHASE3":36757,"PHASE4":36759,"NA":36761},{"trials":36748,"activeCount":99},[],{"trials":36750,"activeCount":99},[],{"trials":36752,"activeCount":99},[36753],{"nctId":36712,"briefTitle":36713,"status":105,"phases":36754,"primaryCompletion":21248,"completion":36715,"start":36716,"enrollment":429,"conditions":36755,"interventions":36756},[88],[27],[36703,36719,36720],{"trials":36758,"activeCount":99},[],{"trials":36760,"activeCount":99},[],{"trials":36762,"activeCount":99},[],{"intervention":36764,"totalTrials":224,"cells":36765},"Gefapixant 45 mg",{"EARLY_PHASE1":36766,"PHASE1":36768,"PHASE2":36770,"PHASE3":36780,"PHASE4":36782,"NA":36784},{"trials":36767,"activeCount":99},[],{"trials":36769,"activeCount":99},[],{"trials":36771,"activeCount":99},[36772],{"nctId":36773,"briefTitle":36774,"status":105,"phases":36775,"primaryCompletion":36776,"completion":36776,"start":36777,"enrollment":3141,"conditions":36778,"interventions":36779},"NCT03482713","Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033)",[88],"2018-06-07","2018-03-16",[20767],[36764],{"trials":36781,"activeCount":99},[],{"trials":36783,"activeCount":99},[],{"trials":36785,"activeCount":99},[],{"intervention":21114,"totalTrials":224,"cells":36787},{"EARLY_PHASE1":36788,"PHASE1":36790,"PHASE2":36792,"PHASE3":36798,"PHASE4":36800,"NA":36802},{"trials":36789,"activeCount":99},[],{"trials":36791,"activeCount":99},[],{"trials":36793,"activeCount":99},[36794],{"nctId":21108,"briefTitle":21109,"status":105,"phases":36795,"primaryCompletion":14494,"completion":5179,"start":14454,"enrollment":21111,"conditions":36796,"interventions":36797},[88],[27],[1422,21114],{"trials":36799,"activeCount":99},[],{"trials":36801,"activeCount":99},[],{"trials":36803,"activeCount":99},[],{"intervention":36805,"totalTrials":224,"cells":36806},"Oral testosterone undecanoate",{"EARLY_PHASE1":36807,"PHASE1":36809,"PHASE2":36811,"PHASE3":36821,"PHASE4":36823,"NA":36825},{"trials":36808,"activeCount":99},[],{"trials":36810,"activeCount":99},[],{"trials":36812,"activeCount":99},[36813],{"nctId":36814,"briefTitle":36815,"status":105,"phases":36816,"primaryCompletion":17096,"completion":17096,"start":14773,"enrollment":4130,"conditions":36817,"interventions":36820},"NCT00434824","Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203)",[88],[36818,36819],"Hypogonadism","Androgens",[36805],{"trials":36822,"activeCount":99},[],{"trials":36824,"activeCount":99},[],{"trials":36826,"activeCount":99},[],{"intervention":20035,"totalTrials":224,"cells":36828},{"EARLY_PHASE1":36829,"PHASE1":36831,"PHASE2":36833,"PHASE3":36839,"PHASE4":36841,"NA":36843},{"trials":36830,"activeCount":99},[],{"trials":36832,"activeCount":99},[],{"trials":36834,"activeCount":99},[36835],{"nctId":20026,"briefTitle":20027,"status":150,"phases":36836,"primaryCompletion":14393,"completion":20029,"start":20030,"enrollment":212,"conditions":36837,"interventions":36838},[88],[20032,20033,20018],[19981,20035,20036],{"trials":36840,"activeCount":99},[],{"trials":36842,"activeCount":99},[],{"trials":36844,"activeCount":99},[],{"intervention":20036,"totalTrials":224,"cells":36846},{"EARLY_PHASE1":36847,"PHASE1":36849,"PHASE2":36851,"PHASE3":36857,"PHASE4":36859,"NA":36861},{"trials":36848,"activeCount":99},[],{"trials":36850,"activeCount":99},[],{"trials":36852,"activeCount":99},[36853],{"nctId":20026,"briefTitle":20027,"status":150,"phases":36854,"primaryCompletion":14393,"completion":20029,"start":20030,"enrollment":212,"conditions":36855,"interventions":36856},[88],[20032,20033,20018],[19981,20035,20036],{"trials":36858,"activeCount":99},[],{"trials":36860,"activeCount":99},[],{"trials":36862,"activeCount":99},[],{"intervention":21579,"totalTrials":224,"cells":36864},{"EARLY_PHASE1":36865,"PHASE1":36867,"PHASE2":36869,"PHASE3":36875,"PHASE4":36877,"NA":36879},{"trials":36866,"activeCount":99},[],{"trials":36868,"activeCount":99},[],{"trials":36870,"activeCount":99},[36871],{"nctId":21573,"briefTitle":21574,"status":150,"phases":36872,"primaryCompletion":15794,"completion":15794,"start":14314,"enrollment":734,"conditions":36873,"interventions":36874},[88],[21577,6286],[5135,5199,21579],{"trials":36876,"activeCount":99},[],{"trials":36878,"activeCount":99},[],{"trials":36880,"activeCount":99},[],{"intervention":36882,"totalTrials":224,"cells":36883},"MK0812 \u002F Duration of Treatment: 12 Weeks",{"EARLY_PHASE1":36884,"PHASE1":36886,"PHASE2":36888,"PHASE3":36897,"PHASE4":36899,"NA":36901},{"trials":36885,"activeCount":99},[],{"trials":36887,"activeCount":99},[],{"trials":36889,"activeCount":99},[36890],{"nctId":36891,"briefTitle":36892,"status":105,"phases":36893,"primaryCompletion":14930,"completion":14930,"start":14229,"enrollment":30057,"conditions":36894,"interventions":36895},"NCT00542022","Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008)",[88],[7197],[36882,36896],"Comparator: placebo (unspecified) \u002F Duration of Treatment: 12 Weeks",{"trials":36898,"activeCount":99},[],{"trials":36900,"activeCount":99},[],{"trials":36902,"activeCount":99},[],{"intervention":36896,"totalTrials":224,"cells":36904},{"EARLY_PHASE1":36905,"PHASE1":36907,"PHASE2":36909,"PHASE3":36915,"PHASE4":36917,"NA":36919},{"trials":36906,"activeCount":99},[],{"trials":36908,"activeCount":99},[],{"trials":36910,"activeCount":99},[36911],{"nctId":36891,"briefTitle":36892,"status":105,"phases":36912,"primaryCompletion":14930,"completion":14930,"start":14229,"enrollment":30057,"conditions":36913,"interventions":36914},[88],[7197],[36882,36896],{"trials":36916,"activeCount":99},[],{"trials":36918,"activeCount":99},[],{"trials":36920,"activeCount":99},[],{"intervention":36922,"totalTrials":224,"cells":36923},"MK-8435 (Org 25935) 4-8 mg",{"EARLY_PHASE1":36924,"PHASE1":36926,"PHASE2":36928,"PHASE3":36939,"PHASE4":36941,"NA":36943},{"trials":36925,"activeCount":99},[],{"trials":36927,"activeCount":99},[],{"trials":36929,"activeCount":99},[36930],{"nctId":36931,"briefTitle":36932,"status":105,"phases":36933,"primaryCompletion":4786,"completion":4786,"start":36934,"enrollment":36935,"conditions":36936,"interventions":36937},"NCT00725075","Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001)",[88],"2007-04-10",215,[14715],[36922,36938],"MK-8435 (Org 25935) 12-16 mg",{"trials":36940,"activeCount":99},[],{"trials":36942,"activeCount":99},[],{"trials":36944,"activeCount":99},[],{"intervention":36938,"totalTrials":224,"cells":36946},{"EARLY_PHASE1":36947,"PHASE1":36949,"PHASE2":36951,"PHASE3":36957,"PHASE4":36959,"NA":36961},{"trials":36948,"activeCount":99},[],{"trials":36950,"activeCount":99},[],{"trials":36952,"activeCount":99},[36953],{"nctId":36931,"briefTitle":36932,"status":105,"phases":36954,"primaryCompletion":4786,"completion":4786,"start":36934,"enrollment":36935,"conditions":36955,"interventions":36956},[88],[14715],[36922,36938],{"trials":36958,"activeCount":99},[],{"trials":36960,"activeCount":99},[],{"trials":36962,"activeCount":99},[],{"intervention":24509,"totalTrials":224,"cells":36964},{"EARLY_PHASE1":36965,"PHASE1":36967,"PHASE2":36969,"PHASE3":36975,"PHASE4":36977,"NA":36979},{"trials":36966,"activeCount":99},[],{"trials":36968,"activeCount":99},[],{"trials":36970,"activeCount":99},[36971],{"nctId":24501,"briefTitle":24502,"status":105,"phases":36972,"primaryCompletion":5507,"completion":5507,"start":24504,"enrollment":2108,"conditions":36973,"interventions":36974},[88],[24506,863,24507],[24492,24509,24510,24511],{"trials":36976,"activeCount":99},[],{"trials":36978,"activeCount":99},[],{"trials":36980,"activeCount":99},[],{"intervention":24510,"totalTrials":224,"cells":36982},{"EARLY_PHASE1":36983,"PHASE1":36985,"PHASE2":36987,"PHASE3":36993,"PHASE4":36995,"NA":36997},{"trials":36984,"activeCount":99},[],{"trials":36986,"activeCount":99},[],{"trials":36988,"activeCount":99},[36989],{"nctId":24501,"briefTitle":24502,"status":105,"phases":36990,"primaryCompletion":5507,"completion":5507,"start":24504,"enrollment":2108,"conditions":36991,"interventions":36992},[88],[24506,863,24507],[24492,24509,24510,24511],{"trials":36994,"activeCount":99},[],{"trials":36996,"activeCount":99},[],{"trials":36998,"activeCount":99},[],{"intervention":24511,"totalTrials":224,"cells":37000},{"EARLY_PHASE1":37001,"PHASE1":37003,"PHASE2":37005,"PHASE3":37011,"PHASE4":37013,"NA":37015},{"trials":37002,"activeCount":99},[],{"trials":37004,"activeCount":99},[],{"trials":37006,"activeCount":99},[37007],{"nctId":24501,"briefTitle":24502,"status":105,"phases":37008,"primaryCompletion":5507,"completion":5507,"start":24504,"enrollment":2108,"conditions":37009,"interventions":37010},[88],[24506,863,24507],[24492,24509,24510,24511],{"trials":37012,"activeCount":99},[],{"trials":37014,"activeCount":99},[],{"trials":37016,"activeCount":99},[],{"intervention":20424,"totalTrials":224,"cells":37018},{"EARLY_PHASE1":37019,"PHASE1":37021,"PHASE2":37023,"PHASE3":37029,"PHASE4":37031,"NA":37033},{"trials":37020,"activeCount":99},[],{"trials":37022,"activeCount":99},[],{"trials":37024,"activeCount":99},[37025],{"nctId":20419,"briefTitle":20420,"status":105,"phases":37026,"primaryCompletion":14713,"completion":13222,"start":14823,"enrollment":417,"conditions":37027,"interventions":37028},[88],[21],[20424,15820,20425,20426],{"trials":37030,"activeCount":99},[],{"trials":37032,"activeCount":99},[],{"trials":37034,"activeCount":99},[],{"intervention":20425,"totalTrials":224,"cells":37036},{"EARLY_PHASE1":37037,"PHASE1":37039,"PHASE2":37041,"PHASE3":37047,"PHASE4":37049,"NA":37051},{"trials":37038,"activeCount":99},[],{"trials":37040,"activeCount":99},[],{"trials":37042,"activeCount":99},[37043],{"nctId":20419,"briefTitle":20420,"status":105,"phases":37044,"primaryCompletion":14713,"completion":13222,"start":14823,"enrollment":417,"conditions":37045,"interventions":37046},[88],[21],[20424,15820,20425,20426],{"trials":37048,"activeCount":99},[],{"trials":37050,"activeCount":99},[],{"trials":37052,"activeCount":99},[],{"intervention":19579,"totalTrials":224,"cells":37054},{"EARLY_PHASE1":37055,"PHASE1":37057,"PHASE2":37059,"PHASE3":37065,"PHASE4":37067,"NA":37069},{"trials":37056,"activeCount":99},[],{"trials":37058,"activeCount":99},[],{"trials":37060,"activeCount":99},[37061],{"nctId":19570,"briefTitle":19571,"status":105,"phases":37062,"primaryCompletion":19573,"completion":19573,"start":19574,"enrollment":19575,"conditions":37063,"interventions":37064},[88],[1109,19577],[19579,14554],{"trials":37066,"activeCount":99},[],{"trials":37068,"activeCount":99},[],{"trials":37070,"activeCount":99},[],{"intervention":14797,"totalTrials":224,"cells":37072},{"EARLY_PHASE1":37073,"PHASE1":37075,"PHASE2":37077,"PHASE3":37083,"PHASE4":37085,"NA":37087},{"trials":37074,"activeCount":99},[],{"trials":37076,"activeCount":99},[],{"trials":37078,"activeCount":99},[37079],{"nctId":14792,"briefTitle":14793,"status":150,"phases":37080,"primaryCompletion":14504,"completion":14504,"start":12814,"enrollment":120,"conditions":37081,"interventions":37082},[88],[11174],[14797,13864],{"trials":37084,"activeCount":99},[],{"trials":37086,"activeCount":99},[],{"trials":37088,"activeCount":99},[],{"intervention":14805,"totalTrials":224,"cells":37090},{"EARLY_PHASE1":37091,"PHASE1":37093,"PHASE2":37095,"PHASE3":37101,"PHASE4":37103,"NA":37105},{"trials":37092,"activeCount":99},[],{"trials":37094,"activeCount":99},[],{"trials":37096,"activeCount":99},[37097],{"nctId":14799,"briefTitle":14800,"status":105,"phases":37098,"primaryCompletion":13870,"completion":13870,"start":5801,"enrollment":14802,"conditions":37099,"interventions":37100},[88],[4397],[14805,14806,14807,14808,14809,14810,14331],{"trials":37102,"activeCount":99},[],{"trials":37104,"activeCount":99},[],{"trials":37106,"activeCount":99},[],{"intervention":14806,"totalTrials":224,"cells":37108},{"EARLY_PHASE1":37109,"PHASE1":37111,"PHASE2":37113,"PHASE3":37119,"PHASE4":37121,"NA":37123},{"trials":37110,"activeCount":99},[],{"trials":37112,"activeCount":99},[],{"trials":37114,"activeCount":99},[37115],{"nctId":14799,"briefTitle":14800,"status":105,"phases":37116,"primaryCompletion":13870,"completion":13870,"start":5801,"enrollment":14802,"conditions":37117,"interventions":37118},[88],[4397],[14805,14806,14807,14808,14809,14810,14331],{"trials":37120,"activeCount":99},[],{"trials":37122,"activeCount":99},[],{"trials":37124,"activeCount":99},[],{"intervention":14807,"totalTrials":224,"cells":37126},{"EARLY_PHASE1":37127,"PHASE1":37129,"PHASE2":37131,"PHASE3":37137,"PHASE4":37139,"NA":37141},{"trials":37128,"activeCount":99},[],{"trials":37130,"activeCount":99},[],{"trials":37132,"activeCount":99},[37133],{"nctId":14799,"briefTitle":14800,"status":105,"phases":37134,"primaryCompletion":13870,"completion":13870,"start":5801,"enrollment":14802,"conditions":37135,"interventions":37136},[88],[4397],[14805,14806,14807,14808,14809,14810,14331],{"trials":37138,"activeCount":99},[],{"trials":37140,"activeCount":99},[],{"trials":37142,"activeCount":99},[],{"intervention":14808,"totalTrials":224,"cells":37144},{"EARLY_PHASE1":37145,"PHASE1":37147,"PHASE2":37149,"PHASE3":37155,"PHASE4":37157,"NA":37159},{"trials":37146,"activeCount":99},[],{"trials":37148,"activeCount":99},[],{"trials":37150,"activeCount":99},[37151],{"nctId":14799,"briefTitle":14800,"status":105,"phases":37152,"primaryCompletion":13870,"completion":13870,"start":5801,"enrollment":14802,"conditions":37153,"interventions":37154},[88],[4397],[14805,14806,14807,14808,14809,14810,14331],{"trials":37156,"activeCount":99},[],{"trials":37158,"activeCount":99},[],{"trials":37160,"activeCount":99},[],{"intervention":14809,"totalTrials":224,"cells":37162},{"EARLY_PHASE1":37163,"PHASE1":37165,"PHASE2":37167,"PHASE3":37173,"PHASE4":37175,"NA":37177},{"trials":37164,"activeCount":99},[],{"trials":37166,"activeCount":99},[],{"trials":37168,"activeCount":99},[37169],{"nctId":14799,"briefTitle":14800,"status":105,"phases":37170,"primaryCompletion":13870,"completion":13870,"start":5801,"enrollment":14802,"conditions":37171,"interventions":37172},[88],[4397],[14805,14806,14807,14808,14809,14810,14331],{"trials":37174,"activeCount":99},[],{"trials":37176,"activeCount":99},[],{"trials":37178,"activeCount":99},[],{"intervention":14810,"totalTrials":224,"cells":37180},{"EARLY_PHASE1":37181,"PHASE1":37183,"PHASE2":37185,"PHASE3":37191,"PHASE4":37193,"NA":37195},{"trials":37182,"activeCount":99},[],{"trials":37184,"activeCount":99},[],{"trials":37186,"activeCount":99},[37187],{"nctId":14799,"briefTitle":14800,"status":105,"phases":37188,"primaryCompletion":13870,"completion":13870,"start":5801,"enrollment":14802,"conditions":37189,"interventions":37190},[88],[4397],[14805,14806,14807,14808,14809,14810,14331],{"trials":37192,"activeCount":99},[],{"trials":37194,"activeCount":99},[],{"trials":37196,"activeCount":99},[],{"intervention":6092,"totalTrials":224,"cells":37198},{"EARLY_PHASE1":37199,"PHASE1":37201,"PHASE2":37203,"PHASE3":37209,"PHASE4":37211,"NA":37213},{"trials":37200,"activeCount":99},[],{"trials":37202,"activeCount":99},[],{"trials":37204,"activeCount":99},[37205],{"nctId":6083,"briefTitle":6084,"status":105,"phases":37206,"primaryCompletion":173,"completion":6086,"start":6087,"enrollment":6088,"conditions":37207,"interventions":37208},[88],[431],[6091,6092,603],{"trials":37210,"activeCount":99},[],{"trials":37212,"activeCount":99},[],{"trials":37214,"activeCount":99},[],{"intervention":1047,"totalTrials":224,"cells":37216},{"EARLY_PHASE1":37217,"PHASE1":37219,"PHASE2":37221,"PHASE3":37227,"PHASE4":37229,"NA":37231},{"trials":37218,"activeCount":99},[],{"trials":37220,"activeCount":99},[],{"trials":37222,"activeCount":99},[37223],{"nctId":1038,"briefTitle":1039,"status":1040,"phases":37224,"primaryCompletion":1042,"completion":1043,"start":1044,"enrollment":99,"conditions":37225,"interventions":37226},[88],[526],[47,1047],{"trials":37228,"activeCount":99},[],{"trials":37230,"activeCount":99},[],{"trials":37232,"activeCount":99},[],{"intervention":37234,"totalTrials":224,"cells":37235},"Testim 1%",{"EARLY_PHASE1":37236,"PHASE1":37238,"PHASE2":37240,"PHASE3":37248,"PHASE4":37250,"NA":37252},{"trials":37237,"activeCount":99},[],{"trials":37239,"activeCount":99},[],{"trials":37241,"activeCount":99},[37242],{"nctId":37243,"briefTitle":37244,"status":150,"phases":37245,"primaryCompletion":15210,"completion":15210,"start":14976,"enrollment":2779,"conditions":37246,"interventions":37247},"NCT00254553","A Study to Test a Measure of Symptoms of Older Men With Low Testosterone On and Off Testosterone Replacement Treatment (P05815)",[88],[36818],[37234],{"trials":37249,"activeCount":99},[],{"trials":37251,"activeCount":99},[],{"trials":37253,"activeCount":99},[],{"intervention":23123,"totalTrials":224,"cells":37255},{"EARLY_PHASE1":37256,"PHASE1":37258,"PHASE2":37260,"PHASE3":37266,"PHASE4":37268,"NA":37270},{"trials":37257,"activeCount":99},[],{"trials":37259,"activeCount":99},[],{"trials":37261,"activeCount":99},[37262],{"nctId":23117,"briefTitle":23118,"status":105,"phases":37263,"primaryCompletion":8619,"completion":14713,"start":15211,"enrollment":23120,"conditions":37264,"interventions":37265},[88],[27,21124],[23123,15245,15245],{"trials":37267,"activeCount":99},[],{"trials":37269,"activeCount":99},[],{"trials":37271,"activeCount":99},[],{"intervention":37273,"totalTrials":224,"cells":37274},"Comparator: A: Pregabalin",{"EARLY_PHASE1":37275,"PHASE1":37277,"PHASE2":37279,"PHASE3":37290,"PHASE4":37292,"NA":37294},{"trials":37276,"activeCount":99},[],{"trials":37278,"activeCount":99},[],{"trials":37280,"activeCount":99},[37281],{"nctId":37282,"briefTitle":37283,"status":1040,"phases":37284,"primaryCompletion":20608,"completion":14445,"start":9610,"enrollment":99,"conditions":37285,"interventions":37287},"NCT00837941","A Study of Single Dose Pain Therapy in Patients With Painful Diabetic Neuropathy (0000-115)",[88],[37286],"Painful Diabetic Neuropathy",[37273,37288,37289],"Comparator: B: Duloxetine","Comparator: C: Diphenhydramine hydrochloride",{"trials":37291,"activeCount":99},[],{"trials":37293,"activeCount":99},[],{"trials":37295,"activeCount":99},[],{"intervention":37288,"totalTrials":224,"cells":37297},{"EARLY_PHASE1":37298,"PHASE1":37300,"PHASE2":37302,"PHASE3":37308,"PHASE4":37310,"NA":37312},{"trials":37299,"activeCount":99},[],{"trials":37301,"activeCount":99},[],{"trials":37303,"activeCount":99},[37304],{"nctId":37282,"briefTitle":37283,"status":1040,"phases":37305,"primaryCompletion":20608,"completion":14445,"start":9610,"enrollment":99,"conditions":37306,"interventions":37307},[88],[37286],[37273,37288,37289],{"trials":37309,"activeCount":99},[],{"trials":37311,"activeCount":99},[],{"trials":37313,"activeCount":99},[],{"intervention":37289,"totalTrials":224,"cells":37315},{"EARLY_PHASE1":37316,"PHASE1":37318,"PHASE2":37320,"PHASE3":37326,"PHASE4":37328,"NA":37330},{"trials":37317,"activeCount":99},[],{"trials":37319,"activeCount":99},[],{"trials":37321,"activeCount":99},[37322],{"nctId":37282,"briefTitle":37283,"status":1040,"phases":37323,"primaryCompletion":20608,"completion":14445,"start":9610,"enrollment":99,"conditions":37324,"interventions":37325},[88],[37286],[37273,37288,37289],{"trials":37327,"activeCount":99},[],{"trials":37329,"activeCount":99},[],{"trials":37331,"activeCount":99},[],{"intervention":37333,"totalTrials":224,"cells":37334},"Comparator: niacin \u002F Duration of Treatment: 17 Weeks",{"EARLY_PHASE1":37335,"PHASE1":37337,"PHASE2":37339,"PHASE3":37349,"PHASE4":37351,"NA":37353},{"trials":37336,"activeCount":99},[],{"trials":37338,"activeCount":99},[],{"trials":37340,"activeCount":99},[37341],{"nctId":37342,"briefTitle":37343,"status":105,"phases":37344,"primaryCompletion":19537,"completion":15038,"start":18806,"enrollment":4121,"conditions":37345,"interventions":37346},"NCT00536237","MK0524A Phase IIb Study (0524A-011)(COMPLETED)",[88],[29159],[37333,37347,37348],"MK0524A, niacin (+) laropiprant \u002F Duration of Treatment: 17 Weeks","Comparator: placebo (unspecified) \u002F Duration of Treatment: 17 Weeks",{"trials":37350,"activeCount":99},[],{"trials":37352,"activeCount":99},[],{"trials":37354,"activeCount":99},[],{"intervention":37347,"totalTrials":224,"cells":37356},{"EARLY_PHASE1":37357,"PHASE1":37359,"PHASE2":37361,"PHASE3":37367,"PHASE4":37369,"NA":37371},{"trials":37358,"activeCount":99},[],{"trials":37360,"activeCount":99},[],{"trials":37362,"activeCount":99},[37363],{"nctId":37342,"briefTitle":37343,"status":105,"phases":37364,"primaryCompletion":19537,"completion":15038,"start":18806,"enrollment":4121,"conditions":37365,"interventions":37366},[88],[29159],[37333,37347,37348],{"trials":37368,"activeCount":99},[],{"trials":37370,"activeCount":99},[],{"trials":37372,"activeCount":99},[],{"intervention":37348,"totalTrials":224,"cells":37374},{"EARLY_PHASE1":37375,"PHASE1":37377,"PHASE2":37379,"PHASE3":37385,"PHASE4":37387,"NA":37389},{"trials":37376,"activeCount":99},[],{"trials":37378,"activeCount":99},[],{"trials":37380,"activeCount":99},[37381],{"nctId":37342,"briefTitle":37343,"status":105,"phases":37382,"primaryCompletion":19537,"completion":15038,"start":18806,"enrollment":4121,"conditions":37383,"interventions":37384},[88],[29159],[37333,37347,37348],{"trials":37386,"activeCount":99},[],{"trials":37388,"activeCount":99},[],{"trials":37390,"activeCount":99},[],{"intervention":1075,"totalTrials":224,"cells":37392},{"EARLY_PHASE1":37393,"PHASE1":37395,"PHASE2":37397,"PHASE3":37403,"PHASE4":37405,"NA":37407},{"trials":37394,"activeCount":99},[],{"trials":37396,"activeCount":99},[],{"trials":37398,"activeCount":99},[37399],{"nctId":1061,"briefTitle":1062,"status":105,"phases":37400,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":110,"conditions":37401,"interventions":37402},[88],[943],[47,1069,1070,1071,1072,1073,562,1074,1075,1076],{"trials":37404,"activeCount":99},[],{"trials":37406,"activeCount":99},[],{"trials":37408,"activeCount":99},[],{"intervention":24603,"totalTrials":224,"cells":37410},{"EARLY_PHASE1":37411,"PHASE1":37413,"PHASE2":37415,"PHASE3":37421,"PHASE4":37423,"NA":37425},{"trials":37412,"activeCount":99},[],{"trials":37414,"activeCount":99},[],{"trials":37416,"activeCount":99},[37417],{"nctId":24597,"briefTitle":24598,"status":105,"phases":37418,"primaryCompletion":5179,"completion":5179,"start":5982,"enrollment":9323,"conditions":37419,"interventions":37420},[88],[22638],[24602,24603],{"trials":37422,"activeCount":99},[],{"trials":37424,"activeCount":99},[],{"trials":37426,"activeCount":99},[],{"intervention":11423,"totalTrials":224,"cells":37428},{"EARLY_PHASE1":37429,"PHASE1":37431,"PHASE2":37433,"PHASE3":37439,"PHASE4":37441,"NA":37443},{"trials":37430,"activeCount":99},[],{"trials":37432,"activeCount":99},[],{"trials":37434,"activeCount":99},[37435],{"nctId":11413,"briefTitle":11414,"status":105,"phases":37436,"primaryCompletion":11416,"completion":11417,"start":11418,"enrollment":2085,"conditions":37437,"interventions":37438},[88],[7639],[7800,11357,11421,11422,11423],{"trials":37440,"activeCount":99},[],{"trials":37442,"activeCount":99},[],{"trials":37444,"activeCount":99},[],{"intervention":37446,"totalTrials":224,"cells":37447},"MK-7622",{"EARLY_PHASE1":37448,"PHASE1":37450,"PHASE2":37452,"PHASE3":37462,"PHASE4":37464,"NA":37466},{"trials":37449,"activeCount":99},[],{"trials":37451,"activeCount":99},[],{"trials":37453,"activeCount":99},[37454],{"nctId":37455,"briefTitle":37456,"status":150,"phases":37457,"primaryCompletion":37458,"completion":37458,"start":17061,"enrollment":16231,"conditions":37459,"interventions":37460},"NCT01852110","Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)",[88],"2016-04-11",[11174],[37446,37461],"AChEI",{"trials":37463,"activeCount":99},[],{"trials":37465,"activeCount":99},[],{"trials":37467,"activeCount":99},[],{"intervention":37461,"totalTrials":224,"cells":37469},{"EARLY_PHASE1":37470,"PHASE1":37472,"PHASE2":37474,"PHASE3":37480,"PHASE4":37482,"NA":37484},{"trials":37471,"activeCount":99},[],{"trials":37473,"activeCount":99},[],{"trials":37475,"activeCount":99},[37476],{"nctId":37455,"briefTitle":37456,"status":150,"phases":37477,"primaryCompletion":37458,"completion":37458,"start":17061,"enrollment":16231,"conditions":37478,"interventions":37479},[88],[11174],[37446,37461],{"trials":37481,"activeCount":99},[],{"trials":37483,"activeCount":99},[],{"trials":37485,"activeCount":99},[],{"intervention":37487,"totalTrials":224,"cells":37488},"MK-1200",{"EARLY_PHASE1":37489,"PHASE1":37491,"PHASE2":37493,"PHASE3":37503,"PHASE4":37505,"NA":37507},{"trials":37490,"activeCount":99},[],{"trials":37492,"activeCount":99},[],{"trials":37494,"activeCount":99},[37495],{"nctId":37496,"briefTitle":37497,"status":105,"phases":37498,"primaryCompletion":7291,"completion":7291,"start":37499,"enrollment":5563,"conditions":37500,"interventions":37501},"NCT06242691","Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)",[87,88],"2024-02-28",[497],[37487,37502],"Antiemetic",{"trials":37504,"activeCount":99},[],{"trials":37506,"activeCount":99},[],{"trials":37508,"activeCount":99},[],{"intervention":37502,"totalTrials":224,"cells":37510},{"EARLY_PHASE1":37511,"PHASE1":37513,"PHASE2":37515,"PHASE3":37521,"PHASE4":37523,"NA":37525},{"trials":37512,"activeCount":99},[],{"trials":37514,"activeCount":99},[],{"trials":37516,"activeCount":99},[37517],{"nctId":37496,"briefTitle":37497,"status":105,"phases":37518,"primaryCompletion":7291,"completion":7291,"start":37499,"enrollment":5563,"conditions":37519,"interventions":37520},[87,88],[497],[37487,37502],{"trials":37522,"activeCount":99},[],{"trials":37524,"activeCount":99},[],{"trials":37526,"activeCount":99},[],{"intervention":37528,"totalTrials":224,"cells":37529},"MK0759",{"EARLY_PHASE1":37530,"PHASE1":37532,"PHASE2":37534,"PHASE3":37542,"PHASE4":37544,"NA":37546},{"trials":37531,"activeCount":99},[],{"trials":37533,"activeCount":99},[],{"trials":37535,"activeCount":99},[37536],{"nctId":37537,"briefTitle":37538,"status":150,"phases":37539,"primaryCompletion":15210,"completion":15210,"start":14228,"enrollment":805,"conditions":37540,"interventions":37541},"NCT00245544","Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004)",[88],[14465],[37528],{"trials":37543,"activeCount":99},[],{"trials":37545,"activeCount":99},[],{"trials":37547,"activeCount":99},[],{"intervention":14818,"totalTrials":224,"cells":37549},{"EARLY_PHASE1":37550,"PHASE1":37552,"PHASE2":37554,"PHASE3":37560,"PHASE4":37562,"NA":37564},{"trials":37551,"activeCount":99},[],{"trials":37553,"activeCount":99},[],{"trials":37555,"activeCount":99},[37556],{"nctId":14812,"briefTitle":14813,"status":150,"phases":37557,"primaryCompletion":13224,"completion":12813,"start":14353,"enrollment":14815,"conditions":37558,"interventions":37559},[88],[15,30],[14657,13864,14818],{"trials":37561,"activeCount":99},[],{"trials":37563,"activeCount":99},[],{"trials":37565,"activeCount":99},[],{"intervention":37567,"totalTrials":224,"cells":37568},"MK0812",{"EARLY_PHASE1":37569,"PHASE1":37571,"PHASE2":37573,"PHASE3":37582,"PHASE4":37584,"NA":37586},{"trials":37570,"activeCount":99},[],{"trials":37572,"activeCount":99},[],{"trials":37574,"activeCount":99},[37575],{"nctId":37576,"briefTitle":37577,"status":150,"phases":37578,"primaryCompletion":24504,"completion":14484,"start":18806,"enrollment":2023,"conditions":37579,"interventions":37581},"NCT00239655","A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)",[88],[37580],"Relapsing-Remitting Multiple Sclerosis",[37567],{"trials":37583,"activeCount":99},[],{"trials":37585,"activeCount":99},[],{"trials":37587,"activeCount":99},[],{"intervention":37589,"totalTrials":224,"cells":37590},"Org 28611",{"EARLY_PHASE1":37591,"PHASE1":37593,"PHASE2":37595,"PHASE3":37605,"PHASE4":37607,"NA":37609},{"trials":37592,"activeCount":99},[],{"trials":37594,"activeCount":99},[],{"trials":37596,"activeCount":99},[37597],{"nctId":37598,"briefTitle":37599,"status":150,"phases":37600,"primaryCompletion":5507,"completion":5507,"start":13891,"enrollment":5983,"conditions":37601,"interventions":37603},"NCT00782951","A Comparison of Analgesic Efficacy Between a Single Dose of ORG 28611, Morphine, and Placebo After Dental Impaction Surgery (Study P05800)",[88],[37602],"Analgesia",[37589,37604],"morphine sulfate",{"trials":37606,"activeCount":99},[],{"trials":37608,"activeCount":99},[],{"trials":37610,"activeCount":99},[],{"intervention":37604,"totalTrials":224,"cells":37612},{"EARLY_PHASE1":37613,"PHASE1":37615,"PHASE2":37617,"PHASE3":37623,"PHASE4":37625,"NA":37627},{"trials":37614,"activeCount":99},[],{"trials":37616,"activeCount":99},[],{"trials":37618,"activeCount":99},[37619],{"nctId":37598,"briefTitle":37599,"status":150,"phases":37620,"primaryCompletion":5507,"completion":5507,"start":13891,"enrollment":5983,"conditions":37621,"interventions":37622},[88],[37602],[37589,37604],{"trials":37624,"activeCount":99},[],{"trials":37626,"activeCount":99},[],{"trials":37628,"activeCount":99},[],{"intervention":14826,"totalTrials":224,"cells":37630},{"EARLY_PHASE1":37631,"PHASE1":37633,"PHASE2":37635,"PHASE3":37641,"PHASE4":37643,"NA":37645},{"trials":37632,"activeCount":99},[],{"trials":37634,"activeCount":99},[],{"trials":37636,"activeCount":99},[37637],{"nctId":14820,"briefTitle":14821,"status":105,"phases":37638,"primaryCompletion":14314,"completion":14314,"start":14823,"enrollment":558,"conditions":37639,"interventions":37640},[88],[9543],[13864,14826],{"trials":37642,"activeCount":99},[],{"trials":37644,"activeCount":99},[],{"trials":37646,"activeCount":99},[],{"intervention":22586,"totalTrials":224,"cells":37648},{"EARLY_PHASE1":37649,"PHASE1":37651,"PHASE2":37653,"PHASE3":37659,"PHASE4":37661,"NA":37663},{"trials":37650,"activeCount":99},[],{"trials":37652,"activeCount":99},[],{"trials":37654,"activeCount":99},[37655],{"nctId":22577,"briefTitle":22578,"status":105,"phases":37656,"primaryCompletion":22580,"completion":22581,"start":22582,"enrollment":1479,"conditions":37657,"interventions":37658},[88],[22584],[22568,22586],{"trials":37660,"activeCount":99},[],{"trials":37662,"activeCount":99},[],{"trials":37664,"activeCount":99},[],{"intervention":14833,"totalTrials":224,"cells":37666},{"EARLY_PHASE1":37667,"PHASE1":37669,"PHASE2":37671,"PHASE3":37677,"PHASE4":37679,"NA":37681},{"trials":37668,"activeCount":99},[],{"trials":37670,"activeCount":99},[],{"trials":37672,"activeCount":99},[37673],{"nctId":14828,"briefTitle":14829,"status":105,"phases":37674,"primaryCompletion":14352,"completion":14352,"start":14540,"enrollment":14815,"conditions":37675,"interventions":37676},[88],[863,865,9217,7085,9169],[14833,14834,13864],{"trials":37678,"activeCount":99},[],{"trials":37680,"activeCount":99},[],{"trials":37682,"activeCount":99},[],{"intervention":14834,"totalTrials":224,"cells":37684},{"EARLY_PHASE1":37685,"PHASE1":37687,"PHASE2":37689,"PHASE3":37695,"PHASE4":37697,"NA":37699},{"trials":37686,"activeCount":99},[],{"trials":37688,"activeCount":99},[],{"trials":37690,"activeCount":99},[37691],{"nctId":14828,"briefTitle":14829,"status":105,"phases":37692,"primaryCompletion":14352,"completion":14352,"start":14540,"enrollment":14815,"conditions":37693,"interventions":37694},[88],[863,865,9217,7085,9169],[14833,14834,13864],{"trials":37696,"activeCount":99},[],{"trials":37698,"activeCount":99},[],{"trials":37700,"activeCount":99},[],{"intervention":37702,"totalTrials":224,"cells":37703},"SCH 56592",{"EARLY_PHASE1":37704,"PHASE1":37706,"PHASE2":37708,"PHASE3":37718,"PHASE4":37720,"NA":37722},{"trials":37705,"activeCount":99},[],{"trials":37707,"activeCount":99},[],{"trials":37709,"activeCount":99},[37710],{"nctId":37711,"briefTitle":37712,"status":105,"phases":37713,"primaryCompletion":14353,"completion":14353,"start":14324,"enrollment":21111,"conditions":37714,"interventions":37716},"NCT00491764","A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED)",[88],[37715],"Onychomycosis",[37702,37702,37702,37702,37717],"Terbinafine",{"trials":37719,"activeCount":99},[],{"trials":37721,"activeCount":99},[],{"trials":37723,"activeCount":99},[],{"intervention":37717,"totalTrials":224,"cells":37725},{"EARLY_PHASE1":37726,"PHASE1":37728,"PHASE2":37730,"PHASE3":37736,"PHASE4":37738,"NA":37740},{"trials":37727,"activeCount":99},[],{"trials":37729,"activeCount":99},[],{"trials":37731,"activeCount":99},[37732],{"nctId":37711,"briefTitle":37712,"status":105,"phases":37733,"primaryCompletion":14353,"completion":14353,"start":14324,"enrollment":21111,"conditions":37734,"interventions":37735},[88],[37715],[37702,37702,37702,37702,37717],{"trials":37737,"activeCount":99},[],{"trials":37739,"activeCount":99},[],{"trials":37741,"activeCount":99},[],{"intervention":14841,"totalTrials":224,"cells":37743},{"EARLY_PHASE1":37744,"PHASE1":37746,"PHASE2":37748,"PHASE3":37754,"PHASE4":37756,"NA":37758},{"trials":37745,"activeCount":99},[],{"trials":37747,"activeCount":99},[],{"trials":37749,"activeCount":99},[37750],{"nctId":14836,"briefTitle":14837,"status":105,"phases":37751,"primaryCompletion":5981,"completion":5981,"start":14540,"enrollment":2585,"conditions":37752,"interventions":37753},[88],[863,865,9217,7085,9169],[14841,14842,14842,14843,14844,13864],{"trials":37755,"activeCount":99},[],{"trials":37757,"activeCount":99},[],{"trials":37759,"activeCount":99},[],{"intervention":14842,"totalTrials":224,"cells":37761},{"EARLY_PHASE1":37762,"PHASE1":37764,"PHASE2":37766,"PHASE3":37772,"PHASE4":37774,"NA":37776},{"trials":37763,"activeCount":99},[],{"trials":37765,"activeCount":99},[],{"trials":37767,"activeCount":99},[37768],{"nctId":14836,"briefTitle":14837,"status":105,"phases":37769,"primaryCompletion":5981,"completion":5981,"start":14540,"enrollment":2585,"conditions":37770,"interventions":37771},[88],[863,865,9217,7085,9169],[14841,14842,14842,14843,14844,13864],{"trials":37773,"activeCount":99},[],{"trials":37775,"activeCount":99},[],{"trials":37777,"activeCount":99},[],{"intervention":14843,"totalTrials":224,"cells":37779},{"EARLY_PHASE1":37780,"PHASE1":37782,"PHASE2":37784,"PHASE3":37790,"PHASE4":37792,"NA":37794},{"trials":37781,"activeCount":99},[],{"trials":37783,"activeCount":99},[],{"trials":37785,"activeCount":99},[37786],{"nctId":14836,"briefTitle":14837,"status":105,"phases":37787,"primaryCompletion":5981,"completion":5981,"start":14540,"enrollment":2585,"conditions":37788,"interventions":37789},[88],[863,865,9217,7085,9169],[14841,14842,14842,14843,14844,13864],{"trials":37791,"activeCount":99},[],{"trials":37793,"activeCount":99},[],{"trials":37795,"activeCount":99},[],{"intervention":14844,"totalTrials":224,"cells":37797},{"EARLY_PHASE1":37798,"PHASE1":37800,"PHASE2":37802,"PHASE3":37808,"PHASE4":37810,"NA":37812},{"trials":37799,"activeCount":99},[],{"trials":37801,"activeCount":99},[],{"trials":37803,"activeCount":99},[37804],{"nctId":14836,"briefTitle":14837,"status":105,"phases":37805,"primaryCompletion":5981,"completion":5981,"start":14540,"enrollment":2585,"conditions":37806,"interventions":37807},[88],[863,865,9217,7085,9169],[14841,14842,14842,14843,14844,13864],{"trials":37809,"activeCount":99},[],{"trials":37811,"activeCount":99},[],{"trials":37813,"activeCount":99},[],{"intervention":14853,"totalTrials":224,"cells":37815},{"EARLY_PHASE1":37816,"PHASE1":37818,"PHASE2":37820,"PHASE3":37826,"PHASE4":37828,"NA":37830},{"trials":37817,"activeCount":99},[],{"trials":37819,"activeCount":99},[],{"trials":37821,"activeCount":99},[37822],{"nctId":14846,"briefTitle":14847,"status":150,"phases":37823,"primaryCompletion":5507,"completion":5507,"start":14705,"enrollment":14849,"conditions":37824,"interventions":37825},[88],[14851],[14853,13864,13985],{"trials":37827,"activeCount":99},[],{"trials":37829,"activeCount":99},[],{"trials":37831,"activeCount":99},[],{"intervention":37833,"totalTrials":224,"cells":37834},"Epinastine Nasal Spray",{"EARLY_PHASE1":37835,"PHASE1":37837,"PHASE2":37839,"PHASE3":37848,"PHASE4":37850,"NA":37852},{"trials":37836,"activeCount":99},[],{"trials":37838,"activeCount":99},[],{"trials":37840,"activeCount":99},[37841],{"nctId":37842,"briefTitle":37843,"status":105,"phases":37844,"primaryCompletion":4419,"completion":4419,"start":15038,"enrollment":37845,"conditions":37846,"interventions":37847},"NCT00407927","A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis",[88],571,[29203],[37833],{"trials":37849,"activeCount":99},[],{"trials":37851,"activeCount":99},[],{"trials":37853,"activeCount":99},[],{"intervention":19037,"totalTrials":224,"cells":37855},{"EARLY_PHASE1":37856,"PHASE1":37858,"PHASE2":37860,"PHASE3":37866,"PHASE4":37868,"NA":37870},{"trials":37857,"activeCount":99},[],{"trials":37859,"activeCount":99},[],{"trials":37861,"activeCount":99},[37862],{"nctId":19030,"briefTitle":19031,"status":150,"phases":37863,"primaryCompletion":15406,"completion":19033,"start":4319,"enrollment":357,"conditions":37864,"interventions":37865},[88],[19035],[11239,19037],{"trials":37867,"activeCount":99},[],{"trials":37869,"activeCount":99},[],{"trials":37871,"activeCount":99},[],{"intervention":34215,"totalTrials":224,"cells":37873},{"EARLY_PHASE1":37874,"PHASE1":37876,"PHASE2":37878,"PHASE3":37884,"PHASE4":37886,"NA":37888},{"trials":37875,"activeCount":99},[],{"trials":37877,"activeCount":99},[],{"trials":37879,"activeCount":99},[37880],{"nctId":34209,"briefTitle":34210,"status":105,"phases":37881,"primaryCompletion":14408,"completion":14408,"start":13891,"enrollment":380,"conditions":37882,"interventions":37883},[88],[34213],[15073,34215],{"trials":37885,"activeCount":99},[],{"trials":37887,"activeCount":99},[],{"trials":37889,"activeCount":99},[],{"intervention":9439,"totalTrials":224,"cells":37891},{"EARLY_PHASE1":37892,"PHASE1":37894,"PHASE2":37896,"PHASE3":37902,"PHASE4":37904,"NA":37906},{"trials":37893,"activeCount":99},[],{"trials":37895,"activeCount":99},[],{"trials":37897,"activeCount":99},[37898],{"nctId":9430,"briefTitle":9431,"status":105,"phases":37899,"primaryCompletion":9433,"completion":9434,"start":9435,"enrollment":429,"conditions":37900,"interventions":37901},[88],[9437],[9384,9439],{"trials":37903,"activeCount":99},[],{"trials":37905,"activeCount":99},[],{"trials":37907,"activeCount":99},[],{"intervention":37909,"totalTrials":224,"cells":37910},"MK-3655",{"EARLY_PHASE1":37911,"PHASE1":37913,"PHASE2":37915,"PHASE3":37925,"PHASE4":37927,"NA":37929},{"trials":37912,"activeCount":99},[],{"trials":37914,"activeCount":99},[],{"trials":37916,"activeCount":99},[37917],{"nctId":37918,"briefTitle":37919,"status":150,"phases":37920,"primaryCompletion":37921,"completion":37921,"start":37922,"enrollment":22593,"conditions":37923,"interventions":37924},"NCT04583423","A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)",[88],"2023-04-13","2020-11-11",[11640],[37909],{"trials":37926,"activeCount":99},[],{"trials":37928,"activeCount":99},[],{"trials":37930,"activeCount":99},[],{"intervention":16603,"totalTrials":224,"cells":37932},{"EARLY_PHASE1":37933,"PHASE1":37935,"PHASE2":37937,"PHASE3":37943,"PHASE4":37945,"NA":37947},{"trials":37934,"activeCount":99},[],{"trials":37936,"activeCount":99},[],{"trials":37938,"activeCount":99},[37939],{"nctId":16597,"briefTitle":16598,"status":150,"phases":37940,"primaryCompletion":5800,"completion":5800,"start":15794,"enrollment":3390,"conditions":37941,"interventions":37942},[88],[16601],[16579,16603],{"trials":37944,"activeCount":99},[],{"trials":37946,"activeCount":99},[],{"trials":37948,"activeCount":99},[],{"intervention":14862,"totalTrials":224,"cells":37950},{"EARLY_PHASE1":37951,"PHASE1":37953,"PHASE2":37955,"PHASE3":37961,"PHASE4":37963,"NA":37965},{"trials":37952,"activeCount":99},[],{"trials":37954,"activeCount":99},[],{"trials":37956,"activeCount":99},[37957],{"nctId":14855,"briefTitle":14856,"status":105,"phases":37958,"primaryCompletion":14445,"completion":14445,"start":14858,"enrollment":14859,"conditions":37959,"interventions":37960},[88],[14337],[14862,13864],{"trials":37962,"activeCount":99},[],{"trials":37964,"activeCount":99},[],{"trials":37966,"activeCount":99},[],{"intervention":35235,"totalTrials":224,"cells":37968},{"EARLY_PHASE1":37969,"PHASE1":37971,"PHASE2":37973,"PHASE3":37979,"PHASE4":37981,"NA":37983},{"trials":37970,"activeCount":99},[],{"trials":37972,"activeCount":99},[],{"trials":37974,"activeCount":99},[37975],{"nctId":35229,"briefTitle":35230,"status":105,"phases":37976,"primaryCompletion":14930,"completion":14930,"start":14595,"enrollment":35232,"conditions":37977,"interventions":37978},[88],[15308],[35235,25590],{"trials":37980,"activeCount":99},[],{"trials":37982,"activeCount":99},[],{"trials":37984,"activeCount":99},[],{"intervention":37986,"totalTrials":224,"cells":37987},"MK2578",{"EARLY_PHASE1":37988,"PHASE1":37990,"PHASE2":37992,"PHASE3":38001,"PHASE4":38003,"NA":38005},{"trials":37989,"activeCount":99},[],{"trials":37991,"activeCount":99},[],{"trials":37993,"activeCount":99},[37994],{"nctId":37995,"briefTitle":37996,"status":150,"phases":37997,"primaryCompletion":4990,"completion":14494,"start":8591,"enrollment":357,"conditions":37998,"interventions":37999},"NCT00968617","A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002)",[88],[195,36490],[37986,37986,37986,38000],"Comparator: darbepoetin alfa",{"trials":38002,"activeCount":99},[],{"trials":38004,"activeCount":99},[],{"trials":38006,"activeCount":99},[],{"intervention":38000,"totalTrials":224,"cells":38008},{"EARLY_PHASE1":38009,"PHASE1":38011,"PHASE2":38013,"PHASE3":38019,"PHASE4":38021,"NA":38023},{"trials":38010,"activeCount":99},[],{"trials":38012,"activeCount":99},[],{"trials":38014,"activeCount":99},[38015],{"nctId":37995,"briefTitle":37996,"status":150,"phases":38016,"primaryCompletion":4990,"completion":14494,"start":8591,"enrollment":357,"conditions":38017,"interventions":38018},[88],[195,36490],[37986,37986,37986,38000],{"trials":38020,"activeCount":99},[],{"trials":38022,"activeCount":99},[],{"trials":38024,"activeCount":99},[],{"intervention":21920,"totalTrials":224,"cells":38026},{"EARLY_PHASE1":38027,"PHASE1":38029,"PHASE2":38031,"PHASE3":38037,"PHASE4":38039,"NA":38041},{"trials":38028,"activeCount":99},[],{"trials":38030,"activeCount":99},[],{"trials":38032,"activeCount":99},[38033],{"nctId":21912,"briefTitle":21913,"status":105,"phases":38034,"primaryCompletion":14384,"completion":14384,"start":21915,"enrollment":21916,"conditions":38035,"interventions":38036},[88],[4397],[21919,21920,21884],{"trials":38038,"activeCount":99},[],{"trials":38040,"activeCount":99},[],{"trials":38042,"activeCount":99},[],{"intervention":14869,"totalTrials":224,"cells":38044},{"EARLY_PHASE1":38045,"PHASE1":38047,"PHASE2":38049,"PHASE3":38055,"PHASE4":38057,"NA":38059},{"trials":38046,"activeCount":99},[],{"trials":38048,"activeCount":99},[],{"trials":38050,"activeCount":99},[38051],{"nctId":14864,"briefTitle":14865,"status":105,"phases":38052,"primaryCompletion":14858,"completion":14858,"start":14540,"enrollment":787,"conditions":38053,"interventions":38054},[88],[30],[14869,14331,14870],{"trials":38056,"activeCount":99},[],{"trials":38058,"activeCount":99},[],{"trials":38060,"activeCount":99},[],{"intervention":14882,"totalTrials":224,"cells":38062},{"EARLY_PHASE1":38063,"PHASE1":38065,"PHASE2":38067,"PHASE3":38073,"PHASE4":38075,"NA":38077},{"trials":38064,"activeCount":99},[],{"trials":38066,"activeCount":99},[],{"trials":38068,"activeCount":99},[38069],{"nctId":14872,"briefTitle":14873,"status":150,"phases":38070,"primaryCompletion":14875,"completion":14875,"start":14876,"enrollment":14877,"conditions":38071,"interventions":38072},[88],[14879],[14881,14882,13864],{"trials":38074,"activeCount":99},[],{"trials":38076,"activeCount":99},[],{"trials":38078,"activeCount":99},[],{"intervention":38080,"totalTrials":224,"cells":38081},"SCH 900538",{"EARLY_PHASE1":38082,"PHASE1":38084,"PHASE2":38086,"PHASE3":38096,"PHASE4":38098,"NA":38100},{"trials":38083,"activeCount":99},[],{"trials":38085,"activeCount":99},[],{"trials":38087,"activeCount":99},[38088],{"nctId":38089,"briefTitle":38090,"status":105,"phases":38091,"primaryCompletion":5801,"completion":5801,"start":13890,"enrollment":38092,"conditions":38093,"interventions":38094},"NCT00673062","Study of the Effect of SCH 900538 on Congestion in Subjects With Seasonal Allergic Rhinitis (Study P05031)(COMPLETED)",[88],265,[29203],[38080,38095],"Pseudoephedrine",{"trials":38097,"activeCount":99},[],{"trials":38099,"activeCount":99},[],{"trials":38101,"activeCount":99},[],{"intervention":38095,"totalTrials":224,"cells":38103},{"EARLY_PHASE1":38104,"PHASE1":38106,"PHASE2":38108,"PHASE3":38114,"PHASE4":38116,"NA":38118},{"trials":38105,"activeCount":99},[],{"trials":38107,"activeCount":99},[],{"trials":38109,"activeCount":99},[38110],{"nctId":38089,"briefTitle":38090,"status":105,"phases":38111,"primaryCompletion":5801,"completion":5801,"start":13890,"enrollment":38092,"conditions":38112,"interventions":38113},[88],[29203],[38080,38095],{"trials":38115,"activeCount":99},[],{"trials":38117,"activeCount":99},[],{"trials":38119,"activeCount":99},[],{"intervention":14891,"totalTrials":224,"cells":38121},{"EARLY_PHASE1":38122,"PHASE1":38124,"PHASE2":38126,"PHASE3":38132,"PHASE4":38134,"NA":38136},{"trials":38123,"activeCount":99},[],{"trials":38125,"activeCount":99},[],{"trials":38127,"activeCount":99},[38128],{"nctId":14884,"briefTitle":14885,"status":150,"phases":38129,"primaryCompletion":14887,"completion":14445,"start":14706,"enrollment":8091,"conditions":38130,"interventions":38131},[88],[14889,27],[14891,14331],{"trials":38133,"activeCount":99},[],{"trials":38135,"activeCount":99},[],{"trials":38137,"activeCount":99},[],{"intervention":1183,"totalTrials":224,"cells":38139},{"EARLY_PHASE1":38140,"PHASE1":38142,"PHASE2":38144,"PHASE3":38150,"PHASE4":38152,"NA":38154},{"trials":38141,"activeCount":99},[],{"trials":38143,"activeCount":99},[],{"trials":38145,"activeCount":99},[38146],{"nctId":1176,"briefTitle":1177,"status":105,"phases":38147,"primaryCompletion":1179,"completion":1179,"start":356,"enrollment":110,"conditions":38148,"interventions":38149},[87,88],[35],[47,923,1182,471,1183,924],{"trials":38151,"activeCount":99},[],{"trials":38153,"activeCount":99},[],{"trials":38155,"activeCount":99},[],{"intervention":34584,"totalTrials":224,"cells":38157},{"EARLY_PHASE1":38158,"PHASE1":38160,"PHASE2":38162,"PHASE3":38168,"PHASE4":38170,"NA":38172},{"trials":38159,"activeCount":99},[],{"trials":38161,"activeCount":99},[],{"trials":38163,"activeCount":99},[38164],{"nctId":34577,"briefTitle":34578,"status":105,"phases":38165,"primaryCompletion":34580,"completion":34580,"start":34581,"enrollment":1272,"conditions":38166,"interventions":38167},[88],[31323,22176],[34557,34574,34584,34585],{"trials":38169,"activeCount":99},[],{"trials":38171,"activeCount":99},[],{"trials":38173,"activeCount":99},[],{"intervention":34585,"totalTrials":224,"cells":38175},{"EARLY_PHASE1":38176,"PHASE1":38178,"PHASE2":38180,"PHASE3":38186,"PHASE4":38188,"NA":38190},{"trials":38177,"activeCount":99},[],{"trials":38179,"activeCount":99},[],{"trials":38181,"activeCount":99},[38182],{"nctId":34577,"briefTitle":34578,"status":105,"phases":38183,"primaryCompletion":34580,"completion":34580,"start":34581,"enrollment":1272,"conditions":38184,"interventions":38185},[88],[31323,22176],[34557,34574,34584,34585],{"trials":38187,"activeCount":99},[],{"trials":38189,"activeCount":99},[],{"trials":38191,"activeCount":99},[],{"intervention":38193,"totalTrials":224,"cells":38194},"MK0822A",{"EARLY_PHASE1":38195,"PHASE1":38197,"PHASE2":38199,"PHASE3":38207,"PHASE4":38209,"NA":38211},{"trials":38196,"activeCount":99},[],{"trials":38198,"activeCount":99},[],{"trials":38200,"activeCount":99},[38201],{"nctId":38202,"briefTitle":38203,"status":105,"phases":38204,"primaryCompletion":14531,"completion":14531,"start":15156,"enrollment":8175,"conditions":38205,"interventions":38206},"NCT00242476","A Study to Assess the Effectiveness of an Investigational Drug in Elderly Subjects With Low Vitamin D Levels (0822A-009)",[88],[26917],[38193],{"trials":38208,"activeCount":99},[],{"trials":38210,"activeCount":99},[],{"trials":38212,"activeCount":99},[],{"intervention":22871,"totalTrials":224,"cells":38214},{"EARLY_PHASE1":38215,"PHASE1":38217,"PHASE2":38219,"PHASE3":38225,"PHASE4":38227,"NA":38229},{"trials":38216,"activeCount":99},[],{"trials":38218,"activeCount":99},[],{"trials":38220,"activeCount":99},[38221],{"nctId":22866,"briefTitle":22867,"status":105,"phases":38222,"primaryCompletion":14352,"completion":14352,"start":14875,"enrollment":4474,"conditions":38223,"interventions":38224},[88],[1109],[22857,22871],{"trials":38226,"activeCount":99},[],{"trials":38228,"activeCount":99},[],{"trials":38230,"activeCount":99},[],{"intervention":4295,"totalTrials":224,"cells":38232},{"EARLY_PHASE1":38233,"PHASE1":38235,"PHASE2":38237,"PHASE3":38243,"PHASE4":38245,"NA":38247},{"trials":38234,"activeCount":99},[],{"trials":38236,"activeCount":99},[],{"trials":38238,"activeCount":99},[38239],{"nctId":4285,"briefTitle":4286,"status":150,"phases":38240,"primaryCompletion":4288,"completion":4288,"start":4289,"enrollment":417,"conditions":38241,"interventions":38242},[88],[4291,4292],[4294,4295,529,1089],{"trials":38244,"activeCount":99},[],{"trials":38246,"activeCount":99},[],{"trials":38248,"activeCount":99},[],{"intervention":24991,"totalTrials":224,"cells":38250},{"EARLY_PHASE1":38251,"PHASE1":38253,"PHASE2":38255,"PHASE3":38261,"PHASE4":38263,"NA":38265},{"trials":38252,"activeCount":99},[],{"trials":38254,"activeCount":99},[],{"trials":38256,"activeCount":99},[38257],{"nctId":24983,"briefTitle":24984,"status":105,"phases":38258,"primaryCompletion":24986,"completion":24986,"start":24987,"enrollment":397,"conditions":38259,"interventions":38260},[88],[24989],[24974,24991,24992],{"trials":38262,"activeCount":99},[],{"trials":38264,"activeCount":99},[],{"trials":38266,"activeCount":99},[],{"intervention":24992,"totalTrials":224,"cells":38268},{"EARLY_PHASE1":38269,"PHASE1":38271,"PHASE2":38273,"PHASE3":38279,"PHASE4":38281,"NA":38283},{"trials":38270,"activeCount":99},[],{"trials":38272,"activeCount":99},[],{"trials":38274,"activeCount":99},[38275],{"nctId":24983,"briefTitle":24984,"status":105,"phases":38276,"primaryCompletion":24986,"completion":24986,"start":24987,"enrollment":397,"conditions":38277,"interventions":38278},[88],[24989],[24974,24991,24992],{"trials":38280,"activeCount":99},[],{"trials":38282,"activeCount":99},[],{"trials":38284,"activeCount":99},[],{"intervention":14898,"totalTrials":224,"cells":38286},{"EARLY_PHASE1":38287,"PHASE1":38289,"PHASE2":38291,"PHASE3":38297,"PHASE4":38299,"NA":38301},{"trials":38288,"activeCount":99},[],{"trials":38290,"activeCount":99},[],{"trials":38292,"activeCount":99},[38293],{"nctId":14893,"briefTitle":14894,"status":105,"phases":38294,"primaryCompletion":5981,"completion":5800,"start":6309,"enrollment":4059,"conditions":38295,"interventions":38296},[88],[4411],[6312,13864,14898],{"trials":38298,"activeCount":99},[],{"trials":38300,"activeCount":99},[],{"trials":38302,"activeCount":99},[],{"intervention":14907,"totalTrials":224,"cells":38304},{"EARLY_PHASE1":38305,"PHASE1":38307,"PHASE2":38309,"PHASE3":38315,"PHASE4":38317,"NA":38319},{"trials":38306,"activeCount":99},[],{"trials":38308,"activeCount":99},[],{"trials":38310,"activeCount":99},[38311],{"nctId":14900,"briefTitle":14901,"status":105,"phases":38312,"primaryCompletion":14228,"completion":14228,"start":14903,"enrollment":14904,"conditions":38313,"interventions":38314},[88],[7020],[14907,13864],{"trials":38316,"activeCount":99},[],{"trials":38318,"activeCount":99},[],{"trials":38320,"activeCount":99},[],{"intervention":38322,"totalTrials":224,"cells":38323},"MK-6913",{"EARLY_PHASE1":38324,"PHASE1":38326,"PHASE2":38328,"PHASE3":38342,"PHASE4":38344,"NA":38346},{"trials":38325,"activeCount":99},[],{"trials":38327,"activeCount":99},[],{"trials":38329,"activeCount":99},[38330],{"nctId":38331,"briefTitle":38332,"status":150,"phases":38333,"primaryCompletion":38334,"completion":38334,"start":38335,"enrollment":4358,"conditions":38336,"interventions":38339},"NCT01015677","A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)",[88],"2010-07-30","2009-12-17",[38337,38338],"Moderate to Severe Vasomotor Symptoms in Postmenopausal","Women",[38322,38340,38341],"17-β estradiol","MK-6913 25 mg",{"trials":38343,"activeCount":99},[],{"trials":38345,"activeCount":99},[],{"trials":38347,"activeCount":99},[],{"intervention":38340,"totalTrials":224,"cells":38349},{"EARLY_PHASE1":38350,"PHASE1":38352,"PHASE2":38354,"PHASE3":38360,"PHASE4":38362,"NA":38364},{"trials":38351,"activeCount":99},[],{"trials":38353,"activeCount":99},[],{"trials":38355,"activeCount":99},[38356],{"nctId":38331,"briefTitle":38332,"status":150,"phases":38357,"primaryCompletion":38334,"completion":38334,"start":38335,"enrollment":4358,"conditions":38358,"interventions":38359},[88],[38337,38338],[38322,38340,38341],{"trials":38361,"activeCount":99},[],{"trials":38363,"activeCount":99},[],{"trials":38365,"activeCount":99},[],{"intervention":38341,"totalTrials":224,"cells":38367},{"EARLY_PHASE1":38368,"PHASE1":38370,"PHASE2":38372,"PHASE3":38378,"PHASE4":38380,"NA":38382},{"trials":38369,"activeCount":99},[],{"trials":38371,"activeCount":99},[],{"trials":38373,"activeCount":99},[38374],{"nctId":38331,"briefTitle":38332,"status":150,"phases":38375,"primaryCompletion":38334,"completion":38334,"start":38335,"enrollment":4358,"conditions":38376,"interventions":38377},[88],[38337,38338],[38322,38340,38341],{"trials":38379,"activeCount":99},[],{"trials":38381,"activeCount":99},[],{"trials":38383,"activeCount":99},[],{"intervention":38385,"totalTrials":224,"cells":38386},"INS316 solution for inhalation",{"EARLY_PHASE1":38387,"PHASE1":38389,"PHASE2":38391,"PHASE3":38401,"PHASE4":38403,"NA":38405},{"trials":38388,"activeCount":99},[],{"trials":38390,"activeCount":99},[],{"trials":38392,"activeCount":99},[38393],{"nctId":38394,"briefTitle":38395,"status":150,"phases":38396,"primaryCompletion":4420,"completion":4420,"start":20197,"enrollment":4059,"conditions":38397,"interventions":38399},"NCT01381666","Evaluation of the Diagnostic Utility of INS316 in Patients With Interstitial Lung Diseases (01-701)",[88],[38398],"Interstitial Lung Disease",[38385,38400],"hypertonic saline 3% sodium chloride solution",{"trials":38402,"activeCount":99},[],{"trials":38404,"activeCount":99},[],{"trials":38406,"activeCount":99},[],{"intervention":38400,"totalTrials":224,"cells":38408},{"EARLY_PHASE1":38409,"PHASE1":38411,"PHASE2":38413,"PHASE3":38419,"PHASE4":38421,"NA":38423},{"trials":38410,"activeCount":99},[],{"trials":38412,"activeCount":99},[],{"trials":38414,"activeCount":99},[38415],{"nctId":38394,"briefTitle":38395,"status":150,"phases":38416,"primaryCompletion":4420,"completion":4420,"start":20197,"enrollment":4059,"conditions":38417,"interventions":38418},[88],[38398],[38385,38400],{"trials":38420,"activeCount":99},[],{"trials":38422,"activeCount":99},[],{"trials":38424,"activeCount":99},[],{"intervention":38426,"totalTrials":224,"cells":38427},"Posaconazole IV",{"EARLY_PHASE1":38428,"PHASE1":38430,"PHASE2":38432,"PHASE3":38442,"PHASE4":38444,"NA":38446},{"trials":38429,"activeCount":99},[],{"trials":38431,"activeCount":99},[],{"trials":38433,"activeCount":99},[38434],{"nctId":38435,"briefTitle":38436,"status":105,"phases":38437,"primaryCompletion":5262,"completion":5262,"start":1907,"enrollment":4741,"conditions":38438,"interventions":38440},"NCT04218851","Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)",[88],[38439],"Invasive Aspergillosis",[38426,38441,17832],"Posaconazole PFS",{"trials":38443,"activeCount":99},[],{"trials":38445,"activeCount":99},[],{"trials":38447,"activeCount":99},[],{"intervention":38441,"totalTrials":224,"cells":38449},{"EARLY_PHASE1":38450,"PHASE1":38452,"PHASE2":38454,"PHASE3":38460,"PHASE4":38462,"NA":38464},{"trials":38451,"activeCount":99},[],{"trials":38453,"activeCount":99},[],{"trials":38455,"activeCount":99},[38456],{"nctId":38435,"briefTitle":38436,"status":105,"phases":38457,"primaryCompletion":5262,"completion":5262,"start":1907,"enrollment":4741,"conditions":38458,"interventions":38459},[88],[38439],[38426,38441,17832],{"trials":38461,"activeCount":99},[],{"trials":38463,"activeCount":99},[],{"trials":38465,"activeCount":99},[],{"intervention":38467,"totalTrials":224,"cells":38468},"Comparator : placebo (unspecified) \u002F Duraton of Treatment: 4 Weeks",{"EARLY_PHASE1":38469,"PHASE1":38471,"PHASE2":38473,"PHASE3":38483,"PHASE4":38485,"NA":38487},{"trials":38470,"activeCount":99},[],{"trials":38472,"activeCount":99},[],{"trials":38474,"activeCount":99},[38475],{"nctId":38476,"briefTitle":38477,"status":105,"phases":38478,"primaryCompletion":14976,"completion":15210,"start":14593,"enrollment":19152,"conditions":38479,"interventions":38480},"NCT00533312","MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)",[88],[7598],[38467,38481,38482],"MK0524A, niacin (+) laropiprant \u002F Duration of Treatment : 4 Weeks","Comparator : niacin \u002F Duraton of Treatment: 4 Weeks",{"trials":38484,"activeCount":99},[],{"trials":38486,"activeCount":99},[],{"trials":38488,"activeCount":99},[],{"intervention":38481,"totalTrials":224,"cells":38490},{"EARLY_PHASE1":38491,"PHASE1":38493,"PHASE2":38495,"PHASE3":38501,"PHASE4":38503,"NA":38505},{"trials":38492,"activeCount":99},[],{"trials":38494,"activeCount":99},[],{"trials":38496,"activeCount":99},[38497],{"nctId":38476,"briefTitle":38477,"status":105,"phases":38498,"primaryCompletion":14976,"completion":15210,"start":14593,"enrollment":19152,"conditions":38499,"interventions":38500},[88],[7598],[38467,38481,38482],{"trials":38502,"activeCount":99},[],{"trials":38504,"activeCount":99},[],{"trials":38506,"activeCount":99},[],{"intervention":38482,"totalTrials":224,"cells":38508},{"EARLY_PHASE1":38509,"PHASE1":38511,"PHASE2":38513,"PHASE3":38519,"PHASE4":38521,"NA":38523},{"trials":38510,"activeCount":99},[],{"trials":38512,"activeCount":99},[],{"trials":38514,"activeCount":99},[38515],{"nctId":38476,"briefTitle":38477,"status":105,"phases":38516,"primaryCompletion":14976,"completion":15210,"start":14593,"enrollment":19152,"conditions":38517,"interventions":38518},[88],[7598],[38467,38481,38482],{"trials":38520,"activeCount":99},[],{"trials":38522,"activeCount":99},[],{"trials":38524,"activeCount":99},[],{"intervention":38526,"totalTrials":224,"cells":38527},"MK0364",{"EARLY_PHASE1":38528,"PHASE1":38530,"PHASE2":38532,"PHASE3":38540,"PHASE4":38542,"NA":38544},{"trials":38529,"activeCount":99},[],{"trials":38531,"activeCount":99},[],{"trials":38533,"activeCount":99},[38534],{"nctId":38535,"briefTitle":38536,"status":105,"phases":38537,"primaryCompletion":14903,"completion":19537,"start":17096,"enrollment":9177,"conditions":38538,"interventions":38539},"NCT00109148","An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006)",[88],[15158],[38526],{"trials":38541,"activeCount":99},[],{"trials":38543,"activeCount":99},[],{"trials":38545,"activeCount":99},[],{"intervention":38547,"totalTrials":224,"cells":38548},"MK0429",{"EARLY_PHASE1":38549,"PHASE1":38551,"PHASE2":38553,"PHASE3":38564,"PHASE4":38566,"NA":38568},{"trials":38550,"activeCount":99},[],{"trials":38552,"activeCount":99},[],{"trials":38554,"activeCount":99},[38555],{"nctId":38556,"briefTitle":38557,"status":105,"phases":38558,"primaryCompletion":38559,"completion":38559,"start":27509,"enrollment":38560,"conditions":38561,"interventions":38563},"NCT00533650","Proof of Concept (Bone Resorption\u002FBone Mineral Density) Study (0429-005)",[88],"2002-10",227,[38562],"Post-Menopausal Osteoporosis",[38547],{"trials":38565,"activeCount":99},[],{"trials":38567,"activeCount":99},[],{"trials":38569,"activeCount":99},[],{"intervention":38571,"totalTrials":224,"cells":38572},"Pleconaril",{"EARLY_PHASE1":38573,"PHASE1":38575,"PHASE2":38577,"PHASE3":38589,"PHASE4":38591,"NA":38593},{"trials":38574,"activeCount":99},[],{"trials":38576,"activeCount":99},[],{"trials":38578,"activeCount":99},[38579],{"nctId":38580,"briefTitle":38581,"status":105,"phases":38582,"primaryCompletion":15505,"completion":15505,"start":12804,"enrollment":38583,"conditions":38584,"interventions":38588},"NCT00394914","Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295)",[88],311,[5985,38585,38586,38587],"Common Cold","Picornavirus Infection","Rhinovirus",[38571],{"trials":38590,"activeCount":99},[],{"trials":38592,"activeCount":99},[],{"trials":38594,"activeCount":99},[],{"intervention":19823,"totalTrials":224,"cells":38596},{"EARLY_PHASE1":38597,"PHASE1":38599,"PHASE2":38601,"PHASE3":38607,"PHASE4":38609,"NA":38611},{"trials":38598,"activeCount":99},[],{"trials":38600,"activeCount":99},[],{"trials":38602,"activeCount":99},[38603],{"nctId":19814,"briefTitle":19815,"status":105,"phases":38604,"primaryCompletion":1986,"completion":19817,"start":19818,"enrollment":19819,"conditions":38605,"interventions":38606},[88],[24],[15839,12959,17381,19822,19823,14925],{"trials":38608,"activeCount":99},[],{"trials":38610,"activeCount":99},[],{"trials":38612,"activeCount":99},[],{"intervention":38614,"totalTrials":224,"cells":38615},"epinastine 0.1%",{"EARLY_PHASE1":38616,"PHASE1":38618,"PHASE2":38620,"PHASE3":38632,"PHASE4":38634,"NA":38636},{"trials":38617,"activeCount":99},[],{"trials":38619,"activeCount":99},[],{"trials":38621,"activeCount":99},[38622],{"nctId":38623,"briefTitle":38624,"status":105,"phases":38625,"primaryCompletion":8619,"completion":8619,"start":4418,"enrollment":2231,"conditions":38626,"interventions":38627},"NCT01382654","Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis",[88],[5965],[38614,38628,38629,38630,38631],"epinastine 0.1% with taste masking agent","epinastine 0.2%","epinastine 0.2% with taste masking agent","azelastine 0.1%",{"trials":38633,"activeCount":99},[],{"trials":38635,"activeCount":99},[],{"trials":38637,"activeCount":99},[],{"intervention":38628,"totalTrials":224,"cells":38639},{"EARLY_PHASE1":38640,"PHASE1":38642,"PHASE2":38644,"PHASE3":38650,"PHASE4":38652,"NA":38654},{"trials":38641,"activeCount":99},[],{"trials":38643,"activeCount":99},[],{"trials":38645,"activeCount":99},[38646],{"nctId":38623,"briefTitle":38624,"status":105,"phases":38647,"primaryCompletion":8619,"completion":8619,"start":4418,"enrollment":2231,"conditions":38648,"interventions":38649},[88],[5965],[38614,38628,38629,38630,38631],{"trials":38651,"activeCount":99},[],{"trials":38653,"activeCount":99},[],{"trials":38655,"activeCount":99},[],{"intervention":38629,"totalTrials":224,"cells":38657},{"EARLY_PHASE1":38658,"PHASE1":38660,"PHASE2":38662,"PHASE3":38668,"PHASE4":38670,"NA":38672},{"trials":38659,"activeCount":99},[],{"trials":38661,"activeCount":99},[],{"trials":38663,"activeCount":99},[38664],{"nctId":38623,"briefTitle":38624,"status":105,"phases":38665,"primaryCompletion":8619,"completion":8619,"start":4418,"enrollment":2231,"conditions":38666,"interventions":38667},[88],[5965],[38614,38628,38629,38630,38631],{"trials":38669,"activeCount":99},[],{"trials":38671,"activeCount":99},[],{"trials":38673,"activeCount":99},[],{"intervention":38630,"totalTrials":224,"cells":38675},{"EARLY_PHASE1":38676,"PHASE1":38678,"PHASE2":38680,"PHASE3":38686,"PHASE4":38688,"NA":38690},{"trials":38677,"activeCount":99},[],{"trials":38679,"activeCount":99},[],{"trials":38681,"activeCount":99},[38682],{"nctId":38623,"briefTitle":38624,"status":105,"phases":38683,"primaryCompletion":8619,"completion":8619,"start":4418,"enrollment":2231,"conditions":38684,"interventions":38685},[88],[5965],[38614,38628,38629,38630,38631],{"trials":38687,"activeCount":99},[],{"trials":38689,"activeCount":99},[],{"trials":38691,"activeCount":99},[],{"intervention":38631,"totalTrials":224,"cells":38693},{"EARLY_PHASE1":38694,"PHASE1":38696,"PHASE2":38698,"PHASE3":38704,"PHASE4":38706,"NA":38708},{"trials":38695,"activeCount":99},[],{"trials":38697,"activeCount":99},[],{"trials":38699,"activeCount":99},[38700],{"nctId":38623,"briefTitle":38624,"status":105,"phases":38701,"primaryCompletion":8619,"completion":8619,"start":4418,"enrollment":2231,"conditions":38702,"interventions":38703},[88],[5965],[38614,38628,38629,38630,38631],{"trials":38705,"activeCount":99},[],{"trials":38707,"activeCount":99},[],{"trials":38709,"activeCount":99},[],{"intervention":38711,"totalTrials":224,"cells":38712},"MK0991, caspofungin acetate",{"EARLY_PHASE1":38713,"PHASE1":38715,"PHASE2":38717,"PHASE3":38727,"PHASE4":38729,"NA":38731},{"trials":38714,"activeCount":99},[],{"trials":38716,"activeCount":99},[],{"trials":38718,"activeCount":99},[38719],{"nctId":38720,"briefTitle":38721,"status":105,"phases":38722,"primaryCompletion":14679,"completion":15063,"start":20197,"enrollment":1349,"conditions":38723,"interventions":38724},"NCT00076869","MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)",[88],[20498],[38711,38725,38726],"Comparator: amphotericin B","Comparator: lipid formulation of amphotericin B and\u002For azole",{"trials":38728,"activeCount":99},[],{"trials":38730,"activeCount":99},[],{"trials":38732,"activeCount":99},[],{"intervention":38725,"totalTrials":224,"cells":38734},{"EARLY_PHASE1":38735,"PHASE1":38737,"PHASE2":38739,"PHASE3":38745,"PHASE4":38747,"NA":38749},{"trials":38736,"activeCount":99},[],{"trials":38738,"activeCount":99},[],{"trials":38740,"activeCount":99},[38741],{"nctId":38720,"briefTitle":38721,"status":105,"phases":38742,"primaryCompletion":14679,"completion":15063,"start":20197,"enrollment":1349,"conditions":38743,"interventions":38744},[88],[20498],[38711,38725,38726],{"trials":38746,"activeCount":99},[],{"trials":38748,"activeCount":99},[],{"trials":38750,"activeCount":99},[],{"intervention":38726,"totalTrials":224,"cells":38752},{"EARLY_PHASE1":38753,"PHASE1":38755,"PHASE2":38757,"PHASE3":38763,"PHASE4":38765,"NA":38767},{"trials":38754,"activeCount":99},[],{"trials":38756,"activeCount":99},[],{"trials":38758,"activeCount":99},[38759],{"nctId":38720,"briefTitle":38721,"status":105,"phases":38760,"primaryCompletion":14679,"completion":15063,"start":20197,"enrollment":1349,"conditions":38761,"interventions":38762},[88],[20498],[38711,38725,38726],{"trials":38764,"activeCount":99},[],{"trials":38766,"activeCount":99},[],{"trials":38768,"activeCount":99},[],{"intervention":38770,"totalTrials":224,"cells":38771},"SCH 619734",{"EARLY_PHASE1":38772,"PHASE1":38774,"PHASE2":38776,"PHASE3":38784,"PHASE4":38786,"NA":38788},{"trials":38773,"activeCount":99},[],{"trials":38775,"activeCount":99},[],{"trials":38777,"activeCount":99},[38778],{"nctId":38779,"briefTitle":38780,"status":105,"phases":38781,"primaryCompletion":14540,"completion":14540,"start":15210,"enrollment":3903,"conditions":38782,"interventions":38783},"NCT00506545","Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Cough From an Unknown Cause (Study P04888)",[88],[35549],[38770],{"trials":38785,"activeCount":99},[],{"trials":38787,"activeCount":99},[],{"trials":38789,"activeCount":99},[],{"intervention":23238,"totalTrials":224,"cells":38791},{"EARLY_PHASE1":38792,"PHASE1":38794,"PHASE2":38796,"PHASE3":38802,"PHASE4":38804,"NA":38806},{"trials":38793,"activeCount":99},[],{"trials":38795,"activeCount":99},[],{"trials":38797,"activeCount":99},[38798],{"nctId":23230,"briefTitle":23231,"status":105,"phases":38799,"primaryCompletion":23233,"completion":23234,"start":23235,"enrollment":5196,"conditions":38800,"interventions":38801},[88],[24],[23238,19833],{"trials":38803,"activeCount":99},[],{"trials":38805,"activeCount":99},[],{"trials":38807,"activeCount":99},[],{"intervention":19059,"totalTrials":224,"cells":38809},{"EARLY_PHASE1":38810,"PHASE1":38812,"PHASE2":38814,"PHASE3":38820,"PHASE4":38822,"NA":38824},{"trials":38811,"activeCount":99},[],{"trials":38813,"activeCount":99},[],{"trials":38815,"activeCount":99},[38816],{"nctId":19054,"briefTitle":19055,"status":105,"phases":38817,"primaryCompletion":14566,"completion":16792,"start":13102,"enrollment":132,"conditions":38818,"interventions":38819},[88],[861],[6312,19059,19060],{"trials":38821,"activeCount":99},[],{"trials":38823,"activeCount":99},[],{"trials":38825,"activeCount":99},[],{"intervention":19060,"totalTrials":224,"cells":38827},{"EARLY_PHASE1":38828,"PHASE1":38830,"PHASE2":38832,"PHASE3":38838,"PHASE4":38840,"NA":38842},{"trials":38829,"activeCount":99},[],{"trials":38831,"activeCount":99},[],{"trials":38833,"activeCount":99},[38834],{"nctId":19054,"briefTitle":19055,"status":105,"phases":38835,"primaryCompletion":14566,"completion":16792,"start":13102,"enrollment":132,"conditions":38836,"interventions":38837},[88],[861],[6312,19059,19060],{"trials":38839,"activeCount":99},[],{"trials":38841,"activeCount":99},[],{"trials":38843,"activeCount":99},[],{"intervention":38845,"totalTrials":224,"cells":38846},"MK0524A, \u002FDuration of Treatment : 8 Weeks",{"EARLY_PHASE1":38847,"PHASE1":38849,"PHASE2":38851,"PHASE3":38860,"PHASE4":38862,"NA":38864},{"trials":38848,"activeCount":99},[],{"trials":38850,"activeCount":99},[],{"trials":38852,"activeCount":99},[38853],{"nctId":38854,"briefTitle":38855,"status":105,"phases":38856,"primaryCompletion":15038,"completion":15038,"start":18806,"enrollment":7127,"conditions":38857,"interventions":38858},"NCT00533676","Endpoint Validation Study (0524A-015)",[88],[29159],[38845,38859],"Comparator : placebo (unspecified) \u002FDuration of Treatment : 8 Weeks",{"trials":38861,"activeCount":99},[],{"trials":38863,"activeCount":99},[],{"trials":38865,"activeCount":99},[],{"intervention":38859,"totalTrials":224,"cells":38867},{"EARLY_PHASE1":38868,"PHASE1":38870,"PHASE2":38872,"PHASE3":38878,"PHASE4":38880,"NA":38882},{"trials":38869,"activeCount":99},[],{"trials":38871,"activeCount":99},[],{"trials":38873,"activeCount":99},[38874],{"nctId":38854,"briefTitle":38855,"status":105,"phases":38875,"primaryCompletion":15038,"completion":15038,"start":18806,"enrollment":7127,"conditions":38876,"interventions":38877},[88],[29159],[38845,38859],{"trials":38879,"activeCount":99},[],{"trials":38881,"activeCount":99},[],{"trials":38883,"activeCount":99},[],{"intervention":38885,"totalTrials":224,"cells":38886},"Org 25935",{"EARLY_PHASE1":38887,"PHASE1":38889,"PHASE2":38891,"PHASE3":38902,"PHASE4":38904,"NA":38906},{"trials":38888,"activeCount":99},[],{"trials":38890,"activeCount":99},[],{"trials":38892,"activeCount":99},[38893],{"nctId":38894,"briefTitle":38895,"status":150,"phases":38896,"primaryCompletion":38897,"completion":38897,"start":38898,"enrollment":212,"conditions":38899,"interventions":38901},"NCT00725725","Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705)",[88],"2010-04-23","2008-07-23",[38900],"Panic Disorder",[38885,38885],{"trials":38903,"activeCount":99},[],{"trials":38905,"activeCount":99},[],{"trials":38907,"activeCount":99},[],{"intervention":38909,"totalTrials":224,"cells":38910},"Doravirine, Tenofovir, Lamivudine - Blinded",{"EARLY_PHASE1":38911,"PHASE1":38913,"PHASE2":38915,"PHASE3":38928,"PHASE4":38930,"NA":38932},{"trials":38912,"activeCount":99},[],{"trials":38914,"activeCount":99},[],{"trials":38916,"activeCount":99},[38917],{"nctId":38918,"briefTitle":38919,"status":105,"phases":38920,"primaryCompletion":26161,"completion":1700,"start":38921,"enrollment":38922,"conditions":38923,"interventions":38925},"NCT02652260","Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)",[88],"2016-03-04",86,[11444,38924],"Central Nervous System",[38909,38926,38927],"Doravirine, Tenofovir, Lamivudine - Open-Label","ATRIPLA^TM",{"trials":38929,"activeCount":99},[],{"trials":38931,"activeCount":99},[],{"trials":38933,"activeCount":99},[],{"intervention":38926,"totalTrials":224,"cells":38935},{"EARLY_PHASE1":38936,"PHASE1":38938,"PHASE2":38940,"PHASE3":38946,"PHASE4":38948,"NA":38950},{"trials":38937,"activeCount":99},[],{"trials":38939,"activeCount":99},[],{"trials":38941,"activeCount":99},[38942],{"nctId":38918,"briefTitle":38919,"status":105,"phases":38943,"primaryCompletion":26161,"completion":1700,"start":38921,"enrollment":38922,"conditions":38944,"interventions":38945},[88],[11444,38924],[38909,38926,38927],{"trials":38947,"activeCount":99},[],{"trials":38949,"activeCount":99},[],{"trials":38951,"activeCount":99},[],{"intervention":38927,"totalTrials":224,"cells":38953},{"EARLY_PHASE1":38954,"PHASE1":38956,"PHASE2":38958,"PHASE3":38964,"PHASE4":38966,"NA":38968},{"trials":38955,"activeCount":99},[],{"trials":38957,"activeCount":99},[],{"trials":38959,"activeCount":99},[38960],{"nctId":38918,"briefTitle":38919,"status":105,"phases":38961,"primaryCompletion":26161,"completion":1700,"start":38921,"enrollment":38922,"conditions":38962,"interventions":38963},[88],[11444,38924],[38909,38926,38927],{"trials":38965,"activeCount":99},[],{"trials":38967,"activeCount":99},[],{"trials":38969,"activeCount":99},[],{"intervention":35075,"totalTrials":224,"cells":38971},{"EARLY_PHASE1":38972,"PHASE1":38974,"PHASE2":38976,"PHASE3":38982,"PHASE4":38984,"NA":38986},{"trials":38973,"activeCount":99},[],{"trials":38975,"activeCount":99},[],{"trials":38977,"activeCount":99},[38978],{"nctId":35067,"briefTitle":35068,"status":150,"phases":38979,"primaryCompletion":35070,"completion":35071,"start":35072,"enrollment":13805,"conditions":38980,"interventions":38981},[88],[35064],[35049,35075],{"trials":38983,"activeCount":99},[],{"trials":38985,"activeCount":99},[],{"trials":38987,"activeCount":99},[],{"intervention":1254,"totalTrials":224,"cells":38989},{"EARLY_PHASE1":38990,"PHASE1":38992,"PHASE2":38994,"PHASE3":39000,"PHASE4":39002,"NA":39004},{"trials":38991,"activeCount":99},[],{"trials":38993,"activeCount":99},[],{"trials":38995,"activeCount":99},[38996],{"nctId":1243,"briefTitle":1244,"status":105,"phases":38997,"primaryCompletion":1246,"completion":1247,"start":1248,"enrollment":1249,"conditions":38998,"interventions":38999},[87,88],[1251],[47,387,386,841,385,1100,1253,1254],{"trials":39001,"activeCount":99},[],{"trials":39003,"activeCount":99},[],{"trials":39005,"activeCount":99},[],{"intervention":39007,"totalTrials":224,"cells":39008},"MK8245 5 mg (twice a day) b.i.d.",{"EARLY_PHASE1":39009,"PHASE1":39011,"PHASE2":39013,"PHASE3":39022,"PHASE4":39024,"NA":39026},{"trials":39010,"activeCount":99},[],{"trials":39012,"activeCount":99},[],{"trials":39014,"activeCount":99},[39015],{"nctId":39016,"briefTitle":39017,"status":150,"phases":39018,"primaryCompletion":20608,"completion":20608,"start":14353,"enrollment":4071,"conditions":39019,"interventions":39020},"NCT00846391","A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)",[88],[15],[39007,39021],"MK8245 50 mg b.i.d.",{"trials":39023,"activeCount":99},[],{"trials":39025,"activeCount":99},[],{"trials":39027,"activeCount":99},[],{"intervention":39021,"totalTrials":224,"cells":39029},{"EARLY_PHASE1":39030,"PHASE1":39032,"PHASE2":39034,"PHASE3":39040,"PHASE4":39042,"NA":39044},{"trials":39031,"activeCount":99},[],{"trials":39033,"activeCount":99},[],{"trials":39035,"activeCount":99},[39036],{"nctId":39016,"briefTitle":39017,"status":150,"phases":39037,"primaryCompletion":20608,"completion":20608,"start":14353,"enrollment":4071,"conditions":39038,"interventions":39039},[88],[15],[39007,39021],{"trials":39041,"activeCount":99},[],{"trials":39043,"activeCount":99},[],{"trials":39045,"activeCount":99},[],{"intervention":39047,"totalTrials":224,"cells":39048},"MK0826, ertapenem sodium \u002FDuration of Treatment: 14 Days",{"EARLY_PHASE1":39049,"PHASE1":39051,"PHASE2":39053,"PHASE3":39062,"PHASE4":39064,"NA":39066},{"trials":39050,"activeCount":99},[],{"trials":39052,"activeCount":99},[],{"trials":39054,"activeCount":99},[39055],{"nctId":39056,"briefTitle":39057,"status":105,"phases":39058,"primaryCompletion":14875,"completion":14875,"start":14876,"enrollment":1150,"conditions":39059,"interventions":39060},"NCT00451386","Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)",[88],[31323,25618,35845],[39047,39061],"Comparator: ceftriaxone sodium \u002FDuration of Treatment: 14 Days",{"trials":39063,"activeCount":99},[],{"trials":39065,"activeCount":99},[],{"trials":39067,"activeCount":99},[],{"intervention":39061,"totalTrials":224,"cells":39069},{"EARLY_PHASE1":39070,"PHASE1":39072,"PHASE2":39074,"PHASE3":39080,"PHASE4":39082,"NA":39084},{"trials":39071,"activeCount":99},[],{"trials":39073,"activeCount":99},[],{"trials":39075,"activeCount":99},[39076],{"nctId":39056,"briefTitle":39057,"status":105,"phases":39077,"primaryCompletion":14875,"completion":14875,"start":14876,"enrollment":1150,"conditions":39078,"interventions":39079},[88],[31323,25618,35845],[39047,39061],{"trials":39081,"activeCount":99},[],{"trials":39083,"activeCount":99},[],{"trials":39085,"activeCount":99},[],{"intervention":33476,"totalTrials":224,"cells":39087},{"EARLY_PHASE1":39088,"PHASE1":39090,"PHASE2":39092,"PHASE3":39098,"PHASE4":39100,"NA":39102},{"trials":39089,"activeCount":99},[],{"trials":39091,"activeCount":99},[],{"trials":39093,"activeCount":99},[39094],{"nctId":33468,"briefTitle":33469,"status":105,"phases":39095,"primaryCompletion":33471,"completion":33471,"start":33472,"enrollment":33473,"conditions":39096,"interventions":39097},[88],[9336],[33441,33476],{"trials":39099,"activeCount":99},[],{"trials":39101,"activeCount":99},[],{"trials":39103,"activeCount":99},[],{"intervention":14933,"totalTrials":224,"cells":39105},{"EARLY_PHASE1":39106,"PHASE1":39108,"PHASE2":39110,"PHASE3":39116,"PHASE4":39118,"NA":39120},{"trials":39107,"activeCount":99},[],{"trials":39109,"activeCount":99},[],{"trials":39111,"activeCount":99},[39112],{"nctId":14927,"briefTitle":14928,"status":105,"phases":39113,"primaryCompletion":14930,"completion":14930,"start":14595,"enrollment":132,"conditions":39114,"interventions":39115},[88],[5985],[14933,14934,14935,13864],{"trials":39117,"activeCount":99},[],{"trials":39119,"activeCount":99},[],{"trials":39121,"activeCount":99},[],{"intervention":14934,"totalTrials":224,"cells":39123},{"EARLY_PHASE1":39124,"PHASE1":39126,"PHASE2":39128,"PHASE3":39134,"PHASE4":39136,"NA":39138},{"trials":39125,"activeCount":99},[],{"trials":39127,"activeCount":99},[],{"trials":39129,"activeCount":99},[39130],{"nctId":14927,"briefTitle":14928,"status":105,"phases":39131,"primaryCompletion":14930,"completion":14930,"start":14595,"enrollment":132,"conditions":39132,"interventions":39133},[88],[5985],[14933,14934,14935,13864],{"trials":39135,"activeCount":99},[],{"trials":39137,"activeCount":99},[],{"trials":39139,"activeCount":99},[],{"intervention":14935,"totalTrials":224,"cells":39141},{"EARLY_PHASE1":39142,"PHASE1":39144,"PHASE2":39146,"PHASE3":39152,"PHASE4":39154,"NA":39156},{"trials":39143,"activeCount":99},[],{"trials":39145,"activeCount":99},[],{"trials":39147,"activeCount":99},[39148],{"nctId":14927,"briefTitle":14928,"status":105,"phases":39149,"primaryCompletion":14930,"completion":14930,"start":14595,"enrollment":132,"conditions":39150,"interventions":39151},[88],[5985],[14933,14934,14935,13864],{"trials":39153,"activeCount":99},[],{"trials":39155,"activeCount":99},[],{"trials":39157,"activeCount":99},[],{"intervention":39159,"totalTrials":224,"cells":39160},"diquafosol tetrasodium ophthalmic solution 2%",{"EARLY_PHASE1":39161,"PHASE1":39163,"PHASE2":39165,"PHASE3":39174,"PHASE4":39176,"NA":39178},{"trials":39162,"activeCount":99},[],{"trials":39164,"activeCount":99},[],{"trials":39166,"activeCount":99},[39167],{"nctId":39168,"briefTitle":39169,"status":150,"phases":39170,"primaryCompletion":14594,"completion":14594,"start":14593,"enrollment":4071,"conditions":39171,"interventions":39173},"NCT01381731","A Double-masked, Randomized, Placebo-controlled,Pilot Study of Diquafosol Tetrasodium in Subjects Following Photorefractive Keratectomy (PRK)",[88],[39172],"Photorefractive Keratectomy",[39159],{"trials":39175,"activeCount":99},[],{"trials":39177,"activeCount":99},[],{"trials":39179,"activeCount":99},[],{"intervention":34030,"totalTrials":224,"cells":39181},{"EARLY_PHASE1":39182,"PHASE1":39184,"PHASE2":39186,"PHASE3":39192,"PHASE4":39194,"NA":39196},{"trials":39183,"activeCount":99},[],{"trials":39185,"activeCount":99},[],{"trials":39187,"activeCount":99},[39188],{"nctId":34023,"briefTitle":34024,"status":105,"phases":39189,"primaryCompletion":34026,"completion":34026,"start":34027,"enrollment":1169,"conditions":39190,"interventions":39191},[88],[5985],[33997,34030],{"trials":39193,"activeCount":99},[],{"trials":39195,"activeCount":99},[],{"trials":39197,"activeCount":99},[],{"intervention":5825,"totalTrials":224,"cells":39199},{"EARLY_PHASE1":39200,"PHASE1":39202,"PHASE2":39204,"PHASE3":39210,"PHASE4":39212,"NA":39214},{"trials":39201,"activeCount":99},[],{"trials":39203,"activeCount":99},[],{"trials":39205,"activeCount":99},[39206],{"nctId":5818,"briefTitle":5819,"status":105,"phases":39207,"primaryCompletion":5821,"completion":5821,"start":5822,"enrollment":2647,"conditions":39208,"interventions":39209},[88],[419],[2905,437,693,795,5825,5826,1751],{"trials":39211,"activeCount":99},[],{"trials":39213,"activeCount":99},[],{"trials":39215,"activeCount":99},[],{"intervention":5826,"totalTrials":224,"cells":39217},{"EARLY_PHASE1":39218,"PHASE1":39220,"PHASE2":39222,"PHASE3":39228,"PHASE4":39230,"NA":39232},{"trials":39219,"activeCount":99},[],{"trials":39221,"activeCount":99},[],{"trials":39223,"activeCount":99},[39224],{"nctId":5818,"briefTitle":5819,"status":105,"phases":39225,"primaryCompletion":5821,"completion":5821,"start":5822,"enrollment":2647,"conditions":39226,"interventions":39227},[88],[419],[2905,437,693,795,5825,5826,1751],{"trials":39229,"activeCount":99},[],{"trials":39231,"activeCount":99},[],{"trials":39233,"activeCount":99},[],{"intervention":14945,"totalTrials":224,"cells":39235},{"EARLY_PHASE1":39236,"PHASE1":39238,"PHASE2":39240,"PHASE3":39246,"PHASE4":39248,"NA":39250},{"trials":39237,"activeCount":99},[],{"trials":39239,"activeCount":99},[],{"trials":39241,"activeCount":99},[39242],{"nctId":14937,"briefTitle":14938,"status":105,"phases":39243,"primaryCompletion":14393,"completion":9313,"start":14940,"enrollment":14941,"conditions":39244,"interventions":39245},[88],[24],[14944,14945,14946,14331],{"trials":39247,"activeCount":99},[],{"trials":39249,"activeCount":99},[],{"trials":39251,"activeCount":99},[],{"intervention":39253,"totalTrials":224,"cells":39254},"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20\u002F40\u002F40\u002F20",{"EARLY_PHASE1":39255,"PHASE1":39257,"PHASE2":39259,"PHASE3":39271,"PHASE4":39273,"NA":39275},{"trials":39256,"activeCount":99},[],{"trials":39258,"activeCount":99},[],{"trials":39260,"activeCount":99},[39261],{"nctId":39262,"briefTitle":39263,"status":105,"phases":39264,"primaryCompletion":14495,"completion":14445,"start":22049,"enrollment":39265,"conditions":39266,"interventions":39268},"NCT00365716","Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)",[88],1158,[7076,39267],"Genital Diseases, Female",[39253,39269,39270],"Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40\u002F40\u002F40\u002F40","Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80\u002F80\u002F40\u002F80",{"trials":39272,"activeCount":99},[],{"trials":39274,"activeCount":99},[],{"trials":39276,"activeCount":99},[],{"intervention":39269,"totalTrials":224,"cells":39278},{"EARLY_PHASE1":39279,"PHASE1":39281,"PHASE2":39283,"PHASE3":39289,"PHASE4":39291,"NA":39293},{"trials":39280,"activeCount":99},[],{"trials":39282,"activeCount":99},[],{"trials":39284,"activeCount":99},[39285],{"nctId":39262,"briefTitle":39263,"status":105,"phases":39286,"primaryCompletion":14495,"completion":14445,"start":22049,"enrollment":39265,"conditions":39287,"interventions":39288},[88],[7076,39267],[39253,39269,39270],{"trials":39290,"activeCount":99},[],{"trials":39292,"activeCount":99},[],{"trials":39294,"activeCount":99},[],{"intervention":39270,"totalTrials":224,"cells":39296},{"EARLY_PHASE1":39297,"PHASE1":39299,"PHASE2":39301,"PHASE3":39307,"PHASE4":39309,"NA":39311},{"trials":39298,"activeCount":99},[],{"trials":39300,"activeCount":99},[],{"trials":39302,"activeCount":99},[39303],{"nctId":39262,"briefTitle":39263,"status":105,"phases":39304,"primaryCompletion":14495,"completion":14445,"start":22049,"enrollment":39265,"conditions":39305,"interventions":39306},[88],[7076,39267],[39253,39269,39270],{"trials":39308,"activeCount":99},[],{"trials":39310,"activeCount":99},[],{"trials":39312,"activeCount":99},[],{"intervention":14954,"totalTrials":224,"cells":39314},{"EARLY_PHASE1":39315,"PHASE1":39317,"PHASE2":39319,"PHASE3":39325,"PHASE4":39327,"NA":39329},{"trials":39316,"activeCount":99},[],{"trials":39318,"activeCount":99},[],{"trials":39320,"activeCount":99},[39321],{"nctId":14948,"briefTitle":14949,"status":105,"phases":39322,"primaryCompletion":5280,"completion":5280,"start":6309,"enrollment":14951,"conditions":39323,"interventions":39324},[88],[14715],[14954,13864],{"trials":39326,"activeCount":99},[],{"trials":39328,"activeCount":99},[],{"trials":39330,"activeCount":99},[],{"intervention":1301,"totalTrials":224,"cells":39332},{"EARLY_PHASE1":39333,"PHASE1":39335,"PHASE2":39337,"PHASE3":39343,"PHASE4":39345,"NA":39347},{"trials":39334,"activeCount":99},[],{"trials":39336,"activeCount":99},[],{"trials":39338,"activeCount":99},[39339],{"nctId":1292,"briefTitle":1293,"status":150,"phases":39340,"primaryCompletion":1295,"completion":1295,"start":1296,"enrollment":1297,"conditions":39341,"interventions":39342},[88],[1299],[1301,1302,47],{"trials":39344,"activeCount":99},[],{"trials":39346,"activeCount":99},[],{"trials":39348,"activeCount":99},[],{"intervention":1302,"totalTrials":224,"cells":39350},{"EARLY_PHASE1":39351,"PHASE1":39353,"PHASE2":39355,"PHASE3":39361,"PHASE4":39363,"NA":39365},{"trials":39352,"activeCount":99},[],{"trials":39354,"activeCount":99},[],{"trials":39356,"activeCount":99},[39357],{"nctId":1292,"briefTitle":1293,"status":150,"phases":39358,"primaryCompletion":1295,"completion":1295,"start":1296,"enrollment":1297,"conditions":39359,"interventions":39360},[88],[1299],[1301,1302,47],{"trials":39362,"activeCount":99},[],{"trials":39364,"activeCount":99},[],{"trials":39366,"activeCount":99},[],{"intervention":39368,"totalTrials":224,"cells":39369},"Org 34517",{"EARLY_PHASE1":39370,"PHASE1":39372,"PHASE2":39374,"PHASE3":39384,"PHASE4":39386,"NA":39388},{"trials":39371,"activeCount":99},[],{"trials":39373,"activeCount":99},[],{"trials":39375,"activeCount":99},[39376],{"nctId":39377,"briefTitle":39378,"status":105,"phases":39379,"primaryCompletion":14531,"completion":14531,"start":17096,"enrollment":15571,"conditions":39380,"interventions":39383},"NCT00212797","A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)",[88],[35317,39381,39382],"Depressive Disorders","Psychotic Disorders",[39368,39368],{"trials":39385,"activeCount":99},[],{"trials":39387,"activeCount":99},[],{"trials":39389,"activeCount":99},[],{"intervention":39391,"totalTrials":224,"cells":39392},"Vaniprevir 600 mg b.i.d.",{"EARLY_PHASE1":39393,"PHASE1":39395,"PHASE2":39397,"PHASE3":39406,"PHASE4":39408,"NA":39410},{"trials":39394,"activeCount":99},[],{"trials":39396,"activeCount":99},[],{"trials":39398,"activeCount":99},[39399],{"nctId":39400,"briefTitle":39401,"status":105,"phases":39402,"primaryCompletion":14103,"completion":14103,"start":20144,"enrollment":700,"conditions":39403,"interventions":39404},"NCT00943761","A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)",[88],[21],[39391,39405,20437,14925],"Vaniprevir 300 mg b.i.d.",{"trials":39407,"activeCount":99},[],{"trials":39409,"activeCount":99},[],{"trials":39411,"activeCount":99},[],{"intervention":39405,"totalTrials":224,"cells":39413},{"EARLY_PHASE1":39414,"PHASE1":39416,"PHASE2":39418,"PHASE3":39424,"PHASE4":39426,"NA":39428},{"trials":39415,"activeCount":99},[],{"trials":39417,"activeCount":99},[],{"trials":39419,"activeCount":99},[39420],{"nctId":39400,"briefTitle":39401,"status":105,"phases":39421,"primaryCompletion":14103,"completion":14103,"start":20144,"enrollment":700,"conditions":39422,"interventions":39423},[88],[21],[39391,39405,20437,14925],{"trials":39425,"activeCount":99},[],{"trials":39427,"activeCount":99},[],{"trials":39429,"activeCount":99},[],{"intervention":1313,"totalTrials":224,"cells":39431},{"EARLY_PHASE1":39432,"PHASE1":39434,"PHASE2":39436,"PHASE3":39442,"PHASE4":39444,"NA":39446},{"trials":39433,"activeCount":99},[],{"trials":39435,"activeCount":99},[],{"trials":39437,"activeCount":99},[39438],{"nctId":1304,"briefTitle":1305,"status":105,"phases":39439,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1309,"conditions":39440,"interventions":39441},[88],[1134],[47,1312,1313],{"trials":39443,"activeCount":99},[],{"trials":39445,"activeCount":99},[],{"trials":39447,"activeCount":99},[],{"intervention":39449,"totalTrials":224,"cells":39450},"Docetaxel plus lonafarnib",{"EARLY_PHASE1":39451,"PHASE1":39453,"PHASE2":39455,"PHASE3":39463,"PHASE4":39465,"NA":39467},{"trials":39452,"activeCount":99},[],{"trials":39454,"activeCount":99},[],{"trials":39456,"activeCount":99},[39457],{"nctId":39458,"briefTitle":39459,"status":150,"phases":39460,"primaryCompletion":13101,"completion":13101,"start":14324,"enrollment":174,"conditions":39461,"interventions":39462},"NCT00539968","A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)",[87,88],[4411,1109,990,2649,991],[39449],{"trials":39464,"activeCount":99},[],{"trials":39466,"activeCount":99},[],{"trials":39468,"activeCount":99},[],{"intervention":39470,"totalTrials":224,"cells":39471},"SCH 900271 15mg",{"EARLY_PHASE1":39472,"PHASE1":39474,"PHASE2":39476,"PHASE3":39486,"PHASE4":39488,"NA":39490},{"trials":39473,"activeCount":99},[],{"trials":39475,"activeCount":99},[],{"trials":39477,"activeCount":99},[39478],{"nctId":39479,"briefTitle":39480,"status":105,"phases":39481,"primaryCompletion":5131,"completion":5131,"start":39482,"enrollment":16250,"conditions":39483,"interventions":39484},"NCT00941603","Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)",[88],"2009-06-29",[14418,13133],[39470,39485,39485,39485,39485],"SCH 900271",{"trials":39487,"activeCount":99},[],{"trials":39489,"activeCount":99},[],{"trials":39491,"activeCount":99},[],{"intervention":39485,"totalTrials":224,"cells":39493},{"EARLY_PHASE1":39494,"PHASE1":39496,"PHASE2":39498,"PHASE3":39504,"PHASE4":39506,"NA":39508},{"trials":39495,"activeCount":99},[],{"trials":39497,"activeCount":99},[],{"trials":39499,"activeCount":99},[39500],{"nctId":39479,"briefTitle":39480,"status":105,"phases":39501,"primaryCompletion":5131,"completion":5131,"start":39482,"enrollment":16250,"conditions":39502,"interventions":39503},[88],[14418,13133],[39470,39485,39485,39485,39485],{"trials":39505,"activeCount":99},[],{"trials":39507,"activeCount":99},[],{"trials":39509,"activeCount":99},[],{"intervention":39511,"totalTrials":224,"cells":39512},"SCH 900636",{"EARLY_PHASE1":39513,"PHASE1":39515,"PHASE2":39517,"PHASE3":39525,"PHASE4":39527,"NA":39529},{"trials":39514,"activeCount":99},[],{"trials":39516,"activeCount":99},[],{"trials":39518,"activeCount":99},[39519],{"nctId":39520,"briefTitle":39521,"status":105,"phases":39522,"primaryCompletion":14705,"completion":14705,"start":15156,"enrollment":3655,"conditions":39523,"interventions":39524},"NCT00844922","Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133\u002FP05842)",[88],[39381,39382,35317],[39511],{"trials":39526,"activeCount":99},[],{"trials":39528,"activeCount":99},[],{"trials":39530,"activeCount":99},[],{"intervention":21018,"totalTrials":224,"cells":39532},{"EARLY_PHASE1":39533,"PHASE1":39535,"PHASE2":39537,"PHASE3":39543,"PHASE4":39545,"NA":39547},{"trials":39534,"activeCount":99},[],{"trials":39536,"activeCount":99},[],{"trials":39538,"activeCount":99},[39539],{"nctId":21010,"briefTitle":21011,"status":1040,"phases":39540,"primaryCompletion":19020,"completion":19020,"start":16592,"enrollment":99,"conditions":39541,"interventions":39542},[88],[21014],[21016,21017,21018,14946,21019],{"trials":39544,"activeCount":99},[],{"trials":39546,"activeCount":99},[],{"trials":39548,"activeCount":99},[],{"intervention":21019,"totalTrials":224,"cells":39550},{"EARLY_PHASE1":39551,"PHASE1":39553,"PHASE2":39555,"PHASE3":39561,"PHASE4":39563,"NA":39565},{"trials":39552,"activeCount":99},[],{"trials":39554,"activeCount":99},[],{"trials":39556,"activeCount":99},[39557],{"nctId":21010,"briefTitle":21011,"status":1040,"phases":39558,"primaryCompletion":19020,"completion":19020,"start":16592,"enrollment":99,"conditions":39559,"interventions":39560},[88],[21014],[21016,21017,21018,14946,21019],{"trials":39562,"activeCount":99},[],{"trials":39564,"activeCount":99},[],{"trials":39566,"activeCount":99},[],{"intervention":2906,"totalTrials":224,"cells":39568},{"EARLY_PHASE1":39569,"PHASE1":39571,"PHASE2":39573,"PHASE3":39579,"PHASE4":39581,"NA":39583},{"trials":39570,"activeCount":99},[],{"trials":39572,"activeCount":99},[],{"trials":39574,"activeCount":99},[39575],{"nctId":2896,"briefTitle":2897,"status":150,"phases":39576,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":2901,"conditions":39577,"interventions":39578},[87,88],[290],[386,1664,1843,2904,714,2905,693,387,390,1444,1253,437,2906],{"trials":39580,"activeCount":99},[],{"trials":39582,"activeCount":99},[],{"trials":39584,"activeCount":99},[],{"intervention":34810,"totalTrials":224,"cells":39586},{"EARLY_PHASE1":39587,"PHASE1":39589,"PHASE2":39591,"PHASE3":39597,"PHASE4":39599,"NA":39601},{"trials":39588,"activeCount":99},[],{"trials":39590,"activeCount":99},[],{"trials":39592,"activeCount":99},[39593],{"nctId":34801,"briefTitle":34802,"status":105,"phases":39594,"primaryCompletion":34804,"completion":34805,"start":34806,"enrollment":34807,"conditions":39595,"interventions":39596},[88],[5985],[34810,34811,34021,34812],{"trials":39598,"activeCount":99},[],{"trials":39600,"activeCount":99},[],{"trials":39602,"activeCount":99},[],{"intervention":34811,"totalTrials":224,"cells":39604},{"EARLY_PHASE1":39605,"PHASE1":39607,"PHASE2":39609,"PHASE3":39615,"PHASE4":39617,"NA":39619},{"trials":39606,"activeCount":99},[],{"trials":39608,"activeCount":99},[],{"trials":39610,"activeCount":99},[39611],{"nctId":34801,"briefTitle":34802,"status":105,"phases":39612,"primaryCompletion":34804,"completion":34805,"start":34806,"enrollment":34807,"conditions":39613,"interventions":39614},[88],[5985],[34810,34811,34021,34812],{"trials":39616,"activeCount":99},[],{"trials":39618,"activeCount":99},[],{"trials":39620,"activeCount":99},[],{"intervention":34812,"totalTrials":224,"cells":39622},{"EARLY_PHASE1":39623,"PHASE1":39625,"PHASE2":39627,"PHASE3":39633,"PHASE4":39635,"NA":39637},{"trials":39624,"activeCount":99},[],{"trials":39626,"activeCount":99},[],{"trials":39628,"activeCount":99},[39629],{"nctId":34801,"briefTitle":34802,"status":105,"phases":39630,"primaryCompletion":34804,"completion":34805,"start":34806,"enrollment":34807,"conditions":39631,"interventions":39632},[88],[5985],[34810,34811,34021,34812],{"trials":39634,"activeCount":99},[],{"trials":39636,"activeCount":99},[],{"trials":39638,"activeCount":99},[],{"intervention":19450,"totalTrials":224,"cells":39640},{"EARLY_PHASE1":39641,"PHASE1":39643,"PHASE2":39645,"PHASE3":39651,"PHASE4":39653,"NA":39655},{"trials":39642,"activeCount":99},[],{"trials":39644,"activeCount":99},[],{"trials":39646,"activeCount":99},[39647],{"nctId":19442,"briefTitle":19443,"status":105,"phases":39648,"primaryCompletion":19445,"completion":19445,"start":19446,"enrollment":19447,"conditions":39649,"interventions":39650},[88],[16472],[19450,19451,16465],{"trials":39652,"activeCount":99},[],{"trials":39654,"activeCount":99},[],{"trials":39656,"activeCount":99},[],{"intervention":19451,"totalTrials":224,"cells":39658},{"EARLY_PHASE1":39659,"PHASE1":39661,"PHASE2":39663,"PHASE3":39669,"PHASE4":39671,"NA":39673},{"trials":39660,"activeCount":99},[],{"trials":39662,"activeCount":99},[],{"trials":39664,"activeCount":99},[39665],{"nctId":19442,"briefTitle":19443,"status":105,"phases":39666,"primaryCompletion":19445,"completion":19445,"start":19446,"enrollment":19447,"conditions":39667,"interventions":39668},[88],[16472],[19450,19451,16465],{"trials":39670,"activeCount":99},[],{"trials":39672,"activeCount":99},[],{"trials":39674,"activeCount":99},[],{"intervention":1361,"totalTrials":224,"cells":39676},{"EARLY_PHASE1":39677,"PHASE1":39679,"PHASE2":39681,"PHASE3":39687,"PHASE4":39689,"NA":39691},{"trials":39678,"activeCount":99},[],{"trials":39680,"activeCount":99},[],{"trials":39682,"activeCount":99},[39683],{"nctId":1354,"briefTitle":1355,"status":150,"phases":39684,"primaryCompletion":1357,"completion":1357,"start":1358,"enrollment":36,"conditions":39685,"interventions":39686},[87,88],[497],[1361,47],{"trials":39688,"activeCount":99},[],{"trials":39690,"activeCount":99},[],{"trials":39692,"activeCount":99},[],{"intervention":39694,"totalTrials":224,"cells":39695},"Uprifosbuvir 450 mg",{"EARLY_PHASE1":39696,"PHASE1":39698,"PHASE2":39700,"PHASE3":39712,"PHASE4":39714,"NA":39716},{"trials":39697,"activeCount":99},[],{"trials":39699,"activeCount":99},[],{"trials":39701,"activeCount":99},[39702],{"nctId":39703,"briefTitle":39704,"status":150,"phases":39705,"primaryCompletion":39706,"completion":39707,"start":39708,"enrollment":787,"conditions":39709,"interventions":39710},"NCT02759315","Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)",[88],"2017-07-27","2017-11-16","2016-05-03",[21],[39694,39711],"Ruzasvir 60 mg",{"trials":39713,"activeCount":99},[],{"trials":39715,"activeCount":99},[],{"trials":39717,"activeCount":99},[],{"intervention":39711,"totalTrials":224,"cells":39719},{"EARLY_PHASE1":39720,"PHASE1":39722,"PHASE2":39724,"PHASE3":39730,"PHASE4":39732,"NA":39734},{"trials":39721,"activeCount":99},[],{"trials":39723,"activeCount":99},[],{"trials":39725,"activeCount":99},[39726],{"nctId":39703,"briefTitle":39704,"status":150,"phases":39727,"primaryCompletion":39706,"completion":39707,"start":39708,"enrollment":787,"conditions":39728,"interventions":39729},[88],[21],[39694,39711],{"trials":39731,"activeCount":99},[],{"trials":39733,"activeCount":99},[],{"trials":39735,"activeCount":99},[],{"intervention":21329,"totalTrials":224,"cells":39737},{"EARLY_PHASE1":39738,"PHASE1":39740,"PHASE2":39742,"PHASE3":39748,"PHASE4":39750,"NA":39752},{"trials":39739,"activeCount":99},[],{"trials":39741,"activeCount":99},[],{"trials":39743,"activeCount":99},[39744],{"nctId":21322,"briefTitle":21323,"status":105,"phases":39745,"primaryCompletion":19585,"completion":19585,"start":21325,"enrollment":21326,"conditions":39746,"interventions":39747},[88],[16472],[21329,21330,19272],{"trials":39749,"activeCount":99},[],{"trials":39751,"activeCount":99},[],{"trials":39753,"activeCount":99},[],{"intervention":21330,"totalTrials":224,"cells":39755},{"EARLY_PHASE1":39756,"PHASE1":39758,"PHASE2":39760,"PHASE3":39766,"PHASE4":39768,"NA":39770},{"trials":39757,"activeCount":99},[],{"trials":39759,"activeCount":99},[],{"trials":39761,"activeCount":99},[39762],{"nctId":21322,"briefTitle":21323,"status":105,"phases":39763,"primaryCompletion":19585,"completion":19585,"start":21325,"enrollment":21326,"conditions":39764,"interventions":39765},[88],[16472],[21329,21330,19272],{"trials":39767,"activeCount":99},[],{"trials":39769,"activeCount":99},[],{"trials":39771,"activeCount":99},[],{"intervention":39773,"totalTrials":224,"cells":39774},"MK-8616",{"EARLY_PHASE1":39775,"PHASE1":39777,"PHASE2":39779,"PHASE3":39790,"PHASE4":39792,"NA":39794},{"trials":39776,"activeCount":99},[],{"trials":39778,"activeCount":99},[],{"trials":39780,"activeCount":99},[39781],{"nctId":39782,"briefTitle":39783,"status":105,"phases":39784,"primaryCompletion":39785,"completion":39785,"start":39786,"enrollment":4421,"conditions":39787,"interventions":39788},"NCT03519867","Efficacy and Safety of Org 25969 Administered After Zemuron® (MK-8616-042)",[88],"2005-05-26","2004-08-01",[16696],[39773,39789],"Zemuron®",{"trials":39791,"activeCount":99},[],{"trials":39793,"activeCount":99},[],{"trials":39795,"activeCount":99},[],{"intervention":39789,"totalTrials":224,"cells":39797},{"EARLY_PHASE1":39798,"PHASE1":39800,"PHASE2":39802,"PHASE3":39808,"PHASE4":39810,"NA":39812},{"trials":39799,"activeCount":99},[],{"trials":39801,"activeCount":99},[],{"trials":39803,"activeCount":99},[39804],{"nctId":39782,"briefTitle":39783,"status":105,"phases":39805,"primaryCompletion":39785,"completion":39785,"start":39786,"enrollment":4421,"conditions":39806,"interventions":39807},[88],[16696],[39773,39789],{"trials":39809,"activeCount":99},[],{"trials":39811,"activeCount":99},[],{"trials":39813,"activeCount":99},[],{"intervention":17578,"totalTrials":224,"cells":39815},{"EARLY_PHASE1":39816,"PHASE1":39818,"PHASE2":39820,"PHASE3":39826,"PHASE4":39828,"NA":39830},{"trials":39817,"activeCount":99},[],{"trials":39819,"activeCount":99},[],{"trials":39821,"activeCount":99},[39822],{"nctId":17570,"briefTitle":17571,"status":150,"phases":39823,"primaryCompletion":17573,"completion":17573,"start":17574,"enrollment":5983,"conditions":39824,"interventions":39825},[88],[27],[17577,17578,11421,17561,17579,17580,11447,17581,11446],{"trials":39827,"activeCount":99},[],{"trials":39829,"activeCount":99},[],{"trials":39831,"activeCount":99},[],{"intervention":17579,"totalTrials":224,"cells":39833},{"EARLY_PHASE1":39834,"PHASE1":39836,"PHASE2":39838,"PHASE3":39844,"PHASE4":39846,"NA":39848},{"trials":39835,"activeCount":99},[],{"trials":39837,"activeCount":99},[],{"trials":39839,"activeCount":99},[39840],{"nctId":17570,"briefTitle":17571,"status":150,"phases":39841,"primaryCompletion":17573,"completion":17573,"start":17574,"enrollment":5983,"conditions":39842,"interventions":39843},[88],[27],[17577,17578,11421,17561,17579,17580,11447,17581,11446],{"trials":39845,"activeCount":99},[],{"trials":39847,"activeCount":99},[],{"trials":39849,"activeCount":99},[],{"intervention":17580,"totalTrials":224,"cells":39851},{"EARLY_PHASE1":39852,"PHASE1":39854,"PHASE2":39856,"PHASE3":39862,"PHASE4":39864,"NA":39866},{"trials":39853,"activeCount":99},[],{"trials":39855,"activeCount":99},[],{"trials":39857,"activeCount":99},[39858],{"nctId":17570,"briefTitle":17571,"status":150,"phases":39859,"primaryCompletion":17573,"completion":17573,"start":17574,"enrollment":5983,"conditions":39860,"interventions":39861},[88],[27],[17577,17578,11421,17561,17579,17580,11447,17581,11446],{"trials":39863,"activeCount":99},[],{"trials":39865,"activeCount":99},[],{"trials":39867,"activeCount":99},[],{"intervention":17581,"totalTrials":224,"cells":39869},{"EARLY_PHASE1":39870,"PHASE1":39872,"PHASE2":39874,"PHASE3":39880,"PHASE4":39882,"NA":39884},{"trials":39871,"activeCount":99},[],{"trials":39873,"activeCount":99},[],{"trials":39875,"activeCount":99},[39876],{"nctId":17570,"briefTitle":17571,"status":150,"phases":39877,"primaryCompletion":17573,"completion":17573,"start":17574,"enrollment":5983,"conditions":39878,"interventions":39879},[88],[27],[17577,17578,11421,17561,17579,17580,11447,17581,11446],{"trials":39881,"activeCount":99},[],{"trials":39883,"activeCount":99},[],{"trials":39885,"activeCount":99},[],{"intervention":13121,"totalTrials":224,"cells":39887},{"EARLY_PHASE1":39888,"PHASE1":39890,"PHASE2":39892,"PHASE3":39898,"PHASE4":39900,"NA":39902},{"trials":39889,"activeCount":99},[],{"trials":39891,"activeCount":99},[],{"trials":39893,"activeCount":99},[39894],{"nctId":13115,"briefTitle":13116,"status":105,"phases":39895,"primaryCompletion":5179,"completion":5179,"start":9610,"enrollment":920,"conditions":39896,"interventions":39897},[88],[13119],[13121,8011,13122,13122],{"trials":39899,"activeCount":99},[],{"trials":39901,"activeCount":99},[],{"trials":39903,"activeCount":99},[],{"intervention":14986,"totalTrials":224,"cells":39905},{"EARLY_PHASE1":39906,"PHASE1":39908,"PHASE2":39910,"PHASE3":39916,"PHASE4":39918,"NA":39920},{"trials":39907,"activeCount":99},[],{"trials":39909,"activeCount":99},[],{"trials":39911,"activeCount":99},[39912],{"nctId":14981,"briefTitle":14982,"status":105,"phases":39913,"primaryCompletion":4990,"completion":4990,"start":14314,"enrollment":8175,"conditions":39914,"interventions":39915},[88],[14715],[14986,14987,13864],{"trials":39917,"activeCount":99},[],{"trials":39919,"activeCount":99},[],{"trials":39921,"activeCount":99},[],{"intervention":14987,"totalTrials":224,"cells":39923},{"EARLY_PHASE1":39924,"PHASE1":39926,"PHASE2":39928,"PHASE3":39934,"PHASE4":39936,"NA":39938},{"trials":39925,"activeCount":99},[],{"trials":39927,"activeCount":99},[],{"trials":39929,"activeCount":99},[39930],{"nctId":14981,"briefTitle":14982,"status":105,"phases":39931,"primaryCompletion":4990,"completion":4990,"start":14314,"enrollment":8175,"conditions":39932,"interventions":39933},[88],[14715],[14986,14987,13864],{"trials":39935,"activeCount":99},[],{"trials":39937,"activeCount":99},[],{"trials":39939,"activeCount":99},[],{"intervention":5511,"totalTrials":224,"cells":39941},{"EARLY_PHASE1":39942,"PHASE1":39944,"PHASE2":39946,"PHASE3":39952,"PHASE4":39954,"NA":39956},{"trials":39943,"activeCount":99},[],{"trials":39945,"activeCount":99},[],{"trials":39947,"activeCount":99},[39948],{"nctId":5504,"briefTitle":5505,"status":105,"phases":39949,"primaryCompletion":5507,"completion":5507,"start":5508,"enrollment":367,"conditions":39950,"interventions":39951},[88],[4789],[5511,562],{"trials":39953,"activeCount":99},[],{"trials":39955,"activeCount":99},[],{"trials":39957,"activeCount":99},[],{"intervention":33183,"totalTrials":224,"cells":39959},{"EARLY_PHASE1":39960,"PHASE1":39962,"PHASE2":39964,"PHASE3":39970,"PHASE4":39972,"NA":39974},{"trials":39961,"activeCount":99},[],{"trials":39963,"activeCount":99},[],{"trials":39965,"activeCount":99},[39966],{"nctId":33176,"briefTitle":33177,"status":150,"phases":39967,"primaryCompletion":4990,"completion":4990,"start":13870,"enrollment":31,"conditions":39968,"interventions":39969},[88],[33180,33181],[5135,33183],{"trials":39971,"activeCount":99},[],{"trials":39973,"activeCount":99},[],{"trials":39975,"activeCount":99},[],{"intervention":14996,"totalTrials":224,"cells":39977},{"EARLY_PHASE1":39978,"PHASE1":39980,"PHASE2":39982,"PHASE3":39988,"PHASE4":39990,"NA":39992},{"trials":39979,"activeCount":99},[],{"trials":39981,"activeCount":99},[],{"trials":39983,"activeCount":99},[39984],{"nctId":14989,"briefTitle":14990,"status":105,"phases":39985,"primaryCompletion":14314,"completion":14314,"start":14687,"enrollment":14992,"conditions":39986,"interventions":39987},[88],[14994],[14996,13864],{"trials":39989,"activeCount":99},[],{"trials":39991,"activeCount":99},[],{"trials":39993,"activeCount":99},[],{"intervention":12732,"totalTrials":224,"cells":39995},{"EARLY_PHASE1":39996,"PHASE1":39998,"PHASE2":40000,"PHASE3":40006,"PHASE4":40008,"NA":40010},{"trials":39997,"activeCount":99},[],{"trials":39999,"activeCount":99},[],{"trials":40001,"activeCount":99},[40002],{"nctId":12723,"briefTitle":12724,"status":150,"phases":40003,"primaryCompletion":12726,"completion":12726,"start":12727,"enrollment":12728,"conditions":40004,"interventions":40005},[88],[12730],[12716,12732,2100],{"trials":40007,"activeCount":99},[],{"trials":40009,"activeCount":99},[],{"trials":40011,"activeCount":99},[],{"intervention":40013,"totalTrials":224,"cells":40014},"Enclitide Chloride",{"EARLY_PHASE1":40015,"PHASE1":40017,"PHASE2":40019,"PHASE3":40029,"PHASE4":40031,"NA":40033},{"trials":40016,"activeCount":99},[],{"trials":40018,"activeCount":99},[],{"trials":40020,"activeCount":99},[40021],{"nctId":40022,"briefTitle":40023,"status":105,"phases":40024,"primaryCompletion":40025,"completion":40025,"start":40026,"enrollment":11649,"conditions":40027,"interventions":40028},"NCT05261126","A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)",[88],"2022-11-28","2022-03-10",[7598,8113],[40013],{"trials":40030,"activeCount":99},[],{"trials":40032,"activeCount":99},[],{"trials":40034,"activeCount":99},[],{"intervention":40036,"totalTrials":224,"cells":40037},"MK0431, sitagliptin phosphate \u002F Duration of Treatment: 21 Weeks",{"EARLY_PHASE1":40038,"PHASE1":40040,"PHASE2":40042,"PHASE3":40054,"PHASE4":40056,"NA":40058},{"trials":40039,"activeCount":99},[],{"trials":40041,"activeCount":99},[],{"trials":40043,"activeCount":99},[40044],{"nctId":40045,"briefTitle":40046,"status":105,"phases":40047,"primaryCompletion":40048,"completion":40049,"start":40050,"enrollment":17097,"conditions":40051,"interventions":40052},"NCT00482079","A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)",[88],"2004-08-25","2006-06-15","2003-05-13",[14097],[40036,40053],"Comparator: placebo (unspecified) \u002F Duration of Treatment: 21 Weeks",{"trials":40055,"activeCount":99},[],{"trials":40057,"activeCount":99},[],{"trials":40059,"activeCount":99},[],{"intervention":40053,"totalTrials":224,"cells":40061},{"EARLY_PHASE1":40062,"PHASE1":40064,"PHASE2":40066,"PHASE3":40072,"PHASE4":40074,"NA":40076},{"trials":40063,"activeCount":99},[],{"trials":40065,"activeCount":99},[],{"trials":40067,"activeCount":99},[40068],{"nctId":40045,"briefTitle":40046,"status":105,"phases":40069,"primaryCompletion":40048,"completion":40049,"start":40050,"enrollment":17097,"conditions":40070,"interventions":40071},[88],[14097],[40036,40053],{"trials":40073,"activeCount":99},[],{"trials":40075,"activeCount":99},[],{"trials":40077,"activeCount":99},[],{"intervention":20349,"totalTrials":224,"cells":40079},{"EARLY_PHASE1":40080,"PHASE1":40082,"PHASE2":40084,"PHASE3":40090,"PHASE4":40092,"NA":40094},{"trials":40081,"activeCount":99},[],{"trials":40083,"activeCount":99},[],{"trials":40085,"activeCount":99},[40086],{"nctId":20341,"briefTitle":20342,"status":105,"phases":40087,"primaryCompletion":20344,"completion":20049,"start":20345,"enrollment":20346,"conditions":40088,"interventions":40089},[88],[33,30],[13882,13883,13884,20349],{"trials":40091,"activeCount":99},[],{"trials":40093,"activeCount":99},[],{"trials":40095,"activeCount":99},[],{"intervention":15007,"totalTrials":224,"cells":40097},{"EARLY_PHASE1":40098,"PHASE1":40100,"PHASE2":40102,"PHASE3":40108,"PHASE4":40110,"NA":40112},{"trials":40099,"activeCount":99},[],{"trials":40101,"activeCount":99},[],{"trials":40103,"activeCount":99},[40104],{"nctId":14998,"briefTitle":14999,"status":105,"phases":40105,"primaryCompletion":15001,"completion":14713,"start":15002,"enrollment":15003,"conditions":40106,"interventions":40107},[88],[15005],[15007,13864],{"trials":40109,"activeCount":99},[],{"trials":40111,"activeCount":99},[],{"trials":40113,"activeCount":99},[],{"intervention":40115,"totalTrials":224,"cells":40116},"MK-6213",{"EARLY_PHASE1":40117,"PHASE1":40119,"PHASE2":40121,"PHASE3":40133,"PHASE4":40135,"NA":40137},{"trials":40118,"activeCount":99},[],{"trials":40120,"activeCount":99},[],{"trials":40122,"activeCount":99},[40123],{"nctId":40124,"briefTitle":40125,"status":105,"phases":40126,"primaryCompletion":40127,"completion":40127,"start":40128,"enrollment":40129,"conditions":40130,"interventions":40131},"NCT00687271","A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006)",[88],"2009-01-08","2008-06-14",334,[7598],[40115,40132],"Atorvastatin calcium",{"trials":40134,"activeCount":99},[],{"trials":40136,"activeCount":99},[],{"trials":40138,"activeCount":99},[],{"intervention":40132,"totalTrials":224,"cells":40140},{"EARLY_PHASE1":40141,"PHASE1":40143,"PHASE2":40145,"PHASE3":40151,"PHASE4":40153,"NA":40155},{"trials":40142,"activeCount":99},[],{"trials":40144,"activeCount":99},[],{"trials":40146,"activeCount":99},[40147],{"nctId":40124,"briefTitle":40125,"status":105,"phases":40148,"primaryCompletion":40127,"completion":40127,"start":40128,"enrollment":40129,"conditions":40149,"interventions":40150},[88],[7598],[40115,40132],{"trials":40152,"activeCount":99},[],{"trials":40154,"activeCount":99},[],{"trials":40156,"activeCount":99},[],{"intervention":40158,"totalTrials":224,"cells":40159},"Efinopegdutide 20 mg\u002FmL",{"EARLY_PHASE1":40160,"PHASE1":40162,"PHASE2":40164,"PHASE3":40175,"PHASE4":40177,"NA":40179},{"trials":40161,"activeCount":99},[],{"trials":40163,"activeCount":99},[],{"trials":40165,"activeCount":99},[40166],{"nctId":40167,"briefTitle":40168,"status":105,"phases":40169,"primaryCompletion":40170,"completion":40170,"start":40171,"enrollment":16694,"conditions":40172,"interventions":40173},"NCT04944992","A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)",[88],"2022-10-19","2021-08-04",[11631,11640],[40158,40174],"Semaglutide 1.34 mg\u002FmL",{"trials":40176,"activeCount":99},[],{"trials":40178,"activeCount":99},[],{"trials":40180,"activeCount":99},[],{"intervention":40174,"totalTrials":224,"cells":40182},{"EARLY_PHASE1":40183,"PHASE1":40185,"PHASE2":40187,"PHASE3":40193,"PHASE4":40195,"NA":40197},{"trials":40184,"activeCount":99},[],{"trials":40186,"activeCount":99},[],{"trials":40188,"activeCount":99},[40189],{"nctId":40167,"briefTitle":40168,"status":105,"phases":40190,"primaryCompletion":40170,"completion":40170,"start":40171,"enrollment":16694,"conditions":40191,"interventions":40192},[88],[11631,11640],[40158,40174],{"trials":40194,"activeCount":99},[],{"trials":40196,"activeCount":99},[],{"trials":40198,"activeCount":99},[],{"intervention":40200,"totalTrials":224,"cells":40201},"MK0639, indinavir sulfate \u002F Duration of Treatment: 48 Weeks",{"EARLY_PHASE1":40202,"PHASE1":40204,"PHASE2":40206,"PHASE3":40215,"PHASE4":40217,"NA":40219},{"trials":40203,"activeCount":99},[],{"trials":40205,"activeCount":99},[],{"trials":40207,"activeCount":99},[40208],{"nctId":40209,"briefTitle":40210,"status":105,"phases":40211,"completion":15118,"start":15584,"enrollment":13715,"conditions":40212,"interventions":40213},"NCT00541463","A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)",[88],[27],[40200,40214],"Comparator: nelfinavir mesylate \u002F Duration of Treatment: 48 Weeks",{"trials":40216,"activeCount":99},[],{"trials":40218,"activeCount":99},[],{"trials":40220,"activeCount":99},[],{"intervention":40214,"totalTrials":224,"cells":40222},{"EARLY_PHASE1":40223,"PHASE1":40225,"PHASE2":40227,"PHASE3":40233,"PHASE4":40235,"NA":40237},{"trials":40224,"activeCount":99},[],{"trials":40226,"activeCount":99},[],{"trials":40228,"activeCount":99},[40229],{"nctId":40209,"briefTitle":40210,"status":105,"phases":40230,"completion":15118,"start":15584,"enrollment":13715,"conditions":40231,"interventions":40232},[88],[27],[40200,40214],{"trials":40234,"activeCount":99},[],{"trials":40236,"activeCount":99},[],{"trials":40238,"activeCount":99},[],{"intervention":40240,"totalTrials":224,"cells":40241},"IL-10",{"EARLY_PHASE1":40242,"PHASE1":40244,"PHASE2":40246,"PHASE3":40260,"PHASE4":40262,"NA":40264},{"trials":40243,"activeCount":99},[],{"trials":40245,"activeCount":99},[],{"trials":40247,"activeCount":99},[40248],{"nctId":40249,"briefTitle":40250,"status":150,"phases":40251,"primaryCompletion":22878,"completion":20197,"start":14876,"enrollment":40252,"conditions":40253,"interventions":40259},"NCT00040131","Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED)",[88],316,[40254,40255,40256,40257,40258],"Bile Duct Diseases","Biliary Tract Diseases","Gallbladder Diseases","Pancreatitis","Pancreatic Diseases",[40240],{"trials":40261,"activeCount":99},[],{"trials":40263,"activeCount":99},[],{"trials":40265,"activeCount":99},[],{"intervention":15015,"totalTrials":224,"cells":40267},{"EARLY_PHASE1":40268,"PHASE1":40270,"PHASE2":40272,"PHASE3":40278,"PHASE4":40280,"NA":40282},{"trials":40269,"activeCount":99},[],{"trials":40271,"activeCount":99},[],{"trials":40273,"activeCount":99},[40274],{"nctId":15009,"briefTitle":15010,"status":105,"phases":40275,"primaryCompletion":14623,"completion":14623,"start":13102,"enrollment":3162,"conditions":40276,"interventions":40277},[88],[15013],[13864,15015,15015,15015,15015,15015],{"trials":40279,"activeCount":99},[],{"trials":40281,"activeCount":99},[],{"trials":40283,"activeCount":99},[],{"intervention":40285,"totalTrials":224,"cells":40286},"V591",{"EARLY_PHASE1":40287,"PHASE1":40289,"PHASE2":40291,"PHASE3":40302,"PHASE4":40304,"NA":40306},{"trials":40288,"activeCount":99},[],{"trials":40290,"activeCount":99},[],{"trials":40292,"activeCount":99},[40293],{"nctId":40294,"briefTitle":40295,"status":150,"phases":40296,"primaryCompletion":40297,"completion":40297,"start":40298,"enrollment":40299,"conditions":40300,"interventions":40301},"NCT04498247","A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)",[87,88],"2021-03-05","2020-08-27",263,[7129],[40285],{"trials":40303,"activeCount":99},[],{"trials":40305,"activeCount":99},[],{"trials":40307,"activeCount":99},[],{"intervention":40309,"totalTrials":224,"cells":40310},"MK0354",{"EARLY_PHASE1":40311,"PHASE1":40313,"PHASE2":40315,"PHASE3":40323,"PHASE4":40325,"NA":40327},{"trials":40312,"activeCount":99},[],{"trials":40314,"activeCount":99},[],{"trials":40316,"activeCount":99},[40317],{"nctId":40318,"briefTitle":40319,"status":150,"phases":40320,"primaryCompletion":12804,"completion":12804,"start":8621,"enrollment":2801,"conditions":40321,"interventions":40322},"NCT00337415","MK0354 Clinical Efficacy and Tolerability Study (0354-004)",[88],[14337],[40309],{"trials":40324,"activeCount":99},[],{"trials":40326,"activeCount":99},[],{"trials":40328,"activeCount":99},[],{"intervention":40330,"totalTrials":224,"cells":40331},"MK0431, sitagliptin phosphate \u002F Duration of Treatment: 12 Weeks",{"EARLY_PHASE1":40332,"PHASE1":40334,"PHASE2":40336,"PHASE3":40347,"PHASE4":40349,"NA":40351},{"trials":40333,"activeCount":99},[],{"trials":40335,"activeCount":99},[],{"trials":40337,"activeCount":99},[40338],{"nctId":40339,"briefTitle":40340,"status":105,"phases":40341,"primaryCompletion":40342,"completion":40342,"start":40343,"enrollment":1550,"conditions":40344,"interventions":40345},"NCT00371007","MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)",[88],"2005-04-25","2004-06-01",[15],[40330,40346],"Comparator : placebo (unspecified) \u002F Duration of Treatment: 12 Weeks",{"trials":40348,"activeCount":99},[],{"trials":40350,"activeCount":99},[],{"trials":40352,"activeCount":99},[],{"intervention":40346,"totalTrials":224,"cells":40354},{"EARLY_PHASE1":40355,"PHASE1":40357,"PHASE2":40359,"PHASE3":40365,"PHASE4":40367,"NA":40369},{"trials":40356,"activeCount":99},[],{"trials":40358,"activeCount":99},[],{"trials":40360,"activeCount":99},[40361],{"nctId":40339,"briefTitle":40340,"status":105,"phases":40362,"primaryCompletion":40342,"completion":40342,"start":40343,"enrollment":1550,"conditions":40363,"interventions":40364},[88],[15],[40330,40346],{"trials":40366,"activeCount":99},[],{"trials":40368,"activeCount":99},[],{"trials":40370,"activeCount":99},[],{"intervention":8178,"totalTrials":224,"cells":40372},{"EARLY_PHASE1":40373,"PHASE1":40375,"PHASE2":40377,"PHASE3":40383,"PHASE4":40385,"NA":40387},{"trials":40374,"activeCount":99},[],{"trials":40376,"activeCount":99},[],{"trials":40378,"activeCount":99},[40379],{"nctId":8170,"briefTitle":8171,"status":105,"phases":40380,"primaryCompletion":1247,"completion":8173,"start":8174,"enrollment":8175,"conditions":40381,"interventions":40382},[88],[314],[84,8178,8179,8143,8145,8146,8180],{"trials":40384,"activeCount":99},[],{"trials":40386,"activeCount":99},[],{"trials":40388,"activeCount":99},[],{"intervention":8179,"totalTrials":224,"cells":40390},{"EARLY_PHASE1":40391,"PHASE1":40393,"PHASE2":40395,"PHASE3":40401,"PHASE4":40403,"NA":40405},{"trials":40392,"activeCount":99},[],{"trials":40394,"activeCount":99},[],{"trials":40396,"activeCount":99},[40397],{"nctId":8170,"briefTitle":8171,"status":105,"phases":40398,"primaryCompletion":1247,"completion":8173,"start":8174,"enrollment":8175,"conditions":40399,"interventions":40400},[88],[314],[84,8178,8179,8143,8145,8146,8180],{"trials":40402,"activeCount":99},[],{"trials":40404,"activeCount":99},[],{"trials":40406,"activeCount":99},[],{"intervention":8180,"totalTrials":224,"cells":40408},{"EARLY_PHASE1":40409,"PHASE1":40411,"PHASE2":40413,"PHASE3":40419,"PHASE4":40421,"NA":40423},{"trials":40410,"activeCount":99},[],{"trials":40412,"activeCount":99},[],{"trials":40414,"activeCount":99},[40415],{"nctId":8170,"briefTitle":8171,"status":105,"phases":40416,"primaryCompletion":1247,"completion":8173,"start":8174,"enrollment":8175,"conditions":40417,"interventions":40418},[88],[314],[84,8178,8179,8143,8145,8146,8180],{"trials":40420,"activeCount":99},[],{"trials":40422,"activeCount":99},[],{"trials":40424,"activeCount":99},[],{"intervention":1492,"totalTrials":224,"cells":40426},{"EARLY_PHASE1":40427,"PHASE1":40429,"PHASE2":40431,"PHASE3":40437,"PHASE4":40439,"NA":40441},{"trials":40428,"activeCount":99},[],{"trials":40430,"activeCount":99},[],{"trials":40432,"activeCount":99},[40433],{"nctId":1485,"briefTitle":1486,"status":105,"phases":40434,"primaryCompletion":1488,"completion":1488,"start":1489,"enrollment":920,"conditions":40435,"interventions":40436},[88],[991],[47,434,1492,390],{"trials":40438,"activeCount":99},[],{"trials":40440,"activeCount":99},[],{"trials":40442,"activeCount":99},[],{"intervention":40444,"totalTrials":224,"cells":40445},"Filorexant",{"EARLY_PHASE1":40446,"PHASE1":40448,"PHASE2":40450,"PHASE3":40461,"PHASE4":40463,"NA":40465},{"trials":40447,"activeCount":99},[],{"trials":40449,"activeCount":99},[],{"trials":40451,"activeCount":99},[40452],{"nctId":40453,"briefTitle":40454,"status":150,"phases":40455,"primaryCompletion":40456,"completion":40456,"start":40457,"enrollment":11541,"conditions":40458,"interventions":40460},"NCT01554176","Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)",[88],"2013-09-03","2012-05-18",[40459],"Major Depressive Disorder, Recurrent",[40444],{"trials":40462,"activeCount":99},[],{"trials":40464,"activeCount":99},[],{"trials":40466,"activeCount":99},[],{"intervention":1504,"totalTrials":224,"cells":40468},{"EARLY_PHASE1":40469,"PHASE1":40471,"PHASE2":40473,"PHASE3":40479,"PHASE4":40481,"NA":40483},{"trials":40470,"activeCount":99},[],{"trials":40472,"activeCount":99},[],{"trials":40474,"activeCount":99},[40475],{"nctId":1494,"briefTitle":1495,"status":105,"phases":40476,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":787,"conditions":40477,"interventions":40478},[88],[1501,1502],[47,387,386,1504,471,967],{"trials":40480,"activeCount":99},[],{"trials":40482,"activeCount":99},[],{"trials":40484,"activeCount":99},[],{"intervention":13031,"totalTrials":224,"cells":40486},{"EARLY_PHASE1":40487,"PHASE1":40489,"PHASE2":40491,"PHASE3":40497,"PHASE4":40499,"NA":40501},{"trials":40488,"activeCount":99},[],{"trials":40490,"activeCount":99},[],{"trials":40492,"activeCount":99},[40493],{"nctId":13023,"briefTitle":13024,"status":105,"phases":40494,"primaryCompletion":13026,"completion":2285,"start":13027,"enrollment":2801,"conditions":40495,"interventions":40496},[88],[13029],[13031,13005,13032],{"trials":40498,"activeCount":99},[],{"trials":40500,"activeCount":99},[],{"trials":40502,"activeCount":99},[],{"intervention":13032,"totalTrials":224,"cells":40504},{"EARLY_PHASE1":40505,"PHASE1":40507,"PHASE2":40509,"PHASE3":40515,"PHASE4":40517,"NA":40519},{"trials":40506,"activeCount":99},[],{"trials":40508,"activeCount":99},[],{"trials":40510,"activeCount":99},[40511],{"nctId":13023,"briefTitle":13024,"status":105,"phases":40512,"primaryCompletion":13026,"completion":2285,"start":13027,"enrollment":2801,"conditions":40513,"interventions":40514},[88],[13029],[13031,13005,13032],{"trials":40516,"activeCount":99},[],{"trials":40518,"activeCount":99},[],{"trials":40520,"activeCount":99},[],{"intervention":40522,"totalTrials":224,"cells":40523},"MK0524",{"EARLY_PHASE1":40524,"PHASE1":40526,"PHASE2":40528,"PHASE3":40537,"PHASE4":40539,"NA":40541},{"trials":40525,"activeCount":99},[],{"trials":40527,"activeCount":99},[],{"trials":40529,"activeCount":99},[40530],{"nctId":40531,"briefTitle":40532,"status":105,"phases":40533,"primaryCompletion":22476,"completion":22476,"start":20226,"enrollment":16534,"conditions":40534,"interventions":40536},"NCT00533208","MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED)",[88],[40535],"Seasonal Allergies",[40522],{"trials":40538,"activeCount":99},[],{"trials":40540,"activeCount":99},[],{"trials":40542,"activeCount":99},[],{"intervention":20507,"totalTrials":224,"cells":40544},{"EARLY_PHASE1":40545,"PHASE1":40547,"PHASE2":40549,"PHASE3":40555,"PHASE4":40557,"NA":40559},{"trials":40546,"activeCount":99},[],{"trials":40548,"activeCount":99},[],{"trials":40550,"activeCount":99},[40551],{"nctId":20501,"briefTitle":20502,"status":105,"phases":40552,"primaryCompletion":8619,"completion":8619,"start":4420,"enrollment":920,"conditions":40553,"interventions":40554},[88],[20505,15597],[20478,20507],{"trials":40556,"activeCount":99},[],{"trials":40558,"activeCount":99},[],{"trials":40560,"activeCount":99},[],{"intervention":40562,"totalTrials":224,"cells":40563},"EBR\u002FGZR FDC",{"EARLY_PHASE1":40564,"PHASE1":40566,"PHASE2":40568,"PHASE3":40580,"PHASE4":40582,"NA":40584},{"trials":40565,"activeCount":99},[],{"trials":40567,"activeCount":99},[],{"trials":40569,"activeCount":99},[40570],{"nctId":40571,"briefTitle":40572,"status":105,"phases":40573,"primaryCompletion":22582,"completion":40574,"start":40575,"enrollment":28,"conditions":40576,"interventions":40577},"NCT03379506","Elbasvir (EBR)\u002FGrazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)",[88],"2020-07-23","2018-01-25",[15847],[40562,40578,40579],"Grazoprevir Oral Granules","Elbasvir Oral Granules",{"trials":40581,"activeCount":99},[],{"trials":40583,"activeCount":99},[],{"trials":40585,"activeCount":99},[],{"intervention":40578,"totalTrials":224,"cells":40587},{"EARLY_PHASE1":40588,"PHASE1":40590,"PHASE2":40592,"PHASE3":40598,"PHASE4":40600,"NA":40602},{"trials":40589,"activeCount":99},[],{"trials":40591,"activeCount":99},[],{"trials":40593,"activeCount":99},[40594],{"nctId":40571,"briefTitle":40572,"status":105,"phases":40595,"primaryCompletion":22582,"completion":40574,"start":40575,"enrollment":28,"conditions":40596,"interventions":40597},[88],[15847],[40562,40578,40579],{"trials":40599,"activeCount":99},[],{"trials":40601,"activeCount":99},[],{"trials":40603,"activeCount":99},[],{"intervention":40579,"totalTrials":224,"cells":40605},{"EARLY_PHASE1":40606,"PHASE1":40608,"PHASE2":40610,"PHASE3":40616,"PHASE4":40618,"NA":40620},{"trials":40607,"activeCount":99},[],{"trials":40609,"activeCount":99},[],{"trials":40611,"activeCount":99},[40612],{"nctId":40571,"briefTitle":40572,"status":105,"phases":40613,"primaryCompletion":22582,"completion":40574,"start":40575,"enrollment":28,"conditions":40614,"interventions":40615},[88],[15847],[40562,40578,40579],{"trials":40617,"activeCount":99},[],{"trials":40619,"activeCount":99},[],{"trials":40621,"activeCount":99},[],{"intervention":15033,"totalTrials":224,"cells":40623},{"EARLY_PHASE1":40624,"PHASE1":40626,"PHASE2":40628,"PHASE3":40634,"PHASE4":40636,"NA":40638},{"trials":40625,"activeCount":99},[],{"trials":40627,"activeCount":99},[],{"trials":40629,"activeCount":99},[40630],{"nctId":15026,"briefTitle":15027,"status":105,"phases":40631,"primaryCompletion":8621,"completion":8621,"start":14228,"enrollment":15029,"conditions":40632,"interventions":40633},[88],[4397],[13864,15032,15032,15032,15032,15032,15032,15032,15033],{"trials":40635,"activeCount":99},[],{"trials":40637,"activeCount":99},[],{"trials":40639,"activeCount":99},[],{"intervention":15041,"totalTrials":224,"cells":40641},{"EARLY_PHASE1":40642,"PHASE1":40644,"PHASE2":40646,"PHASE3":40652,"PHASE4":40654,"NA":40656},{"trials":40643,"activeCount":99},[],{"trials":40645,"activeCount":99},[],{"trials":40647,"activeCount":99},[40648],{"nctId":15035,"briefTitle":15036,"status":150,"phases":40649,"primaryCompletion":14713,"completion":14713,"start":15038,"enrollment":95,"conditions":40650,"interventions":40651},[88],[14994],[15041,13864],{"trials":40653,"activeCount":99},[],{"trials":40655,"activeCount":99},[],{"trials":40657,"activeCount":99},[],{"intervention":40659,"totalTrials":224,"cells":40660},"NM283 plus Peg-IFNα-2a",{"EARLY_PHASE1":40661,"PHASE1":40663,"PHASE2":40665,"PHASE3":40673,"PHASE4":40675,"NA":40677},{"trials":40662,"activeCount":99},[],{"trials":40664,"activeCount":99},[],{"trials":40666,"activeCount":99},[40667],{"nctId":40668,"briefTitle":40669,"status":105,"phases":40670,"primaryCompletion":14858,"completion":13102,"start":8619,"enrollment":20233,"conditions":40671,"interventions":40672},"NCT00395421","Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin",[88],[12957],[40659],{"trials":40674,"activeCount":99},[],{"trials":40676,"activeCount":99},[],{"trials":40678,"activeCount":99},[],{"intervention":24545,"totalTrials":224,"cells":40680},{"EARLY_PHASE1":40681,"PHASE1":40683,"PHASE2":40685,"PHASE3":40691,"PHASE4":40693,"NA":40695},{"trials":40682,"activeCount":99},[],{"trials":40684,"activeCount":99},[],{"trials":40686,"activeCount":99},[40687],{"nctId":24540,"briefTitle":24541,"status":105,"phases":40688,"primaryCompletion":8619,"completion":20258,"start":14903,"enrollment":3162,"conditions":40689,"interventions":40690},[88],[27,21124],[24545,24546,24531,24547,24548],{"trials":40692,"activeCount":99},[],{"trials":40694,"activeCount":99},[],{"trials":40696,"activeCount":99},[],{"intervention":24546,"totalTrials":224,"cells":40698},{"EARLY_PHASE1":40699,"PHASE1":40701,"PHASE2":40703,"PHASE3":40709,"PHASE4":40711,"NA":40713},{"trials":40700,"activeCount":99},[],{"trials":40702,"activeCount":99},[],{"trials":40704,"activeCount":99},[40705],{"nctId":24540,"briefTitle":24541,"status":105,"phases":40706,"primaryCompletion":8619,"completion":20258,"start":14903,"enrollment":3162,"conditions":40707,"interventions":40708},[88],[27,21124],[24545,24546,24531,24547,24548],{"trials":40710,"activeCount":99},[],{"trials":40712,"activeCount":99},[],{"trials":40714,"activeCount":99},[],{"intervention":24547,"totalTrials":224,"cells":40716},{"EARLY_PHASE1":40717,"PHASE1":40719,"PHASE2":40721,"PHASE3":40727,"PHASE4":40729,"NA":40731},{"trials":40718,"activeCount":99},[],{"trials":40720,"activeCount":99},[],{"trials":40722,"activeCount":99},[40723],{"nctId":24540,"briefTitle":24541,"status":105,"phases":40724,"primaryCompletion":8619,"completion":20258,"start":14903,"enrollment":3162,"conditions":40725,"interventions":40726},[88],[27,21124],[24545,24546,24531,24547,24548],{"trials":40728,"activeCount":99},[],{"trials":40730,"activeCount":99},[],{"trials":40732,"activeCount":99},[],{"intervention":24548,"totalTrials":224,"cells":40734},{"EARLY_PHASE1":40735,"PHASE1":40737,"PHASE2":40739,"PHASE3":40745,"PHASE4":40747,"NA":40749},{"trials":40736,"activeCount":99},[],{"trials":40738,"activeCount":99},[],{"trials":40740,"activeCount":99},[40741],{"nctId":24540,"briefTitle":24541,"status":105,"phases":40742,"primaryCompletion":8619,"completion":20258,"start":14903,"enrollment":3162,"conditions":40743,"interventions":40744},[88],[27,21124],[24545,24546,24531,24547,24548],{"trials":40746,"activeCount":99},[],{"trials":40748,"activeCount":99},[],{"trials":40750,"activeCount":99},[],{"intervention":40752,"totalTrials":224,"cells":40753},"MK0991, caspofungin acetate\u002FDuration of Treatment: variable",{"EARLY_PHASE1":40754,"PHASE1":40756,"PHASE2":40758,"PHASE3":40766,"PHASE4":40768,"NA":40770},{"trials":40755,"activeCount":99},[],{"trials":40757,"activeCount":99},[],{"trials":40759,"activeCount":99},[40760],{"nctId":40761,"briefTitle":40762,"status":105,"phases":40763,"primaryCompletion":6464,"completion":6464,"start":14495,"enrollment":1054,"conditions":40764,"interventions":40765},"NCT00083343","Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)",[88],[20491],[40752],{"trials":40767,"activeCount":99},[],{"trials":40769,"activeCount":99},[],{"trials":40771,"activeCount":99},[],{"intervention":40773,"totalTrials":224,"cells":40774},"Benznidazole",{"EARLY_PHASE1":40775,"PHASE1":40777,"PHASE2":40779,"PHASE3":40791,"PHASE4":40793,"NA":40795},{"trials":40776,"activeCount":99},[],{"trials":40778,"activeCount":99},[],{"trials":40780,"activeCount":99},[40781],{"nctId":40782,"briefTitle":40783,"status":105,"phases":40784,"primaryCompletion":40785,"completion":40786,"start":40787,"enrollment":2023,"conditions":40788,"interventions":40790},"NCT01377480","A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)",[88],"2014-07-22","2015-01-12","2011-07-06",[40789],"Chagas Disease",[17832,40773],{"trials":40792,"activeCount":99},[],{"trials":40794,"activeCount":99},[],{"trials":40796,"activeCount":99},[],{"intervention":35528,"totalTrials":224,"cells":40798},{"EARLY_PHASE1":40799,"PHASE1":40801,"PHASE2":40803,"PHASE3":40809,"PHASE4":40811,"NA":40813},{"trials":40800,"activeCount":99},[],{"trials":40802,"activeCount":99},[],{"trials":40804,"activeCount":99},[40805],{"nctId":35523,"briefTitle":35524,"status":1040,"phases":40806,"primaryCompletion":16792,"completion":16792,"start":14566,"enrollment":99,"conditions":40807,"interventions":40808},[88],[14715],[35505,35528],{"trials":40810,"activeCount":99},[],{"trials":40812,"activeCount":99},[],{"trials":40814,"activeCount":99},[],{"intervention":11433,"totalTrials":224,"cells":40816},{"EARLY_PHASE1":40817,"PHASE1":40819,"PHASE2":40821,"PHASE3":40827,"PHASE4":40829,"NA":40831},{"trials":40818,"activeCount":99},[],{"trials":40820,"activeCount":99},[],{"trials":40822,"activeCount":99},[40823],{"nctId":11425,"briefTitle":11426,"status":105,"phases":40824,"primaryCompletion":11428,"completion":11429,"start":11430,"enrollment":9551,"conditions":40825,"interventions":40826},[88],[27],[11357,6235,11433],{"trials":40828,"activeCount":99},[],{"trials":40830,"activeCount":99},[],{"trials":40832,"activeCount":99},[],{"intervention":40834,"totalTrials":224,"cells":40835},"MK-0873 2.5 mg",{"EARLY_PHASE1":40836,"PHASE1":40838,"PHASE2":40840,"PHASE3":40853,"PHASE4":40855,"NA":40857},{"trials":40837,"activeCount":99},[],{"trials":40839,"activeCount":99},[],{"trials":40841,"activeCount":99},[40842],{"nctId":40843,"briefTitle":40844,"status":150,"phases":40845,"primaryCompletion":15143,"completion":15143,"start":40343,"enrollment":40846,"conditions":40847,"interventions":40849},"NCT00132730","An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)",[88],604,[40848,18267],"Lung Diseases",[40834,40850,40851,40852],"MK-0873 1.25 mg","MK-0873 0.75 mg","Usual Care",{"trials":40854,"activeCount":99},[],{"trials":40856,"activeCount":99},[],{"trials":40858,"activeCount":99},[],{"intervention":40850,"totalTrials":224,"cells":40860},{"EARLY_PHASE1":40861,"PHASE1":40863,"PHASE2":40865,"PHASE3":40871,"PHASE4":40873,"NA":40875},{"trials":40862,"activeCount":99},[],{"trials":40864,"activeCount":99},[],{"trials":40866,"activeCount":99},[40867],{"nctId":40843,"briefTitle":40844,"status":150,"phases":40868,"primaryCompletion":15143,"completion":15143,"start":40343,"enrollment":40846,"conditions":40869,"interventions":40870},[88],[40848,18267],[40834,40850,40851,40852],{"trials":40872,"activeCount":99},[],{"trials":40874,"activeCount":99},[],{"trials":40876,"activeCount":99},[],{"intervention":40851,"totalTrials":224,"cells":40878},{"EARLY_PHASE1":40879,"PHASE1":40881,"PHASE2":40883,"PHASE3":40889,"PHASE4":40891,"NA":40893},{"trials":40880,"activeCount":99},[],{"trials":40882,"activeCount":99},[],{"trials":40884,"activeCount":99},[40885],{"nctId":40843,"briefTitle":40844,"status":150,"phases":40886,"primaryCompletion":15143,"completion":15143,"start":40343,"enrollment":40846,"conditions":40887,"interventions":40888},[88],[40848,18267],[40834,40850,40851,40852],{"trials":40890,"activeCount":99},[],{"trials":40892,"activeCount":99},[],{"trials":40894,"activeCount":99},[],{"intervention":40852,"totalTrials":224,"cells":40896},{"EARLY_PHASE1":40897,"PHASE1":40899,"PHASE2":40901,"PHASE3":40907,"PHASE4":40909,"NA":40911},{"trials":40898,"activeCount":99},[],{"trials":40900,"activeCount":99},[],{"trials":40902,"activeCount":99},[40903],{"nctId":40843,"briefTitle":40844,"status":150,"phases":40904,"primaryCompletion":15143,"completion":15143,"start":40343,"enrollment":40846,"conditions":40905,"interventions":40906},[88],[40848,18267],[40834,40850,40851,40852],{"trials":40908,"activeCount":99},[],{"trials":40910,"activeCount":99},[],{"trials":40912,"activeCount":99},[],{"intervention":16253,"totalTrials":224,"cells":40914},{"EARLY_PHASE1":40915,"PHASE1":40917,"PHASE2":40919,"PHASE3":40925,"PHASE4":40927,"NA":40929},{"trials":40916,"activeCount":99},[],{"trials":40918,"activeCount":99},[],{"trials":40920,"activeCount":99},[40921],{"nctId":16247,"briefTitle":16248,"status":105,"phases":40922,"primaryCompletion":5801,"completion":5801,"start":14540,"enrollment":16250,"conditions":40923,"interventions":40924},[88],[16210],[16253,16254,16255,16256,5137],{"trials":40926,"activeCount":99},[],{"trials":40928,"activeCount":99},[],{"trials":40930,"activeCount":99},[],{"intervention":16254,"totalTrials":224,"cells":40932},{"EARLY_PHASE1":40933,"PHASE1":40935,"PHASE2":40937,"PHASE3":40943,"PHASE4":40945,"NA":40947},{"trials":40934,"activeCount":99},[],{"trials":40936,"activeCount":99},[],{"trials":40938,"activeCount":99},[40939],{"nctId":16247,"briefTitle":16248,"status":105,"phases":40940,"primaryCompletion":5801,"completion":5801,"start":14540,"enrollment":16250,"conditions":40941,"interventions":40942},[88],[16210],[16253,16254,16255,16256,5137],{"trials":40944,"activeCount":99},[],{"trials":40946,"activeCount":99},[],{"trials":40948,"activeCount":99},[],{"intervention":16255,"totalTrials":224,"cells":40950},{"EARLY_PHASE1":40951,"PHASE1":40953,"PHASE2":40955,"PHASE3":40961,"PHASE4":40963,"NA":40965},{"trials":40952,"activeCount":99},[],{"trials":40954,"activeCount":99},[],{"trials":40956,"activeCount":99},[40957],{"nctId":16247,"briefTitle":16248,"status":105,"phases":40958,"primaryCompletion":5801,"completion":5801,"start":14540,"enrollment":16250,"conditions":40959,"interventions":40960},[88],[16210],[16253,16254,16255,16256,5137],{"trials":40962,"activeCount":99},[],{"trials":40964,"activeCount":99},[],{"trials":40966,"activeCount":99},[],{"intervention":16256,"totalTrials":224,"cells":40968},{"EARLY_PHASE1":40969,"PHASE1":40971,"PHASE2":40973,"PHASE3":40979,"PHASE4":40981,"NA":40983},{"trials":40970,"activeCount":99},[],{"trials":40972,"activeCount":99},[],{"trials":40974,"activeCount":99},[40975],{"nctId":16247,"briefTitle":16248,"status":105,"phases":40976,"primaryCompletion":5801,"completion":5801,"start":14540,"enrollment":16250,"conditions":40977,"interventions":40978},[88],[16210],[16253,16254,16255,16256,5137],{"trials":40980,"activeCount":99},[],{"trials":40982,"activeCount":99},[],{"trials":40984,"activeCount":99},[],{"intervention":13941,"totalTrials":224,"cells":40986},{"EARLY_PHASE1":40987,"PHASE1":40989,"PHASE2":40991,"PHASE3":40997,"PHASE4":40999,"NA":41001},{"trials":40988,"activeCount":99},[],{"trials":40990,"activeCount":99},[],{"trials":40992,"activeCount":99},[40993],{"nctId":13933,"briefTitle":13934,"status":150,"phases":40994,"primaryCompletion":13936,"completion":13937,"start":13938,"enrollment":901,"conditions":40995,"interventions":40996},[88],[15],[13941,4084],{"trials":40998,"activeCount":99},[],{"trials":41000,"activeCount":99},[],{"trials":41002,"activeCount":99},[],{"intervention":41004,"totalTrials":224,"cells":41005},"tildrakizumab",{"EARLY_PHASE1":41006,"PHASE1":41008,"PHASE2":41010,"PHASE3":41020,"PHASE4":41022,"NA":41024},{"trials":41007,"activeCount":99},[],{"trials":41009,"activeCount":99},[],{"trials":41011,"activeCount":99},[41012],{"nctId":41013,"briefTitle":41014,"status":105,"phases":41015,"primaryCompletion":41016,"completion":16125,"start":41017,"enrollment":15169,"conditions":41018,"interventions":41019},"NCT01225731","A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222\u002FMK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)",[88],"2011-11-04","2010-10-25",[12754],[41004],{"trials":41021,"activeCount":99},[],{"trials":41023,"activeCount":99},[],{"trials":41025,"activeCount":99},[],{"intervention":41027,"totalTrials":224,"cells":41028},"MK2295",{"EARLY_PHASE1":41029,"PHASE1":41031,"PHASE2":41033,"PHASE3":41042,"PHASE4":41044,"NA":41046},{"trials":41030,"activeCount":99},[],{"trials":41032,"activeCount":99},[],{"trials":41034,"activeCount":99},[41035],{"nctId":41036,"briefTitle":41037,"status":105,"phases":41038,"primaryCompletion":14409,"completion":14409,"start":8619,"enrollment":27249,"conditions":41039,"interventions":41041},"NCT00387140","A Study to Evaluate the Safety and Efficacy of an Investigational Drug in the Treatment of Postoperative Dental Pain (MK-2295-005)",[88],[34295,41040],"Tooth Extraction",[41027],{"trials":41043,"activeCount":99},[],{"trials":41045,"activeCount":99},[],{"trials":41047,"activeCount":99},[],{"intervention":41049,"totalTrials":224,"cells":41050},"INS37217 Nasal Spray",{"EARLY_PHASE1":41051,"PHASE1":41053,"PHASE2":41055,"PHASE3":41065,"PHASE4":41067,"NA":41069},{"trials":41052,"activeCount":99},[],{"trials":41054,"activeCount":99},[],{"trials":41056,"activeCount":99},[41057],{"nctId":41058,"briefTitle":41059,"status":105,"phases":41060,"primaryCompletion":17248,"completion":17248,"start":22878,"enrollment":41061,"conditions":41062,"interventions":41064},"NCT00210015","A Study in Subjects With Perennial Allergic Rhinitis",[88],630,[41063],"Perennial Allergic Rhinitis",[41049],{"trials":41066,"activeCount":99},[],{"trials":41068,"activeCount":99},[],{"trials":41070,"activeCount":99},[],{"intervention":41072,"totalTrials":224,"cells":41073},"MK-0634 50 mg",{"EARLY_PHASE1":41074,"PHASE1":41076,"PHASE2":41078,"PHASE3":41088,"PHASE4":41090,"NA":41092},{"trials":41075,"activeCount":99},[],{"trials":41077,"activeCount":99},[],{"trials":41079,"activeCount":99},[41080],{"nctId":41081,"briefTitle":41082,"status":105,"phases":41083,"primaryCompletion":4418,"completion":8619,"start":15063,"enrollment":16357,"conditions":41084,"interventions":41086},"NCT00231790","A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)",[88],[41085],"Urinary Incontinence",[41072,41087],"MK-0634 125 mg",{"trials":41089,"activeCount":99},[],{"trials":41091,"activeCount":99},[],{"trials":41093,"activeCount":99},[],{"intervention":41087,"totalTrials":224,"cells":41095},{"EARLY_PHASE1":41096,"PHASE1":41098,"PHASE2":41100,"PHASE3":41106,"PHASE4":41108,"NA":41110},{"trials":41097,"activeCount":99},[],{"trials":41099,"activeCount":99},[],{"trials":41101,"activeCount":99},[41102],{"nctId":41081,"briefTitle":41082,"status":105,"phases":41103,"primaryCompletion":4418,"completion":8619,"start":15063,"enrollment":16357,"conditions":41104,"interventions":41105},[88],[41085],[41072,41087],{"trials":41107,"activeCount":99},[],{"trials":41109,"activeCount":99},[],{"trials":41111,"activeCount":99},[],{"intervention":41113,"totalTrials":224,"cells":41114},"V502",{"EARLY_PHASE1":41115,"PHASE1":41117,"PHASE2":41119,"PHASE3":41127,"PHASE4":41129,"NA":41131},{"trials":41116,"activeCount":99},[],{"trials":41118,"activeCount":99},[],{"trials":41120,"activeCount":99},[41121],{"nctId":41122,"briefTitle":41123,"status":1040,"phases":41124,"start":8619,"enrollment":99,"conditions":41125,"interventions":41126},"NCT00365443","Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)",[88],[863,7141],[41113],{"trials":41128,"activeCount":99},[],{"trials":41130,"activeCount":99},[],{"trials":41132,"activeCount":99},[],{"intervention":25261,"totalTrials":224,"cells":41134},{"EARLY_PHASE1":41135,"PHASE1":41137,"PHASE2":41139,"PHASE3":41145,"PHASE4":41147,"NA":41149},{"trials":41136,"activeCount":99},[],{"trials":41138,"activeCount":99},[],{"trials":41140,"activeCount":99},[41141],{"nctId":25255,"briefTitle":25256,"status":105,"phases":41142,"primaryCompletion":5194,"completion":5194,"start":25258,"enrollment":19725,"conditions":41143,"interventions":41144},[88],[8625],[25261,22560],{"trials":41146,"activeCount":99},[],{"trials":41148,"activeCount":99},[],{"trials":41150,"activeCount":99},[],{"intervention":41152,"totalTrials":224,"cells":41153},"doxorubicin, cyclophosphamide, paclitaxel, trastuzumab",{"EARLY_PHASE1":41154,"PHASE1":41156,"PHASE2":41158,"PHASE3":41170,"PHASE4":41172,"NA":41174},{"trials":41155,"activeCount":99},[],{"trials":41157,"activeCount":99},[],{"trials":41159,"activeCount":99},[41160],{"nctId":41161,"briefTitle":41162,"status":105,"phases":41163,"primaryCompletion":41164,"completion":41164,"start":41165,"enrollment":41166,"conditions":41167,"interventions":41168},"NCT00550771","Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)",[88],"2010-08-23","2007-07-16",181,[4789],[41152,41169],"PLD, cyclophosphamide, trastuzumab, paclitaxel",{"trials":41171,"activeCount":99},[],{"trials":41173,"activeCount":99},[],{"trials":41175,"activeCount":99},[],{"intervention":41169,"totalTrials":224,"cells":41177},{"EARLY_PHASE1":41178,"PHASE1":41180,"PHASE2":41182,"PHASE3":41188,"PHASE4":41190,"NA":41192},{"trials":41179,"activeCount":99},[],{"trials":41181,"activeCount":99},[],{"trials":41183,"activeCount":99},[41184],{"nctId":41161,"briefTitle":41162,"status":105,"phases":41185,"primaryCompletion":41164,"completion":41164,"start":41165,"enrollment":41166,"conditions":41186,"interventions":41187},[88],[4789],[41152,41169],{"trials":41189,"activeCount":99},[],{"trials":41191,"activeCount":99},[],{"trials":41193,"activeCount":99},[],{"intervention":34130,"totalTrials":224,"cells":41195},{"EARLY_PHASE1":41196,"PHASE1":41198,"PHASE2":41200,"PHASE3":41206,"PHASE4":41208,"NA":41210},{"trials":41197,"activeCount":99},[],{"trials":41199,"activeCount":99},[],{"trials":41201,"activeCount":99},[41202],{"nctId":34125,"briefTitle":34126,"status":105,"phases":41203,"start":15063,"enrollment":20774,"conditions":41204,"interventions":41205},[88],[12957],[34103,34130],{"trials":41207,"activeCount":99},[],{"trials":41209,"activeCount":99},[],{"trials":41211,"activeCount":99},[],{"intervention":4362,"totalTrials":224,"cells":41213},{"EARLY_PHASE1":41214,"PHASE1":41216,"PHASE2":41218,"PHASE3":41224,"PHASE4":41226,"NA":41228},{"trials":41215,"activeCount":99},[],{"trials":41217,"activeCount":99},[],{"trials":41219,"activeCount":99},[41220],{"nctId":4353,"briefTitle":4354,"status":150,"phases":41221,"primaryCompletion":4356,"completion":4356,"start":4357,"enrollment":4358,"conditions":41222,"interventions":41223},[88],[4360],[4362,4363,1089],{"trials":41225,"activeCount":99},[],{"trials":41227,"activeCount":99},[],{"trials":41229,"activeCount":99},[],{"intervention":19465,"totalTrials":224,"cells":41231},{"EARLY_PHASE1":41232,"PHASE1":41234,"PHASE2":41236,"PHASE3":41242,"PHASE4":41244,"NA":41246},{"trials":41233,"activeCount":99},[],{"trials":41235,"activeCount":99},[],{"trials":41237,"activeCount":99},[41238],{"nctId":19457,"briefTitle":19458,"status":105,"phases":41239,"primaryCompletion":19460,"completion":19460,"start":19461,"enrollment":19462,"conditions":41240,"interventions":41241},[87,88],[16472],[19465,19466,19467,19468,16465],{"trials":41243,"activeCount":99},[],{"trials":41245,"activeCount":99},[],{"trials":41247,"activeCount":99},[],{"intervention":19466,"totalTrials":224,"cells":41249},{"EARLY_PHASE1":41250,"PHASE1":41252,"PHASE2":41254,"PHASE3":41260,"PHASE4":41262,"NA":41264},{"trials":41251,"activeCount":99},[],{"trials":41253,"activeCount":99},[],{"trials":41255,"activeCount":99},[41256],{"nctId":19457,"briefTitle":19458,"status":105,"phases":41257,"primaryCompletion":19460,"completion":19460,"start":19461,"enrollment":19462,"conditions":41258,"interventions":41259},[87,88],[16472],[19465,19466,19467,19468,16465],{"trials":41261,"activeCount":99},[],{"trials":41263,"activeCount":99},[],{"trials":41265,"activeCount":99},[],{"intervention":19467,"totalTrials":224,"cells":41267},{"EARLY_PHASE1":41268,"PHASE1":41270,"PHASE2":41272,"PHASE3":41278,"PHASE4":41280,"NA":41282},{"trials":41269,"activeCount":99},[],{"trials":41271,"activeCount":99},[],{"trials":41273,"activeCount":99},[41274],{"nctId":19457,"briefTitle":19458,"status":105,"phases":41275,"primaryCompletion":19460,"completion":19460,"start":19461,"enrollment":19462,"conditions":41276,"interventions":41277},[87,88],[16472],[19465,19466,19467,19468,16465],{"trials":41279,"activeCount":99},[],{"trials":41281,"activeCount":99},[],{"trials":41283,"activeCount":99},[],{"intervention":19468,"totalTrials":224,"cells":41285},{"EARLY_PHASE1":41286,"PHASE1":41288,"PHASE2":41290,"PHASE3":41296,"PHASE4":41298,"NA":41300},{"trials":41287,"activeCount":99},[],{"trials":41289,"activeCount":99},[],{"trials":41291,"activeCount":99},[41292],{"nctId":19457,"briefTitle":19458,"status":105,"phases":41293,"primaryCompletion":19460,"completion":19460,"start":19461,"enrollment":19462,"conditions":41294,"interventions":41295},[87,88],[16472],[19465,19466,19467,19468,16465],{"trials":41297,"activeCount":99},[],{"trials":41299,"activeCount":99},[],{"trials":41301,"activeCount":99},[],{"intervention":2817,"totalTrials":4555,"cells":41303},{"EARLY_PHASE1":41304,"PHASE1":41306,"PHASE2":41342,"PHASE3":41344,"PHASE4":41346,"NA":41348},{"trials":41305,"activeCount":99},[],{"trials":41307,"activeCount":99},[41308,41312,41316,41326,41330,41334],{"nctId":2808,"briefTitle":2809,"status":105,"phases":41309,"primaryCompletion":2811,"completion":2812,"start":2813,"enrollment":22,"conditions":41310,"interventions":41311},[87],[2815],[2817,1677,2818,484,1654,2819],{"nctId":18928,"briefTitle":18929,"status":150,"phases":41313,"primaryCompletion":13140,"completion":15126,"start":18931,"enrollment":14576,"conditions":41314,"interventions":41315},[87],[18933],[6091,18935,6312,2817],{"nctId":41317,"briefTitle":41318,"status":105,"phases":41319,"primaryCompletion":30970,"completion":41320,"start":41321,"enrollment":18999,"conditions":41322,"interventions":41324},"NCT01021748","A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)",[87],"2014-07-16","2009-11-23",[41323],"Locally Advanced or Metastatic Solid Tumors",[2817,41325],"AZD6244",{"nctId":18970,"briefTitle":18971,"status":105,"phases":41327,"primaryCompletion":18973,"completion":8296,"start":14566,"enrollment":2801,"conditions":41328,"interventions":41329},[87],[852],[6312,18935,2817],{"nctId":11460,"briefTitle":11461,"status":150,"phases":41331,"primaryCompletion":11463,"completion":11464,"start":11465,"enrollment":444,"conditions":41332,"interventions":41333},[87],[497,1109],[2817,1843,11468],{"nctId":41335,"briefTitle":41336,"status":105,"phases":41337,"primaryCompletion":13976,"completion":13976,"start":41338,"enrollment":14463,"conditions":41339,"interventions":41341},"NCT00670488","Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)",[87],"2008-04-15",[41340,496,639,290],"Locally Advanced Tumors",[2817],{"trials":41343,"activeCount":99},[],{"trials":41345,"activeCount":99},[],{"trials":41347,"activeCount":99},[],{"trials":41349,"activeCount":99},[],{"intervention":41351,"totalTrials":174,"cells":41352},"MK-6552",{"EARLY_PHASE1":41353,"PHASE1":41355,"PHASE2":41395,"PHASE3":41397,"PHASE4":41399,"NA":41401},{"trials":41354,"activeCount":99},[],{"trials":41356,"activeCount":99},[41357,41366,41373,41381,41387],{"nctId":41358,"briefTitle":41359,"status":105,"phases":41360,"primaryCompletion":41361,"completion":41361,"start":5584,"enrollment":95,"conditions":41362,"interventions":41364},"NCT06665230","A Clinical Study of MK-6552 and Modafinil in Healthy Men (MK-6552-005)",[87],"2023-11-20",[18,41363],"Narcolepsy",[41351,41365],"Modafinil",{"nctId":41367,"briefTitle":41368,"status":150,"phases":41369,"primaryCompletion":7541,"completion":7541,"start":41370,"enrollment":120,"conditions":41371,"interventions":41372},"NCT06567002","A Study of MK-6552 and the Effect of Food in Healthy Participants (MK-6552-006)",[87],"2024-09-09",[18],[41351],{"nctId":41374,"briefTitle":41375,"status":150,"phases":41376,"primaryCompletion":41377,"completion":41377,"start":41378,"enrollment":3308,"conditions":41379,"interventions":41380},"NCT06179407","Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)",[87],"2024-10-23","2024-01-24",[41363],[41351],{"nctId":41382,"briefTitle":41383,"status":105,"phases":41384,"primaryCompletion":535,"completion":535,"start":7009,"enrollment":4071,"conditions":41385,"interventions":41386},"NCT06662396","A Study of Diltiazem With a Single Dose of MK-6552 in Healthy Adult Participants (MK-6552-007)",[87],[18],[41351,6172],{"nctId":41388,"briefTitle":41389,"status":105,"phases":41390,"primaryCompletion":8262,"completion":8262,"start":8173,"enrollment":931,"conditions":41391,"interventions":41392},"NCT06619665","A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003)",[87],[18,41363],[41351,41393,41365,41394],"MK-6552 placebo","Modafinil placebo",{"trials":41396,"activeCount":99},[],{"trials":41398,"activeCount":99},[],{"trials":41400,"activeCount":99},[],{"trials":41402,"activeCount":99},[],{"intervention":6172,"totalTrials":174,"cells":41404},{"EARLY_PHASE1":41405,"PHASE1":41407,"PHASE2":41437,"PHASE3":41439,"PHASE4":41441,"NA":41443},{"trials":41406,"activeCount":99},[],{"trials":41408,"activeCount":99},[41409,41413,41421,41429,41433],{"nctId":6165,"briefTitle":6166,"status":105,"phases":41410,"primaryCompletion":6168,"completion":6169,"start":729,"enrollment":3506,"conditions":41411,"interventions":41412},[87],[18],[5541,6172],{"nctId":41414,"briefTitle":41415,"status":105,"phases":41416,"primaryCompletion":355,"completion":355,"start":41417,"enrollment":569,"conditions":41418,"interventions":41419},"NCT06692647","A Clinical Study of MK-4318 and Diltiazem in Healthy People (MK-4318-003)",[87],"2024-02-09",[18,17251],[41420,6172],"MK-4318",{"nctId":41422,"briefTitle":41423,"status":105,"phases":41424,"primaryCompletion":41425,"completion":41425,"start":7266,"enrollment":661,"conditions":41426,"interventions":41427},"NCT06818968","A Study of the Effect of Multiple Doses of Diltiazem on the Plasma Levels of MK-6916 in Healthy Participants (MK-6916-005)",[87],"2025-08-08",[18],[41428,6172],"MK-6916",{"nctId":11178,"briefTitle":11179,"status":105,"phases":41430,"primaryCompletion":11181,"completion":11181,"start":11182,"enrollment":3655,"conditions":41431,"interventions":41432},[87],[18],[11142,6172],{"nctId":41382,"briefTitle":41383,"status":105,"phases":41434,"primaryCompletion":535,"completion":535,"start":7009,"enrollment":4071,"conditions":41435,"interventions":41436},[87],[18],[41351,6172],{"trials":41438,"activeCount":99},[],{"trials":41440,"activeCount":99},[],{"trials":41442,"activeCount":99},[],{"trials":41444,"activeCount":99},[],{"intervention":41446,"totalTrials":3963,"cells":41447},"MK-8892",{"EARLY_PHASE1":41448,"PHASE1":41450,"PHASE2":41484,"PHASE3":41486,"PHASE4":41488,"NA":41490},{"trials":41449,"activeCount":99},[],{"trials":41451,"activeCount":99},[41452,41461,41469,41476],{"nctId":41453,"briefTitle":41454,"status":150,"phases":41455,"primaryCompletion":41456,"completion":41457,"start":16755,"enrollment":3963,"conditions":41458,"interventions":41460},"NCT02078557","A Multiple Dose Titration Study of MK-8892 in Participants With Pulmonary Hypertension and Left Heart Disease (MK-8892-007)",[87],"2014-08-15","2014-09-10",[11532,41459],"Left Heart Disease",[41446],{"nctId":41462,"briefTitle":41463,"status":105,"phases":41464,"primaryCompletion":41465,"completion":41465,"start":41466,"enrollment":9323,"conditions":41467,"interventions":41468},"NCT01798849","A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)",[87],"2013-07-17","2013-03-15",[144],[41446],{"nctId":41470,"briefTitle":41471,"status":150,"phases":41472,"primaryCompletion":41473,"completion":41473,"start":670,"enrollment":357,"conditions":41474,"interventions":41475},"NCT01934647","Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)",[87],"2014-09-08",[144],[41446],{"nctId":41477,"briefTitle":41478,"status":105,"phases":41479,"primaryCompletion":41480,"completion":41473,"start":41481,"enrollment":3141,"conditions":41482,"interventions":41483},"NCT01926509","Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)",[87],"2014-09-01","2013-11-14",[144],[41446],{"trials":41485,"activeCount":99},[],{"trials":41487,"activeCount":99},[],{"trials":41489,"activeCount":99},[],{"trials":41491,"activeCount":99},[],{"intervention":13272,"totalTrials":202,"cells":41493},{"EARLY_PHASE1":41494,"PHASE1":41496,"PHASE2":41512,"PHASE3":41514,"PHASE4":41516,"NA":41518},{"trials":41495,"activeCount":99},[],{"trials":41497,"activeCount":99},[41498,41502,41508],{"nctId":13265,"briefTitle":13266,"status":150,"phases":41499,"primaryCompletion":13268,"completion":13268,"start":13269,"enrollment":5983,"conditions":41500,"interventions":41501},[87],[4074,9543],[13272,8319,13273],{"nctId":41503,"briefTitle":41504,"status":1040,"phases":41505,"primaryCompletion":18973,"completion":18973,"start":17591,"enrollment":99,"conditions":41506,"interventions":41507},"NCT01832103","The Pharmacokinetics of MK-7145 Following Single Dose Administration in Participants With Moderate Renal Insufficiency (MK-7145-018)",[87],[13409],[13272],{"nctId":22914,"briefTitle":22915,"status":105,"phases":41509,"primaryCompletion":22917,"completion":22918,"start":22919,"enrollment":212,"conditions":41510,"interventions":41511},[87],[30],[13272,22898],{"trials":41513,"activeCount":99},[],{"trials":41515,"activeCount":99},[],{"trials":41517,"activeCount":99},[],{"trials":41519,"activeCount":99},[],{"intervention":421,"totalTrials":202,"cells":41521},{"EARLY_PHASE1":41522,"PHASE1":41524,"PHASE2":41546,"PHASE3":41548,"PHASE4":41550,"NA":41552},{"trials":41523,"activeCount":99},[],{"trials":41525,"activeCount":99},[41526,41534,41542],{"nctId":41527,"briefTitle":41528,"status":105,"phases":41529,"primaryCompletion":41530,"completion":41530,"start":41531,"enrollment":154,"conditions":41532,"interventions":41533},"NCT03745989","Study of MK-8353 + Selumetinib in Advanced\u002FMetastatic Solid Tumors (MK-8353-014)",[87],"2021-03-19","2019-02-22",[176],[421,629],{"nctId":41535,"briefTitle":41536,"status":150,"phases":41537,"primaryCompletion":41538,"completion":41538,"start":41016,"enrollment":9323,"conditions":41539,"interventions":41541},"NCT01358331","A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)",[87],"2014-05-20",[41540],"Tumor, Solid",[421],{"nctId":412,"briefTitle":413,"status":150,"phases":41543,"primaryCompletion":415,"completion":415,"start":416,"enrollment":417,"conditions":41544,"interventions":41545},[87],[290,419],[421,47],{"trials":41547,"activeCount":99},[],{"trials":41549,"activeCount":99},[],{"trials":41551,"activeCount":99},[],{"trials":41553,"activeCount":99},[],{"intervention":41365,"totalTrials":202,"cells":41555},{"EARLY_PHASE1":41556,"PHASE1":41558,"PHASE2":41578,"PHASE3":41580,"PHASE4":41582,"NA":41584},{"trials":41557,"activeCount":99},[],{"trials":41559,"activeCount":99},[41560,41564,41574],{"nctId":41358,"briefTitle":41359,"status":105,"phases":41561,"primaryCompletion":41361,"completion":41361,"start":5584,"enrollment":95,"conditions":41562,"interventions":41563},[87],[18,41363],[41351,41365],{"nctId":41565,"briefTitle":41566,"status":105,"phases":41567,"primaryCompletion":41568,"completion":41568,"start":41569,"enrollment":1621,"conditions":41570,"interventions":41572},"NCT01092780","Pharmacodynamics and Efficacy of MK-7288 in Adults With Sleep Apnea (MK-7288-010)",[87],"2011-05-31","2010-05-26",[41571],"Apnea, Sleep",[41573,41365],"MK-7288",{"nctId":41388,"briefTitle":41389,"status":105,"phases":41575,"primaryCompletion":8262,"completion":8262,"start":8173,"enrollment":931,"conditions":41576,"interventions":41577},[87],[18,41363],[41351,41393,41365,41394],{"trials":41579,"activeCount":99},[],{"trials":41581,"activeCount":99},[],{"trials":41583,"activeCount":99},[],{"trials":41585,"activeCount":99},[],{"intervention":41587,"totalTrials":202,"cells":41588},"V930",{"EARLY_PHASE1":41589,"PHASE1":41591,"PHASE2":41613,"PHASE3":41615,"PHASE4":41617,"NA":41619},{"trials":41590,"activeCount":99},[],{"trials":41592,"activeCount":99},[41593,41600,41606],{"nctId":41594,"briefTitle":41595,"status":105,"phases":41596,"primaryCompletion":14315,"completion":14315,"start":15156,"enrollment":3506,"conditions":41597,"interventions":41599},"NCT00250419","V930 First in Man (FIM) Study (V930-002)(COMPLETED)",[87],[41598],"Cancers Expressing HER-2 and\u002For CEA",[41587],{"nctId":41601,"briefTitle":41602,"status":105,"phases":41603,"primaryCompletion":17095,"completion":17095,"start":14976,"enrollment":120,"conditions":41604,"interventions":41605},"NCT00721461","A Study to Test the Tolerability of an Investigational Electroporation Device in Healthy Adults (V930-001)",[87],[18],[41587],{"nctId":41607,"briefTitle":41608,"status":105,"phases":41609,"primaryCompletion":14315,"completion":9610,"start":5507,"enrollment":1419,"conditions":41610,"interventions":41611},"NCT00647114","A Study to Test V930\u002FV932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and\u002For Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)",[87],[639],[41587,41612],"V932",{"trials":41614,"activeCount":99},[],{"trials":41616,"activeCount":99},[],{"trials":41618,"activeCount":99},[],{"trials":41620,"activeCount":99},[],{"intervention":14423,"totalTrials":202,"cells":41622},{"EARLY_PHASE1":41623,"PHASE1":41625,"PHASE2":41639,"PHASE3":41641,"PHASE4":41643,"NA":41645},{"trials":41624,"activeCount":99},[],{"trials":41626,"activeCount":99},[41627,41631,41635],{"nctId":14414,"briefTitle":14415,"status":105,"phases":41628,"primaryCompletion":13224,"completion":4990,"start":8591,"enrollment":8016,"conditions":41629,"interventions":41630},[87],[14418,13133],[14420,14421,14422,14423,14331],{"nctId":14451,"briefTitle":14452,"status":105,"phases":41632,"primaryCompletion":14454,"completion":14454,"start":5507,"enrollment":3506,"conditions":41633,"interventions":41634},[87],[15],[14457,14458,14423,14331],{"nctId":14638,"briefTitle":14639,"status":105,"phases":41636,"primaryCompletion":14641,"completion":14642,"start":14643,"enrollment":3506,"conditions":41637,"interventions":41638},[87],[7598],[14646,14647,14423,14331],{"trials":41640,"activeCount":99},[],{"trials":41642,"activeCount":99},[],{"trials":41644,"activeCount":99},[],{"trials":41646,"activeCount":99},[],{"intervention":41648,"totalTrials":202,"cells":41649},"MK-8931",{"EARLY_PHASE1":41650,"PHASE1":41652,"PHASE2":41673,"PHASE3":41675,"PHASE4":41677,"NA":41679},{"trials":41651,"activeCount":99},[],{"trials":41653,"activeCount":99},[41654,41660,41667],{"nctId":41655,"briefTitle":41656,"status":105,"phases":41657,"primaryCompletion":22359,"completion":22359,"start":12984,"enrollment":626,"conditions":41658,"interventions":41659},"NCT01496170","A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])",[87],[11174],[41648],{"nctId":41661,"briefTitle":41662,"status":105,"phases":41663,"primaryCompletion":15406,"completion":9575,"start":41664,"enrollment":3655,"conditions":41665,"interventions":41666},"NCT02910739","An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)",[87],"2016-10-11",[27318,11174,27319],[41648],{"nctId":41668,"briefTitle":41669,"status":105,"phases":41670,"primaryCompletion":15845,"completion":15845,"start":8590,"enrollment":95,"conditions":41671,"interventions":41672},"NCT01537757","A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])",[87],[11174],[41648],{"trials":41674,"activeCount":99},[],{"trials":41676,"activeCount":99},[],{"trials":41678,"activeCount":99},[],{"trials":41680,"activeCount":99},[],{"intervention":5627,"totalTrials":202,"cells":41682},{"EARLY_PHASE1":41683,"PHASE1":41685,"PHASE2":41699,"PHASE3":41701,"PHASE4":41703,"NA":41705},{"trials":41684,"activeCount":99},[],{"trials":41686,"activeCount":99},[41687,41691,41695],{"nctId":6191,"briefTitle":6192,"status":105,"phases":41688,"primaryCompletion":6194,"completion":6194,"start":6195,"enrollment":120,"conditions":41689,"interventions":41690},[87],[18],[5627,5541],{"nctId":7538,"briefTitle":7539,"status":105,"phases":41692,"primaryCompletion":1868,"completion":7541,"start":7542,"enrollment":120,"conditions":41693,"interventions":41694},[87],[18],[7488,5627],{"nctId":5620,"briefTitle":5621,"status":105,"phases":41696,"primaryCompletion":985,"completion":985,"start":5623,"enrollment":1624,"conditions":41697,"interventions":41698},[87],[314],[602,5626,5627],{"trials":41700,"activeCount":99},[],{"trials":41702,"activeCount":99},[],{"trials":41704,"activeCount":99},[],{"trials":41706,"activeCount":99},[],{"intervention":41708,"totalTrials":202,"cells":41709},"Enlicitide Chloride",{"EARLY_PHASE1":41710,"PHASE1":41712,"PHASE2":41737,"PHASE3":41739,"PHASE4":41741,"NA":41743},{"trials":41711,"activeCount":99},[],{"trials":41713,"activeCount":99},[41714,41723,41730],{"nctId":41715,"briefTitle":41716,"status":105,"phases":41717,"primaryCompletion":41718,"completion":41718,"start":41719,"enrollment":931,"conditions":41720,"interventions":41722},"NCT05070390","A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007)",[87],"2023-05-03","2021-11-16",[41721],"Moderate Renal Impairment",[41708],{"nctId":41724,"briefTitle":41725,"status":105,"phases":41726,"primaryCompletion":41727,"completion":41727,"start":929,"enrollment":1621,"conditions":41728,"interventions":41729},"NCT06655311","A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)",[87],"2024-01-02",[18,7598],[41708],{"nctId":41731,"briefTitle":41732,"status":105,"phases":41733,"primaryCompletion":41734,"completion":41734,"start":11441,"enrollment":661,"conditions":41735,"interventions":41736},"NCT06814106","A Single- and Multiple-Dose Study of Enlicitide Chloride (MK-0616) in Healthy Chinese Adult Participants (MK 0616-010)",[87],"2023-05-08",[18],[41708],{"trials":41738,"activeCount":99},[],{"trials":41740,"activeCount":99},[],{"trials":41742,"activeCount":99},[],{"trials":41744,"activeCount":99},[],{"intervention":13241,"totalTrials":202,"cells":41746},{"EARLY_PHASE1":41747,"PHASE1":41749,"PHASE2":41763,"PHASE3":41765,"PHASE4":41767,"NA":41769},{"trials":41748,"activeCount":99},[],{"trials":41750,"activeCount":99},[41751,41755,41759],{"nctId":13229,"briefTitle":13230,"status":105,"phases":41752,"primaryCompletion":13232,"completion":13232,"start":13233,"enrollment":13234,"conditions":41753,"interventions":41754},[87],[13236],[13238,13239,13240,5626,13241],{"nctId":20407,"briefTitle":20408,"status":105,"phases":41756,"primaryCompletion":20410,"completion":20410,"start":20411,"enrollment":120,"conditions":41757,"interventions":41758},[87],[20413],[20415,13241,11447],{"nctId":23107,"briefTitle":23108,"status":105,"phases":41760,"primaryCompletion":14314,"completion":14314,"start":14858,"enrollment":931,"conditions":41761,"interventions":41762},[87],[7639,27],[15245,23112,23113],{"trials":41764,"activeCount":99},[],{"trials":41766,"activeCount":99},[],{"trials":41768,"activeCount":99},[],{"trials":41770,"activeCount":99},[],{"intervention":41772,"totalTrials":3197,"cells":41773},"MK-7602",{"EARLY_PHASE1":41774,"PHASE1":41776,"PHASE2":41797,"PHASE3":41799,"PHASE4":41801,"NA":41803},{"trials":41775,"activeCount":99},[],{"trials":41777,"activeCount":99},[41778,41790],{"nctId":41779,"briefTitle":41780,"status":105,"phases":41781,"primaryCompletion":41782,"completion":41782,"start":2257,"enrollment":3655,"conditions":41783,"interventions":41785},"NCT06294912","A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)",[87],"2025-01-06",[41784],"Malaria",[41772,41786,41787,41788,41789],"Artemether\u002Flumefantrine","Primaquine","Artesunate","Atovaquone\u002Fproguanil",{"nctId":41791,"briefTitle":41792,"status":105,"phases":41793,"primaryCompletion":6394,"completion":6394,"start":41794,"enrollment":5616,"conditions":41795,"interventions":41796},"NCT06797674","A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)",[87],"2025-02-10",[18],[41772,6235],{"trials":41798,"activeCount":99},[],{"trials":41800,"activeCount":99},[],{"trials":41802,"activeCount":99},[],{"trials":41804,"activeCount":99},[],{"intervention":4981,"totalTrials":3197,"cells":41806},{"EARLY_PHASE1":41807,"PHASE1":41809,"PHASE2":41826,"PHASE3":41828,"PHASE4":41830,"NA":41832},{"trials":41808,"activeCount":99},[],{"trials":41810,"activeCount":99},[41811,41815],{"nctId":4974,"briefTitle":4975,"status":105,"phases":41812,"primaryCompletion":4977,"completion":4977,"start":4978,"enrollment":700,"conditions":41813,"interventions":41814},[87],[755,756,290],[4981,714],{"nctId":41816,"briefTitle":41817,"status":150,"phases":41818,"primaryCompletion":3704,"completion":3704,"start":41819,"enrollment":120,"conditions":41820,"interventions":41824},"NCT00907517","Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)",[87],"2009-07-29",[41821,41822,33504,41823],"Myelogenous Leukemia, Acute","Leukemia, Lymphocytic, Acute","Myelogenous Leukemia, Chronic, Aggressive Phase",[4981,41825],"Cytarabine",{"trials":41827,"activeCount":99},[],{"trials":41829,"activeCount":99},[],{"trials":41831,"activeCount":99},[],{"trials":41833,"activeCount":99},[],{"intervention":23721,"totalTrials":3197,"cells":41835},{"EARLY_PHASE1":41836,"PHASE1":41838,"PHASE2":41854,"PHASE3":41856,"PHASE4":41858,"NA":41860},{"trials":41837,"activeCount":99},[],{"trials":41839,"activeCount":99},[41840,41844],{"nctId":23716,"briefTitle":23717,"status":105,"phases":41841,"primaryCompletion":14315,"completion":14315,"start":14540,"enrollment":626,"conditions":41842,"interventions":41843},[87],[9368,20657],[23709,23709,23721],{"nctId":41845,"briefTitle":41846,"status":105,"phases":41847,"primaryCompletion":41848,"completion":41848,"start":16802,"enrollment":1624,"conditions":41849,"interventions":41850},"NCT01311882","A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)",[87],"2011-11",[9307],[41851,41852,41853],"MK-4305 40 mg","MK-4305 20 mg","Zopiclone",{"trials":41855,"activeCount":99},[],{"trials":41857,"activeCount":99},[],{"trials":41859,"activeCount":99},[],{"trials":41861,"activeCount":99},[],{"intervention":5934,"totalTrials":3197,"cells":41863},{"EARLY_PHASE1":41864,"PHASE1":41866,"PHASE2":41876,"PHASE3":41878,"PHASE4":41880,"NA":41882},{"trials":41865,"activeCount":99},[],{"trials":41867,"activeCount":99},[41868,41872],{"nctId":5927,"briefTitle":5928,"status":105,"phases":41869,"primaryCompletion":5930,"completion":4408,"start":5931,"enrollment":4071,"conditions":41870,"interventions":41871},[87],[18],[4775,1076,4777,5934],{"nctId":8231,"briefTitle":8232,"status":105,"phases":41873,"primaryCompletion":2504,"completion":5699,"start":8234,"enrollment":3655,"conditions":41874,"interventions":41875},[87],[18],[8237,8238],{"trials":41877,"activeCount":99},[],{"trials":41879,"activeCount":99},[],{"trials":41881,"activeCount":99},[],{"trials":41883,"activeCount":99},[],{"intervention":41885,"totalTrials":3197,"cells":41886},"aprepitant 165 mg",{"EARLY_PHASE1":41887,"PHASE1":41889,"PHASE2":41904,"PHASE3":41906,"PHASE4":41908,"NA":41910},{"trials":41888,"activeCount":99},[],{"trials":41890,"activeCount":99},[41891,41900],{"nctId":41892,"briefTitle":41893,"status":105,"phases":41894,"primaryCompletion":14314,"completion":14314,"start":14313,"enrollment":184,"conditions":41895,"interventions":41896},"NCT00945321","A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)",[87],[5150],[41885,41897,41898,41899],"Comparator: aprepitant 185 mg","Comparator: fosaprepitant 150 mg","Comparator: aprepitant with food",{"nctId":5176,"briefTitle":5177,"status":105,"phases":41901,"primaryCompletion":5179,"completion":5179,"start":4990,"enrollment":3655,"conditions":41902,"interventions":41903},[87],[5181],[5183,5184,5185,529,529,5137,5186],{"trials":41905,"activeCount":99},[],{"trials":41907,"activeCount":99},[],{"trials":41909,"activeCount":99},[],{"trials":41911,"activeCount":99},[],{"intervention":41913,"totalTrials":3197,"cells":41914},"MK-4827",{"EARLY_PHASE1":41915,"PHASE1":41917,"PHASE2":41933,"PHASE3":41935,"PHASE4":41937,"NA":41939},{"trials":41916,"activeCount":99},[],{"trials":41918,"activeCount":99},[41919,41925],{"nctId":41920,"briefTitle":41921,"status":150,"phases":41922,"primaryCompletion":14566,"completion":41848,"start":16592,"enrollment":202,"conditions":41923,"interventions":41924},"NCT01226901","A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)",[87],[290,176],[41913],{"nctId":41926,"briefTitle":41927,"status":105,"phases":41928,"primaryCompletion":16794,"completion":15845,"start":14566,"enrollment":569,"conditions":41929,"interventions":41932},"NCT01294735","Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)",[87],[41930,41931,35],"Recurrence of Solid Tumor","Glioblastoma Multiforme",[41913,1390],{"trials":41934,"activeCount":99},[],{"trials":41936,"activeCount":99},[],{"trials":41938,"activeCount":99},[],{"trials":41940,"activeCount":99},[],{"intervention":14339,"totalTrials":3197,"cells":41942},{"EARLY_PHASE1":41943,"PHASE1":41945,"PHASE2":41955,"PHASE3":41957,"PHASE4":41959,"NA":41961},{"trials":41944,"activeCount":99},[],{"trials":41946,"activeCount":99},[41947,41951],{"nctId":14333,"briefTitle":14334,"status":105,"phases":41948,"primaryCompletion":5982,"completion":13222,"start":6308,"enrollment":661,"conditions":41949,"interventions":41950},[87],[14337],[14339,13864],{"nctId":14399,"briefTitle":14400,"status":105,"phases":41952,"primaryCompletion":5801,"completion":5801,"start":8620,"enrollment":95,"conditions":41953,"interventions":41954},[87],[14337],[14339,13864],{"trials":41956,"activeCount":99},[],{"trials":41958,"activeCount":99},[],{"trials":41960,"activeCount":99},[],{"trials":41962,"activeCount":99},[],{"intervention":629,"totalTrials":3197,"cells":41964},{"EARLY_PHASE1":41965,"PHASE1":41967,"PHASE2":41977,"PHASE3":41979,"PHASE4":41981,"NA":41983},{"trials":41966,"activeCount":99},[],{"trials":41968,"activeCount":99},[41969,41973],{"nctId":41527,"briefTitle":41528,"status":105,"phases":41970,"primaryCompletion":41530,"completion":41530,"start":41531,"enrollment":154,"conditions":41971,"interventions":41972},[87],[176],[421,629],{"nctId":621,"briefTitle":622,"status":150,"phases":41974,"primaryCompletion":624,"completion":624,"start":625,"enrollment":626,"conditions":41975,"interventions":41976},[87],[289],[629,47],{"trials":41978,"activeCount":99},[],{"trials":41980,"activeCount":99},[],{"trials":41982,"activeCount":99},[],{"trials":41984,"activeCount":99},[],{"intervention":14346,"totalTrials":3197,"cells":41986},{"EARLY_PHASE1":41987,"PHASE1":41989,"PHASE2":41999,"PHASE3":42001,"PHASE4":42003,"NA":42005},{"trials":41988,"activeCount":99},[],{"trials":41990,"activeCount":99},[41991,41995],{"nctId":14341,"briefTitle":14342,"status":105,"phases":41992,"primaryCompletion":5179,"completion":5179,"start":12813,"enrollment":9323,"conditions":41993,"interventions":41994},[87],[11195],[14346,14347,13864],{"nctId":14721,"briefTitle":14722,"status":105,"phases":41996,"primaryCompletion":13890,"completion":13890,"start":5507,"enrollment":626,"conditions":41997,"interventions":41998},[87],[11195],[14346,13864,11176,14346],{"trials":42000,"activeCount":99},[],{"trials":42002,"activeCount":99},[],{"trials":42004,"activeCount":99},[],{"trials":42006,"activeCount":99},[],{"intervention":42008,"totalTrials":3197,"cells":42009},"MK-0822",{"EARLY_PHASE1":42010,"PHASE1":42012,"PHASE2":42028,"PHASE3":42030,"PHASE4":42032,"NA":42034},{"trials":42011,"activeCount":99},[],{"trials":42013,"activeCount":99},[42014,42021],{"nctId":42015,"briefTitle":42016,"status":105,"phases":42017,"primaryCompletion":42018,"completion":42018,"start":16403,"enrollment":9323,"conditions":42019,"interventions":42020},"NCT01512667","Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067)",[87],"2012-08-22",[13409],[42008],{"nctId":42022,"briefTitle":42023,"status":105,"phases":42024,"primaryCompletion":42025,"completion":42025,"start":14113,"enrollment":3496,"conditions":42026,"interventions":42027},"NCT01512693","Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070)",[87],"2012-04-24",[7574],[42008],{"trials":42029,"activeCount":99},[],{"trials":42031,"activeCount":99},[],{"trials":42033,"activeCount":99},[],{"trials":42035,"activeCount":99},[],{"intervention":14367,"totalTrials":3197,"cells":42037},{"EARLY_PHASE1":42038,"PHASE1":42040,"PHASE2":42054,"PHASE3":42056,"PHASE4":42058,"NA":42060},{"trials":42039,"activeCount":99},[],{"trials":42041,"activeCount":99},[42042,42046],{"nctId":14360,"briefTitle":14361,"status":105,"phases":42043,"primaryCompletion":14363,"completion":14363,"start":14364,"enrollment":120,"conditions":42044,"interventions":42045},[87],[30],[14367,13864],{"nctId":42047,"briefTitle":42048,"status":105,"phases":42049,"primaryCompletion":42050,"completion":42050,"start":42051,"enrollment":154,"conditions":42052,"interventions":42053},"NCT01033643","A Multiple Dose Study of MK-3614 (MK-3614-002)",[87],"2009-12-09","2009-05-27",[30],[14367],{"trials":42055,"activeCount":99},[],{"trials":42057,"activeCount":99},[],{"trials":42059,"activeCount":99},[],{"trials":42061,"activeCount":99},[],{"intervention":42063,"totalTrials":3197,"cells":42064},"Tedizolid Phosphate Oral Formulation 1",{"EARLY_PHASE1":42065,"PHASE1":42067,"PHASE2":42085,"PHASE3":42087,"PHASE4":42089,"NA":42091},{"trials":42066,"activeCount":99},[],{"trials":42068,"activeCount":99},[42069,42077],{"nctId":42070,"briefTitle":42071,"status":105,"phases":42072,"primaryCompletion":42073,"completion":42073,"start":8262,"enrollment":931,"conditions":42074,"interventions":42075},"NCT06609161","A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)",[87],"2024-08-08",[18],[42063,42076],"Tedizolid Phosphate Oral Formulation 2",{"nctId":42078,"briefTitle":42079,"status":105,"phases":42080,"primaryCompletion":42081,"completion":42081,"start":42082,"enrollment":8016,"conditions":42083,"interventions":42084},"NCT06733688","A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)",[87],"2022-04-15","2022-03-23",[18],[42063,42076],{"trials":42086,"activeCount":99},[],{"trials":42088,"activeCount":99},[],{"trials":42090,"activeCount":99},[],{"trials":42092,"activeCount":99},[],{"intervention":42076,"totalTrials":3197,"cells":42094},{"EARLY_PHASE1":42095,"PHASE1":42097,"PHASE2":42107,"PHASE3":42109,"PHASE4":42111,"NA":42113},{"trials":42096,"activeCount":99},[],{"trials":42098,"activeCount":99},[42099,42103],{"nctId":42070,"briefTitle":42071,"status":105,"phases":42100,"primaryCompletion":42073,"completion":42073,"start":8262,"enrollment":931,"conditions":42101,"interventions":42102},[87],[18],[42063,42076],{"nctId":42078,"briefTitle":42079,"status":105,"phases":42104,"primaryCompletion":42081,"completion":42081,"start":42082,"enrollment":8016,"conditions":42105,"interventions":42106},[87],[18],[42063,42076],{"trials":42108,"activeCount":99},[],{"trials":42110,"activeCount":99},[],{"trials":42112,"activeCount":99},[],{"trials":42114,"activeCount":99},[],{"intervention":5125,"totalTrials":3197,"cells":42116},{"EARLY_PHASE1":42117,"PHASE1":42119,"PHASE2":42129,"PHASE3":42131,"PHASE4":42133,"NA":42135},{"trials":42118,"activeCount":99},[],{"trials":42120,"activeCount":99},[42121,42125],{"nctId":5118,"briefTitle":5119,"status":105,"phases":42122,"primaryCompletion":5121,"completion":5121,"start":5122,"enrollment":4071,"conditions":42123,"interventions":42124},[87],[2410,3246],[4775,529,5125,5126],{"nctId":5995,"briefTitle":5996,"status":105,"phases":42126,"primaryCompletion":4808,"completion":4808,"start":5998,"enrollment":734,"conditions":42127,"interventions":42128},[87],[6000],[6002,1076,5125],{"trials":42130,"activeCount":99},[],{"trials":42132,"activeCount":99},[],{"trials":42134,"activeCount":99},[],{"trials":42136,"activeCount":99},[],{"intervention":18935,"totalTrials":3197,"cells":42138},{"EARLY_PHASE1":42139,"PHASE1":42141,"PHASE2":42151,"PHASE3":42153,"PHASE4":42155,"NA":42157},{"trials":42140,"activeCount":99},[],{"trials":42142,"activeCount":99},[42143,42147],{"nctId":18928,"briefTitle":18929,"status":150,"phases":42144,"primaryCompletion":13140,"completion":15126,"start":18931,"enrollment":14576,"conditions":42145,"interventions":42146},[87],[18933],[6091,18935,6312,2817],{"nctId":18970,"briefTitle":18971,"status":105,"phases":42148,"primaryCompletion":18973,"completion":8296,"start":14566,"enrollment":2801,"conditions":42149,"interventions":42150},[87],[852],[6312,18935,2817],{"trials":42152,"activeCount":99},[],{"trials":42154,"activeCount":99},[],{"trials":42156,"activeCount":99},[],{"trials":42158,"activeCount":99},[],{"intervention":42160,"totalTrials":3197,"cells":42161},"MK-8242",{"EARLY_PHASE1":42162,"PHASE1":42164,"PHASE2":42183,"PHASE3":42185,"PHASE4":42187,"NA":42189},{"trials":42163,"activeCount":99},[],{"trials":42165,"activeCount":99},[42166,42175],{"nctId":42167,"briefTitle":42168,"status":150,"phases":42169,"primaryCompletion":42170,"completion":42170,"start":42171,"enrollment":3506,"conditions":42172,"interventions":42174},"NCT01451437","Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)",[87],"2014-09-05","2011-11-18",[42173],"Acute Myelogenous Leukemia (AML)",[42160],{"nctId":42176,"briefTitle":42177,"status":150,"phases":42178,"primaryCompletion":12853,"completion":42179,"start":42180,"enrollment":1054,"conditions":42181,"interventions":42182},"NCT01463696","Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)",[87],"2015-10-15","2011-12-21",[176],[42160],{"trials":42184,"activeCount":99},[],{"trials":42186,"activeCount":99},[],{"trials":42188,"activeCount":99},[],{"trials":42190,"activeCount":99},[],{"intervention":42192,"totalTrials":3197,"cells":42193},"telcagepant potassium",{"EARLY_PHASE1":42194,"PHASE1":42196,"PHASE2":42216,"PHASE3":42218,"PHASE4":42220,"NA":42222},{"trials":42195,"activeCount":99},[],{"trials":42197,"activeCount":99},[42198,42206],{"nctId":42199,"briefTitle":42200,"status":105,"phases":42201,"primaryCompletion":14504,"completion":14504,"start":14540,"enrollment":1054,"conditions":42202,"interventions":42203},"NCT01209741","Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED)",[87],[4397],[42192,42204,42205],"MK-0974 5Mo5C","MK-0974 12Mo5C",{"nctId":42207,"briefTitle":42208,"status":105,"phases":42209,"primaryCompletion":42210,"completion":42210,"start":20654,"enrollment":120,"conditions":42211,"interventions":42212},"NCT00701389","Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)",[87],"2008-04-10",[14524],[42192,42213,42214,42215],"sumatriptan","sumatriptan placebo","telcagepant potassium placebo",{"trials":42217,"activeCount":99},[],{"trials":42219,"activeCount":99},[],{"trials":42221,"activeCount":99},[],{"trials":42223,"activeCount":99},[],{"intervention":15626,"totalTrials":3197,"cells":42225},{"EARLY_PHASE1":42226,"PHASE1":42228,"PHASE2":42238,"PHASE3":42240,"PHASE4":42242,"NA":42244},{"trials":42227,"activeCount":99},[],{"trials":42229,"activeCount":99},[42230,42234],{"nctId":15618,"briefTitle":15619,"status":105,"phases":42231,"primaryCompletion":15621,"completion":15622,"start":15623,"enrollment":931,"conditions":42232,"interventions":42233},[87],[15],[14487,15626,15627,15628],{"nctId":15641,"briefTitle":15642,"status":105,"phases":42235,"primaryCompletion":8620,"completion":13890,"start":14687,"enrollment":4991,"conditions":42236,"interventions":42237},[87],[15],[15646,13982,15647],{"trials":42239,"activeCount":99},[],{"trials":42241,"activeCount":99},[],{"trials":42243,"activeCount":99},[],{"trials":42245,"activeCount":99},[],{"intervention":42247,"totalTrials":3197,"cells":42248},"Comparator: MK0633",{"EARLY_PHASE1":42249,"PHASE1":42251,"PHASE2":42265,"PHASE3":42267,"PHASE4":42269,"NA":42271},{"trials":42250,"activeCount":99},[],{"trials":42252,"activeCount":99},[42253,42259],{"nctId":42254,"briefTitle":42255,"status":105,"phases":42256,"primaryCompletion":5801,"completion":5801,"start":13890,"enrollment":95,"conditions":42257,"interventions":42258},"NCT00646789","A Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years (0633-019)",[87],[5985],[42247],{"nctId":42260,"briefTitle":42261,"status":105,"phases":42262,"primaryCompletion":13870,"completion":13870,"start":13102,"enrollment":4059,"conditions":42263,"interventions":42264},"NCT00751413","Plasma Levels of MK0633 in Children Ages 6-12 (0633-023)",[87],[5985],[42247],{"trials":42266,"activeCount":99},[],{"trials":42268,"activeCount":99},[],{"trials":42270,"activeCount":99},[],{"trials":42272,"activeCount":99},[],{"intervention":42274,"totalTrials":3197,"cells":42275},"V920",{"EARLY_PHASE1":42276,"PHASE1":42278,"PHASE2":42295,"PHASE3":42297,"PHASE4":42299,"NA":42301},{"trials":42277,"activeCount":99},[],{"trials":42279,"activeCount":99},[42280,42287],{"nctId":42281,"briefTitle":42282,"status":105,"phases":42283,"primaryCompletion":825,"completion":825,"start":15920,"enrollment":2754,"conditions":42284,"interventions":42286},"NCT02269423","Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)",[87],[42285],"Ebola Virus",[42274],{"nctId":42288,"briefTitle":42289,"status":105,"phases":42290,"primaryCompletion":34058,"completion":34058,"start":42291,"enrollment":2754,"conditions":42292,"interventions":42294},"NCT02280408","Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)",[87],"2014-10-07",[42293],"Ebola Viruses",[42274],{"trials":42296,"activeCount":99},[],{"trials":42298,"activeCount":99},[],{"trials":42300,"activeCount":99},[],{"trials":42302,"activeCount":99},[],{"intervention":42304,"totalTrials":3197,"cells":42305},"MK-3866",{"EARLY_PHASE1":42306,"PHASE1":42308,"PHASE2":42327,"PHASE3":42329,"PHASE4":42331,"NA":42333},{"trials":42307,"activeCount":99},[],{"trials":42309,"activeCount":99},[42310,42319],{"nctId":42311,"briefTitle":42312,"status":105,"phases":42313,"primaryCompletion":42314,"completion":42315,"start":42316,"enrollment":184,"conditions":42317,"interventions":42318},"NCT03259087","Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)",[87],"2018-01-28","2018-02-09","2017-09-01",[4074],[42304],{"nctId":42320,"briefTitle":42321,"status":150,"phases":42322,"primaryCompletion":11235,"completion":11235,"start":42323,"enrollment":3308,"conditions":42324,"interventions":42326},"NCT03295266","Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006)",[87],"2017-12-19",[7574,42325],"Antibacterial Agents",[42304],{"trials":42328,"activeCount":99},[],{"trials":42330,"activeCount":99},[],{"trials":42332,"activeCount":99},[],{"trials":42334,"activeCount":99},[],{"intervention":42336,"totalTrials":3197,"cells":42337},"Surotomycin",{"EARLY_PHASE1":42338,"PHASE1":42340,"PHASE2":42355,"PHASE3":42357,"PHASE4":42359,"NA":42361},{"trials":42339,"activeCount":99},[],{"trials":42341,"activeCount":99},[42342,42349],{"nctId":42343,"briefTitle":42344,"status":105,"phases":42345,"primaryCompletion":14314,"completion":14314,"start":13870,"enrollment":3390,"conditions":42346,"interventions":42348},"NCT02835105","A Study of Ascending Single Doses of Surotomycin in Healthy Participants (MK-4261-008)",[87],[42347],"Clostridium Difficile Associated Diarrhea (CDAD)",[42336],{"nctId":42350,"briefTitle":42351,"status":105,"phases":42352,"primaryCompletion":14730,"completion":14730,"start":14713,"enrollment":154,"conditions":42353,"interventions":42354},"NCT02835118","A Study of Ascending Multiple Doses of Oral Surotomycin in Healthy Participants (MK-4261-009)",[87],[42347],[42336],{"trials":42356,"activeCount":99},[],{"trials":42358,"activeCount":99},[],{"trials":42360,"activeCount":99},[],{"trials":42362,"activeCount":99},[],{"intervention":21731,"totalTrials":3197,"cells":42364},{"EARLY_PHASE1":42365,"PHASE1":42367,"PHASE2":42377,"PHASE3":42379,"PHASE4":42381,"NA":42383},{"trials":42366,"activeCount":99},[],{"trials":42368,"activeCount":99},[42369,42373],{"nctId":21723,"briefTitle":21724,"status":105,"phases":42370,"primaryCompletion":14504,"completion":14504,"start":14540,"enrollment":120,"conditions":42371,"interventions":42372},[87],[14156],[14039,21728,21729,21730,21731,21732,21733,21734],{"nctId":21736,"briefTitle":21737,"status":105,"phases":42374,"primaryCompletion":21739,"completion":21740,"start":21739,"enrollment":1054,"conditions":42375,"interventions":42376},[87],[14156],[14039,21743,21729,21744,21731,21733],{"trials":42378,"activeCount":99},[],{"trials":42380,"activeCount":99},[],{"trials":42382,"activeCount":99},[],{"trials":42384,"activeCount":99},[],{"intervention":21733,"totalTrials":3197,"cells":42386},{"EARLY_PHASE1":42387,"PHASE1":42389,"PHASE2":42399,"PHASE3":42401,"PHASE4":42403,"NA":42405},{"trials":42388,"activeCount":99},[],{"trials":42390,"activeCount":99},[42391,42395],{"nctId":21723,"briefTitle":21724,"status":105,"phases":42392,"primaryCompletion":14504,"completion":14504,"start":14540,"enrollment":120,"conditions":42393,"interventions":42394},[87],[14156],[14039,21728,21729,21730,21731,21732,21733,21734],{"nctId":21736,"briefTitle":21737,"status":105,"phases":42396,"primaryCompletion":21739,"completion":21740,"start":21739,"enrollment":1054,"conditions":42397,"interventions":42398},[87],[14156],[14039,21743,21729,21744,21731,21733],{"trials":42400,"activeCount":99},[],{"trials":42402,"activeCount":99},[],{"trials":42404,"activeCount":99},[],{"trials":42406,"activeCount":99},[],{"intervention":42408,"totalTrials":3197,"cells":42409},"MK-4334",{"EARLY_PHASE1":42410,"PHASE1":42412,"PHASE2":42431,"PHASE3":42433,"PHASE4":42435,"NA":42437},{"trials":42411,"activeCount":99},[],{"trials":42413,"activeCount":99},[42414,42422],{"nctId":42415,"briefTitle":42416,"status":1040,"phases":42417,"primaryCompletion":2634,"completion":2634,"start":42418,"enrollment":99,"conditions":42419,"interventions":42420},"NCT03740178","Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)",[87],"2019-09-27",[11174,33202],[42408,42421],"Donepepzil",{"nctId":42423,"briefTitle":42424,"status":105,"phases":42425,"primaryCompletion":19963,"completion":19168,"start":42426,"enrollment":312,"conditions":42427,"interventions":42429},"NCT05136690","Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)",[87],"2022-04-27",[42428],"Cognitive Impairment Associated With Schizophrenia",[42430,42408],"Nicotine patch",{"trials":42432,"activeCount":99},[],{"trials":42434,"activeCount":99},[],{"trials":42436,"activeCount":99},[],{"trials":42438,"activeCount":99},[],{"intervention":42440,"totalTrials":3197,"cells":42441},"Vaniprevir 300 mg",{"EARLY_PHASE1":42442,"PHASE1":42444,"PHASE2":42466,"PHASE3":42468,"PHASE4":42470,"NA":42472},{"trials":42443,"activeCount":99},[],{"trials":42445,"activeCount":99},[42446,42457],{"nctId":42447,"briefTitle":42448,"status":105,"phases":42449,"primaryCompletion":42450,"completion":42451,"start":42452,"enrollment":4741,"conditions":42453,"interventions":42454},"NCT01678131","Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)",[87],"2013-08-27","2013-09-02","2012-10-30",[12957],[42455,42456,14925,42440],"Vaniprevir 600 mg","Peg-IFN alfa-2b",{"nctId":42458,"briefTitle":42459,"status":105,"phases":42460,"primaryCompletion":19365,"completion":42461,"start":42462,"enrollment":558,"conditions":42463,"interventions":42464},"NCT01010906","A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005)",[87],"2010-06-21","2009-07-01",[24],[42440,42465],"Vaniprevir 200 mg",{"trials":42467,"activeCount":99},[],{"trials":42469,"activeCount":99},[],{"trials":42471,"activeCount":99},[],{"trials":42473,"activeCount":99},[],{"intervention":42475,"totalTrials":3197,"cells":42476},"MK-8189",{"EARLY_PHASE1":42477,"PHASE1":42479,"PHASE2":42497,"PHASE3":42499,"PHASE4":42501,"NA":42503},{"trials":42478,"activeCount":99},[],{"trials":42480,"activeCount":99},[42481,42489],{"nctId":42482,"briefTitle":42483,"status":105,"phases":42484,"primaryCompletion":2042,"completion":2042,"start":42485,"enrollment":3496,"conditions":42486,"interventions":42487},"NCT05953740","A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)",[87],"2023-09-15",[14715],[42488,42475],"MK-5720",{"nctId":42490,"briefTitle":42491,"status":105,"phases":42492,"primaryCompletion":19143,"completion":19143,"start":42493,"enrollment":613,"conditions":42494,"interventions":42495},"NCT03565068","A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)",[87],"2018-06-20",[14715],[42475,42496],"Background AAP Therapy",{"trials":42498,"activeCount":99},[],{"trials":42500,"activeCount":99},[],{"trials":42502,"activeCount":99},[],{"trials":42504,"activeCount":99},[],{"intervention":4114,"totalTrials":3197,"cells":42506},{"EARLY_PHASE1":42507,"PHASE1":42509,"PHASE2":42519,"PHASE3":42521,"PHASE4":42523,"NA":42525},{"trials":42508,"activeCount":99},[],{"trials":42510,"activeCount":99},[42511,42515],{"nctId":5598,"briefTitle":5599,"status":105,"phases":42512,"primaryCompletion":5601,"completion":5601,"start":2266,"enrollment":1624,"conditions":42513,"interventions":42514},[87],[18],[602,5604,4114],{"nctId":4108,"briefTitle":4109,"status":105,"phases":42516,"primaryCompletion":2321,"completion":4111,"start":2286,"enrollment":4071,"conditions":42517,"interventions":42518},[87],[18],[56,4114],{"trials":42520,"activeCount":99},[],{"trials":42522,"activeCount":99},[],{"trials":42524,"activeCount":99},[],{"trials":42526,"activeCount":99},[],{"intervention":42528,"totalTrials":3197,"cells":42529},"Comparator: Treatment B",{"EARLY_PHASE1":42530,"PHASE1":42532,"PHASE2":42548,"PHASE3":42550,"PHASE4":42552,"NA":42554},{"trials":42531,"activeCount":99},[],{"trials":42533,"activeCount":99},[42534,42541],{"nctId":42535,"briefTitle":42536,"status":105,"phases":42537,"primaryCompletion":8620,"completion":14408,"start":5281,"enrollment":95,"conditions":42538,"interventions":42539},"NCT01021527","A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED)",[87],[18],[42528,42540],"Comparator: Treatment C",{"nctId":42542,"briefTitle":42543,"status":105,"phases":42544,"primaryCompletion":14875,"completion":18807,"start":20173,"enrollment":95,"conditions":42545,"interventions":42546},"NCT00971633","A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)",[87],[5150],[42547,42528,42540],"Comparator: Treatment A",{"trials":42549,"activeCount":99},[],{"trials":42551,"activeCount":99},[],{"trials":42553,"activeCount":99},[],{"trials":42555,"activeCount":99},[],{"intervention":42540,"totalTrials":3197,"cells":42557},{"EARLY_PHASE1":42558,"PHASE1":42560,"PHASE2":42570,"PHASE3":42572,"PHASE4":42574,"NA":42576},{"trials":42559,"activeCount":99},[],{"trials":42561,"activeCount":99},[42562,42566],{"nctId":42535,"briefTitle":42536,"status":105,"phases":42563,"primaryCompletion":8620,"completion":14408,"start":5281,"enrollment":95,"conditions":42564,"interventions":42565},[87],[18],[42528,42540],{"nctId":42542,"briefTitle":42543,"status":105,"phases":42567,"primaryCompletion":14875,"completion":18807,"start":20173,"enrollment":95,"conditions":42568,"interventions":42569},[87],[5150],[42547,42528,42540],{"trials":42571,"activeCount":99},[],{"trials":42573,"activeCount":99},[],{"trials":42575,"activeCount":99},[],{"trials":42577,"activeCount":99},[],{"intervention":42579,"totalTrials":3197,"cells":42580},"Oxyntomodulin",{"EARLY_PHASE1":42581,"PHASE1":42583,"PHASE2":42601,"PHASE3":42603,"PHASE4":42605,"NA":42607},{"trials":42582,"activeCount":99},[],{"trials":42584,"activeCount":99},[42585,42593],{"nctId":42586,"briefTitle":42587,"status":105,"phases":42588,"primaryCompletion":7018,"completion":7018,"start":5800,"enrollment":95,"conditions":42589,"interventions":42590},"NCT01373450","Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)",[87],[15],[42579,42591,42592],"Liraglutide 0.6 mg","Liraglutide 1.2 mg",{"nctId":42594,"briefTitle":42595,"status":105,"phases":42596,"primaryCompletion":14494,"completion":12813,"start":4990,"enrollment":95,"conditions":42597,"interventions":42598},"NCT01055340","A Study That Will Evaluate Ketogenesis and Glucose-Dependent Insulin Secretion Methodologies in Healthy Male Subjects (MK-0000-159)(COMPLETED)",[87],[15158],[42579,42599,42600],"Comparator: Oxyntomodulin","Comparator: Placebo [ hemaccel-containing saline]",{"trials":42602,"activeCount":99},[],{"trials":42604,"activeCount":99},[],{"trials":42606,"activeCount":99},[],{"trials":42608,"activeCount":99},[],{"intervention":33456,"totalTrials":3197,"cells":42610},{"EARLY_PHASE1":42611,"PHASE1":42613,"PHASE2":42627,"PHASE3":42629,"PHASE4":42631,"NA":42633},{"trials":42612,"activeCount":99},[],{"trials":42614,"activeCount":99},[42615,42619],{"nctId":33448,"briefTitle":33449,"status":105,"phases":42616,"primaryCompletion":33451,"completion":33451,"start":33452,"enrollment":805,"conditions":42617,"interventions":42618},[87],[33454],[33456,33441],{"nctId":42620,"briefTitle":42621,"status":105,"phases":42622,"primaryCompletion":42623,"completion":42623,"start":42624,"enrollment":3655,"conditions":42625,"interventions":42626},"NCT02549014","A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)",[87],"2009-09-29","2009-07-06",[539],[33456],{"trials":42628,"activeCount":99},[],{"trials":42630,"activeCount":99},[],{"trials":42632,"activeCount":99},[],{"trials":42634,"activeCount":99},[],{"intervention":42636,"totalTrials":3197,"cells":42637},"MK-1006",{"EARLY_PHASE1":42638,"PHASE1":42640,"PHASE2":42654,"PHASE3":42656,"PHASE4":42658,"NA":42660},{"trials":42639,"activeCount":99},[],{"trials":42641,"activeCount":99},[42642,42648],{"nctId":42643,"briefTitle":42644,"status":105,"phases":42645,"primaryCompletion":14314,"completion":14314,"start":14823,"enrollment":120,"conditions":42646,"interventions":42647},"NCT00791661","MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)",[87],[15023],[42636],{"nctId":42649,"briefTitle":42650,"status":150,"phases":42651,"primaryCompletion":13224,"completion":13224,"start":13102,"enrollment":2288,"conditions":42652,"interventions":42653},"NCT00758680","A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED)",[87],[14156],[42636],{"trials":42655,"activeCount":99},[],{"trials":42657,"activeCount":99},[],{"trials":42659,"activeCount":99},[],{"trials":42661,"activeCount":99},[],{"intervention":12946,"totalTrials":3197,"cells":42663},{"EARLY_PHASE1":42664,"PHASE1":42666,"PHASE2":42679,"PHASE3":42681,"PHASE4":42683,"NA":42685},{"trials":42665,"activeCount":99},[],{"trials":42667,"activeCount":99},[42668,42675],{"nctId":42669,"briefTitle":42670,"status":105,"phases":42671,"primaryCompletion":2583,"completion":2583,"start":42672,"enrollment":3655,"conditions":42673,"interventions":42674},"NCT06647628","A Clinical Study of MK-1708 in Healthy Elderly Participants (MK-1708-005)",[87],"2024-11-04",[18],[12946],{"nctId":12940,"briefTitle":12941,"status":105,"phases":42676,"primaryCompletion":11799,"completion":11799,"start":12943,"enrollment":95,"conditions":42677,"interventions":42678},[87],[11174],[12946,5604],{"trials":42680,"activeCount":99},[],{"trials":42682,"activeCount":99},[],{"trials":42684,"activeCount":99},[],{"trials":42686,"activeCount":99},[],{"intervention":14570,"totalTrials":3197,"cells":42688},{"EARLY_PHASE1":42689,"PHASE1":42691,"PHASE2":42704,"PHASE3":42706,"PHASE4":42708,"NA":42710},{"trials":42690,"activeCount":99},[],{"trials":42692,"activeCount":99},[42693,42697],{"nctId":14563,"briefTitle":14564,"status":105,"phases":42694,"primaryCompletion":8619,"completion":14566,"start":14567,"enrollment":4273,"conditions":42695,"interventions":42696},[87],[11444,27],[14570,14571,14571,13864],{"nctId":42698,"briefTitle":42699,"status":105,"phases":42700,"primaryCompletion":5280,"completion":5280,"start":15118,"enrollment":688,"conditions":42701,"interventions":42702},"NCT00894114","A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)",[87],[7639],[14570,42703],"Comparator: ALVAC-HIV vaccine",{"trials":42705,"activeCount":99},[],{"trials":42707,"activeCount":99},[],{"trials":42709,"activeCount":99},[],{"trials":42711,"activeCount":99},[],{"intervention":42713,"totalTrials":3197,"cells":42714},"[18F]MK-3328",{"EARLY_PHASE1":42715,"PHASE1":42717,"PHASE2":42732,"PHASE3":42734,"PHASE4":42736,"NA":42738},{"trials":42716,"activeCount":99},[],{"trials":42718,"activeCount":99},[42719,42726],{"nctId":42720,"briefTitle":42721,"status":150,"phases":42722,"primaryCompletion":42723,"completion":42723,"start":5478,"enrollment":805,"conditions":42724,"interventions":42725},"NCT01385033","[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)",[87],"2012-05-15",[11174],[42713],{"nctId":42727,"briefTitle":42728,"status":105,"phases":42729,"primaryCompletion":5981,"completion":5981,"start":20608,"enrollment":569,"conditions":42730,"interventions":42731},"NCT00954538","Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)",[87],[11174],[42713],{"trials":42733,"activeCount":99},[],{"trials":42735,"activeCount":99},[],{"trials":42737,"activeCount":99},[],{"trials":42739,"activeCount":99},[],{"intervention":5481,"totalTrials":3197,"cells":42741},{"EARLY_PHASE1":42742,"PHASE1":42744,"PHASE2":42754,"PHASE3":42756,"PHASE4":42758,"NA":42760},{"trials":42743,"activeCount":99},[],{"trials":42745,"activeCount":99},[42746,42750],{"nctId":5474,"briefTitle":5475,"status":150,"phases":42747,"primaryCompletion":5477,"completion":5477,"start":5478,"enrollment":357,"conditions":42748,"interventions":42749},[87],[677],[5481,1458,1459,5482],{"nctId":7014,"briefTitle":7015,"status":150,"phases":42751,"primaryCompletion":7017,"completion":7017,"start":7018,"enrollment":920,"conditions":42752,"interventions":42753},[87],[7020],[5481,7022,2100,7023,4388,979,7024],{"trials":42755,"activeCount":99},[],{"trials":42757,"activeCount":99},[],{"trials":42759,"activeCount":99},[],{"trials":42761,"activeCount":99},[],{"intervention":8140,"totalTrials":224,"cells":42763},{"EARLY_PHASE1":42764,"PHASE1":42766,"PHASE2":42772,"PHASE3":42774,"PHASE4":42776,"NA":42778},{"trials":42765,"activeCount":99},[],{"trials":42767,"activeCount":99},[42768],{"nctId":8133,"briefTitle":8134,"status":105,"phases":42769,"primaryCompletion":8136,"completion":8136,"start":8137,"enrollment":5616,"conditions":42770,"interventions":42771},[87],[290,369],[8140,8141,8142,8143,8144,8145,8146,8147],{"trials":42773,"activeCount":99},[],{"trials":42775,"activeCount":99},[],{"trials":42777,"activeCount":99},[],{"trials":42779,"activeCount":99},[],{"intervention":8141,"totalTrials":224,"cells":42781},{"EARLY_PHASE1":42782,"PHASE1":42784,"PHASE2":42790,"PHASE3":42792,"PHASE4":42794,"NA":42796},{"trials":42783,"activeCount":99},[],{"trials":42785,"activeCount":99},[42786],{"nctId":8133,"briefTitle":8134,"status":105,"phases":42787,"primaryCompletion":8136,"completion":8136,"start":8137,"enrollment":5616,"conditions":42788,"interventions":42789},[87],[290,369],[8140,8141,8142,8143,8144,8145,8146,8147],{"trials":42791,"activeCount":99},[],{"trials":42793,"activeCount":99},[],{"trials":42795,"activeCount":99},[],{"trials":42797,"activeCount":99},[],{"intervention":8144,"totalTrials":224,"cells":42799},{"EARLY_PHASE1":42800,"PHASE1":42802,"PHASE2":42808,"PHASE3":42810,"PHASE4":42812,"NA":42814},{"trials":42801,"activeCount":99},[],{"trials":42803,"activeCount":99},[42804],{"nctId":8133,"briefTitle":8134,"status":105,"phases":42805,"primaryCompletion":8136,"completion":8136,"start":8137,"enrollment":5616,"conditions":42806,"interventions":42807},[87],[290,369],[8140,8141,8142,8143,8144,8145,8146,8147],{"trials":42809,"activeCount":99},[],{"trials":42811,"activeCount":99},[],{"trials":42813,"activeCount":99},[],{"trials":42815,"activeCount":99},[],{"intervention":8147,"totalTrials":224,"cells":42817},{"EARLY_PHASE1":42818,"PHASE1":42820,"PHASE2":42826,"PHASE3":42828,"PHASE4":42830,"NA":42832},{"trials":42819,"activeCount":99},[],{"trials":42821,"activeCount":99},[42822],{"nctId":8133,"briefTitle":8134,"status":105,"phases":42823,"primaryCompletion":8136,"completion":8136,"start":8137,"enrollment":5616,"conditions":42824,"interventions":42825},[87],[290,369],[8140,8141,8142,8143,8144,8145,8146,8147],{"trials":42827,"activeCount":99},[],{"trials":42829,"activeCount":99},[],{"trials":42831,"activeCount":99},[],{"trials":42833,"activeCount":99},[],{"intervention":42835,"totalTrials":224,"cells":42836},"MK-8655",{"EARLY_PHASE1":42837,"PHASE1":42839,"PHASE2":42848,"PHASE3":42850,"PHASE4":42852,"NA":42854},{"trials":42838,"activeCount":99},[],{"trials":42840,"activeCount":99},[42841],{"nctId":42842,"briefTitle":42843,"status":105,"phases":42844,"primaryCompletion":24874,"completion":24874,"start":42845,"enrollment":444,"conditions":42846,"interventions":42847},"NCT01640873","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)",[87],"2012-09-19",[14156],[42835],{"trials":42849,"activeCount":99},[],{"trials":42851,"activeCount":99},[],{"trials":42853,"activeCount":99},[],{"trials":42855,"activeCount":99},[],{"intervention":42857,"totalTrials":224,"cells":42858},"MK-4482",{"EARLY_PHASE1":42859,"PHASE1":42861,"PHASE2":42871,"PHASE3":42873,"PHASE4":42875,"NA":42877},{"trials":42860,"activeCount":99},[],{"trials":42862,"activeCount":99},[42863],{"nctId":42864,"briefTitle":42865,"status":105,"phases":42866,"primaryCompletion":42867,"completion":42867,"start":42868,"enrollment":3655,"conditions":42869,"interventions":42870},"NCT06816030","A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009)",[87],"2023-08-05","2023-06-28",[18],[42857],{"trials":42872,"activeCount":99},[],{"trials":42874,"activeCount":99},[],{"trials":42876,"activeCount":99},[],{"trials":42878,"activeCount":99},[],{"intervention":41786,"totalTrials":224,"cells":42880},{"EARLY_PHASE1":42881,"PHASE1":42883,"PHASE2":42889,"PHASE3":42891,"PHASE4":42893,"NA":42895},{"trials":42882,"activeCount":99},[],{"trials":42884,"activeCount":99},[42885],{"nctId":41779,"briefTitle":41780,"status":105,"phases":42886,"primaryCompletion":41782,"completion":41782,"start":2257,"enrollment":3655,"conditions":42887,"interventions":42888},[87],[41784],[41772,41786,41787,41788,41789],{"trials":42890,"activeCount":99},[],{"trials":42892,"activeCount":99},[],{"trials":42894,"activeCount":99},[],{"trials":42896,"activeCount":99},[],{"intervention":41787,"totalTrials":224,"cells":42898},{"EARLY_PHASE1":42899,"PHASE1":42901,"PHASE2":42907,"PHASE3":42909,"PHASE4":42911,"NA":42913},{"trials":42900,"activeCount":99},[],{"trials":42902,"activeCount":99},[42903],{"nctId":41779,"briefTitle":41780,"status":105,"phases":42904,"primaryCompletion":41782,"completion":41782,"start":2257,"enrollment":3655,"conditions":42905,"interventions":42906},[87],[41784],[41772,41786,41787,41788,41789],{"trials":42908,"activeCount":99},[],{"trials":42910,"activeCount":99},[],{"trials":42912,"activeCount":99},[],{"trials":42914,"activeCount":99},[],{"intervention":41788,"totalTrials":224,"cells":42916},{"EARLY_PHASE1":42917,"PHASE1":42919,"PHASE2":42925,"PHASE3":42927,"PHASE4":42929,"NA":42931},{"trials":42918,"activeCount":99},[],{"trials":42920,"activeCount":99},[42921],{"nctId":41779,"briefTitle":41780,"status":105,"phases":42922,"primaryCompletion":41782,"completion":41782,"start":2257,"enrollment":3655,"conditions":42923,"interventions":42924},[87],[41784],[41772,41786,41787,41788,41789],{"trials":42926,"activeCount":99},[],{"trials":42928,"activeCount":99},[],{"trials":42930,"activeCount":99},[],{"trials":42932,"activeCount":99},[],{"intervention":41789,"totalTrials":224,"cells":42934},{"EARLY_PHASE1":42935,"PHASE1":42937,"PHASE2":42943,"PHASE3":42945,"PHASE4":42947,"NA":42949},{"trials":42936,"activeCount":99},[],{"trials":42938,"activeCount":99},[42939],{"nctId":41779,"briefTitle":41780,"status":105,"phases":42940,"primaryCompletion":41782,"completion":41782,"start":2257,"enrollment":3655,"conditions":42941,"interventions":42942},[87],[41784],[41772,41786,41787,41788,41789],{"trials":42944,"activeCount":99},[],{"trials":42946,"activeCount":99},[],{"trials":42948,"activeCount":99},[],{"trials":42950,"activeCount":99},[],{"intervention":42952,"totalTrials":224,"cells":42953},"Isoglycemic Clamp",{"EARLY_PHASE1":42954,"PHASE1":42956,"PHASE2":42966,"PHASE3":42968,"PHASE4":42970,"NA":42972},{"trials":42955,"activeCount":99},[],{"trials":42957,"activeCount":99},[42958],{"nctId":42959,"briefTitle":42960,"status":105,"phases":42961,"primaryCompletion":15845,"completion":15845,"start":5982,"enrollment":8016,"conditions":42962,"interventions":42964},"NCT01152242","Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin (0000-168)",[87],[42963],"Diabetes",[42952,42965],"Comparator: insulin glargine",{"trials":42967,"activeCount":99},[],{"trials":42969,"activeCount":99},[],{"trials":42971,"activeCount":99},[],{"trials":42973,"activeCount":99},[],{"intervention":42965,"totalTrials":224,"cells":42975},{"EARLY_PHASE1":42976,"PHASE1":42978,"PHASE2":42984,"PHASE3":42986,"PHASE4":42988,"NA":42990},{"trials":42977,"activeCount":99},[],{"trials":42979,"activeCount":99},[42980],{"nctId":42959,"briefTitle":42960,"status":105,"phases":42981,"primaryCompletion":15845,"completion":15845,"start":5982,"enrollment":8016,"conditions":42982,"interventions":42983},[87],[42963],[42952,42965],{"trials":42985,"activeCount":99},[],{"trials":42987,"activeCount":99},[],{"trials":42989,"activeCount":99},[],{"trials":42991,"activeCount":99},[],{"intervention":14319,"totalTrials":224,"cells":42993},{"EARLY_PHASE1":42994,"PHASE1":42996,"PHASE2":43002,"PHASE3":43004,"PHASE4":43006,"NA":43008},{"trials":42995,"activeCount":99},[],{"trials":42997,"activeCount":99},[42998],{"nctId":14310,"briefTitle":14311,"status":105,"phases":42999,"primaryCompletion":14313,"completion":14314,"start":14315,"enrollment":36,"conditions":43000,"interventions":43001},[87],[14317],[14319,14319,13864],{"trials":43003,"activeCount":99},[],{"trials":43005,"activeCount":99},[],{"trials":43007,"activeCount":99},[],{"trials":43009,"activeCount":99},[],{"intervention":43011,"totalTrials":224,"cells":43012},"MK-2248",{"EARLY_PHASE1":43013,"PHASE1":43015,"PHASE2":43023,"PHASE3":43025,"PHASE4":43027,"NA":43029},{"trials":43014,"activeCount":99},[],{"trials":43016,"activeCount":99},[43017],{"nctId":43018,"briefTitle":43019,"status":105,"phases":43020,"primaryCompletion":15948,"completion":20431,"start":24148,"enrollment":5563,"conditions":43021,"interventions":43022},"NCT02161510","Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002)",[87],[24],[43011],{"trials":43024,"activeCount":99},[],{"trials":43026,"activeCount":99},[],{"trials":43028,"activeCount":99},[],{"trials":43030,"activeCount":99},[],{"intervention":43032,"totalTrials":224,"cells":43033},"MK-8226 BID, 1 mg",{"EARLY_PHASE1":43034,"PHASE1":43036,"PHASE2":43048,"PHASE3":43050,"PHASE4":43052,"NA":43054},{"trials":43035,"activeCount":99},[],{"trials":43037,"activeCount":99},[43038],{"nctId":43039,"briefTitle":43040,"status":105,"phases":43041,"primaryCompletion":43042,"completion":43042,"start":14214,"enrollment":3390,"conditions":43043,"interventions":43044},"NCT01096160","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 in Hypertensive Men (MK-8266-002)",[87],"2010-11-01",[30],[43032,43045,43046,43047,43047],"MK-8266 BID, 1.8 mg","MK-8266 TID, 1.8 mg","MK-8266 TID, 2.4 mg",{"trials":43049,"activeCount":99},[],{"trials":43051,"activeCount":99},[],{"trials":43053,"activeCount":99},[],{"trials":43055,"activeCount":99},[],{"intervention":43045,"totalTrials":224,"cells":43057},{"EARLY_PHASE1":43058,"PHASE1":43060,"PHASE2":43066,"PHASE3":43068,"PHASE4":43070,"NA":43072},{"trials":43059,"activeCount":99},[],{"trials":43061,"activeCount":99},[43062],{"nctId":43039,"briefTitle":43040,"status":105,"phases":43063,"primaryCompletion":43042,"completion":43042,"start":14214,"enrollment":3390,"conditions":43064,"interventions":43065},[87],[30],[43032,43045,43046,43047,43047],{"trials":43067,"activeCount":99},[],{"trials":43069,"activeCount":99},[],{"trials":43071,"activeCount":99},[],{"trials":43073,"activeCount":99},[],{"intervention":43046,"totalTrials":224,"cells":43075},{"EARLY_PHASE1":43076,"PHASE1":43078,"PHASE2":43084,"PHASE3":43086,"PHASE4":43088,"NA":43090},{"trials":43077,"activeCount":99},[],{"trials":43079,"activeCount":99},[43080],{"nctId":43039,"briefTitle":43040,"status":105,"phases":43081,"primaryCompletion":43042,"completion":43042,"start":14214,"enrollment":3390,"conditions":43082,"interventions":43083},[87],[30],[43032,43045,43046,43047,43047],{"trials":43085,"activeCount":99},[],{"trials":43087,"activeCount":99},[],{"trials":43089,"activeCount":99},[],{"trials":43091,"activeCount":99},[],{"intervention":43047,"totalTrials":224,"cells":43093},{"EARLY_PHASE1":43094,"PHASE1":43096,"PHASE2":43102,"PHASE3":43104,"PHASE4":43106,"NA":43108},{"trials":43095,"activeCount":99},[],{"trials":43097,"activeCount":99},[43098],{"nctId":43039,"briefTitle":43040,"status":105,"phases":43099,"primaryCompletion":43042,"completion":43042,"start":14214,"enrollment":3390,"conditions":43100,"interventions":43101},[87],[30],[43032,43045,43046,43047,43047],{"trials":43103,"activeCount":99},[],{"trials":43105,"activeCount":99},[],{"trials":43107,"activeCount":99},[],{"trials":43109,"activeCount":99},[],{"intervention":33506,"totalTrials":224,"cells":43111},{"EARLY_PHASE1":43112,"PHASE1":43114,"PHASE2":43120,"PHASE3":43122,"PHASE4":43124,"NA":43126},{"trials":43113,"activeCount":99},[],{"trials":43115,"activeCount":99},[43116],{"nctId":33500,"briefTitle":33501,"status":150,"phases":43117,"primaryCompletion":14504,"completion":14504,"start":14540,"enrollment":202,"conditions":43118,"interventions":43119},[87],[24421,33504],[33493,33506],{"trials":43121,"activeCount":99},[],{"trials":43123,"activeCount":99},[],{"trials":43125,"activeCount":99},[],{"trials":43127,"activeCount":99},[],{"intervention":43129,"totalTrials":224,"cells":43130},"MK-8291",{"EARLY_PHASE1":43131,"PHASE1":43133,"PHASE2":43144,"PHASE3":43146,"PHASE4":43148,"NA":43150},{"trials":43132,"activeCount":99},[],{"trials":43134,"activeCount":99},[43135],{"nctId":43136,"briefTitle":43137,"status":105,"phases":43138,"primaryCompletion":43139,"completion":43139,"start":43140,"enrollment":3903,"conditions":43141,"interventions":43143},"NCT02336555","The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)",[87],"2016-02-29","2015-03-12",[43142],"Postherpetic Neuralgia",[43129],{"trials":43145,"activeCount":99},[],{"trials":43147,"activeCount":99},[],{"trials":43149,"activeCount":99},[],{"trials":43151,"activeCount":99},[],{"intervention":43153,"totalTrials":224,"cells":43154},"MK-8558",{"EARLY_PHASE1":43155,"PHASE1":43157,"PHASE2":43167,"PHASE3":43169,"PHASE4":43171,"NA":43173},{"trials":43156,"activeCount":99},[],{"trials":43158,"activeCount":99},[43159],{"nctId":43160,"briefTitle":43161,"status":105,"phases":43162,"primaryCompletion":43163,"completion":43163,"start":43164,"enrollment":4242,"conditions":43165,"interventions":43166},"NCT03859739","Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)",[87],"2020-05-29","2019-04-26",[7639],[43153],{"trials":43168,"activeCount":99},[],{"trials":43170,"activeCount":99},[],{"trials":43172,"activeCount":99},[],{"trials":43174,"activeCount":99},[],{"intervention":43176,"totalTrials":224,"cells":43177},"Comparator: sibutramine",{"EARLY_PHASE1":43178,"PHASE1":43180,"PHASE2":43188,"PHASE3":43190,"PHASE4":43192,"NA":43194},{"trials":43179,"activeCount":99},[],{"trials":43181,"activeCount":99},[43182],{"nctId":43183,"briefTitle":43184,"status":105,"phases":43185,"primaryCompletion":20608,"completion":20608,"start":14352,"enrollment":2901,"conditions":43186,"interventions":43187},"NCT00914212","A Functional Magnetic Resonance Imaging (fMRI) Study in Overweight and Obese Men (0000-103)",[87],[15158],[43176],{"trials":43189,"activeCount":99},[],{"trials":43191,"activeCount":99},[],{"trials":43193,"activeCount":99},[],{"trials":43195,"activeCount":99},[],{"intervention":20102,"totalTrials":224,"cells":43197},{"EARLY_PHASE1":43198,"PHASE1":43200,"PHASE2":43206,"PHASE3":43208,"PHASE4":43210,"NA":43212},{"trials":43199,"activeCount":99},[],{"trials":43201,"activeCount":99},[43202],{"nctId":20096,"briefTitle":20097,"status":105,"phases":43203,"primaryCompletion":13222,"completion":13222,"start":14494,"enrollment":3903,"conditions":43204,"interventions":43205},[87],[18,20100,15158],[14234,20102],{"trials":43207,"activeCount":99},[],{"trials":43209,"activeCount":99},[],{"trials":43211,"activeCount":99},[],{"trials":43213,"activeCount":99},[],{"intervention":14328,"totalTrials":224,"cells":43215},{"EARLY_PHASE1":43216,"PHASE1":43218,"PHASE2":43224,"PHASE3":43226,"PHASE4":43228,"NA":43230},{"trials":43217,"activeCount":99},[],{"trials":43219,"activeCount":99},[43220],{"nctId":14321,"briefTitle":14322,"status":105,"phases":43221,"primaryCompletion":13102,"completion":13102,"start":14324,"enrollment":14325,"conditions":43222,"interventions":43223},[87],[18],[14328,14329,14330,14331],{"trials":43225,"activeCount":99},[],{"trials":43227,"activeCount":99},[],{"trials":43229,"activeCount":99},[],{"trials":43231,"activeCount":99},[],{"intervention":14329,"totalTrials":224,"cells":43233},{"EARLY_PHASE1":43234,"PHASE1":43236,"PHASE2":43242,"PHASE3":43244,"PHASE4":43246,"NA":43248},{"trials":43235,"activeCount":99},[],{"trials":43237,"activeCount":99},[43238],{"nctId":14321,"briefTitle":14322,"status":105,"phases":43239,"primaryCompletion":13102,"completion":13102,"start":14324,"enrollment":14325,"conditions":43240,"interventions":43241},[87],[18],[14328,14329,14330,14331],{"trials":43243,"activeCount":99},[],{"trials":43245,"activeCount":99},[],{"trials":43247,"activeCount":99},[],{"trials":43249,"activeCount":99},[],{"intervention":41897,"totalTrials":224,"cells":43251},{"EARLY_PHASE1":43252,"PHASE1":43254,"PHASE2":43260,"PHASE3":43262,"PHASE4":43264,"NA":43266},{"trials":43253,"activeCount":99},[],{"trials":43255,"activeCount":99},[43256],{"nctId":41892,"briefTitle":41893,"status":105,"phases":43257,"primaryCompletion":14314,"completion":14314,"start":14313,"enrollment":184,"conditions":43258,"interventions":43259},[87],[5150],[41885,41897,41898,41899],{"trials":43261,"activeCount":99},[],{"trials":43263,"activeCount":99},[],{"trials":43265,"activeCount":99},[],{"trials":43267,"activeCount":99},[],{"intervention":41898,"totalTrials":224,"cells":43269},{"EARLY_PHASE1":43270,"PHASE1":43272,"PHASE2":43278,"PHASE3":43280,"PHASE4":43282,"NA":43284},{"trials":43271,"activeCount":99},[],{"trials":43273,"activeCount":99},[43274],{"nctId":41892,"briefTitle":41893,"status":105,"phases":43275,"primaryCompletion":14314,"completion":14314,"start":14313,"enrollment":184,"conditions":43276,"interventions":43277},[87],[5150],[41885,41897,41898,41899],{"trials":43279,"activeCount":99},[],{"trials":43281,"activeCount":99},[],{"trials":43283,"activeCount":99},[],{"trials":43285,"activeCount":99},[],{"intervention":41899,"totalTrials":224,"cells":43287},{"EARLY_PHASE1":43288,"PHASE1":43290,"PHASE2":43296,"PHASE3":43298,"PHASE4":43300,"NA":43302},{"trials":43289,"activeCount":99},[],{"trials":43291,"activeCount":99},[43292],{"nctId":41892,"briefTitle":41893,"status":105,"phases":43293,"primaryCompletion":14314,"completion":14314,"start":14313,"enrollment":184,"conditions":43294,"interventions":43295},[87],[5150],[41885,41897,41898,41899],{"trials":43297,"activeCount":99},[],{"trials":43299,"activeCount":99},[],{"trials":43301,"activeCount":99},[],{"trials":43303,"activeCount":99},[],{"intervention":292,"totalTrials":224,"cells":43305},{"EARLY_PHASE1":43306,"PHASE1":43308,"PHASE2":43314,"PHASE3":43316,"PHASE4":43318,"NA":43320},{"trials":43307,"activeCount":99},[],{"trials":43309,"activeCount":99},[43310],{"nctId":282,"briefTitle":283,"status":105,"phases":43311,"primaryCompletion":285,"completion":285,"start":286,"enrollment":287,"conditions":43312,"interventions":43313},[87],[289,290],[292,47,293],{"trials":43315,"activeCount":99},[],{"trials":43317,"activeCount":99},[],{"trials":43319,"activeCount":99},[],{"trials":43321,"activeCount":99},[],{"intervention":293,"totalTrials":224,"cells":43323},{"EARLY_PHASE1":43324,"PHASE1":43326,"PHASE2":43332,"PHASE3":43334,"PHASE4":43336,"NA":43338},{"trials":43325,"activeCount":99},[],{"trials":43327,"activeCount":99},[43328],{"nctId":282,"briefTitle":283,"status":105,"phases":43329,"primaryCompletion":285,"completion":285,"start":286,"enrollment":287,"conditions":43330,"interventions":43331},[87],[289,290],[292,47,293],{"trials":43333,"activeCount":99},[],{"trials":43335,"activeCount":99},[],{"trials":43337,"activeCount":99},[],{"trials":43339,"activeCount":99},[],{"intervention":8019,"totalTrials":224,"cells":43341},{"EARLY_PHASE1":43342,"PHASE1":43344,"PHASE2":43350,"PHASE3":43352,"PHASE4":43354,"NA":43356},{"trials":43343,"activeCount":99},[],{"trials":43345,"activeCount":99},[43346],{"nctId":8013,"briefTitle":8014,"status":105,"phases":43347,"primaryCompletion":73,"completion":73,"start":4069,"enrollment":8016,"conditions":43348,"interventions":43349},[87],[18],[8019,7998,8020],{"trials":43351,"activeCount":99},[],{"trials":43353,"activeCount":99},[],{"trials":43355,"activeCount":99},[],{"trials":43357,"activeCount":99},[],{"intervention":8020,"totalTrials":224,"cells":43359},{"EARLY_PHASE1":43360,"PHASE1":43362,"PHASE2":43368,"PHASE3":43370,"PHASE4":43372,"NA":43374},{"trials":43361,"activeCount":99},[],{"trials":43363,"activeCount":99},[43364],{"nctId":8013,"briefTitle":8014,"status":105,"phases":43365,"primaryCompletion":73,"completion":73,"start":4069,"enrollment":8016,"conditions":43366,"interventions":43367},[87],[18],[8019,7998,8020],{"trials":43369,"activeCount":99},[],{"trials":43371,"activeCount":99},[],{"trials":43373,"activeCount":99},[],{"trials":43375,"activeCount":99},[],{"intervention":43377,"totalTrials":224,"cells":43378},"[14C]Ulonivirine",{"EARLY_PHASE1":43379,"PHASE1":43381,"PHASE2":43390,"PHASE3":43392,"PHASE4":43394,"NA":43396},{"trials":43380,"activeCount":99},[],{"trials":43382,"activeCount":99},[43383],{"nctId":43384,"briefTitle":43385,"status":105,"phases":43386,"primaryCompletion":107,"completion":107,"start":43387,"enrollment":734,"conditions":43388,"interventions":43389},"NCT07334886","A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006)",[87],"2025-09-17",[18],[43377],{"trials":43391,"activeCount":99},[],{"trials":43393,"activeCount":99},[],{"trials":43395,"activeCount":99},[],{"trials":43397,"activeCount":99},[],{"intervention":13273,"totalTrials":224,"cells":43399},{"EARLY_PHASE1":43400,"PHASE1":43402,"PHASE2":43408,"PHASE3":43410,"PHASE4":43412,"NA":43414},{"trials":43401,"activeCount":99},[],{"trials":43403,"activeCount":99},[43404],{"nctId":13265,"briefTitle":13266,"status":150,"phases":43405,"primaryCompletion":13268,"completion":13268,"start":13269,"enrollment":5983,"conditions":43406,"interventions":43407},[87],[4074,9543],[13272,8319,13273],{"trials":43409,"activeCount":99},[],{"trials":43411,"activeCount":99},[],{"trials":43413,"activeCount":99},[],{"trials":43415,"activeCount":99},[],{"intervention":43417,"totalTrials":224,"cells":43418},"MK-1966",{"EARLY_PHASE1":43419,"PHASE1":43421,"PHASE2":43432,"PHASE3":43434,"PHASE4":43436,"NA":43438},{"trials":43420,"activeCount":99},[],{"trials":43422,"activeCount":99},[43423],{"nctId":43424,"briefTitle":43425,"status":150,"phases":43426,"primaryCompletion":41,"completion":41,"start":43427,"enrollment":4071,"conditions":43428,"interventions":43430},"NCT02731742","Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)",[87],"2016-06-22",[43429],"Neoplasms, Advanced",[43417,43431],"SD-101",{"trials":43433,"activeCount":99},[],{"trials":43435,"activeCount":99},[],{"trials":43437,"activeCount":99},[],{"trials":43439,"activeCount":99},[],{"intervention":43431,"totalTrials":224,"cells":43441},{"EARLY_PHASE1":43442,"PHASE1":43444,"PHASE2":43450,"PHASE3":43452,"PHASE4":43454,"NA":43456},{"trials":43443,"activeCount":99},[],{"trials":43445,"activeCount":99},[43446],{"nctId":43424,"briefTitle":43425,"status":150,"phases":43447,"primaryCompletion":41,"completion":41,"start":43427,"enrollment":4071,"conditions":43448,"interventions":43449},[87],[43429],[43417,43431],{"trials":43451,"activeCount":99},[],{"trials":43453,"activeCount":99},[],{"trials":43455,"activeCount":99},[],{"trials":43457,"activeCount":99},[],{"intervention":4995,"totalTrials":224,"cells":43459},{"EARLY_PHASE1":43460,"PHASE1":43462,"PHASE2":43468,"PHASE3":43470,"PHASE4":43472,"NA":43474},{"trials":43461,"activeCount":99},[],{"trials":43463,"activeCount":99},[43464],{"nctId":4987,"briefTitle":4988,"status":105,"phases":43465,"primaryCompletion":4990,"completion":4990,"start":4419,"enrollment":4991,"conditions":43466,"interventions":43467},[87],[903],[4994,714,4995],{"trials":43469,"activeCount":99},[],{"trials":43471,"activeCount":99},[],{"trials":43473,"activeCount":99},[],{"trials":43475,"activeCount":99},[],{"intervention":43477,"totalTrials":224,"cells":43478},"MK-3102",{"EARLY_PHASE1":43479,"PHASE1":43481,"PHASE2":43492,"PHASE3":43494,"PHASE4":43496,"NA":43498},{"trials":43480,"activeCount":99},[],{"trials":43482,"activeCount":99},[43483],{"nctId":43484,"briefTitle":43485,"status":105,"phases":43486,"primaryCompletion":43487,"completion":43488,"start":43489,"enrollment":3655,"conditions":43490,"interventions":43491},"NCT01767688","A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)",[87],"2013-03-01","2013-03-07","2013-01-16",[33],[43477],{"trials":43493,"activeCount":99},[],{"trials":43495,"activeCount":99},[],{"trials":43497,"activeCount":99},[],{"trials":43499,"activeCount":99},[],{"intervention":14347,"totalTrials":224,"cells":43501},{"EARLY_PHASE1":43502,"PHASE1":43504,"PHASE2":43510,"PHASE3":43512,"PHASE4":43514,"NA":43516},{"trials":43503,"activeCount":99},[],{"trials":43505,"activeCount":99},[43506],{"nctId":14341,"briefTitle":14342,"status":105,"phases":43507,"primaryCompletion":5179,"completion":5179,"start":12813,"enrollment":9323,"conditions":43508,"interventions":43509},[87],[11195],[14346,14347,13864],{"trials":43511,"activeCount":99},[],{"trials":43513,"activeCount":99},[],{"trials":43515,"activeCount":99},[],{"trials":43517,"activeCount":99},[],{"intervention":43519,"totalTrials":224,"cells":43520},"MK-8521 35μg",{"EARLY_PHASE1":43521,"PHASE1":43523,"PHASE2":43542,"PHASE3":43544,"PHASE4":43546,"NA":43548},{"trials":43522,"activeCount":99},[],{"trials":43524,"activeCount":99},[43525],{"nctId":43526,"briefTitle":43527,"status":105,"phases":43528,"primaryCompletion":35061,"completion":35061,"start":43529,"enrollment":4991,"conditions":43530,"interventions":43531},"NCT02055547","A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)",[87],"2013-05-10",[15],[43519,43532,43533,43534,43535,43536,43537,43538,43539,43540,43541],"MK-8521 100μg","MK-8521 125μg","MK-8521 150μg","MK-8521 175μg","MK-8521 200μg","MK-8521 300μg","MK-8521 50\u002F72μg","MK-8521 72\u002F125μg","MK-8521 100\u002F150μg","MK-8521 125\u002F150μg",{"trials":43543,"activeCount":99},[],{"trials":43545,"activeCount":99},[],{"trials":43547,"activeCount":99},[],{"trials":43549,"activeCount":99},[],{"intervention":43532,"totalTrials":224,"cells":43551},{"EARLY_PHASE1":43552,"PHASE1":43554,"PHASE2":43560,"PHASE3":43562,"PHASE4":43564,"NA":43566},{"trials":43553,"activeCount":99},[],{"trials":43555,"activeCount":99},[43556],{"nctId":43526,"briefTitle":43527,"status":105,"phases":43557,"primaryCompletion":35061,"completion":35061,"start":43529,"enrollment":4991,"conditions":43558,"interventions":43559},[87],[15],[43519,43532,43533,43534,43535,43536,43537,43538,43539,43540,43541],{"trials":43561,"activeCount":99},[],{"trials":43563,"activeCount":99},[],{"trials":43565,"activeCount":99},[],{"trials":43567,"activeCount":99},[],{"intervention":43533,"totalTrials":224,"cells":43569},{"EARLY_PHASE1":43570,"PHASE1":43572,"PHASE2":43578,"PHASE3":43580,"PHASE4":43582,"NA":43584},{"trials":43571,"activeCount":99},[],{"trials":43573,"activeCount":99},[43574],{"nctId":43526,"briefTitle":43527,"status":105,"phases":43575,"primaryCompletion":35061,"completion":35061,"start":43529,"enrollment":4991,"conditions":43576,"interventions":43577},[87],[15],[43519,43532,43533,43534,43535,43536,43537,43538,43539,43540,43541],{"trials":43579,"activeCount":99},[],{"trials":43581,"activeCount":99},[],{"trials":43583,"activeCount":99},[],{"trials":43585,"activeCount":99},[],{"intervention":43534,"totalTrials":224,"cells":43587},{"EARLY_PHASE1":43588,"PHASE1":43590,"PHASE2":43596,"PHASE3":43598,"PHASE4":43600,"NA":43602},{"trials":43589,"activeCount":99},[],{"trials":43591,"activeCount":99},[43592],{"nctId":43526,"briefTitle":43527,"status":105,"phases":43593,"primaryCompletion":35061,"completion":35061,"start":43529,"enrollment":4991,"conditions":43594,"interventions":43595},[87],[15],[43519,43532,43533,43534,43535,43536,43537,43538,43539,43540,43541],{"trials":43597,"activeCount":99},[],{"trials":43599,"activeCount":99},[],{"trials":43601,"activeCount":99},[],{"trials":43603,"activeCount":99},[],{"intervention":43535,"totalTrials":224,"cells":43605},{"EARLY_PHASE1":43606,"PHASE1":43608,"PHASE2":43614,"PHASE3":43616,"PHASE4":43618,"NA":43620},{"trials":43607,"activeCount":99},[],{"trials":43609,"activeCount":99},[43610],{"nctId":43526,"briefTitle":43527,"status":105,"phases":43611,"primaryCompletion":35061,"completion":35061,"start":43529,"enrollment":4991,"conditions":43612,"interventions":43613},[87],[15],[43519,43532,43533,43534,43535,43536,43537,43538,43539,43540,43541],{"trials":43615,"activeCount":99},[],{"trials":43617,"activeCount":99},[],{"trials":43619,"activeCount":99},[],{"trials":43621,"activeCount":99},[],{"intervention":43536,"totalTrials":224,"cells":43623},{"EARLY_PHASE1":43624,"PHASE1":43626,"PHASE2":43632,"PHASE3":43634,"PHASE4":43636,"NA":43638},{"trials":43625,"activeCount":99},[],{"trials":43627,"activeCount":99},[43628],{"nctId":43526,"briefTitle":43527,"status":105,"phases":43629,"primaryCompletion":35061,"completion":35061,"start":43529,"enrollment":4991,"conditions":43630,"interventions":43631},[87],[15],[43519,43532,43533,43534,43535,43536,43537,43538,43539,43540,43541],{"trials":43633,"activeCount":99},[],{"trials":43635,"activeCount":99},[],{"trials":43637,"activeCount":99},[],{"trials":43639,"activeCount":99},[],{"intervention":43537,"totalTrials":224,"cells":43641},{"EARLY_PHASE1":43642,"PHASE1":43644,"PHASE2":43650,"PHASE3":43652,"PHASE4":43654,"NA":43656},{"trials":43643,"activeCount":99},[],{"trials":43645,"activeCount":99},[43646],{"nctId":43526,"briefTitle":43527,"status":105,"phases":43647,"primaryCompletion":35061,"completion":35061,"start":43529,"enrollment":4991,"conditions":43648,"interventions":43649},[87],[15],[43519,43532,43533,43534,43535,43536,43537,43538,43539,43540,43541],{"trials":43651,"activeCount":99},[],{"trials":43653,"activeCount":99},[],{"trials":43655,"activeCount":99},[],{"trials":43657,"activeCount":99},[],{"intervention":43538,"totalTrials":224,"cells":43659},{"EARLY_PHASE1":43660,"PHASE1":43662,"PHASE2":43668,"PHASE3":43670,"PHASE4":43672,"NA":43674},{"trials":43661,"activeCount":99},[],{"trials":43663,"activeCount":99},[43664],{"nctId":43526,"briefTitle":43527,"status":105,"phases":43665,"primaryCompletion":35061,"completion":35061,"start":43529,"enrollment":4991,"conditions":43666,"interventions":43667},[87],[15],[43519,43532,43533,43534,43535,43536,43537,43538,43539,43540,43541],{"trials":43669,"activeCount":99},[],{"trials":43671,"activeCount":99},[],{"trials":43673,"activeCount":99},[],{"trials":43675,"activeCount":99},[],{"intervention":43539,"totalTrials":224,"cells":43677},{"EARLY_PHASE1":43678,"PHASE1":43680,"PHASE2":43686,"PHASE3":43688,"PHASE4":43690,"NA":43692},{"trials":43679,"activeCount":99},[],{"trials":43681,"activeCount":99},[43682],{"nctId":43526,"briefTitle":43527,"status":105,"phases":43683,"primaryCompletion":35061,"completion":35061,"start":43529,"enrollment":4991,"conditions":43684,"interventions":43685},[87],[15],[43519,43532,43533,43534,43535,43536,43537,43538,43539,43540,43541],{"trials":43687,"activeCount":99},[],{"trials":43689,"activeCount":99},[],{"trials":43691,"activeCount":99},[],{"trials":43693,"activeCount":99},[],{"intervention":43540,"totalTrials":224,"cells":43695},{"EARLY_PHASE1":43696,"PHASE1":43698,"PHASE2":43704,"PHASE3":43706,"PHASE4":43708,"NA":43710},{"trials":43697,"activeCount":99},[],{"trials":43699,"activeCount":99},[43700],{"nctId":43526,"briefTitle":43527,"status":105,"phases":43701,"primaryCompletion":35061,"completion":35061,"start":43529,"enrollment":4991,"conditions":43702,"interventions":43703},[87],[15],[43519,43532,43533,43534,43535,43536,43537,43538,43539,43540,43541],{"trials":43705,"activeCount":99},[],{"trials":43707,"activeCount":99},[],{"trials":43709,"activeCount":99},[],{"trials":43711,"activeCount":99},[],{"intervention":43541,"totalTrials":224,"cells":43713},{"EARLY_PHASE1":43714,"PHASE1":43716,"PHASE2":43722,"PHASE3":43724,"PHASE4":43726,"NA":43728},{"trials":43715,"activeCount":99},[],{"trials":43717,"activeCount":99},[43718],{"nctId":43526,"briefTitle":43527,"status":105,"phases":43719,"primaryCompletion":35061,"completion":35061,"start":43529,"enrollment":4991,"conditions":43720,"interventions":43721},[87],[15],[43519,43532,43533,43534,43535,43536,43537,43538,43539,43540,43541],{"trials":43723,"activeCount":99},[],{"trials":43725,"activeCount":99},[],{"trials":43727,"activeCount":99},[],{"trials":43729,"activeCount":99},[],{"intervention":14357,"totalTrials":224,"cells":43731},{"EARLY_PHASE1":43732,"PHASE1":43734,"PHASE2":43740,"PHASE3":43742,"PHASE4":43744,"NA":43746},{"trials":43733,"activeCount":99},[],{"trials":43735,"activeCount":99},[43736],{"nctId":14349,"briefTitle":14350,"status":105,"phases":43737,"primaryCompletion":14352,"completion":14352,"start":14353,"enrollment":31,"conditions":43738,"interventions":43739},[87],[14355],[14357,14358,13864],{"trials":43741,"activeCount":99},[],{"trials":43743,"activeCount":99},[],{"trials":43745,"activeCount":99},[],{"trials":43747,"activeCount":99},[],{"intervention":14358,"totalTrials":224,"cells":43749},{"EARLY_PHASE1":43750,"PHASE1":43752,"PHASE2":43758,"PHASE3":43760,"PHASE4":43762,"NA":43764},{"trials":43751,"activeCount":99},[],{"trials":43753,"activeCount":99},[43754],{"nctId":14349,"briefTitle":14350,"status":105,"phases":43755,"primaryCompletion":14352,"completion":14352,"start":14353,"enrollment":31,"conditions":43756,"interventions":43757},[87],[14355],[14357,14358,13864],{"trials":43759,"activeCount":99},[],{"trials":43761,"activeCount":99},[],{"trials":43763,"activeCount":99},[],{"trials":43765,"activeCount":99},[],{"intervention":13819,"totalTrials":224,"cells":43767},{"EARLY_PHASE1":43768,"PHASE1":43770,"PHASE2":43776,"PHASE3":43778,"PHASE4":43780,"NA":43782},{"trials":43769,"activeCount":99},[],{"trials":43771,"activeCount":99},[43772],{"nctId":13812,"briefTitle":13813,"status":105,"phases":43773,"primaryCompletion":13815,"completion":13815,"start":13816,"enrollment":9323,"conditions":43774,"interventions":43775},[87],[15],[13819,4084,13820],{"trials":43777,"activeCount":99},[],{"trials":43779,"activeCount":99},[],{"trials":43781,"activeCount":99},[],{"trials":43783,"activeCount":99},[],{"intervention":13820,"totalTrials":224,"cells":43785},{"EARLY_PHASE1":43786,"PHASE1":43788,"PHASE2":43794,"PHASE3":43796,"PHASE4":43798,"NA":43800},{"trials":43787,"activeCount":99},[],{"trials":43789,"activeCount":99},[43790],{"nctId":13812,"briefTitle":13813,"status":105,"phases":43791,"primaryCompletion":13815,"completion":13815,"start":13816,"enrollment":9323,"conditions":43792,"interventions":43793},[87],[15],[13819,4084,13820],{"trials":43795,"activeCount":99},[],{"trials":43797,"activeCount":99},[],{"trials":43799,"activeCount":99},[],{"trials":43801,"activeCount":99},[],{"intervention":43803,"totalTrials":224,"cells":43804},"Glimepiride 2 mg",{"EARLY_PHASE1":43805,"PHASE1":43807,"PHASE2":43817,"PHASE3":43819,"PHASE4":43821,"NA":43823},{"trials":43806,"activeCount":99},[],{"trials":43808,"activeCount":99},[43809],{"nctId":43810,"briefTitle":43811,"status":105,"phases":43812,"primaryCompletion":43813,"completion":17828,"start":13816,"enrollment":335,"conditions":43814,"interventions":43815},"NCT01614769","Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253)",[87],"2013-01-09",[15],[43803,43816],"Glimepiride 4 mg",{"trials":43818,"activeCount":99},[],{"trials":43820,"activeCount":99},[],{"trials":43822,"activeCount":99},[],{"trials":43824,"activeCount":99},[],{"intervention":43816,"totalTrials":224,"cells":43826},{"EARLY_PHASE1":43827,"PHASE1":43829,"PHASE2":43835,"PHASE3":43837,"PHASE4":43839,"NA":43841},{"trials":43828,"activeCount":99},[],{"trials":43830,"activeCount":99},[43831],{"nctId":43810,"briefTitle":43811,"status":105,"phases":43832,"primaryCompletion":43813,"completion":17828,"start":13816,"enrollment":335,"conditions":43833,"interventions":43834},[87],[15],[43803,43816],{"trials":43836,"activeCount":99},[],{"trials":43838,"activeCount":99},[],{"trials":43840,"activeCount":99},[],{"trials":43842,"activeCount":99},[],{"intervention":43844,"totalTrials":224,"cells":43845},"MK1006",{"EARLY_PHASE1":43846,"PHASE1":43848,"PHASE2":43856,"PHASE3":43858,"PHASE4":43860,"NA":43862},{"trials":43847,"activeCount":99},[],{"trials":43849,"activeCount":99},[43850],{"nctId":43851,"briefTitle":43852,"status":105,"phases":43853,"primaryCompletion":14353,"completion":14353,"start":14408,"enrollment":9323,"conditions":43854,"interventions":43855},"NCT00757601","A Study to Test the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK1006 (MK-1006-002)(COMPLETED)",[87],[15],[43844],{"trials":43857,"activeCount":99},[],{"trials":43859,"activeCount":99},[],{"trials":43861,"activeCount":99},[],{"trials":43863,"activeCount":99},[],{"intervention":43865,"totalTrials":224,"cells":43866},"MK-7252",{"EARLY_PHASE1":43867,"PHASE1":43869,"PHASE2":43878,"PHASE3":43880,"PHASE4":43882,"NA":43884},{"trials":43868,"activeCount":99},[],{"trials":43870,"activeCount":99},[43871],{"nctId":43872,"briefTitle":43873,"status":105,"phases":43874,"primaryCompletion":8202,"completion":8202,"start":43875,"enrollment":120,"conditions":43876,"interventions":43877},"NCT03326986","Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001)",[87],"2017-11-10",[539,639],[43865],{"trials":43879,"activeCount":99},[],{"trials":43881,"activeCount":99},[],{"trials":43883,"activeCount":99},[],{"trials":43885,"activeCount":99},[],{"intervention":43887,"totalTrials":224,"cells":43888},"Birabresib",{"EARLY_PHASE1":43889,"PHASE1":43891,"PHASE2":43903,"PHASE3":43905,"PHASE4":43907,"NA":43909},{"trials":43890,"activeCount":99},[],{"trials":43892,"activeCount":99},[43893],{"nctId":43894,"briefTitle":43895,"status":150,"phases":43896,"primaryCompletion":43897,"completion":43897,"start":43898,"enrollment":5563,"conditions":43899,"interventions":43902},"NCT02698176","A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)",[87],"2017-04-26","2016-05-04",[43900,2725,1687,43901],"NUT Midline Carcinoma (NMC)","Castration-resistant Prostate Cancer (CRPC)",[43887],{"trials":43904,"activeCount":99},[],{"trials":43906,"activeCount":99},[],{"trials":43908,"activeCount":99},[],{"trials":43910,"activeCount":99},[],{"intervention":14376,"totalTrials":224,"cells":43912},{"EARLY_PHASE1":43913,"PHASE1":43915,"PHASE2":43921,"PHASE3":43923,"PHASE4":43925,"NA":43927},{"trials":43914,"activeCount":99},[],{"trials":43916,"activeCount":99},[43917],{"nctId":14369,"briefTitle":14370,"status":105,"phases":43918,"primaryCompletion":14372,"completion":14372,"start":14373,"enrollment":154,"conditions":43919,"interventions":43920},[87],[30],[14376,14377,13864],{"trials":43922,"activeCount":99},[],{"trials":43924,"activeCount":99},[],{"trials":43926,"activeCount":99},[],{"trials":43928,"activeCount":99},[],{"intervention":43930,"totalTrials":224,"cells":43931},"MK-8583",{"EARLY_PHASE1":43932,"PHASE1":43934,"PHASE2":43944,"PHASE3":43946,"PHASE4":43948,"NA":43950},{"trials":43933,"activeCount":99},[],{"trials":43935,"activeCount":99},[43936],{"nctId":43937,"briefTitle":43938,"status":105,"phases":43939,"primaryCompletion":43940,"completion":43940,"start":43941,"enrollment":174,"conditions":43942,"interventions":43943},"NCT03552536","MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)",[87],"2019-03-11","2018-10-07",[7639],[43930],{"trials":43945,"activeCount":99},[],{"trials":43947,"activeCount":99},[],{"trials":43949,"activeCount":99},[],{"trials":43951,"activeCount":99},[],{"intervention":19301,"totalTrials":224,"cells":43953},{"EARLY_PHASE1":43954,"PHASE1":43956,"PHASE2":43962,"PHASE3":43964,"PHASE4":43966,"NA":43968},{"trials":43955,"activeCount":99},[],{"trials":43957,"activeCount":99},[43958],{"nctId":19296,"briefTitle":19297,"status":150,"phases":43959,"primaryCompletion":6309,"completion":6309,"start":15156,"enrollment":3141,"conditions":43960,"interventions":43961},[87],[302],[4994,19301],{"trials":43963,"activeCount":99},[],{"trials":43965,"activeCount":99},[],{"trials":43967,"activeCount":99},[],{"trials":43969,"activeCount":99},[],{"intervention":43971,"totalTrials":224,"cells":43972},"Unlabeled ertugliflozin for oral use",{"EARLY_PHASE1":43973,"PHASE1":43975,"PHASE2":43987,"PHASE3":43989,"PHASE4":43991,"NA":43993},{"trials":43974,"activeCount":99},[],{"trials":43976,"activeCount":99},[43977],{"nctId":43978,"briefTitle":43979,"status":105,"phases":43980,"primaryCompletion":43981,"completion":43982,"start":31788,"enrollment":734,"conditions":43983,"interventions":43984},"NCT02411929","A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)",[87],"2015-01-30","2015-02-09",[15],[43971,43985,43986],"14^C-labeled ertugliflozin for IV use","14^C-labeled ertugliflozin for oral use",{"trials":43988,"activeCount":99},[],{"trials":43990,"activeCount":99},[],{"trials":43992,"activeCount":99},[],{"trials":43994,"activeCount":99},[],{"intervention":43985,"totalTrials":224,"cells":43996},{"EARLY_PHASE1":43997,"PHASE1":43999,"PHASE2":44005,"PHASE3":44007,"PHASE4":44009,"NA":44011},{"trials":43998,"activeCount":99},[],{"trials":44000,"activeCount":99},[44001],{"nctId":43978,"briefTitle":43979,"status":105,"phases":44002,"primaryCompletion":43981,"completion":43982,"start":31788,"enrollment":734,"conditions":44003,"interventions":44004},[87],[15],[43971,43985,43986],{"trials":44006,"activeCount":99},[],{"trials":44008,"activeCount":99},[],{"trials":44010,"activeCount":99},[],{"trials":44012,"activeCount":99},[],{"intervention":43986,"totalTrials":224,"cells":44014},{"EARLY_PHASE1":44015,"PHASE1":44017,"PHASE2":44023,"PHASE3":44025,"PHASE4":44027,"NA":44029},{"trials":44016,"activeCount":99},[],{"trials":44018,"activeCount":99},[44019],{"nctId":43978,"briefTitle":43979,"status":105,"phases":44020,"primaryCompletion":43981,"completion":43982,"start":31788,"enrollment":734,"conditions":44021,"interventions":44022},[87],[15],[43971,43985,43986],{"trials":44024,"activeCount":99},[],{"trials":44026,"activeCount":99},[],{"trials":44028,"activeCount":99},[],{"trials":44030,"activeCount":99},[],{"intervention":14387,"totalTrials":224,"cells":44032},{"EARLY_PHASE1":44033,"PHASE1":44035,"PHASE2":44041,"PHASE3":44043,"PHASE4":44045,"NA":44047},{"trials":44034,"activeCount":99},[],{"trials":44036,"activeCount":99},[44037],{"nctId":14379,"briefTitle":14380,"status":105,"phases":44038,"primaryCompletion":14382,"completion":14383,"start":14384,"enrollment":1621,"conditions":44039,"interventions":44040},[87],[15],[14387,14331],{"trials":44042,"activeCount":99},[],{"trials":44044,"activeCount":99},[],{"trials":44046,"activeCount":99},[],{"trials":44048,"activeCount":99},[],{"intervention":22910,"totalTrials":224,"cells":44050},{"EARLY_PHASE1":44051,"PHASE1":44053,"PHASE2":44059,"PHASE3":44061,"PHASE4":44063,"NA":44065},{"trials":44052,"activeCount":99},[],{"trials":44054,"activeCount":99},[44055],{"nctId":22905,"briefTitle":22906,"status":105,"phases":44056,"primaryCompletion":6308,"completion":13224,"start":14314,"enrollment":287,"conditions":44057,"interventions":44058},[87],[30],[22898,22910,22911,22912],{"trials":44060,"activeCount":99},[],{"trials":44062,"activeCount":99},[],{"trials":44064,"activeCount":99},[],{"trials":44066,"activeCount":99},[],{"intervention":22911,"totalTrials":224,"cells":44068},{"EARLY_PHASE1":44069,"PHASE1":44071,"PHASE2":44077,"PHASE3":44079,"PHASE4":44081,"NA":44083},{"trials":44070,"activeCount":99},[],{"trials":44072,"activeCount":99},[44073],{"nctId":22905,"briefTitle":22906,"status":105,"phases":44074,"primaryCompletion":6308,"completion":13224,"start":14314,"enrollment":287,"conditions":44075,"interventions":44076},[87],[30],[22898,22910,22911,22912],{"trials":44078,"activeCount":99},[],{"trials":44080,"activeCount":99},[],{"trials":44082,"activeCount":99},[],{"trials":44084,"activeCount":99},[],{"intervention":22912,"totalTrials":224,"cells":44086},{"EARLY_PHASE1":44087,"PHASE1":44089,"PHASE2":44095,"PHASE3":44097,"PHASE4":44099,"NA":44101},{"trials":44088,"activeCount":99},[],{"trials":44090,"activeCount":99},[44091],{"nctId":22905,"briefTitle":22906,"status":105,"phases":44092,"primaryCompletion":6308,"completion":13224,"start":14314,"enrollment":287,"conditions":44093,"interventions":44094},[87],[30],[22898,22910,22911,22912],{"trials":44096,"activeCount":99},[],{"trials":44098,"activeCount":99},[],{"trials":44100,"activeCount":99},[],{"trials":44102,"activeCount":99},[],{"intervention":20252,"totalTrials":224,"cells":44104},{"EARLY_PHASE1":44105,"PHASE1":44107,"PHASE2":44113,"PHASE3":44115,"PHASE4":44117,"NA":44119},{"trials":44106,"activeCount":99},[],{"trials":44108,"activeCount":99},[44109],{"nctId":20247,"briefTitle":20248,"status":105,"phases":44110,"primaryCompletion":5800,"completion":7018,"start":8591,"enrollment":212,"conditions":44111,"interventions":44112},[87],[14337],[14970,14971,20252,20253],{"trials":44114,"activeCount":99},[],{"trials":44116,"activeCount":99},[],{"trials":44118,"activeCount":99},[],{"trials":44120,"activeCount":99},[],{"intervention":20253,"totalTrials":224,"cells":44122},{"EARLY_PHASE1":44123,"PHASE1":44125,"PHASE2":44131,"PHASE3":44133,"PHASE4":44135,"NA":44137},{"trials":44124,"activeCount":99},[],{"trials":44126,"activeCount":99},[44127],{"nctId":20247,"briefTitle":20248,"status":105,"phases":44128,"primaryCompletion":5800,"completion":7018,"start":8591,"enrollment":212,"conditions":44129,"interventions":44130},[87],[14337],[14970,14971,20252,20253],{"trials":44132,"activeCount":99},[],{"trials":44134,"activeCount":99},[],{"trials":44136,"activeCount":99},[],{"trials":44138,"activeCount":99},[],{"intervention":44140,"totalTrials":224,"cells":44141},"MK-5478",{"EARLY_PHASE1":44142,"PHASE1":44144,"PHASE2":44155,"PHASE3":44157,"PHASE4":44159,"NA":44161},{"trials":44143,"activeCount":99},[],{"trials":44145,"activeCount":99},[44146],{"nctId":44147,"briefTitle":44148,"status":105,"phases":44149,"primaryCompletion":44150,"completion":44150,"start":32775,"enrollment":805,"conditions":44151,"interventions":44152},"NCT01025843","Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)",[87],"2010-05-01",[30],[44140,44153,44154],"Comparator: Candesartan cilexetil","Comparator: Pbo",{"trials":44156,"activeCount":99},[],{"trials":44158,"activeCount":99},[],{"trials":44160,"activeCount":99},[],{"trials":44162,"activeCount":99},[],{"intervention":44153,"totalTrials":224,"cells":44164},{"EARLY_PHASE1":44165,"PHASE1":44167,"PHASE2":44173,"PHASE3":44175,"PHASE4":44177,"NA":44179},{"trials":44166,"activeCount":99},[],{"trials":44168,"activeCount":99},[44169],{"nctId":44147,"briefTitle":44148,"status":105,"phases":44170,"primaryCompletion":44150,"completion":44150,"start":32775,"enrollment":805,"conditions":44171,"interventions":44172},[87],[30],[44140,44153,44154],{"trials":44174,"activeCount":99},[],{"trials":44176,"activeCount":99},[],{"trials":44178,"activeCount":99},[],{"trials":44180,"activeCount":99},[],{"intervention":44154,"totalTrials":224,"cells":44182},{"EARLY_PHASE1":44183,"PHASE1":44185,"PHASE2":44191,"PHASE3":44193,"PHASE4":44195,"NA":44197},{"trials":44184,"activeCount":99},[],{"trials":44186,"activeCount":99},[44187],{"nctId":44147,"briefTitle":44148,"status":105,"phases":44188,"primaryCompletion":44150,"completion":44150,"start":32775,"enrollment":805,"conditions":44189,"interventions":44190},[87],[30],[44140,44153,44154],{"trials":44192,"activeCount":99},[],{"trials":44194,"activeCount":99},[],{"trials":44196,"activeCount":99},[],{"trials":44198,"activeCount":99},[],{"intervention":44200,"totalTrials":224,"cells":44201},"tolterodine tartrate",{"EARLY_PHASE1":44202,"PHASE1":44204,"PHASE2":44215,"PHASE3":44217,"PHASE4":44219,"NA":44221},{"trials":44203,"activeCount":99},[],{"trials":44205,"activeCount":99},[44206],{"nctId":44207,"briefTitle":44208,"status":105,"phases":44209,"primaryCompletion":44210,"completion":44210,"start":44211,"enrollment":805,"conditions":44212,"interventions":44213},"NCT00768521","A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)",[87],"2009-01-19","2008-09-03",[34244],[44200,44214],"Comparator: Placebo to tolterodine tartrate",{"trials":44216,"activeCount":99},[],{"trials":44218,"activeCount":99},[],{"trials":44220,"activeCount":99},[],{"trials":44222,"activeCount":99},[],{"intervention":44214,"totalTrials":224,"cells":44224},{"EARLY_PHASE1":44225,"PHASE1":44227,"PHASE2":44233,"PHASE3":44235,"PHASE4":44237,"NA":44239},{"trials":44226,"activeCount":99},[],{"trials":44228,"activeCount":99},[44229],{"nctId":44207,"briefTitle":44208,"status":105,"phases":44230,"primaryCompletion":44210,"completion":44210,"start":44211,"enrollment":805,"conditions":44231,"interventions":44232},[87],[34244],[44200,44214],{"trials":44234,"activeCount":99},[],{"trials":44236,"activeCount":99},[],{"trials":44238,"activeCount":99},[],{"trials":44240,"activeCount":99},[],{"intervention":14397,"totalTrials":224,"cells":44242},{"EARLY_PHASE1":44243,"PHASE1":44245,"PHASE2":44251,"PHASE3":44253,"PHASE4":44255,"NA":44257},{"trials":44244,"activeCount":99},[],{"trials":44246,"activeCount":99},[44247],{"nctId":14389,"briefTitle":14390,"status":105,"phases":44248,"primaryCompletion":14392,"completion":14392,"start":14393,"enrollment":5077,"conditions":44249,"interventions":44250},[87],[14395],[14397,13864],{"trials":44252,"activeCount":99},[],{"trials":44254,"activeCount":99},[],{"trials":44256,"activeCount":99},[],{"trials":44258,"activeCount":99},[],{"intervention":44260,"totalTrials":224,"cells":44261},"Posaconazole 12 mg\u002Fkg\u002Fday BID",{"EARLY_PHASE1":44262,"PHASE1":44264,"PHASE2":44276,"PHASE3":44278,"PHASE4":44280,"NA":44282},{"trials":44263,"activeCount":99},[],{"trials":44265,"activeCount":99},[44266],{"nctId":44267,"briefTitle":44268,"status":150,"phases":44269,"primaryCompletion":44270,"completion":44270,"start":13826,"enrollment":34807,"conditions":44271,"interventions":44272},"NCT01716234","A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)",[87],"2015-04-01",[24476],[44260,44273,44274,44275],"Posaconazole 18 mg\u002Fkg\u002Fday BID","Posaconazole 18 mg\u002Fkg\u002Fday TID","Posaconazole 12 mg\u002Fkg\u002Fday TID",{"trials":44277,"activeCount":99},[],{"trials":44279,"activeCount":99},[],{"trials":44281,"activeCount":99},[],{"trials":44283,"activeCount":99},[],{"intervention":44273,"totalTrials":224,"cells":44285},{"EARLY_PHASE1":44286,"PHASE1":44288,"PHASE2":44294,"PHASE3":44296,"PHASE4":44298,"NA":44300},{"trials":44287,"activeCount":99},[],{"trials":44289,"activeCount":99},[44290],{"nctId":44267,"briefTitle":44268,"status":150,"phases":44291,"primaryCompletion":44270,"completion":44270,"start":13826,"enrollment":34807,"conditions":44292,"interventions":44293},[87],[24476],[44260,44273,44274,44275],{"trials":44295,"activeCount":99},[],{"trials":44297,"activeCount":99},[],{"trials":44299,"activeCount":99},[],{"trials":44301,"activeCount":99},[],{"intervention":44274,"totalTrials":224,"cells":44303},{"EARLY_PHASE1":44304,"PHASE1":44306,"PHASE2":44312,"PHASE3":44314,"PHASE4":44316,"NA":44318},{"trials":44305,"activeCount":99},[],{"trials":44307,"activeCount":99},[44308],{"nctId":44267,"briefTitle":44268,"status":150,"phases":44309,"primaryCompletion":44270,"completion":44270,"start":13826,"enrollment":34807,"conditions":44310,"interventions":44311},[87],[24476],[44260,44273,44274,44275],{"trials":44313,"activeCount":99},[],{"trials":44315,"activeCount":99},[],{"trials":44317,"activeCount":99},[],{"trials":44319,"activeCount":99},[],{"intervention":44275,"totalTrials":224,"cells":44321},{"EARLY_PHASE1":44322,"PHASE1":44324,"PHASE2":44330,"PHASE3":44332,"PHASE4":44334,"NA":44336},{"trials":44323,"activeCount":99},[],{"trials":44325,"activeCount":99},[44326],{"nctId":44267,"briefTitle":44268,"status":150,"phases":44327,"primaryCompletion":44270,"completion":44270,"start":13826,"enrollment":34807,"conditions":44328,"interventions":44329},[87],[24476],[44260,44273,44274,44275],{"trials":44331,"activeCount":99},[],{"trials":44333,"activeCount":99},[],{"trials":44335,"activeCount":99},[],{"trials":44337,"activeCount":99},[],{"intervention":9398,"totalTrials":224,"cells":44339},{"EARLY_PHASE1":44340,"PHASE1":44342,"PHASE2":44348,"PHASE3":44350,"PHASE4":44352,"NA":44354},{"trials":44341,"activeCount":99},[],{"trials":44343,"activeCount":99},[44344],{"nctId":9391,"briefTitle":9392,"status":105,"phases":44345,"primaryCompletion":1897,"completion":1897,"start":9394,"enrollment":7797,"conditions":44346,"interventions":44347},[87],[9396],[9384,9398,9399],{"trials":44349,"activeCount":99},[],{"trials":44351,"activeCount":99},[],{"trials":44353,"activeCount":99},[],{"trials":44355,"activeCount":99},[],{"intervention":9399,"totalTrials":224,"cells":44357},{"EARLY_PHASE1":44358,"PHASE1":44360,"PHASE2":44366,"PHASE3":44368,"PHASE4":44370,"NA":44372},{"trials":44359,"activeCount":99},[],{"trials":44361,"activeCount":99},[44362],{"nctId":9391,"briefTitle":9392,"status":105,"phases":44363,"primaryCompletion":1897,"completion":1897,"start":9394,"enrollment":7797,"conditions":44364,"interventions":44365},[87],[9396],[9384,9398,9399],{"trials":44367,"activeCount":99},[],{"trials":44369,"activeCount":99},[],{"trials":44371,"activeCount":99},[],{"trials":44373,"activeCount":99},[],{"intervention":34774,"totalTrials":224,"cells":44375},{"EARLY_PHASE1":44376,"PHASE1":44378,"PHASE2":44384,"PHASE3":44386,"PHASE4":44388,"NA":44390},{"trials":44377,"activeCount":99},[],{"trials":44379,"activeCount":99},[44380],{"nctId":34769,"briefTitle":34770,"status":105,"phases":44381,"primaryCompletion":14730,"completion":8591,"start":14352,"enrollment":4059,"conditions":44382,"interventions":44383},[87],[15],[13894,34774,34775],{"trials":44385,"activeCount":99},[],{"trials":44387,"activeCount":99},[],{"trials":44389,"activeCount":99},[],{"trials":44391,"activeCount":99},[],{"intervention":34775,"totalTrials":224,"cells":44393},{"EARLY_PHASE1":44394,"PHASE1":44396,"PHASE2":44402,"PHASE3":44404,"PHASE4":44406,"NA":44408},{"trials":44395,"activeCount":99},[],{"trials":44397,"activeCount":99},[44398],{"nctId":34769,"briefTitle":34770,"status":105,"phases":44399,"primaryCompletion":14730,"completion":8591,"start":14352,"enrollment":4059,"conditions":44400,"interventions":44401},[87],[15],[13894,34774,34775],{"trials":44403,"activeCount":99},[],{"trials":44405,"activeCount":99},[],{"trials":44407,"activeCount":99},[],{"trials":44409,"activeCount":99},[],{"intervention":14412,"totalTrials":224,"cells":44411},{"EARLY_PHASE1":44412,"PHASE1":44414,"PHASE2":44420,"PHASE3":44422,"PHASE4":44424,"NA":44426},{"trials":44413,"activeCount":99},[],{"trials":44415,"activeCount":99},[44416],{"nctId":14405,"briefTitle":14406,"status":105,"phases":44417,"primaryCompletion":14408,"completion":14408,"start":14409,"enrollment":367,"conditions":44418,"interventions":44419},[87],[15],[14412,13864],{"trials":44421,"activeCount":99},[],{"trials":44423,"activeCount":99},[],{"trials":44425,"activeCount":99},[],{"trials":44427,"activeCount":99},[],{"intervention":14421,"totalTrials":224,"cells":44429},{"EARLY_PHASE1":44430,"PHASE1":44432,"PHASE2":44438,"PHASE3":44440,"PHASE4":44442,"NA":44444},{"trials":44431,"activeCount":99},[],{"trials":44433,"activeCount":99},[44434],{"nctId":14414,"briefTitle":14415,"status":105,"phases":44435,"primaryCompletion":13224,"completion":4990,"start":8591,"enrollment":8016,"conditions":44436,"interventions":44437},[87],[14418,13133],[14420,14421,14422,14423,14331],{"trials":44439,"activeCount":99},[],{"trials":44441,"activeCount":99},[],{"trials":44443,"activeCount":99},[],{"trials":44445,"activeCount":99},[],{"intervention":14422,"totalTrials":224,"cells":44447},{"EARLY_PHASE1":44448,"PHASE1":44450,"PHASE2":44456,"PHASE3":44458,"PHASE4":44460,"NA":44462},{"trials":44449,"activeCount":99},[],{"trials":44451,"activeCount":99},[44452],{"nctId":14414,"briefTitle":14415,"status":105,"phases":44453,"primaryCompletion":13224,"completion":4990,"start":8591,"enrollment":8016,"conditions":44454,"interventions":44455},[87],[14418,13133],[14420,14421,14422,14423,14331],{"trials":44457,"activeCount":99},[],{"trials":44459,"activeCount":99},[],{"trials":44461,"activeCount":99},[],{"trials":44463,"activeCount":99},[],{"intervention":44465,"totalTrials":224,"cells":44466},"Nedocromil",{"EARLY_PHASE1":44467,"PHASE1":44469,"PHASE2":44479,"PHASE3":44481,"PHASE4":44483,"NA":44485},{"trials":44468,"activeCount":99},[],{"trials":44470,"activeCount":99},[44471],{"nctId":44472,"briefTitle":44473,"status":105,"phases":44474,"primaryCompletion":14566,"completion":21145,"start":12813,"enrollment":3655,"conditions":44475,"interventions":44476},"NCT01061333","Early Airway Response to Allergen in Asthmatics (MK-0000-176)",[87],[5985],[44465,44477,44478],"Comparator: Montelukast","Comparator: Mometasone",{"trials":44480,"activeCount":99},[],{"trials":44482,"activeCount":99},[],{"trials":44484,"activeCount":99},[],{"trials":44486,"activeCount":99},[],{"intervention":44477,"totalTrials":224,"cells":44488},{"EARLY_PHASE1":44489,"PHASE1":44491,"PHASE2":44497,"PHASE3":44499,"PHASE4":44501,"NA":44503},{"trials":44490,"activeCount":99},[],{"trials":44492,"activeCount":99},[44493],{"nctId":44472,"briefTitle":44473,"status":105,"phases":44494,"primaryCompletion":14566,"completion":21145,"start":12813,"enrollment":3655,"conditions":44495,"interventions":44496},[87],[5985],[44465,44477,44478],{"trials":44498,"activeCount":99},[],{"trials":44500,"activeCount":99},[],{"trials":44502,"activeCount":99},[],{"trials":44504,"activeCount":99},[],{"intervention":44478,"totalTrials":224,"cells":44506},{"EARLY_PHASE1":44507,"PHASE1":44509,"PHASE2":44515,"PHASE3":44517,"PHASE4":44519,"NA":44521},{"trials":44508,"activeCount":99},[],{"trials":44510,"activeCount":99},[44511],{"nctId":44472,"briefTitle":44473,"status":105,"phases":44512,"primaryCompletion":14566,"completion":21145,"start":12813,"enrollment":3655,"conditions":44513,"interventions":44514},[87],[5985],[44465,44477,44478],{"trials":44516,"activeCount":99},[],{"trials":44518,"activeCount":99},[],{"trials":44520,"activeCount":99},[],{"trials":44522,"activeCount":99},[],{"intervention":113,"totalTrials":224,"cells":44524},{"EARLY_PHASE1":44525,"PHASE1":44527,"PHASE2":44533,"PHASE3":44535,"PHASE4":44537,"NA":44539},{"trials":44526,"activeCount":99},[],{"trials":44528,"activeCount":99},[44529],{"nctId":103,"briefTitle":104,"status":105,"phases":44530,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":44531,"interventions":44532},[87],[18],[94,113],{"trials":44534,"activeCount":99},[],{"trials":44536,"activeCount":99},[],{"trials":44538,"activeCount":99},[],{"trials":44540,"activeCount":99},[],{"intervention":44542,"totalTrials":224,"cells":44543},"MK0731",{"EARLY_PHASE1":44544,"PHASE1":44546,"PHASE2":44554,"PHASE3":44556,"PHASE4":44558,"NA":44560},{"trials":44545,"activeCount":99},[],{"trials":44547,"activeCount":99},[44548],{"nctId":44549,"briefTitle":44550,"status":105,"phases":44551,"primaryCompletion":14687,"completion":14687,"start":14930,"enrollment":154,"conditions":44552,"interventions":44553},"NCT00104364","A Study of MK0731 in Patients With Advanced Solid Tumors (0731-002)(COMPLETED)",[87],[639],[44542],{"trials":44555,"activeCount":99},[],{"trials":44557,"activeCount":99},[],{"trials":44559,"activeCount":99},[],{"trials":44561,"activeCount":99},[],{"intervention":44563,"totalTrials":224,"cells":44564},"ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous",{"EARLY_PHASE1":44565,"PHASE1":44567,"PHASE2":44580,"PHASE3":44582,"PHASE4":44584,"NA":44586},{"trials":44566,"activeCount":99},[],{"trials":44568,"activeCount":99},[44569],{"nctId":44570,"briefTitle":44571,"status":105,"phases":44572,"primaryCompletion":20279,"completion":20279,"start":12985,"enrollment":14074,"conditions":44573,"interventions":44574},"NCT01385566","A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)",[87],[14395],[44563,44575,44576,44577,44578,44579],"ZOSTAVAX™ (Zoster Vaccine Live) 1\u002F3 Dose Subcutaneous","ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal","ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal","Full Dose Intradermal Placebo","Intradermal Placebo",{"trials":44581,"activeCount":99},[],{"trials":44583,"activeCount":99},[],{"trials":44585,"activeCount":99},[],{"trials":44587,"activeCount":99},[],{"intervention":44575,"totalTrials":224,"cells":44589},{"EARLY_PHASE1":44590,"PHASE1":44592,"PHASE2":44598,"PHASE3":44600,"PHASE4":44602,"NA":44604},{"trials":44591,"activeCount":99},[],{"trials":44593,"activeCount":99},[44594],{"nctId":44570,"briefTitle":44571,"status":105,"phases":44595,"primaryCompletion":20279,"completion":20279,"start":12985,"enrollment":14074,"conditions":44596,"interventions":44597},[87],[14395],[44563,44575,44576,44577,44578,44579],{"trials":44599,"activeCount":99},[],{"trials":44601,"activeCount":99},[],{"trials":44603,"activeCount":99},[],{"trials":44605,"activeCount":99},[],{"intervention":44576,"totalTrials":224,"cells":44607},{"EARLY_PHASE1":44608,"PHASE1":44610,"PHASE2":44616,"PHASE3":44618,"PHASE4":44620,"NA":44622},{"trials":44609,"activeCount":99},[],{"trials":44611,"activeCount":99},[44612],{"nctId":44570,"briefTitle":44571,"status":105,"phases":44613,"primaryCompletion":20279,"completion":20279,"start":12985,"enrollment":14074,"conditions":44614,"interventions":44615},[87],[14395],[44563,44575,44576,44577,44578,44579],{"trials":44617,"activeCount":99},[],{"trials":44619,"activeCount":99},[],{"trials":44621,"activeCount":99},[],{"trials":44623,"activeCount":99},[],{"intervention":44577,"totalTrials":224,"cells":44625},{"EARLY_PHASE1":44626,"PHASE1":44628,"PHASE2":44634,"PHASE3":44636,"PHASE4":44638,"NA":44640},{"trials":44627,"activeCount":99},[],{"trials":44629,"activeCount":99},[44630],{"nctId":44570,"briefTitle":44571,"status":105,"phases":44631,"primaryCompletion":20279,"completion":20279,"start":12985,"enrollment":14074,"conditions":44632,"interventions":44633},[87],[14395],[44563,44575,44576,44577,44578,44579],{"trials":44635,"activeCount":99},[],{"trials":44637,"activeCount":99},[],{"trials":44639,"activeCount":99},[],{"trials":44641,"activeCount":99},[],{"intervention":44578,"totalTrials":224,"cells":44643},{"EARLY_PHASE1":44644,"PHASE1":44646,"PHASE2":44652,"PHASE3":44654,"PHASE4":44656,"NA":44658},{"trials":44645,"activeCount":99},[],{"trials":44647,"activeCount":99},[44648],{"nctId":44570,"briefTitle":44571,"status":105,"phases":44649,"primaryCompletion":20279,"completion":20279,"start":12985,"enrollment":14074,"conditions":44650,"interventions":44651},[87],[14395],[44563,44575,44576,44577,44578,44579],{"trials":44653,"activeCount":99},[],{"trials":44655,"activeCount":99},[],{"trials":44657,"activeCount":99},[],{"trials":44659,"activeCount":99},[],{"intervention":44579,"totalTrials":224,"cells":44661},{"EARLY_PHASE1":44662,"PHASE1":44664,"PHASE2":44670,"PHASE3":44672,"PHASE4":44674,"NA":44676},{"trials":44663,"activeCount":99},[],{"trials":44665,"activeCount":99},[44666],{"nctId":44570,"briefTitle":44571,"status":105,"phases":44667,"primaryCompletion":20279,"completion":20279,"start":12985,"enrollment":14074,"conditions":44668,"interventions":44669},[87],[14395],[44563,44575,44576,44577,44578,44579],{"trials":44671,"activeCount":99},[],{"trials":44673,"activeCount":99},[],{"trials":44675,"activeCount":99},[],{"trials":44677,"activeCount":99},[],{"intervention":7003,"totalTrials":224,"cells":44679},{"EARLY_PHASE1":44680,"PHASE1":44682,"PHASE2":44688,"PHASE3":44690,"PHASE4":44692,"NA":44694},{"trials":44681,"activeCount":99},[],{"trials":44683,"activeCount":99},[44684],{"nctId":6996,"briefTitle":6997,"status":105,"phases":44685,"primaryCompletion":6999,"completion":6999,"start":7000,"enrollment":31,"conditions":44686,"interventions":44687},[87],[290],[7003,979],{"trials":44689,"activeCount":99},[],{"trials":44691,"activeCount":99},[],{"trials":44693,"activeCount":99},[],{"trials":44695,"activeCount":99},[],{"intervention":44697,"totalTrials":224,"cells":44698},"Pembrolizumab Dose C",{"EARLY_PHASE1":44699,"PHASE1":44701,"PHASE2":44714,"PHASE3":44716,"PHASE4":44718,"NA":44720},{"trials":44700,"activeCount":99},[],{"trials":44702,"activeCount":99},[44703],{"nctId":44704,"briefTitle":44705,"status":105,"phases":44706,"primaryCompletion":44707,"completion":44707,"start":9214,"enrollment":44708,"conditions":44709,"interventions":44710},"NCT03665597","Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555\u002FKEYNOTE-555)",[87],"2023-12-04",138,[35],[44697,44711,44712,44713],"Pembrolizumab Dose A","Pembrolizumab Dose B","Pembrolizumab Dose D",{"trials":44715,"activeCount":99},[],{"trials":44717,"activeCount":99},[],{"trials":44719,"activeCount":99},[],{"trials":44721,"activeCount":99},[],{"intervention":44711,"totalTrials":224,"cells":44723},{"EARLY_PHASE1":44724,"PHASE1":44726,"PHASE2":44732,"PHASE3":44734,"PHASE4":44736,"NA":44738},{"trials":44725,"activeCount":99},[],{"trials":44727,"activeCount":99},[44728],{"nctId":44704,"briefTitle":44705,"status":105,"phases":44729,"primaryCompletion":44707,"completion":44707,"start":9214,"enrollment":44708,"conditions":44730,"interventions":44731},[87],[35],[44697,44711,44712,44713],{"trials":44733,"activeCount":99},[],{"trials":44735,"activeCount":99},[],{"trials":44737,"activeCount":99},[],{"trials":44739,"activeCount":99},[],{"intervention":44712,"totalTrials":224,"cells":44741},{"EARLY_PHASE1":44742,"PHASE1":44744,"PHASE2":44750,"PHASE3":44752,"PHASE4":44754,"NA":44756},{"trials":44743,"activeCount":99},[],{"trials":44745,"activeCount":99},[44746],{"nctId":44704,"briefTitle":44705,"status":105,"phases":44747,"primaryCompletion":44707,"completion":44707,"start":9214,"enrollment":44708,"conditions":44748,"interventions":44749},[87],[35],[44697,44711,44712,44713],{"trials":44751,"activeCount":99},[],{"trials":44753,"activeCount":99},[],{"trials":44755,"activeCount":99},[],{"trials":44757,"activeCount":99},[],{"intervention":44713,"totalTrials":224,"cells":44759},{"EARLY_PHASE1":44760,"PHASE1":44762,"PHASE2":44768,"PHASE3":44770,"PHASE4":44772,"NA":44774},{"trials":44761,"activeCount":99},[],{"trials":44763,"activeCount":99},[44764],{"nctId":44704,"briefTitle":44705,"status":105,"phases":44765,"primaryCompletion":44707,"completion":44707,"start":9214,"enrollment":44708,"conditions":44766,"interventions":44767},[87],[35],[44697,44711,44712,44713],{"trials":44769,"activeCount":99},[],{"trials":44771,"activeCount":99},[],{"trials":44773,"activeCount":99},[],{"trials":44775,"activeCount":99},[],{"intervention":44777,"totalTrials":224,"cells":44778},"MK0431, sitagliptin phosphate \u002F Duration of Treatment : 1 Days",{"EARLY_PHASE1":44779,"PHASE1":44781,"PHASE2":44790,"PHASE3":44792,"PHASE4":44794,"NA":44796},{"trials":44780,"activeCount":99},[],{"trials":44782,"activeCount":99},[44783],{"nctId":44784,"briefTitle":44785,"status":105,"phases":44786,"primaryCompletion":5508,"completion":5508,"start":20197,"enrollment":120,"conditions":44787,"interventions":44789},"NCT00418366","A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)",[87],[13409,44788],"Hemodialysis",[44777],{"trials":44791,"activeCount":99},[],{"trials":44793,"activeCount":99},[],{"trials":44795,"activeCount":99},[],{"trials":44797,"activeCount":99},[],{"intervention":44799,"totalTrials":224,"cells":44800},"Calderasib OCT",{"EARLY_PHASE1":44801,"PHASE1":44803,"PHASE2":44814,"PHASE3":44816,"PHASE4":44818,"NA":44820},{"trials":44802,"activeCount":99},[],{"trials":44804,"activeCount":99},[44805],{"nctId":44806,"briefTitle":44807,"status":105,"phases":44808,"primaryCompletion":44809,"completion":44810,"start":4408,"enrollment":13439,"conditions":44811,"interventions":44812},"NCT06942741","A Study to Evaluate the Effect of Formulation and Food on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-011)",[87],"2025-06-22","2025-08-04",[18],[44799,44813],"Calderasib FCT",{"trials":44815,"activeCount":99},[],{"trials":44817,"activeCount":99},[],{"trials":44819,"activeCount":99},[],{"trials":44821,"activeCount":99},[],{"intervention":44813,"totalTrials":224,"cells":44823},{"EARLY_PHASE1":44824,"PHASE1":44826,"PHASE2":44832,"PHASE3":44834,"PHASE4":44836,"NA":44838},{"trials":44825,"activeCount":99},[],{"trials":44827,"activeCount":99},[44828],{"nctId":44806,"briefTitle":44807,"status":105,"phases":44829,"primaryCompletion":44809,"completion":44810,"start":4408,"enrollment":13439,"conditions":44830,"interventions":44831},[87],[18],[44799,44813],{"trials":44833,"activeCount":99},[],{"trials":44835,"activeCount":99},[],{"trials":44837,"activeCount":99},[],{"trials":44839,"activeCount":99},[],{"intervention":32856,"totalTrials":224,"cells":44841},{"EARLY_PHASE1":44842,"PHASE1":44844,"PHASE2":44850,"PHASE3":44852,"PHASE4":44854,"NA":44856},{"trials":44843,"activeCount":99},[],{"trials":44845,"activeCount":99},[44846],{"nctId":32849,"briefTitle":32850,"status":105,"phases":44847,"primaryCompletion":32852,"completion":32852,"start":32853,"enrollment":1349,"conditions":44848,"interventions":44849},[87],[14715],[16932,32856],{"trials":44851,"activeCount":99},[],{"trials":44853,"activeCount":99},[],{"trials":44855,"activeCount":99},[],{"trials":44857,"activeCount":99},[],{"intervention":44859,"totalTrials":224,"cells":44860},"10 mg MK-0941 DFC",{"EARLY_PHASE1":44861,"PHASE1":44863,"PHASE2":44872,"PHASE3":44874,"PHASE4":44876,"NA":44878},{"trials":44862,"activeCount":99},[],{"trials":44864,"activeCount":99},[44865],{"nctId":44866,"briefTitle":44867,"status":105,"phases":44868,"primaryCompletion":5281,"completion":14408,"start":14504,"enrollment":931,"conditions":44869,"interventions":44870},"NCT00567112","Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)",[87],[15],[44859,44871,44871,44871],"10 mg MK-0941 OCT",{"trials":44873,"activeCount":99},[],{"trials":44875,"activeCount":99},[],{"trials":44877,"activeCount":99},[],{"trials":44879,"activeCount":99},[],{"intervention":44871,"totalTrials":224,"cells":44881},{"EARLY_PHASE1":44882,"PHASE1":44884,"PHASE2":44890,"PHASE3":44892,"PHASE4":44894,"NA":44896},{"trials":44883,"activeCount":99},[],{"trials":44885,"activeCount":99},[44886],{"nctId":44866,"briefTitle":44867,"status":105,"phases":44887,"primaryCompletion":5281,"completion":14408,"start":14504,"enrollment":931,"conditions":44888,"interventions":44889},[87],[15],[44859,44871,44871,44871],{"trials":44891,"activeCount":99},[],{"trials":44893,"activeCount":99},[],{"trials":44895,"activeCount":99},[],{"trials":44897,"activeCount":99},[],{"intervention":44899,"totalTrials":224,"cells":44900},"L-697,661",{"EARLY_PHASE1":44901,"PHASE1":44903,"PHASE2":44911,"PHASE3":44913,"PHASE4":44915,"NA":44917},{"trials":44902,"activeCount":99},[],{"trials":44904,"activeCount":99},[44905],{"nctId":44906,"briefTitle":44907,"status":105,"phases":44908,"enrollment":36,"conditions":44909,"interventions":44910},"NCT00000628","A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine",[87],[27],[44899,17756],{"trials":44912,"activeCount":99},[],{"trials":44914,"activeCount":99},[],{"trials":44916,"activeCount":99},[],{"trials":44918,"activeCount":99},[],{"intervention":41325,"totalTrials":224,"cells":44920},{"EARLY_PHASE1":44921,"PHASE1":44923,"PHASE2":44929,"PHASE3":44931,"PHASE4":44933,"NA":44935},{"trials":44922,"activeCount":99},[],{"trials":44924,"activeCount":99},[44925],{"nctId":41317,"briefTitle":41318,"status":105,"phases":44926,"primaryCompletion":30970,"completion":41320,"start":41321,"enrollment":18999,"conditions":44927,"interventions":44928},[87],[41323],[2817,41325],{"trials":44930,"activeCount":99},[],{"trials":44932,"activeCount":99},[],{"trials":44934,"activeCount":99},[],{"trials":44936,"activeCount":99},[],{"intervention":44938,"totalTrials":224,"cells":44939},"Monovalent MRKAd5 HIV-1 gag vaccine",{"EARLY_PHASE1":44940,"PHASE1":44942,"PHASE2":44952,"PHASE3":44954,"PHASE4":44956,"NA":44958},{"trials":44941,"activeCount":99},[],{"trials":44943,"activeCount":99},[44944],{"nctId":44945,"briefTitle":44946,"status":105,"phases":44947,"primaryCompletion":15211,"completion":6308,"start":17248,"enrollment":14253,"conditions":44948,"interventions":44949},"NCT00849680","A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag\u002FPol\u002FNef Vaccine in Healthy Adults (V520-016)",[87],[11444,27],[44938,44950,44950,44950,44950,44950,44950,44951],"Trivalent MRKAd5 HIV-1 gag\u002Fpol\u002Fnef vaccine","Comparator: Placebo to MRKAd5 HIV-1 gag vaccine",{"trials":44953,"activeCount":99},[],{"trials":44955,"activeCount":99},[],{"trials":44957,"activeCount":99},[],{"trials":44959,"activeCount":99},[],{"intervention":44950,"totalTrials":224,"cells":44961},{"EARLY_PHASE1":44962,"PHASE1":44964,"PHASE2":44970,"PHASE3":44972,"PHASE4":44974,"NA":44976},{"trials":44963,"activeCount":99},[],{"trials":44965,"activeCount":99},[44966],{"nctId":44945,"briefTitle":44946,"status":105,"phases":44967,"primaryCompletion":15211,"completion":6308,"start":17248,"enrollment":14253,"conditions":44968,"interventions":44969},[87],[11444,27],[44938,44950,44950,44950,44950,44950,44950,44951],{"trials":44971,"activeCount":99},[],{"trials":44973,"activeCount":99},[],{"trials":44975,"activeCount":99},[],{"trials":44977,"activeCount":99},[],{"intervention":44951,"totalTrials":224,"cells":44979},{"EARLY_PHASE1":44980,"PHASE1":44982,"PHASE2":44988,"PHASE3":44990,"PHASE4":44992,"NA":44994},{"trials":44981,"activeCount":99},[],{"trials":44983,"activeCount":99},[44984],{"nctId":44945,"briefTitle":44946,"status":105,"phases":44985,"primaryCompletion":15211,"completion":6308,"start":17248,"enrollment":14253,"conditions":44986,"interventions":44987},[87],[11444,27],[44938,44950,44950,44950,44950,44950,44950,44951],{"trials":44989,"activeCount":99},[],{"trials":44991,"activeCount":99},[],{"trials":44993,"activeCount":99},[],{"trials":44995,"activeCount":99},[],{"intervention":44997,"totalTrials":224,"cells":44998},"[14C]Calderasib",{"EARLY_PHASE1":44999,"PHASE1":45001,"PHASE2":45010,"PHASE3":45012,"PHASE4":45014,"NA":45016},{"trials":45000,"activeCount":99},[],{"trials":45002,"activeCount":99},[45003],{"nctId":45004,"briefTitle":45005,"status":105,"phases":45006,"primaryCompletion":2872,"completion":2872,"start":45007,"enrollment":734,"conditions":45008,"interventions":45009},"NCT06687759","A Study of Calderasib (MK-1084) Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)",[87],"2024-06-26",[18],[44997],{"trials":45011,"activeCount":99},[],{"trials":45013,"activeCount":99},[],{"trials":45015,"activeCount":99},[],{"trials":45017,"activeCount":99},[],{"intervention":42204,"totalTrials":224,"cells":45019},{"EARLY_PHASE1":45020,"PHASE1":45022,"PHASE2":45028,"PHASE3":45030,"PHASE4":45032,"NA":45034},{"trials":45021,"activeCount":99},[],{"trials":45023,"activeCount":99},[45024],{"nctId":42199,"briefTitle":42200,"status":105,"phases":45025,"primaryCompletion":14504,"completion":14504,"start":14540,"enrollment":1054,"conditions":45026,"interventions":45027},[87],[4397],[42192,42204,42205],{"trials":45029,"activeCount":99},[],{"trials":45031,"activeCount":99},[],{"trials":45033,"activeCount":99},[],{"trials":45035,"activeCount":99},[],{"intervention":42205,"totalTrials":224,"cells":45037},{"EARLY_PHASE1":45038,"PHASE1":45040,"PHASE2":45046,"PHASE3":45048,"PHASE4":45050,"NA":45052},{"trials":45039,"activeCount":99},[],{"trials":45041,"activeCount":99},[45042],{"nctId":42199,"briefTitle":42200,"status":105,"phases":45043,"primaryCompletion":14504,"completion":14504,"start":14540,"enrollment":1054,"conditions":45044,"interventions":45045},[87],[4397],[42192,42204,42205],{"trials":45047,"activeCount":99},[],{"trials":45049,"activeCount":99},[],{"trials":45051,"activeCount":99},[],{"trials":45053,"activeCount":99},[],{"intervention":45055,"totalTrials":224,"cells":45056},"MK-3402",{"EARLY_PHASE1":45057,"PHASE1":45059,"PHASE2":45069,"PHASE3":45071,"PHASE4":45073,"NA":45075},{"trials":45058,"activeCount":99},[],{"trials":45060,"activeCount":99},[45061],{"nctId":45062,"briefTitle":45063,"status":150,"phases":45064,"primaryCompletion":45065,"completion":45066,"start":19169,"enrollment":3308,"conditions":45067,"interventions":45068},"NCT04678505","Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)",[87],"2021-04-15","2021-04-27",[4074],[45055],{"trials":45070,"activeCount":99},[],{"trials":45072,"activeCount":99},[],{"trials":45074,"activeCount":99},[],{"trials":45076,"activeCount":99},[],{"intervention":45078,"totalTrials":224,"cells":45079},"Comparator: MK0429",{"EARLY_PHASE1":45080,"PHASE1":45082,"PHASE2":45090,"PHASE3":45092,"PHASE4":45094,"NA":45096},{"trials":45081,"activeCount":99},[],{"trials":45083,"activeCount":99},[45084],{"nctId":45085,"briefTitle":45086,"status":105,"phases":45087,"primaryCompletion":14540,"completion":14540,"start":14483,"enrollment":31,"conditions":45088,"interventions":45089},"NCT00302471","MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)",[87],[2410],[45078,45078,45078,45078],{"trials":45091,"activeCount":99},[],{"trials":45093,"activeCount":99},[],{"trials":45095,"activeCount":99},[],{"trials":45097,"activeCount":99},[],{"intervention":45099,"totalTrials":224,"cells":45100},"MK6592",{"EARLY_PHASE1":45101,"PHASE1":45103,"PHASE2":45112,"PHASE3":45114,"PHASE4":45116,"NA":45118},{"trials":45102,"activeCount":99},[],{"trials":45104,"activeCount":99},[45105],{"nctId":45106,"briefTitle":45107,"status":150,"phases":45108,"primaryCompletion":13891,"completion":13891,"start":15038,"enrollment":312,"conditions":45109,"interventions":45110},"NCT00359671","Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001)",[87],[497],[45099,45111],"comparator: docetaxel",{"trials":45113,"activeCount":99},[],{"trials":45115,"activeCount":99},[],{"trials":45117,"activeCount":99},[],{"trials":45119,"activeCount":99},[],{"intervention":45111,"totalTrials":224,"cells":45121},{"EARLY_PHASE1":45122,"PHASE1":45124,"PHASE2":45130,"PHASE3":45132,"PHASE4":45134,"NA":45136},{"trials":45123,"activeCount":99},[],{"trials":45125,"activeCount":99},[45126],{"nctId":45106,"briefTitle":45107,"status":150,"phases":45127,"primaryCompletion":13891,"completion":13891,"start":15038,"enrollment":312,"conditions":45128,"interventions":45129},[87],[497],[45099,45111],{"trials":45131,"activeCount":99},[],{"trials":45133,"activeCount":99},[],{"trials":45135,"activeCount":99},[],{"trials":45137,"activeCount":99},[],{"intervention":45139,"totalTrials":224,"cells":45140},"V935",{"EARLY_PHASE1":45141,"PHASE1":45143,"PHASE2":45155,"PHASE3":45157,"PHASE4":45159,"NA":45161},{"trials":45142,"activeCount":99},[],{"trials":45144,"activeCount":99},[45145],{"nctId":45146,"briefTitle":45147,"status":105,"phases":45148,"primaryCompletion":16802,"completion":16802,"start":13102,"enrollment":661,"conditions":45149,"interventions":45153},"NCT00753415","A Study of V934\u002FV935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)",[87],[2576,1109,35,45150,45151,702,45152,4411],"Upper GI Tract Carcinoma","Colon Carcinoma","Bladder Carcinoma",[45139,45154],"V934-EP",{"trials":45156,"activeCount":99},[],{"trials":45158,"activeCount":99},[],{"trials":45160,"activeCount":99},[],{"trials":45162,"activeCount":99},[],{"intervention":45154,"totalTrials":224,"cells":45164},{"EARLY_PHASE1":45165,"PHASE1":45167,"PHASE2":45173,"PHASE3":45175,"PHASE4":45177,"NA":45179},{"trials":45166,"activeCount":99},[],{"trials":45168,"activeCount":99},[45169],{"nctId":45146,"briefTitle":45147,"status":105,"phases":45170,"primaryCompletion":16802,"completion":16802,"start":13102,"enrollment":661,"conditions":45171,"interventions":45172},[87],[2576,1109,35,45150,45151,702,45152,4411],[45139,45154],{"trials":45174,"activeCount":99},[],{"trials":45176,"activeCount":99},[],{"trials":45178,"activeCount":99},[],{"trials":45180,"activeCount":99},[],{"intervention":45182,"totalTrials":224,"cells":45183},"[18F]MK-6240, ~185 MBq",{"EARLY_PHASE1":45184,"PHASE1":45186,"PHASE2":45196,"PHASE3":45198,"PHASE4":45200,"NA":45202},{"trials":45185,"activeCount":99},[],{"trials":45187,"activeCount":99},[45188],{"nctId":45189,"briefTitle":45190,"status":105,"phases":45191,"primaryCompletion":45192,"completion":45192,"start":2033,"enrollment":5563,"conditions":45193,"interventions":45194},"NCT02562989","[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)",[87],"2016-12-27",[11174,27318],[45182,45195],"[18F]MK-6240, ~160 MBq",{"trials":45197,"activeCount":99},[],{"trials":45199,"activeCount":99},[],{"trials":45201,"activeCount":99},[],{"trials":45203,"activeCount":99},[],{"intervention":45195,"totalTrials":224,"cells":45205},{"EARLY_PHASE1":45206,"PHASE1":45208,"PHASE2":45214,"PHASE3":45216,"PHASE4":45218,"NA":45220},{"trials":45207,"activeCount":99},[],{"trials":45209,"activeCount":99},[45210],{"nctId":45189,"briefTitle":45190,"status":105,"phases":45211,"primaryCompletion":45192,"completion":45192,"start":2033,"enrollment":5563,"conditions":45212,"interventions":45213},[87],[11174,27318],[45182,45195],{"trials":45215,"activeCount":99},[],{"trials":45217,"activeCount":99},[],{"trials":45219,"activeCount":99},[],{"trials":45221,"activeCount":99},[],{"intervention":45223,"totalTrials":224,"cells":45224},"MK-8226",{"EARLY_PHASE1":45225,"PHASE1":45227,"PHASE2":45238,"PHASE3":45240,"PHASE4":45242,"NA":45244},{"trials":45226,"activeCount":99},[],{"trials":45228,"activeCount":99},[45229],{"nctId":45230,"briefTitle":45231,"status":150,"phases":45232,"primaryCompletion":45233,"completion":45233,"start":45234,"enrollment":2801,"conditions":45235,"interventions":45237},"NCT01732510","A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003)",[87],"2014-10-20","2012-12-21",[45236],"Atopic Dermatitis",[45223],{"trials":45239,"activeCount":99},[],{"trials":45241,"activeCount":99},[],{"trials":45243,"activeCount":99},[],{"trials":45245,"activeCount":99},[],{"intervention":45247,"totalTrials":224,"cells":45248},"MK-0616",{"EARLY_PHASE1":45249,"PHASE1":45251,"PHASE2":45261,"PHASE3":45263,"PHASE4":45265,"NA":45267},{"trials":45250,"activeCount":99},[],{"trials":45252,"activeCount":99},[45253],{"nctId":45254,"briefTitle":45255,"status":105,"phases":45256,"primaryCompletion":45257,"completion":45257,"start":45258,"enrollment":120,"conditions":45259,"interventions":45260},"NCT06592339","A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)",[87],"2022-12-29","2022-10-25",[7598],[45247],{"trials":45262,"activeCount":99},[],{"trials":45264,"activeCount":99},[],{"trials":45266,"activeCount":99},[],{"trials":45268,"activeCount":99},[],{"intervention":45270,"totalTrials":224,"cells":45271},"Ustekinumab",{"EARLY_PHASE1":45272,"PHASE1":45274,"PHASE2":45283,"PHASE3":45285,"PHASE4":45287,"NA":45289},{"trials":45273,"activeCount":99},[],{"trials":45275,"activeCount":99},[45276],{"nctId":45277,"briefTitle":45278,"status":105,"phases":45279,"primaryCompletion":12984,"completion":12984,"start":21145,"enrollment":3390,"conditions":45280,"interventions":45281},"NCT01276847","A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)",[87],[12754],[45270,45282],"Etanercept",{"trials":45284,"activeCount":99},[],{"trials":45286,"activeCount":99},[],{"trials":45288,"activeCount":99},[],{"trials":45290,"activeCount":99},[],{"intervention":45292,"totalTrials":224,"cells":45293},"Laropiprant",{"EARLY_PHASE1":45294,"PHASE1":45296,"PHASE2":45305,"PHASE3":45307,"PHASE4":45309,"NA":45311},{"trials":45295,"activeCount":99},[],{"trials":45297,"activeCount":99},[45298],{"nctId":45299,"briefTitle":45300,"status":105,"phases":45301,"primaryCompletion":16794,"completion":16794,"start":41848,"enrollment":558,"conditions":45302,"interventions":45304},"NCT01451619","A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)",[87],[45303],"Rosacea",[45292],{"trials":45306,"activeCount":99},[],{"trials":45308,"activeCount":99},[],{"trials":45310,"activeCount":99},[],{"trials":45312,"activeCount":99},[],{"intervention":15627,"totalTrials":224,"cells":45314},{"EARLY_PHASE1":45315,"PHASE1":45317,"PHASE2":45323,"PHASE3":45325,"PHASE4":45327,"NA":45329},{"trials":45316,"activeCount":99},[],{"trials":45318,"activeCount":99},[45319],{"nctId":15618,"briefTitle":15619,"status":105,"phases":45320,"primaryCompletion":15621,"completion":15622,"start":15623,"enrollment":931,"conditions":45321,"interventions":45322},[87],[15],[14487,15626,15627,15628],{"trials":45324,"activeCount":99},[],{"trials":45326,"activeCount":99},[],{"trials":45328,"activeCount":99},[],{"trials":45330,"activeCount":99},[],{"intervention":15628,"totalTrials":224,"cells":45332},{"EARLY_PHASE1":45333,"PHASE1":45335,"PHASE2":45341,"PHASE3":45343,"PHASE4":45345,"NA":45347},{"trials":45334,"activeCount":99},[],{"trials":45336,"activeCount":99},[45337],{"nctId":15618,"briefTitle":15619,"status":105,"phases":45338,"primaryCompletion":15621,"completion":15622,"start":15623,"enrollment":931,"conditions":45339,"interventions":45340},[87],[15],[14487,15626,15627,15628],{"trials":45342,"activeCount":99},[],{"trials":45344,"activeCount":99},[],{"trials":45346,"activeCount":99},[],{"trials":45348,"activeCount":99},[],{"intervention":33379,"totalTrials":224,"cells":45350},{"EARLY_PHASE1":45351,"PHASE1":45353,"PHASE2":45359,"PHASE3":45361,"PHASE4":45363,"NA":45365},{"trials":45352,"activeCount":99},[],{"trials":45354,"activeCount":99},[45355],{"nctId":33374,"briefTitle":33375,"status":105,"phases":45356,"primaryCompletion":20258,"completion":5982,"start":12813,"enrollment":805,"conditions":45357,"interventions":45358},[87],[12957],[33379,33361,33380,33381],{"trials":45360,"activeCount":99},[],{"trials":45362,"activeCount":99},[],{"trials":45364,"activeCount":99},[],{"trials":45366,"activeCount":99},[],{"intervention":33380,"totalTrials":224,"cells":45368},{"EARLY_PHASE1":45369,"PHASE1":45371,"PHASE2":45377,"PHASE3":45379,"PHASE4":45381,"NA":45383},{"trials":45370,"activeCount":99},[],{"trials":45372,"activeCount":99},[45373],{"nctId":33374,"briefTitle":33375,"status":105,"phases":45374,"primaryCompletion":20258,"completion":5982,"start":12813,"enrollment":805,"conditions":45375,"interventions":45376},[87],[12957],[33379,33361,33380,33381],{"trials":45378,"activeCount":99},[],{"trials":45380,"activeCount":99},[],{"trials":45382,"activeCount":99},[],{"trials":45384,"activeCount":99},[],{"intervention":33381,"totalTrials":224,"cells":45386},{"EARLY_PHASE1":45387,"PHASE1":45389,"PHASE2":45395,"PHASE3":45397,"PHASE4":45399,"NA":45401},{"trials":45388,"activeCount":99},[],{"trials":45390,"activeCount":99},[45391],{"nctId":33374,"briefTitle":33375,"status":105,"phases":45392,"primaryCompletion":20258,"completion":5982,"start":12813,"enrollment":805,"conditions":45393,"interventions":45394},[87],[12957],[33379,33361,33380,33381],{"trials":45396,"activeCount":99},[],{"trials":45398,"activeCount":99},[],{"trials":45400,"activeCount":99},[],{"trials":45402,"activeCount":99},[],{"intervention":45404,"totalTrials":224,"cells":45405},"INS115644 Ophthalmic Solution",{"EARLY_PHASE1":45406,"PHASE1":45408,"PHASE2":45416,"PHASE3":45418,"PHASE4":45420,"NA":45422},{"trials":45407,"activeCount":99},[],{"trials":45409,"activeCount":99},[45410],{"nctId":45411,"briefTitle":45412,"status":105,"phases":45413,"primaryCompletion":9610,"completion":9610,"start":4419,"enrollment":1621,"conditions":45414,"interventions":45415},"NCT00443924","Study of INS115644 Ophthalmic Solution in Subjects With Ocular Hypertension or Glaucoma",[87],[17147,17159],[45404,45404,45404,45404],{"trials":45417,"activeCount":99},[],{"trials":45419,"activeCount":99},[],{"trials":45421,"activeCount":99},[],{"trials":45423,"activeCount":99},[],{"intervention":45425,"totalTrials":224,"cells":45426},"MK-8457",{"EARLY_PHASE1":45427,"PHASE1":45429,"PHASE2":45439,"PHASE3":45441,"PHASE4":45443,"NA":45445},{"trials":45428,"activeCount":99},[],{"trials":45430,"activeCount":99},[45431],{"nctId":45432,"briefTitle":45433,"status":105,"phases":45434,"primaryCompletion":45435,"completion":45436,"start":4289,"enrollment":4741,"conditions":45437,"interventions":45438},"NCT01446003","A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)",[87],"2012-02-18","2012-03-03",[30],[45425],{"trials":45440,"activeCount":99},[],{"trials":45442,"activeCount":99},[],{"trials":45444,"activeCount":99},[],{"trials":45446,"activeCount":99},[],{"intervention":45448,"totalTrials":224,"cells":45449},"RV16UB",{"EARLY_PHASE1":45450,"PHASE1":45452,"PHASE2":45463,"PHASE3":45465,"PHASE4":45467,"NA":45469},{"trials":45451,"activeCount":99},[],{"trials":45453,"activeCount":99},[45454],{"nctId":45455,"briefTitle":45456,"status":105,"phases":45457,"primaryCompletion":45458,"completion":45459,"start":17061,"enrollment":17672,"conditions":45460,"interventions":45461},"NCT01866306","A Study to Evaluate the Safety and Use of Human Rhinovirus in Healthy and Asthmatic Participants (MK-0000-218)",[87],"2015-12-25","2016-01-18",[5985],[45448,45462],"LABA",{"trials":45464,"activeCount":99},[],{"trials":45466,"activeCount":99},[],{"trials":45468,"activeCount":99},[],{"trials":45470,"activeCount":99},[],{"intervention":45462,"totalTrials":224,"cells":45472},{"EARLY_PHASE1":45473,"PHASE1":45475,"PHASE2":45481,"PHASE3":45483,"PHASE4":45485,"NA":45487},{"trials":45474,"activeCount":99},[],{"trials":45476,"activeCount":99},[45477],{"nctId":45455,"briefTitle":45456,"status":105,"phases":45478,"primaryCompletion":45458,"completion":45459,"start":17061,"enrollment":17672,"conditions":45479,"interventions":45480},[87],[5985],[45448,45462],{"trials":45482,"activeCount":99},[],{"trials":45484,"activeCount":99},[],{"trials":45486,"activeCount":99},[],{"trials":45488,"activeCount":99},[],{"intervention":373,"totalTrials":224,"cells":45490},{"EARLY_PHASE1":45491,"PHASE1":45493,"PHASE2":45499,"PHASE3":45501,"PHASE4":45503,"NA":45505},{"trials":45492,"activeCount":99},[],{"trials":45494,"activeCount":99},[45495],{"nctId":362,"briefTitle":363,"status":150,"phases":45496,"primaryCompletion":365,"completion":365,"start":366,"enrollment":367,"conditions":45497,"interventions":45498},[87],[290,369,370,371],[373,47],{"trials":45500,"activeCount":99},[],{"trials":45502,"activeCount":99},[],{"trials":45504,"activeCount":99},[],{"trials":45506,"activeCount":99},[],{"intervention":45508,"totalTrials":224,"cells":45509},"dabigatran etexilate",{"EARLY_PHASE1":45510,"PHASE1":45512,"PHASE2":45522,"PHASE3":45524,"PHASE4":45526,"NA":45528},{"trials":45511,"activeCount":99},[],{"trials":45513,"activeCount":99},[45514],{"nctId":45515,"briefTitle":45516,"status":105,"phases":45517,"primaryCompletion":12984,"completion":12984,"start":5981,"enrollment":184,"conditions":45518,"interventions":45520},"NCT01379300","A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)",[87],[45519],"Thrombosis",[45508,45521],"rivaroxaban",{"trials":45523,"activeCount":99},[],{"trials":45525,"activeCount":99},[],{"trials":45527,"activeCount":99},[],{"trials":45529,"activeCount":99},[],{"intervention":45521,"totalTrials":224,"cells":45531},{"EARLY_PHASE1":45532,"PHASE1":45534,"PHASE2":45540,"PHASE3":45542,"PHASE4":45544,"NA":45546},{"trials":45533,"activeCount":99},[],{"trials":45535,"activeCount":99},[45536],{"nctId":45515,"briefTitle":45516,"status":105,"phases":45537,"primaryCompletion":12984,"completion":12984,"start":5981,"enrollment":184,"conditions":45538,"interventions":45539},[87],[45519],[45508,45521],{"trials":45541,"activeCount":99},[],{"trials":45543,"activeCount":99},[],{"trials":45545,"activeCount":99},[],{"trials":45547,"activeCount":99},[],{"intervention":12831,"totalTrials":224,"cells":45549},{"EARLY_PHASE1":45550,"PHASE1":45552,"PHASE2":45558,"PHASE3":45560,"PHASE4":45562,"NA":45564},{"trials":45551,"activeCount":99},[],{"trials":45553,"activeCount":99},[45554],{"nctId":12825,"briefTitle":12826,"status":105,"phases":45555,"primaryCompletion":4202,"completion":4202,"start":12828,"enrollment":25,"conditions":45556,"interventions":45557},[87],[18],[7801,7335,12831,12832],{"trials":45559,"activeCount":99},[],{"trials":45561,"activeCount":99},[],{"trials":45563,"activeCount":99},[],{"trials":45565,"activeCount":99},[],{"intervention":12832,"totalTrials":224,"cells":45567},{"EARLY_PHASE1":45568,"PHASE1":45570,"PHASE2":45576,"PHASE3":45578,"PHASE4":45580,"NA":45582},{"trials":45569,"activeCount":99},[],{"trials":45571,"activeCount":99},[45572],{"nctId":12825,"briefTitle":12826,"status":105,"phases":45573,"primaryCompletion":4202,"completion":4202,"start":12828,"enrollment":25,"conditions":45574,"interventions":45575},[87],[18],[7801,7335,12831,12832],{"trials":45577,"activeCount":99},[],{"trials":45579,"activeCount":99},[],{"trials":45581,"activeCount":99},[],{"trials":45583,"activeCount":99},[],{"intervention":45585,"totalTrials":224,"cells":45586},"MK-8510",{"EARLY_PHASE1":45587,"PHASE1":45589,"PHASE2":45601,"PHASE3":45603,"PHASE4":45605,"NA":45607},{"trials":45588,"activeCount":99},[],{"trials":45590,"activeCount":99},[45591],{"nctId":45592,"briefTitle":45593,"status":1040,"phases":45594,"primaryCompletion":45595,"completion":45595,"start":45596,"enrollment":99,"conditions":45597,"interventions":45600},"NCT05700734","MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)",[87],"2024-02-14","2023-04-17",[11444,45598,45599,9502],"Human Immunodeficiency Virus 1","Immunodeficiency Virus Type 1, Human",[45585],{"trials":45602,"activeCount":99},[],{"trials":45604,"activeCount":99},[],{"trials":45606,"activeCount":99},[],{"trials":45608,"activeCount":99},[],{"intervention":45610,"totalTrials":224,"cells":45611},"Raltegravir 1200 mg",{"EARLY_PHASE1":45612,"PHASE1":45614,"PHASE2":45627,"PHASE3":45629,"PHASE4":45631,"NA":45633},{"trials":45613,"activeCount":99},[],{"trials":45615,"activeCount":99},[45616],{"nctId":45617,"briefTitle":45618,"status":105,"phases":45619,"primaryCompletion":45620,"completion":45621,"start":45622,"enrollment":805,"conditions":45623,"interventions":45624},"NCT02473367","The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824)",[87],"2015-08-29","2015-10-09","2015-06-23",[7650],[45610,45625,45626],"TUMS","Leader Antacid",{"trials":45628,"activeCount":99},[],{"trials":45630,"activeCount":99},[],{"trials":45632,"activeCount":99},[],{"trials":45634,"activeCount":99},[],{"intervention":45625,"totalTrials":224,"cells":45636},{"EARLY_PHASE1":45637,"PHASE1":45639,"PHASE2":45645,"PHASE3":45647,"PHASE4":45649,"NA":45651},{"trials":45638,"activeCount":99},[],{"trials":45640,"activeCount":99},[45641],{"nctId":45617,"briefTitle":45618,"status":105,"phases":45642,"primaryCompletion":45620,"completion":45621,"start":45622,"enrollment":805,"conditions":45643,"interventions":45644},[87],[7650],[45610,45625,45626],{"trials":45646,"activeCount":99},[],{"trials":45648,"activeCount":99},[],{"trials":45650,"activeCount":99},[],{"trials":45652,"activeCount":99},[],{"intervention":45626,"totalTrials":224,"cells":45654},{"EARLY_PHASE1":45655,"PHASE1":45657,"PHASE2":45663,"PHASE3":45665,"PHASE4":45667,"NA":45669},{"trials":45656,"activeCount":99},[],{"trials":45658,"activeCount":99},[45659],{"nctId":45617,"briefTitle":45618,"status":105,"phases":45660,"primaryCompletion":45620,"completion":45621,"start":45622,"enrollment":805,"conditions":45661,"interventions":45662},[87],[7650],[45610,45625,45626],{"trials":45664,"activeCount":99},[],{"trials":45666,"activeCount":99},[],{"trials":45668,"activeCount":99},[],{"trials":45670,"activeCount":99},[],{"intervention":45672,"totalTrials":224,"cells":45673},"MK-7680",{"EARLY_PHASE1":45674,"PHASE1":45676,"PHASE2":45684,"PHASE3":45686,"PHASE4":45688,"NA":45690},{"trials":45675,"activeCount":99},[],{"trials":45677,"activeCount":99},[45678],{"nctId":45679,"briefTitle":45680,"status":105,"phases":45681,"primaryCompletion":19635,"completion":20431,"start":23090,"enrollment":5563,"conditions":45682,"interventions":45683},"NCT02269059","Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)",[87],[24],[45672],{"trials":45685,"activeCount":99},[],{"trials":45687,"activeCount":99},[],{"trials":45689,"activeCount":99},[],{"trials":45691,"activeCount":99},[],{"intervention":45693,"totalTrials":224,"cells":45694},"MK-4618",{"EARLY_PHASE1":45695,"PHASE1":45697,"PHASE2":45708,"PHASE3":45710,"PHASE4":45712,"NA":45714},{"trials":45696,"activeCount":99},[],{"trials":45698,"activeCount":99},[45699],{"nctId":45700,"briefTitle":45701,"status":105,"phases":45702,"primaryCompletion":4329,"completion":4329,"start":45703,"enrollment":3506,"conditions":45704,"interventions":45705},"NCT01337674","Co-Administration of MK-4618 With Antihypertensive Agents (MK-4618-010)",[87],"2011-04-01",[30],[45693,45706,45707],"Metoprolol","Amlodipine",{"trials":45709,"activeCount":99},[],{"trials":45711,"activeCount":99},[],{"trials":45713,"activeCount":99},[],{"trials":45715,"activeCount":99},[],{"intervention":45706,"totalTrials":224,"cells":45717},{"EARLY_PHASE1":45718,"PHASE1":45720,"PHASE2":45726,"PHASE3":45728,"PHASE4":45730,"NA":45732},{"trials":45719,"activeCount":99},[],{"trials":45721,"activeCount":99},[45722],{"nctId":45700,"briefTitle":45701,"status":105,"phases":45723,"primaryCompletion":4329,"completion":4329,"start":45703,"enrollment":3506,"conditions":45724,"interventions":45725},[87],[30],[45693,45706,45707],{"trials":45727,"activeCount":99},[],{"trials":45729,"activeCount":99},[],{"trials":45731,"activeCount":99},[],{"trials":45733,"activeCount":99},[],{"intervention":45707,"totalTrials":224,"cells":45735},{"EARLY_PHASE1":45736,"PHASE1":45738,"PHASE2":45744,"PHASE3":45746,"PHASE4":45748,"NA":45750},{"trials":45737,"activeCount":99},[],{"trials":45739,"activeCount":99},[45740],{"nctId":45700,"briefTitle":45701,"status":105,"phases":45741,"primaryCompletion":4329,"completion":4329,"start":45703,"enrollment":3506,"conditions":45742,"interventions":45743},[87],[30],[45693,45706,45707],{"trials":45745,"activeCount":99},[],{"trials":45747,"activeCount":99},[],{"trials":45749,"activeCount":99},[],{"trials":45751,"activeCount":99},[],{"intervention":42213,"totalTrials":224,"cells":45753},{"EARLY_PHASE1":45754,"PHASE1":45756,"PHASE2":45762,"PHASE3":45764,"PHASE4":45766,"NA":45768},{"trials":45755,"activeCount":99},[],{"trials":45757,"activeCount":99},[45758],{"nctId":42207,"briefTitle":42208,"status":105,"phases":45759,"primaryCompletion":42210,"completion":42210,"start":20654,"enrollment":120,"conditions":45760,"interventions":45761},[87],[14524],[42192,42213,42214,42215],{"trials":45763,"activeCount":99},[],{"trials":45765,"activeCount":99},[],{"trials":45767,"activeCount":99},[],{"trials":45769,"activeCount":99},[],{"intervention":42214,"totalTrials":224,"cells":45771},{"EARLY_PHASE1":45772,"PHASE1":45774,"PHASE2":45780,"PHASE3":45782,"PHASE4":45784,"NA":45786},{"trials":45773,"activeCount":99},[],{"trials":45775,"activeCount":99},[45776],{"nctId":42207,"briefTitle":42208,"status":105,"phases":45777,"primaryCompletion":42210,"completion":42210,"start":20654,"enrollment":120,"conditions":45778,"interventions":45779},[87],[14524],[42192,42213,42214,42215],{"trials":45781,"activeCount":99},[],{"trials":45783,"activeCount":99},[],{"trials":45785,"activeCount":99},[],{"trials":45787,"activeCount":99},[],{"intervention":42215,"totalTrials":224,"cells":45789},{"EARLY_PHASE1":45790,"PHASE1":45792,"PHASE2":45798,"PHASE3":45800,"PHASE4":45802,"NA":45804},{"trials":45791,"activeCount":99},[],{"trials":45793,"activeCount":99},[45794],{"nctId":42207,"briefTitle":42208,"status":105,"phases":45795,"primaryCompletion":42210,"completion":42210,"start":20654,"enrollment":120,"conditions":45796,"interventions":45797},[87],[14524],[42192,42213,42214,42215],{"trials":45799,"activeCount":99},[],{"trials":45801,"activeCount":99},[],{"trials":45803,"activeCount":99},[],{"trials":45805,"activeCount":99},[],{"intervention":45807,"totalTrials":224,"cells":45808},"IDX21459",{"EARLY_PHASE1":45809,"PHASE1":45811,"PHASE2":45820,"PHASE3":45822,"PHASE4":45824,"NA":45826},{"trials":45810,"activeCount":99},[],{"trials":45812,"activeCount":99},[45813],{"nctId":45814,"briefTitle":45815,"status":150,"phases":45816,"primaryCompletion":20319,"completion":20319,"start":45817,"enrollment":1054,"conditions":45818,"interventions":45819},"NCT02112942","Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects",[87],"2014-03",[12957],[45807],{"trials":45821,"activeCount":99},[],{"trials":45823,"activeCount":99},[],{"trials":45825,"activeCount":99},[],{"trials":45827,"activeCount":99},[],{"intervention":45829,"totalTrials":224,"cells":45830},"Ridaforolimus 100 mg",{"EARLY_PHASE1":45831,"PHASE1":45833,"PHASE2":45844,"PHASE3":45846,"PHASE4":45848,"NA":45850},{"trials":45832,"activeCount":99},[],{"trials":45834,"activeCount":99},[45835],{"nctId":45836,"briefTitle":45837,"status":105,"phases":45838,"primaryCompletion":15769,"completion":45839,"start":32767,"enrollment":3141,"conditions":45840,"interventions":45842},"NCT00874731","A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)",[87],"2010-04-30",[45841],"Metastatic or Locally Advanced Cancer",[45829,45843],"Ridaforolimus 40 mg",{"trials":45845,"activeCount":99},[],{"trials":45847,"activeCount":99},[],{"trials":45849,"activeCount":99},[],{"trials":45851,"activeCount":99},[],{"intervention":45843,"totalTrials":224,"cells":45853},{"EARLY_PHASE1":45854,"PHASE1":45856,"PHASE2":45862,"PHASE3":45864,"PHASE4":45866,"NA":45868},{"trials":45855,"activeCount":99},[],{"trials":45857,"activeCount":99},[45858],{"nctId":45836,"briefTitle":45837,"status":105,"phases":45859,"primaryCompletion":15769,"completion":45839,"start":32767,"enrollment":3141,"conditions":45860,"interventions":45861},[87],[45841],[45829,45843],{"trials":45863,"activeCount":99},[],{"trials":45865,"activeCount":99},[],{"trials":45867,"activeCount":99},[],{"trials":45869,"activeCount":99},[],{"intervention":45871,"totalTrials":224,"cells":45872},"Pembrolizumab Pre-Resection",{"EARLY_PHASE1":45873,"PHASE1":45875,"PHASE2":45886,"PHASE3":45888,"PHASE4":45890,"NA":45892},{"trials":45874,"activeCount":99},[],{"trials":45876,"activeCount":99},[45877],{"nctId":45878,"briefTitle":45879,"status":150,"phases":45880,"primaryCompletion":45881,"completion":45881,"start":11428,"enrollment":335,"conditions":45882,"interventions":45884},"NCT02212730","A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)",[87],"2019-07-05",[45883],"Renal Cell Cancer",[45871,45885],"Pembrolizumab Post-Resection",{"trials":45887,"activeCount":99},[],{"trials":45889,"activeCount":99},[],{"trials":45891,"activeCount":99},[],{"trials":45893,"activeCount":99},[],{"intervention":45885,"totalTrials":224,"cells":45895},{"EARLY_PHASE1":45896,"PHASE1":45898,"PHASE2":45904,"PHASE3":45906,"PHASE4":45908,"NA":45910},{"trials":45897,"activeCount":99},[],{"trials":45899,"activeCount":99},[45900],{"nctId":45878,"briefTitle":45879,"status":150,"phases":45901,"primaryCompletion":45881,"completion":45881,"start":11428,"enrollment":335,"conditions":45902,"interventions":45903},[87],[45883],[45871,45885],{"trials":45905,"activeCount":99},[],{"trials":45907,"activeCount":99},[],{"trials":45909,"activeCount":99},[],{"trials":45911,"activeCount":99},[],{"intervention":45913,"totalTrials":224,"cells":45914},"INS117548",{"EARLY_PHASE1":45915,"PHASE1":45917,"PHASE2":45925,"PHASE3":45927,"PHASE4":45929,"NA":45931},{"trials":45916,"activeCount":99},[],{"trials":45918,"activeCount":99},[45919],{"nctId":45920,"briefTitle":45921,"status":105,"phases":45922,"primaryCompletion":14352,"completion":14352,"start":14315,"enrollment":11407,"conditions":45923,"interventions":45924},"NCT00767793","A Placebo-Controlled Study of INS117548 Ophthalmic Solution in Subjects With Glaucoma (P08650)",[87],[17137],[45913,45913,45913],{"trials":45926,"activeCount":99},[],{"trials":45928,"activeCount":99},[],{"trials":45930,"activeCount":99},[],{"trials":45932,"activeCount":99},[],{"intervention":4760,"totalTrials":224,"cells":45934},{"EARLY_PHASE1":45935,"PHASE1":45937,"PHASE2":45943,"PHASE3":45945,"PHASE4":45947,"NA":45949},{"trials":45936,"activeCount":99},[],{"trials":45938,"activeCount":99},[45939],{"nctId":4752,"briefTitle":4753,"status":105,"phases":45940,"primaryCompletion":4755,"completion":4755,"start":4756,"enrollment":3903,"conditions":45941,"interventions":45942},[87],[4758],[4760,1677],{"trials":45944,"activeCount":99},[],{"trials":45946,"activeCount":99},[],{"trials":45948,"activeCount":99},[],{"trials":45950,"activeCount":99},[],{"intervention":45952,"totalTrials":224,"cells":45953},"Dextrose 5% in water",{"EARLY_PHASE1":45954,"PHASE1":45956,"PHASE2":45966,"PHASE3":45968,"PHASE4":45970,"NA":45972},{"trials":45955,"activeCount":99},[],{"trials":45957,"activeCount":99},[45958],{"nctId":45959,"briefTitle":45960,"status":105,"phases":45961,"primaryCompletion":1386,"completion":1386,"start":45962,"enrollment":45963,"conditions":45964,"interventions":45965},"NCT01075984","Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520)",[87],"2010-02-23",279,[17830],[17832,45952],{"trials":45967,"activeCount":99},[],{"trials":45969,"activeCount":99},[],{"trials":45971,"activeCount":99},[],{"trials":45973,"activeCount":99},[],{"intervention":400,"totalTrials":224,"cells":45975},{"EARLY_PHASE1":45976,"PHASE1":45978,"PHASE2":45984,"PHASE3":45986,"PHASE4":45988,"NA":45990},{"trials":45977,"activeCount":99},[],{"trials":45979,"activeCount":99},[45980],{"nctId":392,"briefTitle":393,"status":105,"phases":45981,"primaryCompletion":395,"completion":395,"start":396,"enrollment":397,"conditions":45982,"interventions":45983},[87],[382],[400,47],{"trials":45985,"activeCount":99},[],{"trials":45987,"activeCount":99},[],{"trials":45989,"activeCount":99},[],{"trials":45991,"activeCount":99},[],{"intervention":13299,"totalTrials":224,"cells":45993},{"EARLY_PHASE1":45994,"PHASE1":45996,"PHASE2":46002,"PHASE3":46004,"PHASE4":46006,"NA":46008},{"trials":45995,"activeCount":99},[],{"trials":45997,"activeCount":99},[45998],{"nctId":13293,"briefTitle":13294,"status":105,"phases":45999,"primaryCompletion":1795,"completion":1795,"start":13296,"enrollment":2801,"conditions":46000,"interventions":46001},[87],[18],[13189,13299,13300,13301],{"trials":46003,"activeCount":99},[],{"trials":46005,"activeCount":99},[],{"trials":46007,"activeCount":99},[],{"trials":46009,"activeCount":99},[],{"intervention":410,"totalTrials":224,"cells":46011},{"EARLY_PHASE1":46012,"PHASE1":46014,"PHASE2":46020,"PHASE3":46022,"PHASE4":46024,"NA":46026},{"trials":46013,"activeCount":99},[],{"trials":46015,"activeCount":99},[46016],{"nctId":402,"briefTitle":403,"status":150,"phases":46017,"primaryCompletion":405,"completion":405,"start":406,"enrollment":407,"conditions":46018,"interventions":46019},[87],[279,302],[410,410,47],{"trials":46021,"activeCount":99},[],{"trials":46023,"activeCount":99},[],{"trials":46025,"activeCount":99},[],{"trials":46027,"activeCount":99},[],{"intervention":433,"totalTrials":224,"cells":46029},{"EARLY_PHASE1":46030,"PHASE1":46032,"PHASE2":46038,"PHASE3":46040,"PHASE4":46042,"NA":46044},{"trials":46031,"activeCount":99},[],{"trials":46033,"activeCount":99},[46034],{"nctId":423,"briefTitle":424,"status":105,"phases":46035,"primaryCompletion":426,"completion":427,"start":428,"enrollment":429,"conditions":46036,"interventions":46037},[87],[431],[47,433,434,435,436,437],{"trials":46039,"activeCount":99},[],{"trials":46041,"activeCount":99},[],{"trials":46043,"activeCount":99},[],{"trials":46045,"activeCount":99},[],{"intervention":436,"totalTrials":224,"cells":46047},{"EARLY_PHASE1":46048,"PHASE1":46050,"PHASE2":46056,"PHASE3":46058,"PHASE4":46060,"NA":46062},{"trials":46049,"activeCount":99},[],{"trials":46051,"activeCount":99},[46052],{"nctId":423,"briefTitle":424,"status":105,"phases":46053,"primaryCompletion":426,"completion":427,"start":428,"enrollment":429,"conditions":46054,"interventions":46055},[87],[431],[47,433,434,435,436,437],{"trials":46057,"activeCount":99},[],{"trials":46059,"activeCount":99},[],{"trials":46061,"activeCount":99},[],{"trials":46063,"activeCount":99},[],{"intervention":448,"totalTrials":224,"cells":46065},{"EARLY_PHASE1":46066,"PHASE1":46068,"PHASE2":46074,"PHASE3":46076,"PHASE4":46078,"NA":46080},{"trials":46067,"activeCount":99},[],{"trials":46069,"activeCount":99},[46070],{"nctId":439,"briefTitle":440,"status":105,"phases":46071,"primaryCompletion":442,"completion":442,"start":443,"enrollment":444,"conditions":46072,"interventions":46073},[87],[446],[448,47],{"trials":46075,"activeCount":99},[],{"trials":46077,"activeCount":99},[],{"trials":46079,"activeCount":99},[],{"trials":46081,"activeCount":99},[],{"intervention":5587,"totalTrials":224,"cells":46083},{"EARLY_PHASE1":46084,"PHASE1":46086,"PHASE2":46092,"PHASE3":46094,"PHASE4":46096,"NA":46098},{"trials":46085,"activeCount":99},[],{"trials":46087,"activeCount":99},[46088],{"nctId":5580,"briefTitle":5581,"status":105,"phases":46089,"primaryCompletion":5583,"completion":5583,"start":5584,"enrollment":1621,"conditions":46090,"interventions":46091},[87],[18],[602,5587],{"trials":46093,"activeCount":99},[],{"trials":46095,"activeCount":99},[],{"trials":46097,"activeCount":99},[],{"trials":46099,"activeCount":99},[],{"intervention":46101,"totalTrials":224,"cells":46102},"Allyl Isothiocyanate",{"EARLY_PHASE1":46103,"PHASE1":46105,"PHASE2":46115,"PHASE3":46117,"PHASE4":46119,"NA":46121},{"trials":46104,"activeCount":99},[],{"trials":46106,"activeCount":99},[46107],{"nctId":46108,"briefTitle":46109,"status":105,"phases":46110,"primaryCompletion":1684,"completion":1684,"start":46111,"enrollment":95,"conditions":46112,"interventions":46113},"NCT06809569","A Study to Evaluate Laser Speckle Contrast Imaging to Assess Changes in Chemical Agent-Induced Skin Blood Flow in Healthy Participants (MK-0000-420)",[87],"2023-09-25",[18],[46101,46114],"Capsaicin",{"trials":46116,"activeCount":99},[],{"trials":46118,"activeCount":99},[],{"trials":46120,"activeCount":99},[],{"trials":46122,"activeCount":99},[],{"intervention":46114,"totalTrials":224,"cells":46124},{"EARLY_PHASE1":46125,"PHASE1":46127,"PHASE2":46133,"PHASE3":46135,"PHASE4":46137,"NA":46139},{"trials":46126,"activeCount":99},[],{"trials":46128,"activeCount":99},[46129],{"nctId":46108,"briefTitle":46109,"status":105,"phases":46130,"primaryCompletion":1684,"completion":1684,"start":46111,"enrollment":95,"conditions":46131,"interventions":46132},[87],[18],[46101,46114],{"trials":46134,"activeCount":99},[],{"trials":46136,"activeCount":99},[],{"trials":46138,"activeCount":99},[],{"trials":46140,"activeCount":99},[],{"intervention":46142,"totalTrials":224,"cells":46143},"MK-8666",{"EARLY_PHASE1":46144,"PHASE1":46146,"PHASE2":46156,"PHASE3":46158,"PHASE4":46160,"NA":46162},{"trials":46145,"activeCount":99},[],{"trials":46147,"activeCount":99},[46148],{"nctId":46149,"briefTitle":46150,"status":105,"phases":46151,"primaryCompletion":46152,"completion":46152,"start":46153,"enrollment":18999,"conditions":46154,"interventions":46155},"NCT01971554","Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)",[87],"2014-04-26","2013-10-14",[15],[46142],{"trials":46157,"activeCount":99},[],{"trials":46159,"activeCount":99},[],{"trials":46161,"activeCount":99},[],{"trials":46163,"activeCount":99},[],{"intervention":14457,"totalTrials":224,"cells":46165},{"EARLY_PHASE1":46166,"PHASE1":46168,"PHASE2":46174,"PHASE3":46176,"PHASE4":46178,"NA":46180},{"trials":46167,"activeCount":99},[],{"trials":46169,"activeCount":99},[46170],{"nctId":14451,"briefTitle":14452,"status":105,"phases":46171,"primaryCompletion":14454,"completion":14454,"start":5507,"enrollment":3506,"conditions":46172,"interventions":46173},[87],[15],[14457,14458,14423,14331],{"trials":46175,"activeCount":99},[],{"trials":46177,"activeCount":99},[],{"trials":46179,"activeCount":99},[],{"trials":46181,"activeCount":99},[],{"intervention":14458,"totalTrials":224,"cells":46183},{"EARLY_PHASE1":46184,"PHASE1":46186,"PHASE2":46192,"PHASE3":46194,"PHASE4":46196,"NA":46198},{"trials":46185,"activeCount":99},[],{"trials":46187,"activeCount":99},[46188],{"nctId":14451,"briefTitle":14452,"status":105,"phases":46189,"primaryCompletion":14454,"completion":14454,"start":5507,"enrollment":3506,"conditions":46190,"interventions":46191},[87],[15],[14457,14458,14423,14331],{"trials":46193,"activeCount":99},[],{"trials":46195,"activeCount":99},[],{"trials":46197,"activeCount":99},[],{"trials":46199,"activeCount":99},[],{"intervention":459,"totalTrials":224,"cells":46201},{"EARLY_PHASE1":46202,"PHASE1":46204,"PHASE2":46210,"PHASE3":46212,"PHASE4":46214,"NA":46216},{"trials":46203,"activeCount":99},[],{"trials":46205,"activeCount":99},[46206],{"nctId":450,"briefTitle":451,"status":105,"phases":46207,"primaryCompletion":453,"completion":453,"start":454,"enrollment":455,"conditions":46208,"interventions":46209},[87],[290],[458,47,434,437,435,459,460,461],{"trials":46211,"activeCount":99},[],{"trials":46213,"activeCount":99},[],{"trials":46215,"activeCount":99},[],{"trials":46217,"activeCount":99},[],{"intervention":14470,"totalTrials":224,"cells":46219},{"EARLY_PHASE1":46220,"PHASE1":46222,"PHASE2":46228,"PHASE3":46230,"PHASE4":46232,"NA":46234},{"trials":46221,"activeCount":99},[],{"trials":46223,"activeCount":99},[46224],{"nctId":14460,"briefTitle":14461,"status":105,"phases":46225,"primaryCompletion":14315,"completion":14315,"start":14454,"enrollment":14463,"conditions":46226,"interventions":46227},[87],[14465,14466,14467,14468],[14470,13864],{"trials":46229,"activeCount":99},[],{"trials":46231,"activeCount":99},[],{"trials":46233,"activeCount":99},[],{"trials":46235,"activeCount":99},[],{"intervention":46237,"totalTrials":224,"cells":46238},"SCH 420814 10 mg",{"EARLY_PHASE1":46239,"PHASE1":46241,"PHASE2":46254,"PHASE3":46256,"PHASE4":46258,"NA":46260},{"trials":46240,"activeCount":99},[],{"trials":46242,"activeCount":99},[46243],{"nctId":46244,"briefTitle":46245,"status":105,"phases":46246,"primaryCompletion":45839,"completion":46247,"start":46248,"enrollment":95,"conditions":46249,"interventions":46250},"NCT00845000","Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)",[87],"2010-05-14","2009-04-21",[19998],[46237,46251,46252,46253],"SCH 420814 100 mg","Levodopa","Carbidopa",{"trials":46255,"activeCount":99},[],{"trials":46257,"activeCount":99},[],{"trials":46259,"activeCount":99},[],{"trials":46261,"activeCount":99},[],{"intervention":46251,"totalTrials":224,"cells":46263},{"EARLY_PHASE1":46264,"PHASE1":46266,"PHASE2":46272,"PHASE3":46274,"PHASE4":46276,"NA":46278},{"trials":46265,"activeCount":99},[],{"trials":46267,"activeCount":99},[46268],{"nctId":46244,"briefTitle":46245,"status":105,"phases":46269,"primaryCompletion":45839,"completion":46247,"start":46248,"enrollment":95,"conditions":46270,"interventions":46271},[87],[19998],[46237,46251,46252,46253],{"trials":46273,"activeCount":99},[],{"trials":46275,"activeCount":99},[],{"trials":46277,"activeCount":99},[],{"trials":46279,"activeCount":99},[],{"intervention":46252,"totalTrials":224,"cells":46281},{"EARLY_PHASE1":46282,"PHASE1":46284,"PHASE2":46290,"PHASE3":46292,"PHASE4":46294,"NA":46296},{"trials":46283,"activeCount":99},[],{"trials":46285,"activeCount":99},[46286],{"nctId":46244,"briefTitle":46245,"status":105,"phases":46287,"primaryCompletion":45839,"completion":46247,"start":46248,"enrollment":95,"conditions":46288,"interventions":46289},[87],[19998],[46237,46251,46252,46253],{"trials":46291,"activeCount":99},[],{"trials":46293,"activeCount":99},[],{"trials":46295,"activeCount":99},[],{"trials":46297,"activeCount":99},[],{"intervention":46253,"totalTrials":224,"cells":46299},{"EARLY_PHASE1":46300,"PHASE1":46302,"PHASE2":46308,"PHASE3":46310,"PHASE4":46312,"NA":46314},{"trials":46301,"activeCount":99},[],{"trials":46303,"activeCount":99},[46304],{"nctId":46244,"briefTitle":46245,"status":105,"phases":46305,"primaryCompletion":45839,"completion":46247,"start":46248,"enrollment":95,"conditions":46306,"interventions":46307},[87],[19998],[46237,46251,46252,46253],{"trials":46309,"activeCount":99},[],{"trials":46311,"activeCount":99},[],{"trials":46313,"activeCount":99},[],{"trials":46315,"activeCount":99},[],{"intervention":5956,"totalTrials":224,"cells":46317},{"EARLY_PHASE1":46318,"PHASE1":46320,"PHASE2":46326,"PHASE3":46328,"PHASE4":46330,"NA":46332},{"trials":46319,"activeCount":99},[],{"trials":46321,"activeCount":99},[46322],{"nctId":5948,"briefTitle":5949,"status":105,"phases":46323,"primaryCompletion":5951,"completion":5952,"start":5953,"enrollment":95,"conditions":46324,"interventions":46325},[87],[2410],[4278,1076,4777,5956],{"trials":46327,"activeCount":99},[],{"trials":46329,"activeCount":99},[],{"trials":46331,"activeCount":99},[],{"trials":46333,"activeCount":99},[],{"intervention":46335,"totalTrials":224,"cells":46336},"MK2206 every other day",{"EARLY_PHASE1":46337,"PHASE1":46339,"PHASE2":46348,"PHASE3":46350,"PHASE4":46352,"NA":46354},{"trials":46338,"activeCount":99},[],{"trials":46340,"activeCount":99},[46341],{"nctId":46342,"briefTitle":46343,"status":105,"phases":46344,"primaryCompletion":12985,"completion":12985,"start":6308,"enrollment":120,"conditions":46345,"interventions":46346},"NCT01071018","A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)",[87],[176],[46335,46347],"MK2206 once weekly",{"trials":46349,"activeCount":99},[],{"trials":46351,"activeCount":99},[],{"trials":46353,"activeCount":99},[],{"trials":46355,"activeCount":99},[],{"intervention":46347,"totalTrials":224,"cells":46357},{"EARLY_PHASE1":46358,"PHASE1":46360,"PHASE2":46366,"PHASE3":46368,"PHASE4":46370,"NA":46372},{"trials":46359,"activeCount":99},[],{"trials":46361,"activeCount":99},[46362],{"nctId":46342,"briefTitle":46343,"status":105,"phases":46363,"primaryCompletion":12985,"completion":12985,"start":6308,"enrollment":120,"conditions":46364,"interventions":46365},[87],[176],[46335,46347],{"trials":46367,"activeCount":99},[],{"trials":46369,"activeCount":99},[],{"trials":46371,"activeCount":99},[],{"trials":46373,"activeCount":99},[],{"intervention":7527,"totalTrials":224,"cells":46375},{"EARLY_PHASE1":46376,"PHASE1":46378,"PHASE2":46384,"PHASE3":46386,"PHASE4":46388,"NA":46390},{"trials":46377,"activeCount":99},[],{"trials":46379,"activeCount":99},[46380],{"nctId":7520,"briefTitle":7521,"status":105,"phases":46381,"primaryCompletion":1610,"completion":7523,"start":7524,"enrollment":3655,"conditions":46382,"interventions":46383},[87],[18],[7527,7528],{"trials":46385,"activeCount":99},[],{"trials":46387,"activeCount":99},[],{"trials":46389,"activeCount":99},[],{"trials":46391,"activeCount":99},[],{"intervention":46393,"totalTrials":224,"cells":46394},"MK-8876",{"EARLY_PHASE1":46395,"PHASE1":46397,"PHASE2":46406,"PHASE3":46408,"PHASE4":46410,"NA":46412},{"trials":46396,"activeCount":99},[],{"trials":46398,"activeCount":99},[46399],{"nctId":46400,"briefTitle":46401,"status":105,"phases":46402,"primaryCompletion":34026,"completion":34026,"start":46403,"enrollment":3308,"conditions":46404,"interventions":46405},"NCT01930058","Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003)",[87],"2013-10-02",[24],[46393],{"trials":46407,"activeCount":99},[],{"trials":46409,"activeCount":99},[],{"trials":46411,"activeCount":99},[],{"trials":46413,"activeCount":99},[],{"intervention":472,"totalTrials":224,"cells":46415},{"EARLY_PHASE1":46416,"PHASE1":46418,"PHASE2":46424,"PHASE3":46426,"PHASE4":46428,"NA":46430},{"trials":46417,"activeCount":99},[],{"trials":46419,"activeCount":99},[46420],{"nctId":463,"briefTitle":464,"status":105,"phases":46421,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":46422,"interventions":46423},[87],[290],[471,47,386,385,461,387,390,472],{"trials":46425,"activeCount":99},[],{"trials":46427,"activeCount":99},[],{"trials":46429,"activeCount":99},[],{"trials":46431,"activeCount":99},[],{"intervention":46433,"totalTrials":224,"cells":46434},"MK-8266 0.1 mg",{"EARLY_PHASE1":46435,"PHASE1":46437,"PHASE2":46447,"PHASE3":46449,"PHASE4":46451,"NA":46453},{"trials":46436,"activeCount":99},[],{"trials":46438,"activeCount":99},[46439],{"nctId":46440,"briefTitle":46441,"status":105,"phases":46442,"primaryCompletion":46247,"completion":46247,"start":46443,"enrollment":9323,"conditions":46444,"interventions":46445},"NCT01025791","A Single Dose Study of MK-8266 (MK-8266-001)",[87],"2009-11-18",[30],[46433,46446],"MK-8266 1.0 mg",{"trials":46448,"activeCount":99},[],{"trials":46450,"activeCount":99},[],{"trials":46452,"activeCount":99},[],{"trials":46454,"activeCount":99},[],{"intervention":46446,"totalTrials":224,"cells":46456},{"EARLY_PHASE1":46457,"PHASE1":46459,"PHASE2":46465,"PHASE3":46467,"PHASE4":46469,"NA":46471},{"trials":46458,"activeCount":99},[],{"trials":46460,"activeCount":99},[46461],{"nctId":46440,"briefTitle":46441,"status":105,"phases":46462,"primaryCompletion":46247,"completion":46247,"start":46443,"enrollment":9323,"conditions":46463,"interventions":46464},[87],[30],[46433,46446],{"trials":46466,"activeCount":99},[],{"trials":46468,"activeCount":99},[],{"trials":46470,"activeCount":99},[],{"trials":46472,"activeCount":99},[],{"intervention":46474,"totalTrials":224,"cells":46475},"MK-0873 Patch",{"EARLY_PHASE1":46476,"PHASE1":46478,"PHASE2":46489,"PHASE3":46491,"PHASE4":46493,"NA":46495},{"trials":46477,"activeCount":99},[],{"trials":46479,"activeCount":99},[46480],{"nctId":46481,"briefTitle":46482,"status":105,"phases":46483,"primaryCompletion":4328,"completion":4328,"start":44150,"enrollment":184,"conditions":46484,"interventions":46486},"NCT01140061","Safety, Tolerability and Pharmacokinetics of MK-0873 Following Patch Application in Healthy Participants and Psoriasis Participants (MK-0873-020)",[87],[46485],"Plaque Psoriasis",[46474,46487,46488],"MK-0873 Cream","Plain patch",{"trials":46490,"activeCount":99},[],{"trials":46492,"activeCount":99},[],{"trials":46494,"activeCount":99},[],{"trials":46496,"activeCount":99},[],{"intervention":46487,"totalTrials":224,"cells":46498},{"EARLY_PHASE1":46499,"PHASE1":46501,"PHASE2":46507,"PHASE3":46509,"PHASE4":46511,"NA":46513},{"trials":46500,"activeCount":99},[],{"trials":46502,"activeCount":99},[46503],{"nctId":46481,"briefTitle":46482,"status":105,"phases":46504,"primaryCompletion":4328,"completion":4328,"start":44150,"enrollment":184,"conditions":46505,"interventions":46506},[87],[46485],[46474,46487,46488],{"trials":46508,"activeCount":99},[],{"trials":46510,"activeCount":99},[],{"trials":46512,"activeCount":99},[],{"trials":46514,"activeCount":99},[],{"intervention":46488,"totalTrials":224,"cells":46516},{"EARLY_PHASE1":46517,"PHASE1":46519,"PHASE2":46525,"PHASE3":46527,"PHASE4":46529,"NA":46531},{"trials":46518,"activeCount":99},[],{"trials":46520,"activeCount":99},[46521],{"nctId":46481,"briefTitle":46482,"status":105,"phases":46522,"primaryCompletion":4328,"completion":4328,"start":44150,"enrollment":184,"conditions":46523,"interventions":46524},[87],[46485],[46474,46487,46488],{"trials":46526,"activeCount":99},[],{"trials":46528,"activeCount":99},[],{"trials":46530,"activeCount":99},[],{"trials":46532,"activeCount":99},[],{"intervention":21728,"totalTrials":224,"cells":46534},{"EARLY_PHASE1":46535,"PHASE1":46537,"PHASE2":46543,"PHASE3":46545,"PHASE4":46547,"NA":46549},{"trials":46536,"activeCount":99},[],{"trials":46538,"activeCount":99},[46539],{"nctId":21723,"briefTitle":21724,"status":105,"phases":46540,"primaryCompletion":14504,"completion":14504,"start":14540,"enrollment":120,"conditions":46541,"interventions":46542},[87],[14156],[14039,21728,21729,21730,21731,21732,21733,21734],{"trials":46544,"activeCount":99},[],{"trials":46546,"activeCount":99},[],{"trials":46548,"activeCount":99},[],{"trials":46550,"activeCount":99},[],{"intervention":21730,"totalTrials":224,"cells":46552},{"EARLY_PHASE1":46553,"PHASE1":46555,"PHASE2":46561,"PHASE3":46563,"PHASE4":46565,"NA":46567},{"trials":46554,"activeCount":99},[],{"trials":46556,"activeCount":99},[46557],{"nctId":21723,"briefTitle":21724,"status":105,"phases":46558,"primaryCompletion":14504,"completion":14504,"start":14540,"enrollment":120,"conditions":46559,"interventions":46560},[87],[14156],[14039,21728,21729,21730,21731,21732,21733,21734],{"trials":46562,"activeCount":99},[],{"trials":46564,"activeCount":99},[],{"trials":46566,"activeCount":99},[],{"trials":46568,"activeCount":99},[],{"intervention":21732,"totalTrials":224,"cells":46570},{"EARLY_PHASE1":46571,"PHASE1":46573,"PHASE2":46579,"PHASE3":46581,"PHASE4":46583,"NA":46585},{"trials":46572,"activeCount":99},[],{"trials":46574,"activeCount":99},[46575],{"nctId":21723,"briefTitle":21724,"status":105,"phases":46576,"primaryCompletion":14504,"completion":14504,"start":14540,"enrollment":120,"conditions":46577,"interventions":46578},[87],[14156],[14039,21728,21729,21730,21731,21732,21733,21734],{"trials":46580,"activeCount":99},[],{"trials":46582,"activeCount":99},[],{"trials":46584,"activeCount":99},[],{"trials":46586,"activeCount":99},[],{"intervention":21734,"totalTrials":224,"cells":46588},{"EARLY_PHASE1":46589,"PHASE1":46591,"PHASE2":46597,"PHASE3":46599,"PHASE4":46601,"NA":46603},{"trials":46590,"activeCount":99},[],{"trials":46592,"activeCount":99},[46593],{"nctId":21723,"briefTitle":21724,"status":105,"phases":46594,"primaryCompletion":14504,"completion":14504,"start":14540,"enrollment":120,"conditions":46595,"interventions":46596},[87],[14156],[14039,21728,21729,21730,21731,21732,21733,21734],{"trials":46598,"activeCount":99},[],{"trials":46600,"activeCount":99},[],{"trials":46602,"activeCount":99},[],{"trials":46604,"activeCount":99},[],{"intervention":46606,"totalTrials":224,"cells":46607},"[14C] MK-5475",{"EARLY_PHASE1":46608,"PHASE1":46610,"PHASE2":46618,"PHASE3":46620,"PHASE4":46622,"NA":46624},{"trials":46609,"activeCount":99},[],{"trials":46611,"activeCount":99},[46612],{"nctId":46613,"briefTitle":46614,"status":105,"phases":46615,"primaryCompletion":929,"completion":45258,"start":2094,"enrollment":734,"conditions":46616,"interventions":46617},"NCT06777602","A Clinical Study To Understand How Radiolabeled MK-5475 Is Taken Up By The Body, Broken Down And Then Removed From The Body in Healthy Participants (MK-5475-011)",[87],[18],[46606],{"trials":46619,"activeCount":99},[],{"trials":46621,"activeCount":99},[],{"trials":46623,"activeCount":99},[],{"trials":46625,"activeCount":99},[],{"intervention":34248,"totalTrials":224,"cells":46627},{"EARLY_PHASE1":46628,"PHASE1":46630,"PHASE2":46636,"PHASE3":46638,"PHASE4":46640,"NA":46642},{"trials":46629,"activeCount":99},[],{"trials":46631,"activeCount":99},[46632],{"nctId":34238,"briefTitle":34239,"status":150,"phases":46633,"primaryCompletion":34241,"completion":34241,"start":34242,"enrollment":3963,"conditions":46634,"interventions":46635},[87],[34244,34245],[34231,34247,34248],{"trials":46637,"activeCount":99},[],{"trials":46639,"activeCount":99},[],{"trials":46641,"activeCount":99},[],{"trials":46643,"activeCount":99},[],{"intervention":46645,"totalTrials":224,"cells":46646},"V920 Vaccine",{"EARLY_PHASE1":46647,"PHASE1":46649,"PHASE2":46660,"PHASE3":46662,"PHASE4":46664,"NA":46666},{"trials":46648,"activeCount":99},[],{"trials":46650,"activeCount":99},[46651],{"nctId":46652,"briefTitle":46653,"status":105,"phases":46654,"primaryCompletion":46655,"completion":46655,"start":46656,"enrollment":46657,"conditions":46658,"interventions":46659},"NCT02314923","Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)",[87],"2016-06-23","2014-12-05",513,[42285],[46645],{"trials":46661,"activeCount":99},[],{"trials":46663,"activeCount":99},[],{"trials":46665,"activeCount":99},[],{"trials":46667,"activeCount":99},[],{"intervention":46669,"totalTrials":224,"cells":46670},"MK-0457",{"EARLY_PHASE1":46671,"PHASE1":46673,"PHASE2":46681,"PHASE3":46683,"PHASE4":46685,"NA":46687},{"trials":46672,"activeCount":99},[],{"trials":46674,"activeCount":99},[46675],{"nctId":46676,"briefTitle":46677,"status":150,"phases":46678,"primaryCompletion":14687,"completion":14687,"start":14930,"enrollment":36,"conditions":46679,"interventions":46680},"NCT02532868","A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)",[87],[639],[46669],{"trials":46682,"activeCount":99},[],{"trials":46684,"activeCount":99},[],{"trials":46686,"activeCount":99},[],{"trials":46688,"activeCount":99},[],{"intervention":46690,"totalTrials":224,"cells":46691},"Comparator: Placebo 5mg",{"EARLY_PHASE1":46692,"PHASE1":46694,"PHASE2":46705,"PHASE3":46707,"PHASE4":46709,"NA":46711},{"trials":46693,"activeCount":99},[],{"trials":46695,"activeCount":99},[46696],{"nctId":46697,"briefTitle":46698,"status":105,"phases":46699,"primaryCompletion":14730,"completion":4990,"start":14353,"enrollment":14904,"conditions":46700,"interventions":46701},"NCT00777608","A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED)",[87],[11174],[46690,46702,46703,46704],"Donepezil 5 - 10 mg","Comparator: Placebo 5-10 mg","Donepezil 10 mg",{"trials":46706,"activeCount":99},[],{"trials":46708,"activeCount":99},[],{"trials":46710,"activeCount":99},[],{"trials":46712,"activeCount":99},[],{"intervention":46702,"totalTrials":224,"cells":46714},{"EARLY_PHASE1":46715,"PHASE1":46717,"PHASE2":46723,"PHASE3":46725,"PHASE4":46727,"NA":46729},{"trials":46716,"activeCount":99},[],{"trials":46718,"activeCount":99},[46719],{"nctId":46697,"briefTitle":46698,"status":105,"phases":46720,"primaryCompletion":14730,"completion":4990,"start":14353,"enrollment":14904,"conditions":46721,"interventions":46722},[87],[11174],[46690,46702,46703,46704],{"trials":46724,"activeCount":99},[],{"trials":46726,"activeCount":99},[],{"trials":46728,"activeCount":99},[],{"trials":46730,"activeCount":99},[],{"intervention":46703,"totalTrials":224,"cells":46732},{"EARLY_PHASE1":46733,"PHASE1":46735,"PHASE2":46741,"PHASE3":46743,"PHASE4":46745,"NA":46747},{"trials":46734,"activeCount":99},[],{"trials":46736,"activeCount":99},[46737],{"nctId":46697,"briefTitle":46698,"status":105,"phases":46738,"primaryCompletion":14730,"completion":4990,"start":14353,"enrollment":14904,"conditions":46739,"interventions":46740},[87],[11174],[46690,46702,46703,46704],{"trials":46742,"activeCount":99},[],{"trials":46744,"activeCount":99},[],{"trials":46746,"activeCount":99},[],{"trials":46748,"activeCount":99},[],{"intervention":46704,"totalTrials":224,"cells":46750},{"EARLY_PHASE1":46751,"PHASE1":46753,"PHASE2":46759,"PHASE3":46761,"PHASE4":46763,"NA":46765},{"trials":46752,"activeCount":99},[],{"trials":46754,"activeCount":99},[46755],{"nctId":46697,"briefTitle":46698,"status":105,"phases":46756,"primaryCompletion":14730,"completion":4990,"start":14353,"enrollment":14904,"conditions":46757,"interventions":46758},[87],[11174],[46690,46702,46703,46704],{"trials":46760,"activeCount":99},[],{"trials":46762,"activeCount":99},[],{"trials":46764,"activeCount":99},[],{"trials":46766,"activeCount":99},[],{"intervention":14478,"totalTrials":224,"cells":46768},{"EARLY_PHASE1":46769,"PHASE1":46771,"PHASE2":46777,"PHASE3":46779,"PHASE4":46781,"NA":46783},{"trials":46770,"activeCount":99},[],{"trials":46772,"activeCount":99},[46773],{"nctId":14472,"briefTitle":14473,"status":105,"phases":46774,"primaryCompletion":13101,"completion":13101,"start":14314,"enrollment":2023,"conditions":46775,"interventions":46776},[87],[14395],[14477,14478,13864],{"trials":46778,"activeCount":99},[],{"trials":46780,"activeCount":99},[],{"trials":46782,"activeCount":99},[],{"trials":46784,"activeCount":99},[],{"intervention":46786,"totalTrials":224,"cells":46787},"MK-2748",{"EARLY_PHASE1":46788,"PHASE1":46790,"PHASE2":46798,"PHASE3":46800,"PHASE4":46802,"NA":46804},{"trials":46789,"activeCount":99},[],{"trials":46791,"activeCount":99},[46792],{"nctId":46793,"briefTitle":46794,"status":105,"phases":46795,"primaryCompletion":20411,"completion":20411,"start":15845,"enrollment":154,"conditions":46796,"interventions":46797},"NCT01593735","A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)",[87],[24],[46786],{"trials":46799,"activeCount":99},[],{"trials":46801,"activeCount":99},[],{"trials":46803,"activeCount":99},[],{"trials":46805,"activeCount":99},[],{"intervention":41573,"totalTrials":224,"cells":46807},{"EARLY_PHASE1":46808,"PHASE1":46810,"PHASE2":46816,"PHASE3":46818,"PHASE4":46820,"NA":46822},{"trials":46809,"activeCount":99},[],{"trials":46811,"activeCount":99},[46812],{"nctId":41565,"briefTitle":41566,"status":105,"phases":46813,"primaryCompletion":41568,"completion":41568,"start":41569,"enrollment":1621,"conditions":46814,"interventions":46815},[87],[41571],[41573,41365],{"trials":46817,"activeCount":99},[],{"trials":46819,"activeCount":99},[],{"trials":46821,"activeCount":99},[],{"trials":46823,"activeCount":99},[],{"intervention":4257,"totalTrials":224,"cells":46825},{"EARLY_PHASE1":46826,"PHASE1":46828,"PHASE2":46834,"PHASE3":46836,"PHASE4":46838,"NA":46840},{"trials":46827,"activeCount":99},[],{"trials":46829,"activeCount":99},[46830],{"nctId":4249,"briefTitle":4250,"status":105,"phases":46831,"primaryCompletion":4252,"completion":4252,"start":4253,"enrollment":193,"conditions":46832,"interventions":46833},[87],[4255],[4257,4258,4259,4260,1089],{"trials":46835,"activeCount":99},[],{"trials":46837,"activeCount":99},[],{"trials":46839,"activeCount":99},[],{"trials":46841,"activeCount":99},[],{"intervention":4258,"totalTrials":224,"cells":46843},{"EARLY_PHASE1":46844,"PHASE1":46846,"PHASE2":46852,"PHASE3":46854,"PHASE4":46856,"NA":46858},{"trials":46845,"activeCount":99},[],{"trials":46847,"activeCount":99},[46848],{"nctId":4249,"briefTitle":4250,"status":105,"phases":46849,"primaryCompletion":4252,"completion":4252,"start":4253,"enrollment":193,"conditions":46850,"interventions":46851},[87],[4255],[4257,4258,4259,4260,1089],{"trials":46853,"activeCount":99},[],{"trials":46855,"activeCount":99},[],{"trials":46857,"activeCount":99},[],{"trials":46859,"activeCount":99},[],{"intervention":4260,"totalTrials":224,"cells":46861},{"EARLY_PHASE1":46862,"PHASE1":46864,"PHASE2":46870,"PHASE3":46872,"PHASE4":46874,"NA":46876},{"trials":46863,"activeCount":99},[],{"trials":46865,"activeCount":99},[46866],{"nctId":4249,"briefTitle":4250,"status":105,"phases":46867,"primaryCompletion":4252,"completion":4252,"start":4253,"enrollment":193,"conditions":46868,"interventions":46869},[87],[4255],[4257,4258,4259,4260,1089],{"trials":46871,"activeCount":99},[],{"trials":46873,"activeCount":99},[],{"trials":46875,"activeCount":99},[],{"trials":46877,"activeCount":99},[],{"intervention":14489,"totalTrials":224,"cells":46879},{"EARLY_PHASE1":46880,"PHASE1":46882,"PHASE2":46888,"PHASE3":46890,"PHASE4":46892,"NA":46894},{"trials":46881,"activeCount":99},[],{"trials":46883,"activeCount":99},[46884],{"nctId":14480,"briefTitle":14481,"status":105,"phases":46885,"primaryCompletion":14483,"completion":14483,"start":14484,"enrollment":3655,"conditions":46886,"interventions":46887},[87],[14156],[14487,14488,14489,14331],{"trials":46889,"activeCount":99},[],{"trials":46891,"activeCount":99},[],{"trials":46893,"activeCount":99},[],{"trials":46895,"activeCount":99},[],{"intervention":46897,"totalTrials":224,"cells":46898},"MK-8150",{"EARLY_PHASE1":46899,"PHASE1":46901,"PHASE2":46912,"PHASE3":46914,"PHASE4":46916,"NA":46918},{"trials":46900,"activeCount":99},[],{"trials":46902,"activeCount":99},[46903],{"nctId":46904,"briefTitle":46905,"status":105,"phases":46906,"primaryCompletion":13948,"completion":46907,"start":46908,"enrollment":722,"conditions":46909,"interventions":46911},"NCT01656408","A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)",[87],"2013-05-23","2012-08-01",[30,46910],"Isolated Systolic Hypertension",[46897],{"trials":46913,"activeCount":99},[],{"trials":46915,"activeCount":99},[],{"trials":46917,"activeCount":99},[],{"trials":46919,"activeCount":99},[],{"intervention":46921,"totalTrials":224,"cells":46922},"PegIFN alfa-2b",{"EARLY_PHASE1":46923,"PHASE1":46925,"PHASE2":46934,"PHASE3":46936,"PHASE4":46938,"NA":46940},{"trials":46924,"activeCount":99},[],{"trials":46926,"activeCount":99},[46927],{"nctId":46928,"briefTitle":46929,"status":150,"phases":46930,"primaryCompletion":11376,"completion":15958,"start":46931,"enrollment":3308,"conditions":46932,"interventions":46933},"NCT01636960","A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)",[87],"2012-12-25",[883],[46921],{"trials":46935,"activeCount":99},[],{"trials":46937,"activeCount":99},[],{"trials":46939,"activeCount":99},[],{"trials":46941,"activeCount":99},[],{"intervention":46943,"totalTrials":224,"cells":46944},"A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine",{"EARLY_PHASE1":46945,"PHASE1":46947,"PHASE2":46959,"PHASE3":46961,"PHASE4":46963,"NA":46965},{"trials":46946,"activeCount":99},[],{"trials":46948,"activeCount":99},[46949],{"nctId":46950,"briefTitle":46951,"status":105,"phases":46952,"primaryCompletion":14540,"completion":14540,"start":14324,"enrollment":4741,"conditions":46953,"interventions":46954},"NCT01181310","Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED)",[87],[11195],[46943,46955,46956,46957,46958],"B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg","C: MK-3134 25 mg + Scopolamine 0.5 mg","D: Donepezil 10 mg + Scopolamine 0.5 mg","E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg",{"trials":46960,"activeCount":99},[],{"trials":46962,"activeCount":99},[],{"trials":46964,"activeCount":99},[],{"trials":46966,"activeCount":99},[],{"intervention":46955,"totalTrials":224,"cells":46968},{"EARLY_PHASE1":46969,"PHASE1":46971,"PHASE2":46977,"PHASE3":46979,"PHASE4":46981,"NA":46983},{"trials":46970,"activeCount":99},[],{"trials":46972,"activeCount":99},[46973],{"nctId":46950,"briefTitle":46951,"status":105,"phases":46974,"primaryCompletion":14540,"completion":14540,"start":14324,"enrollment":4741,"conditions":46975,"interventions":46976},[87],[11195],[46943,46955,46956,46957,46958],{"trials":46978,"activeCount":99},[],{"trials":46980,"activeCount":99},[],{"trials":46982,"activeCount":99},[],{"trials":46984,"activeCount":99},[],{"intervention":46956,"totalTrials":224,"cells":46986},{"EARLY_PHASE1":46987,"PHASE1":46989,"PHASE2":46995,"PHASE3":46997,"PHASE4":46999,"NA":47001},{"trials":46988,"activeCount":99},[],{"trials":46990,"activeCount":99},[46991],{"nctId":46950,"briefTitle":46951,"status":105,"phases":46992,"primaryCompletion":14540,"completion":14540,"start":14324,"enrollment":4741,"conditions":46993,"interventions":46994},[87],[11195],[46943,46955,46956,46957,46958],{"trials":46996,"activeCount":99},[],{"trials":46998,"activeCount":99},[],{"trials":47000,"activeCount":99},[],{"trials":47002,"activeCount":99},[],{"intervention":46957,"totalTrials":224,"cells":47004},{"EARLY_PHASE1":47005,"PHASE1":47007,"PHASE2":47013,"PHASE3":47015,"PHASE4":47017,"NA":47019},{"trials":47006,"activeCount":99},[],{"trials":47008,"activeCount":99},[47009],{"nctId":46950,"briefTitle":46951,"status":105,"phases":47010,"primaryCompletion":14540,"completion":14540,"start":14324,"enrollment":4741,"conditions":47011,"interventions":47012},[87],[11195],[46943,46955,46956,46957,46958],{"trials":47014,"activeCount":99},[],{"trials":47016,"activeCount":99},[],{"trials":47018,"activeCount":99},[],{"trials":47020,"activeCount":99},[],{"intervention":46958,"totalTrials":224,"cells":47022},{"EARLY_PHASE1":47023,"PHASE1":47025,"PHASE2":47031,"PHASE3":47033,"PHASE4":47035,"NA":47037},{"trials":47024,"activeCount":99},[],{"trials":47026,"activeCount":99},[47027],{"nctId":46950,"briefTitle":46951,"status":105,"phases":47028,"primaryCompletion":14540,"completion":14540,"start":14324,"enrollment":4741,"conditions":47029,"interventions":47030},[87],[11195],[46943,46955,46956,46957,46958],{"trials":47032,"activeCount":99},[],{"trials":47034,"activeCount":99},[],{"trials":47036,"activeCount":99},[],{"trials":47038,"activeCount":99},[],{"intervention":47040,"totalTrials":224,"cells":47041},"Prevnar™",{"EARLY_PHASE1":47042,"PHASE1":47044,"PHASE2":47056,"PHASE3":47058,"PHASE4":47060,"NA":47062},{"trials":47043,"activeCount":99},[],{"trials":47045,"activeCount":99},[47046],{"nctId":47047,"briefTitle":47048,"status":105,"phases":47049,"primaryCompletion":47050,"completion":47051,"start":2900,"enrollment":2779,"conditions":47052,"interventions":47053},"NCT01215175","Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)",[87],"2010-04-16","2011-01-05",[16472],[47040,47054,47055],"V114, Aluminum Adjuvanted","V114, Aluminum Nonadjuvanted",{"trials":47057,"activeCount":99},[],{"trials":47059,"activeCount":99},[],{"trials":47061,"activeCount":99},[],{"trials":47063,"activeCount":99},[],{"intervention":47054,"totalTrials":224,"cells":47065},{"EARLY_PHASE1":47066,"PHASE1":47068,"PHASE2":47074,"PHASE3":47076,"PHASE4":47078,"NA":47080},{"trials":47067,"activeCount":99},[],{"trials":47069,"activeCount":99},[47070],{"nctId":47047,"briefTitle":47048,"status":105,"phases":47071,"primaryCompletion":47050,"completion":47051,"start":2900,"enrollment":2779,"conditions":47072,"interventions":47073},[87],[16472],[47040,47054,47055],{"trials":47075,"activeCount":99},[],{"trials":47077,"activeCount":99},[],{"trials":47079,"activeCount":99},[],{"trials":47081,"activeCount":99},[],{"intervention":47055,"totalTrials":224,"cells":47083},{"EARLY_PHASE1":47084,"PHASE1":47086,"PHASE2":47092,"PHASE3":47094,"PHASE4":47096,"NA":47098},{"trials":47085,"activeCount":99},[],{"trials":47087,"activeCount":99},[47088],{"nctId":47047,"briefTitle":47048,"status":105,"phases":47089,"primaryCompletion":47050,"completion":47051,"start":2900,"enrollment":2779,"conditions":47090,"interventions":47091},[87],[16472],[47040,47054,47055],{"trials":47093,"activeCount":99},[],{"trials":47095,"activeCount":99},[],{"trials":47097,"activeCount":99},[],{"trials":47099,"activeCount":99},[],{"intervention":14498,"totalTrials":224,"cells":47101},{"EARLY_PHASE1":47102,"PHASE1":47104,"PHASE2":47110,"PHASE3":47112,"PHASE4":47114,"NA":47116},{"trials":47103,"activeCount":99},[],{"trials":47105,"activeCount":99},[47106],{"nctId":14491,"briefTitle":14492,"status":105,"phases":47107,"primaryCompletion":14484,"completion":14494,"start":14495,"enrollment":3496,"conditions":47108,"interventions":47109},[87],[24],[14498,13864,14499,14498],{"trials":47111,"activeCount":99},[],{"trials":47113,"activeCount":99},[],{"trials":47115,"activeCount":99},[],{"trials":47117,"activeCount":99},[],{"intervention":14499,"totalTrials":224,"cells":47119},{"EARLY_PHASE1":47120,"PHASE1":47122,"PHASE2":47128,"PHASE3":47130,"PHASE4":47132,"NA":47134},{"trials":47121,"activeCount":99},[],{"trials":47123,"activeCount":99},[47124],{"nctId":14491,"briefTitle":14492,"status":105,"phases":47125,"primaryCompletion":14484,"completion":14494,"start":14495,"enrollment":3496,"conditions":47126,"interventions":47127},[87],[24],[14498,13864,14499,14498],{"trials":47129,"activeCount":99},[],{"trials":47131,"activeCount":99},[],{"trials":47133,"activeCount":99},[],{"trials":47135,"activeCount":99},[],{"intervention":47137,"totalTrials":224,"cells":47138},"adavosertib 20 mg",{"EARLY_PHASE1":47139,"PHASE1":47141,"PHASE2":47153,"PHASE3":47155,"PHASE4":47157,"NA":47159},{"trials":47140,"activeCount":99},[],{"trials":47142,"activeCount":99},[47143],{"nctId":47144,"briefTitle":47145,"status":150,"phases":47146,"primaryCompletion":22919,"completion":22919,"start":47147,"enrollment":5983,"conditions":47148,"interventions":47149},"NCT01047007","A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU\u002FCDDP in Patients With Advanced Solid Tumor (1775-005",[87],"2010-01-18",[176],[47137,47150,47151,47152],"5-FU 1000 mg\u002Fm^2\u002Fday","CDDP","adavosertib 65 mg",{"trials":47154,"activeCount":99},[],{"trials":47156,"activeCount":99},[],{"trials":47158,"activeCount":99},[],{"trials":47160,"activeCount":99},[],{"intervention":47150,"totalTrials":224,"cells":47162},{"EARLY_PHASE1":47163,"PHASE1":47165,"PHASE2":47171,"PHASE3":47173,"PHASE4":47175,"NA":47177},{"trials":47164,"activeCount":99},[],{"trials":47166,"activeCount":99},[47167],{"nctId":47144,"briefTitle":47145,"status":150,"phases":47168,"primaryCompletion":22919,"completion":22919,"start":47147,"enrollment":5983,"conditions":47169,"interventions":47170},[87],[176],[47137,47150,47151,47152],{"trials":47172,"activeCount":99},[],{"trials":47174,"activeCount":99},[],{"trials":47176,"activeCount":99},[],{"trials":47178,"activeCount":99},[],{"intervention":47151,"totalTrials":224,"cells":47180},{"EARLY_PHASE1":47181,"PHASE1":47183,"PHASE2":47189,"PHASE3":47191,"PHASE4":47193,"NA":47195},{"trials":47182,"activeCount":99},[],{"trials":47184,"activeCount":99},[47185],{"nctId":47144,"briefTitle":47145,"status":150,"phases":47186,"primaryCompletion":22919,"completion":22919,"start":47147,"enrollment":5983,"conditions":47187,"interventions":47188},[87],[176],[47137,47150,47151,47152],{"trials":47190,"activeCount":99},[],{"trials":47192,"activeCount":99},[],{"trials":47194,"activeCount":99},[],{"trials":47196,"activeCount":99},[],{"intervention":47152,"totalTrials":224,"cells":47198},{"EARLY_PHASE1":47199,"PHASE1":47201,"PHASE2":47207,"PHASE3":47209,"PHASE4":47211,"NA":47213},{"trials":47200,"activeCount":99},[],{"trials":47202,"activeCount":99},[47203],{"nctId":47144,"briefTitle":47145,"status":150,"phases":47204,"primaryCompletion":22919,"completion":22919,"start":47147,"enrollment":5983,"conditions":47205,"interventions":47206},[87],[176],[47137,47150,47151,47152],{"trials":47208,"activeCount":99},[],{"trials":47210,"activeCount":99},[],{"trials":47212,"activeCount":99},[],{"trials":47214,"activeCount":99},[],{"intervention":42421,"totalTrials":224,"cells":47216},{"EARLY_PHASE1":47217,"PHASE1":47219,"PHASE2":47225,"PHASE3":47227,"PHASE4":47229,"NA":47231},{"trials":47218,"activeCount":99},[],{"trials":47220,"activeCount":99},[47221],{"nctId":42415,"briefTitle":42416,"status":1040,"phases":47222,"primaryCompletion":2634,"completion":2634,"start":42418,"enrollment":99,"conditions":47223,"interventions":47224},[87],[11174,33202],[42408,42421],{"trials":47226,"activeCount":99},[],{"trials":47228,"activeCount":99},[],{"trials":47230,"activeCount":99},[],{"trials":47232,"activeCount":99},[],{"intervention":47234,"totalTrials":224,"cells":47235},"V710 (30 µg) with MAA",{"EARLY_PHASE1":47236,"PHASE1":47238,"PHASE2":47247,"PHASE3":47249,"PHASE4":47251,"NA":47253},{"trials":47237,"activeCount":99},[],{"trials":47239,"activeCount":99},[47240],{"nctId":47241,"briefTitle":47242,"status":105,"phases":47243,"primaryCompletion":14540,"completion":14540,"start":4418,"enrollment":287,"conditions":47244,"interventions":47245},"NCT01324440","Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)",[87],[14533],[47234,47246],"V710 (30 µg) without MAA",{"trials":47248,"activeCount":99},[],{"trials":47250,"activeCount":99},[],{"trials":47252,"activeCount":99},[],{"trials":47254,"activeCount":99},[],{"intervention":47246,"totalTrials":224,"cells":47256},{"EARLY_PHASE1":47257,"PHASE1":47259,"PHASE2":47265,"PHASE3":47267,"PHASE4":47269,"NA":47271},{"trials":47258,"activeCount":99},[],{"trials":47260,"activeCount":99},[47261],{"nctId":47241,"briefTitle":47242,"status":105,"phases":47262,"primaryCompletion":14540,"completion":14540,"start":4418,"enrollment":287,"conditions":47263,"interventions":47264},[87],[14533],[47234,47246],{"trials":47266,"activeCount":99},[],{"trials":47268,"activeCount":99},[],{"trials":47270,"activeCount":99},[],{"trials":47272,"activeCount":99},[],{"intervention":33556,"totalTrials":224,"cells":47274},{"EARLY_PHASE1":47275,"PHASE1":47277,"PHASE2":47283,"PHASE3":47285,"PHASE4":47287,"NA":47289},{"trials":47276,"activeCount":99},[],{"trials":47278,"activeCount":99},[47279],{"nctId":33551,"briefTitle":33552,"status":105,"phases":47280,"primaryCompletion":17591,"completion":17591,"start":20279,"enrollment":5616,"conditions":47281,"interventions":47282},[87],[21],[33537,20435,20436,33556],{"trials":47284,"activeCount":99},[],{"trials":47286,"activeCount":99},[],{"trials":47288,"activeCount":99},[],{"trials":47290,"activeCount":99},[],{"intervention":41825,"totalTrials":224,"cells":47292},{"EARLY_PHASE1":47293,"PHASE1":47295,"PHASE2":47301,"PHASE3":47303,"PHASE4":47305,"NA":47307},{"trials":47294,"activeCount":99},[],{"trials":47296,"activeCount":99},[47297],{"nctId":41816,"briefTitle":41817,"status":150,"phases":47298,"primaryCompletion":3704,"completion":3704,"start":41819,"enrollment":120,"conditions":47299,"interventions":47300},[87],[41821,41822,33504,41823],[4981,41825],{"trials":47302,"activeCount":99},[],{"trials":47304,"activeCount":99},[],{"trials":47306,"activeCount":99},[],{"trials":47308,"activeCount":99},[],{"intervention":14508,"totalTrials":224,"cells":47310},{"EARLY_PHASE1":47311,"PHASE1":47313,"PHASE2":47319,"PHASE3":47321,"PHASE4":47323,"NA":47325},{"trials":47312,"activeCount":99},[],{"trials":47314,"activeCount":99},[47315],{"nctId":14501,"briefTitle":14502,"status":105,"phases":47316,"primaryCompletion":5281,"completion":5281,"start":14504,"enrollment":154,"conditions":47317,"interventions":47318},[87],[14506],[14508,14509,14331],{"trials":47320,"activeCount":99},[],{"trials":47322,"activeCount":99},[],{"trials":47324,"activeCount":99},[],{"trials":47326,"activeCount":99},[],{"intervention":14509,"totalTrials":224,"cells":47328},{"EARLY_PHASE1":47329,"PHASE1":47331,"PHASE2":47337,"PHASE3":47339,"PHASE4":47341,"NA":47343},{"trials":47330,"activeCount":99},[],{"trials":47332,"activeCount":99},[47333],{"nctId":14501,"briefTitle":14502,"status":105,"phases":47334,"primaryCompletion":5281,"completion":5281,"start":14504,"enrollment":154,"conditions":47335,"interventions":47336},[87],[14506],[14508,14509,14331],{"trials":47338,"activeCount":99},[],{"trials":47340,"activeCount":99},[],{"trials":47342,"activeCount":99},[],{"trials":47344,"activeCount":99},[],{"intervention":42455,"totalTrials":224,"cells":47346},{"EARLY_PHASE1":47347,"PHASE1":47349,"PHASE2":47355,"PHASE3":47357,"PHASE4":47359,"NA":47361},{"trials":47348,"activeCount":99},[],{"trials":47350,"activeCount":99},[47351],{"nctId":42447,"briefTitle":42448,"status":105,"phases":47352,"primaryCompletion":42450,"completion":42451,"start":42452,"enrollment":4741,"conditions":47353,"interventions":47354},[87],[12957],[42455,42456,14925,42440],{"trials":47356,"activeCount":99},[],{"trials":47358,"activeCount":99},[],{"trials":47360,"activeCount":99},[],{"trials":47362,"activeCount":99},[],{"intervention":12991,"totalTrials":224,"cells":47364},{"EARLY_PHASE1":47365,"PHASE1":47367,"PHASE2":47373,"PHASE3":47375,"PHASE4":47377,"NA":47379},{"trials":47366,"activeCount":99},[],{"trials":47368,"activeCount":99},[47369],{"nctId":12981,"briefTitle":12982,"status":105,"phases":47370,"primaryCompletion":12984,"completion":12984,"start":12985,"enrollment":4242,"conditions":47371,"interventions":47372},[87],[12987],[12989,12990,12991],{"trials":47374,"activeCount":99},[],{"trials":47376,"activeCount":99},[],{"trials":47378,"activeCount":99},[],{"trials":47380,"activeCount":99},[],{"intervention":47382,"totalTrials":224,"cells":47383},"AP23573",{"EARLY_PHASE1":47384,"PHASE1":47386,"PHASE2":47396,"PHASE3":47398,"PHASE4":47400,"NA":47402},{"trials":47385,"activeCount":99},[],{"trials":47387,"activeCount":99},[47388],{"nctId":47389,"briefTitle":47390,"status":105,"phases":47391,"primaryCompletion":14228,"completion":14228,"start":17096,"enrollment":5983,"conditions":47392,"interventions":47395},"NCT00087451","Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)",[87],[47393,992,47394],"Malignant Glioma","Gliosarcoma",[47382],{"trials":47397,"activeCount":99},[],{"trials":47399,"activeCount":99},[],{"trials":47401,"activeCount":99},[],{"trials":47403,"activeCount":99},[],{"intervention":47405,"totalTrials":224,"cells":47406},"MAALOX",{"EARLY_PHASE1":47407,"PHASE1":47409,"PHASE2":47418,"PHASE3":47420,"PHASE4":47422,"NA":47424},{"trials":47408,"activeCount":99},[],{"trials":47410,"activeCount":99},[47411],{"nctId":47412,"briefTitle":47413,"status":105,"phases":47414,"primaryCompletion":47415,"completion":47415,"start":19810,"enrollment":931,"conditions":47416,"interventions":47417},"NCT01930045","A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295)",[87],"2013-12-10",[27],[17577,47405],{"trials":47419,"activeCount":99},[],{"trials":47421,"activeCount":99},[],{"trials":47423,"activeCount":99},[],{"trials":47425,"activeCount":99},[],{"intervention":47427,"totalTrials":224,"cells":47428},"Prednisone 15 mg",{"EARLY_PHASE1":47429,"PHASE1":47431,"PHASE2":47440,"PHASE3":47442,"PHASE4":47444,"NA":47446},{"trials":47430,"activeCount":99},[],{"trials":47432,"activeCount":99},[47433],{"nctId":47434,"briefTitle":47435,"status":105,"phases":47436,"primaryCompletion":14445,"completion":14445,"start":14315,"enrollment":700,"conditions":47437,"interventions":47438},"NCT00746512","A Study of the Effects of Oral Prednisone in Patients With Rheumatoid Arthritis (MK0000-088)",[87],[7020],[47427,47439],"Prednisone 7.5 mg",{"trials":47441,"activeCount":99},[],{"trials":47443,"activeCount":99},[],{"trials":47445,"activeCount":99},[],{"trials":47447,"activeCount":99},[],{"intervention":47439,"totalTrials":224,"cells":47449},{"EARLY_PHASE1":47450,"PHASE1":47452,"PHASE2":47458,"PHASE3":47460,"PHASE4":47462,"NA":47464},{"trials":47451,"activeCount":99},[],{"trials":47453,"activeCount":99},[47454],{"nctId":47434,"briefTitle":47435,"status":105,"phases":47455,"primaryCompletion":14445,"completion":14445,"start":14315,"enrollment":700,"conditions":47456,"interventions":47457},[87],[7020],[47427,47439],{"trials":47459,"activeCount":99},[],{"trials":47461,"activeCount":99},[],{"trials":47463,"activeCount":99},[],{"trials":47465,"activeCount":99},[],{"intervention":42488,"totalTrials":224,"cells":47467},{"EARLY_PHASE1":47468,"PHASE1":47470,"PHASE2":47476,"PHASE3":47478,"PHASE4":47480,"NA":47482},{"trials":47469,"activeCount":99},[],{"trials":47471,"activeCount":99},[47472],{"nctId":42482,"briefTitle":42483,"status":105,"phases":47473,"primaryCompletion":2042,"completion":2042,"start":42485,"enrollment":3496,"conditions":47474,"interventions":47475},[87],[14715],[42488,42475],{"trials":47477,"activeCount":99},[],{"trials":47479,"activeCount":99},[],{"trials":47481,"activeCount":99},[],{"trials":47483,"activeCount":99},[],{"intervention":47485,"totalTrials":224,"cells":47486},"MK-0941 20 mg",{"EARLY_PHASE1":47487,"PHASE1":47489,"PHASE2":47498,"PHASE3":47500,"PHASE4":47502,"NA":47504},{"trials":47488,"activeCount":99},[],{"trials":47490,"activeCount":99},[47491],{"nctId":47492,"briefTitle":47493,"status":150,"phases":47494,"primaryCompletion":14445,"completion":14445,"start":13870,"enrollment":626,"conditions":47495,"interventions":47496},"NCT00830791","A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Participants With Renal Insufficiency (MK-0941-015-02)",[87],[14156],[47485,47497],"MK-0941 5 mg",{"trials":47499,"activeCount":99},[],{"trials":47501,"activeCount":99},[],{"trials":47503,"activeCount":99},[],{"trials":47505,"activeCount":99},[],{"intervention":47497,"totalTrials":224,"cells":47507},{"EARLY_PHASE1":47508,"PHASE1":47510,"PHASE2":47516,"PHASE3":47518,"PHASE4":47520,"NA":47522},{"trials":47509,"activeCount":99},[],{"trials":47511,"activeCount":99},[47512],{"nctId":47492,"briefTitle":47493,"status":150,"phases":47513,"primaryCompletion":14445,"completion":14445,"start":13870,"enrollment":626,"conditions":47514,"interventions":47515},[87],[14156],[47485,47497],{"trials":47517,"activeCount":99},[],{"trials":47519,"activeCount":99},[],{"trials":47521,"activeCount":99},[],{"trials":47523,"activeCount":99},[],{"intervention":47525,"totalTrials":224,"cells":47526},"MK-1697",{"EARLY_PHASE1":47527,"PHASE1":47529,"PHASE2":47538,"PHASE3":47540,"PHASE4":47542,"NA":47544},{"trials":47528,"activeCount":99},[],{"trials":47530,"activeCount":99},[47531],{"nctId":47532,"briefTitle":47533,"status":150,"phases":47534,"primaryCompletion":7647,"completion":7647,"start":47535,"enrollment":4059,"conditions":47536,"interventions":47537},"NCT03515824","Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)",[87],"2018-08-13",[290,371,2482],[47525],{"trials":47539,"activeCount":99},[],{"trials":47541,"activeCount":99},[],{"trials":47543,"activeCount":99},[],{"trials":47545,"activeCount":99},[],{"intervention":47547,"totalTrials":224,"cells":47548},"90 mg MK-0517",{"EARLY_PHASE1":47549,"PHASE1":47551,"PHASE2":47567,"PHASE3":47569,"PHASE4":47571,"NA":47573},{"trials":47550,"activeCount":99},[],{"trials":47552,"activeCount":99},[47553],{"nctId":47554,"briefTitle":47555,"status":105,"phases":47556,"primaryCompletion":24504,"completion":14484,"start":14903,"enrollment":18221,"conditions":47557,"interventions":47558},"NCT00990821","A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)",[87],[5150,16210],[47547,47559,47560,47561,47562,47563,47559,47562,47564,47565,47566],"100 mg MK-0517","100 MK-0517 (PS80) + 2 mg midazolam","115 mg MK-0517","150 mg MK-0517","40 mg MK-0517","40 mg Aprepitant","125 mg Aprepitant","2 mg Midazolam",{"trials":47568,"activeCount":99},[],{"trials":47570,"activeCount":99},[],{"trials":47572,"activeCount":99},[],{"trials":47574,"activeCount":99},[],{"intervention":47559,"totalTrials":224,"cells":47576},{"EARLY_PHASE1":47577,"PHASE1":47579,"PHASE2":47585,"PHASE3":47587,"PHASE4":47589,"NA":47591},{"trials":47578,"activeCount":99},[],{"trials":47580,"activeCount":99},[47581],{"nctId":47554,"briefTitle":47555,"status":105,"phases":47582,"primaryCompletion":24504,"completion":14484,"start":14903,"enrollment":18221,"conditions":47583,"interventions":47584},[87],[5150,16210],[47547,47559,47560,47561,47562,47563,47559,47562,47564,47565,47566],{"trials":47586,"activeCount":99},[],{"trials":47588,"activeCount":99},[],{"trials":47590,"activeCount":99},[],{"trials":47592,"activeCount":99},[],{"intervention":47560,"totalTrials":224,"cells":47594},{"EARLY_PHASE1":47595,"PHASE1":47597,"PHASE2":47603,"PHASE3":47605,"PHASE4":47607,"NA":47609},{"trials":47596,"activeCount":99},[],{"trials":47598,"activeCount":99},[47599],{"nctId":47554,"briefTitle":47555,"status":105,"phases":47600,"primaryCompletion":24504,"completion":14484,"start":14903,"enrollment":18221,"conditions":47601,"interventions":47602},[87],[5150,16210],[47547,47559,47560,47561,47562,47563,47559,47562,47564,47565,47566],{"trials":47604,"activeCount":99},[],{"trials":47606,"activeCount":99},[],{"trials":47608,"activeCount":99},[],{"trials":47610,"activeCount":99},[],{"intervention":47561,"totalTrials":224,"cells":47612},{"EARLY_PHASE1":47613,"PHASE1":47615,"PHASE2":47621,"PHASE3":47623,"PHASE4":47625,"NA":47627},{"trials":47614,"activeCount":99},[],{"trials":47616,"activeCount":99},[47617],{"nctId":47554,"briefTitle":47555,"status":105,"phases":47618,"primaryCompletion":24504,"completion":14484,"start":14903,"enrollment":18221,"conditions":47619,"interventions":47620},[87],[5150,16210],[47547,47559,47560,47561,47562,47563,47559,47562,47564,47565,47566],{"trials":47622,"activeCount":99},[],{"trials":47624,"activeCount":99},[],{"trials":47626,"activeCount":99},[],{"trials":47628,"activeCount":99},[],{"intervention":47562,"totalTrials":224,"cells":47630},{"EARLY_PHASE1":47631,"PHASE1":47633,"PHASE2":47639,"PHASE3":47641,"PHASE4":47643,"NA":47645},{"trials":47632,"activeCount":99},[],{"trials":47634,"activeCount":99},[47635],{"nctId":47554,"briefTitle":47555,"status":105,"phases":47636,"primaryCompletion":24504,"completion":14484,"start":14903,"enrollment":18221,"conditions":47637,"interventions":47638},[87],[5150,16210],[47547,47559,47560,47561,47562,47563,47559,47562,47564,47565,47566],{"trials":47640,"activeCount":99},[],{"trials":47642,"activeCount":99},[],{"trials":47644,"activeCount":99},[],{"trials":47646,"activeCount":99},[],{"intervention":47563,"totalTrials":224,"cells":47648},{"EARLY_PHASE1":47649,"PHASE1":47651,"PHASE2":47657,"PHASE3":47659,"PHASE4":47661,"NA":47663},{"trials":47650,"activeCount":99},[],{"trials":47652,"activeCount":99},[47653],{"nctId":47554,"briefTitle":47555,"status":105,"phases":47654,"primaryCompletion":24504,"completion":14484,"start":14903,"enrollment":18221,"conditions":47655,"interventions":47656},[87],[5150,16210],[47547,47559,47560,47561,47562,47563,47559,47562,47564,47565,47566],{"trials":47658,"activeCount":99},[],{"trials":47660,"activeCount":99},[],{"trials":47662,"activeCount":99},[],{"trials":47664,"activeCount":99},[],{"intervention":47564,"totalTrials":224,"cells":47666},{"EARLY_PHASE1":47667,"PHASE1":47669,"PHASE2":47675,"PHASE3":47677,"PHASE4":47679,"NA":47681},{"trials":47668,"activeCount":99},[],{"trials":47670,"activeCount":99},[47671],{"nctId":47554,"briefTitle":47555,"status":105,"phases":47672,"primaryCompletion":24504,"completion":14484,"start":14903,"enrollment":18221,"conditions":47673,"interventions":47674},[87],[5150,16210],[47547,47559,47560,47561,47562,47563,47559,47562,47564,47565,47566],{"trials":47676,"activeCount":99},[],{"trials":47678,"activeCount":99},[],{"trials":47680,"activeCount":99},[],{"trials":47682,"activeCount":99},[],{"intervention":47565,"totalTrials":224,"cells":47684},{"EARLY_PHASE1":47685,"PHASE1":47687,"PHASE2":47693,"PHASE3":47695,"PHASE4":47697,"NA":47699},{"trials":47686,"activeCount":99},[],{"trials":47688,"activeCount":99},[47689],{"nctId":47554,"briefTitle":47555,"status":105,"phases":47690,"primaryCompletion":24504,"completion":14484,"start":14903,"enrollment":18221,"conditions":47691,"interventions":47692},[87],[5150,16210],[47547,47559,47560,47561,47562,47563,47559,47562,47564,47565,47566],{"trials":47694,"activeCount":99},[],{"trials":47696,"activeCount":99},[],{"trials":47698,"activeCount":99},[],{"trials":47700,"activeCount":99},[],{"intervention":47566,"totalTrials":224,"cells":47702},{"EARLY_PHASE1":47703,"PHASE1":47705,"PHASE2":47711,"PHASE3":47713,"PHASE4":47715,"NA":47717},{"trials":47704,"activeCount":99},[],{"trials":47706,"activeCount":99},[47707],{"nctId":47554,"briefTitle":47555,"status":105,"phases":47708,"primaryCompletion":24504,"completion":14484,"start":14903,"enrollment":18221,"conditions":47709,"interventions":47710},[87],[5150,16210],[47547,47559,47560,47561,47562,47563,47559,47562,47564,47565,47566],{"trials":47712,"activeCount":99},[],{"trials":47714,"activeCount":99},[],{"trials":47716,"activeCount":99},[],{"trials":47718,"activeCount":99},[],{"intervention":15646,"totalTrials":224,"cells":47720},{"EARLY_PHASE1":47721,"PHASE1":47723,"PHASE2":47729,"PHASE3":47731,"PHASE4":47733,"NA":47735},{"trials":47722,"activeCount":99},[],{"trials":47724,"activeCount":99},[47725],{"nctId":15641,"briefTitle":15642,"status":105,"phases":47726,"primaryCompletion":8620,"completion":13890,"start":14687,"enrollment":4991,"conditions":47727,"interventions":47728},[87],[15],[15646,13982,15647],{"trials":47730,"activeCount":99},[],{"trials":47732,"activeCount":99},[],{"trials":47734,"activeCount":99},[],{"trials":47736,"activeCount":99},[],{"intervention":19116,"totalTrials":224,"cells":47738},{"EARLY_PHASE1":47739,"PHASE1":47741,"PHASE2":47747,"PHASE3":47749,"PHASE4":47751,"NA":47753},{"trials":47740,"activeCount":99},[],{"trials":47742,"activeCount":99},[47743],{"nctId":19109,"briefTitle":19110,"status":105,"phases":47744,"primaryCompletion":19112,"completion":19112,"start":19113,"enrollment":15321,"conditions":47745,"interventions":47746},[87],[16472],[16474,19116,19117],{"trials":47748,"activeCount":99},[],{"trials":47750,"activeCount":99},[],{"trials":47752,"activeCount":99},[],{"trials":47754,"activeCount":99},[],{"intervention":19117,"totalTrials":224,"cells":47756},{"EARLY_PHASE1":47757,"PHASE1":47759,"PHASE2":47765,"PHASE3":47767,"PHASE4":47769,"NA":47771},{"trials":47758,"activeCount":99},[],{"trials":47760,"activeCount":99},[47761],{"nctId":19109,"briefTitle":19110,"status":105,"phases":47762,"primaryCompletion":19112,"completion":19112,"start":19113,"enrollment":15321,"conditions":47763,"interventions":47764},[87],[16472],[16474,19116,19117],{"trials":47766,"activeCount":99},[],{"trials":47768,"activeCount":99},[],{"trials":47770,"activeCount":99},[],{"trials":47772,"activeCount":99},[],{"intervention":518,"totalTrials":224,"cells":47774},{"EARLY_PHASE1":47775,"PHASE1":47777,"PHASE2":47783,"PHASE3":47785,"PHASE4":47787,"NA":47789},{"trials":47776,"activeCount":99},[],{"trials":47778,"activeCount":99},[47779],{"nctId":511,"briefTitle":512,"status":105,"phases":47780,"primaryCompletion":514,"completion":514,"start":515,"enrollment":429,"conditions":47781,"interventions":47782},[87],[279],[518,47],{"trials":47784,"activeCount":99},[],{"trials":47786,"activeCount":99},[],{"trials":47788,"activeCount":99},[],{"trials":47790,"activeCount":99},[],{"intervention":47792,"totalTrials":224,"cells":47793},"Comparator: MK-8033",{"EARLY_PHASE1":47794,"PHASE1":47796,"PHASE2":47807,"PHASE3":47809,"PHASE4":47811,"NA":47813},{"trials":47795,"activeCount":99},[],{"trials":47797,"activeCount":99},[47798],{"nctId":47799,"briefTitle":47800,"status":105,"phases":47801,"primaryCompletion":47802,"completion":47803,"start":19573,"enrollment":14576,"conditions":47804,"interventions":47805},"NCT00559182","A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001)",[87],"2010-06-10","2010-07-09",[852],[47792,47806],"Comparator: MK-8033 +\u002F- omeprazole",{"trials":47808,"activeCount":99},[],{"trials":47810,"activeCount":99},[],{"trials":47812,"activeCount":99},[],{"trials":47814,"activeCount":99},[],{"intervention":47806,"totalTrials":224,"cells":47816},{"EARLY_PHASE1":47817,"PHASE1":47819,"PHASE2":47825,"PHASE3":47827,"PHASE4":47829,"NA":47831},{"trials":47818,"activeCount":99},[],{"trials":47820,"activeCount":99},[47821],{"nctId":47799,"briefTitle":47800,"status":105,"phases":47822,"primaryCompletion":47802,"completion":47803,"start":19573,"enrollment":14576,"conditions":47823,"interventions":47824},[87],[852],[47792,47806],{"trials":47826,"activeCount":99},[],{"trials":47828,"activeCount":99},[],{"trials":47830,"activeCount":99},[],{"trials":47832,"activeCount":99},[],{"intervention":530,"totalTrials":224,"cells":47834},{"EARLY_PHASE1":47835,"PHASE1":47837,"PHASE2":47843,"PHASE3":47845,"PHASE4":47847,"NA":47849},{"trials":47836,"activeCount":99},[],{"trials":47838,"activeCount":99},[47839],{"nctId":520,"briefTitle":521,"status":150,"phases":47840,"primaryCompletion":523,"completion":523,"start":524,"enrollment":22,"conditions":47841,"interventions":47842},[87],[526],[47,528,529,530],{"trials":47844,"activeCount":99},[],{"trials":47846,"activeCount":99},[],{"trials":47848,"activeCount":99},[],{"trials":47850,"activeCount":99},[],{"intervention":47852,"totalTrials":224,"cells":47853},"MK0683, vorinostat",{"EARLY_PHASE1":47854,"PHASE1":47856,"PHASE2":47864,"PHASE3":47866,"PHASE4":47868,"NA":47870},{"trials":47855,"activeCount":99},[],{"trials":47857,"activeCount":99},[47858],{"nctId":47859,"briefTitle":47860,"status":150,"phases":47861,"primaryCompletion":4419,"completion":4419,"start":15210,"enrollment":202,"conditions":47862,"interventions":47863},"NCT00424775","A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)",[87],[290],[47852],{"trials":47865,"activeCount":99},[],{"trials":47867,"activeCount":99},[],{"trials":47869,"activeCount":99},[],{"trials":47871,"activeCount":99},[],{"intervention":42591,"totalTrials":224,"cells":47873},{"EARLY_PHASE1":47874,"PHASE1":47876,"PHASE2":47882,"PHASE3":47884,"PHASE4":47886,"NA":47888},{"trials":47875,"activeCount":99},[],{"trials":47877,"activeCount":99},[47878],{"nctId":42586,"briefTitle":42587,"status":105,"phases":47879,"primaryCompletion":7018,"completion":7018,"start":5800,"enrollment":95,"conditions":47880,"interventions":47881},[87],[15],[42579,42591,42592],{"trials":47883,"activeCount":99},[],{"trials":47885,"activeCount":99},[],{"trials":47887,"activeCount":99},[],{"trials":47889,"activeCount":99},[],{"intervention":42592,"totalTrials":224,"cells":47891},{"EARLY_PHASE1":47892,"PHASE1":47894,"PHASE2":47900,"PHASE3":47902,"PHASE4":47904,"NA":47906},{"trials":47893,"activeCount":99},[],{"trials":47895,"activeCount":99},[47896],{"nctId":42586,"briefTitle":42587,"status":105,"phases":47897,"primaryCompletion":7018,"completion":7018,"start":5800,"enrollment":95,"conditions":47898,"interventions":47899},[87],[15],[42579,42591,42592],{"trials":47901,"activeCount":99},[],{"trials":47903,"activeCount":99},[],{"trials":47905,"activeCount":99},[],{"trials":47907,"activeCount":99},[],{"intervention":47909,"totalTrials":224,"cells":47910},"MK-1029 10 mg",{"EARLY_PHASE1":47911,"PHASE1":47913,"PHASE2":47923,"PHASE3":47925,"PHASE4":47927,"NA":47929},{"trials":47912,"activeCount":99},[],{"trials":47914,"activeCount":99},[47915],{"nctId":47916,"briefTitle":47917,"status":105,"phases":47918,"primaryCompletion":47919,"completion":47919,"start":16496,"enrollment":3655,"conditions":47920,"interventions":47921},"NCT01343407","A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)",[87],"2012-01-09",[5985],[47909,47922],"MK-1029 100 mg",{"trials":47924,"activeCount":99},[],{"trials":47926,"activeCount":99},[],{"trials":47928,"activeCount":99},[],{"trials":47930,"activeCount":99},[],{"intervention":47922,"totalTrials":224,"cells":47932},{"EARLY_PHASE1":47933,"PHASE1":47935,"PHASE2":47941,"PHASE3":47943,"PHASE4":47945,"NA":47947},{"trials":47934,"activeCount":99},[],{"trials":47936,"activeCount":99},[47937],{"nctId":47916,"briefTitle":47917,"status":105,"phases":47938,"primaryCompletion":47919,"completion":47919,"start":16496,"enrollment":3655,"conditions":47939,"interventions":47940},[87],[5985],[47909,47922],{"trials":47942,"activeCount":99},[],{"trials":47944,"activeCount":99},[],{"trials":47946,"activeCount":99},[],{"trials":47948,"activeCount":99},[],{"intervention":47950,"totalTrials":224,"cells":47951},"fluticasone propionate",{"EARLY_PHASE1":47952,"PHASE1":47954,"PHASE2":47966,"PHASE3":47968,"PHASE4":47970,"NA":47972},{"trials":47953,"activeCount":99},[],{"trials":47955,"activeCount":99},[47956],{"nctId":47957,"briefTitle":47958,"status":105,"phases":47959,"primaryCompletion":14445,"completion":14445,"start":14314,"enrollment":4059,"conditions":47960,"interventions":47962},"NCT00869596","Study of Biomarkers of Airway Inflammation (0000-128)",[87],[47961],"Airway Inflammation",[47950,47963,47964,47965],"Comparator: Placebo to fluticasone","Comparator: Lipopolysaccharide","Comparator: albuterol",{"trials":47967,"activeCount":99},[],{"trials":47969,"activeCount":99},[],{"trials":47971,"activeCount":99},[],{"trials":47973,"activeCount":99},[],{"intervention":47963,"totalTrials":224,"cells":47975},{"EARLY_PHASE1":47976,"PHASE1":47978,"PHASE2":47984,"PHASE3":47986,"PHASE4":47988,"NA":47990},{"trials":47977,"activeCount":99},[],{"trials":47979,"activeCount":99},[47980],{"nctId":47957,"briefTitle":47958,"status":105,"phases":47981,"primaryCompletion":14445,"completion":14445,"start":14314,"enrollment":4059,"conditions":47982,"interventions":47983},[87],[47961],[47950,47963,47964,47965],{"trials":47985,"activeCount":99},[],{"trials":47987,"activeCount":99},[],{"trials":47989,"activeCount":99},[],{"trials":47991,"activeCount":99},[],{"intervention":47964,"totalTrials":224,"cells":47993},{"EARLY_PHASE1":47994,"PHASE1":47996,"PHASE2":48002,"PHASE3":48004,"PHASE4":48006,"NA":48008},{"trials":47995,"activeCount":99},[],{"trials":47997,"activeCount":99},[47998],{"nctId":47957,"briefTitle":47958,"status":105,"phases":47999,"primaryCompletion":14445,"completion":14445,"start":14314,"enrollment":4059,"conditions":48000,"interventions":48001},[87],[47961],[47950,47963,47964,47965],{"trials":48003,"activeCount":99},[],{"trials":48005,"activeCount":99},[],{"trials":48007,"activeCount":99},[],{"trials":48009,"activeCount":99},[],{"intervention":47965,"totalTrials":224,"cells":48011},{"EARLY_PHASE1":48012,"PHASE1":48014,"PHASE2":48020,"PHASE3":48022,"PHASE4":48024,"NA":48026},{"trials":48013,"activeCount":99},[],{"trials":48015,"activeCount":99},[48016],{"nctId":47957,"briefTitle":47958,"status":105,"phases":48017,"primaryCompletion":14445,"completion":14445,"start":14314,"enrollment":4059,"conditions":48018,"interventions":48019},[87],[47961],[47950,47963,47964,47965],{"trials":48021,"activeCount":99},[],{"trials":48023,"activeCount":99},[],{"trials":48025,"activeCount":99},[],{"trials":48027,"activeCount":99},[],{"intervention":561,"totalTrials":224,"cells":48029},{"EARLY_PHASE1":48030,"PHASE1":48032,"PHASE2":48038,"PHASE3":48040,"PHASE4":48042,"NA":48044},{"trials":48031,"activeCount":99},[],{"trials":48033,"activeCount":99},[48034],{"nctId":552,"briefTitle":553,"status":105,"phases":48035,"primaryCompletion":555,"completion":556,"start":557,"enrollment":558,"conditions":48036,"interventions":48037},[87],[540],[47,388,561,562,386,387],{"trials":48039,"activeCount":99},[],{"trials":48041,"activeCount":99},[],{"trials":48043,"activeCount":99},[],{"trials":48045,"activeCount":99},[],{"intervention":48047,"totalTrials":224,"cells":48048},"MK-8325",{"EARLY_PHASE1":48049,"PHASE1":48051,"PHASE2":48060,"PHASE3":48062,"PHASE4":48064,"NA":48066},{"trials":48050,"activeCount":99},[],{"trials":48052,"activeCount":99},[48053],{"nctId":48054,"briefTitle":48055,"status":150,"phases":48056,"primaryCompletion":48057,"completion":48057,"start":16794,"enrollment":661,"conditions":48058,"interventions":48059},"NCT01554189","A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002)",[87],"2013-04",[21],[48047],{"trials":48061,"activeCount":99},[],{"trials":48063,"activeCount":99},[],{"trials":48065,"activeCount":99},[],{"trials":48067,"activeCount":99},[],{"intervention":5152,"totalTrials":224,"cells":48069},{"EARLY_PHASE1":48070,"PHASE1":48072,"PHASE2":48078,"PHASE3":48080,"PHASE4":48082,"NA":48084},{"trials":48071,"activeCount":99},[],{"trials":48073,"activeCount":99},[48074],{"nctId":5143,"briefTitle":5144,"status":150,"phases":48075,"primaryCompletion":5146,"completion":5146,"start":5147,"enrollment":5148,"conditions":48076,"interventions":48077},[87],[5150],[5152,5153,5154,5137,529],{"trials":48079,"activeCount":99},[],{"trials":48081,"activeCount":99},[],{"trials":48083,"activeCount":99},[],{"trials":48085,"activeCount":99},[],{"intervention":5153,"totalTrials":224,"cells":48087},{"EARLY_PHASE1":48088,"PHASE1":48090,"PHASE2":48096,"PHASE3":48098,"PHASE4":48100,"NA":48102},{"trials":48089,"activeCount":99},[],{"trials":48091,"activeCount":99},[48092],{"nctId":5143,"briefTitle":5144,"status":150,"phases":48093,"primaryCompletion":5146,"completion":5146,"start":5147,"enrollment":5148,"conditions":48094,"interventions":48095},[87],[5150],[5152,5153,5154,5137,529],{"trials":48097,"activeCount":99},[],{"trials":48099,"activeCount":99},[],{"trials":48101,"activeCount":99},[],{"trials":48103,"activeCount":99},[],{"intervention":48105,"totalTrials":224,"cells":48106},"MK0457, VX-680",{"EARLY_PHASE1":48107,"PHASE1":48109,"PHASE2":48117,"PHASE3":48119,"PHASE4":48121,"NA":48123},{"trials":48108,"activeCount":99},[],{"trials":48110,"activeCount":99},[48111],{"nctId":48112,"briefTitle":48113,"status":150,"phases":48114,"primaryCompletion":15505,"completion":15505,"start":14903,"conditions":48115,"interventions":48116},"NCT00099346","MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)",[87],[419,497],[48105],{"trials":48118,"activeCount":99},[],{"trials":48120,"activeCount":99},[],{"trials":48122,"activeCount":99},[],{"trials":48124,"activeCount":99},[],{"intervention":48126,"totalTrials":224,"cells":48127},"Comparator: ridaforolimus + dalotuzumab",{"EARLY_PHASE1":48128,"PHASE1":48130,"PHASE2":48138,"PHASE3":48140,"PHASE4":48142,"NA":48144},{"trials":48129,"activeCount":99},[],{"trials":48131,"activeCount":99},[48132],{"nctId":48133,"briefTitle":48134,"status":105,"phases":48135,"primaryCompletion":16592,"completion":16592,"start":5801,"enrollment":23629,"conditions":48136,"interventions":48137},"NCT00730379","A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)",[87],[290],[48126],{"trials":48139,"activeCount":99},[],{"trials":48141,"activeCount":99},[],{"trials":48143,"activeCount":99},[],{"trials":48145,"activeCount":99},[],{"intervention":48147,"totalTrials":224,"cells":48148},"200 mg of pembrolizumab",{"EARLY_PHASE1":48149,"PHASE1":48151,"PHASE2":48162,"PHASE3":48164,"PHASE4":48166,"NA":48168},{"trials":48150,"activeCount":99},[],{"trials":48152,"activeCount":99},[48153],{"nctId":48154,"briefTitle":48155,"status":150,"phases":48156,"primaryCompletion":48157,"completion":48157,"start":48158,"enrollment":3903,"conditions":48159,"interventions":48160},"NCT04135352","A Study of Intratumoral\u002FIntralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced\u002FMetastatic or Recurrent Malignancies (V938-001)",[87],"2022-08-24","2019-11-04",[324],[48147,48161],"V938",{"trials":48163,"activeCount":99},[],{"trials":48165,"activeCount":99},[],{"trials":48167,"activeCount":99},[],{"trials":48169,"activeCount":99},[],{"intervention":48161,"totalTrials":224,"cells":48171},{"EARLY_PHASE1":48172,"PHASE1":48174,"PHASE2":48180,"PHASE3":48182,"PHASE4":48184,"NA":48186},{"trials":48173,"activeCount":99},[],{"trials":48175,"activeCount":99},[48176],{"nctId":48154,"briefTitle":48155,"status":150,"phases":48177,"primaryCompletion":48157,"completion":48157,"start":48158,"enrollment":3903,"conditions":48178,"interventions":48179},[87],[324],[48147,48161],{"trials":48181,"activeCount":99},[],{"trials":48183,"activeCount":99},[],{"trials":48185,"activeCount":99},[],{"trials":48187,"activeCount":99},[],{"intervention":48189,"totalTrials":224,"cells":48190},"Gemcitabine and Cisplatin or Gemcitabine and Carboplatin",{"EARLY_PHASE1":48191,"PHASE1":48193,"PHASE2":48203,"PHASE3":48205,"PHASE4":48207,"NA":48209},{"trials":48192,"activeCount":99},[],{"trials":48194,"activeCount":99},[48195],{"nctId":48196,"briefTitle":48197,"status":105,"phases":48198,"primaryCompletion":47802,"completion":48199,"start":14251,"enrollment":14325,"conditions":48200,"interventions":48202},"NCT00599755","Phase I Imaging Study Evaluating Gem\u002FCis or Gem\u002FCarbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3)",[87],"2011-04-13",[48201,314],"Carcinoma",[48189],{"trials":48204,"activeCount":99},[],{"trials":48206,"activeCount":99},[],{"trials":48208,"activeCount":99},[],{"trials":48210,"activeCount":99},[],{"intervention":48212,"totalTrials":224,"cells":48213},"MK-1496",{"EARLY_PHASE1":48214,"PHASE1":48216,"PHASE2":48225,"PHASE3":48227,"PHASE4":48229,"NA":48231},{"trials":48215,"activeCount":99},[],{"trials":48217,"activeCount":99},[48218],{"nctId":48219,"briefTitle":48220,"status":105,"phases":48221,"primaryCompletion":16592,"completion":11479,"start":9610,"enrollment":36,"conditions":48222,"interventions":48224},"NCT00880568","Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED)",[87],[290,48223],"Malignant",[48212,48212],{"trials":48226,"activeCount":99},[],{"trials":48228,"activeCount":99},[],{"trials":48230,"activeCount":99},[],{"trials":48232,"activeCount":99},[],{"intervention":13238,"totalTrials":224,"cells":48234},{"EARLY_PHASE1":48235,"PHASE1":48237,"PHASE2":48243,"PHASE3":48245,"PHASE4":48247,"NA":48249},{"trials":48236,"activeCount":99},[],{"trials":48238,"activeCount":99},[48239],{"nctId":13229,"briefTitle":13230,"status":105,"phases":48240,"primaryCompletion":13232,"completion":13232,"start":13233,"enrollment":13234,"conditions":48241,"interventions":48242},[87],[13236],[13238,13239,13240,5626,13241],{"trials":48244,"activeCount":99},[],{"trials":48246,"activeCount":99},[],{"trials":48248,"activeCount":99},[],{"trials":48250,"activeCount":99},[],{"intervention":13239,"totalTrials":224,"cells":48252},{"EARLY_PHASE1":48253,"PHASE1":48255,"PHASE2":48261,"PHASE3":48263,"PHASE4":48265,"NA":48267},{"trials":48254,"activeCount":99},[],{"trials":48256,"activeCount":99},[48257],{"nctId":13229,"briefTitle":13230,"status":105,"phases":48258,"primaryCompletion":13232,"completion":13232,"start":13233,"enrollment":13234,"conditions":48259,"interventions":48260},[87],[13236],[13238,13239,13240,5626,13241],{"trials":48262,"activeCount":99},[],{"trials":48264,"activeCount":99},[],{"trials":48266,"activeCount":99},[],{"trials":48268,"activeCount":99},[],{"intervention":13240,"totalTrials":224,"cells":48270},{"EARLY_PHASE1":48271,"PHASE1":48273,"PHASE2":48279,"PHASE3":48281,"PHASE4":48283,"NA":48285},{"trials":48272,"activeCount":99},[],{"trials":48274,"activeCount":99},[48275],{"nctId":13229,"briefTitle":13230,"status":105,"phases":48276,"primaryCompletion":13232,"completion":13232,"start":13233,"enrollment":13234,"conditions":48277,"interventions":48278},[87],[13236],[13238,13239,13240,5626,13241],{"trials":48280,"activeCount":99},[],{"trials":48282,"activeCount":99},[],{"trials":48284,"activeCount":99},[],{"trials":48286,"activeCount":99},[],{"intervention":48288,"totalTrials":224,"cells":48289},"V950",{"EARLY_PHASE1":48290,"PHASE1":48292,"PHASE2":48301,"PHASE3":48303,"PHASE4":48305,"NA":48307},{"trials":48291,"activeCount":99},[],{"trials":48293,"activeCount":99},[48294],{"nctId":48295,"briefTitle":48296,"status":105,"phases":48297,"primaryCompletion":33570,"completion":33570,"start":4419,"enrollment":38922,"conditions":48298,"interventions":48299},"NCT00464334","A Study of V950 in People With Alzheimer Disease (V950-001 AM7)",[87],[9369],[48288,48300],"ISCOMATRIX™",{"trials":48302,"activeCount":99},[],{"trials":48304,"activeCount":99},[],{"trials":48306,"activeCount":99},[],{"trials":48308,"activeCount":99},[],{"intervention":48300,"totalTrials":224,"cells":48310},{"EARLY_PHASE1":48311,"PHASE1":48313,"PHASE2":48319,"PHASE3":48321,"PHASE4":48323,"NA":48325},{"trials":48312,"activeCount":99},[],{"trials":48314,"activeCount":99},[48315],{"nctId":48295,"briefTitle":48296,"status":105,"phases":48316,"primaryCompletion":33570,"completion":33570,"start":4419,"enrollment":38922,"conditions":48317,"interventions":48318},[87],[9369],[48288,48300],{"trials":48320,"activeCount":99},[],{"trials":48322,"activeCount":99},[],{"trials":48324,"activeCount":99},[],{"trials":48326,"activeCount":99},[],{"intervention":23524,"totalTrials":224,"cells":48328},{"EARLY_PHASE1":48329,"PHASE1":48331,"PHASE2":48337,"PHASE3":48339,"PHASE4":48341,"NA":48343},{"trials":48330,"activeCount":99},[],{"trials":48332,"activeCount":99},[48333],{"nctId":23519,"briefTitle":23520,"status":105,"phases":48334,"primaryCompletion":14823,"completion":14823,"start":14858,"enrollment":4059,"conditions":48335,"interventions":48336},[87],[21195],[20747,23524],{"trials":48338,"activeCount":99},[],{"trials":48340,"activeCount":99},[],{"trials":48342,"activeCount":99},[],{"trials":48344,"activeCount":99},[],{"intervention":14526,"totalTrials":224,"cells":48346},{"EARLY_PHASE1":48347,"PHASE1":48349,"PHASE2":48355,"PHASE3":48357,"PHASE4":48359,"NA":48361},{"trials":48348,"activeCount":99},[],{"trials":48350,"activeCount":99},[48351],{"nctId":14520,"briefTitle":14521,"status":105,"phases":48352,"primaryCompletion":14408,"completion":6308,"start":5507,"enrollment":4059,"conditions":48353,"interventions":48354},[87],[14524],[14526,13864],{"trials":48356,"activeCount":99},[],{"trials":48358,"activeCount":99},[],{"trials":48360,"activeCount":99},[],{"trials":48362,"activeCount":99},[],{"intervention":48364,"totalTrials":224,"cells":48365},"Comparator: Testosterone 300 mg, intramuscular",{"EARLY_PHASE1":48366,"PHASE1":48368,"PHASE2":48378,"PHASE3":48380,"PHASE4":48382,"NA":48384},{"trials":48367,"activeCount":99},[],{"trials":48369,"activeCount":99},[48370],{"nctId":48371,"briefTitle":48372,"status":105,"phases":48373,"primaryCompletion":14353,"completion":14353,"start":14687,"enrollment":1624,"conditions":48374,"interventions":48375},"NCT00816712","A Study to Evaluate the Effect of Testosterone on Muscle Fractional Synthetic Rate (MK-0000-064)",[87],[14506],[48364,48376,48377],"Comparator: Testosterone 100 mg, Intramuscular","Comparator: Placebo given by Intramuscular",{"trials":48379,"activeCount":99},[],{"trials":48381,"activeCount":99},[],{"trials":48383,"activeCount":99},[],{"trials":48385,"activeCount":99},[],{"intervention":48376,"totalTrials":224,"cells":48387},{"EARLY_PHASE1":48388,"PHASE1":48390,"PHASE2":48396,"PHASE3":48398,"PHASE4":48400,"NA":48402},{"trials":48389,"activeCount":99},[],{"trials":48391,"activeCount":99},[48392],{"nctId":48371,"briefTitle":48372,"status":105,"phases":48393,"primaryCompletion":14353,"completion":14353,"start":14687,"enrollment":1624,"conditions":48394,"interventions":48395},[87],[14506],[48364,48376,48377],{"trials":48397,"activeCount":99},[],{"trials":48399,"activeCount":99},[],{"trials":48401,"activeCount":99},[],{"trials":48403,"activeCount":99},[],{"intervention":48377,"totalTrials":224,"cells":48405},{"EARLY_PHASE1":48406,"PHASE1":48408,"PHASE2":48414,"PHASE3":48416,"PHASE4":48418,"NA":48420},{"trials":48407,"activeCount":99},[],{"trials":48409,"activeCount":99},[48410],{"nctId":48371,"briefTitle":48372,"status":105,"phases":48411,"primaryCompletion":14353,"completion":14353,"start":14687,"enrollment":1624,"conditions":48412,"interventions":48413},[87],[14506],[48364,48376,48377],{"trials":48415,"activeCount":99},[],{"trials":48417,"activeCount":99},[],{"trials":48419,"activeCount":99},[],{"trials":48421,"activeCount":99},[],{"intervention":48423,"totalTrials":224,"cells":48424},"MK-8723",{"EARLY_PHASE1":48425,"PHASE1":48427,"PHASE2":48437,"PHASE3":48439,"PHASE4":48441,"NA":48443},{"trials":48426,"activeCount":99},[],{"trials":48428,"activeCount":99},[48429],{"nctId":48430,"briefTitle":48431,"status":105,"phases":48432,"primaryCompletion":48433,"completion":48433,"start":12955,"enrollment":4421,"conditions":48434,"interventions":48436},"NCT01963260","Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)",[87],"2015-04-26",[48435],"Immune Thrombocytopenia Purpura",[48423],{"trials":48438,"activeCount":99},[],{"trials":48440,"activeCount":99},[],{"trials":48442,"activeCount":99},[],{"trials":48444,"activeCount":99},[],{"intervention":11468,"totalTrials":224,"cells":48446},{"EARLY_PHASE1":48447,"PHASE1":48449,"PHASE2":48455,"PHASE3":48457,"PHASE4":48459,"NA":48461},{"trials":48448,"activeCount":99},[],{"trials":48450,"activeCount":99},[48451],{"nctId":11460,"briefTitle":11461,"status":150,"phases":48452,"primaryCompletion":11463,"completion":11464,"start":11465,"enrollment":444,"conditions":48453,"interventions":48454},[87],[497,1109],[2817,1843,11468],{"trials":48456,"activeCount":99},[],{"trials":48458,"activeCount":99},[],{"trials":48460,"activeCount":99},[],{"trials":48462,"activeCount":99},[],{"intervention":48464,"totalTrials":224,"cells":48465},"Co-administration of 50 mg sitagliptin and 500 mg metformin",{"EARLY_PHASE1":48466,"PHASE1":48468,"PHASE2":48479,"PHASE3":48481,"PHASE4":48483,"NA":48485},{"trials":48467,"activeCount":99},[],{"trials":48469,"activeCount":99},[48470],{"nctId":48471,"briefTitle":48472,"status":105,"phases":48473,"primaryCompletion":12813,"completion":12813,"start":4990,"enrollment":1624,"conditions":48474,"interventions":48475},"NCT01093794","Bioequivalence Study of Sitagliptin\u002FMetformin Combination Tablet (MK0431A-122)",[87],[14156],[48464,48476,48477,48478],"sitagliptin\u002Fmetformin 50 mg\u002F500 mg","Co-administration of 50 mg sitagliptin and 850 mg metformin","sitagliptin\u002Fmetformin 50 mg\u002F850 mg",{"trials":48480,"activeCount":99},[],{"trials":48482,"activeCount":99},[],{"trials":48484,"activeCount":99},[],{"trials":48486,"activeCount":99},[],{"intervention":48476,"totalTrials":224,"cells":48488},{"EARLY_PHASE1":48489,"PHASE1":48491,"PHASE2":48497,"PHASE3":48499,"PHASE4":48501,"NA":48503},{"trials":48490,"activeCount":99},[],{"trials":48492,"activeCount":99},[48493],{"nctId":48471,"briefTitle":48472,"status":105,"phases":48494,"primaryCompletion":12813,"completion":12813,"start":4990,"enrollment":1624,"conditions":48495,"interventions":48496},[87],[14156],[48464,48476,48477,48478],{"trials":48498,"activeCount":99},[],{"trials":48500,"activeCount":99},[],{"trials":48502,"activeCount":99},[],{"trials":48504,"activeCount":99},[],{"intervention":48477,"totalTrials":224,"cells":48506},{"EARLY_PHASE1":48507,"PHASE1":48509,"PHASE2":48515,"PHASE3":48517,"PHASE4":48519,"NA":48521},{"trials":48508,"activeCount":99},[],{"trials":48510,"activeCount":99},[48511],{"nctId":48471,"briefTitle":48472,"status":105,"phases":48512,"primaryCompletion":12813,"completion":12813,"start":4990,"enrollment":1624,"conditions":48513,"interventions":48514},[87],[14156],[48464,48476,48477,48478],{"trials":48516,"activeCount":99},[],{"trials":48518,"activeCount":99},[],{"trials":48520,"activeCount":99},[],{"trials":48522,"activeCount":99},[],{"intervention":48478,"totalTrials":224,"cells":48524},{"EARLY_PHASE1":48525,"PHASE1":48527,"PHASE2":48533,"PHASE3":48535,"PHASE4":48537,"NA":48539},{"trials":48526,"activeCount":99},[],{"trials":48528,"activeCount":99},[48529],{"nctId":48471,"briefTitle":48472,"status":105,"phases":48530,"primaryCompletion":12813,"completion":12813,"start":4990,"enrollment":1624,"conditions":48531,"interventions":48532},[87],[14156],[48464,48476,48477,48478],{"trials":48534,"activeCount":99},[],{"trials":48536,"activeCount":99},[],{"trials":48538,"activeCount":99},[],{"trials":48540,"activeCount":99},[],{"intervention":48542,"totalTrials":224,"cells":48543},"Comparator: Amlodipine",{"EARLY_PHASE1":48544,"PHASE1":48546,"PHASE2":48555,"PHASE3":48557,"PHASE4":48559,"NA":48561},{"trials":48545,"activeCount":99},[],{"trials":48547,"activeCount":99},[48548],{"nctId":48549,"briefTitle":48550,"status":105,"phases":48551,"primaryCompletion":16592,"completion":16592,"start":14494,"enrollment":312,"conditions":48552,"interventions":48553},"NCT01130168","The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED)",[87],[30],[48542,48554],"Comparator: ISMN ER",{"trials":48556,"activeCount":99},[],{"trials":48558,"activeCount":99},[],{"trials":48560,"activeCount":99},[],{"trials":48562,"activeCount":99},[],{"intervention":48554,"totalTrials":224,"cells":48564},{"EARLY_PHASE1":48565,"PHASE1":48567,"PHASE2":48573,"PHASE3":48575,"PHASE4":48577,"NA":48579},{"trials":48566,"activeCount":99},[],{"trials":48568,"activeCount":99},[48569],{"nctId":48549,"briefTitle":48550,"status":105,"phases":48570,"primaryCompletion":16592,"completion":16592,"start":14494,"enrollment":312,"conditions":48571,"interventions":48572},[87],[30],[48542,48554],{"trials":48574,"activeCount":99},[],{"trials":48576,"activeCount":99},[],{"trials":48578,"activeCount":99},[],{"trials":48580,"activeCount":99},[],{"intervention":48582,"totalTrials":224,"cells":48583},"TUMS® Ultra Strength",{"EARLY_PHASE1":48584,"PHASE1":48586,"PHASE2":48595,"PHASE3":48597,"PHASE4":48599,"NA":48601},{"trials":48585,"activeCount":99},[],{"trials":48587,"activeCount":99},[48588],{"nctId":48589,"briefTitle":48590,"status":105,"phases":48591,"primaryCompletion":6799,"completion":6799,"start":22359,"enrollment":36,"conditions":48592,"interventions":48593},"NCT01622673","A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)",[87],[27],[17577,48582,48594],"MINTOX® Maximum Strength",{"trials":48596,"activeCount":99},[],{"trials":48598,"activeCount":99},[],{"trials":48600,"activeCount":99},[],{"trials":48602,"activeCount":99},[],{"intervention":48594,"totalTrials":224,"cells":48604},{"EARLY_PHASE1":48605,"PHASE1":48607,"PHASE2":48613,"PHASE3":48615,"PHASE4":48617,"NA":48619},{"trials":48606,"activeCount":99},[],{"trials":48608,"activeCount":99},[48609],{"nctId":48589,"briefTitle":48590,"status":105,"phases":48610,"primaryCompletion":6799,"completion":6799,"start":22359,"enrollment":36,"conditions":48611,"interventions":48612},[87],[27],[17577,48582,48594],{"trials":48614,"activeCount":99},[],{"trials":48616,"activeCount":99},[],{"trials":48618,"activeCount":99},[],{"trials":48620,"activeCount":99},[],{"intervention":23589,"totalTrials":224,"cells":48622},{"EARLY_PHASE1":48623,"PHASE1":48625,"PHASE2":48631,"PHASE3":48633,"PHASE4":48635,"NA":48637},{"trials":48624,"activeCount":99},[],{"trials":48626,"activeCount":99},[48627],{"nctId":23581,"briefTitle":23582,"status":105,"phases":48628,"primaryCompletion":23584,"completion":23585,"start":23586,"enrollment":1190,"conditions":48629,"interventions":48630},[87],[4255],[23574,23589,23590],{"trials":48632,"activeCount":99},[],{"trials":48634,"activeCount":99},[],{"trials":48636,"activeCount":99},[],{"trials":48638,"activeCount":99},[],{"intervention":23590,"totalTrials":224,"cells":48640},{"EARLY_PHASE1":48641,"PHASE1":48643,"PHASE2":48649,"PHASE3":48651,"PHASE4":48653,"NA":48655},{"trials":48642,"activeCount":99},[],{"trials":48644,"activeCount":99},[48645],{"nctId":23581,"briefTitle":23582,"status":105,"phases":48646,"primaryCompletion":23584,"completion":23585,"start":23586,"enrollment":1190,"conditions":48647,"interventions":48648},[87],[4255],[23574,23589,23590],{"trials":48650,"activeCount":99},[],{"trials":48652,"activeCount":99},[],{"trials":48654,"activeCount":99},[],{"trials":48656,"activeCount":99},[],{"intervention":14543,"totalTrials":224,"cells":48658},{"EARLY_PHASE1":48659,"PHASE1":48661,"PHASE2":48667,"PHASE3":48669,"PHASE4":48671,"NA":48673},{"trials":48660,"activeCount":99},[],{"trials":48662,"activeCount":99},[48663],{"nctId":14537,"briefTitle":14538,"status":105,"phases":48664,"primaryCompletion":14540,"completion":14454,"start":5507,"enrollment":13805,"conditions":48665,"interventions":48666},[87],[18],[14543,14331],{"trials":48668,"activeCount":99},[],{"trials":48670,"activeCount":99},[],{"trials":48672,"activeCount":99},[],{"trials":48674,"activeCount":99},[],{"intervention":7345,"totalTrials":224,"cells":48676},{"EARLY_PHASE1":48677,"PHASE1":48679,"PHASE2":48685,"PHASE3":48687,"PHASE4":48689,"NA":48691},{"trials":48678,"activeCount":99},[],{"trials":48680,"activeCount":99},[48681],{"nctId":7337,"briefTitle":7338,"status":105,"phases":48682,"primaryCompletion":1064,"completion":1064,"start":7340,"enrollment":4071,"conditions":48683,"interventions":48684},[87],[7342,7343],[7280,7345],{"trials":48686,"activeCount":99},[],{"trials":48688,"activeCount":99},[],{"trials":48690,"activeCount":99},[],{"trials":48692,"activeCount":99},[],{"intervention":42547,"totalTrials":224,"cells":48694},{"EARLY_PHASE1":48695,"PHASE1":48697,"PHASE2":48703,"PHASE3":48705,"PHASE4":48707,"NA":48709},{"trials":48696,"activeCount":99},[],{"trials":48698,"activeCount":99},[48699],{"nctId":42542,"briefTitle":42543,"status":105,"phases":48700,"primaryCompletion":14875,"completion":18807,"start":20173,"enrollment":95,"conditions":48701,"interventions":48702},[87],[5150],[42547,42528,42540],{"trials":48704,"activeCount":99},[],{"trials":48706,"activeCount":99},[],{"trials":48708,"activeCount":99},[],{"trials":48710,"activeCount":99},[],{"intervention":48712,"totalTrials":224,"cells":48713},"MK0752,",{"EARLY_PHASE1":48714,"PHASE1":48716,"PHASE2":48726,"PHASE3":48728,"PHASE4":48730,"NA":48732},{"trials":48715,"activeCount":99},[],{"trials":48717,"activeCount":99},[48718],{"nctId":48719,"briefTitle":48720,"status":150,"phases":48721,"primaryCompletion":4418,"completion":8619,"start":19537,"enrollment":4421,"conditions":48722,"interventions":48725},"NCT00100152","A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia\u002FLymphoma (ALL)(0752-013)",[87],[48723,48724,5538,196],"Leukemia, Lymphoblastic, Acute, T-cell","Myelogenous Leukemia",[48712],{"trials":48727,"activeCount":99},[],{"trials":48729,"activeCount":99},[],{"trials":48731,"activeCount":99},[],{"trials":48733,"activeCount":99},[],{"intervention":48735,"totalTrials":224,"cells":48736},"MK-3281",{"EARLY_PHASE1":48737,"PHASE1":48739,"PHASE2":48749,"PHASE3":48751,"PHASE4":48753,"NA":48755},{"trials":48738,"activeCount":99},[],{"trials":48740,"activeCount":99},[48741],{"nctId":48742,"briefTitle":48743,"status":105,"phases":48744,"primaryCompletion":48745,"completion":48745,"start":48746,"enrollment":558,"conditions":48747,"interventions":48748},"NCT00635804","Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)",[87],"2009-12-22","2008-02-19",[24],[48735],{"trials":48750,"activeCount":99},[],{"trials":48752,"activeCount":99},[],{"trials":48754,"activeCount":99},[],{"trials":48756,"activeCount":99},[],{"intervention":41420,"totalTrials":224,"cells":48758},{"EARLY_PHASE1":48759,"PHASE1":48761,"PHASE2":48767,"PHASE3":48769,"PHASE4":48771,"NA":48773},{"trials":48760,"activeCount":99},[],{"trials":48762,"activeCount":99},[48763],{"nctId":41414,"briefTitle":41415,"status":105,"phases":48764,"primaryCompletion":355,"completion":355,"start":41417,"enrollment":569,"conditions":48765,"interventions":48766},[87],[18,17251],[41420,6172],{"trials":48768,"activeCount":99},[],{"trials":48770,"activeCount":99},[],{"trials":48772,"activeCount":99},[],{"trials":48774,"activeCount":99},[],{"intervention":48776,"totalTrials":224,"cells":48777},"Octavalent HPV with 15 mcg IMX \u002F AAHS",{"EARLY_PHASE1":48778,"PHASE1":48780,"PHASE2":48793,"PHASE3":48795,"PHASE4":48797,"NA":48799},{"trials":48779,"activeCount":99},[],{"trials":48781,"activeCount":99},[48782],{"nctId":48783,"briefTitle":48784,"status":105,"phases":48785,"primaryCompletion":14454,"completion":8591,"start":17461,"enrollment":1827,"conditions":48786,"interventions":48788},"NCT00851643","Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)",[87],[48787,863,865,9217,7085],"Human Papilloma Virus",[48776,48789,48790,48791,48792],"Octavalent HPV with 30 mcg IMX \u002F AAHS","Octavalent HPV with 60 mcg IMX \u002F AAHS","Octavalent HPV with 120 mcg IMX \u002F AAHS","Comparator: Quadrivalent HPV Vaccine",{"trials":48794,"activeCount":99},[],{"trials":48796,"activeCount":99},[],{"trials":48798,"activeCount":99},[],{"trials":48800,"activeCount":99},[],{"intervention":48789,"totalTrials":224,"cells":48802},{"EARLY_PHASE1":48803,"PHASE1":48805,"PHASE2":48811,"PHASE3":48813,"PHASE4":48815,"NA":48817},{"trials":48804,"activeCount":99},[],{"trials":48806,"activeCount":99},[48807],{"nctId":48783,"briefTitle":48784,"status":105,"phases":48808,"primaryCompletion":14454,"completion":8591,"start":17461,"enrollment":1827,"conditions":48809,"interventions":48810},[87],[48787,863,865,9217,7085],[48776,48789,48790,48791,48792],{"trials":48812,"activeCount":99},[],{"trials":48814,"activeCount":99},[],{"trials":48816,"activeCount":99},[],{"trials":48818,"activeCount":99},[],{"intervention":48790,"totalTrials":224,"cells":48820},{"EARLY_PHASE1":48821,"PHASE1":48823,"PHASE2":48829,"PHASE3":48831,"PHASE4":48833,"NA":48835},{"trials":48822,"activeCount":99},[],{"trials":48824,"activeCount":99},[48825],{"nctId":48783,"briefTitle":48784,"status":105,"phases":48826,"primaryCompletion":14454,"completion":8591,"start":17461,"enrollment":1827,"conditions":48827,"interventions":48828},[87],[48787,863,865,9217,7085],[48776,48789,48790,48791,48792],{"trials":48830,"activeCount":99},[],{"trials":48832,"activeCount":99},[],{"trials":48834,"activeCount":99},[],{"trials":48836,"activeCount":99},[],{"intervention":48791,"totalTrials":224,"cells":48838},{"EARLY_PHASE1":48839,"PHASE1":48841,"PHASE2":48847,"PHASE3":48849,"PHASE4":48851,"NA":48853},{"trials":48840,"activeCount":99},[],{"trials":48842,"activeCount":99},[48843],{"nctId":48783,"briefTitle":48784,"status":105,"phases":48844,"primaryCompletion":14454,"completion":8591,"start":17461,"enrollment":1827,"conditions":48845,"interventions":48846},[87],[48787,863,865,9217,7085],[48776,48789,48790,48791,48792],{"trials":48848,"activeCount":99},[],{"trials":48850,"activeCount":99},[],{"trials":48852,"activeCount":99},[],{"trials":48854,"activeCount":99},[],{"intervention":48792,"totalTrials":224,"cells":48856},{"EARLY_PHASE1":48857,"PHASE1":48859,"PHASE2":48865,"PHASE3":48867,"PHASE4":48869,"NA":48871},{"trials":48858,"activeCount":99},[],{"trials":48860,"activeCount":99},[48861],{"nctId":48783,"briefTitle":48784,"status":105,"phases":48862,"primaryCompletion":14454,"completion":8591,"start":17461,"enrollment":1827,"conditions":48863,"interventions":48864},[87],[48787,863,865,9217,7085],[48776,48789,48790,48791,48792],{"trials":48866,"activeCount":99},[],{"trials":48868,"activeCount":99},[],{"trials":48870,"activeCount":99},[],{"trials":48872,"activeCount":99},[],{"intervention":21908,"totalTrials":224,"cells":48874},{"EARLY_PHASE1":48875,"PHASE1":48877,"PHASE2":48883,"PHASE3":48885,"PHASE4":48887,"NA":48889},{"trials":48876,"activeCount":99},[],{"trials":48878,"activeCount":99},[48879],{"nctId":21902,"briefTitle":21903,"status":105,"phases":48880,"primaryCompletion":2890,"completion":2890,"start":21905,"enrollment":335,"conditions":48881,"interventions":48882},[87],[4397],[21884,21908],{"trials":48884,"activeCount":99},[],{"trials":48886,"activeCount":99},[],{"trials":48888,"activeCount":99},[],{"trials":48890,"activeCount":99},[],{"intervention":19547,"totalTrials":224,"cells":48892},{"EARLY_PHASE1":48893,"PHASE1":48895,"PHASE2":48901,"PHASE3":48903,"PHASE4":48905,"NA":48907},{"trials":48894,"activeCount":99},[],{"trials":48896,"activeCount":99},[48897],{"nctId":19541,"briefTitle":19542,"status":105,"phases":48898,"primaryCompletion":14594,"completion":14228,"start":14706,"enrollment":19544,"conditions":48899,"interventions":48900},[87],[14552],[14682,19547],{"trials":48902,"activeCount":99},[],{"trials":48904,"activeCount":99},[],{"trials":48906,"activeCount":99},[],{"trials":48908,"activeCount":99},[],{"intervention":48910,"totalTrials":224,"cells":48911},"Vibegron 100 mg",{"EARLY_PHASE1":48912,"PHASE1":48914,"PHASE2":48924,"PHASE3":48926,"PHASE4":48928,"NA":48930},{"trials":48913,"activeCount":99},[],{"trials":48915,"activeCount":99},[48916],{"nctId":48917,"briefTitle":48918,"status":105,"phases":48919,"primaryCompletion":48920,"completion":48920,"start":48921,"enrollment":626,"conditions":48922,"interventions":48923},"NCT01628042","A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)",[87],"2013-01-25","2012-07-16",[34244],[48910],{"trials":48925,"activeCount":99},[],{"trials":48927,"activeCount":99},[],{"trials":48929,"activeCount":99},[],{"trials":48931,"activeCount":99},[],{"intervention":48933,"totalTrials":224,"cells":48934},"V160 Low Dose IM",{"EARLY_PHASE1":48935,"PHASE1":48937,"PHASE2":48954,"PHASE3":48956,"PHASE4":48958,"NA":48960},{"trials":48936,"activeCount":99},[],{"trials":48938,"activeCount":99},[48939],{"nctId":48940,"briefTitle":48941,"status":105,"phases":48942,"primaryCompletion":48943,"completion":48944,"start":48945,"enrollment":3541,"conditions":48946,"interventions":48947},"NCT01986010","Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)",[87],"2016-04-19","2017-03-14","2013-11-25",[35003],[48933,48948,48949,48950,48951,48952,48953],"V160 Medium Dose IM","V160 High Dose IM","V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg \u002Fdose IM","V160 High Dose plus MAPA 225 µg \u002Fdose IM","V160 Maximum Dose IM","V160 Medium Dose ID",{"trials":48955,"activeCount":99},[],{"trials":48957,"activeCount":99},[],{"trials":48959,"activeCount":99},[],{"trials":48961,"activeCount":99},[],{"intervention":48948,"totalTrials":224,"cells":48963},{"EARLY_PHASE1":48964,"PHASE1":48966,"PHASE2":48972,"PHASE3":48974,"PHASE4":48976,"NA":48978},{"trials":48965,"activeCount":99},[],{"trials":48967,"activeCount":99},[48968],{"nctId":48940,"briefTitle":48941,"status":105,"phases":48969,"primaryCompletion":48943,"completion":48944,"start":48945,"enrollment":3541,"conditions":48970,"interventions":48971},[87],[35003],[48933,48948,48949,48950,48951,48952,48953],{"trials":48973,"activeCount":99},[],{"trials":48975,"activeCount":99},[],{"trials":48977,"activeCount":99},[],{"trials":48979,"activeCount":99},[],{"intervention":48949,"totalTrials":224,"cells":48981},{"EARLY_PHASE1":48982,"PHASE1":48984,"PHASE2":48990,"PHASE3":48992,"PHASE4":48994,"NA":48996},{"trials":48983,"activeCount":99},[],{"trials":48985,"activeCount":99},[48986],{"nctId":48940,"briefTitle":48941,"status":105,"phases":48987,"primaryCompletion":48943,"completion":48944,"start":48945,"enrollment":3541,"conditions":48988,"interventions":48989},[87],[35003],[48933,48948,48949,48950,48951,48952,48953],{"trials":48991,"activeCount":99},[],{"trials":48993,"activeCount":99},[],{"trials":48995,"activeCount":99},[],{"trials":48997,"activeCount":99},[],{"intervention":48950,"totalTrials":224,"cells":48999},{"EARLY_PHASE1":49000,"PHASE1":49002,"PHASE2":49008,"PHASE3":49010,"PHASE4":49012,"NA":49014},{"trials":49001,"activeCount":99},[],{"trials":49003,"activeCount":99},[49004],{"nctId":48940,"briefTitle":48941,"status":105,"phases":49005,"primaryCompletion":48943,"completion":48944,"start":48945,"enrollment":3541,"conditions":49006,"interventions":49007},[87],[35003],[48933,48948,48949,48950,48951,48952,48953],{"trials":49009,"activeCount":99},[],{"trials":49011,"activeCount":99},[],{"trials":49013,"activeCount":99},[],{"trials":49015,"activeCount":99},[],{"intervention":48951,"totalTrials":224,"cells":49017},{"EARLY_PHASE1":49018,"PHASE1":49020,"PHASE2":49026,"PHASE3":49028,"PHASE4":49030,"NA":49032},{"trials":49019,"activeCount":99},[],{"trials":49021,"activeCount":99},[49022],{"nctId":48940,"briefTitle":48941,"status":105,"phases":49023,"primaryCompletion":48943,"completion":48944,"start":48945,"enrollment":3541,"conditions":49024,"interventions":49025},[87],[35003],[48933,48948,48949,48950,48951,48952,48953],{"trials":49027,"activeCount":99},[],{"trials":49029,"activeCount":99},[],{"trials":49031,"activeCount":99},[],{"trials":49033,"activeCount":99},[],{"intervention":48952,"totalTrials":224,"cells":49035},{"EARLY_PHASE1":49036,"PHASE1":49038,"PHASE2":49044,"PHASE3":49046,"PHASE4":49048,"NA":49050},{"trials":49037,"activeCount":99},[],{"trials":49039,"activeCount":99},[49040],{"nctId":48940,"briefTitle":48941,"status":105,"phases":49041,"primaryCompletion":48943,"completion":48944,"start":48945,"enrollment":3541,"conditions":49042,"interventions":49043},[87],[35003],[48933,48948,48949,48950,48951,48952,48953],{"trials":49045,"activeCount":99},[],{"trials":49047,"activeCount":99},[],{"trials":49049,"activeCount":99},[],{"trials":49051,"activeCount":99},[],{"intervention":48953,"totalTrials":224,"cells":49053},{"EARLY_PHASE1":49054,"PHASE1":49056,"PHASE2":49062,"PHASE3":49064,"PHASE4":49066,"NA":49068},{"trials":49055,"activeCount":99},[],{"trials":49057,"activeCount":99},[49058],{"nctId":48940,"briefTitle":48941,"status":105,"phases":49059,"primaryCompletion":48943,"completion":48944,"start":48945,"enrollment":3541,"conditions":49060,"interventions":49061},[87],[35003],[48933,48948,48949,48950,48951,48952,48953],{"trials":49063,"activeCount":99},[],{"trials":49065,"activeCount":99},[],{"trials":49067,"activeCount":99},[],{"trials":49069,"activeCount":99},[],{"intervention":8155,"totalTrials":224,"cells":49071},{"EARLY_PHASE1":49072,"PHASE1":49074,"PHASE2":49080,"PHASE3":49082,"PHASE4":49084,"NA":49086},{"trials":49073,"activeCount":99},[],{"trials":49075,"activeCount":99},[49076],{"nctId":8149,"briefTitle":8150,"status":105,"phases":49077,"primaryCompletion":2634,"completion":2634,"start":8152,"enrollment":28,"conditions":49078,"interventions":49079},[87],[279,314,1552],[8155,8156,84,8143,8145,8157,8158,8146,8159,8160,8161,8162],{"trials":49081,"activeCount":99},[],{"trials":49083,"activeCount":99},[],{"trials":49085,"activeCount":99},[],{"trials":49087,"activeCount":99},[],{"intervention":8156,"totalTrials":224,"cells":49089},{"EARLY_PHASE1":49090,"PHASE1":49092,"PHASE2":49098,"PHASE3":49100,"PHASE4":49102,"NA":49104},{"trials":49091,"activeCount":99},[],{"trials":49093,"activeCount":99},[49094],{"nctId":8149,"briefTitle":8150,"status":105,"phases":49095,"primaryCompletion":2634,"completion":2634,"start":8152,"enrollment":28,"conditions":49096,"interventions":49097},[87],[279,314,1552],[8155,8156,84,8143,8145,8157,8158,8146,8159,8160,8161,8162],{"trials":49099,"activeCount":99},[],{"trials":49101,"activeCount":99},[],{"trials":49103,"activeCount":99},[],{"trials":49105,"activeCount":99},[],{"intervention":8157,"totalTrials":224,"cells":49107},{"EARLY_PHASE1":49108,"PHASE1":49110,"PHASE2":49116,"PHASE3":49118,"PHASE4":49120,"NA":49122},{"trials":49109,"activeCount":99},[],{"trials":49111,"activeCount":99},[49112],{"nctId":8149,"briefTitle":8150,"status":105,"phases":49113,"primaryCompletion":2634,"completion":2634,"start":8152,"enrollment":28,"conditions":49114,"interventions":49115},[87],[279,314,1552],[8155,8156,84,8143,8145,8157,8158,8146,8159,8160,8161,8162],{"trials":49117,"activeCount":99},[],{"trials":49119,"activeCount":99},[],{"trials":49121,"activeCount":99},[],{"trials":49123,"activeCount":99},[],{"intervention":8158,"totalTrials":224,"cells":49125},{"EARLY_PHASE1":49126,"PHASE1":49128,"PHASE2":49134,"PHASE3":49136,"PHASE4":49138,"NA":49140},{"trials":49127,"activeCount":99},[],{"trials":49129,"activeCount":99},[49130],{"nctId":8149,"briefTitle":8150,"status":105,"phases":49131,"primaryCompletion":2634,"completion":2634,"start":8152,"enrollment":28,"conditions":49132,"interventions":49133},[87],[279,314,1552],[8155,8156,84,8143,8145,8157,8158,8146,8159,8160,8161,8162],{"trials":49135,"activeCount":99},[],{"trials":49137,"activeCount":99},[],{"trials":49139,"activeCount":99},[],{"trials":49141,"activeCount":99},[],{"intervention":8159,"totalTrials":224,"cells":49143},{"EARLY_PHASE1":49144,"PHASE1":49146,"PHASE2":49152,"PHASE3":49154,"PHASE4":49156,"NA":49158},{"trials":49145,"activeCount":99},[],{"trials":49147,"activeCount":99},[49148],{"nctId":8149,"briefTitle":8150,"status":105,"phases":49149,"primaryCompletion":2634,"completion":2634,"start":8152,"enrollment":28,"conditions":49150,"interventions":49151},[87],[279,314,1552],[8155,8156,84,8143,8145,8157,8158,8146,8159,8160,8161,8162],{"trials":49153,"activeCount":99},[],{"trials":49155,"activeCount":99},[],{"trials":49157,"activeCount":99},[],{"trials":49159,"activeCount":99},[],{"intervention":8160,"totalTrials":224,"cells":49161},{"EARLY_PHASE1":49162,"PHASE1":49164,"PHASE2":49170,"PHASE3":49172,"PHASE4":49174,"NA":49176},{"trials":49163,"activeCount":99},[],{"trials":49165,"activeCount":99},[49166],{"nctId":8149,"briefTitle":8150,"status":105,"phases":49167,"primaryCompletion":2634,"completion":2634,"start":8152,"enrollment":28,"conditions":49168,"interventions":49169},[87],[279,314,1552],[8155,8156,84,8143,8145,8157,8158,8146,8159,8160,8161,8162],{"trials":49171,"activeCount":99},[],{"trials":49173,"activeCount":99},[],{"trials":49175,"activeCount":99},[],{"trials":49177,"activeCount":99},[],{"intervention":8162,"totalTrials":224,"cells":49179},{"EARLY_PHASE1":49180,"PHASE1":49182,"PHASE2":49188,"PHASE3":49190,"PHASE4":49192,"NA":49194},{"trials":49181,"activeCount":99},[],{"trials":49183,"activeCount":99},[49184],{"nctId":8149,"briefTitle":8150,"status":105,"phases":49185,"primaryCompletion":2634,"completion":2634,"start":8152,"enrollment":28,"conditions":49186,"interventions":49187},[87],[279,314,1552],[8155,8156,84,8143,8145,8157,8158,8146,8159,8160,8161,8162],{"trials":49189,"activeCount":99},[],{"trials":49191,"activeCount":99},[],{"trials":49193,"activeCount":99},[],{"trials":49195,"activeCount":99},[],{"intervention":5472,"totalTrials":224,"cells":49197},{"EARLY_PHASE1":49198,"PHASE1":49200,"PHASE2":49206,"PHASE3":49208,"PHASE4":49210,"NA":49212},{"trials":49199,"activeCount":99},[],{"trials":49201,"activeCount":99},[49202],{"nctId":5462,"briefTitle":5463,"status":150,"phases":49203,"primaryCompletion":5465,"completion":5465,"start":5466,"enrollment":3963,"conditions":49204,"interventions":49205},[87],[290,176,5468,5469,5470],[1390,1074,5472,437,2905,1069,562,1073],{"trials":49207,"activeCount":99},[],{"trials":49209,"activeCount":99},[],{"trials":49211,"activeCount":99},[],{"trials":49213,"activeCount":99},[],{"intervention":6066,"totalTrials":224,"cells":49215},{"EARLY_PHASE1":49216,"PHASE1":49218,"PHASE2":49224,"PHASE3":49226,"PHASE4":49228,"NA":49230},{"trials":49217,"activeCount":99},[],{"trials":49219,"activeCount":99},[49220],{"nctId":6058,"briefTitle":6059,"status":105,"phases":49221,"primaryCompletion":6061,"completion":6062,"start":6063,"enrollment":805,"conditions":49222,"interventions":49223},[87],[419],[6066,693,437,6067],{"trials":49225,"activeCount":99},[],{"trials":49227,"activeCount":99},[],{"trials":49229,"activeCount":99},[],{"trials":49231,"activeCount":99},[],{"intervention":6067,"totalTrials":224,"cells":49233},{"EARLY_PHASE1":49234,"PHASE1":49236,"PHASE2":49242,"PHASE3":49244,"PHASE4":49246,"NA":49248},{"trials":49235,"activeCount":99},[],{"trials":49237,"activeCount":99},[49238],{"nctId":6058,"briefTitle":6059,"status":105,"phases":49239,"primaryCompletion":6061,"completion":6062,"start":6063,"enrollment":805,"conditions":49240,"interventions":49241},[87],[419],[6066,693,437,6067],{"trials":49243,"activeCount":99},[],{"trials":49245,"activeCount":99},[],{"trials":49247,"activeCount":99},[],{"trials":49249,"activeCount":99},[],{"intervention":41851,"totalTrials":224,"cells":49251},{"EARLY_PHASE1":49252,"PHASE1":49254,"PHASE2":49260,"PHASE3":49262,"PHASE4":49264,"NA":49266},{"trials":49253,"activeCount":99},[],{"trials":49255,"activeCount":99},[49256],{"nctId":41845,"briefTitle":41846,"status":105,"phases":49257,"primaryCompletion":41848,"completion":41848,"start":16802,"enrollment":1624,"conditions":49258,"interventions":49259},[87],[9307],[41851,41852,41853],{"trials":49261,"activeCount":99},[],{"trials":49263,"activeCount":99},[],{"trials":49265,"activeCount":99},[],{"trials":49267,"activeCount":99},[],{"intervention":41852,"totalTrials":224,"cells":49269},{"EARLY_PHASE1":49270,"PHASE1":49272,"PHASE2":49278,"PHASE3":49280,"PHASE4":49282,"NA":49284},{"trials":49271,"activeCount":99},[],{"trials":49273,"activeCount":99},[49274],{"nctId":41845,"briefTitle":41846,"status":105,"phases":49275,"primaryCompletion":41848,"completion":41848,"start":16802,"enrollment":1624,"conditions":49276,"interventions":49277},[87],[9307],[41851,41852,41853],{"trials":49279,"activeCount":99},[],{"trials":49281,"activeCount":99},[],{"trials":49283,"activeCount":99},[],{"trials":49285,"activeCount":99},[],{"intervention":49287,"totalTrials":224,"cells":49288},"MK-1075",{"EARLY_PHASE1":49289,"PHASE1":49291,"PHASE2":49301,"PHASE3":49303,"PHASE4":49305,"NA":49307},{"trials":49290,"activeCount":99},[],{"trials":49292,"activeCount":99},[49293],{"nctId":49294,"briefTitle":49295,"status":105,"phases":49296,"primaryCompletion":49297,"completion":49297,"start":49298,"enrollment":3308,"conditions":49299,"interventions":49300},"NCT02392494","Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)",[87],"2015-08-10","2015-04-28",[24],[49287],{"trials":49302,"activeCount":99},[],{"trials":49304,"activeCount":99},[],{"trials":49306,"activeCount":99},[],{"trials":49308,"activeCount":99},[],{"intervention":49310,"totalTrials":224,"cells":49311},"Treatment A: Doravirine 100 mg film coated",{"EARLY_PHASE1":49312,"PHASE1":49314,"PHASE2":49329,"PHASE3":49331,"PHASE4":49333,"NA":49335},{"trials":49313,"activeCount":99},[],{"trials":49315,"activeCount":99},[49316],{"nctId":49317,"briefTitle":49318,"status":105,"phases":49319,"primaryCompletion":49320,"completion":49320,"start":49321,"enrollment":3655,"conditions":49322,"interventions":49324},"NCT02549040","Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)",[87],"2015-12-24","2015-09-21",[49323],"Human Immunodeficiency Virus-1 (HIV-1)",[49310,49325,49326,49327,49328],"Treatment B: Doravirine 150 mg","Treatment C: Doravirine 150 mg","Treatment D: Doravirine 150 mg","Treatment E: Doravirine 100 mg",{"trials":49330,"activeCount":99},[],{"trials":49332,"activeCount":99},[],{"trials":49334,"activeCount":99},[],{"trials":49336,"activeCount":99},[],{"intervention":49325,"totalTrials":224,"cells":49338},{"EARLY_PHASE1":49339,"PHASE1":49341,"PHASE2":49347,"PHASE3":49349,"PHASE4":49351,"NA":49353},{"trials":49340,"activeCount":99},[],{"trials":49342,"activeCount":99},[49343],{"nctId":49317,"briefTitle":49318,"status":105,"phases":49344,"primaryCompletion":49320,"completion":49320,"start":49321,"enrollment":3655,"conditions":49345,"interventions":49346},[87],[49323],[49310,49325,49326,49327,49328],{"trials":49348,"activeCount":99},[],{"trials":49350,"activeCount":99},[],{"trials":49352,"activeCount":99},[],{"trials":49354,"activeCount":99},[],{"intervention":49326,"totalTrials":224,"cells":49356},{"EARLY_PHASE1":49357,"PHASE1":49359,"PHASE2":49365,"PHASE3":49367,"PHASE4":49369,"NA":49371},{"trials":49358,"activeCount":99},[],{"trials":49360,"activeCount":99},[49361],{"nctId":49317,"briefTitle":49318,"status":105,"phases":49362,"primaryCompletion":49320,"completion":49320,"start":49321,"enrollment":3655,"conditions":49363,"interventions":49364},[87],[49323],[49310,49325,49326,49327,49328],{"trials":49366,"activeCount":99},[],{"trials":49368,"activeCount":99},[],{"trials":49370,"activeCount":99},[],{"trials":49372,"activeCount":99},[],{"intervention":49327,"totalTrials":224,"cells":49374},{"EARLY_PHASE1":49375,"PHASE1":49377,"PHASE2":49383,"PHASE3":49385,"PHASE4":49387,"NA":49389},{"trials":49376,"activeCount":99},[],{"trials":49378,"activeCount":99},[49379],{"nctId":49317,"briefTitle":49318,"status":105,"phases":49380,"primaryCompletion":49320,"completion":49320,"start":49321,"enrollment":3655,"conditions":49381,"interventions":49382},[87],[49323],[49310,49325,49326,49327,49328],{"trials":49384,"activeCount":99},[],{"trials":49386,"activeCount":99},[],{"trials":49388,"activeCount":99},[],{"trials":49390,"activeCount":99},[],{"intervention":49328,"totalTrials":224,"cells":49392},{"EARLY_PHASE1":49393,"PHASE1":49395,"PHASE2":49401,"PHASE3":49403,"PHASE4":49405,"NA":49407},{"trials":49394,"activeCount":99},[],{"trials":49396,"activeCount":99},[49397],{"nctId":49317,"briefTitle":49318,"status":105,"phases":49398,"primaryCompletion":49320,"completion":49320,"start":49321,"enrollment":3655,"conditions":49399,"interventions":49400},[87],[49323],[49310,49325,49326,49327,49328],{"trials":49402,"activeCount":99},[],{"trials":49404,"activeCount":99},[],{"trials":49406,"activeCount":99},[],{"trials":49408,"activeCount":99},[],{"intervention":9862,"totalTrials":224,"cells":49410},{"EARLY_PHASE1":49411,"PHASE1":49413,"PHASE2":49419,"PHASE3":49421,"PHASE4":49423,"NA":49425},{"trials":49412,"activeCount":99},[],{"trials":49414,"activeCount":99},[49415],{"nctId":9856,"briefTitle":9857,"status":105,"phases":49416,"primaryCompletion":453,"completion":453,"start":9859,"enrollment":120,"conditions":49417,"interventions":49418},[87],[18],[9849,7800,9862],{"trials":49420,"activeCount":99},[],{"trials":49422,"activeCount":99},[],{"trials":49424,"activeCount":99},[],{"trials":49426,"activeCount":99},[],{"intervention":49428,"totalTrials":224,"cells":49429},"Low-Dose MK-8351",{"EARLY_PHASE1":49430,"PHASE1":49432,"PHASE2":49441,"PHASE3":49443,"PHASE4":49445,"NA":49447},{"trials":49431,"activeCount":99},[],{"trials":49433,"activeCount":99},[49434],{"nctId":49435,"briefTitle":49436,"status":1040,"phases":49437,"primaryCompletion":7017,"completion":7017,"start":19011,"enrollment":99,"conditions":49438,"interventions":49439},"NCT01926002","A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)",[87],[5985],[49428,49440],"High-Dose MK-8351",{"trials":49442,"activeCount":99},[],{"trials":49444,"activeCount":99},[],{"trials":49446,"activeCount":99},[],{"trials":49448,"activeCount":99},[],{"intervention":49440,"totalTrials":224,"cells":49450},{"EARLY_PHASE1":49451,"PHASE1":49453,"PHASE2":49459,"PHASE3":49461,"PHASE4":49463,"NA":49465},{"trials":49452,"activeCount":99},[],{"trials":49454,"activeCount":99},[49455],{"nctId":49435,"briefTitle":49436,"status":1040,"phases":49456,"primaryCompletion":7017,"completion":7017,"start":19011,"enrollment":99,"conditions":49457,"interventions":49458},[87],[5985],[49428,49440],{"trials":49460,"activeCount":99},[],{"trials":49462,"activeCount":99},[],{"trials":49464,"activeCount":99},[],{"trials":49466,"activeCount":99},[],{"intervention":21961,"totalTrials":224,"cells":49468},{"EARLY_PHASE1":49469,"PHASE1":49471,"PHASE2":49477,"PHASE3":49479,"PHASE4":49481,"NA":49483},{"trials":49470,"activeCount":99},[],{"trials":49472,"activeCount":99},[49473],{"nctId":21956,"briefTitle":21957,"status":105,"phases":49474,"primaryCompletion":12813,"completion":12813,"start":14494,"enrollment":95,"conditions":49475,"interventions":49476},[87],[18],[14147,21961,21962],{"trials":49478,"activeCount":99},[],{"trials":49480,"activeCount":99},[],{"trials":49482,"activeCount":99},[],{"trials":49484,"activeCount":99},[],{"intervention":21962,"totalTrials":224,"cells":49486},{"EARLY_PHASE1":49487,"PHASE1":49489,"PHASE2":49495,"PHASE3":49497,"PHASE4":49499,"NA":49501},{"trials":49488,"activeCount":99},[],{"trials":49490,"activeCount":99},[49491],{"nctId":21956,"briefTitle":21957,"status":105,"phases":49492,"primaryCompletion":12813,"completion":12813,"start":14494,"enrollment":95,"conditions":49493,"interventions":49494},[87],[18],[14147,21961,21962],{"trials":49496,"activeCount":99},[],{"trials":49498,"activeCount":99},[],{"trials":49500,"activeCount":99},[],{"trials":49502,"activeCount":99},[],{"intervention":42496,"totalTrials":224,"cells":49504},{"EARLY_PHASE1":49505,"PHASE1":49507,"PHASE2":49513,"PHASE3":49515,"PHASE4":49517,"NA":49519},{"trials":49506,"activeCount":99},[],{"trials":49508,"activeCount":99},[49509],{"nctId":42490,"briefTitle":42491,"status":105,"phases":49510,"primaryCompletion":19143,"completion":19143,"start":42493,"enrollment":613,"conditions":49511,"interventions":49512},[87],[14715],[42475,42496],{"trials":49514,"activeCount":99},[],{"trials":49516,"activeCount":99},[],{"trials":49518,"activeCount":99},[],{"trials":49520,"activeCount":99},[],{"intervention":49522,"totalTrials":224,"cells":49523},"Comparator: fluticasone",{"EARLY_PHASE1":49524,"PHASE1":49526,"PHASE2":49534,"PHASE3":49536,"PHASE4":49538,"NA":49540},{"trials":49525,"activeCount":99},[],{"trials":49527,"activeCount":99},[49528],{"nctId":49529,"briefTitle":49530,"status":105,"phases":49531,"primaryCompletion":14313,"completion":14314,"start":14687,"enrollment":5563,"conditions":49532,"interventions":49533},"NCT00623714","Induced Sputum Study (0000-065)",[87],[5985],[49522],{"trials":49535,"activeCount":99},[],{"trials":49537,"activeCount":99},[],{"trials":49539,"activeCount":99},[],{"trials":49541,"activeCount":99},[],{"intervention":49543,"totalTrials":224,"cells":49544},"IV Tedizolid Phosphate",{"EARLY_PHASE1":49545,"PHASE1":49547,"PHASE2":49560,"PHASE3":49562,"PHASE4":49564,"NA":49566},{"trials":49546,"activeCount":99},[],{"trials":49548,"activeCount":99},[49549],{"nctId":49550,"briefTitle":49551,"status":105,"phases":49552,"primaryCompletion":49553,"completion":49554,"start":49555,"enrollment":14576,"conditions":49556,"interventions":49558},"NCT03217565","A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)",[87],"2023-03-18","2023-04-06","2019-02-06",[49557],"Gram-Positive Infections",[49543,49559],"Oral Suspension Tedizolid Phosphate",{"trials":49561,"activeCount":99},[],{"trials":49563,"activeCount":99},[],{"trials":49565,"activeCount":99},[],{"trials":49567,"activeCount":99},[],{"intervention":49559,"totalTrials":224,"cells":49569},{"EARLY_PHASE1":49570,"PHASE1":49572,"PHASE2":49578,"PHASE3":49580,"PHASE4":49582,"NA":49584},{"trials":49571,"activeCount":99},[],{"trials":49573,"activeCount":99},[49574],{"nctId":49550,"briefTitle":49551,"status":105,"phases":49575,"primaryCompletion":49553,"completion":49554,"start":49555,"enrollment":14576,"conditions":49576,"interventions":49577},[87],[49557],[49543,49559],{"trials":49579,"activeCount":99},[],{"trials":49581,"activeCount":99},[],{"trials":49583,"activeCount":99},[],{"trials":49585,"activeCount":99},[],{"intervention":49587,"totalTrials":224,"cells":49588},"MK6349",{"EARLY_PHASE1":49589,"PHASE1":49591,"PHASE2":49600,"PHASE3":49602,"PHASE4":49604,"NA":49606},{"trials":49590,"activeCount":99},[],{"trials":49592,"activeCount":99},[49593],{"nctId":49594,"briefTitle":49595,"status":150,"phases":49596,"primaryCompletion":14887,"completion":14352,"start":5507,"enrollment":1624,"conditions":49597,"interventions":49598},"NCT00943371","A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002)",[87],[15],[49587,49599],"Comparator: Placebo to MK6349",{"trials":49601,"activeCount":99},[],{"trials":49603,"activeCount":99},[],{"trials":49605,"activeCount":99},[],{"trials":49607,"activeCount":99},[],{"intervention":49599,"totalTrials":224,"cells":49609},{"EARLY_PHASE1":49610,"PHASE1":49612,"PHASE2":49618,"PHASE3":49620,"PHASE4":49622,"NA":49624},{"trials":49611,"activeCount":99},[],{"trials":49613,"activeCount":99},[49614],{"nctId":49594,"briefTitle":49595,"status":150,"phases":49615,"primaryCompletion":14887,"completion":14352,"start":5507,"enrollment":1624,"conditions":49616,"interventions":49617},[87],[15],[49587,49599],{"trials":49619,"activeCount":99},[],{"trials":49621,"activeCount":99},[],{"trials":49623,"activeCount":99},[],{"trials":49625,"activeCount":99},[],{"intervention":49627,"totalTrials":224,"cells":49628},"MK-5823",{"EARLY_PHASE1":49629,"PHASE1":49631,"PHASE2":49639,"PHASE3":49641,"PHASE4":49643,"NA":49645},{"trials":49630,"activeCount":99},[],{"trials":49632,"activeCount":99},[49633],{"nctId":49634,"briefTitle":49635,"status":150,"phases":49636,"primaryCompletion":6799,"completion":6799,"start":22359,"enrollment":120,"conditions":49637,"interventions":49638},"NCT01614782","A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)",[87],[15],[49627],{"trials":49640,"activeCount":99},[],{"trials":49642,"activeCount":99},[],{"trials":49644,"activeCount":99},[],{"trials":49646,"activeCount":99},[],{"intervention":19708,"totalTrials":224,"cells":49648},{"EARLY_PHASE1":49649,"PHASE1":49651,"PHASE2":49657,"PHASE3":49659,"PHASE4":49661,"NA":49663},{"trials":49650,"activeCount":99},[],{"trials":49652,"activeCount":99},[49653],{"nctId":19701,"briefTitle":19702,"status":105,"phases":49654,"primaryCompletion":19704,"completion":19704,"start":19705,"enrollment":8016,"conditions":49655,"interventions":49656},[87],[18],[19708,7800],{"trials":49658,"activeCount":99},[],{"trials":49660,"activeCount":99},[],{"trials":49662,"activeCount":99},[],{"trials":49664,"activeCount":99},[],{"intervention":49666,"totalTrials":224,"cells":49667},"Treatment A",{"EARLY_PHASE1":49668,"PHASE1":49670,"PHASE2":49685,"PHASE3":49687,"PHASE4":49689,"NA":49691},{"trials":49669,"activeCount":99},[],{"trials":49671,"activeCount":99},[49672],{"nctId":49673,"briefTitle":49674,"status":105,"phases":49675,"primaryCompletion":49676,"completion":49676,"start":49677,"enrollment":4741,"conditions":49678,"interventions":49679},"NCT01244035","Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008)",[87],"2010-12-23","2010-08-19",[30],[49666,49680,49681,49682,49683,49684],"Treatment B","Treatment C","Treatment D","Treatment E","Treatment F",{"trials":49686,"activeCount":99},[],{"trials":49688,"activeCount":99},[],{"trials":49690,"activeCount":99},[],{"trials":49692,"activeCount":99},[],{"intervention":49680,"totalTrials":224,"cells":49694},{"EARLY_PHASE1":49695,"PHASE1":49697,"PHASE2":49703,"PHASE3":49705,"PHASE4":49707,"NA":49709},{"trials":49696,"activeCount":99},[],{"trials":49698,"activeCount":99},[49699],{"nctId":49673,"briefTitle":49674,"status":105,"phases":49700,"primaryCompletion":49676,"completion":49676,"start":49677,"enrollment":4741,"conditions":49701,"interventions":49702},[87],[30],[49666,49680,49681,49682,49683,49684],{"trials":49704,"activeCount":99},[],{"trials":49706,"activeCount":99},[],{"trials":49708,"activeCount":99},[],{"trials":49710,"activeCount":99},[],{"intervention":49681,"totalTrials":224,"cells":49712},{"EARLY_PHASE1":49713,"PHASE1":49715,"PHASE2":49721,"PHASE3":49723,"PHASE4":49725,"NA":49727},{"trials":49714,"activeCount":99},[],{"trials":49716,"activeCount":99},[49717],{"nctId":49673,"briefTitle":49674,"status":105,"phases":49718,"primaryCompletion":49676,"completion":49676,"start":49677,"enrollment":4741,"conditions":49719,"interventions":49720},[87],[30],[49666,49680,49681,49682,49683,49684],{"trials":49722,"activeCount":99},[],{"trials":49724,"activeCount":99},[],{"trials":49726,"activeCount":99},[],{"trials":49728,"activeCount":99},[],{"intervention":49682,"totalTrials":224,"cells":49730},{"EARLY_PHASE1":49731,"PHASE1":49733,"PHASE2":49739,"PHASE3":49741,"PHASE4":49743,"NA":49745},{"trials":49732,"activeCount":99},[],{"trials":49734,"activeCount":99},[49735],{"nctId":49673,"briefTitle":49674,"status":105,"phases":49736,"primaryCompletion":49676,"completion":49676,"start":49677,"enrollment":4741,"conditions":49737,"interventions":49738},[87],[30],[49666,49680,49681,49682,49683,49684],{"trials":49740,"activeCount":99},[],{"trials":49742,"activeCount":99},[],{"trials":49744,"activeCount":99},[],{"trials":49746,"activeCount":99},[],{"intervention":49683,"totalTrials":224,"cells":49748},{"EARLY_PHASE1":49749,"PHASE1":49751,"PHASE2":49757,"PHASE3":49759,"PHASE4":49761,"NA":49763},{"trials":49750,"activeCount":99},[],{"trials":49752,"activeCount":99},[49753],{"nctId":49673,"briefTitle":49674,"status":105,"phases":49754,"primaryCompletion":49676,"completion":49676,"start":49677,"enrollment":4741,"conditions":49755,"interventions":49756},[87],[30],[49666,49680,49681,49682,49683,49684],{"trials":49758,"activeCount":99},[],{"trials":49760,"activeCount":99},[],{"trials":49762,"activeCount":99},[],{"trials":49764,"activeCount":99},[],{"intervention":49684,"totalTrials":224,"cells":49766},{"EARLY_PHASE1":49767,"PHASE1":49769,"PHASE2":49775,"PHASE3":49777,"PHASE4":49779,"NA":49781},{"trials":49768,"activeCount":99},[],{"trials":49770,"activeCount":99},[49771],{"nctId":49673,"briefTitle":49674,"status":105,"phases":49772,"primaryCompletion":49676,"completion":49676,"start":49677,"enrollment":4741,"conditions":49773,"interventions":49774},[87],[30],[49666,49680,49681,49682,49683,49684],{"trials":49776,"activeCount":99},[],{"trials":49778,"activeCount":99},[],{"trials":49780,"activeCount":99},[],{"trials":49782,"activeCount":99},[],{"intervention":49784,"totalTrials":224,"cells":49785},"MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) \u002F Duration of Treatment - Up to 8 Cycles or 6 months",{"EARLY_PHASE1":49786,"PHASE1":49788,"PHASE2":49797,"PHASE3":49799,"PHASE4":49801,"NA":49803},{"trials":49787,"activeCount":99},[],{"trials":49789,"activeCount":99},[49790],{"nctId":49791,"briefTitle":49792,"status":150,"phases":49793,"primaryCompletion":49794,"completion":49794,"start":17198,"enrollment":558,"conditions":49795,"interventions":49796},"NCT00109109","A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)",[87],"2006-02-14",[526],[49784],{"trials":49798,"activeCount":99},[],{"trials":49800,"activeCount":99},[],{"trials":49802,"activeCount":99},[],{"trials":49804,"activeCount":99},[],{"intervention":41428,"totalTrials":224,"cells":49806},{"EARLY_PHASE1":49807,"PHASE1":49809,"PHASE2":49815,"PHASE3":49817,"PHASE4":49819,"NA":49821},{"trials":49808,"activeCount":99},[],{"trials":49810,"activeCount":99},[49811],{"nctId":41422,"briefTitle":41423,"status":105,"phases":49812,"primaryCompletion":41425,"completion":41425,"start":7266,"enrollment":661,"conditions":49813,"interventions":49814},[87],[18],[41428,6172],{"trials":49816,"activeCount":99},[],{"trials":49818,"activeCount":99},[],{"trials":49820,"activeCount":99},[],{"trials":49822,"activeCount":99},[],{"intervention":16389,"totalTrials":224,"cells":49824},{"EARLY_PHASE1":49825,"PHASE1":49827,"PHASE2":49833,"PHASE3":49835,"PHASE4":49837,"NA":49839},{"trials":49826,"activeCount":99},[],{"trials":49828,"activeCount":99},[49829],{"nctId":16384,"briefTitle":16385,"status":105,"phases":49830,"primaryCompletion":5507,"completion":5507,"start":13891,"enrollment":8,"conditions":49831,"interventions":49832},[87],[14337],[16389,16390,13122],{"trials":49834,"activeCount":99},[],{"trials":49836,"activeCount":99},[],{"trials":49838,"activeCount":99},[],{"trials":49840,"activeCount":99},[],{"intervention":16390,"totalTrials":224,"cells":49842},{"EARLY_PHASE1":49843,"PHASE1":49845,"PHASE2":49851,"PHASE3":49853,"PHASE4":49855,"NA":49857},{"trials":49844,"activeCount":99},[],{"trials":49846,"activeCount":99},[49847],{"nctId":16384,"briefTitle":16385,"status":105,"phases":49848,"primaryCompletion":5507,"completion":5507,"start":13891,"enrollment":8,"conditions":49849,"interventions":49850},[87],[14337],[16389,16390,13122],{"trials":49852,"activeCount":99},[],{"trials":49854,"activeCount":99},[],{"trials":49856,"activeCount":99},[],{"trials":49858,"activeCount":99},[],{"intervention":14561,"totalTrials":224,"cells":49860},{"EARLY_PHASE1":49861,"PHASE1":49863,"PHASE2":49869,"PHASE3":49871,"PHASE4":49873,"NA":49875},{"trials":49862,"activeCount":99},[],{"trials":49864,"activeCount":99},[49865],{"nctId":14556,"briefTitle":14557,"status":105,"phases":49866,"primaryCompletion":14445,"completion":14445,"start":6309,"enrollment":4071,"conditions":49867,"interventions":49868},[87],[14156],[14561,13864],{"trials":49870,"activeCount":99},[],{"trials":49872,"activeCount":99},[],{"trials":49874,"activeCount":99},[],{"trials":49876,"activeCount":99},[],{"intervention":14571,"totalTrials":224,"cells":49878},{"EARLY_PHASE1":49879,"PHASE1":49881,"PHASE2":49887,"PHASE3":49889,"PHASE4":49891,"NA":49893},{"trials":49880,"activeCount":99},[],{"trials":49882,"activeCount":99},[49883],{"nctId":14563,"briefTitle":14564,"status":105,"phases":49884,"primaryCompletion":8619,"completion":14566,"start":14567,"enrollment":4273,"conditions":49885,"interventions":49886},[87],[11444,27],[14570,14571,14571,13864],{"trials":49888,"activeCount":99},[],{"trials":49890,"activeCount":99},[],{"trials":49892,"activeCount":99},[],{"trials":49894,"activeCount":99},[],{"intervention":49896,"totalTrials":224,"cells":49897},"Posaconazole 200 mg",{"EARLY_PHASE1":49898,"PHASE1":49900,"PHASE2":49909,"PHASE3":49911,"PHASE4":49913,"NA":49915},{"trials":49899,"activeCount":99},[],{"trials":49901,"activeCount":99},[49902],{"nctId":49903,"briefTitle":49904,"status":105,"phases":49905,"primaryCompletion":13223,"completion":13223,"start":5280,"enrollment":1132,"conditions":49906,"interventions":49907},"NCT01777763","Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065\u002FP05615)",[87],[24476],[49896,49908],"Posaconazole 300 mg",{"trials":49910,"activeCount":99},[],{"trials":49912,"activeCount":99},[],{"trials":49914,"activeCount":99},[],{"trials":49916,"activeCount":99},[],{"intervention":49908,"totalTrials":224,"cells":49918},{"EARLY_PHASE1":49919,"PHASE1":49921,"PHASE2":49927,"PHASE3":49929,"PHASE4":49931,"NA":49933},{"trials":49920,"activeCount":99},[],{"trials":49922,"activeCount":99},[49923],{"nctId":49903,"briefTitle":49904,"status":105,"phases":49924,"primaryCompletion":13223,"completion":13223,"start":5280,"enrollment":1132,"conditions":49925,"interventions":49926},[87],[24476],[49896,49908],{"trials":49928,"activeCount":99},[],{"trials":49930,"activeCount":99},[],{"trials":49932,"activeCount":99},[],{"trials":49934,"activeCount":99},[],{"intervention":49936,"totalTrials":224,"cells":49937},"Vildagliptin",{"EARLY_PHASE1":49938,"PHASE1":49940,"PHASE2":49948,"PHASE3":49950,"PHASE4":49952,"NA":49954},{"trials":49939,"activeCount":99},[],{"trials":49941,"activeCount":99},[49942],{"nctId":49943,"briefTitle":49944,"status":105,"phases":49945,"primaryCompletion":6799,"completion":6799,"start":12984,"enrollment":9323,"conditions":49946,"interventions":49947},"NCT01537120","Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)",[87],[15],[49936],{"trials":49949,"activeCount":99},[],{"trials":49951,"activeCount":99},[],{"trials":49953,"activeCount":99},[],{"trials":49955,"activeCount":99},[],{"intervention":49957,"totalTrials":224,"cells":49958},"Comparator: MK0752, Notch Inhibitor",{"EARLY_PHASE1":49959,"PHASE1":49961,"PHASE2":49975,"PHASE3":49977,"PHASE4":49979,"NA":49981},{"trials":49960,"activeCount":99},[],{"trials":49962,"activeCount":99},[49963],{"nctId":49964,"briefTitle":49965,"status":105,"phases":49966,"primaryCompletion":16591,"completion":16591,"start":14593,"enrollment":722,"conditions":49967,"interventions":49970},"NCT00106145","A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)",[87],[49968,49969],"Advanced Breast Cancer","Other Solid Tumors",[49957,49971,49972,49973,49974],"Comparator: MK0752, Notch Inhibitor - 450 mg","Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off","Comparator: MK0752, Notch Inhibitor - 1 day on, 6 off","Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg",{"trials":49976,"activeCount":99},[],{"trials":49978,"activeCount":99},[],{"trials":49980,"activeCount":99},[],{"trials":49982,"activeCount":99},[],{"intervention":49971,"totalTrials":224,"cells":49984},{"EARLY_PHASE1":49985,"PHASE1":49987,"PHASE2":49993,"PHASE3":49995,"PHASE4":49997,"NA":49999},{"trials":49986,"activeCount":99},[],{"trials":49988,"activeCount":99},[49989],{"nctId":49964,"briefTitle":49965,"status":105,"phases":49990,"primaryCompletion":16591,"completion":16591,"start":14593,"enrollment":722,"conditions":49991,"interventions":49992},[87],[49968,49969],[49957,49971,49972,49973,49974],{"trials":49994,"activeCount":99},[],{"trials":49996,"activeCount":99},[],{"trials":49998,"activeCount":99},[],{"trials":50000,"activeCount":99},[],{"intervention":49972,"totalTrials":224,"cells":50002},{"EARLY_PHASE1":50003,"PHASE1":50005,"PHASE2":50011,"PHASE3":50013,"PHASE4":50015,"NA":50017},{"trials":50004,"activeCount":99},[],{"trials":50006,"activeCount":99},[50007],{"nctId":49964,"briefTitle":49965,"status":105,"phases":50008,"primaryCompletion":16591,"completion":16591,"start":14593,"enrollment":722,"conditions":50009,"interventions":50010},[87],[49968,49969],[49957,49971,49972,49973,49974],{"trials":50012,"activeCount":99},[],{"trials":50014,"activeCount":99},[],{"trials":50016,"activeCount":99},[],{"trials":50018,"activeCount":99},[],{"intervention":49973,"totalTrials":224,"cells":50020},{"EARLY_PHASE1":50021,"PHASE1":50023,"PHASE2":50029,"PHASE3":50031,"PHASE4":50033,"NA":50035},{"trials":50022,"activeCount":99},[],{"trials":50024,"activeCount":99},[50025],{"nctId":49964,"briefTitle":49965,"status":105,"phases":50026,"primaryCompletion":16591,"completion":16591,"start":14593,"enrollment":722,"conditions":50027,"interventions":50028},[87],[49968,49969],[49957,49971,49972,49973,49974],{"trials":50030,"activeCount":99},[],{"trials":50032,"activeCount":99},[],{"trials":50034,"activeCount":99},[],{"trials":50036,"activeCount":99},[],{"intervention":49974,"totalTrials":224,"cells":50038},{"EARLY_PHASE1":50039,"PHASE1":50041,"PHASE2":50047,"PHASE3":50049,"PHASE4":50051,"NA":50053},{"trials":50040,"activeCount":99},[],{"trials":50042,"activeCount":99},[50043],{"nctId":49964,"briefTitle":49965,"status":105,"phases":50044,"primaryCompletion":16591,"completion":16591,"start":14593,"enrollment":722,"conditions":50045,"interventions":50046},[87],[49968,49969],[49957,49971,49972,49973,49974],{"trials":50048,"activeCount":99},[],{"trials":50050,"activeCount":99},[],{"trials":50052,"activeCount":99},[],{"trials":50054,"activeCount":99},[],{"intervention":21743,"totalTrials":224,"cells":50056},{"EARLY_PHASE1":50057,"PHASE1":50059,"PHASE2":50065,"PHASE3":50067,"PHASE4":50069,"NA":50071},{"trials":50058,"activeCount":99},[],{"trials":50060,"activeCount":99},[50061],{"nctId":21736,"briefTitle":21737,"status":105,"phases":50062,"primaryCompletion":21739,"completion":21740,"start":21739,"enrollment":1054,"conditions":50063,"interventions":50064},[87],[14156],[14039,21743,21729,21744,21731,21733],{"trials":50066,"activeCount":99},[],{"trials":50068,"activeCount":99},[],{"trials":50070,"activeCount":99},[],{"trials":50072,"activeCount":99},[],{"intervention":21744,"totalTrials":224,"cells":50074},{"EARLY_PHASE1":50075,"PHASE1":50077,"PHASE2":50083,"PHASE3":50085,"PHASE4":50087,"NA":50089},{"trials":50076,"activeCount":99},[],{"trials":50078,"activeCount":99},[50079],{"nctId":21736,"briefTitle":21737,"status":105,"phases":50080,"primaryCompletion":21739,"completion":21740,"start":21739,"enrollment":1054,"conditions":50081,"interventions":50082},[87],[14156],[14039,21743,21729,21744,21731,21733],{"trials":50084,"activeCount":99},[],{"trials":50086,"activeCount":99},[],{"trials":50088,"activeCount":99},[],{"trials":50090,"activeCount":99},[],{"intervention":50092,"totalTrials":224,"cells":50093},"MK0974 Ethanolate formulation",{"EARLY_PHASE1":50094,"PHASE1":50096,"PHASE2":50105,"PHASE3":50107,"PHASE4":50109,"NA":50111},{"trials":50095,"activeCount":99},[],{"trials":50097,"activeCount":99},[50098],{"nctId":50099,"briefTitle":50100,"status":105,"phases":50101,"primaryCompletion":13890,"completion":13890,"start":8620,"enrollment":8016,"conditions":50102,"interventions":50103},"NCT00965887","Bioequivalence of Two Tablet Forms of MK0974 (0974-045)",[87],[4397],[50092,50104],"Comparator: MK0974 Hydrate formulation",{"trials":50106,"activeCount":99},[],{"trials":50108,"activeCount":99},[],{"trials":50110,"activeCount":99},[],{"trials":50112,"activeCount":99},[],{"intervention":50104,"totalTrials":224,"cells":50114},{"EARLY_PHASE1":50115,"PHASE1":50117,"PHASE2":50123,"PHASE3":50125,"PHASE4":50127,"NA":50129},{"trials":50116,"activeCount":99},[],{"trials":50118,"activeCount":99},[50119],{"nctId":50099,"briefTitle":50100,"status":105,"phases":50120,"primaryCompletion":13890,"completion":13890,"start":8620,"enrollment":8016,"conditions":50121,"interventions":50122},[87],[4397],[50092,50104],{"trials":50124,"activeCount":99},[],{"trials":50126,"activeCount":99},[],{"trials":50128,"activeCount":99},[],{"trials":50130,"activeCount":99},[],{"intervention":14579,"totalTrials":224,"cells":50132},{"EARLY_PHASE1":50133,"PHASE1":50135,"PHASE2":50141,"PHASE3":50143,"PHASE4":50145,"NA":50147},{"trials":50134,"activeCount":99},[],{"trials":50136,"activeCount":99},[50137],{"nctId":14573,"briefTitle":14574,"status":105,"phases":50138,"primaryCompletion":14313,"completion":14314,"start":5801,"enrollment":14576,"conditions":50139,"interventions":50140},[87],[30],[14579,13864],{"trials":50142,"activeCount":99},[],{"trials":50144,"activeCount":99},[],{"trials":50146,"activeCount":99},[],{"trials":50148,"activeCount":99},[],{"intervention":50150,"totalTrials":224,"cells":50151},"MK-1092, 4.0 nmol\u002Fkg",{"EARLY_PHASE1":50152,"PHASE1":50154,"PHASE2":50169,"PHASE3":50171,"PHASE4":50173,"NA":50175},{"trials":50153,"activeCount":99},[],{"trials":50155,"activeCount":99},[50156],{"nctId":50157,"briefTitle":50158,"status":105,"phases":50159,"primaryCompletion":2007,"completion":2007,"start":34804,"enrollment":50160,"conditions":50161,"interventions":50162},"NCT03170544","Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)",[87],69,[4255,15],[50150,50163,50164,50165,50166,50167,50168,14059],"MK-1092, 8.0 nmol\u002Fkg","MK-1092, 16 nmol\u002Fkg","MK-1092, 32 nmol\u002Fkg","MK-1092, 64 nmol\u002Fkg","Glargine 3.0 nmol\u002Fkg","Lispro 1.2 nmol\u002Fkg",{"trials":50170,"activeCount":99},[],{"trials":50172,"activeCount":99},[],{"trials":50174,"activeCount":99},[],{"trials":50176,"activeCount":99},[],{"intervention":50163,"totalTrials":224,"cells":50178},{"EARLY_PHASE1":50179,"PHASE1":50181,"PHASE2":50187,"PHASE3":50189,"PHASE4":50191,"NA":50193},{"trials":50180,"activeCount":99},[],{"trials":50182,"activeCount":99},[50183],{"nctId":50157,"briefTitle":50158,"status":105,"phases":50184,"primaryCompletion":2007,"completion":2007,"start":34804,"enrollment":50160,"conditions":50185,"interventions":50186},[87],[4255,15],[50150,50163,50164,50165,50166,50167,50168,14059],{"trials":50188,"activeCount":99},[],{"trials":50190,"activeCount":99},[],{"trials":50192,"activeCount":99},[],{"trials":50194,"activeCount":99},[],{"intervention":50164,"totalTrials":224,"cells":50196},{"EARLY_PHASE1":50197,"PHASE1":50199,"PHASE2":50205,"PHASE3":50207,"PHASE4":50209,"NA":50211},{"trials":50198,"activeCount":99},[],{"trials":50200,"activeCount":99},[50201],{"nctId":50157,"briefTitle":50158,"status":105,"phases":50202,"primaryCompletion":2007,"completion":2007,"start":34804,"enrollment":50160,"conditions":50203,"interventions":50204},[87],[4255,15],[50150,50163,50164,50165,50166,50167,50168,14059],{"trials":50206,"activeCount":99},[],{"trials":50208,"activeCount":99},[],{"trials":50210,"activeCount":99},[],{"trials":50212,"activeCount":99},[],{"intervention":50165,"totalTrials":224,"cells":50214},{"EARLY_PHASE1":50215,"PHASE1":50217,"PHASE2":50223,"PHASE3":50225,"PHASE4":50227,"NA":50229},{"trials":50216,"activeCount":99},[],{"trials":50218,"activeCount":99},[50219],{"nctId":50157,"briefTitle":50158,"status":105,"phases":50220,"primaryCompletion":2007,"completion":2007,"start":34804,"enrollment":50160,"conditions":50221,"interventions":50222},[87],[4255,15],[50150,50163,50164,50165,50166,50167,50168,14059],{"trials":50224,"activeCount":99},[],{"trials":50226,"activeCount":99},[],{"trials":50228,"activeCount":99},[],{"trials":50230,"activeCount":99},[],{"intervention":50166,"totalTrials":224,"cells":50232},{"EARLY_PHASE1":50233,"PHASE1":50235,"PHASE2":50241,"PHASE3":50243,"PHASE4":50245,"NA":50247},{"trials":50234,"activeCount":99},[],{"trials":50236,"activeCount":99},[50237],{"nctId":50157,"briefTitle":50158,"status":105,"phases":50238,"primaryCompletion":2007,"completion":2007,"start":34804,"enrollment":50160,"conditions":50239,"interventions":50240},[87],[4255,15],[50150,50163,50164,50165,50166,50167,50168,14059],{"trials":50242,"activeCount":99},[],{"trials":50244,"activeCount":99},[],{"trials":50246,"activeCount":99},[],{"trials":50248,"activeCount":99},[],{"intervention":50167,"totalTrials":224,"cells":50250},{"EARLY_PHASE1":50251,"PHASE1":50253,"PHASE2":50259,"PHASE3":50261,"PHASE4":50263,"NA":50265},{"trials":50252,"activeCount":99},[],{"trials":50254,"activeCount":99},[50255],{"nctId":50157,"briefTitle":50158,"status":105,"phases":50256,"primaryCompletion":2007,"completion":2007,"start":34804,"enrollment":50160,"conditions":50257,"interventions":50258},[87],[4255,15],[50150,50163,50164,50165,50166,50167,50168,14059],{"trials":50260,"activeCount":99},[],{"trials":50262,"activeCount":99},[],{"trials":50264,"activeCount":99},[],{"trials":50266,"activeCount":99},[],{"intervention":50168,"totalTrials":224,"cells":50268},{"EARLY_PHASE1":50269,"PHASE1":50271,"PHASE2":50277,"PHASE3":50279,"PHASE4":50281,"NA":50283},{"trials":50270,"activeCount":99},[],{"trials":50272,"activeCount":99},[50273],{"nctId":50157,"briefTitle":50158,"status":105,"phases":50274,"primaryCompletion":2007,"completion":2007,"start":34804,"enrollment":50160,"conditions":50275,"interventions":50276},[87],[4255,15],[50150,50163,50164,50165,50166,50167,50168,14059],{"trials":50278,"activeCount":99},[],{"trials":50280,"activeCount":99},[],{"trials":50282,"activeCount":99},[],{"trials":50284,"activeCount":99},[],{"intervention":14599,"totalTrials":224,"cells":50286},{"EARLY_PHASE1":50287,"PHASE1":50289,"PHASE2":50295,"PHASE3":50297,"PHASE4":50299,"NA":50301},{"trials":50288,"activeCount":99},[],{"trials":50290,"activeCount":99},[50291],{"nctId":14590,"briefTitle":14591,"status":105,"phases":50292,"primaryCompletion":14593,"completion":14594,"start":14595,"enrollment":154,"conditions":50293,"interventions":50294},[87],[14597],[14599,14331],{"trials":50296,"activeCount":99},[],{"trials":50298,"activeCount":99},[],{"trials":50300,"activeCount":99},[],{"trials":50302,"activeCount":99},[],{"intervention":41612,"totalTrials":224,"cells":50304},{"EARLY_PHASE1":50305,"PHASE1":50307,"PHASE2":50313,"PHASE3":50315,"PHASE4":50317,"NA":50319},{"trials":50306,"activeCount":99},[],{"trials":50308,"activeCount":99},[50309],{"nctId":41607,"briefTitle":41608,"status":105,"phases":50310,"primaryCompletion":14315,"completion":9610,"start":5507,"enrollment":1419,"conditions":50311,"interventions":50312},[87],[639],[41587,41612],{"trials":50314,"activeCount":99},[],{"trials":50316,"activeCount":99},[],{"trials":50318,"activeCount":99},[],{"trials":50320,"activeCount":99},[],{"intervention":50322,"totalTrials":224,"cells":50323},"V526",{"EARLY_PHASE1":50324,"PHASE1":50326,"PHASE2":50335,"PHASE3":50337,"PHASE4":50339,"NA":50341},{"trials":50325,"activeCount":99},[],{"trials":50327,"activeCount":99},[50328],{"nctId":50329,"briefTitle":50330,"status":105,"phases":50331,"primaryCompletion":12804,"completion":21145,"start":14593,"enrollment":912,"conditions":50332,"interventions":50333},"NCT00850616","Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)",[87],[7390,27],[50322,50334],"Comparator: Placebo to V526",{"trials":50336,"activeCount":99},[],{"trials":50338,"activeCount":99},[],{"trials":50340,"activeCount":99},[],{"trials":50342,"activeCount":99},[],{"intervention":50334,"totalTrials":224,"cells":50344},{"EARLY_PHASE1":50345,"PHASE1":50347,"PHASE2":50353,"PHASE3":50355,"PHASE4":50357,"NA":50359},{"trials":50346,"activeCount":99},[],{"trials":50348,"activeCount":99},[50349],{"nctId":50329,"briefTitle":50330,"status":105,"phases":50350,"primaryCompletion":12804,"completion":21145,"start":14593,"enrollment":912,"conditions":50351,"interventions":50352},[87],[7390,27],[50322,50334],{"trials":50354,"activeCount":99},[],{"trials":50356,"activeCount":99},[],{"trials":50358,"activeCount":99},[],{"trials":50360,"activeCount":99},[],{"intervention":50362,"totalTrials":224,"cells":50363},"[¹⁴C]Enlicitide chloride",{"EARLY_PHASE1":50364,"PHASE1":50366,"PHASE2":50376,"PHASE3":50378,"PHASE4":50380,"NA":50382},{"trials":50365,"activeCount":99},[],{"trials":50367,"activeCount":99},[50368],{"nctId":50369,"briefTitle":50370,"status":105,"phases":50371,"primaryCompletion":50372,"completion":50372,"start":50373,"enrollment":734,"conditions":50374,"interventions":50375},"NCT06658626","A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)",[87],"2023-08-02","2023-03-10",[18],[50362],{"trials":50377,"activeCount":99},[],{"trials":50379,"activeCount":99},[],{"trials":50381,"activeCount":99},[],{"trials":50383,"activeCount":99},[],{"intervention":50385,"totalTrials":224,"cells":50386},"[14C]MK-8527",{"EARLY_PHASE1":50387,"PHASE1":50389,"PHASE2":50399,"PHASE3":50401,"PHASE4":50403,"NA":50405},{"trials":50388,"activeCount":99},[],{"trials":50390,"activeCount":99},[50391],{"nctId":50392,"briefTitle":50393,"status":105,"phases":50394,"primaryCompletion":50395,"completion":50395,"start":50396,"enrollment":734,"conditions":50397,"interventions":50398},"NCT06826989","A Study of MK-8527 in Healthy Adult Participants (MK-8527-013)",[87],"2025-06-04","2025-03-19",[18],[50385],{"trials":50400,"activeCount":99},[],{"trials":50402,"activeCount":99},[],{"trials":50404,"activeCount":99},[],{"trials":50406,"activeCount":99},[],{"intervention":14607,"totalTrials":224,"cells":50408},{"EARLY_PHASE1":50409,"PHASE1":50411,"PHASE2":50417,"PHASE3":50419,"PHASE4":50421,"NA":50423},{"trials":50410,"activeCount":99},[],{"trials":50412,"activeCount":99},[50413],{"nctId":14601,"briefTitle":14602,"status":105,"phases":50414,"primaryCompletion":5281,"completion":5281,"start":14409,"enrollment":931,"conditions":50415,"interventions":50416},[87],[14605],[14607,13864,14608,14609],{"trials":50418,"activeCount":99},[],{"trials":50420,"activeCount":99},[],{"trials":50422,"activeCount":99},[],{"trials":50424,"activeCount":99},[],{"intervention":14608,"totalTrials":224,"cells":50426},{"EARLY_PHASE1":50427,"PHASE1":50429,"PHASE2":50435,"PHASE3":50437,"PHASE4":50439,"NA":50441},{"trials":50428,"activeCount":99},[],{"trials":50430,"activeCount":99},[50431],{"nctId":14601,"briefTitle":14602,"status":105,"phases":50432,"primaryCompletion":5281,"completion":5281,"start":14409,"enrollment":931,"conditions":50433,"interventions":50434},[87],[14605],[14607,13864,14608,14609],{"trials":50436,"activeCount":99},[],{"trials":50438,"activeCount":99},[],{"trials":50440,"activeCount":99},[],{"trials":50442,"activeCount":99},[],{"intervention":14609,"totalTrials":224,"cells":50444},{"EARLY_PHASE1":50445,"PHASE1":50447,"PHASE2":50453,"PHASE3":50455,"PHASE4":50457,"NA":50459},{"trials":50446,"activeCount":99},[],{"trials":50448,"activeCount":99},[50449],{"nctId":14601,"briefTitle":14602,"status":105,"phases":50450,"primaryCompletion":5281,"completion":5281,"start":14409,"enrollment":931,"conditions":50451,"interventions":50452},[87],[14605],[14607,13864,14608,14609],{"trials":50454,"activeCount":99},[],{"trials":50456,"activeCount":99},[],{"trials":50458,"activeCount":99},[],{"trials":50460,"activeCount":99},[],{"intervention":50462,"totalTrials":224,"cells":50463},"Stable isotope tracer",{"EARLY_PHASE1":50464,"PHASE1":50466,"PHASE2":50475,"PHASE3":50477,"PHASE4":50479,"NA":50481},{"trials":50465,"activeCount":99},[],{"trials":50467,"activeCount":99},[50468],{"nctId":50469,"briefTitle":50470,"status":105,"phases":50471,"primaryCompletion":50472,"completion":50472,"start":35323,"enrollment":120,"conditions":50473,"interventions":50474},"NCT00860392","A Comparison of Measurements of Ketone Body Flux Versus Ketone Body Concentration as a Pharmacodynamic Marker of Hepatic Fatty Acid Oxidation (0000-110)",[87],"2009-07-08",[42963],[50462],{"trials":50476,"activeCount":99},[],{"trials":50478,"activeCount":99},[],{"trials":50480,"activeCount":99},[],{"trials":50482,"activeCount":99},[],{"intervention":14618,"totalTrials":224,"cells":50484},{"EARLY_PHASE1":50485,"PHASE1":50487,"PHASE2":50493,"PHASE3":50495,"PHASE4":50497,"NA":50499},{"trials":50486,"activeCount":99},[],{"trials":50488,"activeCount":99},[50489],{"nctId":14611,"briefTitle":14612,"status":150,"phases":50490,"primaryCompletion":14614,"completion":14614,"start":14615,"enrollment":931,"conditions":50491,"interventions":50492},[87],[7639],[14618,13864],{"trials":50494,"activeCount":99},[],{"trials":50496,"activeCount":99},[],{"trials":50498,"activeCount":99},[],{"trials":50500,"activeCount":99},[],{"intervention":50502,"totalTrials":224,"cells":50503},"Peg-Interferon",{"EARLY_PHASE1":50504,"PHASE1":50506,"PHASE2":50516,"PHASE3":50518,"PHASE4":50520,"NA":50522},{"trials":50505,"activeCount":99},[],{"trials":50507,"activeCount":99},[50508],{"nctId":50509,"briefTitle":50510,"status":1040,"phases":50511,"primaryCompletion":16793,"completion":16793,"start":15845,"enrollment":99,"conditions":50512,"interventions":50513},"NCT01547312","Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)",[87],[12957],[50502,14925,50514,50515],"800 mg Grazoprevir","100 mg Grazoprevir",{"trials":50517,"activeCount":99},[],{"trials":50519,"activeCount":99},[],{"trials":50521,"activeCount":99},[],{"trials":50523,"activeCount":99},[],{"intervention":50514,"totalTrials":224,"cells":50525},{"EARLY_PHASE1":50526,"PHASE1":50528,"PHASE2":50534,"PHASE3":50536,"PHASE4":50538,"NA":50540},{"trials":50527,"activeCount":99},[],{"trials":50529,"activeCount":99},[50530],{"nctId":50509,"briefTitle":50510,"status":1040,"phases":50531,"primaryCompletion":16793,"completion":16793,"start":15845,"enrollment":99,"conditions":50532,"interventions":50533},[87],[12957],[50502,14925,50514,50515],{"trials":50535,"activeCount":99},[],{"trials":50537,"activeCount":99},[],{"trials":50539,"activeCount":99},[],{"trials":50541,"activeCount":99},[],{"intervention":50515,"totalTrials":224,"cells":50543},{"EARLY_PHASE1":50544,"PHASE1":50546,"PHASE2":50552,"PHASE3":50554,"PHASE4":50556,"NA":50558},{"trials":50545,"activeCount":99},[],{"trials":50547,"activeCount":99},[50548],{"nctId":50509,"briefTitle":50510,"status":1040,"phases":50549,"primaryCompletion":16793,"completion":16793,"start":15845,"enrollment":99,"conditions":50550,"interventions":50551},[87],[12957],[50502,14925,50514,50515],{"trials":50553,"activeCount":99},[],{"trials":50555,"activeCount":99},[],{"trials":50557,"activeCount":99},[],{"trials":50559,"activeCount":99},[],{"intervention":50561,"totalTrials":224,"cells":50562},"MK-1972",{"EARLY_PHASE1":50563,"PHASE1":50565,"PHASE2":50574,"PHASE3":50576,"PHASE4":50578,"NA":50580},{"trials":50564,"activeCount":99},[],{"trials":50566,"activeCount":99},[50567],{"nctId":50568,"briefTitle":50569,"status":150,"phases":50570,"primaryCompletion":13907,"completion":13907,"start":50571,"enrollment":95,"conditions":50572,"interventions":50573},"NCT01353898","Study of MK-1972 in Human Immunodeficiency Virus (HIV)-1 Infected Participants Who Have Not Previously Received Antiretroviral Therapy (MK-1972-003)",[87],"2011-06-21",[7639],[50561],{"trials":50575,"activeCount":99},[],{"trials":50577,"activeCount":99},[],{"trials":50579,"activeCount":99},[],{"trials":50581,"activeCount":99},[],{"intervention":50583,"totalTrials":224,"cells":50584},"Famotidine FCT",{"EARLY_PHASE1":50585,"PHASE1":50587,"PHASE2":50597,"PHASE3":50599,"PHASE4":50601,"NA":50603},{"trials":50586,"activeCount":99},[],{"trials":50588,"activeCount":99},[50589],{"nctId":50590,"briefTitle":50591,"status":105,"phases":50592,"primaryCompletion":4418,"completion":4418,"start":12804,"enrollment":154,"conditions":50593,"interventions":50595},"NCT00945750","A Study to Assess the Bioequivalence of Famotidine Chewable Tablets and Film-Coated Tablets (0208-144)",[87],[50594],"Heartburn",[50583,50596],"Famotidine CT",{"trials":50598,"activeCount":99},[],{"trials":50600,"activeCount":99},[],{"trials":50602,"activeCount":99},[],{"trials":50604,"activeCount":99},[],{"intervention":50596,"totalTrials":224,"cells":50606},{"EARLY_PHASE1":50607,"PHASE1":50609,"PHASE2":50615,"PHASE3":50617,"PHASE4":50619,"NA":50621},{"trials":50608,"activeCount":99},[],{"trials":50610,"activeCount":99},[50611],{"nctId":50590,"briefTitle":50591,"status":105,"phases":50612,"primaryCompletion":4418,"completion":4418,"start":12804,"enrollment":154,"conditions":50613,"interventions":50614},[87],[50594],[50583,50596],{"trials":50616,"activeCount":99},[],{"trials":50618,"activeCount":99},[],{"trials":50620,"activeCount":99},[],{"trials":50622,"activeCount":99},[],{"intervention":50624,"totalTrials":224,"cells":50625},"SCH 900800",{"EARLY_PHASE1":50626,"PHASE1":50628,"PHASE2":50636,"PHASE3":50638,"PHASE4":50640,"NA":50642},{"trials":50627,"activeCount":99},[],{"trials":50629,"activeCount":99},[50630],{"nctId":50631,"briefTitle":50632,"status":1040,"phases":50633,"primaryCompletion":33547,"completion":33547,"start":19020,"enrollment":99,"conditions":50634,"interventions":50635},"NCT01500707","Single Dose Study to Assess the Pharmacokinetics of SCH 900800 in Subjects With Parkinson's Disease Being Treated With Levodopa (L-DOPA) (P08235)",[87],[14605],[50624],{"trials":50637,"activeCount":99},[],{"trials":50639,"activeCount":99},[],{"trials":50641,"activeCount":99},[],{"trials":50643,"activeCount":99},[],{"intervention":50645,"totalTrials":224,"cells":50646},"200 mg MK-1075",{"EARLY_PHASE1":50647,"PHASE1":50649,"PHASE2":50660,"PHASE3":50662,"PHASE4":50664,"NA":50666},{"trials":50648,"activeCount":99},[],{"trials":50650,"activeCount":99},[50651],{"nctId":50652,"briefTitle":50653,"status":105,"phases":50654,"primaryCompletion":21497,"completion":21497,"start":45622,"enrollment":95,"conditions":50655,"interventions":50657},"NCT02461563","A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)",[87],[50656],"Hepatitis C Virus Infection",[50645,50658,50659],"400 mg MK-1075","800 mg MK-1075",{"trials":50661,"activeCount":99},[],{"trials":50663,"activeCount":99},[],{"trials":50665,"activeCount":99},[],{"trials":50667,"activeCount":99},[],{"intervention":50658,"totalTrials":224,"cells":50669},{"EARLY_PHASE1":50670,"PHASE1":50672,"PHASE2":50678,"PHASE3":50680,"PHASE4":50682,"NA":50684},{"trials":50671,"activeCount":99},[],{"trials":50673,"activeCount":99},[50674],{"nctId":50652,"briefTitle":50653,"status":105,"phases":50675,"primaryCompletion":21497,"completion":21497,"start":45622,"enrollment":95,"conditions":50676,"interventions":50677},[87],[50656],[50645,50658,50659],{"trials":50679,"activeCount":99},[],{"trials":50681,"activeCount":99},[],{"trials":50683,"activeCount":99},[],{"trials":50685,"activeCount":99},[],{"intervention":50659,"totalTrials":224,"cells":50687},{"EARLY_PHASE1":50688,"PHASE1":50690,"PHASE2":50696,"PHASE3":50698,"PHASE4":50700,"NA":50702},{"trials":50689,"activeCount":99},[],{"trials":50691,"activeCount":99},[50692],{"nctId":50652,"briefTitle":50653,"status":105,"phases":50693,"primaryCompletion":21497,"completion":21497,"start":45622,"enrollment":95,"conditions":50694,"interventions":50695},[87],[50656],[50645,50658,50659],{"trials":50697,"activeCount":99},[],{"trials":50699,"activeCount":99},[],{"trials":50701,"activeCount":99},[],{"trials":50703,"activeCount":99},[],{"intervention":50705,"totalTrials":224,"cells":50706},"Ertugliflozin 2 mg single dose",{"EARLY_PHASE1":50707,"PHASE1":50709,"PHASE2":50722,"PHASE3":50724,"PHASE4":50726,"NA":50728},{"trials":50708,"activeCount":99},[],{"trials":50710,"activeCount":99},[50711],{"nctId":50712,"briefTitle":50713,"status":105,"phases":50714,"primaryCompletion":50715,"completion":50715,"start":32794,"enrollment":13439,"conditions":50716,"interventions":50718},"NCT01054300","Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)",[87],"2010-04-07",[33,50717],"Adult",[50705,50719,50720,50721],"Ertugliflozin 2 mg split into twice daily","Ertugliflozin 4 mg single dose","Ertugliflozin 4 mg split into twice daily",{"trials":50723,"activeCount":99},[],{"trials":50725,"activeCount":99},[],{"trials":50727,"activeCount":99},[],{"trials":50729,"activeCount":99},[],{"intervention":50719,"totalTrials":224,"cells":50731},{"EARLY_PHASE1":50732,"PHASE1":50734,"PHASE2":50740,"PHASE3":50742,"PHASE4":50744,"NA":50746},{"trials":50733,"activeCount":99},[],{"trials":50735,"activeCount":99},[50736],{"nctId":50712,"briefTitle":50713,"status":105,"phases":50737,"primaryCompletion":50715,"completion":50715,"start":32794,"enrollment":13439,"conditions":50738,"interventions":50739},[87],[33,50717],[50705,50719,50720,50721],{"trials":50741,"activeCount":99},[],{"trials":50743,"activeCount":99},[],{"trials":50745,"activeCount":99},[],{"trials":50747,"activeCount":99},[],{"intervention":50720,"totalTrials":224,"cells":50749},{"EARLY_PHASE1":50750,"PHASE1":50752,"PHASE2":50758,"PHASE3":50760,"PHASE4":50762,"NA":50764},{"trials":50751,"activeCount":99},[],{"trials":50753,"activeCount":99},[50754],{"nctId":50712,"briefTitle":50713,"status":105,"phases":50755,"primaryCompletion":50715,"completion":50715,"start":32794,"enrollment":13439,"conditions":50756,"interventions":50757},[87],[33,50717],[50705,50719,50720,50721],{"trials":50759,"activeCount":99},[],{"trials":50761,"activeCount":99},[],{"trials":50763,"activeCount":99},[],{"trials":50765,"activeCount":99},[],{"intervention":50721,"totalTrials":224,"cells":50767},{"EARLY_PHASE1":50768,"PHASE1":50770,"PHASE2":50776,"PHASE3":50778,"PHASE4":50780,"NA":50782},{"trials":50769,"activeCount":99},[],{"trials":50771,"activeCount":99},[50772],{"nctId":50712,"briefTitle":50713,"status":105,"phases":50773,"primaryCompletion":50715,"completion":50715,"start":32794,"enrollment":13439,"conditions":50774,"interventions":50775},[87],[33,50717],[50705,50719,50720,50721],{"trials":50777,"activeCount":99},[],{"trials":50779,"activeCount":99},[],{"trials":50781,"activeCount":99},[],{"trials":50783,"activeCount":99},[],{"intervention":50785,"totalTrials":224,"cells":50786},"MK-4250",{"EARLY_PHASE1":50787,"PHASE1":50789,"PHASE2":50799,"PHASE3":50801,"PHASE4":50803,"NA":50805},{"trials":50788,"activeCount":99},[],{"trials":50790,"activeCount":99},[50791],{"nctId":50792,"briefTitle":50793,"status":105,"phases":50794,"primaryCompletion":50795,"completion":50795,"start":50796,"enrollment":120,"conditions":50797,"interventions":50798},"NCT03351699","Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002)",[87],"2018-11-02","2018-01-18",[7639],[50785],{"trials":50800,"activeCount":99},[],{"trials":50802,"activeCount":99},[],{"trials":50804,"activeCount":99},[],{"trials":50806,"activeCount":99},[],{"intervention":50808,"totalTrials":224,"cells":50809},"MK-8266",{"EARLY_PHASE1":50810,"PHASE1":50812,"PHASE2":50820,"PHASE3":50822,"PHASE4":50824,"NA":50826},{"trials":50811,"activeCount":99},[],{"trials":50813,"activeCount":99},[50814],{"nctId":50815,"briefTitle":50816,"status":105,"phases":50817,"primaryCompletion":33471,"completion":4328,"start":43042,"enrollment":3655,"conditions":50818,"interventions":50819},"NCT01263314","Safety, Tolerability, and Pharmacokinetics of MK-8266 in Elderly Participants With High Blood Pressure (MK-8266-003)",[87],[30],[50808],{"trials":50821,"activeCount":99},[],{"trials":50823,"activeCount":99},[],{"trials":50825,"activeCount":99},[],{"trials":50827,"activeCount":99},[],{"intervention":50829,"totalTrials":224,"cells":50830},"[11C]MK-6884",{"EARLY_PHASE1":50831,"PHASE1":50833,"PHASE2":50843,"PHASE3":50845,"PHASE4":50847,"NA":50849},{"trials":50832,"activeCount":99},[],{"trials":50834,"activeCount":99},[50835],{"nctId":50836,"briefTitle":50837,"status":105,"phases":50838,"primaryCompletion":50839,"completion":50839,"start":50840,"enrollment":805,"conditions":50841,"interventions":50842},"NCT02621606","[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001)",[87],"2017-12-28","2016-01-08",[11174],[50829],{"trials":50844,"activeCount":99},[],{"trials":50846,"activeCount":99},[],{"trials":50848,"activeCount":99},[],{"trials":50850,"activeCount":99},[],{"intervention":14627,"totalTrials":224,"cells":50852},{"EARLY_PHASE1":50853,"PHASE1":50855,"PHASE2":50861,"PHASE3":50863,"PHASE4":50865,"NA":50867},{"trials":50854,"activeCount":99},[],{"trials":50856,"activeCount":99},[50857],{"nctId":14620,"briefTitle":14621,"status":150,"phases":50858,"primaryCompletion":14623,"completion":14623,"start":13870,"enrollment":12,"conditions":50859,"interventions":50860},[87],[14625],[14627,13864,14628],{"trials":50862,"activeCount":99},[],{"trials":50864,"activeCount":99},[],{"trials":50866,"activeCount":99},[],{"trials":50868,"activeCount":99},[],{"intervention":14628,"totalTrials":224,"cells":50870},{"EARLY_PHASE1":50871,"PHASE1":50873,"PHASE2":50879,"PHASE3":50881,"PHASE4":50883,"NA":50885},{"trials":50872,"activeCount":99},[],{"trials":50874,"activeCount":99},[50875],{"nctId":14620,"briefTitle":14621,"status":150,"phases":50876,"primaryCompletion":14623,"completion":14623,"start":13870,"enrollment":12,"conditions":50877,"interventions":50878},[87],[14625],[14627,13864,14628],{"trials":50880,"activeCount":99},[],{"trials":50882,"activeCount":99},[],{"trials":50884,"activeCount":99},[],{"trials":50886,"activeCount":99},[],{"intervention":50888,"totalTrials":224,"cells":50889},"Sitagliptin phosphate anhydrous formulation",{"EARLY_PHASE1":50890,"PHASE1":50892,"PHASE2":50901,"PHASE3":50903,"PHASE4":50905,"NA":50907},{"trials":50891,"activeCount":99},[],{"trials":50893,"activeCount":99},[50894],{"nctId":50895,"briefTitle":50896,"status":105,"phases":50897,"primaryCompletion":14679,"completion":14706,"start":18806,"enrollment":95,"conditions":50898,"interventions":50899},"NCT00944450","Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)",[87],[15],[50888,50900],"Comparator: sitagliptin phosphate monohydrate form",{"trials":50902,"activeCount":99},[],{"trials":50904,"activeCount":99},[],{"trials":50906,"activeCount":99},[],{"trials":50908,"activeCount":99},[],{"intervention":50900,"totalTrials":224,"cells":50910},{"EARLY_PHASE1":50911,"PHASE1":50913,"PHASE2":50919,"PHASE3":50921,"PHASE4":50923,"NA":50925},{"trials":50912,"activeCount":99},[],{"trials":50914,"activeCount":99},[50915],{"nctId":50895,"briefTitle":50896,"status":105,"phases":50916,"primaryCompletion":14679,"completion":14706,"start":18806,"enrollment":95,"conditions":50917,"interventions":50918},[87],[15],[50888,50900],{"trials":50920,"activeCount":99},[],{"trials":50922,"activeCount":99},[],{"trials":50924,"activeCount":99},[],{"trials":50926,"activeCount":99},[],{"intervention":50928,"totalTrials":224,"cells":50929},"MK-8504",{"EARLY_PHASE1":50930,"PHASE1":50932,"PHASE2":50943,"PHASE3":50945,"PHASE4":50947,"NA":50949},{"trials":50931,"activeCount":99},[],{"trials":50933,"activeCount":99},[50934],{"nctId":50935,"briefTitle":50936,"status":105,"phases":50937,"primaryCompletion":50938,"completion":50939,"start":50940,"enrollment":95,"conditions":50941,"interventions":50942},"NCT03188523","Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)",[87],"2018-05-21","2018-06-04","2017-09-08",[7639],[50928],{"trials":50944,"activeCount":99},[],{"trials":50946,"activeCount":99},[],{"trials":50948,"activeCount":99},[],{"trials":50950,"activeCount":99},[],{"intervention":14636,"totalTrials":224,"cells":50952},{"EARLY_PHASE1":50953,"PHASE1":50955,"PHASE2":50961,"PHASE3":50963,"PHASE4":50965,"NA":50967},{"trials":50954,"activeCount":99},[],{"trials":50956,"activeCount":99},[50957],{"nctId":14630,"briefTitle":14631,"status":105,"phases":50958,"primaryCompletion":6309,"completion":6309,"start":13890,"enrollment":36,"conditions":50959,"interventions":50960},[87],[14634],[14331,14636],{"trials":50962,"activeCount":99},[],{"trials":50964,"activeCount":99},[],{"trials":50966,"activeCount":99},[],{"trials":50968,"activeCount":99},[],{"intervention":23112,"totalTrials":224,"cells":50970},{"EARLY_PHASE1":50971,"PHASE1":50973,"PHASE2":50979,"PHASE3":50981,"PHASE4":50983,"NA":50985},{"trials":50972,"activeCount":99},[],{"trials":50974,"activeCount":99},[50975],{"nctId":23107,"briefTitle":23108,"status":105,"phases":50976,"primaryCompletion":14314,"completion":14314,"start":14858,"enrollment":931,"conditions":50977,"interventions":50978},[87],[7639,27],[15245,23112,23113],{"trials":50980,"activeCount":99},[],{"trials":50982,"activeCount":99},[],{"trials":50984,"activeCount":99},[],{"trials":50986,"activeCount":99},[],{"intervention":6002,"totalTrials":224,"cells":50988},{"EARLY_PHASE1":50989,"PHASE1":50991,"PHASE2":50997,"PHASE3":50999,"PHASE4":51001,"NA":51003},{"trials":50990,"activeCount":99},[],{"trials":50992,"activeCount":99},[50993],{"nctId":5995,"briefTitle":5996,"status":105,"phases":50994,"primaryCompletion":4808,"completion":4808,"start":5998,"enrollment":734,"conditions":50995,"interventions":50996},[87],[6000],[6002,1076,5125],{"trials":50998,"activeCount":99},[],{"trials":51000,"activeCount":99},[],{"trials":51002,"activeCount":99},[],{"trials":51004,"activeCount":99},[],{"intervention":22841,"totalTrials":224,"cells":51006},{"EARLY_PHASE1":51007,"PHASE1":51009,"PHASE2":51015,"PHASE3":51017,"PHASE4":51019,"NA":51021},{"trials":51008,"activeCount":99},[],{"trials":51010,"activeCount":99},[51011],{"nctId":22836,"briefTitle":22837,"status":105,"phases":51012,"primaryCompletion":13224,"completion":4990,"start":14623,"enrollment":95,"conditions":51013,"interventions":51014},[87],[30],[22841,22841,14377,22842,22843],{"trials":51016,"activeCount":99},[],{"trials":51018,"activeCount":99},[],{"trials":51020,"activeCount":99},[],{"trials":51022,"activeCount":99},[],{"intervention":22842,"totalTrials":224,"cells":51024},{"EARLY_PHASE1":51025,"PHASE1":51027,"PHASE2":51033,"PHASE3":51035,"PHASE4":51037,"NA":51039},{"trials":51026,"activeCount":99},[],{"trials":51028,"activeCount":99},[51029],{"nctId":22836,"briefTitle":22837,"status":105,"phases":51030,"primaryCompletion":13224,"completion":4990,"start":14623,"enrollment":95,"conditions":51031,"interventions":51032},[87],[30],[22841,22841,14377,22842,22843],{"trials":51034,"activeCount":99},[],{"trials":51036,"activeCount":99},[],{"trials":51038,"activeCount":99},[],{"trials":51040,"activeCount":99},[],{"intervention":22843,"totalTrials":224,"cells":51042},{"EARLY_PHASE1":51043,"PHASE1":51045,"PHASE2":51051,"PHASE3":51053,"PHASE4":51055,"NA":51057},{"trials":51044,"activeCount":99},[],{"trials":51046,"activeCount":99},[51047],{"nctId":22836,"briefTitle":22837,"status":105,"phases":51048,"primaryCompletion":13224,"completion":4990,"start":14623,"enrollment":95,"conditions":51049,"interventions":51050},[87],[30],[22841,22841,14377,22842,22843],{"trials":51052,"activeCount":99},[],{"trials":51054,"activeCount":99},[],{"trials":51056,"activeCount":99},[],{"trials":51058,"activeCount":99},[],{"intervention":42599,"totalTrials":224,"cells":51060},{"EARLY_PHASE1":51061,"PHASE1":51063,"PHASE2":51069,"PHASE3":51071,"PHASE4":51073,"NA":51075},{"trials":51062,"activeCount":99},[],{"trials":51064,"activeCount":99},[51065],{"nctId":42594,"briefTitle":42595,"status":105,"phases":51066,"primaryCompletion":14494,"completion":12813,"start":4990,"enrollment":95,"conditions":51067,"interventions":51068},[87],[15158],[42579,42599,42600],{"trials":51070,"activeCount":99},[],{"trials":51072,"activeCount":99},[],{"trials":51074,"activeCount":99},[],{"trials":51076,"activeCount":99},[],{"intervention":42600,"totalTrials":224,"cells":51078},{"EARLY_PHASE1":51079,"PHASE1":51081,"PHASE2":51087,"PHASE3":51089,"PHASE4":51091,"NA":51093},{"trials":51080,"activeCount":99},[],{"trials":51082,"activeCount":99},[51083],{"nctId":42594,"briefTitle":42595,"status":105,"phases":51084,"primaryCompletion":14494,"completion":12813,"start":4990,"enrollment":95,"conditions":51085,"interventions":51086},[87],[15158],[42579,42599,42600],{"trials":51088,"activeCount":99},[],{"trials":51090,"activeCount":99},[],{"trials":51092,"activeCount":99},[],{"trials":51094,"activeCount":99},[],{"intervention":8070,"totalTrials":224,"cells":51096},{"EARLY_PHASE1":51097,"PHASE1":51099,"PHASE2":51105,"PHASE3":51107,"PHASE4":51109,"NA":51111},{"trials":51098,"activeCount":99},[],{"trials":51100,"activeCount":99},[51101],{"nctId":8063,"briefTitle":8064,"status":105,"phases":51102,"primaryCompletion":8066,"completion":8067,"start":7595,"enrollment":1624,"conditions":51103,"interventions":51104},[87],[18],[8070,7998],{"trials":51106,"activeCount":99},[],{"trials":51108,"activeCount":99},[],{"trials":51110,"activeCount":99},[],{"trials":51112,"activeCount":99},[],{"intervention":14646,"totalTrials":224,"cells":51114},{"EARLY_PHASE1":51115,"PHASE1":51117,"PHASE2":51123,"PHASE3":51125,"PHASE4":51127,"NA":51129},{"trials":51116,"activeCount":99},[],{"trials":51118,"activeCount":99},[51119],{"nctId":14638,"briefTitle":14639,"status":105,"phases":51120,"primaryCompletion":14641,"completion":14642,"start":14643,"enrollment":3506,"conditions":51121,"interventions":51122},[87],[7598],[14646,14647,14423,14331],{"trials":51124,"activeCount":99},[],{"trials":51126,"activeCount":99},[],{"trials":51128,"activeCount":99},[],{"trials":51130,"activeCount":99},[],{"intervention":35622,"totalTrials":224,"cells":51132},{"EARLY_PHASE1":51133,"PHASE1":51135,"PHASE2":51141,"PHASE3":51143,"PHASE4":51145,"NA":51147},{"trials":51134,"activeCount":99},[],{"trials":51136,"activeCount":99},[51137],{"nctId":35617,"briefTitle":35618,"status":105,"phases":51138,"primaryCompletion":13890,"completion":13890,"start":8620,"enrollment":4421,"conditions":51139,"interventions":51140},[87],[4397],[15032,35622],{"trials":51142,"activeCount":99},[],{"trials":51144,"activeCount":99},[],{"trials":51146,"activeCount":99},[],{"trials":51148,"activeCount":99},[],{"intervention":51150,"totalTrials":224,"cells":51151},"V590",{"EARLY_PHASE1":51152,"PHASE1":51154,"PHASE2":51165,"PHASE3":51167,"PHASE4":51169,"NA":51171},{"trials":51153,"activeCount":99},[],{"trials":51155,"activeCount":99},[51156],{"nctId":51157,"briefTitle":51158,"status":150,"phases":51159,"primaryCompletion":51160,"completion":51160,"start":51161,"enrollment":51162,"conditions":51163,"interventions":51164},"NCT04569786","Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)",[87],"2021-02-18","2020-10-29",232,[7129],[51150],{"trials":51166,"activeCount":99},[],{"trials":51168,"activeCount":99},[],{"trials":51170,"activeCount":99},[],{"trials":51172,"activeCount":99},[],{"intervention":13411,"totalTrials":224,"cells":51174},{"EARLY_PHASE1":51175,"PHASE1":51177,"PHASE2":51183,"PHASE3":51185,"PHASE4":51187,"NA":51189},{"trials":51176,"activeCount":99},[],{"trials":51178,"activeCount":99},[51179],{"nctId":13403,"briefTitle":13404,"status":105,"phases":51180,"primaryCompletion":13406,"completion":13406,"start":13407,"enrollment":626,"conditions":51181,"interventions":51182},[87],[13409],[13411,13412,13413,7362],{"trials":51184,"activeCount":99},[],{"trials":51186,"activeCount":99},[],{"trials":51188,"activeCount":99},[],{"trials":51190,"activeCount":99},[],{"intervention":13412,"totalTrials":224,"cells":51192},{"EARLY_PHASE1":51193,"PHASE1":51195,"PHASE2":51201,"PHASE3":51203,"PHASE4":51205,"NA":51207},{"trials":51194,"activeCount":99},[],{"trials":51196,"activeCount":99},[51197],{"nctId":13403,"briefTitle":13404,"status":105,"phases":51198,"primaryCompletion":13406,"completion":13406,"start":13407,"enrollment":626,"conditions":51199,"interventions":51200},[87],[13409],[13411,13412,13413,7362],{"trials":51202,"activeCount":99},[],{"trials":51204,"activeCount":99},[],{"trials":51206,"activeCount":99},[],{"trials":51208,"activeCount":99},[],{"intervention":13413,"totalTrials":224,"cells":51210},{"EARLY_PHASE1":51211,"PHASE1":51213,"PHASE2":51219,"PHASE3":51221,"PHASE4":51223,"NA":51225},{"trials":51212,"activeCount":99},[],{"trials":51214,"activeCount":99},[51215],{"nctId":13403,"briefTitle":13404,"status":105,"phases":51216,"primaryCompletion":13406,"completion":13406,"start":13407,"enrollment":626,"conditions":51217,"interventions":51218},[87],[13409],[13411,13412,13413,7362],{"trials":51220,"activeCount":99},[],{"trials":51222,"activeCount":99},[],{"trials":51224,"activeCount":99},[],{"trials":51226,"activeCount":99},[],{"intervention":51228,"totalTrials":224,"cells":51229},"V512",{"EARLY_PHASE1":51230,"PHASE1":51232,"PHASE2":51242,"PHASE3":51244,"PHASE4":51246,"NA":51248},{"trials":51231,"activeCount":99},[],{"trials":51233,"activeCount":99},[51234],{"nctId":51235,"briefTitle":51236,"status":105,"phases":51237,"primaryCompletion":5507,"completion":13870,"start":8619,"enrollment":20743,"conditions":51238,"interventions":51240},"NCT00851266","A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults",[87],[51239],"Influenza",[51228,51241],"Comparator: Placebo to V512",{"trials":51243,"activeCount":99},[],{"trials":51245,"activeCount":99},[],{"trials":51247,"activeCount":99},[],{"trials":51249,"activeCount":99},[],{"intervention":51241,"totalTrials":224,"cells":51251},{"EARLY_PHASE1":51252,"PHASE1":51254,"PHASE2":51260,"PHASE3":51262,"PHASE4":51264,"NA":51266},{"trials":51253,"activeCount":99},[],{"trials":51255,"activeCount":99},[51256],{"nctId":51235,"briefTitle":51236,"status":105,"phases":51257,"primaryCompletion":5507,"completion":13870,"start":8619,"enrollment":20743,"conditions":51258,"interventions":51259},[87],[51239],[51228,51241],{"trials":51261,"activeCount":99},[],{"trials":51263,"activeCount":99},[],{"trials":51265,"activeCount":99},[],{"trials":51267,"activeCount":99},[],{"intervention":41393,"totalTrials":224,"cells":51269},{"EARLY_PHASE1":51270,"PHASE1":51272,"PHASE2":51278,"PHASE3":51280,"PHASE4":51282,"NA":51284},{"trials":51271,"activeCount":99},[],{"trials":51273,"activeCount":99},[51274],{"nctId":41388,"briefTitle":41389,"status":105,"phases":51275,"primaryCompletion":8262,"completion":8262,"start":8173,"enrollment":931,"conditions":51276,"interventions":51277},[87],[18,41363],[41351,41393,41365,41394],{"trials":51279,"activeCount":99},[],{"trials":51281,"activeCount":99},[],{"trials":51283,"activeCount":99},[],{"trials":51285,"activeCount":99},[],{"intervention":41394,"totalTrials":224,"cells":51287},{"EARLY_PHASE1":51288,"PHASE1":51290,"PHASE2":51296,"PHASE3":51298,"PHASE4":51300,"NA":51302},{"trials":51289,"activeCount":99},[],{"trials":51291,"activeCount":99},[51292],{"nctId":41388,"briefTitle":41389,"status":105,"phases":51293,"primaryCompletion":8262,"completion":8262,"start":8173,"enrollment":931,"conditions":51294,"interventions":51295},[87],[18,41363],[41351,41393,41365,41394],{"trials":51297,"activeCount":99},[],{"trials":51299,"activeCount":99},[],{"trials":51301,"activeCount":99},[],{"trials":51303,"activeCount":99},[],{"intervention":14673,"totalTrials":224,"cells":51305},{"EARLY_PHASE1":51306,"PHASE1":51308,"PHASE2":51314,"PHASE3":51316,"PHASE4":51318,"NA":51320},{"trials":51307,"activeCount":99},[],{"trials":51309,"activeCount":99},[51310],{"nctId":14668,"briefTitle":14669,"status":105,"phases":51311,"primaryCompletion":14315,"completion":14315,"start":13891,"enrollment":3390,"conditions":51312,"interventions":51313},[87],[24],[14673,13864],{"trials":51315,"activeCount":99},[],{"trials":51317,"activeCount":99},[],{"trials":51319,"activeCount":99},[],{"trials":51321,"activeCount":99},[],{"intervention":51323,"totalTrials":224,"cells":51324},"SCH 721015 with SCH 209702",{"EARLY_PHASE1":51325,"PHASE1":51327,"PHASE2":51336,"PHASE3":51338,"PHASE4":51340,"NA":51342},{"trials":51326,"activeCount":99},[],{"trials":51328,"activeCount":99},[51329],{"nctId":51330,"briefTitle":51331,"status":105,"phases":51332,"primaryCompletion":20608,"completion":20608,"start":4418,"enrollment":3496,"conditions":51333,"interventions":51335},"NCT00536588","A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)",[87],[51334],"Bladder Neoplasms",[51323],{"trials":51337,"activeCount":99},[],{"trials":51339,"activeCount":99},[],{"trials":51341,"activeCount":99},[],{"trials":51343,"activeCount":99},[],{"intervention":42430,"totalTrials":224,"cells":51345},{"EARLY_PHASE1":51346,"PHASE1":51348,"PHASE2":51354,"PHASE3":51356,"PHASE4":51358,"NA":51360},{"trials":51347,"activeCount":99},[],{"trials":51349,"activeCount":99},[51350],{"nctId":42423,"briefTitle":42424,"status":105,"phases":51351,"primaryCompletion":19963,"completion":19168,"start":42426,"enrollment":312,"conditions":51352,"interventions":51353},[87],[42428],[42430,42408],{"trials":51355,"activeCount":99},[],{"trials":51357,"activeCount":99},[],{"trials":51359,"activeCount":99},[],{"trials":51361,"activeCount":99},[],{"intervention":14691,"totalTrials":224,"cells":51363},{"EARLY_PHASE1":51364,"PHASE1":51366,"PHASE2":51372,"PHASE3":51374,"PHASE4":51376,"NA":51378},{"trials":51365,"activeCount":99},[],{"trials":51367,"activeCount":99},[51368],{"nctId":14684,"briefTitle":14685,"status":105,"phases":51369,"primaryCompletion":14687,"completion":14687,"start":13891,"enrollment":920,"conditions":51370,"interventions":51371},[87],[14689],[14691,14692,13864],{"trials":51373,"activeCount":99},[],{"trials":51375,"activeCount":99},[],{"trials":51377,"activeCount":99},[],{"trials":51379,"activeCount":99},[],{"intervention":14692,"totalTrials":224,"cells":51381},{"EARLY_PHASE1":51382,"PHASE1":51384,"PHASE2":51390,"PHASE3":51392,"PHASE4":51394,"NA":51396},{"trials":51383,"activeCount":99},[],{"trials":51385,"activeCount":99},[51386],{"nctId":14684,"briefTitle":14685,"status":105,"phases":51387,"primaryCompletion":14687,"completion":14687,"start":13891,"enrollment":920,"conditions":51388,"interventions":51389},[87],[14689],[14691,14692,13864],{"trials":51391,"activeCount":99},[],{"trials":51393,"activeCount":99},[],{"trials":51395,"activeCount":99},[],{"trials":51397,"activeCount":99},[],{"intervention":7022,"totalTrials":224,"cells":51399},{"EARLY_PHASE1":51400,"PHASE1":51402,"PHASE2":51408,"PHASE3":51410,"PHASE4":51412,"NA":51414},{"trials":51401,"activeCount":99},[],{"trials":51403,"activeCount":99},[51404],{"nctId":7014,"briefTitle":7015,"status":150,"phases":51405,"primaryCompletion":7017,"completion":7017,"start":7018,"enrollment":920,"conditions":51406,"interventions":51407},[87],[7020],[5481,7022,2100,7023,4388,979,7024],{"trials":51409,"activeCount":99},[],{"trials":51411,"activeCount":99},[],{"trials":51413,"activeCount":99},[],{"trials":51415,"activeCount":99},[],{"intervention":7023,"totalTrials":224,"cells":51417},{"EARLY_PHASE1":51418,"PHASE1":51420,"PHASE2":51426,"PHASE3":51428,"PHASE4":51430,"NA":51432},{"trials":51419,"activeCount":99},[],{"trials":51421,"activeCount":99},[51422],{"nctId":7014,"briefTitle":7015,"status":150,"phases":51423,"primaryCompletion":7017,"completion":7017,"start":7018,"enrollment":920,"conditions":51424,"interventions":51425},[87],[7020],[5481,7022,2100,7023,4388,979,7024],{"trials":51427,"activeCount":99},[],{"trials":51429,"activeCount":99},[],{"trials":51431,"activeCount":99},[],{"trials":51433,"activeCount":99},[],{"intervention":14699,"totalTrials":224,"cells":51435},{"EARLY_PHASE1":51436,"PHASE1":51438,"PHASE2":51444,"PHASE3":51446,"PHASE4":51448,"NA":51450},{"trials":51437,"activeCount":99},[],{"trials":51439,"activeCount":99},[51440],{"nctId":14694,"briefTitle":14695,"status":105,"phases":51441,"primaryCompletion":13870,"completion":13870,"start":14353,"enrollment":154,"conditions":51442,"interventions":51443},[87],[18],[14699,14700,13864],{"trials":51445,"activeCount":99},[],{"trials":51447,"activeCount":99},[],{"trials":51449,"activeCount":99},[],{"trials":51451,"activeCount":99},[],{"intervention":14700,"totalTrials":224,"cells":51453},{"EARLY_PHASE1":51454,"PHASE1":51456,"PHASE2":51462,"PHASE3":51464,"PHASE4":51466,"NA":51468},{"trials":51455,"activeCount":99},[],{"trials":51457,"activeCount":99},[51458],{"nctId":14694,"briefTitle":14695,"status":105,"phases":51459,"primaryCompletion":13870,"completion":13870,"start":14353,"enrollment":154,"conditions":51460,"interventions":51461},[87],[18],[14699,14700,13864],{"trials":51463,"activeCount":99},[],{"trials":51465,"activeCount":99},[],{"trials":51467,"activeCount":99},[],{"trials":51469,"activeCount":99},[],{"intervention":665,"totalTrials":224,"cells":51471},{"EARLY_PHASE1":51472,"PHASE1":51474,"PHASE2":51480,"PHASE3":51482,"PHASE4":51484,"NA":51486},{"trials":51473,"activeCount":99},[],{"trials":51475,"activeCount":99},[51476],{"nctId":656,"briefTitle":657,"status":150,"phases":51477,"primaryCompletion":659,"completion":659,"start":660,"enrollment":661,"conditions":51478,"interventions":51479},[87],[663],[665,42],{"trials":51481,"activeCount":99},[],{"trials":51483,"activeCount":99},[],{"trials":51485,"activeCount":99},[],{"trials":51487,"activeCount":99},[],{"intervention":680,"totalTrials":224,"cells":51489},{"EARLY_PHASE1":51490,"PHASE1":51492,"PHASE2":51498,"PHASE3":51500,"PHASE4":51502,"NA":51504},{"trials":51491,"activeCount":99},[],{"trials":51493,"activeCount":99},[51494],{"nctId":667,"briefTitle":668,"status":105,"phases":51495,"primaryCompletion":356,"completion":356,"start":670,"enrollment":671,"conditions":51496,"interventions":51497},[87],[673,526,674,675,676,677,678],[47,680,681],{"trials":51499,"activeCount":99},[],{"trials":51501,"activeCount":99},[],{"trials":51503,"activeCount":99},[],{"trials":51505,"activeCount":99},[],{"intervention":681,"totalTrials":224,"cells":51507},{"EARLY_PHASE1":51508,"PHASE1":51510,"PHASE2":51516,"PHASE3":51518,"PHASE4":51520,"NA":51522},{"trials":51509,"activeCount":99},[],{"trials":51511,"activeCount":99},[51512],{"nctId":667,"briefTitle":668,"status":105,"phases":51513,"primaryCompletion":356,"completion":356,"start":670,"enrollment":671,"conditions":51514,"interventions":51515},[87],[673,526,674,675,676,677,678],[47,680,681],{"trials":51517,"activeCount":99},[],{"trials":51519,"activeCount":99},[],{"trials":51521,"activeCount":99},[],{"trials":51523,"activeCount":99},[],{"intervention":14717,"totalTrials":224,"cells":51525},{"EARLY_PHASE1":51526,"PHASE1":51528,"PHASE2":51534,"PHASE3":51536,"PHASE4":51538,"NA":51540},{"trials":51527,"activeCount":99},[],{"trials":51529,"activeCount":99},[51530],{"nctId":14710,"briefTitle":14711,"status":105,"phases":51531,"primaryCompletion":13101,"completion":13101,"start":14713,"enrollment":2901,"conditions":51532,"interventions":51533},[87],[14715],[14717,14718,13864,14719,14719],{"trials":51535,"activeCount":99},[],{"trials":51537,"activeCount":99},[],{"trials":51539,"activeCount":99},[],{"trials":51541,"activeCount":99},[],{"intervention":14718,"totalTrials":224,"cells":51543},{"EARLY_PHASE1":51544,"PHASE1":51546,"PHASE2":51552,"PHASE3":51554,"PHASE4":51556,"NA":51558},{"trials":51545,"activeCount":99},[],{"trials":51547,"activeCount":99},[51548],{"nctId":14710,"briefTitle":14711,"status":105,"phases":51549,"primaryCompletion":13101,"completion":13101,"start":14713,"enrollment":2901,"conditions":51550,"interventions":51551},[87],[14715],[14717,14718,13864,14719,14719],{"trials":51553,"activeCount":99},[],{"trials":51555,"activeCount":99},[],{"trials":51557,"activeCount":99},[],{"trials":51559,"activeCount":99},[],{"intervention":14719,"totalTrials":224,"cells":51561},{"EARLY_PHASE1":51562,"PHASE1":51564,"PHASE2":51570,"PHASE3":51572,"PHASE4":51574,"NA":51576},{"trials":51563,"activeCount":99},[],{"trials":51565,"activeCount":99},[51566],{"nctId":14710,"briefTitle":14711,"status":105,"phases":51567,"primaryCompletion":13101,"completion":13101,"start":14713,"enrollment":2901,"conditions":51568,"interventions":51569},[87],[14715],[14717,14718,13864,14719,14719],{"trials":51571,"activeCount":99},[],{"trials":51573,"activeCount":99},[],{"trials":51575,"activeCount":99},[],{"trials":51577,"activeCount":99},[],{"intervention":51579,"totalTrials":224,"cells":51580},"MK-0893 10 mg",{"EARLY_PHASE1":51581,"PHASE1":51583,"PHASE2":51596,"PHASE3":51598,"PHASE4":51600,"NA":51602},{"trials":51582,"activeCount":99},[],{"trials":51584,"activeCount":99},[51585],{"nctId":51586,"briefTitle":51587,"status":105,"phases":51588,"primaryCompletion":24504,"completion":24504,"start":14976,"enrollment":931,"conditions":51589,"interventions":51590},"NCT02012166","A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)",[87],[15],[51579,51591,51592,51593,51594,14059,51595],"MK-0893 40 mg","MK-0893 200 mg","MK-0893 1000 mg","Sandostatine®","Glucagon",{"trials":51597,"activeCount":99},[],{"trials":51599,"activeCount":99},[],{"trials":51601,"activeCount":99},[],{"trials":51603,"activeCount":99},[],{"intervention":51591,"totalTrials":224,"cells":51605},{"EARLY_PHASE1":51606,"PHASE1":51608,"PHASE2":51614,"PHASE3":51616,"PHASE4":51618,"NA":51620},{"trials":51607,"activeCount":99},[],{"trials":51609,"activeCount":99},[51610],{"nctId":51586,"briefTitle":51587,"status":105,"phases":51611,"primaryCompletion":24504,"completion":24504,"start":14976,"enrollment":931,"conditions":51612,"interventions":51613},[87],[15],[51579,51591,51592,51593,51594,14059,51595],{"trials":51615,"activeCount":99},[],{"trials":51617,"activeCount":99},[],{"trials":51619,"activeCount":99},[],{"trials":51621,"activeCount":99},[],{"intervention":51592,"totalTrials":224,"cells":51623},{"EARLY_PHASE1":51624,"PHASE1":51626,"PHASE2":51632,"PHASE3":51634,"PHASE4":51636,"NA":51638},{"trials":51625,"activeCount":99},[],{"trials":51627,"activeCount":99},[51628],{"nctId":51586,"briefTitle":51587,"status":105,"phases":51629,"primaryCompletion":24504,"completion":24504,"start":14976,"enrollment":931,"conditions":51630,"interventions":51631},[87],[15],[51579,51591,51592,51593,51594,14059,51595],{"trials":51633,"activeCount":99},[],{"trials":51635,"activeCount":99},[],{"trials":51637,"activeCount":99},[],{"trials":51639,"activeCount":99},[],{"intervention":51593,"totalTrials":224,"cells":51641},{"EARLY_PHASE1":51642,"PHASE1":51644,"PHASE2":51650,"PHASE3":51652,"PHASE4":51654,"NA":51656},{"trials":51643,"activeCount":99},[],{"trials":51645,"activeCount":99},[51646],{"nctId":51586,"briefTitle":51587,"status":105,"phases":51647,"primaryCompletion":24504,"completion":24504,"start":14976,"enrollment":931,"conditions":51648,"interventions":51649},[87],[15],[51579,51591,51592,51593,51594,14059,51595],{"trials":51651,"activeCount":99},[],{"trials":51653,"activeCount":99},[],{"trials":51655,"activeCount":99},[],{"trials":51657,"activeCount":99},[],{"intervention":51594,"totalTrials":224,"cells":51659},{"EARLY_PHASE1":51660,"PHASE1":51662,"PHASE2":51668,"PHASE3":51670,"PHASE4":51672,"NA":51674},{"trials":51661,"activeCount":99},[],{"trials":51663,"activeCount":99},[51664],{"nctId":51586,"briefTitle":51587,"status":105,"phases":51665,"primaryCompletion":24504,"completion":24504,"start":14976,"enrollment":931,"conditions":51666,"interventions":51667},[87],[15],[51579,51591,51592,51593,51594,14059,51595],{"trials":51669,"activeCount":99},[],{"trials":51671,"activeCount":99},[],{"trials":51673,"activeCount":99},[],{"trials":51675,"activeCount":99},[],{"intervention":51595,"totalTrials":224,"cells":51677},{"EARLY_PHASE1":51678,"PHASE1":51680,"PHASE2":51686,"PHASE3":51688,"PHASE4":51690,"NA":51692},{"trials":51679,"activeCount":99},[],{"trials":51681,"activeCount":99},[51682],{"nctId":51586,"briefTitle":51587,"status":105,"phases":51683,"primaryCompletion":24504,"completion":24504,"start":14976,"enrollment":931,"conditions":51684,"interventions":51685},[87],[15],[51579,51591,51592,51593,51594,14059,51595],{"trials":51687,"activeCount":99},[],{"trials":51689,"activeCount":99},[],{"trials":51691,"activeCount":99},[],{"trials":51693,"activeCount":99},[],{"intervention":51695,"totalTrials":224,"cells":51696},"MK-2225",{"EARLY_PHASE1":51697,"PHASE1":51699,"PHASE2":51709,"PHASE3":51711,"PHASE4":51713,"NA":51715},{"trials":51698,"activeCount":99},[],{"trials":51700,"activeCount":99},[51701],{"nctId":51702,"briefTitle":51703,"status":105,"phases":51704,"primaryCompletion":51705,"completion":51705,"start":11604,"enrollment":626,"conditions":51706,"interventions":51708},"NCT06643390","A Study of MK-2225 in Healthy Participants (MK-2225-003)",[87],"2025-07-14",[51707],"Systemic Sclerosis",[51695],{"trials":51710,"activeCount":99},[],{"trials":51712,"activeCount":99},[],{"trials":51714,"activeCount":99},[],{"trials":51716,"activeCount":99},[],{"intervention":51718,"totalTrials":224,"cells":51719},"Birabresib Dose 20 mg",{"EARLY_PHASE1":51720,"PHASE1":51722,"PHASE2":51733,"PHASE3":51735,"PHASE4":51737,"NA":51739},{"trials":51721,"activeCount":99},[],{"trials":51723,"activeCount":99},[51724],{"nctId":51725,"briefTitle":51726,"status":150,"phases":51727,"primaryCompletion":50796,"completion":51728,"start":51729,"enrollment":3308,"conditions":51730,"interventions":51732},"NCT02698189","A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)",[87],"2021-09-09","2016-05-19",[51731,5079],"AML Including AML de Novo and AML Secondary to MDS",[51718],{"trials":51734,"activeCount":99},[],{"trials":51736,"activeCount":99},[],{"trials":51738,"activeCount":99},[],{"trials":51740,"activeCount":99},[],{"intervention":51742,"totalTrials":224,"cells":51743},"MK-8237",{"EARLY_PHASE1":51744,"PHASE1":51746,"PHASE2":51758,"PHASE3":51760,"PHASE4":51762,"NA":51764},{"trials":51745,"activeCount":99},[],{"trials":51747,"activeCount":99},[51748],{"nctId":51749,"briefTitle":51750,"status":105,"phases":51751,"primaryCompletion":27828,"completion":51752,"start":51753,"enrollment":3506,"conditions":51754,"interventions":51756},"NCT01852825","MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009)",[87],"2015-08-03","2013-11-27",[5965,51755],"Allergic Rhinoconjunctivitis",[51742,51757],"NAC",{"trials":51759,"activeCount":99},[],{"trials":51761,"activeCount":99},[],{"trials":51763,"activeCount":99},[],{"trials":51765,"activeCount":99},[],{"intervention":51757,"totalTrials":224,"cells":51767},{"EARLY_PHASE1":51768,"PHASE1":51770,"PHASE2":51776,"PHASE3":51778,"PHASE4":51780,"NA":51782},{"trials":51769,"activeCount":99},[],{"trials":51771,"activeCount":99},[51772],{"nctId":51749,"briefTitle":51750,"status":105,"phases":51773,"primaryCompletion":27828,"completion":51752,"start":51753,"enrollment":3506,"conditions":51774,"interventions":51775},[87],[5965,51755],[51742,51757],{"trials":51777,"activeCount":99},[],{"trials":51779,"activeCount":99},[],{"trials":51781,"activeCount":99},[],{"trials":51783,"activeCount":99},[],{"intervention":51785,"totalTrials":224,"cells":51786},"vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin",{"EARLY_PHASE1":51787,"PHASE1":51789,"PHASE2":51797,"PHASE3":51799,"PHASE4":51801,"NA":51803},{"trials":51788,"activeCount":99},[],{"trials":51790,"activeCount":99},[51791],{"nctId":51792,"briefTitle":51793,"status":105,"phases":51794,"primaryCompletion":14454,"completion":14454,"start":15063,"enrollment":13439,"conditions":51795,"interventions":51796},"NCT00106626","Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors",[87],[852],[51785],{"trials":51798,"activeCount":99},[],{"trials":51800,"activeCount":99},[],{"trials":51802,"activeCount":99},[],{"trials":51804,"activeCount":99},[],{"intervention":51806,"totalTrials":224,"cells":51807},"Low-dose V180 with low-dose ISCOMATRIX™ adjuvant",{"EARLY_PHASE1":51808,"PHASE1":51810,"PHASE2":51833,"PHASE3":51835,"PHASE4":51837,"NA":51839},{"trials":51809,"activeCount":99},[],{"trials":51811,"activeCount":99},[51812],{"nctId":51813,"briefTitle":51814,"status":105,"phases":51815,"primaryCompletion":51816,"completion":51817,"start":51818,"enrollment":16208,"conditions":51819,"interventions":51821},"NCT01477580","Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)",[87],"2014-01-23","2014-12-11","2012-07-23",[51820],"Dengue",[51806,51822,51823,51824,51825,51826,51827,51828,51829,51830,51831,51832],"Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant","Medium-dose V180","Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant","Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant","Medium-dose V180 with Alhydrogel™ adjuvant","High-dose V180","High-dose V180 with low-dose ISCOMATRIX™ adjuvant","High-dose V180 with medium-dose ISCOMATRIX™ adjuvant","Low-dose V180 with high-dose ISCOMATRIX™ adjuvant","Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant","High-dose V180 with high-dose ISCOMATRIX™ adjuvant",{"trials":51834,"activeCount":99},[],{"trials":51836,"activeCount":99},[],{"trials":51838,"activeCount":99},[],{"trials":51840,"activeCount":99},[],{"intervention":51822,"totalTrials":224,"cells":51842},{"EARLY_PHASE1":51843,"PHASE1":51845,"PHASE2":51851,"PHASE3":51853,"PHASE4":51855,"NA":51857},{"trials":51844,"activeCount":99},[],{"trials":51846,"activeCount":99},[51847],{"nctId":51813,"briefTitle":51814,"status":105,"phases":51848,"primaryCompletion":51816,"completion":51817,"start":51818,"enrollment":16208,"conditions":51849,"interventions":51850},[87],[51820],[51806,51822,51823,51824,51825,51826,51827,51828,51829,51830,51831,51832],{"trials":51852,"activeCount":99},[],{"trials":51854,"activeCount":99},[],{"trials":51856,"activeCount":99},[],{"trials":51858,"activeCount":99},[],{"intervention":51823,"totalTrials":224,"cells":51860},{"EARLY_PHASE1":51861,"PHASE1":51863,"PHASE2":51869,"PHASE3":51871,"PHASE4":51873,"NA":51875},{"trials":51862,"activeCount":99},[],{"trials":51864,"activeCount":99},[51865],{"nctId":51813,"briefTitle":51814,"status":105,"phases":51866,"primaryCompletion":51816,"completion":51817,"start":51818,"enrollment":16208,"conditions":51867,"interventions":51868},[87],[51820],[51806,51822,51823,51824,51825,51826,51827,51828,51829,51830,51831,51832],{"trials":51870,"activeCount":99},[],{"trials":51872,"activeCount":99},[],{"trials":51874,"activeCount":99},[],{"trials":51876,"activeCount":99},[],{"intervention":51824,"totalTrials":224,"cells":51878},{"EARLY_PHASE1":51879,"PHASE1":51881,"PHASE2":51887,"PHASE3":51889,"PHASE4":51891,"NA":51893},{"trials":51880,"activeCount":99},[],{"trials":51882,"activeCount":99},[51883],{"nctId":51813,"briefTitle":51814,"status":105,"phases":51884,"primaryCompletion":51816,"completion":51817,"start":51818,"enrollment":16208,"conditions":51885,"interventions":51886},[87],[51820],[51806,51822,51823,51824,51825,51826,51827,51828,51829,51830,51831,51832],{"trials":51888,"activeCount":99},[],{"trials":51890,"activeCount":99},[],{"trials":51892,"activeCount":99},[],{"trials":51894,"activeCount":99},[],{"intervention":51825,"totalTrials":224,"cells":51896},{"EARLY_PHASE1":51897,"PHASE1":51899,"PHASE2":51905,"PHASE3":51907,"PHASE4":51909,"NA":51911},{"trials":51898,"activeCount":99},[],{"trials":51900,"activeCount":99},[51901],{"nctId":51813,"briefTitle":51814,"status":105,"phases":51902,"primaryCompletion":51816,"completion":51817,"start":51818,"enrollment":16208,"conditions":51903,"interventions":51904},[87],[51820],[51806,51822,51823,51824,51825,51826,51827,51828,51829,51830,51831,51832],{"trials":51906,"activeCount":99},[],{"trials":51908,"activeCount":99},[],{"trials":51910,"activeCount":99},[],{"trials":51912,"activeCount":99},[],{"intervention":51826,"totalTrials":224,"cells":51914},{"EARLY_PHASE1":51915,"PHASE1":51917,"PHASE2":51923,"PHASE3":51925,"PHASE4":51927,"NA":51929},{"trials":51916,"activeCount":99},[],{"trials":51918,"activeCount":99},[51919],{"nctId":51813,"briefTitle":51814,"status":105,"phases":51920,"primaryCompletion":51816,"completion":51817,"start":51818,"enrollment":16208,"conditions":51921,"interventions":51922},[87],[51820],[51806,51822,51823,51824,51825,51826,51827,51828,51829,51830,51831,51832],{"trials":51924,"activeCount":99},[],{"trials":51926,"activeCount":99},[],{"trials":51928,"activeCount":99},[],{"trials":51930,"activeCount":99},[],{"intervention":51827,"totalTrials":224,"cells":51932},{"EARLY_PHASE1":51933,"PHASE1":51935,"PHASE2":51941,"PHASE3":51943,"PHASE4":51945,"NA":51947},{"trials":51934,"activeCount":99},[],{"trials":51936,"activeCount":99},[51937],{"nctId":51813,"briefTitle":51814,"status":105,"phases":51938,"primaryCompletion":51816,"completion":51817,"start":51818,"enrollment":16208,"conditions":51939,"interventions":51940},[87],[51820],[51806,51822,51823,51824,51825,51826,51827,51828,51829,51830,51831,51832],{"trials":51942,"activeCount":99},[],{"trials":51944,"activeCount":99},[],{"trials":51946,"activeCount":99},[],{"trials":51948,"activeCount":99},[],{"intervention":51828,"totalTrials":224,"cells":51950},{"EARLY_PHASE1":51951,"PHASE1":51953,"PHASE2":51959,"PHASE3":51961,"PHASE4":51963,"NA":51965},{"trials":51952,"activeCount":99},[],{"trials":51954,"activeCount":99},[51955],{"nctId":51813,"briefTitle":51814,"status":105,"phases":51956,"primaryCompletion":51816,"completion":51817,"start":51818,"enrollment":16208,"conditions":51957,"interventions":51958},[87],[51820],[51806,51822,51823,51824,51825,51826,51827,51828,51829,51830,51831,51832],{"trials":51960,"activeCount":99},[],{"trials":51962,"activeCount":99},[],{"trials":51964,"activeCount":99},[],{"trials":51966,"activeCount":99},[],{"intervention":51829,"totalTrials":224,"cells":51968},{"EARLY_PHASE1":51969,"PHASE1":51971,"PHASE2":51977,"PHASE3":51979,"PHASE4":51981,"NA":51983},{"trials":51970,"activeCount":99},[],{"trials":51972,"activeCount":99},[51973],{"nctId":51813,"briefTitle":51814,"status":105,"phases":51974,"primaryCompletion":51816,"completion":51817,"start":51818,"enrollment":16208,"conditions":51975,"interventions":51976},[87],[51820],[51806,51822,51823,51824,51825,51826,51827,51828,51829,51830,51831,51832],{"trials":51978,"activeCount":99},[],{"trials":51980,"activeCount":99},[],{"trials":51982,"activeCount":99},[],{"trials":51984,"activeCount":99},[],{"intervention":51830,"totalTrials":224,"cells":51986},{"EARLY_PHASE1":51987,"PHASE1":51989,"PHASE2":51995,"PHASE3":51997,"PHASE4":51999,"NA":52001},{"trials":51988,"activeCount":99},[],{"trials":51990,"activeCount":99},[51991],{"nctId":51813,"briefTitle":51814,"status":105,"phases":51992,"primaryCompletion":51816,"completion":51817,"start":51818,"enrollment":16208,"conditions":51993,"interventions":51994},[87],[51820],[51806,51822,51823,51824,51825,51826,51827,51828,51829,51830,51831,51832],{"trials":51996,"activeCount":99},[],{"trials":51998,"activeCount":99},[],{"trials":52000,"activeCount":99},[],{"trials":52002,"activeCount":99},[],{"intervention":51831,"totalTrials":224,"cells":52004},{"EARLY_PHASE1":52005,"PHASE1":52007,"PHASE2":52013,"PHASE3":52015,"PHASE4":52017,"NA":52019},{"trials":52006,"activeCount":99},[],{"trials":52008,"activeCount":99},[52009],{"nctId":51813,"briefTitle":51814,"status":105,"phases":52010,"primaryCompletion":51816,"completion":51817,"start":51818,"enrollment":16208,"conditions":52011,"interventions":52012},[87],[51820],[51806,51822,51823,51824,51825,51826,51827,51828,51829,51830,51831,51832],{"trials":52014,"activeCount":99},[],{"trials":52016,"activeCount":99},[],{"trials":52018,"activeCount":99},[],{"trials":52020,"activeCount":99},[],{"intervention":51832,"totalTrials":224,"cells":52022},{"EARLY_PHASE1":52023,"PHASE1":52025,"PHASE2":52031,"PHASE3":52033,"PHASE4":52035,"NA":52037},{"trials":52024,"activeCount":99},[],{"trials":52026,"activeCount":99},[52027],{"nctId":51813,"briefTitle":51814,"status":105,"phases":52028,"primaryCompletion":51816,"completion":51817,"start":51818,"enrollment":16208,"conditions":52029,"interventions":52030},[87],[51820],[51806,51822,51823,51824,51825,51826,51827,51828,51829,51830,51831,51832],{"trials":52032,"activeCount":99},[],{"trials":52034,"activeCount":99},[],{"trials":52036,"activeCount":99},[],{"trials":52038,"activeCount":99},[],{"intervention":52040,"totalTrials":224,"cells":52041},"Drug: SCH 900518 Biologic: Peginterferon alfa-2b",{"EARLY_PHASE1":52042,"PHASE1":52044,"PHASE2":52053,"PHASE3":52055,"PHASE4":52057,"NA":52059},{"trials":52043,"activeCount":99},[],{"trials":52045,"activeCount":99},[52046],{"nctId":52047,"briefTitle":52048,"status":105,"phases":52049,"primaryCompletion":13102,"completion":13102,"start":13891,"enrollment":1419,"conditions":52050,"interventions":52051},"NCT01081158","Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)",[87],[21],[52040,52040,52052,52052],"Drug: SCH 900518 Drug: Ritonavir",{"trials":52054,"activeCount":99},[],{"trials":52056,"activeCount":99},[],{"trials":52058,"activeCount":99},[],{"trials":52060,"activeCount":99},[],{"intervention":52052,"totalTrials":224,"cells":52062},{"EARLY_PHASE1":52063,"PHASE1":52065,"PHASE2":52071,"PHASE3":52073,"PHASE4":52075,"NA":52077},{"trials":52064,"activeCount":99},[],{"trials":52066,"activeCount":99},[52067],{"nctId":52047,"briefTitle":52048,"status":105,"phases":52068,"primaryCompletion":13102,"completion":13102,"start":13891,"enrollment":1419,"conditions":52069,"interventions":52070},[87],[21],[52040,52040,52052,52052],{"trials":52072,"activeCount":99},[],{"trials":52074,"activeCount":99},[],{"trials":52076,"activeCount":99},[],{"trials":52078,"activeCount":99},[],{"intervention":34664,"totalTrials":224,"cells":52080},{"EARLY_PHASE1":52081,"PHASE1":52083,"PHASE2":52089,"PHASE3":52091,"PHASE4":52093,"NA":52095},{"trials":52082,"activeCount":99},[],{"trials":52084,"activeCount":99},[52085],{"nctId":34658,"briefTitle":34659,"status":105,"phases":52086,"primaryCompletion":15794,"completion":15794,"start":5982,"enrollment":34396,"conditions":52087,"interventions":52088},[87],[34662],[34664,34651,34651],{"trials":52090,"activeCount":99},[],{"trials":52092,"activeCount":99},[],{"trials":52094,"activeCount":99},[],{"trials":52096,"activeCount":99},[],{"intervention":52098,"totalTrials":224,"cells":52099},"Posaconazole IV solution",{"EARLY_PHASE1":52100,"PHASE1":52102,"PHASE2":52114,"PHASE3":52116,"PHASE4":52118,"NA":52120},{"trials":52101,"activeCount":99},[],{"trials":52103,"activeCount":99},[52104],{"nctId":52105,"briefTitle":52106,"status":105,"phases":52107,"primaryCompletion":52108,"completion":52109,"start":52110,"enrollment":901,"conditions":52111,"interventions":52112},"NCT02452034","Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)",[87],"2018-06-26","2018-09-03","2015-09-07",[20505],[52098,52113],"Posaconazole powder for oral suspension",{"trials":52115,"activeCount":99},[],{"trials":52117,"activeCount":99},[],{"trials":52119,"activeCount":99},[],{"trials":52121,"activeCount":99},[],{"intervention":52113,"totalTrials":224,"cells":52123},{"EARLY_PHASE1":52124,"PHASE1":52126,"PHASE2":52132,"PHASE3":52134,"PHASE4":52136,"NA":52138},{"trials":52125,"activeCount":99},[],{"trials":52127,"activeCount":99},[52128],{"nctId":52105,"briefTitle":52106,"status":105,"phases":52129,"primaryCompletion":52108,"completion":52109,"start":52110,"enrollment":901,"conditions":52130,"interventions":52131},[87],[20505],[52098,52113],{"trials":52133,"activeCount":99},[],{"trials":52135,"activeCount":99},[],{"trials":52137,"activeCount":99},[],{"trials":52139,"activeCount":99},[],{"intervention":32945,"totalTrials":224,"cells":52141},{"EARLY_PHASE1":52142,"PHASE1":52144,"PHASE2":52150,"PHASE3":52152,"PHASE4":52154,"NA":52156},{"trials":52143,"activeCount":99},[],{"trials":52145,"activeCount":99},[52146],{"nctId":32940,"briefTitle":32941,"status":105,"phases":52147,"primaryCompletion":14408,"completion":14408,"start":13891,"enrollment":367,"conditions":52148,"interventions":52149},[87],[15],[13863,32945],{"trials":52151,"activeCount":99},[],{"trials":52153,"activeCount":99},[],{"trials":52155,"activeCount":99},[],{"trials":52157,"activeCount":99},[],{"intervention":52159,"totalTrials":224,"cells":52160},"ondansetron clinical trial formulation",{"EARLY_PHASE1":52161,"PHASE1":52163,"PHASE2":52172,"PHASE3":52174,"PHASE4":52176,"NA":52178},{"trials":52162,"activeCount":99},[],{"trials":52164,"activeCount":99},[52165],{"nctId":52166,"briefTitle":52167,"status":105,"phases":52168,"primaryCompletion":18806,"completion":14679,"start":14229,"enrollment":700,"conditions":52169,"interventions":52170},"NCT00972595","Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106)",[87],[5150],[52159,52171],"ondansetron marketed formulation",{"trials":52173,"activeCount":99},[],{"trials":52175,"activeCount":99},[],{"trials":52177,"activeCount":99},[],{"trials":52179,"activeCount":99},[],{"intervention":52171,"totalTrials":224,"cells":52181},{"EARLY_PHASE1":52182,"PHASE1":52184,"PHASE2":52190,"PHASE3":52192,"PHASE4":52194,"NA":52196},{"trials":52183,"activeCount":99},[],{"trials":52185,"activeCount":99},[52186],{"nctId":52166,"briefTitle":52167,"status":105,"phases":52187,"primaryCompletion":18806,"completion":14679,"start":14229,"enrollment":700,"conditions":52188,"interventions":52189},[87],[5150],[52159,52171],{"trials":52191,"activeCount":99},[],{"trials":52193,"activeCount":99},[],{"trials":52195,"activeCount":99},[],{"trials":52197,"activeCount":99},[],{"intervention":7371,"totalTrials":224,"cells":52199},{"EARLY_PHASE1":52200,"PHASE1":52202,"PHASE2":52208,"PHASE3":52210,"PHASE4":52212,"NA":52214},{"trials":52201,"activeCount":99},[],{"trials":52203,"activeCount":99},[52204],{"nctId":7364,"briefTitle":7365,"status":105,"phases":52205,"primaryCompletion":7367,"completion":7368,"start":6177,"enrollment":3655,"conditions":52206,"interventions":52207},[87],[18],[7280,7371],{"trials":52209,"activeCount":99},[],{"trials":52211,"activeCount":99},[],{"trials":52213,"activeCount":99},[],{"trials":52215,"activeCount":99},[],{"intervention":52217,"totalTrials":224,"cells":52218},"MK-4074 200 mg",{"EARLY_PHASE1":52219,"PHASE1":52221,"PHASE2":52231,"PHASE3":52233,"PHASE4":52235,"NA":52237},{"trials":52220,"activeCount":99},[],{"trials":52222,"activeCount":99},[52223],{"nctId":52224,"briefTitle":52225,"status":105,"phases":52226,"primaryCompletion":171,"completion":52227,"start":15901,"enrollment":4741,"conditions":52228,"interventions":52229},"NCT01431521","Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)",[87],"2012-10-01",[11630],[52217,52230],"Pioglitazone hydrochloride 30 mg",{"trials":52232,"activeCount":99},[],{"trials":52234,"activeCount":99},[],{"trials":52236,"activeCount":99},[],{"trials":52238,"activeCount":99},[],{"intervention":52230,"totalTrials":224,"cells":52240},{"EARLY_PHASE1":52241,"PHASE1":52243,"PHASE2":52249,"PHASE3":52251,"PHASE4":52253,"NA":52255},{"trials":52242,"activeCount":99},[],{"trials":52244,"activeCount":99},[52245],{"nctId":52224,"briefTitle":52225,"status":105,"phases":52246,"primaryCompletion":171,"completion":52227,"start":15901,"enrollment":4741,"conditions":52247,"interventions":52248},[87],[11630],[52217,52230],{"trials":52250,"activeCount":99},[],{"trials":52252,"activeCount":99},[],{"trials":52254,"activeCount":99},[],{"trials":52256,"activeCount":99},[],{"intervention":52258,"totalTrials":224,"cells":52259},"MK-8150 2.0 mg",{"EARLY_PHASE1":52260,"PHASE1":52262,"PHASE2":52291,"PHASE3":52293,"PHASE4":52295,"NA":52297},{"trials":52261,"activeCount":99},[],{"trials":52263,"activeCount":99},[52264],{"nctId":52265,"briefTitle":52266,"status":105,"phases":52267,"primaryCompletion":52268,"completion":52269,"start":52270,"enrollment":5616,"conditions":52271,"interventions":52273},"NCT01590810","A Single Rising Dose Study of MK-8150 (MK-8150-001)",[87],"2013-01-24","2013-02-05","2012-05-07",[30,52272],"Isolated Systolic Hypertension (ISH)",[52258,52274,52275,52276,52277,52278,52279,52280,52281,52282,52283,52284,52285,52286,52287,52288,52289,52290],"MK-8150 10 mg","MK-8150 40 mg","MK-8150 90 mg","MK-8150 5.0 mg","MK-8150 20 mg","MK-8150 60 mg","MK-8150 120 mg","MK-8150 160 mg","MK-8150 320 mg","MK-8150 600 mg","MK-8150 900 mg","MK-8150 1200 mg","MK-8150 50 mg","MK-8150 100 mg","MK-8150 200 mg","MK-8150 400 mg","MK-8150 500 mg",{"trials":52292,"activeCount":99},[],{"trials":52294,"activeCount":99},[],{"trials":52296,"activeCount":99},[],{"trials":52298,"activeCount":99},[],{"intervention":52274,"totalTrials":224,"cells":52300},{"EARLY_PHASE1":52301,"PHASE1":52303,"PHASE2":52309,"PHASE3":52311,"PHASE4":52313,"NA":52315},{"trials":52302,"activeCount":99},[],{"trials":52304,"activeCount":99},[52305],{"nctId":52265,"briefTitle":52266,"status":105,"phases":52306,"primaryCompletion":52268,"completion":52269,"start":52270,"enrollment":5616,"conditions":52307,"interventions":52308},[87],[30,52272],[52258,52274,52275,52276,52277,52278,52279,52280,52281,52282,52283,52284,52285,52286,52287,52288,52289,52290],{"trials":52310,"activeCount":99},[],{"trials":52312,"activeCount":99},[],{"trials":52314,"activeCount":99},[],{"trials":52316,"activeCount":99},[],{"intervention":52275,"totalTrials":224,"cells":52318},{"EARLY_PHASE1":52319,"PHASE1":52321,"PHASE2":52327,"PHASE3":52329,"PHASE4":52331,"NA":52333},{"trials":52320,"activeCount":99},[],{"trials":52322,"activeCount":99},[52323],{"nctId":52265,"briefTitle":52266,"status":105,"phases":52324,"primaryCompletion":52268,"completion":52269,"start":52270,"enrollment":5616,"conditions":52325,"interventions":52326},[87],[30,52272],[52258,52274,52275,52276,52277,52278,52279,52280,52281,52282,52283,52284,52285,52286,52287,52288,52289,52290],{"trials":52328,"activeCount":99},[],{"trials":52330,"activeCount":99},[],{"trials":52332,"activeCount":99},[],{"trials":52334,"activeCount":99},[],{"intervention":52276,"totalTrials":224,"cells":52336},{"EARLY_PHASE1":52337,"PHASE1":52339,"PHASE2":52345,"PHASE3":52347,"PHASE4":52349,"NA":52351},{"trials":52338,"activeCount":99},[],{"trials":52340,"activeCount":99},[52341],{"nctId":52265,"briefTitle":52266,"status":105,"phases":52342,"primaryCompletion":52268,"completion":52269,"start":52270,"enrollment":5616,"conditions":52343,"interventions":52344},[87],[30,52272],[52258,52274,52275,52276,52277,52278,52279,52280,52281,52282,52283,52284,52285,52286,52287,52288,52289,52290],{"trials":52346,"activeCount":99},[],{"trials":52348,"activeCount":99},[],{"trials":52350,"activeCount":99},[],{"trials":52352,"activeCount":99},[],{"intervention":52277,"totalTrials":224,"cells":52354},{"EARLY_PHASE1":52355,"PHASE1":52357,"PHASE2":52363,"PHASE3":52365,"PHASE4":52367,"NA":52369},{"trials":52356,"activeCount":99},[],{"trials":52358,"activeCount":99},[52359],{"nctId":52265,"briefTitle":52266,"status":105,"phases":52360,"primaryCompletion":52268,"completion":52269,"start":52270,"enrollment":5616,"conditions":52361,"interventions":52362},[87],[30,52272],[52258,52274,52275,52276,52277,52278,52279,52280,52281,52282,52283,52284,52285,52286,52287,52288,52289,52290],{"trials":52364,"activeCount":99},[],{"trials":52366,"activeCount":99},[],{"trials":52368,"activeCount":99},[],{"trials":52370,"activeCount":99},[],{"intervention":52278,"totalTrials":224,"cells":52372},{"EARLY_PHASE1":52373,"PHASE1":52375,"PHASE2":52381,"PHASE3":52383,"PHASE4":52385,"NA":52387},{"trials":52374,"activeCount":99},[],{"trials":52376,"activeCount":99},[52377],{"nctId":52265,"briefTitle":52266,"status":105,"phases":52378,"primaryCompletion":52268,"completion":52269,"start":52270,"enrollment":5616,"conditions":52379,"interventions":52380},[87],[30,52272],[52258,52274,52275,52276,52277,52278,52279,52280,52281,52282,52283,52284,52285,52286,52287,52288,52289,52290],{"trials":52382,"activeCount":99},[],{"trials":52384,"activeCount":99},[],{"trials":52386,"activeCount":99},[],{"trials":52388,"activeCount":99},[],{"intervention":52279,"totalTrials":224,"cells":52390},{"EARLY_PHASE1":52391,"PHASE1":52393,"PHASE2":52399,"PHASE3":52401,"PHASE4":52403,"NA":52405},{"trials":52392,"activeCount":99},[],{"trials":52394,"activeCount":99},[52395],{"nctId":52265,"briefTitle":52266,"status":105,"phases":52396,"primaryCompletion":52268,"completion":52269,"start":52270,"enrollment":5616,"conditions":52397,"interventions":52398},[87],[30,52272],[52258,52274,52275,52276,52277,52278,52279,52280,52281,52282,52283,52284,52285,52286,52287,52288,52289,52290],{"trials":52400,"activeCount":99},[],{"trials":52402,"activeCount":99},[],{"trials":52404,"activeCount":99},[],{"trials":52406,"activeCount":99},[],{"intervention":52280,"totalTrials":224,"cells":52408},{"EARLY_PHASE1":52409,"PHASE1":52411,"PHASE2":52417,"PHASE3":52419,"PHASE4":52421,"NA":52423},{"trials":52410,"activeCount":99},[],{"trials":52412,"activeCount":99},[52413],{"nctId":52265,"briefTitle":52266,"status":105,"phases":52414,"primaryCompletion":52268,"completion":52269,"start":52270,"enrollment":5616,"conditions":52415,"interventions":52416},[87],[30,52272],[52258,52274,52275,52276,52277,52278,52279,52280,52281,52282,52283,52284,52285,52286,52287,52288,52289,52290],{"trials":52418,"activeCount":99},[],{"trials":52420,"activeCount":99},[],{"trials":52422,"activeCount":99},[],{"trials":52424,"activeCount":99},[],{"intervention":52281,"totalTrials":224,"cells":52426},{"EARLY_PHASE1":52427,"PHASE1":52429,"PHASE2":52435,"PHASE3":52437,"PHASE4":52439,"NA":52441},{"trials":52428,"activeCount":99},[],{"trials":52430,"activeCount":99},[52431],{"nctId":52265,"briefTitle":52266,"status":105,"phases":52432,"primaryCompletion":52268,"completion":52269,"start":52270,"enrollment":5616,"conditions":52433,"interventions":52434},[87],[30,52272],[52258,52274,52275,52276,52277,52278,52279,52280,52281,52282,52283,52284,52285,52286,52287,52288,52289,52290],{"trials":52436,"activeCount":99},[],{"trials":52438,"activeCount":99},[],{"trials":52440,"activeCount":99},[],{"trials":52442,"activeCount":99},[],{"intervention":52282,"totalTrials":224,"cells":52444},{"EARLY_PHASE1":52445,"PHASE1":52447,"PHASE2":52453,"PHASE3":52455,"PHASE4":52457,"NA":52459},{"trials":52446,"activeCount":99},[],{"trials":52448,"activeCount":99},[52449],{"nctId":52265,"briefTitle":52266,"status":105,"phases":52450,"primaryCompletion":52268,"completion":52269,"start":52270,"enrollment":5616,"conditions":52451,"interventions":52452},[87],[30,52272],[52258,52274,52275,52276,52277,52278,52279,52280,52281,52282,52283,52284,52285,52286,52287,52288,52289,52290],{"trials":52454,"activeCount":99},[],{"trials":52456,"activeCount":99},[],{"trials":52458,"activeCount":99},[],{"trials":52460,"activeCount":99},[],{"intervention":52283,"totalTrials":224,"cells":52462},{"EARLY_PHASE1":52463,"PHASE1":52465,"PHASE2":52471,"PHASE3":52473,"PHASE4":52475,"NA":52477},{"trials":52464,"activeCount":99},[],{"trials":52466,"activeCount":99},[52467],{"nctId":52265,"briefTitle":52266,"status":105,"phases":52468,"primaryCompletion":52268,"completion":52269,"start":52270,"enrollment":5616,"conditions":52469,"interventions":52470},[87],[30,52272],[52258,52274,52275,52276,52277,52278,52279,52280,52281,52282,52283,52284,52285,52286,52287,52288,52289,52290],{"trials":52472,"activeCount":99},[],{"trials":52474,"activeCount":99},[],{"trials":52476,"activeCount":99},[],{"trials":52478,"activeCount":99},[],{"intervention":52284,"totalTrials":224,"cells":52480},{"EARLY_PHASE1":52481,"PHASE1":52483,"PHASE2":52489,"PHASE3":52491,"PHASE4":52493,"NA":52495},{"trials":52482,"activeCount":99},[],{"trials":52484,"activeCount":99},[52485],{"nctId":52265,"briefTitle":52266,"status":105,"phases":52486,"primaryCompletion":52268,"completion":52269,"start":52270,"enrollment":5616,"conditions":52487,"interventions":52488},[87],[30,52272],[52258,52274,52275,52276,52277,52278,52279,52280,52281,52282,52283,52284,52285,52286,52287,52288,52289,52290],{"trials":52490,"activeCount":99},[],{"trials":52492,"activeCount":99},[],{"trials":52494,"activeCount":99},[],{"trials":52496,"activeCount":99},[],{"intervention":52285,"totalTrials":224,"cells":52498},{"EARLY_PHASE1":52499,"PHASE1":52501,"PHASE2":52507,"PHASE3":52509,"PHASE4":52511,"NA":52513},{"trials":52500,"activeCount":99},[],{"trials":52502,"activeCount":99},[52503],{"nctId":52265,"briefTitle":52266,"status":105,"phases":52504,"primaryCompletion":52268,"completion":52269,"start":52270,"enrollment":5616,"conditions":52505,"interventions":52506},[87],[30,52272],[52258,52274,52275,52276,52277,52278,52279,52280,52281,52282,52283,52284,52285,52286,52287,52288,52289,52290],{"trials":52508,"activeCount":99},[],{"trials":52510,"activeCount":99},[],{"trials":52512,"activeCount":99},[],{"trials":52514,"activeCount":99},[],{"intervention":52286,"totalTrials":224,"cells":52516},{"EARLY_PHASE1":52517,"PHASE1":52519,"PHASE2":52525,"PHASE3":52527,"PHASE4":52529,"NA":52531},{"trials":52518,"activeCount":99},[],{"trials":52520,"activeCount":99},[52521],{"nctId":52265,"briefTitle":52266,"status":105,"phases":52522,"primaryCompletion":52268,"completion":52269,"start":52270,"enrollment":5616,"conditions":52523,"interventions":52524},[87],[30,52272],[52258,52274,52275,52276,52277,52278,52279,52280,52281,52282,52283,52284,52285,52286,52287,52288,52289,52290],{"trials":52526,"activeCount":99},[],{"trials":52528,"activeCount":99},[],{"trials":52530,"activeCount":99},[],{"trials":52532,"activeCount":99},[],{"intervention":52287,"totalTrials":224,"cells":52534},{"EARLY_PHASE1":52535,"PHASE1":52537,"PHASE2":52543,"PHASE3":52545,"PHASE4":52547,"NA":52549},{"trials":52536,"activeCount":99},[],{"trials":52538,"activeCount":99},[52539],{"nctId":52265,"briefTitle":52266,"status":105,"phases":52540,"primaryCompletion":52268,"completion":52269,"start":52270,"enrollment":5616,"conditions":52541,"interventions":52542},[87],[30,52272],[52258,52274,52275,52276,52277,52278,52279,52280,52281,52282,52283,52284,52285,52286,52287,52288,52289,52290],{"trials":52544,"activeCount":99},[],{"trials":52546,"activeCount":99},[],{"trials":52548,"activeCount":99},[],{"trials":52550,"activeCount":99},[],{"intervention":52288,"totalTrials":224,"cells":52552},{"EARLY_PHASE1":52553,"PHASE1":52555,"PHASE2":52561,"PHASE3":52563,"PHASE4":52565,"NA":52567},{"trials":52554,"activeCount":99},[],{"trials":52556,"activeCount":99},[52557],{"nctId":52265,"briefTitle":52266,"status":105,"phases":52558,"primaryCompletion":52268,"completion":52269,"start":52270,"enrollment":5616,"conditions":52559,"interventions":52560},[87],[30,52272],[52258,52274,52275,52276,52277,52278,52279,52280,52281,52282,52283,52284,52285,52286,52287,52288,52289,52290],{"trials":52562,"activeCount":99},[],{"trials":52564,"activeCount":99},[],{"trials":52566,"activeCount":99},[],{"trials":52568,"activeCount":99},[],{"intervention":52289,"totalTrials":224,"cells":52570},{"EARLY_PHASE1":52571,"PHASE1":52573,"PHASE2":52579,"PHASE3":52581,"PHASE4":52583,"NA":52585},{"trials":52572,"activeCount":99},[],{"trials":52574,"activeCount":99},[52575],{"nctId":52265,"briefTitle":52266,"status":105,"phases":52576,"primaryCompletion":52268,"completion":52269,"start":52270,"enrollment":5616,"conditions":52577,"interventions":52578},[87],[30,52272],[52258,52274,52275,52276,52277,52278,52279,52280,52281,52282,52283,52284,52285,52286,52287,52288,52289,52290],{"trials":52580,"activeCount":99},[],{"trials":52582,"activeCount":99},[],{"trials":52584,"activeCount":99},[],{"trials":52586,"activeCount":99},[],{"intervention":52290,"totalTrials":224,"cells":52588},{"EARLY_PHASE1":52589,"PHASE1":52591,"PHASE2":52597,"PHASE3":52599,"PHASE4":52601,"NA":52603},{"trials":52590,"activeCount":99},[],{"trials":52592,"activeCount":99},[52593],{"nctId":52265,"briefTitle":52266,"status":105,"phases":52594,"primaryCompletion":52268,"completion":52269,"start":52270,"enrollment":5616,"conditions":52595,"interventions":52596},[87],[30,52272],[52258,52274,52275,52276,52277,52278,52279,52280,52281,52282,52283,52284,52285,52286,52287,52288,52289,52290],{"trials":52598,"activeCount":99},[],{"trials":52600,"activeCount":99},[],{"trials":52602,"activeCount":99},[],{"trials":52604,"activeCount":99},[],{"intervention":52606,"totalTrials":224,"cells":52607},"Comparator: erlotinib + dalotuzumab",{"EARLY_PHASE1":52608,"PHASE1":52610,"PHASE2":52620,"PHASE3":52622,"PHASE4":52624,"NA":52626},{"trials":52609,"activeCount":99},[],{"trials":52611,"activeCount":99},[52612],{"nctId":52613,"briefTitle":52614,"status":105,"phases":52615,"primaryCompletion":12813,"completion":5981,"start":14313,"enrollment":13234,"conditions":52616,"interventions":52618},"NCT00729742","Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)",[87],[52617],"Carcinoma, Non-small Cell Lung",[52606,52619],"Comparator: erlotinib monotherapy",{"trials":52621,"activeCount":99},[],{"trials":52623,"activeCount":99},[],{"trials":52625,"activeCount":99},[],{"trials":52627,"activeCount":99},[],{"intervention":52619,"totalTrials":224,"cells":52629},{"EARLY_PHASE1":52630,"PHASE1":52632,"PHASE2":52638,"PHASE3":52640,"PHASE4":52642,"NA":52644},{"trials":52631,"activeCount":99},[],{"trials":52633,"activeCount":99},[52634],{"nctId":52613,"briefTitle":52614,"status":105,"phases":52635,"primaryCompletion":12813,"completion":5981,"start":14313,"enrollment":13234,"conditions":52636,"interventions":52637},[87],[52617],[52606,52619],{"trials":52639,"activeCount":99},[],{"trials":52641,"activeCount":99},[],{"trials":52643,"activeCount":99},[],{"trials":52645,"activeCount":99},[],{"intervention":52647,"totalTrials":224,"cells":52648},"V330",{"EARLY_PHASE1":52649,"PHASE1":52651,"PHASE2":52660,"PHASE3":52662,"PHASE4":52664,"NA":52666},{"trials":52650,"activeCount":99},[],{"trials":52652,"activeCount":99},[52653],{"nctId":52654,"briefTitle":52655,"status":105,"phases":52656,"primaryCompletion":1619,"completion":1619,"start":52657,"enrollment":776,"conditions":52658,"interventions":52659},"NCT06630117","A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)",[87],"2024-03-01",[18],[52647],{"trials":52661,"activeCount":99},[],{"trials":52663,"activeCount":99},[],{"trials":52665,"activeCount":99},[],{"trials":52667,"activeCount":99},[],{"intervention":52669,"totalTrials":224,"cells":52670},"MK-6325",{"EARLY_PHASE1":52671,"PHASE1":52673,"PHASE2":52681,"PHASE3":52683,"PHASE4":52685,"NA":52687},{"trials":52672,"activeCount":99},[],{"trials":52674,"activeCount":99},[52675],{"nctId":52676,"briefTitle":52677,"status":105,"phases":52678,"primaryCompletion":16794,"completion":16794,"start":5981,"enrollment":8016,"conditions":52679,"interventions":52680},"NCT01329913","Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)",[87],[24],[52669,52669,52669],{"trials":52682,"activeCount":99},[],{"trials":52684,"activeCount":99},[],{"trials":52686,"activeCount":99},[],{"trials":52688,"activeCount":99},[],{"intervention":19360,"totalTrials":224,"cells":52690},{"EARLY_PHASE1":52691,"PHASE1":52693,"PHASE2":52699,"PHASE3":52701,"PHASE4":52703,"NA":52705},{"trials":52692,"activeCount":99},[],{"trials":52694,"activeCount":99},[52695],{"nctId":19353,"briefTitle":19354,"status":105,"phases":52696,"primaryCompletion":4990,"completion":8590,"start":14324,"enrollment":19356,"conditions":52697,"interventions":52698},[87],[19358,196],[4994,19360],{"trials":52700,"activeCount":99},[],{"trials":52702,"activeCount":99},[],{"trials":52704,"activeCount":99},[],{"trials":52706,"activeCount":99},[],{"intervention":42465,"totalTrials":224,"cells":52708},{"EARLY_PHASE1":52709,"PHASE1":52711,"PHASE2":52717,"PHASE3":52719,"PHASE4":52721,"NA":52723},{"trials":52710,"activeCount":99},[],{"trials":52712,"activeCount":99},[52713],{"nctId":42458,"briefTitle":42459,"status":105,"phases":52714,"primaryCompletion":19365,"completion":42461,"start":42462,"enrollment":558,"conditions":52715,"interventions":52716},[87],[24],[42440,42465],{"trials":52718,"activeCount":99},[],{"trials":52720,"activeCount":99},[],{"trials":52722,"activeCount":99},[],{"trials":52724,"activeCount":99},[],{"intervention":52726,"totalTrials":224,"cells":52727},"1 mg islatravir",{"EARLY_PHASE1":52728,"PHASE1":52730,"PHASE2":52745,"PHASE3":52747,"PHASE4":52749,"NA":52751},{"trials":52729,"activeCount":99},[],{"trials":52731,"activeCount":99},[52732],{"nctId":52733,"briefTitle":52734,"status":105,"phases":52735,"primaryCompletion":52736,"completion":52736,"start":52737,"enrollment":154,"conditions":52738,"interventions":52739},"NCT02217904","A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003)",[87],"2017-05-11","2015-09-17",[11444],[52726,52740,52741,52742,52743,52744],"2 mg islatravir","10 mg islatravir","30 mg islatravir","0.5 mg islatravir","0.25 mg islatravir",{"trials":52746,"activeCount":99},[],{"trials":52748,"activeCount":99},[],{"trials":52750,"activeCount":99},[],{"trials":52752,"activeCount":99},[],{"intervention":52740,"totalTrials":224,"cells":52754},{"EARLY_PHASE1":52755,"PHASE1":52757,"PHASE2":52763,"PHASE3":52765,"PHASE4":52767,"NA":52769},{"trials":52756,"activeCount":99},[],{"trials":52758,"activeCount":99},[52759],{"nctId":52733,"briefTitle":52734,"status":105,"phases":52760,"primaryCompletion":52736,"completion":52736,"start":52737,"enrollment":154,"conditions":52761,"interventions":52762},[87],[11444],[52726,52740,52741,52742,52743,52744],{"trials":52764,"activeCount":99},[],{"trials":52766,"activeCount":99},[],{"trials":52768,"activeCount":99},[],{"trials":52770,"activeCount":99},[],{"intervention":52741,"totalTrials":224,"cells":52772},{"EARLY_PHASE1":52773,"PHASE1":52775,"PHASE2":52781,"PHASE3":52783,"PHASE4":52785,"NA":52787},{"trials":52774,"activeCount":99},[],{"trials":52776,"activeCount":99},[52777],{"nctId":52733,"briefTitle":52734,"status":105,"phases":52778,"primaryCompletion":52736,"completion":52736,"start":52737,"enrollment":154,"conditions":52779,"interventions":52780},[87],[11444],[52726,52740,52741,52742,52743,52744],{"trials":52782,"activeCount":99},[],{"trials":52784,"activeCount":99},[],{"trials":52786,"activeCount":99},[],{"trials":52788,"activeCount":99},[],{"intervention":52742,"totalTrials":224,"cells":52790},{"EARLY_PHASE1":52791,"PHASE1":52793,"PHASE2":52799,"PHASE3":52801,"PHASE4":52803,"NA":52805},{"trials":52792,"activeCount":99},[],{"trials":52794,"activeCount":99},[52795],{"nctId":52733,"briefTitle":52734,"status":105,"phases":52796,"primaryCompletion":52736,"completion":52736,"start":52737,"enrollment":154,"conditions":52797,"interventions":52798},[87],[11444],[52726,52740,52741,52742,52743,52744],{"trials":52800,"activeCount":99},[],{"trials":52802,"activeCount":99},[],{"trials":52804,"activeCount":99},[],{"trials":52806,"activeCount":99},[],{"intervention":52743,"totalTrials":224,"cells":52808},{"EARLY_PHASE1":52809,"PHASE1":52811,"PHASE2":52817,"PHASE3":52819,"PHASE4":52821,"NA":52823},{"trials":52810,"activeCount":99},[],{"trials":52812,"activeCount":99},[52813],{"nctId":52733,"briefTitle":52734,"status":105,"phases":52814,"primaryCompletion":52736,"completion":52736,"start":52737,"enrollment":154,"conditions":52815,"interventions":52816},[87],[11444],[52726,52740,52741,52742,52743,52744],{"trials":52818,"activeCount":99},[],{"trials":52820,"activeCount":99},[],{"trials":52822,"activeCount":99},[],{"trials":52824,"activeCount":99},[],{"intervention":52744,"totalTrials":224,"cells":52826},{"EARLY_PHASE1":52827,"PHASE1":52829,"PHASE2":52835,"PHASE3":52837,"PHASE4":52839,"NA":52841},{"trials":52828,"activeCount":99},[],{"trials":52830,"activeCount":99},[52831],{"nctId":52733,"briefTitle":52734,"status":105,"phases":52832,"primaryCompletion":52736,"completion":52736,"start":52737,"enrollment":154,"conditions":52833,"interventions":52834},[87],[11444],[52726,52740,52741,52742,52743,52744],{"trials":52836,"activeCount":99},[],{"trials":52838,"activeCount":99},[],{"trials":52840,"activeCount":99},[],{"trials":52842,"activeCount":99},[],{"intervention":9578,"totalTrials":224,"cells":52844},{"EARLY_PHASE1":52845,"PHASE1":52847,"PHASE2":52853,"PHASE3":52855,"PHASE4":52857,"NA":52859},{"trials":52846,"activeCount":99},[],{"trials":52848,"activeCount":99},[52849],{"nctId":9571,"briefTitle":9572,"status":105,"phases":52850,"primaryCompletion":9574,"completion":9574,"start":9575,"enrollment":444,"conditions":52851,"interventions":52852},[87],[4255,15],[9578,9579,9580,9581,4259,9582],{"trials":52854,"activeCount":99},[],{"trials":52856,"activeCount":99},[],{"trials":52858,"activeCount":99},[],{"trials":52860,"activeCount":99},[],{"intervention":9579,"totalTrials":224,"cells":52862},{"EARLY_PHASE1":52863,"PHASE1":52865,"PHASE2":52871,"PHASE3":52873,"PHASE4":52875,"NA":52877},{"trials":52864,"activeCount":99},[],{"trials":52866,"activeCount":99},[52867],{"nctId":9571,"briefTitle":9572,"status":105,"phases":52868,"primaryCompletion":9574,"completion":9574,"start":9575,"enrollment":444,"conditions":52869,"interventions":52870},[87],[4255,15],[9578,9579,9580,9581,4259,9582],{"trials":52872,"activeCount":99},[],{"trials":52874,"activeCount":99},[],{"trials":52876,"activeCount":99},[],{"trials":52878,"activeCount":99},[],{"intervention":9580,"totalTrials":224,"cells":52880},{"EARLY_PHASE1":52881,"PHASE1":52883,"PHASE2":52889,"PHASE3":52891,"PHASE4":52893,"NA":52895},{"trials":52882,"activeCount":99},[],{"trials":52884,"activeCount":99},[52885],{"nctId":9571,"briefTitle":9572,"status":105,"phases":52886,"primaryCompletion":9574,"completion":9574,"start":9575,"enrollment":444,"conditions":52887,"interventions":52888},[87],[4255,15],[9578,9579,9580,9581,4259,9582],{"trials":52890,"activeCount":99},[],{"trials":52892,"activeCount":99},[],{"trials":52894,"activeCount":99},[],{"trials":52896,"activeCount":99},[],{"intervention":9581,"totalTrials":224,"cells":52898},{"EARLY_PHASE1":52899,"PHASE1":52901,"PHASE2":52907,"PHASE3":52909,"PHASE4":52911,"NA":52913},{"trials":52900,"activeCount":99},[],{"trials":52902,"activeCount":99},[52903],{"nctId":9571,"briefTitle":9572,"status":105,"phases":52904,"primaryCompletion":9574,"completion":9574,"start":9575,"enrollment":444,"conditions":52905,"interventions":52906},[87],[4255,15],[9578,9579,9580,9581,4259,9582],{"trials":52908,"activeCount":99},[],{"trials":52910,"activeCount":99},[],{"trials":52912,"activeCount":99},[],{"trials":52914,"activeCount":99},[],{"intervention":9582,"totalTrials":224,"cells":52916},{"EARLY_PHASE1":52917,"PHASE1":52919,"PHASE2":52925,"PHASE3":52927,"PHASE4":52929,"NA":52931},{"trials":52918,"activeCount":99},[],{"trials":52920,"activeCount":99},[52921],{"nctId":9571,"briefTitle":9572,"status":105,"phases":52922,"primaryCompletion":9574,"completion":9574,"start":9575,"enrollment":444,"conditions":52923,"interventions":52924},[87],[4255,15],[9578,9579,9580,9581,4259,9582],{"trials":52926,"activeCount":99},[],{"trials":52928,"activeCount":99},[],{"trials":52930,"activeCount":99},[],{"trials":52932,"activeCount":99},[],{"intervention":13387,"totalTrials":224,"cells":52934},{"EARLY_PHASE1":52935,"PHASE1":52937,"PHASE2":52943,"PHASE3":52945,"PHASE4":52947,"NA":52949},{"trials":52936,"activeCount":99},[],{"trials":52938,"activeCount":99},[52939],{"nctId":13379,"briefTitle":13380,"status":105,"phases":52940,"primaryCompletion":13382,"completion":13383,"start":13384,"enrollment":931,"conditions":52941,"interventions":52942},[87],[18],[13363,13387],{"trials":52944,"activeCount":99},[],{"trials":52946,"activeCount":99},[],{"trials":52948,"activeCount":99},[],{"trials":52950,"activeCount":99},[],{"intervention":52952,"totalTrials":224,"cells":52953},"MK-0873 2% Cream",{"EARLY_PHASE1":52954,"PHASE1":52956,"PHASE2":52966,"PHASE3":52968,"PHASE4":52970,"NA":52972},{"trials":52955,"activeCount":99},[],{"trials":52957,"activeCount":99},[52958],{"nctId":52959,"briefTitle":52960,"status":105,"phases":52961,"primaryCompletion":45703,"completion":45703,"start":43042,"enrollment":120,"conditions":52962,"interventions":52963},"NCT01235728","A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)",[87],[12754,46485],[52952,52964,52965],"MK-0873 vehicle (placebo) Cream","Calcitriol Cream",{"trials":52967,"activeCount":99},[],{"trials":52969,"activeCount":99},[],{"trials":52971,"activeCount":99},[],{"trials":52973,"activeCount":99},[],{"intervention":52964,"totalTrials":224,"cells":52975},{"EARLY_PHASE1":52976,"PHASE1":52978,"PHASE2":52984,"PHASE3":52986,"PHASE4":52988,"NA":52990},{"trials":52977,"activeCount":99},[],{"trials":52979,"activeCount":99},[52980],{"nctId":52959,"briefTitle":52960,"status":105,"phases":52981,"primaryCompletion":45703,"completion":45703,"start":43042,"enrollment":120,"conditions":52982,"interventions":52983},[87],[12754,46485],[52952,52964,52965],{"trials":52985,"activeCount":99},[],{"trials":52987,"activeCount":99},[],{"trials":52989,"activeCount":99},[],{"trials":52991,"activeCount":99},[],{"intervention":52965,"totalTrials":224,"cells":52993},{"EARLY_PHASE1":52994,"PHASE1":52996,"PHASE2":53002,"PHASE3":53004,"PHASE4":53006,"NA":53008},{"trials":52995,"activeCount":99},[],{"trials":52997,"activeCount":99},[52998],{"nctId":52959,"briefTitle":52960,"status":105,"phases":52999,"primaryCompletion":45703,"completion":45703,"start":43042,"enrollment":120,"conditions":53000,"interventions":53001},[87],[12754,46485],[52952,52964,52965],{"trials":53003,"activeCount":99},[],{"trials":53005,"activeCount":99},[],{"trials":53007,"activeCount":99},[],{"trials":53009,"activeCount":99},[],{"intervention":53011,"totalTrials":224,"cells":53012},"MK 0773",{"EARLY_PHASE1":53013,"PHASE1":53015,"PHASE2":53023,"PHASE3":53025,"PHASE4":53027,"NA":53029},{"trials":53014,"activeCount":99},[],{"trials":53016,"activeCount":99},[53017],{"nctId":53018,"briefTitle":53019,"status":105,"phases":53020,"primaryCompletion":17461,"completion":14314,"start":14228,"enrollment":2647,"conditions":53021,"interventions":53022},"NCT01011725","Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women (0773-003)",[87],[14552],[53011],{"trials":53024,"activeCount":99},[],{"trials":53026,"activeCount":99},[],{"trials":53028,"activeCount":99},[],{"trials":53030,"activeCount":99},[],{"intervention":22536,"totalTrials":224,"cells":53032},{"EARLY_PHASE1":53033,"PHASE1":53035,"PHASE2":53041,"PHASE3":53043,"PHASE4":53045,"NA":53047},{"trials":53034,"activeCount":99},[],{"trials":53036,"activeCount":99},[53037],{"nctId":22529,"briefTitle":22530,"status":105,"phases":53038,"primaryCompletion":13140,"completion":22532,"start":22533,"enrollment":4059,"conditions":53039,"interventions":53040},[87],[15],[13885,22536,22537,22538],{"trials":53042,"activeCount":99},[],{"trials":53044,"activeCount":99},[],{"trials":53046,"activeCount":99},[],{"trials":53048,"activeCount":99},[],{"intervention":22537,"totalTrials":224,"cells":53050},{"EARLY_PHASE1":53051,"PHASE1":53053,"PHASE2":53059,"PHASE3":53061,"PHASE4":53063,"NA":53065},{"trials":53052,"activeCount":99},[],{"trials":53054,"activeCount":99},[53055],{"nctId":22529,"briefTitle":22530,"status":105,"phases":53056,"primaryCompletion":13140,"completion":22532,"start":22533,"enrollment":4059,"conditions":53057,"interventions":53058},[87],[15],[13885,22536,22537,22538],{"trials":53060,"activeCount":99},[],{"trials":53062,"activeCount":99},[],{"trials":53064,"activeCount":99},[],{"trials":53066,"activeCount":99},[],{"intervention":22538,"totalTrials":224,"cells":53068},{"EARLY_PHASE1":53069,"PHASE1":53071,"PHASE2":53077,"PHASE3":53079,"PHASE4":53081,"NA":53083},{"trials":53070,"activeCount":99},[],{"trials":53072,"activeCount":99},[53073],{"nctId":22529,"briefTitle":22530,"status":105,"phases":53074,"primaryCompletion":13140,"completion":22532,"start":22533,"enrollment":4059,"conditions":53075,"interventions":53076},[87],[15],[13885,22536,22537,22538],{"trials":53078,"activeCount":99},[],{"trials":53080,"activeCount":99},[],{"trials":53082,"activeCount":99},[],{"trials":53084,"activeCount":99},[],{"intervention":5183,"totalTrials":224,"cells":53086},{"EARLY_PHASE1":53087,"PHASE1":53089,"PHASE2":53095,"PHASE3":53097,"PHASE4":53099,"NA":53101},{"trials":53088,"activeCount":99},[],{"trials":53090,"activeCount":99},[53091],{"nctId":5176,"briefTitle":5177,"status":105,"phases":53092,"primaryCompletion":5179,"completion":5179,"start":4990,"enrollment":3655,"conditions":53093,"interventions":53094},[87],[5181],[5183,5184,5185,529,529,5137,5186],{"trials":53096,"activeCount":99},[],{"trials":53098,"activeCount":99},[],{"trials":53100,"activeCount":99},[],{"trials":53102,"activeCount":99},[],{"intervention":5185,"totalTrials":224,"cells":53104},{"EARLY_PHASE1":53105,"PHASE1":53107,"PHASE2":53113,"PHASE3":53115,"PHASE4":53117,"NA":53119},{"trials":53106,"activeCount":99},[],{"trials":53108,"activeCount":99},[53109],{"nctId":5176,"briefTitle":5177,"status":105,"phases":53110,"primaryCompletion":5179,"completion":5179,"start":4990,"enrollment":3655,"conditions":53111,"interventions":53112},[87],[5181],[5183,5184,5185,529,529,5137,5186],{"trials":53114,"activeCount":99},[],{"trials":53116,"activeCount":99},[],{"trials":53118,"activeCount":99},[],{"trials":53120,"activeCount":99},[],{"intervention":5186,"totalTrials":224,"cells":53122},{"EARLY_PHASE1":53123,"PHASE1":53125,"PHASE2":53131,"PHASE3":53133,"PHASE4":53135,"NA":53137},{"trials":53124,"activeCount":99},[],{"trials":53126,"activeCount":99},[53127],{"nctId":5176,"briefTitle":5177,"status":105,"phases":53128,"primaryCompletion":5179,"completion":5179,"start":4990,"enrollment":3655,"conditions":53129,"interventions":53130},[87],[5181],[5183,5184,5185,529,529,5137,5186],{"trials":53132,"activeCount":99},[],{"trials":53134,"activeCount":99},[],{"trials":53136,"activeCount":99},[],{"trials":53138,"activeCount":99},[],{"intervention":53140,"totalTrials":224,"cells":53141},"[14C]Elpipodect",{"EARLY_PHASE1":53142,"PHASE1":53144,"PHASE2":53154,"PHASE3":53156,"PHASE4":53158,"NA":53160},{"trials":53143,"activeCount":99},[],{"trials":53145,"activeCount":99},[53146],{"nctId":53147,"briefTitle":53148,"status":105,"phases":53149,"primaryCompletion":53150,"completion":53150,"start":53151,"enrollment":4555,"conditions":53152,"interventions":53153},"NCT06626464","A Study of Elpipodect (MK-8189) Human Absorption, Metabolism, and Excretion in Healthy Male Participants (MK-8189-010)",[87],"2022-07-08","2022-05-13",[18],[53140],{"trials":53155,"activeCount":99},[],{"trials":53157,"activeCount":99},[],{"trials":53159,"activeCount":99},[],{"trials":53161,"activeCount":99},[],{"intervention":53163,"totalTrials":224,"cells":53164},"MK-1006 DFC",{"EARLY_PHASE1":53165,"PHASE1":53167,"PHASE2":53176,"PHASE3":53178,"PHASE4":53180,"NA":53182},{"trials":53166,"activeCount":99},[],{"trials":53168,"activeCount":99},[53169],{"nctId":53170,"briefTitle":53171,"status":105,"phases":53172,"primaryCompletion":8591,"completion":13101,"start":14445,"enrollment":95,"conditions":53173,"interventions":53174},"NCT00979459","A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)",[87],[14156],[53163,53175],"MK-1006 FCT",{"trials":53177,"activeCount":99},[],{"trials":53179,"activeCount":99},[],{"trials":53181,"activeCount":99},[],{"trials":53183,"activeCount":99},[],{"intervention":53175,"totalTrials":224,"cells":53185},{"EARLY_PHASE1":53186,"PHASE1":53188,"PHASE2":53194,"PHASE3":53196,"PHASE4":53198,"NA":53200},{"trials":53187,"activeCount":99},[],{"trials":53189,"activeCount":99},[53190],{"nctId":53170,"briefTitle":53171,"status":105,"phases":53191,"primaryCompletion":8591,"completion":13101,"start":14445,"enrollment":95,"conditions":53192,"interventions":53193},[87],[14156],[53163,53175],{"trials":53195,"activeCount":99},[],{"trials":53197,"activeCount":99},[],{"trials":53199,"activeCount":99},[],{"trials":53201,"activeCount":99},[],{"intervention":733,"totalTrials":224,"cells":53203},{"EARLY_PHASE1":53204,"PHASE1":53206,"PHASE2":53212,"PHASE3":53214,"PHASE4":53216,"NA":53218},{"trials":53205,"activeCount":99},[],{"trials":53207,"activeCount":99},[53208],{"nctId":726,"briefTitle":727,"status":105,"phases":53209,"primaryCompletion":729,"completion":729,"start":730,"enrollment":174,"conditions":53210,"interventions":53211},[87],[690],[733,47],{"trials":53213,"activeCount":99},[],{"trials":53215,"activeCount":99},[],{"trials":53217,"activeCount":99},[],{"trials":53219,"activeCount":99},[],{"intervention":53221,"totalTrials":224,"cells":53222},"fenofibrate",{"EARLY_PHASE1":53223,"PHASE1":53225,"PHASE2":53233,"PHASE3":53235,"PHASE4":53237,"NA":53239},{"trials":53224,"activeCount":99},[],{"trials":53226,"activeCount":99},[53227],{"nctId":53228,"briefTitle":53229,"status":105,"phases":53230,"primaryCompletion":17248,"completion":4420,"start":14772,"enrollment":4071,"conditions":53231,"interventions":53232},"NCT00928694","Fenofibrate Bioequivalence Study (0767-031)",[87],[14337],[53221,53221],{"trials":53234,"activeCount":99},[],{"trials":53236,"activeCount":99},[],{"trials":53238,"activeCount":99},[],{"trials":53240,"activeCount":99},[],{"intervention":42703,"totalTrials":224,"cells":53242},{"EARLY_PHASE1":53243,"PHASE1":53245,"PHASE2":53251,"PHASE3":53253,"PHASE4":53255,"NA":53257},{"trials":53244,"activeCount":99},[],{"trials":53246,"activeCount":99},[53247],{"nctId":42698,"briefTitle":42699,"status":105,"phases":53248,"primaryCompletion":5280,"completion":5280,"start":15118,"enrollment":688,"conditions":53249,"interventions":53250},[87],[7639],[14570,42703],{"trials":53252,"activeCount":99},[],{"trials":53254,"activeCount":99},[],{"trials":53256,"activeCount":99},[],{"trials":53258,"activeCount":99},[],{"intervention":53260,"totalTrials":224,"cells":53261},"MK-0249 7.5 mg",{"EARLY_PHASE1":53262,"PHASE1":53264,"PHASE2":53275,"PHASE3":53277,"PHASE4":53279,"NA":53281},{"trials":53263,"activeCount":99},[],{"trials":53265,"activeCount":99},[53266],{"nctId":53267,"briefTitle":53268,"status":150,"phases":53269,"primaryCompletion":14920,"completion":14920,"start":53270,"enrollment":3963,"conditions":53271,"interventions":53272},"NCT00874939","A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)",[87],"2009-04-06",[11174,11195],[53260,53273,53274],"MK-0249 25 mg","Donepezil 5mg",{"trials":53276,"activeCount":99},[],{"trials":53278,"activeCount":99},[],{"trials":53280,"activeCount":99},[],{"trials":53282,"activeCount":99},[],{"intervention":53273,"totalTrials":224,"cells":53284},{"EARLY_PHASE1":53285,"PHASE1":53287,"PHASE2":53293,"PHASE3":53295,"PHASE4":53297,"NA":53299},{"trials":53286,"activeCount":99},[],{"trials":53288,"activeCount":99},[53289],{"nctId":53267,"briefTitle":53268,"status":150,"phases":53290,"primaryCompletion":14920,"completion":14920,"start":53270,"enrollment":3963,"conditions":53291,"interventions":53292},[87],[11174,11195],[53260,53273,53274],{"trials":53294,"activeCount":99},[],{"trials":53296,"activeCount":99},[],{"trials":53298,"activeCount":99},[],{"trials":53300,"activeCount":99},[],{"intervention":53274,"totalTrials":224,"cells":53302},{"EARLY_PHASE1":53303,"PHASE1":53305,"PHASE2":53311,"PHASE3":53313,"PHASE4":53315,"NA":53317},{"trials":53304,"activeCount":99},[],{"trials":53306,"activeCount":99},[53307],{"nctId":53267,"briefTitle":53268,"status":150,"phases":53308,"primaryCompletion":14920,"completion":14920,"start":53270,"enrollment":3963,"conditions":53309,"interventions":53310},[87],[11174,11195],[53260,53273,53274],{"trials":53312,"activeCount":99},[],{"trials":53314,"activeCount":99},[],{"trials":53316,"activeCount":99},[],{"trials":53318,"activeCount":99},[],{"intervention":14925,"totalTrials":14325,"cells":53320},{"EARLY_PHASE1":53321,"PHASE1":53323,"PHASE2":53333,"PHASE3":53436,"PHASE4":53537,"NA":53578},{"trials":53322,"activeCount":99},[],{"trials":53324,"activeCount":99},[53325,53329],{"nctId":42447,"briefTitle":42448,"status":105,"phases":53326,"primaryCompletion":42450,"completion":42451,"start":42452,"enrollment":4741,"conditions":53327,"interventions":53328},[87],[12957],[42455,42456,14925,42440],{"nctId":50509,"briefTitle":50510,"status":1040,"phases":53330,"primaryCompletion":16793,"completion":16793,"start":15845,"enrollment":99,"conditions":53331,"interventions":53332},[87],[12957],[50502,14925,50514,50515],{"trials":53334,"activeCount":99},[53335,53339,53348,53352,53360,53364,53368,53372,53376,53384,53388,53392,53396,53400,53404,53408,53412,53416,53420,53424,53428,53432],{"nctId":15813,"briefTitle":15814,"status":105,"phases":53336,"primaryCompletion":13102,"completion":14823,"start":15210,"enrollment":15816,"conditions":53337,"interventions":53338},[88],[12957],[12989,15819,15820,15820],{"nctId":53340,"briefTitle":53341,"status":105,"phases":53342,"primaryCompletion":48945,"completion":53343,"start":14104,"enrollment":23629,"conditions":53344,"interventions":53346},"NCT01710501","A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)",[88],"2014-01-29",[53345],"Chronic Hepatitis C (CHC)",[15839,53347,14925],"pegylated interferon alfa-2b",{"nctId":20998,"briefTitle":20999,"status":105,"phases":53349,"primaryCompletion":21001,"completion":14004,"start":21002,"enrollment":9366,"conditions":53350,"interventions":53351},[88],[21],[14923,14924,14925],{"nctId":53353,"briefTitle":53354,"status":150,"phases":53355,"primaryCompletion":53356,"completion":53356,"start":53357,"enrollment":174,"conditions":53358,"interventions":53359},"NCT01440595","Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)",[88],"2012-05-01","2011-11-28",[21],[15839,15859,14925],{"nctId":34053,"briefTitle":34054,"status":150,"phases":53361,"primaryCompletion":34056,"completion":34057,"start":34058,"enrollment":1977,"conditions":53362,"interventions":53363},[88],[34060,24,34061,34062,19783,34063,34064,16461],[19843,14925],{"nctId":15822,"briefTitle":15823,"status":105,"phases":53365,"primaryCompletion":13891,"completion":13891,"start":15156,"enrollment":15825,"conditions":53366,"interventions":53367},[88],[12957],[15784,15828,14925],{"nctId":20419,"briefTitle":20420,"status":105,"phases":53369,"primaryCompletion":14713,"completion":13222,"start":14823,"enrollment":417,"conditions":53370,"interventions":53371},[88],[21],[20424,15820,20425,20426],{"nctId":20428,"briefTitle":20429,"status":105,"phases":53373,"primaryCompletion":20431,"completion":20431,"start":20410,"enrollment":5196,"conditions":53374,"interventions":53375},[88],[20433],[20415,20435,14925,20436,11447,20437],{"nctId":53377,"briefTitle":53378,"status":105,"phases":53379,"primaryCompletion":53380,"completion":14055,"start":53381,"enrollment":3506,"conditions":53382,"interventions":53383},"NCT01716156","A Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039)",[88],"2013-12-09","2013-01-18",[24],[15839,14925],{"nctId":19796,"briefTitle":19797,"status":105,"phases":53385,"primaryCompletion":19799,"completion":19800,"start":19801,"enrollment":19802,"conditions":53386,"interventions":53387},[88],[24],[15839,17381,14925],{"nctId":34119,"briefTitle":34120,"status":105,"phases":53389,"start":14903,"conditions":53390,"interventions":53391},[88],[12957],[34103,34117,15820],{"nctId":33385,"briefTitle":33386,"status":105,"phases":53393,"primaryCompletion":20258,"completion":20258,"start":8591,"enrollment":2770,"conditions":53394,"interventions":53395},[88],[20413],[33361,15886,14925],{"nctId":19806,"briefTitle":19807,"status":105,"phases":53397,"primaryCompletion":19809,"completion":19809,"start":19810,"enrollment":16208,"conditions":53398,"interventions":53399},[88],[24],[15839,17381,14925],{"nctId":19814,"briefTitle":19815,"status":105,"phases":53401,"primaryCompletion":1986,"completion":19817,"start":19818,"enrollment":19819,"conditions":53402,"interventions":53403},[88],[24],[15839,12959,17381,19822,19823,14925],{"nctId":14917,"briefTitle":14918,"status":105,"phases":53405,"primaryCompletion":13978,"completion":14113,"start":14920,"enrollment":397,"conditions":53406,"interventions":53407},[88],[24],[14923,14924,14925,13864],{"nctId":39400,"briefTitle":39401,"status":105,"phases":53409,"primaryCompletion":14103,"completion":14103,"start":20144,"enrollment":700,"conditions":53410,"interventions":53411},[88],[21],[39391,39405,20437,14925],{"nctId":19825,"briefTitle":19826,"status":105,"phases":53413,"primaryCompletion":19828,"completion":19829,"start":19830,"enrollment":2788,"conditions":53414,"interventions":53415},[88],[24],[15839,17381,14925,19833],{"nctId":19835,"briefTitle":19836,"status":105,"phases":53417,"primaryCompletion":19838,"completion":19839,"start":19840,"enrollment":2695,"conditions":53418,"interventions":53419},[88],[24],[15839,12959,17381,19822,19843,14925],{"nctId":15830,"briefTitle":15831,"status":105,"phases":53421,"primaryCompletion":15833,"completion":15834,"start":15835,"enrollment":15836,"conditions":53422,"interventions":53423},[88],[21],[15839,15784,15840,14925],{"nctId":19845,"briefTitle":19846,"status":105,"phases":53425,"primaryCompletion":19848,"completion":19848,"start":13269,"enrollment":18324,"conditions":53426,"interventions":53427},[88],[12987],[15839,17381,14925],{"nctId":33264,"briefTitle":33265,"status":150,"phases":53429,"primaryCompletion":33267,"completion":33268,"start":33269,"enrollment":15967,"conditions":53430,"interventions":53431},[88],[24],[12959,19822,14925],{"nctId":33398,"briefTitle":33399,"status":105,"phases":53433,"primaryCompletion":20410,"completion":33401,"start":7018,"enrollment":14325,"conditions":53434,"interventions":53435},[88],[21],[33361,15886,14925],{"trials":53437,"activeCount":99},[53438,53442,53446,53452,53456,53460,53464,53468,53472,53476,53480,53484,53490,53494,53498,53504,53508,53515,53521,53525,53529,53533],{"nctId":15853,"briefTitle":15854,"status":105,"phases":53439,"primaryCompletion":14104,"completion":14104,"start":15856,"enrollment":322,"conditions":53440,"interventions":53441},[89],[21],[15784,15859,14925],{"nctId":15861,"briefTitle":15862,"status":105,"phases":53443,"primaryCompletion":15864,"completion":15864,"start":15865,"enrollment":15866,"conditions":53444,"interventions":53445},[89],[15868],[15784,15870,14925],{"nctId":53447,"briefTitle":53448,"status":105,"phases":53449,"primaryCompletion":19020,"completion":19020,"start":13891,"enrollment":1977,"conditions":53450,"interventions":53451},"NCT00761735","5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)",[89],[21],[15859,14925],{"nctId":15872,"briefTitle":15873,"status":1040,"phases":53453,"primaryCompletion":1001,"completion":1001,"start":15875,"enrollment":99,"conditions":53454,"interventions":53455},[89],[12957],[15784,15878,14925,15784,15859,14925],{"nctId":21023,"briefTitle":21024,"status":105,"phases":53457,"primaryCompletion":21026,"completion":1095,"start":15835,"enrollment":19628,"conditions":53458,"interventions":53459},[89],[21],[21016,21029,15820],{"nctId":15880,"briefTitle":15881,"status":105,"phases":53461,"primaryCompletion":5179,"completion":5179,"start":14313,"enrollment":15883,"conditions":53462,"interventions":53463},[89],[21],[15784,15886,14925],{"nctId":24347,"briefTitle":24348,"status":105,"phases":53465,"primaryCompletion":24350,"completion":9164,"start":24351,"enrollment":15029,"conditions":53466,"interventions":53467},[89],[24353],[24336,14925],{"nctId":15888,"briefTitle":15889,"status":105,"phases":53469,"primaryCompletion":15891,"completion":15891,"start":15892,"enrollment":15893,"conditions":53470,"interventions":53471},[89],[21],[15896,14925,15784],{"nctId":21031,"briefTitle":21032,"status":105,"phases":53473,"primaryCompletion":21034,"completion":21034,"start":21035,"enrollment":184,"conditions":53474,"interventions":53475},[89],[21],[14923,21038,15820],{"nctId":21040,"briefTitle":21041,"status":105,"phases":53477,"primaryCompletion":21043,"completion":14112,"start":21044,"enrollment":13805,"conditions":53478,"interventions":53479},[89],[21],[21016,21038,15820],{"nctId":23246,"briefTitle":23247,"status":105,"phases":53481,"primaryCompletion":23249,"completion":23250,"start":16765,"enrollment":15960,"conditions":53482,"interventions":53483},[89],[24],[19833,15828,14925,23253],{"nctId":53485,"briefTitle":53486,"status":105,"phases":53487,"primaryCompletion":14504,"completion":14504,"start":19537,"enrollment":1169,"conditions":53488,"interventions":53489},"NCT00104052","Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)",[89],[21],[15870,15820],{"nctId":15898,"briefTitle":15899,"status":105,"phases":53491,"primaryCompletion":15901,"completion":15901,"start":15902,"enrollment":15903,"conditions":53492,"interventions":53493},[89],[21],[15784,15859,14925,15906],{"nctId":15908,"briefTitle":15909,"status":1040,"phases":53495,"primaryCompletion":15911,"completion":15911,"start":15912,"enrollment":99,"conditions":53496,"interventions":53497},[89],[12957],[15784,15915,14925],{"nctId":53499,"briefTitle":53500,"status":105,"phases":53501,"primaryCompletion":15794,"completion":15794,"start":14875,"enrollment":132,"conditions":53502,"interventions":53503},"NCT00686517","Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552\u002FMK-4031-137)",[89],[24],[15934,14925],{"nctId":15917,"briefTitle":15918,"status":150,"phases":53505,"primaryCompletion":15920,"completion":15920,"start":15921,"enrollment":15922,"conditions":53506,"interventions":53507},[88,89],[21,15924],[15784,15926,15859,14925],{"nctId":53509,"briefTitle":53510,"status":105,"phases":53511,"primaryCompletion":14408,"completion":14408,"start":20219,"enrollment":53512,"conditions":53513,"interventions":53514},"NCT00302081","Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)",[89],696,[21],[15870,15870,15870,15820,15820],{"nctId":53516,"briefTitle":53517,"status":105,"phases":53518,"primaryCompletion":5179,"completion":5179,"start":14324,"enrollment":892,"conditions":53519,"interventions":53520},"NCT00687219","Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)",[89],[21,27951],[15859,14925],{"nctId":15928,"briefTitle":15929,"status":105,"phases":53522,"primaryCompletion":4990,"completion":4990,"start":13102,"enrollment":15931,"conditions":53523,"interventions":53524},[89],[21],[15784,15934,14925,15935],{"nctId":15937,"briefTitle":15938,"status":105,"phases":53526,"primaryCompletion":14494,"completion":14494,"start":13102,"enrollment":15940,"conditions":53527,"interventions":53528},[89],[21],[15859,14925,15784],{"nctId":15954,"briefTitle":15955,"status":105,"phases":53530,"primaryCompletion":15957,"completion":15958,"start":15959,"enrollment":15960,"conditions":53531,"interventions":53532},[89],[21],[15784,15840,14925],{"nctId":15964,"briefTitle":15965,"status":105,"phases":53534,"primaryCompletion":9164,"completion":9164,"start":11368,"enrollment":15967,"conditions":53535,"interventions":53536},[89],[21],[15784,15859,14925,15970],{"trials":53538,"activeCount":99},[53539,53545,53553,53559,53566,53572],{"nctId":53540,"briefTitle":53541,"status":150,"phases":53542,"primaryCompletion":14315,"completion":14315,"start":24504,"enrollment":5983,"conditions":53543,"interventions":53544},"NCT00687544","Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)",[90],[21,15924,27],[15859,14925],{"nctId":53546,"briefTitle":53547,"status":150,"phases":53548,"primaryCompletion":14003,"completion":14003,"start":53549,"enrollment":700,"conditions":53550,"interventions":53551},"NCT01606800","Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)",[90],"2013-01-01",[21],[53552,15820],"PEG-IFN alfa-2b",{"nctId":53554,"briefTitle":53555,"status":150,"phases":53556,"primaryCompletion":14454,"completion":14454,"start":15211,"enrollment":1601,"conditions":53557,"interventions":53558},"NCT00255008","Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)",[90],[21],[15870,15820,15870,15820],{"nctId":53560,"briefTitle":53561,"status":105,"phases":53562,"primaryCompletion":15794,"completion":15794,"start":14687,"enrollment":613,"conditions":53563,"interventions":53564},"NCT00686777","Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)",[90],[21],[53565,14925],"Pegylated Interferon alfa-2b",{"nctId":53567,"briefTitle":53568,"status":150,"phases":53569,"primaryCompletion":14858,"completion":14858,"start":19537,"enrollment":110,"conditions":53570,"interventions":53571},"NCT00255034","Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron\u002FRibavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)",[90],[21],[15859,15859,14925,14925],{"nctId":53573,"briefTitle":53574,"status":105,"phases":53575,"primaryCompletion":5801,"completion":5801,"start":15211,"enrollment":787,"conditions":53576,"interventions":53577},"NCT00202839","Peg-Intron\u002FRibavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)",[90],[21],[15828,15828,14925,14925],{"trials":53579,"activeCount":99},[53580,53586,53593,53600,53609,53615,53621,53628,53635,53642,53650,53657,53664,53673,53680,53686],{"nctId":53581,"briefTitle":53582,"status":105,"phases":53583,"primaryCompletion":5982,"completion":5982,"start":13890,"enrollment":688,"conditions":53584,"interventions":53585},"NCT00705224","Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)",[],[21,12987],[14924,14925],{"nctId":53587,"briefTitle":53588,"status":105,"phases":53589,"primaryCompletion":14408,"completion":14408,"start":14595,"enrollment":53590,"conditions":53591,"interventions":53592},"NCT00727259","Evaluation of Satisfaction in Patients Receiving PegIntron Pen\u002FRebetol for Hepatitis C (Study P04067)",[],1995,[21],[15859,14925],{"nctId":53594,"briefTitle":53595,"status":105,"phases":53596,"primaryCompletion":14313,"completion":14313,"start":14504,"enrollment":53597,"conditions":53598,"interventions":53599},"NCT00724373","Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)",[],442,[21],[15859,14925],{"nctId":53601,"briefTitle":53602,"status":105,"phases":53603,"primaryCompletion":53604,"completion":53604,"start":5280,"enrollment":53605,"conditions":53606,"interventions":53607},"NCT01098097","Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011)",[],"2011-10",963,[21],[53608,14925],"Peginterferon alpha",{"nctId":53610,"briefTitle":53611,"status":105,"phases":53612,"primaryCompletion":21145,"completion":21145,"start":14887,"enrollment":14230,"conditions":53613,"interventions":53614},"NCT00725751","Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With\u002FWithout Substitution Therapy (P05255)",[],[21],[15934,14925],{"nctId":53616,"briefTitle":53617,"status":150,"phases":53618,"primaryCompletion":5801,"completion":5801,"start":14595,"enrollment":11225,"conditions":53619,"interventions":53620},"NCT00723879","Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)",[],[21,15924],[15859,14925],{"nctId":53622,"briefTitle":53623,"status":105,"phases":53624,"primaryCompletion":23091,"completion":23091,"start":15063,"enrollment":53625,"conditions":53626,"interventions":53627},"NCT00724893","Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)",[],2430,[21,24],[1099,14925],{"nctId":53629,"briefTitle":53630,"status":105,"phases":53631,"primaryCompletion":5801,"completion":5801,"start":6464,"enrollment":53632,"conditions":53633,"interventions":53634},"NCT00705666","Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)",[],789,[21,15924],[15859,14925],{"nctId":53636,"briefTitle":53637,"status":105,"phases":53638,"primaryCompletion":53604,"completion":53604,"start":5801,"enrollment":53639,"conditions":53640,"interventions":53641},"NCT00724451","Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)",[],1128,[24,21],[15859,14925,15886],{"nctId":53643,"briefTitle":53644,"status":105,"phases":53645,"primaryCompletion":20279,"completion":20279,"start":9610,"enrollment":15321,"conditions":53646,"interventions":53649},"NCT00863109","Quality of Life During Treatment of Chronic Hepatitis C (P05278\u002FMK-4031-336)",[],[21,53647,53648],"Genotype 1","HCV-1",[15859,14925],{"nctId":53651,"briefTitle":53652,"status":105,"phases":53653,"primaryCompletion":15794,"completion":15794,"start":15156,"enrollment":53654,"conditions":53655,"interventions":53656},"NCT00723632","Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)",[],901,[21,24],[15870,15820],{"nctId":53658,"briefTitle":53659,"status":105,"phases":53660,"primaryCompletion":14353,"completion":14353,"start":14593,"enrollment":53661,"conditions":53662,"interventions":53663},"NCT00724295","Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)",[],1077,[21,24],[15870,15820],{"nctId":53665,"briefTitle":53666,"status":150,"phases":53667,"primaryCompletion":53668,"completion":53668,"start":53669,"enrollment":202,"conditions":53670,"interventions":53671},"NCT01340573","Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)",[],"2007-10-29","2007-03-23",[12957],[53672,14925],"PegIntron Pen",{"nctId":53674,"briefTitle":53675,"status":150,"phases":53676,"primaryCompletion":5179,"completion":5179,"start":5801,"enrollment":53677,"conditions":53678,"interventions":53679},"NCT00856024","ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b\u002FRibavirin in Brazil (P05632)",[],902,[21],[15859,14925],{"nctId":53681,"briefTitle":53682,"status":150,"phases":53683,"primaryCompletion":5800,"completion":5800,"start":13870,"enrollment":5802,"conditions":53684,"interventions":53685},"NCT00725842","Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)",[],[24,21],[42456,14925],{"nctId":53687,"briefTitle":53688,"status":105,"phases":53689,"primaryCompletion":9610,"completion":9610,"start":15211,"enrollment":13060,"conditions":53690,"interventions":53691},"NCT00704522","Adherence in Patients Receiving PegIntron Pen\u002FRebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)",[],[21,15924],[15859,14925],{"intervention":13145,"totalTrials":1419,"cells":53693},{"EARLY_PHASE1":53694,"PHASE1":53696,"PHASE2":53702,"PHASE3":53712,"PHASE4":53845,"NA":53862},{"trials":53695,"activeCount":99},[],{"trials":53697,"activeCount":99},[53698],{"nctId":14659,"briefTitle":14660,"status":105,"phases":53699,"primaryCompletion":14662,"completion":14663,"start":14664,"enrollment":95,"conditions":53700,"interventions":53701},[87],[15],[14126,13864],{"trials":53703,"activeCount":99},[53704,53708],{"nctId":13845,"briefTitle":13846,"status":105,"phases":53705,"primaryCompletion":13848,"completion":13849,"start":13850,"enrollment":13851,"conditions":53706,"interventions":53707},[88],[13853],[13145,4084,13855],{"nctId":13867,"briefTitle":13868,"status":105,"phases":53709,"primaryCompletion":13870,"completion":13870,"start":5281,"enrollment":110,"conditions":53710,"interventions":53711},[88],[33],[13873,13145,4084],{"trials":53713,"activeCount":99},[53714,53718,53722,53726,53730,53734,53738,53742,53746,53750,53754,53758,53762,53766,53770,53774,53778,53782,53786,53790,53794,53798,53802,53806,53810,53814,53818,53822,53826,53830,53834,53838],{"nctId":13953,"briefTitle":13954,"status":105,"phases":53715,"primaryCompletion":13956,"completion":13956,"start":13957,"enrollment":13958,"conditions":53716,"interventions":53717},[89],[15],[13145,13864,13914,4084,13961],{"nctId":16121,"briefTitle":16122,"status":105,"phases":53719,"primaryCompletion":16124,"completion":16124,"start":16125,"enrollment":16126,"conditions":53720,"interventions":53721},[89],[15],[13913,13145],{"nctId":16006,"briefTitle":16007,"status":105,"phases":53723,"primaryCompletion":16009,"completion":16009,"start":16010,"enrollment":16011,"conditions":53724,"interventions":53725},[89],[15],[16014,13145,13146],{"nctId":26242,"briefTitle":26243,"status":105,"phases":53727,"primaryCompletion":26245,"completion":26245,"start":26246,"enrollment":26247,"conditions":53728,"interventions":53729},[89],[15],[13145,26231],{"nctId":13989,"briefTitle":13990,"status":105,"phases":53731,"primaryCompletion":13992,"completion":13993,"start":13994,"enrollment":13995,"conditions":53732,"interventions":53733},[89],[15],[13145,13864,13998,4084],{"nctId":14010,"briefTitle":14011,"status":105,"phases":53735,"primaryCompletion":14013,"completion":14013,"start":14014,"enrollment":1685,"conditions":53736,"interventions":53737},[89],[15],[13145,14017,4084,14018],{"nctId":14051,"briefTitle":14052,"status":105,"phases":53739,"primaryCompletion":14054,"completion":14054,"start":14055,"enrollment":14056,"conditions":53740,"interventions":53741},[89],[15],[13883,14049,4084,13145,13146,14059],{"nctId":14061,"briefTitle":14062,"status":105,"phases":53743,"primaryCompletion":14064,"completion":14064,"start":14065,"enrollment":2182,"conditions":53744,"interventions":53745},[89],[15],[13145,14018,4084],{"nctId":27925,"briefTitle":27926,"status":105,"phases":53747,"primaryCompletion":14976,"completion":15155,"start":14229,"enrollment":27928,"conditions":53748,"interventions":53749},[89],[33],[13145,13145,27914],{"nctId":28436,"briefTitle":28437,"status":105,"phases":53751,"primaryCompletion":8621,"completion":14409,"start":14679,"enrollment":28439,"conditions":53752,"interventions":53753},[89],[33],[14126,28425],{"nctId":14089,"briefTitle":14090,"status":105,"phases":53755,"primaryCompletion":14092,"completion":14093,"start":14094,"enrollment":14095,"conditions":53756,"interventions":53757},[89],[14097],[13145,4084,13914],{"nctId":14109,"briefTitle":14110,"status":105,"phases":53759,"primaryCompletion":14112,"completion":14112,"start":14113,"enrollment":14114,"conditions":53760,"interventions":53761},[89],[15],[13145,4084,4084],{"nctId":15317,"briefTitle":15318,"status":105,"phases":53763,"primaryCompletion":15320,"completion":15320,"start":5147,"enrollment":15321,"conditions":53764,"interventions":53765},[89],[15023],[13864,13145,15324],{"nctId":21244,"briefTitle":21245,"status":105,"phases":53767,"primaryCompletion":21247,"completion":21247,"start":21248,"enrollment":11541,"conditions":53768,"interventions":53769},[89],[33,5942],[13145,13961],{"nctId":14118,"briefTitle":14119,"status":105,"phases":53771,"primaryCompletion":14121,"completion":14122,"start":14123,"enrollment":2555,"conditions":53772,"interventions":53773},[89],[15],[14126,13864,14127,14040,14128],{"nctId":23455,"briefTitle":23456,"status":105,"phases":53775,"primaryCompletion":1660,"completion":1660,"start":23458,"enrollment":22,"conditions":53776,"interventions":53777},[89],[15],[23444,13145],{"nctId":14130,"briefTitle":14131,"status":150,"phases":53779,"primaryCompletion":14133,"completion":14133,"start":14134,"enrollment":14135,"conditions":53780,"interventions":53781},[89],[15],[14138,13145,13122,4084,13146],{"nctId":23462,"briefTitle":23463,"status":105,"phases":53783,"primaryCompletion":23465,"completion":23465,"start":23466,"enrollment":5196,"conditions":53784,"interventions":53785},[89],[15],[23444,13145],{"nctId":16173,"briefTitle":16174,"status":105,"phases":53787,"primaryCompletion":2095,"completion":2095,"start":16176,"enrollment":16177,"conditions":53788,"interventions":53789},[89],[14156],[13913,13145,16180,16181],{"nctId":14140,"briefTitle":14141,"status":105,"phases":53791,"primaryCompletion":13925,"completion":13925,"start":14143,"enrollment":14144,"conditions":53792,"interventions":53793},[89],[15],[13883,14147,14148,4084,13145],{"nctId":14150,"briefTitle":14151,"status":105,"phases":53795,"primaryCompletion":14153,"completion":14153,"start":14154,"enrollment":8416,"conditions":53796,"interventions":53797},[89],[13950,14156],[13145,4084,14158,14159],{"nctId":14161,"briefTitle":14162,"status":105,"phases":53799,"primaryCompletion":14164,"completion":14164,"start":14165,"enrollment":14166,"conditions":53800,"interventions":53801},[89],[33],[14126,14169,14170,14040],{"nctId":14189,"briefTitle":14190,"status":105,"phases":53803,"primaryCompletion":14192,"completion":14193,"start":14194,"enrollment":14195,"conditions":53804,"interventions":53805},[89],[15],[13145,14198,13146,4084],{"nctId":14200,"briefTitle":14201,"status":105,"phases":53807,"primaryCompletion":14203,"completion":14204,"start":14205,"enrollment":14206,"conditions":53808,"interventions":53809},[89],[15],[13145,14059,4084],{"nctId":23470,"briefTitle":23471,"status":105,"phases":53811,"primaryCompletion":23473,"completion":23473,"start":23474,"enrollment":23475,"conditions":53812,"interventions":53813},[89],[15],[13145,23444],{"nctId":17537,"briefTitle":17538,"status":105,"phases":53815,"primaryCompletion":14730,"completion":14730,"start":13890,"enrollment":17540,"conditions":53816,"interventions":53817},[89],[17542,15023],[14126,17544,17545],{"nctId":21256,"briefTitle":21257,"status":105,"phases":53819,"primaryCompletion":14531,"completion":14531,"start":14595,"enrollment":21259,"conditions":53820,"interventions":53821},[89],[33,16106],[14126,14128],{"nctId":15568,"briefTitle":15569,"status":105,"phases":53823,"primaryCompletion":4419,"completion":4419,"start":14705,"enrollment":15571,"conditions":53824,"interventions":53825},[89],[15],[13145,15574,13864,15575],{"nctId":14236,"briefTitle":14237,"status":105,"phases":53827,"primaryCompletion":14239,"completion":9574,"start":2571,"enrollment":14240,"conditions":53828,"interventions":53829},[89],[15],[13145,4084,14079,13971],{"nctId":21263,"briefTitle":21264,"status":105,"phases":53831,"primaryCompletion":21266,"completion":21266,"start":21267,"enrollment":21268,"conditions":53832,"interventions":53833},[89],[33,21270],[13145,13961],{"nctId":13137,"briefTitle":13138,"status":150,"phases":53835,"primaryCompletion":13140,"completion":13140,"start":13141,"enrollment":13142,"conditions":53836,"interventions":53837},[89],[15],[13145,8011,4084,13146,13146],{"nctId":53839,"briefTitle":53840,"status":105,"phases":53841,"primaryCompletion":23584,"completion":23584,"start":35314,"enrollment":53842,"conditions":53843,"interventions":53844},"NCT00790205","Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)",[89],14671,[15],[13145],{"trials":53846,"activeCount":99},[53847,53854,53858],{"nctId":53848,"briefTitle":53849,"status":150,"phases":53850,"primaryCompletion":21936,"completion":21936,"start":53851,"enrollment":335,"conditions":53852,"interventions":53853},"NCT00832624","The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)",[90],"2008-11-26",[15666],[14126],{"nctId":18579,"briefTitle":18580,"status":105,"phases":53855,"primaryCompletion":18582,"completion":18582,"start":18583,"enrollment":18584,"conditions":53856,"interventions":53857},[90],[15],[13145,18566],{"nctId":14281,"briefTitle":14282,"status":105,"phases":53859,"primaryCompletion":14284,"completion":14284,"start":14285,"enrollment":14286,"conditions":53860,"interventions":53861},[90],[15],[4084,13145,14289,14290,13146,14198],{"trials":53863,"activeCount":99},[53864,53871,53875],{"nctId":53865,"briefTitle":53866,"status":105,"phases":53867,"primaryCompletion":33547,"completion":33547,"start":6309,"enrollment":53868,"conditions":53869,"interventions":53870},"NCT01062048","Januvia Re-examination Study (MK-0431-181)",[],3483,[15],[13145,14018,14059],{"nctId":14294,"briefTitle":14295,"status":105,"phases":53872,"primaryCompletion":14297,"completion":14297,"start":14298,"enrollment":14299,"conditions":53873,"interventions":53874},[],[15],[4084,13145,14018,14302],{"nctId":53876,"briefTitle":53877,"status":105,"phases":53878,"primaryCompletion":14494,"completion":14494,"start":14313,"enrollment":53879,"conditions":53880,"interventions":53881},"NCT01354990","A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)",[],2974,[33],[13145],{"intervention":8594,"totalTrials":661,"cells":53883},{"EARLY_PHASE1":53884,"PHASE1":53886,"PHASE2":53888,"PHASE3":53905,"PHASE4":53971,"NA":54007},{"trials":53885,"activeCount":99},[],{"trials":53887,"activeCount":99},[],{"trials":53889,"activeCount":99},[53890,53897],{"nctId":53891,"briefTitle":53892,"status":105,"phases":53893,"primaryCompletion":53894,"completion":53894,"start":4328,"enrollment":4991,"conditions":53895,"interventions":53896},"NCT01313520","A Study to Evaluate the Effectiveness of Infliximab and Changes in Hand and Wrist Magnetic Resonance Imaging (MRI) in Participants With Active Rheumatoid Arthritis (RA) (P08136)",[88],"2012-03-01",[7197],[8594],{"nctId":53898,"briefTitle":53899,"status":105,"phases":53900,"primaryCompletion":53901,"completion":53901,"start":53902,"enrollment":4059,"conditions":53903,"interventions":53904},"NCT00687362","A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)",[88],"2008-11-11","2006-05-30",[12754],[8594],{"trials":53906,"activeCount":99},[53907,53913,53919,53923,53927,53931,53935,53942,53946,53950,53957,53961,53967],{"nctId":53908,"briefTitle":53909,"status":105,"phases":53910,"primaryCompletion":14352,"completion":14352,"start":14705,"enrollment":36935,"conditions":53911,"interventions":53912},"NCT00687401","A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)",[89],[12754],[8594],{"nctId":53914,"briefTitle":53915,"status":105,"phases":53916,"primaryCompletion":14313,"completion":9610,"start":14454,"enrollment":3141,"conditions":53917,"interventions":53918},"NCT00686686","Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)",[89],[12754],[8594],{"nctId":29350,"briefTitle":29351,"status":150,"phases":53920,"primaryCompletion":16802,"completion":16802,"start":14730,"enrollment":2754,"conditions":53921,"interventions":53922},[89],[12754],[8594,29339],{"nctId":8587,"briefTitle":8588,"status":150,"phases":53924,"primaryCompletion":8590,"completion":8590,"start":8591,"enrollment":1624,"conditions":53925,"interventions":53926},[89],[7169],[8594,2413,8595,8596],{"nctId":29873,"briefTitle":29874,"status":150,"phases":53928,"primaryCompletion":14408,"completion":14408,"start":14324,"enrollment":734,"conditions":53929,"interventions":53930},[89],[7020],[12756,29862],{"nctId":12748,"briefTitle":12749,"status":105,"phases":53932,"primaryCompletion":12751,"completion":12751,"start":12752,"enrollment":1959,"conditions":53933,"interventions":53934},[89],[12754],[12756,12757],{"nctId":53936,"briefTitle":53937,"status":105,"phases":53938,"primaryCompletion":53939,"completion":53939,"start":34628,"enrollment":1190,"conditions":53940,"interventions":53941},"NCT00202865","Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352)",[89],"2007-05-01",[12769],[12756],{"nctId":30651,"briefTitle":30652,"status":105,"phases":53943,"primaryCompletion":30654,"completion":30654,"start":30655,"enrollment":5196,"conditions":53944,"interventions":53945},[89],[7197],[30640,8594,30640],{"nctId":8598,"briefTitle":8599,"status":150,"phases":53947,"primaryCompletion":8601,"completion":8601,"start":8602,"enrollment":3308,"conditions":53948,"interventions":53949},[89],[8604],[8594,8606,2413,8606],{"nctId":53951,"briefTitle":53952,"status":105,"phases":53953,"primaryCompletion":4418,"completion":4418,"start":15063,"enrollment":53954,"conditions":53955,"interventions":53956},"NCT00254982","Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)",[89],593,[12754],[8594],{"nctId":25112,"briefTitle":25113,"status":150,"phases":53958,"primaryCompletion":6308,"completion":6308,"start":13891,"enrollment":19725,"conditions":53959,"interventions":53960},[89],[9066],[8594,8596],{"nctId":53962,"briefTitle":53963,"status":150,"phases":53964,"primaryCompletion":13870,"completion":13870,"start":8621,"enrollment":11128,"conditions":53965,"interventions":53966},"NCT00358670","Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563)",[89],[12754],[12756,12756],{"nctId":23534,"briefTitle":23535,"status":105,"phases":53968,"primaryCompletion":16802,"completion":12985,"start":14445,"enrollment":1827,"conditions":53969,"interventions":53970},[89],[16739,23538],[8594,20747],{"trials":53972,"activeCount":99},[53973,53980,53987,53993,54001],{"nctId":53974,"briefTitle":53975,"status":150,"phases":53976,"primaryCompletion":14823,"completion":14823,"start":14687,"enrollment":357,"conditions":53977,"interventions":53979},"NCT00686894","Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab (Study P04440)",[90],[12769,53978],"SpA",[8594],{"nctId":53981,"briefTitle":53982,"status":105,"phases":53983,"primaryCompletion":35597,"completion":35597,"start":53984,"enrollment":184,"conditions":53985,"interventions":53986},"NCT00779012","A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED)",[90],"2004-10-01",[12769],[8594],{"nctId":53988,"briefTitle":53989,"status":1040,"phases":53990,"primaryCompletion":15794,"completion":15794,"start":12813,"enrollment":99,"conditions":53991,"interventions":53992},"NCT01148901","Effectiveness and Safety of Early Treatment With Infliximab for Hip Arthritis Associated With Ankylosing Spondylitis (AS) (P06451)",[90],[16739],[8594],{"nctId":53994,"briefTitle":53995,"status":105,"phases":53996,"primaryCompletion":53997,"completion":53997,"start":53998,"enrollment":569,"conditions":53999,"interventions":54000},"NCT00794898","Efficacy of Remicade in the Treatment of Active Rheumatoid Arthritis Despite Methotrexate (Study P03027)",[90],"2004-04-01","2003-07-01",[7197],[8594],{"nctId":54002,"briefTitle":54003,"status":105,"phases":54004,"primaryCompletion":4330,"completion":4330,"start":23413,"enrollment":1054,"conditions":54005,"interventions":54006},"NCT00686595","A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)",[90],[12754],[8594],{"trials":54008,"activeCount":99},[54009,54015,54022,54029,54035,54041,54047,54053,54060,54066,54073,54079,54088,54094,54102,54109,54116],{"nctId":54010,"briefTitle":54011,"status":150,"phases":54012,"primaryCompletion":14887,"completion":14887,"start":14593,"enrollment":184,"conditions":54013,"interventions":54014},"NCT00705471","Impact of Infliximab in Fistulizing Crohn's Disease on Health Care Resources (Study P04204)(TERMINATED)",[],[7227],[8594],{"nctId":54016,"briefTitle":54017,"status":105,"phases":54018,"primaryCompletion":20258,"completion":20258,"start":14678,"enrollment":54019,"conditions":54020,"interventions":54021},"NCT00724958","Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)",[],348,[8604],[8594],{"nctId":54023,"briefTitle":54024,"status":105,"phases":54025,"primaryCompletion":15794,"completion":15794,"start":20226,"enrollment":54026,"conditions":54027,"interventions":54028},"NCT00818168","Remicade Safety Line (Ankylosing Spondylitis)(Study P03275)(COMPLETED)",[],320,[12769],[8594],{"nctId":54030,"briefTitle":54031,"status":105,"phases":54032,"primaryCompletion":6309,"completion":6309,"start":14484,"enrollment":444,"conditions":54033,"interventions":54034},"NCT00724243","Safety and Effectiveness of Infliximab in Slovakia When Used for Rheumatoid Arthritis (Study P04741)(COMPLETED)",[],[7020],[8594],{"nctId":54036,"briefTitle":54037,"status":105,"phases":54038,"primaryCompletion":11394,"completion":11394,"start":192,"enrollment":2901,"conditions":54039,"interventions":54040},"NCT01349920","Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)",[],[7227],[8594],{"nctId":54042,"briefTitle":54043,"status":105,"phases":54044,"primaryCompletion":15794,"completion":15794,"start":22635,"enrollment":24841,"conditions":54045,"interventions":54046},"NCT00748826","Remicade Safety Line (Study P03236)(COMPLETED)",[],[7197],[8594],{"nctId":54048,"briefTitle":54049,"status":105,"phases":54050,"primaryCompletion":14858,"completion":14858,"start":14687,"enrollment":14977,"conditions":54051,"interventions":54052},"NCT00741104","A Feasibility Study Exploring the Effect of Remicade on the Disease Activity in RA Patients (Study P05417)",[],[7020],[8594],{"nctId":54054,"briefTitle":54055,"status":105,"phases":54056,"primaryCompletion":14315,"completion":14315,"start":24504,"enrollment":54057,"conditions":54058,"interventions":54059},"NCT00705289","A Study to Observe Characteristics of Rheumatoid Arthritis in Patients Using Infliximab (Study P04250)",[],728,[7020],[8594],{"nctId":54061,"briefTitle":54062,"status":105,"phases":54063,"primaryCompletion":53604,"completion":23091,"start":6309,"enrollment":13995,"conditions":54064,"interventions":54065},"NCT00779675","Assessment of Long-Term Infliximab for Psoriasis (P05319)",[],[12754],[8594],{"nctId":54067,"briefTitle":54068,"status":105,"phases":54069,"primaryCompletion":16591,"completion":16591,"start":6464,"enrollment":54070,"conditions":54071,"interventions":54072},"NCT00727298","Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)",[],4485,[7197,12769,12744,12754,8604],[8594],{"nctId":54074,"briefTitle":54075,"status":105,"phases":54076,"primaryCompletion":13222,"completion":13222,"start":14887,"enrollment":15321,"conditions":54077,"interventions":54078},"NCT00749398","Photographic Library of Moderate to Severe Psoriasis Subjects Treated With Infliximab (Study P05047)",[],[12754],[8594],{"nctId":54080,"briefTitle":54081,"status":105,"phases":54082,"primaryCompletion":54083,"completion":54083,"start":35597,"enrollment":54084,"conditions":54085,"interventions":54086},"NCT00705484","European Safety Registry in Ulcerative Colitis (P04808)",[],"2016-10-20",2239,[9066],[12756,54087],"Standard Therapy",{"nctId":54089,"briefTitle":54090,"status":105,"phases":54091,"primaryCompletion":12813,"completion":12813,"start":8619,"enrollment":3506,"conditions":54092,"interventions":54093},"NCT00725452","Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900)",[],[12754],[8594],{"nctId":54095,"briefTitle":54096,"status":1040,"phases":54097,"primaryCompletion":14713,"completion":14713,"start":14315,"enrollment":99,"conditions":54098,"interventions":54099},"NCT00724672","A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)",[],[7020],[54100,12756,54101],"etanercept","adalimumab",{"nctId":54103,"briefTitle":54104,"status":105,"phases":54105,"primaryCompletion":12813,"completion":12813,"start":14229,"enrollment":54106,"conditions":54107,"interventions":54108},"NCT00725543","Investigation of 9 Consecutive Remicade Infusions in Ankylosing Spondylitis in Austria (Study P04044)(COMPLETED)",[],358,[12769],[8594],{"nctId":54110,"briefTitle":54111,"status":105,"phases":54112,"primaryCompletion":20258,"completion":20258,"start":15001,"enrollment":54113,"conditions":54114,"interventions":54115},"NCT00725621","Real Life Dosing of Remicade for Rheumatoid Arthritis in Austria Monitored Over 9 Infusions (Study P03756)(COMPLETED)",[],516,[7020],[8594],{"nctId":54117,"briefTitle":54118,"status":105,"phases":54119,"primaryCompletion":15794,"completion":15794,"start":6308,"enrollment":15128,"conditions":54120,"interventions":54121},"NCT00988832","An Audit of Patients With Crohn's Disease Treated With Infliximab (P06066)",[],[8604],[8594],{"intervention":17013,"totalTrials":5616,"cells":54123},{"EARLY_PHASE1":54124,"PHASE1":54126,"PHASE2":54142,"PHASE3":54189,"PHASE4":54301,"NA":54314},{"trials":54125,"activeCount":99},[],{"trials":54127,"activeCount":99},[54128,54136],{"nctId":54129,"briefTitle":54130,"status":105,"phases":54131,"primaryCompletion":18367,"completion":18367,"start":54132,"enrollment":15119,"conditions":54133,"interventions":54135},"NCT02028065","A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)",[87],"2014-01-03",[16653,54134],"Anaphylaxis",[17013],{"nctId":54137,"briefTitle":54138,"status":105,"phases":54139,"primaryCompletion":13040,"completion":13040,"start":36143,"enrollment":444,"conditions":54140,"interventions":54141},"NCT02011490","Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)",[87],[13409,4074],[17025],{"trials":54143,"activeCount":99},[54144,54152,54156,54165,54173,54177,54185],{"nctId":54145,"briefTitle":54146,"status":105,"phases":54147,"primaryCompletion":17008,"completion":54148,"start":54149,"enrollment":920,"conditions":54150,"interventions":54151},"NCT00591786","A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Japanese Participants. Part A (P05957)",[88],"2006-10-19","2005-12-05",[17011],[17013],{"nctId":34917,"briefTitle":34918,"status":105,"phases":54153,"primaryCompletion":34920,"completion":34920,"start":34921,"enrollment":34922,"conditions":54154,"interventions":54155},[88],[17011],[17013,34908],{"nctId":54157,"briefTitle":54158,"status":105,"phases":54159,"primaryCompletion":54160,"completion":54161,"start":54162,"enrollment":920,"conditions":54163,"interventions":54164},"NCT00591409","A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part A: Japanese Participants (P05956)",[88],"2006-09-22","2006-12-18","2006-01-03",[17011],[17025],{"nctId":54166,"briefTitle":54167,"status":105,"phases":54168,"primaryCompletion":54169,"completion":54169,"start":54170,"enrollment":892,"conditions":54171,"interventions":54172},"NCT00552929","A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)",[88],"2006-09-15","2005-10-04",[17011],[17013],{"nctId":17005,"briefTitle":17006,"status":105,"phases":54174,"primaryCompletion":17008,"completion":17008,"start":17009,"enrollment":920,"conditions":54175,"interventions":54176},[88],[17011],[17013,16687,16688],{"nctId":54178,"briefTitle":54179,"status":105,"phases":54180,"primaryCompletion":54181,"completion":54181,"start":54182,"enrollment":700,"conditions":54183,"interventions":54184},"NCT00379613","Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg\u002Fkg Esmeron® (19.4.205)(P05942)",[88],"2004-07-14","2003-11-07",[17011],[17025],{"nctId":34926,"briefTitle":34927,"status":105,"phases":54186,"primaryCompletion":34929,"completion":34929,"start":17179,"enrollment":4358,"conditions":54187,"interventions":54188},[88],[16696],[17013,34908],{"trials":54190,"activeCount":99},[54191,54198,54205,54209,54217,54221,54227,54233,54237,54241,54245,54249,54257,54263,54269,54273,54277,54281,54285,54289,54293,54297],{"nctId":54192,"briefTitle":54193,"status":105,"phases":54194,"primaryCompletion":54195,"completion":54195,"start":30655,"enrollment":154,"conditions":54196,"interventions":54197},"NCT00482599","Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function (19.4.304)(P05948)(COMPLETED)",[89],"2006-04-13",[17011],[17013],{"nctId":54199,"briefTitle":54200,"status":105,"phases":54201,"primaryCompletion":20841,"completion":20841,"start":54202,"enrollment":32902,"conditions":54203,"interventions":54204},"NCT00298831","Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)",[89],"2005-10-27",[17011],[17013,16687],{"nctId":28240,"briefTitle":28241,"status":105,"phases":54206,"primaryCompletion":28243,"completion":28243,"start":28244,"enrollment":28245,"conditions":54207,"interventions":54208},[89],[17011],[17013,28229],{"nctId":54210,"briefTitle":54211,"status":105,"phases":54212,"primaryCompletion":54213,"completion":54213,"start":54214,"enrollment":50160,"conditions":54215,"interventions":54216},"NCT00702715","Comparison of 4.0 mg\u002Fkg Sugammadex at 1-2 Post Tetanic Counts (PTC) in Renal or Control Patients (19.4.328)(P05769)",[89],"2010-03-15","2008-09-24",[16668],[17025],{"nctId":22707,"briefTitle":22708,"status":105,"phases":54218,"primaryCompletion":22710,"completion":22710,"start":20637,"enrollment":13439,"conditions":54219,"interventions":54220},[89],[17011],[17013,16687,22087,22088],{"nctId":54222,"briefTitle":54223,"status":105,"phases":54224,"primaryCompletion":5982,"completion":5982,"start":14623,"enrollment":164,"conditions":54225,"interventions":54226},"NCT00826176","Efficacy and Safety of 4.0 mg\u002Fkg Sugammadex at 1-2 PTC in Chinese and European Subjects (Study 19.4.335)(P05775AM1)(COMPLETED)",[89],[17011,16696],[17013],{"nctId":54228,"briefTitle":54229,"status":105,"phases":54230,"primaryCompletion":14687,"completion":5281,"start":14887,"enrollment":21259,"conditions":54231,"interventions":54232},"NCT00535496","Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)",[89],[16696],[17025],{"nctId":20810,"briefTitle":20811,"status":105,"phases":54234,"primaryCompletion":13222,"completion":13222,"start":14623,"enrollment":5700,"conditions":54235,"interventions":54236},[89],[17011,16696],[17013,17026],{"nctId":20816,"briefTitle":20817,"status":105,"phases":54238,"primaryCompletion":20819,"completion":20820,"start":20821,"enrollment":407,"conditions":54239,"interventions":54240},[89],[17011],[16687,17013,20824,20825],{"nctId":20827,"briefTitle":20828,"status":105,"phases":54242,"primaryCompletion":20830,"completion":20831,"start":20832,"enrollment":4121,"conditions":54243,"interventions":54244},[89],[20834],[17013,20824,20836],{"nctId":20838,"briefTitle":20839,"status":105,"phases":54246,"primaryCompletion":20841,"completion":20842,"start":20843,"enrollment":11407,"conditions":54247,"interventions":54248},[89],[17011],[17013,17026],{"nctId":54250,"briefTitle":54251,"status":105,"phases":54252,"primaryCompletion":54253,"completion":54253,"start":54254,"enrollment":2023,"conditions":54255,"interventions":54256},"NCT00420680","Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients (19.4.309)(P05934)",[89],"2006-08-01","2005-11-07",[16668],[17013,17013],{"nctId":54258,"briefTitle":54259,"status":105,"phases":54260,"primaryCompletion":15266,"completion":17300,"start":54202,"enrollment":38922,"conditions":54261,"interventions":54262},"NCT00475215","Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017)",[89],[17011],[17013,16687],{"nctId":54264,"briefTitle":54265,"status":105,"phases":54266,"primaryCompletion":14713,"completion":14713,"start":14408,"enrollment":4555,"conditions":54267,"interventions":54268},"NCT00656799","Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)",[89],[16696],[17025,16687],{"nctId":20847,"briefTitle":20848,"status":105,"phases":54270,"primaryCompletion":20850,"completion":20850,"start":20851,"enrollment":1023,"conditions":54271,"interventions":54272},[89],[16696],[17025,17026],{"nctId":31863,"briefTitle":31864,"status":105,"phases":54274,"primaryCompletion":14352,"completion":5280,"start":6309,"enrollment":407,"conditions":54275,"interventions":54276},[89],[16668,16696],[17013,31852],{"nctId":20855,"briefTitle":20856,"status":105,"phases":54278,"primaryCompletion":20858,"completion":20858,"start":20859,"enrollment":16728,"conditions":54279,"interventions":54280},[89],[17011],[17013,20824],{"nctId":17017,"briefTitle":17018,"status":105,"phases":54282,"primaryCompletion":17020,"completion":17021,"start":17022,"enrollment":537,"conditions":54283,"interventions":54284},[89],[17011],[17025,17026,17027,17028,17029],{"nctId":17289,"briefTitle":17290,"status":105,"phases":54286,"primaryCompletion":13101,"completion":13101,"start":14823,"enrollment":7797,"conditions":54287,"interventions":54288},[89],[16696],[17028,17025,17294],{"nctId":20867,"briefTitle":20868,"status":105,"phases":54290,"primaryCompletion":14315,"completion":14315,"start":13890,"enrollment":920,"conditions":54291,"interventions":54292},[89],[16668],[17013,20824,16687],{"nctId":17296,"briefTitle":17297,"status":105,"phases":54294,"primaryCompletion":17299,"completion":17300,"start":17301,"enrollment":11225,"conditions":54295,"interventions":54296},[89],[17011],[17013,17278,16687],{"nctId":32680,"briefTitle":32681,"status":105,"phases":54298,"primaryCompletion":32683,"completion":32683,"start":32684,"enrollment":32685,"conditions":54299,"interventions":54300},[89],[16696,32687,32688,32689,32690],[17013,32669],{"trials":54302,"activeCount":99},[54303,54310],{"nctId":54304,"briefTitle":54305,"status":105,"phases":54306,"primaryCompletion":13815,"completion":13815,"start":192,"enrollment":4535,"conditions":54307,"interventions":54309},"NCT01728584","A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982)",[90],[54308],"Gallbladder Disease",[16687,17013],{"nctId":17307,"briefTitle":17308,"status":1040,"phases":54311,"primaryCompletion":17310,"completion":17310,"start":17311,"enrollment":99,"conditions":54312,"interventions":54313},[90],[16696],[16687,17013,17314,17315,17278],{"trials":54315,"activeCount":99},[54316],{"nctId":54317,"briefTitle":54318,"status":105,"phases":54319,"primaryCompletion":13223,"completion":13223,"start":13222,"enrollment":54320,"conditions":54321,"interventions":54323},"NCT01213264","Observational Study to Evaluate the Current Neuromuscular Monitoring Practice Used After Different Types of Surgery, for Which Neuromuscular Blocking Agents Were Used, With or Without Blocking Reversal (P06556)",[],659,[54322],"Neuromuscular Monitoring After Administration of Neuromuscular Blocking Agents in Different Types of Surgery",[17013,54324],"Other NMB-Reversal Agents Used in Routine Anesthesiology Practice",{"intervention":15859,"totalTrials":626,"cells":54326},{"EARLY_PHASE1":54327,"PHASE1":54329,"PHASE2":54331,"PHASE3":54337,"PHASE4":54415,"NA":54429},{"trials":54328,"activeCount":99},[],{"trials":54330,"activeCount":99},[],{"trials":54332,"activeCount":99},[54333],{"nctId":53353,"briefTitle":53354,"status":150,"phases":54334,"primaryCompletion":53356,"completion":53356,"start":53357,"enrollment":174,"conditions":54335,"interventions":54336},[88],[21],[15839,15859,14925],{"trials":54338,"activeCount":99},[54339,54343,54347,54351,54355,54362,54366,54370,54377,54381,54385,54389,54397,54401,54407,54411],{"nctId":15853,"briefTitle":15854,"status":105,"phases":54340,"primaryCompletion":14104,"completion":14104,"start":15856,"enrollment":322,"conditions":54341,"interventions":54342},[89],[21],[15784,15859,14925],{"nctId":15861,"briefTitle":15862,"status":105,"phases":54344,"primaryCompletion":15864,"completion":15864,"start":15865,"enrollment":15866,"conditions":54345,"interventions":54346},[89],[15868],[15784,15870,14925],{"nctId":53447,"briefTitle":53448,"status":105,"phases":54348,"primaryCompletion":19020,"completion":19020,"start":13891,"enrollment":1977,"conditions":54349,"interventions":54350},[89],[21],[15859,14925],{"nctId":15872,"briefTitle":15873,"status":1040,"phases":54352,"primaryCompletion":1001,"completion":1001,"start":15875,"enrollment":99,"conditions":54353,"interventions":54354},[89],[12957],[15784,15878,14925,15784,15859,14925],{"nctId":54356,"briefTitle":54357,"status":105,"phases":54358,"primaryCompletion":14730,"completion":14730,"start":38559,"enrollment":1387,"conditions":54359,"interventions":54361},"NCT00049842","Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)",[89],[12957,54360],"Liver Fibrosis",[15870],{"nctId":29075,"briefTitle":29076,"status":150,"phases":54363,"primaryCompletion":14566,"completion":14566,"start":15038,"enrollment":23677,"conditions":54364,"interventions":54365},[89],[21],[15859,29064],{"nctId":53485,"briefTitle":53486,"status":105,"phases":54367,"primaryCompletion":14504,"completion":14504,"start":19537,"enrollment":1169,"conditions":54368,"interventions":54369},[89],[21],[15870,15820],{"nctId":54371,"briefTitle":54372,"status":105,"phases":54373,"primaryCompletion":14352,"completion":14352,"start":24504,"enrollment":14325,"conditions":54374,"interventions":54376},"NCT00686790","Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)",[89],[54375,17614],"Hepatitis D, Chronic",[15859],{"nctId":15898,"briefTitle":15899,"status":105,"phases":54378,"primaryCompletion":15901,"completion":15901,"start":15902,"enrollment":15903,"conditions":54379,"interventions":54380},[89],[21],[15784,15859,14925,15906],{"nctId":15917,"briefTitle":15918,"status":150,"phases":54382,"primaryCompletion":15920,"completion":15920,"start":15921,"enrollment":15922,"conditions":54383,"interventions":54384},[88,89],[21,15924],[15784,15926,15859,14925],{"nctId":53509,"briefTitle":53510,"status":105,"phases":54386,"primaryCompletion":14408,"completion":14408,"start":20219,"enrollment":53512,"conditions":54387,"interventions":54388},[89],[21],[15870,15870,15870,15820,15820],{"nctId":54390,"briefTitle":54391,"status":105,"phases":54392,"primaryCompletion":14408,"completion":14408,"start":21167,"enrollment":54393,"conditions":54394,"interventions":54396},"NCT00048724","Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)",[89],631,[12957,54395],"Cirrhosis",[15870],{"nctId":53516,"briefTitle":53517,"status":105,"phases":54398,"primaryCompletion":5179,"completion":5179,"start":14324,"enrollment":892,"conditions":54399,"interventions":54400},[89],[21,27951],[15859,14925],{"nctId":54402,"briefTitle":54403,"status":105,"phases":54404,"primaryCompletion":8591,"completion":8591,"start":22317,"enrollment":2779,"conditions":54405,"interventions":54406},"NCT00759109","Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733\u002FMK-4031-085)",[89],[1727],[15859],{"nctId":15937,"briefTitle":15938,"status":105,"phases":54408,"primaryCompletion":14494,"completion":14494,"start":13102,"enrollment":15940,"conditions":54409,"interventions":54410},[89],[21],[15859,14925,15784],{"nctId":15964,"briefTitle":15965,"status":105,"phases":54412,"primaryCompletion":9164,"completion":9164,"start":11368,"enrollment":15967,"conditions":54413,"interventions":54414},[89],[21],[15784,15859,14925,15970],{"trials":54416,"activeCount":99},[54417,54421,54425],{"nctId":53540,"briefTitle":53541,"status":150,"phases":54418,"primaryCompletion":14315,"completion":14315,"start":24504,"enrollment":5983,"conditions":54419,"interventions":54420},[90],[21,15924,27],[15859,14925],{"nctId":53554,"briefTitle":53555,"status":150,"phases":54422,"primaryCompletion":14454,"completion":14454,"start":15211,"enrollment":1601,"conditions":54423,"interventions":54424},[90],[21],[15870,15820,15870,15820],{"nctId":53567,"briefTitle":53568,"status":150,"phases":54426,"primaryCompletion":14858,"completion":14858,"start":19537,"enrollment":110,"conditions":54427,"interventions":54428},[90],[21],[15859,15859,14925,14925],{"trials":54430,"activeCount":99},[54431,54438,54445,54449,54453,54457,54461,54465,54469,54473,54477,54481],{"nctId":54432,"briefTitle":54433,"status":105,"phases":54434,"primaryCompletion":8591,"completion":8591,"start":14705,"enrollment":54435,"conditions":54436,"interventions":54437},"NCT00723931","PegIntron Injection Surveillance Plan (Study P04123)",[],1267,[21],[15859],{"nctId":54439,"briefTitle":54440,"status":105,"phases":54441,"primaryCompletion":14352,"completion":14352,"start":14976,"enrollment":1685,"conditions":54442,"interventions":54443},"NCT00723892","Adherence in Patients Receiving PegIntron\u002FRebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)",[],[21,15924],[15859,54444],"Rebetol",{"nctId":53587,"briefTitle":53588,"status":105,"phases":54446,"primaryCompletion":14408,"completion":14408,"start":14595,"enrollment":53590,"conditions":54447,"interventions":54448},[],[21],[15859,14925],{"nctId":53594,"briefTitle":53595,"status":105,"phases":54450,"primaryCompletion":14313,"completion":14313,"start":14504,"enrollment":53597,"conditions":54451,"interventions":54452},[],[21],[15859,14925],{"nctId":53616,"briefTitle":53617,"status":150,"phases":54454,"primaryCompletion":5801,"completion":5801,"start":14595,"enrollment":11225,"conditions":54455,"interventions":54456},[],[21,15924],[15859,14925],{"nctId":53629,"briefTitle":53630,"status":105,"phases":54458,"primaryCompletion":5801,"completion":5801,"start":6464,"enrollment":53632,"conditions":54459,"interventions":54460},[],[21,15924],[15859,14925],{"nctId":53636,"briefTitle":53637,"status":105,"phases":54462,"primaryCompletion":53604,"completion":53604,"start":5801,"enrollment":53639,"conditions":54463,"interventions":54464},[],[24,21],[15859,14925,15886],{"nctId":53643,"briefTitle":53644,"status":105,"phases":54466,"primaryCompletion":20279,"completion":20279,"start":9610,"enrollment":15321,"conditions":54467,"interventions":54468},[],[21,53647,53648],[15859,14925],{"nctId":53651,"briefTitle":53652,"status":105,"phases":54470,"primaryCompletion":15794,"completion":15794,"start":15156,"enrollment":53654,"conditions":54471,"interventions":54472},[],[21,24],[15870,15820],{"nctId":53658,"briefTitle":53659,"status":105,"phases":54474,"primaryCompletion":14353,"completion":14353,"start":14593,"enrollment":53661,"conditions":54475,"interventions":54476},[],[21,24],[15870,15820],{"nctId":53674,"briefTitle":53675,"status":150,"phases":54478,"primaryCompletion":5179,"completion":5179,"start":5801,"enrollment":53677,"conditions":54479,"interventions":54480},[],[21],[15859,14925],{"nctId":53687,"briefTitle":53688,"status":105,"phases":54482,"primaryCompletion":9610,"completion":9610,"start":15211,"enrollment":13060,"conditions":54483,"interventions":54484},[],[21,15924],[15859,14925],{"intervention":1390,"totalTrials":4242,"cells":54486},{"EARLY_PHASE1":54487,"PHASE1":54489,"PHASE2":54499,"PHASE3":54605,"PHASE4":54615,"NA":54625},{"trials":54488,"activeCount":99},[],{"trials":54490,"activeCount":99},[54491,54495],{"nctId":41926,"briefTitle":41927,"status":105,"phases":54492,"primaryCompletion":16794,"completion":15845,"start":14566,"enrollment":569,"conditions":54493,"interventions":54494},[87],[41930,41931,35],[41913,1390],{"nctId":5462,"briefTitle":5463,"status":150,"phases":54496,"primaryCompletion":5465,"completion":5465,"start":5466,"enrollment":3963,"conditions":54497,"interventions":54498},[87],[290,176,5468,5469,5470],[1390,1074,5472,437,2905,1069,562,1073],{"trials":54500,"activeCount":99},[54501,54509,54517,54528,54538,54548,54559,54567,54576,54580,54589,54597],{"nctId":54502,"briefTitle":54503,"status":105,"phases":54504,"primaryCompletion":54505,"completion":54505,"start":54506,"enrollment":154,"conditions":54507,"interventions":54508},"NCT00684567","Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)",[88],"2007-10-31","2005-09-27",[992],[1390],{"nctId":54510,"briefTitle":54511,"status":105,"phases":54512,"primaryCompletion":28243,"completion":28243,"start":54513,"enrollment":28245,"conditions":54514,"interventions":54516},"NCT00831545","Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)",[88],"2000-12-01",[54515,35,4789,369],"Metastases of Central Nervous System",[1390],{"nctId":54518,"briefTitle":54519,"status":105,"phases":54520,"primaryCompletion":54521,"completion":54522,"start":54523,"enrollment":3390,"conditions":54524,"interventions":54526},"NCT00424554","Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)",[88],"2010-01-11","2011-02-16","2006-09-26",[54525],"Glioma",[54527],"temozolomide",{"nctId":54529,"briefTitle":54530,"status":150,"phases":54531,"primaryCompletion":54532,"completion":54533,"start":20698,"enrollment":18584,"conditions":54534,"interventions":54537},"NCT00632203","Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III\u002FIV Non-Small Cell Lung Cancer Patients (Study P05146)",[88],"2011-01-06","2011-01-07",[369,54535,54536,1901],"Adenocarcinoma","Carcinoma, Large Cell",[1390],{"nctId":54539,"briefTitle":54540,"status":105,"phases":54541,"primaryCompletion":54542,"completion":54543,"start":54544,"enrollment":14576,"conditions":54545,"interventions":54547},"NCT00687323","Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)",[88],"2011-05-09","2012-12-23","2007-07-30",[54546,673],"Leukemia, Acute Myeloid",[54527],{"nctId":54549,"briefTitle":54550,"status":150,"phases":54551,"primaryCompletion":54552,"completion":54552,"start":54553,"enrollment":38922,"conditions":54554,"interventions":54558},"NCT00423150","Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)",[88],"2009-06-11","2007-01-26",[54555,54556,369,54557],"Colorectal Neoplasm","Head and Neck Neoplasm","Esophageal Neoplasm",[1390],{"nctId":54560,"briefTitle":54561,"status":105,"phases":54562,"primaryCompletion":54563,"completion":54563,"start":54564,"enrollment":626,"conditions":54565,"interventions":54566},"NCT00783393","SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)",[88],"2005-06-17","2003-05-27",[30515],[1390],{"nctId":54568,"briefTitle":54569,"status":150,"phases":54570,"primaryCompletion":54571,"completion":54571,"start":54572,"enrollment":120,"conditions":54573,"interventions":54575},"NCT00034697","Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)",[88],"2003-01-30","2001-06-28",[22882,369,54574],"Brain Neoplasms",[54527],{"nctId":1381,"briefTitle":1382,"status":105,"phases":54577,"primaryCompletion":1384,"completion":1385,"start":1386,"enrollment":1387,"conditions":54578,"interventions":54579},[88],[883],[47,386,387,1071,1390],{"nctId":54581,"briefTitle":54582,"status":150,"phases":54583,"primaryCompletion":54584,"completion":54584,"start":19658,"enrollment":4555,"conditions":54585,"interventions":54588},"NCT00638963","Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)",[88],"2010-06-30",[4789,54586,54587],"Brain Neoplasm","Second Neoplasm",[54527],{"nctId":54590,"briefTitle":54591,"status":105,"phases":54592,"primaryCompletion":11465,"completion":11465,"start":54593,"enrollment":2023,"conditions":54594,"interventions":54596},"NCT00392171","The Effects of Continuous 28-day (28\u002F28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5\u002F28) Treatment (P04601)",[88],"2006-06-09",[54525,30515,54595,992],"Oligodendroglioma",[1390],{"nctId":54598,"briefTitle":54599,"status":105,"phases":54600,"primaryCompletion":54601,"completion":54601,"start":54602,"enrollment":14941,"conditions":54603,"interventions":54604},"NCT00076856","Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)",[88],"2006-03-31","2004-03-31",[369,324,54574],[1390],{"trials":54606,"activeCount":99},[54607,54611],{"nctId":30509,"briefTitle":30510,"status":105,"phases":54608,"primaryCompletion":30512,"completion":30512,"start":30513,"enrollment":25889,"conditions":54609,"interventions":54610},[89],[992,30515],[1390,30498],{"nctId":11581,"briefTitle":11582,"status":105,"phases":54612,"primaryCompletion":11584,"completion":11584,"start":11585,"enrollment":11586,"conditions":54613,"interventions":54614},[89],[35],[1390,1071],{"trials":54616,"activeCount":99},[54617],{"nctId":54618,"briefTitle":54619,"status":105,"phases":54620,"primaryCompletion":54621,"completion":54621,"start":54622,"enrollment":4358,"conditions":54623,"interventions":54624},"NCT00686725","Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)",[90],"2011-09-28","2008-06-24",[992],[1390],{"trials":54626,"activeCount":99},[54627,54635,54641,54647],{"nctId":54628,"briefTitle":54629,"status":105,"phases":54630,"primaryCompletion":54631,"completion":54631,"start":4418,"enrollment":54632,"conditions":54633,"interventions":54634},"NCT00705198","Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)",[],"2016-07",1804,[54525,30515],[1390,1390],{"nctId":54636,"briefTitle":54637,"status":105,"phases":54638,"primaryCompletion":14353,"completion":14353,"start":8621,"enrollment":765,"conditions":54639,"interventions":54640},"NCT00704808","Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy\u002FTemozolomide and Adjuvant Temozolomide (Study P04739)",[],[992],[1390],{"nctId":54642,"briefTitle":54643,"status":105,"phases":54644,"primaryCompletion":9610,"completion":9610,"start":15505,"enrollment":287,"conditions":54645,"interventions":54646},"NCT00725010","Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)",[],[992],[1390],{"nctId":54648,"briefTitle":54649,"status":105,"phases":54650,"primaryCompletion":12985,"completion":12985,"start":8620,"enrollment":54651,"conditions":54652,"interventions":54653},"NCT00723827","Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)",[],682,[992,54525,30515],[1390],{"intervention":17754,"totalTrials":805,"cells":54655},{"EARLY_PHASE1":54656,"PHASE1":54658,"PHASE2":54666,"PHASE3":54699,"PHASE4":54717,"NA":54733},{"trials":54657,"activeCount":99},[],{"trials":54659,"activeCount":99},[54660],{"nctId":54661,"briefTitle":54662,"status":105,"phases":54663,"enrollment":95,"conditions":54664,"interventions":54665},"NCT00002351","A Study of L-735,524 in HIV-Positive Children and Adolescents",[87],[27],[17754],{"trials":54667,"activeCount":99},[54668,54675,54679,54683,54687,54691,54695],{"nctId":54669,"briefTitle":54670,"status":105,"phases":54671,"enrollment":4555,"conditions":54672,"interventions":54673},"NCT00002235","A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors",[88],[27],[17754,54674,6235],"Nelfinavir mesylate",{"nctId":20439,"briefTitle":20440,"status":20441,"phases":54676,"enrollment":734,"conditions":54677,"interventions":54678},[88],[27],[17754,11447,11421,17755],{"nctId":35202,"briefTitle":35203,"status":105,"phases":54680,"enrollment":154,"conditions":54681,"interventions":54682},[88],[27],[35193,17754],{"nctId":20446,"briefTitle":20447,"status":20441,"phases":54684,"enrollment":920,"conditions":54685,"interventions":54686},[88],[27],[17754,11447],{"nctId":20456,"briefTitle":20457,"status":105,"phases":54688,"enrollment":154,"conditions":54689,"interventions":54690},[88],[27],[17754,11447],{"nctId":35208,"briefTitle":35209,"status":35210,"phases":54692,"enrollment":2545,"conditions":54693,"interventions":54694},[88],[27],[35193,17754,11421,17755],{"nctId":20462,"briefTitle":20463,"status":20441,"phases":54696,"enrollment":1479,"conditions":54697,"interventions":54698},[88],[27],[17754,11447,11421,17755],{"trials":54700,"activeCount":99},[54701,54705,54711],{"nctId":24440,"briefTitle":24441,"status":105,"phases":54702,"enrollment":2023,"conditions":54703,"interventions":54704},[89],[27],[17754,6235,24445,24429],{"nctId":54706,"briefTitle":54707,"status":105,"phases":54708,"enrollment":1150,"conditions":54709,"interventions":54710},"NCT00002208","A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC",[89],[27],[17754,11421,17755,17756],{"nctId":54712,"briefTitle":54713,"status":105,"phases":54714,"enrollment":11193,"conditions":54715,"interventions":54716},"NCT00002406","A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients",[89],[27],[17754],{"trials":54718,"activeCount":99},[54719,54725,54729],{"nctId":54720,"briefTitle":54721,"status":105,"phases":54722,"enrollment":8416,"conditions":54723,"interventions":54724},"NCT00002179","The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection",[90],[27],[17754,11421,17756],{"nctId":17748,"briefTitle":17749,"status":105,"phases":54726,"enrollment":1349,"conditions":54727,"interventions":54728},[90],[27,17752],[17754,11421,17755,17756,17757,17735],{"nctId":17759,"briefTitle":17760,"status":105,"phases":54730,"enrollment":1387,"conditions":54731,"interventions":54732},[90],[27],[17754,11421,17755,17756,17735],{"trials":54734,"activeCount":99},[54735,54741,54747,54753,54759,54766],{"nctId":54736,"briefTitle":54737,"status":105,"phases":54738,"enrollment":120,"conditions":54739,"interventions":54740},"NCT00002375","Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients",[91],[27],[17754,54674],{"nctId":54742,"briefTitle":54743,"status":105,"phases":54744,"enrollment":8,"conditions":54745,"interventions":54746},"NCT00002430","A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations",[91],[27],[17754,54674,11421,17755],{"nctId":54748,"briefTitle":54749,"status":105,"phases":54750,"enrollment":1387,"conditions":54751,"interventions":54752},"NCT00002354","A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients",[91],[27],[17754,17755],{"nctId":54754,"briefTitle":54755,"status":105,"phases":54756,"enrollment":1818,"conditions":54757,"interventions":54758},"NCT00002155","A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells\u002Fmm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT\u002F3TC",[91],[27],[17754,11421,17756],{"nctId":54760,"briefTitle":54761,"status":105,"phases":54762,"completion":54763,"enrollment":2735,"conditions":54764,"interventions":54765},"NCT00002443","The Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs",[91],"1996-01",[27],[17754,17756],{"nctId":54767,"briefTitle":54768,"status":105,"phases":54769,"enrollment":1479,"conditions":54770,"interventions":54771},"NCT00002387","The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz",[91],[27],[17754,6235],{"intervention":54444,"totalTrials":569,"cells":54773},{"EARLY_PHASE1":54774,"PHASE1":54776,"PHASE2":54778,"PHASE3":54780,"PHASE4":54806,"NA":54808},{"trials":54775,"activeCount":99},[],{"trials":54777,"activeCount":99},[],{"trials":54779,"activeCount":99},[],{"trials":54781,"activeCount":99},[54782,54788,54792,54798],{"nctId":54783,"briefTitle":54784,"status":150,"phases":54785,"primaryCompletion":8621,"completion":8621,"start":14772,"enrollment":4421,"conditions":54786,"interventions":54787},"NCT00811967","Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)",[89],[21,27951],[15828,54444],{"nctId":27428,"briefTitle":27429,"status":105,"phases":54789,"primaryCompletion":14504,"completion":14504,"start":15001,"enrollment":27431,"conditions":54790,"interventions":54791},[89],[21],[15828,15828,27434,27417,27435],{"nctId":54793,"briefTitle":54794,"status":150,"phases":54795,"primaryCompletion":14858,"completion":14858,"start":14976,"enrollment":18625,"conditions":54796,"interventions":54797},"NCT00441584","The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)",[89],[21],[15828,54444],{"nctId":54799,"briefTitle":54800,"status":105,"phases":54801,"primaryCompletion":14887,"completion":14887,"start":15304,"enrollment":54802,"conditions":54803,"interventions":54805},"NCT00039871","PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)",[89],2333,[34060,21,54804,27951],"Fibrosis",[15828,27434],{"trials":54807,"activeCount":99},[],{"trials":54809,"activeCount":99},[54810,54814,54820,54827,54833,54839,54845,54852,54860,54868,54875,54881,54887,54894,54901],{"nctId":54439,"briefTitle":54440,"status":105,"phases":54811,"primaryCompletion":14352,"completion":14352,"start":14976,"enrollment":1685,"conditions":54812,"interventions":54813},[],[21,15924],[15859,54444],{"nctId":54815,"briefTitle":54816,"status":105,"phases":54817,"primaryCompletion":14353,"completion":14353,"start":6464,"enrollment":2268,"conditions":54818,"interventions":54819},"NCT00724230","Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)",[],[21,24],[15828,54444],{"nctId":54821,"briefTitle":54822,"status":105,"phases":54823,"primaryCompletion":14445,"completion":14445,"start":12804,"enrollment":54824,"conditions":54825,"interventions":54826},"NCT00724854","Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)",[],1146,[21,24],[15828,54444],{"nctId":54828,"briefTitle":54829,"status":105,"phases":54830,"primaryCompletion":14730,"completion":14730,"start":14930,"enrollment":14240,"conditions":54831,"interventions":54832},"NCT00704964","Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413)",[],[24,12957],[15828,54444],{"nctId":54834,"briefTitle":54835,"status":1040,"phases":54836,"primaryCompletion":13224,"completion":13224,"start":13870,"enrollment":99,"conditions":54837,"interventions":54838},"NCT00704756","An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN)",[],[21,24],[15828,54444],{"nctId":54840,"briefTitle":54841,"status":105,"phases":54842,"primaryCompletion":5179,"completion":5179,"start":14483,"enrollment":19628,"conditions":54843,"interventions":54844},"NCT00725205","Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)",[],[21,24],[15828,54444],{"nctId":54846,"briefTitle":54847,"status":105,"phases":54848,"primaryCompletion":13870,"completion":13870,"start":17095,"enrollment":19606,"conditions":54849,"interventions":54851},"NCT00726557","Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408\u002FMK-4031-261)",[],[21,54850],"Substance Abuse, Intravenous",[15828,54444],{"nctId":54853,"briefTitle":54854,"status":105,"phases":54855,"primaryCompletion":5280,"completion":5280,"start":15063,"enrollment":54856,"conditions":54857,"interventions":54858},"NCT00727311","Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED)",[],2302,[21,24],[54859,54444],"PegIntron (peginterferon alfa-2b; SCH 54031) injector",{"nctId":54861,"briefTitle":54862,"status":105,"phases":54863,"primaryCompletion":14454,"completion":14454,"start":15156,"enrollment":54864,"conditions":54865,"interventions":54866},"NCT00704717","Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301)",[],185,[21,24],[54867,54444],"PegIntron (peginterferon alfa-2b; SCH 54031) pen",{"nctId":54869,"briefTitle":54870,"status":150,"phases":54871,"primaryCompletion":14324,"completion":14324,"start":14705,"enrollment":202,"conditions":54872,"interventions":54873},"NCT00727077","Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)",[],[21,24],[54874,54444],"IntronA",{"nctId":54876,"briefTitle":54877,"status":105,"phases":54878,"primaryCompletion":14454,"completion":14454,"start":17095,"enrollment":4358,"conditions":54879,"interventions":54880},"NCT00728494","Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron\u002FRebetol and a Patient Assistance Program (Study P04671)",[],[21,24],[15828,54444],{"nctId":54882,"briefTitle":54883,"status":105,"phases":54884,"primaryCompletion":13101,"completion":13101,"start":14678,"enrollment":20655,"conditions":54885,"interventions":54886},"NCT00709059","Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1\u002F4\u002F5\u002F6 (Study P04243)",[],[21],[15828,54444],{"nctId":54888,"briefTitle":54889,"status":150,"phases":54890,"primaryCompletion":14504,"completion":14504,"start":14706,"enrollment":1249,"conditions":54891,"interventions":54892},"NCT00705107","Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247)",[],[21,24],[54893,54444],"PegIntron pen",{"nctId":54895,"briefTitle":54896,"status":105,"phases":54897,"primaryCompletion":5179,"completion":5179,"start":14454,"enrollment":54898,"conditions":54899,"interventions":54900},"NCT00724464","Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)",[],332,[21,24],[15828,54444],{"nctId":54902,"briefTitle":54903,"status":105,"phases":54904,"primaryCompletion":14823,"completion":14823,"start":8621,"enrollment":54905,"conditions":54906,"interventions":54907},"NCT00709228","Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)",[],496,[24],[15828,54444],{"intervention":15828,"totalTrials":569,"cells":54909},{"EARLY_PHASE1":54910,"PHASE1":54912,"PHASE2":54914,"PHASE3":54926,"PHASE4":54952,"NA":54958},{"trials":54911,"activeCount":99},[],{"trials":54913,"activeCount":99},[],{"trials":54915,"activeCount":99},[54916,54920],{"nctId":15822,"briefTitle":15823,"status":105,"phases":54917,"primaryCompletion":13891,"completion":13891,"start":15156,"enrollment":15825,"conditions":54918,"interventions":54919},[88],[12957],[15784,15828,14925],{"nctId":54921,"briefTitle":54922,"status":105,"phases":54923,"primaryCompletion":14531,"completion":14531,"start":14594,"enrollment":50160,"conditions":54924,"interventions":54925},"NCT00787371","Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)",[88],[21,24],[15828,15828,15828],{"trials":54927,"activeCount":99},[54928,54932,54936,54940,54944,54948],{"nctId":54783,"briefTitle":54784,"status":150,"phases":54929,"primaryCompletion":8621,"completion":8621,"start":14772,"enrollment":4421,"conditions":54930,"interventions":54931},[89],[21,27951],[15828,54444],{"nctId":27428,"briefTitle":27429,"status":105,"phases":54933,"primaryCompletion":14504,"completion":14504,"start":15001,"enrollment":27431,"conditions":54934,"interventions":54935},[89],[21],[15828,15828,27434,27417,27435],{"nctId":23246,"briefTitle":23247,"status":105,"phases":54937,"primaryCompletion":23249,"completion":23250,"start":16765,"enrollment":15960,"conditions":54938,"interventions":54939},[89],[24],[19833,15828,14925,23253],{"nctId":54793,"briefTitle":54794,"status":150,"phases":54941,"primaryCompletion":14858,"completion":14858,"start":14976,"enrollment":18625,"conditions":54942,"interventions":54943},[89],[21],[15828,54444],{"nctId":54799,"briefTitle":54800,"status":105,"phases":54945,"primaryCompletion":14887,"completion":14887,"start":15304,"enrollment":54802,"conditions":54946,"interventions":54947},[89],[34060,21,54804,27951],[15828,27434],{"nctId":15944,"briefTitle":15945,"status":1040,"phases":54949,"primaryCompletion":15947,"completion":15911,"start":15948,"enrollment":99,"conditions":54950,"interventions":54951},[89],[24],[15951,15784,15828,15952],{"trials":54953,"activeCount":99},[54954],{"nctId":53573,"briefTitle":53574,"status":105,"phases":54955,"primaryCompletion":5801,"completion":5801,"start":15211,"enrollment":787,"conditions":54956,"interventions":54957},[90],[21],[15828,15828,14925,14925],{"trials":54959,"activeCount":99},[54960,54964,54968,54972,54976,54980,54984,54988,54992,54996],{"nctId":54815,"briefTitle":54816,"status":105,"phases":54961,"primaryCompletion":14353,"completion":14353,"start":6464,"enrollment":2268,"conditions":54962,"interventions":54963},[],[21,24],[15828,54444],{"nctId":54821,"briefTitle":54822,"status":105,"phases":54965,"primaryCompletion":14445,"completion":14445,"start":12804,"enrollment":54824,"conditions":54966,"interventions":54967},[],[21,24],[15828,54444],{"nctId":54828,"briefTitle":54829,"status":105,"phases":54969,"primaryCompletion":14730,"completion":14730,"start":14930,"enrollment":14240,"conditions":54970,"interventions":54971},[],[24,12957],[15828,54444],{"nctId":54834,"briefTitle":54835,"status":1040,"phases":54973,"primaryCompletion":13224,"completion":13224,"start":13870,"enrollment":99,"conditions":54974,"interventions":54975},[],[21,24],[15828,54444],{"nctId":54840,"briefTitle":54841,"status":105,"phases":54977,"primaryCompletion":5179,"completion":5179,"start":14483,"enrollment":19628,"conditions":54978,"interventions":54979},[],[21,24],[15828,54444],{"nctId":54846,"briefTitle":54847,"status":105,"phases":54981,"primaryCompletion":13870,"completion":13870,"start":17095,"enrollment":19606,"conditions":54982,"interventions":54983},[],[21,54850],[15828,54444],{"nctId":54876,"briefTitle":54877,"status":105,"phases":54985,"primaryCompletion":14454,"completion":14454,"start":17095,"enrollment":4358,"conditions":54986,"interventions":54987},[],[21,24],[15828,54444],{"nctId":54882,"briefTitle":54883,"status":105,"phases":54989,"primaryCompletion":13101,"completion":13101,"start":14678,"enrollment":20655,"conditions":54990,"interventions":54991},[],[21],[15828,54444],{"nctId":54895,"briefTitle":54896,"status":105,"phases":54993,"primaryCompletion":5179,"completion":5179,"start":14454,"enrollment":54898,"conditions":54994,"interventions":54995},[],[21,24],[15828,54444],{"nctId":54902,"briefTitle":54903,"status":105,"phases":54997,"primaryCompletion":14823,"completion":14823,"start":8621,"enrollment":54905,"conditions":54998,"interventions":54999},[],[24],[15828,54444],{"intervention":15839,"totalTrials":931,"cells":55001},{"EARLY_PHASE1":55002,"PHASE1":55004,"PHASE2":55031,"PHASE3":55073,"PHASE4":55087,"NA":55089},{"trials":55003,"activeCount":99},[],{"trials":55005,"activeCount":99},[55006,55010,55017,55023],{"nctId":19769,"briefTitle":19770,"status":105,"phases":55007,"primaryCompletion":19772,"completion":19772,"start":19773,"enrollment":120,"conditions":55008,"interventions":55009},[87],[12957,4074],[15839,17381],{"nctId":55011,"briefTitle":55012,"status":105,"phases":55013,"primaryCompletion":55014,"completion":55014,"start":19810,"enrollment":3963,"conditions":55015,"interventions":55016},"NCT01537900","A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010)",[87],"2014-07-31",[24],[15839],{"nctId":55018,"briefTitle":55019,"status":105,"phases":55020,"primaryCompletion":14285,"completion":14285,"start":45962,"enrollment":21259,"conditions":55021,"interventions":55022},"NCT00998985","A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)",[87],[24],[15839],{"nctId":55024,"briefTitle":55025,"status":105,"phases":55026,"primaryCompletion":42170,"completion":55027,"start":55028,"enrollment":4421,"conditions":55029,"interventions":55030},"NCT01390428","Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013)",[87],"2014-09-12","2011-07-28",[24],[15839],{"trials":55032,"activeCount":99},[55033,55037,55041,55045,55049,55053,55057,55061,55065,55069],{"nctId":53340,"briefTitle":53341,"status":105,"phases":55034,"primaryCompletion":48945,"completion":53343,"start":14104,"enrollment":23629,"conditions":55035,"interventions":55036},[88],[53345],[15839,53347,14925],{"nctId":53353,"briefTitle":53354,"status":150,"phases":55038,"primaryCompletion":53356,"completion":53356,"start":53357,"enrollment":174,"conditions":55039,"interventions":55040},[88],[21],[15839,15859,14925],{"nctId":53377,"briefTitle":53378,"status":105,"phases":55042,"primaryCompletion":53380,"completion":14055,"start":53381,"enrollment":3506,"conditions":55043,"interventions":55044},[88],[24],[15839,14925],{"nctId":19796,"briefTitle":19797,"status":105,"phases":55046,"primaryCompletion":19799,"completion":19800,"start":19801,"enrollment":19802,"conditions":55047,"interventions":55048},[88],[24],[15839,17381,14925],{"nctId":19806,"briefTitle":19807,"status":105,"phases":55050,"primaryCompletion":19809,"completion":19809,"start":19810,"enrollment":16208,"conditions":55051,"interventions":55052},[88],[24],[15839,17381,14925],{"nctId":19814,"briefTitle":19815,"status":105,"phases":55054,"primaryCompletion":1986,"completion":19817,"start":19818,"enrollment":19819,"conditions":55055,"interventions":55056},[88],[24],[15839,12959,17381,19822,19823,14925],{"nctId":19825,"briefTitle":19826,"status":105,"phases":55058,"primaryCompletion":19828,"completion":19829,"start":19830,"enrollment":2788,"conditions":55059,"interventions":55060},[88],[24],[15839,17381,14925,19833],{"nctId":19835,"briefTitle":19836,"status":105,"phases":55062,"primaryCompletion":19838,"completion":19839,"start":19840,"enrollment":2695,"conditions":55063,"interventions":55064},[88],[24],[15839,12959,17381,19822,19843,14925],{"nctId":15830,"briefTitle":15831,"status":105,"phases":55066,"primaryCompletion":15833,"completion":15834,"start":15835,"enrollment":15836,"conditions":55067,"interventions":55068},[88],[21],[15839,15784,15840,14925],{"nctId":19845,"briefTitle":19846,"status":105,"phases":55070,"primaryCompletion":19848,"completion":19848,"start":13269,"enrollment":18324,"conditions":55071,"interventions":55072},[88],[12987],[15839,17381,14925],{"trials":55074,"activeCount":99},[55075,55079,55083],{"nctId":19854,"briefTitle":19855,"status":105,"phases":55076,"primaryCompletion":19857,"completion":19858,"start":19859,"enrollment":19587,"conditions":55077,"interventions":55078},[88,89],[24],[15839,17381],{"nctId":17374,"briefTitle":17375,"status":105,"phases":55080,"primaryCompletion":17377,"completion":17378,"start":16755,"enrollment":3390,"conditions":55081,"interventions":55082},[88,89],[12957],[15839,17381,17363],{"nctId":19867,"briefTitle":19868,"status":105,"phases":55084,"primaryCompletion":19870,"completion":12953,"start":1095,"enrollment":19871,"conditions":55085,"interventions":55086},[88,89],[12987],[15839,17381],{"trials":55088,"activeCount":99},[],{"trials":55090,"activeCount":99},[55091],{"nctId":55092,"briefTitle":55093,"status":105,"phases":55094,"primaryCompletion":55095,"completion":55095,"start":55096,"enrollment":55097,"conditions":55098,"interventions":55099},"NCT01667081","Durability of Virologic Response and\u002For Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)",[],"2021-03-31","2012-10-17",2438,[24],[15839],{"intervention":17832,"totalTrials":3655,"cells":55101},{"EARLY_PHASE1":55102,"PHASE1":55104,"PHASE2":55123,"PHASE3":55139,"PHASE4":55171,"NA":55184},{"trials":55103,"activeCount":99},[],{"trials":55105,"activeCount":99},[55106,55113,55117],{"nctId":55107,"briefTitle":55108,"status":105,"phases":55109,"primaryCompletion":55110,"completion":55110,"start":16681,"enrollment":367,"conditions":55111,"interventions":55112},"NCT03336502","Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120)",[87],"2018-11-26",[17830],[17832],{"nctId":45959,"briefTitle":45960,"status":105,"phases":55114,"primaryCompletion":1386,"completion":1386,"start":45962,"enrollment":45963,"conditions":55115,"interventions":55116},[87],[17830],[17832,45952],{"nctId":55118,"briefTitle":55119,"status":105,"phases":55120,"primaryCompletion":454,"completion":454,"start":19800,"enrollment":2801,"conditions":55121,"interventions":55122},"NCT02387983","Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)",[87],[17830],[17832],{"trials":55124,"activeCount":99},[55125,55131,55135],{"nctId":55126,"briefTitle":55127,"status":105,"phases":55128,"primaryCompletion":16793,"completion":16793,"start":14454,"enrollment":3390,"conditions":55129,"interventions":55130},"NCT00550732","A Study to Examine the Efficacy and Safety of Posaconazole When Introduced Early in the Treatment of Refractory Fungal Infections (P05090 AM2)",[88],[22319],[17832],{"nctId":38435,"briefTitle":38436,"status":105,"phases":55132,"primaryCompletion":5262,"completion":5262,"start":1907,"enrollment":4741,"conditions":55133,"interventions":55134},[88],[38439],[38426,38441,17832],{"nctId":40782,"briefTitle":40783,"status":105,"phases":55136,"primaryCompletion":40785,"completion":40786,"start":40787,"enrollment":2023,"conditions":55137,"interventions":55138},[88],[40789],[17832,40773],{"trials":55140,"activeCount":99},[55141,55145,55149,55157,55161,55165],{"nctId":24469,"briefTitle":24470,"status":105,"phases":55142,"primaryCompletion":24472,"completion":24473,"start":24474,"enrollment":16142,"conditions":55143,"interventions":55144},[89],[24476,24477],[17832,24458],{"nctId":24480,"briefTitle":24481,"status":105,"phases":55146,"primaryCompletion":24483,"completion":24483,"start":24484,"enrollment":429,"conditions":55147,"interventions":55148},[89],[20498],[17832,24458],{"nctId":55150,"briefTitle":55151,"status":105,"phases":55152,"primaryCompletion":22317,"completion":22317,"start":55153,"enrollment":55154,"conditions":55155,"interventions":55156},"NCT00034658","Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041)",[89],"1998-12",336,[22319],[17832],{"nctId":25339,"briefTitle":25340,"status":105,"phases":55158,"primaryCompletion":14352,"completion":14352,"start":14409,"enrollment":3655,"conditions":55159,"interventions":55160},[89],[25343],[17832,25328],{"nctId":25346,"briefTitle":25347,"status":105,"phases":55162,"primaryCompletion":14494,"completion":14494,"start":14823,"enrollment":25349,"conditions":55163,"interventions":55164},[89],[25351],[17832,25328],{"nctId":55166,"briefTitle":55167,"status":105,"phases":55168,"primaryCompletion":13224,"completion":13224,"start":14823,"enrollment":18999,"conditions":55169,"interventions":55170},"NCT00811642","Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)",[89],[17830],[17832],{"trials":55172,"activeCount":99},[55173,55177],{"nctId":17824,"briefTitle":17825,"status":150,"phases":55174,"primaryCompletion":17827,"completion":17827,"start":17828,"enrollment":3506,"conditions":55175,"interventions":55176},[90],[17830],[17832,17811],{"nctId":55178,"briefTitle":55179,"status":105,"phases":55180,"primaryCompletion":9610,"completion":9610,"start":14454,"enrollment":613,"conditions":55181,"interventions":55183},"NCT00686543","Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)",[90],[17830,55182,20505],"Acute Myelogenous Leukemia",[17832],{"trials":55185,"activeCount":99},[55186,55192],{"nctId":55187,"briefTitle":55188,"status":105,"phases":55189,"primaryCompletion":5801,"completion":5801,"start":14484,"enrollment":19659,"conditions":55190,"interventions":55191},"NCT00726609","Post-marketing Surveillance Study of Invasive Mycosis With Posaconazole (Study P04641)",[],[22319],[17832],{"nctId":55193,"briefTitle":55194,"status":55195,"phases":55196,"conditions":55197,"interventions":55198},"NCT00686621","Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113)","APPROVED_FOR_MARKETING",[],[22319],[17832],{"intervention":16687,"totalTrials":4071,"cells":55200},{"EARLY_PHASE1":55201,"PHASE1":55203,"PHASE2":55205,"PHASE3":55211,"PHASE4":55249,"NA":55263},{"trials":55202,"activeCount":99},[],{"trials":55204,"activeCount":99},[],{"trials":55206,"activeCount":99},[55207],{"nctId":17005,"briefTitle":17006,"status":105,"phases":55208,"primaryCompletion":17008,"completion":17008,"start":17009,"enrollment":920,"conditions":55209,"interventions":55210},[88],[17011],[17013,16687,16688],{"trials":55212,"activeCount":99},[55213,55217,55221,55225,55229,55233,55237,55241,55245],{"nctId":54199,"briefTitle":54200,"status":105,"phases":55214,"primaryCompletion":20841,"completion":20841,"start":54202,"enrollment":32902,"conditions":55215,"interventions":55216},[89],[17011],[17013,16687],{"nctId":22707,"briefTitle":22708,"status":105,"phases":55218,"primaryCompletion":22710,"completion":22710,"start":20637,"enrollment":13439,"conditions":55219,"interventions":55220},[89],[17011],[17013,16687,22087,22088],{"nctId":20816,"briefTitle":20817,"status":105,"phases":55222,"primaryCompletion":20819,"completion":20820,"start":20821,"enrollment":407,"conditions":55223,"interventions":55224},[89],[17011],[16687,17013,20824,20825],{"nctId":54258,"briefTitle":54259,"status":105,"phases":55226,"primaryCompletion":15266,"completion":17300,"start":54202,"enrollment":38922,"conditions":55227,"interventions":55228},[89],[17011],[17013,16687],{"nctId":54264,"briefTitle":54265,"status":105,"phases":55230,"primaryCompletion":14713,"completion":14713,"start":14408,"enrollment":4555,"conditions":55231,"interventions":55232},[89],[16696],[17025,16687],{"nctId":17017,"briefTitle":17018,"status":105,"phases":55234,"primaryCompletion":17020,"completion":17021,"start":17022,"enrollment":537,"conditions":55235,"interventions":55236},[89],[17011],[17025,17026,17027,17028,17029],{"nctId":17289,"briefTitle":17290,"status":105,"phases":55238,"primaryCompletion":13101,"completion":13101,"start":14823,"enrollment":7797,"conditions":55239,"interventions":55240},[89],[16696],[17028,17025,17294],{"nctId":20867,"briefTitle":20868,"status":105,"phases":55242,"primaryCompletion":14315,"completion":14315,"start":13890,"enrollment":920,"conditions":55243,"interventions":55244},[89],[16668],[17013,20824,16687],{"nctId":17296,"briefTitle":17297,"status":105,"phases":55246,"primaryCompletion":17299,"completion":17300,"start":17301,"enrollment":11225,"conditions":55247,"interventions":55248},[89],[17011],[17013,17278,16687],{"trials":55250,"activeCount":99},[55251,55255,55259],{"nctId":16677,"briefTitle":16678,"status":105,"phases":55252,"primaryCompletion":16680,"completion":16680,"start":16681,"enrollment":16682,"conditions":55253,"interventions":55254},[90],[16684],[16672,16640,16655,16686,16687,16688],{"nctId":54304,"briefTitle":54305,"status":105,"phases":55256,"primaryCompletion":13815,"completion":13815,"start":192,"enrollment":4535,"conditions":55257,"interventions":55258},[90],[54308],[16687,17013],{"nctId":17307,"briefTitle":17308,"status":1040,"phases":55260,"primaryCompletion":17310,"completion":17310,"start":17311,"enrollment":99,"conditions":55261,"interventions":55262},[90],[16696],[16687,17013,17314,17315,17278],{"trials":55264,"activeCount":99},[55265],{"nctId":55266,"briefTitle":55267,"status":105,"phases":55268,"primaryCompletion":5179,"completion":5179,"start":14504,"enrollment":55269,"conditions":55270,"interventions":55271},"NCT00902070","Protocol for Eslax Intravenous Drug Use Investigation (Study P06082)",[],3969,[16668],[16687],{"intervention":11421,"totalTrials":95,"cells":55273},{"EARLY_PHASE1":55274,"PHASE1":55276,"PHASE2":55282,"PHASE3":55304,"PHASE4":55310,"NA":55324},{"trials":55275,"activeCount":99},[],{"trials":55277,"activeCount":99},[55278],{"nctId":19683,"briefTitle":19684,"status":105,"phases":55279,"primaryCompletion":321,"completion":321,"start":1700,"enrollment":805,"conditions":55280,"interventions":55281},[87],[18],[7800,11421],{"trials":55283,"activeCount":99},[55284,55288,55292,55296,55300],{"nctId":11413,"briefTitle":11414,"status":105,"phases":55285,"primaryCompletion":11416,"completion":11417,"start":11418,"enrollment":2085,"conditions":55286,"interventions":55287},[88],[7639],[7800,11357,11421,11422,11423],{"nctId":20439,"briefTitle":20440,"status":20441,"phases":55289,"enrollment":734,"conditions":55290,"interventions":55291},[88],[27],[17754,11447,11421,17755],{"nctId":17570,"briefTitle":17571,"status":150,"phases":55293,"primaryCompletion":17573,"completion":17573,"start":17574,"enrollment":5983,"conditions":55294,"interventions":55295},[88],[27],[17577,17578,11421,17561,17579,17580,11447,17581,11446],{"nctId":35208,"briefTitle":35209,"status":35210,"phases":55297,"enrollment":2545,"conditions":55298,"interventions":55299},[88],[27],[35193,17754,11421,17755],{"nctId":20462,"briefTitle":20463,"status":20441,"phases":55301,"enrollment":1479,"conditions":55302,"interventions":55303},[88],[27],[17754,11447,11421,17755],{"trials":55305,"activeCount":99},[55306],{"nctId":54706,"briefTitle":54707,"status":105,"phases":55307,"enrollment":1150,"conditions":55308,"interventions":55309},[89],[27],[17754,11421,17755,17756],{"trials":55311,"activeCount":99},[55312,55316,55320],{"nctId":54720,"briefTitle":54721,"status":105,"phases":55313,"enrollment":8416,"conditions":55314,"interventions":55315},[90],[27],[17754,11421,17756],{"nctId":17748,"briefTitle":17749,"status":105,"phases":55317,"enrollment":1349,"conditions":55318,"interventions":55319},[90],[27,17752],[17754,11421,17755,17756,17757,17735],{"nctId":17759,"briefTitle":17760,"status":105,"phases":55321,"enrollment":1387,"conditions":55322,"interventions":55323},[90],[27],[17754,11421,17755,17756,17735],{"trials":55325,"activeCount":99},[55326,55330],{"nctId":54742,"briefTitle":54743,"status":105,"phases":55327,"enrollment":8,"conditions":55328,"interventions":55329},[91],[27],[17754,54674,11421,17755],{"nctId":54754,"briefTitle":54755,"status":105,"phases":55331,"enrollment":1818,"conditions":55332,"interventions":55333},[91],[27],[17754,11421,17756],{"intervention":14059,"totalTrials":335,"cells":55335},{"EARLY_PHASE1":55336,"PHASE1":55338,"PHASE2":55348,"PHASE3":55354,"PHASE4":55376,"NA":55382},{"trials":55337,"activeCount":99},[],{"trials":55339,"activeCount":99},[55340,55344],{"nctId":50157,"briefTitle":50158,"status":105,"phases":55341,"primaryCompletion":2007,"completion":2007,"start":34804,"enrollment":50160,"conditions":55342,"interventions":55343},[87],[4255,15],[50150,50163,50164,50165,50166,50167,50168,14059],{"nctId":51586,"briefTitle":51587,"status":105,"phases":55345,"primaryCompletion":24504,"completion":24504,"start":14976,"enrollment":931,"conditions":55346,"interventions":55347},[87],[15],[51579,51591,51592,51593,51594,14059,51595],{"trials":55349,"activeCount":99},[55350],{"nctId":32961,"briefTitle":32962,"status":105,"phases":55351,"primaryCompletion":14494,"completion":14494,"start":13870,"enrollment":14325,"conditions":55352,"interventions":55353},[88],[15],[13863,14059],{"trials":55355,"activeCount":99},[55356,55360,55364,55368,55372],{"nctId":14051,"briefTitle":14052,"status":105,"phases":55357,"primaryCompletion":14054,"completion":14054,"start":14055,"enrollment":14056,"conditions":55358,"interventions":55359},[89],[15],[13883,14049,4084,13145,13146,14059],{"nctId":14069,"briefTitle":14070,"status":105,"phases":55361,"primaryCompletion":14072,"completion":14072,"start":14073,"enrollment":14074,"conditions":55362,"interventions":55363},[89],[15],[14077,4084,14078,14059,14079],{"nctId":16160,"briefTitle":16161,"status":105,"phases":55365,"primaryCompletion":16163,"completion":16163,"start":16164,"enrollment":16165,"conditions":55366,"interventions":55367},[89],[15],[13913,13961,14059],{"nctId":14200,"briefTitle":14201,"status":105,"phases":55369,"primaryCompletion":14203,"completion":14204,"start":14205,"enrollment":14206,"conditions":55370,"interventions":55371},[89],[15],[13145,14059,4084],{"nctId":14218,"briefTitle":14219,"status":105,"phases":55373,"primaryCompletion":4344,"completion":4344,"start":14221,"enrollment":13142,"conditions":55374,"interventions":55375},[89],[15],[13883,14049,14059,4084],{"trials":55377,"activeCount":99},[55378],{"nctId":16189,"briefTitle":16190,"status":105,"phases":55379,"primaryCompletion":2602,"completion":2602,"start":16192,"enrollment":743,"conditions":55380,"interventions":55381},[90],[15],[13913,14059],{"trials":55383,"activeCount":99},[55384],{"nctId":53865,"briefTitle":53866,"status":105,"phases":55385,"primaryCompletion":33547,"completion":33547,"start":6309,"enrollment":53868,"conditions":55386,"interventions":55387},[],[15],[13145,14018,14059],{"intervention":15934,"totalTrials":734,"cells":55389},{"EARLY_PHASE1":55390,"PHASE1":55392,"PHASE2":55394,"PHASE3":55408,"PHASE4":55426,"NA":55432},{"trials":55391,"activeCount":99},[],{"trials":55393,"activeCount":99},[],{"trials":55395,"activeCount":99},[55396,55400],{"nctId":53340,"briefTitle":53341,"status":105,"phases":55397,"primaryCompletion":48945,"completion":53343,"start":14104,"enrollment":23629,"conditions":55398,"interventions":55399},[88],[53345],[15839,53347,14925],{"nctId":55401,"briefTitle":55402,"status":105,"phases":55403,"primaryCompletion":11429,"completion":11429,"start":55404,"enrollment":444,"conditions":55405,"interventions":55406},"NCT02155322","A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)",[88],"2014-08-19",[35],[55407,55407],"Pegylated Interferon Alfa-2b",{"trials":55409,"activeCount":99},[55410,55414,55418,55422],{"nctId":24447,"briefTitle":24448,"status":105,"phases":55411,"primaryCompletion":14313,"completion":14313,"start":4418,"enrollment":9323,"conditions":55412,"interventions":55413},[89],[24451],[15934,24429],{"nctId":53499,"briefTitle":53500,"status":105,"phases":55415,"primaryCompletion":15794,"completion":15794,"start":14875,"enrollment":132,"conditions":55416,"interventions":55417},[89],[24],[15934,14925],{"nctId":15928,"briefTitle":15929,"status":105,"phases":55419,"primaryCompletion":4990,"completion":4990,"start":13102,"enrollment":15931,"conditions":55420,"interventions":55421},[89],[21],[15784,15934,14925,15935],{"nctId":24415,"briefTitle":24416,"status":150,"phases":55423,"primaryCompletion":24418,"completion":24418,"start":24419,"enrollment":16682,"conditions":55424,"interventions":55425},[88,89],[24421],[15934,24423],{"trials":55427,"activeCount":99},[55428],{"nctId":53560,"briefTitle":53561,"status":105,"phases":55429,"primaryCompletion":15794,"completion":15794,"start":14687,"enrollment":613,"conditions":55430,"interventions":55431},[90],[21],[53565,14925],{"trials":55433,"activeCount":99},[55434],{"nctId":53610,"briefTitle":53611,"status":105,"phases":55435,"primaryCompletion":21145,"completion":21145,"start":14887,"enrollment":14230,"conditions":55436,"interventions":55437},[],[21],[15934,14925],{"intervention":17577,"totalTrials":734,"cells":55439},{"EARLY_PHASE1":55440,"PHASE1":55442,"PHASE2":55452,"PHASE3":55458,"PHASE4":55464,"NA":55474},{"trials":55441,"activeCount":99},[],{"trials":55443,"activeCount":99},[55444,55448],{"nctId":47412,"briefTitle":47413,"status":105,"phases":55445,"primaryCompletion":47415,"completion":47415,"start":19810,"enrollment":931,"conditions":55446,"interventions":55447},[87],[27],[17577,47405],{"nctId":48589,"briefTitle":48590,"status":105,"phases":55449,"primaryCompletion":6799,"completion":6799,"start":22359,"enrollment":36,"conditions":55450,"interventions":55451},[87],[27],[17577,48582,48594],{"trials":55453,"activeCount":99},[55454],{"nctId":17570,"briefTitle":17571,"status":150,"phases":55455,"primaryCompletion":17573,"completion":17573,"start":17574,"enrollment":5983,"conditions":55456,"interventions":55457},[88],[27],[17577,17578,11421,17561,17579,17580,11447,17581,11446],{"trials":55459,"activeCount":99},[55460],{"nctId":25133,"briefTitle":25134,"status":105,"phases":55461,"primaryCompletion":25136,"completion":25137,"start":13269,"enrollment":25138,"conditions":55462,"interventions":55463},[89],[7650],[25141,17577,25122],{"trials":55465,"activeCount":99},[55466],{"nctId":55467,"briefTitle":55468,"status":105,"phases":55469,"primaryCompletion":55470,"completion":55470,"start":55471,"enrollment":95,"conditions":55472,"interventions":55473},"NCT03667547","Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)",[90],"2018-10-23","2018-09-27",[11396],[17577],{"trials":55475,"activeCount":99},[55476,55483,55491],{"nctId":55477,"briefTitle":55478,"status":55195,"phases":55479,"conditions":55480,"interventions":55481},"NCT00377065","Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)",[],[27],[55482],"raltegravir",{"nctId":55484,"briefTitle":55485,"status":105,"phases":55486,"primaryCompletion":18998,"completion":18998,"start":14623,"enrollment":55487,"conditions":55488,"interventions":55489},"NCT01048671","Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)",[],482,[27],[17577,55490],"ARV",{"nctId":55492,"briefTitle":55493,"status":105,"phases":55494,"primaryCompletion":20431,"completion":20431,"start":5179,"enrollment":55495,"conditions":55496,"interventions":55497},"NCT01213316","A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)",[],451,[7639],[17577,17577],{"intervention":17755,"totalTrials":734,"cells":55499},{"EARLY_PHASE1":55500,"PHASE1":55502,"PHASE2":55504,"PHASE3":55518,"PHASE4":55524,"NA":55534},{"trials":55501,"activeCount":99},[],{"trials":55503,"activeCount":99},[],{"trials":55505,"activeCount":99},[55506,55510,55514],{"nctId":20439,"briefTitle":20440,"status":20441,"phases":55507,"enrollment":734,"conditions":55508,"interventions":55509},[88],[27],[17754,11447,11421,17755],{"nctId":35208,"briefTitle":35209,"status":35210,"phases":55511,"enrollment":2545,"conditions":55512,"interventions":55513},[88],[27],[35193,17754,11421,17755],{"nctId":20462,"briefTitle":20463,"status":20441,"phases":55515,"enrollment":1479,"conditions":55516,"interventions":55517},[88],[27],[17754,11447,11421,17755],{"trials":55519,"activeCount":99},[55520],{"nctId":54706,"briefTitle":54707,"status":105,"phases":55521,"enrollment":1150,"conditions":55522,"interventions":55523},[89],[27],[17754,11421,17755,17756],{"trials":55525,"activeCount":99},[55526,55530],{"nctId":17748,"briefTitle":17749,"status":105,"phases":55527,"enrollment":1349,"conditions":55528,"interventions":55529},[90],[27,17752],[17754,11421,17755,17756,17757,17735],{"nctId":17759,"briefTitle":17760,"status":105,"phases":55531,"enrollment":1387,"conditions":55532,"interventions":55533},[90],[27],[17754,11421,17755,17756,17735],{"trials":55535,"activeCount":99},[55536,55540],{"nctId":54742,"briefTitle":54743,"status":105,"phases":55537,"enrollment":8,"conditions":55538,"interventions":55539},[91],[27],[17754,54674,11421,17755],{"nctId":54748,"briefTitle":54749,"status":105,"phases":55541,"enrollment":1387,"conditions":55542,"interventions":55543},[91],[27],[17754,17755],{"intervention":14420,"totalTrials":357,"cells":55545},{"EARLY_PHASE1":55546,"PHASE1":55548,"PHASE2":55554,"PHASE3":55560,"PHASE4":55580,"NA":55582},{"trials":55547,"activeCount":99},[],{"trials":55549,"activeCount":99},[55550],{"nctId":14414,"briefTitle":14415,"status":105,"phases":55551,"primaryCompletion":13224,"completion":4990,"start":8591,"enrollment":8016,"conditions":55552,"interventions":55553},[87],[14418,13133],[14420,14421,14422,14423,14331],{"trials":55555,"activeCount":99},[55556],{"nctId":15060,"briefTitle":15061,"status":105,"phases":55557,"primaryCompletion":15063,"completion":15063,"start":14594,"enrollment":15064,"conditions":55558,"interventions":55559},[88],[14337],[14420,14331],{"trials":55561,"activeCount":99},[55562,55566,55570,55574],{"nctId":25962,"briefTitle":25963,"status":105,"phases":55563,"primaryCompletion":15038,"completion":15038,"start":24504,"enrollment":25965,"conditions":55564,"interventions":55565},[89],[25967,25968],[14420,25951],{"nctId":24631,"briefTitle":24632,"status":105,"phases":55567,"primaryCompletion":4419,"completion":4419,"start":14531,"enrollment":24634,"conditions":55568,"interventions":55569},[89],[7598,7610],[14420,23556],{"nctId":23337,"briefTitle":23338,"status":105,"phases":55571,"primaryCompletion":5801,"completion":6309,"start":13891,"enrollment":23340,"conditions":55572,"interventions":55573},[89],[14418,16417],[22385,14420,23343],{"nctId":55575,"briefTitle":55576,"status":1040,"phases":55577,"primaryCompletion":8591,"start":14315,"enrollment":99,"conditions":55578,"interventions":55579},"NCT00664287","Extended Release (ER) Niacin\u002FLaropiprant Add on Study (0524A-082)",[89],[14337],[14420],{"trials":55581,"activeCount":99},[],{"trials":55583,"activeCount":99},[55584],{"nctId":55585,"briefTitle":55586,"status":150,"phases":55587,"primaryCompletion":20279,"completion":20279,"start":15794,"enrollment":55588,"conditions":55589,"interventions":55590},"NCT01228019","Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)",[],1166,[7598,16417],[55591],"Niacin (+) laropiprant",{"intervention":14924,"totalTrials":357,"cells":55593},{"EARLY_PHASE1":55594,"PHASE1":55596,"PHASE2":55598,"PHASE3":55624,"PHASE4":55626,"NA":55628},{"trials":55595,"activeCount":99},[],{"trials":55597,"activeCount":99},[],{"trials":55599,"activeCount":99},[55600,55604,55608,55612,55616,55620],{"nctId":20998,"briefTitle":20999,"status":105,"phases":55601,"primaryCompletion":21001,"completion":14004,"start":21002,"enrollment":9366,"conditions":55602,"interventions":55603},[88],[21],[14923,14924,14925],{"nctId":34112,"briefTitle":34113,"status":105,"phases":55605,"start":17096,"conditions":55606,"interventions":55607},[87,88],[12957],[34103,34117],{"nctId":20428,"briefTitle":20429,"status":105,"phases":55609,"primaryCompletion":20431,"completion":20431,"start":20410,"enrollment":5196,"conditions":55610,"interventions":55611},[88],[20433],[20415,20435,14925,20436,11447,20437],{"nctId":34119,"briefTitle":34120,"status":105,"phases":55613,"start":14903,"conditions":55614,"interventions":55615},[88],[12957],[34103,34117,15820],{"nctId":14917,"briefTitle":14918,"status":105,"phases":55617,"primaryCompletion":13978,"completion":14113,"start":14920,"enrollment":397,"conditions":55618,"interventions":55619},[88],[24],[14923,14924,14925,13864],{"nctId":39400,"briefTitle":39401,"status":105,"phases":55621,"primaryCompletion":14103,"completion":14103,"start":20144,"enrollment":700,"conditions":55622,"interventions":55623},[88],[21],[39391,39405,20437,14925],{"trials":55625,"activeCount":99},[],{"trials":55627,"activeCount":99},[],{"trials":55629,"activeCount":99},[55630],{"nctId":53581,"briefTitle":53582,"status":105,"phases":55631,"primaryCompletion":5982,"completion":5982,"start":13890,"enrollment":688,"conditions":55632,"interventions":55633},[],[21,12987],[14924,14925],{"intervention":17756,"totalTrials":357,"cells":55635},{"EARLY_PHASE1":55636,"PHASE1":55638,"PHASE2":55644,"PHASE3":55646,"PHASE4":55652,"NA":55666},{"trials":55637,"activeCount":99},[],{"trials":55639,"activeCount":99},[55640],{"nctId":44906,"briefTitle":44907,"status":105,"phases":55641,"enrollment":36,"conditions":55642,"interventions":55643},[87],[27],[44899,17756],{"trials":55645,"activeCount":99},[],{"trials":55647,"activeCount":99},[55648],{"nctId":54706,"briefTitle":54707,"status":105,"phases":55649,"enrollment":1150,"conditions":55650,"interventions":55651},[89],[27],[17754,11421,17755,17756],{"trials":55653,"activeCount":99},[55654,55658,55662],{"nctId":54720,"briefTitle":54721,"status":105,"phases":55655,"enrollment":8416,"conditions":55656,"interventions":55657},[90],[27],[17754,11421,17756],{"nctId":17748,"briefTitle":17749,"status":105,"phases":55659,"enrollment":1349,"conditions":55660,"interventions":55661},[90],[27,17752],[17754,11421,17755,17756,17757,17735],{"nctId":17759,"briefTitle":17760,"status":105,"phases":55663,"enrollment":1387,"conditions":55664,"interventions":55665},[90],[27],[17754,11421,17755,17756,17735],{"trials":55667,"activeCount":99},[55668,55672],{"nctId":54754,"briefTitle":54755,"status":105,"phases":55669,"enrollment":1818,"conditions":55670,"interventions":55671},[91],[27],[17754,11421,17756],{"nctId":54760,"briefTitle":54761,"status":105,"phases":55673,"completion":54763,"enrollment":2735,"conditions":55674,"interventions":55675},[91],[27],[17754,17756],{"intervention":6235,"totalTrials":4555,"cells":55677},{"EARLY_PHASE1":55678,"PHASE1":55680,"PHASE2":55690,"PHASE3":55700,"PHASE4":55706,"NA":55708},{"trials":55679,"activeCount":99},[],{"trials":55681,"activeCount":99},[55682,55686],{"nctId":41791,"briefTitle":41792,"status":105,"phases":55683,"primaryCompletion":6394,"completion":6394,"start":41794,"enrollment":5616,"conditions":55684,"interventions":55685},[87],[18],[41772,6235],{"nctId":6230,"briefTitle":6231,"status":105,"phases":55687,"primaryCompletion":2722,"completion":2722,"start":1188,"enrollment":3655,"conditions":55688,"interventions":55689},[87],[18],[5541,6235],{"trials":55691,"activeCount":99},[55692,55696],{"nctId":54669,"briefTitle":54670,"status":105,"phases":55693,"enrollment":4555,"conditions":55694,"interventions":55695},[88],[27],[17754,54674,6235],{"nctId":11425,"briefTitle":11426,"status":105,"phases":55697,"primaryCompletion":11428,"completion":11429,"start":11430,"enrollment":9551,"conditions":55698,"interventions":55699},[88],[27],[11357,6235,11433],{"trials":55701,"activeCount":99},[55702],{"nctId":24440,"briefTitle":24441,"status":105,"phases":55703,"enrollment":2023,"conditions":55704,"interventions":55705},[89],[27],[17754,6235,24445,24429],{"trials":55707,"activeCount":99},[],{"trials":55709,"activeCount":99},[55710],{"nctId":54767,"briefTitle":54768,"status":105,"phases":55711,"enrollment":1479,"conditions":55712,"interventions":55713},[91],[27],[17754,6235],{"intervention":15231,"totalTrials":4555,"cells":55715},{"EARLY_PHASE1":55716,"PHASE1":55718,"PHASE2":55720,"PHASE3":55722,"PHASE4":55744,"NA":55746},{"trials":55717,"activeCount":99},[],{"trials":55719,"activeCount":99},[],{"trials":55721,"activeCount":99},[],{"trials":55723,"activeCount":99},[55724,55728,55732,55736,55740],{"nctId":15222,"briefTitle":15223,"status":105,"phases":55725,"primaryCompletion":15225,"completion":15226,"start":15227,"enrollment":15228,"conditions":55726,"interventions":55727},[89],[30],[15231,15232,13864],{"nctId":24835,"briefTitle":24836,"status":105,"phases":55729,"primaryCompletion":24838,"completion":24839,"start":24840,"enrollment":24841,"conditions":55730,"interventions":55731},[89],[30],[15231,14870],{"nctId":29425,"briefTitle":29426,"status":105,"phases":55733,"primaryCompletion":29428,"completion":29428,"start":29429,"enrollment":29430,"conditions":55734,"interventions":55735},[89],[30],[29414,29433,29434],{"nctId":15385,"briefTitle":15386,"status":105,"phases":55737,"primaryCompletion":15388,"completion":15389,"start":15390,"enrollment":15391,"conditions":55738,"interventions":55739},[89],[30],[15231,14331],{"nctId":15485,"briefTitle":15486,"status":105,"phases":55741,"primaryCompletion":15390,"completion":15225,"start":15488,"enrollment":15489,"conditions":55742,"interventions":55743},[89],[30],[15231,14331,15492],{"trials":55745,"activeCount":99},[],{"trials":55747,"activeCount":99},[55748],{"nctId":55749,"briefTitle":55750,"status":105,"phases":55751,"primaryCompletion":5280,"completion":5280,"start":15211,"enrollment":15353,"conditions":55752,"interventions":55753},"NCT00617877","Antihypertensive Response to Losartan and Genetic Polymorphisms",[91],[30],[15231,55754],"Comparator: Hydrochlorothiazide",{"intervention":1099,"totalTrials":4555,"cells":55756},{"EARLY_PHASE1":55757,"PHASE1":55759,"PHASE2":55767,"PHASE3":55777,"PHASE4":55779,"NA":55789},{"trials":55758,"activeCount":99},[],{"trials":55760,"activeCount":99},[55761],{"nctId":55762,"briefTitle":55763,"status":105,"phases":55764,"primaryCompletion":23091,"completion":23091,"start":41848,"enrollment":9323,"conditions":55765,"interventions":55766},"NCT01432535","Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)",[87],[13409],[1099],{"trials":55768,"activeCount":99},[55769,55773],{"nctId":1091,"briefTitle":1092,"status":105,"phases":55770,"primaryCompletion":1094,"completion":1094,"start":1095,"enrollment":1096,"conditions":55771,"interventions":55772},[87,88],[702,35],[47,1099,1100],{"nctId":15842,"briefTitle":15843,"status":105,"phases":55774,"primaryCompletion":15845,"completion":6799,"start":8591,"enrollment":4358,"conditions":55775,"interventions":55776},[88],[27,24,15847],[1099,15849,15784],{"trials":55778,"activeCount":99},[],{"trials":55780,"activeCount":99},[55781,55785],{"nctId":15974,"briefTitle":15975,"status":1040,"phases":55782,"primaryCompletion":15977,"completion":15977,"start":15978,"enrollment":99,"conditions":55783,"interventions":55784},[90],[24],[12989,1099,15849],{"nctId":15982,"briefTitle":15983,"status":105,"phases":55786,"primaryCompletion":15985,"completion":15985,"start":15986,"enrollment":3226,"conditions":55787,"interventions":55788},[90],[24],[12989,1099,15849],{"trials":55790,"activeCount":99},[55791],{"nctId":53622,"briefTitle":53623,"status":105,"phases":55792,"primaryCompletion":23091,"completion":23091,"start":15063,"enrollment":53625,"conditions":55793,"interventions":55794},[],[21,24],[1099,14925],{"intervention":14018,"totalTrials":174,"cells":55796},{"EARLY_PHASE1":55797,"PHASE1":55799,"PHASE2":55801,"PHASE3":55803,"PHASE4":55813,"NA":55815},{"trials":55798,"activeCount":99},[],{"trials":55800,"activeCount":99},[],{"trials":55802,"activeCount":99},[],{"trials":55804,"activeCount":99},[55805,55809],{"nctId":14010,"briefTitle":14011,"status":105,"phases":55806,"primaryCompletion":14013,"completion":14013,"start":14014,"enrollment":1685,"conditions":55807,"interventions":55808},[89],[15],[13145,14017,4084,14018],{"nctId":14061,"briefTitle":14062,"status":105,"phases":55810,"primaryCompletion":14064,"completion":14064,"start":14065,"enrollment":2182,"conditions":55811,"interventions":55812},[89],[15],[13145,14018,4084],{"trials":55814,"activeCount":99},[],{"trials":55816,"activeCount":99},[55817,55821,55827],{"nctId":53865,"briefTitle":53866,"status":105,"phases":55818,"primaryCompletion":33547,"completion":33547,"start":6309,"enrollment":53868,"conditions":55819,"interventions":55820},[],[15],[13145,14018,14059],{"nctId":55822,"briefTitle":55823,"status":105,"phases":55824,"primaryCompletion":14494,"completion":14494,"start":20608,"enrollment":2223,"conditions":55825,"interventions":55826},"NCT00907881","The OBSTACLE Hypoglycemia Study (MK-0000-158)",[],[14156],[14018],{"nctId":14294,"briefTitle":14295,"status":105,"phases":55828,"primaryCompletion":14297,"completion":14297,"start":14298,"enrollment":14299,"conditions":55829,"interventions":55830},[],[15],[4084,13145,14018,14302],{"intervention":7024,"totalTrials":174,"cells":55832},{"EARLY_PHASE1":55833,"PHASE1":55835,"PHASE2":55841,"PHASE3":55843,"PHASE4":55849,"NA":55862},{"trials":55834,"activeCount":99},[],{"trials":55836,"activeCount":99},[55837],{"nctId":7014,"briefTitle":7015,"status":150,"phases":55838,"primaryCompletion":7017,"completion":7017,"start":7018,"enrollment":920,"conditions":55839,"interventions":55840},[87],[7020],[5481,7022,2100,7023,4388,979,7024],{"trials":55842,"activeCount":99},[],{"trials":55844,"activeCount":99},[55845],{"nctId":27824,"briefTitle":27825,"status":105,"phases":55846,"primaryCompletion":27827,"completion":9214,"start":27828,"enrollment":27829,"conditions":55847,"interventions":55848},[89],[27831],[27813,27833,27834,7024,27835,27836],{"trials":55850,"activeCount":99},[55851,55858],{"nctId":55852,"briefTitle":55853,"status":105,"phases":55854,"primaryCompletion":14353,"completion":14353,"start":14858,"enrollment":23677,"conditions":55855,"interventions":55856},"NCT00730912","Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539)",[90],[41063],[55857,55857,55857],"loratadine",{"nctId":18423,"briefTitle":18424,"status":105,"phases":55859,"primaryCompletion":12814,"completion":12814,"start":18426,"enrollment":920,"conditions":55860,"interventions":55861},[90],[18428],[7024,18410],{"trials":55863,"activeCount":99},[55864],{"nctId":55865,"briefTitle":55866,"status":105,"phases":55867,"primaryCompletion":14313,"completion":14313,"start":8620,"enrollment":1703,"conditions":55868,"interventions":55872},"NCT00762983","Observation of Use of Claritin (Loratadine) Tablet, RediTabs, and Dry Syrup in Children (Study P05834)(COMPLETED)",[],[27831,55869,55870,55871],"Rhinitis, Allergic, Perennial","Urticaria","Pruritus",[55857],{"intervention":16479,"totalTrials":174,"cells":55874},{"EARLY_PHASE1":55875,"PHASE1":55877,"PHASE2":55879,"PHASE3":55881,"PHASE4":55903,"NA":55905},{"trials":55876,"activeCount":99},[],{"trials":55878,"activeCount":99},[],{"trials":55880,"activeCount":99},[],{"trials":55882,"activeCount":99},[55883,55887,55891,55899],{"nctId":16468,"briefTitle":16469,"status":105,"phases":55884,"primaryCompletion":1640,"completion":1640,"start":1984,"enrollment":3605,"conditions":55885,"interventions":55886},[89],[16472],[16465,16474,16441,16475,16476,16477,16478,16479],{"nctId":17711,"briefTitle":17712,"status":105,"phases":55888,"primaryCompletion":1600,"completion":1600,"start":17714,"enrollment":17715,"conditions":55889,"interventions":55890},[89],[16472],[16474,17718,17700,17719,16479],{"nctId":55892,"briefTitle":55893,"status":105,"phases":55894,"primaryCompletion":55895,"completion":55895,"start":55896,"enrollment":2779,"conditions":55897,"interventions":55898},"NCT03843632","Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)",[89],"2020-06-19","2019-03-01",[15311],[16479],{"nctId":16481,"briefTitle":16482,"status":105,"phases":55900,"primaryCompletion":16484,"completion":16484,"start":709,"enrollment":16485,"conditions":55901,"interventions":55902},[89],[16472,16487],[16474,16465,16441,16475,16476,16489,16490,16479,16477],{"trials":55904,"activeCount":99},[],{"trials":55906,"activeCount":99},[55907],{"nctId":55908,"briefTitle":55909,"status":105,"phases":55910,"primaryCompletion":15845,"completion":15845,"start":14324,"enrollment":55911,"conditions":55912,"interventions":55913},"NCT01062061","Re-examination Study For Varivax (V210-059 AM2)",[],754,[15311],[16479],{"intervention":55915,"totalTrials":174,"cells":55916},"Remicade",{"EARLY_PHASE1":55917,"PHASE1":55919,"PHASE2":55921,"PHASE3":55923,"PHASE4":55925,"NA":55940},{"trials":55918,"activeCount":99},[],{"trials":55920,"activeCount":99},[],{"trials":55922,"activeCount":99},[],{"trials":55924,"activeCount":99},[],{"trials":55926,"activeCount":99},[55927,55933],{"nctId":55928,"briefTitle":55929,"status":105,"phases":55930,"primaryCompletion":15063,"completion":15063,"start":15063,"enrollment":335,"conditions":55931,"interventions":55932},"NCT00778869","Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)",[90],[12769],[55915],{"nctId":55934,"briefTitle":55935,"status":105,"phases":55936,"primaryCompletion":55937,"completion":15747,"start":53984,"enrollment":347,"conditions":55938,"interventions":55939},"NCT00779935","Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)",[90],"2005-10-01",[12769],[55915],{"trials":55941,"activeCount":99},[55942,55948,55954],{"nctId":55943,"briefTitle":55944,"status":105,"phases":55945,"primaryCompletion":15794,"completion":15794,"start":22878,"enrollment":29682,"conditions":55946,"interventions":55947},"NCT00818272","Remicade Safety Line (Crohn's Disease)(Study P03288)(COMPLETED)",[],[8604],[55915],{"nctId":55949,"briefTitle":55950,"status":105,"phases":55951,"primaryCompletion":20258,"completion":20258,"start":14678,"enrollment":494,"conditions":55952,"interventions":55953},"NCT00725296","Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)",[],[12744],[55915],{"nctId":55955,"briefTitle":55956,"status":105,"phases":55957,"primaryCompletion":20411,"completion":20411,"start":20226,"enrollment":55958,"conditions":55959,"interventions":55960},"NCT00705614","Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035)",[],2662,[8604],[55915],{"intervention":15886,"totalTrials":3963,"cells":55962},{"EARLY_PHASE1":55963,"PHASE1":55965,"PHASE2":55967,"PHASE3":55977,"PHASE4":55983,"NA":55985},{"trials":55964,"activeCount":99},[],{"trials":55966,"activeCount":99},[],{"trials":55968,"activeCount":99},[55969,55973],{"nctId":33385,"briefTitle":33386,"status":105,"phases":55970,"primaryCompletion":20258,"completion":20258,"start":8591,"enrollment":2770,"conditions":55971,"interventions":55972},[88],[20413],[33361,15886,14925],{"nctId":33398,"briefTitle":33399,"status":105,"phases":55974,"primaryCompletion":20410,"completion":33401,"start":7018,"enrollment":14325,"conditions":55975,"interventions":55976},[88],[21],[33361,15886,14925],{"trials":55978,"activeCount":99},[55979],{"nctId":15880,"briefTitle":15881,"status":105,"phases":55980,"primaryCompletion":5179,"completion":5179,"start":14313,"enrollment":15883,"conditions":55981,"interventions":55982},[89],[21],[15784,15886,14925],{"trials":55984,"activeCount":99},[],{"trials":55986,"activeCount":99},[55987],{"nctId":53636,"briefTitle":53637,"status":105,"phases":55988,"primaryCompletion":53604,"completion":53604,"start":5801,"enrollment":53639,"conditions":55989,"interventions":55990},[],[24,21],[15859,14925,15886],{"intervention":53552,"totalTrials":3963,"cells":55992},{"EARLY_PHASE1":55993,"PHASE1":55995,"PHASE2":56001,"PHASE3":56003,"PHASE4":56005,"NA":56011},{"trials":55994,"activeCount":99},[],{"trials":55996,"activeCount":99},[55997],{"nctId":42447,"briefTitle":42448,"status":105,"phases":55998,"primaryCompletion":42450,"completion":42451,"start":42452,"enrollment":4741,"conditions":55999,"interventions":56000},[87],[12957],[42455,42456,14925,42440],{"trials":56002,"activeCount":99},[],{"trials":56004,"activeCount":99},[],{"trials":56006,"activeCount":99},[56007],{"nctId":53546,"briefTitle":53547,"status":150,"phases":56008,"primaryCompletion":14003,"completion":14003,"start":53549,"enrollment":700,"conditions":56009,"interventions":56010},[90],[21],[53552,15820],{"trials":56012,"activeCount":99},[56013,56019],{"nctId":56014,"briefTitle":56015,"status":105,"phases":56016,"primaryCompletion":12984,"completion":12984,"start":24504,"enrollment":51162,"conditions":56017,"interventions":56018},"NCT00736242","Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)",[],[12957,24,27],[53552,15849],{"nctId":53681,"briefTitle":53682,"status":150,"phases":56020,"primaryCompletion":5800,"completion":5800,"start":13870,"enrollment":5802,"conditions":56021,"interventions":56022},[],[24,21],[42456,14925],{"intervention":15849,"totalTrials":3963,"cells":56024},{"EARLY_PHASE1":56025,"PHASE1":56027,"PHASE2":56029,"PHASE3":56035,"PHASE4":56037,"NA":56047},{"trials":56026,"activeCount":99},[],{"trials":56028,"activeCount":99},[],{"trials":56030,"activeCount":99},[56031],{"nctId":15842,"briefTitle":15843,"status":105,"phases":56032,"primaryCompletion":15845,"completion":6799,"start":8591,"enrollment":4358,"conditions":56033,"interventions":56034},[88],[27,24,15847],[1099,15849,15784],{"trials":56036,"activeCount":99},[],{"trials":56038,"activeCount":99},[56039,56043],{"nctId":15974,"briefTitle":15975,"status":1040,"phases":56040,"primaryCompletion":15977,"completion":15977,"start":15978,"enrollment":99,"conditions":56041,"interventions":56042},[90],[24],[12989,1099,15849],{"nctId":15982,"briefTitle":15983,"status":105,"phases":56044,"primaryCompletion":15985,"completion":15985,"start":15986,"enrollment":3226,"conditions":56045,"interventions":56046},[90],[24],[12989,1099,15849],{"trials":56048,"activeCount":99},[56049],{"nctId":56014,"briefTitle":56015,"status":105,"phases":56050,"primaryCompletion":12984,"completion":12984,"start":24504,"enrollment":51162,"conditions":56051,"interventions":56052},[],[12957,24,27],[53552,15849],{"intervention":26271,"totalTrials":202,"cells":56054},{"EARLY_PHASE1":56055,"PHASE1":56057,"PHASE2":56059,"PHASE3":56061,"PHASE4":56071,"NA":56073},{"trials":56056,"activeCount":99},[],{"trials":56058,"activeCount":99},[],{"trials":56060,"activeCount":99},[],{"trials":56062,"activeCount":99},[56063,56067],{"nctId":26266,"briefTitle":26267,"status":105,"phases":56064,"primaryCompletion":14483,"completion":14483,"start":15156,"enrollment":1919,"conditions":56065,"interventions":56066},[89],[14395],[26271,26255,26271],{"nctId":26312,"briefTitle":26313,"status":105,"phases":56068,"primaryCompletion":11385,"completion":11385,"start":12954,"enrollment":2512,"conditions":56069,"interventions":56070},[89],[14395],[26271,26301],{"trials":56072,"activeCount":99},[],{"trials":56074,"activeCount":99},[56075],{"nctId":56076,"briefTitle":56077,"status":105,"phases":56078,"primaryCompletion":19679,"completion":19679,"start":42723,"enrollment":56079,"conditions":56080,"interventions":56081},"NCT01600079","ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)",[],1505647,[14395,14775],[26271],{"intervention":54674,"totalTrials":202,"cells":56083},{"EARLY_PHASE1":56084,"PHASE1":56086,"PHASE2":56088,"PHASE3":56094,"PHASE4":56096,"NA":56098},{"trials":56085,"activeCount":99},[],{"trials":56087,"activeCount":99},[],{"trials":56089,"activeCount":99},[56090],{"nctId":54669,"briefTitle":54670,"status":105,"phases":56091,"enrollment":4555,"conditions":56092,"interventions":56093},[88],[27],[17754,54674,6235],{"trials":56095,"activeCount":99},[],{"trials":56097,"activeCount":99},[],{"trials":56099,"activeCount":99},[56100,56104],{"nctId":54736,"briefTitle":54737,"status":105,"phases":56101,"enrollment":120,"conditions":56102,"interventions":56103},[91],[27],[17754,54674],{"nctId":54742,"briefTitle":54743,"status":105,"phases":56105,"enrollment":8,"conditions":56106,"interventions":56107},[91],[27],[17754,54674,11421,17755],{"intervention":56109,"totalTrials":3197,"cells":56110},"Vicriviroc maleate",{"EARLY_PHASE1":56111,"PHASE1":56113,"PHASE2":56115,"PHASE3":56124,"PHASE4":56126,"NA":56128},{"trials":56112,"activeCount":99},[],{"trials":56114,"activeCount":99},[],{"trials":56116,"activeCount":99},[56117],{"nctId":56118,"briefTitle":56119,"status":105,"phases":56120,"primaryCompletion":56121,"completion":56121,"start":19425,"enrollment":18324,"conditions":56122,"interventions":56123},"NCT00686829","Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100)",[88],"2010-10-21",[7390,27],[56109],{"trials":56125,"activeCount":99},[],{"trials":56127,"activeCount":99},[],{"trials":56129,"activeCount":99},[56130],{"nctId":56131,"briefTitle":56132,"status":105,"phases":56133,"primaryCompletion":13222,"completion":13222,"start":13891,"enrollment":765,"conditions":56134,"interventions":56135},"NCT00705419","Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999)",[],[27],[56109,56109,56136],"Emtricitabine 200 mg\u002F tenofovir disoproxil fumarate 300 mg",{"intervention":45282,"totalTrials":3197,"cells":56138},{"EARLY_PHASE1":56139,"PHASE1":56141,"PHASE2":56147,"PHASE3":56149,"PHASE4":56151,"NA":56153},{"trials":56140,"activeCount":99},[],{"trials":56142,"activeCount":99},[56143],{"nctId":45277,"briefTitle":45278,"status":105,"phases":56144,"primaryCompletion":12984,"completion":12984,"start":21145,"enrollment":3390,"conditions":56145,"interventions":56146},[87],[12754],[45270,45282],{"trials":56148,"activeCount":99},[],{"trials":56150,"activeCount":99},[],{"trials":56152,"activeCount":99},[],{"trials":56154,"activeCount":99},[56155],{"nctId":54095,"briefTitle":54096,"status":1040,"phases":56156,"primaryCompletion":14713,"completion":14713,"start":14315,"enrollment":99,"conditions":56157,"interventions":56158},[],[7020],[54100,12756,54101],{"intervention":56160,"totalTrials":3197,"cells":56161},"L-743,872",{"EARLY_PHASE1":56162,"PHASE1":56164,"PHASE2":56166,"PHASE3":56175,"PHASE4":56177,"NA":56179},{"trials":56163,"activeCount":99},[],{"trials":56165,"activeCount":99},[],{"trials":56167,"activeCount":99},[56168],{"nctId":56169,"briefTitle":56170,"status":150,"phases":56171,"enrollment":367,"conditions":56172,"interventions":56174},"NCT00005920","Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole",[88],[56173,27],"Candidiasis, Oral",[56160],{"trials":56176,"activeCount":99},[],{"trials":56178,"activeCount":99},[],{"trials":56180,"activeCount":99},[56181],{"nctId":56182,"briefTitle":56183,"status":105,"phases":56184,"enrollment":931,"conditions":56185,"interventions":56186},"NCT00005921","A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis",[91],[35063,27],[56160],{"intervention":56188,"totalTrials":3197,"cells":56189},"Caelyx",{"EARLY_PHASE1":56190,"PHASE1":56192,"PHASE2":56194,"PHASE3":56196,"PHASE4":56198,"NA":56206},{"trials":56191,"activeCount":99},[],{"trials":56193,"activeCount":99},[],{"trials":56195,"activeCount":99},[],{"trials":56197,"activeCount":99},[],{"trials":56199,"activeCount":99},[56200],{"nctId":56201,"briefTitle":56202,"status":150,"phases":56203,"primaryCompletion":20887,"completion":20887,"start":13899,"enrollment":9323,"conditions":56204,"interventions":56205},"NCT00604968","Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and\u002For Metastatic Breast Cancer (Study P05059)",[90],[1108],[56188],{"trials":56207,"activeCount":99},[56208],{"nctId":56209,"briefTitle":56210,"status":105,"phases":56211,"primaryCompletion":14353,"completion":14353,"start":19537,"enrollment":32902,"conditions":56212,"interventions":56213},"NCT00743431","Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)",[],[1288],[56188],{"intervention":53672,"totalTrials":3197,"cells":56215},{"EARLY_PHASE1":56216,"PHASE1":56218,"PHASE2":56220,"PHASE3":56222,"PHASE4":56224,"NA":56226},{"trials":56217,"activeCount":99},[],{"trials":56219,"activeCount":99},[],{"trials":56221,"activeCount":99},[],{"trials":56223,"activeCount":99},[],{"trials":56225,"activeCount":99},[],{"trials":56227,"activeCount":99},[56228,56232],{"nctId":53665,"briefTitle":53666,"status":150,"phases":56229,"primaryCompletion":53668,"completion":53668,"start":53669,"enrollment":202,"conditions":56230,"interventions":56231},[],[12957],[53672,14925],{"nctId":54888,"briefTitle":54889,"status":150,"phases":56233,"primaryCompletion":14504,"completion":14504,"start":14706,"enrollment":1249,"conditions":56234,"interventions":56235},[],[21,24],[54893,54444],{"intervention":22487,"totalTrials":3197,"cells":56237},{"EARLY_PHASE1":56238,"PHASE1":56240,"PHASE2":56242,"PHASE3":56244,"PHASE4":56250,"NA":56252},{"trials":56239,"activeCount":99},[],{"trials":56241,"activeCount":99},[],{"trials":56243,"activeCount":99},[],{"trials":56245,"activeCount":99},[56246],{"nctId":22480,"briefTitle":22481,"status":150,"phases":56247,"primaryCompletion":22483,"completion":22483,"start":22484,"enrollment":1550,"conditions":56248,"interventions":56249},[88,89],[35],[22444,22487],{"trials":56251,"activeCount":99},[],{"trials":56253,"activeCount":99},[56254],{"nctId":56255,"briefTitle":56256,"status":105,"phases":56257,"primaryCompletion":56258,"completion":56258,"start":17461,"enrollment":14135,"conditions":56259,"interventions":56260},"NCT00723710","Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)",[],"2012-09",[35],[56261],"Intron A",{"intervention":56263,"totalTrials":224,"cells":56264},"SCH 900460",{"EARLY_PHASE1":56265,"PHASE1":56267,"PHASE2":56269,"PHASE3":56271,"PHASE4":56273,"NA":56275},{"trials":56266,"activeCount":99},[],{"trials":56268,"activeCount":99},[],{"trials":56270,"activeCount":99},[],{"trials":56272,"activeCount":99},[],{"trials":56274,"activeCount":99},[],{"trials":56276,"activeCount":99},[56277],{"nctId":56278,"briefTitle":56279,"status":105,"phases":56280,"primaryCompletion":13870,"completion":13870,"start":15505,"enrollment":14941,"conditions":56281,"interventions":56283},"NCT00780585","A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)",[],[56282],"Psychosis",[56263],{"intervention":56285,"totalTrials":224,"cells":56286},"Comparator: vorinostat",{"EARLY_PHASE1":56287,"PHASE1":56289,"PHASE2":56291,"PHASE3":56293,"PHASE4":56295,"NA":56297},{"trials":56288,"activeCount":99},[],{"trials":56290,"activeCount":99},[],{"trials":56292,"activeCount":99},[],{"trials":56294,"activeCount":99},[],{"trials":56296,"activeCount":99},[],{"trials":56298,"activeCount":99},[56299],{"nctId":56300,"briefTitle":56301,"status":2796,"phases":56302,"conditions":56303,"interventions":56305},"NCT00419367","Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)",[],[56304],"Lymphoma, T-Cell, Cutaneous",[56285],{"intervention":56307,"totalTrials":224,"cells":56308},"Physician standard-of-care",{"EARLY_PHASE1":56309,"PHASE1":56311,"PHASE2":56313,"PHASE3":56315,"PHASE4":56317,"NA":56319},{"trials":56310,"activeCount":99},[],{"trials":56312,"activeCount":99},[],{"trials":56314,"activeCount":99},[],{"trials":56316,"activeCount":99},[],{"trials":56318,"activeCount":99},[],{"trials":56320,"activeCount":99},[56321],{"nctId":56322,"briefTitle":56323,"status":105,"phases":56324,"primaryCompletion":56325,"completion":56325,"start":41848,"enrollment":19356,"conditions":56326,"interventions":56327},"NCT01218360","Observational Study of Disease Severity in Participants Diagnosed With Crohn's Disease and Long Term Impact of Treatment Strategies in Participants With Moderate to Severe Crohn's Disease (Protocol P06484)",[],"2015-01",[7227],[56307],{"intervention":56329,"totalTrials":224,"cells":56330},"Posaconazole or alternative fungal treatment",{"EARLY_PHASE1":56331,"PHASE1":56333,"PHASE2":56335,"PHASE3":56337,"PHASE4":56339,"NA":56341},{"trials":56332,"activeCount":99},[],{"trials":56334,"activeCount":99},[],{"trials":56336,"activeCount":99},[],{"trials":56338,"activeCount":99},[],{"trials":56340,"activeCount":99},[],{"trials":56342,"activeCount":99},[56343],{"nctId":56344,"briefTitle":56345,"status":1040,"phases":56346,"primaryCompletion":5981,"completion":5800,"start":5801,"enrollment":99,"conditions":56347,"interventions":56348},"NCT00704951","Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN)",[],[22319],[56329],{"intervention":56350,"totalTrials":224,"cells":56351},"Cuprimine",{"EARLY_PHASE1":56352,"PHASE1":56354,"PHASE2":56356,"PHASE3":56358,"PHASE4":56360,"NA":56362},{"trials":56353,"activeCount":99},[],{"trials":56355,"activeCount":99},[],{"trials":56357,"activeCount":99},[],{"trials":56359,"activeCount":99},[],{"trials":56361,"activeCount":99},[],{"trials":56363,"activeCount":99},[56364],{"nctId":56365,"briefTitle":56366,"status":2796,"phases":56367,"conditions":56368,"interventions":56370},"NCT01374282","Post Marketing Surveillance Study of Cuprimine",[],[56369],"Scleroderma",[56350],{"intervention":56372,"totalTrials":224,"cells":56373},"Sitagliptin\u002Fmetformin",{"EARLY_PHASE1":56374,"PHASE1":56376,"PHASE2":56378,"PHASE3":56380,"PHASE4":56382,"NA":56384},{"trials":56375,"activeCount":99},[],{"trials":56377,"activeCount":99},[],{"trials":56379,"activeCount":99},[],{"trials":56381,"activeCount":99},[],{"trials":56383,"activeCount":99},[],{"trials":56385,"activeCount":99},[56386],{"nctId":56387,"briefTitle":56388,"status":105,"phases":56389,"primaryCompletion":20279,"completion":20279,"start":14314,"enrollment":15408,"conditions":56390,"interventions":56391},"NCT01065766","Sitagliptin\u002FMetformin (JANUMET) Re-examination Study (0431A-182)",[],[15],[56372],{"intervention":56393,"totalTrials":224,"cells":56394},"Statin Therapy",{"EARLY_PHASE1":56395,"PHASE1":56397,"PHASE2":56399,"PHASE3":56401,"PHASE4":56403,"NA":56405},{"trials":56396,"activeCount":99},[],{"trials":56398,"activeCount":99},[],{"trials":56400,"activeCount":99},[],{"trials":56402,"activeCount":99},[],{"trials":56404,"activeCount":99},[],{"trials":56406,"activeCount":99},[56407],{"nctId":56408,"briefTitle":56409,"status":150,"phases":56410,"primaryCompletion":16103,"completion":16103,"start":2811,"enrollment":8175,"conditions":56411,"interventions":56412},"NCT01421277","Study of Treatment Used for Migraine Headaches (MK-0974-076)",[],[4397],[56393],{"intervention":53608,"totalTrials":224,"cells":56414},{"EARLY_PHASE1":56415,"PHASE1":56417,"PHASE2":56419,"PHASE3":56421,"PHASE4":56423,"NA":56425},{"trials":56416,"activeCount":99},[],{"trials":56418,"activeCount":99},[],{"trials":56420,"activeCount":99},[],{"trials":56422,"activeCount":99},[],{"trials":56424,"activeCount":99},[],{"trials":56426,"activeCount":99},[56427],{"nctId":53601,"briefTitle":53602,"status":105,"phases":56428,"primaryCompletion":53604,"completion":53604,"start":5280,"enrollment":53605,"conditions":56429,"interventions":56430},[],[21],[53608,14925],{"intervention":14302,"totalTrials":224,"cells":56432},{"EARLY_PHASE1":56433,"PHASE1":56435,"PHASE2":56437,"PHASE3":56439,"PHASE4":56441,"NA":56443},{"trials":56434,"activeCount":99},[],{"trials":56436,"activeCount":99},[],{"trials":56438,"activeCount":99},[],{"trials":56440,"activeCount":99},[],{"trials":56442,"activeCount":99},[],{"trials":56444,"activeCount":99},[56445],{"nctId":14294,"briefTitle":14295,"status":105,"phases":56446,"primaryCompletion":14297,"completion":14297,"start":14298,"enrollment":14299,"conditions":56447,"interventions":56448},[],[15],[4084,13145,14018,14302],{"intervention":56450,"totalTrials":224,"cells":56451},"Rotavirus Vaccine",{"EARLY_PHASE1":56452,"PHASE1":56454,"PHASE2":56456,"PHASE3":56458,"PHASE4":56460,"NA":56462},{"trials":56453,"activeCount":99},[],{"trials":56455,"activeCount":99},[],{"trials":56457,"activeCount":99},[],{"trials":56459,"activeCount":99},[],{"trials":56461,"activeCount":99},[],{"trials":56463,"activeCount":99},[56464],{"nctId":56465,"briefTitle":56466,"status":150,"phases":56467,"primaryCompletion":41848,"completion":41848,"start":5982,"enrollment":1132,"conditions":56468,"interventions":56470},"NCT01195844","Gastroenteritis From Rotavirus Infection in Brazilian Children Less Than 5 Years of Age (Study V260-031).",[],[56469],"Pediatric Gastroenteritis",[56450],{"intervention":56472,"totalTrials":224,"cells":56473},"Interferon α-2b",{"EARLY_PHASE1":56474,"PHASE1":56476,"PHASE2":56478,"PHASE3":56480,"PHASE4":56482,"NA":56484},{"trials":56475,"activeCount":99},[],{"trials":56477,"activeCount":99},[],{"trials":56479,"activeCount":99},[],{"trials":56481,"activeCount":99},[],{"trials":56483,"activeCount":99},[],{"trials":56485,"activeCount":99},[56486],{"nctId":56487,"briefTitle":56488,"status":105,"phases":56489,"primaryCompletion":14445,"completion":14445,"start":56490,"enrollment":44708,"conditions":56491,"interventions":56492},"NCT00749684","Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083)",[],"1996-12",[35],[56472],{"intervention":12771,"totalTrials":224,"cells":56494},{"EARLY_PHASE1":56495,"PHASE1":56497,"PHASE2":56499,"PHASE3":56501,"PHASE4":56503,"NA":56505},{"trials":56496,"activeCount":99},[],{"trials":56498,"activeCount":99},[],{"trials":56500,"activeCount":99},[],{"trials":56502,"activeCount":99},[],{"trials":56504,"activeCount":99},[],{"trials":56506,"activeCount":99},[56507],{"nctId":12763,"briefTitle":12764,"status":105,"phases":56508,"primaryCompletion":12766,"completion":12766,"start":4990,"enrollment":12767,"conditions":56509,"interventions":56510},[],[7197,12744,12769],[12771,2100],{"intervention":55754,"totalTrials":224,"cells":56512},{"EARLY_PHASE1":56513,"PHASE1":56515,"PHASE2":56517,"PHASE3":56519,"PHASE4":56521,"NA":56523},{"trials":56514,"activeCount":99},[],{"trials":56516,"activeCount":99},[],{"trials":56518,"activeCount":99},[],{"trials":56520,"activeCount":99},[],{"trials":56522,"activeCount":99},[],{"trials":56524,"activeCount":99},[56525],{"nctId":55749,"briefTitle":55750,"status":105,"phases":56526,"primaryCompletion":5280,"completion":5280,"start":15211,"enrollment":15353,"conditions":56527,"interventions":56528},[91],[30],[15231,55754],{"intervention":56136,"totalTrials":224,"cells":56530},{"EARLY_PHASE1":56531,"PHASE1":56533,"PHASE2":56535,"PHASE3":56537,"PHASE4":56539,"NA":56541},{"trials":56532,"activeCount":99},[],{"trials":56534,"activeCount":99},[],{"trials":56536,"activeCount":99},[],{"trials":56538,"activeCount":99},[],{"trials":56540,"activeCount":99},[],{"trials":56542,"activeCount":99},[56543],{"nctId":56131,"briefTitle":56132,"status":105,"phases":56544,"primaryCompletion":13222,"completion":13222,"start":13891,"enrollment":765,"conditions":56545,"interventions":56546},[],[27],[56109,56109,56136],{"intervention":56548,"totalTrials":224,"cells":56549},"Sitagliptin Phosphate\u002FMetformin HCl",{"EARLY_PHASE1":56550,"PHASE1":56552,"PHASE2":56554,"PHASE3":56556,"PHASE4":56558,"NA":56560},{"trials":56551,"activeCount":99},[],{"trials":56553,"activeCount":99},[],{"trials":56555,"activeCount":99},[],{"trials":56557,"activeCount":99},[],{"trials":56559,"activeCount":99},[],{"trials":56561,"activeCount":99},[56562],{"nctId":56563,"briefTitle":56564,"status":150,"phases":56565,"primaryCompletion":14494,"completion":14494,"start":14314,"enrollment":5196,"conditions":56566,"interventions":56567},"NCT01357148","A Post Marketing Safety Study of Sitagliptin Phosphate\u002FMetformin Hydrochloride (JANUMET®) (MK-0431A-235)",[],[33],[56548],{"intervention":56569,"totalTrials":224,"cells":56570},"Standard of Care PegIntron",{"EARLY_PHASE1":56571,"PHASE1":56573,"PHASE2":56575,"PHASE3":56577,"PHASE4":56579,"NA":56581},{"trials":56572,"activeCount":99},[],{"trials":56574,"activeCount":99},[],{"trials":56576,"activeCount":99},[],{"trials":56578,"activeCount":99},[],{"trials":56580,"activeCount":99},[],{"trials":56582,"activeCount":99},[56583],{"nctId":56584,"briefTitle":56585,"status":105,"phases":56586,"primaryCompletion":5800,"completion":5800,"start":13101,"enrollment":3197,"conditions":56587,"interventions":56588},"NCT01054742","Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2)",[],[24],[56569,56589],"Standard of Care Ribavirin",{"intervention":56589,"totalTrials":224,"cells":56591},{"EARLY_PHASE1":56592,"PHASE1":56594,"PHASE2":56596,"PHASE3":56598,"PHASE4":56600,"NA":56602},{"trials":56593,"activeCount":99},[],{"trials":56595,"activeCount":99},[],{"trials":56597,"activeCount":99},[],{"trials":56599,"activeCount":99},[],{"trials":56601,"activeCount":99},[],{"trials":56603,"activeCount":99},[56604],{"nctId":56584,"briefTitle":56585,"status":105,"phases":56605,"primaryCompletion":5800,"completion":5800,"start":13101,"enrollment":3197,"conditions":56606,"interventions":56607},[],[24],[56569,56589],{"intervention":56609,"totalTrials":224,"cells":56610},"Sulphonylurea",{"EARLY_PHASE1":56611,"PHASE1":56613,"PHASE2":56615,"PHASE3":56617,"PHASE4":56619,"NA":56621},{"trials":56612,"activeCount":99},[],{"trials":56614,"activeCount":99},[],{"trials":56616,"activeCount":99},[],{"trials":56618,"activeCount":99},[],{"trials":56620,"activeCount":99},[],{"trials":56622,"activeCount":99},[56623],{"nctId":56624,"briefTitle":56625,"status":105,"phases":56626,"primaryCompletion":22359,"completion":22359,"start":5981,"enrollment":56627,"conditions":56628,"interventions":56629},"NCT01278485","Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-402)",[],726,[15],[56609,56630],"Metformn",{"intervention":56630,"totalTrials":224,"cells":56632},{"EARLY_PHASE1":56633,"PHASE1":56635,"PHASE2":56637,"PHASE3":56639,"PHASE4":56641,"NA":56643},{"trials":56634,"activeCount":99},[],{"trials":56636,"activeCount":99},[],{"trials":56638,"activeCount":99},[],{"trials":56640,"activeCount":99},[],{"trials":56642,"activeCount":99},[],{"trials":56644,"activeCount":99},[56645],{"nctId":56624,"briefTitle":56625,"status":105,"phases":56646,"primaryCompletion":22359,"completion":22359,"start":5981,"enrollment":56627,"conditions":56647,"interventions":56648},[],[15],[56609,56630],{"intervention":56650,"totalTrials":224,"cells":56651},"Tetanus & Diphtheria booster vaccine",{"EARLY_PHASE1":56652,"PHASE1":56654,"PHASE2":56656,"PHASE3":56658,"PHASE4":56660,"NA":56662},{"trials":56653,"activeCount":99},[],{"trials":56655,"activeCount":99},[],{"trials":56657,"activeCount":99},[],{"trials":56659,"activeCount":99},[],{"trials":56661,"activeCount":99},[],{"trials":56663,"activeCount":99},[56664],{"nctId":56665,"briefTitle":56666,"status":105,"phases":56667,"primaryCompletion":41848,"completion":41848,"start":20258,"enrollment":34922,"conditions":56668,"interventions":56670},"NCT01119703","Vaccine Hyporesponse in Healthy Elderly Participants (MK-0000-131 AM2)",[],[56669],"Vaccine Response Impaired",[56650,56671,56672],"TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine]","Dukoral® Traveler's Diarrhea Vaccine",{"intervention":56671,"totalTrials":224,"cells":56674},{"EARLY_PHASE1":56675,"PHASE1":56677,"PHASE2":56679,"PHASE3":56681,"PHASE4":56683,"NA":56685},{"trials":56676,"activeCount":99},[],{"trials":56678,"activeCount":99},[],{"trials":56680,"activeCount":99},[],{"trials":56682,"activeCount":99},[],{"trials":56684,"activeCount":99},[],{"trials":56686,"activeCount":99},[56687],{"nctId":56665,"briefTitle":56666,"status":105,"phases":56688,"primaryCompletion":41848,"completion":41848,"start":20258,"enrollment":34922,"conditions":56689,"interventions":56690},[],[56669],[56650,56671,56672],{"intervention":56672,"totalTrials":224,"cells":56692},{"EARLY_PHASE1":56693,"PHASE1":56695,"PHASE2":56697,"PHASE3":56699,"PHASE4":56701,"NA":56703},{"trials":56694,"activeCount":99},[],{"trials":56696,"activeCount":99},[],{"trials":56698,"activeCount":99},[],{"trials":56700,"activeCount":99},[],{"trials":56702,"activeCount":99},[],{"trials":56704,"activeCount":99},[56705],{"nctId":56665,"briefTitle":56666,"status":105,"phases":56706,"primaryCompletion":41848,"completion":41848,"start":20258,"enrollment":34922,"conditions":56707,"interventions":56708},[],[56669],[56650,56671,56672],{"intervention":56710,"totalTrials":224,"cells":56711},"EMEND",{"EARLY_PHASE1":56712,"PHASE1":56714,"PHASE2":56716,"PHASE3":56718,"PHASE4":56720,"NA":56722},{"trials":56713,"activeCount":99},[],{"trials":56715,"activeCount":99},[],{"trials":56717,"activeCount":99},[],{"trials":56719,"activeCount":99},[],{"trials":56721,"activeCount":99},[],{"trials":56723,"activeCount":99},[56724],{"nctId":56725,"briefTitle":56726,"status":105,"phases":56727,"primaryCompletion":53604,"completion":53604,"start":15505,"enrollment":56728,"conditions":56729,"interventions":56730},"NCT01074255","Re-examination Study of EMEND (Aprepitant) (MK-0869-184)",[],3546,[5252],[56710],{"intervention":54859,"totalTrials":224,"cells":56732},{"EARLY_PHASE1":56733,"PHASE1":56735,"PHASE2":56737,"PHASE3":56739,"PHASE4":56741,"NA":56743},{"trials":56734,"activeCount":99},[],{"trials":56736,"activeCount":99},[],{"trials":56738,"activeCount":99},[],{"trials":56740,"activeCount":99},[],{"trials":56742,"activeCount":99},[],{"trials":56744,"activeCount":99},[56745],{"nctId":54853,"briefTitle":54854,"status":105,"phases":56746,"primaryCompletion":5280,"completion":5280,"start":15063,"enrollment":54856,"conditions":56747,"interventions":56748},[],[21,24],[54859,54444],{"intervention":55490,"totalTrials":224,"cells":56750},{"EARLY_PHASE1":56751,"PHASE1":56753,"PHASE2":56755,"PHASE3":56757,"PHASE4":56759,"NA":56761},{"trials":56752,"activeCount":99},[],{"trials":56754,"activeCount":99},[],{"trials":56756,"activeCount":99},[],{"trials":56758,"activeCount":99},[],{"trials":56760,"activeCount":99},[],{"trials":56762,"activeCount":99},[56763],{"nctId":55484,"briefTitle":55485,"status":105,"phases":56764,"primaryCompletion":18998,"completion":18998,"start":14623,"enrollment":55487,"conditions":56765,"interventions":56766},[],[27],[17577,55490],{"intervention":54867,"totalTrials":224,"cells":56768},{"EARLY_PHASE1":56769,"PHASE1":56771,"PHASE2":56773,"PHASE3":56775,"PHASE4":56777,"NA":56779},{"trials":56770,"activeCount":99},[],{"trials":56772,"activeCount":99},[],{"trials":56774,"activeCount":99},[],{"trials":56776,"activeCount":99},[],{"trials":56778,"activeCount":99},[],{"trials":56780,"activeCount":99},[56781],{"nctId":54861,"briefTitle":54862,"status":105,"phases":56782,"primaryCompletion":14454,"completion":14454,"start":15156,"enrollment":54864,"conditions":56783,"interventions":56784},[],[21,24],[54867,54444],{"intervention":54087,"totalTrials":224,"cells":56786},{"EARLY_PHASE1":56787,"PHASE1":56789,"PHASE2":56791,"PHASE3":56793,"PHASE4":56795,"NA":56797},{"trials":56788,"activeCount":99},[],{"trials":56790,"activeCount":99},[],{"trials":56792,"activeCount":99},[],{"trials":56794,"activeCount":99},[],{"trials":56796,"activeCount":99},[],{"trials":56798,"activeCount":99},[56799],{"nctId":54080,"briefTitle":54081,"status":105,"phases":56800,"primaryCompletion":54083,"completion":54083,"start":35597,"enrollment":54084,"conditions":56801,"interventions":56802},[],[9066],[12756,54087],{"intervention":54874,"totalTrials":224,"cells":56804},{"EARLY_PHASE1":56805,"PHASE1":56807,"PHASE2":56809,"PHASE3":56811,"PHASE4":56813,"NA":56815},{"trials":56806,"activeCount":99},[],{"trials":56808,"activeCount":99},[],{"trials":56810,"activeCount":99},[],{"trials":56812,"activeCount":99},[],{"trials":56814,"activeCount":99},[],{"trials":56816,"activeCount":99},[56817],{"nctId":54869,"briefTitle":54870,"status":150,"phases":56818,"primaryCompletion":14324,"completion":14324,"start":14705,"enrollment":202,"conditions":56819,"interventions":56820},[],[21,24],[54874,54444],{"intervention":54101,"totalTrials":224,"cells":56822},{"EARLY_PHASE1":56823,"PHASE1":56825,"PHASE2":56827,"PHASE3":56829,"PHASE4":56831,"NA":56833},{"trials":56824,"activeCount":99},[],{"trials":56826,"activeCount":99},[],{"trials":56828,"activeCount":99},[],{"trials":56830,"activeCount":99},[],{"trials":56832,"activeCount":99},[],{"trials":56834,"activeCount":99},[56835],{"nctId":54095,"briefTitle":54096,"status":1040,"phases":56836,"primaryCompletion":14713,"completion":14713,"start":14315,"enrollment":99,"conditions":56837,"interventions":56838},[],[7020],[54100,12756,54101],{"intervention":54324,"totalTrials":224,"cells":56840},{"EARLY_PHASE1":56841,"PHASE1":56843,"PHASE2":56845,"PHASE3":56847,"PHASE4":56849,"NA":56851},{"trials":56842,"activeCount":99},[],{"trials":56844,"activeCount":99},[],{"trials":56846,"activeCount":99},[],{"trials":56848,"activeCount":99},[],{"trials":56850,"activeCount":99},[],{"trials":56852,"activeCount":99},[56853],{"nctId":54317,"briefTitle":54318,"status":105,"phases":56854,"primaryCompletion":13223,"completion":13223,"start":13222,"enrollment":54320,"conditions":56855,"interventions":56856},[],[54322],[17013,54324],{"intervention":56858,"totalTrials":224,"cells":56859},"Posaconazole oral suspension 40 mg\u002FmL",{"EARLY_PHASE1":56860,"PHASE1":56862,"PHASE2":56864,"PHASE3":56866,"PHASE4":56868,"NA":56870},{"trials":56861,"activeCount":99},[],{"trials":56863,"activeCount":99},[],{"trials":56865,"activeCount":99},[],{"trials":56867,"activeCount":99},[],{"trials":56869,"activeCount":99},[],{"trials":56871,"activeCount":99},[56872],{"nctId":56873,"briefTitle":56874,"status":105,"phases":56875,"primaryCompletion":26082,"completion":26082,"start":13223,"enrollment":15571,"conditions":56876,"interventions":56877},"NCT01436578","Safety and Efficacy of Posaconazole Oral Suspension in Usual Practice in Korea (P08547)",[],[24476],[56858]]